data_1vre_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1vre _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.438 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -70.27 -47.35 61.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.305 -0.872 . . . . 0.0 109.212 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 31.8 mtp180 -53.98 -36.01 62.44 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.247 -0.908 . . . . 0.0 109.193 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -74.59 -40.38 61.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.309 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.443 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 61.0 t -66.06 -23.71 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.284 -0.885 . . . . 0.0 109.192 179.606 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.517 HG11 ' CD1' ' A' ' 130' ' ' TRP . 50.9 t -76.74 -44.89 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -0.853 . . . . 0.0 109.338 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.42 ' O ' ' HG3' ' A' ' 15' ' ' LYS . . . -74.04 -15.96 61.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.764 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -86.21 -24.16 26.19 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.149 -0.969 . . . . 0.0 109.816 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.6 p -95.16 -10.96 29.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.214 -0.929 . . . . 0.0 109.8 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.562 ' CE3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.8 -28.73 17.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 0.0 109.863 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.42 ' HG3' ' O ' ' A' ' 11' ' ' ALA . 10.6 mtmt -74.57 -12.73 60.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 109.812 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -101.52 -55.05 2.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -0.988 . . . . 0.0 109.528 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.505 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 86.0 mt -67.5 -35.5 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.271 -0.893 . . . . 0.0 109.593 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.562 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -105.59 33.73 3.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.285 -0.884 . . . . 0.0 109.728 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -84.58 0.03 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 p -101.08 -18.81 16.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.703 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.471 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 9.4 p-10 -85.51 -16.99 37.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.207 -0.933 . . . . 0.0 109.902 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.401 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.4 t30 62.39 17.0 9.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.263 -0.898 . . . . 0.0 109.676 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.88 29.65 5.75 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.471 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -70.88 -46.99 61.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -1.174 . . . . 0.0 109.546 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.432 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.85 38.19 3.19 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.505 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 34.6 t -124.01 -43.12 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.233 -1.157 . . . . 0.0 108.64 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.485 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -88.81 -32.0 11.77 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.54 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.508 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 15.5 ptpt -62.19 -35.57 79.25 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.232 -1.158 . . . . 0.0 109.124 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.508 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 17.2 pt-20 -86.42 -21.08 27.32 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -0.972 . . . . 0.0 109.31 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 38.5 t -87.98 -59.38 2.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.398 -0.814 . . . . 0.0 109.692 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.2 m-85 -53.67 -42.99 68.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.275 -0.891 . . . . 0.0 109.669 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.453 ' CA ' HG12 ' A' ' 55' ' ' VAL . 17.8 m -52.02 -50.25 61.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.15 -0.969 . . . . 0.0 109.252 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.405 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 0.2 OUTLIER -62.5 -44.73 95.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.26 179.649 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.514 ' CG ' HD22 ' A' ' 106' ' ' LEU . 3.9 t80 -57.81 -46.66 84.36 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.35 -0.844 . . . . 0.0 109.206 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.464 HD11 ' CG2' ' A' ' 55' ' ' VAL . 11.1 mt -59.26 -44.34 92.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.715 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 46.8 t -66.7 -64.32 0.88 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.204 -0.935 . . . . 0.0 109.749 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.39 -26.57 20.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.218 -0.926 . . . . 0.0 109.827 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.471 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 16.2 m-70 -123.79 104.92 9.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.857 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.6 m170 -85.99 8.24 21.3 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.428 -0.795 . . . . 0.0 109.758 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -98.54 -11.66 21.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.129 -0.982 . . . . 0.0 109.623 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.562 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -105.84 -11.77 16.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.209 -0.932 . . . . 0.0 110.081 -179.793 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.456 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -58.46 -60.26 4.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.938 -1.101 . . . . 0.0 109.26 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.81 -28.24 63.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.088 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.507 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 28.5 t -68.85 -47.77 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.376 -0.828 . . . . 0.0 109.088 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.509 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -71.19 -37.08 72.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.557 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.77 34.23 1.57 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.519 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 13.4 m-85 -125.92 168.61 13.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -1.162 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.0 t -105.92 -13.68 15.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.406 -0.809 . . . . 0.0 109.479 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.77 -162.97 28.28 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.49 -19.55 35.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.297 -1.119 . . . . 0.0 109.778 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 14.9 p -87.76 52.15 2.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -0.902 . . . . 0.0 109.739 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -127.12 133.77 25.42 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.923 . . . . 0.0 109.581 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -67.23 -29.01 39.69 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.908 1.478 . . . . 0.0 110.063 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.519 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.27 -38.28 40.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.515 HG22 ' CD2' ' A' ' 47' ' ' PHE . 94.4 t -51.2 -46.78 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -1.095 . . . . 0.0 109.421 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.456 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -64.2 -17.12 63.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.902 . . . . 0.0 109.494 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.83 -47.38 15.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.453 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 9.6 mt -73.23 -60.69 2.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.178 -0.951 . . . . 0.0 109.476 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.507 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -47.65 -31.19 7.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.45 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -78.38 -60.54 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -1.148 . . . . 0.0 109.438 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -52.43 -39.2 60.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.286 -0.884 . . . . 0.0 109.493 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.453 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 41.3 t -64.63 -48.32 85.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -47.78 -44.74 28.69 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.184 -0.947 . . . . 0.0 109.636 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 67' ' ' GLY . . . -49.2 -52.74 24.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.409 -0.807 . . . . 0.0 109.778 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.1 tp60 -49.82 -44.02 49.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.095 -1.003 . . . . 0.0 109.268 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.47 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 82.7 mt -63.2 -28.04 44.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.336 -0.852 . . . . 0.0 108.851 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.532 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -71.41 -55.22 7.84 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.44 -24.48 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.238 -1.154 . . . . 0.0 109.116 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.09 -18.09 33.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.413 -0.805 . . . . 0.0 109.57 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.47 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 41.0 t -75.07 -16.04 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.511 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 74.6 m -88.45 11.06 18.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.129 -0.982 . . . . 0.0 110.143 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.8 m-70 -161.73 61.37 0.25 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.048 -1.033 . . . . 0.0 109.926 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.468 ' CD2' ' HA ' ' A' ' 70' ' ' VAL . 3.1 mm? . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.483 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.413 ' HG2' ' O ' ' A' ' 72' ' ' HIS . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.405 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 71.6 t -84.1 -17.01 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.39 -0.819 . . . . 0.0 109.405 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -39.39 70.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -69.91 -48.17 59.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.243 -0.911 . . . . 0.0 109.331 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.437 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.7 OUTLIER -58.68 -46.78 86.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 109.214 179.7 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.463 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.9 mttt -52.92 -34.78 56.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.246 -0.909 . . . . 0.0 109.148 179.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -69.3 -42.98 74.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.339 -0.851 . . . . 0.0 109.391 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.2 t -50.97 -40.15 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.302 -0.874 . . . . 0.0 109.338 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.459 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -58.05 -50.48 65.73 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.42 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 97.6 t -54.62 -35.88 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -1.034 . . . . 0.0 108.95 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 1.5 mpt_? -66.08 -45.02 82.75 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.359 -0.838 . . . . 0.0 108.97 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.447 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 16.5 m80 -64.71 -12.2 44.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.441 -0.787 . . . . 0.0 109.766 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.42 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -74.27 -8.48 56.37 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.032 -1.042 . . . . 0.0 110.426 -179.657 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -152.04 57.75 0.43 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.512 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.5 m-30 -88.35 -169.74 2.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.265 -1.138 . . . . 0.0 109.728 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.52 -8.77 87.12 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.507 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.0 p-10 -112.22 -23.75 10.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.862 -1.375 . . . . 0.0 109.975 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 51.33 28.43 4.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.134 -0.978 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 38.4 m170 -129.32 38.42 3.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.512 HD11 ' CD2' ' A' ' 93' ' ' TYR . 51.2 mt -87.72 154.6 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.065 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.409 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.86 149.83 27.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.129 -0.982 . . . . 0.0 110.159 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -80.17 -8.83 59.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.358 -0.839 . . . . 0.0 109.588 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 105' ' ' PRO . 14.5 pt-20 -68.62 -30.24 68.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.1 -1.0 . . . . 0.0 109.336 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.562 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 70.4 m-85 -82.47 -21.24 35.65 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.312 -0.867 . . . . 0.0 109.737 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.439 ' O ' ' N ' ' A' ' 107' ' ' GLY . 5.2 m-85 -57.66 -68.83 0.2 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.389 -0.819 . . . . 0.0 110.465 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.505 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 8.4 mt-10 -43.62 -60.21 2.78 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.45 -0.781 . . . . 0.0 111.022 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.505 ' CD ' ' CB ' ' A' ' 104' ' ' GLU . 9.3 Cg_endo -56.5 -50.59 11.41 Favored 'Trans proline' 0 C--N 1.304 -1.802 0 O-C-N 123.756 1.398 . . . . 0.0 110.052 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.514 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.3 tm? -65.52 -19.67 66.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.158 -0.963 . . . . 0.0 109.333 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -79.99 -44.9 8.68 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.52 -47.07 77.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.217 -1.167 . . . . 0.0 109.337 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 48.7 m -63.66 -16.77 61.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.32 -0.862 . . . . 0.0 109.508 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.511 HD21 ' CE2' ' A' ' 134' ' ' TYR . 6.3 tt -75.41 -40.24 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.673 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.437 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.8 mt -63.12 -30.06 71.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.937 . . . . 0.0 109.718 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 1.4 t -73.2 -20.9 60.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 109.639 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.416 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -88.29 -31.25 19.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.582 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.48 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.0 OUTLIER -55.6 -35.75 66.17 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.853 . . . . 0.0 109.992 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 20.8 pt-20 -57.75 -22.54 47.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.117 -0.989 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.416 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -56.98 -40.56 76.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.211 -0.931 . . . . 0.0 109.355 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.449 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 11.2 ttt85 -77.59 -62.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.543 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.444 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 8.7 pt -91.69 43.26 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.459 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -52.99 124.46 27.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 101.06 -37.06 3.78 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.401 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 26.4 mmtt -89.12 -24.52 22.22 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 109.293 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.444 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -72.12 86.9 1.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.323 -0.861 . . . . 0.0 109.586 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.444 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 12.1 p-10 -83.66 -171.98 3.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.348 -0.845 . . . . 0.0 109.859 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -64.15 -42.58 96.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.299 -0.876 . . . . 0.0 109.778 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.444 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -61.09 -29.96 70.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.128 -0.983 . . . . 0.0 109.334 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.93 -50.35 42.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.527 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.463 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.5 ptpt -71.79 -28.37 63.57 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.463 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.9 t0 -76.51 -49.28 16.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.267 -0.896 . . . . 0.0 109.332 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.443 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -56.53 -45.25 81.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.391 -0.818 . . . . 0.0 109.261 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.517 ' CD1' HG11 ' A' ' 10' ' ' VAL . 5.4 m0 -73.54 -32.07 64.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.36 -0.838 . . . . 0.0 109.134 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.414 ' CB ' ' O ' ' A' ' 127' ' ' LYS . . . -65.03 -24.69 67.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.291 -0.88 . . . . 0.0 109.185 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.23 -26.97 16.41 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.386 -0.821 . . . . 0.0 109.265 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.68 -44.46 17.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.325 -0.859 . . . . 0.0 109.577 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.511 ' CE2' HD21 ' A' ' 110' ' ' LEU . 2.8 m-85 -57.45 -27.61 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.943 . . . . 0.0 109.493 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.45 -46.32 89.07 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.355 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -74.58 -28.28 60.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.33 -0.857 . . . . 0.0 109.587 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 81.4 mt -68.62 -60.24 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.453 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.2 p -67.52 -48.76 66.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.382 -0.824 . . . . 0.0 109.774 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.64 -29.85 26.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.85 -17.55 55.45 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.157 -1.202 . . . . 0.0 109.825 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.437 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 9.3 tt -89.57 -23.44 21.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 109.82 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.461 HD12 HG22 ' A' ' 142' ' ' ILE . 44.0 mm -70.7 -16.71 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.219 -0.925 . . . . 0.0 109.82 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.463 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.5 OUTLIER -61.39 -68.01 0.35 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -0.966 . . . . 0.0 109.175 179.808 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -66.04 -19.37 67.84 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.459 ' N ' ' HA3' ' A' ' 87' ' ' GLY . 24.6 tp . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.316 -1.108 . . . . 0.0 109.597 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 121.153 0.501 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -70.82 -40.96 72.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.06 -1.025 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -51.04 -52.73 40.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.113 -0.992 . . . . 0.0 109.297 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 60.1 mm-40 -49.72 -41.73 44.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.926 . . . . 0.0 109.268 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.402 HG13 ' HB2' ' A' ' 129' ' ' ALA . 23.7 t -71.25 -29.91 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -0.883 . . . . 0.0 108.88 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.503 HG11 ' CD1' ' A' ' 130' ' ' TRP . 41.5 t -78.59 -43.73 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.494 -0.754 . . . . 0.0 109.051 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.71 -13.19 60.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.443 -0.786 . . . . 0.0 109.78 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.5 m -92.13 -27.65 17.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 110.094 -179.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -87.73 -14.53 39.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.166 -0.959 . . . . 0.0 109.843 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -86.2 -18.4 32.27 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -0.95 . . . . 0.0 109.781 -179.802 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -80.28 1.97 26.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.142 -0.974 . . . . 0.0 109.784 179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -114.22 -53.95 2.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.103 -0.998 . . . . 0.0 109.333 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.462 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 54.7 mt -63.94 -35.19 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.468 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.4 38.27 2.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.912 . . . . 0.0 109.791 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.83 -88.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.1 p -109.41 17.38 21.51 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.305 -1.115 . . . . 0.0 109.683 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.438 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 2.9 p-10 -125.88 -3.93 7.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.453 ' O ' ' ND2' ' A' ' 22' ' ' ASN . 6.4 t30 57.15 19.25 4.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.293 -0.88 . . . . 0.0 109.452 -179.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.48 27.22 30.63 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.439 ' O ' ' HD2' ' A' ' 28' ' ' LYS . . . -52.56 -38.26 59.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.348 -1.089 . . . . 0.0 109.698 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.405 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.44 18.97 38.67 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.462 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 25.5 t -117.3 -14.22 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.136 -1.214 . . . . 0.0 109.46 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.45 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -110.03 -29.46 3.77 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.015 -1.634 . . . . 0.0 109.015 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.467 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -77.8 -28.47 50.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.187 -1.184 . . . . 0.0 109.458 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.401 ' OE1' ' O ' ' A' ' 25' ' ' GLY . 1.6 pm0 -95.38 -16.0 22.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.633 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 37.0 t -87.98 -62.49 1.48 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -0.925 . . . . 0.0 109.66 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.447 ' O ' ' CD1' ' A' ' 35' ' ' LEU . 10.8 m-85 -50.27 -30.96 12.94 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.143 -0.973 . . . . 0.0 109.694 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.419 ' HA ' HD11 ' A' ' 35' ' ' LEU . 52.6 m -61.64 -30.97 71.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.4 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 6.7 mmtt -74.57 -47.44 32.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.283 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.508 ' CG ' HD22 ' A' ' 106' ' ' LEU . 5.1 t80 -57.85 -46.16 85.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.419 -0.801 . . . . 0.0 109.535 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.458 ' CD1' HG21 ' A' ' 55' ' ' VAL . 6.8 mt -60.3 -46.89 88.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -0.882 . . . . 0.0 109.775 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 54.3 p -65.14 -49.9 68.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.284 -0.885 . . . . 0.0 109.769 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -70.45 -25.9 63.41 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.192 -0.943 . . . . 0.0 109.765 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.447 ' N ' ' O ' ' A' ' 34' ' ' PHE . 21.3 m-70 -126.14 117.76 23.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.204 -0.935 . . . . 0.0 109.866 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.2 m170 -94.75 -15.33 23.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.455 -0.778 . . . . 0.0 109.56 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -71.59 -7.62 48.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.17 -0.956 . . . . 0.0 109.882 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.519 ' HE2' ' CD1' ' A' ' 102' ' ' TYR . 4.9 mmt -118.77 -12.08 9.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.012 -1.055 . . . . 0.0 110.115 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.457 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -56.53 -53.53 56.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.943 -1.098 . . . . 0.0 109.254 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -64.25 -27.9 69.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.102 179.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.516 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 13.0 t -67.95 -53.38 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.417 -0.802 . . . . 0.0 109.171 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.513 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 38.9 m-85 -61.93 -19.02 62.28 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 29.66 6.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CD2' HG22 ' A' ' 55' ' ' VAL . 14.1 m-85 -126.37 168.84 13.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -1.138 . . . . 0.0 109.941 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.5 t -114.67 20.11 15.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.452 -0.78 . . . . 0.0 109.166 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.78 -163.74 28.24 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.93 39.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -1.17 . . . . 0.0 109.645 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 16.1 m -140.53 22.94 2.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 109.675 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -110.43 145.67 32.71 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.24 -0.913 . . . . 0.0 109.692 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -77.57 56.15 5.46 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.972 1.511 . . . . 0.0 110.169 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.523 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -135.06 -38.4 0.19 Allowed Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.524 HG22 ' CD2' ' A' ' 47' ' ' PHE . 47.5 t -50.0 -26.65 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.242 -1.152 . . . . 0.0 109.596 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.467 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -81.1 -7.81 59.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.292 -0.88 . . . . 0.0 110.002 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -91.73 -31.37 15.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.067 -1.021 . . . . 0.0 109.747 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.449 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 10.1 mt -83.04 -64.09 1.24 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.115 -0.991 . . . . 0.0 109.697 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.45 ' HA3' ' CA ' ' A' ' 27' ' ' GLY . . . -51.39 -44.81 53.16 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.452 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -53.49 -39.15 64.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.225 -1.162 . . . . 0.0 109.611 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -89.63 -32.31 17.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.252 -0.905 . . . . 0.0 109.633 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.449 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 57.7 t -65.27 -47.95 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.566 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.431 HD13 ' CG1' ' A' ' 26' ' ' VAL . 2.9 mm? -47.3 -45.27 24.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.198 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.44 ' HA ' ' OD1' ' A' ' 22' ' ' ASN . . . -53.65 -39.95 65.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.175 -0.953 . . . . 0.0 110.077 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.463 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 6.8 tp-100 -59.78 -39.54 85.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.964 -1.085 . . . . 0.0 108.903 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.484 HD12 HG22 ' A' ' 66' ' ' ILE . 26.7 mm -62.44 -42.14 94.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.405 -0.809 . . . . 0.0 108.9 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.525 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.6 -51.32 55.06 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.562 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.6 t -58.47 -26.8 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.318 -1.107 . . . . 0.0 109.411 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.83 -28.19 26.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.32 -0.863 . . . . 0.0 109.704 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.458 ' CG1' HG13 ' A' ' 10' ' ' VAL . 54.1 t -75.83 -23.33 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.2 p -63.57 -13.48 42.05 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 110.034 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.442 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 15.4 m-70 -124.01 -77.53 0.59 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.106 -0.996 . . . . 0.0 109.957 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.442 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 53.5 mt . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.672 -0.643 . . . . 0.0 109.734 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 4.7 ttp . . . . . 0 N--CA 1.495 1.783 0 CA-C-O 121.281 0.562 . . . . 0.0 109.694 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 42.8 t -65.39 -15.41 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.218 -0.926 . . . . 0.0 109.61 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.06 -52.22 20.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.973 . . . . 0.0 109.377 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -71.25 -41.05 70.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.461 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 2.1 mtp -58.8 -48.58 80.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.305 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 11.1 mttt -50.8 -38.57 49.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.151 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.413 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -66.83 -44.55 80.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.401 -0.812 . . . . 0.0 109.408 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.42 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 14.4 t -58.23 -37.94 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.157 -0.964 . . . . 0.0 109.264 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.425 ' CA ' ' HG ' ' A' ' 141' ' ' LEU . . . -63.34 -49.08 73.36 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.403 HG22 ' HA3' ' A' ' 144' ' ' GLY . 57.4 t -51.44 -38.45 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -1.059 . . . . 0.0 109.453 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.53 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 2.8 mpt_? -59.22 -25.62 64.15 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -0.944 . . . . 0.0 109.336 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.516 ' CD2' HD12 ' A' ' 98' ' ' ILE . 4.5 m80 -87.38 16.32 5.49 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.397 -0.814 . . . . 0.0 109.643 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.424 ' O ' ' HG3' ' A' ' 96' ' ' LYS . 23.3 ttmt -75.27 -67.48 0.65 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.941 -1.1 . . . . 0.0 110.167 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.406 ' HA2' ' HG3' ' A' ' 96' ' ' LYS . . . -145.7 56.07 0.53 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.53 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -82.46 -100.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 110.342 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -96.48 -57.28 1.13 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.516 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -84.37 -28.45 26.98 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.415 -1.05 . . . . 0.0 108.594 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.503 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 14.6 tttm 64.41 -48.99 0.3 Allowed 'General case' 0 N--CA 1.505 2.283 0 O-C-N 121.75 -0.594 . . . . 0.0 112.271 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.458 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 64.2 m170 -50.0 -97.21 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.628 -1.295 . . . . 0.0 111.234 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.516 HD12 ' CD2' ' A' ' 90' ' ' HIS . 14.9 mt 65.4 154.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 121.035 -1.04 . . . . 0.0 109.572 -178.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.415 ' HE3' ' HB3' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -158.32 150.75 22.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.268 -0.895 . . . . 0.0 109.828 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.414 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -77.82 -10.21 59.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.569 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.0 mt-10 -67.68 -35.77 79.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 109.597 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.519 ' CD1' ' HE2' ' A' ' 41' ' ' MET . 76.5 m-85 -81.15 -16.48 52.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.344 -0.847 . . . . 0.0 110.146 -179.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.414 ' HB2' ' O ' ' A' ' 100' ' ' ALA . 4.2 m-85 -58.32 -57.49 12.66 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.158 -0.963 . . . . 0.0 109.973 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -53.75 -58.05 14.84 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 109.755 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 39.7 Cg_exo -50.81 -62.17 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.628 1.33 . . . . 0.0 109.76 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.508 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -53.77 -24.75 16.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -0.895 . . . . 0.0 109.241 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.518 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -74.68 -51.49 8.04 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.096 -1.601 . . . . 0.0 109.096 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -54.22 -55.43 28.17 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -1.169 . . . . 0.0 109.456 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 54.9 m -53.33 -22.76 7.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.349 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.4 tt -65.88 -48.51 71.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.314 -0.866 . . . . 0.0 109.632 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 11.6 mt -57.54 -36.56 71.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.184 -0.948 . . . . 0.0 109.544 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -67.44 -33.81 75.9 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.595 179.966 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -81.69 -25.73 35.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -0.924 . . . . 0.0 109.663 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.534 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.9 mmt -58.45 -47.73 83.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.918 . . . . 0.0 110.205 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.449 ' O ' ' N ' ' A' ' 119' ' ' GLY . 6.4 pt-20 -50.05 -23.54 2.14 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.068 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.411 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 19.1 m170 -50.2 -40.73 48.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.993 -1.067 . . . . 0.0 109.783 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.17 -56.14 3.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.7 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.459 HG12 ' CG1' ' A' ' 17' ' ' ILE . 5.7 pt -104.34 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.143 -0.973 . . . . 0.0 109.633 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -63.15 -20.11 62.41 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.51 -29.23 10.28 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.412 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.2 mppt? -94.26 -23.44 17.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -1.189 . . . . 0.0 109.803 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.415 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 3.8 tpt -63.89 86.35 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.18 -0.95 . . . . 0.0 109.616 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.403 ' OD1' ' HB1' ' A' ' 126' ' ' ALA . 12.2 p-10 -87.14 -168.73 2.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -70.29 -39.98 74.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -0.932 . . . . 0.0 109.628 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -65.05 -31.11 72.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.095 -1.003 . . . . 0.0 108.98 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.403 ' HB1' ' OD1' ' A' ' 123' ' ' ASN . . . -66.27 -50.8 62.48 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.107 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.467 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.5 ptpt -70.53 -27.67 64.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.913 . . . . 0.0 109.124 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.467 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.1 t0 -79.33 -32.57 43.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.374 -0.829 . . . . 0.0 108.953 179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.409 ' HB1' HG22 ' A' ' 10' ' ' VAL . . . -72.42 -47.69 47.15 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.433 -0.792 . . . . 0.0 109.126 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.534 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 12.5 m0 -71.54 -21.54 61.88 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.269 -0.895 . . . . 0.0 108.976 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.415 ' HB2' ' O ' ' A' ' 128' ' ' ASP . . . -53.24 -34.3 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -0.889 . . . . 0.0 109.038 179.075 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -97.22 -15.4 20.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.417 -0.802 . . . . 0.0 109.494 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.418 ' HB2' HG21 ' A' ' 10' ' ' VAL . . . -81.51 -67.79 0.75 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.252 -0.905 . . . . 0.0 109.854 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.518 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.4 OUTLIER -55.31 -21.25 14.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.032 -1.043 . . . . 0.0 109.268 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -80.92 -49.56 10.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.299 -0.876 . . . . 0.0 108.944 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -73.21 -26.45 61.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.399 -0.813 . . . . 0.0 109.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.416 HD12 ' HA ' ' A' ' 134' ' ' TYR . 43.9 mt -67.88 -61.21 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 109.183 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.89 -14.2 43.51 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.346 -0.846 . . . . 0.0 109.907 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.43 -36.01 24.69 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.67 -27.9 66.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -1.184 . . . . 0.0 109.916 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.461 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 7.8 tt -74.39 -5.61 43.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.194 -0.941 . . . . 0.0 110.138 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 49.8 mm -90.66 18.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.98 -1.075 . . . . 0.0 109.843 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.8 m -95.25 -63.41 1.17 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.947 . . . . 0.0 109.593 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.403 ' HA3' HG22 ' A' ' 88' ' ' VAL . . . -68.12 -22.52 74.35 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.455 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.354 -1.086 . . . . 0.0 109.535 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.296 0.569 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -65.13 -51.39 61.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.366 -0.834 . . . . 0.0 109.552 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -53.43 -32.3 49.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.08 -1.013 . . . . 0.0 108.921 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 47.8 tp60 -71.48 -44.07 65.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.166 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.405 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 30.0 t -65.12 -30.65 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.291 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.436 ' HA ' ' CD1' ' A' ' 130' ' ' TRP . 84.8 t -70.04 -41.75 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.369 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.8 -14.67 60.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -0.869 . . . . 0.0 109.764 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.1 -33.25 19.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.1 p -85.55 -15.73 41.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.739 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.549 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -86.99 -18.98 29.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.811 -179.893 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.8 mtpp -80.99 0.32 36.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.194 -0.941 . . . . 0.0 109.898 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -115.83 -53.65 2.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.081 -1.012 . . . . 0.0 109.439 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.447 HD11 ' CH2' ' A' ' 130' ' ' TRP . 64.7 mt -67.3 -32.78 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.549 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -103.07 31.92 4.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.872 . . . . 0.0 109.647 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.7 -86.39 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.0 p -95.25 -35.71 11.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.752 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.41 ' O ' ' HB2' ' A' ' 24' ' ' ALA . 2.9 p30 -71.24 -17.12 62.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.26 -0.9 . . . . 0.0 109.81 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 58.31 24.8 11.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.133 -0.979 . . . . 0.0 109.455 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.78 32.95 7.69 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.419 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . . . -81.11 -66.34 0.9 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -1.108 . . . . 0.0 109.816 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 29' ' ' GLU . . . -52.74 -22.98 13.0 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.459 HG11 ' CD1' ' A' ' 63' ' ' LEU . 38.5 t -74.82 -32.21 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.846 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.01 -55.48 2.93 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.416 ' HB3' ' HA ' ' A' ' 56' ' ' ALA . 6.6 ptpp? -57.31 -19.63 23.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.187 -1.184 . . . . 0.0 110.053 -179.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.468 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -98.35 -30.42 12.59 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.972 -1.08 . . . . 0.0 109.579 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.3 t -82.32 -55.48 4.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.34 -0.85 . . . . 0.0 109.538 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 12.2 m-85 -54.55 -37.44 65.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.357 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.435 ' CG2' HG12 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.56 -54.72 37.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.213 -0.929 . . . . 0.0 109.232 179.624 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -57.11 -47.82 80.15 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.212 -0.93 . . . . 0.0 109.335 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.511 ' CG ' HD22 ' A' ' 106' ' ' LEU . 5.4 t80 -55.07 -52.24 63.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.3 -0.875 . . . . 0.0 109.28 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.461 ' CD2' ' HA ' ' A' ' 42' ' ' ALA . 6.8 mt -59.3 -41.14 88.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.255 -0.903 . . . . 0.0 109.664 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.425 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 20.6 t -63.1 -61.19 2.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.657 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.475 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -63.37 -26.72 68.88 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.236 -0.915 . . . . 0.0 109.684 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.499 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 12.1 m-70 -118.9 107.53 13.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.691 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -88.34 -24.29 23.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 109.362 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 40' ' ' ASP . 25.5 p-10 -65.39 -19.16 65.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.408 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.544 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -95.21 -17.6 21.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.292 -0.88 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.461 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -57.43 -62.78 1.54 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.975 . . . . 0.0 109.38 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.56 -26.38 43.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.51 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 21.1 t -73.63 -48.76 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 109.239 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.472 ' CE2' ' HB3' ' A' ' 41' ' ' MET . 27.1 m-85 -68.26 -26.9 65.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.22 -0.925 . . . . 0.0 109.549 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 108.66 27.49 4.92 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.532 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.3 m-85 -123.74 167.29 14.22 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.176 . . . . 0.0 109.868 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 t -102.81 -20.93 14.13 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.421 -0.799 . . . . 0.0 109.203 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.9 -163.91 23.72 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.425 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -94.73 34.11 1.38 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.298 -1.119 . . . . 0.0 109.698 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 24.4 p -133.0 21.23 4.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.68 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -106.64 139.48 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.607 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.6 -16.96 57.94 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.954 1.502 . . . . 0.0 110.105 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.532 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -56.27 -39.8 83.05 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.498 HG22 ' CD2' ' A' ' 47' ' ' PHE . 84.1 t -51.04 -37.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -1.098 . . . . 0.0 109.38 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.456 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -73.74 -6.6 47.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.305 -0.872 . . . . 0.0 109.721 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -91.62 -27.16 18.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.011 . . . . 0.0 109.57 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.41 HD23 ' HA ' ' A' ' 58' ' ' LEU . 10.0 mt -91.43 -64.0 1.18 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.175 -0.953 . . . . 0.0 109.627 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.515 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.18 -41.94 39.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -62.84 -23.85 67.5 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -1.149 . . . . 0.0 109.691 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.73 -28.37 12.51 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.679 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 59.6 t -67.22 -56.49 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.287 -0.883 . . . . 0.0 109.848 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.459 ' CD1' HG11 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -48.2 -38.4 18.19 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.961 . . . . 0.0 109.616 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.21 53.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.449 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.454 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 5.7 tp-100 -62.7 -36.17 82.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.232 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.445 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 41.6 mt -66.92 -37.07 78.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.355 -0.841 . . . . 0.0 109.186 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.539 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.81 -48.27 56.18 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 179.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.6 t -61.42 -27.99 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.357 -1.084 . . . . 0.0 109.43 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.86 -32.98 24.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.319 -0.863 . . . . 0.0 109.503 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.445 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 56.5 t -66.58 -22.67 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 41.3 m -67.31 -12.36 59.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.948 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.431 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 14.0 m-70 -122.85 -83.92 0.66 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.123 -0.986 . . . . 0.0 109.918 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.433 ' CD1' ' HA ' ' A' ' 70' ' ' VAL . 35.1 mt . . . . . 0 N--CA 1.494 1.773 0 O-C-N 121.65 -0.657 . . . . 0.0 109.676 -179.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 5.5 ttp . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.293 0.568 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.453 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.2 t -72.14 -29.41 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.01 -41.91 97.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.253 -0.904 . . . . 0.0 109.435 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -71.98 -50.8 25.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.513 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.437 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.2 OUTLIER -62.47 -38.66 90.69 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 109.149 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.453 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -60.06 -38.04 81.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.265 -0.897 . . . . 0.0 109.099 179.44 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -67.92 -41.34 82.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.258 -0.901 . . . . 0.0 109.21 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.456 HG13 ' CD1' ' A' ' 141' ' ' LEU . 30.8 t -55.48 -50.52 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.328 -0.857 . . . . 0.0 109.119 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.412 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -56.55 -53.58 42.47 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.411 HG22 ' HA3' ' A' ' 144' ' ' GLY . 79.1 t -53.85 -34.24 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.438 -1.037 . . . . 0.0 108.947 179.355 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mmm180 -72.13 -48.72 41.54 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.413 -0.804 . . . . 0.0 109.051 179.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.503 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 14.5 m80 -56.48 -27.38 56.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.04 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.404 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -66.46 -12.07 55.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 110.289 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -136.08 49.85 0.87 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.509 ' CD2' HD11 ' A' ' 98' ' ' ILE . 4.3 m-30 -89.61 -168.71 2.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -1.174 . . . . 0.0 109.795 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -78.6 -52.19 5.2 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.51 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 17.8 p-10 -62.3 -29.41 70.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -1.186 . . . . 0.0 109.657 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.435 ' O ' ' CD2' ' A' ' 97' ' ' HIS . 12.0 mtmm 53.54 29.36 8.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.671 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.435 ' CD2' ' O ' ' A' ' 96' ' ' LYS . 39.0 m170 -136.29 45.31 2.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.284 -0.885 . . . . 0.0 109.57 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.509 HD11 ' CD2' ' A' ' 93' ' ' TYR . 62.2 mt -87.55 154.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.298 -0.876 . . . . 0.0 109.727 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.405 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -144.12 148.35 34.96 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.282 -0.886 . . . . 0.0 110.104 -179.84 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.68 -3.56 57.86 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.698 -0.627 . . . . 0.0 109.609 179.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 8.8 pt-20 -74.95 -29.16 60.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.074 -1.016 . . . . 0.0 109.477 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.544 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 59.8 m-85 -81.78 -22.1 37.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.726 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -54.03 -63.46 1.14 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.221 -0.924 . . . . 0.0 110.263 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.5 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -48.98 -58.41 8.69 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.132 -0.98 . . . . 0.0 110.13 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.5 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.6 Cg_exo -49.85 -62.53 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.598 1.315 . . . . 0.0 110.026 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.511 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -54.59 -22.02 12.12 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.255 -0.903 . . . . 0.0 109.547 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.66 -50.36 5.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.44 95.19 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.133 -1.216 . . . . 0.0 109.557 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.4 t -66.62 -21.36 66.12 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.461 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 2.7 tt -71.96 -41.97 67.12 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 109.626 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.407 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.3 mt -58.97 -30.25 67.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 0.0 109.573 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 3.6 m -68.64 -33.99 74.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.713 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.501 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -81.47 -33.46 31.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.259 -0.9 . . . . 0.0 109.782 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.494 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -45.89 -47.55 16.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.313 -0.867 . . . . 0.0 110.341 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.457 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 18.8 pt-20 -51.94 -22.48 3.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 0.0 110.015 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 24.0 m170 -53.7 -30.7 44.98 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.012 -1.055 . . . . 0.0 109.81 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.407 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -95.42 -68.9 0.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.133 -0.979 . . . . 0.0 109.93 -179.775 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.474 HG13 ' N ' ' A' ' 119' ' ' GLY . 33.2 pt -75.11 -36.85 39.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.025 -1.047 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.474 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 39.52 -96.84 0.01 OUTLIER Glycine 0 N--CA 1.498 2.828 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.54 -42.45 10.09 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.432 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 3.3 mtpt -72.42 -21.9 61.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.112 -1.228 . . . . 0.0 109.771 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.429 ' N ' ' O ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -66.23 90.53 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.157 -0.964 . . . . 0.0 109.57 179.829 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.436 ' OD1' ' CB ' ' A' ' 126' ' ' ALA . 17.8 p-10 -84.94 -179.88 7.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.566 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -64.01 -40.25 95.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.405 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -63.98 -30.51 71.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.191 -0.943 . . . . 0.0 109.196 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.436 ' CB ' ' OD1' ' A' ' 123' ' ' ASN . . . -67.03 -50.5 61.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.406 -0.809 . . . . 0.0 109.322 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.411 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 15.0 ptpt -71.88 -30.02 64.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.289 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.411 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 59.5 t0 -77.13 -44.02 31.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.2 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.405 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -63.82 -41.62 97.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.48 -0.763 . . . . 0.0 109.065 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.494 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 3.5 m0 -75.25 -25.01 57.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.32 -0.863 . . . . 0.0 109.012 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -68.43 -37.2 80.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -0.886 . . . . 0.0 108.987 179.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -78.83 -24.58 44.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.324 -0.86 . . . . 0.0 109.297 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -83.27 -50.41 8.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.359 -0.838 . . . . 0.0 109.543 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.461 ' OH ' ' CD2' ' A' ' 110' ' ' LEU . 3.7 m-85 -50.35 -31.68 15.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.18 -0.95 . . . . 0.0 109.306 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.94 -35.68 57.11 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.341 -0.849 . . . . 0.0 108.986 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.83 -36.12 37.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.385 -0.822 . . . . 0.0 109.287 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 58.6 mt -66.58 -58.96 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.88 . . . . 0.0 109.087 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.408 ' O ' HG13 ' A' ' 142' ' ' ILE . 2.0 p -67.3 -19.81 65.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.386 -0.821 . . . . 0.0 109.644 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -72.1 -42.65 50.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.86 -23.03 65.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -1.146 . . . . 0.0 109.673 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.456 ' CD1' HG13 ' A' ' 86' ' ' VAL . 7.6 tt -80.34 -34.07 36.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.682 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.408 HG13 ' O ' ' A' ' 138' ' ' SER . 43.4 mt -73.79 -3.45 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 110.145 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.6 m -68.77 -59.43 3.1 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.011 -1.056 . . . . 0.0 109.621 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.411 ' HA3' HG22 ' A' ' 88' ' ' VAL . . . -88.38 4.4 85.28 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.417 HD11 ' CD2' ' A' ' 141' ' ' LEU . 4.4 tt . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.056 -1.261 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.326 0.584 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 83.8 mt-30 -81.86 -52.08 7.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.426 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -49.61 -30.96 9.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.223 -0.923 . . . . 0.0 109.521 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.426 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 6.3 mm-40 -72.1 -42.91 65.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.266 -0.896 . . . . 0.0 109.278 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.406 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 42.9 t -63.25 -32.15 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.274 -0.891 . . . . 0.0 109.243 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.433 HG21 ' CB ' ' A' ' 133' ' ' ALA . 70.7 t -66.12 -45.99 88.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.368 -0.833 . . . . 0.0 109.344 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.71 -10.56 59.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 109.821 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.3 p -92.88 -24.29 18.51 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.138 -0.976 . . . . 0.0 109.979 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.504 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 18.3 p -97.55 -8.98 27.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.092 -1.005 . . . . 0.0 109.959 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.6 -20.15 22.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.018 -1.051 . . . . 0.0 109.569 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -80.8 3.22 23.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.97 -56.49 2.1 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.066 -1.022 . . . . 0.0 109.512 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.469 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 51.2 mt -62.35 -30.26 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.51 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -107.42 32.41 4.69 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -0.91 . . . . 0.0 109.618 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -69.41 1.21 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 84.5 p -109.99 -29.96 8.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.281 -1.129 . . . . 0.0 109.663 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.454 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 6.8 p-10 -78.78 -20.2 50.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.896 . . . . 0.0 109.67 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.459 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 24.8 t30 57.61 28.41 15.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.185 -0.947 . . . . 0.0 109.516 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.408 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 93.51 25.39 18.59 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.454 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -73.2 -47.08 46.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.252 -1.146 . . . . 0.0 109.592 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.469 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.28 17.86 45.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.801 -1.319 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.447 ' CG1' HD13 ' A' ' 63' ' ' LEU . 21.2 t -109.48 -25.81 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.25 179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.429 ' CA ' HD23 ' A' ' 63' ' ' LEU . . . -94.43 -43.19 3.76 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.469 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.3 OUTLIER -62.19 -31.49 72.01 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.096 -1.238 . . . . 0.0 109.577 -179.837 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.448 ' OE2' ' CB ' ' A' ' 113' ' ' ALA . 14.5 pt-20 -89.38 -15.99 32.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.929 . . . . 0.0 109.618 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 15.8 t -90.15 -63.14 1.32 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.476 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 16.8 m-85 -47.54 -33.95 7.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.423 ' HA ' HG12 ' A' ' 55' ' ' VAL . 51.5 m -55.39 -40.75 71.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.172 -0.955 . . . . 0.0 109.421 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.41 -49.41 27.22 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.264 -0.897 . . . . 0.0 109.456 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.514 ' CZ ' ' HB2' ' A' ' 106' ' ' LEU . 3.9 t80 -52.06 -46.51 65.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.339 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 45' ' ' PHE . 17.6 mt -58.07 -47.12 84.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.529 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.4 t -65.35 -55.83 15.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.569 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.421 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -61.54 -24.47 66.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.465 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 17.2 m-70 -124.9 103.88 8.29 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.269 -0.894 . . . . 0.0 109.722 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.5 m170 -86.29 -18.99 30.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.366 -0.834 . . . . 0.0 109.454 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -71.96 -9.66 58.68 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.283 -0.885 . . . . 0.0 109.893 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.514 ' HE1' ' CG ' ' A' ' 102' ' ' TYR . 29.7 mmm -119.38 -15.8 9.05 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 110.079 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.448 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.03 -47.7 44.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.041 . . . . 0.0 109.424 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.25 -31.6 64.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.331 -0.855 . . . . 0.0 109.093 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.51 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 15.9 t -60.51 -37.31 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.408 -0.808 . . . . 0.0 109.141 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.497 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.2 m-85 -76.86 -18.46 58.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.764 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 102.44 23.46 8.93 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.525 ' CD2' HG22 ' A' ' 55' ' ' VAL . 9.8 m-85 -122.49 167.33 13.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -1.137 . . . . 0.0 109.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 12.5 t -112.62 21.3 15.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 109.233 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.95 -172.42 25.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.95 -6.86 51.57 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -1.167 . . . . 0.0 109.976 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 62.2 p -94.3 43.41 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.056 -1.028 . . . . 0.0 109.73 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -123.77 129.18 24.91 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.649 179.933 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -67.97 -28.93 34.98 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.776 1.408 . . . . 0.0 110.022 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.467 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.49 -30.15 33.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 47' ' ' PHE . 95.5 t -50.93 -32.78 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -1.116 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.467 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -80.72 -6.22 58.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.312 -0.867 . . . . 0.0 109.809 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.22 -27.15 20.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.104 -0.998 . . . . 0.0 109.596 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.448 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 10.4 mt -89.78 -65.81 0.98 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.713 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.476 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.94 -42.16 29.61 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.452 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -56.19 -45.36 79.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.166 -1.196 . . . . 0.0 109.361 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 39.6 mttp -80.79 -38.17 28.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.386 -0.821 . . . . 0.0 109.403 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.448 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 42.3 t -59.79 -50.18 81.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 0.0 109.619 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.447 HD13 ' CG1' ' A' ' 26' ' ' VAL . 1.2 mm? -47.12 -46.63 23.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.255 -0.903 . . . . 0.0 109.85 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.94 -51.07 43.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.814 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.7 tp60 -50.28 -53.77 26.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.124 -0.985 . . . . 0.0 109.438 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 45.0 mt -51.27 -39.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 109.27 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.536 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.16 -56.09 24.15 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -57.3 -25.73 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.346 -1.09 . . . . 0.0 109.428 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.466 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -85.38 -30.46 23.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.376 -0.827 . . . . 0.0 109.632 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.465 ' HA ' ' CD2' ' A' ' 73' ' ' LEU . 74.1 t -66.77 -17.11 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -0.936 . . . . 0.0 109.838 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.464 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 40.9 t -90.21 21.09 3.95 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.155 -0.966 . . . . 0.0 109.975 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.464 ' CG ' ' O ' ' A' ' 71' ' ' SER . 10.3 m-70 -157.9 44.12 0.32 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.058 -1.026 . . . . 0.0 109.881 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.465 ' CD2' ' HA ' ' A' ' 70' ' ' VAL . 3.6 mm? . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.95 . . . . 0.0 109.413 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.457 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 21.7 ttp . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.252 0.549 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 27.1 t -70.53 -21.95 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.511 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.18 -42.94 83.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.207 -0.933 . . . . 0.0 109.285 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -78.98 -48.39 14.56 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.269 -0.894 . . . . 0.0 109.322 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.465 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.6 OUTLIER -57.39 -52.03 66.99 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -0.885 . . . . 0.0 109.27 179.677 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.447 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.12 -34.18 29.72 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 108.909 179.398 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.426 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -71.38 -39.69 71.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.362 -0.836 . . . . 0.0 108.951 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.407 ' O ' ' HG2' ' A' ' 89' ' ' ARG . 53.1 t -61.79 -49.94 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.333 -0.854 . . . . 0.0 109.118 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.468 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -55.16 -38.0 65.8 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 95.6 t -60.08 -18.94 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.3 -1.117 . . . . 0.0 109.447 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.524 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.5 OUTLIER -82.63 -19.04 39.06 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.264 -0.898 . . . . 0.0 109.127 179.7 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.523 ' CD2' HD12 ' A' ' 98' ' ' ILE . 4.0 m80 -89.98 19.3 4.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.409 ' O ' ' HD3' ' A' ' 96' ' ' LYS . 2.4 mtmt -80.44 -59.14 2.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.164 -0.96 . . . . 0.0 110.776 -178.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.41 ' HA2' ' HD3' ' A' ' 96' ' ' LYS . . . -148.51 56.77 0.48 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.524 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -82.46 -103.17 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 110.012 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -102.16 -62.68 0.74 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.51 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 2.0 t30 -68.21 -41.27 81.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.46 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 0.3 OUTLIER 65.66 -57.63 0.32 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.124 0.487 . . . . 0.0 109.852 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.444 ' N ' ' HG3' ' A' ' 96' ' ' LYS . 44.1 m170 -62.93 79.53 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.215 -0.928 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.523 HD12 ' CD2' ' A' ' 90' ' ' HIS . 31.8 mt -109.18 158.85 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 109.233 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.5 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.6 mptp? -140.49 139.61 35.15 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.068 -1.02 . . . . 0.0 110.288 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.469 ' CB ' HG22 ' A' ' 142' ' ' ILE . . . -78.55 -2.63 39.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.835 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -76.1 -26.43 56.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.996 -1.065 . . . . 0.0 109.439 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.514 ' CG ' ' HE1' ' A' ' 41' ' ' MET . 83.9 m-85 -85.24 10.13 13.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.384 -0.823 . . . . 0.0 110.076 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -83.35 -61.28 1.89 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 109.671 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.495 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -51.01 -57.57 13.31 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.441 -0.787 . . . . 0.0 110.644 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 5.2 Cg_endo -54.01 -43.76 55.35 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.59 1.311 . . . . 0.0 110.142 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 34' ' ' PHE . 2.5 tm? -64.12 -17.03 63.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.179 -0.951 . . . . 0.0 109.542 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.74 -36.98 12.37 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.29 -59.62 4.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.196 -1.179 . . . . 0.0 109.63 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.7 t -60.29 -18.9 52.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.27 -0.894 . . . . 0.0 109.565 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.519 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 3.2 tt -76.76 -36.57 56.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.253 -0.905 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 11.9 mt -63.85 -28.77 70.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.189 -0.944 . . . . 0.0 109.435 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -34.43 78.2 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.312 -0.868 . . . . 0.0 109.6 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.448 ' CB ' ' OE2' ' A' ' 29' ' ' GLU . . . -75.58 -38.22 59.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.526 ' HG2' ' CZ3' ' A' ' 130' ' ' TRP . 0.0 OUTLIER -47.34 -44.19 23.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.297 -0.877 . . . . 0.0 110.017 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.6 OUTLIER -52.42 -22.08 4.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.307 -0.871 . . . . 0.0 109.962 -179.771 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.411 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 21.1 m170 -56.53 -35.86 68.58 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.146 -0.972 . . . . 0.0 110.247 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.469 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -90.8 -86.86 0.2 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.011 -1.056 . . . . 0.0 110.176 -179.583 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.468 HG13 ' N ' ' A' ' 119' ' ' GLY . 34.9 pt -56.61 -36.31 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.811 -1.18 . . . . 0.0 109.608 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.468 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.77 -98.99 0.01 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.519 -1.033 . . . . 0.0 110.519 179.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.35 -44.77 8.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.441 ' O ' ' N ' ' A' ' 123' ' ' ASN . 44.3 mttt -68.28 -25.77 65.32 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.074 -1.25 . . . . 0.0 110.032 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.457 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.0 OUTLIER -65.52 80.6 0.06 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.982 -1.073 . . . . 0.0 108.845 179.384 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.471 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 12.2 p-10 -82.12 -174.29 5.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.297 -0.877 . . . . 0.0 110.13 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.401 ' O ' ' CG ' ' A' ' 127' ' ' LYS . . . -62.26 -45.31 93.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.376 -0.828 . . . . 0.0 109.897 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.471 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -62.6 -30.93 71.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.146 -0.971 . . . . 0.0 109.575 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.405 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -68.74 -44.76 73.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 109.264 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.475 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 1.6 ptpt -75.19 -29.83 60.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.375 -0.828 . . . . 0.0 109.664 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.475 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 44.2 t0 -79.22 -46.12 18.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.391 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.406 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -57.55 -47.79 81.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.42 -0.8 . . . . 0.0 109.308 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.526 ' CZ3' ' HG2' ' A' ' 114' ' ' MET . 7.3 m0 -71.92 -29.7 64.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.4 -0.812 . . . . 0.0 109.371 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.78 -25.92 68.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.235 -0.916 . . . . 0.0 108.974 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.4 ' O ' ' HB2' ' A' ' 135' ' ' ALA . . . -101.05 -24.95 14.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.421 -0.8 . . . . 0.0 109.169 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.433 ' CB ' HG21 ' A' ' 10' ' ' VAL . . . -67.44 -51.89 46.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.287 -0.883 . . . . 0.0 109.334 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.507 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 21.3 m-85 -52.76 -29.04 25.03 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 109.231 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.4 ' HB2' ' O ' ' A' ' 132' ' ' ALA . . . -60.84 -46.41 90.68 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 108.835 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.82 -44.34 56.04 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 109.169 179.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.466 HG12 ' CB ' ' A' ' 69' ' ' ALA . 18.1 mt -64.3 -57.75 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.256 -0.903 . . . . 0.0 108.93 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.45 ' O ' ' CD1' ' A' ' 142' ' ' ILE . 2.0 p -67.87 -25.74 65.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.217 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.434 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -73.4 -46.59 25.5 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.25 -22.47 66.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -1.122 . . . . 0.0 109.712 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.465 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 8.4 tt -69.22 -33.46 73.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.665 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.469 HG22 ' CB ' ' A' ' 100' ' ' ALA . 3.9 mt -82.9 10.01 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.2 -0.937 . . . . 0.0 110.318 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.447 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 75.7 m -73.97 -22.6 59.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.996 -1.065 . . . . 0.0 108.887 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -127.77 1.42 6.86 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.471 ' CD1' ' C ' ' A' ' 145' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.718 0 O-C-N 120.85 -1.382 . . . . 0.0 110.015 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.41 ' O ' HG22 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.231 0.539 . . . . 0.0 109.819 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -68.62 -58.49 4.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.717 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.519 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -50.15 -24.57 2.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.221 -0.924 . . . . 0.0 109.895 -179.773 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.519 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 50.1 tp60 -80.66 -41.39 23.88 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 109.493 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.472 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 67.1 t -62.09 -24.54 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.47 HG12 ' CD1' ' A' ' 130' ' ' TRP . 89.1 t -66.84 -45.05 88.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.39 -0.819 . . . . 0.0 109.661 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.55 -11.35 60.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.296 -0.877 . . . . 0.0 110.193 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 m -92.7 -22.94 19.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.005 -1.06 . . . . 0.0 109.804 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.438 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 19.3 p -96.71 -10.52 26.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.249 -0.907 . . . . 0.0 110.131 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.571 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.74 -20.83 21.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.078 -1.014 . . . . 0.0 109.892 -179.801 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -79.19 -13.04 59.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.947 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -102.27 -47.87 4.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.089 -1.007 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.45 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 34.8 mt -70.81 -31.55 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -0.924 . . . . 0.0 109.745 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.571 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -106.96 33.88 3.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.915 . . . . 0.0 109.716 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.64 -71.82 0.62 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 76.5 p -110.65 -27.91 8.71 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.657 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -79.01 -20.24 49.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 0.0 109.658 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.432 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 27.0 t30 55.67 24.09 6.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.584 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.17 24.57 12.47 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.408 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -66.1 -55.08 18.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -1.137 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.457 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -86.14 11.43 62.91 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 37.8 t -97.99 -29.65 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.115 -1.227 . . . . 0.0 109.338 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.441 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -89.91 -45.16 4.6 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.457 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 11.3 ptpt -56.19 -31.89 63.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.158 -1.201 . . . . 0.0 109.569 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.45 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 24.3 pt-20 -92.3 -16.67 25.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.929 . . . . 0.0 109.722 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.401 ' SG ' ' CB ' ' A' ' 110' ' ' LEU . 36.6 t -85.27 -67.67 0.78 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.205 -0.934 . . . . 0.0 109.809 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.452 ' CB ' HG11 ' A' ' 55' ' ' VAL . 10.4 m-85 -48.35 -29.13 3.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.247 -0.908 . . . . 0.0 109.935 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -53.06 -59.06 5.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.201 -0.937 . . . . 0.0 109.488 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 3.9 mttp -55.9 -53.15 60.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.261 -0.899 . . . . 0.0 109.717 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CG ' HD22 ' A' ' 106' ' ' LEU . 8.9 t80 -49.34 -53.09 23.95 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.224 -0.922 . . . . 0.0 109.734 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.512 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 20.1 mt -54.23 -46.35 72.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.229 -0.919 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.08 -59.84 3.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.185 -0.947 . . . . 0.0 109.713 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.425 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -58.24 -23.66 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.669 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.425 ' CD2' ' HB3' ' A' ' 37' ' ' ALA . 22.2 m-70 -120.79 95.83 4.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.688 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.5 m170 -82.76 6.03 19.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.244 -0.91 . . . . 0.0 110.02 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -97.48 -20.38 17.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.099 -1.001 . . . . 0.0 109.523 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.509 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 65.4 mmm -104.85 -19.84 13.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -0.896 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.465 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.08 -35.62 16.49 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 109.43 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.4 -27.54 46.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.304 -0.873 . . . . 0.0 109.099 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.527 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 32.3 t -66.71 -60.74 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.483 ' CD2' HD21 ' A' ' 35' ' ' LEU . 67.4 m-85 -51.29 -28.3 11.64 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.291 -0.881 . . . . 0.0 109.504 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.409 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.3 24.85 4.92 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.538 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 8.7 m-85 -121.86 166.24 14.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 110.066 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.8 t -106.0 -19.78 13.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.422 -0.799 . . . . 0.0 108.892 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.65 -162.5 19.64 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.88 15.5 23.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -1.118 . . . . 0.0 109.798 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 19.5 m -109.18 25.12 12.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.118 -0.989 . . . . 0.0 109.497 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.426 ' OD1' HG23 ' A' ' 55' ' ' VAL . 0.9 OUTLIER -118.87 140.59 28.79 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.33 -0.856 . . . . 0.0 109.543 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -69.55 -13.36 35.09 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.957 1.504 . . . . 0.0 110.509 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.538 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.49 -40.62 39.6 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.512 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 39.2 t -50.05 -45.92 23.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.321 -1.105 . . . . 0.0 109.55 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.456 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -61.8 -16.65 51.65 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.3 -36.64 39.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.915 . . . . 0.0 109.645 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.459 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 11.5 mt -87.07 -60.03 2.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.157 -0.964 . . . . 0.0 109.638 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.441 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -46.9 -48.9 18.35 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.419 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -56.39 -38.58 71.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -1.166 . . . . 0.0 109.695 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -83.86 -29.9 26.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.663 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 38.7 t -71.61 -47.87 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.305 -0.872 . . . . 0.0 109.652 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -48.99 -50.27 36.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 109.656 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.97 -44.97 20.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.363 -0.836 . . . . 0.0 110.017 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 28.8 tp60 -57.72 -52.69 64.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.127 -0.983 . . . . 0.0 109.332 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.459 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 96.1 mt -53.89 -36.65 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.184 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.51 -55.38 27.7 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.31 -23.17 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -1.141 . . . . 0.0 109.17 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.88 -23.24 25.31 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.413 -0.805 . . . . 0.0 109.579 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 53.3 t -72.76 -21.31 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.898 . . . . 0.0 109.757 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.442 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 53.9 m -88.67 39.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.154 -0.966 . . . . 0.0 109.975 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.442 ' ND1' ' O ' ' A' ' 71' ' ' SER . 16.2 m-70 -151.13 -62.1 0.18 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.097 -1.002 . . . . 0.0 109.908 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.523 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 4.4 mm? . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.191 0.519 . . . . 0.0 110.638 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.442 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 41.4 ttp . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.289 0.566 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.408 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 90.6 t -83.26 -17.52 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.593 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.77 -30.6 45.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.578 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.461 ' HG3' ' N ' ' A' ' 83' ' ' MET . 23.9 pt-20 -86.17 -42.65 13.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.669 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.475 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 92.0 mmm -63.93 -35.29 80.17 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.011 -1.056 . . . . 0.0 108.845 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.454 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -52.62 -37.23 57.99 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.029 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -69.06 -27.36 65.56 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -74.88 -46.56 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.816 . . . . 0.0 108.962 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.443 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -63.93 -34.7 90.63 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.454 ' CG2' ' O ' ' A' ' 84' ' ' LYS . 53.3 t -58.9 -37.2 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.356 -1.085 . . . . 0.0 109.206 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 85' ' ' ALA . 17.3 mmm180 -64.76 -31.13 72.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.01 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.542 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 52.5 m80 -77.38 -2.6 35.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.427 -0.796 . . . . 0.0 109.897 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.8 ttmt -98.07 64.38 1.67 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.077 -1.014 . . . . 0.0 109.638 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.416 ' O ' ' O ' ' A' ' 93' ' ' TYR . . . 147.28 2.6 0.5 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.314 -1.422 . . . . 0.0 111.772 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.542 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.8 m-85 -56.13 -167.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.38 -1.659 . . . . 0.0 110.022 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.55 -40.17 13.3 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.527 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 3.7 t30 -59.38 -47.23 86.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.457 -1.025 . . . . 0.0 108.479 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.8 tttt 59.96 13.89 3.97 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.494 -0.754 . . . . 0.0 110.928 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.467 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 14.2 m-70 -131.6 44.08 2.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.046 -1.034 . . . . 0.0 108.923 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.421 HD12 ' HB3' ' A' ' 90' ' ' HIS . 67.8 mt -78.97 154.96 4.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.46 -0.775 . . . . 0.0 110.01 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.467 ' CE ' ' O ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -145.34 148.83 33.83 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.81 0.814 . . . . 0.0 110.084 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.469 ' HB1' ' CD1' ' A' ' 142' ' ' ILE . . . -81.9 -16.99 48.76 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.555 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -60.82 -27.01 67.74 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.002 -1.061 . . . . 0.0 109.208 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.555 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 93.4 m-85 -83.41 -20.23 34.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.18 -0.95 . . . . 0.0 110.246 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.432 ' HB2' ' O ' ' A' ' 100' ' ' ALA . 5.4 m-85 -59.38 -65.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.101 -0.999 . . . . 0.0 110.206 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -44.42 -60.13 3.21 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 110.872 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' CD ' ' CB ' ' A' ' 104' ' ' GLU . 11.1 Cg_endo -59.7 -26.56 82.56 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 123.827 1.435 . . . . 0.0 110.343 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.518 HD22 ' CG ' ' A' ' 34' ' ' PHE . 2.4 tm? -79.4 -19.18 50.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.113 -0.992 . . . . 0.0 109.444 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.93 -38.7 9.11 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.1 -54.11 48.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -1.171 . . . . 0.0 109.673 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.8 m -57.46 -26.16 60.79 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -0.905 . . . . 0.0 109.598 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.401 ' CB ' ' SG ' ' A' ' 30' ' ' CYS . 8.7 tt -69.41 -39.71 77.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.54 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.5 mt -58.71 -33.37 70.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.222 -0.924 . . . . 0.0 109.643 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.9 t -67.37 -27.92 67.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.18 -0.95 . . . . 0.0 109.66 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -83.28 -36.5 24.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.704 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.478 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 5.2 mmt -49.52 -42.86 44.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 109.864 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -51.99 -22.67 4.18 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.232 -0.918 . . . . 0.0 109.954 -179.72 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.444 ' N ' ' CD2' ' A' ' 116' ' ' HIS . 15.7 m170 -68.59 -22.53 64.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.947 . . . . 0.0 110.004 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.45 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -93.29 -50.03 5.67 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.861 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.466 ' O ' ' N ' ' A' ' 120' ' ' GLY . 13.2 pt -104.42 -36.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.151 -0.968 . . . . 0.0 109.439 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 122' ' ' MET . . . 42.81 -94.27 0.01 OUTLIER Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.67 -42.03 10.22 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.442 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -76.68 -17.38 59.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.04 -1.271 . . . . 0.0 109.697 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.454 ' N ' ' O ' ' A' ' 119' ' ' GLY . 4.8 tpt -72.52 92.48 1.49 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.137 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.412 ' O ' ' HB3' ' A' ' 126' ' ' ALA . 8.3 p-10 -93.5 176.86 6.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 109.826 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.416 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -54.76 -50.1 69.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 109.759 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.433 ' HB3' HG12 ' A' ' 9' ' ' VAL . . . -54.7 -24.7 23.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.242 -0.911 . . . . 0.0 109.715 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.71 -51.24 11.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.956 . . . . 0.0 109.521 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.453 ' O ' ' CB ' ' A' ' 131' ' ' ALA . 19.6 ptpt -71.66 -28.22 63.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.258 -0.901 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.437 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 35.7 t0 -78.89 -38.56 37.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.472 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -69.96 -45.71 66.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.449 -0.782 . . . . 0.0 109.444 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.512 ' O ' ' CD1' ' A' ' 134' ' ' TYR . 6.8 m0 -72.97 -21.82 60.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.366 -0.834 . . . . 0.0 109.295 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.453 ' CB ' ' O ' ' A' ' 127' ' ' LYS . . . -76.22 -23.94 54.61 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.155 -0.966 . . . . 0.0 109.091 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -99.03 -23.4 15.3 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.411 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -82.21 -37.35 26.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.39 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.512 ' CD1' ' O ' ' A' ' 130' ' ' TRP . 4.8 m-30 -49.37 -27.87 4.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.285 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.4 -29.5 53.13 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 108.913 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.1 t0 -80.08 -44.2 20.45 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.431 -0.793 . . . . 0.0 109.205 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.453 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.0 mt -65.28 -55.48 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.076 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.69 -41.82 74.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.478 -0.764 . . . . 0.0 109.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.34 -52.17 33.55 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.401 ' HB3' ' HA ' ' A' ' 80' ' ' VAL . . . -53.68 -28.75 35.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -1.175 . . . . 0.0 109.791 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.475 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 9.4 tt -71.47 -10.03 59.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.199 -0.938 . . . . 0.0 110.049 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.469 ' CD1' ' HB1' ' A' ' 100' ' ' ALA . 44.1 mm -91.01 38.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.039 -1.038 . . . . 0.0 109.919 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.402 ' HB3' ' HG2' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -115.52 -28.68 6.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.374 -0.829 . . . . 0.0 109.228 179.671 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.4 20.68 4.93 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.029 -1.629 . . . . 0.0 109.029 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.506 ' CD1' ' CB ' ' A' ' 90' ' ' HIS . 2.6 tt . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.277 -1.131 . . . . 0.0 109.794 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -74.78 -48.23 26.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.212 -0.93 . . . . 0.0 109.246 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.418 ' O ' ' HB ' ' A' ' 10' ' ' VAL . 7.7 tmm_? -54.28 -42.93 70.58 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.046 -1.034 . . . . 0.0 108.765 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -52.14 -38.29 57.04 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.18 -0.95 . . . . 0.0 108.603 179.227 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.452 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 44.8 t -72.71 -26.45 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.032 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.444 ' HA ' ' NE1' ' A' ' 130' ' ' TRP . 78.0 t -75.69 -45.68 38.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.515 -0.741 . . . . 0.0 109.153 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.59 -13.06 60.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 0.0 109.748 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 t -92.12 -28.57 17.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.125 -0.985 . . . . 0.0 109.829 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.2 p -90.83 -11.88 38.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.156 -0.965 . . . . 0.0 109.963 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.44 -21.73 21.77 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.073 -1.017 . . . . 0.0 109.532 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.7 mtpp -76.66 -3.61 38.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.226 -0.921 . . . . 0.0 109.679 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -109.51 -55.78 2.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.093 -1.005 . . . . 0.0 109.519 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.429 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 23.6 mt -60.55 -40.51 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.283 -0.886 . . . . 0.0 109.592 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.56 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -97.33 33.33 2.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.694 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.19 -80.04 0.07 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 54.2 p -112.02 12.98 20.7 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.22 -1.165 . . . . 0.0 109.829 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.455 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 10.4 p-10 -119.15 -17.07 9.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.086 -1.009 . . . . 0.0 109.791 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.449 ' OD1' ' CB ' ' A' ' 64' ' ' ALA . 25.3 t-20 55.88 29.26 13.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.671 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.405 ' HA3' ' CG ' ' A' ' 63' ' ' LEU . . . 90.88 23.28 30.72 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.455 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -61.45 -48.52 80.76 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.79 20.15 40.84 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.456 HG13 ' CD1' ' A' ' 63' ' ' LEU . 22.7 t -114.12 -17.69 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -1.123 . . . . 0.0 109.069 179.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.416 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -105.92 -25.57 6.43 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.48 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.3 ptpt -75.91 -33.43 59.9 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.288 -1.125 . . . . 0.0 109.558 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.48 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 1.1 pm0 -94.78 -13.88 25.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.181 -0.95 . . . . 0.0 109.722 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 32.0 t -88.33 -59.81 2.13 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -0.96 . . . . 0.0 109.562 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.518 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.1 m-85 -56.48 -29.17 61.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.153 -0.967 . . . . 0.0 109.533 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.401 HG22 HG12 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -54.66 -60.42 3.38 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.657 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.5 -50.62 62.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.505 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.0 t80 -50.68 -48.2 58.57 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.226 -0.921 . . . . 0.0 109.306 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.459 ' CD2' ' HA ' ' A' ' 42' ' ' ALA . 19.0 mt -58.26 -43.67 88.03 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 55.9 m -67.01 -69.1 0.33 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -0.936 . . . . 0.0 109.877 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.439 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -50.87 -24.19 3.38 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.25 -0.906 . . . . 0.0 109.921 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.482 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 12.3 m-70 -128.17 106.69 9.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.141 -0.974 . . . . 0.0 109.957 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.6 m170 -85.64 -19.76 30.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.558 -0.714 . . . . 0.0 109.283 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -70.55 -16.23 62.85 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.311 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.473 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -101.61 -15.44 17.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.792 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.459 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.84 -66.31 0.55 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.006 . . . . 0.0 109.246 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -53.17 -24.62 11.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.92 . . . . 0.0 109.123 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.527 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 2.5 t -71.37 -56.25 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.515 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.7 m-85 -60.59 -24.96 65.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.335 -0.853 . . . . 0.0 109.528 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.53 26.81 5.75 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CD2' HG22 ' A' ' 55' ' ' VAL . 10.2 m-85 -123.65 168.23 12.93 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.247 -1.149 . . . . 0.0 109.814 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -106.77 -18.16 14.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.24 -175.67 47.58 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.66 -13.55 43.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.853 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.17 44.11 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 55' ' ' VAL . 3.1 m-20 -130.37 123.77 20.74 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.176 -0.952 . . . . 0.0 109.592 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -66.3 -22.94 52.42 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.886 1.466 . . . . 0.0 110.087 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.519 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.99 -29.93 28.97 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.524 HG22 ' CD2' ' A' ' 47' ' ' PHE . 49.0 t -57.69 -42.69 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -1.165 . . . . 0.0 109.476 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.469 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -68.58 -19.53 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.243 -0.91 . . . . 0.0 109.553 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.68 -37.92 24.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.912 . . . . 0.0 109.426 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.2 mt -76.0 -65.99 0.84 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.925 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.518 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -47.34 -47.18 22.19 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -57.8 -38.14 75.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -1.171 . . . . 0.0 109.618 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -77.01 -28.42 54.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.918 . . . . 0.0 109.605 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 47.8 t -80.45 -41.28 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 109.572 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.456 ' CD1' HG13 ' A' ' 26' ' ' VAL . 0.7 OUTLIER -47.71 -49.96 26.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.903 . . . . 0.0 109.906 179.895 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.449 ' CB ' ' OD1' ' A' ' 22' ' ' ASN . . . -49.38 -50.91 38.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.122 -0.986 . . . . 0.0 109.828 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 34.1 tp60 -49.1 -47.67 45.02 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.07 -1.019 . . . . 0.0 109.34 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.412 HD12 HG23 ' A' ' 137' ' ' ILE . 24.3 mm -56.51 -45.71 82.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.362 -0.836 . . . . 0.0 108.963 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.524 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -61.46 -51.02 60.57 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.7 t -57.57 -31.36 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -1.065 . . . . 0.0 109.705 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.464 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -82.21 -33.86 29.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.537 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.436 HG11 ' CG1' ' A' ' 10' ' ' VAL . 56.1 t -65.89 -18.95 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -75.05 -15.39 60.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 22.4 m-70 -115.46 -88.96 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.784 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.453 ' CD2' ' O ' ' A' ' 69' ' ' ALA . 19.3 mt . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.425 -0.797 . . . . 0.0 109.975 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 31.0 ttp . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.298 0.571 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.405 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 38.8 t -76.28 -25.2 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.321 -0.862 . . . . 0.0 109.321 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.28 -44.69 84.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.361 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -83.94 -44.58 14.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.37 -0.831 . . . . 0.0 109.309 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.428 ' SD ' ' CG2' ' A' ' 137' ' ' ILE . 0.0 OUTLIER -58.38 -58.57 7.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.306 179.777 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -52.05 -31.44 30.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.175 -0.953 . . . . 0.0 108.97 179.563 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -66.8 -45.51 78.14 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.36 -0.838 . . . . 0.0 109.023 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.401 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 31.5 t -51.01 -47.68 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.307 -0.871 . . . . 0.0 109.193 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' A' ' 145' ' ' LEU . . . -53.65 -51.39 48.85 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 85.8 t -53.99 -35.34 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.321 -1.105 . . . . 0.0 109.006 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.516 ' HB3' ' CE1' ' A' ' 93' ' ' TYR . 5.4 mmm180 -70.6 -55.1 9.61 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.382 -0.823 . . . . 0.0 109.09 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.469 ' CB ' ' CD1' ' A' ' 145' ' ' LEU . 12.4 m80 -52.31 -29.75 25.0 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.893 . . . . 0.0 108.971 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.407 ' O ' ' HG2' ' A' ' 91' ' ' LYS . 1.6 ttmt -68.0 -9.97 49.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.486 -0.759 . . . . 0.0 110.124 -179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.55 51.36 0.7 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.516 ' CE1' ' HB3' ' A' ' 89' ' ' ARG . 3.2 m-30 -106.41 -167.02 1.24 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.176 -1.191 . . . . 0.0 109.66 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.0 -38.13 93.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.527 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 10.7 t30 -78.96 -44.6 22.11 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.469 -1.018 . . . . 0.0 109.403 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.451 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.8 OUTLIER 71.94 -54.78 0.68 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 179.615 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.445 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 9.1 m170 -48.67 -87.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.097 -1.002 . . . . 0.0 109.944 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.445 ' HB ' ' O ' ' A' ' 97' ' ' HIS . 54.1 mt 59.48 156.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.714 . . . . 0.0 109.938 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.508 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.59 144.15 25.08 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 -179.841 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.41 -8.64 59.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.713 -0.617 . . . . 0.0 109.545 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -75.72 -21.54 57.44 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.101 -0.999 . . . . 0.0 109.375 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.508 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -84.94 -15.32 44.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.304 -0.872 . . . . 0.0 109.853 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -63.26 -65.88 0.62 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.207 -0.933 . . . . 0.0 110.248 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.484 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.5 -59.0 3.71 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.516 -0.74 . . . . 0.0 111.087 -179.317 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 4.9 Cg_endo -52.59 -55.79 3.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.671 1.353 . . . . 0.0 110.06 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.505 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -58.66 -21.2 53.52 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.338 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.98 -47.95 17.51 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.74 -53.88 53.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.161 -1.199 . . . . 0.0 109.562 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.8 m -54.98 -25.27 28.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.204 -0.935 . . . . 0.0 109.564 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -64.66 -37.04 86.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.666 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.412 HD21 ' HA ' ' A' ' 127' ' ' LYS . 11.6 mt -64.7 -42.55 95.2 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -65.1 -23.14 67.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.749 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.409 ' HB3' ' OE2' ' A' ' 29' ' ' GLU . . . -85.24 -38.65 18.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.95 . . . . 0.0 109.693 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.541 ' CE ' ' CE3' ' A' ' 130' ' ' TRP . 0.0 OUTLIER -53.16 -44.69 68.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.815 -179.861 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.475 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 12.2 mt-10 -47.47 -28.35 2.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.243 -0.911 . . . . 0.0 109.668 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.464 ' N ' ' CD2' ' A' ' 116' ' ' HIS . 15.7 m170 -57.81 -27.07 62.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -0.997 . . . . 0.0 109.817 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.429 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -90.25 -65.59 1.0 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.252 -0.905 . . . . 0.0 109.871 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.488 HG13 ' N ' ' A' ' 119' ' ' GLY . 41.8 pt -87.51 -37.48 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 109.496 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.488 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 40.91 -93.47 0.01 OUTLIER Glycine 0 N--CA 1.497 2.76 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -42.9 -41.43 4.54 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.456 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 34.6 mmtt -76.23 -28.24 57.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.13 -1.218 . . . . 0.0 109.748 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.464 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -59.21 102.01 0.12 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.173 -0.955 . . . . 0.0 109.317 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.424 ' O ' ' HB2' ' A' ' 126' ' ' ALA . 9.2 p-10 -98.62 -178.7 4.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.244 -0.91 . . . . 0.0 109.772 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.05 -43.27 99.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 109.761 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -65.03 -24.38 67.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.094 -1.004 . . . . 0.0 109.306 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 123' ' ' ASN . . . -72.67 -48.71 36.89 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.325 -0.859 . . . . 0.0 109.432 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.495 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.8 ptpt -73.39 -29.75 62.82 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.258 -0.901 . . . . 0.0 109.671 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.495 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 12.5 t0 -75.15 -38.34 61.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.192 -0.942 . . . . 0.0 109.273 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.452 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -66.63 -43.88 83.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -0.825 . . . . 0.0 109.104 179.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.541 ' CE3' ' CE ' ' A' ' 114' ' ' MET . 11.1 m0 -73.58 -32.75 64.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.312 -0.868 . . . . 0.0 109.192 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.52 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -47.64 -27.68 2.01 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.271 -0.893 . . . . 0.0 109.414 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -108.69 -14.72 14.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.399 -0.813 . . . . 0.0 109.665 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.431 ' CB ' ' HA ' ' A' ' 130' ' ' TRP . . . -73.49 -69.13 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.957 . . . . 0.0 110.153 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.535 ' CD2' ' O ' ' A' ' 130' ' ' TRP . 11.6 p90 -58.31 -20.14 40.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.844 -1.16 . . . . 0.0 109.127 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.423 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -73.61 -40.85 63.51 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.241 -0.912 . . . . 0.0 108.893 179.315 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.63 -30.52 56.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.352 -0.843 . . . . 0.0 109.055 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.464 HG12 ' CB ' ' A' ' 69' ' ' ALA . 58.5 mt -68.28 -59.99 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.401 -0.812 . . . . 0.0 109.151 179.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -57.56 -18.77 21.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.347 -0.846 . . . . 0.0 109.714 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.74 -52.2 21.31 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.47 -25.82 17.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.27 -1.135 . . . . 0.0 109.744 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.407 HD23 ' O ' ' A' ' 141' ' ' LEU . 7.3 tt -74.05 -11.58 60.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -0.912 . . . . 0.0 110.016 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.442 ' CG2' ' O ' ' A' ' 142' ' ' ILE . 98.3 mt -91.53 21.47 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.081 -1.012 . . . . 0.0 109.714 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -109.6 -20.35 12.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.156 -0.965 . . . . 0.0 109.83 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.14 -22.63 3.78 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.469 ' CD1' ' CB ' ' A' ' 90' ' ' HIS . 3.4 tp . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.11 -1.23 . . . . 0.0 109.77 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.427 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.16 0.505 . . . . 0.0 110.044 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -60.98 -56.34 22.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.671 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.409 ' HG3' ' HB2' ' A' ' 73' ' ' LEU . 9.7 ttp180 -51.86 -26.22 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.141 -0.975 . . . . 0.0 109.598 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 39.3 tp60 -85.27 -49.35 8.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.435 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 41.5 t -52.05 -28.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.267 -0.896 . . . . 0.0 109.687 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.51 HG12 ' CD1' ' A' ' 130' ' ' TRP . 84.8 t -64.99 -53.68 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.898 . . . . 0.0 109.624 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.83 -17.6 64.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.3 -32.6 38.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.181 -0.949 . . . . 0.0 109.698 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.503 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 41.0 p -94.54 -11.57 29.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.545 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -87.06 -18.09 31.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.047 -1.033 . . . . 0.0 109.873 -179.825 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -85.65 -15.64 41.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.167 -0.958 . . . . 0.0 109.608 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -96.64 -53.83 3.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.51 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.467 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 62.0 mt -68.49 -43.12 84.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.285 -0.884 . . . . 0.0 109.508 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.429 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -100.43 34.99 2.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.375 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.73 -86.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.3 p -106.95 13.59 27.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.238 -1.154 . . . . 0.0 110.066 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.441 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 3.2 p30 -122.59 -9.84 8.41 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.121 -0.987 . . . . 0.0 110.177 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.472 ' O ' ' ND2' ' A' ' 22' ' ' ASN . 6.7 t30 57.06 18.36 3.99 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.271 -0.893 . . . . 0.0 109.584 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.414 ' O ' ' HB ' ' A' ' 26' ' ' VAL . . . 85.76 32.63 17.9 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.731 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.405 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -57.25 -47.81 80.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.189 -1.183 . . . . 0.0 109.18 179.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.43 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -85.72 9.48 68.26 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.414 ' HB ' ' O ' ' A' ' 23' ' ' GLY . 9.2 t -95.48 -39.27 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.135 -1.215 . . . . 0.0 109.353 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.45 ' CA ' HD23 ' A' ' 63' ' ' LEU . . . -81.89 -51.81 4.35 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.45 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.9 ptpt -50.39 -30.97 13.57 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.202 -1.175 . . . . 0.0 109.604 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.45 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.3 pt-20 -89.48 -22.43 22.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.444 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.7 t -86.98 -39.6 15.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.343 -0.848 . . . . 0.0 109.645 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.403 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 10.1 m-85 -75.37 -42.21 54.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.879 . . . . 0.0 109.857 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.405 ' OG1' ' O ' ' A' ' 28' ' ' LYS . 20.4 m -51.69 -49.05 63.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.089 -1.007 . . . . 0.0 109.394 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.9 . . . . 0.0 109.434 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.513 ' CG ' HD22 ' A' ' 106' ' ' LEU . 3.6 t80 -65.09 -46.76 79.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.493 HD21 ' CD2' ' A' ' 45' ' ' PHE . 10.8 mt -59.94 -47.6 85.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.0 t -61.17 -57.78 11.05 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.173 -0.954 . . . . 0.0 109.783 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.91 -27.28 68.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.183 -0.948 . . . . 0.0 109.841 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.453 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 18.8 m-70 -121.93 105.61 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 109.781 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -87.2 -18.96 29.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.378 -0.826 . . . . 0.0 109.405 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -68.85 -19.08 64.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.905 . . . . 0.0 109.509 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.41 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 73.9 mmm -106.51 -23.61 12.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.288 -0.883 . . . . 0.0 109.712 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.465 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.96 -42.92 39.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.117 -0.989 . . . . 0.0 109.57 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.78 -28.19 60.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.31 -0.868 . . . . 0.0 109.255 179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.521 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 38.0 t -66.37 -49.46 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.332 -0.855 . . . . 0.0 109.424 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 50.6 m-85 -62.06 -30.93 71.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.739 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.19 31.68 2.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.041 -1.623 . . . . 0.0 109.041 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.521 ' CD2' HG22 ' A' ' 55' ' ' VAL . 13.0 m-85 -125.79 173.07 9.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.36 -1.082 . . . . 0.0 109.746 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.61 20.9 13.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.865 . . . . 0.0 109.301 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.54 -161.95 27.35 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.5 29.46 1.72 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -1.134 . . . . 0.0 109.66 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.3 p -125.92 26.79 6.51 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.73 138.43 22.09 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.614 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -69.29 -25.43 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.962 1.507 . . . . 0.0 110.069 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 57' ' ' ASP . . . -57.61 -31.49 63.7 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' CD2' ' A' ' 47' ' ' PHE . 70.2 t -53.85 -34.87 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.269 -1.136 . . . . 0.0 109.532 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.441 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -79.25 -7.48 58.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.316 -0.865 . . . . 0.0 109.856 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.409 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 7.7 m-20 -88.81 -38.77 14.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.72 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 58' ' ' LEU . 8.9 mt -74.81 -63.63 1.21 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 0.0 109.514 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.419 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -49.77 -34.57 21.99 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.431 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -68.04 -49.62 60.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.235 -1.156 . . . . 0.0 109.467 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -71.69 -44.07 64.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.376 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 83.6 t -55.96 -51.47 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.629 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.0 mm? -46.45 -49.53 18.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.238 -0.913 . . . . 0.0 110.169 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.433 ' HA ' ' OD1' ' A' ' 22' ' ' ASN . . . -54.25 -39.01 66.43 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.089 -1.007 . . . . 0.0 109.907 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 23.5 tp60 -56.74 -39.49 74.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.992 -1.067 . . . . 0.0 108.931 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 89.9 mt -66.98 -34.85 72.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.423 -0.798 . . . . 0.0 108.863 179.354 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.07 -51.34 45.75 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.74 -27.6 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.267 -1.137 . . . . 0.0 108.796 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.412 ' O ' HD23 ' A' ' 73' ' ' LEU . . . -84.7 -27.38 27.07 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.634 -0.666 . . . . 0.0 109.507 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.455 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 40.9 t -58.81 -17.28 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.32 -0.862 . . . . 0.0 109.7 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.441 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 1.2 t -56.15 -43.49 78.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.926 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.441 ' ND1' ' O ' ' A' ' 71' ' ' SER . 33.4 m-70 -138.73 102.73 4.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 0.0 109.979 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.463 ' CD1' HG13 ' A' ' 10' ' ' VAL . 36.1 mt . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.28 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.199 0.524 . . . . 0.0 109.667 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 75.4 t -63.8 -15.56 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.712 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -80.01 -12.95 59.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.124 -0.985 . . . . 0.0 109.875 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -99.44 -48.13 4.89 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.71 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.411 ' HE2' ' O ' ' A' ' 137' ' ' ILE . 97.6 mmm -59.78 -44.91 93.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.152 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.04 -30.55 15.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.209 -0.932 . . . . 0.0 108.786 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -82.45 -36.38 26.63 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.498 -0.751 . . . . 0.0 109.112 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.427 ' CG1' HD11 ' A' ' 141' ' ' LEU . 89.2 t -59.22 -51.59 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.277 -0.889 . . . . 0.0 109.334 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.47 ' N ' ' HG ' ' A' ' 141' ' ' LEU . . . -53.06 -48.65 58.09 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.629 -1.789 . . . . 0.0 108.629 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 91' ' ' LYS . 99.0 t -47.38 -27.94 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.49 -1.006 . . . . 0.0 109.645 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.521 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 17.5 mmt180 -70.27 -42.72 71.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.128 -0.983 . . . . 0.0 108.804 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.456 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 12.3 m80 -65.56 -12.42 52.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 0.2 OUTLIER -68.1 -13.21 62.03 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.327 -0.858 . . . . 0.0 110.399 -179.667 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.75 58.99 0.38 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.462 -1.352 . . . . 0.0 110.098 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.521 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 3.6 m-30 -92.32 -172.46 3.11 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.158 -1.201 . . . . 0.0 109.241 179.212 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.36 -34.77 90.8 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.507 -1.837 . . . . 0.0 108.507 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.521 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.8 OUTLIER -82.94 -58.94 2.66 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.541 -0.976 . . . . 0.0 108.924 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.483 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 3.0 pttt 79.45 -19.82 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.774 -0.579 . . . . 0.0 111.02 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.406 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 5.7 m170 -92.24 40.64 1.05 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.666 -1.271 . . . . 0.0 109.44 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.448 HD12 ' CD2' ' A' ' 90' ' ' HIS . 65.3 mt -72.77 164.27 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.363 -0.836 . . . . 0.0 109.754 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 98' ' ' ILE . 0.1 OUTLIER -145.07 141.79 29.15 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.349 -0.844 . . . . 0.0 109.889 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.97 5.28 16.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 46.4 mm-40 -83.99 -32.63 24.86 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.99 -1.069 . . . . 0.0 109.463 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.404 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 95.6 m-85 -75.72 -10.73 59.68 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.275 -0.891 . . . . 0.0 109.958 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -62.93 -61.31 2.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.157 -0.964 . . . . 0.0 110.176 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.493 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -50.22 -55.58 24.07 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 109.881 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.493 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 32.3 Cg_exo -51.05 -62.68 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 123.712 1.375 . . . . 0.0 109.934 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.513 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -55.75 -24.45 35.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.54 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.74 -45.51 12.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.64 -38.59 87.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -1.188 . . . . 0.0 109.652 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -20.49 64.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.531 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.409 ' O ' ' HG2' ' A' ' 114' ' ' MET . 1.9 tt -74.58 -39.69 62.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.695 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.1 mt -62.73 -30.06 71.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.258 -0.901 . . . . 0.0 109.558 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.7 t -72.53 -25.27 61.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.289 -0.882 . . . . 0.0 109.764 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.471 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.06 -38.76 18.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.244 -0.91 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.516 ' HE3' ' CZ3' ' A' ' 130' ' ' TRP . 5.9 mmt -46.66 -45.07 19.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.33 -0.856 . . . . 0.0 110.055 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -49.21 -25.2 2.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 109.611 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.471 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 26.5 m170 -57.46 -37.43 72.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.574 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.467 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 2.1 ttt85 -83.89 -70.41 0.57 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.699 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.437 HD11 ' CA ' ' A' ' 122' ' ' MET . 14.1 pt -82.44 53.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.173 -0.954 . . . . 0.0 109.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -59.43 123.78 34.4 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.32 -36.81 3.82 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.414 ' O ' ' N ' ' A' ' 123' ' ' ASN . 15.6 mtpt -84.58 -30.73 24.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.27 -1.135 . . . . 0.0 109.399 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.437 ' CA ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -64.37 81.63 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.329 -0.857 . . . . 0.0 109.446 179.776 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.445 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.1 p30 -86.8 -168.68 2.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.754 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.446 ' O ' ' CB ' ' A' ' 128' ' ' ASP . . . -64.3 -46.21 84.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.489 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.462 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -57.28 -24.38 54.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.276 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.48 -58.36 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.415 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 0.2 OUTLIER -68.49 -25.85 65.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.588 -179.823 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 124' ' ' ALA . 25.0 t70 -80.75 -39.71 26.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.543 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.93 -41.82 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.848 . . . . 0.0 109.279 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.516 ' CZ3' ' HE3' ' A' ' 114' ' ' MET . 3.8 m0 -73.74 -24.52 59.9 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.163 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.04 -24.52 59.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.192 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.58 -40.58 12.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.858 . . . . 0.0 109.458 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.418 ' HB3' HD12 ' A' ' 73' ' ' LEU . . . -70.97 -45.58 63.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.399 -0.813 . . . . 0.0 109.537 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.45 ' OH ' ' CE ' ' A' ' 114' ' ' MET . 3.2 m-85 -50.08 -32.15 14.93 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.908 . . . . 0.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.88 -37.11 70.21 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.19 -0.944 . . . . 0.0 108.866 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.17 -33.0 44.42 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.38 -0.825 . . . . 0.0 109.231 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.411 ' O ' ' HE2' ' A' ' 83' ' ' MET . 24.9 mt -65.77 -60.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.334 -0.854 . . . . 0.0 108.833 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.41 ' O ' HG13 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -66.93 -37.39 84.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.589 -0.694 . . . . 0.0 109.669 -179.775 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.44 -44.9 59.16 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.31 -18.36 64.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.21 -1.171 . . . . 0.0 109.82 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.47 ' HG ' ' N ' ' A' ' 87' ' ' GLY . 6.7 tt -87.73 -23.77 24.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 109.78 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.41 HG13 ' O ' ' A' ' 138' ' ' SER . 50.9 mt -82.68 8.03 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 0.0 110.275 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -86.95 -35.92 18.61 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.008 -1.058 . . . . 0.0 109.502 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.402 ' HA3' HG22 ' A' ' 88' ' ' VAL . . . -104.43 5.85 45.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.456 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 1.5 tt . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.075 -1.25 . . . . 0.0 109.19 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.228 0.537 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -84.98 -46.21 11.44 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.218 -0.926 . . . . 0.0 109.735 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.445 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 4.3 ptm180 -51.7 -32.06 28.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.445 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 5.5 mm100 -70.2 -47.62 60.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.215 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 80.9 t -56.44 -30.75 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.285 -0.884 . . . . 0.0 109.176 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.405 HG12 ' CD1' ' A' ' 130' ' ' TRP . 83.1 t -64.14 -55.02 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -0.836 . . . . 0.0 109.221 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.9 -14.04 62.64 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.613 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.5 m -84.44 -27.18 27.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.15 -0.969 . . . . 0.0 109.724 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.503 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 25.3 p -98.94 -7.2 27.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.152 -0.967 . . . . 0.0 109.69 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.545 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -89.27 -21.48 23.18 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.151 -0.968 . . . . 0.0 109.646 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.3 mtpm? -79.31 2.31 21.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 110.092 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -116.45 -54.4 2.46 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.06 -1.025 . . . . 0.0 109.525 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.441 HG12 ' HB3' ' A' ' 117' ' ' ARG . 43.2 mt -66.49 -32.25 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.292 -0.88 . . . . 0.0 109.518 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.483 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.92 35.39 2.92 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.713 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.7 -81.57 0.05 OUTLIER Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 p -108.78 -34.86 6.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -1.128 . . . . 0.0 109.58 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.429 ' OD1' ' N ' ' A' ' 22' ' ' ASN . 37.8 p30 -75.91 -15.05 60.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.909 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.429 ' N ' ' OD1' ' A' ' 21' ' ' ASP . 24.8 t30 63.18 16.0 9.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.147 -0.971 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.412 ' O ' ' HB ' ' A' ' 26' ' ' VAL . . . 100.11 17.36 25.21 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.404 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -50.07 -36.81 30.76 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.094 -1.239 . . . . 0.0 109.774 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.446 ' HA2' ' CE ' ' A' ' 28' ' ' LYS . . . -92.97 13.61 67.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.412 ' HB ' ' O ' ' A' ' 23' ' ' GLY . 54.5 t -95.4 -28.3 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.045 -1.268 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.425 ' HA3' ' O ' ' A' ' 59' ' ' GLY . . . -91.47 -44.52 4.28 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.471 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 10.8 ptpt -51.61 -33.66 34.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.195 -1.179 . . . . 0.0 109.089 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.457 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 19.0 pt-20 -91.44 -29.41 17.05 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.218 -0.926 . . . . 0.0 109.243 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.419 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 18.0 t -84.83 -68.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 110.065 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.532 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 22.1 m-85 -45.94 -32.6 2.8 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.564 -178.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.412 ' HA ' HG12 ' A' ' 55' ' ' VAL . 5.6 m -59.04 -52.16 66.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.929 -1.107 . . . . 0.0 109.124 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.409 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 36.3 mttt -55.44 -48.21 74.8 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.069 -1.019 . . . . 0.0 109.311 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.509 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.9 t80 -54.83 -54.48 41.74 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.31 -0.869 . . . . 0.0 109.336 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.469 ' CD1' HG22 ' A' ' 55' ' ' VAL . 46.0 mt -55.39 -43.29 75.05 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.64 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -68.17 0.37 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.679 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.406 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -53.37 -30.09 37.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.214 -0.929 . . . . 0.0 109.626 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.497 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 10.8 m-70 -115.2 99.84 7.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.754 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 24.7 m170 -82.3 -14.4 55.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.453 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -74.21 -13.78 60.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.152 -0.968 . . . . 0.0 109.62 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.509 ' HE2' ' CG ' ' A' ' 102' ' ' TYR . 2.6 mmt -104.83 -27.34 11.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.13 -0.981 . . . . 0.0 109.91 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.45 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.24 -41.53 27.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.037 -1.039 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.43 -26.02 59.81 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -0.85 . . . . 0.0 108.782 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.532 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 2.9 t -72.61 -47.34 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.525 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 25.0 m-85 -65.61 -32.74 74.49 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.874 . . . . 0.0 109.47 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.14 27.94 3.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.525 ' CD2' HG22 ' A' ' 55' ' ' VAL . 8.6 m-85 -123.21 172.95 8.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.21 -1.17 . . . . 0.0 109.828 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.56 19.51 16.78 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.371 -0.83 . . . . 0.0 109.215 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 151.83 -163.8 30.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.74 36.24 1.7 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -1.171 . . . . 0.0 109.704 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 67.3 p -147.46 28.94 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.613 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 54' ' ' GLY . 0.4 OUTLIER -108.15 143.62 27.76 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.639 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -65.95 70.27 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.998 1.525 . . . . 0.0 110.059 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.523 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -155.19 -43.56 0.02 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 47' ' ' PHE . 61.6 t -53.0 -40.1 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.357 -1.084 . . . . 0.0 109.496 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.471 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -63.93 -20.31 65.76 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.487 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.55 -57.76 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.301 -0.875 . . . . 0.0 109.236 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -57.56 -63.3 1.28 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.462 -0.774 . . . . 0.0 110.28 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.532 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -54.59 -21.7 22.24 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -83.94 -6.12 59.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.126 -1.22 . . . . 0.0 110.684 -179.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 56.9 mttt -113.19 -12.3 13.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.972 -1.08 . . . . 0.0 110.002 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 93.4 t -83.2 -25.65 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.099 -1.001 . . . . 0.0 110.68 -179.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.531 ' N ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -70.28 -4.8 23.66 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.706 -1.246 . . . . 0.0 110.697 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.479 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -85.16 -42.45 14.72 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.834 -1.166 . . . . 0.0 109.559 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.8 mm-40 -56.57 -47.99 78.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.107 -0.996 . . . . 0.0 108.807 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.46 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 80.1 mt -57.32 -34.69 46.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.85 -57.26 12.66 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.1 t -57.33 -23.7 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.267 -1.137 . . . . 0.0 109.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.408 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -86.71 -27.88 23.43 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.447 -0.783 . . . . 0.0 109.582 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.46 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 54.5 t -70.46 -12.39 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.181 -0.949 . . . . 0.0 109.826 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.0 t -82.58 6.63 17.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.033 . . . . 0.0 110.061 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.467 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 23.9 m-70 -140.08 -88.88 0.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.004 -1.06 . . . . 0.0 109.685 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.428 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 29.8 mt . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.468 -0.77 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.467 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 17.2 tmm? . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.266 0.555 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 69.3 t -71.04 -20.27 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.63 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.29 74.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.712 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -76.7 -53.45 7.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.574 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.403 ' HA ' HG23 ' A' ' 86' ' ' VAL . 2.8 mtp -53.31 -41.07 65.28 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.201 -0.937 . . . . 0.0 109.435 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.442 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 0.7 OUTLIER -52.17 -31.88 33.43 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.175 -0.953 . . . . 0.0 108.723 179.24 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.432 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -71.3 -36.75 71.74 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.482 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 45.5 t -56.89 -51.75 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.199 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -51.8 -46.75 54.38 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.856 -1.698 . . . . 0.0 108.856 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 60.8 t -50.41 -25.75 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -1.173 . . . . 0.0 109.292 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.474 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 0.2 OUTLIER -81.3 -53.3 6.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.325 -0.859 . . . . 0.0 108.743 179.352 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.512 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 21.1 m80 -54.72 -21.91 12.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.053 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 34.0 ttpt -67.69 -12.93 61.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.448 -0.782 . . . . 0.0 110.243 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.07 55.58 0.55 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.512 ' OH ' ' CE1' ' A' ' 90' ' ' HIS . 3.8 m-30 -89.59 -100.23 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.322 -1.105 . . . . 0.0 109.645 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.44 -50.05 0.02 OUTLIER Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.066 -2.013 . . . . 0.0 108.066 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.532 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.8 p-10 -67.17 -30.44 70.41 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.489 -1.006 . . . . 0.0 108.521 178.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 43.5 mttt 51.98 22.24 1.75 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.636 -0.665 . . . . 0.0 109.805 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.2 m170 -128.64 49.48 2.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.338 -0.851 . . . . 0.0 109.149 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.474 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 76.3 mt -84.93 158.74 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.857 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.489 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -142.02 144.91 33.87 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.356 -0.84 . . . . 0.0 109.983 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.405 ' HB1' HD11 ' A' ' 142' ' ' ILE . . . -80.98 -15.86 55.07 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.679 -0.638 . . . . 0.0 109.36 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 54.3 mm-40 -67.86 -22.38 65.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.128 -0.983 . . . . 0.0 109.471 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.509 ' CG ' ' HE2' ' A' ' 41' ' ' MET . 57.2 m-85 -86.32 -26.39 24.93 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 109.79 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -51.28 -59.06 4.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.23 -0.919 . . . . 0.0 110.281 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.491 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -54.65 -58.78 12.67 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.203 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.491 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.4 Cg_exo -48.25 -53.13 7.18 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 O-C-N 123.639 1.337 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.509 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.2 tm? -59.48 -18.0 36.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -0.941 . . . . 0.0 109.858 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.41 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -83.99 -42.56 7.56 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.71 -57.78 9.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.078 -1.248 . . . . 0.0 109.684 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.5 t -60.66 -16.25 37.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.778 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.517 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 3.2 tt -78.53 -36.42 44.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.075 -1.016 . . . . 0.0 109.715 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.437 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.9 mt -64.36 -28.78 69.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.069 -1.019 . . . . 0.0 109.423 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 14.1 t -66.63 -35.22 79.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.699 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.494 ' HA ' ' CD2' ' A' ' 116' ' ' HIS . . . -80.29 -31.63 38.22 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.655 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.533 ' HG2' ' CZ3' ' A' ' 130' ' ' TRP . 0.0 OUTLIER -47.35 -38.09 12.34 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.019 -179.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.471 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.9 OUTLIER -62.65 -14.0 38.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.074 -1.017 . . . . 0.0 109.705 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.494 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.9 m170 -53.9 -37.54 63.88 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.911 -1.118 . . . . 0.0 109.443 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.441 ' HB3' HG12 ' A' ' 17' ' ' ILE . 1.1 ttt85 -89.81 -51.62 5.4 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.2 -0.938 . . . . 0.0 109.82 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.407 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 2.8 pt -110.04 48.73 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.161 -0.962 . . . . 0.0 109.897 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -59.57 -18.29 44.08 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.17 -30.61 9.14 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.407 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.7 mtpp -94.47 -25.81 16.73 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.164 -1.198 . . . . 0.0 109.537 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 1.8 tpt -61.09 96.73 0.05 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.889 . . . . 0.0 109.431 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 125' ' ' ALA . 8.0 p30 -106.14 -162.54 0.87 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.744 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -67.08 -46.25 74.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.355 -0.841 . . . . 0.0 110.134 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.419 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -63.58 -21.55 66.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.074 -1.016 . . . . 0.0 109.779 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.4 -47.15 14.83 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.177 -0.952 . . . . 0.0 109.563 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.44 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.6 ptpt -74.02 -30.68 62.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -0.891 . . . . 0.0 109.685 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.44 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -73.94 -53.34 10.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.93 . . . . 0.0 109.738 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -55.09 -43.41 73.97 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.35 -0.844 . . . . 0.0 109.71 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.533 ' CZ3' ' HG2' ' A' ' 114' ' ' MET . 7.5 m0 -76.09 -27.15 57.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.245 -0.909 . . . . 0.0 109.565 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.26 -30.42 68.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.169 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.78 -26.39 21.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.38 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -82.06 -48.38 11.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.501 ' CE2' ' HE1' ' A' ' 114' ' ' MET . 9.1 m-30 -52.42 -31.01 32.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.293 -0.88 . . . . 0.0 109.337 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.75 -46.39 63.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -0.875 . . . . 0.0 109.219 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -73.91 -30.53 62.64 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.312 -0.867 . . . . 0.0 109.221 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.404 HG23 HG12 ' A' ' 66' ' ' ILE . 59.4 mt -67.98 -60.78 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.314 -0.866 . . . . 0.0 108.973 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 3.6 m -66.96 -31.47 72.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.487 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.16 -38.41 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.17 -23.74 66.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -1.141 . . . . 0.0 109.528 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.482 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 10.0 tt -76.34 -2.39 31.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 110.116 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' A' ' 142' ' ' ILE . 40.6 mm -92.15 31.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.961 -1.087 . . . . 0.0 109.902 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.442 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -108.73 -34.23 6.75 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.283 -0.885 . . . . 0.0 109.381 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.79 21.89 7.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.421 HD12 ' HB3' ' A' ' 90' ' ' HIS . 14.3 tp . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.345 -1.091 . . . . 0.0 110.004 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.257 0.551 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -71.24 -55.45 8.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.438 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 2.8 ptm180 -50.92 -32.36 20.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.447 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.438 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 9.4 tp-100 -70.29 -39.01 75.13 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.294 -0.879 . . . . 0.0 109.349 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.4 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 22.0 t -69.38 -27.63 35.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.453 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.487 HG12 ' CD1' ' A' ' 130' ' ' TRP . 97.2 t -71.95 -37.96 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.596 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.98 -14.75 60.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.855 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 t -90.87 -25.62 19.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.429 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 19.7 p -93.56 -12.41 29.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 109.952 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.21 -24.31 21.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.084 -1.01 . . . . 0.0 109.788 -179.842 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -75.23 -8.37 56.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -103.7 -54.06 2.65 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.085 -1.009 . . . . 0.0 109.68 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.466 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 46.4 mt -65.79 -36.67 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.246 -0.909 . . . . 0.0 109.712 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.564 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.69 33.56 3.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.778 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.09 -66.98 2.36 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 88.3 p -115.61 -19.64 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -1.134 . . . . 0.0 109.558 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.466 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 7.5 p-10 -87.17 -19.08 28.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.894 . . . . 0.0 109.654 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.459 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 26.2 t30 58.57 22.89 10.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.05 23.69 10.4 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.466 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -70.45 -43.43 69.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -1.159 . . . . 0.0 109.603 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.408 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -88.39 14.46 59.44 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.466 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 44.0 t -108.64 -26.15 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -1.228 . . . . 0.0 109.317 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.36 -36.86 4.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.463 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.0 ptpt -66.41 -29.07 69.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.176 -1.191 . . . . 0.0 109.554 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.463 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 13.1 pt-20 -93.86 -20.34 20.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -0.935 . . . . 0.0 109.675 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.0 t -88.25 -59.86 2.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.234 -0.916 . . . . 0.0 109.866 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.508 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.8 m-85 -54.48 -30.11 52.16 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 109.81 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.463 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.0 OUTLIER -55.32 -58.47 7.57 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.162 -0.961 . . . . 0.0 109.336 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -54.31 -45.29 72.55 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.878 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.505 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.0 t80 -56.36 -59.09 5.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.962 . . . . 0.0 109.286 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.468 HD11 ' CG2' ' A' ' 55' ' ' VAL . 26.6 mt -51.15 -43.71 61.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 109.632 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.456 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 2.6 t -68.82 -71.27 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.911 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.464 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -49.52 -29.89 7.52 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.888 . . . . 0.0 109.787 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.489 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 12.9 m-70 -117.85 107.49 14.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.266 -0.896 . . . . 0.0 109.944 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -86.59 -25.4 24.98 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.475 -0.765 . . . . 0.0 108.967 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -66.97 -21.62 65.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.229 -0.919 . . . . 0.0 108.931 179.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.494 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -94.99 -27.63 15.55 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.413 -0.805 . . . . 0.0 109.55 179.846 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.441 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.06 -45.0 64.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.064 -1.023 . . . . 0.0 109.248 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.4 84.51 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.341 -0.849 . . . . 0.0 109.184 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.501 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 52.7 t -62.96 -60.24 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.31 -0.868 . . . . 0.0 109.156 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.41 ' CD2' HD21 ' A' ' 35' ' ' LEU . 62.0 m-85 -61.54 -31.97 72.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.192 -0.942 . . . . 0.0 109.009 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.06 -138.59 15.08 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.523 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 2.0 m-85 61.64 162.6 0.07 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.211 -1.17 . . . . 0.0 109.915 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 32.2 t -106.71 23.36 14.42 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.42 -161.06 31.45 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.456 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -92.32 -21.4 20.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.711 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.6 p -90.8 56.89 3.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.147 -0.97 . . . . 0.0 109.669 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.468 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -120.1 139.99 29.23 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.208 -0.933 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -62.11 -31.59 83.28 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.98 1.516 . . . . 0.0 110.067 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.523 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -37.25 40.04 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.468 ' CG2' HD11 ' A' ' 35' ' ' LEU . 93.4 t -50.2 -37.49 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -1.103 . . . . 0.0 109.445 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -75.65 -21.47 57.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.881 . . . . 0.0 109.299 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.403 ' O ' ' HB2' ' A' ' 61' ' ' LYS . 6.0 t70 -81.41 -40.03 24.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.486 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.6 mt -74.93 -59.59 2.67 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.508 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.5 -48.48 42.05 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.448 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -59.59 -48.41 81.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -1.106 . . . . 0.0 109.468 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.403 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 12.4 mttt -62.93 -33.24 74.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.883 . . . . 0.0 109.461 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 55.1 t -75.08 -49.47 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.323 -0.861 . . . . 0.0 109.527 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.439 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.0 mm? -48.68 -46.23 40.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.14 -49.31 32.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.785 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -53.72 -51.58 62.84 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.277 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.463 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 61.0 mt -53.91 -39.21 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.339 -0.85 . . . . 0.0 109.131 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.525 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -59.52 -54.5 37.19 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -60.19 -29.98 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -1.147 . . . . 0.0 109.268 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.56 -5.58 59.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.406 -0.809 . . . . 0.0 109.989 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.463 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 42.2 t -90.56 -16.37 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.99 -1.069 . . . . 0.0 109.954 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.27 16.52 5.16 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.157 -0.964 . . . . 0.0 110.101 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -137.8 -86.59 0.28 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.305 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.413 HD12 HG13 ' A' ' 10' ' ' VAL . 68.1 mt . . . . . 0 N--CA 1.496 1.831 0 O-C-N 121.302 -0.873 . . . . 0.0 110.035 179.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 24.3 t -75.83 -22.87 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.599 -0.84 . . . . 0.0 109.117 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.17 -22.2 27.13 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.24 -0.912 . . . . 0.0 109.137 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -90.98 -37.55 13.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.339 -0.851 . . . . 0.0 109.541 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.46 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.0 OUTLIER -67.11 -51.8 49.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.124 -0.985 . . . . 0.0 109.07 179.667 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.79 -31.33 66.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.258 -0.901 . . . . 0.0 108.752 179.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -67.33 -42.6 83.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 109.006 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.411 ' HB ' ' HG ' ' A' ' 141' ' ' LEU . 21.8 t -53.83 -44.62 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 108.83 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.426 ' HA2' HD11 ' A' ' 145' ' ' LEU . . . -58.98 -51.46 59.1 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.426 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 55.1 t -58.22 -23.08 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.341 -1.094 . . . . 0.0 109.023 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -86.64 -50.06 7.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.391 -0.818 . . . . 0.0 109.074 179.713 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.472 ' HB3' ' CD1' ' A' ' 98' ' ' ILE . 2.9 m80 -48.42 -44.55 35.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.755 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.426 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -58.94 -17.94 29.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.179 -0.951 . . . . 0.0 109.822 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.25 37.86 3.39 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.467 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.2 m-30 -93.76 -166.01 1.43 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -1.107 . . . . 0.0 109.519 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.51 -33.86 24.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.501 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 2.2 t30 -69.41 -59.0 3.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.486 -1.008 . . . . 0.0 109.299 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 76.13 -12.97 0.95 Allowed 'General case' 0 N--CA 1.507 2.42 0 O-C-N 121.572 -0.705 . . . . 0.0 111.491 179.589 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.3 m170 -99.78 41.94 1.13 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.633 -1.292 . . . . 0.0 109.018 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.472 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 57.3 mt -76.07 152.35 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.404 -0.81 . . . . 0.0 110.46 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.441 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 8.5 mttp -142.2 138.9 31.83 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 121.661 0.743 . . . . 0.0 109.809 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.47 ' HB1' ' CG2' ' A' ' 142' ' ' ILE . . . -75.42 -6.8 51.91 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.713 -0.617 . . . . 0.0 109.511 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 6.0 pt-20 -74.12 -26.63 60.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.09 -1.006 . . . . 0.0 109.301 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.494 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 33.3 m-85 -81.63 -21.25 38.35 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.865 . . . . 0.0 109.724 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -55.84 -63.0 1.32 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.334 -0.854 . . . . 0.0 110.289 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.5 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.7 mt-10 -48.91 -57.82 10.25 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.165 -0.959 . . . . 0.0 110.129 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.5 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -49.62 -63.18 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.632 1.333 . . . . 0.0 110.05 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.505 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.0 tm? -55.1 -24.9 27.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.292 -0.88 . . . . 0.0 109.43 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.1 -48.74 5.9 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.85 95.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.124 -1.221 . . . . 0.0 109.646 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 58.4 m -65.33 -19.14 65.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 0.0 109.606 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 106' ' ' LEU . 1.5 tt -73.89 -38.78 64.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.617 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 11.9 mt -60.53 -35.75 76.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 109.619 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 9.3 t -65.13 -33.83 76.95 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.666 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -81.16 -35.11 31.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.206 -0.934 . . . . 0.0 109.794 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.491 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 0.6 OUTLIER -54.71 -28.85 50.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.812 -179.867 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.45 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -68.48 -13.88 62.62 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.253 -0.904 . . . . 0.0 109.244 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.407 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 24.2 m170 -65.56 -45.18 84.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.085 -1.009 . . . . 0.0 109.772 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.412 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -74.54 -47.95 29.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.459 HG12 ' CG1' ' A' ' 17' ' ' ILE . 4.5 pt -114.32 54.99 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.274 -0.891 . . . . 0.0 109.633 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -66.27 -18.18 66.98 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -97.63 -26.35 9.97 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.412 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.5 mmtt -96.14 -25.43 15.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.262 -1.14 . . . . 0.0 109.621 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.403 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -64.23 104.67 0.78 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.25 -0.906 . . . . 0.0 109.545 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.478 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 5.0 p-10 -106.29 -171.08 1.83 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.379 -0.825 . . . . 0.0 109.537 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.99 -55.31 26.89 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.844 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.478 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -54.23 -26.54 29.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.132 -0.98 . . . . 0.0 109.439 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -71.45 -54.59 10.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -0.973 . . . . 0.0 109.359 179.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.446 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 18.3 ptpt -70.04 -25.2 63.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.346 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.446 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.6 t0 -81.71 -34.56 30.52 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -0.853 . . . . 0.0 109.326 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.4 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.21 -41.47 63.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.353 -0.842 . . . . 0.0 109.371 179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.491 ' CE3' ' SD ' ' A' ' 114' ' ' MET . 8.5 m0 -75.47 -24.38 56.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 109.242 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.88 -29.4 64.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.26 -34.32 16.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.66 -43.49 69.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.373 -0.829 . . . . 0.0 109.393 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.457 ' OH ' ' CE ' ' A' ' 114' ' ' MET . 3.1 m-85 -52.02 -28.89 18.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.4 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.63 -31.15 59.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.318 -0.864 . . . . 0.0 109.458 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.18 -39.67 22.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.472 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.41 ' CG2' ' SD ' ' A' ' 83' ' ' MET . 76.0 mt -66.38 -57.56 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.255 -0.903 . . . . 0.0 109.35 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.404 ' O ' HG13 ' A' ' 142' ' ' ILE . 1.5 p -68.65 -27.1 65.69 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.857 . . . . 0.0 109.653 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.409 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -65.28 -53.59 31.94 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.06 -16.46 31.6 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.248 -1.148 . . . . 0.0 109.859 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.46 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 8.1 tt -89.89 -39.18 13.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.836 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.47 ' CG2' ' HB1' ' A' ' 100' ' ' ALA . 11.2 mt -66.09 -11.17 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.135 -0.978 . . . . 0.0 110.002 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.02 -59.35 4.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.091 -1.006 . . . . 0.0 109.228 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.414 ' CA ' HG22 ' A' ' 88' ' ' VAL . . . -82.09 4.25 76.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.433 ' HB3' ' HA ' ' A' ' 142' ' ' ILE . 51.7 tp . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.004 -1.292 . . . . 0.0 109.382 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 21.9 mt-30 -81.7 -53.03 6.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.182 -0.949 . . . . 0.0 109.819 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.27 -27.96 10.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.149 -0.969 . . . . 0.0 109.606 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -77.45 -44.27 29.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.89 . . . . 0.0 109.284 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.46 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 46.3 t -62.98 -25.06 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.293 -0.88 . . . . 0.0 109.184 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.458 ' CG1' HG11 ' A' ' 70' ' ' VAL . 86.5 t -72.56 -46.93 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.416 -0.802 . . . . 0.0 109.358 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.68 -11.33 60.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.331 -0.856 . . . . 0.0 109.854 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.6 m -91.63 -21.23 20.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 109.694 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.1 p -101.87 -9.26 20.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.27 -0.894 . . . . 0.0 109.963 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.553 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.63 -19.9 23.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.097 -1.002 . . . . 0.0 109.771 -179.857 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -81.62 -10.7 59.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.223 -0.923 . . . . 0.0 109.933 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.62 -54.44 2.58 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.062 -1.024 . . . . 0.0 109.656 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.445 ' CG1' HG12 ' A' ' 118' ' ' ILE . 59.5 mt -66.04 -35.38 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 0.0 109.623 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.553 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -104.45 31.1 4.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.668 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.28 -70.46 0.95 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.8 p -107.5 -37.13 6.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.215 -1.167 . . . . 0.0 109.751 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -72.42 -19.73 61.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.261 -0.899 . . . . 0.0 109.714 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 24.9 t30 56.8 26.21 11.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.209 -0.932 . . . . 0.0 109.657 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.16 23.91 23.56 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.401 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -67.97 -49.58 60.81 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 0.0 109.579 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.441 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -87.83 13.08 61.86 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.403 HG13 ' CD1' ' A' ' 63' ' ' LEU . 17.2 t -98.68 -30.59 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.094 -1.239 . . . . 0.0 109.241 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.434 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -90.06 -43.37 5.05 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.464 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 7.2 ptpt -56.07 -33.23 64.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.17 -1.194 . . . . 0.0 109.559 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.456 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 11.0 pt-20 -89.6 -18.57 26.31 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.958 . . . . 0.0 109.686 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.23 -61.52 1.68 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.6 m-85 -51.64 -31.82 26.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.185 -0.947 . . . . 0.0 109.885 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.459 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.1 OUTLIER -56.03 -55.57 31.3 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.188 -0.945 . . . . 0.0 109.594 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -57.45 -49.11 77.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.316 -0.865 . . . . 0.0 109.678 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.509 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.3 t80 -50.91 -51.17 54.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.185 -0.947 . . . . 0.0 109.609 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.466 ' CD1' HG22 ' A' ' 55' ' ' VAL . 12.8 mt -56.41 -46.13 80.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.868 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.407 ' HB2' ' HB1' ' A' ' 50' ' ' ALA . 13.5 t -60.75 -57.59 12.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.194 -0.941 . . . . 0.0 109.83 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.32 -21.84 66.27 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.481 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 15.3 m-70 -122.76 105.95 10.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.833 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -87.02 -21.13 26.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.436 -0.79 . . . . 0.0 109.264 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -73.27 -20.24 60.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.491 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -96.65 -18.6 19.6 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 109.629 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.453 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -59.88 -57.53 12.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.472 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.73 -23.31 63.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -0.932 . . . . 0.0 109.345 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.517 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 49.5 t -75.05 -57.08 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.342 -0.849 . . . . 0.0 109.504 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.508 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -55.77 -35.25 66.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.95 . . . . 0.0 109.514 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.39 28.08 2.91 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.522 ' CD2' HG22 ' A' ' 55' ' ' VAL . 9.3 m-85 -123.14 -168.66 1.8 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 109.784 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.1 t -133.62 21.43 3.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.507 -0.746 . . . . 0.0 109.123 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 139.84 -161.72 26.28 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.407 ' HB1' ' HB2' ' A' ' 36' ' ' SER . . . -91.44 36.74 0.94 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.232 -1.158 . . . . 0.0 109.724 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.7 m -132.68 19.04 4.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.628 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -107.13 133.84 20.14 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.575 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.38 -19.87 55.26 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.947 1.498 . . . . 0.0 109.974 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.61 -27.63 64.06 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.522 HG22 ' CD2' ' A' ' 47' ' ' PHE . 99.3 t -57.18 -35.19 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -1.167 . . . . 0.0 109.405 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.464 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -79.34 -3.83 48.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.89 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.4 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 1.1 m-20 -94.97 -29.97 14.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.046 -1.034 . . . . 0.0 109.397 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.46 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 7.1 mt -86.02 -63.56 1.3 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.161 -0.962 . . . . 0.0 109.524 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.507 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -54.49 -28.83 45.91 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.457 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -63.1 -53.04 59.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.149 -1.207 . . . . 0.0 109.518 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.3 mtpt -76.25 -43.54 41.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.281 -0.887 . . . . 0.0 109.321 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.46 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 63.0 t -50.16 -49.14 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.308 -0.87 . . . . 0.0 109.591 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.445 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.0 mm? -47.51 -45.68 26.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.144 -0.973 . . . . 0.0 109.729 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.67 -50.9 31.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.244 -0.91 . . . . 0.0 109.903 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.1 tp60 -49.9 -49.21 50.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.139 -0.976 . . . . 0.0 109.491 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 71.1 mt -56.2 -35.83 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.325 -0.86 . . . . 0.0 109.138 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.84 -54.9 25.4 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.156 -1.578 . . . . 0.0 109.156 179.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.0 t -59.57 -24.48 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.9 -25.46 26.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.307 -0.871 . . . . 0.0 109.534 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.458 HG11 ' CG1' ' A' ' 10' ' ' VAL . 55.1 t -73.66 -18.38 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 109.665 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -89.35 15.3 9.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -0.93 . . . . 0.0 109.927 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 14.0 m-70 -155.97 45.59 0.45 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.076 -1.015 . . . . 0.0 109.899 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 69.3 mt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.874 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 39.8 ttp . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 121.263 0.554 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.407 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 58.1 t -66.86 -19.23 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.226 -0.921 . . . . 0.0 109.456 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.8 -36.32 75.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 0.0 109.434 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -81.58 -49.81 10.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.437 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.402 ' HA ' HG23 ' A' ' 86' ' ' VAL . 4.4 mtp -53.04 -45.68 68.13 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.277 -0.889 . . . . 0.0 109.362 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.416 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -51.4 -37.53 48.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 109.086 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.431 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -65.33 -35.35 80.71 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.404 -0.81 . . . . 0.0 109.153 179.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.402 HG23 ' HA ' ' A' ' 83' ' ' MET . 28.9 t -62.4 -53.09 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.318 -0.864 . . . . 0.0 109.216 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.401 ' HA2' HD23 ' A' ' 141' ' ' LEU . . . -53.12 -42.2 61.67 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 97.7 t -52.63 -27.89 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -1.136 . . . . 0.0 109.345 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.47 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 2.0 mmm180 -78.96 -51.22 9.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.094 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.505 ' CD2' ' CE2' ' A' ' 93' ' ' TYR . 43.2 m80 -54.0 -22.35 10.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.387 -0.821 . . . . 0.0 109.127 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.4 ttmt -64.99 -11.33 37.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.478 -0.764 . . . . 0.0 110.281 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.76 55.63 0.52 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CE2' ' CD2' ' A' ' 90' ' ' HIS . 4.4 m-30 -90.44 -170.15 2.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.306 -1.114 . . . . 0.0 109.661 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.11 -53.35 10.8 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.517 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.5 p-10 -62.06 -30.08 70.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.166 -1.196 . . . . 0.0 109.68 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.9 mtmt 60.62 35.62 19.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 109.942 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.407 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 47.5 m170 -132.97 -83.98 0.47 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.06 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.472 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 22.6 mt 60.06 153.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 110.387 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.531 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -152.71 135.09 15.09 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.626 0.727 . . . . 0.0 109.725 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -72.95 -6.32 44.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.735 -0.603 . . . . 0.0 109.544 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.462 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.8 mm-40 -76.36 -24.07 54.17 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.028 -1.045 . . . . 0.0 109.115 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.531 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 73.0 m-85 -85.95 -26.52 25.46 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.328 -0.858 . . . . 0.0 109.732 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -50.82 -59.03 4.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 110.278 -179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.495 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -54.71 -59.07 11.47 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.289 -179.355 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.5 Cg_exo -47.94 -55.69 3.79 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.712 1.375 . . . . 0.0 110.308 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.509 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -55.99 -21.42 21.08 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.933 . . . . 0.0 109.652 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.61 -48.31 10.71 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.58 -47.46 85.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -1.164 . . . . 0.0 109.826 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.04 -25.12 65.09 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 1.3 tt -69.44 -40.72 77.05 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.688 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 14.8 mt -59.17 -32.78 70.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.228 -0.92 . . . . 0.0 109.677 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.9 p -66.83 -29.8 69.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 109.901 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.41 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -83.33 -38.82 21.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.176 -0.952 . . . . 0.0 109.845 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.498 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 5.2 mmt -48.45 -46.54 37.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 110.033 -179.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.455 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -47.96 -25.95 1.56 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 -179.633 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.448 ' ND1' ' OE1' ' A' ' 29' ' ' GLU . 18.3 m170 -54.65 -45.78 73.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.065 -1.022 . . . . 0.0 110.029 -179.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.416 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 7.0 ttt85 -78.17 -60.37 2.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.202 -0.936 . . . . 0.0 110.033 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.445 HG12 ' CG1' ' A' ' 17' ' ' ILE . 4.5 pt -104.7 52.36 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.172 -0.955 . . . . 0.0 109.82 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.455 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -63.5 -20.09 63.17 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -91.78 -24.29 25.85 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.418 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 25.1 mttt -100.01 -21.23 15.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.183 . . . . 0.0 109.711 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.407 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 5.0 tpt -60.94 98.37 0.07 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.562 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.442 ' OD1' ' N ' ' A' ' 123' ' ' ASN . 14.5 p-10 -96.36 -174.37 3.04 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.28 -0.887 . . . . 0.0 109.667 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.18 79.81 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.429 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -69.26 -27.21 65.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -0.906 . . . . 0.0 109.355 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.406 ' HB1' ' OD1' ' A' ' 123' ' ' ASN . . . -71.93 -45.41 61.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.461 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 5.0 ptpt -74.54 -27.92 60.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.119 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.461 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -81.88 -36.56 28.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.357 -0.84 . . . . 0.0 109.115 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.46 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -68.7 -47.37 66.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.365 -0.835 . . . . 0.0 109.134 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.498 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 3.5 m0 -70.13 -25.77 63.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.337 -0.852 . . . . 0.0 108.985 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.95 -34.88 74.0 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -81.91 -28.78 32.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.282 -0.886 . . . . 0.0 109.423 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -78.59 -47.75 16.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.335 -0.853 . . . . 0.0 109.62 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -49.5 -29.17 6.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.02 61.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.373 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -80.32 -36.48 34.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.479 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 65.3 mt -66.69 -58.12 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.293 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 1.8 p -64.74 -23.73 67.34 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -0.876 . . . . 0.0 109.597 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -73.42 -39.33 51.03 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.18 -31.09 70.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -1.16 . . . . 0.0 109.654 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.458 ' O ' ' CD2' ' A' ' 141' ' ' LEU . 8.5 tt -73.24 -6.53 46.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.225 -0.922 . . . . 0.0 110.028 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.406 ' O ' HG21 ' A' ' 142' ' ' ILE . 45.7 mm -88.67 16.59 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 109.936 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.416 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 4.8 t -95.93 -43.08 7.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.62 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -107.94 16.07 36.58 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.455 ' O ' ' HG ' ' A' ' 145' ' ' LEU . 11.3 tp . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.162 -1.199 . . . . 0.0 109.585 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 121.586 0.708 . . . . 0.0 109.106 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.419 ' O ' HG23 ' A' ' 10' ' ' VAL . 28.1 mt-30 -70.05 -26.44 64.02 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.521 -179.138 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.8 tmm_? -77.21 -41.03 42.96 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.188 -1.005 . . . . 0.0 108.829 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -56.76 -29.37 62.53 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.471 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 14.2 t -81.65 -29.53 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.524 HG12 ' CD1' ' A' ' 130' ' ' TRP . 53.1 t -76.92 -37.59 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.565 -0.709 . . . . 0.0 109.311 179.611 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.2 -11.4 59.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.323 -0.861 . . . . 0.0 109.937 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -92.67 -34.01 14.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.808 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.0 p -83.58 -15.96 47.17 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.276 -0.89 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -87.15 -23.58 24.79 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.119 -0.988 . . . . 0.0 109.483 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.1 mtpt -75.78 -5.36 45.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.811 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.416 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.7 OUTLIER -110.76 -58.83 2.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.053 -1.029 . . . . 0.0 109.592 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.466 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 26.5 mt -56.94 -35.12 46.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -104.97 34.8 3.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.282 -0.886 . . . . 0.0 109.67 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.14 -72.26 0.56 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.7 p -112.05 -31.01 7.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.221 -1.164 . . . . 0.0 109.618 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.432 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 9.6 p-10 -76.45 -16.79 59.59 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -0.908 . . . . 0.0 109.792 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 31.4 t30 60.47 24.96 14.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.228 -0.92 . . . . 0.0 109.554 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.21 38.4 5.69 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.432 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -83.32 -39.36 20.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.636 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.434 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -89.32 17.19 53.42 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 28.5 t -105.96 -40.22 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -1.209 . . . . 0.0 109.378 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.471 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -86.78 -40.14 7.29 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.477 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.0 ptpt -59.87 -30.16 68.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -1.188 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.477 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 8.5 pt-20 -93.19 -22.21 19.19 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.7 t -88.21 -62.38 1.5 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.966 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.505 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 23.0 m-85 -50.54 -35.81 31.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.332 -0.855 . . . . 0.0 110.179 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.436 ' CA ' HG12 ' A' ' 55' ' ' VAL . 18.6 m -53.14 -54.78 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.985 -1.072 . . . . 0.0 109.2 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.79 -43.02 85.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.156 -0.965 . . . . 0.0 108.944 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.436 ' O ' ' N ' ' A' ' 38' ' ' HIS . 90.4 t80 -55.32 -63.26 1.22 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -0.806 . . . . 0.0 109.1 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.454 ' CD2' ' HA ' ' A' ' 42' ' ' ALA . 5.7 mt -47.82 -43.89 28.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.435 -0.79 . . . . 0.0 109.71 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.89 -63.43 1.21 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.574 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -59.12 -24.35 62.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.465 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 16.1 m-70 -118.62 99.12 6.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.288 -0.882 . . . . 0.0 109.648 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.4 m170 -83.88 -19.95 33.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.593 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -70.0 -11.23 60.72 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.256 -0.903 . . . . 0.0 109.895 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.428 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 83.0 mmm -113.34 -21.6 10.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.111 -0.993 . . . . 0.0 109.888 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.454 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.81 -46.56 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.024 -1.047 . . . . 0.0 109.592 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.61 -21.22 61.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.254 -0.904 . . . . 0.0 109.312 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.5 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 7.1 t -77.28 -38.48 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.316 -0.865 . . . . 0.0 109.278 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.45 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 12.8 m-85 -70.47 -27.61 64.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.85 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 111.96 20.97 6.53 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.523 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 6.1 m-85 -119.75 164.88 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.282 -1.128 . . . . 0.0 109.801 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.28 -15.33 20.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.446 -0.784 . . . . 0.0 109.213 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.417 ' O ' ' OD2' ' A' ' 52' ' ' ASP . . . -164.57 -155.3 8.33 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.98 -0.21 27.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.438 -1.036 . . . . 0.0 110.079 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.0 t -107.24 51.9 0.73 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.949 -1.094 . . . . 0.0 109.861 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.417 ' OD2' ' O ' ' A' ' 49' ' ' GLY . 0.6 OUTLIER -131.23 149.25 73.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.255 -0.903 . . . . 0.0 109.674 179.799 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_exo -65.8 -24.31 54.43 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.973 1.512 . . . . 0.0 110.296 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.523 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -48.45 -35.87 16.33 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.454 HG21 ' CD1' ' A' ' 35' ' ' LEU . 57.5 t -61.26 -35.61 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -1.109 . . . . 0.0 109.445 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.471 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.39 -11.26 60.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.34 -31.2 16.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.606 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 58' ' ' LEU . 7.8 mt -88.42 -62.68 1.44 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.973 . . . . 0.0 109.725 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.505 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -50.15 -33.52 22.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -71.81 -43.83 64.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -1.18 . . . . 0.0 109.718 -179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.8 mtpp -74.95 -36.99 62.09 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 61.1 t -61.8 -47.65 92.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.819 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.429 ' N ' HD22 ' A' ' 63' ' ' LEU . 1.6 mm? -47.28 -46.31 24.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.16 -0.962 . . . . 0.0 109.899 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -47.44 -48.4 26.59 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.403 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 17.9 tp60 -52.64 -49.69 64.65 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.101 -0.999 . . . . 0.0 109.407 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 72.2 mt -58.1 -27.64 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.256 -0.902 . . . . 0.0 109.195 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.527 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.78 -54.88 8.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -60.67 -21.26 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.25 -1.147 . . . . 0.0 109.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.59 -25.15 23.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.461 ' CG1' HG11 ' A' ' 10' ' ' VAL . 41.4 t -73.08 -11.74 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.248 -0.907 . . . . 0.0 109.731 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -92.36 25.4 2.98 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 109.592 179.977 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.451 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 28.0 m-70 -142.68 -75.34 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.525 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.9 mm? . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.711 -0.618 . . . . 0.0 110.297 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.451 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 5.6 tmm? . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.342 0.591 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.413 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 73.0 t -79.58 -18.77 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.693 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -48.82 -51.43 29.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.788 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.52 -45.36 31.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.44 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 1.6 mtp -54.78 -53.44 55.18 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -51.12 -33.05 24.74 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.935 . . . . 0.0 109.202 179.696 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.405 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -68.89 -42.99 76.21 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.371 -0.831 . . . . 0.0 109.295 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.42 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 14.4 t -58.99 -41.45 83.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.133 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.421 ' O ' HD11 ' A' ' 145' ' ' LEU . . . -55.77 -48.86 69.26 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 179.497 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 78.1 t -52.71 -40.24 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.247 -1.149 . . . . 0.0 108.901 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -64.28 -50.94 65.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.398 -0.814 . . . . 0.0 109.01 179.273 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.509 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 25.4 m80 -55.5 -38.7 69.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.314 -0.866 . . . . 0.0 109.316 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.404 ' HD3' ' O ' ' A' ' 145' ' ' LEU . 10.0 ttpp -62.72 -15.8 54.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.304 -0.872 . . . . 0.0 109.982 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -124.06 43.28 1.43 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -88.13 -171.68 3.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.3 -1.118 . . . . 0.0 109.683 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.75 -44.6 7.16 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.5 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.1 p-10 -64.92 -33.22 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -1.134 . . . . 0.0 109.593 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.7 tttt 55.12 20.23 3.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.212 -0.93 . . . . 0.0 109.809 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -129.6 55.84 1.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.33 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.468 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 73.4 mt -90.32 156.3 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.327 -0.858 . . . . 0.0 110.193 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.511 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 2.7 mptt -143.34 131.6 22.01 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.486 -0.759 . . . . 0.0 109.665 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -73.25 -9.02 58.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.458 -0.777 . . . . 0.0 109.795 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.6 -23.2 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.511 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 73.7 m-85 -84.9 -15.84 43.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.125 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.402 ' O ' ' N ' ' A' ' 107' ' ' GLY . 3.6 m-85 -60.61 -68.75 0.27 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.195 -0.941 . . . . 0.0 110.368 -179.483 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.48 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.8 OUTLIER -44.37 -59.06 4.22 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.403 -0.811 . . . . 0.0 111.096 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 9.8 Cg_endo -55.06 -55.4 3.22 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.629 1.331 . . . . 0.0 110.034 -179.39 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.457 ' O ' ' CD1' ' A' ' 106' ' ' LEU . 3.0 tm? -62.78 -18.57 62.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' CE1' ' A' ' 134' ' ' TYR . . . -85.39 -39.85 8.15 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.16 45.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.231 -1.158 . . . . 0.0 109.489 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -21.5 11.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -67.58 -41.29 84.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.735 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.419 HD21 ' HB2' ' A' ' 130' ' ' TRP . 11.6 mt -60.65 -41.44 94.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.143 -0.973 . . . . 0.0 109.562 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.3 t -64.31 -29.94 71.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.852 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -83.37 -36.34 24.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.195 -0.941 . . . . 0.0 109.641 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.47 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.1 mtt -48.79 -35.89 15.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 110.3 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.439 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.7 OUTLIER -58.42 -23.19 56.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.116 -0.99 . . . . 0.0 109.66 -179.506 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.427 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 9.6 m170 -54.72 -49.14 71.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.133 -0.98 . . . . 0.0 109.56 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.466 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.1 OUTLIER -67.22 -62.61 1.34 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -0.929 . . . . 0.0 109.504 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.449 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 13.9 pt -92.03 47.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.262 -0.899 . . . . 0.0 109.431 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.91 125.47 37.25 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.42 -36.08 4.3 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.449 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.9 mmtp -87.46 -28.45 22.08 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.128 -1.219 . . . . 0.0 109.318 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -68.92 104.2 2.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.356 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 6.8 p30 -103.38 -170.14 1.74 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.37 -0.831 . . . . 0.0 109.992 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.32 -41.25 98.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.446 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -64.29 -25.15 67.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.747 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -79.07 -46.69 17.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.144 -0.973 . . . . 0.0 109.884 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.474 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 18.3 ptpt -74.11 -25.65 59.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.097 -1.002 . . . . 0.0 109.461 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.474 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 26.3 t0 -83.73 -43.11 15.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.323 -0.86 . . . . 0.0 109.195 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.471 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -60.98 -46.11 92.06 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.436 -0.79 . . . . 0.0 108.996 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.524 ' CD1' HG12 ' A' ' 10' ' ' VAL . 6.8 m0 -70.34 -31.0 68.09 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -55.89 -25.18 41.47 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.538 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.4 -32.84 15.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.494 -0.753 . . . . 0.0 109.151 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.59 -63.63 1.35 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.465 -0.772 . . . . 0.0 109.723 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.517 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.84 -25.37 4.41 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.947 . . . . 0.0 109.081 -179.979 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.52 -47.73 18.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -0.9 . . . . 0.0 109.031 179.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.41 -29.28 62.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.385 -0.822 . . . . 0.0 109.205 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.416 HD12 ' HA ' ' A' ' 134' ' ' TYR . 5.4 mt -66.99 -59.65 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.336 -0.852 . . . . 0.0 108.909 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 31.1 p -60.07 -26.54 66.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.556 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -77.55 -25.08 63.8 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.25 -29.82 63.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -1.12 . . . . 0.0 109.562 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.44 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 10.4 tt -75.1 -10.76 59.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.913 . . . . 0.0 109.864 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.413 ' O ' ' CG2' ' A' ' 142' ' ' ILE . 44.5 mm -92.41 37.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.132 -0.98 . . . . 0.0 109.697 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 21.5 m -116.74 -23.29 8.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.679 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.57 -8.49 6.91 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.425 HD11 ' HB2' ' A' ' 90' ' ' HIS . 26.3 tp . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.073 -1.251 . . . . 0.0 109.558 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.29 0.567 . . . . 0.0 109.655 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 -70.22 -47.14 62.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 109.58 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.54 -29.33 58.75 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.159 -0.963 . . . . 0.0 109.24 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -80.52 -37.79 30.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.371 -0.83 . . . . 0.0 108.86 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.408 HG13 ' HA ' ' A' ' 126' ' ' ALA . 57.7 t -72.5 -32.22 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.463 -0.773 . . . . 0.0 108.993 179.372 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.402 ' HA ' ' CD1' ' A' ' 130' ' ' TRP . 55.4 t -71.31 -37.89 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.468 -0.77 . . . . 0.0 109.272 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.62 -13.02 60.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.846 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 t -92.24 -24.27 19.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.139 -0.976 . . . . 0.0 109.961 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.459 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 16.7 p -91.28 -17.75 25.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.196 -0.94 . . . . 0.0 109.976 -179.718 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.517 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -84.35 -19.38 33.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 109.762 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.6 mtpt -83.46 1.83 39.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.998 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -118.04 -54.71 2.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.45 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.462 HD11 ' CH2' ' A' ' 130' ' ' TRP . 81.3 mt -66.51 -33.09 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.275 -0.89 . . . . 0.0 109.467 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.517 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.67 33.08 3.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.575 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.65 -87.84 0.01 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.6 p -101.0 -21.44 15.04 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.406 ' HB2' ' HB2' ' A' ' 24' ' ' ALA . 18.0 p-10 -81.63 -23.16 37.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.594 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.5 t30 57.09 29.36 16.41 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' HA3' ' CD2' ' A' ' 63' ' ' LEU . . . 90.68 38.66 6.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 21' ' ' ASP . . . -80.82 -58.2 3.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.266 -1.138 . . . . 0.0 109.643 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.468 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -73.18 -22.2 79.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.468 HG12 ' CD2' ' A' ' 63' ' ' LEU . 23.5 t -66.04 -29.19 46.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -1.103 . . . . 0.0 109.544 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.42 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -80.11 -56.38 3.27 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.471 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 14.6 ptpt -54.28 -24.95 20.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.177 -1.19 . . . . 0.0 110.175 -179.355 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 25' ' ' GLY . 18.8 pt-20 -97.75 -18.43 18.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.99 -1.069 . . . . 0.0 109.899 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.438 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 35.5 t -89.16 -68.84 0.75 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -0.937 . . . . 0.0 109.785 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.464 ' CB ' HG11 ' A' ' 55' ' ' VAL . 12.9 m-85 -48.17 -31.26 5.48 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.21 -0.931 . . . . 0.0 109.83 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.467 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.55 -54.02 46.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.931 . . . . 0.0 109.61 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' OG ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -60.49 -38.65 84.97 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.877 -179.887 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.1 t80 -59.11 -52.64 64.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.167 -0.958 . . . . 0.0 109.705 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.464 ' CD1' HG22 ' A' ' 55' ' ' VAL . 4.2 mt -58.86 -48.79 80.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.239 -0.913 . . . . 0.0 109.842 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.401 ' OG ' ' O ' ' A' ' 33' ' ' LYS . 3.3 p -56.0 -52.68 63.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.731 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.452 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -72.53 -25.13 61.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 0.0 109.713 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.452 ' CD2' ' HB3' ' A' ' 37' ' ' ALA . 18.6 m-70 -120.35 109.04 14.87 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.767 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -89.86 -21.55 22.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.408 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -71.07 -21.15 62.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.336 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.499 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -96.64 -13.87 22.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.885 . . . . 0.0 109.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.418 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -56.02 -64.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.095 -1.003 . . . . 0.0 109.514 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -54.79 -25.23 26.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.277 -0.89 . . . . 0.0 109.369 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.515 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 39.0 t -75.97 -43.69 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.499 ' CE2' ' HB3' ' A' ' 41' ' ' MET . 18.1 m-85 -73.35 -18.44 61.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.911 . . . . 0.0 109.67 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.415 ' O ' ' CD1' ' A' ' 47' ' ' PHE . . . 95.03 26.47 12.49 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.525 ' CD2' HG22 ' A' ' 55' ' ' VAL . 15.1 m-85 -126.9 -177.1 3.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -1.128 . . . . 0.0 109.982 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.99 16.21 7.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.461 -0.774 . . . . 0.0 109.415 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 144.84 -163.42 27.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.7 -17.79 52.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.308 -1.113 . . . . 0.0 109.826 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -85.14 49.92 1.84 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.932 . . . . 0.0 109.665 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.32 122.9 15.14 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.611 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -65.83 -25.9 52.67 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.872 1.459 . . . . 0.0 110.077 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.51 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.89 -33.4 43.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 47' ' ' PHE . 97.6 t -52.01 -33.62 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -1.142 . . . . 0.0 109.298 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . . . -74.1 -4.29 34.71 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.289 -0.882 . . . . 0.0 109.578 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -90.18 -36.02 15.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.122 -0.986 . . . . 0.0 109.791 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.452 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 10.6 mt -83.99 -62.16 1.64 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.032 -1.042 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.42 ' HA3' ' CA ' ' A' ' 27' ' ' GLY . . . -52.46 -28.36 28.34 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -64.72 -53.67 43.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.062 -1.257 . . . . 0.0 109.756 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.7 mttm -79.56 -43.75 22.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.452 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 94.8 t -46.8 -58.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.389 -0.819 . . . . 0.0 110.229 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.468 ' CD2' HG12 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -46.43 -38.84 9.59 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.205 -0.934 . . . . 0.0 109.987 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.47 -42.15 61.4 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.935 . . . . 0.0 109.521 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.407 ' HB2' ' O ' ' A' ' 62' ' ' VAL . 3.2 mm100 -60.67 -42.12 96.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.172 -0.955 . . . . 0.0 109.321 179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 88.9 mt -61.13 -33.49 56.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.24 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.517 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.38 -53.66 24.04 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.921 -1.672 . . . . 0.0 108.921 179.621 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.4 t -59.84 -24.24 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.315 -1.109 . . . . 0.0 109.207 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.09 -30.33 22.66 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.408 -0.807 . . . . 0.0 109.578 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.456 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 48.2 t -63.5 -21.21 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.495 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.08 44.0 1.16 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.179 -0.951 . . . . 0.0 109.874 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.452 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 4.3 m-70 -152.15 -84.07 0.08 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.129 -0.982 . . . . 0.0 110.311 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.514 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.6 mm? . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.774 -0.579 . . . . 0.0 110.559 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.452 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 3.1 tmm? . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.227 0.536 . . . . 0.0 109.774 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.4 t -73.81 -8.07 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.922 . . . . 0.0 110.071 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -77.74 -32.09 52.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.989 -1.069 . . . . 0.0 109.712 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -99.34 -41.45 7.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.925 . . . . 0.0 109.639 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.461 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 2.4 mtp -62.53 -47.79 82.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.188 -0.945 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.403 ' HG2' ' HB2' ' A' ' 143' ' ' SER . 0.1 OUTLIER -54.96 -35.73 64.58 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.255 -0.903 . . . . 0.0 109.279 179.694 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -64.23 -35.39 80.65 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.229 -0.919 . . . . 0.0 109.266 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.458 ' CG1' HD13 ' A' ' 141' ' ' LEU . 28.6 t -55.08 -48.96 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.352 -0.843 . . . . 0.0 109.42 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.41 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -51.99 -50.42 44.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.454 HG22 ' CA ' ' A' ' 144' ' ' GLY . 97.0 t -48.68 -25.3 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.327 -1.102 . . . . 0.0 109.596 179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.505 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.2 mmt180 -77.08 -44.67 29.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.179 -0.951 . . . . 0.0 109.127 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.476 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 17.7 m80 -58.78 -19.87 44.7 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.349 -0.845 . . . . 0.0 109.196 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.416 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 25.5 ttpt -68.04 -15.09 63.45 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.419 -0.801 . . . . 0.0 109.851 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.91 50.51 0.81 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.8 m-30 -94.23 -172.41 2.8 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.237 -1.155 . . . . 0.0 109.328 179.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.74 -40.3 53.27 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.515 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 1.7 t30 -78.39 -44.68 24.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.464 -1.021 . . . . 0.0 109.001 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 71.93 -54.24 0.68 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.396 -0.815 . . . . 0.0 110.314 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 28.9 m170 -66.69 69.2 0.07 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.974 . . . . 0.0 110.115 -179.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.459 HG22 HD12 ' A' ' 98' ' ' ILE . 84.5 mt -100.61 161.76 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.93 . . . . 0.0 109.329 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.466 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -136.92 142.54 42.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.139 -0.975 . . . . 0.0 109.726 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.16 -0.41 51.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.878 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.511 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 7.6 pt-20 -78.74 -28.43 44.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.104 -0.998 . . . . 0.0 109.676 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.511 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 92.8 m-85 -78.03 -13.52 59.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 109.845 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.481 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -57.9 -64.57 0.86 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.203 -0.936 . . . . 0.0 110.192 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.483 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.3 mt-10 -51.38 -55.87 25.35 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.169 -0.957 . . . . 0.0 110.208 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.483 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 33.6 Cg_exo -49.42 -54.27 5.71 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.69 1.363 . . . . 0.0 110.19 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.518 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.1 tm? -57.05 -19.46 19.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.223 -0.923 . . . . 0.0 109.599 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.53 -39.82 20.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.63 -57.14 12.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.243 -1.151 . . . . 0.0 109.614 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.2 m -56.91 -23.23 43.48 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.608 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.454 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 4.4 tt -70.38 -43.77 69.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.558 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.2 mt -57.06 -30.43 64.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.503 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.4 t -66.65 -39.01 88.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.208 -0.933 . . . . 0.0 109.633 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.42 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -75.15 -39.82 60.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.668 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.551 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.2 mmt -48.05 -40.31 22.59 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.203 -0.936 . . . . 0.0 109.874 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -54.11 -24.57 18.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.264 -0.897 . . . . 0.0 109.746 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.42 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -49.65 -53.08 26.36 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.184 -0.947 . . . . 0.0 109.697 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.405 ' HG2' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -75.19 -72.55 0.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.153 -0.967 . . . . 0.0 109.579 -179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.439 HG12 ' CD1' ' A' ' 17' ' ' ILE . 3.1 pt -86.42 56.32 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.916 . . . . 0.0 109.657 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -68.35 -23.69 74.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -94.77 -21.7 25.45 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.404 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 59.2 mttt -100.64 -21.47 15.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.627 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.43 ' CB ' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.16 80.43 0.13 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.327 -0.858 . . . . 0.0 109.632 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.451 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.9 p30 -83.79 -163.93 0.84 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.612 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -71.46 -42.17 68.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.451 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -62.67 -24.02 67.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' HG13 ' A' ' 9' ' ' VAL . . . -77.18 -52.8 8.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.595 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.445 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 15.5 ptpt -67.46 -33.2 74.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.918 . . . . 0.0 109.363 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.445 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.0 t70 -73.17 -55.42 6.49 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.413 179.774 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -51.23 -43.42 61.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.405 -0.809 . . . . 0.0 109.373 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.551 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 2.8 m0 -75.74 -29.34 58.85 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.351 -0.843 . . . . 0.0 109.107 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.07 -27.85 65.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.183 179.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.31 -26.63 21.02 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.305 -0.872 . . . . 0.0 109.28 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.418 ' O ' ' CD1' ' A' ' 137' ' ' ILE . . . -79.49 -45.22 19.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.415 -0.803 . . . . 0.0 109.503 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.454 ' OH ' ' CD2' ' A' ' 110' ' ' LEU . 5.8 m-85 -48.99 -31.61 7.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.08 -36.41 69.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.29 -0.881 . . . . 0.0 109.39 179.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.57 -40.37 29.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.524 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.461 ' O ' ' CE ' ' A' ' 83' ' ' MET . 1.9 mp -67.42 -56.68 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.864 . . . . 0.0 109.139 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.6 p -68.26 -26.58 65.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.739 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -71.02 -35.78 64.56 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.48 -21.69 66.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.189 -1.183 . . . . 0.0 109.763 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.481 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.2 tt -82.32 -12.62 57.87 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -0.945 . . . . 0.0 109.944 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 36.5 mt -79.61 3.26 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.138 -0.976 . . . . 0.0 110.157 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.403 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 9.5 m -89.92 -45.06 9.48 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.015 -1.053 . . . . 0.0 109.632 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.454 ' CA ' HG22 ' A' ' 88' ' ' VAL . . . -82.56 -28.58 38.81 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.452 HD11 ' CD2' ' A' ' 141' ' ' LEU . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.378 -1.072 . . . . 0.0 109.609 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.198 0.523 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -62.02 -52.83 62.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.539 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.45 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 7.5 ptm180 -50.47 -33.9 22.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.34 179.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.45 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 56.6 tp60 -75.57 -46.62 30.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.7 t -60.54 -34.85 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.178 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.508 HG12 ' CD1' ' A' ' 130' ' ' TRP . 69.8 t -64.66 -48.73 83.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.36 -0.838 . . . . 0.0 109.343 179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.35 -11.53 60.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 109.675 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -91.17 -25.51 19.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.135 -0.978 . . . . 0.0 109.717 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 p -98.01 -11.75 22.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.183 -0.948 . . . . 0.0 109.809 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.551 ' CE3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.8 -28.39 20.48 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.082 -1.011 . . . . 0.0 109.657 -179.882 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -70.76 -15.26 62.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -99.55 -61.52 1.36 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.644 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.446 HD11 ' CH2' ' A' ' 130' ' ' TRP . 55.8 mt -57.9 -39.13 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.711 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.551 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -102.64 36.09 2.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.702 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.8 -82.5 0.06 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.0 p -97.93 -26.24 14.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 0.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -80.75 -23.8 39.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.639 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 27.2 t30 56.92 22.07 6.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.97 23.44 9.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.412 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -69.57 -54.31 14.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 109.619 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.439 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -85.93 10.98 63.59 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.467 HG13 ' CD2' ' A' ' 63' ' ' LEU . 35.8 t -104.84 -22.66 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.241 . . . . 0.0 109.202 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.436 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -98.95 -35.43 4.83 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.481 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 15.0 ptpt -68.88 -27.04 65.44 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.189 -1.183 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.436 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 17.5 pt-20 -100.82 -5.97 25.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 110.087 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.5 t -95.99 -67.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.054 -1.029 . . . . 0.0 109.978 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -47.18 -29.78 2.53 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.206 -0.934 . . . . 0.0 110.149 -179.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.436 ' CA ' HG12 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -52.74 -63.25 1.2 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.074 -1.016 . . . . 0.0 109.207 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.405 ' O ' ' HB2' ' A' ' 37' ' ' ALA . 0.3 OUTLIER -50.35 -47.49 55.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.341 -0.849 . . . . 0.0 109.242 179.699 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.512 ' CG ' HD22 ' A' ' 106' ' ' LEU . 7.8 t80 -56.46 -51.26 69.1 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.18 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.509 HD21 ' CG ' ' A' ' 45' ' ' PHE . 19.5 mt -58.32 -44.7 88.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.496 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -62.95 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.344 -0.848 . . . . 0.0 109.612 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.418 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -52.8 -24.48 9.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.626 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.45 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 19.0 m-70 -125.0 101.74 7.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.299 -0.876 . . . . 0.0 109.738 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -84.51 -17.48 38.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.398 -0.814 . . . . 0.0 109.503 179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -67.87 -16.11 63.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.54 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 89.6 mmm -120.04 -15.02 8.82 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 110.019 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.417 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.04 -44.84 41.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.913 -1.117 . . . . 0.0 109.525 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.0 -29.75 60.97 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.322 -0.861 . . . . 0.0 109.26 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.486 HG11 ' ND2' ' A' ' 95' ' ' ASN . 2.4 t -60.89 -27.99 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.342 -0.849 . . . . 0.0 109.173 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.519 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 8.3 m-85 -82.64 -27.8 31.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.103 -0.998 . . . . 0.0 109.683 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.448 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.84 20.26 6.51 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.525 ' CD2' HG22 ' A' ' 55' ' ' VAL . 3.6 m-85 -117.88 172.84 7.12 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.231 -1.159 . . . . 0.0 109.653 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.6 t -115.28 22.09 13.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.331 -0.856 . . . . 0.0 109.029 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.45 -170.8 28.93 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.86 11.28 11.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -1.168 . . . . 0.0 109.97 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.04 20.3 18.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.994 . . . . 0.0 109.557 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.403 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -101.31 136.42 19.67 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.54 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -68.03 -17.01 45.97 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.916 1.482 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.0 -36.88 61.38 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 47' ' ' PHE . 61.2 t -51.71 -33.27 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.238 -1.154 . . . . 0.0 109.449 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.481 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -79.28 -13.77 59.45 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.252 -0.905 . . . . 0.0 109.787 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -90.21 -23.14 21.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.184 -0.947 . . . . 0.0 109.494 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.4 mt -90.89 -66.43 0.93 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.902 . . . . 0.0 109.906 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.93 -30.89 38.27 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -1.217 . . . . 0.0 109.479 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.407 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 17.0 mttt -94.34 -38.44 10.98 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.42 -0.8 . . . . 0.0 109.485 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 91.4 t -51.43 -57.99 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.38 -0.825 . . . . 0.0 109.794 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.467 ' CD2' HG13 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.31 -45.0 24.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.227 -0.921 . . . . 0.0 109.677 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.407 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -47.66 -40.74 20.67 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.687 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 35.2 tp60 -64.79 -41.28 95.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.195 -0.941 . . . . 0.0 109.164 179.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 59.4 mt -60.79 -37.31 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -0.843 . . . . 0.0 109.144 179.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.76 29.68 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.2 t -58.04 -24.81 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -1.125 . . . . 0.0 109.17 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.0 -34.21 22.4 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.418 -0.801 . . . . 0.0 109.433 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.456 ' CG1' HG11 ' A' ' 10' ' ' VAL . 50.7 t -63.95 -19.33 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -0.899 . . . . 0.0 109.425 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 24.1 m -62.2 -41.93 98.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.196 -0.94 . . . . 0.0 109.667 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 71' ' ' SER . 8.7 m-70 -131.02 84.48 2.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.724 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 42.1 mt . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 109.6 179.95 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.7 tmm? . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.272 0.558 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.406 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 54.8 t -76.86 -22.51 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.258 -0.901 . . . . 0.0 109.605 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.47 -17.89 61.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.851 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -92.57 -49.84 5.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 109.761 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.416 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 95.8 mmm -60.74 -45.91 92.49 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.067 -1.021 . . . . 0.0 109.156 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.439 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 2.0 mttt -51.73 -31.17 25.34 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.128 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.448 ' O ' ' CG ' ' A' ' 89' ' ' ARG . . . -79.47 -32.02 42.53 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.462 -0.774 . . . . 0.0 108.956 179.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.454 ' CG1' HD13 ' A' ' 141' ' ' LEU . 45.2 t -69.86 -41.69 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.127 -0.983 . . . . 0.0 109.273 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.411 ' O ' HD11 ' A' ' 145' ' ' LEU . . . -66.31 -43.49 92.69 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.931 -1.667 . . . . 0.0 108.931 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.439 ' CG2' ' O ' ' A' ' 84' ' ' LYS . 97.0 t -59.25 -29.4 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -1.191 . . . . 0.0 109.178 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.478 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.9 OUTLIER -76.63 -45.7 28.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -0.871 . . . . 0.0 109.316 179.773 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.512 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 22.0 m80 -59.18 -20.67 55.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.088 179.428 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 ttpt -70.23 -9.54 56.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.89 . . . . 0.0 110.188 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.4 54.57 0.55 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.516 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.9 m-30 -88.8 -168.99 2.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -1.167 . . . . 0.0 109.613 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -76.49 -36.46 38.48 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.486 ' ND2' HG11 ' A' ' 44' ' ' VAL . 16.7 p-10 -79.67 -24.66 41.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.046 -1.267 . . . . 0.0 110.009 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 ttmm 51.41 26.79 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.153 -0.967 . . . . 0.0 109.499 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 4.6 m-70 -134.28 42.97 2.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.42 -0.8 . . . . 0.0 109.323 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.516 HD11 ' CD2' ' A' ' 93' ' ' TYR . 58.9 mt -86.03 156.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 110.061 -179.633 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.456 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.28 143.69 25.08 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.706 0.765 . . . . 0.0 109.882 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.1 -6.37 56.3 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.717 -0.614 . . . . 0.0 109.622 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -72.95 -28.73 62.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.091 -1.006 . . . . 0.0 109.359 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.54 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 44.8 m-85 -79.93 -20.42 45.72 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -57.37 -68.13 0.26 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.338 -0.851 . . . . 0.0 110.555 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 3.4 mt-10 -43.24 -59.96 2.81 Favored Pre-proline 0 N--CA 1.495 1.808 0 O-C-N 121.516 -0.74 . . . . 0.0 111.016 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' CD ' ' CB ' ' A' ' 104' ' ' GLU . 8.8 Cg_endo -55.99 -42.52 65.93 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.732 1.385 . . . . 0.0 110.199 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.512 HD22 ' CG ' ' A' ' 34' ' ' PHE . 2.9 tm? -66.75 -27.18 67.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.475 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.36 -38.8 37.8 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.45 -48.42 72.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -1.127 . . . . 0.0 109.539 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.2 m -62.31 -26.46 68.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.548 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.3 tt -70.42 -40.22 73.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 109.563 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.441 HD12 ' N ' ' A' ' 131' ' ' ALA . 13.0 mt -58.96 -32.04 69.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.426 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.53 -27.75 64.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.282 -0.886 . . . . 0.0 109.523 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.43 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -84.18 -35.07 23.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.224 -0.922 . . . . 0.0 109.689 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.49 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 4.3 mmt -46.93 -50.4 18.95 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.285 -0.884 . . . . 0.0 110.227 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.475 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 8.5 pt-20 -47.23 -24.76 0.78 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 110.276 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.43 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 19.8 m170 -53.65 -31.33 47.08 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.709 -1.244 . . . . 0.0 109.651 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.41 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -91.89 -68.39 0.8 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.19 -0.944 . . . . 0.0 110.127 -179.655 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.46 HG13 ' N ' ' A' ' 119' ' ' GLY . 18.3 pt -78.21 -34.16 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.116 -0.99 . . . . 0.0 109.756 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.475 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . 41.2 -98.73 0.01 OUTLIER Glycine 0 N--CA 1.498 2.794 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.61 -39.46 10.56 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.448 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.6 OUTLIER -73.29 -18.13 61.24 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.044 -1.268 . . . . 0.0 109.919 -179.806 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.459 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -79.45 107.06 11.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 179.571 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.4 p-10 -111.61 -171.23 1.8 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.926 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.445 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.47 -49.0 79.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.424 -0.798 . . . . 0.0 109.963 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -57.83 -20.72 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.516 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -85.44 -55.73 3.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.311 -0.868 . . . . 0.0 109.791 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.445 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -69.69 -24.78 63.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.781 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -80.04 -45.35 18.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.236 -0.915 . . . . 0.0 109.524 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.402 ' HB3' HG22 ' A' ' 10' ' ' VAL . . . -65.25 -45.89 82.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.391 -0.818 . . . . 0.0 109.391 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.508 ' CD1' HG12 ' A' ' 10' ' ' VAL . 4.7 m0 -66.41 -29.4 69.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -0.864 . . . . 0.0 109.34 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.441 ' N ' HD12 ' A' ' 111' ' ' LEU . . . -69.64 -28.06 65.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 108.932 179.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.81 -31.72 15.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.44 -0.787 . . . . 0.0 109.359 179.614 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.06 -39.78 68.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.398 -0.814 . . . . 0.0 109.206 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.415 ' O ' ' HB3' ' A' ' 138' ' ' SER . 5.3 m-30 -52.64 -30.89 34.05 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.342 -0.849 . . . . 0.0 109.064 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.58 -35.07 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.336 -0.852 . . . . 0.0 109.242 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -77.89 -39.07 44.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.33 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.416 ' O ' ' CE ' ' A' ' 83' ' ' MET . 12.2 mt -65.82 -58.48 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.297 -0.877 . . . . 0.0 109.109 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.417 ' O ' ' HB3' ' A' ' 141' ' ' LEU . 0.1 OUTLIER -68.51 -28.25 66.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -58.38 -52.72 51.09 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.04 -23.28 13.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.259 -1.142 . . . . 0.0 109.535 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.454 HD13 ' CG1' ' A' ' 86' ' ' VAL . 10.5 tt -81.73 -18.12 45.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.703 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.459 ' CG2' ' O ' ' A' ' 142' ' ' ILE . 69.3 mt -89.88 37.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.78 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 60.7 m -117.84 -36.15 3.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.073 -1.017 . . . . 0.0 109.688 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.412 ' HA3' HG22 ' A' ' 88' ' ' VAL . . . -105.12 -18.01 12.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.411 HD11 ' O ' ' A' ' 87' ' ' GLY . 4.9 tp . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.123 -1.221 . . . . 0.0 109.581 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.405 ' O ' HG22 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 46.9 mt-30 -81.35 -46.86 14.05 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.131 -0.981 . . . . 0.0 109.621 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.455 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -54.84 -31.66 59.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.089 -1.007 . . . . 0.0 109.468 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.455 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 27.7 mm100 -70.78 -37.43 73.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 109.336 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 5' ' ' ALA . 47.3 t -69.71 -29.18 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.441 HG13 ' CD2' ' A' ' 73' ' ' LEU . 63.8 t -70.73 -43.76 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.309 -0.869 . . . . 0.0 109.291 179.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.61 -12.79 60.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.319 -0.863 . . . . 0.0 109.771 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.0 t -91.89 -27.79 17.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.403 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 18.7 p -90.93 -13.85 32.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.141 -0.974 . . . . 0.0 110.032 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.534 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -88.44 -15.07 36.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.068 -1.02 . . . . 0.0 109.865 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.42 -0.58 55.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.947 . . . . 0.0 109.924 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -113.3 -49.67 2.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.034 -1.041 . . . . 0.0 109.602 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.464 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 58.5 mt -69.43 -36.19 70.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.251 -0.906 . . . . 0.0 109.575 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.434 ' CB ' ' HA ' ' A' ' 22' ' ' ASN . . . -102.14 33.17 3.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 109.72 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -61.81 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 p -120.39 -36.74 3.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -1.123 . . . . 0.0 109.594 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.456 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 2.0 p30 -71.26 -19.15 62.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.261 -0.899 . . . . 0.0 109.665 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.434 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 28.4 t30 57.53 19.65 5.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -0.929 . . . . 0.0 109.635 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.413 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 105.46 19.36 10.58 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.456 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -64.91 -52.39 56.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -1.181 . . . . 0.0 109.596 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.472 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.23 -22.73 75.65 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.464 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 15.5 t -71.09 -41.01 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -1.086 . . . . 0.0 109.855 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' CA ' HD23 ' A' ' 63' ' ' LEU . . . -74.93 -57.19 4.53 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.472 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 15.8 ptpt -47.39 -31.3 3.93 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.208 -1.172 . . . . 0.0 110.228 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.426 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 23.4 pt-20 -95.79 -17.81 20.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.058 -1.026 . . . . 0.0 109.939 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 29.3 t -83.54 -68.11 0.74 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.948 . . . . 0.0 109.8 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.513 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.8 m-85 -50.32 -32.04 16.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -51.95 -55.05 22.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.1 -1.0 . . . . 0.0 109.165 179.718 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -57.68 -48.6 79.07 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.32 -0.862 . . . . 0.0 109.268 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.519 ' CG ' HD22 ' A' ' 106' ' ' LEU . 3.1 t80 -55.04 -49.05 72.54 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.195 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.465 ' CD2' ' HA ' ' A' ' 42' ' ' ALA . 23.2 mt -59.83 -41.57 91.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.854 . . . . 0.0 109.725 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.79 -63.34 1.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.935 . . . . 0.0 109.818 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.473 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -58.25 -21.36 48.12 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.203 -0.936 . . . . 0.0 109.886 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.473 ' CD2' ' HB3' ' A' ' 37' ' ' ALA . 16.5 m-70 -126.74 106.71 9.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.922 . . . . 0.0 109.933 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 5.5 m170 -85.88 -20.44 29.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.535 -0.728 . . . . 0.0 109.249 179.292 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -73.05 -20.29 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.248 -0.908 . . . . 0.0 109.098 179.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.485 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -91.86 -20.43 21.46 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -0.866 . . . . 0.0 109.537 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.465 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.26 -56.48 20.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.302 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.61 63.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.288 -0.882 . . . . 0.0 109.255 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.509 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 22.4 t -71.4 -58.45 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.288 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.515 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 39.7 m-85 -57.2 -40.69 77.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.58 35.18 1.1 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CD2' HG22 ' A' ' 55' ' ' VAL . 13.0 m-85 -125.62 169.0 12.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 109.858 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 t -112.34 18.07 18.85 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.351 -0.843 . . . . 0.0 109.372 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.3 -164.05 29.28 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.43 25.31 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -1.155 . . . . 0.0 109.716 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 37.6 m -124.78 31.04 5.77 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.623 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.54 135.45 21.9 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 109.642 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -64.07 -18.21 62.71 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.929 1.489 . . . . 0.0 109.972 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.518 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.62 -39.08 94.65 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.518 HG22 ' CD2' ' A' ' 47' ' ' PHE . 65.6 t -52.09 -38.56 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.322 -1.105 . . . . 0.0 109.411 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.467 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -74.01 -12.22 60.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 0.0 109.659 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -92.76 -35.5 13.4 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.972 . . . . 0.0 109.662 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.452 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 1.9 mt -79.43 -61.16 2.09 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.241 -0.912 . . . . 0.0 109.873 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.513 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -55.61 -36.47 64.8 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.467 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -60.85 -52.63 64.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.09 -1.241 . . . . 0.0 109.365 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.6 mttt -67.5 -41.99 83.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.308 -0.87 . . . . 0.0 109.183 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.452 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 63.3 t -56.42 -44.51 80.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.175 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.458 ' CD2' ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -48.17 -46.07 34.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.65 -49.46 56.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.107 -0.995 . . . . 0.0 109.33 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -52.99 -37.66 61.55 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -0.892 . . . . 0.0 109.088 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.568 ' CG2' ' CE1' ' A' ' 134' ' ' TYR . 34.7 mm -67.87 -35.75 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 109.063 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.43 -47.22 44.06 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 43.9 t -62.45 -25.43 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.361 -1.082 . . . . 0.0 109.439 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.41 ' O ' ' HB2' ' A' ' 73' ' ' LEU . . . -84.83 -30.7 24.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.411 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 53.8 t -62.68 -37.23 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.488 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.2 p -51.39 -69.28 0.12 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.923 . . . . 0.0 109.348 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.412 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 9.0 m-70 -90.82 45.32 1.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 109.192 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.46 HD23 ' CB ' ' A' ' 133' ' ' ALA . 30.4 tp . . . . . 0 C--N 1.305 -1.356 0 O-C-N 121.244 -0.91 . . . . 0.0 109.526 -179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.412 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 8.3 tmm? . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.416 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 37.9 t -62.01 -24.46 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.857 . . . . 0.0 109.108 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.65 -52.86 55.11 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.266 -0.896 . . . . 0.0 109.23 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -66.91 -46.16 75.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.113 179.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.6 mtp -52.61 -48.91 66.01 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.453 ' NZ ' ' O ' ' A' ' 140' ' ' ALA . 0.2 OUTLIER -52.63 -34.22 50.27 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.182 -0.949 . . . . 0.0 108.894 179.389 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -66.58 -15.87 63.75 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.463 ' HB ' ' CD1' ' A' ' 141' ' ' LEU . 11.3 t -85.81 -32.52 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.033 -1.042 . . . . 0.0 108.624 179.315 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.464 ' CA ' HD23 ' A' ' 141' ' ' LEU . . . -71.26 -43.32 55.6 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 179.176 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.407 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 96.3 t -55.65 -25.93 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.38 -1.07 . . . . 0.0 108.62 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.509 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.3 OUTLIER -76.06 -49.53 17.25 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 108.996 179.301 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.482 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 24.5 m80 -62.04 -21.71 65.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.379 -0.826 . . . . 0.0 109.01 179.553 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.407 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.2 OUTLIER -63.58 -14.13 48.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.396 -0.815 . . . . 0.0 109.972 -179.884 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.47 53.46 0.58 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.509 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.9 m-30 -91.31 -173.2 3.53 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -1.168 . . . . 0.0 109.349 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.45 -25.51 54.0 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 179.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.509 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 1.2 t30 -82.34 -45.49 14.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.463 -1.022 . . . . 0.0 109.179 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 9.0 ttpt 72.3 -53.75 0.69 Allowed 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.464 -0.773 . . . . 0.0 110.224 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 38.1 m170 -65.61 73.07 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.119 -0.988 . . . . 0.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.462 ' N ' ' O ' ' A' ' 96' ' ' LYS . 48.8 mt -104.81 155.03 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.521 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.508 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.7 mptp? -138.72 149.76 45.43 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.231 -0.918 . . . . 0.0 109.948 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.45 ' CB ' HG12 ' A' ' 142' ' ' ILE . . . -87.45 -18.79 29.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.527 -0.733 . . . . 0.0 109.628 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.45 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 17.7 pt-20 -67.22 -19.64 65.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.508 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 52.6 m-85 -82.06 -21.41 36.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.249 -0.907 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.41 ' HB2' ' O ' ' A' ' 100' ' ' ALA . 4.5 m-85 -60.42 -64.56 0.91 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.294 -0.879 . . . . 0.0 110.205 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.487 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.77 -58.75 4.2 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.462 -0.774 . . . . 0.0 110.987 -179.328 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 7.4 Cg_endo -55.06 -47.29 27.26 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 123.63 1.332 . . . . 0.0 110.082 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.519 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.2 tm? -61.75 -22.43 65.39 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.151 -0.968 . . . . 0.0 109.428 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.98 -48.24 11.89 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.79 -51.26 70.75 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 109.595 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 m -58.9 -18.77 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.658 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.499 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 1.2 tt -75.71 -31.14 59.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.178 -0.951 . . . . 0.0 109.722 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.2 mt -71.29 -29.03 64.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 0.0 109.581 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.13 -34.29 70.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.916 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.404 ' HB3' ' HG3' ' A' ' 29' ' ' GLU . . . -80.89 -29.55 35.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.719 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.499 ' CE ' ' CD2' ' A' ' 110' ' ' LEU . 2.7 mtt -61.72 -34.16 75.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.896 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.448 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -61.49 -17.85 56.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.174 -0.954 . . . . 0.0 109.409 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -57.94 -49.14 77.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.721 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.1 ttt85 -74.25 -65.68 0.82 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.698 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.453 HG12 ' CD1' ' A' ' 17' ' ' ILE . 7.0 pt -92.31 53.19 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.258 -0.901 . . . . 0.0 109.726 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.448 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.49 -15.12 61.1 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.39 -30.95 6.68 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.71 -26.02 17.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -1.16 . . . . 0.0 109.791 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.42 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -60.19 97.67 0.05 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 -179.903 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 15.7 p-10 -106.42 -171.5 1.91 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.417 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.15 -49.48 77.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.388 -0.82 . . . . 0.0 109.952 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -58.4 -26.22 62.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.05 -1.031 . . . . 0.0 109.321 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -76.95 -54.01 7.11 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.231 -0.918 . . . . 0.0 109.849 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.417 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 6.3 ptmm? -70.9 -29.29 65.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.058 -1.026 . . . . 0.0 109.792 -179.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -77.85 -42.03 34.91 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -0.93 . . . . 0.0 109.607 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -65.53 -50.16 66.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.407 179.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.52 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 4.0 m0 -64.55 -28.77 69.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.299 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -65.23 -28.81 69.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.188 -0.945 . . . . 0.0 109.064 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -90.58 -24.32 20.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.395 -0.816 . . . . 0.0 109.373 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.46 ' CB ' HD23 ' A' ' 73' ' ' LEU . . . -77.47 -62.8 1.54 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.355 -0.841 . . . . 0.0 109.685 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.568 ' CE1' ' CG2' ' A' ' 66' ' ' ILE . 16.2 m-30 -52.0 -26.19 10.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.228 -0.92 . . . . 0.0 109.577 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.67 -44.85 69.64 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.208 -0.932 . . . . 0.0 108.904 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -75.41 -32.27 60.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.407 -0.808 . . . . 0.0 109.281 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.1 mt -67.46 -59.29 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.321 -0.862 . . . . 0.0 109.313 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.442 ' O ' ' CD1' ' A' ' 142' ' ' ILE . 2.4 p -67.25 -13.72 62.24 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.312 -0.868 . . . . 0.0 109.805 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.457 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -84.96 -21.74 54.69 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.453 ' O ' ' NZ ' ' A' ' 84' ' ' LYS . . . -86.24 -10.36 54.78 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 110.054 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.464 HD23 ' CA ' ' A' ' 87' ' ' GLY . 3.0 tt -89.14 17.24 6.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.029 -1.045 . . . . 0.0 109.882 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.457 ' CD1' ' HA2' ' A' ' 139' ' ' GLY . 1.9 mp -107.52 7.15 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.099 -1.001 . . . . 0.0 110.121 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.77 -34.48 11.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.945 -1.097 . . . . 0.0 109.63 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.83 11.1 27.52 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.459 HD12 ' CB ' ' A' ' 90' ' ' HIS . 11.4 tp . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.106 -1.232 . . . . 0.0 109.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.295 0.569 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 -64.34 -44.57 91.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.219 -0.926 . . . . 0.0 109.69 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -48.68 -50.55 32.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.512 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -59.0 -48.38 81.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 0.0 109.057 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.41 HG13 ' HA ' ' A' ' 126' ' ' ALA . 48.6 t -59.83 -36.11 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 0.0 109.145 179.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.463 HG13 ' CD1' ' A' ' 73' ' ' LEU . 65.7 t -72.14 -46.47 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.36 -0.837 . . . . 0.0 109.116 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.03 -18.01 61.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.53 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.8 t -87.12 -25.44 24.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.415 HG23 ' HB1' ' A' ' 126' ' ' ALA . 3.2 p -91.08 -17.19 26.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.547 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -87.02 -15.67 37.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.923 . . . . 0.0 109.841 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -84.45 -14.34 49.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.113 -0.992 . . . . 0.0 109.596 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -98.84 -51.25 3.94 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.156 -0.965 . . . . 0.0 109.614 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.49 HD11 ' CH2' ' A' ' 130' ' ' TRP . 62.2 mt -69.11 -36.41 73.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.249 -0.907 . . . . 0.0 109.585 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.547 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.27 33.16 3.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.692 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.2 -81.75 0.05 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.8 p -102.04 -17.49 16.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -1.149 . . . . 0.0 109.725 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.464 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 5.5 p-10 -89.02 -19.65 25.38 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.218 -0.926 . . . . 0.0 109.656 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 19.0 t30 59.32 24.57 13.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.238 -0.914 . . . . 0.0 109.674 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.94 22.69 14.93 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.027 -1.629 . . . . 0.0 109.027 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.464 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -71.12 -43.63 67.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.295 -1.12 . . . . 0.0 109.71 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.407 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.91 22.84 20.04 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.438 HG21 ' CG2' ' A' ' 17' ' ' ILE . 16.9 t -115.14 -34.23 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -1.194 . . . . 0.0 109.057 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.464 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -92.57 -39.39 5.31 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.469 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 2.5 ptmt -63.85 -30.01 71.14 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -1.225 . . . . 0.0 109.381 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.443 ' HG3' ' N ' ' A' ' 30' ' ' CYS . 6.5 pt-20 -92.59 -22.2 19.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.443 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 37.8 t -85.47 -51.44 6.52 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.294 -0.879 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.506 ' CE2' ' HB3' ' A' ' 58' ' ' LEU . 3.7 m-85 -53.63 -32.27 50.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.668 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 16.6 m -62.36 -28.38 69.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.968 . . . . 0.0 109.222 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.3 mmtt -81.65 -40.11 23.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.509 ' CD1' HD22 ' A' ' 106' ' ' LEU . 1.5 t80 -65.84 -55.55 16.51 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.265 -0.897 . . . . 0.0 109.362 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.451 ' CD1' HG22 ' A' ' 55' ' ' VAL . 25.3 mt -50.08 -44.62 52.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 0.0 109.722 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 40.1 p -66.36 -68.29 0.38 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.181 -0.949 . . . . 0.0 109.647 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.5 -27.17 15.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.452 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 17.7 m-70 -120.06 101.41 7.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -0.86 . . . . 0.0 109.756 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -83.63 -19.01 36.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.404 -0.81 . . . . 0.0 109.371 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 44' ' ' VAL . 7.8 p-10 -72.51 -13.02 61.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.597 179.576 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.479 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -105.6 -14.94 15.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.938 -179.826 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.06 -65.23 0.61 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.005 -1.06 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.42 -20.91 48.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.486 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 38.7 t -77.95 -39.0 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.288 -0.883 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.3 m-85 -74.39 -21.65 59.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.231 -0.918 . . . . 0.0 109.531 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.92 25.21 7.28 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CD2' HG22 ' A' ' 55' ' ' VAL . 10.7 m-85 -123.76 175.85 6.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -1.112 . . . . 0.0 109.802 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.57 18.4 15.04 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.392 -0.817 . . . . 0.0 109.352 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 147.97 -163.87 28.87 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.09 31.8 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.64 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.1 t -130.46 25.58 5.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.629 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.04 138.18 20.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -66.67 -22.77 49.97 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.994 1.523 . . . . 0.0 109.976 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.519 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.97 -31.67 58.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.53 HG22 ' CD2' ' A' ' 47' ' ' PHE . 92.9 t -54.19 -35.9 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.22 -1.164 . . . . 0.0 109.379 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.469 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -78.53 -5.16 51.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 0.0 109.809 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.42 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 37.0 m-20 -93.55 -27.45 16.62 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.03 -1.044 . . . . 0.0 109.558 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.506 ' HB3' ' CE2' ' A' ' 31' ' ' PHE . 6.4 mt -88.13 -63.97 1.22 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.073 -1.017 . . . . 0.0 109.354 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.464 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -51.19 -37.07 37.27 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -67.32 -34.34 77.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.859 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 0.0 OUTLIER -87.06 -34.49 19.15 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 109.785 -179.82 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 24.4 t -67.24 -47.46 81.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.935 . . . . 0.0 109.719 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 63' ' ' LEU . 1.8 mm? -47.89 -46.99 32.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.79 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.78 -48.08 20.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.257 -0.902 . . . . 0.0 109.973 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -55.4 -53.3 58.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.111 -0.993 . . . . 0.0 109.42 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 52.2 mt -51.77 -38.47 22.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.362 -0.836 . . . . 0.0 109.176 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.543 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.06 -55.69 28.84 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.465 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 98.9 t -59.94 -29.2 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -1.126 . . . . 0.0 109.758 -179.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.45 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -84.76 -10.64 57.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 110.075 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.456 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 42.1 t -71.53 -42.32 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.012 -1.055 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.31 -12.49 59.96 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.056 -1.027 . . . . 0.0 110.032 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.483 ' N ' ' ND1' ' A' ' 72' ' ' HIS . 9.0 m80 -110.99 52.6 0.73 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.145 -0.972 . . . . 0.0 109.998 -179.306 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.463 ' CD1' HG13 ' A' ' 10' ' ' VAL . 90.0 mt . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.936 . . . . 0.0 109.168 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.412 ' HG2' ' HB3' ' A' ' 72' ' ' HIS . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.48 -30.51 46.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.364 -0.835 . . . . 0.0 108.747 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.77 -42.09 97.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.355 -0.841 . . . . 0.0 108.864 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -61.59 -53.06 61.26 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.368 -0.833 . . . . 0.0 108.931 179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 80.5 mmm -57.72 -40.41 79.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.278 -0.888 . . . . 0.0 108.829 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.88 -35.73 46.19 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.243 -0.911 . . . . 0.0 108.606 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -74.18 -36.06 64.03 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.425 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 49.0 t -56.92 -43.89 81.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.306 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.45 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -67.21 -51.38 38.78 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 179.173 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.445 HG22 ' CA ' ' A' ' 144' ' ' GLY . 53.1 t -58.76 -22.39 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.497 -1.002 . . . . 0.0 109.197 179.234 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.7 mmm180 -75.41 -41.59 55.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 109.13 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.514 ' HA ' ' CG ' ' A' ' 93' ' ' TYR . 4.8 m80 -60.31 -28.74 68.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.087 179.335 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 2.0 ttmt -52.44 -26.28 12.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 110.308 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -130.23 45.28 1.15 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.586 -1.292 . . . . 0.0 110.132 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.514 ' CG ' ' HA ' ' A' ' 90' ' ' HIS . 3.2 m-30 -86.01 -170.7 3.22 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.081 -1.246 . . . . 0.0 109.503 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.5 -48.15 45.88 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.486 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.5 OUTLIER -72.95 -44.69 60.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.472 -1.017 . . . . 0.0 109.163 179.777 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.477 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 6.4 tttp 72.55 -54.1 0.69 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.354 -0.841 . . . . 0.0 110.145 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -62.91 78.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.188 -0.945 . . . . 0.0 109.871 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.462 HG22 HD12 ' A' ' 98' ' ' ILE . 71.4 mt -113.46 163.27 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.125 -0.984 . . . . 0.0 109.69 -179.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -140.86 135.38 31.3 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.791 179.784 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.42 ' HA ' ' CD1' ' A' ' 103' ' ' PHE . . . -79.14 1.29 24.9 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.275 -0.89 . . . . 0.0 109.84 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.519 ' OE2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -80.45 -26.43 38.34 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 109.545 179.88 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.519 ' CD1' ' OE2' ' A' ' 101' ' ' GLU . 93.3 m-85 -78.03 -10.33 59.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.185 -0.947 . . . . 0.0 109.703 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.483 ' CE2' HD22 ' A' ' 141' ' ' LEU . 6.5 m-85 -62.51 -60.71 3.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 110.066 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.494 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.0 mt-10 -52.54 -55.72 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.203 -0.936 . . . . 0.0 110.004 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.494 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.97 -62.42 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.69 1.363 . . . . 0.0 109.768 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.509 HD22 ' CD1' ' A' ' 34' ' ' PHE . 3.4 tm? -55.83 -23.38 30.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.36 -0.838 . . . . 0.0 109.314 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.2 -48.17 9.97 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.41 -33.53 74.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.137 -1.213 . . . . 0.0 109.585 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.73 -27.86 63.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.216 -0.928 . . . . 0.0 109.5 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.449 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 2.2 tt -69.67 -35.6 75.29 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.447 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -59.73 -34.17 72.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 t -68.72 -33.03 73.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.669 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.424 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -76.37 -39.93 52.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.635 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.506 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 4.2 mtt -50.06 -38.58 38.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.17 -22.52 6.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.194 -0.941 . . . . 0.0 109.561 179.779 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.424 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -57.52 -47.75 81.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.4 ttt85 -73.06 -61.93 1.64 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.472 HG22 ' CG1' ' A' ' 17' ' ' ILE . 14.6 pt -97.27 55.88 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.331 -0.855 . . . . 0.0 109.63 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -62.17 -14.44 46.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -107.73 -27.44 5.18 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.41 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 6.2 mttm -93.92 -13.44 27.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -1.212 . . . . 0.0 110.146 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.408 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 4.0 tpt -71.99 98.23 2.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.509 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.405 ' O ' ' HB3' ' A' ' 126' ' ' ALA . 2.4 p-10 -104.6 169.16 8.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.447 -0.783 . . . . 0.0 109.514 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -49.16 -51.75 30.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.25 -0.906 . . . . 0.0 109.625 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -53.03 -26.72 16.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -0.931 . . . . 0.0 109.441 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.415 ' HB1' HG23 ' A' ' 13' ' ' THR . . . -75.69 -58.01 3.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.566 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.465 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 15.1 ptpt -63.68 -29.29 70.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.147 -0.97 . . . . 0.0 109.286 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.465 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 43.0 t0 -77.32 -43.04 34.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.411 -0.806 . . . . 0.0 109.407 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.454 ' HB3' ' CG2' ' A' ' 10' ' ' VAL . . . -65.34 -39.61 92.59 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 109.212 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.506 ' CZ3' ' HE2' ' A' ' 114' ' ' MET . 4.4 m0 -77.52 -28.32 52.01 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.353 -0.842 . . . . 0.0 108.986 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -66.34 -30.29 70.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.323 -0.861 . . . . 0.0 109.026 179.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.45 -34.06 20.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.393 -0.817 . . . . 0.0 109.167 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -74.07 -36.78 64.34 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.441 -0.787 . . . . 0.0 109.13 179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.458 ' OH ' ' CE ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -57.65 -23.74 52.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.386 -0.821 . . . . 0.0 109.39 179.728 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.4 -32.01 42.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.547 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -80.86 -35.38 32.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.459 ' O ' ' CE ' ' A' ' 83' ' ' MET . 45.5 mt -74.62 -54.21 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.206 -0.934 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 12.2 p -71.0 -40.98 71.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 109.577 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -57.49 -47.53 87.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.86 -26.27 9.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.244 -1.151 . . . . 0.0 109.586 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.483 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.5 tt -84.98 -18.62 33.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.773 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 76.5 mt -83.04 7.0 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 110.108 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.1 m -101.81 -27.6 12.92 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.056 -1.028 . . . . 0.0 109.62 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.445 ' CA ' HG22 ' A' ' 88' ' ' VAL . . . -100.07 -25.03 9.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.462 HD11 ' CD2' ' A' ' 141' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.287 -1.125 . . . . 0.0 109.561 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.431 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.253 0.549 . . . . 0.0 109.613 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -66.62 -54.02 27.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.794 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.473 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 1.2 ttp180 -50.06 -32.44 15.57 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.207 -0.933 . . . . 0.0 109.571 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 30.9 mm-40 -75.83 -43.85 43.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.332 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.472 HG13 ' CB ' ' A' ' 129' ' ' ALA . 24.5 t -61.67 -32.8 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.6 t -62.18 -45.63 98.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.4 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.6 -15.24 60.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 0.0 109.686 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -84.34 -24.04 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 109.694 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.478 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 35.5 p -100.5 -12.54 19.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.868 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -89.83 -27.65 19.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.102 -0.999 . . . . 0.0 109.81 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.7 mtpp -74.74 -9.87 58.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.167 -0.958 . . . . 0.0 109.708 179.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -102.31 -61.29 1.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.59 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.474 ' CG1' HG12 ' A' ' 118' ' ' ILE . 42.5 mt -57.74 -41.1 78.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 109.625 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.566 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -101.39 34.48 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.75 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.69 -69.11 1.32 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 p -113.94 -25.3 8.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 109.518 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 17.7 p-10 -80.65 -19.3 45.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.679 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.3 t30 60.32 21.34 10.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.262 -0.899 . . . . 0.0 109.641 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.81 20.39 31.47 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -65.5 -50.88 63.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.218 -1.166 . . . . 0.0 109.532 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.46 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.94 -5.0 86.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 43.5 t -87.47 -33.08 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.996 -1.296 . . . . 0.0 109.724 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.97 -41.01 9.87 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.46 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.3 ptpt -63.67 -31.87 73.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -1.18 . . . . 0.0 109.826 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.437 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 15.8 pt-20 -89.58 -14.71 34.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.167 -0.958 . . . . 0.0 110.083 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 42.2 t -91.58 -63.66 1.22 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.137 -0.977 . . . . 0.0 109.999 -179.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.513 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 14.3 m-85 -54.19 -37.34 64.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.226 -0.922 . . . . 0.0 109.907 -179.53 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.458 ' OG1' ' CG1' ' A' ' 55' ' ' VAL . 8.7 m -53.18 -32.88 50.15 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.051 -1.031 . . . . 0.0 108.907 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 3.9 mmtt -76.14 -47.48 24.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.34 -0.85 . . . . 0.0 109.067 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.512 ' CG ' HD22 ' A' ' 106' ' ' LEU . 5.1 t80 -61.41 -49.64 76.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.52 HD21 ' CD2' ' A' ' 45' ' ' PHE . 70.2 mt -54.83 -44.22 73.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.129 -0.982 . . . . 0.0 109.401 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.47 ' HB3' ' CB ' ' A' ' 50' ' ' ALA . 82.7 p -73.48 -66.09 0.74 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.366 -0.834 . . . . 0.0 109.982 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.456 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -49.61 -30.08 8.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.205 -0.934 . . . . 0.0 109.702 -179.724 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.422 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 23.0 m-70 -123.63 110.12 14.6 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.264 -0.898 . . . . 0.0 109.785 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -88.93 -18.66 27.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.502 -0.748 . . . . 0.0 109.31 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -66.51 -21.1 66.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.264 -0.897 . . . . 0.0 109.227 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.519 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 88.6 mmm -107.91 -23.94 11.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 109.75 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.37 -34.29 15.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.865 -1.147 . . . . 0.0 109.136 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.67 -36.75 70.73 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.354 -0.841 . . . . 0.0 109.118 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.521 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 20.4 t -58.41 -63.7 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.034 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.52 ' CD2' HD21 ' A' ' 35' ' ' LEU . 84.4 m-85 -56.42 -27.59 56.97 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.319 -0.863 . . . . 0.0 109.1 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 42' ' ' ALA . . . 108.99 -138.45 14.76 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 1.7 m-85 61.04 170.65 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.105 -1.232 . . . . 0.0 109.83 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.4 t -115.01 25.79 10.63 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.67 -163.94 27.51 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.47 ' CB ' ' HB3' ' A' ' 36' ' ' SER . . . -89.25 16.36 7.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.165 -1.197 . . . . 0.0 109.901 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.99 35.29 4.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.116 -0.99 . . . . 0.0 109.691 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.465 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 2.8 t70 -114.43 137.37 22.58 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.616 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -62.75 -24.46 74.65 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.92 1.484 . . . . 0.0 110.067 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.54 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -40.7 47.22 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.462 HG22 ' CD2' ' A' ' 47' ' ' PHE . 67.3 t -49.95 -34.03 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -1.143 . . . . 0.0 109.474 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.453 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -75.72 -20.66 58.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -86.37 -46.81 9.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.639 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -64.59 -62.76 1.39 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.204 -0.935 . . . . 0.0 109.581 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.513 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.97 -47.44 40.14 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -57.41 -40.21 77.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -1.185 . . . . 0.0 109.587 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -74.55 -24.37 58.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 51.2 t -81.9 -49.14 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.901 . . . . 0.0 109.641 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -48.15 -46.6 34.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.926 . . . . 0.0 109.751 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.8 -50.86 59.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.256 -0.902 . . . . 0.0 109.821 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 33.5 tp60 -48.75 -51.25 29.97 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.087 -1.008 . . . . 0.0 109.577 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.492 HD12 ' CE2' ' A' ' 134' ' ' TYR . 96.7 mt -56.46 -30.97 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.223 -0.923 . . . . 0.0 109.043 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.536 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -68.66 -56.9 8.71 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.8 t -57.8 -20.71 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.247 -1.149 . . . . 0.0 109.243 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.412 ' O ' HD23 ' A' ' 73' ' ' LEU . . . -88.02 -34.1 18.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.675 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.458 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 55.1 t -60.84 -15.89 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.202 -0.936 . . . . 0.0 109.887 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.501 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 23.9 m -91.55 16.14 11.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.182 -0.949 . . . . 0.0 110.29 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.9 m-70 -160.95 40.82 0.16 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.926 -1.109 . . . . 0.0 110.37 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.473 ' HB2' ' CG ' ' A' ' 7' ' ' ARG . 22.7 mt . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.013 -1.055 . . . . 0.0 109.479 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.445 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 14.7 ttp . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.291 0.567 . . . . 0.0 109.694 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.45 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.5 t -70.39 -23.1 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.222 -0.924 . . . . 0.0 109.284 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.76 -37.03 73.37 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.214 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.39 -49.12 11.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.264 179.681 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.461 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 3.1 mtp -59.47 -46.17 89.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.233 -0.917 . . . . 0.0 109.103 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 3.8 tptp -53.49 -33.4 54.2 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 108.915 179.426 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.414 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -70.9 -33.43 70.55 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.401 -0.812 . . . . 0.0 109.248 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.4 HG23 ' HA ' ' A' ' 83' ' ' MET . 44.4 t -62.66 -52.25 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 109.237 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -52.35 -42.55 56.71 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.422 ' HA ' ' HD2' ' A' ' 91' ' ' LYS . 95.7 t -51.8 -26.6 7.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.346 -1.091 . . . . 0.0 109.231 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.418 ' HB2' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -80.91 -24.76 38.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.273 -0.892 . . . . 0.0 108.848 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.493 ' HB3' HD12 ' A' ' 98' ' ' ILE . 41.4 m80 -82.1 -4.67 57.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.528 -0.732 . . . . 0.0 109.894 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.422 ' HD2' ' HA ' ' A' ' 88' ' ' VAL . 8.9 ptmm? -81.8 -8.64 59.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.796 -1.19 . . . . 0.0 110.357 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -164.33 59.42 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.153 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.428 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 0.9 OUTLIER -84.21 -163.5 0.8 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.267 . . . . 0.0 109.25 179.021 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.9 -26.48 74.31 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 -179.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.521 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 18.7 p-10 -91.79 -32.88 15.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.258 . . . . 0.0 109.933 -179.668 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.441 ' O ' ' CD2' ' A' ' 97' ' ' HIS . 0.0 OUTLIER 56.85 30.93 18.72 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.129 -0.982 . . . . 0.0 109.649 179.894 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.441 ' CD2' ' O ' ' A' ' 96' ' ' LYS . 38.2 m170 -137.44 47.44 2.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.159 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.493 HD12 ' HB3' ' A' ' 90' ' ' HIS . 59.7 mt -89.9 159.78 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.286 -0.884 . . . . 0.0 110.576 -179.172 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.473 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -152.27 142.17 22.08 Favored 'General case' 0 N--CA 1.487 1.424 0 CA-C-O 121.636 0.732 . . . . 0.0 109.684 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.431 ' CB ' HG22 ' A' ' 142' ' ' ILE . . . -78.98 -3.02 42.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.647 -0.658 . . . . 0.0 109.62 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -73.11 -33.19 65.42 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.975 -1.078 . . . . 0.0 109.488 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.519 ' CD1' ' HG3' ' A' ' 41' ' ' MET . 85.9 m-85 -78.46 -15.58 58.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.244 -0.91 . . . . 0.0 110.125 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.453 ' O ' ' N ' ' A' ' 107' ' ' GLY . 4.6 m-85 -59.66 -63.4 1.31 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.163 -0.961 . . . . 0.0 110.248 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.477 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.4 mt-10 -45.49 -58.43 5.95 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.427 -0.796 . . . . 0.0 110.797 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.477 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 11.2 Cg_endo -59.99 -46.1 20.89 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.748 1.394 . . . . 0.0 109.923 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.512 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.2 tm? -67.11 -20.02 65.72 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 109.25 179.709 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -84.47 -47.38 5.45 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.55 -28.26 66.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -1.114 . . . . 0.0 109.354 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.89 -34.74 69.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.3 -0.875 . . . . 0.0 109.482 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.453 ' CD1' ' OH ' ' A' ' 134' ' ' TYR . 2.5 tt -65.38 -34.43 78.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.198 -0.938 . . . . 0.0 109.425 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 11.2 mt -58.51 -35.48 72.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.097 -1.002 . . . . 0.0 109.132 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 21.2 t -70.09 -26.31 63.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.429 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.502 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.93 -33.15 21.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.444 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 0.8 OUTLIER -53.87 -44.26 70.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.995 -179.675 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.452 ' O ' ' N ' ' A' ' 119' ' ' GLY . 8.1 pt-20 -51.77 -23.01 4.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.23 -0.919 . . . . 0.0 109.818 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.502 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 20.9 m170 -48.97 -41.44 34.17 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.165 -0.959 . . . . 0.0 109.71 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.3 ttt85 -83.48 -55.77 4.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.432 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.474 HG12 ' CG1' ' A' ' 17' ' ' ILE . 3.9 pt -106.64 59.23 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.302 -0.874 . . . . 0.0 109.558 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -67.48 -29.29 73.94 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.75 -18.2 56.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.416 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.1 mttt -105.04 -20.36 13.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.067 -1.255 . . . . 0.0 110.102 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.421 ' N ' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -73.01 80.99 1.21 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.421 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.41 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.2 p30 -82.29 -162.17 0.53 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -0.853 . . . . 0.0 109.706 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -69.13 -43.13 74.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.469 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.477 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -60.76 -32.25 71.56 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.171 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -68.42 -53.03 26.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.462 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.46 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.3 ptpt -70.45 -29.03 65.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.193 -0.942 . . . . 0.0 109.379 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.46 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 24.2 t0 -80.42 -40.72 25.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.329 -0.857 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -61.66 -42.91 99.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.478 ' CE2' ' OG1' ' A' ' 13' ' ' THR . 9.2 m0 -75.4 -34.24 61.04 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.3 -0.875 . . . . 0.0 108.846 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.85 -23.48 31.07 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.163 -0.961 . . . . 0.0 108.764 178.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -92.39 -46.28 7.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.43 -0.794 . . . . 0.0 109.308 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.34 -54.08 10.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.263 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.492 ' CE2' HD12 ' A' ' 66' ' ' ILE . 1.3 t80 -49.78 -30.46 9.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.215 179.608 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -74.61 -38.33 62.6 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.309 -0.869 . . . . 0.0 108.877 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.38 -31.69 48.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.399 -0.813 . . . . 0.0 109.27 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 54.9 mt -66.8 -60.53 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.258 -0.901 . . . . 0.0 108.909 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.408 ' O ' HG12 ' A' ' 142' ' ' ILE . 26.4 p -66.98 -18.09 65.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -0.795 . . . . 0.0 109.765 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -75.31 -45.81 17.79 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.13 -22.0 65.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.222 -1.163 . . . . 0.0 109.808 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.461 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 2.9 tt -77.87 -13.9 59.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 0.0 109.957 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.431 HG22 ' CB ' ' A' ' 100' ' ' ALA . 37.1 mm -79.68 -12.99 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.417 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 27.5 m -68.54 -64.67 0.82 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.103 -0.998 . . . . 0.0 109.733 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.56 -11.28 68.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . . . . . . . . . 9.7 tt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.036 -1.273 . . . . 0.0 109.301 179.987 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.451 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.232 0.539 . . . . 0.0 109.73 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.41 ' O ' HG23 ' A' ' 10' ' ' VAL . 75.8 mt-30 -58.38 -55.74 31.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 109.661 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.452 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 3.0 ttp180 -49.11 -37.9 23.1 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.286 -0.884 . . . . 0.0 109.625 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -74.28 -40.59 62.21 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.381 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 5' ' ' ALA . 39.5 t -65.0 -24.85 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.89 . . . . 0.0 109.449 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.458 HG12 ' CD1' ' A' ' 130' ' ' TRP . 97.4 t -70.02 -34.72 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.236 -0.915 . . . . 0.0 109.559 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.09 -13.16 59.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -0.901 . . . . 0.0 109.913 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.74 -19.6 22.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.14 -0.975 . . . . 0.0 109.845 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.493 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.5 p -101.29 -14.83 17.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.126 -0.984 . . . . 0.0 109.956 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.548 ' CE3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -87.03 -32.42 20.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.687 -179.776 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.2 mtpt -69.71 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.606 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.9 m-20 -99.24 -60.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.118 -0.989 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.451 ' CG1' HG12 ' A' ' 118' ' ' ILE . 66.3 mt -61.17 -41.15 88.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.262 -0.899 . . . . 0.0 109.538 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.548 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -96.34 31.67 2.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.293 -0.879 . . . . 0.0 109.511 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.48 -69.9 1.11 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.6 p -110.29 -32.66 6.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -1.163 . . . . 0.0 109.613 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -74.93 -18.98 60.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.905 . . . . 0.0 109.638 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 19.6 t30 59.39 21.08 9.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 109.597 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.416 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 97.89 34.68 5.36 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.36 -56.34 3.57 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.229 -1.16 . . . . 0.0 109.576 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.473 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -66.53 -14.74 62.87 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.485 ' CG1' ' CD2' ' A' ' 63' ' ' LEU . 37.8 t -89.18 -11.59 10.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -1.185 . . . . 0.0 109.942 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.506 ' CA ' ' CD1' ' A' ' 63' ' ' LEU . . . -100.06 -41.77 2.76 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.473 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -74.74 -22.15 58.96 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.119 -1.224 . . . . 0.0 110.003 -179.512 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.447 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 22.3 pt-20 -92.38 -21.96 19.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.116 -0.99 . . . . 0.0 109.701 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.4 t -87.18 -68.0 0.78 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.254 -0.903 . . . . 0.0 110.083 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 29.2 m-85 -46.62 -33.43 4.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.292 -0.88 . . . . 0.0 110.246 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.47 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.79 -52.11 61.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.067 -1.02 . . . . 0.0 109.384 179.699 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.4 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 7.2 mttt -65.18 -46.03 82.45 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.281 -0.887 . . . . 0.0 109.698 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CG ' HD22 ' A' ' 106' ' ' LEU . 9.4 t80 -49.53 -49.43 46.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.228 -0.92 . . . . 0.0 109.544 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.493 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 14.1 mt -57.99 -46.75 84.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.491 ' O ' ' CD2' ' A' ' 39' ' ' HIS . 0.4 OUTLIER -64.56 -62.15 1.76 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.923 . . . . 0.0 109.525 179.907 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.48 -27.15 23.66 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.222 -0.924 . . . . 0.0 109.524 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.456 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 18.9 m-70 -120.49 97.27 5.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.491 ' CD2' ' O ' ' A' ' 36' ' ' SER . 64.4 m170 -83.08 4.15 27.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.016 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.405 ' OD2' ' OH ' ' A' ' 102' ' ' TYR . 17.6 p-10 -94.95 -13.4 25.38 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.081 -1.012 . . . . 0.0 109.942 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' VAL . 98.0 mmm -112.85 -19.25 12.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.086 -1.009 . . . . 0.0 109.966 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -47.64 -40.34 19.44 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.181 -0.949 . . . . 0.0 109.859 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.154 -0.966 . . . . 0.0 109.509 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.52 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 45.9 t -81.2 -34.64 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.557 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.503 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 24.0 m-85 -76.88 -11.66 59.85 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 110.124 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.4 25.47 25.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CD2' HG22 ' A' ' 55' ' ' VAL . 14.0 m-85 -125.58 168.64 13.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.912 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.99 -17.39 14.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.416 -0.802 . . . . 0.0 109.202 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.98 -161.6 23.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.99 28.34 3.58 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.325 -1.103 . . . . 0.0 109.713 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 72.1 p -118.02 -16.36 9.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.257 -0.902 . . . . 0.0 109.795 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.1 p-10 -73.07 142.74 82.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.213 -0.93 . . . . 0.0 109.706 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -72.89 -17.38 25.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.976 1.514 . . . . 0.0 110.19 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.5 -38.54 35.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.518 HG22 ' CD2' ' A' ' 47' ' ' PHE . 63.2 t -51.09 -35.92 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.469 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -71.15 -7.15 44.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.27 -0.894 . . . . 0.0 109.691 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.76 -28.26 18.38 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.065 -1.022 . . . . 0.0 109.648 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.456 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 11.5 mt -88.73 -63.74 1.25 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.071 -1.018 . . . . 0.0 109.681 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.515 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -50.29 -46.99 43.79 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.3 -24.46 19.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -1.156 . . . . 0.0 109.662 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.26 -23.79 12.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.717 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.456 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 43.4 t -73.23 -56.72 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.983 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.506 ' CD1' ' CA ' ' A' ' 27' ' ' GLY . 0.2 OUTLIER -47.22 -41.13 17.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.141 -0.974 . . . . 0.0 109.851 -179.927 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.98 -43.19 50.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.469 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 7.2 tp-100 -62.69 -41.5 99.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.083 -1.011 . . . . 0.0 109.195 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.492 HD13 ' CE1' ' A' ' 134' ' ' TYR . 63.0 mt -57.95 -36.18 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.278 -0.889 . . . . 0.0 108.83 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.522 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.88 -59.63 8.86 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 108.689 -1.765 . . . . 0.0 108.689 179.294 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 74.3 t -54.35 -26.16 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.276 -1.132 . . . . 0.0 109.04 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.94 -28.88 25.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.41 -0.806 . . . . 0.0 109.594 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.434 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 52.5 t -68.8 -9.64 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.499 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 18.3 t -93.2 33.57 1.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.007 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.499 ' CG ' ' O ' ' A' ' 71' ' ' SER . 9.1 m-70 -160.25 -87.41 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.189 -0.944 . . . . 0.0 109.731 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.452 ' HB2' ' CG ' ' A' ' 7' ' ' ARG . 24.3 mt . . . . . 0 N--CA 1.496 1.859 0 O-C-N 121.482 -0.762 . . . . 0.0 110.037 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 64.4 ttp . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.228 0.537 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.411 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 98.0 t -60.1 -18.19 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.24 -0.912 . . . . 0.0 109.421 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -80.8 -21.28 41.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.295 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.91 -47.39 7.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.544 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.439 ' CB ' ' HB3' ' A' ' 140' ' ' ALA . 99.2 mmm -62.15 -41.08 97.93 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.027 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.411 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -52.98 -32.61 47.17 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.052 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.417 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -76.31 -33.25 59.03 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.077 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.403 HG13 HD13 ' A' ' 141' ' ' LEU . 71.3 t -65.05 -53.12 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.076 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.42 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -53.51 -39.84 60.93 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 85.7 t -53.98 -28.34 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -1.113 . . . . 0.0 109.266 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.8 mmt180 -75.19 -48.9 21.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 0.0 108.959 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.468 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 54.1 m80 -57.64 -22.37 45.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.306 -0.871 . . . . 0.0 108.912 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.4 -9.82 59.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.414 -0.804 . . . . 0.0 109.941 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.76 50.39 0.75 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.6 m-30 -92.1 -174.11 3.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -1.15 . . . . 0.0 109.512 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.89 -28.48 41.86 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.52 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.7 OUTLIER -83.76 -46.17 12.54 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.579 -0.953 . . . . 0.0 108.923 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.6 mtpt 72.72 -49.96 0.7 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.56 -0.713 . . . . 0.0 110.76 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.3 m170 -66.46 63.14 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.01 -1.056 . . . . 0.0 110.596 -179.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.448 ' N ' ' O ' ' A' ' 96' ' ' LYS . 96.7 mt -94.08 159.15 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.089 -1.007 . . . . 0.0 109.235 179.431 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.418 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -139.63 141.78 37.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.17 -0.956 . . . . 0.0 109.852 -179.929 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.86 8.24 18.12 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.855 . . . . 0.0 109.685 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -85.09 -29.9 24.5 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.151 -0.968 . . . . 0.0 108.697 179.784 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.418 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 93.5 m-85 -79.09 -17.01 55.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.32 -0.862 . . . . 0.0 109.636 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -56.6 -60.14 3.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.23 -0.919 . . . . 0.0 110.169 -179.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.484 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.4 mt-10 -52.82 -57.41 16.15 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.148 -0.97 . . . . 0.0 110.066 -179.453 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 34.7 Cg_exo -48.88 -58.88 1.49 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 O-C-N 123.626 1.329 . . . . 0.0 110.13 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.518 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -54.94 -28.89 54.64 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.388 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.26 -50.12 13.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.42 -37.49 87.72 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -1.128 . . . . 0.0 109.503 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 t -68.48 -35.25 77.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.326 -0.859 . . . . 0.0 109.576 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.435 HD23 ' CG1' ' A' ' 26' ' ' VAL . 3.8 tt -67.02 -31.57 72.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.398 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.434 HD12 ' N ' ' A' ' 131' ' ' ALA . 12.1 mt -61.43 -33.35 73.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.161 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 2.7 t -72.93 -26.77 61.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.398 179.68 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.48 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -85.46 -22.75 28.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.487 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.6 mtt -65.0 -36.43 84.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.351 -0.843 . . . . 0.0 109.882 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' N ' ' A' ' 119' ' ' GLY . 12.5 pt-20 -58.53 -18.47 29.73 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.464 179.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.48 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 28.4 m170 -56.04 -36.12 67.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.223 -0.923 . . . . 0.0 109.483 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -89.72 -42.37 11.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.309 -0.87 . . . . 0.0 109.362 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.462 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 3.1 pt -119.03 57.01 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.865 . . . . 0.0 109.473 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -64.57 -18.67 63.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.31 -28.53 8.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.434 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.8 mttt -94.44 -17.51 22.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.184 -1.186 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.462 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -76.54 86.2 3.24 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.109 -0.995 . . . . 0.0 109.371 179.762 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -93.61 -163.2 1.02 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.845 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.439 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -68.44 -44.57 74.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -0.856 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.455 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -61.54 -26.06 67.69 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.112 -0.992 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.99 -52.57 8.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.314 -0.866 . . . . 0.0 109.792 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.439 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 9.7 ptmm? -71.74 -25.69 62.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.215 -0.928 . . . . 0.0 109.906 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -84.32 -36.32 22.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.112 -0.992 . . . . 0.0 109.745 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.95 -43.18 72.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.361 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.493 ' CE2' ' OG1' ' A' ' 13' ' ' THR . 4.5 m0 -71.41 -36.72 71.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.281 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.434 ' N ' HD12 ' A' ' 111' ' ' LEU . . . -60.97 -33.9 73.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.119 179.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.66 -30.78 36.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.32 -0.862 . . . . 0.0 109.277 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.13 -40.19 24.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.354 -0.841 . . . . 0.0 109.288 179.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.492 ' CE1' HD13 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -50.26 -34.75 24.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.264 179.642 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.38 -28.26 62.9 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.083 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -83.43 -39.25 20.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.381 -0.824 . . . . 0.0 109.337 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.431 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.6 mt -65.95 -58.25 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.149 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -68.66 -19.7 64.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.403 -0.81 . . . . 0.0 109.63 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -65.96 -57.73 10.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.439 ' HB3' ' CB ' ' A' ' 83' ' ' MET . . . -49.33 -26.36 3.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 0.0 109.756 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.413 HD23 ' HB2' ' A' ' 145' ' ' LEU . 7.5 tt -74.41 -12.47 60.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.97 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' A' ' 142' ' ' ILE . 75.6 mt -91.37 21.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.089 -1.007 . . . . 0.0 109.763 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.4 t -105.82 -32.87 8.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.167 -0.958 . . . . 0.0 109.691 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -121.46 16.39 9.1 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.42 ' HB2' ' CA ' ' A' ' 87' ' ' GLY . 4.5 tt . . . . . 0 N--CA 1.491 1.584 0 O-C-N 121.109 -1.23 . . . . 0.0 110.126 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.231 0.539 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -60.14 -44.25 95.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.459 ' CG ' ' HB3' ' A' ' 73' ' ' LEU . 5.6 ttp180 -57.17 -29.27 63.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.506 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -82.89 -34.26 26.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.829 . . . . 0.0 109.45 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 57.8 t -67.62 -19.57 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.177 -0.952 . . . . 0.0 109.589 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.448 HG21 ' CB ' ' A' ' 133' ' ' ALA . 93.0 t -73.82 -47.1 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -0.947 . . . . 0.0 109.627 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.26 -13.98 62.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.935 . . . . 0.0 109.841 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.63 -21.65 20.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.184 -0.948 . . . . 0.0 109.9 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -97.67 -12.76 22.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.141 -0.974 . . . . 0.0 110.023 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.03 -28.06 17.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.037 -1.039 . . . . 0.0 109.726 -179.884 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -73.26 -10.92 60.26 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.852 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -104.06 -46.71 4.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.108 -0.995 . . . . 0.0 109.62 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.469 ' CG1' HG12 ' A' ' 118' ' ' ILE . 40.5 mt -70.23 -39.58 77.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.276 -0.89 . . . . 0.0 109.685 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.564 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.1 34.42 2.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.552 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.51 -65.47 3.53 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 26.6 p -111.96 -33.67 6.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.236 -1.155 . . . . 0.0 109.714 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -76.63 -18.3 58.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.739 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.426 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 4.3 t30 57.77 20.47 6.51 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.6 21.52 19.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.02 -54.3 23.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.299 -1.118 . . . . 0.0 109.566 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.48 2.02 74.22 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.462 ' CG1' HD13 ' A' ' 63' ' ' LEU . 36.9 t -91.94 -40.31 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.053 -1.263 . . . . 0.0 109.529 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.44 -50.54 5.67 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.658 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.468 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 6.4 ptpt -52.7 -30.29 31.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.148 -1.207 . . . . 0.0 109.784 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.453 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.5 pt-20 -91.96 -22.7 19.87 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 109.847 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.4 t -83.14 -65.4 1.01 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.183 -0.948 . . . . 0.0 109.989 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.497 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 11.3 m-85 -48.46 -29.32 3.98 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 110.024 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.411 ' HA ' HD11 ' A' ' 35' ' ' LEU . 19.5 m -62.98 -60.95 2.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 109.649 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.406 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 13.0 mttm -50.02 -38.02 35.6 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.583 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.51 ' CG ' HD22 ' A' ' 106' ' ' LEU . 13.2 t80 -69.09 -54.91 12.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.552 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.511 HD21 ' CD2' ' A' ' 45' ' ' PHE . 12.4 mt -50.57 -44.11 56.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.625 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.438 ' HB3' ' CB ' ' A' ' 50' ' ' ALA . 18.9 p -65.73 -51.45 59.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.234 -0.916 . . . . 0.0 109.719 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.438 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -67.32 -19.42 65.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.239 -0.913 . . . . 0.0 109.755 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 37' ' ' ALA . 27.8 m-70 -124.51 101.33 7.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.955 . . . . 0.0 109.721 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -86.35 3.53 43.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 110.04 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -93.39 -20.37 20.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.032 -1.043 . . . . 0.0 109.534 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.484 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 88.1 mmm -104.68 -23.29 13.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.703 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.461 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.26 -34.14 14.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.096 -1.003 . . . . 0.0 109.614 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.12 -22.48 48.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.35 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.513 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 46.8 t -74.35 -58.3 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -0.868 . . . . 0.0 109.49 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.515 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 68.1 m-85 -52.47 -31.21 33.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.567 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.62 2.89 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 10.4 m-85 -124.02 166.96 14.84 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.304 -1.115 . . . . 0.0 109.761 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.0 t -105.36 -21.07 13.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.39 -0.819 . . . . 0.0 109.114 179.308 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -169.43 -163.63 23.79 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.438 ' CB ' ' HB3' ' A' ' 36' ' ' SER . . . -93.29 29.01 2.02 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.196 -1.179 . . . . 0.0 109.615 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.53 27.78 6.42 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.603 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.478 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.9 p-10 -116.52 141.09 27.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.88 . . . . 0.0 109.708 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -67.41 -22.58 45.24 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 124.01 1.531 . . . . 0.0 110.135 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.524 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.83 -38.58 37.67 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.506 HG22 ' CD2' ' A' ' 47' ' ' PHE . 88.4 t -50.8 -39.7 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -1.092 . . . . 0.0 109.428 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.468 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.02 -20.53 61.68 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.306 -0.871 . . . . 0.0 109.256 179.572 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -74.3 -37.29 63.69 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.48 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.447 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 10.0 mt -85.42 -56.16 3.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -0.95 . . . . 0.0 109.555 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.497 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -48.52 -49.07 27.54 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.41 -39.41 87.29 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -1.174 . . . . 0.0 109.74 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.3 mttt -77.83 -30.26 51.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.274 -0.891 . . . . 0.0 109.646 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.447 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 41.6 t -76.19 -51.86 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.593 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.462 HD13 ' CG1' ' A' ' 26' ' ' VAL . 2.1 mm? -48.93 -47.29 43.68 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.66 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.16 -42.95 41.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.735 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.471 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 7.4 tp-100 -58.33 -43.66 88.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 109.384 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.451 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 40.7 mt -59.58 -38.7 76.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.264 -0.898 . . . . 0.0 109.033 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.44 -53.43 28.76 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.279 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 51.8 t -54.06 -31.16 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.317 -1.108 . . . . 0.0 108.962 179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.407 ' O ' ' CD2' ' A' ' 73' ' ' LEU . . . -82.35 -31.46 29.79 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.385 -0.822 . . . . 0.0 109.27 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 52.1 t -69.96 -15.3 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.332 -0.855 . . . . 0.0 109.629 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.6 m -85.21 10.86 11.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.039 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -126.27 -72.96 0.63 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.07 -1.019 . . . . 0.0 109.685 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.495 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 3.7 mm? . . . . . 0 N--CA 1.493 1.683 0 O-C-N 121.848 -0.533 . . . . 0.0 110.642 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 ttp . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 121.209 0.528 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 99.0 t -62.9 -22.72 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.284 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -77.43 -21.04 53.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.291 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -90.06 -49.18 6.73 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.331 -0.856 . . . . 0.0 109.529 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.464 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 93.6 mmm -60.9 -40.28 92.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.125 -0.985 . . . . 0.0 109.008 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -53.04 -31.22 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.243 -0.911 . . . . 0.0 108.556 179.175 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.409 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -75.79 -31.36 59.44 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.201 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 53.9 t -65.37 -50.33 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.096 179.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.464 ' CA ' HD23 ' A' ' 141' ' ' LEU . . . -54.43 -41.95 73.75 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.409 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 88.2 t -51.36 -25.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.333 -1.098 . . . . 0.0 109.021 179.415 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.424 ' HB3' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -78.35 -33.33 49.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.364 -0.835 . . . . 0.0 108.904 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.546 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 30.9 m80 -80.86 4.7 18.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.398 -0.813 . . . . 0.0 109.611 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.42 ' O ' ' HG2' ' A' ' 91' ' ' LYS . 5.8 ttpp -88.63 -10.24 49.3 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.096 -1.003 . . . . 0.0 110.137 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -160.42 43.95 0.42 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.014 -1.565 . . . . 0.0 111.045 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.546 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.6 m-85 -75.17 -165.18 0.37 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.68 -1.483 . . . . 0.0 109.195 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.3 -36.75 55.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.42 -1.872 . . . . 0.0 108.42 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.513 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 1.7 t30 -72.16 -58.51 3.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.574 -0.956 . . . . 0.0 109.07 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.485 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 1.9 tttp 76.5 -15.67 0.7 Allowed 'General case' 0 N--CA 1.506 2.358 0 O-C-N 121.637 -0.664 . . . . 0.0 111.391 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.435 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 65.9 m170 -98.73 44.01 1.04 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.598 -1.314 . . . . 0.0 109.119 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.418 HD12 ' HB3' ' A' ' 90' ' ' HIS . 71.6 mt -75.22 159.04 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.331 -0.856 . . . . 0.0 109.878 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.435 ' CE ' ' O ' ' A' ' 97' ' ' HIS . 1.0 OUTLIER -142.49 141.98 32.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.377 -0.827 . . . . 0.0 109.948 -179.971 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.36 2.15 26.02 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.468 -0.77 . . . . 0.0 109.565 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mt-10 -77.61 -34.53 53.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 109.55 179.837 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.484 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 61.6 m-85 -80.42 -0.05 35.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.37 -0.831 . . . . 0.0 110.361 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.452 ' CD2' ' OG ' ' A' ' 138' ' ' SER . 3.0 m-85 -70.48 -55.37 9.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.012 -1.055 . . . . 0.0 109.75 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.482 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.2 tt0 -59.61 -52.11 76.31 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.185 -0.947 . . . . 0.0 109.746 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.482 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.3 Cg_exo -54.32 -56.13 2.78 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 123.819 1.431 . . . . 0.0 109.843 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.51 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.3 tm? -55.31 -31.12 61.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' O ' ' CB ' ' A' ' 110' ' ' LEU . . . -76.06 -48.09 10.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.59 10.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.263 -1.139 . . . . 0.0 109.421 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.9 t -55.19 -21.51 14.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.271 -0.893 . . . . 0.0 109.298 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.45 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.0 OUTLIER -69.27 -48.84 60.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.329 -0.857 . . . . 0.0 109.532 179.88 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.5 mt -55.04 -34.66 63.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.098 -1.001 . . . . 0.0 109.159 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.15 -31.67 70.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.324 179.657 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.494 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -81.43 -38.41 26.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.409 179.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.409 ' HG2' ' O ' ' A' ' 110' ' ' LEU . 5.5 mmt -50.38 -45.03 55.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.234 -0.916 . . . . 0.0 109.518 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -49.66 -24.71 2.37 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.888 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.494 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 18.8 m170 -58.49 -50.87 72.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.958 . . . . 0.0 109.495 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.404 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -67.56 -52.43 38.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.474 179.898 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.487 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 6.1 pt -116.64 65.37 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.25 -0.906 . . . . 0.0 109.707 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -66.48 -10.4 53.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -106.28 -39.55 2.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.487 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 8.7 mmmt -82.24 -25.75 33.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.029 -1.277 . . . . 0.0 109.97 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.432 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.55 84.17 0.1 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.997 -1.065 . . . . 0.0 109.164 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 18.7 p-10 -88.15 -171.46 3.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.373 -0.829 . . . . 0.0 109.792 -179.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -61.05 -45.2 95.75 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.276 -0.89 . . . . 0.0 109.766 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.417 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -60.95 -30.13 70.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.382 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.99 -49.15 54.45 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.921 . . . . 0.0 109.475 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.46 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 0.7 OUTLIER -72.41 -30.67 64.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 109.558 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.46 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 25.5 t0 -78.88 -35.15 44.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.241 -0.912 . . . . 0.0 109.279 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.417 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -66.59 -47.37 72.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.322 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.466 ' O ' ' CD1' ' A' ' 134' ' ' TYR . 13.9 m0 -72.56 -27.38 62.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.163 -0.96 . . . . 0.0 108.716 179.538 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.75 -15.12 57.79 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.349 -0.845 . . . . 0.0 108.957 178.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -110.98 -29.26 7.98 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.163 -0.96 . . . . 0.0 109.095 179.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.448 ' CB ' HG21 ' A' ' 10' ' ' VAL . . . -83.19 -45.46 13.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.436 -0.79 . . . . 0.0 109.559 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.548 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -58.52 -18.58 30.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 109.25 179.914 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.548 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -84.35 -33.13 23.92 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.222 -0.924 . . . . 0.0 108.512 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.58 -36.42 38.19 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.464 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.1 mt -64.56 -61.44 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.452 ' OG ' ' CD2' ' A' ' 103' ' ' PHE . 4.0 t -66.5 -22.4 66.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.583 -0.698 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.96 -52.99 25.23 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.16 -24.61 4.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -1.186 . . . . 0.0 109.436 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.464 HD23 ' CA ' ' A' ' 87' ' ' GLY . 5.8 tt -74.25 -22.62 59.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.648 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 69.4 mt -81.81 6.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.177 -0.952 . . . . 0.0 110.193 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.2 t -95.46 -36.13 11.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.005 -1.059 . . . . 0.0 109.71 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.15 14.29 28.48 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.449 ' CD2' ' O ' ' A' ' 145' ' ' LEU . 4.6 tt . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.061 -1.258 . . . . 0.0 110.055 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.262 0.553 . . . . 0.0 109.587 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -62.37 -57.71 10.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 110.127 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -28.22 5.35 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.011 -1.055 . . . . 0.0 109.6 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.7 tp60 -78.6 -39.83 36.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.423 -0.798 . . . . 0.0 108.924 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.488 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 90.0 t -66.7 -33.67 64.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.043 179.336 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.495 HG12 ' CD1' ' A' ' 130' ' ' TRP . 84.0 t -69.31 -47.51 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.432 -0.793 . . . . 0.0 109.372 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.62 -13.92 62.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.306 -0.871 . . . . 0.0 109.754 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.5 t -90.73 -26.09 19.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.144 -0.972 . . . . 0.0 109.791 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.4 p -97.29 -10.24 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 110.031 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.528 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -92.48 -19.52 21.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.03 -1.044 . . . . 0.0 109.839 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.3 mtpp -81.94 -11.8 58.7 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.915 . . . . 0.0 109.748 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.49 -55.63 2.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.656 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.462 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 61.0 mt -64.36 -36.64 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.609 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.519 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -101.85 33.7 2.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.626 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.4 -85.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.8 p -97.96 -23.94 15.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.301 -1.117 . . . . 0.0 109.678 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -82.34 -19.88 38.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.655 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.413 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 18.5 t30 56.38 25.12 9.15 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.262 -0.899 . . . . 0.0 109.621 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.45 24.94 12.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.91 -52.55 23.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -1.143 . . . . 0.0 109.648 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.03 -12.98 83.08 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.434 ' CG1' HD13 ' A' ' 63' ' ' LEU . 30.7 t -82.03 -36.05 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.129 -1.218 . . . . 0.0 109.873 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.431 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -78.05 -41.32 18.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.466 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 17.4 ptpt -66.1 -29.55 69.89 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.137 -1.214 . . . . 0.0 110.125 -179.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.42 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 22.5 pt-20 -92.5 -20.98 20.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.176 -0.952 . . . . 0.0 109.881 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.1 t -82.8 -60.14 2.27 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 21.0 m-85 -57.5 -32.27 66.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.888 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.458 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.1 OUTLIER -52.3 -53.66 41.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.178 -0.951 . . . . 0.0 109.392 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -59.69 -50.59 73.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.309 -0.869 . . . . 0.0 109.562 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.51 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.5 t80 -50.63 -47.26 58.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.505 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 17.6 mt -61.14 -45.37 94.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.413 ' OG ' ' N ' ' A' ' 37' ' ' ALA . 29.8 p -67.38 -55.15 14.94 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.224 -0.922 . . . . 0.0 109.817 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.413 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -61.28 -26.53 67.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.189 -0.945 . . . . 0.0 109.708 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.444 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 21.9 m-70 -124.49 110.55 14.63 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.224 -0.922 . . . . 0.0 109.881 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -89.47 -8.87 51.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.472 -0.767 . . . . 0.0 109.697 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -81.94 -16.37 50.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.066 -1.021 . . . . 0.0 109.568 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.514 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 3.9 mmt -104.65 -17.12 14.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.19 -0.944 . . . . 0.0 109.789 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.441 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -54.12 -51.87 62.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.047 -1.033 . . . . 0.0 109.267 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.7 -27.44 68.34 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 109.227 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.519 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 9.1 t -69.54 -55.45 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.354 -0.841 . . . . 0.0 109.04 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.505 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.5 m-85 -57.44 -28.77 63.62 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.286 -0.884 . . . . 0.0 109.58 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.65 29.62 4.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 12.6 m-85 -126.06 172.24 10.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.75 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.8 t -115.83 19.68 15.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.339 -0.85 . . . . 0.0 109.289 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.92 -164.18 28.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.96 26.32 2.84 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.171 -1.194 . . . . 0.0 109.648 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 26.6 m -121.52 28.59 7.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.626 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.14 135.41 23.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.252 -0.905 . . . . 0.0 109.569 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.2 -21.0 55.78 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.916 1.482 . . . . 0.0 110.061 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.518 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.52 -36.36 47.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.512 HG22 ' CD2' ' A' ' 47' ' ' PHE . 59.8 t -53.45 -42.22 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.266 -1.137 . . . . 0.0 109.456 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.454 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -67.86 -21.15 65.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.407 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.12 -37.25 29.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.289 -0.882 . . . . 0.0 109.524 179.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.7 mt -75.81 -61.56 1.88 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.515 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.72 -50.66 30.87 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.432 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.12 -37.27 64.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.278 -1.13 . . . . 0.0 109.493 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 25.2 mttt -80.24 -26.38 39.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.508 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 59.9 t -82.17 -49.06 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.188 -0.945 . . . . 0.0 109.556 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.434 HD13 ' CG1' ' A' ' 26' ' ' VAL . 2.2 mm? -47.83 -46.8 31.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.25 -0.906 . . . . 0.0 109.657 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.64 -52.32 31.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.925 . . . . 0.0 109.85 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.457 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 6.3 tp-100 -50.89 -45.92 60.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.053 -1.03 . . . . 0.0 109.346 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.459 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 42.1 mt -57.53 -39.06 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.298 -0.876 . . . . 0.0 109.097 179.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.528 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.99 -54.19 32.21 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.6 t -56.8 -29.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -1.113 . . . . 0.0 109.466 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.26 -31.31 27.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.345 -0.847 . . . . 0.0 109.659 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 51.5 t -61.57 -18.03 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.21 -0.931 . . . . 0.0 109.672 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.436 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -89.33 -1.29 58.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.163 -0.96 . . . . 0.0 110.131 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.458 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 18.9 m-70 -135.84 52.47 1.99 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.989 -1.069 . . . . 0.0 109.954 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.408 HD13 HG13 ' A' ' 10' ' ' VAL . 34.9 mt . . . . . 0 N--CA 1.492 1.648 0 O-C-N 121.123 -0.986 . . . . 0.0 109.442 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.458 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 52.6 ttp . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.418 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 95.8 t -76.97 -0.65 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 110.012 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.76 -31.12 26.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.04 -1.038 . . . . 0.0 109.366 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -94.74 -44.59 7.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.45 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.401 ' HG2' ' OE1' ' A' ' 65' ' ' GLN . 3.4 mtp -55.12 -50.03 70.27 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.228 -0.92 . . . . 0.0 109.35 179.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.459 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.3 mtpt -50.38 -40.71 50.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.151 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.436 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -57.66 -34.14 69.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.372 -0.83 . . . . 0.0 109.274 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 4.0 t -68.0 -35.13 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.139 -0.976 . . . . 0.0 109.024 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.424 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -64.16 -49.45 66.55 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.735 -1.746 . . . . 0.0 108.735 179.611 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.465 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 83.9 t -55.94 -19.7 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.371 -1.076 . . . . 0.0 109.575 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.517 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.0 OUTLIER -84.67 -45.15 12.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.802 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.515 ' CD2' HD13 ' A' ' 98' ' ' ILE . 3.7 m80 -64.12 -10.52 23.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.44 -0.788 . . . . 0.0 110.637 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.465 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -82.25 7.4 13.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.83 -1.169 . . . . 0.0 110.335 -179.817 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.93 51.96 0.31 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.517 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.3 m-30 -91.85 -168.61 2.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -1.156 . . . . 0.0 109.912 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -63.5 -19.75 62.77 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.519 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 10.3 p-10 -105.06 -26.05 12.28 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.056 -1.261 . . . . 0.0 110.062 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.6 mttt 49.49 29.86 3.13 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.141 -0.974 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.5 m170 -137.34 29.43 2.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.297 -0.877 . . . . 0.0 109.693 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.515 HD13 ' CD2' ' A' ' 90' ' ' HIS . 35.6 mt -72.51 158.99 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.181 -0.949 . . . . 0.0 109.684 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.406 ' N ' HG21 ' A' ' 98' ' ' ILE . 0.0 OUTLIER -142.64 174.06 10.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.817 -179.844 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.404 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -100.88 -19.17 16.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.51 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -68.21 -20.61 64.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.224 -0.922 . . . . 0.0 109.563 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.514 ' CD2' ' HG3' ' A' ' 41' ' ' MET . 46.7 m-85 -80.17 -22.06 42.37 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.201 -0.937 . . . . 0.0 109.675 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.403 ' HB2' ' O ' ' A' ' 100' ' ' ALA . 3.2 m-85 -58.99 -62.59 1.77 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.328 -0.858 . . . . 0.0 110.244 -179.295 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.484 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.1 mt-10 -45.06 -58.69 5.22 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.848 . . . . 0.0 110.867 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 9.6 Cg_endo -56.49 -47.95 21.41 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.665 1.35 . . . . 0.0 110.213 -179.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.51 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -65.78 -20.54 66.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.165 -0.959 . . . . 0.0 109.459 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.64 -42.78 9.71 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.18 -49.33 74.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -1.212 . . . . 0.0 109.538 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.68 -18.16 52.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.649 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.481 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 0.7 OUTLIER -73.86 -35.29 64.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.929 . . . . 0.0 109.76 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.453 HD21 ' CB ' ' A' ' 130' ' ' TRP . 14.3 mt -68.36 -32.49 72.61 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.673 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 m -71.66 -22.4 61.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -87.13 -39.29 15.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.488 ' SD ' ' CZ3' ' A' ' 130' ' ' TRP . 1.6 mtt -56.41 -36.33 68.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.323 -0.86 . . . . 0.0 109.863 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.456 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -54.37 -21.25 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.168 -0.957 . . . . 0.0 109.533 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 17.6 m170 -65.27 -23.75 67.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 109.905 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.462 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 4.5 ttt85 -94.07 -69.6 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.101 -0.999 . . . . 0.0 109.861 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.457 HG13 ' N ' ' A' ' 119' ' ' GLY . 16.5 pt -78.28 -32.9 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.205 -0.934 . . . . 0.0 109.61 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.457 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.09 -97.23 0.01 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -46.64 -45.11 17.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.45 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 2.8 mptt -69.67 -11.61 60.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.42 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -84.33 79.79 9.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.087 -1.008 . . . . 0.0 109.383 179.556 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.451 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.4 p30 -80.52 -165.81 0.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.606 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -69.68 -44.56 70.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.92 . . . . 0.0 109.441 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.451 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -57.67 -36.6 72.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.191 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -61.05 -53.53 55.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.303 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 14.8 ptpt -70.48 -29.66 66.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.323 -0.861 . . . . 0.0 109.427 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.464 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.7 t70 -74.48 -50.34 18.68 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.324 -0.86 . . . . 0.0 109.34 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.488 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -59.67 -43.34 94.03 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.256 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.528 ' HB3' ' CE2' ' A' ' 134' ' ' TYR . 4.9 m0 -73.99 -23.1 59.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.267 -0.896 . . . . 0.0 109.022 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 128' ' ' ASP . . . -68.48 -26.82 65.67 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.301 -0.874 . . . . 0.0 108.662 178.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.54 -24.16 17.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.449 -0.782 . . . . 0.0 109.1 179.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.58 -59.52 2.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.6 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.528 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 12.1 m-85 -51.76 -27.91 13.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.16 -0.963 . . . . 0.0 109.271 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.92 -53.37 32.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.122 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -70.26 -35.77 74.0 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.22 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 29.1 mt -68.85 -57.23 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.351 -0.843 . . . . 0.0 109.469 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.2 p -68.91 -27.91 66.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.771 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -68.37 -47.6 56.79 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -56.61 -30.06 62.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.207 -1.172 . . . . 0.0 109.715 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.454 ' CD2' HD11 ' A' ' 145' ' ' LEU . 8.2 tt -68.72 -18.77 64.3 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.729 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.481 HD12 HG22 ' A' ' 142' ' ' ILE . 39.5 mm -76.47 -3.81 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 0.0 110.043 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.459 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 3.1 m -81.95 -49.01 10.77 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.445 179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 84' ' ' LYS . . . -83.94 -8.36 84.24 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.454 HD11 ' CD2' ' A' ' 141' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.07 -1.253 . . . . 0.0 109.14 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -71.34 -49.21 44.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.292 -0.88 . . . . 0.0 109.669 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -48.64 -31.14 6.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.224 -0.923 . . . . 0.0 109.769 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 42.4 mm-40 -80.87 -49.14 11.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.907 . . . . 0.0 109.648 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.461 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 36.9 t -53.91 -26.82 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.184 -0.948 . . . . 0.0 109.507 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.512 HG12 ' CD1' ' A' ' 130' ' ' TRP . 99.0 t -68.41 -54.65 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.519 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.74 -16.09 62.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.816 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 t -86.79 -27.33 23.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.184 -0.947 . . . . 0.0 109.78 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 p -93.79 -12.54 28.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.886 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.568 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.37 -28.53 17.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.088 -1.007 . . . . 0.0 109.684 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -70.83 -13.79 62.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -0.891 . . . . 0.0 109.788 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -101.68 -53.74 2.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.984 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.447 ' CG1' HG12 ' A' ' 118' ' ' ILE . 42.2 mt -63.77 -36.61 77.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.262 -0.899 . . . . 0.0 109.603 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.568 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.13 25.65 8.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.311 -0.868 . . . . 0.0 109.728 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.23 -80.41 0.14 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.411 ' O ' ' HB3' ' A' ' 21' ' ' ASP . 77.9 p -98.21 55.15 1.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -1.129 . . . . 0.0 109.563 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.411 ' HB3' ' O ' ' A' ' 20' ' ' SER . 7.3 p-10 -177.18 -33.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.356 -0.84 . . . . 0.0 109.915 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.468 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 20.6 t30 63.72 37.79 9.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.408 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 78.47 29.06 54.1 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.405 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -75.97 -52.17 10.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.665 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.75 -22.99 68.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.472 HG13 ' CD2' ' A' ' 63' ' ' LEU . 48.5 t -67.54 -19.79 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.307 -1.113 . . . . 0.0 109.757 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.414 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -91.9 -46.81 3.55 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.466 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.2 ptpt -63.38 -20.81 65.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.153 -1.204 . . . . 0.0 109.787 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 25' ' ' GLY . 11.0 pt-20 -99.11 -26.53 14.18 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.4 t -85.09 -51.84 6.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.261 -0.899 . . . . 0.0 109.636 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.521 ' CE2' ' HB3' ' A' ' 58' ' ' LEU . 3.1 m-85 -60.08 -46.04 90.91 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.241 -0.912 . . . . 0.0 109.937 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.424 ' N ' HG12 ' A' ' 55' ' ' VAL . 53.1 m -49.63 -35.78 22.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.144 -0.972 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.403 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 1.4 mttm -75.79 -43.77 44.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.4 179.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.517 ' CG ' HD22 ' A' ' 106' ' ' LEU . 6.6 t80 -60.99 -53.19 60.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.294 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.482 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 31.1 mt -57.02 -42.35 80.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.875 . . . . 0.0 109.617 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.402 ' HB2' ' HB1' ' A' ' 50' ' ' ALA . 43.4 t -65.58 -59.29 4.11 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -0.935 . . . . 0.0 109.582 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.8 -26.47 68.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.189 -0.944 . . . . 0.0 109.631 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.459 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 17.2 m-70 -120.94 108.5 13.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.74 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -88.66 -21.31 24.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.42 -0.8 . . . . 0.0 109.306 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -68.11 -13.51 62.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.548 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.553 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -104.6 -16.55 14.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.921 -179.814 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -53.13 -66.26 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.066 -1.021 . . . . 0.0 109.634 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.84 -21.89 44.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.606 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 31.8 t -76.76 -37.16 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.2 m-85 -76.77 -27.21 55.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.93 . . . . 0.0 109.497 -179.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.97 27.2 4.37 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.516 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 10.4 m-85 -123.66 173.33 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -1.147 . . . . 0.0 109.909 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.2 t -109.37 -15.93 14.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.432 -0.792 . . . . 0.0 109.199 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.64 -164.57 29.03 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.402 ' HB1' ' HB2' ' A' ' 36' ' ' SER . . . -94.26 32.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -1.193 . . . . 0.0 109.617 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 25.8 t -134.89 26.68 3.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.289 -0.882 . . . . 0.0 109.618 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.408 ' OD1' ' HB3' ' A' ' 47' ' ' PHE . 5.2 p-10 -104.39 150.12 38.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.213 -0.929 . . . . 0.0 109.715 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -74.99 -1.93 11.87 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.042 1.549 . . . . 0.0 110.439 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -77.48 -35.58 36.51 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.482 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 77.3 t -51.36 -44.34 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -1.116 . . . . 0.0 109.538 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.463 ' HB1' ' CB ' ' A' ' 28' ' ' LYS . . . -71.86 -7.22 47.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -0.855 . . . . 0.0 109.938 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.36 -30.0 14.72 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CE2' ' A' ' 31' ' ' PHE . 3.9 mt -84.66 -61.44 1.79 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 109.702 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.414 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -51.51 -30.57 27.06 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.51 -52.8 59.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.152 -1.204 . . . . 0.0 109.704 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.5 mttp -73.41 -41.75 62.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.1 t -50.95 -63.67 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.472 ' CD2' HG13 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -46.84 -40.66 14.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.214 -0.929 . . . . 0.0 109.887 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.58 -38.69 55.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -0.94 . . . . 0.0 109.422 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 17.5 tp60 -65.08 -39.87 93.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.313 179.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 67.5 mt -62.46 -34.98 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.074 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.538 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.73 29.84 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.5 t -59.9 -24.24 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -1.119 . . . . 0.0 109.165 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.94 -24.49 26.54 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.443 -0.786 . . . . 0.0 109.425 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.453 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 52.0 t -68.02 -17.23 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.232 -0.918 . . . . 0.0 109.609 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.504 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.8 OUTLIER -89.65 41.62 1.05 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.146 -0.971 . . . . 0.0 109.703 179.954 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.1 m-70 -161.26 -73.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.588 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.513 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.4 mm? . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.68 -0.638 . . . . 0.0 110.448 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 58.1 ttp . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.273 0.558 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.454 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 47.5 t -74.53 -22.46 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.201 -0.937 . . . . 0.0 109.519 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.52 -58.44 6.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -74.84 -44.11 50.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.461 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.6 OUTLIER -57.84 -57.58 12.15 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.454 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 34.5 tttt -51.49 -32.07 26.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.203 179.722 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -68.94 -43.99 73.96 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 109.311 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.4 t -54.89 -40.29 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.201 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.416 ' HA2' HD23 ' A' ' 141' ' ' LEU . . . -53.58 -49.23 58.32 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.476 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 72.8 t -53.59 -49.29 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.305 -1.115 . . . . 0.0 109.084 179.533 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.518 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -49.68 -37.55 29.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.189 -0.944 . . . . 0.0 109.658 179.703 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.485 ' CD2' HD13 ' A' ' 98' ' ' ILE . 22.9 m80 -71.4 -3.69 22.2 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.476 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -78.96 -11.58 60.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.732 -1.23 . . . . 0.0 110.24 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -151.85 57.73 0.43 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -87.57 -170.73 3.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -1.133 . . . . 0.0 109.534 179.614 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.66 -29.54 67.22 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.518 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.9 p-10 -99.24 -32.89 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -1.183 . . . . 0.0 109.505 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.456 ' O ' ' CD ' ' A' ' 96' ' ' LYS . 0.0 OUTLIER 67.74 7.36 5.65 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.414 -0.804 . . . . 0.0 110.397 179.612 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.419 ' O ' ' O ' ' A' ' 98' ' ' ILE . 3.1 m170 -95.86 -87.84 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.012 -1.055 . . . . 0.0 108.981 178.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.485 HD13 ' CD2' ' A' ' 90' ' ' HIS . 15.3 mt 58.65 152.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.363 -0.836 . . . . 0.0 110.694 179.342 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.526 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.48 135.5 14.72 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 121.727 0.775 . . . . 0.0 109.807 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -72.23 -7.31 48.61 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.658 -0.651 . . . . 0.0 109.532 179.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.448 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 5.8 pt-20 -75.54 -23.74 56.66 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.086 179.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.553 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 25.5 m-85 -85.41 -20.38 29.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.854 . . . . 0.0 109.631 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.454 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.5 m-85 -55.95 -61.05 2.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.26 -0.9 . . . . 0.0 110.045 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.497 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -52.37 -57.62 14.77 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.066 -1.021 . . . . 0.0 109.839 -179.66 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.497 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.9 Cg_exo -50.72 -63.57 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.667 1.351 . . . . 0.0 109.886 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.517 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -56.54 -26.76 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.295 -0.878 . . . . 0.0 109.342 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.507 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -75.62 -46.05 15.86 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.71 -51.86 66.68 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -1.193 . . . . 0.0 109.273 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 t -56.33 -22.25 29.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.875 . . . . 0.0 109.247 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.4 HD23 ' HE1' ' A' ' 114' ' ' MET . 4.4 tt -67.46 -48.61 66.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.585 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' A' ' 130' ' ' TRP . 12.6 mt -54.36 -31.68 55.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.137 -0.977 . . . . 0.0 109.398 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -65.84 -49.47 68.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.657 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.476 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -71.45 -32.52 68.42 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.601 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.4 ' HE1' HD23 ' A' ' 110' ' ' LEU . 3.4 mmt -47.57 -38.57 14.59 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.265 -0.897 . . . . 0.0 110.023 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.421 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -63.77 -16.92 62.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.565 -179.776 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.476 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 37.0 m170 -60.78 -43.97 97.39 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.082 -1.011 . . . . 0.0 109.779 -179.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.409 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -72.81 -59.37 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.781 -179.7 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.447 HG12 ' CG1' ' A' ' 17' ' ' ILE . 12.3 pt -94.0 40.53 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -0.941 . . . . 0.0 109.876 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.421 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -53.46 117.07 6.52 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 112.73 -31.34 6.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.529 -1.829 . . . . 0.0 108.529 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -98.98 -24.87 14.76 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.339 -1.095 . . . . 0.0 109.13 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 6.5 tpt -67.56 96.34 0.52 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.025 179.428 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.472 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 12.5 p-10 -100.73 -172.11 2.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 0.0 109.621 -179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -58.71 -52.93 63.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.881 . . . . 0.0 110.045 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.472 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -54.63 -24.91 23.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.157 -0.965 . . . . 0.0 109.418 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -76.16 -54.06 7.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.353 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.462 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 16.7 ptpt -70.0 -30.22 67.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.919 . . . . 0.0 109.358 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.462 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 63.4 t0 -76.91 -38.3 53.75 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.4 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.461 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -66.91 -43.87 82.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.402 -0.811 . . . . 0.0 109.347 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.512 ' CD1' HG12 ' A' ' 10' ' ' VAL . 9.9 m0 -75.34 -33.01 61.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.251 -0.905 . . . . 0.0 109.011 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.505 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -52.41 -39.2 60.64 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 108.984 179.205 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.71 -23.0 24.3 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.391 -0.818 . . . . 0.0 108.985 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.453 ' O ' ' CD1' ' A' ' 137' ' ' ILE . . . -83.45 -63.17 1.41 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 109.518 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.507 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.1 OUTLIER -51.59 -23.97 4.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.182 -0.949 . . . . 0.0 109.098 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.81 -36.78 56.69 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.266 -0.896 . . . . 0.0 109.012 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -78.95 -38.73 36.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.409 -0.807 . . . . 0.0 109.235 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 133' ' ' ALA . 1.4 mp -62.42 -54.89 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.343 -0.848 . . . . 0.0 108.802 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 83.6 p -68.44 -17.7 64.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -0.885 . . . . 0.0 109.659 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.39 -35.21 20.97 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.46 -25.5 63.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -1.151 . . . . 0.0 109.621 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.461 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 9.9 tt -74.04 -16.49 61.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 109.831 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 51.2 mm -88.19 15.42 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.996 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.6 t -93.25 -45.16 7.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -83.94 -23.3 52.94 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.129 -1.589 . . . . 0.0 109.129 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.258 -1.142 . . . . 0.0 109.579 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.193 0.521 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -66.47 -48.0 71.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.16 -0.963 . . . . 0.0 109.345 179.815 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.0 ttp180 -60.84 -24.04 65.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.214 179.605 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.3 tp60 -83.02 -49.26 9.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.444 -0.785 . . . . 0.0 109.186 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.468 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 86.3 t -51.56 -27.43 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.404 -0.81 . . . . 0.0 109.498 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.455 ' CG1' HG11 ' A' ' 70' ' ' VAL . 61.1 t -65.02 -52.22 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.769 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.05 -19.2 64.09 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.202 -0.936 . . . . 0.0 109.596 179.87 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.85 -23.84 36.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.556 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.427 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 21.2 p -99.89 -13.22 19.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.789 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.02 -28.31 19.16 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.128 -0.982 . . . . 0.0 109.759 -179.836 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 14.9 mttt -75.88 -8.7 57.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.904 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -105.4 -47.37 3.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.103 -0.998 . . . . 0.0 109.63 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.481 HD11 ' CH2' ' A' ' 130' ' ' TRP . 57.8 mt -71.9 -35.4 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.218 -0.926 . . . . 0.0 109.635 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.03 33.82 3.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.678 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.14 -75.99 0.2 Allowed Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.2 p -103.73 -37.47 7.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -1.16 . . . . 0.0 109.597 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 16.0 p-10 -71.61 -20.54 61.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.61 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.461 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 19.9 t30 57.55 25.29 11.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.627 179.956 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.06 19.94 24.91 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.34 -59.52 3.12 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -1.146 . . . . 0.0 109.56 179.959 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.467 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -67.02 -12.46 60.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.4 HG21 ' CG2' ' A' ' 17' ' ' ILE . 37.5 t -84.82 -41.25 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.149 -1.206 . . . . 0.0 109.868 -179.819 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.439 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -74.33 -36.73 49.42 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.306 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.467 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 9.7 ptpt -73.2 -26.55 61.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.109 -1.23 . . . . 0.0 110.207 -179.459 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.453 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pt-20 -95.42 -20.65 18.91 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.066 -1.021 . . . . 0.0 109.993 -179.746 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 37.3 t -88.19 -66.73 0.89 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 110.085 -179.577 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.517 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.6 m-85 -48.06 -31.53 5.59 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.048 -179.546 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.468 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.0 OUTLIER -56.17 -51.18 68.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.083 -1.011 . . . . 0.0 109.348 179.705 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 6.2 mttp -59.61 -48.64 80.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.285 -0.884 . . . . 0.0 109.533 179.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.516 ' CG ' HD22 ' A' ' 106' ' ' LEU . 5.8 t80 -52.63 -47.77 66.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.453 179.863 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.515 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 21.5 mt -58.93 -44.01 91.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.288 -0.882 . . . . 0.0 109.607 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -68.73 -60.98 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.47 -23.05 9.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -0.921 . . . . 0.0 109.589 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.413 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 28.5 m-70 -126.24 102.37 7.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.278 -0.889 . . . . 0.0 109.716 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.4 m170 -85.64 6.86 25.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.329 -0.857 . . . . 0.0 109.9 179.699 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -95.09 -18.12 21.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.128 -0.983 . . . . 0.0 109.427 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.424 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 38.7 mmm -107.03 -19.45 13.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.754 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.39 -46.34 37.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.036 -1.04 . . . . 0.0 109.562 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.3 -26.05 60.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.099 179.478 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.52 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 27.9 t -70.62 -33.75 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.431 -0.793 . . . . 0.0 109.342 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.497 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 10.2 m-85 -78.98 -31.17 44.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.48 26.88 4.07 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.511 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 10.0 m-85 -124.02 166.85 15.02 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -1.156 . . . . 0.0 109.706 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.0 t -104.92 -11.16 16.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.855 . . . . 0.0 109.444 179.359 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.9 -164.82 31.84 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.57 30.33 2.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -1.186 . . . . 0.0 109.629 179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.65 27.7 5.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -115.62 142.13 28.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.253 -0.904 . . . . 0.0 109.632 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -66.22 -17.8 54.99 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.054 1.555 . . . . 0.0 110.111 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -53.37 -39.84 60.0 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.515 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 94.4 t -54.98 -34.86 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.401 -1.058 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.455 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.89 -27.93 62.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.28 -0.887 . . . . 0.0 109.449 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.54 -31.99 60.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 2.0 mt -81.97 -62.55 1.6 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.307 -0.871 . . . . 0.0 109.631 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.517 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.68 -51.56 27.84 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.953 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -51.92 -37.18 51.68 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -1.145 . . . . 0.0 109.412 179.879 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -81.27 -27.69 35.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.512 179.856 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 46.5 t -77.84 -49.64 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.303 -0.873 . . . . 0.0 109.704 -179.909 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -47.51 -51.25 21.23 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.714 179.796 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.73 -47.14 20.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.251 -0.906 . . . . 0.0 110.089 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -52.76 -53.72 44.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.099 -1.001 . . . . 0.0 109.356 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.515 HD12 ' CE2' ' A' ' 134' ' ' TYR . 55.9 mt -55.49 -34.43 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.174 -0.954 . . . . 0.0 109.074 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.48 -54.07 31.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.751 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.8 t -60.98 -24.93 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -1.121 . . . . 0.0 109.27 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.66 -27.93 25.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.355 -0.84 . . . . 0.0 109.555 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.463 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 46.2 t -68.13 -9.75 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.219 -0.925 . . . . 0.0 109.78 179.833 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.7 t -92.26 29.93 1.57 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.046 -1.034 . . . . 0.0 109.763 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.449 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 9.4 m-70 -155.27 -91.93 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.817 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.403 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 9.2 mt . . . . . 0 N--CA 1.496 1.858 0 O-C-N 121.331 -0.856 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.449 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 18.3 tmm? . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.303 0.573 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 96.1 t -77.59 -20.59 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.414 179.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.42 -52.4 65.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 109.444 179.88 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.73 -50.65 41.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.429 179.75 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.462 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.8 OUTLIER -56.34 -56.51 20.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 109.313 179.737 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.483 ' CG ' ' CB ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -53.54 -24.44 13.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.205 179.555 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.416 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -77.9 -44.13 27.97 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.407 -0.808 . . . . 0.0 109.479 179.78 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.454 ' CG1' HD13 ' A' ' 141' ' ' LEU . 21.0 t -53.17 -35.35 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.472 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -60.66 -48.36 86.63 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.468 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 64.9 t -57.65 -18.82 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.423 -1.045 . . . . 0.0 109.432 179.332 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.1 OUTLIER -86.72 -46.1 10.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.134 -0.978 . . . . 0.0 109.087 179.617 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.483 ' HA ' ' CE2' ' A' ' 93' ' ' TYR . 14.3 m80 -56.39 -37.5 70.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 109.564 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -60.96 -16.68 45.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.298 -0.876 . . . . 0.0 109.935 -179.863 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -119.97 40.76 2.11 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.7 m-30 -90.42 -172.12 3.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 109.53 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.9 -28.67 37.08 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.906 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.52 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.6 OUTLIER -79.95 -47.94 14.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.478 -1.013 . . . . 0.0 109.18 179.78 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.471 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.7 OUTLIER 75.13 -48.51 0.63 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.623 -0.673 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 97' ' ' HIS . 25.1 m170 -68.05 59.44 0.07 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.802 -1.186 . . . . 0.0 110.466 -179.516 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.405 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 56.1 mt -90.41 156.96 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.069 -1.019 . . . . 0.0 109.027 179.488 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.499 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -137.94 138.93 39.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.056 -1.027 . . . . 0.0 110.055 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -81.15 -3.69 52.95 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -0.873 . . . . 0.0 109.883 179.693 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 43.1 mm-40 -81.38 -22.25 38.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.006 -1.059 . . . . 0.0 109.489 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.499 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 55.0 m-85 -79.96 -15.09 57.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.309 -0.869 . . . . 0.0 109.891 -179.816 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -62.93 -61.55 2.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.242 -0.911 . . . . 0.0 110.063 -179.847 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.481 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.4 OUTLIER -44.85 -58.83 4.86 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 110.746 -179.46 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 9.9 Cg_endo -57.45 -45.95 30.91 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.682 1.359 . . . . 0.0 110.003 -179.569 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.516 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.3 tm? -65.91 -20.09 66.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.301 179.789 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.4 ' HA2' ' CE1' ' A' ' 134' ' ' TYR . . . -86.29 -49.04 4.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.54 -45.49 92.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.2 -1.176 . . . . 0.0 109.537 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.9 m -61.56 -28.97 69.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.494 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.456 ' CD1' ' OH ' ' A' ' 134' ' ' TYR . 3.7 tt -67.23 -40.03 86.31 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.204 -0.935 . . . . 0.0 109.369 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.412 HD21 ' HB2' ' A' ' 130' ' ' TRP . 12.7 mt -54.17 -36.32 63.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.163 -0.961 . . . . 0.0 109.047 179.763 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.8 t -67.01 -30.72 70.9 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.459 179.711 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.444 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -79.96 -38.94 31.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 179.923 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 4.6 mmt -48.42 -42.91 33.49 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.228 -0.92 . . . . 0.0 109.618 179.959 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -50.67 -24.37 3.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.489 179.843 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.444 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 17.6 m170 -52.0 -53.1 45.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.959 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -72.44 -58.73 3.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.894 . . . . 0.0 109.5 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.466 HD11 ' CA ' ' A' ' 122' ' ' MET . 6.5 pt -102.58 60.79 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.587 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -69.57 -11.01 64.65 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.886 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -105.72 -30.03 4.75 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.861 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' A' ' 123' ' ' ASN . 12.7 mttm -93.05 -24.52 18.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.173 -1.192 . . . . 0.0 110.078 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.466 ' CA ' HD11 ' A' ' 118' ' ' ILE . 0.9 OUTLIER -64.17 79.55 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.088 -1.008 . . . . 0.0 109.432 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.46 ' N ' ' O ' ' A' ' 121' ' ' LYS . 8.5 p30 -81.54 -164.52 0.79 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 -179.839 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -70.74 -38.46 73.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.181 -0.95 . . . . 0.0 109.376 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.462 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -62.74 -33.43 75.12 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.293 -0.879 . . . . 0.0 109.234 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -67.25 -52.3 42.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.534 179.851 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.455 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 0.5 OUTLIER -71.04 -29.38 65.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.341 179.835 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.455 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 48.6 t0 -79.81 -32.15 40.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.302 -0.873 . . . . 0.0 109.362 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.468 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.08 -43.43 61.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.418 -0.801 . . . . 0.0 109.322 179.752 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.481 ' CH2' HD11 ' A' ' 17' ' ' ILE . 9.4 m0 -74.86 -25.8 59.23 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.257 -0.902 . . . . 0.0 108.716 179.489 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.48 -26.89 68.77 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.235 -0.916 . . . . 0.0 108.693 178.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.45 -40.98 9.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.51 -0.744 . . . . 0.0 109.14 179.517 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -73.6 -58.95 2.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.4 -0.812 . . . . 0.0 109.103 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.515 ' CE2' HD12 ' A' ' 66' ' ' ILE . 1.9 t80 -50.87 -28.07 8.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.33 -0.856 . . . . 0.0 108.997 179.381 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -73.02 -41.35 64.31 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.037 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -76.68 -29.06 56.16 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.483 -0.76 . . . . 0.0 109.059 179.42 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 42.1 mt -66.54 -61.59 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 108.738 179.532 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.3 p -66.35 -20.6 66.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.431 -0.793 . . . . 0.0 109.726 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.35 -26.98 50.17 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 -179.872 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.0 -19.32 54.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.25 -1.147 . . . . 0.0 109.723 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.462 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 10.3 tt -79.53 -6.94 58.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.061 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.42 ' O ' HG21 ' A' ' 142' ' ' ILE . 57.5 mt -86.78 9.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.002 -1.061 . . . . 0.0 110.122 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.483 ' CB ' ' CG ' ' A' ' 84' ' ' LYS . 7.2 m -83.08 -43.31 16.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.933 -1.104 . . . . 0.0 109.436 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.461 ' HA3' ' CG2' ' A' ' 88' ' ' VAL . . . -97.05 -21.24 21.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.472 ' N ' ' HA3' ' A' ' 87' ' ' GLY . 10.7 tp . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.423 -1.045 . . . . 0.0 109.53 179.928 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.257 0.551 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -58.23 -54.95 41.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.607 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.403 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 10.1 ttp180 -50.8 -31.43 16.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 179.872 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.1 tp60 -80.18 -42.05 24.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.331 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.456 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 57.3 t -59.34 -25.07 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -0.911 . . . . 0.0 109.433 179.803 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.511 HG12 ' CD1' ' A' ' 130' ' ' TRP . 86.4 t -67.48 -52.39 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.55 -12.12 56.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.873 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.19 -26.65 21.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.138 -0.976 . . . . 0.0 109.891 -179.854 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.494 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 28.2 p -99.65 -7.7 25.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.107 -0.996 . . . . 0.0 109.893 179.948 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.55 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.18 -19.83 22.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.02 -1.05 . . . . 0.0 109.562 -179.759 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 45.1 mtpt -79.74 -15.01 58.31 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.715 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.28 -54.82 3.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.663 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.519 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 56.9 mt -65.87 -42.18 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.642 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.55 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -96.45 31.78 2.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.211 -0.93 . . . . 0.0 109.711 -179.855 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.97 -73.29 0.39 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.94 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.6 p -107.04 -26.26 11.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.257 -1.143 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.463 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 10.5 p-10 -81.01 -19.32 44.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.694 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.422 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 5.3 t30 58.39 22.16 9.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.651 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.408 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 101.73 31.09 5.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.463 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -84.1 -46.49 11.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.261 -1.14 . . . . 0.0 109.584 179.925 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.38 -1.78 86.61 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.91 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.519 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 21.2 t -88.2 -40.24 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.041 -1.27 . . . . 0.0 109.426 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.448 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.49 -53.91 4.51 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.545 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.466 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 18.2 ptpt -48.9 -31.7 7.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.101 -1.235 . . . . 0.0 109.673 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.456 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 24.5 pt-20 -91.62 -21.32 20.87 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.215 -0.928 . . . . 0.0 109.387 179.713 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.4 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 20.8 t -87.6 -64.58 1.13 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.346 -0.847 . . . . 0.0 109.767 -179.794 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.512 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 10.5 m-85 -48.28 -34.29 10.18 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 109.955 -179.566 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.409 HG23 ' O ' ' A' ' 28' ' ' LYS . 0.2 OUTLIER -56.74 -54.73 42.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 109.273 179.659 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -55.28 -51.39 66.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 179.847 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.516 ' CD1' HD22 ' A' ' 106' ' ' LEU . 2.0 t80 -54.54 -51.7 64.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 109.54 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.469 HD11 ' CG2' ' A' ' 55' ' ' VAL . 16.3 mt -54.81 -45.85 74.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.667 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.9 -59.21 3.46 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.257 -0.902 . . . . 0.0 109.671 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.4 -22.41 53.85 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 0.0 109.624 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.412 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 38.9 m-70 -131.0 107.85 9.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 109.786 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 48.7 m170 -88.9 -12.53 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.364 -0.835 . . . . 0.0 109.753 179.748 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -73.69 -16.89 61.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.123 -0.986 . . . . 0.0 109.715 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.5 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 73.0 mmm -109.13 -16.25 14.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.165 -0.96 . . . . 0.0 109.882 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.466 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.58 -51.3 28.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.986 -1.071 . . . . 0.0 109.498 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.02 -28.14 64.18 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.127 179.526 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 38.8 t -66.02 -32.1 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.407 -0.808 . . . . 0.0 109.265 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.515 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 29.3 m-85 -82.48 -25.68 33.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.159 -0.963 . . . . 0.0 109.503 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.49 26.79 5.5 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.779 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.54 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.2 m-85 -123.43 167.93 13.21 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.37 -1.077 . . . . 0.0 109.888 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 t -109.91 19.17 19.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.385 -0.822 . . . . 0.0 109.282 179.508 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.37 -163.33 29.52 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -179.946 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.19 40.72 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -1.157 . . . . 0.0 109.732 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 20.9 t -139.74 21.02 2.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.687 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.21 139.02 20.06 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.678 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -61.21 -24.73 79.56 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 123.951 1.5 . . . . 0.0 110.089 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.54 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.25 -39.32 42.62 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' CD2' ' A' ' 47' ' ' PHE . 59.4 t -51.31 -36.28 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -1.129 . . . . 0.0 109.367 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -73.38 -10.22 59.51 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.354 -0.841 . . . . 0.0 109.591 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.412 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 59.5 m-20 -86.78 -57.03 3.13 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.13 -0.981 . . . . 0.0 109.551 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.449 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 10.0 mt -63.29 -61.06 2.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.512 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -47.95 -37.38 15.69 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.46 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -69.72 -59.88 2.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.107 -1.231 . . . . 0.0 109.507 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -57.51 -46.57 83.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.268 -0.895 . . . . 0.0 109.34 179.749 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.449 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 51.4 t -56.66 -52.12 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.268 -0.895 . . . . 0.0 109.558 179.771 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.413 HD23 ' CA ' ' A' ' 27' ' ' GLY . 1.4 mm? -47.06 -46.04 22.08 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.182 -0.949 . . . . 0.0 109.753 179.875 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.19 -49.52 52.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.597 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 16.1 tp60 -50.2 -48.75 54.1 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.272 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.446 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 50.1 mt -57.15 -39.21 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.374 -0.829 . . . . 0.0 109.025 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.22 -53.23 41.25 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.944 -1.662 . . . . 0.0 108.944 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.8 t -59.08 -26.73 34.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -1.089 . . . . 0.0 109.35 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.418 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -84.62 -28.6 26.39 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.421 -0.799 . . . . 0.0 109.58 179.966 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.46 ' CG1' HG11 ' A' ' 10' ' ' VAL . 58.1 t -61.39 -15.78 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.922 . . . . 0.0 109.733 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -90.94 26.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.212 -0.93 . . . . 0.0 109.959 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.42 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 7.9 m-70 -155.72 -87.0 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.016 . . . . 0.0 109.81 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.42 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 21.2 mt . . . . . 0 N--CA 1.495 1.815 0 O-C-N 121.455 -0.778 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 37.2 ttp . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.3 0.571 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 47.9 t -81.19 -21.63 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 179.846 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -28.7 63.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.427 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -81.48 -52.3 7.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.29 -0.881 . . . . 0.0 109.5 179.875 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.458 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 99.3 mmm -56.44 -39.81 73.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.186 -0.946 . . . . 0.0 108.975 179.683 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.411 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -52.02 -28.65 17.83 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.077 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.412 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -80.08 -33.09 39.13 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.552 -0.718 . . . . 0.0 109.097 179.324 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.402 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.9 t -69.62 -33.83 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.22 179.688 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.462 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -65.37 -39.61 95.94 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 91' ' ' LYS . 90.3 t -58.7 -28.08 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.268 -1.137 . . . . 0.0 109.213 179.657 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.516 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -73.69 -25.94 60.48 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.349 -0.844 . . . . 0.0 109.26 179.641 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.46 ' CB ' HD12 ' A' ' 98' ' ' ILE . 18.5 m80 -88.04 18.19 4.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.375 -0.828 . . . . 0.0 110.169 -179.085 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.403 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 1.6 tttt -79.35 -60.56 2.32 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.02 -1.05 . . . . 0.0 110.52 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.43 ' HA2' ' HB2' ' A' ' 96' ' ' LYS . . . -148.24 57.58 0.48 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -179.497 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.516 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-85 -86.62 -148.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.308 -1.113 . . . . 0.0 109.812 -179.864 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -45.24 -70.22 0.65 Allowed Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.522 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.7 OUTLIER -66.79 -50.4 62.79 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 108.802 179.559 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.477 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.0 OUTLIER 76.58 -34.58 0.23 Allowed 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.399 -0.813 . . . . 0.0 111.48 179.277 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.474 ' N ' ' HG3' ' A' ' 96' ' ' LYS . 14.2 m170 -87.1 60.52 6.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.466 -1.396 . . . . 0.0 109.554 179.854 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.46 HD12 ' CB ' ' A' ' 90' ' ' HIS . 83.6 mt -87.21 155.06 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.122 -0.986 . . . . 0.0 110.224 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -133.97 141.37 47.25 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.528 -0.732 . . . . 0.0 109.724 -179.941 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.471 ' CB ' HG22 ' A' ' 142' ' ' ILE . . . -82.1 -3.28 54.43 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.358 -0.839 . . . . 0.0 110.213 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.467 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 16.9 pt-20 -78.95 -23.49 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.909 -1.12 . . . . 0.0 109.54 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.5 ' CD2' ' HG3' ' A' ' 41' ' ' MET . 71.8 m-85 -80.33 -7.0 58.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.23 -0.918 . . . . 0.0 110.026 179.837 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -70.0 -66.91 0.53 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.115 -0.99 . . . . 0.0 110.092 -179.561 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.492 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.78 -60.02 3.48 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.494 -0.754 . . . . 0.0 110.743 -179.338 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.492 ' CD ' ' CB ' ' A' ' 104' ' ' GLU . 4.2 Cg_endo -52.87 -55.7 3.5 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.683 1.359 . . . . 0.0 109.995 -179.5 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.516 HD22 ' CD1' ' A' ' 34' ' ' PHE . 3.3 tm? -59.98 -19.76 54.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.283 179.745 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -75.33 -45.72 18.04 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.57 -46.79 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.134 -1.215 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.5 m -64.87 -17.64 64.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.251 -0.905 . . . . 0.0 109.407 179.584 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.515 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 4.9 tt -74.63 -41.87 59.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.947 . . . . 0.0 109.685 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.24 -28.89 68.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.115 -0.991 . . . . 0.0 109.39 179.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.7 t -60.26 -46.15 90.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.334 -0.854 . . . . 0.0 109.64 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.465 ' HA ' ' CD2' ' A' ' 116' ' ' HIS . . . -66.29 -36.92 84.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.533 ' HG2' ' CZ3' ' A' ' 130' ' ' TRP . 0.0 OUTLIER -47.28 -42.69 21.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.316 -0.865 . . . . 0.0 109.85 179.904 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.458 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.97 -24.01 15.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.277 -0.889 . . . . 0.0 109.766 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.465 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.6 m170 -52.38 -55.16 23.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 109.842 -179.784 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.426 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 3.8 ttt85 -72.03 -66.09 0.69 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.188 -0.945 . . . . 0.0 109.833 -179.841 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.444 HG12 ' CD1' ' A' ' 17' ' ' ILE . 6.6 pt -94.57 58.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.114 -0.991 . . . . 0.0 109.748 -179.826 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.75 -39.49 95.26 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -85.92 -13.46 69.29 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.867 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.414 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.2 mttm -104.71 -20.84 13.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.07 -1.253 . . . . 0.0 109.883 -179.812 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.42 ' N ' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.47 90.45 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.213 179.71 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.474 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 9.1 p-10 -92.5 -172.61 3.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.224 -0.922 . . . . 0.0 110.029 -179.619 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -63.65 -48.99 75.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.46 -0.775 . . . . 0.0 110.308 -179.426 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.474 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -60.52 -24.88 65.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.428 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -75.18 -49.27 20.0 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.461 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.463 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 20.1 ptpt -73.04 -30.85 64.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -0.911 . . . . 0.0 109.74 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.463 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.5 t0 -76.71 -41.93 43.42 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.456 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -64.02 -43.28 96.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.368 -0.833 . . . . 0.0 109.376 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.533 ' CZ3' ' HG2' ' A' ' 114' ' ' MET . 6.8 m0 -75.6 -26.24 57.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.288 -0.882 . . . . 0.0 109.314 179.761 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -64.94 -26.4 68.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.454 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -96.82 -26.37 15.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.441 -0.787 . . . . 0.0 109.276 179.659 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.405 ' HB2' HG21 ' A' ' 10' ' ' VAL . . . -73.93 -57.69 3.8 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.364 -0.835 . . . . 0.0 109.449 179.819 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.492 ' CE2' ' HE1' ' A' ' 114' ' ' MET . 17.2 m-30 -50.36 -29.18 9.4 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.333 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.27 -43.95 69.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.372 -0.83 . . . . 0.0 109.08 179.554 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -75.16 -33.32 61.47 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.352 -0.843 . . . . 0.0 109.238 179.663 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.418 HG12 ' CB ' ' A' ' 69' ' ' ALA . 3.5 mt -67.9 -59.06 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.314 -0.866 . . . . 0.0 109.192 179.667 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.2 -48.76 64.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.717 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -50.91 -28.59 17.4 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.189 -1.565 . . . . 0.0 109.189 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.06 3.21 31.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -1.132 . . . . 0.0 110.048 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.458 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 7.2 tt -97.97 -24.38 15.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.933 -1.104 . . . . 0.0 109.804 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.471 HG22 ' CB ' ' A' ' 100' ' ' ALA . 6.8 mt -87.2 18.23 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.382 -179.446 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.411 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -77.96 -20.67 52.27 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.107 -0.996 . . . . 0.0 108.872 179.489 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.35 1.51 5.71 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.838 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.462 ' HB2' ' CA ' ' A' ' 87' ' ' GLY . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.681 0 O-C-N 120.849 -1.383 . . . . 0.0 110.1 -179.825 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.402 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.301 0.572 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -70.92 -48.5 53.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.217 -0.927 . . . . 0.0 109.509 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 13.9 ptm180 -56.31 -30.83 63.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.277 -0.889 . . . . 0.0 109.348 179.856 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.434 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 17.7 mm-40 -73.74 -41.73 62.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.436 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.464 ' CG1' ' O ' ' A' ' 125' ' ' ALA . 21.6 t -61.4 -22.54 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.481 HG12 ' CD1' ' A' ' 130' ' ' TRP . 66.4 t -73.37 -43.31 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 109.673 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.79 -8.03 54.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.288 -0.883 . . . . 0.0 110.016 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.5 m -94.23 -30.3 14.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.043 . . . . 0.0 109.826 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.509 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.2 p -92.91 -13.17 29.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.954 -179.835 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.04 -19.49 27.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.117 -0.989 . . . . 0.0 109.849 -179.741 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.2 mtpt -83.87 -4.06 58.38 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.928 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.66 -53.31 2.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.788 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.483 HD11 ' CH2' ' A' ' 130' ' ' TRP . 60.9 mt -66.16 -36.28 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.455 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.56 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -104.29 27.34 7.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.51 -69.52 1.07 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 p -107.21 -36.95 6.41 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -1.141 . . . . 0.0 109.59 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -71.79 -20.04 61.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.922 . . . . 0.0 109.667 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 17.5 t30 54.54 30.44 13.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.268 -0.895 . . . . 0.0 109.593 -179.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.75 59.99 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.4 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -68.59 -47.3 67.09 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.108 -1.231 . . . . 0.0 109.52 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.472 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.23 12.97 62.94 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.473 ' CG1' HD13 ' A' ' 63' ' ' LEU . 11.3 t -97.84 -32.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.139 -1.212 . . . . 0.0 109.116 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 31' ' ' PHE . . . -86.69 -44.24 5.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.489 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 7.7 ptpt -53.87 -35.41 61.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -1.195 . . . . 0.0 109.386 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.47 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.3 pt-20 -86.85 -26.83 23.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 109.366 179.714 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.411 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 30.4 t -85.11 -58.31 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.366 -0.834 . . . . 0.0 109.684 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.518 ' CZ ' ' HA2' ' A' ' 59' ' ' GLY . 3.4 m-85 -47.3 -32.57 4.82 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.333 -0.854 . . . . 0.0 109.915 -179.72 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.54 -49.22 78.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.158 179.669 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -52.28 64.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.571 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.508 ' CG ' HD22 ' A' ' 106' ' ' LEU . 6.8 t80 -52.4 -54.48 31.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.189 -0.944 . . . . 0.0 109.483 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.512 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 38.2 mt -55.7 -43.67 76.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.665 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 9.6 t -68.81 -65.43 0.7 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.732 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.449 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -52.67 -27.35 16.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.723 -179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.468 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 16.2 m-70 -123.06 106.72 11.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.914 . . . . 0.0 109.837 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -87.36 -20.83 26.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.429 -0.795 . . . . 0.0 109.294 179.542 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.4 p-10 -66.15 -17.9 65.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.371 179.478 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.51 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 84.6 mmm -106.14 -24.5 12.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.266 -0.896 . . . . 0.0 109.705 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.464 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.88 -46.14 42.18 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.078 -1.014 . . . . 0.0 109.61 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.75 -21.12 60.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.302 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.46 ' CG2' ' OD1' ' A' ' 95' ' ' ASN . 35.8 t -76.16 -40.83 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.299 -0.876 . . . . 0.0 109.412 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -67.26 -41.79 84.97 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 109.576 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.46 32.94 1.07 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.52 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.4 m-85 -125.04 173.15 8.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.225 -1.162 . . . . 0.0 109.629 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 17.6 t -111.51 19.38 18.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 109.371 179.547 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.11 -167.34 30.07 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.86 -23.0 39.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.203 -1.175 . . . . 0.0 109.66 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 12.5 m -84.74 51.24 2.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.923 . . . . 0.0 109.676 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -120.51 136.21 25.13 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.597 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -68.06 -33.45 25.42 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.97 1.511 . . . . 0.0 110.033 -179.906 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.52 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.41 -32.39 30.21 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.512 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 91.7 t -53.92 -41.61 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.268 -1.136 . . . . 0.0 109.501 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.489 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -74.5 -11.01 60.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.262 -0.899 . . . . 0.0 109.872 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.409 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 11.4 t0 -91.73 -33.3 15.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.111 -0.993 . . . . 0.0 109.375 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.506 ' HB3' ' CE2' ' A' ' 31' ' ' PHE . 1.6 mt -81.59 -64.25 1.22 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.348 -0.845 . . . . 0.0 110.201 -179.786 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.518 ' HA2' ' CZ ' ' A' ' 31' ' ' PHE . . . -56.09 -20.77 29.1 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.37 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -72.24 -40.76 67.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.109 -1.23 . . . . 0.0 109.761 -179.719 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 57' ' ' ASP . 28.6 mttt -84.46 -43.67 14.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.601 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 61.6 t -52.56 -47.18 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.128 -0.983 . . . . 0.0 109.48 179.879 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.473 HD13 ' CG1' ' A' ' 26' ' ' VAL . 0.8 OUTLIER -48.09 -47.85 33.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.108 -0.995 . . . . 0.0 109.773 179.81 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.409 ' HB2' ' O ' ' A' ' 61' ' ' LYS . . . -49.6 -49.38 47.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.912 . . . . 0.0 109.653 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -49.06 -54.96 13.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.135 -0.978 . . . . 0.0 109.378 179.849 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.459 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 83.7 mt -52.36 -35.32 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.313 -0.867 . . . . 0.0 109.05 179.554 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.85 -57.11 15.21 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.869 -1.693 . . . . 0.0 108.869 179.416 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.5 t -57.58 -25.91 25.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -1.135 . . . . 0.0 109.253 179.76 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.07 -19.58 34.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.391 -0.818 . . . . 0.0 109.5 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 53.0 t -75.47 -14.47 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.686 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.488 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -90.41 35.64 0.88 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.109 -0.994 . . . . 0.0 109.96 -179.824 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 71' ' ' SER . 6.0 m-70 -161.68 -84.75 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.063 -1.023 . . . . 0.0 109.918 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.439 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 42.2 mt . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.599 -0.688 . . . . 0.0 109.97 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 59.0 ttp . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.249 0.547 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.8 t -73.07 -14.63 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.872 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.78 -35.08 72.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.126 -0.983 . . . . 0.0 109.835 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.411 ' O ' HG23 ' A' ' 86' ' ' VAL . 10.7 tt0 -98.82 -40.97 7.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.666 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.418 ' HA ' HG23 ' A' ' 86' ' ' VAL . 1.7 mtp -62.18 -46.55 88.43 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.419 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 13.1 tttt -56.18 -39.27 72.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.172 -0.955 . . . . 0.0 109.172 179.65 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -63.19 -39.65 95.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.388 179.709 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.505 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 48.8 t -51.92 -47.96 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -52.94 -49.88 53.15 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.624 -1.791 . . . . 0.0 108.624 179.548 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.414 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.1 t -53.13 -34.75 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.389 -1.065 . . . . 0.0 109.249 179.462 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 24.6 mmm180 -69.56 -49.21 56.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.865 . . . . 0.0 109.416 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.475 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 10.7 m80 -61.63 -15.41 39.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.235 -0.916 . . . . 0.0 109.363 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.8 ttmt -43.21 -33.49 0.94 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.466 -0.771 . . . . 0.0 110.917 -179.568 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.39 60.95 0.28 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.11 -1.519 . . . . 0.0 110.675 -179.502 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.9 m-30 -69.83 -166.0 0.1 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.014 -1.286 . . . . 0.0 109.257 178.64 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.31 -22.63 61.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.612 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.489 ' O ' ' CB ' ' A' ' 96' ' ' LYS . 0.2 OUTLIER -93.61 -44.06 8.38 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.381 -1.07 . . . . 0.0 109.321 -179.955 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.489 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 27.4 mttt 79.58 -32.14 0.14 Allowed 'General case' 0 N--CA 1.509 2.512 0 O-C-N 121.954 -0.467 . . . . 0.0 111.278 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.431 ' HB2' ' OD1' ' A' ' 95' ' ' ASN . 30.7 m170 -60.69 -99.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.518 -1.364 . . . . 0.0 109.99 -179.6 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.501 ' O ' ' CD ' ' A' ' 99' ' ' LYS . 6.1 mt 62.83 129.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.778 -1.201 . . . . 0.0 109.903 -179.546 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.518 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -145.4 143.35 30.03 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 122.237 1.018 . . . . 0.0 110.85 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.417 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -69.12 -19.61 64.04 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.047 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -64.9 -32.77 74.64 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.772 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.518 ' CD2' ' HB2' ' A' ' 99' ' ' LYS . 22.9 m-85 -81.26 -25.62 36.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.589 -0.694 . . . . 0.0 109.956 179.847 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.487 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.4 m-85 -53.46 -65.88 0.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.22 -0.925 . . . . 0.0 110.344 -179.382 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.487 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.6 mt-10 -46.53 -59.43 5.06 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.251 -0.906 . . . . 0.0 110.512 -179.194 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 41.0 Cg_exo -45.42 -55.06 3.78 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.712 1.375 . . . . 0.0 110.621 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.508 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.0 tm? -55.43 -39.13 69.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.34 -40.33 97.75 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.27 -55.07 27.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -1.162 . . . . 0.0 109.766 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.1 t -60.16 -27.43 67.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.202 -0.937 . . . . 0.0 109.703 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.437 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 3.2 tt -70.35 -38.92 74.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.205 -0.935 . . . . 0.0 109.589 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.08 -29.39 68.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.15 -0.969 . . . . 0.0 109.41 179.897 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 m -73.49 -29.7 62.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.784 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.467 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -80.68 -38.3 29.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.949 . . . . 0.0 109.569 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.503 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 1.9 mtt -50.1 -39.68 43.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.283 -0.885 . . . . 0.0 109.463 179.857 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.5 OUTLIER -51.67 -24.74 6.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.23 -0.919 . . . . 0.0 109.382 179.565 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.467 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 33.8 m170 -55.67 -49.67 72.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.327 -0.858 . . . . 0.0 109.829 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.438 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 2.9 ttt85 -70.1 -65.37 0.73 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.272 -0.892 . . . . 0.0 109.696 -179.837 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.457 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 13.5 pt -87.97 46.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 109.565 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.451 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.49 125.25 35.92 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 95.71 -30.44 8.39 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.743 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.401 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 19.2 mmtt -90.11 -28.71 18.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.227 -1.161 . . . . 0.0 109.166 179.682 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.457 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 1.2 ttt -71.37 107.38 4.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.437 -0.789 . . . . 0.0 109.359 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.4 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 10.0 p30 -109.72 -162.1 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.177 -0.952 . . . . 0.0 109.894 -179.776 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.43 ' HA ' ' HD3' ' A' ' 127' ' ' LYS . . . -67.55 -45.78 74.67 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.346 -0.847 . . . . 0.0 109.64 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.464 ' O ' ' CG1' ' A' ' 9' ' ' VAL . . . -57.62 -24.03 54.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -86.23 -57.06 3.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.8 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.43 ' HD3' ' HA ' ' A' ' 124' ' ' ALA . 0.1 OUTLIER -65.94 -27.33 68.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.153 -0.967 . . . . 0.0 109.692 -179.735 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.416 ' HB3' ' O ' ' A' ' 124' ' ' ALA . 32.1 t70 -80.55 -49.95 10.65 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.311 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -57.7 -50.47 73.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.394 -0.816 . . . . 0.0 109.282 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.509 ' CE2' ' OG1' ' A' ' 13' ' ' THR . 4.8 m0 -63.89 -30.96 71.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.237 -0.915 . . . . 0.0 108.877 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.98 -30.09 67.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 108.89 179.166 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.6 -28.52 23.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.392 -0.818 . . . . 0.0 109.194 179.501 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.85 -40.81 21.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.406 -0.809 . . . . 0.0 109.473 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.455 ' OH ' ' CE ' ' A' ' 114' ' ' MET . 1.8 m-85 -50.26 -32.01 15.65 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.45 -34.78 72.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.281 -0.887 . . . . 0.0 109.242 179.638 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.27 -39.68 39.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 0.0 109.371 179.692 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 54.5 mt -66.05 -58.12 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.274 -0.891 . . . . 0.0 109.145 179.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.11 -17.5 64.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.291 -0.881 . . . . 0.0 109.645 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 142' ' ' ILE . . . -68.25 -55.56 12.59 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.23 -28.19 4.38 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.505 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -74.82 -21.55 59.22 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -0.893 . . . . 0.0 109.536 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.443 HD12 HG22 ' A' ' 142' ' ' ILE . 91.0 mt -83.78 8.36 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.292 -0.88 . . . . 0.0 110.096 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.3 m -100.13 -46.0 5.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.04 -1.038 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.414 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -68.86 -31.55 72.94 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.475 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.414 179.869 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.193 0.521 . . . . 0.0 109.819 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -66.67 -33.96 76.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.638 179.903 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 42.9 mtp180 -54.75 -41.82 70.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.644 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -74.73 -36.55 62.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.239 -0.913 . . . . 0.0 109.549 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 33.3 t -71.26 -35.8 59.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.151 -0.968 . . . . 0.0 108.987 179.628 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.446 HG12 ' CD1' ' A' ' 130' ' ' TRP . 41.9 t -67.46 -37.24 78.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.399 -0.813 . . . . 0.0 109.057 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.26 -16.29 56.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.345 -0.847 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.6 t -90.3 -22.72 21.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.891 -179.625 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.8 p -95.24 -12.28 26.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 110.028 -179.851 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.575 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.31 -15.07 27.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.042 -1.037 . . . . 0.0 109.973 -179.895 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mtpt -85.92 -2.0 57.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.73 -45.16 3.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.996 -1.065 . . . . 0.0 109.667 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.445 ' CG2' HG21 ' A' ' 26' ' ' VAL . 45.8 mt -72.47 -36.34 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.446 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.575 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -103.02 31.67 4.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.323 -0.86 . . . . 0.0 109.588 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.62 -78.73 0.1 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.54 -27.74 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 13.4 p-10 -80.01 -20.15 46.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 0.0 109.607 179.959 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.4 t30 56.16 27.7 11.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.875 . . . . 0.0 109.645 179.997 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.94 22.38 42.51 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.415 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -59.21 -52.37 65.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -1.161 . . . . 0.0 109.569 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.412 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -92.92 26.11 16.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.445 HG21 ' CG2' ' A' ' 17' ' ' ILE . 39.2 t -110.14 -22.73 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.29 -1.123 . . . . 0.0 108.887 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.405 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -100.15 -26.97 8.01 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 179.79 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.467 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 14.2 ptpt -70.19 -34.99 73.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.245 -1.15 . . . . 0.0 109.385 179.789 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.467 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -92.34 -8.9 43.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.157 -0.964 . . . . 0.0 109.839 179.678 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.6 t -93.25 -61.3 1.6 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.067 -1.021 . . . . 0.0 109.722 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.501 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.9 m-85 -55.64 -30.56 61.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.926 . . . . 0.0 109.768 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.437 ' CA ' HG12 ' A' ' 55' ' ' VAL . 17.8 m -58.35 -48.01 81.96 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.125 -0.984 . . . . 0.0 109.395 179.794 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.31 -41.33 98.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.317 -0.865 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.52 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.4 t80 -62.14 -44.67 96.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.251 -0.905 . . . . 0.0 109.43 179.84 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.5 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 15.7 mt -62.8 -45.53 92.22 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.2 p -66.28 -46.75 75.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.738 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 -21.4 62.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 33.7 m-70 -127.82 114.31 17.07 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.758 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -93.22 5.29 52.03 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.357 -0.839 . . . . 0.0 109.984 179.736 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -95.6 -22.18 17.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.044 -1.035 . . . . 0.0 109.486 179.811 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.512 ' HE2' ' CD2' ' A' ' 102' ' ' TYR . 0.4 OUTLIER -97.01 -22.45 16.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.309 -0.87 . . . . 0.0 109.615 179.977 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.43 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.16 -50.75 61.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.196 -0.94 . . . . 0.0 109.536 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -66.41 -21.39 66.22 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.895 . . . . 0.0 109.585 179.897 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.49 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 52.6 t -79.73 -55.98 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.461 ' CD2' HD21 ' A' ' 35' ' ' LEU . 33.7 m-85 -53.74 -40.9 66.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.79 31.78 1.41 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 -179.849 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.513 ' CD2' HG22 ' A' ' 55' ' ' VAL . 11.9 m-85 -125.36 -179.07 4.44 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -1.176 . . . . 0.0 109.749 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.9 t -123.99 19.17 9.25 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.417 -0.802 . . . . 0.0 109.299 179.481 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.44 -163.38 27.53 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.92 -19.08 55.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.698 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 8.5 t -85.41 50.13 1.89 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -128.62 117.8 19.84 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.615 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -59.28 -29.54 90.56 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.842 1.443 . . . . 0.0 110.108 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.96 -34.49 38.44 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.513 HG22 ' CD2' ' A' ' 47' ' ' PHE . 89.3 t -52.26 -31.47 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.274 -1.133 . . . . 0.0 109.636 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.456 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -77.36 -21.86 52.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.487 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.83 -45.55 16.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.9 . . . . 0.0 109.557 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.435 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 2.9 mt -68.25 -59.06 3.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -0.925 . . . . 0.0 109.535 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -51.17 -54.8 21.77 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.421 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -53.19 -37.61 62.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -1.17 . . . . 0.0 109.59 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 mttm -77.98 -25.79 48.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.435 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 41.9 t -82.61 -40.91 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.418 ' HG ' ' HB ' ' A' ' 26' ' ' VAL . 1.6 mm? -50.11 -55.03 16.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.554 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -43.67 36.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.229 -0.919 . . . . 0.0 109.71 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.409 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 0.2 OUTLIER -51.59 -54.17 30.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 179.79 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 69.2 mt -55.48 -34.65 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.263 -0.898 . . . . 0.0 108.98 179.721 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.542 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.84 -55.15 18.23 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.5 t -57.79 -22.12 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.322 -1.105 . . . . 0.0 109.138 179.759 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.68 -31.17 21.18 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.392 -0.818 . . . . 0.0 109.461 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 53.0 t -69.24 -17.09 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 109.484 179.728 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -61.97 -37.93 86.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -0.941 . . . . 0.0 109.912 -179.832 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.409 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 22.5 m-70 -129.29 81.73 2.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 109.885 -179.815 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.435 ' CD1' HG13 ' A' ' 10' ' ' VAL . 53.5 mt . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.892 . . . . 0.0 109.461 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.409 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 49.5 ttp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.287 0.565 . . . . 0.0 109.652 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.455 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 60.0 t -77.29 -0.53 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 110.036 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.11 -24.12 26.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.04 -1.038 . . . . 0.0 109.595 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -106.77 -41.05 5.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.545 179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.444 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 10.1 mtp -67.98 -40.81 83.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.219 -0.926 . . . . 0.0 108.949 179.653 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 6.0 tttt -56.28 -28.56 59.12 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 179.009 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.405 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -78.49 -31.92 47.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.48 -0.763 . . . . 0.0 109.056 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.485 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 47.3 t -62.72 -41.78 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.245 -0.91 . . . . 0.0 109.06 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.418 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -54.06 -41.78 69.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.356 -1.898 . . . . 0.0 108.356 179.53 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 97.5 t -56.34 -46.54 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.426 -1.043 . . . . 0.0 109.252 179.475 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.508 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 10.4 mpt_? -52.05 -29.96 23.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.028 -1.045 . . . . 0.0 109.054 179.466 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.507 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 34.6 m80 -84.22 9.51 12.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.417 -0.802 . . . . 0.0 110.022 -179.894 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 25.0 ttpt -104.36 -11.74 16.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.034 -1.041 . . . . 0.0 110.241 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.17 18.79 2.31 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.142 -1.504 . . . . 0.0 110.855 -179.242 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.508 ' CZ ' ' HB3' ' A' ' 89' ' ' ARG . 1.6 m-85 -58.9 -164.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.644 -1.504 . . . . 0.0 109.174 179.317 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.77 -31.21 40.83 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 179.625 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.495 ' O ' ' CB ' ' A' ' 96' ' ' LYS . 0.5 OUTLIER -81.14 -48.67 11.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.529 -0.983 . . . . 0.0 108.787 179.703 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.8 tmtt? 76.83 -19.3 0.43 Allowed 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.652 -0.655 . . . . 0.0 111.901 179.162 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.419 ' HB2' ' OD1' ' A' ' 95' ' ' ASN . 37.8 m170 -72.31 -95.82 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.443 -1.411 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.469 HG13 ' ND2' ' A' ' 95' ' ' ASN . 8.1 mt 61.71 148.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 120.858 -1.151 . . . . 0.0 110.511 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.425 ' HG3' ' O ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -156.88 149.66 23.63 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 121.943 0.878 . . . . 0.0 110.521 179.812 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.83 -7.29 55.18 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.681 179.613 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.567 ' CG ' ' CD2' ' A' ' 102' ' ' TYR . 12.0 pt-20 -71.38 -34.23 70.24 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.95 -1.094 . . . . 0.0 109.082 179.461 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.567 ' CD2' ' CG ' ' A' ' 101' ' ' GLU . 94.3 m-85 -80.3 -25.46 39.35 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 109.329 179.566 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.501 ' CD2' ' OG ' ' A' ' 138' ' ' SER . 2.7 m-85 -48.12 -62.16 1.62 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.358 -0.839 . . . . 0.0 110.236 -179.798 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -51.97 -59.84 7.41 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.177 -0.952 . . . . 0.0 110.173 -179.366 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 36.1 Cg_exo -47.53 -59.69 1.15 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.586 1.309 . . . . 0.0 110.229 179.91 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.52 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -54.29 -22.57 12.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.91 . . . . 0.0 109.406 179.906 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.01 -44.09 9.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.96 -49.96 74.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -1.163 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 75.6 m -56.65 -31.29 64.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 109.603 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 2.6 tt -62.75 -43.83 97.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.602 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.7 mt -53.87 -39.19 65.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 13.5 t -62.3 -32.02 72.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.235 -0.915 . . . . 0.0 109.503 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.408 ' HB3' ' OE2' ' A' ' 29' ' ' GLU . . . -78.91 -39.73 34.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.41 179.758 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.547 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -48.72 -45.73 39.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -48.32 -29.31 3.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -0.927 . . . . 0.0 109.968 -179.838 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.419 ' CE1' ' OE1' ' A' ' 29' ' ' GLU . 17.5 m170 -49.9 -56.4 10.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.082 -1.011 . . . . 0.0 109.817 -179.826 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.8 ttt85 -69.77 -63.57 1.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.849 -179.82 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.457 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 4.7 pt -96.61 58.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.313 -0.867 . . . . 0.0 109.709 -179.789 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.36 -20.32 71.38 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.73 -21.1 17.21 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.865 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.457 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -100.62 -19.37 16.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -1.187 . . . . 0.0 109.884 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -66.95 79.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.051 -1.031 . . . . 0.0 109.799 -179.927 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.435 ' OD1' ' N ' ' A' ' 123' ' ' ASN . 15.7 p-10 -80.13 -171.97 3.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.172 179.589 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -70.12 -31.35 68.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.066 -1.021 . . . . 0.0 109.907 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.18 -23.69 61.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.038 -1.039 . . . . 0.0 109.024 179.668 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -74.88 -47.55 29.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 108.892 179.403 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.468 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 6.9 ptpt -71.79 -31.28 66.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.413 -0.805 . . . . 0.0 109.232 179.569 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.468 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.4 t70 -75.78 -48.52 21.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -58.55 -44.57 89.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.422 -0.799 . . . . 0.0 109.493 179.844 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.547 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 7.0 m0 -74.88 -26.17 59.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.245 179.838 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.12 -27.3 65.45 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.246 -0.909 . . . . 0.0 108.979 179.415 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -93.46 -23.06 18.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.192 179.502 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.436 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -79.81 -42.88 23.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.395 -0.816 . . . . 0.0 109.556 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -49.26 -33.32 12.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.207 -0.933 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.74 -25.15 49.02 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.229 -0.919 . . . . 0.0 108.938 179.412 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.436 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.7 t0 -85.95 -40.76 15.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.387 -0.821 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.405 ' O ' ' HE1' ' A' ' 83' ' ' MET . 1.6 mp -65.8 -59.6 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 108.824 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.501 ' OG ' ' CD2' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -64.6 -25.22 67.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.243 -0.911 . . . . 0.0 109.745 -179.85 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -55.68 -49.56 65.02 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.95 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.94 -17.75 64.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.234 -1.156 . . . . 0.0 109.845 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.485 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 5.1 tt -84.19 -33.38 24.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.15 -0.969 . . . . 0.0 109.738 -179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 138' ' ' SER . 50.6 mt -68.48 -9.25 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 110.065 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 67.6 m -70.51 -65.15 0.77 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.069 -1.019 . . . . 0.0 109.595 179.835 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.45 -7.37 64.09 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.462 ' CD1' ' CB ' ' A' ' 90' ' ' HIS . 5.9 tt . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.08 -1.247 . . . . 0.0 109.48 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.161 0.505 . . . . 0.0 109.647 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.69 -47.74 18.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.401 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 8.3 ptm180 -52.54 -32.69 41.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.153 -0.967 . . . . 0.0 108.738 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.401 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 49.4 tp60 -71.16 -36.01 71.85 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 47.5 t -73.3 -31.74 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.391 -0.818 . . . . 0.0 108.942 179.196 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.511 HG11 ' CD1' ' A' ' 130' ' ' TRP . 41.9 t -70.03 -37.49 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.743 . . . . 0.0 109.357 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.08 -16.35 58.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.691 179.903 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.4 -27.22 21.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.925 . . . . 0.0 109.693 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.2 p -88.5 -14.2 38.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.79 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.54 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.34 -20.55 21.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.125 -0.985 . . . . 0.0 109.717 -179.767 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.5 mtpp -79.74 -0.05 32.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.839 179.694 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -113.32 -56.35 2.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.011 -1.055 . . . . 0.0 109.553 179.856 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.464 ' CG1' HG12 ' A' ' 118' ' ' ILE . 73.9 mt -62.54 -34.18 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.202 -0.936 . . . . 0.0 109.55 179.939 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.526 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.5 36.66 2.44 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.271 -0.893 . . . . 0.0 109.771 -179.889 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.86 -88.19 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.9 p -112.28 15.04 20.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -1.132 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 4.3 p-10 -122.1 -9.14 8.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.164 -0.96 . . . . 0.0 110.032 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.449 ' O ' ' ND2' ' A' ' 22' ' ' ASN . 9.0 t30 56.41 20.17 4.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.565 -179.711 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.06 34.32 30.45 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.719 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.402 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -56.39 -43.99 79.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -1.139 . . . . 0.0 109.62 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.476 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.96 -18.32 72.67 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.466 HG12 ' CD2' ' A' ' 63' ' ' LEU . 25.7 t -68.76 -31.86 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.551 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.411 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.23 -54.32 4.44 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.611 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.476 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.7 ptpt -55.19 -24.71 28.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -1.163 . . . . 0.0 110.108 -179.487 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 25' ' ' GLY . 23.1 pt-20 -98.23 -16.15 19.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.001 -1.062 . . . . 0.0 109.851 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.402 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 40.5 t -90.78 -60.19 1.98 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.186 -0.946 . . . . 0.0 110.014 -179.628 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -59.83 -32.0 70.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.218 -0.926 . . . . 0.0 110.167 -179.412 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.457 ' OG1' ' CG1' ' A' ' 55' ' ' VAL . 16.6 m -60.65 -45.05 95.55 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.096 -1.002 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -64.7 -29.26 70.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 179.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.51 ' CG ' HD22 ' A' ' 106' ' ' LEU . 17.0 t80 -78.3 -49.58 13.39 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.279 -0.888 . . . . 0.0 109.458 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.504 HD21 ' CD2' ' A' ' 45' ' ' PHE . 13.3 mt -51.84 -46.43 64.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.333 -0.854 . . . . 0.0 109.687 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.3 t -61.82 -59.96 4.36 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 109.677 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.35 -23.04 66.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.24 -0.912 . . . . 0.0 109.73 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.451 ' N ' ' O ' ' A' ' 34' ' ' PHE . 25.5 m-70 -121.22 99.35 6.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 109.688 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -85.33 -19.79 30.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.309 -0.87 . . . . 0.0 109.531 179.936 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -69.28 -20.53 63.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.695 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.515 ' HE1' ' CD1' ' A' ' 102' ' ' TYR . 7.3 mmm -108.83 -16.83 14.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.201 -0.937 . . . . 0.0 109.824 -179.927 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.463 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -50.47 -41.0 52.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 0.0 109.378 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -76.47 -32.1 58.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.299 -0.876 . . . . 0.0 109.159 179.583 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 24.7 t -59.18 -56.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.384 -0.823 . . . . 0.0 109.245 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.522 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 62.4 m-85 -54.19 -31.03 51.77 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.21 29.68 3.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.873 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.522 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.5 m-85 -123.81 167.6 13.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 17.93 20.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.885 . . . . 0.0 109.422 179.625 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.74 -164.06 29.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.5 28.71 2.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -1.15 . . . . 0.0 109.618 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 99.5 p -126.91 28.1 5.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.08 137.44 22.44 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -65.67 -24.46 55.19 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.931 1.49 . . . . 0.0 110.095 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.52 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.22 -36.33 44.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' CD2' ' A' ' 47' ' ' PHE . 94.6 t -50.99 -39.9 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.299 -1.118 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -76.54 -1.25 26.42 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.292 -0.88 . . . . 0.0 109.831 179.714 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -96.47 -27.45 14.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.05 -1.031 . . . . 0.0 109.703 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.414 HD23 ' HA ' ' A' ' 58' ' ' LEU . 6.9 mt -86.65 -62.27 1.55 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.411 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -57.62 -24.67 53.65 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.46 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -66.53 -31.61 72.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.634 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.414 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 9.3 mtpt -101.82 -39.58 7.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.428 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 58.3 t -51.7 -53.77 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.27 -0.894 . . . . 0.0 109.857 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.466 ' CD2' HG12 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -45.9 -44.5 14.63 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.321 -0.862 . . . . 0.0 110.42 -179.705 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.432 ' HA ' ' OD1' ' A' ' 22' ' ' ASN . . . -52.99 -30.02 32.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.025 . . . . 0.0 109.674 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 60.7 tp60 -69.49 -31.97 70.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 108.834 179.178 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 94.0 mt -72.97 -31.5 35.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.413 -0.804 . . . . 0.0 108.861 179.271 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.54 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.09 -48.37 40.12 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 179.551 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.1 t -63.66 -24.17 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.246 -1.149 . . . . 0.0 109.113 179.736 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.04 -26.46 25.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.468 -0.77 . . . . 0.0 109.481 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.453 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 48.6 t -67.57 -13.71 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.212 -0.93 . . . . 0.0 109.718 179.842 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.418 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -81.09 -16.9 51.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.849 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.457 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 5.7 m-70 -128.76 66.99 1.41 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.177 -0.952 . . . . 0.0 109.672 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.452 ' CD1' HG12 ' A' ' 10' ' ' VAL . 65.2 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.305 -0.872 . . . . 0.0 109.534 179.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.457 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 11.8 tmm? . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.324 0.583 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.411 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.6 t -73.13 -20.43 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.895 . . . . 0.0 109.421 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.3 -56.63 19.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 179.761 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.18 -53.2 53.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.355 -0.841 . . . . 0.0 109.233 179.664 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.401 ' HG3' ' O ' ' A' ' 79' ' ' MET . 0.5 OUTLIER -53.15 -57.05 11.79 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.68 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.443 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.86 -29.17 18.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.013 179.488 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -72.39 -42.82 64.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.43 -0.794 . . . . 0.0 109.133 179.608 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.405 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 16.7 t -62.27 -35.77 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.017 179.621 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.427 ' HA2' ' HB2' ' A' ' 145' ' ' LEU . . . -57.46 -44.2 93.75 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.591 -1.803 . . . . 0.0 108.591 179.612 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 90.2 t -54.96 -35.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.285 -1.127 . . . . 0.0 109.033 179.397 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 6.9 mpt_? -70.69 -30.79 67.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.387 -0.821 . . . . 0.0 109.163 179.55 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.525 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 27.5 m80 -80.04 2.85 22.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.346 -0.846 . . . . 0.0 109.974 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.3 ttmt -101.07 14.01 33.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.057 -1.027 . . . . 0.0 110.011 -179.539 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -169.41 31.51 0.16 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.231 -1.462 . . . . 0.0 110.543 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.525 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.9 m-85 -74.08 -163.82 0.2 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.739 -1.448 . . . . 0.0 109.688 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -65.29 -53.45 32.78 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.521 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.518 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 14.6 p-10 -67.37 -33.67 75.69 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -1.164 . . . . 0.0 109.849 -179.729 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 mttt 55.27 21.19 3.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.241 -0.912 . . . . 0.0 109.633 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -128.3 48.66 2.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.49 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.514 HD12 ' CD2' ' A' ' 90' ' ' HIS . 61.9 mt -86.33 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.771 -179.883 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.471 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 4.8 mptt -141.73 143.52 33.56 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.325 -0.859 . . . . 0.0 109.766 -179.895 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.19 6.93 17.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.851 179.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.26 -21.12 21.24 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.178 -0.951 . . . . 0.0 108.779 179.723 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.515 ' CD1' ' HE1' ' A' ' 41' ' ' MET . 61.5 m-85 -85.16 -13.16 50.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.495 ' CZ ' ' CD2' ' A' ' 145' ' ' LEU . 4.3 m-85 -61.07 -61.2 2.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.164 -0.96 . . . . 0.0 110.038 -179.818 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.489 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -49.44 -56.94 13.53 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.881 -179.612 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.489 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -50.94 -62.0 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.684 1.36 . . . . 0.0 109.929 179.741 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.51 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.0 tm? -57.99 -25.86 61.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.29 -0.881 . . . . 0.0 109.46 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -72.97 -39.55 54.04 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.985 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.43 -50.0 71.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.217 -1.167 . . . . 0.0 109.479 179.863 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 9.0 m -57.3 -20.64 29.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 109.482 179.832 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 1.1 tt -69.18 -46.17 68.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.746 -179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.409 HD21 ' HB2' ' A' ' 130' ' ' TRP . 12.4 mt -58.56 -30.5 67.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.142 -0.974 . . . . 0.0 109.442 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.3 m -73.45 -40.87 63.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.246 -0.909 . . . . 0.0 109.671 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.408 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -74.46 -31.01 62.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.235 -0.915 . . . . 0.0 109.653 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.503 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.8 mmt -60.06 -43.05 95.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.2 OUTLIER -49.81 -25.37 3.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.778 -179.884 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.408 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 15.9 m170 -53.76 -56.21 19.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.204 -0.935 . . . . 0.0 109.797 -179.862 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.412 ' HD2' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -64.59 -58.64 5.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.153 -0.967 . . . . 0.0 109.749 -179.877 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.464 HG12 ' CG1' ' A' ' 17' ' ' ILE . 5.3 pt -103.04 59.59 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.922 . . . . 0.0 109.737 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.77 -27.72 73.58 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.932 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -95.69 -17.59 35.35 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.408 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 5.4 mptt -101.7 -23.37 14.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 109.758 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.463 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.3 OUTLIER -71.29 83.9 0.77 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.138 -0.977 . . . . 0.0 109.581 179.937 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.43 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.3 p30 -81.39 -167.88 1.64 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.327 -0.858 . . . . 0.0 109.54 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -65.95 -47.81 73.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.43 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -56.96 -31.68 65.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.395 179.768 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -66.63 -53.03 38.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.822 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 2.5 ptpt -70.01 -26.6 64.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.263 179.727 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.464 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 38.7 t0 -82.53 -36.18 26.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 109.426 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.407 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -67.02 -43.26 83.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.758 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.511 ' CD1' HG11 ' A' ' 10' ' ' VAL . 12.1 m0 -76.7 -29.13 56.13 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.238 -0.913 . . . . 0.0 109.062 179.903 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.467 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -50.68 -43.05 57.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.319 -0.863 . . . . 0.0 109.098 179.43 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.13 -17.32 35.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.419 -0.801 . . . . 0.0 109.228 179.33 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.409 ' O ' HD13 ' A' ' 137' ' ' ILE . . . -88.01 -61.57 1.69 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.246 -0.909 . . . . 0.0 109.704 179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.505 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.1 OUTLIER -50.47 -27.01 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.07 -1.019 . . . . 0.0 109.144 -179.825 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.23 -31.56 30.2 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.305 -0.872 . . . . 0.0 108.795 179.17 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -82.1 -37.83 25.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.448 -0.783 . . . . 0.0 109.405 179.729 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.465 ' N ' HD12 ' A' ' 137' ' ' ILE . 1.6 mp -65.86 -58.4 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 108.776 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -29.87 70.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.445 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -70.5 -35.63 68.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.48 -23.94 66.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -1.176 . . . . 0.0 109.614 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.411 HD23 ' HB2' ' A' ' 145' ' ' LEU . 8.7 tt -74.55 -17.3 60.76 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.254 -0.904 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.445 ' CD1' ' HA2' ' A' ' 139' ' ' GLY . 58.7 mt -76.39 -0.96 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 110.101 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.443 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 19.5 m -66.91 -32.9 74.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.991 -1.068 . . . . 0.0 109.051 179.669 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.4 -10.98 8.33 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.62 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.495 ' CD2' ' CZ ' ' A' ' 103' ' ' PHE . 19.2 tp . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.041 -1.27 . . . . 0.0 109.571 -179.904 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.244 0.545 . . . . 0.0 109.796 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 42.1 mt-30 -78.29 -52.27 8.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.169 -0.957 . . . . 0.0 109.887 -179.856 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.98 -29.37 12.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.97 -1.081 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -70.71 -45.21 65.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 0.0 108.778 179.353 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.447 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 44.8 t -62.12 -31.25 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.364 -0.835 . . . . 0.0 108.859 179.27 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.419 HG13 ' CD1' ' A' ' 73' ' ' LEU . 98.6 t -66.03 -50.13 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.512 -0.743 . . . . 0.0 109.4 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.11 61.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.9 m -83.45 -25.05 31.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.105 -0.997 . . . . 0.0 109.744 -179.919 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.477 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 38.2 p -100.22 -10.18 21.64 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.92 . . . . 0.0 110.043 -179.907 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.12 -25.8 19.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.027 -1.046 . . . . 0.0 109.609 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.9 mtpp -76.05 -12.8 60.19 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.224 -0.923 . . . . 0.0 109.641 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.454 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.4 OUTLIER -103.02 -52.67 3.0 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.466 HD11 ' CH2' ' A' ' 130' ' ' TRP . 44.1 mt -65.14 -34.78 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.271 -0.893 . . . . 0.0 109.581 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -107.91 35.24 3.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.719 -179.948 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.1 -84.14 0.03 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 78.3 p -97.51 -23.41 16.04 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.307 -1.114 . . . . 0.0 109.617 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -83.34 -21.45 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.449 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 9.9 t30 56.79 20.57 5.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.92 . . . . 0.0 109.61 179.998 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.2 20.94 11.39 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.49 -47.52 69.8 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.414 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -93.34 31.63 6.26 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.427 HG13 ' CD1' ' A' ' 63' ' ' LEU . 41.9 t -119.05 -35.91 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.297 -1.12 . . . . 0.0 108.942 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.458 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -90.26 -41.17 5.58 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.766 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.467 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.3 ptpt -61.08 -30.63 70.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 109.587 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.467 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -90.41 -25.16 20.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.124 -0.985 . . . . 0.0 109.422 179.798 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 41.4 t -85.54 -50.63 7.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.353 -0.842 . . . . 0.0 109.574 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 5.0 m-30 -55.2 -37.56 67.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.585 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 98.6 m -55.82 -45.89 78.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.901 . . . . 0.0 109.347 179.772 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.402 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 13.6 mttp -66.59 -47.63 72.12 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.403 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.516 ' CG ' HD22 ' A' ' 106' ' ' LEU . 4.3 t80 -55.7 -49.94 71.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.297 179.794 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.5 HD23 ' CG ' ' A' ' 45' ' ' PHE . 32.3 mt -59.48 -45.1 92.63 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.89 -61.68 2.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.691 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.401 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -58.04 -28.64 64.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.694 -179.906 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.51 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 9.4 m-70 -118.0 103.38 9.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.718 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -85.61 -21.45 28.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.34 -0.85 . . . . 0.0 109.345 179.634 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.2 p-10 -68.23 -20.49 64.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.912 . . . . 0.0 109.275 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.476 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 92.2 mmm -103.26 -22.35 13.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.581 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.443 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -51.17 -44.45 61.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.031 -1.043 . . . . 0.0 109.338 179.825 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.68 -23.38 59.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.346 -0.846 . . . . 0.0 109.136 179.565 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.51 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 29.2 t -73.44 -39.96 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.423 -0.798 . . . . 0.0 109.202 179.733 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.524 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -68.89 -38.95 79.97 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.573 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.404 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 117.66 28.22 2.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.882 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.3 m-85 -122.31 172.23 8.47 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.199 -1.177 . . . . 0.0 109.692 -179.981 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 11.7 t -111.13 19.22 18.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.316 -0.865 . . . . 0.0 109.351 179.493 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.95 -164.0 29.87 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.79 5.82 41.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -1.162 . . . . 0.0 110.073 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 15.2 t -110.09 42.27 1.56 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.001 -1.062 . . . . 0.0 109.548 179.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.85 131.54 23.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 0.0 109.624 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -61.34 -20.47 68.36 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 123.81 1.426 . . . . 0.0 109.949 -179.949 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.9 -35.95 88.52 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.508 HG22 ' CD2' ' A' ' 47' ' ' PHE . 58.9 t -54.56 -22.78 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -1.095 . . . . 0.0 109.468 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -86.47 -19.44 29.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.319 -0.863 . . . . 0.0 109.571 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.409 ' O ' ' HB2' ' A' ' 61' ' ' LYS . 0.3 OUTLIER -88.11 -26.45 22.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.296 -0.878 . . . . 0.0 109.588 -179.994 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.428 HD12 ' CD2' ' A' ' 45' ' ' PHE . 2.7 mt -86.44 -66.58 0.89 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.188 -0.945 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.553 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -49.46 -37.06 25.1 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.434 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -72.45 -22.32 61.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.151 -1.205 . . . . 0.0 109.946 -179.698 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 4.7 mttp -94.55 -21.9 18.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.122 -0.986 . . . . 0.0 109.827 -179.868 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 58' ' ' LEU . 23.3 t -83.71 -46.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.938 . . . . 0.0 109.889 -179.784 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.427 ' CD1' HG13 ' A' ' 26' ' ' VAL . 2.9 mm? -47.86 -46.88 31.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -51.91 25.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.194 -0.941 . . . . 0.0 109.992 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -50.65 -42.98 57.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.07 -1.019 . . . . 0.0 109.438 -179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 39.8 mt -61.34 -38.36 79.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.312 -0.868 . . . . 0.0 109.238 179.621 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.539 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.73 -50.97 57.62 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.873 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.4 t -61.22 -29.96 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.083 -1.245 . . . . 0.0 109.467 -179.823 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.447 ' O ' ' CD2' ' A' ' 73' ' ' LEU . . . -84.72 -14.52 48.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.424 -0.798 . . . . 0.0 110.094 -179.42 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.475 ' HA ' ' CD1' ' A' ' 73' ' ' LEU . 41.6 t -84.64 -43.36 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.027 -1.046 . . . . 0.0 110.091 -179.409 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.35 -24.75 2.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.987 -1.07 . . . . 0.0 109.33 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.45 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 3.2 m-70 -93.83 -114.08 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.532 -0.73 . . . . 0.0 109.946 -179.787 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.475 ' CD1' ' HA ' ' A' ' 70' ' ' VAL . 16.5 mt . . . . . 0 N--CA 1.5 2.056 0 O-C-N 121.027 -1.045 . . . . 0.0 110.392 -179.289 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.5 t -51.21 -31.11 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.076 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.24 -35.61 76.3 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -61.27 -52.97 62.49 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.215 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.41 ' HE1' ' O ' ' A' ' 137' ' ' ILE . 86.5 mmm -56.96 -38.56 73.13 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.255 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -35.74 40.96 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -67.89 -32.37 72.81 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.508 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 48.6 t -59.38 -51.95 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 108.785 179.432 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.416 ' O ' HD11 ' A' ' 145' ' ' LEU . . . -56.66 -52.94 47.42 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.061 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.417 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 63.3 t -51.75 -33.26 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.397 -1.061 . . . . 0.0 108.817 179.065 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.508 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.0 mmm180 -76.43 -49.75 15.88 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.189 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.552 ' ND1' ' CZ ' ' A' ' 93' ' ' TYR . 2.1 m80 -58.92 -21.24 57.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.464 -0.772 . . . . 0.0 109.115 179.332 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.465 ' N ' HD13 ' A' ' 145' ' ' LEU . 0.0 OUTLIER -66.72 -12.08 57.07 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.314 -0.866 . . . . 0.0 110.254 -179.704 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.31 53.49 0.6 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.634 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.552 ' CZ ' ' ND1' ' A' ' 90' ' ' HIS . 3.1 m-30 -89.23 -164.36 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.238 -1.154 . . . . 0.0 109.702 179.734 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.14 -51.14 19.33 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.51 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 17.1 p-10 -69.16 -32.36 71.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.14 -1.212 . . . . 0.0 109.828 -179.686 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.8 tttm 58.26 18.86 5.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.197 -0.939 . . . . 0.0 109.699 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 15.4 m170 -125.75 41.27 3.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.69 -179.935 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.508 HD13 ' CD2' ' A' ' 90' ' ' HIS . 36.4 mt -81.32 155.75 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.184 -0.947 . . . . 0.0 109.679 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.447 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.1 mptp? -136.58 145.58 45.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.884 -179.825 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -86.4 11.77 11.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.954 179.853 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.566 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 15.5 pt-20 -95.48 -24.21 16.76 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.107 -0.995 . . . . 0.0 109.557 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.566 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 88.7 m-85 -83.03 -7.39 59.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.928 179.722 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -66.87 -52.17 46.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.096 -1.002 . . . . 0.0 109.945 -179.739 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.495 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.5 tm-20 -56.54 -55.61 40.99 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.131 -0.98 . . . . 0.0 109.867 -179.685 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.83 -61.85 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 123.755 1.397 . . . . 0.0 109.83 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.516 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -55.75 -23.78 31.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.291 -0.88 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.99 -48.67 6.84 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.981 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.36 65.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -1.191 . . . . 0.0 109.414 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.0 m -75.28 -31.01 60.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.872 . . . . 0.0 109.518 179.893 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.451 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 1.0 OUTLIER -70.13 -30.16 67.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.41 179.905 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.413 HD21 ' HB2' ' A' ' 130' ' ' TRP . 11.1 mt -64.34 -32.11 73.59 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.348 179.767 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.4 OUTLIER -74.89 -26.2 59.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 109.54 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.405 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.77 -35.78 20.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.247 -0.908 . . . . 0.0 109.518 -179.885 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.485 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 2.8 mtt -49.44 -45.08 46.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 0.0 110.116 -179.717 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 119' ' ' GLY . 13.3 pt-20 -50.27 -25.69 3.98 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.153 -0.967 . . . . 0.0 109.907 -179.719 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.405 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 29.7 m170 -50.12 -39.92 44.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.635 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.447 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 3.2 ttt85 -80.17 -61.7 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.179 -0.951 . . . . 0.0 109.539 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.454 ' CG2' ' HB3' ' A' ' 16' ' ' ASP . 7.2 pt -89.35 44.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.236 -0.915 . . . . 0.0 109.521 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -51.62 123.07 18.15 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 102.12 -39.82 2.64 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.873 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.431 ' O ' ' N ' ' A' ' 123' ' ' ASN . 29.9 mttp -83.54 -29.5 27.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -1.14 . . . . 0.0 109.439 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.412 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.26 76.73 0.1 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.235 179.727 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.447 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.4 p30 -79.8 -167.67 1.33 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.311 -0.868 . . . . 0.0 109.875 -179.714 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.412 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.95 -45.9 87.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.839 . . . . 0.0 109.531 179.868 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -58.07 -33.46 69.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.283 -0.886 . . . . 0.0 109.283 179.832 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.01 -53.38 20.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.28 -0.888 . . . . 0.0 109.417 179.832 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.438 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.9 ptpt -70.47 -26.84 63.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.191 -0.943 . . . . 0.0 109.356 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.438 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.8 t70 -81.91 -39.81 23.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.357 179.557 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -62.37 -43.54 98.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.375 -0.828 . . . . 0.0 109.241 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.485 ' CE3' ' SD ' ' A' ' 114' ' ' MET . 9.0 m0 -75.57 -31.89 60.17 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.304 -0.873 . . . . 0.0 108.7 179.563 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.46 -30.84 61.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 108.631 178.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.11 -28.89 22.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.797 . . . . 0.0 109.101 179.477 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -82.93 -52.65 6.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.431 -0.793 . . . . 0.0 109.465 179.899 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.451 ' CZ ' HD12 ' A' ' 66' ' ' ILE . 0.1 OUTLIER -49.85 -30.05 9.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 0.0 109.376 179.85 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -78.73 -27.62 44.87 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.275 -0.891 . . . . 0.0 108.984 179.456 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' A' ' 133' ' ' ALA . 2.4 t0 -84.12 -39.86 18.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.435 -0.791 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.41 ' O ' ' HE1' ' A' ' 83' ' ' MET . 8.2 mt -67.7 -56.33 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.497 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 87.2 p -69.37 -36.7 77.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.334 -0.853 . . . . 0.0 109.607 -179.91 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.461 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -56.23 -23.11 39.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.942 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.03 59.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 0.0 109.998 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.508 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 0.2 OUTLIER -91.4 -19.45 22.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.109 -0.994 . . . . 0.0 109.811 -179.847 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.461 ' CD1' ' HA2' ' A' ' 139' ' ' GLY . 3.2 mp -80.06 3.37 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.218 -0.926 . . . . 0.0 110.115 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 23.4 m -100.8 -31.09 11.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.01 -1.057 . . . . 0.0 109.925 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -93.1 -21.47 30.14 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.465 HD13 ' N ' ' A' ' 91' ' ' LYS . 12.8 tp . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.179 -1.189 . . . . 0.0 109.315 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 120.941 0.4 . . . . 0.0 110.187 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 65.7 mt-30 -70.99 -50.5 33.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.967 -1.083 . . . . 0.0 109.43 -179.754 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.432 ' HG2' ' HB2' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -53.06 -24.25 9.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.048 179.583 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 5.8 mp0 -83.16 -53.29 5.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.434 -0.791 . . . . 0.0 109.521 179.893 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -55.37 -33.99 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.399 -179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.499 HG12 ' CD1' ' A' ' 130' ' ' TRP . 93.8 t -57.33 -43.17 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.95 -10.12 59.16 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.271 -0.893 . . . . 0.0 109.896 179.836 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 t -93.56 -26.21 17.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.123 -0.986 . . . . 0.0 109.99 -179.718 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.484 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 20.6 p -95.74 -15.25 22.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -0.971 . . . . 0.0 109.965 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.567 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.49 -23.02 23.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.065 -1.022 . . . . 0.0 109.686 -179.933 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 73.4 mttt -81.6 1.67 32.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.934 . . . . 0.0 109.852 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.57 -48.51 2.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.128 -0.982 . . . . 0.0 109.263 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.442 ' CD1' ' CH2' ' A' ' 130' ' ' TRP . 42.0 mt -71.31 -28.76 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.432 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.567 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -109.33 34.42 3.77 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.235 -0.916 . . . . 0.0 109.603 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.15 -86.93 0.01 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.9 p -100.77 -24.46 14.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -1.145 . . . . 0.0 109.706 -179.99 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -81.02 -20.77 41.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.936 . . . . 0.0 109.699 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.8 t30 56.93 30.06 17.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.592 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.417 ' HA3' ' CD2' ' A' ' 63' ' ' LEU . . . 88.53 37.71 7.4 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.02 -49.63 12.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -1.144 . . . . 0.0 109.655 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.476 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -76.23 -23.55 70.88 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 -179.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.466 HG11 ' CD1' ' A' ' 63' ' ' LEU . 41.5 t -67.01 -27.2 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.334 -1.097 . . . . 0.0 109.817 -179.936 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.69 -50.79 4.07 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.476 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.2 ptpt -57.62 -24.17 55.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -1.203 . . . . 0.0 110.041 -179.556 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.428 ' O ' ' CD ' ' A' ' 33' ' ' LYS . 12.2 pt-20 -97.06 -28.39 14.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.036 -1.04 . . . . 0.0 109.768 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.407 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 37.1 t -83.99 -52.5 6.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 109.709 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 3.7 m-30 -60.45 -45.27 94.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.322 -0.861 . . . . 0.0 109.787 -179.806 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.428 ' CA ' HG12 ' A' ' 55' ' ' VAL . 21.1 m -52.07 -41.3 62.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.13 -0.981 . . . . 0.0 109.453 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.428 ' CD ' ' O ' ' A' ' 29' ' ' GLU . 8.1 mtpt -68.98 -48.18 63.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.564 179.918 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.512 ' CG ' HD22 ' A' ' 106' ' ' LEU . 9.0 t80 -58.91 -49.86 76.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.514 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.497 HD23 ' CG ' ' A' ' 45' ' ' PHE . 32.8 mt -57.35 -45.49 84.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 109.698 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.412 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 1.3 t -63.33 -59.83 4.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.194 -0.941 . . . . 0.0 109.758 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.442 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -59.95 -26.91 66.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.898 . . . . 0.0 109.724 -179.909 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.445 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 19.6 m-70 -119.69 104.32 10.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.771 -179.944 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 54.5 m170 -86.45 -21.93 26.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.604 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -67.66 -16.38 64.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -0.891 . . . . 0.0 109.525 179.644 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.42 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 89.7 mmm -109.35 -24.41 11.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.464 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.14 -40.46 23.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -77.06 -21.34 54.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.376 179.728 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.516 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 39.6 t -75.09 -39.71 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 0.0 109.563 179.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.523 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 15.6 m-85 -68.08 -31.06 70.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.616 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.406 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.42 27.24 3.68 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 179.919 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.523 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.9 m-85 -122.77 171.41 9.2 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.29 -1.123 . . . . 0.0 109.653 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.9 t -111.14 23.47 14.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.212 179.58 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.84 -163.78 27.59 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.412 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -93.13 29.81 1.79 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 18.3 m -126.52 22.98 6.92 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 109.633 -179.956 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.41 137.94 19.58 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.236 -0.915 . . . . 0.0 109.615 179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -66.51 -24.14 49.39 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 123.919 1.484 . . . . 0.0 110.07 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -54.24 -31.66 50.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.901 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' CD2' ' A' ' 47' ' ' PHE . 97.5 t -53.66 -53.71 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.268 -1.136 . . . . 0.0 109.568 -179.946 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.458 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -63.07 -14.79 52.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.906 . . . . 0.0 109.769 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.52 -44.21 11.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.17 -0.956 . . . . 0.0 109.694 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -70.22 -63.62 1.05 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.219 -0.926 . . . . 0.0 110.051 -179.8 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.54 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -51.9 -29.3 26.76 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.765 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.458 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -67.93 -40.65 83.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -1.203 . . . . 0.0 110.029 -179.708 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 43.4 mttm -80.85 -36.31 31.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 109.928 -179.77 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.448 HG23 ' CE2' ' A' ' 31' ' ' PHE . 86.1 t -59.39 -53.98 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 0.0 109.903 -179.786 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.466 ' CD1' HG11 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -47.0 -38.72 11.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.195 -0.94 . . . . 0.0 109.833 -179.936 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.88 -49.32 63.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.625 179.925 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -52.8 -48.2 67.06 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.966 . . . . 0.0 109.437 179.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.457 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 98.8 mt -55.89 -32.98 33.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.296 -0.878 . . . . 0.0 109.165 179.662 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.538 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.99 -57.86 9.01 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 179.503 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.9 t -55.31 -26.17 18.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -1.111 . . . . 0.0 109.05 179.803 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -26.23 26.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.445 -0.784 . . . . 0.0 109.535 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.469 ' HA ' ' CD2' ' A' ' 73' ' ' LEU . 40.0 t -59.87 -19.36 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 179.859 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 34.0 t -88.7 10.14 21.81 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.221 -0.924 . . . . 0.0 110.203 -179.688 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.45 ' ND1' ' O ' ' A' ' 71' ' ' SER . 19.3 m-70 -147.76 50.73 1.05 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.972 -1.08 . . . . 0.0 109.82 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.469 ' CD2' ' HA ' ' A' ' 70' ' ' VAL . 3.7 mm? . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.343 -0.848 . . . . 0.0 109.494 179.811 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.422 ' HB2' ' HB3' ' A' ' 72' ' ' HIS . 3.9 tmm? . . . . . 0 N--CA 1.493 1.689 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.463 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.4 t -67.72 -26.66 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.358 -0.839 . . . . 0.0 109.199 179.607 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.24 -48.07 81.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.291 -0.88 . . . . 0.0 109.365 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -78.19 -48.1 16.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.876 . . . . 0.0 109.286 179.67 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.415 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 2.7 mtp -57.22 -56.81 16.98 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.26 -0.9 . . . . 0.0 109.243 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -51.4 -32.86 27.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.19 -0.944 . . . . 0.0 108.856 179.372 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.421 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -65.58 -39.72 91.93 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.268 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.454 ' CG1' HD12 ' A' ' 141' ' ' LEU . 56.3 t -52.99 -50.22 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.291 -0.88 . . . . 0.0 109.18 179.502 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -50.5 -49.77 38.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 179.732 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.421 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 91.5 t -49.71 -26.23 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.324 -1.104 . . . . 0.0 109.309 179.591 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.4 mmt180 -78.76 -48.52 14.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.381 -0.824 . . . . 0.0 108.872 179.452 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.415 ' HB3' HD12 ' A' ' 145' ' ' LEU . 13.3 m80 -55.5 -28.28 53.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.441 -0.787 . . . . 0.0 109.327 179.618 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -67.93 -10.05 50.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.319 -0.863 . . . . 0.0 110.04 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -138.73 50.71 0.79 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.792 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.5 m-30 -101.59 -168.55 1.57 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.18 -1.188 . . . . 0.0 109.584 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.96 -49.47 16.72 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.516 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.7 OUTLIER -68.02 -51.03 51.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.439 -1.036 . . . . 0.0 109.221 179.796 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.479 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.7 tttt 74.64 -48.69 0.65 Allowed 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.528 -0.732 . . . . 0.0 110.844 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -67.81 61.22 0.07 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.958 -1.089 . . . . 0.0 110.248 -179.553 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 96' ' ' LYS . 65.9 mt -92.03 161.24 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.041 . . . . 0.0 109.462 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.491 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -139.8 139.38 36.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.102 -0.999 . . . . 0.0 110.017 -179.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.448 ' HB3' ' CD1' ' A' ' 142' ' ' ILE . . . -79.13 -5.9 55.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.421 -0.8 . . . . 0.0 109.621 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -70.67 -31.52 68.47 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.103 -0.998 . . . . 0.0 109.694 179.944 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.491 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 75.5 m-85 -82.79 4.93 23.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 110.529 -179.314 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.432 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.5 m-85 -77.09 -57.57 3.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.959 -1.088 . . . . 0.0 109.783 179.704 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -58.31 -50.83 85.91 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.851 -179.698 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' CD ' ' N ' ' A' ' 104' ' ' GLU . 24.8 Cg_exo -55.62 -57.49 1.56 Allowed 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.888 1.468 . . . . 0.0 109.768 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.512 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.2 tm? -57.49 -19.5 24.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.401 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.51 -51.08 4.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.953 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.72 -54.3 48.41 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.166 -1.196 . . . . 0.0 109.572 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.5 t -55.98 -25.17 42.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.407 ' HB2' ' O ' ' A' ' 106' ' ' LEU . 5.2 tt -67.39 -45.16 77.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.916 . . . . 0.0 109.734 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.452 HD21 ' CB ' ' A' ' 130' ' ' TRP . 13.8 mt -56.6 -31.86 64.68 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.653 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.52 -30.41 70.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.906 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.423 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -82.86 -34.21 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.893 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.405 ' CE ' ' OH ' ' A' ' 134' ' ' TYR . 5.9 mmt -46.39 -45.33 17.77 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.3 -0.875 . . . . 0.0 110.34 -179.713 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -50.32 -23.2 2.16 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.11 -0.993 . . . . 0.0 110.223 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.423 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -57.0 -46.88 81.96 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.051 -1.031 . . . . 0.0 109.703 -179.809 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.442 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 1.9 ttt85 -73.11 -55.8 5.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 109.815 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.485 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 5.3 pt -99.92 48.69 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.127 -0.983 . . . . 0.0 110.103 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.09 100.98 0.11 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 179.64 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.44 -45.33 1.14 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.485 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.3 mmtt -82.23 -24.1 35.02 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.251 -1.146 . . . . 0.0 109.154 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.419 ' HE1' HD22 ' A' ' 111' ' ' LEU . 0.0 OUTLIER -65.97 79.58 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.441 -0.787 . . . . 0.0 109.595 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -88.22 -178.64 5.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.894 . . . . 0.0 110.186 -179.793 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -55.23 -34.73 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.874 -179.696 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.61 -14.4 62.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.668 179.896 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -90.43 -50.73 5.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.07 -1.019 . . . . 0.0 109.624 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.443 ' O ' ' CB ' ' A' ' 131' ' ' ALA . 15.1 ptpt -69.42 -27.77 65.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.262 179.776 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.437 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.0 t0 -79.07 -52.56 8.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.32 -0.862 . . . . 0.0 109.486 179.772 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -56.66 -54.34 47.22 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.374 -0.829 . . . . 0.0 109.765 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.499 ' CD1' HG12 ' A' ' 10' ' ' VAL . 4.1 m0 -63.46 -27.83 69.55 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.443 ' CB ' ' O ' ' A' ' 127' ' ' LYS . . . -68.39 -25.46 65.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.225 -0.922 . . . . 0.0 108.78 179.202 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.22 -41.93 14.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.44 -0.787 . . . . 0.0 109.121 179.466 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.436 ' CB ' HD13 ' A' ' 73' ' ' LEU . . . -70.19 -56.12 7.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.515 -0.74 . . . . 0.0 109.781 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 134' ' ' TYR . 9.0 m-30 -47.39 -27.96 1.88 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.296 -0.877 . . . . 0.0 109.636 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.98 -43.18 65.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.258 -0.901 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.76 -36.57 59.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.341 -0.85 . . . . 0.0 109.325 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.411 ' CD1' ' O ' ' A' ' 133' ' ' ALA . 1.3 mp -66.64 -58.44 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 108.885 179.717 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 31.7 p -66.97 -24.08 66.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.251 -0.906 . . . . 0.0 109.62 179.882 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.32 -28.78 55.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.16 -22.86 60.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -1.138 . . . . 0.0 109.595 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.456 ' O ' ' CD2' ' A' ' 141' ' ' LEU . 3.8 tt -86.46 11.6 12.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 109.986 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.448 ' CD1' ' HB3' ' A' ' 100' ' ' ALA . 44.0 mm -100.29 19.29 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.074 -1.016 . . . . 0.0 109.683 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.451 ' CB ' ' HG3' ' A' ' 84' ' ' LYS . 4.4 m -108.11 -52.65 2.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.634 179.962 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.407 ' O ' ' HA ' ' A' ' 88' ' ' VAL . . . -75.96 -7.75 84.3 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.415 HD12 ' HB3' ' A' ' 90' ' ' HIS . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.465 0 O-C-N 120.953 -1.322 . . . . 0.0 108.432 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.28 0.562 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -64.81 -46.1 83.43 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.409 ' HG3' ' HB3' ' A' ' 73' ' ' LEU . 38.6 ttp180 -55.38 -34.27 64.17 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.206 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -73.87 -41.66 61.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.261 -0.899 . . . . 0.0 109.176 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.469 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 59.7 t -57.42 -29.85 34.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.336 -0.853 . . . . 0.0 109.426 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.406 HG11 HG12 ' A' ' 70' ' ' VAL . 91.9 t -66.03 -52.14 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 109.468 179.793 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.56 -9.75 51.4 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.307 -0.871 . . . . 0.0 109.988 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 p -92.94 -24.43 18.41 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.045 -1.035 . . . . 0.0 109.774 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.4 p -98.49 -7.76 27.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 110.065 -179.939 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -95.14 -23.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.093 . . . . 0.0 109.588 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.2 mttm -77.08 -2.49 34.4 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.206 -0.933 . . . . 0.0 109.852 179.756 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -114.02 -51.12 2.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.085 -1.009 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.463 HG13 ' CG2' ' A' ' 118' ' ' ILE . 56.3 mt -66.34 -31.52 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.919 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.566 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -108.77 34.03 3.9 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.315 -0.866 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.31 -85.0 0.02 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.8 p -95.68 -31.45 13.23 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -1.14 . . . . 0.0 109.58 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 21' ' ' ASP . 24.5 p-10 -75.51 -21.97 57.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.295 -0.878 . . . . 0.0 109.591 180.0 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.45 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 4.3 t30 56.57 21.85 6.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.207 -0.933 . . . . 0.0 109.523 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 98.82 21.67 15.55 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -71.04 -56.85 5.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -1.146 . . . . 0.0 109.637 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.46 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -70.85 -21.08 78.04 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.925 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.462 ' O ' ' CB ' ' A' ' 30' ' ' CYS . 46.6 t -70.65 -35.03 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.284 -1.127 . . . . 0.0 110.005 -179.778 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.02 -43.72 13.33 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 -179.308 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.46 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.8 ptpt -64.28 -26.39 68.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -1.217 . . . . 0.0 110.155 -179.385 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.412 ' HG2' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -100.68 -11.41 20.0 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.045 -1.034 . . . . 0.0 110.156 -179.73 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.462 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 34.1 t -93.05 -68.19 0.81 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 109.888 -179.797 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CD1' HD23 ' A' ' 106' ' ' LEU . 10.3 m-85 -50.32 -30.48 12.14 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 110.004 -179.604 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.44 ' CA ' HG12 ' A' ' 55' ' ' VAL . 15.7 m -54.33 -53.18 57.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.064 -1.023 . . . . 0.0 109.221 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.405 ' HD3' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -55.44 -48.56 74.26 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.932 . . . . 0.0 109.243 179.737 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.517 ' CG ' HD22 ' A' ' 106' ' ' LEU . 3.8 t80 -54.33 -49.65 69.23 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.322 -0.862 . . . . 0.0 109.255 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.49 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 24.2 mt -60.1 -46.09 90.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.642 179.866 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.439 ' OG ' ' N ' ' A' ' 37' ' ' ALA . 8.9 p -61.21 -54.41 44.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.732 -179.91 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.439 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -67.86 -27.09 66.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.226 -0.921 . . . . 0.0 109.62 -179.927 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.514 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 10.0 m-70 -117.51 107.37 14.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.754 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 56.3 m170 -88.41 -19.9 25.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.408 -0.808 . . . . 0.0 109.356 179.648 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -71.04 -11.29 60.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.71 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.558 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -107.61 -27.73 10.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.007 . . . . 0.0 109.943 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -46.99 -48.14 21.79 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.13 -0.981 . . . . 0.0 109.796 -179.825 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.6 -28.78 65.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.122 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.494 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 21.3 t -70.15 -38.4 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.273 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.513 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 9.8 m-85 -77.27 -29.93 54.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.243 -0.911 . . . . 0.0 109.612 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.14 29.51 3.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.374 -1.491 . . . . 0.0 109.374 179.825 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.514 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.0 m-85 -124.25 166.99 14.91 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -1.167 . . . . 0.0 109.91 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.2 t -104.29 -20.3 13.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.421 -0.8 . . . . 0.0 109.127 179.343 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.83 -164.69 24.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.816 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.15 35.84 1.26 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -1.179 . . . . 0.0 109.69 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 56.4 p -135.07 23.2 3.53 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 109.533 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.493 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.8 p-10 -107.69 138.79 20.11 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -60.33 -20.73 64.18 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.934 1.491 . . . . 0.0 109.995 -179.964 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.71 -44.75 54.95 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.49 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 80.3 t -51.45 -37.99 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.401 -1.058 . . . . 0.0 109.31 179.776 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.456 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -71.72 -24.45 61.8 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.28 -0.887 . . . . 0.0 109.251 179.602 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -79.33 -37.96 36.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.376 179.778 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.6 mt -77.19 -60.98 2.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.527 179.926 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.494 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.66 -46.65 38.42 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.46 -42.04 70.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.39 179.842 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.8 mttt -76.54 -29.17 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.262 -0.899 . . . . 0.0 109.354 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 47.6 t -78.58 -49.95 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.417 ' O ' ' HB ' ' A' ' 66' ' ' ILE . 1.0 OUTLIER -48.43 -46.1 37.19 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.82 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.72 -49.93 69.58 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.303 -0.873 . . . . 0.0 109.564 179.939 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.402 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 8.1 tp-100 -50.9 -43.32 59.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 109.31 179.813 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.446 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 31.8 mm -57.6 -43.6 83.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.284 -0.885 . . . . 0.0 108.758 179.477 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.532 ' N ' ' CZ2' ' A' ' 14' ' ' TRP . . . -60.83 -55.16 31.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.775 -1.73 . . . . 0.0 108.775 179.371 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.3 t -54.03 -35.32 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.346 -1.09 . . . . 0.0 109.435 179.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -79.8 -30.38 40.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.88 . . . . 0.0 109.42 179.825 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.459 ' O ' ' CD2' ' A' ' 73' ' ' LEU . 48.9 t -68.68 -16.43 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.262 -0.899 . . . . 0.0 109.584 179.895 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.41 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.2 m -90.03 -0.05 57.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.172 -0.955 . . . . 0.0 110.199 -179.897 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.462 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 21.4 m-70 -140.02 50.85 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.983 -1.073 . . . . 0.0 109.767 -179.872 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.459 ' CD2' ' O ' ' A' ' 70' ' ' VAL . 4.3 mm? . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.934 . . . . 0.0 109.465 179.967 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' MET . . . . . 0.462 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 28.2 ttp . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.258 0.551 . . . . 0.0 109.829 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 45.9 t -68.61 -11.64 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.964 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.44 -37.41 43.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.03 -1.044 . . . . 0.0 109.44 179.904 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -88.65 -41.18 12.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.412 ' HA ' HG23 ' A' ' 86' ' ' VAL . 8.9 mtp -60.36 -41.04 92.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.94 . . . . 0.0 109.247 179.809 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.46 ' CE ' ' HB3' ' A' ' 143' ' ' SER . 0.0 OUTLIER -51.8 -42.04 62.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.784 179.171 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -61.28 -39.68 91.31 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.494 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 23.9 t -56.98 -51.86 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.277 -0.89 . . . . 0.0 108.774 179.496 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 145' ' ' LEU . . . -60.86 -53.59 43.95 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.655 -2.178 . . . . 0.0 107.655 178.826 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.457 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 78.7 t -48.8 -24.96 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.451 -1.029 . . . . 0.0 109.445 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.515 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 7.5 mmm180 -83.6 -43.85 15.22 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.021 -1.049 . . . . 0.0 108.729 179.238 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.505 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 19.5 m80 -58.75 -33.73 70.59 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.379 -0.825 . . . . 0.0 109.698 179.589 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -61.45 -15.78 40.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 110.434 -179.29 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.46 46.73 1.05 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.257 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.515 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.7 m-30 -87.28 -173.13 4.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.195 -1.179 . . . . 0.0 109.402 179.51 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.26 -26.42 52.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 179.668 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.494 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.6 OUTLIER -76.86 -55.23 5.67 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.559 -0.965 . . . . 0.0 109.101 179.704 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.48 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 10.3 tptp 77.09 -19.02 0.45 Allowed 'General case' 0 N--CA 1.508 2.469 0 O-C-N 121.765 -0.585 . . . . 0.0 111.472 179.871 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.409 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 8.2 m170 -94.05 44.01 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.601 -1.312 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.42 ' CD1' ' O ' ' A' ' 90' ' ' HIS . 36.3 mt -74.84 160.46 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.758 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.496 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -151.21 136.24 17.43 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.349 -0.845 . . . . 0.0 109.987 179.984 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.94 -5.52 44.26 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.573 -0.704 . . . . 0.0 109.506 179.301 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mm-40 -74.98 -30.66 61.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.07 -1.019 . . . . 0.0 109.439 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.558 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 36.0 m-85 -75.66 -23.54 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.299 -0.876 . . . . 0.0 109.889 -179.746 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -54.39 -64.16 0.92 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.56 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.48 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.81 -58.55 5.25 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 110.856 -179.111 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 11.3 Cg_endo -59.49 -46.62 20.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.639 1.336 . . . . 0.0 109.63 -179.666 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.517 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.1 tm? -60.98 -27.29 68.19 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.216 -0.927 . . . . 0.0 108.841 179.414 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.402 ' HA3' ' CD2' ' A' ' 134' ' ' TYR . . . -81.34 -38.0 16.16 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 179.508 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.19 -60.13 4.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 0.0 109.345 179.782 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.0 m -52.42 -24.86 8.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.902 . . . . 0.0 109.18 179.67 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.401 HD23 ' HE1' ' A' ' 114' ' ' MET . 2.3 tt -66.51 -48.19 70.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.347 -0.846 . . . . 0.0 109.421 179.811 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.409 HD21 ' HB2' ' A' ' 130' ' ' TRP . 13.0 mt -57.65 -32.32 67.17 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.947 . . . . 0.0 109.216 179.729 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.4 m -73.82 -38.52 64.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.339 -0.85 . . . . 0.0 109.429 179.823 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.417 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -72.61 -35.71 67.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.292 -0.88 . . . . 0.0 109.387 179.791 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.401 ' HE1' HD23 ' A' ' 110' ' ' LEU . 4.2 mmt -51.39 -42.15 61.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.44 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.3 OUTLIER -50.7 -23.7 2.85 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.99 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.417 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 21.2 m170 -53.71 -26.71 24.29 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.882 . . . . 0.0 110.094 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.411 ' HG2' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -101.7 -73.31 0.66 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.026 -1.046 . . . . 0.0 109.877 -179.848 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.463 ' CG2' HG13 ' A' ' 17' ' ' ILE . 24.9 pt -65.33 -33.83 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.875 -1.14 . . . . 0.0 109.169 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.44 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . 45.43 -108.64 0.23 Allowed Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.08 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.32 -35.88 10.16 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -179.47 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.456 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 40.3 mttt -68.06 -22.25 64.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.155 -1.203 . . . . 0.0 109.699 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.453 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -74.99 72.42 2.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.068 -1.02 . . . . 0.0 109.111 179.443 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.417 ' OD1' ' N ' ' A' ' 123' ' ' ASN . 15.0 p-10 -73.43 -175.88 2.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.275 -0.891 . . . . 0.0 109.882 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -59.08 -45.99 89.42 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 109.302 179.86 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.464 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -60.12 -33.0 71.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.315 -0.865 . . . . 0.0 109.074 179.662 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -66.98 -51.99 48.32 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.272 -0.893 . . . . 0.0 109.429 179.698 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.463 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 14.4 ptpt -71.61 -28.96 64.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.251 -0.906 . . . . 0.0 109.546 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.463 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 39.3 t0 -80.07 -43.39 21.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.331 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.469 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -56.28 -46.1 79.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.325 -0.86 . . . . 0.0 109.213 179.675 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.464 ' CZ2' ' CD1' ' A' ' 14' ' ' TRP . 13.1 m0 -74.63 -32.39 62.28 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.258 -0.901 . . . . 0.0 108.581 179.585 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.54 -26.02 53.68 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.92 -30.66 14.04 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.315 -0.866 . . . . 0.0 109.063 179.476 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.408 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -83.08 -54.38 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.493 -0.754 . . . . 0.0 109.412 179.845 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.56 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -48.87 -27.31 2.96 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.362 -179.938 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.56 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -80.98 -32.08 34.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 108.776 179.335 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.408 ' N ' ' O ' ' A' ' 133' ' ' ALA . 3.1 m-20 -81.7 -35.67 29.54 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.431 -0.793 . . . . 0.0 109.272 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 137' ' ' ILE . 1.4 mp -66.39 -60.53 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.207 -0.933 . . . . 0.0 108.545 179.409 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.14 -12.06 46.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.95 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -75.78 -46.25 14.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.969 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.55 -28.73 68.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -1.142 . . . . 0.0 109.702 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.494 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 1.7 tt -71.64 -22.09 61.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.298 -0.876 . . . . 0.0 109.667 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 86.9 mt -78.12 1.34 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.177 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 143' ' ' SER . . . . . 0.46 ' HB3' ' CE ' ' A' ' 84' ' ' LYS . 68.2 m -81.35 -44.6 17.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.045 . . . . 0.0 109.718 -179.974 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 88' ' ' VAL . . . -110.85 11.12 29.78 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.88 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.027 -1.278 . . . . 0.0 110.014 -179.83 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.26 0.552 . . . . 0.0 109.82 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -81.31 -43.01 19.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 109.911 -179.765 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.456 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 12.4 ptm180 -53.78 -35.0 60.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.617 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.456 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 6.8 mm-40 -71.96 -47.74 50.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.921 . . . . 0.0 109.541 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 125' ' ' ALA . 33.1 t -60.09 -27.09 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.257 -0.902 . . . . 0.0 109.461 179.954 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.487 HG12 ' CD1' ' A' ' 130' ' ' TRP . 54.9 t -70.63 -49.11 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.287 -0.883 . . . . 0.0 109.475 179.899 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.9 -16.25 62.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.866 . . . . 0.0 109.795 -179.988 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.59 -26.16 26.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.705 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.407 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 20.7 p -95.15 -9.61 32.98 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.197 -0.94 . . . . 0.0 109.959 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.57 ' CE3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.61 -17.25 24.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.026 -1.046 . . . . 0.0 109.963 -179.882 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.4 mtpt -80.06 -13.71 59.09 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.121 -0.987 . . . . 0.0 109.585 179.658 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.408 ' O ' ' NE ' ' A' ' 117' ' ' ARG . 68.2 m-20 -98.62 -55.43 2.74 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.561 179.802 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.421 HG12 ' HB3' ' A' ' 117' ' ' ARG . 30.8 mt -65.39 -28.74 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.211 -0.931 . . . . 0.0 109.12 179.698 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.57 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -111.42 36.56 3.18 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 179.806 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.55 -86.77 0.02 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.7 p -104.98 9.76 34.4 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -1.17 . . . . 0.0 109.94 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.407 ' OD1' ' HA ' ' A' ' 18' ' ' ALA . 2.3 p30 -119.3 -12.41 9.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.1 -1.0 . . . . 0.0 109.848 179.907 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.441 ' O ' HD11 ' A' ' 63' ' ' LEU . 14.8 t-20 64.03 13.03 7.4 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.234 -0.916 . . . . 0.0 109.838 -179.758 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.465 ' HA2' ' CG2' ' A' ' 26' ' ' VAL . . . 96.3 16.28 38.2 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.918 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.415 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -48.35 -38.19 18.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.221 -1.164 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.41 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -87.29 14.53 57.43 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.465 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 15.7 t -102.21 -29.44 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.075 -1.25 . . . . 0.0 109.558 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -92.26 -37.08 6.03 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.657 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.468 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.7 ptpt -64.07 -31.7 72.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.172 -1.193 . . . . 0.0 109.549 -179.857 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.468 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 19.6 pt-20 -94.46 -19.13 20.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.125 -0.985 . . . . 0.0 109.642 179.882 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.459 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 35.4 t -89.25 -53.6 4.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.867 -179.78 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 15.9 m-85 -63.41 -34.85 78.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 109.774 -179.688 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.457 ' CA ' HG12 ' A' ' 55' ' ' VAL . 12.4 m -58.71 -36.05 73.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.09 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.81 -42.22 50.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.874 . . . . 0.0 109.291 179.571 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.512 ' CG ' HD22 ' A' ' 106' ' ' LEU . 12.7 t80 -63.07 -47.41 83.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -0.887 . . . . 0.0 109.313 179.661 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.504 HD21 ' CD2' ' A' ' 45' ' ' PHE . 22.0 mt -57.16 -43.69 82.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.876 . . . . 0.0 109.739 179.925 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.6 t -68.76 -63.52 1.04 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 109.706 -179.923 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.56 -24.45 8.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.262 -0.899 . . . . 0.0 109.7 -179.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.417 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 25.6 m-70 -125.49 104.29 8.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.805 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -86.71 -5.23 59.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.389 -0.819 . . . . 0.0 109.855 179.661 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -82.16 -21.99 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.099 -1.001 . . . . 0.0 109.535 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' MET . . . . . 0.414 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 88.4 mmm -101.12 -23.88 14.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.244 -0.91 . . . . 0.0 109.692 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.437 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.62 -38.13 20.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.226 -0.921 . . . . 0.0 109.632 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.67 -28.56 60.89 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.422 179.76 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.509 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 52.5 t -67.17 -59.69 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.514 179.844 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.508 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 68.1 m-85 -50.79 -42.08 57.72 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.236 -0.915 . . . . 0.0 109.586 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.07 35.84 0.92 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.735 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.508 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.36 166.79 15.34 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.119 -1.224 . . . . 0.0 109.762 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.6 t -111.2 21.62 16.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.411 -0.805 . . . . 0.0 109.117 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 146.08 177.59 20.87 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -179.788 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -68.79 -13.78 62.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -1.181 . . . . 0.0 109.828 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 71.9 p -87.85 45.55 1.29 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.103 -0.998 . . . . 0.0 109.688 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.52 132.45 24.26 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -69.23 -22.17 34.89 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 123.874 1.46 . . . . 0.0 110.083 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.501 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -57.39 -26.93 57.48 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.458 ' CG2' HD11 ' A' ' 35' ' ' LEU . 87.1 t -58.33 -51.94 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.179 -1.189 . . . . 0.0 109.637 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.454 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -58.21 -22.6 52.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.928 . . . . 0.0 109.552 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.96 -60.31 2.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.874 . . . . 0.0 109.604 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -55.88 -59.04 5.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.677 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.516 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.54 -60.76 5.59 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.466 ' HA ' ' CD2' ' A' ' 63' ' ' LEU . . . -48.23 -33.97 9.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 0.0 109.654 179.788 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -77.76 -20.26 53.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.319 -0.863 . . . . 0.0 109.419 179.769 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.505 HG23 ' CZ ' ' A' ' 31' ' ' PHE . 49.4 t -81.24 -61.16 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.31 -0.869 . . . . 0.0 109.677 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.466 ' CD2' ' HA ' ' A' ' 60' ' ' ALA . 0.3 OUTLIER -46.07 -43.07 14.33 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.27 -0.894 . . . . 0.0 109.835 179.914 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.25 -40.23 33.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.96 -1.088 . . . . 0.0 109.477 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -65.83 -43.37 88.77 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.249 -0.907 . . . . 0.0 109.153 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.462 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 33.9 mt -59.96 -40.13 82.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.412 -0.805 . . . . 0.0 109.182 179.68 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.537 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.04 -50.79 62.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.88 -30.53 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 109.334 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -82.81 -24.92 33.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.404 -0.81 . . . . 0.0 109.588 -179.963 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.463 ' CG1' HG11 ' A' ' 10' ' ' VAL . 46.2 t -69.8 -9.06 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.855 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.509 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 24.9 p -91.39 30.9 1.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.058 -1.027 . . . . 0.0 109.938 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.509 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.5 m-70 -160.69 -89.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.633 179.875 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.422 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 15.0 mt . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.367 -0.833 . . . . 0.0 109.985 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.4 tmm? . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.191 0.519 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.414 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 46.7 t -80.33 -19.6 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.612 179.931 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.41 -40.59 97.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.593 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -87.0 -45.6 10.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.537 179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.5 mtp -59.48 -56.92 15.91 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.257 179.765 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.414 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -52.43 -27.04 14.36 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.236 -0.915 . . . . 0.0 109.091 179.546 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -71.04 -35.93 72.14 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.707 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.419 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 16.5 t -58.72 -38.77 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.221 -0.924 . . . . 0.0 109.226 179.868 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.411 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -55.86 -47.75 77.09 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.531 -1.827 . . . . 0.0 108.531 179.588 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 79.7 t -55.13 -36.13 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.32 -1.106 . . . . 0.0 108.955 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . 0.507 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mpt_? -69.01 -52.33 29.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 108.991 179.398 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' HIS . . . . . 0.503 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 16.9 m80 -56.35 -29.22 61.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.836 . . . . 0.0 109.288 179.581 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 ttmt -66.23 -13.07 59.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.285 -0.884 . . . . 0.0 110.06 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.25 47.66 1.01 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.936 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.507 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -91.42 -169.29 2.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.346 -1.091 . . . . 0.0 109.817 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.26 -52.82 7.3 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.647 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.509 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 11.9 p-10 -61.49 -31.65 71.64 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.128 -1.219 . . . . 0.0 109.486 -179.798 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.5 tttt 60.42 32.94 20.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -0.864 . . . . 0.0 110.147 179.595 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' HIS . . . . . 0.406 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 54.3 m170 -129.24 -85.31 0.55 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.186 -0.946 . . . . 0.0 109.092 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.478 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 17.7 mt 60.13 151.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.806 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.517 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -147.16 131.65 17.69 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 179.743 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.09 -12.51 61.54 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.647 -0.658 . . . . 0.0 109.461 179.5 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.414 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 1.0 OUTLIER -73.23 -19.75 61.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.092 -1.005 . . . . 0.0 109.255 179.517 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.517 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 34.4 m-85 -88.48 -22.42 23.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.417 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -54.39 -58.91 5.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.068 -179.703 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.497 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -54.3 -58.0 15.85 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.112 -0.993 . . . . 0.0 110.097 -179.498 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.497 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.7 Cg_exo -49.18 -59.83 1.09 Allowed 'Trans proline' 0 C--N 1.309 -1.533 0 O-C-N 123.62 1.326 . . . . 0.0 110.095 179.89 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.512 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.3 tm? -53.71 -27.28 27.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.555 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.06 -45.96 9.79 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 -179.976 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -60.64 -52.87 63.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.625 -179.986 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 17.3 m -57.66 -27.74 63.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.656 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.457 ' CD2' ' HE2' ' A' ' 114' ' ' MET . 4.1 tt -67.37 -43.08 82.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.215 -0.928 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.439 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.8 mt -56.51 -34.24 66.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.537 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.402 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 10.6 t -64.12 -34.44 78.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.721 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 113' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -81.57 -28.44 33.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.233 -0.917 . . . . 0.0 109.782 -179.732 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 114' ' ' MET . . . . . 0.474 ' HE3' ' CZ3' ' A' ' 130' ' ' TRP . 5.8 mmt -51.47 -35.51 40.17 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.96 . . . . 0.0 110.291 -179.563 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 7.1 pt-20 -64.85 -12.28 46.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.086 -1.009 . . . . 0.0 110.164 -179.548 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 116' ' ' HIS . . . . . 0.427 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 14.7 m170 -67.59 -27.15 66.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.943 -1.098 . . . . 0.0 109.52 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.421 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -94.16 -64.45 1.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.791 179.976 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 119' ' ' GLY . 24.3 pt -84.3 -34.85 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.641 -179.898 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . 0.478 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 42.39 -94.94 0.01 OUTLIER Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -44.03 -48.22 7.98 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -179.146 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.448 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -67.32 -22.64 65.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.116 -1.226 . . . . 0.0 109.895 -179.877 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 122' ' ' MET . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -71.1 96.55 1.36 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.086 -1.008 . . . . 0.0 109.098 179.51 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.434 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 8.5 p30 -100.36 -161.52 0.87 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.265 -0.897 . . . . 0.0 110.062 -179.5 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.409 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -72.86 -45.58 57.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.354 -0.841 . . . . 0.0 109.655 -179.945 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . 0.434 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -62.47 -30.41 71.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.196 -0.94 . . . . 0.0 109.036 179.731 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.47 -50.23 47.36 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.446 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 18.8 ptpt -72.1 -27.55 62.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 179.774 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 128' ' ' ASP . . . . . 0.446 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 62.2 t0 -80.44 -41.3 24.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.168 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -63.91 -45.71 88.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 109.152 179.55 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.492 ' CE3' ' OH ' ' A' ' 134' ' ' TYR . 5.0 m0 -73.02 -25.73 61.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.368 -0.833 . . . . 0.0 109.138 179.544 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -65.43 -34.08 77.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.289 -0.882 . . . . 0.0 108.926 179.218 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.47 -20.76 24.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.372 -0.83 . . . . 0.0 109.333 179.564 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -79.39 -53.39 6.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.525 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.492 ' OH ' ' CE3' ' A' ' 130' ' ' TRP . 10.4 m-30 -53.0 -28.4 23.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.334 179.929 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.9 -48.58 52.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.053 179.465 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.89 -34.31 66.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.322 -0.861 . . . . 0.0 109.225 179.642 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 64.1 mt -66.73 -59.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.348 -0.845 . . . . 0.0 109.16 179.743 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.2 p -67.87 -25.98 65.79 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.677 -179.931 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -68.87 -46.57 59.59 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -179.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.51 -26.89 45.41 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -1.172 . . . . 0.0 109.66 179.975 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.417 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.1 tt -77.29 -16.35 59.01 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.203 -0.936 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.9 mt -76.5 -0.73 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.14 -0.975 . . . . 0.0 110.151 -179.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.0 m -84.37 -43.96 14.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.037 -1.04 . . . . 0.0 109.632 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -85.53 -16.55 63.85 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.945 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.411 ' N ' ' HA3' ' A' ' 87' ' ' GLY . 6.8 tp . . . . . 0 N--CA 1.488 1.43 0 O-C-N 121.195 -1.179 . . . . 0.0 108.943 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.446 HD12 ' CD1' ' A' ' 73' ' ' LEU . 12.0 mt -128.86 165.39 21.11 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.127 -1.219 . . . . 0.0 109.747 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.59 168.4 15.79 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.249 -0.907 . . . . 0.0 109.905 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -63.31 -40.5 97.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.333 -0.855 . . . . 0.0 109.403 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.438 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . -63.3 -41.97 99.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.318 -0.864 . . . . 0.0 109.307 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -70.27 -47.35 61.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.305 -0.872 . . . . 0.0 109.212 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 31.8 mtp180 -53.98 -36.01 62.44 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.247 -0.908 . . . . 0.0 109.193 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -74.59 -40.38 61.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.309 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.443 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 61.0 t -66.06 -23.71 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.284 -0.885 . . . . 0.0 109.192 179.606 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.517 HG11 ' CD1' ' A' ' 130' ' ' TRP . 50.9 t -76.74 -44.89 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -0.853 . . . . 0.0 109.338 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.42 ' O ' ' HG3' ' A' ' 15' ' ' LYS . . . -74.04 -15.96 61.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.764 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -86.21 -24.16 26.19 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.149 -0.969 . . . . 0.0 109.816 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.6 p -95.16 -10.96 29.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.214 -0.929 . . . . 0.0 109.8 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.562 ' CE3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.8 -28.73 17.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 0.0 109.863 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.42 ' HG3' ' O ' ' A' ' 11' ' ' ALA . 10.6 mtmt -74.57 -12.73 60.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 109.812 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -101.52 -55.05 2.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -0.988 . . . . 0.0 109.528 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.505 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 86.0 mt -67.5 -35.5 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.271 -0.893 . . . . 0.0 109.593 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.562 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -105.59 33.73 3.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.285 -0.884 . . . . 0.0 109.728 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -84.58 0.03 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 p -101.08 -18.81 16.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.703 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.471 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 9.4 p-10 -85.51 -16.99 37.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.207 -0.933 . . . . 0.0 109.902 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.401 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.4 t30 62.39 17.0 9.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.263 -0.898 . . . . 0.0 109.676 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.88 29.65 5.75 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.471 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -70.88 -46.99 61.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -1.174 . . . . 0.0 109.546 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.432 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.85 38.19 3.19 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.505 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 34.6 t -124.01 -43.12 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.233 -1.157 . . . . 0.0 108.64 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.485 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -88.81 -32.0 11.77 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.54 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.508 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 15.5 ptpt -62.19 -35.57 79.25 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.232 -1.158 . . . . 0.0 109.124 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.508 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 17.2 pt-20 -86.42 -21.08 27.32 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -0.972 . . . . 0.0 109.31 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 38.5 t -87.98 -59.38 2.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.398 -0.814 . . . . 0.0 109.692 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.2 m-85 -53.67 -42.99 68.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.275 -0.891 . . . . 0.0 109.669 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.453 ' CA ' HG12 ' A' ' 55' ' ' VAL . 17.8 m -52.02 -50.25 61.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.15 -0.969 . . . . 0.0 109.252 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.405 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 0.2 OUTLIER -62.5 -44.73 95.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.26 179.649 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.514 ' CG ' HD22 ' A' ' 106' ' ' LEU . 3.9 t80 -57.81 -46.66 84.36 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.35 -0.844 . . . . 0.0 109.206 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.464 HD11 ' CG2' ' A' ' 55' ' ' VAL . 11.1 mt -59.26 -44.34 92.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.715 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 46.8 t -66.7 -64.32 0.88 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.204 -0.935 . . . . 0.0 109.749 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.39 -26.57 20.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.218 -0.926 . . . . 0.0 109.827 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.471 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 16.2 m-70 -123.79 104.92 9.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.857 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.6 m170 -85.99 8.24 21.3 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.428 -0.795 . . . . 0.0 109.758 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -98.54 -11.66 21.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.129 -0.982 . . . . 0.0 109.623 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.562 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -105.84 -11.77 16.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.209 -0.932 . . . . 0.0 110.081 -179.793 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.456 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -58.46 -60.26 4.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.938 -1.101 . . . . 0.0 109.26 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.81 -28.24 63.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.088 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.507 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 28.5 t -68.85 -47.77 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.376 -0.828 . . . . 0.0 109.088 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.509 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -71.19 -37.08 72.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.557 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.77 34.23 1.57 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.519 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 13.4 m-85 -125.92 168.61 13.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -1.162 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.0 t -105.92 -13.68 15.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.406 -0.809 . . . . 0.0 109.479 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.77 -162.97 28.28 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.49 -19.55 35.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.297 -1.119 . . . . 0.0 109.778 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 14.9 p -87.76 52.15 2.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -0.902 . . . . 0.0 109.739 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -127.12 133.77 25.42 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.923 . . . . 0.0 109.581 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -67.23 -29.01 39.69 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.908 1.478 . . . . 0.0 110.063 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.519 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.27 -38.28 40.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.515 HG22 ' CD2' ' A' ' 47' ' ' PHE . 94.4 t -51.2 -46.78 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -1.095 . . . . 0.0 109.421 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.456 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -64.2 -17.12 63.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.902 . . . . 0.0 109.494 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.83 -47.38 15.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.516 HD21 ' C1A' ' A' ' 148' ' ' HEM . 9.6 mt -73.23 -60.69 2.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.178 -0.951 . . . . 0.0 109.476 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.507 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -47.65 -31.19 7.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.45 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -78.38 -60.54 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -1.148 . . . . 0.0 109.438 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -52.43 -39.2 60.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.286 -0.884 . . . . 0.0 109.493 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.453 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 41.3 t -64.63 -48.32 85.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -47.78 -44.74 28.69 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.184 -0.947 . . . . 0.0 109.636 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 67' ' ' GLY . . . -49.2 -52.74 24.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.409 -0.807 . . . . 0.0 109.778 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.1 tp60 -49.82 -44.02 49.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.095 -1.003 . . . . 0.0 109.268 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.47 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 82.7 mt -63.2 -28.04 44.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.336 -0.852 . . . . 0.0 108.851 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.532 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -71.41 -55.22 7.84 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.44 -24.48 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.238 -1.154 . . . . 0.0 109.116 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.09 -18.09 33.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.413 -0.805 . . . . 0.0 109.57 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.47 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 41.0 t -75.07 -16.04 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.511 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 74.6 m -88.45 11.06 18.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.129 -0.982 . . . . 0.0 110.143 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.8 m-70 -161.73 61.37 0.25 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.048 -1.033 . . . . 0.0 109.926 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.468 ' CD2' ' HA ' ' A' ' 70' ' ' VAL . 3.1 mm? -75.17 -42.9 54.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -78.37 -26.57 59.23 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.64 87.68 6.0 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -1.162 . . . . 0.0 109.663 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.413 ' HB2' HG21 ' A' ' 80' ' ' VAL . 3.7 pm0 -94.96 43.32 1.09 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 109.474 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -113.65 -21.36 5.78 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -126.04 -57.93 1.4 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -1.196 . . . . 0.0 110.031 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.413 ' HG2' ' O ' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -50.83 -24.6 3.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.052 -1.03 . . . . 0.0 109.284 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.413 HG21 ' HB2' ' A' ' 76' ' ' GLU . 71.6 t -84.1 -17.01 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.39 -0.819 . . . . 0.0 109.405 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -39.39 70.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -69.91 -48.17 59.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.243 -0.911 . . . . 0.0 109.331 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.437 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.7 OUTLIER -58.68 -46.78 86.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 109.214 179.7 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.463 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.9 mttt -52.92 -34.78 56.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.246 -0.909 . . . . 0.0 109.148 179.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -69.3 -42.98 74.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.339 -0.851 . . . . 0.0 109.391 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.2 t -50.97 -40.15 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.302 -0.874 . . . . 0.0 109.338 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.459 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -58.05 -50.48 65.73 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.42 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 97.6 t -54.62 -35.88 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -1.034 . . . . 0.0 108.95 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 1.5 mpt_? -66.08 -45.02 82.75 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.359 -0.838 . . . . 0.0 108.97 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.447 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 16.5 m80 -64.71 -12.2 44.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.441 -0.787 . . . . 0.0 109.766 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.44 ' HG3' ' N ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -74.27 -8.48 56.37 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.032 -1.042 . . . . 0.0 110.426 -179.657 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -152.04 57.75 0.43 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.512 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.5 m-30 -88.35 -169.74 2.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.265 -1.138 . . . . 0.0 109.728 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.52 -8.77 87.12 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.507 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.0 p-10 -112.22 -23.75 10.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.862 -1.375 . . . . 0.0 109.975 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 51.33 28.43 4.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.134 -0.978 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 38.4 m170 -129.32 38.42 3.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.512 HD11 ' CD2' ' A' ' 93' ' ' TYR . 51.2 mt -87.72 154.6 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.065 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.409 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.86 149.83 27.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.129 -0.982 . . . . 0.0 110.159 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -80.17 -8.83 59.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.358 -0.839 . . . . 0.0 109.588 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 105' ' ' PRO . 14.5 pt-20 -68.62 -30.24 68.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.1 -1.0 . . . . 0.0 109.336 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.562 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 70.4 m-85 -82.47 -21.24 35.65 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.312 -0.867 . . . . 0.0 109.737 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.543 ' CZ ' ' CHC' ' A' ' 148' ' ' HEM . 5.2 m-85 -57.66 -68.83 0.2 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.389 -0.819 . . . . 0.0 110.465 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.505 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 8.4 mt-10 -43.62 -60.21 2.78 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.45 -0.781 . . . . 0.0 111.022 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.505 ' CD ' ' CB ' ' A' ' 104' ' ' GLU . 9.3 Cg_endo -56.5 -50.59 11.41 Favored 'Trans proline' 0 C--N 1.304 -1.802 0 O-C-N 123.756 1.398 . . . . 0.0 110.052 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.514 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.3 tm? -65.52 -19.67 66.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.158 -0.963 . . . . 0.0 109.333 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -79.99 -44.9 8.68 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.52 -47.07 77.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.217 -1.167 . . . . 0.0 109.337 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 48.7 m -63.66 -16.77 61.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.32 -0.862 . . . . 0.0 109.508 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.511 HD21 ' CE2' ' A' ' 134' ' ' TYR . 6.3 tt -75.41 -40.24 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.673 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.437 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.8 mt -63.12 -30.06 71.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.937 . . . . 0.0 109.718 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 1.4 t -73.2 -20.9 60.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 109.639 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.416 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -88.29 -31.25 19.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.582 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.48 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.0 OUTLIER -55.6 -35.75 66.17 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.853 . . . . 0.0 109.992 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 20.8 pt-20 -57.75 -22.54 47.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.117 -0.989 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.416 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -56.98 -40.56 76.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.211 -0.931 . . . . 0.0 109.355 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.449 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 11.2 ttt85 -77.59 -62.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.543 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.444 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 8.7 pt -91.69 43.26 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.459 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -52.99 124.46 27.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 101.06 -37.06 3.78 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.401 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 26.4 mmtt -89.12 -24.52 22.22 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 109.293 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.444 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -72.12 86.9 1.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.323 -0.861 . . . . 0.0 109.586 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.444 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 12.1 p-10 -83.66 -171.98 3.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.348 -0.845 . . . . 0.0 109.859 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -64.15 -42.58 96.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.299 -0.876 . . . . 0.0 109.778 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.444 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -61.09 -29.96 70.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.128 -0.983 . . . . 0.0 109.334 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.93 -50.35 42.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.527 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.463 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.5 ptpt -71.79 -28.37 63.57 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.463 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.9 t0 -76.51 -49.28 16.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.267 -0.896 . . . . 0.0 109.332 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.443 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -56.53 -45.25 81.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.391 -0.818 . . . . 0.0 109.261 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.517 ' CD1' HG11 ' A' ' 10' ' ' VAL . 5.4 m0 -73.54 -32.07 64.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.36 -0.838 . . . . 0.0 109.134 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.414 ' CB ' ' O ' ' A' ' 127' ' ' LYS . . . -65.03 -24.69 67.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.291 -0.88 . . . . 0.0 109.185 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.23 -26.97 16.41 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.386 -0.821 . . . . 0.0 109.265 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.68 -44.46 17.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.325 -0.859 . . . . 0.0 109.577 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.511 ' CE2' HD21 ' A' ' 110' ' ' LEU . 2.8 m-85 -57.45 -27.61 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.943 . . . . 0.0 109.493 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.45 -46.32 89.07 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.355 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -74.58 -28.28 60.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.33 -0.857 . . . . 0.0 109.587 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 81.4 mt -68.62 -60.24 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.453 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.2 p -67.52 -48.76 66.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.382 -0.824 . . . . 0.0 109.774 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.64 -29.85 26.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.85 -17.55 55.45 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.157 -1.202 . . . . 0.0 109.825 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.437 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 9.3 tt -89.57 -23.44 21.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 109.82 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.461 HD12 HG22 ' A' ' 142' ' ' ILE . 44.0 mm -70.7 -16.71 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.219 -0.925 . . . . 0.0 109.82 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.463 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.5 OUTLIER -61.39 -68.01 0.35 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -0.966 . . . . 0.0 109.175 179.808 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -66.04 -19.37 67.84 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.478 ' O ' ' HG2' ' A' ' 146' ' ' GLN . 24.6 tp -58.75 170.28 0.83 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.316 -1.108 . . . . 0.0 109.597 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.478 ' HG2' ' O ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 36.33 46.83 0.44 Allowed 'General case' 0 N--CA 1.502 2.138 0 CA-C-O 121.336 0.589 . . . . 0.0 111.044 -179.86 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.44 ' N ' ' HG3' ' A' ' 91' ' ' LYS . 4.0 t . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.659 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.543 ' CHC' ' CZ ' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.498 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.409 HD11 HD11 ' A' ' 73' ' ' LEU . 10.8 mt -61.02 176.95 0.37 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -1.116 . . . . 0.0 109.404 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.404 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 77.7 p -134.27 -159.81 1.0 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.917 . . . . 0.0 109.775 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.79 -27.74 20.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.544 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.29 -34.98 15.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.373 -0.829 . . . . 0.0 109.684 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.404 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 27.9 mt-30 -70.82 -40.96 72.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.06 -1.025 . . . . 0.0 109.527 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.456 ' NH2' ' HA3' ' A' ' 74' ' ' GLY . 11.0 ttm180 -51.04 -52.73 40.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.113 -0.992 . . . . 0.0 109.297 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 60.1 mm-40 -49.72 -41.73 44.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.926 . . . . 0.0 109.268 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.402 HG13 ' HB2' ' A' ' 129' ' ' ALA . 23.7 t -71.25 -29.91 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -0.883 . . . . 0.0 108.88 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.503 HG11 ' CD1' ' A' ' 130' ' ' TRP . 41.5 t -78.59 -43.73 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.494 -0.754 . . . . 0.0 109.051 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.71 -13.19 60.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.443 -0.786 . . . . 0.0 109.78 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.5 m -92.13 -27.65 17.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 110.094 -179.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -87.73 -14.53 39.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.166 -0.959 . . . . 0.0 109.843 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -86.2 -18.4 32.27 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -0.95 . . . . 0.0 109.781 -179.802 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -80.28 1.97 26.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.142 -0.974 . . . . 0.0 109.784 179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -114.22 -53.95 2.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.103 -0.998 . . . . 0.0 109.333 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.462 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 54.7 mt -63.94 -35.19 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.468 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.4 38.27 2.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.912 . . . . 0.0 109.791 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.83 -88.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.1 p -109.41 17.38 21.51 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.305 -1.115 . . . . 0.0 109.683 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.438 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 2.9 p-10 -125.88 -3.93 7.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.453 ' O ' ' ND2' ' A' ' 22' ' ' ASN . 6.4 t30 57.15 19.25 4.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.293 -0.88 . . . . 0.0 109.452 -179.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.48 27.22 30.63 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.439 ' O ' ' HD2' ' A' ' 28' ' ' LYS . . . -52.56 -38.26 59.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.348 -1.089 . . . . 0.0 109.698 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.405 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.44 18.97 38.67 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.462 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 25.5 t -117.3 -14.22 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.136 -1.214 . . . . 0.0 109.46 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.45 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -110.03 -29.46 3.77 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.015 -1.634 . . . . 0.0 109.015 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.467 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -77.8 -28.47 50.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.187 -1.184 . . . . 0.0 109.458 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.401 ' OE1' ' O ' ' A' ' 25' ' ' GLY . 1.6 pm0 -95.38 -16.0 22.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.633 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 37.0 t -87.98 -62.49 1.48 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -0.925 . . . . 0.0 109.66 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.504 ' CZ ' ' O ' ' A' ' 149' ' ' CMO . 10.8 m-85 -50.27 -30.96 12.94 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.143 -0.973 . . . . 0.0 109.694 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.419 ' HA ' HD11 ' A' ' 35' ' ' LEU . 52.6 m -61.64 -30.97 71.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.4 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 6.7 mmtt -74.57 -47.44 32.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.283 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.508 ' CG ' HD22 ' A' ' 106' ' ' LEU . 5.1 t80 -57.85 -46.16 85.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.419 -0.801 . . . . 0.0 109.535 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.458 ' CD1' HG21 ' A' ' 55' ' ' VAL . 6.8 mt -60.3 -46.89 88.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -0.882 . . . . 0.0 109.775 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 54.3 p -65.14 -49.9 68.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.284 -0.885 . . . . 0.0 109.769 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -70.45 -25.9 63.41 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.192 -0.943 . . . . 0.0 109.765 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.447 ' N ' ' O ' ' A' ' 34' ' ' PHE . 21.3 m-70 -126.14 117.76 23.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.204 -0.935 . . . . 0.0 109.866 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.2 m170 -94.75 -15.33 23.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.455 -0.778 . . . . 0.0 109.56 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -71.59 -7.62 48.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.17 -0.956 . . . . 0.0 109.882 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.519 ' HE2' ' CD1' ' A' ' 102' ' ' TYR . 4.9 mmt -118.77 -12.08 9.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.012 -1.055 . . . . 0.0 110.115 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.457 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -56.53 -53.53 56.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.943 -1.098 . . . . 0.0 109.254 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -64.25 -27.9 69.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.102 179.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.516 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 13.0 t -67.95 -53.38 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.417 -0.802 . . . . 0.0 109.171 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.513 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 38.9 m-85 -61.93 -19.02 62.28 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 29.66 6.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CD2' HG22 ' A' ' 55' ' ' VAL . 14.1 m-85 -126.37 168.84 13.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -1.138 . . . . 0.0 109.941 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.5 t -114.67 20.11 15.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.452 -0.78 . . . . 0.0 109.166 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.78 -163.74 28.24 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.93 39.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -1.17 . . . . 0.0 109.645 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 16.1 m -140.53 22.94 2.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 109.675 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -110.43 145.67 32.71 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.24 -0.913 . . . . 0.0 109.692 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -77.57 56.15 5.46 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.972 1.511 . . . . 0.0 110.169 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.523 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -135.06 -38.4 0.19 Allowed Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.524 HG22 ' CD2' ' A' ' 47' ' ' PHE . 47.5 t -50.0 -26.65 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.242 -1.152 . . . . 0.0 109.596 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.467 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -81.1 -7.81 59.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.292 -0.88 . . . . 0.0 110.002 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -91.73 -31.37 15.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.067 -1.021 . . . . 0.0 109.747 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.525 HD21 ' C1A' ' A' ' 148' ' ' HEM . 10.1 mt -83.04 -64.09 1.24 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.115 -0.991 . . . . 0.0 109.697 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.45 ' HA3' ' CA ' ' A' ' 27' ' ' GLY . . . -51.39 -44.81 53.16 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.452 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -53.49 -39.15 64.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.225 -1.162 . . . . 0.0 109.611 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.456 ' HD3' ' CGD' ' A' ' 148' ' ' HEM . 17.5 mttt -89.63 -32.31 17.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.252 -0.905 . . . . 0.0 109.633 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.449 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 57.7 t -65.27 -47.95 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.566 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.431 HD13 ' CG1' ' A' ' 26' ' ' VAL . 2.9 mm? -47.3 -45.27 24.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.198 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.44 ' HA ' ' OD1' ' A' ' 22' ' ' ASN . . . -53.65 -39.95 65.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.175 -0.953 . . . . 0.0 110.077 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.463 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 6.8 tp-100 -59.78 -39.54 85.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.964 -1.085 . . . . 0.0 108.903 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.484 HD12 HG22 ' A' ' 66' ' ' ILE . 26.7 mm -62.44 -42.14 94.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.405 -0.809 . . . . 0.0 108.9 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.525 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.6 -51.32 55.06 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.562 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.6 t -58.47 -26.8 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.318 -1.107 . . . . 0.0 109.411 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.83 -28.19 26.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.32 -0.863 . . . . 0.0 109.704 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.458 ' CG1' HG13 ' A' ' 10' ' ' VAL . 54.1 t -75.83 -23.33 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.2 p -63.57 -13.48 42.05 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 110.034 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.487 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.4 m-70 -124.01 -77.53 0.59 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.106 -0.996 . . . . 0.0 109.957 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.442 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 53.5 mt 59.78 -79.52 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.672 -0.643 . . . . 0.0 109.734 -179.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -54.64 -29.81 49.63 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.37 125.29 43.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.319 -1.106 . . . . 0.0 109.527 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -114.35 41.62 2.26 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.583 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.55 -32.33 7.0 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 22.2 ttmt -128.51 -30.01 2.38 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -1.146 . . . . 0.0 110.386 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 4.7 ttp -47.23 -62.38 1.45 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.065 -1.022 . . . . 0.0 109.694 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 42.8 t -65.39 -15.41 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.218 -0.926 . . . . 0.0 109.61 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.06 -52.22 20.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.973 . . . . 0.0 109.377 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -71.25 -41.05 70.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.461 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 2.1 mtp -58.8 -48.58 80.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.305 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 11.1 mttt -50.8 -38.57 49.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.151 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.413 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -66.83 -44.55 80.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.401 -0.812 . . . . 0.0 109.408 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.42 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 14.4 t -58.23 -37.94 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.157 -0.964 . . . . 0.0 109.264 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.425 ' CA ' ' HG ' ' A' ' 141' ' ' LEU . . . -63.34 -49.08 73.36 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.403 HG22 ' HA3' ' A' ' 144' ' ' GLY . 57.4 t -51.44 -38.45 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -1.059 . . . . 0.0 109.453 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.53 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 2.8 mpt_? -59.22 -25.62 64.15 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -0.944 . . . . 0.0 109.336 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.516 ' CD2' HD12 ' A' ' 98' ' ' ILE . 4.5 m80 -87.38 16.32 5.49 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.397 -0.814 . . . . 0.0 109.643 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.424 ' O ' ' HG3' ' A' ' 96' ' ' LYS . 23.3 ttmt -75.27 -67.48 0.65 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.941 -1.1 . . . . 0.0 110.167 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.406 ' HA2' ' HG3' ' A' ' 96' ' ' LYS . . . -145.7 56.07 0.53 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.53 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -82.46 -100.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 110.342 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -96.48 -57.28 1.13 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.516 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.2 OUTLIER -84.37 -28.45 26.98 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.415 -1.05 . . . . 0.0 108.594 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.503 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 14.6 tttm 64.41 -48.99 0.3 Allowed 'General case' 0 N--CA 1.505 2.283 0 O-C-N 121.75 -0.594 . . . . 0.0 112.271 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.458 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 64.2 m170 -50.0 -97.21 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.628 -1.295 . . . . 0.0 111.234 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.516 HD12 ' CD2' ' A' ' 90' ' ' HIS . 14.9 mt 65.4 154.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 121.035 -1.04 . . . . 0.0 109.572 -178.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.415 ' HE3' ' HB3' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -158.32 150.75 22.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.268 -0.895 . . . . 0.0 109.828 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.414 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -77.82 -10.21 59.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.569 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.0 mt-10 -67.68 -35.77 79.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 109.597 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.519 ' CD1' ' HE2' ' A' ' 41' ' ' MET . 76.5 m-85 -81.15 -16.48 52.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.344 -0.847 . . . . 0.0 110.146 -179.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.559 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 4.2 m-85 -58.32 -57.49 12.66 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.158 -0.963 . . . . 0.0 109.973 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -53.75 -58.05 14.84 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 109.755 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 39.7 Cg_exo -50.81 -62.17 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.628 1.33 . . . . 0.0 109.76 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.508 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -53.77 -24.75 16.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -0.895 . . . . 0.0 109.241 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.518 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -74.68 -51.49 8.04 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.096 -1.601 . . . . 0.0 109.096 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -54.22 -55.43 28.17 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -1.169 . . . . 0.0 109.456 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 54.9 m -53.33 -22.76 7.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.349 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.4 tt -65.88 -48.51 71.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.314 -0.866 . . . . 0.0 109.632 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 11.6 mt -57.54 -36.56 71.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.184 -0.948 . . . . 0.0 109.544 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -67.44 -33.81 75.9 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.595 179.966 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -81.69 -25.73 35.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -0.924 . . . . 0.0 109.663 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.534 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.9 mmt -58.45 -47.73 83.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.918 . . . . 0.0 110.205 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.449 ' O ' ' N ' ' A' ' 119' ' ' GLY . 6.4 pt-20 -50.05 -23.54 2.14 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.068 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.411 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 19.1 m170 -50.2 -40.73 48.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.993 -1.067 . . . . 0.0 109.783 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.17 -56.14 3.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.7 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.459 HG12 ' CG1' ' A' ' 17' ' ' ILE . 5.7 pt -104.34 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.143 -0.973 . . . . 0.0 109.633 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -63.15 -20.11 62.41 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.51 -29.23 10.28 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.412 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.2 mppt? -94.26 -23.44 17.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -1.189 . . . . 0.0 109.803 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.415 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 3.8 tpt -63.89 86.35 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.18 -0.95 . . . . 0.0 109.616 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.403 ' OD1' ' HB1' ' A' ' 126' ' ' ALA . 12.2 p-10 -87.14 -168.73 2.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -70.29 -39.98 74.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -0.932 . . . . 0.0 109.628 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -65.05 -31.11 72.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.095 -1.003 . . . . 0.0 108.98 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.403 ' HB1' ' OD1' ' A' ' 123' ' ' ASN . . . -66.27 -50.8 62.48 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.107 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.467 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.5 ptpt -70.53 -27.67 64.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.913 . . . . 0.0 109.124 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.467 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.1 t0 -79.33 -32.57 43.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.374 -0.829 . . . . 0.0 108.953 179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.409 ' HB1' HG22 ' A' ' 10' ' ' VAL . . . -72.42 -47.69 47.15 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.433 -0.792 . . . . 0.0 109.126 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.534 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 12.5 m0 -71.54 -21.54 61.88 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.269 -0.895 . . . . 0.0 108.976 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.415 ' HB2' ' O ' ' A' ' 128' ' ' ASP . . . -53.24 -34.3 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -0.889 . . . . 0.0 109.038 179.075 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -97.22 -15.4 20.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.417 -0.802 . . . . 0.0 109.494 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.418 ' HB2' HG21 ' A' ' 10' ' ' VAL . . . -81.51 -67.79 0.75 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.252 -0.905 . . . . 0.0 109.854 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.518 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.4 OUTLIER -55.31 -21.25 14.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.032 -1.043 . . . . 0.0 109.268 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -80.92 -49.56 10.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.299 -0.876 . . . . 0.0 108.944 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -73.21 -26.45 61.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.399 -0.813 . . . . 0.0 109.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.416 HD12 ' HA ' ' A' ' 134' ' ' TYR . 43.9 mt -67.88 -61.21 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 109.183 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -62.89 -14.2 43.51 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.346 -0.846 . . . . 0.0 109.907 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.43 -36.01 24.69 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.67 -27.9 66.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -1.184 . . . . 0.0 109.916 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.461 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 7.8 tt -74.39 -5.61 43.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.194 -0.941 . . . . 0.0 110.138 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.447 HG21 ' NE2' ' A' ' 146' ' ' GLN . 49.8 mm -90.66 18.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.98 -1.075 . . . . 0.0 109.843 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.8 m -95.25 -63.41 1.17 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.947 . . . . 0.0 109.593 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.403 ' HA3' HG22 ' A' ' 88' ' ' VAL . . . -68.12 -22.52 74.35 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.455 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER -56.4 -168.63 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.354 -1.086 . . . . 0.0 109.535 179.935 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.447 ' NE2' HG21 ' A' ' 142' ' ' ILE . 10.3 mt-30 55.63 92.75 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.407 ' HB3' ' CG ' ' A' ' 91' ' ' LYS . 19.2 p . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.625 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.559 ' CMC' ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.504 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 7.8 mt -93.01 176.35 6.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -1.165 . . . . 0.0 109.875 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.08 -166.52 1.22 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.338 -0.851 . . . . 0.0 109.891 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -84.02 -23.38 30.97 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.141 -0.974 . . . . 0.0 109.796 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.38 -36.13 12.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.599 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -65.13 -51.39 61.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.366 -0.834 . . . . 0.0 109.552 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.461 ' NH1' ' HA3' ' A' ' 74' ' ' GLY . 7.5 ptm180 -53.43 -32.3 49.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.08 -1.013 . . . . 0.0 108.921 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 47.8 tp60 -71.48 -44.07 65.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.166 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.405 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 30.0 t -65.12 -30.65 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.291 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.436 ' HA ' ' CD1' ' A' ' 130' ' ' TRP . 84.8 t -70.04 -41.75 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.369 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.8 -14.67 60.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -0.869 . . . . 0.0 109.764 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.1 -33.25 19.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.1 p -85.55 -15.73 41.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.739 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.549 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -86.99 -18.98 29.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.811 -179.893 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.8 mtpp -80.99 0.32 36.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.194 -0.941 . . . . 0.0 109.898 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -115.83 -53.65 2.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.081 -1.012 . . . . 0.0 109.439 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.447 HD11 ' CH2' ' A' ' 130' ' ' TRP . 64.7 mt -67.3 -32.78 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.549 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -103.07 31.92 4.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.872 . . . . 0.0 109.647 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.7 -86.39 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.0 p -95.25 -35.71 11.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.752 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.41 ' O ' ' HB2' ' A' ' 24' ' ' ALA . 2.9 p30 -71.24 -17.12 62.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.26 -0.9 . . . . 0.0 109.81 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 58.31 24.8 11.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.133 -0.979 . . . . 0.0 109.455 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.78 32.95 7.69 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.419 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . . . -81.11 -66.34 0.9 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -1.108 . . . . 0.0 109.816 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 29' ' ' GLU . . . -52.74 -22.98 13.0 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.459 HG11 ' CD1' ' A' ' 63' ' ' LEU . 38.5 t -74.82 -32.21 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.846 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.01 -55.48 2.93 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.416 ' HB3' ' HA ' ' A' ' 56' ' ' ALA . 6.6 ptpp? -57.31 -19.63 23.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.187 -1.184 . . . . 0.0 110.053 -179.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.468 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -98.35 -30.42 12.59 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.972 -1.08 . . . . 0.0 109.579 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.3 t -82.32 -55.48 4.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.34 -0.85 . . . . 0.0 109.538 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 12.2 m-85 -54.55 -37.44 65.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.357 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.435 ' CG2' HG12 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.56 -54.72 37.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.213 -0.929 . . . . 0.0 109.232 179.624 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -57.11 -47.82 80.15 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.212 -0.93 . . . . 0.0 109.335 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.511 ' CG ' HD22 ' A' ' 106' ' ' LEU . 5.4 t80 -55.07 -52.24 63.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.3 -0.875 . . . . 0.0 109.28 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.461 ' CD2' ' HA ' ' A' ' 42' ' ' ALA . 6.8 mt -59.3 -41.14 88.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.255 -0.903 . . . . 0.0 109.664 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.425 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 20.6 t -63.1 -61.19 2.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.657 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.475 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -63.37 -26.72 68.88 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.236 -0.915 . . . . 0.0 109.684 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.499 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 12.1 m-70 -118.9 107.53 13.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.691 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -88.34 -24.29 23.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 109.362 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 40' ' ' ASP . 25.5 p-10 -65.39 -19.16 65.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.408 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.544 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -95.21 -17.6 21.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.292 -0.88 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.461 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -57.43 -62.78 1.54 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.975 . . . . 0.0 109.38 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.56 -26.38 43.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.51 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 21.1 t -73.63 -48.76 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 109.239 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.472 ' CE2' ' HB3' ' A' ' 41' ' ' MET . 27.1 m-85 -68.26 -26.9 65.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.22 -0.925 . . . . 0.0 109.549 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 108.66 27.49 4.92 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.532 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.3 m-85 -123.74 167.29 14.22 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.176 . . . . 0.0 109.868 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 t -102.81 -20.93 14.13 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.421 -0.799 . . . . 0.0 109.203 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.9 -163.91 23.72 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.425 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -94.73 34.11 1.38 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.298 -1.119 . . . . 0.0 109.698 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 24.4 p -133.0 21.23 4.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.68 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -106.64 139.48 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.607 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.6 -16.96 57.94 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.954 1.502 . . . . 0.0 110.105 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.532 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -56.27 -39.8 83.05 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.498 HG22 ' CD2' ' A' ' 47' ' ' PHE . 84.1 t -51.04 -37.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -1.098 . . . . 0.0 109.38 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.456 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -73.74 -6.6 47.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.305 -0.872 . . . . 0.0 109.721 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -91.62 -27.16 18.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.011 . . . . 0.0 109.57 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.5 HD21 ' C1A' ' A' ' 148' ' ' HEM . 10.0 mt -91.43 -64.0 1.18 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.175 -0.953 . . . . 0.0 109.627 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.515 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.18 -41.94 39.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -62.84 -23.85 67.5 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -1.149 . . . . 0.0 109.691 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.73 -28.37 12.51 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.679 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.437 HG21 ' C ' ' A' ' 149' ' ' CMO . 59.6 t -67.22 -56.49 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.287 -0.883 . . . . 0.0 109.848 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.459 ' CD1' HG11 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -48.2 -38.4 18.19 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.961 . . . . 0.0 109.616 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.21 53.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.449 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.454 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 5.7 tp-100 -62.7 -36.17 82.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.232 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.445 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 41.6 mt -66.92 -37.07 78.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.355 -0.841 . . . . 0.0 109.186 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.539 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.81 -48.27 56.18 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 179.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.6 t -61.42 -27.99 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.357 -1.084 . . . . 0.0 109.43 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.86 -32.98 24.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.319 -0.863 . . . . 0.0 109.503 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.445 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 56.5 t -66.58 -22.67 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 41.3 m -67.31 -12.36 59.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.948 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.483 ' O ' ' N ' ' A' ' 74' ' ' GLY . 14.0 m-70 -122.85 -83.92 0.66 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.123 -0.986 . . . . 0.0 109.918 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.433 ' CD1' ' HA ' ' A' ' 70' ' ' VAL . 35.1 mt 60.85 -77.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.65 -0.657 . . . . 0.0 109.676 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.46 -29.84 40.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.796 -1.721 . . . . 0.0 108.796 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -87.56 160.44 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.381 -1.07 . . . . 0.0 109.372 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -148.73 67.29 1.05 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.654 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -126.3 -44.03 0.26 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.241 -1.544 . . . . 0.0 109.241 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 22.5 ttpp -122.04 -26.04 4.83 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 110.124 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 5.5 ttp -48.01 -50.65 26.95 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.064 -1.023 . . . . 0.0 109.726 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.453 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.2 t -72.14 -29.41 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.01 -41.91 97.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.253 -0.904 . . . . 0.0 109.435 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -71.98 -50.8 25.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.513 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.437 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.2 OUTLIER -62.47 -38.66 90.69 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 109.149 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.453 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -60.06 -38.04 81.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.265 -0.897 . . . . 0.0 109.099 179.44 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -67.92 -41.34 82.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.258 -0.901 . . . . 0.0 109.21 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.456 HG13 ' CD1' ' A' ' 141' ' ' LEU . 30.8 t -55.48 -50.52 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.328 -0.857 . . . . 0.0 109.119 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.412 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -56.55 -53.58 42.47 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.411 HG22 ' HA3' ' A' ' 144' ' ' GLY . 79.1 t -53.85 -34.24 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.438 -1.037 . . . . 0.0 108.947 179.355 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mmm180 -72.13 -48.72 41.54 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.413 -0.804 . . . . 0.0 109.051 179.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.503 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 14.5 m80 -56.48 -27.38 56.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.04 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.47 ' HG3' ' CA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -66.46 -12.07 55.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 110.289 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -136.08 49.85 0.87 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.509 ' CD2' HD11 ' A' ' 98' ' ' ILE . 4.3 m-30 -89.61 -168.71 2.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -1.174 . . . . 0.0 109.795 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -78.6 -52.19 5.2 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.51 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 17.8 p-10 -62.3 -29.41 70.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -1.186 . . . . 0.0 109.657 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.435 ' O ' ' CD2' ' A' ' 97' ' ' HIS . 12.0 mtmm 53.54 29.36 8.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.671 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.435 ' CD2' ' O ' ' A' ' 96' ' ' LYS . 39.0 m170 -136.29 45.31 2.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.284 -0.885 . . . . 0.0 109.57 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.509 HD11 ' CD2' ' A' ' 93' ' ' TYR . 62.2 mt -87.55 154.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.298 -0.876 . . . . 0.0 109.727 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.405 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -144.12 148.35 34.96 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.282 -0.886 . . . . 0.0 110.104 -179.84 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.68 -3.56 57.86 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.698 -0.627 . . . . 0.0 109.609 179.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 8.8 pt-20 -74.95 -29.16 60.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.074 -1.016 . . . . 0.0 109.477 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.544 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 59.8 m-85 -81.78 -22.1 37.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.726 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.527 ' CE1' ' CHC' ' A' ' 148' ' ' HEM . 4.0 m-85 -54.03 -63.46 1.14 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.221 -0.924 . . . . 0.0 110.263 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.5 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -48.98 -58.41 8.69 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.132 -0.98 . . . . 0.0 110.13 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.5 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.6 Cg_exo -49.85 -62.53 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.598 1.315 . . . . 0.0 110.026 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.511 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -54.59 -22.02 12.12 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.255 -0.903 . . . . 0.0 109.547 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.66 -50.36 5.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.44 95.19 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.133 -1.216 . . . . 0.0 109.557 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.4 t -66.62 -21.36 66.12 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.461 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 2.7 tt -71.96 -41.97 67.12 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 109.626 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.407 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.3 mt -58.97 -30.25 67.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 0.0 109.573 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 3.6 m -68.64 -33.99 74.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.713 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.501 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -81.47 -33.46 31.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.259 -0.9 . . . . 0.0 109.782 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.494 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -45.89 -47.55 16.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.313 -0.867 . . . . 0.0 110.341 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.457 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 18.8 pt-20 -51.94 -22.48 3.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 0.0 110.015 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 24.0 m170 -53.7 -30.7 44.98 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.012 -1.055 . . . . 0.0 109.81 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.407 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -95.42 -68.9 0.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.133 -0.979 . . . . 0.0 109.93 -179.775 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.474 HG13 ' N ' ' A' ' 119' ' ' GLY . 33.2 pt -75.11 -36.85 39.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.025 -1.047 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.474 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 39.52 -96.84 0.01 OUTLIER Glycine 0 N--CA 1.498 2.828 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.54 -42.45 10.09 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.432 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 3.3 mtpt -72.42 -21.9 61.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.112 -1.228 . . . . 0.0 109.771 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.429 ' N ' ' O ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -66.23 90.53 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.157 -0.964 . . . . 0.0 109.57 179.829 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.436 ' OD1' ' CB ' ' A' ' 126' ' ' ALA . 17.8 p-10 -84.94 -179.88 7.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.566 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -64.01 -40.25 95.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.405 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -63.98 -30.51 71.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.191 -0.943 . . . . 0.0 109.196 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.436 ' CB ' ' OD1' ' A' ' 123' ' ' ASN . . . -67.03 -50.5 61.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.406 -0.809 . . . . 0.0 109.322 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.411 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 15.0 ptpt -71.88 -30.02 64.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.289 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.411 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 59.5 t0 -77.13 -44.02 31.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.2 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.405 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -63.82 -41.62 97.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.48 -0.763 . . . . 0.0 109.065 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.494 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 3.5 m0 -75.25 -25.01 57.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.32 -0.863 . . . . 0.0 109.012 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -68.43 -37.2 80.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -0.886 . . . . 0.0 108.987 179.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -78.83 -24.58 44.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.324 -0.86 . . . . 0.0 109.297 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -83.27 -50.41 8.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.359 -0.838 . . . . 0.0 109.543 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.461 ' OH ' ' CD2' ' A' ' 110' ' ' LEU . 3.7 m-85 -50.35 -31.68 15.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.18 -0.95 . . . . 0.0 109.306 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.94 -35.68 57.11 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.341 -0.849 . . . . 0.0 108.986 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.83 -36.12 37.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.385 -0.822 . . . . 0.0 109.287 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 58.6 mt -66.58 -58.96 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.88 . . . . 0.0 109.087 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.408 ' O ' HG13 ' A' ' 142' ' ' ILE . 2.0 p -67.3 -19.81 65.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.386 -0.821 . . . . 0.0 109.644 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -72.1 -42.65 50.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.86 -23.03 65.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -1.146 . . . . 0.0 109.673 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.456 ' CD1' HG13 ' A' ' 86' ' ' VAL . 7.6 tt -80.34 -34.07 36.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.682 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.408 HG13 ' O ' ' A' ' 138' ' ' SER . 43.4 mt -73.79 -3.45 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 110.145 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.6 m -68.77 -59.43 3.1 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.011 -1.056 . . . . 0.0 109.621 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.411 ' HA3' HG22 ' A' ' 88' ' ' VAL . . . -88.38 4.4 85.28 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.468 ' O ' ' HG2' ' A' ' 146' ' ' GLN . 4.4 tt -78.02 178.75 7.26 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.056 -1.261 . . . . 0.0 109.48 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.468 ' HG2' ' O ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 41.69 39.22 1.11 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.655 -0.653 . . . . 0.0 110.606 -179.744 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.47 ' CA ' ' HG3' ' A' ' 91' ' ' LYS . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.748 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.527 ' CHC' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.49 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.455 HD12 ' CD1' ' A' ' 73' ' ' LEU . 11.6 mt -86.9 164.94 16.29 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -1.157 . . . . 0.0 109.796 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 p -142.22 -172.8 3.67 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 109.777 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -81.1 -25.52 36.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -0.886 . . . . 0.0 109.631 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.82 -23.54 22.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.572 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 83.8 mt-30 -81.86 -52.08 7.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.426 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -49.61 -30.96 9.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.223 -0.923 . . . . 0.0 109.521 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.426 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 6.3 mm-40 -72.1 -42.91 65.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.266 -0.896 . . . . 0.0 109.278 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.406 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 42.9 t -63.25 -32.15 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.274 -0.891 . . . . 0.0 109.243 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.433 HG21 ' CB ' ' A' ' 133' ' ' ALA . 70.7 t -66.12 -45.99 88.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.368 -0.833 . . . . 0.0 109.344 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.71 -10.56 59.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 109.821 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.3 p -92.88 -24.29 18.51 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.138 -0.976 . . . . 0.0 109.979 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.504 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 18.3 p -97.55 -8.98 27.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.092 -1.005 . . . . 0.0 109.959 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.6 -20.15 22.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.018 -1.051 . . . . 0.0 109.569 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -80.8 3.22 23.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.97 -56.49 2.1 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.066 -1.022 . . . . 0.0 109.512 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.469 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 51.2 mt -62.35 -30.26 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.51 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -107.42 32.41 4.69 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -0.91 . . . . 0.0 109.618 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -69.41 1.21 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 84.5 p -109.99 -29.96 8.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.281 -1.129 . . . . 0.0 109.663 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.454 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 6.8 p-10 -78.78 -20.2 50.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.896 . . . . 0.0 109.67 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.459 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 24.8 t30 57.61 28.41 15.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.185 -0.947 . . . . 0.0 109.516 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.408 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 93.51 25.39 18.59 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.454 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -73.2 -47.08 46.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.252 -1.146 . . . . 0.0 109.592 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.28 17.86 45.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.801 -1.319 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.447 ' CG1' HD13 ' A' ' 63' ' ' LEU . 21.2 t -109.48 -25.81 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.25 179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.429 ' CA ' HD23 ' A' ' 63' ' ' LEU . . . -94.43 -43.19 3.76 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.469 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.3 OUTLIER -62.19 -31.49 72.01 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.096 -1.238 . . . . 0.0 109.577 -179.837 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.448 ' OE2' ' CB ' ' A' ' 113' ' ' ALA . 14.5 pt-20 -89.38 -15.99 32.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.929 . . . . 0.0 109.618 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 15.8 t -90.15 -63.14 1.32 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.476 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 16.8 m-85 -47.54 -33.95 7.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.423 ' HA ' HG12 ' A' ' 55' ' ' VAL . 51.5 m -55.39 -40.75 71.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.172 -0.955 . . . . 0.0 109.421 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.41 -49.41 27.22 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.264 -0.897 . . . . 0.0 109.456 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.514 ' CZ ' ' HB2' ' A' ' 106' ' ' LEU . 3.9 t80 -52.06 -46.51 65.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.339 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.487 HD23 ' CD2' ' A' ' 45' ' ' PHE . 17.6 mt -58.07 -47.12 84.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.529 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.4 t -65.35 -55.83 15.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.569 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.421 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -61.54 -24.47 66.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.465 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 17.2 m-70 -124.9 103.88 8.29 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.269 -0.894 . . . . 0.0 109.722 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.5 m170 -86.29 -18.99 30.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.366 -0.834 . . . . 0.0 109.454 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -71.96 -9.66 58.68 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.283 -0.885 . . . . 0.0 109.893 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.514 ' HE1' ' CG ' ' A' ' 102' ' ' TYR . 29.7 mmm -119.38 -15.8 9.05 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 110.079 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.448 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.03 -47.7 44.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.041 . . . . 0.0 109.424 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.25 -31.6 64.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.331 -0.855 . . . . 0.0 109.093 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.51 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 15.9 t -60.51 -37.31 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.408 -0.808 . . . . 0.0 109.141 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.497 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.2 m-85 -76.86 -18.46 58.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.764 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 102.44 23.46 8.93 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.525 ' CD2' HG22 ' A' ' 55' ' ' VAL . 9.8 m-85 -122.49 167.33 13.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -1.137 . . . . 0.0 109.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 12.5 t -112.62 21.3 15.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 109.233 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.95 -172.42 25.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.95 -6.86 51.57 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -1.167 . . . . 0.0 109.976 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 62.2 p -94.3 43.41 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.056 -1.028 . . . . 0.0 109.73 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -123.77 129.18 24.91 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.649 179.933 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -67.97 -28.93 34.98 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.776 1.408 . . . . 0.0 110.022 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.467 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.49 -30.15 33.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 47' ' ' PHE . 95.5 t -50.93 -32.78 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -1.116 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.467 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -80.72 -6.22 58.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.312 -0.867 . . . . 0.0 109.809 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.22 -27.15 20.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.104 -0.998 . . . . 0.0 109.596 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.509 HD21 ' C1A' ' A' ' 148' ' ' HEM . 10.4 mt -89.78 -65.81 0.98 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.713 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.476 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.94 -42.16 29.61 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.452 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -56.19 -45.36 79.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.166 -1.196 . . . . 0.0 109.361 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 39.6 mttp -80.79 -38.17 28.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.386 -0.821 . . . . 0.0 109.403 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.448 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 42.3 t -59.79 -50.18 81.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 0.0 109.619 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.447 HD13 ' CG1' ' A' ' 26' ' ' VAL . 1.2 mm? -47.12 -46.63 23.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.255 -0.903 . . . . 0.0 109.85 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.94 -51.07 43.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.814 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.7 tp60 -50.28 -53.77 26.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.124 -0.985 . . . . 0.0 109.438 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 45.0 mt -51.27 -39.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 109.27 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.536 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.16 -56.09 24.15 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -57.3 -25.73 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.346 -1.09 . . . . 0.0 109.428 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.466 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -85.38 -30.46 23.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.376 -0.827 . . . . 0.0 109.632 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.465 ' HA ' ' CD2' ' A' ' 73' ' ' LEU . 74.1 t -66.77 -17.11 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -0.936 . . . . 0.0 109.838 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.464 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 40.9 t -90.21 21.09 3.95 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.155 -0.966 . . . . 0.0 109.975 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.464 ' CG ' ' O ' ' A' ' 71' ' ' SER . 10.3 m-70 -157.9 44.12 0.32 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.058 -1.026 . . . . 0.0 109.881 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.465 ' CD2' ' HA ' ' A' ' 70' ' ' VAL . 3.6 mm? -69.82 -44.27 70.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.95 . . . . 0.0 109.413 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -90.13 -22.92 33.75 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.75 103.18 13.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.302 -1.116 . . . . 0.0 109.554 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.09 40.48 1.33 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.62 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.04 19.58 53.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -176.89 -35.11 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.238 -1.154 . . . . 0.0 109.706 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.457 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 21.7 ttp -47.53 -51.1 21.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.18 -0.95 . . . . 0.0 109.81 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 27.1 t -70.53 -21.95 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.511 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.18 -42.94 83.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.207 -0.933 . . . . 0.0 109.285 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -78.98 -48.39 14.56 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.269 -0.894 . . . . 0.0 109.322 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.465 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.6 OUTLIER -57.39 -52.03 66.99 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -0.885 . . . . 0.0 109.27 179.677 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.447 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.12 -34.18 29.72 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 108.909 179.398 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.426 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -71.38 -39.69 71.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.362 -0.836 . . . . 0.0 108.951 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.407 ' O ' ' HG2' ' A' ' 89' ' ' ARG . 53.1 t -61.79 -49.94 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.333 -0.854 . . . . 0.0 109.118 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.468 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -55.16 -38.0 65.8 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 95.6 t -60.08 -18.94 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.3 -1.117 . . . . 0.0 109.447 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.524 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.5 OUTLIER -82.63 -19.04 39.06 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.264 -0.898 . . . . 0.0 109.127 179.7 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.523 ' CD2' HD12 ' A' ' 98' ' ' ILE . 4.0 m80 -89.98 19.3 4.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.409 ' O ' ' HD3' ' A' ' 96' ' ' LYS . 2.4 mtmt -80.44 -59.14 2.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.164 -0.96 . . . . 0.0 110.776 -178.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.41 ' HA2' ' HD3' ' A' ' 96' ' ' LYS . . . -148.51 56.77 0.48 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.524 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -82.46 -103.17 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 110.012 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -102.16 -62.68 0.74 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.51 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 2.0 t30 -68.21 -41.27 81.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.46 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 0.3 OUTLIER 65.66 -57.63 0.32 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.124 0.487 . . . . 0.0 109.852 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.444 ' N ' ' HG3' ' A' ' 96' ' ' LYS . 44.1 m170 -62.93 79.53 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.215 -0.928 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.523 HD12 ' CD2' ' A' ' 90' ' ' HIS . 31.8 mt -109.18 158.85 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 109.233 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.5 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.6 mptp? -140.49 139.61 35.15 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.068 -1.02 . . . . 0.0 110.288 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.469 ' CB ' HG22 ' A' ' 142' ' ' ILE . . . -78.55 -2.63 39.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.835 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -76.1 -26.43 56.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.996 -1.065 . . . . 0.0 109.439 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.514 ' CG ' ' HE1' ' A' ' 41' ' ' MET . 83.9 m-85 -85.24 10.13 13.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.384 -0.823 . . . . 0.0 110.076 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.507 ' CE1' ' HHC' ' A' ' 148' ' ' HEM . 3.3 m-85 -83.35 -61.28 1.89 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 109.671 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.495 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -51.01 -57.57 13.31 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.441 -0.787 . . . . 0.0 110.644 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 5.2 Cg_endo -54.01 -43.76 55.35 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.59 1.311 . . . . 0.0 110.142 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 34' ' ' PHE . 2.5 tm? -64.12 -17.03 63.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.179 -0.951 . . . . 0.0 109.542 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.74 -36.98 12.37 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.29 -59.62 4.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.196 -1.179 . . . . 0.0 109.63 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.7 t -60.29 -18.9 52.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.27 -0.894 . . . . 0.0 109.565 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.519 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 3.2 tt -76.76 -36.57 56.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.253 -0.905 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 11.9 mt -63.85 -28.77 70.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.189 -0.944 . . . . 0.0 109.435 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -34.43 78.2 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.312 -0.868 . . . . 0.0 109.6 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.448 ' CB ' ' OE2' ' A' ' 29' ' ' GLU . . . -75.58 -38.22 59.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.526 ' HG2' ' CZ3' ' A' ' 130' ' ' TRP . 0.0 OUTLIER -47.34 -44.19 23.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.297 -0.877 . . . . 0.0 110.017 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.6 OUTLIER -52.42 -22.08 4.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.307 -0.871 . . . . 0.0 109.962 -179.771 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.411 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 21.1 m170 -56.53 -35.86 68.58 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.146 -0.972 . . . . 0.0 110.247 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.469 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -90.8 -86.86 0.2 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.011 -1.056 . . . . 0.0 110.176 -179.583 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.468 HG13 ' N ' ' A' ' 119' ' ' GLY . 34.9 pt -56.61 -36.31 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.811 -1.18 . . . . 0.0 109.608 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.468 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.77 -98.99 0.01 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.519 -1.033 . . . . 0.0 110.519 179.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.35 -44.77 8.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.441 ' O ' ' N ' ' A' ' 123' ' ' ASN . 44.3 mttt -68.28 -25.77 65.32 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.074 -1.25 . . . . 0.0 110.032 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.457 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.0 OUTLIER -65.52 80.6 0.06 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.982 -1.073 . . . . 0.0 108.845 179.384 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.471 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 12.2 p-10 -82.12 -174.29 5.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.297 -0.877 . . . . 0.0 110.13 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.401 ' O ' ' CG ' ' A' ' 127' ' ' LYS . . . -62.26 -45.31 93.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.376 -0.828 . . . . 0.0 109.897 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.471 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -62.6 -30.93 71.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.146 -0.971 . . . . 0.0 109.575 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.405 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -68.74 -44.76 73.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 109.264 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.475 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 1.6 ptpt -75.19 -29.83 60.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.375 -0.828 . . . . 0.0 109.664 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.475 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 44.2 t0 -79.22 -46.12 18.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.391 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.406 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -57.55 -47.79 81.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.42 -0.8 . . . . 0.0 109.308 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.526 ' CZ3' ' HG2' ' A' ' 114' ' ' MET . 7.3 m0 -71.92 -29.7 64.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.4 -0.812 . . . . 0.0 109.371 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.78 -25.92 68.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.235 -0.916 . . . . 0.0 108.974 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.4 ' O ' ' HB2' ' A' ' 135' ' ' ALA . . . -101.05 -24.95 14.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.421 -0.8 . . . . 0.0 109.169 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.433 ' CB ' HG21 ' A' ' 10' ' ' VAL . . . -67.44 -51.89 46.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.287 -0.883 . . . . 0.0 109.334 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.507 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 21.3 m-85 -52.76 -29.04 25.03 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 109.231 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.4 ' HB2' ' O ' ' A' ' 132' ' ' ALA . . . -60.84 -46.41 90.68 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 108.835 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.82 -44.34 56.04 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 109.169 179.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.466 HG12 ' CB ' ' A' ' 69' ' ' ALA . 18.1 mt -64.3 -57.75 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.256 -0.903 . . . . 0.0 108.93 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.45 ' O ' ' CD1' ' A' ' 142' ' ' ILE . 2.0 p -67.87 -25.74 65.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.217 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.434 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -73.4 -46.59 25.5 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.25 -22.47 66.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -1.122 . . . . 0.0 109.712 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.465 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 8.4 tt -69.22 -33.46 73.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.665 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.469 HG22 ' CB ' ' A' ' 100' ' ' ALA . 3.9 mt -82.9 10.01 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.2 -0.937 . . . . 0.0 110.318 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.447 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 75.7 m -73.97 -22.6 59.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.996 -1.065 . . . . 0.0 108.887 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -127.77 1.42 6.86 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.503 ' O ' ' CB ' ' A' ' 146' ' ' GLN . 0.2 OUTLIER -100.37 129.6 46.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.85 -1.382 . . . . 0.0 110.015 -179.809 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.503 ' CB ' ' O ' ' A' ' 145' ' ' LEU . 1.0 OUTLIER 162.45 44.81 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 178.123 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.446 ' OG ' ' NZ ' ' A' ' 96' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.567 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.509 ' C1A' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.469 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 133' ' ' ALA . 11.9 mt 57.06 165.56 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.159 -1.201 . . . . 0.0 110.128 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.426 ' O ' ' HG2' ' A' ' 7' ' ' ARG . 6.6 p -128.04 -168.66 1.93 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.268 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.51 -16.22 56.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.218 -0.926 . . . . 0.0 110.191 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.41 ' O ' HG22 ' A' ' 9' ' ' VAL . . . -101.03 -36.13 9.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.065 -1.022 . . . . 0.0 109.819 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -68.62 -58.49 4.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.717 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.519 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -50.15 -24.57 2.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.221 -0.924 . . . . 0.0 109.895 -179.773 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.519 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 50.1 tp60 -80.66 -41.39 23.88 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 109.493 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.472 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 67.1 t -62.09 -24.54 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.47 HG12 ' CD1' ' A' ' 130' ' ' TRP . 89.1 t -66.84 -45.05 88.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.39 -0.819 . . . . 0.0 109.661 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.55 -11.35 60.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.296 -0.877 . . . . 0.0 110.193 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 m -92.7 -22.94 19.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.005 -1.06 . . . . 0.0 109.804 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.438 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 19.3 p -96.71 -10.52 26.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.249 -0.907 . . . . 0.0 110.131 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.571 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.74 -20.83 21.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.078 -1.014 . . . . 0.0 109.892 -179.801 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -79.19 -13.04 59.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.947 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -102.27 -47.87 4.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.089 -1.007 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.45 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 34.8 mt -70.81 -31.55 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -0.924 . . . . 0.0 109.745 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.571 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -106.96 33.88 3.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.915 . . . . 0.0 109.716 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.64 -71.82 0.62 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 76.5 p -110.65 -27.91 8.71 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.657 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -79.01 -20.24 49.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 0.0 109.658 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.432 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 27.0 t30 55.67 24.09 6.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.584 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.17 24.57 12.47 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.408 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -66.1 -55.08 18.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -1.137 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.457 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -86.14 11.43 62.91 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 37.8 t -97.99 -29.65 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.115 -1.227 . . . . 0.0 109.338 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.441 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -89.91 -45.16 4.6 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.457 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 11.3 ptpt -56.19 -31.89 63.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.158 -1.201 . . . . 0.0 109.569 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.45 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 24.3 pt-20 -92.3 -16.67 25.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.929 . . . . 0.0 109.722 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.401 ' SG ' ' CB ' ' A' ' 110' ' ' LEU . 36.6 t -85.27 -67.67 0.78 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.205 -0.934 . . . . 0.0 109.809 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.508 ' CZ ' ' O ' ' A' ' 149' ' ' CMO . 10.4 m-85 -48.35 -29.13 3.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.247 -0.908 . . . . 0.0 109.935 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -53.06 -59.06 5.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.201 -0.937 . . . . 0.0 109.488 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 3.9 mttp -55.9 -53.15 60.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.261 -0.899 . . . . 0.0 109.717 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CG ' HD22 ' A' ' 106' ' ' LEU . 8.9 t80 -49.34 -53.09 23.95 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.224 -0.922 . . . . 0.0 109.734 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.512 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 20.1 mt -54.23 -46.35 72.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.229 -0.919 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.08 -59.84 3.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.185 -0.947 . . . . 0.0 109.713 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.425 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -58.24 -23.66 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.669 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.425 ' CD2' ' HB3' ' A' ' 37' ' ' ALA . 22.2 m-70 -120.79 95.83 4.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.688 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.5 m170 -82.76 6.03 19.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.244 -0.91 . . . . 0.0 110.02 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -97.48 -20.38 17.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.099 -1.001 . . . . 0.0 109.523 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.509 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 65.4 mmm -104.85 -19.84 13.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -0.896 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.465 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.08 -35.62 16.49 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 109.43 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.4 -27.54 46.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.304 -0.873 . . . . 0.0 109.099 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.527 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 32.3 t -66.71 -60.74 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.483 ' CD2' HD21 ' A' ' 35' ' ' LEU . 67.4 m-85 -51.29 -28.3 11.64 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.291 -0.881 . . . . 0.0 109.504 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.409 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.3 24.85 4.92 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.538 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 8.7 m-85 -121.86 166.24 14.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 110.066 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.8 t -106.0 -19.78 13.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.422 -0.799 . . . . 0.0 108.892 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.65 -162.5 19.64 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.88 15.5 23.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -1.118 . . . . 0.0 109.798 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 19.5 m -109.18 25.12 12.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.118 -0.989 . . . . 0.0 109.497 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.426 ' OD1' HG23 ' A' ' 55' ' ' VAL . 0.9 OUTLIER -118.87 140.59 28.79 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.33 -0.856 . . . . 0.0 109.543 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -69.55 -13.36 35.09 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.957 1.504 . . . . 0.0 110.509 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.538 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.49 -40.62 39.6 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.512 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 39.2 t -50.05 -45.92 23.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.321 -1.105 . . . . 0.0 109.55 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.456 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -61.8 -16.65 51.65 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.3 -36.64 39.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.915 . . . . 0.0 109.645 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.459 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 11.5 mt -87.07 -60.03 2.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.157 -0.964 . . . . 0.0 109.638 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.441 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -46.9 -48.9 18.35 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.419 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -56.39 -38.58 71.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -1.166 . . . . 0.0 109.695 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -83.86 -29.9 26.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.663 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 38.7 t -71.61 -47.87 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.305 -0.872 . . . . 0.0 109.652 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -48.99 -50.27 36.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 109.656 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.97 -44.97 20.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.363 -0.836 . . . . 0.0 110.017 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 28.8 tp60 -57.72 -52.69 64.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.127 -0.983 . . . . 0.0 109.332 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.459 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 96.1 mt -53.89 -36.65 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.184 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.51 -55.38 27.7 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.31 -23.17 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -1.141 . . . . 0.0 109.17 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.88 -23.24 25.31 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.413 -0.805 . . . . 0.0 109.579 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 53.3 t -72.76 -21.31 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.898 . . . . 0.0 109.757 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.442 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 53.9 m -88.67 39.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.154 -0.966 . . . . 0.0 109.975 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.523 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.2 m-70 -151.13 -62.1 0.18 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.097 -1.002 . . . . 0.0 109.908 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.523 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 4.4 mm? 42.37 -88.89 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.191 0.519 . . . . 0.0 110.638 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -56.45 -30.6 58.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.43 57.32 3.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -1.107 . . . . 0.0 109.537 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -65.41 -23.93 67.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.703 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -60.0 -29.52 68.2 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.496 ' HE3' ' CE1' ' A' ' 72' ' ' HIS . 5.5 ttpp -104.11 -47.35 4.19 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.769 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.442 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 41.4 ttp -49.6 -28.56 5.88 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.408 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 90.6 t -83.26 -17.52 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.593 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.41 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -78.77 -30.6 45.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.578 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.461 ' HG3' ' N ' ' A' ' 83' ' ' MET . 23.9 pt-20 -86.17 -42.65 13.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.669 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.475 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 92.0 mmm -63.93 -35.29 80.17 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.011 -1.056 . . . . 0.0 108.845 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.454 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -52.62 -37.23 57.99 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.029 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -69.06 -27.36 65.56 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -74.88 -46.56 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.816 . . . . 0.0 108.962 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.443 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -63.93 -34.7 90.63 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.454 ' CG2' ' O ' ' A' ' 84' ' ' LYS . 53.3 t -58.9 -37.2 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.356 -1.085 . . . . 0.0 109.206 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 85' ' ' ALA . 17.3 mmm180 -64.76 -31.13 72.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.01 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.542 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 52.5 m80 -77.38 -2.6 35.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.427 -0.796 . . . . 0.0 109.897 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.507 ' CG ' ' CB ' ' A' ' 147' ' ' SER . 6.8 ttmt -98.07 64.38 1.67 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.077 -1.014 . . . . 0.0 109.638 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.416 ' O ' ' O ' ' A' ' 93' ' ' TYR . . . 147.28 2.6 0.5 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.314 -1.422 . . . . 0.0 111.772 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.542 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.8 m-85 -56.13 -167.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.38 -1.659 . . . . 0.0 110.022 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.55 -40.17 13.3 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.527 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 3.7 t30 -59.38 -47.23 86.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.457 -1.025 . . . . 0.0 108.479 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.8 tttt 59.96 13.89 3.97 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.494 -0.754 . . . . 0.0 110.928 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.467 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 14.2 m-70 -131.6 44.08 2.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.046 -1.034 . . . . 0.0 108.923 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.421 HD12 ' HB3' ' A' ' 90' ' ' HIS . 67.8 mt -78.97 154.96 4.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.46 -0.775 . . . . 0.0 110.01 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.467 ' CE ' ' O ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -145.34 148.83 33.83 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.81 0.814 . . . . 0.0 110.084 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.469 ' HB1' ' CD1' ' A' ' 142' ' ' ILE . . . -81.9 -16.99 48.76 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.555 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -60.82 -27.01 67.74 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.002 -1.061 . . . . 0.0 109.208 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.555 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 93.4 m-85 -83.41 -20.23 34.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.18 -0.95 . . . . 0.0 110.246 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.558 ' CD2' ' CMC' ' A' ' 148' ' ' HEM . 5.4 m-85 -59.38 -65.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.101 -0.999 . . . . 0.0 110.206 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -44.42 -60.13 3.21 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 110.872 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' CD ' ' CB ' ' A' ' 104' ' ' GLU . 11.1 Cg_endo -59.7 -26.56 82.56 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 123.827 1.435 . . . . 0.0 110.343 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.518 HD22 ' CG ' ' A' ' 34' ' ' PHE . 2.4 tm? -79.4 -19.18 50.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.113 -0.992 . . . . 0.0 109.444 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.93 -38.7 9.11 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.1 -54.11 48.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -1.171 . . . . 0.0 109.673 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.8 m -57.46 -26.16 60.79 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -0.905 . . . . 0.0 109.598 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.401 ' CB ' ' SG ' ' A' ' 30' ' ' CYS . 8.7 tt -69.41 -39.71 77.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.54 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.5 mt -58.71 -33.37 70.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.222 -0.924 . . . . 0.0 109.643 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.9 t -67.37 -27.92 67.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.18 -0.95 . . . . 0.0 109.66 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -83.28 -36.5 24.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.704 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.478 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 5.2 mmt -49.52 -42.86 44.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 109.864 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -51.99 -22.67 4.18 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.232 -0.918 . . . . 0.0 109.954 -179.72 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.444 ' N ' ' CD2' ' A' ' 116' ' ' HIS . 15.7 m170 -68.59 -22.53 64.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.947 . . . . 0.0 110.004 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.45 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -93.29 -50.03 5.67 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.861 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.466 ' O ' ' N ' ' A' ' 120' ' ' GLY . 13.2 pt -104.42 -36.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.151 -0.968 . . . . 0.0 109.439 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 122' ' ' MET . . . 42.81 -94.27 0.01 OUTLIER Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.67 -42.03 10.22 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.442 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -76.68 -17.38 59.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.04 -1.271 . . . . 0.0 109.697 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.454 ' N ' ' O ' ' A' ' 119' ' ' GLY . 4.8 tpt -72.52 92.48 1.49 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.137 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.412 ' O ' ' HB3' ' A' ' 126' ' ' ALA . 8.3 p-10 -93.5 176.86 6.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 109.826 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.416 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -54.76 -50.1 69.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 109.759 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.433 ' HB3' HG12 ' A' ' 9' ' ' VAL . . . -54.7 -24.7 23.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.242 -0.911 . . . . 0.0 109.715 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.71 -51.24 11.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.956 . . . . 0.0 109.521 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.453 ' O ' ' CB ' ' A' ' 131' ' ' ALA . 19.6 ptpt -71.66 -28.22 63.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.258 -0.901 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.437 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 35.7 t0 -78.89 -38.56 37.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.472 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -69.96 -45.71 66.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.449 -0.782 . . . . 0.0 109.444 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.512 ' O ' ' CD1' ' A' ' 134' ' ' TYR . 6.8 m0 -72.97 -21.82 60.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.366 -0.834 . . . . 0.0 109.295 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.453 ' CB ' ' O ' ' A' ' 127' ' ' LYS . . . -76.22 -23.94 54.61 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.155 -0.966 . . . . 0.0 109.091 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -99.03 -23.4 15.3 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.411 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.44 ' HA ' HD12 ' A' ' 2' ' ' LEU . . . -82.21 -37.35 26.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.39 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.512 ' CD1' ' O ' ' A' ' 130' ' ' TRP . 4.8 m-30 -49.37 -27.87 4.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.285 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.4 -29.5 53.13 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 108.913 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.1 t0 -80.08 -44.2 20.45 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.431 -0.793 . . . . 0.0 109.205 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.453 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.0 mt -65.28 -55.48 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.076 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.69 -41.82 74.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.478 -0.764 . . . . 0.0 109.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.34 -52.17 33.55 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.401 ' HB3' ' HA ' ' A' ' 80' ' ' VAL . . . -53.68 -28.75 35.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -1.175 . . . . 0.0 109.791 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.475 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 9.4 tt -71.47 -10.03 59.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.199 -0.938 . . . . 0.0 110.049 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.469 ' CD1' ' HB1' ' A' ' 100' ' ' ALA . 44.1 mm -91.01 38.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.039 -1.038 . . . . 0.0 109.919 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.402 ' HB3' ' HG2' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -115.52 -28.68 6.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.374 -0.829 . . . . 0.0 109.228 179.671 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.4 20.68 4.93 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.029 -1.629 . . . . 0.0 109.029 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.506 ' CD1' ' CB ' ' A' ' 90' ' ' HIS . 2.6 tt -108.86 15.25 23.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -1.131 . . . . 0.0 109.794 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.461 ' NE2' HD22 ' A' ' 145' ' ' LEU . 7.1 mp0 -113.19 68.73 0.68 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.997 -1.064 . . . . 0.0 109.668 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.507 ' CB ' ' CG ' ' A' ' 91' ' ' LYS . 4.8 p . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.655 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.558 ' CMC' ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.508 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.418 ' CD1' ' HA ' ' A' ' 133' ' ' ALA . 11.7 mt 57.3 163.82 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.396 -1.061 . . . . 0.0 109.833 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.9 p -140.14 -158.33 0.85 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.924 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.07 -35.58 14.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.51 -0.744 . . . . 0.0 109.288 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.13 -21.5 21.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.873 . . . . 0.0 109.392 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -74.78 -48.23 26.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.212 -0.93 . . . . 0.0 109.246 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.418 ' O ' ' HB ' ' A' ' 10' ' ' VAL . 7.7 tmm_? -54.28 -42.93 70.58 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.046 -1.034 . . . . 0.0 108.765 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -52.14 -38.29 57.04 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.18 -0.95 . . . . 0.0 108.603 179.227 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.452 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 44.8 t -72.71 -26.45 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.032 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.444 ' HA ' ' NE1' ' A' ' 130' ' ' TRP . 78.0 t -75.69 -45.68 38.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.515 -0.741 . . . . 0.0 109.153 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.59 -13.06 60.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 0.0 109.748 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 t -92.12 -28.57 17.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.125 -0.985 . . . . 0.0 109.829 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.2 p -90.83 -11.88 38.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.156 -0.965 . . . . 0.0 109.963 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.44 -21.73 21.77 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.073 -1.017 . . . . 0.0 109.532 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.7 mtpp -76.66 -3.61 38.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.226 -0.921 . . . . 0.0 109.679 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -109.51 -55.78 2.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.093 -1.005 . . . . 0.0 109.519 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.429 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 23.6 mt -60.55 -40.51 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.283 -0.886 . . . . 0.0 109.592 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.56 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -97.33 33.33 2.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.694 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.19 -80.04 0.07 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 54.2 p -112.02 12.98 20.7 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.22 -1.165 . . . . 0.0 109.829 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.455 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 10.4 p-10 -119.15 -17.07 9.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.086 -1.009 . . . . 0.0 109.791 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.449 ' OD1' ' CB ' ' A' ' 64' ' ' ALA . 25.3 t-20 55.88 29.26 13.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.671 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.405 ' HA3' ' CG ' ' A' ' 63' ' ' LEU . . . 90.88 23.28 30.72 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.455 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -61.45 -48.52 80.76 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.79 20.15 40.84 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.456 HG13 ' CD1' ' A' ' 63' ' ' LEU . 22.7 t -114.12 -17.69 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -1.123 . . . . 0.0 109.069 179.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.416 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -105.92 -25.57 6.43 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.48 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.3 ptpt -75.91 -33.43 59.9 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.288 -1.125 . . . . 0.0 109.558 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.48 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 1.1 pm0 -94.78 -13.88 25.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.181 -0.95 . . . . 0.0 109.722 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 32.0 t -88.33 -59.81 2.13 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -0.96 . . . . 0.0 109.562 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.518 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.1 m-85 -56.48 -29.17 61.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.153 -0.967 . . . . 0.0 109.533 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.401 HG22 HG12 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -54.66 -60.42 3.38 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.657 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.5 -50.62 62.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.505 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.0 t80 -50.68 -48.2 58.57 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.226 -0.921 . . . . 0.0 109.306 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.459 ' CD2' ' HA ' ' A' ' 42' ' ' ALA . 19.0 mt -58.26 -43.67 88.03 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 55.9 m -67.01 -69.1 0.33 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -0.936 . . . . 0.0 109.877 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.439 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -50.87 -24.19 3.38 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.25 -0.906 . . . . 0.0 109.921 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.482 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 12.3 m-70 -128.17 106.69 9.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.141 -0.974 . . . . 0.0 109.957 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.6 m170 -85.64 -19.76 30.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.558 -0.714 . . . . 0.0 109.283 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -70.55 -16.23 62.85 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.311 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.473 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -101.61 -15.44 17.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.792 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.459 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.84 -66.31 0.55 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.006 . . . . 0.0 109.246 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -53.17 -24.62 11.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.92 . . . . 0.0 109.123 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.527 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 2.5 t -71.37 -56.25 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.515 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.7 m-85 -60.59 -24.96 65.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.335 -0.853 . . . . 0.0 109.528 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.53 26.81 5.75 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CD2' HG22 ' A' ' 55' ' ' VAL . 10.2 m-85 -123.65 168.23 12.93 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.247 -1.149 . . . . 0.0 109.814 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -106.77 -18.16 14.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.24 -175.67 47.58 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.66 -13.55 43.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.853 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.17 44.11 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 55' ' ' VAL . 3.1 m-20 -130.37 123.77 20.74 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.176 -0.952 . . . . 0.0 109.592 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -66.3 -22.94 52.42 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.886 1.466 . . . . 0.0 110.087 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.519 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.99 -29.93 28.97 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.524 HG22 ' CD2' ' A' ' 47' ' ' PHE . 49.0 t -57.69 -42.69 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -1.165 . . . . 0.0 109.476 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.469 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -68.58 -19.53 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.243 -0.91 . . . . 0.0 109.553 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.68 -37.92 24.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.912 . . . . 0.0 109.426 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.519 HD21 ' C1A' ' A' ' 148' ' ' HEM . 1.2 mt -76.0 -65.99 0.84 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.925 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.518 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -47.34 -47.18 22.19 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -57.8 -38.14 75.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -1.171 . . . . 0.0 109.618 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -77.01 -28.42 54.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.918 . . . . 0.0 109.605 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.445 HG21 ' C ' ' A' ' 149' ' ' CMO . 47.8 t -80.45 -41.28 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 109.572 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.456 ' CD1' HG13 ' A' ' 26' ' ' VAL . 0.7 OUTLIER -47.71 -49.96 26.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.903 . . . . 0.0 109.906 179.895 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.449 ' CB ' ' OD1' ' A' ' 22' ' ' ASN . . . -49.38 -50.91 38.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.122 -0.986 . . . . 0.0 109.828 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 34.1 tp60 -49.1 -47.67 45.02 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.07 -1.019 . . . . 0.0 109.34 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.425 HD13 HBC2 ' A' ' 148' ' ' HEM . 24.3 mm -56.51 -45.71 82.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.362 -0.836 . . . . 0.0 108.963 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.524 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -61.46 -51.02 60.57 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.7 t -57.57 -31.36 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -1.065 . . . . 0.0 109.705 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.464 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -82.21 -33.86 29.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.537 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.436 HG11 ' CG1' ' A' ' 10' ' ' VAL . 56.1 t -65.89 -18.95 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -75.05 -15.39 60.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.47 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.4 m-70 -115.46 -88.96 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.784 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.453 ' CD2' ' O ' ' A' ' 69' ' ' ALA . 19.3 mt 63.63 -71.86 0.06 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.425 -0.797 . . . . 0.0 109.975 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -60.35 -28.05 66.52 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -93.78 140.52 29.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -1.111 . . . . 0.0 109.571 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.74 58.11 1.77 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.2 -0.937 . . . . 0.0 109.633 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -138.06 16.97 3.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.401 ' O ' ' N ' ' A' ' 81' ' ' ALA . 17.0 ttpt -168.4 -42.59 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 109.906 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 31.0 ttp -47.98 -38.77 17.66 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.129 -0.982 . . . . 0.0 109.565 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.405 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 38.8 t -76.28 -25.2 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.321 -0.862 . . . . 0.0 109.321 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.401 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -57.28 -44.69 84.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.361 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -83.94 -44.58 14.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.37 -0.831 . . . . 0.0 109.309 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.428 ' SD ' ' CG2' ' A' ' 137' ' ' ILE . 0.0 OUTLIER -58.38 -58.57 7.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.306 179.777 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -52.05 -31.44 30.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.175 -0.953 . . . . 0.0 108.97 179.563 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -66.8 -45.51 78.14 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.36 -0.838 . . . . 0.0 109.023 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.401 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 31.5 t -51.01 -47.68 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.307 -0.871 . . . . 0.0 109.193 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' A' ' 145' ' ' LEU . . . -53.65 -51.39 48.85 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 85.8 t -53.99 -35.34 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.321 -1.105 . . . . 0.0 109.006 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.516 ' HB3' ' CE1' ' A' ' 93' ' ' TYR . 5.4 mmm180 -70.6 -55.1 9.61 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.382 -0.823 . . . . 0.0 109.09 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.469 ' CB ' ' CD1' ' A' ' 145' ' ' LEU . 12.4 m80 -52.31 -29.75 25.0 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.893 . . . . 0.0 108.971 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.458 ' CG ' ' HA ' ' A' ' 147' ' ' SER . 1.6 ttmt -68.0 -9.97 49.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.486 -0.759 . . . . 0.0 110.124 -179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.55 51.36 0.7 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.516 ' CE1' ' HB3' ' A' ' 89' ' ' ARG . 3.2 m-30 -106.41 -167.02 1.24 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.176 -1.191 . . . . 0.0 109.66 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.0 -38.13 93.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.527 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 10.7 t30 -78.96 -44.6 22.11 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.469 -1.018 . . . . 0.0 109.403 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.451 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.8 OUTLIER 71.94 -54.78 0.68 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 179.615 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.445 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 9.1 m170 -48.67 -87.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.097 -1.002 . . . . 0.0 109.944 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.445 ' HB ' ' O ' ' A' ' 97' ' ' HIS . 54.1 mt 59.48 156.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.714 . . . . 0.0 109.938 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.508 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.59 144.15 25.08 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 -179.841 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.41 -8.64 59.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.713 -0.617 . . . . 0.0 109.545 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -75.72 -21.54 57.44 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.101 -0.999 . . . . 0.0 109.375 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.508 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -84.94 -15.32 44.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.304 -0.872 . . . . 0.0 109.853 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.457 ' CE1' ' HHC' ' A' ' 148' ' ' HEM . 3.7 m-85 -63.26 -65.88 0.62 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.207 -0.933 . . . . 0.0 110.248 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.484 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.5 -59.0 3.71 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.516 -0.74 . . . . 0.0 111.087 -179.317 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 4.9 Cg_endo -52.59 -55.79 3.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.671 1.353 . . . . 0.0 110.06 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.505 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -58.66 -21.2 53.52 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.338 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.98 -47.95 17.51 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.74 -53.88 53.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.161 -1.199 . . . . 0.0 109.562 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.8 m -54.98 -25.27 28.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.204 -0.935 . . . . 0.0 109.564 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -64.66 -37.04 86.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.666 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.412 HD21 ' HA ' ' A' ' 127' ' ' LYS . 11.6 mt -64.7 -42.55 95.2 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -65.1 -23.14 67.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.749 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.409 ' HB3' ' OE2' ' A' ' 29' ' ' GLU . . . -85.24 -38.65 18.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.95 . . . . 0.0 109.693 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.541 ' CE ' ' CE3' ' A' ' 130' ' ' TRP . 0.0 OUTLIER -53.16 -44.69 68.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.815 -179.861 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.475 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 12.2 mt-10 -47.47 -28.35 2.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.243 -0.911 . . . . 0.0 109.668 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.464 ' N ' ' CD2' ' A' ' 116' ' ' HIS . 15.7 m170 -57.81 -27.07 62.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -0.997 . . . . 0.0 109.817 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.429 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -90.25 -65.59 1.0 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.252 -0.905 . . . . 0.0 109.871 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.488 HG13 ' N ' ' A' ' 119' ' ' GLY . 41.8 pt -87.51 -37.48 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 109.496 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.488 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 40.91 -93.47 0.01 OUTLIER Glycine 0 N--CA 1.497 2.76 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -42.9 -41.43 4.54 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.456 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 34.6 mmtt -76.23 -28.24 57.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.13 -1.218 . . . . 0.0 109.748 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.464 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -59.21 102.01 0.12 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.173 -0.955 . . . . 0.0 109.317 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.424 ' O ' ' HB2' ' A' ' 126' ' ' ALA . 9.2 p-10 -98.62 -178.7 4.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.244 -0.91 . . . . 0.0 109.772 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.05 -43.27 99.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 109.761 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -65.03 -24.38 67.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.094 -1.004 . . . . 0.0 109.306 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 123' ' ' ASN . . . -72.67 -48.71 36.89 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.325 -0.859 . . . . 0.0 109.432 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.495 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.8 ptpt -73.39 -29.75 62.82 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.258 -0.901 . . . . 0.0 109.671 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.495 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 12.5 t0 -75.15 -38.34 61.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.192 -0.942 . . . . 0.0 109.273 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.452 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -66.63 -43.88 83.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -0.825 . . . . 0.0 109.104 179.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.541 ' CE3' ' CE ' ' A' ' 114' ' ' MET . 11.1 m0 -73.58 -32.75 64.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.312 -0.868 . . . . 0.0 109.192 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.52 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -47.64 -27.68 2.01 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.271 -0.893 . . . . 0.0 109.414 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -108.69 -14.72 14.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.399 -0.813 . . . . 0.0 109.665 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.431 ' CB ' ' HA ' ' A' ' 130' ' ' TRP . . . -73.49 -69.13 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.957 . . . . 0.0 110.153 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.535 ' CD2' ' O ' ' A' ' 130' ' ' TRP . 11.6 p90 -58.31 -20.14 40.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.844 -1.16 . . . . 0.0 109.127 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.423 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -73.61 -40.85 63.51 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.241 -0.912 . . . . 0.0 108.893 179.315 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.63 -30.52 56.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.352 -0.843 . . . . 0.0 109.055 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.464 HG12 ' CB ' ' A' ' 69' ' ' ALA . 58.5 mt -68.28 -59.99 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.401 -0.812 . . . . 0.0 109.151 179.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -57.56 -18.77 21.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.347 -0.846 . . . . 0.0 109.714 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.74 -52.2 21.31 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.47 -25.82 17.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.27 -1.135 . . . . 0.0 109.744 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.407 HD23 ' O ' ' A' ' 141' ' ' LEU . 7.3 tt -74.05 -11.58 60.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -0.912 . . . . 0.0 110.016 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.442 ' CG2' ' O ' ' A' ' 142' ' ' ILE . 98.3 mt -91.53 21.47 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.081 -1.012 . . . . 0.0 109.714 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -109.6 -20.35 12.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.156 -0.965 . . . . 0.0 109.83 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.14 -22.63 3.78 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.469 ' CD1' ' CB ' ' A' ' 90' ' ' HIS . 3.4 tp -62.74 -98.49 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.11 -1.23 . . . . 0.0 109.77 -179.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 47.35 33.56 2.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.945 -1.097 . . . . 0.0 110.121 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.458 ' HA ' ' CG ' ' A' ' 91' ' ' LYS . 3.6 p . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.061 -1.024 . . . . 0.0 109.678 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.519 ' C1A' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.445 ' C ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.411 ' HG ' ' HB3' ' A' ' 73' ' ' LEU . 4.5 mm? -92.07 145.32 24.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.266 -1.138 . . . . 0.0 109.996 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 p -115.95 -166.34 1.13 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.368 -0.832 . . . . 0.0 109.52 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.1 -33.13 59.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.266 -0.896 . . . . 0.0 110.173 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.427 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . -81.02 -47.11 14.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.143 -0.973 . . . . 0.0 110.044 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -60.98 -56.34 22.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.671 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.409 ' HG3' ' HB2' ' A' ' 73' ' ' LEU . 9.7 ttp180 -51.86 -26.22 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.141 -0.975 . . . . 0.0 109.598 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 39.3 tp60 -85.27 -49.35 8.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.435 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 41.5 t -52.05 -28.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.267 -0.896 . . . . 0.0 109.687 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.51 HG12 ' CD1' ' A' ' 130' ' ' TRP . 84.8 t -64.99 -53.68 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.898 . . . . 0.0 109.624 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.83 -17.6 64.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.3 -32.6 38.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.181 -0.949 . . . . 0.0 109.698 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.503 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 41.0 p -94.54 -11.57 29.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.545 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -87.06 -18.09 31.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.047 -1.033 . . . . 0.0 109.873 -179.825 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -85.65 -15.64 41.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.167 -0.958 . . . . 0.0 109.608 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -96.64 -53.83 3.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.51 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.467 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 62.0 mt -68.49 -43.12 84.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.285 -0.884 . . . . 0.0 109.508 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.429 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -100.43 34.99 2.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.375 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.73 -86.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.3 p -106.95 13.59 27.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.238 -1.154 . . . . 0.0 110.066 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.441 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 3.2 p30 -122.59 -9.84 8.41 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.121 -0.987 . . . . 0.0 110.177 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.472 ' O ' ' ND2' ' A' ' 22' ' ' ASN . 6.7 t30 57.06 18.36 3.99 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.271 -0.893 . . . . 0.0 109.584 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.414 ' O ' ' HB ' ' A' ' 26' ' ' VAL . . . 85.76 32.63 17.9 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.731 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.405 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -57.25 -47.81 80.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.189 -1.183 . . . . 0.0 109.18 179.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.43 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -85.72 9.48 68.26 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.414 ' HB ' ' O ' ' A' ' 23' ' ' GLY . 9.2 t -95.48 -39.27 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.135 -1.215 . . . . 0.0 109.353 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.45 ' CA ' HD23 ' A' ' 63' ' ' LEU . . . -81.89 -51.81 4.35 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.45 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.9 ptpt -50.39 -30.97 13.57 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.202 -1.175 . . . . 0.0 109.604 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.45 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.3 pt-20 -89.48 -22.43 22.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.444 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.7 t -86.98 -39.6 15.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.343 -0.848 . . . . 0.0 109.645 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.509 ' CE2' ' O ' ' A' ' 149' ' ' CMO . 10.1 m-85 -75.37 -42.21 54.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.879 . . . . 0.0 109.857 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.405 ' OG1' ' O ' ' A' ' 28' ' ' LYS . 20.4 m -51.69 -49.05 63.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.089 -1.007 . . . . 0.0 109.394 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.9 . . . . 0.0 109.434 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.513 ' CG ' HD22 ' A' ' 106' ' ' LEU . 3.6 t80 -65.09 -46.76 79.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.493 HD21 ' CD2' ' A' ' 45' ' ' PHE . 10.8 mt -59.94 -47.6 85.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.0 t -61.17 -57.78 11.05 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.173 -0.954 . . . . 0.0 109.783 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.91 -27.28 68.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.183 -0.948 . . . . 0.0 109.841 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.453 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 18.8 m-70 -121.93 105.61 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 109.781 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -87.2 -18.96 29.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.378 -0.826 . . . . 0.0 109.405 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -68.85 -19.08 64.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.905 . . . . 0.0 109.509 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.469 ' HE3' ' CMB' ' A' ' 148' ' ' HEM . 73.9 mmm -106.51 -23.61 12.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.288 -0.883 . . . . 0.0 109.712 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.465 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.96 -42.92 39.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.117 -0.989 . . . . 0.0 109.57 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.78 -28.19 60.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.31 -0.868 . . . . 0.0 109.255 179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.521 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 38.0 t -66.37 -49.46 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.332 -0.855 . . . . 0.0 109.424 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 50.6 m-85 -62.06 -30.93 71.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.739 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.19 31.68 2.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.041 -1.623 . . . . 0.0 109.041 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.521 ' CD2' HG22 ' A' ' 55' ' ' VAL . 13.0 m-85 -125.79 173.07 9.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.36 -1.082 . . . . 0.0 109.746 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.61 20.9 13.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.865 . . . . 0.0 109.301 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.54 -161.95 27.35 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.5 29.46 1.72 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -1.134 . . . . 0.0 109.66 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.3 p -125.92 26.79 6.51 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.73 138.43 22.09 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.614 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -69.29 -25.43 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.962 1.507 . . . . 0.0 110.069 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 57' ' ' ASP . . . -57.61 -31.49 63.7 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' CD2' ' A' ' 47' ' ' PHE . 70.2 t -53.85 -34.87 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.269 -1.136 . . . . 0.0 109.532 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.441 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -79.25 -7.48 58.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.316 -0.865 . . . . 0.0 109.856 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.409 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 7.7 m-20 -88.81 -38.77 14.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.72 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.499 HD21 ' C1A' ' A' ' 148' ' ' HEM . 8.9 mt -74.81 -63.63 1.21 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 0.0 109.514 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.419 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -49.77 -34.57 21.99 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.431 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -68.04 -49.62 60.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.235 -1.156 . . . . 0.0 109.467 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -71.69 -44.07 64.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.376 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 83.6 t -55.96 -51.47 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.629 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.0 mm? -46.45 -49.53 18.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.238 -0.913 . . . . 0.0 110.169 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.433 ' HA ' ' OD1' ' A' ' 22' ' ' ASN . . . -54.25 -39.01 66.43 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.089 -1.007 . . . . 0.0 109.907 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 23.5 tp60 -56.74 -39.49 74.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.992 -1.067 . . . . 0.0 108.931 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 89.9 mt -66.98 -34.85 72.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.423 -0.798 . . . . 0.0 108.863 179.354 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.07 -51.34 45.75 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.74 -27.6 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.267 -1.137 . . . . 0.0 108.796 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.412 ' O ' HD23 ' A' ' 73' ' ' LEU . . . -84.7 -27.38 27.07 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.634 -0.666 . . . . 0.0 109.507 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.455 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 40.9 t -58.81 -17.28 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.32 -0.862 . . . . 0.0 109.7 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.441 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 1.2 t -56.15 -43.49 78.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.926 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.441 ' ND1' ' O ' ' A' ' 71' ' ' SER . 33.4 m-70 -138.73 102.73 4.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 0.0 109.979 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.463 ' CD1' HG13 ' A' ' 10' ' ' VAL . 36.1 mt -95.55 -37.15 11.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.28 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.61 -21.11 35.23 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.021 -1.631 . . . . 0.0 109.021 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -81.86 -172.43 3.9 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -1.189 . . . . 0.0 109.694 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -166.12 51.53 0.09 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.515 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -99.48 -54.63 1.07 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 32.1 ttpt -124.33 -31.7 3.26 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.249 -1.148 . . . . 0.0 109.941 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -47.66 -62.96 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.181 -0.949 . . . . 0.0 109.667 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 75.4 t -63.8 -15.56 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.712 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -80.01 -12.95 59.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.124 -0.985 . . . . 0.0 109.875 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -99.44 -48.13 4.89 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.71 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.411 ' HE2' ' O ' ' A' ' 137' ' ' ILE . 97.6 mmm -59.78 -44.91 93.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.152 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.04 -30.55 15.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.209 -0.932 . . . . 0.0 108.786 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -82.45 -36.38 26.63 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.498 -0.751 . . . . 0.0 109.112 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.427 ' CG1' HD11 ' A' ' 141' ' ' LEU . 89.2 t -59.22 -51.59 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.277 -0.889 . . . . 0.0 109.334 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.47 ' N ' ' HG ' ' A' ' 141' ' ' LEU . . . -53.06 -48.65 58.09 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.629 -1.789 . . . . 0.0 108.629 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 91' ' ' LYS . 99.0 t -47.38 -27.94 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.49 -1.006 . . . . 0.0 109.645 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.521 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 17.5 mmt180 -70.27 -42.72 71.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.128 -0.983 . . . . 0.0 108.804 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.456 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 12.3 m80 -65.56 -12.42 52.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.467 ' HD2' ' CB ' ' A' ' 147' ' ' SER . 0.2 OUTLIER -68.1 -13.21 62.03 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.327 -0.858 . . . . 0.0 110.399 -179.667 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.75 58.99 0.38 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.462 -1.352 . . . . 0.0 110.098 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.521 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 3.6 m-30 -92.32 -172.46 3.11 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.158 -1.201 . . . . 0.0 109.241 179.212 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.36 -34.77 90.8 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.507 -1.837 . . . . 0.0 108.507 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.521 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.8 OUTLIER -82.94 -58.94 2.66 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.541 -0.976 . . . . 0.0 108.924 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.483 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 3.0 pttt 79.45 -19.82 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.774 -0.579 . . . . 0.0 111.02 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.406 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 5.7 m170 -92.24 40.64 1.05 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.666 -1.271 . . . . 0.0 109.44 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.448 HD12 ' CD2' ' A' ' 90' ' ' HIS . 65.3 mt -72.77 164.27 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.363 -0.836 . . . . 0.0 109.754 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.434 ' N ' HG23 ' A' ' 98' ' ' ILE . 0.1 OUTLIER -145.07 141.79 29.15 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.349 -0.844 . . . . 0.0 109.889 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.97 5.28 16.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 46.4 mm-40 -83.99 -32.63 24.86 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.99 -1.069 . . . . 0.0 109.463 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.458 ' CB ' HBB2 ' A' ' 148' ' ' HEM . 95.6 m-85 -75.72 -10.73 59.68 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.275 -0.891 . . . . 0.0 109.958 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.532 ' CE1' ' CHC' ' A' ' 148' ' ' HEM . 4.1 m-85 -62.93 -61.31 2.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.157 -0.964 . . . . 0.0 110.176 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.493 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -50.22 -55.58 24.07 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 109.881 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.493 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 32.3 Cg_exo -51.05 -62.68 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 123.712 1.375 . . . . 0.0 109.934 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.513 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -55.75 -24.45 35.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.54 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.74 -45.51 12.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.64 -38.59 87.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -1.188 . . . . 0.0 109.652 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -20.49 64.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.531 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.409 ' O ' ' HG2' ' A' ' 114' ' ' MET . 1.9 tt -74.58 -39.69 62.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.695 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.1 mt -62.73 -30.06 71.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.258 -0.901 . . . . 0.0 109.558 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.7 t -72.53 -25.27 61.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.289 -0.882 . . . . 0.0 109.764 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.471 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.06 -38.76 18.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.244 -0.91 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.516 ' HE3' ' CZ3' ' A' ' 130' ' ' TRP . 5.9 mmt -46.66 -45.07 19.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.33 -0.856 . . . . 0.0 110.055 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -49.21 -25.2 2.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 109.611 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.471 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 26.5 m170 -57.46 -37.43 72.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.574 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.467 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 2.1 ttt85 -83.89 -70.41 0.57 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.699 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.437 HD11 ' CA ' ' A' ' 122' ' ' MET . 14.1 pt -82.44 53.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.173 -0.954 . . . . 0.0 109.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -59.43 123.78 34.4 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.32 -36.81 3.82 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.414 ' O ' ' N ' ' A' ' 123' ' ' ASN . 15.6 mtpt -84.58 -30.73 24.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.27 -1.135 . . . . 0.0 109.399 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.437 ' CA ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -64.37 81.63 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.329 -0.857 . . . . 0.0 109.446 179.776 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.445 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.1 p30 -86.8 -168.68 2.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.754 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.446 ' O ' ' CB ' ' A' ' 128' ' ' ASP . . . -64.3 -46.21 84.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.489 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.462 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -57.28 -24.38 54.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.276 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.48 -58.36 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.415 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 0.2 OUTLIER -68.49 -25.85 65.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.588 -179.823 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 124' ' ' ALA . 25.0 t70 -80.75 -39.71 26.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.543 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.93 -41.82 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.848 . . . . 0.0 109.279 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.516 ' CZ3' ' HE3' ' A' ' 114' ' ' MET . 3.8 m0 -73.74 -24.52 59.9 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.163 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.04 -24.52 59.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.192 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.58 -40.58 12.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.858 . . . . 0.0 109.458 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.418 ' HB3' HD12 ' A' ' 73' ' ' LEU . . . -70.97 -45.58 63.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.399 -0.813 . . . . 0.0 109.537 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.45 ' OH ' ' CE ' ' A' ' 114' ' ' MET . 3.2 m-85 -50.08 -32.15 14.93 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.908 . . . . 0.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.88 -37.11 70.21 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.19 -0.944 . . . . 0.0 108.866 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.17 -33.0 44.42 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.38 -0.825 . . . . 0.0 109.231 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.411 ' O ' ' HE2' ' A' ' 83' ' ' MET . 24.9 mt -65.77 -60.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.334 -0.854 . . . . 0.0 108.833 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.41 ' O ' HG13 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -66.93 -37.39 84.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.589 -0.694 . . . . 0.0 109.669 -179.775 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.44 -44.9 59.16 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.31 -18.36 64.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.21 -1.171 . . . . 0.0 109.82 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.47 ' HG ' ' N ' ' A' ' 87' ' ' GLY . 6.7 tt -87.73 -23.77 24.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 109.78 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.41 HG13 ' O ' ' A' ' 138' ' ' SER . 50.9 mt -82.68 8.03 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 0.0 110.275 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -86.95 -35.92 18.61 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.008 -1.058 . . . . 0.0 109.502 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.402 ' HA3' HG22 ' A' ' 88' ' ' VAL . . . -104.43 5.85 45.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.467 ' CD2' ' HG3' ' A' ' 146' ' ' GLN . 1.5 tt -91.84 -175.59 4.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.075 -1.25 . . . . 0.0 109.19 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.467 ' HG3' ' CD2' ' A' ' 145' ' ' LEU . 17.6 mt-30 56.48 83.93 0.09 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.142 -0.974 . . . . 0.0 110.12 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.467 ' CB ' ' HD2' ' A' ' 91' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.63 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.532 ' CHC' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.509 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.9 mt -94.67 159.45 15.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -1.142 . . . . 0.0 109.639 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.403 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 1.2 p -133.25 -179.2 5.36 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.641 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -75.49 -28.4 59.19 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.647 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.61 -24.61 29.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.904 . . . . 0.0 109.584 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.403 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 29.9 mt-30 -84.98 -46.21 11.44 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.218 -0.926 . . . . 0.0 109.735 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.445 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 4.3 ptm180 -51.7 -32.06 28.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.445 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 5.5 mm100 -70.2 -47.62 60.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.215 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 80.9 t -56.44 -30.75 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.285 -0.884 . . . . 0.0 109.176 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.405 HG12 ' CD1' ' A' ' 130' ' ' TRP . 83.1 t -64.14 -55.02 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -0.836 . . . . 0.0 109.221 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.9 -14.04 62.64 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.613 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.5 m -84.44 -27.18 27.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.15 -0.969 . . . . 0.0 109.724 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.503 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 25.3 p -98.94 -7.2 27.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.152 -0.967 . . . . 0.0 109.69 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.545 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -89.27 -21.48 23.18 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.151 -0.968 . . . . 0.0 109.646 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.3 mtpm? -79.31 2.31 21.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 110.092 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -116.45 -54.4 2.46 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.06 -1.025 . . . . 0.0 109.525 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.441 HG12 ' HB3' ' A' ' 117' ' ' ARG . 43.2 mt -66.49 -32.25 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.292 -0.88 . . . . 0.0 109.518 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.483 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.92 35.39 2.92 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.713 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.7 -81.57 0.05 OUTLIER Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 p -108.78 -34.86 6.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -1.128 . . . . 0.0 109.58 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.429 ' OD1' ' N ' ' A' ' 22' ' ' ASN . 37.8 p30 -75.91 -15.05 60.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.909 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.429 ' N ' ' OD1' ' A' ' 21' ' ' ASP . 24.8 t30 63.18 16.0 9.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.147 -0.971 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.412 ' O ' ' HB ' ' A' ' 26' ' ' VAL . . . 100.11 17.36 25.21 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.404 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -50.07 -36.81 30.76 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.094 -1.239 . . . . 0.0 109.774 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.446 ' HA2' ' CE ' ' A' ' 28' ' ' LYS . . . -92.97 13.61 67.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.412 ' HB ' ' O ' ' A' ' 23' ' ' GLY . 54.5 t -95.4 -28.3 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.045 -1.268 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.425 ' HA3' ' O ' ' A' ' 59' ' ' GLY . . . -91.47 -44.52 4.28 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.471 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 10.8 ptpt -51.61 -33.66 34.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.195 -1.179 . . . . 0.0 109.089 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.457 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 19.0 pt-20 -91.44 -29.41 17.05 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.218 -0.926 . . . . 0.0 109.243 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.419 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 18.0 t -84.83 -68.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 110.065 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.532 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 22.1 m-85 -45.94 -32.6 2.8 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.564 -178.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.412 ' HA ' HG12 ' A' ' 55' ' ' VAL . 5.6 m -59.04 -52.16 66.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.929 -1.107 . . . . 0.0 109.124 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.409 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 36.3 mttt -55.44 -48.21 74.8 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.069 -1.019 . . . . 0.0 109.311 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.509 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.9 t80 -54.83 -54.48 41.74 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.31 -0.869 . . . . 0.0 109.336 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.469 ' CD1' HG22 ' A' ' 55' ' ' VAL . 46.0 mt -55.39 -43.29 75.05 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.64 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -68.17 0.37 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.679 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.406 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -53.37 -30.09 37.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.214 -0.929 . . . . 0.0 109.626 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.497 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 10.8 m-70 -115.2 99.84 7.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.754 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 24.7 m170 -82.3 -14.4 55.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.453 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -74.21 -13.78 60.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.152 -0.968 . . . . 0.0 109.62 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.509 ' HE2' ' CG ' ' A' ' 102' ' ' TYR . 2.6 mmt -104.83 -27.34 11.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.13 -0.981 . . . . 0.0 109.91 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.45 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.24 -41.53 27.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.037 -1.039 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.43 -26.02 59.81 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -0.85 . . . . 0.0 108.782 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.532 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 2.9 t -72.61 -47.34 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.525 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 25.0 m-85 -65.61 -32.74 74.49 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.874 . . . . 0.0 109.47 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.14 27.94 3.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.525 ' CD2' HG22 ' A' ' 55' ' ' VAL . 8.6 m-85 -123.21 172.95 8.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.21 -1.17 . . . . 0.0 109.828 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.56 19.51 16.78 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.371 -0.83 . . . . 0.0 109.215 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 151.83 -163.8 30.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -98.74 36.24 1.7 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -1.171 . . . . 0.0 109.704 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 67.3 p -147.46 28.94 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.613 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 54' ' ' GLY . 0.4 OUTLIER -108.15 143.62 27.76 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.639 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -65.95 70.27 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.998 1.525 . . . . 0.0 110.059 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.523 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -155.19 -43.56 0.02 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 47' ' ' PHE . 61.6 t -53.0 -40.1 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.357 -1.084 . . . . 0.0 109.496 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.471 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -63.93 -20.31 65.76 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.487 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.55 -57.76 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.301 -0.875 . . . . 0.0 109.236 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.513 HD21 ' C1A' ' A' ' 148' ' ' HEM . 0.4 OUTLIER -57.56 -63.3 1.28 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.462 -0.774 . . . . 0.0 110.28 -179.85 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.532 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -54.59 -21.7 22.24 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -83.94 -6.12 59.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.126 -1.22 . . . . 0.0 110.684 -179.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 56.9 mttt -113.19 -12.3 13.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.972 -1.08 . . . . 0.0 110.002 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.437 HG21 ' C ' ' A' ' 149' ' ' CMO . 93.4 t -83.2 -25.65 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.099 -1.001 . . . . 0.0 110.68 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.531 ' N ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -70.28 -4.8 23.66 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.706 -1.246 . . . . 0.0 110.697 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.479 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -85.16 -42.45 14.72 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.834 -1.166 . . . . 0.0 109.559 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.8 mm-40 -56.57 -47.99 78.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.107 -0.996 . . . . 0.0 108.807 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.46 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 80.1 mt -57.32 -34.69 46.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.85 -57.26 12.66 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.1 t -57.33 -23.7 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.267 -1.137 . . . . 0.0 109.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.408 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -86.71 -27.88 23.43 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.447 -0.783 . . . . 0.0 109.582 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.46 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 54.5 t -70.46 -12.39 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.181 -0.949 . . . . 0.0 109.826 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.0 t -82.58 6.63 17.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.033 . . . . 0.0 110.061 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' GLY . 23.9 m-70 -140.08 -88.88 0.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.004 -1.06 . . . . 0.0 109.685 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.428 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 29.8 mt 62.29 -74.23 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.468 -0.77 . . . . 0.0 109.823 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.488 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.77 -30.69 44.62 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -101.68 91.51 4.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -1.083 . . . . 0.0 109.443 179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -89.76 42.92 1.12 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.646 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -113.6 -17.43 7.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 8.4 ttmt -134.53 -41.19 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.15 -1.206 . . . . 0.0 109.894 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.467 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 17.2 tmm? -48.91 -42.71 37.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.955 . . . . 0.0 109.741 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 69.3 t -71.04 -20.27 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.63 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.29 74.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.712 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -76.7 -53.45 7.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.574 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.403 ' HA ' HG23 ' A' ' 86' ' ' VAL . 2.8 mtp -53.31 -41.07 65.28 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.201 -0.937 . . . . 0.0 109.435 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.442 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 0.7 OUTLIER -52.17 -31.88 33.43 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.175 -0.953 . . . . 0.0 108.723 179.24 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.432 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -71.3 -36.75 71.74 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.482 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 45.5 t -56.89 -51.75 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.199 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -51.8 -46.75 54.38 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.856 -1.698 . . . . 0.0 108.856 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 60.8 t -50.41 -25.75 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -1.173 . . . . 0.0 109.292 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.474 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 0.2 OUTLIER -81.3 -53.3 6.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.325 -0.859 . . . . 0.0 108.743 179.352 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.512 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 21.1 m80 -54.72 -21.91 12.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.053 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.465 ' CD ' ' HA ' ' A' ' 147' ' ' SER . 34.0 ttpt -67.69 -12.93 61.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.448 -0.782 . . . . 0.0 110.243 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.07 55.58 0.55 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.512 ' OH ' ' CE1' ' A' ' 90' ' ' HIS . 3.8 m-30 -89.59 -100.23 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.322 -1.105 . . . . 0.0 109.645 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.44 -50.05 0.02 OUTLIER Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.066 -2.013 . . . . 0.0 108.066 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.532 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.8 p-10 -67.17 -30.44 70.41 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.489 -1.006 . . . . 0.0 108.521 178.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 43.5 mttt 51.98 22.24 1.75 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.636 -0.665 . . . . 0.0 109.805 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.2 m170 -128.64 49.48 2.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.338 -0.851 . . . . 0.0 109.149 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.474 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 76.3 mt -84.93 158.74 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.857 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.489 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -142.02 144.91 33.87 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.356 -0.84 . . . . 0.0 109.983 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.405 ' HB1' HD11 ' A' ' 142' ' ' ILE . . . -80.98 -15.86 55.07 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.679 -0.638 . . . . 0.0 109.36 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 54.3 mm-40 -67.86 -22.38 65.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.128 -0.983 . . . . 0.0 109.471 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.509 ' CG ' ' HE2' ' A' ' 41' ' ' MET . 57.2 m-85 -86.32 -26.39 24.93 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 109.79 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.514 ' CE1' ' HHC' ' A' ' 148' ' ' HEM . 3.7 m-85 -51.28 -59.06 4.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.23 -0.919 . . . . 0.0 110.281 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.491 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -54.65 -58.78 12.67 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.203 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.491 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.4 Cg_exo -48.25 -53.13 7.18 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 O-C-N 123.639 1.337 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.509 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.2 tm? -59.48 -18.0 36.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -0.941 . . . . 0.0 109.858 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.41 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -83.99 -42.56 7.56 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.71 -57.78 9.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.078 -1.248 . . . . 0.0 109.684 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.5 t -60.66 -16.25 37.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.778 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.517 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 3.2 tt -78.53 -36.42 44.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.075 -1.016 . . . . 0.0 109.715 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.437 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.9 mt -64.36 -28.78 69.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.069 -1.019 . . . . 0.0 109.423 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 14.1 t -66.63 -35.22 79.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.699 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.494 ' HA ' ' CD2' ' A' ' 116' ' ' HIS . . . -80.29 -31.63 38.22 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.655 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.533 ' HG2' ' CZ3' ' A' ' 130' ' ' TRP . 0.0 OUTLIER -47.35 -38.09 12.34 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.019 -179.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.471 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.9 OUTLIER -62.65 -14.0 38.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.074 -1.017 . . . . 0.0 109.705 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.494 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.9 m170 -53.9 -37.54 63.88 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.911 -1.118 . . . . 0.0 109.443 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.441 ' HB3' HG12 ' A' ' 17' ' ' ILE . 1.1 ttt85 -89.81 -51.62 5.4 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.2 -0.938 . . . . 0.0 109.82 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.407 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 2.8 pt -110.04 48.73 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.161 -0.962 . . . . 0.0 109.897 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -59.57 -18.29 44.08 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.17 -30.61 9.14 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.407 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.7 mtpp -94.47 -25.81 16.73 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.164 -1.198 . . . . 0.0 109.537 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 1.8 tpt -61.09 96.73 0.05 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.889 . . . . 0.0 109.431 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 125' ' ' ALA . 8.0 p30 -106.14 -162.54 0.87 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.744 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -67.08 -46.25 74.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.355 -0.841 . . . . 0.0 110.134 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.419 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -63.58 -21.55 66.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.074 -1.016 . . . . 0.0 109.779 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.4 -47.15 14.83 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.177 -0.952 . . . . 0.0 109.563 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.44 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.6 ptpt -74.02 -30.68 62.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -0.891 . . . . 0.0 109.685 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.44 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -73.94 -53.34 10.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.93 . . . . 0.0 109.738 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -55.09 -43.41 73.97 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.35 -0.844 . . . . 0.0 109.71 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.533 ' CZ3' ' HG2' ' A' ' 114' ' ' MET . 7.5 m0 -76.09 -27.15 57.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.245 -0.909 . . . . 0.0 109.565 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.26 -30.42 68.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.169 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.78 -26.39 21.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.38 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -82.06 -48.38 11.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.501 ' CE2' ' HE1' ' A' ' 114' ' ' MET . 9.1 m-30 -52.42 -31.01 32.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.293 -0.88 . . . . 0.0 109.337 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.75 -46.39 63.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -0.875 . . . . 0.0 109.219 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -73.91 -30.53 62.64 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.312 -0.867 . . . . 0.0 109.221 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.404 HG23 HG12 ' A' ' 66' ' ' ILE . 59.4 mt -67.98 -60.78 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.314 -0.866 . . . . 0.0 108.973 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 3.6 m -66.96 -31.47 72.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.487 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.16 -38.41 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.17 -23.74 66.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -1.141 . . . . 0.0 109.528 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.482 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 10.0 tt -76.34 -2.39 31.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 110.116 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' A' ' 142' ' ' ILE . 40.6 mm -92.15 31.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.961 -1.087 . . . . 0.0 109.902 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.442 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -108.73 -34.23 6.75 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.283 -0.885 . . . . 0.0 109.381 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.79 21.89 7.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.421 HD12 ' HB3' ' A' ' 90' ' ' HIS . 14.3 tp -100.89 2.39 40.86 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.345 -1.091 . . . . 0.0 110.004 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 5.2 mp0 -111.25 67.2 0.64 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.85 -1.156 . . . . 0.0 109.836 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.465 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 3.4 m . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.661 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.514 ' HHC' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.509 ' O ' ' CE1' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.467 HD12 ' CB ' ' A' ' 133' ' ' ALA . 65.4 mt -74.93 -168.48 0.75 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -1.149 . . . . 0.0 109.485 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.411 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 0.7 OUTLIER -93.63 172.61 8.15 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.216 -0.928 . . . . 0.0 109.6 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -71.16 -19.2 62.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.51 -32.85 13.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.166 -0.959 . . . . 0.0 109.683 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.411 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 57.8 mt-30 -71.24 -55.45 8.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.708 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.438 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 2.8 ptm180 -50.92 -32.36 20.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.447 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.438 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 9.4 tp-100 -70.29 -39.01 75.13 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.294 -0.879 . . . . 0.0 109.349 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.4 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 22.0 t -69.38 -27.63 35.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.453 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.487 HG12 ' CD1' ' A' ' 130' ' ' TRP . 97.2 t -71.95 -37.96 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.596 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.98 -14.75 60.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.855 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 t -90.87 -25.62 19.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.429 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 19.7 p -93.56 -12.41 29.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 109.952 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.21 -24.31 21.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.084 -1.01 . . . . 0.0 109.788 -179.842 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -75.23 -8.37 56.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -103.7 -54.06 2.65 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.085 -1.009 . . . . 0.0 109.68 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.466 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 46.4 mt -65.79 -36.67 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.246 -0.909 . . . . 0.0 109.712 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.564 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.69 33.56 3.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.778 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.09 -66.98 2.36 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 88.3 p -115.61 -19.64 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -1.134 . . . . 0.0 109.558 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.466 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 7.5 p-10 -87.17 -19.08 28.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.894 . . . . 0.0 109.654 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.459 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 26.2 t30 58.57 22.89 10.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.05 23.69 10.4 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.466 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -70.45 -43.43 69.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -1.159 . . . . 0.0 109.603 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.408 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -88.39 14.46 59.44 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.466 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 44.0 t -108.64 -26.15 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -1.228 . . . . 0.0 109.317 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -97.36 -36.86 4.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.463 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.0 ptpt -66.41 -29.07 69.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.176 -1.191 . . . . 0.0 109.554 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.463 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 13.1 pt-20 -93.86 -20.34 20.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -0.935 . . . . 0.0 109.675 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.0 t -88.25 -59.86 2.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.234 -0.916 . . . . 0.0 109.866 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.508 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.8 m-85 -54.48 -30.11 52.16 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 109.81 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.463 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.0 OUTLIER -55.32 -58.47 7.57 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.162 -0.961 . . . . 0.0 109.336 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -54.31 -45.29 72.55 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.878 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.505 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.0 t80 -56.36 -59.09 5.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.962 . . . . 0.0 109.286 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.468 HD11 ' CG2' ' A' ' 55' ' ' VAL . 26.6 mt -51.15 -43.71 61.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 109.632 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.456 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 2.6 t -68.82 -71.27 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.911 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.464 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -49.52 -29.89 7.52 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.888 . . . . 0.0 109.787 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.489 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 12.9 m-70 -117.85 107.49 14.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.266 -0.896 . . . . 0.0 109.944 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -86.59 -25.4 24.98 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.475 -0.765 . . . . 0.0 108.967 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -66.97 -21.62 65.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.229 -0.919 . . . . 0.0 108.931 179.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.494 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -94.99 -27.63 15.55 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.413 -0.805 . . . . 0.0 109.55 179.846 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.441 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.06 -45.0 64.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.064 -1.023 . . . . 0.0 109.248 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.4 84.51 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.341 -0.849 . . . . 0.0 109.184 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.501 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 52.7 t -62.96 -60.24 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.31 -0.868 . . . . 0.0 109.156 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.526 ' CE1' ' C1B' ' A' ' 148' ' ' HEM . 62.0 m-85 -61.54 -31.97 72.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.192 -0.942 . . . . 0.0 109.009 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.06 -138.59 15.08 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.523 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 2.0 m-85 61.64 162.6 0.07 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.211 -1.17 . . . . 0.0 109.915 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 32.2 t -106.71 23.36 14.42 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.42 -161.06 31.45 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.456 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -92.32 -21.4 20.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.711 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.6 p -90.8 56.89 3.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.147 -0.97 . . . . 0.0 109.669 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.468 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -120.1 139.99 29.23 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.208 -0.933 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -62.11 -31.59 83.28 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.98 1.516 . . . . 0.0 110.067 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.523 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -37.25 40.04 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.468 ' CG2' HD11 ' A' ' 35' ' ' LEU . 93.4 t -50.2 -37.49 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -1.103 . . . . 0.0 109.445 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -75.65 -21.47 57.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.881 . . . . 0.0 109.299 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.403 ' O ' ' HB2' ' A' ' 61' ' ' LYS . 6.0 t70 -81.41 -40.03 24.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.486 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.512 HD21 ' C1A' ' A' ' 148' ' ' HEM . 1.6 mt -74.93 -59.59 2.67 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.508 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.5 -48.48 42.05 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.448 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -59.59 -48.41 81.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -1.106 . . . . 0.0 109.468 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.403 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 12.4 mttt -62.93 -33.24 74.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.883 . . . . 0.0 109.461 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.429 HG21 ' C1D' ' A' ' 148' ' ' HEM . 55.1 t -75.08 -49.47 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.323 -0.861 . . . . 0.0 109.527 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.439 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.0 mm? -48.68 -46.23 40.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.14 -49.31 32.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.785 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -53.72 -51.58 62.84 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.277 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.463 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 61.0 mt -53.91 -39.21 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.339 -0.85 . . . . 0.0 109.131 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.525 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -59.52 -54.5 37.19 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -60.19 -29.98 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -1.147 . . . . 0.0 109.268 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.56 -5.58 59.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.406 -0.809 . . . . 0.0 109.989 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.463 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 42.2 t -90.56 -16.37 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.99 -1.069 . . . . 0.0 109.954 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.27 16.52 5.16 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.157 -0.964 . . . . 0.0 110.101 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.524 ' CD2' ' HA3' ' A' ' 77' ' ' GLY . 36.6 m-70 -137.8 -86.59 0.28 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.305 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.417 HD11 ' CD1' ' A' ' 2' ' ' LEU . 68.1 mt 45.35 34.47 1.52 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.302 -0.873 . . . . 0.0 110.035 179.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -165.4 -47.73 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -107.96 -175.0 2.66 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.59 -0.947 . . . . 0.0 108.862 179.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -72.96 -42.99 62.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.025 -1.047 . . . . 0.0 108.789 179.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.524 ' HA3' ' CD2' ' A' ' 72' ' ' HIS . . . 44.9 26.34 1.16 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 28.5 ttmt 50.25 20.56 0.66 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.242 -1.152 . . . . 0.0 110.134 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.35 -28.18 15.69 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.999 -1.063 . . . . 0.0 108.593 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 24.3 t -75.83 -22.87 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.599 -0.84 . . . . 0.0 109.117 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.17 -22.2 27.13 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.24 -0.912 . . . . 0.0 109.137 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -90.98 -37.55 13.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.339 -0.851 . . . . 0.0 109.541 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.46 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.0 OUTLIER -67.11 -51.8 49.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.124 -0.985 . . . . 0.0 109.07 179.667 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.79 -31.33 66.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.258 -0.901 . . . . 0.0 108.752 179.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -67.33 -42.6 83.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 109.006 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.411 ' HB ' ' HG ' ' A' ' 141' ' ' LEU . 21.8 t -53.83 -44.62 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 108.83 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.426 ' HA2' HD11 ' A' ' 145' ' ' LEU . . . -58.98 -51.46 59.1 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.426 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 55.1 t -58.22 -23.08 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.341 -1.094 . . . . 0.0 109.023 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -86.64 -50.06 7.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.391 -0.818 . . . . 0.0 109.074 179.713 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.472 ' HB3' ' CD1' ' A' ' 98' ' ' ILE . 2.9 m80 -48.42 -44.55 35.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.755 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.426 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -58.94 -17.94 29.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.179 -0.951 . . . . 0.0 109.822 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.25 37.86 3.39 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.533 ' CD2' ' CBA' ' A' ' 148' ' ' HEM . 3.2 m-30 -93.76 -166.01 1.43 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -1.107 . . . . 0.0 109.519 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.51 -33.86 24.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.501 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 2.2 t30 -69.41 -59.0 3.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.486 -1.008 . . . . 0.0 109.299 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 76.13 -12.97 0.95 Allowed 'General case' 0 N--CA 1.507 2.42 0 O-C-N 121.572 -0.705 . . . . 0.0 111.491 179.589 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.3 m170 -99.78 41.94 1.13 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.633 -1.292 . . . . 0.0 109.018 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.472 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 57.3 mt -76.07 152.35 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.404 -0.81 . . . . 0.0 110.46 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.441 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 8.5 mttp -142.2 138.9 31.83 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 121.661 0.743 . . . . 0.0 109.809 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.47 ' HB1' ' CG2' ' A' ' 142' ' ' ILE . . . -75.42 -6.8 51.91 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.713 -0.617 . . . . 0.0 109.511 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 6.0 pt-20 -74.12 -26.63 60.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.09 -1.006 . . . . 0.0 109.301 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.494 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 33.3 m-85 -81.63 -21.25 38.35 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.865 . . . . 0.0 109.724 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.486 ' CE1' ' HHC' ' A' ' 148' ' ' HEM . 3.3 m-85 -55.84 -63.0 1.32 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.334 -0.854 . . . . 0.0 110.289 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.5 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.7 mt-10 -48.91 -57.82 10.25 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.165 -0.959 . . . . 0.0 110.129 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.5 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -49.62 -63.18 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.632 1.333 . . . . 0.0 110.05 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.505 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.0 tm? -55.1 -24.9 27.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.292 -0.88 . . . . 0.0 109.43 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.1 -48.74 5.9 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.85 95.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.124 -1.221 . . . . 0.0 109.646 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 58.4 m -65.33 -19.14 65.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 0.0 109.606 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 106' ' ' LEU . 1.5 tt -73.89 -38.78 64.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.617 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 11.9 mt -60.53 -35.75 76.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 109.619 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 9.3 t -65.13 -33.83 76.95 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.666 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -81.16 -35.11 31.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.206 -0.934 . . . . 0.0 109.794 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.491 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 0.6 OUTLIER -54.71 -28.85 50.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.812 -179.867 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.45 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -68.48 -13.88 62.62 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.253 -0.904 . . . . 0.0 109.244 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.407 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 24.2 m170 -65.56 -45.18 84.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.085 -1.009 . . . . 0.0 109.772 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.412 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -74.54 -47.95 29.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.459 HG12 ' CG1' ' A' ' 17' ' ' ILE . 4.5 pt -114.32 54.99 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.274 -0.891 . . . . 0.0 109.633 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -66.27 -18.18 66.98 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -97.63 -26.35 9.97 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.412 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.5 mmtt -96.14 -25.43 15.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.262 -1.14 . . . . 0.0 109.621 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.403 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -64.23 104.67 0.78 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.25 -0.906 . . . . 0.0 109.545 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.478 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 5.0 p-10 -106.29 -171.08 1.83 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.379 -0.825 . . . . 0.0 109.537 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.99 -55.31 26.89 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.844 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.478 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -54.23 -26.54 29.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.132 -0.98 . . . . 0.0 109.439 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -71.45 -54.59 10.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -0.973 . . . . 0.0 109.359 179.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.446 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 18.3 ptpt -70.04 -25.2 63.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.346 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.446 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.6 t0 -81.71 -34.56 30.52 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -0.853 . . . . 0.0 109.326 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.4 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.21 -41.47 63.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.353 -0.842 . . . . 0.0 109.371 179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.491 ' CE3' ' SD ' ' A' ' 114' ' ' MET . 8.5 m0 -75.47 -24.38 56.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 109.242 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.88 -29.4 64.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.405 ' O ' HD23 ' A' ' 2' ' ' LEU . . . -89.26 -34.32 16.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.467 ' CB ' HD12 ' A' ' 2' ' ' LEU . . . -70.66 -43.49 69.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.373 -0.829 . . . . 0.0 109.393 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.457 ' OH ' ' CE ' ' A' ' 114' ' ' MET . 3.1 m-85 -52.02 -28.89 18.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.4 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.63 -31.15 59.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.318 -0.864 . . . . 0.0 109.458 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.18 -39.67 22.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.472 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.41 ' CG2' ' SD ' ' A' ' 83' ' ' MET . 76.0 mt -66.38 -57.56 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.255 -0.903 . . . . 0.0 109.35 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.404 ' O ' HG13 ' A' ' 142' ' ' ILE . 1.5 p -68.65 -27.1 65.69 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.857 . . . . 0.0 109.653 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.409 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -65.28 -53.59 31.94 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.06 -16.46 31.6 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.248 -1.148 . . . . 0.0 109.859 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.46 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 8.1 tt -89.89 -39.18 13.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.836 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.47 ' CG2' ' HB1' ' A' ' 100' ' ' ALA . 11.2 mt -66.09 -11.17 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.135 -0.978 . . . . 0.0 110.002 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.02 -59.35 4.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.091 -1.006 . . . . 0.0 109.228 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.414 ' CA ' HG22 ' A' ' 88' ' ' VAL . . . -82.09 4.25 76.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.454 ' HG ' ' N ' ' A' ' 146' ' ' GLN . 51.7 tp -82.94 171.35 13.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.004 -1.292 . . . . 0.0 109.382 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.454 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 57.91 71.7 0.56 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.294 -0.879 . . . . 0.0 109.608 -179.724 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.405 ' HB2' ' CG ' ' A' ' 91' ' ' LYS . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.613 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.533 ' CBA' ' CD2' ' A' ' 93' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.5 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.412 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.9 mt -149.69 158.77 44.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.15 -1.206 . . . . 0.0 109.456 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.6 p -134.58 -171.82 2.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.264 -0.898 . . . . 0.0 109.621 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.98 -20.06 50.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.935 . . . . 0.0 109.557 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.31 -32.12 18.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.227 -0.921 . . . . 0.0 109.581 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 21.9 mt-30 -81.7 -53.03 6.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.182 -0.949 . . . . 0.0 109.819 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.27 -27.96 10.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.149 -0.969 . . . . 0.0 109.606 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -77.45 -44.27 29.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.89 . . . . 0.0 109.284 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.46 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 46.3 t -62.98 -25.06 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.293 -0.88 . . . . 0.0 109.184 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.458 ' CG1' HG11 ' A' ' 70' ' ' VAL . 86.5 t -72.56 -46.93 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.416 -0.802 . . . . 0.0 109.358 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.68 -11.33 60.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.331 -0.856 . . . . 0.0 109.854 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.6 m -91.63 -21.23 20.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 109.694 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.1 p -101.87 -9.26 20.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.27 -0.894 . . . . 0.0 109.963 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.553 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.63 -19.9 23.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.097 -1.002 . . . . 0.0 109.771 -179.857 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -81.62 -10.7 59.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.223 -0.923 . . . . 0.0 109.933 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.62 -54.44 2.58 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.062 -1.024 . . . . 0.0 109.656 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.445 ' CG1' HG12 ' A' ' 118' ' ' ILE . 59.5 mt -66.04 -35.38 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 0.0 109.623 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.553 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -104.45 31.1 4.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.668 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.28 -70.46 0.95 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.8 p -107.5 -37.13 6.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.215 -1.167 . . . . 0.0 109.751 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -72.42 -19.73 61.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.261 -0.899 . . . . 0.0 109.714 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 24.9 t30 56.8 26.21 11.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.209 -0.932 . . . . 0.0 109.657 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.16 23.91 23.56 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.401 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -67.97 -49.58 60.81 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 0.0 109.579 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.441 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -87.83 13.08 61.86 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.403 HG13 ' CD1' ' A' ' 63' ' ' LEU . 17.2 t -98.68 -30.59 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.094 -1.239 . . . . 0.0 109.241 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.434 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -90.06 -43.37 5.05 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.464 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 7.2 ptpt -56.07 -33.23 64.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.17 -1.194 . . . . 0.0 109.559 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.456 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 11.0 pt-20 -89.6 -18.57 26.31 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.958 . . . . 0.0 109.686 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.23 -61.52 1.68 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.6 m-85 -51.64 -31.82 26.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.185 -0.947 . . . . 0.0 109.885 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.459 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.1 OUTLIER -56.03 -55.57 31.3 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.188 -0.945 . . . . 0.0 109.594 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -57.45 -49.11 77.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.316 -0.865 . . . . 0.0 109.678 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.509 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.3 t80 -50.91 -51.17 54.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.185 -0.947 . . . . 0.0 109.609 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.466 ' CD1' HG22 ' A' ' 55' ' ' VAL . 12.8 mt -56.41 -46.13 80.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.868 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.407 ' HB2' ' HB1' ' A' ' 50' ' ' ALA . 13.5 t -60.75 -57.59 12.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.194 -0.941 . . . . 0.0 109.83 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.32 -21.84 66.27 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.481 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 15.3 m-70 -122.76 105.95 10.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.833 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -87.02 -21.13 26.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.436 -0.79 . . . . 0.0 109.264 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -73.27 -20.24 60.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.511 ' CE ' ' CMB' ' A' ' 148' ' ' HEM . 0.0 OUTLIER -96.65 -18.6 19.6 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 109.629 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.453 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -59.88 -57.53 12.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.472 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.73 -23.31 63.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -0.932 . . . . 0.0 109.345 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.517 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 49.5 t -75.05 -57.08 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.342 -0.849 . . . . 0.0 109.504 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.508 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -55.77 -35.25 66.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.95 . . . . 0.0 109.514 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.39 28.08 2.91 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.522 ' CD2' HG22 ' A' ' 55' ' ' VAL . 9.3 m-85 -123.14 -168.66 1.8 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 109.784 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.1 t -133.62 21.43 3.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.507 -0.746 . . . . 0.0 109.123 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 139.84 -161.72 26.28 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.407 ' HB1' ' HB2' ' A' ' 36' ' ' SER . . . -91.44 36.74 0.94 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.232 -1.158 . . . . 0.0 109.724 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.7 m -132.68 19.04 4.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.628 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -107.13 133.84 20.14 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.575 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.38 -19.87 55.26 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.947 1.498 . . . . 0.0 109.974 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.61 -27.63 64.06 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.522 HG22 ' CD2' ' A' ' 47' ' ' PHE . 99.3 t -57.18 -35.19 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -1.167 . . . . 0.0 109.405 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.464 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -79.34 -3.83 48.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.89 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.4 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 1.1 m-20 -94.97 -29.97 14.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.046 -1.034 . . . . 0.0 109.397 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.507 HD21 ' C1A' ' A' ' 148' ' ' HEM . 7.1 mt -86.02 -63.56 1.3 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.161 -0.962 . . . . 0.0 109.524 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.507 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -54.49 -28.83 45.91 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.457 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -63.1 -53.04 59.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.149 -1.207 . . . . 0.0 109.518 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.481 ' CB ' ' CGD' ' A' ' 148' ' ' HEM . 11.3 mtpt -76.25 -43.54 41.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.281 -0.887 . . . . 0.0 109.321 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.47 HG21 ' C1D' ' A' ' 148' ' ' HEM . 63.0 t -50.16 -49.14 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.308 -0.87 . . . . 0.0 109.591 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.445 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.0 mm? -47.51 -45.68 26.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.144 -0.973 . . . . 0.0 109.729 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.67 -50.9 31.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.244 -0.91 . . . . 0.0 109.903 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.1 tp60 -49.9 -49.21 50.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.139 -0.976 . . . . 0.0 109.491 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 71.1 mt -56.2 -35.83 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.325 -0.86 . . . . 0.0 109.138 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.84 -54.9 25.4 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.156 -1.578 . . . . 0.0 109.156 179.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.0 t -59.57 -24.48 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.9 -25.46 26.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.307 -0.871 . . . . 0.0 109.534 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.458 HG11 ' CG1' ' A' ' 10' ' ' VAL . 55.1 t -73.66 -18.38 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 109.665 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -89.35 15.3 9.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -0.93 . . . . 0.0 109.927 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 14.0 m-70 -155.97 45.59 0.45 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.076 -1.015 . . . . 0.0 109.899 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 69.3 mt -82.79 -27.79 30.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.54 -23.55 60.21 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -126.7 119.0 25.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.252 -1.146 . . . . 0.0 109.576 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -106.34 39.73 1.76 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.217 -0.927 . . . . 0.0 109.624 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -88.36 -21.7 43.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 2.8 ttpt -131.14 -37.97 1.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -1.169 . . . . 0.0 109.847 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 39.8 ttp -47.93 -53.16 16.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 109.627 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.407 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 58.1 t -66.86 -19.23 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.226 -0.921 . . . . 0.0 109.456 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.8 -36.32 75.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 0.0 109.434 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 22.3 tp10 -81.58 -49.81 10.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.437 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.402 ' HA ' HG23 ' A' ' 86' ' ' VAL . 4.4 mtp -53.04 -45.68 68.13 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.277 -0.889 . . . . 0.0 109.362 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.416 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -51.4 -37.53 48.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 109.086 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.431 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -65.33 -35.35 80.71 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.404 -0.81 . . . . 0.0 109.153 179.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.402 HG23 ' HA ' ' A' ' 83' ' ' MET . 28.9 t -62.4 -53.09 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.318 -0.864 . . . . 0.0 109.216 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.401 ' HA2' HD23 ' A' ' 141' ' ' LEU . . . -53.12 -42.2 61.67 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 97.7 t -52.63 -27.89 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -1.136 . . . . 0.0 109.345 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.47 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 2.0 mmm180 -78.96 -51.22 9.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.094 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.505 ' CD2' ' CE2' ' A' ' 93' ' ' TYR . 43.2 m80 -54.0 -22.35 10.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.387 -0.821 . . . . 0.0 109.127 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.509 ' CG ' ' CB ' ' A' ' 147' ' ' SER . 14.4 ttmt -64.99 -11.33 37.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.478 -0.764 . . . . 0.0 110.281 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.76 55.63 0.52 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CE2' ' CD2' ' A' ' 90' ' ' HIS . 4.4 m-30 -90.44 -170.15 2.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.306 -1.114 . . . . 0.0 109.661 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.11 -53.35 10.8 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.517 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.5 p-10 -62.06 -30.08 70.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.166 -1.196 . . . . 0.0 109.68 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.9 mtmt 60.62 35.62 19.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 109.942 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.407 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 47.5 m170 -132.97 -83.98 0.47 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.06 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.472 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 22.6 mt 60.06 153.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 110.387 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.531 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -152.71 135.09 15.09 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.626 0.727 . . . . 0.0 109.725 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -72.95 -6.32 44.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.735 -0.603 . . . . 0.0 109.544 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.462 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.8 mm-40 -76.36 -24.07 54.17 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.028 -1.045 . . . . 0.0 109.115 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.531 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 73.0 m-85 -85.95 -26.52 25.46 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.328 -0.858 . . . . 0.0 109.732 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.514 ' CE1' ' CAB' ' A' ' 148' ' ' HEM . 4.1 m-85 -50.82 -59.03 4.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 110.278 -179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.495 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -54.71 -59.07 11.47 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.289 -179.355 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.5 Cg_exo -47.94 -55.69 3.79 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.712 1.375 . . . . 0.0 110.308 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.509 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -55.99 -21.42 21.08 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.933 . . . . 0.0 109.652 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.61 -48.31 10.71 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.58 -47.46 85.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -1.164 . . . . 0.0 109.826 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.04 -25.12 65.09 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 1.3 tt -69.44 -40.72 77.05 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.688 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 14.8 mt -59.17 -32.78 70.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.228 -0.92 . . . . 0.0 109.677 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.9 p -66.83 -29.8 69.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 109.901 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.41 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -83.33 -38.82 21.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.176 -0.952 . . . . 0.0 109.845 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.498 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 5.2 mmt -48.45 -46.54 37.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 110.033 -179.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.455 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -47.96 -25.95 1.56 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 -179.633 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.448 ' ND1' ' OE1' ' A' ' 29' ' ' GLU . 18.3 m170 -54.65 -45.78 73.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.065 -1.022 . . . . 0.0 110.029 -179.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.416 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 7.0 ttt85 -78.17 -60.37 2.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.202 -0.936 . . . . 0.0 110.033 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.445 HG12 ' CG1' ' A' ' 17' ' ' ILE . 4.5 pt -104.7 52.36 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.172 -0.955 . . . . 0.0 109.82 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.455 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -63.5 -20.09 63.17 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -91.78 -24.29 25.85 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.418 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 25.1 mttt -100.01 -21.23 15.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.183 . . . . 0.0 109.711 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.407 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 5.0 tpt -60.94 98.37 0.07 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.562 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.442 ' OD1' ' N ' ' A' ' 123' ' ' ASN . 14.5 p-10 -96.36 -174.37 3.04 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.28 -0.887 . . . . 0.0 109.667 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.18 79.81 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.429 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -69.26 -27.21 65.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -0.906 . . . . 0.0 109.355 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.406 ' HB1' ' OD1' ' A' ' 123' ' ' ASN . . . -71.93 -45.41 61.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.461 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 5.0 ptpt -74.54 -27.92 60.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.119 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.461 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -81.88 -36.56 28.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.357 -0.84 . . . . 0.0 109.115 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.46 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -68.7 -47.37 66.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.365 -0.835 . . . . 0.0 109.134 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.498 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 3.5 m0 -70.13 -25.77 63.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.337 -0.852 . . . . 0.0 108.985 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.95 -34.88 74.0 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -81.91 -28.78 32.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.282 -0.886 . . . . 0.0 109.423 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -78.59 -47.75 16.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.335 -0.853 . . . . 0.0 109.62 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -49.5 -29.17 6.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.02 61.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.373 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -80.32 -36.48 34.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.479 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 65.3 mt -66.69 -58.12 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.293 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 1.8 p -64.74 -23.73 67.34 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -0.876 . . . . 0.0 109.597 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -73.42 -39.33 51.03 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.18 -31.09 70.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -1.16 . . . . 0.0 109.654 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.458 ' O ' ' CD2' ' A' ' 141' ' ' LEU . 8.5 tt -73.24 -6.53 46.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.225 -0.922 . . . . 0.0 110.028 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.406 ' O ' HG21 ' A' ' 142' ' ' ILE . 45.7 mm -88.67 16.59 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 109.936 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.416 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 4.8 t -95.93 -43.08 7.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.62 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -107.94 16.07 36.58 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.455 ' O ' ' HG ' ' A' ' 145' ' ' LEU . 11.3 tp -105.92 16.28 25.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.162 -1.199 . . . . 0.0 109.585 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -99.13 62.54 1.28 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.916 -1.115 . . . . 0.0 109.754 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.509 ' CB ' ' CG ' ' A' ' 91' ' ' LYS . 9.2 p . . . . . 0 N--CA 1.493 1.686 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.866 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.514 ' CAB' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.489 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.519 ' CD2' ' CB ' ' A' ' 132' ' ' ALA . 9.1 mt -152.66 176.42 11.76 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -1.17 . . . . 0.0 111.464 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.503 ' HA ' ' CB ' ' A' ' 7' ' ' ARG . 3.1 p 68.63 -178.71 0.22 Allowed 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 122.46 1.124 . . . . 0.0 111.573 178.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.482 ' O ' ' CB ' ' A' ' 5' ' ' ALA . . . 38.51 27.68 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.357 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 4' ' ' ALA . . . 164.51 -62.26 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.456 -0.777 . . . . 0.0 109.106 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.471 ' HB3' ' CD2' ' A' ' 2' ' ' LEU . 28.1 mt-30 -70.05 -26.44 64.02 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.521 -179.138 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.503 ' CB ' ' HA ' ' A' ' 3' ' ' SER . 2.8 tmm_? -77.21 -41.03 42.96 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.188 -1.005 . . . . 0.0 108.829 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -56.76 -29.37 62.53 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.471 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 14.2 t -81.65 -29.53 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.524 HG12 ' CD1' ' A' ' 130' ' ' TRP . 53.1 t -76.92 -37.59 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.565 -0.709 . . . . 0.0 109.311 179.611 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.2 -11.4 59.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.323 -0.861 . . . . 0.0 109.937 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -92.67 -34.01 14.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.808 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.0 p -83.58 -15.96 47.17 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.276 -0.89 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -87.15 -23.58 24.79 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.119 -0.988 . . . . 0.0 109.483 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.1 mtpt -75.78 -5.36 45.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.811 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.416 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.7 OUTLIER -110.76 -58.83 2.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.053 -1.029 . . . . 0.0 109.592 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.466 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 26.5 mt -56.94 -35.12 46.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -104.97 34.8 3.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.282 -0.886 . . . . 0.0 109.67 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.14 -72.26 0.56 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.7 p -112.05 -31.01 7.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.221 -1.164 . . . . 0.0 109.618 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.432 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 9.6 p-10 -76.45 -16.79 59.59 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -0.908 . . . . 0.0 109.792 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 31.4 t30 60.47 24.96 14.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.228 -0.92 . . . . 0.0 109.554 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.21 38.4 5.69 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.432 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -83.32 -39.36 20.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.636 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.434 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -89.32 17.19 53.42 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 28.5 t -105.96 -40.22 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -1.209 . . . . 0.0 109.378 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.471 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -86.78 -40.14 7.29 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.477 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.0 ptpt -59.87 -30.16 68.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -1.188 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.477 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 8.5 pt-20 -93.19 -22.21 19.19 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.7 t -88.21 -62.38 1.5 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.966 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.505 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 23.0 m-85 -50.54 -35.81 31.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.332 -0.855 . . . . 0.0 110.179 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.436 ' CA ' HG12 ' A' ' 55' ' ' VAL . 18.6 m -53.14 -54.78 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.985 -1.072 . . . . 0.0 109.2 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.79 -43.02 85.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.156 -0.965 . . . . 0.0 108.944 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.436 ' O ' ' N ' ' A' ' 38' ' ' HIS . 90.4 t80 -55.32 -63.26 1.22 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -0.806 . . . . 0.0 109.1 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.454 ' CD2' ' HA ' ' A' ' 42' ' ' ALA . 5.7 mt -47.82 -43.89 28.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.435 -0.79 . . . . 0.0 109.71 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.89 -63.43 1.21 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.574 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -59.12 -24.35 62.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.465 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 16.1 m-70 -118.62 99.12 6.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.288 -0.882 . . . . 0.0 109.648 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.4 m170 -83.88 -19.95 33.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.593 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -70.0 -11.23 60.72 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.256 -0.903 . . . . 0.0 109.895 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.465 ' HE3' ' CMB' ' A' ' 148' ' ' HEM . 83.0 mmm -113.34 -21.6 10.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.111 -0.993 . . . . 0.0 109.888 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.454 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.81 -46.56 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.024 -1.047 . . . . 0.0 109.592 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.61 -21.22 61.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.254 -0.904 . . . . 0.0 109.312 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.5 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 7.1 t -77.28 -38.48 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.316 -0.865 . . . . 0.0 109.278 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.45 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 12.8 m-85 -70.47 -27.61 64.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.85 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 111.96 20.97 6.53 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.523 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 6.1 m-85 -119.75 164.88 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.282 -1.128 . . . . 0.0 109.801 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.28 -15.33 20.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.446 -0.784 . . . . 0.0 109.213 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.417 ' O ' ' OD2' ' A' ' 52' ' ' ASP . . . -164.57 -155.3 8.33 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.98 -0.21 27.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.438 -1.036 . . . . 0.0 110.079 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.0 t -107.24 51.9 0.73 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.949 -1.094 . . . . 0.0 109.861 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.417 ' OD2' ' O ' ' A' ' 49' ' ' GLY . 0.6 OUTLIER -131.23 149.25 73.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.255 -0.903 . . . . 0.0 109.674 179.799 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_exo -65.8 -24.31 54.43 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.973 1.512 . . . . 0.0 110.296 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.523 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -48.45 -35.87 16.33 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.454 HG21 ' CD1' ' A' ' 35' ' ' LEU . 57.5 t -61.26 -35.61 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -1.109 . . . . 0.0 109.445 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.471 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.39 -11.26 60.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.34 -31.2 16.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.606 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.511 HD21 ' C1A' ' A' ' 148' ' ' HEM . 7.8 mt -88.42 -62.68 1.44 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.973 . . . . 0.0 109.725 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.505 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -50.15 -33.52 22.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -71.81 -43.83 64.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -1.18 . . . . 0.0 109.718 -179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.8 mtpp -74.95 -36.99 62.09 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.431 HG21 ' C1D' ' A' ' 148' ' ' HEM . 61.1 t -61.8 -47.65 92.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.819 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.429 ' N ' HD22 ' A' ' 63' ' ' LEU . 1.6 mm? -47.28 -46.31 24.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.16 -0.962 . . . . 0.0 109.899 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -47.44 -48.4 26.59 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.403 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 17.9 tp60 -52.64 -49.69 64.65 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.101 -0.999 . . . . 0.0 109.407 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 72.2 mt -58.1 -27.64 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.256 -0.902 . . . . 0.0 109.195 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.527 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.78 -54.88 8.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -60.67 -21.26 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.25 -1.147 . . . . 0.0 109.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.59 -25.15 23.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.461 ' CG1' HG11 ' A' ' 10' ' ' VAL . 41.4 t -73.08 -11.74 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.248 -0.907 . . . . 0.0 109.731 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -92.36 25.4 2.98 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 109.592 179.977 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.518 ' O ' ' N ' ' A' ' 74' ' ' GLY . 28.0 m-70 -142.68 -75.34 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.525 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.9 mm? 51.2 -85.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.711 -0.618 . . . . 0.0 110.297 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.52 -28.05 35.77 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -76.72 63.47 2.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -1.135 . . . . 0.0 109.461 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -69.84 82.67 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.526 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 173.7 -33.27 0.11 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 108.851 -1.699 . . . . 0.0 108.851 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 11.7 ttpt -109.06 -34.6 6.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 109.472 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.451 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 5.6 tmm? -52.92 -36.28 59.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.279 -0.888 . . . . 0.0 109.55 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.413 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 73.0 t -79.58 -18.77 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.693 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -48.82 -51.43 29.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.788 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.52 -45.36 31.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.44 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 1.6 mtp -54.78 -53.44 55.18 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.413 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -51.12 -33.05 24.74 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.935 . . . . 0.0 109.202 179.696 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.405 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -68.89 -42.99 76.21 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.371 -0.831 . . . . 0.0 109.295 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.42 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 14.4 t -58.99 -41.45 83.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.133 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.421 ' O ' HD11 ' A' ' 145' ' ' LEU . . . -55.77 -48.86 69.26 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 179.497 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 78.1 t -52.71 -40.24 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.247 -1.149 . . . . 0.0 108.901 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -64.28 -50.94 65.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.398 -0.814 . . . . 0.0 109.01 179.273 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.509 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 25.4 m80 -55.5 -38.7 69.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.314 -0.866 . . . . 0.0 109.316 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.444 ' HA ' ' CB ' ' A' ' 147' ' ' SER . 10.0 ttpp -62.72 -15.8 54.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.304 -0.872 . . . . 0.0 109.982 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -124.06 43.28 1.43 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -88.13 -171.68 3.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.3 -1.118 . . . . 0.0 109.683 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.75 -44.6 7.16 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.5 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.1 p-10 -64.92 -33.22 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -1.134 . . . . 0.0 109.593 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.7 tttt 55.12 20.23 3.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.212 -0.93 . . . . 0.0 109.809 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -129.6 55.84 1.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.33 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.468 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 73.4 mt -90.32 156.3 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.327 -0.858 . . . . 0.0 110.193 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.511 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 2.7 mptt -143.34 131.6 22.01 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.486 -0.759 . . . . 0.0 109.665 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -73.25 -9.02 58.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.458 -0.777 . . . . 0.0 109.795 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.6 -23.2 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.511 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 73.7 m-85 -84.9 -15.84 43.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.125 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.44 ' CE1' ' CAB' ' A' ' 148' ' ' HEM . 3.6 m-85 -60.61 -68.75 0.27 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.195 -0.941 . . . . 0.0 110.368 -179.483 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.48 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.8 OUTLIER -44.37 -59.06 4.22 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.403 -0.811 . . . . 0.0 111.096 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 9.8 Cg_endo -55.06 -55.4 3.22 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.629 1.331 . . . . 0.0 110.034 -179.39 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.457 ' O ' ' CD1' ' A' ' 106' ' ' LEU . 3.0 tm? -62.78 -18.57 62.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' CE1' ' A' ' 134' ' ' TYR . . . -85.39 -39.85 8.15 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.16 45.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.231 -1.158 . . . . 0.0 109.489 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -21.5 11.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -67.58 -41.29 84.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.735 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.419 HD21 ' HB2' ' A' ' 130' ' ' TRP . 11.6 mt -60.65 -41.44 94.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.143 -0.973 . . . . 0.0 109.562 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.3 t -64.31 -29.94 71.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.852 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -83.37 -36.34 24.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.195 -0.941 . . . . 0.0 109.641 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.47 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.1 mtt -48.79 -35.89 15.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 110.3 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.439 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.7 OUTLIER -58.42 -23.19 56.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.116 -0.99 . . . . 0.0 109.66 -179.506 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.427 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 9.6 m170 -54.72 -49.14 71.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.133 -0.98 . . . . 0.0 109.56 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.466 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.1 OUTLIER -67.22 -62.61 1.34 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -0.929 . . . . 0.0 109.504 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.449 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 13.9 pt -92.03 47.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.262 -0.899 . . . . 0.0 109.431 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.91 125.47 37.25 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.42 -36.08 4.3 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.449 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.9 mmtp -87.46 -28.45 22.08 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.128 -1.219 . . . . 0.0 109.318 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -68.92 104.2 2.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.356 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 6.8 p30 -103.38 -170.14 1.74 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.37 -0.831 . . . . 0.0 109.992 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.32 -41.25 98.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.446 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -64.29 -25.15 67.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.747 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -79.07 -46.69 17.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.144 -0.973 . . . . 0.0 109.884 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.474 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 18.3 ptpt -74.11 -25.65 59.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.097 -1.002 . . . . 0.0 109.461 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.474 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 26.3 t0 -83.73 -43.11 15.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.323 -0.86 . . . . 0.0 109.195 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.471 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -60.98 -46.11 92.06 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.436 -0.79 . . . . 0.0 108.996 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.524 ' CD1' HG12 ' A' ' 10' ' ' VAL . 6.8 m0 -70.34 -31.0 68.09 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -55.89 -25.18 41.47 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.538 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.519 ' CB ' ' CD2' ' A' ' 2' ' ' LEU . . . -91.4 -32.84 15.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.494 -0.753 . . . . 0.0 109.151 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.59 -63.63 1.35 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.465 -0.772 . . . . 0.0 109.723 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.517 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.84 -25.37 4.41 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.947 . . . . 0.0 109.081 -179.979 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.52 -47.73 18.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -0.9 . . . . 0.0 109.031 179.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.41 -29.28 62.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.385 -0.822 . . . . 0.0 109.205 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.416 HD12 ' HA ' ' A' ' 134' ' ' TYR . 5.4 mt -66.99 -59.65 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.336 -0.852 . . . . 0.0 108.909 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 31.1 p -60.07 -26.54 66.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.556 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -77.55 -25.08 63.8 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.25 -29.82 63.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -1.12 . . . . 0.0 109.562 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.44 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 10.4 tt -75.1 -10.76 59.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.913 . . . . 0.0 109.864 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.413 ' O ' ' CG2' ' A' ' 142' ' ' ILE . 44.5 mm -92.41 37.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.132 -0.98 . . . . 0.0 109.697 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 21.5 m -116.74 -23.29 8.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.679 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.57 -8.49 6.91 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.476 ' HG ' ' N ' ' A' ' 146' ' ' GLN . 26.3 tp -72.32 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.073 -1.251 . . . . 0.0 109.558 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.476 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 1.3 mp0 47.3 37.24 5.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.001 -1.062 . . . . 0.0 110.074 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.456 ' OG ' ' CD1' ' A' ' 145' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.494 1.739 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.817 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.511 ' C1A' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.6 mt 52.3 -178.17 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.321 -1.105 . . . . 0.0 109.619 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.3 p -133.86 -168.55 2.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 110.03 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.59 -22.24 40.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.446 -0.784 . . . . 0.0 109.95 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.39 -34.26 13.53 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.916 . . . . 0.0 109.655 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 -70.22 -47.14 62.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 109.58 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.54 -29.33 58.75 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.159 -0.963 . . . . 0.0 109.24 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -80.52 -37.79 30.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.371 -0.83 . . . . 0.0 108.86 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.408 HG13 ' HA ' ' A' ' 126' ' ' ALA . 57.7 t -72.5 -32.22 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.463 -0.773 . . . . 0.0 108.993 179.372 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.402 ' HA ' ' CD1' ' A' ' 130' ' ' TRP . 55.4 t -71.31 -37.89 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.468 -0.77 . . . . 0.0 109.272 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.62 -13.02 60.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.846 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 t -92.24 -24.27 19.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.139 -0.976 . . . . 0.0 109.961 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.459 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 16.7 p -91.28 -17.75 25.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.196 -0.94 . . . . 0.0 109.976 -179.718 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.517 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -84.35 -19.38 33.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 109.762 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.6 mtpt -83.46 1.83 39.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.998 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -118.04 -54.71 2.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.45 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.462 HD11 ' CH2' ' A' ' 130' ' ' TRP . 81.3 mt -66.51 -33.09 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.275 -0.89 . . . . 0.0 109.467 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.517 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.67 33.08 3.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.575 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.65 -87.84 0.01 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.6 p -101.0 -21.44 15.04 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.406 ' HB2' ' HB2' ' A' ' 24' ' ' ALA . 18.0 p-10 -81.63 -23.16 37.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.594 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.5 t30 57.09 29.36 16.41 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' HA3' ' CD2' ' A' ' 63' ' ' LEU . . . 90.68 38.66 6.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 21' ' ' ASP . . . -80.82 -58.2 3.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.266 -1.138 . . . . 0.0 109.643 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.468 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -73.18 -22.2 79.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.468 HG12 ' CD2' ' A' ' 63' ' ' LEU . 23.5 t -66.04 -29.19 46.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -1.103 . . . . 0.0 109.544 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.42 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -80.11 -56.38 3.27 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.471 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 14.6 ptpt -54.28 -24.95 20.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.177 -1.19 . . . . 0.0 110.175 -179.355 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 25' ' ' GLY . 18.8 pt-20 -97.75 -18.43 18.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.99 -1.069 . . . . 0.0 109.899 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.438 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 35.5 t -89.16 -68.84 0.75 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -0.937 . . . . 0.0 109.785 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.477 ' CE2' ' O ' ' A' ' 149' ' ' CMO . 12.9 m-85 -48.17 -31.26 5.48 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.21 -0.931 . . . . 0.0 109.83 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.467 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.55 -54.02 46.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.931 . . . . 0.0 109.61 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' OG ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -60.49 -38.65 84.97 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.877 -179.887 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.1 t80 -59.11 -52.64 64.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.167 -0.958 . . . . 0.0 109.705 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.464 ' CD1' HG22 ' A' ' 55' ' ' VAL . 4.2 mt -58.86 -48.79 80.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.239 -0.913 . . . . 0.0 109.842 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.401 ' OG ' ' O ' ' A' ' 33' ' ' LYS . 3.3 p -56.0 -52.68 63.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.731 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.452 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -72.53 -25.13 61.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 0.0 109.713 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.452 ' CD2' ' HB3' ' A' ' 37' ' ' ALA . 18.6 m-70 -120.35 109.04 14.87 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.767 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -89.86 -21.55 22.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.408 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -71.07 -21.15 62.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.336 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.499 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -96.64 -13.87 22.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.885 . . . . 0.0 109.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.418 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -56.02 -64.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.095 -1.003 . . . . 0.0 109.514 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -54.79 -25.23 26.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.277 -0.89 . . . . 0.0 109.369 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.515 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 39.0 t -75.97 -43.69 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.499 ' CE2' ' HB3' ' A' ' 41' ' ' MET . 18.1 m-85 -73.35 -18.44 61.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.911 . . . . 0.0 109.67 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.415 ' O ' ' CD1' ' A' ' 47' ' ' PHE . . . 95.03 26.47 12.49 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.525 ' CD2' HG22 ' A' ' 55' ' ' VAL . 15.1 m-85 -126.9 -177.1 3.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -1.128 . . . . 0.0 109.982 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.99 16.21 7.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.461 -0.774 . . . . 0.0 109.415 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 144.84 -163.42 27.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.7 -17.79 52.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.308 -1.113 . . . . 0.0 109.826 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -85.14 49.92 1.84 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.932 . . . . 0.0 109.665 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.32 122.9 15.14 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.611 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -65.83 -25.9 52.67 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.872 1.459 . . . . 0.0 110.077 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.51 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.89 -33.4 43.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 47' ' ' PHE . 97.6 t -52.01 -33.62 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -1.142 . . . . 0.0 109.298 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . . . -74.1 -4.29 34.71 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.289 -0.882 . . . . 0.0 109.578 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -90.18 -36.02 15.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.122 -0.986 . . . . 0.0 109.791 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.47 ' CD2' ' O1D' ' A' ' 148' ' ' HEM . 10.6 mt -83.99 -62.16 1.64 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.032 -1.042 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.42 ' HA3' ' CA ' ' A' ' 27' ' ' GLY . . . -52.46 -28.36 28.34 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -64.72 -53.67 43.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.062 -1.257 . . . . 0.0 109.756 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.7 mttm -79.56 -43.75 22.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.468 HG21 ' C ' ' A' ' 149' ' ' CMO . 94.8 t -46.8 -58.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.389 -0.819 . . . . 0.0 110.229 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.468 ' CD2' HG12 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -46.43 -38.84 9.59 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.205 -0.934 . . . . 0.0 109.987 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.47 -42.15 61.4 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.935 . . . . 0.0 109.521 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.407 ' HB2' ' O ' ' A' ' 62' ' ' VAL . 3.2 mm100 -60.67 -42.12 96.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.172 -0.955 . . . . 0.0 109.321 179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 88.9 mt -61.13 -33.49 56.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.24 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.517 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.38 -53.66 24.04 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.921 -1.672 . . . . 0.0 108.921 179.621 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.4 t -59.84 -24.24 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.315 -1.109 . . . . 0.0 109.207 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.09 -30.33 22.66 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.408 -0.807 . . . . 0.0 109.578 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.456 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 48.2 t -63.5 -21.21 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.495 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.08 44.0 1.16 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.179 -0.951 . . . . 0.0 109.874 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.529 ' O ' ' N ' ' A' ' 74' ' ' GLY . 4.3 m-70 -152.15 -84.07 0.08 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.129 -0.982 . . . . 0.0 110.311 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.514 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.6 mm? 44.59 -87.7 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.774 -0.579 . . . . 0.0 110.559 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -48.3 -27.01 5.25 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -106.41 84.11 1.97 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.265 -1.138 . . . . 0.0 109.512 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -89.55 44.36 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.633 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -119.11 -12.71 6.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.405 ' O ' ' HB2' ' A' ' 81' ' ' ALA . 0.0 OUTLIER -130.14 -38.02 1.43 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.07 -1.253 . . . . 0.0 109.876 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.452 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 3.1 tmm? -49.78 -44.95 49.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -0.939 . . . . 0.0 109.774 -179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.4 t -73.81 -8.07 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.922 . . . . 0.0 110.071 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 78' ' ' LYS . . . -77.74 -32.09 52.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.989 -1.069 . . . . 0.0 109.712 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -99.34 -41.45 7.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.925 . . . . 0.0 109.639 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.461 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 2.4 mtp -62.53 -47.79 82.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.188 -0.945 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.403 ' HG2' ' HB2' ' A' ' 143' ' ' SER . 0.1 OUTLIER -54.96 -35.73 64.58 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.255 -0.903 . . . . 0.0 109.279 179.694 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -64.23 -35.39 80.65 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.229 -0.919 . . . . 0.0 109.266 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.458 ' CG1' HD13 ' A' ' 141' ' ' LEU . 28.6 t -55.08 -48.96 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.352 -0.843 . . . . 0.0 109.42 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.41 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -51.99 -50.42 44.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.454 HG22 ' CA ' ' A' ' 144' ' ' GLY . 97.0 t -48.68 -25.3 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.327 -1.102 . . . . 0.0 109.596 179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.505 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.2 mmt180 -77.08 -44.67 29.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.179 -0.951 . . . . 0.0 109.127 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.476 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 17.7 m80 -58.78 -19.87 44.7 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.349 -0.845 . . . . 0.0 109.196 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.463 ' CD ' ' HA ' ' A' ' 147' ' ' SER . 25.5 ttpt -68.04 -15.09 63.45 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.419 -0.801 . . . . 0.0 109.851 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.91 50.51 0.81 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.8 m-30 -94.23 -172.41 2.8 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.237 -1.155 . . . . 0.0 109.328 179.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.74 -40.3 53.27 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.515 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 1.7 t30 -78.39 -44.68 24.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.464 -1.021 . . . . 0.0 109.001 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 71.93 -54.24 0.68 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.396 -0.815 . . . . 0.0 110.314 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 28.9 m170 -66.69 69.2 0.07 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.974 . . . . 0.0 110.115 -179.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.459 HG22 HD12 ' A' ' 98' ' ' ILE . 84.5 mt -100.61 161.76 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.93 . . . . 0.0 109.329 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.466 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -136.92 142.54 42.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.139 -0.975 . . . . 0.0 109.726 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.16 -0.41 51.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.878 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.511 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 7.6 pt-20 -78.74 -28.43 44.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.104 -0.998 . . . . 0.0 109.676 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.511 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 92.8 m-85 -78.03 -13.52 59.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 109.845 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.562 ' CD2' ' CMC' ' A' ' 148' ' ' HEM . 4.2 m-85 -57.9 -64.57 0.86 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.203 -0.936 . . . . 0.0 110.192 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.483 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.3 mt-10 -51.38 -55.87 25.35 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.169 -0.957 . . . . 0.0 110.208 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.483 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 33.6 Cg_exo -49.42 -54.27 5.71 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.69 1.363 . . . . 0.0 110.19 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.518 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.1 tm? -57.05 -19.46 19.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.223 -0.923 . . . . 0.0 109.599 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.53 -39.82 20.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.63 -57.14 12.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.243 -1.151 . . . . 0.0 109.614 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.2 m -56.91 -23.23 43.48 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.608 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.454 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 4.4 tt -70.38 -43.77 69.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.558 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.2 mt -57.06 -30.43 64.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.503 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.4 t -66.65 -39.01 88.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.208 -0.933 . . . . 0.0 109.633 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.42 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -75.15 -39.82 60.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.668 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.551 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.2 mmt -48.05 -40.31 22.59 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.203 -0.936 . . . . 0.0 109.874 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -54.11 -24.57 18.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.264 -0.897 . . . . 0.0 109.746 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.42 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -49.65 -53.08 26.36 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.184 -0.947 . . . . 0.0 109.697 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.405 ' HG2' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -75.19 -72.55 0.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.153 -0.967 . . . . 0.0 109.579 -179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.439 HG12 ' CD1' ' A' ' 17' ' ' ILE . 3.1 pt -86.42 56.32 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.916 . . . . 0.0 109.657 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -68.35 -23.69 74.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -94.77 -21.7 25.45 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.404 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 59.2 mttt -100.64 -21.47 15.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.627 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.43 ' CB ' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.16 80.43 0.13 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.327 -0.858 . . . . 0.0 109.632 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.451 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.9 p30 -83.79 -163.93 0.84 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.612 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -71.46 -42.17 68.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.451 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -62.67 -24.02 67.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' HG13 ' A' ' 9' ' ' VAL . . . -77.18 -52.8 8.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.595 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.445 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 15.5 ptpt -67.46 -33.2 74.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.918 . . . . 0.0 109.363 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.445 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.0 t70 -73.17 -55.42 6.49 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.413 179.774 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -51.23 -43.42 61.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.405 -0.809 . . . . 0.0 109.373 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.551 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 2.8 m0 -75.74 -29.34 58.85 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.351 -0.843 . . . . 0.0 109.107 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.07 -27.85 65.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.183 179.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.31 -26.63 21.02 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.305 -0.872 . . . . 0.0 109.28 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.418 ' O ' ' CD1' ' A' ' 137' ' ' ILE . . . -79.49 -45.22 19.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.415 -0.803 . . . . 0.0 109.503 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.454 ' OH ' ' CD2' ' A' ' 110' ' ' LEU . 5.8 m-85 -48.99 -31.61 7.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.08 -36.41 69.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.29 -0.881 . . . . 0.0 109.39 179.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.57 -40.37 29.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.524 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.461 ' O ' ' CE ' ' A' ' 83' ' ' MET . 1.9 mp -67.42 -56.68 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.864 . . . . 0.0 109.139 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.6 p -68.26 -26.58 65.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.739 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -71.02 -35.78 64.56 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.48 -21.69 66.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.189 -1.183 . . . . 0.0 109.763 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.481 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.2 tt -82.32 -12.62 57.87 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -0.945 . . . . 0.0 109.944 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 36.5 mt -79.61 3.26 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.138 -0.976 . . . . 0.0 110.157 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.403 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 9.5 m -89.92 -45.06 9.48 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.015 -1.053 . . . . 0.0 109.632 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.454 ' CA ' HG22 ' A' ' 88' ' ' VAL . . . -82.56 -28.58 38.81 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.47 ' O ' ' HG2' ' A' ' 146' ' ' GLN . 0.3 OUTLIER -58.83 -163.54 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -1.072 . . . . 0.0 109.609 179.94 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.473 ' O ' ' CG ' ' A' ' 146' ' ' GLN . 0.0 OUTLIER 27.92 59.95 0.11 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-O 121.517 0.675 . . . . 0.0 111.789 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.463 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 21.7 m . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.08 -1.012 . . . . 0.0 109.653 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.562 ' CMC' ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.477 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.459 ' N ' HD22 ' A' ' 2' ' ' LEU . 4.3 mm? -84.92 144.19 28.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.31 -1.112 . . . . 0.0 109.65 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.412 ' OG ' ' CG ' ' A' ' 6' ' ' GLN . 0.7 OUTLIER -88.2 178.23 6.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.573 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -72.39 -18.61 61.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.223 -0.923 . . . . 0.0 109.792 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.87 -40.05 8.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.785 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.412 ' CG ' ' OG ' ' A' ' 3' ' ' SER . 76.8 mt-30 -62.02 -52.83 62.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.539 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.45 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 7.5 ptm180 -50.47 -33.9 22.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.34 179.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.45 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 56.6 tp60 -75.57 -46.62 30.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.7 t -60.54 -34.85 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.178 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.508 HG12 ' CD1' ' A' ' 130' ' ' TRP . 69.8 t -64.66 -48.73 83.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.36 -0.838 . . . . 0.0 109.343 179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.35 -11.53 60.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 109.675 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -91.17 -25.51 19.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.135 -0.978 . . . . 0.0 109.717 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 p -98.01 -11.75 22.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.183 -0.948 . . . . 0.0 109.809 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.551 ' CE3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.8 -28.39 20.48 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.082 -1.011 . . . . 0.0 109.657 -179.882 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -70.76 -15.26 62.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -99.55 -61.52 1.36 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.644 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.446 HD11 ' CH2' ' A' ' 130' ' ' TRP . 55.8 mt -57.9 -39.13 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.711 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.551 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -102.64 36.09 2.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.702 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.8 -82.5 0.06 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.0 p -97.93 -26.24 14.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 0.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -80.75 -23.8 39.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.639 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 27.2 t30 56.92 22.07 6.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.97 23.44 9.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.412 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -69.57 -54.31 14.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 109.619 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.439 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -85.93 10.98 63.59 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.467 HG13 ' CD2' ' A' ' 63' ' ' LEU . 35.8 t -104.84 -22.66 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.241 . . . . 0.0 109.202 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.436 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -98.95 -35.43 4.83 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.481 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 15.0 ptpt -68.88 -27.04 65.44 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.189 -1.183 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.436 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 17.5 pt-20 -100.82 -5.97 25.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 110.087 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.5 t -95.99 -67.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.054 -1.029 . . . . 0.0 109.978 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -47.18 -29.78 2.53 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.206 -0.934 . . . . 0.0 110.149 -179.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.436 ' CA ' HG12 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -52.74 -63.25 1.2 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.074 -1.016 . . . . 0.0 109.207 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.405 ' O ' ' HB2' ' A' ' 37' ' ' ALA . 0.3 OUTLIER -50.35 -47.49 55.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.341 -0.849 . . . . 0.0 109.242 179.699 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.512 ' CG ' HD22 ' A' ' 106' ' ' LEU . 7.8 t80 -56.46 -51.26 69.1 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.18 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.509 HD21 ' CG ' ' A' ' 45' ' ' PHE . 19.5 mt -58.32 -44.7 88.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.496 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -62.95 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.344 -0.848 . . . . 0.0 109.612 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.418 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -52.8 -24.48 9.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.626 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.45 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 19.0 m-70 -125.0 101.74 7.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.299 -0.876 . . . . 0.0 109.738 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -84.51 -17.48 38.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.398 -0.814 . . . . 0.0 109.503 179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -67.87 -16.11 63.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.54 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 89.6 mmm -120.04 -15.02 8.82 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 110.019 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.417 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.04 -44.84 41.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.913 -1.117 . . . . 0.0 109.525 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.0 -29.75 60.97 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.322 -0.861 . . . . 0.0 109.26 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.486 HG11 ' ND2' ' A' ' 95' ' ' ASN . 2.4 t -60.89 -27.99 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.342 -0.849 . . . . 0.0 109.173 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.519 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 8.3 m-85 -82.64 -27.8 31.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.103 -0.998 . . . . 0.0 109.683 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.448 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.84 20.26 6.51 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.525 ' CD2' HG22 ' A' ' 55' ' ' VAL . 3.6 m-85 -117.88 172.84 7.12 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.231 -1.159 . . . . 0.0 109.653 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.6 t -115.28 22.09 13.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.331 -0.856 . . . . 0.0 109.029 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.45 -170.8 28.93 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.86 11.28 11.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -1.168 . . . . 0.0 109.97 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.04 20.3 18.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.994 . . . . 0.0 109.557 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.403 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -101.31 136.42 19.67 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.54 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -68.03 -17.01 45.97 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.916 1.482 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.0 -36.88 61.38 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 47' ' ' PHE . 61.2 t -51.71 -33.27 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.238 -1.154 . . . . 0.0 109.449 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.481 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -79.28 -13.77 59.45 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.252 -0.905 . . . . 0.0 109.787 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -90.21 -23.14 21.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.184 -0.947 . . . . 0.0 109.494 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.517 HD21 ' C1A' ' A' ' 148' ' ' HEM . 3.4 mt -90.89 -66.43 0.93 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.902 . . . . 0.0 109.906 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.93 -30.89 38.27 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -1.217 . . . . 0.0 109.479 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.478 ' HB2' ' CGD' ' A' ' 148' ' ' HEM . 17.0 mttt -94.34 -38.44 10.98 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.42 -0.8 . . . . 0.0 109.485 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 91.4 t -51.43 -57.99 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.38 -0.825 . . . . 0.0 109.794 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.467 ' CD2' HG13 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.31 -45.0 24.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.227 -0.921 . . . . 0.0 109.677 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.407 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -47.66 -40.74 20.67 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.687 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 35.2 tp60 -64.79 -41.28 95.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.195 -0.941 . . . . 0.0 109.164 179.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 59.4 mt -60.79 -37.31 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -0.843 . . . . 0.0 109.144 179.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.76 29.68 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.2 t -58.04 -24.81 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -1.125 . . . . 0.0 109.17 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.0 -34.21 22.4 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.418 -0.801 . . . . 0.0 109.433 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.456 ' CG1' HG11 ' A' ' 10' ' ' VAL . 50.7 t -63.95 -19.33 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -0.899 . . . . 0.0 109.425 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 24.1 m -62.2 -41.93 98.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.196 -0.94 . . . . 0.0 109.667 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 71' ' ' SER . 8.7 m-70 -131.02 84.48 2.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.724 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.417 ' HB3' ' HG ' ' A' ' 2' ' ' LEU . 42.1 mt -81.64 -46.58 14.16 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 109.6 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.8 -22.64 61.28 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.66 118.38 29.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -1.141 . . . . 0.0 109.65 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -114.41 49.07 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.62 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -105.84 -19.83 9.92 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.6 tttt -138.59 -45.24 0.49 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -1.181 . . . . 0.0 109.826 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -49.35 -33.12 12.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.947 . . . . 0.0 109.753 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.406 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 54.8 t -76.86 -22.51 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.258 -0.901 . . . . 0.0 109.605 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.47 -17.89 61.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.851 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -92.57 -49.84 5.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 109.761 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.416 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 95.8 mmm -60.74 -45.91 92.49 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.067 -1.021 . . . . 0.0 109.156 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.439 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 2.0 mttt -51.73 -31.17 25.34 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.128 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.448 ' O ' ' CG ' ' A' ' 89' ' ' ARG . . . -79.47 -32.02 42.53 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.462 -0.774 . . . . 0.0 108.956 179.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.454 ' CG1' HD13 ' A' ' 141' ' ' LEU . 45.2 t -69.86 -41.69 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.127 -0.983 . . . . 0.0 109.273 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.411 ' O ' HD11 ' A' ' 145' ' ' LEU . . . -66.31 -43.49 92.69 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.931 -1.667 . . . . 0.0 108.931 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.439 ' CG2' ' O ' ' A' ' 84' ' ' LYS . 97.0 t -59.25 -29.4 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -1.191 . . . . 0.0 109.178 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.478 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.9 OUTLIER -76.63 -45.7 28.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -0.871 . . . . 0.0 109.316 179.773 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.512 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 22.0 m80 -59.18 -20.67 55.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.088 179.428 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.449 ' CD ' ' OXT' ' A' ' 147' ' ' SER . 8.1 ttpt -70.23 -9.54 56.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.89 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.4 54.57 0.55 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.516 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.9 m-30 -88.8 -168.99 2.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -1.167 . . . . 0.0 109.613 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -76.49 -36.46 38.48 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.486 ' ND2' HG11 ' A' ' 44' ' ' VAL . 16.7 p-10 -79.67 -24.66 41.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.046 -1.267 . . . . 0.0 110.009 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 ttmm 51.41 26.79 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.153 -0.967 . . . . 0.0 109.499 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 4.6 m-70 -134.28 42.97 2.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.42 -0.8 . . . . 0.0 109.323 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.516 HD11 ' CD2' ' A' ' 93' ' ' TYR . 58.9 mt -86.03 156.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 110.061 -179.633 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.456 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.28 143.69 25.08 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.706 0.765 . . . . 0.0 109.882 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.1 -6.37 56.3 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.717 -0.614 . . . . 0.0 109.622 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -72.95 -28.73 62.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.091 -1.006 . . . . 0.0 109.359 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.54 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 44.8 m-85 -79.93 -20.42 45.72 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.547 ' CE1' ' CAB' ' A' ' 148' ' ' HEM . 5.5 m-85 -57.37 -68.13 0.26 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.338 -0.851 . . . . 0.0 110.555 -179.332 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 3.4 mt-10 -43.24 -59.96 2.81 Favored Pre-proline 0 N--CA 1.495 1.808 0 O-C-N 121.516 -0.74 . . . . 0.0 111.016 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' CD ' ' CB ' ' A' ' 104' ' ' GLU . 8.8 Cg_endo -55.99 -42.52 65.93 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.732 1.385 . . . . 0.0 110.199 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.512 HD22 ' CG ' ' A' ' 34' ' ' PHE . 2.9 tm? -66.75 -27.18 67.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.475 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.36 -38.8 37.8 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.45 -48.42 72.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -1.127 . . . . 0.0 109.539 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.2 m -62.31 -26.46 68.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.548 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.3 tt -70.42 -40.22 73.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 109.563 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.441 HD12 ' N ' ' A' ' 131' ' ' ALA . 13.0 mt -58.96 -32.04 69.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.426 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.53 -27.75 64.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.282 -0.886 . . . . 0.0 109.523 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.43 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -84.18 -35.07 23.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.224 -0.922 . . . . 0.0 109.689 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.49 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 4.3 mmt -46.93 -50.4 18.95 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.285 -0.884 . . . . 0.0 110.227 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.475 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 8.5 pt-20 -47.23 -24.76 0.78 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 110.276 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.43 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 19.8 m170 -53.65 -31.33 47.08 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.709 -1.244 . . . . 0.0 109.651 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.41 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -91.89 -68.39 0.8 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.19 -0.944 . . . . 0.0 110.127 -179.655 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.46 HG13 ' N ' ' A' ' 119' ' ' GLY . 18.3 pt -78.21 -34.16 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.116 -0.99 . . . . 0.0 109.756 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.475 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . 41.2 -98.73 0.01 OUTLIER Glycine 0 N--CA 1.498 2.794 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.61 -39.46 10.56 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.448 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.6 OUTLIER -73.29 -18.13 61.24 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.044 -1.268 . . . . 0.0 109.919 -179.806 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.459 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -79.45 107.06 11.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 179.571 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.4 p-10 -111.61 -171.23 1.8 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.926 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.445 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.47 -49.0 79.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.424 -0.798 . . . . 0.0 109.963 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -57.83 -20.72 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.516 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -85.44 -55.73 3.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.311 -0.868 . . . . 0.0 109.791 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.445 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -69.69 -24.78 63.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.781 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -80.04 -45.35 18.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.236 -0.915 . . . . 0.0 109.524 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.402 ' HB3' HG22 ' A' ' 10' ' ' VAL . . . -65.25 -45.89 82.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.391 -0.818 . . . . 0.0 109.391 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.508 ' CD1' HG12 ' A' ' 10' ' ' VAL . 4.7 m0 -66.41 -29.4 69.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -0.864 . . . . 0.0 109.34 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.441 ' N ' HD12 ' A' ' 111' ' ' LEU . . . -69.64 -28.06 65.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 108.932 179.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.81 -31.72 15.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.44 -0.787 . . . . 0.0 109.359 179.614 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.417 ' HB2' HD13 ' A' ' 2' ' ' LEU . . . -72.06 -39.78 68.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.398 -0.814 . . . . 0.0 109.206 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.415 ' O ' ' HB3' ' A' ' 138' ' ' SER . 5.3 m-30 -52.64 -30.89 34.05 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.342 -0.849 . . . . 0.0 109.064 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.58 -35.07 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.336 -0.852 . . . . 0.0 109.242 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.407 ' HB2' HD23 ' A' ' 2' ' ' LEU . 1.2 t70 -77.89 -39.07 44.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.33 179.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.416 ' O ' ' CE ' ' A' ' 83' ' ' MET . 12.2 mt -65.82 -58.48 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.297 -0.877 . . . . 0.0 109.109 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.417 ' O ' ' HB3' ' A' ' 141' ' ' LEU . 0.1 OUTLIER -68.51 -28.25 66.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -58.38 -52.72 51.09 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.04 -23.28 13.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.259 -1.142 . . . . 0.0 109.535 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.454 HD13 ' CG1' ' A' ' 86' ' ' VAL . 10.5 tt -81.73 -18.12 45.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.703 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.459 ' CG2' ' O ' ' A' ' 142' ' ' ILE . 69.3 mt -89.88 37.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.78 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 60.7 m -117.84 -36.15 3.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.073 -1.017 . . . . 0.0 109.688 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.412 ' HA3' HG22 ' A' ' 88' ' ' VAL . . . -105.12 -18.01 12.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.437 ' HG ' ' N ' ' A' ' 146' ' ' GLN . 4.9 tp -65.31 -102.47 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.123 -1.221 . . . . 0.0 109.581 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.437 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 1.4 mp0 47.2 28.44 0.99 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.835 -1.166 . . . . 0.0 110.012 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.449 ' OXT' ' CD ' ' A' ' 91' ' ' LYS . 3.1 m . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.95 -1.024 . . . . 0.0 109.589 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.547 ' CAB' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.411 ' O ' ' O ' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.466 HD12 ' CD1' ' A' ' 73' ' ' LEU . 12.3 mt 53.81 174.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.277 -1.131 . . . . 0.0 109.644 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.407 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 60.3 p -159.48 -157.88 0.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.183 -0.948 . . . . 0.0 109.964 179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.93 -31.79 18.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.539 -0.726 . . . . 0.0 109.408 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.405 ' O ' HG22 ' A' ' 9' ' ' VAL . . . -94.22 -16.43 23.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.343 -0.848 . . . . 0.0 109.61 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.407 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 46.9 mt-30 -81.35 -46.86 14.05 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.131 -0.981 . . . . 0.0 109.621 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.455 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -54.84 -31.66 59.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.089 -1.007 . . . . 0.0 109.468 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.455 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 27.7 mm100 -70.78 -37.43 73.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 109.336 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 5' ' ' ALA . 47.3 t -69.71 -29.18 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.441 HG13 ' CD2' ' A' ' 73' ' ' LEU . 63.8 t -70.73 -43.76 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.309 -0.869 . . . . 0.0 109.291 179.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.61 -12.79 60.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.319 -0.863 . . . . 0.0 109.771 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.0 t -91.89 -27.79 17.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.403 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 18.7 p -90.93 -13.85 32.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.141 -0.974 . . . . 0.0 110.032 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.534 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -88.44 -15.07 36.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.068 -1.02 . . . . 0.0 109.865 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.42 -0.58 55.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.947 . . . . 0.0 109.924 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -113.3 -49.67 2.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.034 -1.041 . . . . 0.0 109.602 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.464 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 58.5 mt -69.43 -36.19 70.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.251 -0.906 . . . . 0.0 109.575 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.434 ' CB ' ' HA ' ' A' ' 22' ' ' ASN . . . -102.14 33.17 3.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 109.72 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -61.81 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 p -120.39 -36.74 3.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -1.123 . . . . 0.0 109.594 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.456 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 2.0 p30 -71.26 -19.15 62.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.261 -0.899 . . . . 0.0 109.665 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.434 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 28.4 t30 57.53 19.65 5.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -0.929 . . . . 0.0 109.635 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.413 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 105.46 19.36 10.58 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.456 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -64.91 -52.39 56.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -1.181 . . . . 0.0 109.596 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.472 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.23 -22.73 75.65 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.464 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 15.5 t -71.09 -41.01 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -1.086 . . . . 0.0 109.855 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' CA ' HD23 ' A' ' 63' ' ' LEU . . . -74.93 -57.19 4.53 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.472 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 15.8 ptpt -47.39 -31.3 3.93 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.208 -1.172 . . . . 0.0 110.228 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.426 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 23.4 pt-20 -95.79 -17.81 20.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.058 -1.026 . . . . 0.0 109.939 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 29.3 t -83.54 -68.11 0.74 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.948 . . . . 0.0 109.8 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.513 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.8 m-85 -50.32 -32.04 16.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -51.95 -55.05 22.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.1 -1.0 . . . . 0.0 109.165 179.718 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -57.68 -48.6 79.07 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.32 -0.862 . . . . 0.0 109.268 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.519 ' CG ' HD22 ' A' ' 106' ' ' LEU . 3.1 t80 -55.04 -49.05 72.54 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.195 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.465 ' CD2' ' HA ' ' A' ' 42' ' ' ALA . 23.2 mt -59.83 -41.57 91.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.854 . . . . 0.0 109.725 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.79 -63.34 1.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.935 . . . . 0.0 109.818 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.473 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -58.25 -21.36 48.12 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.203 -0.936 . . . . 0.0 109.886 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.473 ' CD2' ' HB3' ' A' ' 37' ' ' ALA . 16.5 m-70 -126.74 106.71 9.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.922 . . . . 0.0 109.933 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 5.5 m170 -85.88 -20.44 29.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.535 -0.728 . . . . 0.0 109.249 179.292 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -73.05 -20.29 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.248 -0.908 . . . . 0.0 109.098 179.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.485 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -91.86 -20.43 21.46 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -0.866 . . . . 0.0 109.537 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.465 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.26 -56.48 20.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.302 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.61 63.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.288 -0.882 . . . . 0.0 109.255 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.509 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 22.4 t -71.4 -58.45 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.288 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.515 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 39.7 m-85 -57.2 -40.69 77.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.58 35.18 1.1 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CD2' HG22 ' A' ' 55' ' ' VAL . 13.0 m-85 -125.62 169.0 12.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 109.858 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 t -112.34 18.07 18.85 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.351 -0.843 . . . . 0.0 109.372 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.3 -164.05 29.28 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.43 25.31 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -1.155 . . . . 0.0 109.716 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 37.6 m -124.78 31.04 5.77 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.623 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.54 135.45 21.9 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 109.642 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -64.07 -18.21 62.71 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.929 1.489 . . . . 0.0 109.972 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.518 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.62 -39.08 94.65 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.518 HG22 ' CD2' ' A' ' 47' ' ' PHE . 65.6 t -52.09 -38.56 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.322 -1.105 . . . . 0.0 109.411 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.467 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -74.01 -12.22 60.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 0.0 109.659 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -92.76 -35.5 13.4 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.972 . . . . 0.0 109.662 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.51 HD21 ' C1A' ' A' ' 148' ' ' HEM . 1.9 mt -79.43 -61.16 2.09 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.241 -0.912 . . . . 0.0 109.873 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.513 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -55.61 -36.47 64.8 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.467 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -60.85 -52.63 64.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.09 -1.241 . . . . 0.0 109.365 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.452 ' HB2' ' CGD' ' A' ' 148' ' ' HEM . 16.6 mttt -67.5 -41.99 83.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.308 -0.87 . . . . 0.0 109.183 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.452 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 63.3 t -56.42 -44.51 80.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.175 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.458 ' CD2' ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -48.17 -46.07 34.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.65 -49.46 56.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.107 -0.995 . . . . 0.0 109.33 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -52.99 -37.66 61.55 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -0.892 . . . . 0.0 109.088 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.568 ' CG2' ' CE1' ' A' ' 134' ' ' TYR . 34.7 mm -67.87 -35.75 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 109.063 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.43 -47.22 44.06 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 43.9 t -62.45 -25.43 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.361 -1.082 . . . . 0.0 109.439 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.41 ' O ' ' HB2' ' A' ' 73' ' ' LEU . . . -84.83 -30.7 24.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.411 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 53.8 t -62.68 -37.23 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.488 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.2 p -51.39 -69.28 0.12 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.923 . . . . 0.0 109.348 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.412 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 9.0 m-70 -90.82 45.32 1.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 109.192 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.466 ' CD1' HD12 ' A' ' 2' ' ' LEU . 30.4 tp -86.59 -16.53 36.49 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.244 -0.91 . . . . 0.0 109.526 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.7 -28.35 47.33 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.62 -157.12 0.59 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.327 -1.102 . . . . 0.0 109.543 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -173.36 46.38 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.913 . . . . 0.0 109.64 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -127.22 17.58 6.22 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.423 ' O ' ' N ' ' A' ' 81' ' ' ALA . 33.0 ttpt -163.25 -46.94 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.052 -1.264 . . . . 0.0 109.87 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.412 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 8.3 tmm? -48.25 -44.08 33.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.129 -0.982 . . . . 0.0 109.473 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.416 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 37.9 t -62.01 -24.46 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.857 . . . . 0.0 109.108 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.423 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -64.65 -52.86 55.11 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.266 -0.896 . . . . 0.0 109.23 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -66.91 -46.16 75.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.113 179.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.6 mtp -52.61 -48.91 66.01 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.453 ' NZ ' ' O ' ' A' ' 140' ' ' ALA . 0.2 OUTLIER -52.63 -34.22 50.27 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.182 -0.949 . . . . 0.0 108.894 179.389 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -66.58 -15.87 63.75 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.463 ' HB ' ' CD1' ' A' ' 141' ' ' LEU . 11.3 t -85.81 -32.52 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.033 -1.042 . . . . 0.0 108.624 179.315 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.464 ' CA ' HD23 ' A' ' 141' ' ' LEU . . . -71.26 -43.32 55.6 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 179.176 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.407 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 96.3 t -55.65 -25.93 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.38 -1.07 . . . . 0.0 108.62 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.509 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.3 OUTLIER -76.06 -49.53 17.25 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 108.996 179.301 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.482 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 24.5 m80 -62.04 -21.71 65.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.379 -0.826 . . . . 0.0 109.01 179.553 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.47 ' HG3' ' CB ' ' A' ' 147' ' ' SER . 0.2 OUTLIER -63.58 -14.13 48.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.396 -0.815 . . . . 0.0 109.972 -179.884 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.47 53.46 0.58 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.509 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.9 m-30 -91.31 -173.2 3.53 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -1.168 . . . . 0.0 109.349 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.45 -25.51 54.0 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 179.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.509 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 1.2 t30 -82.34 -45.49 14.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.463 -1.022 . . . . 0.0 109.179 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 9.0 ttpt 72.3 -53.75 0.69 Allowed 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.464 -0.773 . . . . 0.0 110.224 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 38.1 m170 -65.61 73.07 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.119 -0.988 . . . . 0.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.462 ' N ' ' O ' ' A' ' 96' ' ' LYS . 48.8 mt -104.81 155.03 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.521 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.508 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.7 mptp? -138.72 149.76 45.43 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.231 -0.918 . . . . 0.0 109.948 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.45 ' CB ' HG12 ' A' ' 142' ' ' ILE . . . -87.45 -18.79 29.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.527 -0.733 . . . . 0.0 109.628 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.45 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 17.7 pt-20 -67.22 -19.64 65.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.508 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 52.6 m-85 -82.06 -21.41 36.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.249 -0.907 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.52 ' CE1' ' CAB' ' A' ' 148' ' ' HEM . 4.5 m-85 -60.42 -64.56 0.91 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.294 -0.879 . . . . 0.0 110.205 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.487 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.77 -58.75 4.2 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.462 -0.774 . . . . 0.0 110.987 -179.328 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 7.4 Cg_endo -55.06 -47.29 27.26 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 123.63 1.332 . . . . 0.0 110.082 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.519 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.2 tm? -61.75 -22.43 65.39 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.151 -0.968 . . . . 0.0 109.428 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.98 -48.24 11.89 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.79 -51.26 70.75 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 109.595 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 m -58.9 -18.77 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.658 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.499 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 1.2 tt -75.71 -31.14 59.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.178 -0.951 . . . . 0.0 109.722 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.2 mt -71.29 -29.03 64.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 0.0 109.581 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.13 -34.29 70.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.916 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.404 ' HB3' ' HG3' ' A' ' 29' ' ' GLU . . . -80.89 -29.55 35.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.719 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.499 ' CE ' ' CD2' ' A' ' 110' ' ' LEU . 2.7 mtt -61.72 -34.16 75.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.896 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.448 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -61.49 -17.85 56.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.174 -0.954 . . . . 0.0 109.409 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -57.94 -49.14 77.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.721 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.1 ttt85 -74.25 -65.68 0.82 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.698 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.453 HG12 ' CD1' ' A' ' 17' ' ' ILE . 7.0 pt -92.31 53.19 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.258 -0.901 . . . . 0.0 109.726 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.448 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.49 -15.12 61.1 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.39 -30.95 6.68 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.71 -26.02 17.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -1.16 . . . . 0.0 109.791 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.42 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -60.19 97.67 0.05 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 -179.903 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 15.7 p-10 -106.42 -171.5 1.91 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.417 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.15 -49.48 77.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.388 -0.82 . . . . 0.0 109.952 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -58.4 -26.22 62.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.05 -1.031 . . . . 0.0 109.321 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -76.95 -54.01 7.11 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.231 -0.918 . . . . 0.0 109.849 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.417 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 6.3 ptmm? -70.9 -29.29 65.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.058 -1.026 . . . . 0.0 109.792 -179.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -77.85 -42.03 34.91 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -0.93 . . . . 0.0 109.607 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -65.53 -50.16 66.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.407 179.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.52 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 4.0 m0 -64.55 -28.77 69.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.299 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -65.23 -28.81 69.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.188 -0.945 . . . . 0.0 109.064 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -90.58 -24.32 20.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.395 -0.816 . . . . 0.0 109.373 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.46 ' CB ' HD23 ' A' ' 73' ' ' LEU . . . -77.47 -62.8 1.54 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.355 -0.841 . . . . 0.0 109.685 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.568 ' CE1' ' CG2' ' A' ' 66' ' ' ILE . 16.2 m-30 -52.0 -26.19 10.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.228 -0.92 . . . . 0.0 109.577 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.67 -44.85 69.64 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.208 -0.932 . . . . 0.0 108.904 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -75.41 -32.27 60.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.407 -0.808 . . . . 0.0 109.281 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.1 mt -67.46 -59.29 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.321 -0.862 . . . . 0.0 109.313 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.442 ' O ' ' CD1' ' A' ' 142' ' ' ILE . 2.4 p -67.25 -13.72 62.24 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.312 -0.868 . . . . 0.0 109.805 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.457 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -84.96 -21.74 54.69 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.453 ' O ' ' NZ ' ' A' ' 84' ' ' LYS . . . -86.24 -10.36 54.78 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 110.054 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.464 HD23 ' CA ' ' A' ' 87' ' ' GLY . 3.0 tt -89.14 17.24 6.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.029 -1.045 . . . . 0.0 109.882 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.457 ' CD1' ' HA2' ' A' ' 139' ' ' GLY . 1.9 mp -107.52 7.15 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.099 -1.001 . . . . 0.0 110.121 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.77 -34.48 11.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.945 -1.097 . . . . 0.0 109.63 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.83 11.1 27.52 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.459 HD12 ' CB ' ' A' ' 90' ' ' HIS . 11.4 tp -98.43 -11.66 22.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.106 -1.232 . . . . 0.0 109.863 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -98.34 62.21 1.46 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.044 -1.035 . . . . 0.0 109.725 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.47 ' CB ' ' HG3' ' A' ' 91' ' ' LYS . 2.7 m . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.696 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.52 ' CAB' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.504 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.429 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.429 ' HB2' ' O ' ' A' ' 1' ' ' GLY . 4.3 mm? 57.96 160.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.521 -0.987 . . . . 0.0 109.747 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.408 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -141.68 168.05 20.68 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.154 -0.966 . . . . 0.0 109.876 179.916 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -64.63 -28.16 69.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.365 -0.835 . . . . 0.0 109.601 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.21 -42.25 19.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.596 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 -64.34 -44.57 91.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.219 -0.926 . . . . 0.0 109.69 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.455 ' NH1' ' HA3' ' A' ' 74' ' ' GLY . 73.7 mtp180 -48.68 -50.55 32.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.512 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -59.0 -48.38 81.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 0.0 109.057 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.41 HG13 ' HA ' ' A' ' 126' ' ' ALA . 48.6 t -59.83 -36.11 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 0.0 109.145 179.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.463 HG13 ' CD1' ' A' ' 73' ' ' LEU . 65.7 t -72.14 -46.47 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.36 -0.837 . . . . 0.0 109.116 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.03 -18.01 61.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.53 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.8 t -87.12 -25.44 24.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.415 HG23 ' HB1' ' A' ' 126' ' ' ALA . 3.2 p -91.08 -17.19 26.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.547 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -87.02 -15.67 37.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.923 . . . . 0.0 109.841 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -84.45 -14.34 49.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.113 -0.992 . . . . 0.0 109.596 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -98.84 -51.25 3.94 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.156 -0.965 . . . . 0.0 109.614 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.49 HD11 ' CH2' ' A' ' 130' ' ' TRP . 62.2 mt -69.11 -36.41 73.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.249 -0.907 . . . . 0.0 109.585 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.547 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.27 33.16 3.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.692 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.2 -81.75 0.05 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.8 p -102.04 -17.49 16.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -1.149 . . . . 0.0 109.725 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.464 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 5.5 p-10 -89.02 -19.65 25.38 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.218 -0.926 . . . . 0.0 109.656 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 19.0 t30 59.32 24.57 13.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.238 -0.914 . . . . 0.0 109.674 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.94 22.69 14.93 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.027 -1.629 . . . . 0.0 109.027 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.464 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -71.12 -43.63 67.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.295 -1.12 . . . . 0.0 109.71 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.407 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.91 22.84 20.04 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.438 HG21 ' CG2' ' A' ' 17' ' ' ILE . 16.9 t -115.14 -34.23 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -1.194 . . . . 0.0 109.057 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.464 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -92.57 -39.39 5.31 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.469 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 2.5 ptmt -63.85 -30.01 71.14 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -1.225 . . . . 0.0 109.381 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.443 ' HG3' ' N ' ' A' ' 30' ' ' CYS . 6.5 pt-20 -92.59 -22.2 19.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.443 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 37.8 t -85.47 -51.44 6.52 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.294 -0.879 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.506 ' CE2' ' HB3' ' A' ' 58' ' ' LEU . 3.7 m-85 -53.63 -32.27 50.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.668 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 16.6 m -62.36 -28.38 69.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.968 . . . . 0.0 109.222 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.3 mmtt -81.65 -40.11 23.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.509 ' CD1' HD22 ' A' ' 106' ' ' LEU . 1.5 t80 -65.84 -55.55 16.51 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.265 -0.897 . . . . 0.0 109.362 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.451 ' CD1' HG22 ' A' ' 55' ' ' VAL . 25.3 mt -50.08 -44.62 52.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 0.0 109.722 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 40.1 p -66.36 -68.29 0.38 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.181 -0.949 . . . . 0.0 109.647 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.5 -27.17 15.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.452 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 17.7 m-70 -120.06 101.41 7.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -0.86 . . . . 0.0 109.756 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -83.63 -19.01 36.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.404 -0.81 . . . . 0.0 109.371 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 44' ' ' VAL . 7.8 p-10 -72.51 -13.02 61.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.597 179.576 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.479 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -105.6 -14.94 15.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.938 -179.826 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.06 -65.23 0.61 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.005 -1.06 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.42 -20.91 48.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.486 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 38.7 t -77.95 -39.0 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.288 -0.883 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.3 m-85 -74.39 -21.65 59.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.231 -0.918 . . . . 0.0 109.531 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.92 25.21 7.28 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CD2' HG22 ' A' ' 55' ' ' VAL . 10.7 m-85 -123.76 175.85 6.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -1.112 . . . . 0.0 109.802 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.57 18.4 15.04 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.392 -0.817 . . . . 0.0 109.352 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 147.97 -163.87 28.87 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.09 31.8 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.64 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.1 t -130.46 25.58 5.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.629 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.04 138.18 20.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -66.67 -22.77 49.97 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.994 1.523 . . . . 0.0 109.976 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.519 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.97 -31.67 58.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.53 HG22 ' CD2' ' A' ' 47' ' ' PHE . 92.9 t -54.19 -35.9 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.22 -1.164 . . . . 0.0 109.379 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.469 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -78.53 -5.16 51.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 0.0 109.809 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.42 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 37.0 m-20 -93.55 -27.45 16.62 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.03 -1.044 . . . . 0.0 109.558 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.52 HD21 ' C1A' ' A' ' 148' ' ' HEM . 6.4 mt -88.13 -63.97 1.22 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.073 -1.017 . . . . 0.0 109.354 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.464 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -51.19 -37.07 37.27 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -67.32 -34.34 77.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.859 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 0.0 OUTLIER -87.06 -34.49 19.15 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 109.785 -179.82 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.445 HG21 ' C ' ' A' ' 149' ' ' CMO . 24.4 t -67.24 -47.46 81.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.935 . . . . 0.0 109.719 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 63' ' ' LEU . 1.8 mm? -47.89 -46.99 32.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.79 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.78 -48.08 20.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.257 -0.902 . . . . 0.0 109.973 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -55.4 -53.3 58.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.111 -0.993 . . . . 0.0 109.42 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 52.2 mt -51.77 -38.47 22.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.362 -0.836 . . . . 0.0 109.176 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.543 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.06 -55.69 28.84 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.465 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 98.9 t -59.94 -29.2 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -1.126 . . . . 0.0 109.758 -179.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.45 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -84.76 -10.64 57.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 110.075 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.456 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 42.1 t -71.53 -42.32 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.012 -1.055 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.31 -12.49 59.96 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.056 -1.027 . . . . 0.0 110.032 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.483 ' N ' ' ND1' ' A' ' 72' ' ' HIS . 9.0 m80 -110.99 52.6 0.73 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.145 -0.972 . . . . 0.0 109.998 -179.306 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.463 ' CD1' HG13 ' A' ' 10' ' ' VAL . 90.0 mt -102.7 -35.14 8.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.936 . . . . 0.0 109.168 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.455 ' HA3' ' NH1' ' A' ' 7' ' ' ARG . . . -74.68 -48.05 13.75 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.732 -1.747 . . . . 0.0 108.732 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -136.51 -131.68 0.14 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.475 -1.015 . . . . 0.0 108.907 179.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.463 ' CB ' ' HB3' ' A' ' 72' ' ' HIS . 1.4 mt-10 50.75 31.35 5.84 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 120.961 -1.087 . . . . 0.0 108.8 -179.69 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.408 ' O ' ' HB ' ' A' ' 80' ' ' VAL . . . -47.59 -26.04 3.6 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 25.5 ttpt -55.44 -34.98 64.94 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.585 -0.95 . . . . 0.0 108.874 178.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.412 ' HG2' ' HB3' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -57.46 -29.08 63.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.156 -0.965 . . . . 0.0 108.884 179.551 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.408 ' HB ' ' O ' ' A' ' 77' ' ' GLY . 57.7 t -60.48 -30.51 46.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.364 -0.835 . . . . 0.0 108.747 179.236 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.77 -42.09 97.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.355 -0.841 . . . . 0.0 108.864 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -61.59 -53.06 61.26 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.368 -0.833 . . . . 0.0 108.931 179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 80.5 mmm -57.72 -40.41 79.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.278 -0.888 . . . . 0.0 108.829 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.88 -35.73 46.19 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.243 -0.911 . . . . 0.0 108.606 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -74.18 -36.06 64.03 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.425 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 49.0 t -56.92 -43.89 81.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.306 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.45 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -67.21 -51.38 38.78 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 179.173 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.445 HG22 ' CA ' ' A' ' 144' ' ' GLY . 53.1 t -58.76 -22.39 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.497 -1.002 . . . . 0.0 109.197 179.234 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.7 mmm180 -75.41 -41.59 55.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 109.13 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.514 ' HA ' ' CG ' ' A' ' 93' ' ' TYR . 4.8 m80 -60.31 -28.74 68.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.087 179.335 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 2.0 ttmt -52.44 -26.28 12.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 110.308 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -130.23 45.28 1.15 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.586 -1.292 . . . . 0.0 110.132 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.514 ' CG ' ' HA ' ' A' ' 90' ' ' HIS . 3.2 m-30 -86.01 -170.7 3.22 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.081 -1.246 . . . . 0.0 109.503 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.5 -48.15 45.88 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.486 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.5 OUTLIER -72.95 -44.69 60.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.472 -1.017 . . . . 0.0 109.163 179.777 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.477 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 6.4 tttp 72.55 -54.1 0.69 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.354 -0.841 . . . . 0.0 110.145 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -62.91 78.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.188 -0.945 . . . . 0.0 109.871 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.462 HG22 HD12 ' A' ' 98' ' ' ILE . 71.4 mt -113.46 163.27 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.125 -0.984 . . . . 0.0 109.69 -179.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -140.86 135.38 31.3 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.791 179.784 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.42 ' HA ' ' CD1' ' A' ' 103' ' ' PHE . . . -79.14 1.29 24.9 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.275 -0.89 . . . . 0.0 109.84 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.519 ' OE2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -80.45 -26.43 38.34 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 109.545 179.88 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.519 ' CD1' ' OE2' ' A' ' 101' ' ' GLU . 93.3 m-85 -78.03 -10.33 59.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.185 -0.947 . . . . 0.0 109.703 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.569 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 6.5 m-85 -62.51 -60.71 3.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 110.066 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.494 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.0 mt-10 -52.54 -55.72 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.203 -0.936 . . . . 0.0 110.004 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.494 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.97 -62.42 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.69 1.363 . . . . 0.0 109.768 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.509 HD22 ' CD1' ' A' ' 34' ' ' PHE . 3.4 tm? -55.83 -23.38 30.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.36 -0.838 . . . . 0.0 109.314 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.2 -48.17 9.97 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.41 -33.53 74.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.137 -1.213 . . . . 0.0 109.585 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.73 -27.86 63.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.216 -0.928 . . . . 0.0 109.5 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.449 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 2.2 tt -69.67 -35.6 75.29 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.447 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -59.73 -34.17 72.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 t -68.72 -33.03 73.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.669 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.424 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -76.37 -39.93 52.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.635 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.506 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 4.2 mtt -50.06 -38.58 38.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.17 -22.52 6.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.194 -0.941 . . . . 0.0 109.561 179.779 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.424 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -57.52 -47.75 81.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.4 ttt85 -73.06 -61.93 1.64 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.472 HG22 ' CG1' ' A' ' 17' ' ' ILE . 14.6 pt -97.27 55.88 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.331 -0.855 . . . . 0.0 109.63 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -62.17 -14.44 46.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -107.73 -27.44 5.18 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.41 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 6.2 mttm -93.92 -13.44 27.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -1.212 . . . . 0.0 110.146 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.408 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 4.0 tpt -71.99 98.23 2.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.509 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.405 ' O ' ' HB3' ' A' ' 126' ' ' ALA . 2.4 p-10 -104.6 169.16 8.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.447 -0.783 . . . . 0.0 109.514 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -49.16 -51.75 30.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.25 -0.906 . . . . 0.0 109.625 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -53.03 -26.72 16.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -0.931 . . . . 0.0 109.441 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.415 ' HB1' HG23 ' A' ' 13' ' ' THR . . . -75.69 -58.01 3.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.566 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.465 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 15.1 ptpt -63.68 -29.29 70.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.147 -0.97 . . . . 0.0 109.286 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.465 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 43.0 t0 -77.32 -43.04 34.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.411 -0.806 . . . . 0.0 109.407 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.454 ' HB3' ' CG2' ' A' ' 10' ' ' VAL . . . -65.34 -39.61 92.59 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 109.212 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.506 ' CZ3' ' HE2' ' A' ' 114' ' ' MET . 4.4 m0 -77.52 -28.32 52.01 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.353 -0.842 . . . . 0.0 108.986 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -66.34 -30.29 70.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.323 -0.861 . . . . 0.0 109.026 179.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.45 -34.06 20.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.393 -0.817 . . . . 0.0 109.167 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.412 ' HA ' HD23 ' A' ' 2' ' ' LEU . . . -74.07 -36.78 64.34 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.441 -0.787 . . . . 0.0 109.13 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.458 ' OH ' ' CE ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -57.65 -23.74 52.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.386 -0.821 . . . . 0.0 109.39 179.728 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.4 -32.01 42.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.547 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -80.86 -35.38 32.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.459 ' O ' ' CE ' ' A' ' 83' ' ' MET . 45.5 mt -74.62 -54.21 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.206 -0.934 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 12.2 p -71.0 -40.98 71.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 109.577 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -57.49 -47.53 87.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.86 -26.27 9.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.244 -1.151 . . . . 0.0 109.586 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.483 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.5 tt -84.98 -18.62 33.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.773 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.41 ' O ' ' NE2' ' A' ' 146' ' ' GLN . 76.5 mt -83.04 7.0 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 110.108 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.1 m -101.81 -27.6 12.92 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.056 -1.028 . . . . 0.0 109.62 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.445 ' CA ' HG22 ' A' ' 88' ' ' VAL . . . -100.07 -25.03 9.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.462 HD11 ' CD2' ' A' ' 141' ' ' LEU . 0.5 OUTLIER -63.85 -142.12 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.287 -1.125 . . . . 0.0 109.561 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 145' ' ' LEU . 3.3 mt-30 55.73 53.67 9.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.141 -0.974 . . . . 0.0 110.283 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.426 ' HA ' ' HG3' ' A' ' 91' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.016 -1.052 . . . . 0.0 109.607 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.569 ' CMC' ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.445 ' C ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.486 ' N ' ' CD2' ' A' ' 2' ' ' LEU . 4.4 mm? -95.21 166.96 11.65 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.264 -1.139 . . . . 0.0 109.71 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.414 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -99.49 167.39 10.64 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 109.638 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.29 -22.91 65.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.287 -0.883 . . . . 0.0 109.667 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.431 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . -88.58 -48.08 7.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -66.62 -54.02 27.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.794 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.473 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 1.2 ttp180 -50.06 -32.44 15.57 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.207 -0.933 . . . . 0.0 109.571 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 30.9 mm-40 -75.83 -43.85 43.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.332 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.472 HG13 ' CB ' ' A' ' 129' ' ' ALA . 24.5 t -61.67 -32.8 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.6 t -62.18 -45.63 98.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.4 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.6 -15.24 60.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 0.0 109.686 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -84.34 -24.04 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 109.694 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.478 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 35.5 p -100.5 -12.54 19.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.868 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -89.83 -27.65 19.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.102 -0.999 . . . . 0.0 109.81 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.7 mtpp -74.74 -9.87 58.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.167 -0.958 . . . . 0.0 109.708 179.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -102.31 -61.29 1.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.59 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.474 ' CG1' HG12 ' A' ' 118' ' ' ILE . 42.5 mt -57.74 -41.1 78.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 109.625 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.566 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -101.39 34.48 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.75 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.69 -69.11 1.32 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 p -113.94 -25.3 8.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 109.518 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 17.7 p-10 -80.65 -19.3 45.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.679 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.3 t30 60.32 21.34 10.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.262 -0.899 . . . . 0.0 109.641 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.81 20.39 31.47 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -65.5 -50.88 63.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.218 -1.166 . . . . 0.0 109.532 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.46 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.94 -5.0 86.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 43.5 t -87.47 -33.08 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.996 -1.296 . . . . 0.0 109.724 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.97 -41.01 9.87 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.46 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.3 ptpt -63.67 -31.87 73.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -1.18 . . . . 0.0 109.826 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.437 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 15.8 pt-20 -89.58 -14.71 34.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.167 -0.958 . . . . 0.0 110.083 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 42.2 t -91.58 -63.66 1.22 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.137 -0.977 . . . . 0.0 109.999 -179.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.513 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 14.3 m-85 -54.19 -37.34 64.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.226 -0.922 . . . . 0.0 109.907 -179.53 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.458 ' OG1' ' CG1' ' A' ' 55' ' ' VAL . 8.7 m -53.18 -32.88 50.15 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.051 -1.031 . . . . 0.0 108.907 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 3.9 mmtt -76.14 -47.48 24.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.34 -0.85 . . . . 0.0 109.067 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.512 ' CG ' HD22 ' A' ' 106' ' ' LEU . 5.1 t80 -61.41 -49.64 76.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.52 HD21 ' CD2' ' A' ' 45' ' ' PHE . 70.2 mt -54.83 -44.22 73.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.129 -0.982 . . . . 0.0 109.401 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.47 ' HB3' ' CB ' ' A' ' 50' ' ' ALA . 82.7 p -73.48 -66.09 0.74 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.366 -0.834 . . . . 0.0 109.982 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.456 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -49.61 -30.08 8.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.205 -0.934 . . . . 0.0 109.702 -179.724 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.422 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 23.0 m-70 -123.63 110.12 14.6 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.264 -0.898 . . . . 0.0 109.785 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -88.93 -18.66 27.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.502 -0.748 . . . . 0.0 109.31 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -66.51 -21.1 66.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.264 -0.897 . . . . 0.0 109.227 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.519 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 88.6 mmm -107.91 -23.94 11.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 109.75 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.37 -34.29 15.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.865 -1.147 . . . . 0.0 109.136 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.67 -36.75 70.73 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.354 -0.841 . . . . 0.0 109.118 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.521 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 20.4 t -58.41 -63.7 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.034 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.613 ' CE1' ' C1B' ' A' ' 148' ' ' HEM . 84.4 m-85 -56.42 -27.59 56.97 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.319 -0.863 . . . . 0.0 109.1 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 42' ' ' ALA . . . 108.99 -138.45 14.76 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 1.7 m-85 61.04 170.65 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.105 -1.232 . . . . 0.0 109.83 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.4 t -115.01 25.79 10.63 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.67 -163.94 27.51 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.47 ' CB ' ' HB3' ' A' ' 36' ' ' SER . . . -89.25 16.36 7.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.165 -1.197 . . . . 0.0 109.901 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.99 35.29 4.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.116 -0.99 . . . . 0.0 109.691 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.465 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 2.8 t70 -114.43 137.37 22.58 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.616 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -62.75 -24.46 74.65 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.92 1.484 . . . . 0.0 110.067 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.54 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -40.7 47.22 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.462 HG22 ' CD2' ' A' ' 47' ' ' PHE . 67.3 t -49.95 -34.03 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -1.143 . . . . 0.0 109.474 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.453 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -75.72 -20.66 58.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -86.37 -46.81 9.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.639 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.51 HD21 ' C1A' ' A' ' 148' ' ' HEM . 0.9 OUTLIER -64.59 -62.76 1.39 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.204 -0.935 . . . . 0.0 109.581 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.513 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.97 -47.44 40.14 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -57.41 -40.21 77.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -1.185 . . . . 0.0 109.587 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -74.55 -24.37 58.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.41 HG21 ' C ' ' A' ' 149' ' ' CMO . 51.2 t -81.9 -49.14 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.901 . . . . 0.0 109.641 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -48.15 -46.6 34.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.926 . . . . 0.0 109.751 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.8 -50.86 59.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.256 -0.902 . . . . 0.0 109.821 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 33.5 tp60 -48.75 -51.25 29.97 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.087 -1.008 . . . . 0.0 109.577 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.492 HD12 ' CE2' ' A' ' 134' ' ' TYR . 96.7 mt -56.46 -30.97 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.223 -0.923 . . . . 0.0 109.043 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.536 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -68.66 -56.9 8.71 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.8 t -57.8 -20.71 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.247 -1.149 . . . . 0.0 109.243 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.412 ' O ' HD23 ' A' ' 73' ' ' LEU . . . -88.02 -34.1 18.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.675 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.458 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 55.1 t -60.84 -15.89 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.202 -0.936 . . . . 0.0 109.887 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.501 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 23.9 m -91.55 16.14 11.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.182 -0.949 . . . . 0.0 110.29 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.9 m-70 -160.95 40.82 0.16 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.926 -1.109 . . . . 0.0 110.37 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.473 ' HB2' ' CG ' ' A' ' 7' ' ' ARG . 22.7 mt -68.69 -37.67 79.72 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.013 -1.055 . . . . 0.0 109.479 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.63 -26.22 36.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -103.64 96.64 6.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -1.112 . . . . 0.0 109.583 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.83 33.47 1.67 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.518 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -82.35 -24.97 52.93 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -133.14 -37.62 0.98 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.251 -1.147 . . . . 0.0 109.967 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.445 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 14.7 ttp -47.84 -48.19 31.06 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.19 -0.944 . . . . 0.0 109.694 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.45 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.5 t -70.39 -23.1 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.222 -0.924 . . . . 0.0 109.284 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.76 -37.03 73.37 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.214 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.39 -49.12 11.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.264 179.681 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.461 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 3.1 mtp -59.47 -46.17 89.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.233 -0.917 . . . . 0.0 109.103 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 3.8 tptp -53.49 -33.4 54.2 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 108.915 179.426 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.414 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -70.9 -33.43 70.55 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.401 -0.812 . . . . 0.0 109.248 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.4 HG23 ' HA ' ' A' ' 83' ' ' MET . 44.4 t -62.66 -52.25 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 109.237 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -52.35 -42.55 56.71 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.422 ' HA ' ' HD2' ' A' ' 91' ' ' LYS . 95.7 t -51.8 -26.6 7.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.346 -1.091 . . . . 0.0 109.231 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.418 ' HB2' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -80.91 -24.76 38.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.273 -0.892 . . . . 0.0 108.848 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.493 ' HB3' HD12 ' A' ' 98' ' ' ILE . 41.4 m80 -82.1 -4.67 57.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.528 -0.732 . . . . 0.0 109.894 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.422 ' HD2' ' HA ' ' A' ' 88' ' ' VAL . 8.9 ptmm? -81.8 -8.64 59.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.796 -1.19 . . . . 0.0 110.357 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -164.33 59.42 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.153 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.519 ' CG ' HBA1 ' A' ' 148' ' ' HEM . 0.9 OUTLIER -84.21 -163.5 0.8 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.267 . . . . 0.0 109.25 179.021 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.9 -26.48 74.31 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 -179.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.521 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 18.7 p-10 -91.79 -32.88 15.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.258 . . . . 0.0 109.933 -179.668 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.441 ' O ' ' CD2' ' A' ' 97' ' ' HIS . 0.0 OUTLIER 56.85 30.93 18.72 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.129 -0.982 . . . . 0.0 109.649 179.894 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.441 ' CD2' ' O ' ' A' ' 96' ' ' LYS . 38.2 m170 -137.44 47.44 2.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.159 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.493 HD12 ' HB3' ' A' ' 90' ' ' HIS . 59.7 mt -89.9 159.78 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.286 -0.884 . . . . 0.0 110.576 -179.172 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.473 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -152.27 142.17 22.08 Favored 'General case' 0 N--CA 1.487 1.424 0 CA-C-O 121.636 0.732 . . . . 0.0 109.684 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.431 ' CB ' HG22 ' A' ' 142' ' ' ILE . . . -78.98 -3.02 42.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.647 -0.658 . . . . 0.0 109.62 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -73.11 -33.19 65.42 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.975 -1.078 . . . . 0.0 109.488 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.519 ' CD1' ' HG3' ' A' ' 41' ' ' MET . 85.9 m-85 -78.46 -15.58 58.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.244 -0.91 . . . . 0.0 110.125 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.564 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 4.6 m-85 -59.66 -63.4 1.31 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.163 -0.961 . . . . 0.0 110.248 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.477 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.4 mt-10 -45.49 -58.43 5.95 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.427 -0.796 . . . . 0.0 110.797 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.477 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 11.2 Cg_endo -59.99 -46.1 20.89 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.748 1.394 . . . . 0.0 109.923 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.512 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.2 tm? -67.11 -20.02 65.72 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 109.25 179.709 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -84.47 -47.38 5.45 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.55 -28.26 66.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -1.114 . . . . 0.0 109.354 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.89 -34.74 69.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.3 -0.875 . . . . 0.0 109.482 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.453 ' CD1' ' OH ' ' A' ' 134' ' ' TYR . 2.5 tt -65.38 -34.43 78.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.198 -0.938 . . . . 0.0 109.425 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 11.2 mt -58.51 -35.48 72.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.097 -1.002 . . . . 0.0 109.132 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 21.2 t -70.09 -26.31 63.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.429 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.502 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.93 -33.15 21.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.444 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 0.8 OUTLIER -53.87 -44.26 70.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.995 -179.675 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.452 ' O ' ' N ' ' A' ' 119' ' ' GLY . 8.1 pt-20 -51.77 -23.01 4.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.23 -0.919 . . . . 0.0 109.818 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.502 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 20.9 m170 -48.97 -41.44 34.17 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.165 -0.959 . . . . 0.0 109.71 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.3 ttt85 -83.48 -55.77 4.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.432 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.474 HG12 ' CG1' ' A' ' 17' ' ' ILE . 3.9 pt -106.64 59.23 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.302 -0.874 . . . . 0.0 109.558 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -67.48 -29.29 73.94 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.75 -18.2 56.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.416 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.1 mttt -105.04 -20.36 13.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.067 -1.255 . . . . 0.0 110.102 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.421 ' N ' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -73.01 80.99 1.21 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.421 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.41 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.2 p30 -82.29 -162.17 0.53 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -0.853 . . . . 0.0 109.706 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -69.13 -43.13 74.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.469 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.477 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -60.76 -32.25 71.56 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.171 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -68.42 -53.03 26.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.462 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.46 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.3 ptpt -70.45 -29.03 65.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.193 -0.942 . . . . 0.0 109.379 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.46 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 24.2 t0 -80.42 -40.72 25.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.329 -0.857 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -61.66 -42.91 99.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.478 ' CE2' ' OG1' ' A' ' 13' ' ' THR . 9.2 m0 -75.4 -34.24 61.04 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.3 -0.875 . . . . 0.0 108.846 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.85 -23.48 31.07 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.163 -0.961 . . . . 0.0 108.764 178.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -92.39 -46.28 7.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.43 -0.794 . . . . 0.0 109.308 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.34 -54.08 10.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.263 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.492 ' CE2' HD12 ' A' ' 66' ' ' ILE . 1.3 t80 -49.78 -30.46 9.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.215 179.608 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -74.61 -38.33 62.6 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.309 -0.869 . . . . 0.0 108.877 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.38 -31.69 48.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.399 -0.813 . . . . 0.0 109.27 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 54.9 mt -66.8 -60.53 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.258 -0.901 . . . . 0.0 108.909 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.408 ' O ' HG12 ' A' ' 142' ' ' ILE . 26.4 p -66.98 -18.09 65.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -0.795 . . . . 0.0 109.765 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -75.31 -45.81 17.79 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.13 -22.0 65.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.222 -1.163 . . . . 0.0 109.808 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.461 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 2.9 tt -77.87 -13.9 59.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 0.0 109.957 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.431 HG22 ' CB ' ' A' ' 100' ' ' ALA . 37.1 mm -79.68 -12.99 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.417 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 27.5 m -68.54 -64.67 0.82 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.103 -0.998 . . . . 0.0 109.733 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.56 -11.28 68.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.504 ' O ' ' CG ' ' A' ' 146' ' ' GLN . 9.7 tt -86.27 173.71 9.57 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.036 -1.273 . . . . 0.0 109.301 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.504 ' CG ' ' O ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 63.36 29.15 15.69 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.684 -0.635 . . . . 0.0 110.226 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.414 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 9.9 p . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.787 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.613 ' C1B' ' CE1' ' A' ' 45' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.505 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 1' ' ' GLY . 4.1 mm? 60.02 141.71 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.627 -0.925 . . . . 0.0 110.153 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.417 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -130.71 168.75 16.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.064 -1.023 . . . . 0.0 109.766 179.913 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.73 -38.67 72.69 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -0.891 . . . . 0.0 109.695 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.451 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . -69.29 -56.55 7.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.27 -0.894 . . . . 0.0 109.73 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.41 ' O ' HG23 ' A' ' 10' ' ' VAL . 75.8 mt-30 -58.38 -55.74 31.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 109.661 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.452 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 3.0 ttp180 -49.11 -37.9 23.1 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.286 -0.884 . . . . 0.0 109.625 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -74.28 -40.59 62.21 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.381 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 5' ' ' ALA . 39.5 t -65.0 -24.85 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.89 . . . . 0.0 109.449 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.458 HG12 ' CD1' ' A' ' 130' ' ' TRP . 97.4 t -70.02 -34.72 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.236 -0.915 . . . . 0.0 109.559 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.09 -13.16 59.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -0.901 . . . . 0.0 109.913 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.74 -19.6 22.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.14 -0.975 . . . . 0.0 109.845 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.493 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.5 p -101.29 -14.83 17.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.126 -0.984 . . . . 0.0 109.956 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.548 ' CE3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -87.03 -32.42 20.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.687 -179.776 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.2 mtpt -69.71 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.606 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.9 m-20 -99.24 -60.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.118 -0.989 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.451 ' CG1' HG12 ' A' ' 118' ' ' ILE . 66.3 mt -61.17 -41.15 88.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.262 -0.899 . . . . 0.0 109.538 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.548 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -96.34 31.67 2.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.293 -0.879 . . . . 0.0 109.511 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.48 -69.9 1.11 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.6 p -110.29 -32.66 6.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -1.163 . . . . 0.0 109.613 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -74.93 -18.98 60.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.905 . . . . 0.0 109.638 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 19.6 t30 59.39 21.08 9.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 109.597 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.416 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 97.89 34.68 5.36 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.36 -56.34 3.57 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.229 -1.16 . . . . 0.0 109.576 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.473 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -66.53 -14.74 62.87 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.485 ' CG1' ' CD2' ' A' ' 63' ' ' LEU . 37.8 t -89.18 -11.59 10.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -1.185 . . . . 0.0 109.942 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.506 ' CA ' ' CD1' ' A' ' 63' ' ' LEU . . . -100.06 -41.77 2.76 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.473 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -74.74 -22.15 58.96 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.119 -1.224 . . . . 0.0 110.003 -179.512 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.447 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 22.3 pt-20 -92.38 -21.96 19.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.116 -0.99 . . . . 0.0 109.701 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.4 t -87.18 -68.0 0.78 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.254 -0.903 . . . . 0.0 110.083 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 29.2 m-85 -46.62 -33.43 4.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.292 -0.88 . . . . 0.0 110.246 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.47 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.79 -52.11 61.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.067 -1.02 . . . . 0.0 109.384 179.699 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.4 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 7.2 mttt -65.18 -46.03 82.45 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.281 -0.887 . . . . 0.0 109.698 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CG ' HD22 ' A' ' 106' ' ' LEU . 9.4 t80 -49.53 -49.43 46.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.228 -0.92 . . . . 0.0 109.544 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.493 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 14.1 mt -57.99 -46.75 84.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.491 ' O ' ' CD2' ' A' ' 39' ' ' HIS . 0.4 OUTLIER -64.56 -62.15 1.76 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.923 . . . . 0.0 109.525 179.907 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.48 -27.15 23.66 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.222 -0.924 . . . . 0.0 109.524 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.456 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 18.9 m-70 -120.49 97.27 5.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.491 ' CD2' ' O ' ' A' ' 36' ' ' SER . 64.4 m170 -83.08 4.15 27.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.016 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.405 ' OD2' ' OH ' ' A' ' 102' ' ' TYR . 17.6 p-10 -94.95 -13.4 25.38 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.081 -1.012 . . . . 0.0 109.942 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.458 ' CE ' HMB3 ' A' ' 148' ' ' HEM . 98.0 mmm -112.85 -19.25 12.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.086 -1.009 . . . . 0.0 109.966 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -47.64 -40.34 19.44 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.181 -0.949 . . . . 0.0 109.859 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.154 -0.966 . . . . 0.0 109.509 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.52 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 45.9 t -81.2 -34.64 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.557 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.503 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 24.0 m-85 -76.88 -11.66 59.85 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 110.124 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.4 25.47 25.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CD2' HG22 ' A' ' 55' ' ' VAL . 14.0 m-85 -125.58 168.64 13.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.912 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.99 -17.39 14.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.416 -0.802 . . . . 0.0 109.202 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.98 -161.6 23.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.99 28.34 3.58 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.325 -1.103 . . . . 0.0 109.713 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 72.1 p -118.02 -16.36 9.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.257 -0.902 . . . . 0.0 109.795 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.1 p-10 -73.07 142.74 82.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.213 -0.93 . . . . 0.0 109.706 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -72.89 -17.38 25.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.976 1.514 . . . . 0.0 110.19 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.5 -38.54 35.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.518 HG22 ' CD2' ' A' ' 47' ' ' PHE . 63.2 t -51.09 -35.92 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.469 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -71.15 -7.15 44.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.27 -0.894 . . . . 0.0 109.691 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.76 -28.26 18.38 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.065 -1.022 . . . . 0.0 109.648 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.527 HD21 ' C1A' ' A' ' 148' ' ' HEM . 11.5 mt -88.73 -63.74 1.25 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.071 -1.018 . . . . 0.0 109.681 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.515 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -50.29 -46.99 43.79 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.3 -24.46 19.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -1.156 . . . . 0.0 109.662 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.26 -23.79 12.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.717 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.456 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 43.4 t -73.23 -56.72 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.983 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.506 ' CD1' ' CA ' ' A' ' 27' ' ' GLY . 0.2 OUTLIER -47.22 -41.13 17.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.141 -0.974 . . . . 0.0 109.851 -179.927 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.98 -43.19 50.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.469 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 7.2 tp-100 -62.69 -41.5 99.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.083 -1.011 . . . . 0.0 109.195 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.492 HD13 ' CE1' ' A' ' 134' ' ' TYR . 63.0 mt -57.95 -36.18 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.278 -0.889 . . . . 0.0 108.83 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.522 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.88 -59.63 8.86 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 108.689 -1.765 . . . . 0.0 108.689 179.294 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 74.3 t -54.35 -26.16 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.276 -1.132 . . . . 0.0 109.04 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.94 -28.88 25.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.41 -0.806 . . . . 0.0 109.594 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.434 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 52.5 t -68.8 -9.64 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.499 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 18.3 t -93.2 33.57 1.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.007 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.499 ' CG ' ' O ' ' A' ' 71' ' ' SER . 9.1 m-70 -160.25 -87.41 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.189 -0.944 . . . . 0.0 109.731 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.452 ' HB2' ' CG ' ' A' ' 7' ' ' ARG . 24.3 mt 63.33 -72.07 0.05 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.482 -0.762 . . . . 0.0 110.037 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -75.97 -20.67 77.5 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.208 -1.557 . . . . 0.0 109.208 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -107.12 95.95 6.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.239 -1.154 . . . . 0.0 109.635 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -92.76 35.3 1.04 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.531 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.1 63.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.404 ' O ' ' N ' ' A' ' 81' ' ' ALA . 12.5 ttpp -140.54 -39.3 0.43 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.274 . . . . 0.0 110.099 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 64.4 ttp -47.78 -56.32 7.66 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.148 -0.97 . . . . 0.0 109.683 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.411 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 98.0 t -60.1 -18.19 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.24 -0.912 . . . . 0.0 109.421 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.404 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -80.8 -21.28 41.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.295 179.714 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.91 -47.39 7.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.544 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.439 ' CB ' ' HB3' ' A' ' 140' ' ' ALA . 99.2 mmm -62.15 -41.08 97.93 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.027 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.411 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -52.98 -32.61 47.17 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.052 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.417 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -76.31 -33.25 59.03 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.077 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.403 HG13 HD13 ' A' ' 141' ' ' LEU . 71.3 t -65.05 -53.12 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.076 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.42 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -53.51 -39.84 60.93 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 85.7 t -53.98 -28.34 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -1.113 . . . . 0.0 109.266 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.8 mmt180 -75.19 -48.9 21.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 0.0 108.959 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.468 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 54.1 m80 -57.64 -22.37 45.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.306 -0.871 . . . . 0.0 108.912 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.459 ' CG ' ' HA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -72.4 -9.82 59.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.414 -0.804 . . . . 0.0 109.941 179.86 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.76 50.39 0.75 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.6 m-30 -92.1 -174.11 3.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -1.15 . . . . 0.0 109.512 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.89 -28.48 41.86 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.52 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.7 OUTLIER -83.76 -46.17 12.54 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.579 -0.953 . . . . 0.0 108.923 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.6 mtpt 72.72 -49.96 0.7 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.56 -0.713 . . . . 0.0 110.76 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.3 m170 -66.46 63.14 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.01 -1.056 . . . . 0.0 110.596 -179.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.448 ' N ' ' O ' ' A' ' 96' ' ' LYS . 96.7 mt -94.08 159.15 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.089 -1.007 . . . . 0.0 109.235 179.431 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.418 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -139.63 141.78 37.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.17 -0.956 . . . . 0.0 109.852 -179.929 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.86 8.24 18.12 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.855 . . . . 0.0 109.685 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -85.09 -29.9 24.5 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.151 -0.968 . . . . 0.0 108.697 179.784 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.462 ' CB ' HBB2 ' A' ' 148' ' ' HEM . 93.5 m-85 -79.09 -17.01 55.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.32 -0.862 . . . . 0.0 109.636 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.536 ' CE1' ' CAB' ' A' ' 148' ' ' HEM . 4.0 m-85 -56.6 -60.14 3.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.23 -0.919 . . . . 0.0 110.169 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.484 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.4 mt-10 -52.82 -57.41 16.15 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.148 -0.97 . . . . 0.0 110.066 -179.453 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 34.7 Cg_exo -48.88 -58.88 1.49 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 O-C-N 123.626 1.329 . . . . 0.0 110.13 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.518 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -54.94 -28.89 54.64 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.388 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.26 -50.12 13.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.42 -37.49 87.72 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -1.128 . . . . 0.0 109.503 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 t -68.48 -35.25 77.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.326 -0.859 . . . . 0.0 109.576 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.435 HD23 ' CG1' ' A' ' 26' ' ' VAL . 3.8 tt -67.02 -31.57 72.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.398 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.434 HD12 ' N ' ' A' ' 131' ' ' ALA . 12.1 mt -61.43 -33.35 73.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.161 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 2.7 t -72.93 -26.77 61.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.398 179.68 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.48 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -85.46 -22.75 28.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.487 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.6 mtt -65.0 -36.43 84.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.351 -0.843 . . . . 0.0 109.882 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' N ' ' A' ' 119' ' ' GLY . 12.5 pt-20 -58.53 -18.47 29.73 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.464 179.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.48 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 28.4 m170 -56.04 -36.12 67.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.223 -0.923 . . . . 0.0 109.483 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -89.72 -42.37 11.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.309 -0.87 . . . . 0.0 109.362 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.462 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 3.1 pt -119.03 57.01 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.865 . . . . 0.0 109.473 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -64.57 -18.67 63.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.31 -28.53 8.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.434 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.8 mttt -94.44 -17.51 22.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.184 -1.186 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.462 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -76.54 86.2 3.24 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.109 -0.995 . . . . 0.0 109.371 179.762 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -93.61 -163.2 1.02 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.845 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.439 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -68.44 -44.57 74.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -0.856 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.455 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -61.54 -26.06 67.69 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.112 -0.992 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.99 -52.57 8.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.314 -0.866 . . . . 0.0 109.792 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.439 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 9.7 ptmm? -71.74 -25.69 62.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.215 -0.928 . . . . 0.0 109.906 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -84.32 -36.32 22.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.112 -0.992 . . . . 0.0 109.745 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.95 -43.18 72.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.361 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.493 ' CE2' ' OG1' ' A' ' 13' ' ' THR . 4.5 m0 -71.41 -36.72 71.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.281 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.434 ' N ' HD12 ' A' ' 111' ' ' LEU . . . -60.97 -33.9 73.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.119 179.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.66 -30.78 36.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.32 -0.862 . . . . 0.0 109.277 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.13 -40.19 24.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.354 -0.841 . . . . 0.0 109.288 179.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.492 ' CE1' HD13 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -50.26 -34.75 24.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.264 179.642 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.38 -28.26 62.9 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.083 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -83.43 -39.25 20.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.381 -0.824 . . . . 0.0 109.337 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.431 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.6 mt -65.95 -58.25 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.149 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -68.66 -19.7 64.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.403 -0.81 . . . . 0.0 109.63 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -65.96 -57.73 10.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.439 ' HB3' ' CB ' ' A' ' 83' ' ' MET . . . -49.33 -26.36 3.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 0.0 109.756 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.413 HD23 ' HB2' ' A' ' 145' ' ' LEU . 7.5 tt -74.41 -12.47 60.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.97 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' A' ' 142' ' ' ILE . 75.6 mt -91.37 21.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.089 -1.007 . . . . 0.0 109.763 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.4 t -105.82 -32.87 8.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.167 -0.958 . . . . 0.0 109.691 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -121.46 16.39 9.1 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.42 ' HB2' ' CA ' ' A' ' 87' ' ' GLY . 4.5 tt -98.71 2.12 46.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.109 -1.23 . . . . 0.0 110.126 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -113.22 68.12 0.67 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.038 -1.039 . . . . 0.0 109.682 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.459 ' HA ' ' CG ' ' A' ' 91' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.536 ' CAB' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.404 ' C ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 mt -60.22 163.55 4.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.195 -1.179 . . . . 0.0 109.766 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 p -136.49 -172.55 3.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 109.542 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -10.14 59.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.936 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -107.57 -50.11 3.13 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.142 -0.974 . . . . 0.0 109.547 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -60.14 -44.25 95.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.459 ' CG ' ' HB3' ' A' ' 73' ' ' LEU . 5.6 ttp180 -57.17 -29.27 63.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.506 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -82.89 -34.26 26.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.829 . . . . 0.0 109.45 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 57.8 t -67.62 -19.57 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.177 -0.952 . . . . 0.0 109.589 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.448 HG21 ' CB ' ' A' ' 133' ' ' ALA . 93.0 t -73.82 -47.1 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -0.947 . . . . 0.0 109.627 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.26 -13.98 62.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.935 . . . . 0.0 109.841 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.63 -21.65 20.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.184 -0.948 . . . . 0.0 109.9 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -97.67 -12.76 22.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.141 -0.974 . . . . 0.0 110.023 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.03 -28.06 17.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.037 -1.039 . . . . 0.0 109.726 -179.884 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -73.26 -10.92 60.26 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.852 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -104.06 -46.71 4.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.108 -0.995 . . . . 0.0 109.62 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.469 ' CG1' HG12 ' A' ' 118' ' ' ILE . 40.5 mt -70.23 -39.58 77.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.276 -0.89 . . . . 0.0 109.685 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.564 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.1 34.42 2.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.552 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.51 -65.47 3.53 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 26.6 p -111.96 -33.67 6.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.236 -1.155 . . . . 0.0 109.714 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -76.63 -18.3 58.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.739 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.426 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 4.3 t30 57.77 20.47 6.51 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.6 21.52 19.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.02 -54.3 23.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.299 -1.118 . . . . 0.0 109.566 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.48 2.02 74.22 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.462 ' CG1' HD13 ' A' ' 63' ' ' LEU . 36.9 t -91.94 -40.31 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.053 -1.263 . . . . 0.0 109.529 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.44 -50.54 5.67 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.658 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.468 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 6.4 ptpt -52.7 -30.29 31.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.148 -1.207 . . . . 0.0 109.784 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.453 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.5 pt-20 -91.96 -22.7 19.87 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 109.847 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.4 t -83.14 -65.4 1.01 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.183 -0.948 . . . . 0.0 109.989 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.497 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 11.3 m-85 -48.46 -29.32 3.98 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 110.024 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.411 ' HA ' HD11 ' A' ' 35' ' ' LEU . 19.5 m -62.98 -60.95 2.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 109.649 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.406 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 13.0 mttm -50.02 -38.02 35.6 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.583 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' CG ' HD22 ' A' ' 106' ' ' LEU . 13.2 t80 -69.09 -54.91 12.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.552 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.511 HD21 ' CD2' ' A' ' 45' ' ' PHE . 12.4 mt -50.57 -44.11 56.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.625 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.438 ' HB3' ' CB ' ' A' ' 50' ' ' ALA . 18.9 p -65.73 -51.45 59.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.234 -0.916 . . . . 0.0 109.719 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.438 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -67.32 -19.42 65.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.239 -0.913 . . . . 0.0 109.755 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 37' ' ' ALA . 27.8 m-70 -124.51 101.33 7.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.955 . . . . 0.0 109.721 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -86.35 3.53 43.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 110.04 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -93.39 -20.37 20.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.032 -1.043 . . . . 0.0 109.534 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.484 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 88.1 mmm -104.68 -23.29 13.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.703 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.461 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.26 -34.14 14.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.096 -1.003 . . . . 0.0 109.614 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.12 -22.48 48.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.35 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.513 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 46.8 t -74.35 -58.3 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -0.868 . . . . 0.0 109.49 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.515 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 68.1 m-85 -52.47 -31.21 33.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.567 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.62 2.89 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 10.4 m-85 -124.02 166.96 14.84 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.304 -1.115 . . . . 0.0 109.761 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.0 t -105.36 -21.07 13.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.39 -0.819 . . . . 0.0 109.114 179.308 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -169.43 -163.63 23.79 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.438 ' CB ' ' HB3' ' A' ' 36' ' ' SER . . . -93.29 29.01 2.02 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.196 -1.179 . . . . 0.0 109.615 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.53 27.78 6.42 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.603 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.478 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.9 p-10 -116.52 141.09 27.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.88 . . . . 0.0 109.708 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -67.41 -22.58 45.24 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 124.01 1.531 . . . . 0.0 110.135 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.524 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.83 -38.58 37.67 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.506 HG22 ' CD2' ' A' ' 47' ' ' PHE . 88.4 t -50.8 -39.7 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -1.092 . . . . 0.0 109.428 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.468 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.02 -20.53 61.68 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.306 -0.871 . . . . 0.0 109.256 179.572 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -74.3 -37.29 63.69 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.48 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.447 ' O ' ' CG2' ' A' ' 62' ' ' VAL . 10.0 mt -85.42 -56.16 3.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -0.95 . . . . 0.0 109.555 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.497 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -48.52 -49.07 27.54 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.41 -39.41 87.29 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -1.174 . . . . 0.0 109.74 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.3 mttt -77.83 -30.26 51.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.274 -0.891 . . . . 0.0 109.646 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.447 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 41.6 t -76.19 -51.86 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.593 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.462 HD13 ' CG1' ' A' ' 26' ' ' VAL . 2.1 mm? -48.93 -47.29 43.68 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.66 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.16 -42.95 41.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.735 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.471 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 7.4 tp-100 -58.33 -43.66 88.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 109.384 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.451 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 40.7 mt -59.58 -38.7 76.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.264 -0.898 . . . . 0.0 109.033 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.44 -53.43 28.76 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.279 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 51.8 t -54.06 -31.16 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.317 -1.108 . . . . 0.0 108.962 179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.407 ' O ' ' CD2' ' A' ' 73' ' ' LEU . . . -82.35 -31.46 29.79 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.385 -0.822 . . . . 0.0 109.27 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 52.1 t -69.96 -15.3 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.332 -0.855 . . . . 0.0 109.629 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.6 m -85.21 10.86 11.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.039 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.528 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.1 m-70 -126.27 -72.96 0.63 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.07 -1.019 . . . . 0.0 109.685 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.495 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 3.7 mm? 42.73 -88.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.848 -0.533 . . . . 0.0 110.642 179.669 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -50.29 -27.06 10.36 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -115.15 86.75 2.51 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -1.094 . . . . 0.0 109.406 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.415 ' HA ' ' HB3' ' A' ' 79' ' ' MET . 0.6 OUTLIER -90.95 20.2 5.03 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.774 -179.883 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.77 -28.44 73.5 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 17.9 ttpp -123.09 -29.96 3.82 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.181 -1.187 . . . . 0.0 110.083 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.415 ' HB3' ' HA ' ' A' ' 76' ' ' GLU . 10.7 ttp -47.76 -57.99 4.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.154 -0.966 . . . . 0.0 109.672 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 99.0 t -62.9 -22.72 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.284 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -77.43 -21.04 53.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.291 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -90.06 -49.18 6.73 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.331 -0.856 . . . . 0.0 109.529 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.464 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 93.6 mmm -60.9 -40.28 92.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.125 -0.985 . . . . 0.0 109.008 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -53.04 -31.22 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.243 -0.911 . . . . 0.0 108.556 179.175 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.409 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -75.79 -31.36 59.44 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.201 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 53.9 t -65.37 -50.33 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.096 179.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.464 ' CA ' HD23 ' A' ' 141' ' ' LEU . . . -54.43 -41.95 73.75 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.409 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 88.2 t -51.36 -25.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.333 -1.098 . . . . 0.0 109.021 179.415 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.424 ' HB3' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -78.35 -33.33 49.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.364 -0.835 . . . . 0.0 108.904 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.546 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 30.9 m80 -80.86 4.7 18.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.398 -0.813 . . . . 0.0 109.611 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.46 ' CD ' ' HA ' ' A' ' 147' ' ' SER . 5.8 ttpp -88.63 -10.24 49.3 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.096 -1.003 . . . . 0.0 110.137 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -160.42 43.95 0.42 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.014 -1.565 . . . . 0.0 111.045 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.546 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.6 m-85 -75.17 -165.18 0.37 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.68 -1.483 . . . . 0.0 109.195 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.3 -36.75 55.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.42 -1.872 . . . . 0.0 108.42 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.513 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 1.7 t30 -72.16 -58.51 3.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.574 -0.956 . . . . 0.0 109.07 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.485 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 1.9 tttp 76.5 -15.67 0.7 Allowed 'General case' 0 N--CA 1.506 2.358 0 O-C-N 121.637 -0.664 . . . . 0.0 111.391 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.435 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 65.9 m170 -98.73 44.01 1.04 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.598 -1.314 . . . . 0.0 109.119 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.418 HD12 ' HB3' ' A' ' 90' ' ' HIS . 71.6 mt -75.22 159.04 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.331 -0.856 . . . . 0.0 109.878 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.435 ' CE ' ' O ' ' A' ' 97' ' ' HIS . 1.0 OUTLIER -142.49 141.98 32.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.377 -0.827 . . . . 0.0 109.948 -179.971 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.36 2.15 26.02 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.468 -0.77 . . . . 0.0 109.565 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mt-10 -77.61 -34.53 53.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 109.55 179.837 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.484 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 61.6 m-85 -80.42 -0.05 35.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.37 -0.831 . . . . 0.0 110.361 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.469 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 3.0 m-85 -70.48 -55.37 9.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.012 -1.055 . . . . 0.0 109.75 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.482 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.2 tt0 -59.61 -52.11 76.31 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.185 -0.947 . . . . 0.0 109.746 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.482 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.3 Cg_exo -54.32 -56.13 2.78 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 123.819 1.431 . . . . 0.0 109.843 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.51 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.3 tm? -55.31 -31.12 61.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' O ' ' CB ' ' A' ' 110' ' ' LEU . . . -76.06 -48.09 10.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.59 10.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.263 -1.139 . . . . 0.0 109.421 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.9 t -55.19 -21.51 14.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.271 -0.893 . . . . 0.0 109.298 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.45 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.0 OUTLIER -69.27 -48.84 60.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.329 -0.857 . . . . 0.0 109.532 179.88 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.5 mt -55.04 -34.66 63.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.098 -1.001 . . . . 0.0 109.159 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.15 -31.67 70.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.324 179.657 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.494 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -81.43 -38.41 26.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.409 179.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.409 ' HG2' ' O ' ' A' ' 110' ' ' LEU . 5.5 mmt -50.38 -45.03 55.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.234 -0.916 . . . . 0.0 109.518 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -49.66 -24.71 2.37 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.888 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.494 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 18.8 m170 -58.49 -50.87 72.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.958 . . . . 0.0 109.495 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.404 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -67.56 -52.43 38.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.474 179.898 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.487 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 6.1 pt -116.64 65.37 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.25 -0.906 . . . . 0.0 109.707 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -66.48 -10.4 53.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -106.28 -39.55 2.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.487 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 8.7 mmmt -82.24 -25.75 33.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.029 -1.277 . . . . 0.0 109.97 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.432 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.55 84.17 0.1 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.997 -1.065 . . . . 0.0 109.164 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 18.7 p-10 -88.15 -171.46 3.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.373 -0.829 . . . . 0.0 109.792 -179.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -61.05 -45.2 95.75 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.276 -0.89 . . . . 0.0 109.766 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.417 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -60.95 -30.13 70.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.382 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.99 -49.15 54.45 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.921 . . . . 0.0 109.475 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.46 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 0.7 OUTLIER -72.41 -30.67 64.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 109.558 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.46 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 25.5 t0 -78.88 -35.15 44.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.241 -0.912 . . . . 0.0 109.279 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.417 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -66.59 -47.37 72.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.322 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.466 ' O ' ' CD1' ' A' ' 134' ' ' TYR . 13.9 m0 -72.56 -27.38 62.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.163 -0.96 . . . . 0.0 108.716 179.538 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.75 -15.12 57.79 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.349 -0.845 . . . . 0.0 108.957 178.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -110.98 -29.26 7.98 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.163 -0.96 . . . . 0.0 109.095 179.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.448 ' CB ' HG21 ' A' ' 10' ' ' VAL . . . -83.19 -45.46 13.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.436 -0.79 . . . . 0.0 109.559 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.548 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -58.52 -18.58 30.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 109.25 179.914 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.548 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -84.35 -33.13 23.92 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.222 -0.924 . . . . 0.0 108.512 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.58 -36.42 38.19 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.464 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.1 mt -64.56 -61.44 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.46 ' OG ' ' CMC' ' A' ' 148' ' ' HEM . 4.0 t -66.5 -22.4 66.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.583 -0.698 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.96 -52.99 25.23 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.16 -24.61 4.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -1.186 . . . . 0.0 109.436 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.464 HD23 ' CA ' ' A' ' 87' ' ' GLY . 5.8 tt -74.25 -22.62 59.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.648 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 69.4 mt -81.81 6.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.177 -0.952 . . . . 0.0 110.193 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.2 t -95.46 -36.13 11.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.005 -1.059 . . . . 0.0 109.71 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.15 14.29 28.48 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.449 ' CD2' ' O ' ' A' ' 145' ' ' LEU . 4.6 tt -100.12 3.76 44.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.061 -1.258 . . . . 0.0 110.055 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -107.3 65.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.015 -1.053 . . . . 0.0 109.671 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.46 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 4.6 p . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.602 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.507 ' C1B' ' CE1' ' A' ' 45' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.439 ' C ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.432 ' N ' ' CD2' ' A' ' 2' ' ' LEU . 4.5 mm? -76.73 160.6 29.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -1.174 . . . . 0.0 109.64 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 p -102.28 -170.15 1.77 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.251 -0.906 . . . . 0.0 109.672 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.53 -30.16 57.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.029 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.409 ' O ' HG22 ' A' ' 9' ' ' VAL . . . -85.08 -44.49 12.96 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.082 -1.011 . . . . 0.0 109.587 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.407 ' HB3' HD11 ' A' ' 2' ' ' LEU . 37.1 mt-30 -62.37 -57.71 10.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 110.127 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -28.22 5.35 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.011 -1.055 . . . . 0.0 109.6 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.7 tp60 -78.6 -39.83 36.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.423 -0.798 . . . . 0.0 108.924 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.488 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 90.0 t -66.7 -33.67 64.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.043 179.336 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.495 HG12 ' CD1' ' A' ' 130' ' ' TRP . 84.0 t -69.31 -47.51 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.432 -0.793 . . . . 0.0 109.372 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.62 -13.92 62.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.306 -0.871 . . . . 0.0 109.754 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.5 t -90.73 -26.09 19.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.144 -0.972 . . . . 0.0 109.791 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.4 p -97.29 -10.24 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 110.031 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.528 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -92.48 -19.52 21.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.03 -1.044 . . . . 0.0 109.839 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.3 mtpp -81.94 -11.8 58.7 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.915 . . . . 0.0 109.748 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.49 -55.63 2.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.656 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.462 ' HA ' ' CD ' ' A' ' 117' ' ' ARG . 61.0 mt -64.36 -36.64 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.609 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.519 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -101.85 33.7 2.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.626 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.4 -85.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.8 p -97.96 -23.94 15.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.301 -1.117 . . . . 0.0 109.678 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -82.34 -19.88 38.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.655 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.413 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 18.5 t30 56.38 25.12 9.15 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.262 -0.899 . . . . 0.0 109.621 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.45 24.94 12.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -69.91 -52.55 23.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -1.143 . . . . 0.0 109.648 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.03 -12.98 83.08 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.434 ' CG1' HD13 ' A' ' 63' ' ' LEU . 30.7 t -82.03 -36.05 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.129 -1.218 . . . . 0.0 109.873 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.431 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -78.05 -41.32 18.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.466 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 17.4 ptpt -66.1 -29.55 69.89 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.137 -1.214 . . . . 0.0 110.125 -179.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.42 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 22.5 pt-20 -92.5 -20.98 20.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.176 -0.952 . . . . 0.0 109.881 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.1 t -82.8 -60.14 2.27 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 21.0 m-85 -57.5 -32.27 66.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.888 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.458 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.1 OUTLIER -52.3 -53.66 41.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.178 -0.951 . . . . 0.0 109.392 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -59.69 -50.59 73.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.309 -0.869 . . . . 0.0 109.562 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.5 t80 -50.63 -47.26 58.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.505 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 17.6 mt -61.14 -45.37 94.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.413 ' OG ' ' N ' ' A' ' 37' ' ' ALA . 29.8 p -67.38 -55.15 14.94 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.224 -0.922 . . . . 0.0 109.817 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.413 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -61.28 -26.53 67.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.189 -0.945 . . . . 0.0 109.708 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.444 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 21.9 m-70 -124.49 110.55 14.63 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.224 -0.922 . . . . 0.0 109.881 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -89.47 -8.87 51.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.472 -0.767 . . . . 0.0 109.697 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -81.94 -16.37 50.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.066 -1.021 . . . . 0.0 109.568 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.514 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 3.9 mmt -104.65 -17.12 14.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.19 -0.944 . . . . 0.0 109.789 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.441 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -54.12 -51.87 62.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.047 -1.033 . . . . 0.0 109.267 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.7 -27.44 68.34 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 109.227 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.519 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 9.1 t -69.54 -55.45 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.354 -0.841 . . . . 0.0 109.04 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.505 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.5 m-85 -57.44 -28.77 63.62 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.286 -0.884 . . . . 0.0 109.58 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.65 29.62 4.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 12.6 m-85 -126.06 172.24 10.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.75 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.8 t -115.83 19.68 15.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.339 -0.85 . . . . 0.0 109.289 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.92 -164.18 28.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.96 26.32 2.84 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.171 -1.194 . . . . 0.0 109.648 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 26.6 m -121.52 28.59 7.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.626 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.14 135.41 23.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.252 -0.905 . . . . 0.0 109.569 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.2 -21.0 55.78 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.916 1.482 . . . . 0.0 110.061 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.518 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.52 -36.36 47.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.512 HG22 ' CD2' ' A' ' 47' ' ' PHE . 59.8 t -53.45 -42.22 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.266 -1.137 . . . . 0.0 109.456 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.454 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -67.86 -21.15 65.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.407 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.12 -37.25 29.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.289 -0.882 . . . . 0.0 109.524 179.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.512 HD21 ' C1A' ' A' ' 148' ' ' HEM . 1.7 mt -75.81 -61.56 1.88 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.515 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.72 -50.66 30.87 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.432 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.12 -37.27 64.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.278 -1.13 . . . . 0.0 109.493 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 25.2 mttt -80.24 -26.38 39.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.508 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.435 HG21 ' C ' ' A' ' 149' ' ' CMO . 59.9 t -82.17 -49.06 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.188 -0.945 . . . . 0.0 109.556 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.434 HD13 ' CG1' ' A' ' 26' ' ' VAL . 2.2 mm? -47.83 -46.8 31.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.25 -0.906 . . . . 0.0 109.657 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.64 -52.32 31.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.925 . . . . 0.0 109.85 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.457 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 6.3 tp-100 -50.89 -45.92 60.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.053 -1.03 . . . . 0.0 109.346 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.459 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 42.1 mt -57.53 -39.06 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.298 -0.876 . . . . 0.0 109.097 179.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.528 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.99 -54.19 32.21 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.6 t -56.8 -29.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -1.113 . . . . 0.0 109.466 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.26 -31.31 27.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.345 -0.847 . . . . 0.0 109.659 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 51.5 t -61.57 -18.03 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.21 -0.931 . . . . 0.0 109.672 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.436 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -89.33 -1.29 58.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.163 -0.96 . . . . 0.0 110.131 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.458 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 18.9 m-70 -135.84 52.47 1.99 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.989 -1.069 . . . . 0.0 109.954 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.408 HD13 HG13 ' A' ' 10' ' ' VAL . 34.9 mt -93.18 -34.59 13.54 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -0.986 . . . . 0.0 109.442 179.774 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -73.68 -26.75 68.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -126.43 92.97 3.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.368 -1.078 . . . . 0.0 109.337 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -91.72 34.89 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.829 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -85.48 -20.41 56.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.3 tppt? -125.15 -33.71 2.84 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -1.169 . . . . 0.0 109.911 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.458 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 52.6 ttp -50.26 -36.43 31.29 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.17 -0.956 . . . . 0.0 109.512 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.418 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 95.8 t -76.97 -0.65 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 110.012 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.76 -31.12 26.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.04 -1.038 . . . . 0.0 109.366 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -94.74 -44.59 7.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.45 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.401 ' HG2' ' OE1' ' A' ' 65' ' ' GLN . 3.4 mtp -55.12 -50.03 70.27 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.228 -0.92 . . . . 0.0 109.35 179.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.459 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.3 mtpt -50.38 -40.71 50.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.151 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.436 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -57.66 -34.14 69.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.372 -0.83 . . . . 0.0 109.274 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 4.0 t -68.0 -35.13 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.139 -0.976 . . . . 0.0 109.024 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.424 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -64.16 -49.45 66.55 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.735 -1.746 . . . . 0.0 108.735 179.611 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.465 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 83.9 t -55.94 -19.7 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.371 -1.076 . . . . 0.0 109.575 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.517 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.0 OUTLIER -84.67 -45.15 12.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.802 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.515 ' CD2' HD13 ' A' ' 98' ' ' ILE . 3.7 m80 -64.12 -10.52 23.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.44 -0.788 . . . . 0.0 110.637 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.465 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -82.25 7.4 13.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.83 -1.169 . . . . 0.0 110.335 -179.817 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.93 51.96 0.31 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.517 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.3 m-30 -91.85 -168.61 2.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -1.156 . . . . 0.0 109.912 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -63.5 -19.75 62.77 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.519 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 10.3 p-10 -105.06 -26.05 12.28 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.056 -1.261 . . . . 0.0 110.062 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.6 mttt 49.49 29.86 3.13 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.141 -0.974 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.5 m170 -137.34 29.43 2.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.297 -0.877 . . . . 0.0 109.693 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.515 HD13 ' CD2' ' A' ' 90' ' ' HIS . 35.6 mt -72.51 158.99 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.181 -0.949 . . . . 0.0 109.684 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.406 ' N ' HG21 ' A' ' 98' ' ' ILE . 0.0 OUTLIER -142.64 174.06 10.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.817 -179.844 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.404 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -100.88 -19.17 16.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.51 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -68.21 -20.61 64.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.224 -0.922 . . . . 0.0 109.563 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.514 ' CD2' ' HG3' ' A' ' 41' ' ' MET . 46.7 m-85 -80.17 -22.06 42.37 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.201 -0.937 . . . . 0.0 109.675 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.522 ' CE1' ' HHC' ' A' ' 148' ' ' HEM . 3.2 m-85 -58.99 -62.59 1.77 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.328 -0.858 . . . . 0.0 110.244 -179.295 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.484 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.1 mt-10 -45.06 -58.69 5.22 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.848 . . . . 0.0 110.867 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 9.6 Cg_endo -56.49 -47.95 21.41 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.665 1.35 . . . . 0.0 110.213 -179.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.51 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -65.78 -20.54 66.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.165 -0.959 . . . . 0.0 109.459 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.64 -42.78 9.71 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.18 -49.33 74.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -1.212 . . . . 0.0 109.538 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.68 -18.16 52.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.649 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.481 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 0.7 OUTLIER -73.86 -35.29 64.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.929 . . . . 0.0 109.76 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.453 HD21 ' CB ' ' A' ' 130' ' ' TRP . 14.3 mt -68.36 -32.49 72.61 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.673 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 m -71.66 -22.4 61.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -87.13 -39.29 15.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.488 ' SD ' ' CZ3' ' A' ' 130' ' ' TRP . 1.6 mtt -56.41 -36.33 68.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.323 -0.86 . . . . 0.0 109.863 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.456 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -54.37 -21.25 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.168 -0.957 . . . . 0.0 109.533 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 17.6 m170 -65.27 -23.75 67.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 109.905 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.462 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 4.5 ttt85 -94.07 -69.6 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.101 -0.999 . . . . 0.0 109.861 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.457 HG13 ' N ' ' A' ' 119' ' ' GLY . 16.5 pt -78.28 -32.9 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.205 -0.934 . . . . 0.0 109.61 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.457 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.09 -97.23 0.01 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -46.64 -45.11 17.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.45 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 2.8 mptt -69.67 -11.61 60.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.42 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -84.33 79.79 9.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.087 -1.008 . . . . 0.0 109.383 179.556 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.451 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.4 p30 -80.52 -165.81 0.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.606 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -69.68 -44.56 70.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.92 . . . . 0.0 109.441 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.451 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -57.67 -36.6 72.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.191 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -61.05 -53.53 55.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.303 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 14.8 ptpt -70.48 -29.66 66.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.323 -0.861 . . . . 0.0 109.427 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.464 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.7 t70 -74.48 -50.34 18.68 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.324 -0.86 . . . . 0.0 109.34 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.488 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -59.67 -43.34 94.03 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.256 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.528 ' HB3' ' CE2' ' A' ' 134' ' ' TYR . 4.9 m0 -73.99 -23.1 59.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.267 -0.896 . . . . 0.0 109.022 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 128' ' ' ASP . . . -68.48 -26.82 65.67 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.301 -0.874 . . . . 0.0 108.662 178.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.54 -24.16 17.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.449 -0.782 . . . . 0.0 109.1 179.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.427 ' HA ' HD23 ' A' ' 2' ' ' LEU . . . -70.58 -59.52 2.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.6 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.528 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 12.1 m-85 -51.76 -27.91 13.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.16 -0.963 . . . . 0.0 109.271 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.92 -53.37 32.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.122 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -70.26 -35.77 74.0 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.22 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 29.1 mt -68.85 -57.23 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.351 -0.843 . . . . 0.0 109.469 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.2 p -68.91 -27.91 66.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.771 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -68.37 -47.6 56.79 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -56.61 -30.06 62.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.207 -1.172 . . . . 0.0 109.715 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.454 ' CD2' HD11 ' A' ' 145' ' ' LEU . 8.2 tt -68.72 -18.77 64.3 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.729 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.481 HD12 HG22 ' A' ' 142' ' ' ILE . 39.5 mm -76.47 -3.81 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 0.0 110.043 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.459 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 3.1 m -81.95 -49.01 10.77 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.445 179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 84' ' ' LYS . . . -83.94 -8.36 84.24 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.503 ' CD2' ' NE2' ' A' ' 146' ' ' GLN . 0.4 OUTLIER -79.66 -171.26 2.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.07 -1.253 . . . . 0.0 109.14 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.503 ' NE2' ' CD2' ' A' ' 145' ' ' LEU . 11.6 mp0 55.17 72.75 0.46 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.119 -0.988 . . . . 0.0 109.588 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.459 ' HB2' ' CG ' ' A' ' 91' ' ' LYS . 1.7 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.651 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.522 ' HHC' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.515 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.446 ' N ' HD22 ' A' ' 2' ' ' LEU . 4.4 mm? 55.64 170.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -1.145 . . . . 0.0 109.65 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.6 173.13 11.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.22 -0.925 . . . . 0.0 109.704 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -68.1 -28.11 67.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.329 -0.857 . . . . 0.0 109.572 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.33 -41.82 19.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.435 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -71.34 -49.21 44.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.292 -0.88 . . . . 0.0 109.669 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -48.64 -31.14 6.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.224 -0.923 . . . . 0.0 109.769 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 42.4 mm-40 -80.87 -49.14 11.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.907 . . . . 0.0 109.648 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.461 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 36.9 t -53.91 -26.82 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.184 -0.948 . . . . 0.0 109.507 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.512 HG12 ' CD1' ' A' ' 130' ' ' TRP . 99.0 t -68.41 -54.65 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.519 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.74 -16.09 62.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.816 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 t -86.79 -27.33 23.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.184 -0.947 . . . . 0.0 109.78 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 p -93.79 -12.54 28.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.886 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.568 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.37 -28.53 17.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.088 -1.007 . . . . 0.0 109.684 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -70.83 -13.79 62.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -0.891 . . . . 0.0 109.788 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -101.68 -53.74 2.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.984 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.447 ' CG1' HG12 ' A' ' 118' ' ' ILE . 42.2 mt -63.77 -36.61 77.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.262 -0.899 . . . . 0.0 109.603 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.568 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -102.13 25.65 8.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.311 -0.868 . . . . 0.0 109.728 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.23 -80.41 0.14 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.411 ' O ' ' HB3' ' A' ' 21' ' ' ASP . 77.9 p -98.21 55.15 1.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -1.129 . . . . 0.0 109.563 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.411 ' HB3' ' O ' ' A' ' 20' ' ' SER . 7.3 p-10 -177.18 -33.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.356 -0.84 . . . . 0.0 109.915 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.468 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 20.6 t30 63.72 37.79 9.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.408 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 78.47 29.06 54.1 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.405 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -75.97 -52.17 10.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.665 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.75 -22.99 68.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.472 HG13 ' CD2' ' A' ' 63' ' ' LEU . 48.5 t -67.54 -19.79 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.307 -1.113 . . . . 0.0 109.757 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.414 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -91.9 -46.81 3.55 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.466 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.2 ptpt -63.38 -20.81 65.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.153 -1.204 . . . . 0.0 109.787 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 25' ' ' GLY . 11.0 pt-20 -99.11 -26.53 14.18 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.4 t -85.09 -51.84 6.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.261 -0.899 . . . . 0.0 109.636 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.521 ' CE2' ' HB3' ' A' ' 58' ' ' LEU . 3.1 m-85 -60.08 -46.04 90.91 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.241 -0.912 . . . . 0.0 109.937 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.424 ' N ' HG12 ' A' ' 55' ' ' VAL . 53.1 m -49.63 -35.78 22.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.144 -0.972 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.403 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 1.4 mttm -75.79 -43.77 44.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.4 179.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.517 ' CG ' HD22 ' A' ' 106' ' ' LEU . 6.6 t80 -60.99 -53.19 60.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.294 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.482 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 31.1 mt -57.02 -42.35 80.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.875 . . . . 0.0 109.617 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.402 ' HB2' ' HB1' ' A' ' 50' ' ' ALA . 43.4 t -65.58 -59.29 4.11 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -0.935 . . . . 0.0 109.582 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.8 -26.47 68.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.189 -0.944 . . . . 0.0 109.631 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.459 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 17.2 m-70 -120.94 108.5 13.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.74 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -88.66 -21.31 24.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.42 -0.8 . . . . 0.0 109.306 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -68.11 -13.51 62.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.548 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.553 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -104.6 -16.55 14.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.921 -179.814 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -53.13 -66.26 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.066 -1.021 . . . . 0.0 109.634 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.84 -21.89 44.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.606 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 31.8 t -76.76 -37.16 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.2 m-85 -76.77 -27.21 55.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.93 . . . . 0.0 109.497 -179.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.97 27.2 4.37 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.516 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 10.4 m-85 -123.66 173.33 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -1.147 . . . . 0.0 109.909 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.2 t -109.37 -15.93 14.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.432 -0.792 . . . . 0.0 109.199 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.64 -164.57 29.03 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.402 ' HB1' ' HB2' ' A' ' 36' ' ' SER . . . -94.26 32.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -1.193 . . . . 0.0 109.617 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 25.8 t -134.89 26.68 3.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.289 -0.882 . . . . 0.0 109.618 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.408 ' OD1' ' HB3' ' A' ' 47' ' ' PHE . 5.2 p-10 -104.39 150.12 38.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.213 -0.929 . . . . 0.0 109.715 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -74.99 -1.93 11.87 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.042 1.549 . . . . 0.0 110.439 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -77.48 -35.58 36.51 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.482 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 77.3 t -51.36 -44.34 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -1.116 . . . . 0.0 109.538 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.463 ' HB1' ' CB ' ' A' ' 28' ' ' LYS . . . -71.86 -7.22 47.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -0.855 . . . . 0.0 109.938 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.36 -30.0 14.72 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CE2' ' A' ' 31' ' ' PHE . 3.9 mt -84.66 -61.44 1.79 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 109.702 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.414 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -51.51 -30.57 27.06 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -63.51 -52.8 59.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.152 -1.204 . . . . 0.0 109.704 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.5 mttp -73.41 -41.75 62.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.441 HG21 ' C ' ' A' ' 149' ' ' CMO . 87.1 t -50.95 -63.67 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.818 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.472 ' CD2' HG13 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -46.84 -40.66 14.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.214 -0.929 . . . . 0.0 109.887 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.58 -38.69 55.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -0.94 . . . . 0.0 109.422 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 17.5 tp60 -65.08 -39.87 93.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.313 179.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 67.5 mt -62.46 -34.98 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.074 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.538 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.73 29.84 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.5 t -59.9 -24.24 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -1.119 . . . . 0.0 109.165 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.94 -24.49 26.54 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.443 -0.786 . . . . 0.0 109.425 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.453 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 52.0 t -68.02 -17.23 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.232 -0.918 . . . . 0.0 109.609 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.504 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.8 OUTLIER -89.65 41.62 1.05 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.146 -0.971 . . . . 0.0 109.703 179.954 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' GLY . 8.1 m-70 -161.26 -73.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.588 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.513 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.4 mm? 50.76 -86.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.68 -0.638 . . . . 0.0 110.448 179.499 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -58.65 -21.85 51.37 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.47 75.56 1.97 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -1.135 . . . . 0.0 109.581 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -85.21 10.02 13.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.927 . . . . 0.0 109.977 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -79.23 -23.92 62.31 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.086 -1.605 . . . . 0.0 109.086 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -122.07 -38.5 2.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.285 -1.127 . . . . 0.0 109.627 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 58.1 ttp -50.04 -38.55 38.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.454 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 47.5 t -74.53 -22.46 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.201 -0.937 . . . . 0.0 109.519 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.52 -58.44 6.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -74.84 -44.11 50.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.461 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.6 OUTLIER -57.84 -57.58 12.15 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.454 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 34.5 tttt -51.49 -32.07 26.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.203 179.722 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -68.94 -43.99 73.96 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 109.311 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.4 t -54.89 -40.29 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.201 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.416 ' HA2' HD23 ' A' ' 141' ' ' LEU . . . -53.58 -49.23 58.32 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.476 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 72.8 t -53.59 -49.29 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.305 -1.115 . . . . 0.0 109.084 179.533 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.518 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -49.68 -37.55 29.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.189 -0.944 . . . . 0.0 109.658 179.703 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.485 ' CD2' HD13 ' A' ' 98' ' ' ILE . 22.9 m80 -71.4 -3.69 22.2 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.476 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -78.96 -11.58 60.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.732 -1.23 . . . . 0.0 110.24 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -151.85 57.73 0.43 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -87.57 -170.73 3.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -1.133 . . . . 0.0 109.534 179.614 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.66 -29.54 67.22 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.518 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 16.9 p-10 -99.24 -32.89 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -1.183 . . . . 0.0 109.505 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.456 ' O ' ' CD ' ' A' ' 96' ' ' LYS . 0.0 OUTLIER 67.74 7.36 5.65 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.414 -0.804 . . . . 0.0 110.397 179.612 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.419 ' O ' ' O ' ' A' ' 98' ' ' ILE . 3.1 m170 -95.86 -87.84 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.012 -1.055 . . . . 0.0 108.981 178.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.485 HD13 ' CD2' ' A' ' 90' ' ' HIS . 15.3 mt 58.65 152.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.363 -0.836 . . . . 0.0 110.694 179.342 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.526 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.48 135.5 14.72 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 121.727 0.775 . . . . 0.0 109.807 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -72.23 -7.31 48.61 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.658 -0.651 . . . . 0.0 109.532 179.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.448 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 5.8 pt-20 -75.54 -23.74 56.66 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.086 179.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.553 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 25.5 m-85 -85.41 -20.38 29.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.854 . . . . 0.0 109.631 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.569 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 4.5 m-85 -55.95 -61.05 2.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.26 -0.9 . . . . 0.0 110.045 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.497 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -52.37 -57.62 14.77 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.066 -1.021 . . . . 0.0 109.839 -179.66 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.497 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.9 Cg_exo -50.72 -63.57 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.667 1.351 . . . . 0.0 109.886 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.517 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -56.54 -26.76 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.295 -0.878 . . . . 0.0 109.342 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.507 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -75.62 -46.05 15.86 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.71 -51.86 66.68 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -1.193 . . . . 0.0 109.273 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 t -56.33 -22.25 29.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.875 . . . . 0.0 109.247 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.4 HD23 ' HE1' ' A' ' 114' ' ' MET . 4.4 tt -67.46 -48.61 66.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.585 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' A' ' 130' ' ' TRP . 12.6 mt -54.36 -31.68 55.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.137 -0.977 . . . . 0.0 109.398 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -65.84 -49.47 68.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.657 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.476 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -71.45 -32.52 68.42 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.601 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.4 ' HE1' HD23 ' A' ' 110' ' ' LEU . 3.4 mmt -47.57 -38.57 14.59 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.265 -0.897 . . . . 0.0 110.023 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.421 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -63.77 -16.92 62.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.565 -179.776 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.476 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 37.0 m170 -60.78 -43.97 97.39 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.082 -1.011 . . . . 0.0 109.779 -179.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.409 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -72.81 -59.37 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.781 -179.7 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.447 HG12 ' CG1' ' A' ' 17' ' ' ILE . 12.3 pt -94.0 40.53 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -0.941 . . . . 0.0 109.876 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.421 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -53.46 117.07 6.52 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 112.73 -31.34 6.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.529 -1.829 . . . . 0.0 108.529 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -98.98 -24.87 14.76 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.339 -1.095 . . . . 0.0 109.13 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 6.5 tpt -67.56 96.34 0.52 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.025 179.428 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.472 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 12.5 p-10 -100.73 -172.11 2.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 0.0 109.621 -179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -58.71 -52.93 63.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.881 . . . . 0.0 110.045 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.472 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -54.63 -24.91 23.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.157 -0.965 . . . . 0.0 109.418 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -76.16 -54.06 7.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.353 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.462 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 16.7 ptpt -70.0 -30.22 67.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.919 . . . . 0.0 109.358 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.462 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 63.4 t0 -76.91 -38.3 53.75 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.4 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.461 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -66.91 -43.87 82.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.402 -0.811 . . . . 0.0 109.347 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.512 ' CD1' HG12 ' A' ' 10' ' ' VAL . 9.9 m0 -75.34 -33.01 61.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.251 -0.905 . . . . 0.0 109.011 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.505 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -52.41 -39.2 60.64 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 108.984 179.205 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.71 -23.0 24.3 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.391 -0.818 . . . . 0.0 108.985 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.453 ' O ' ' CD1' ' A' ' 137' ' ' ILE . . . -83.45 -63.17 1.41 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 109.518 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.507 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.1 OUTLIER -51.59 -23.97 4.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.182 -0.949 . . . . 0.0 109.098 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.81 -36.78 56.69 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.266 -0.896 . . . . 0.0 109.012 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -78.95 -38.73 36.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.409 -0.807 . . . . 0.0 109.235 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 133' ' ' ALA . 1.4 mp -62.42 -54.89 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.343 -0.848 . . . . 0.0 108.802 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 83.6 p -68.44 -17.7 64.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -0.885 . . . . 0.0 109.659 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.39 -35.21 20.97 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.46 -25.5 63.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -1.151 . . . . 0.0 109.621 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.461 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 9.9 tt -74.04 -16.49 61.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 109.831 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 51.2 mm -88.19 15.42 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.996 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.6 t -93.25 -45.16 7.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -83.94 -23.3 52.94 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.129 -1.589 . . . . 0.0 109.129 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.3 -169.06 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -1.142 . . . . 0.0 109.579 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 54.8 66.72 1.16 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.257 -0.902 . . . . 0.0 109.681 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.423 ' OXT' ' CE ' ' A' ' 91' ' ' LYS . 16.0 p . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.682 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.569 ' CMC' ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.441 ' C ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 mt -143.59 161.46 38.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.321 -1.105 . . . . 0.0 109.758 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -140.69 -171.35 3.21 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.308 -0.87 . . . . 0.0 109.817 -179.818 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.71 -35.63 57.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.883 . . . . 0.0 109.853 -179.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -76.17 -41.86 48.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.328 -0.858 . . . . 0.0 109.663 -179.864 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -66.47 -48.0 71.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.16 -0.963 . . . . 0.0 109.345 179.815 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.0 ttp180 -60.84 -24.04 65.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.214 179.605 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.3 tp60 -83.02 -49.26 9.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.444 -0.785 . . . . 0.0 109.186 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.468 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 86.3 t -51.56 -27.43 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.404 -0.81 . . . . 0.0 109.498 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.455 ' CG1' HG11 ' A' ' 70' ' ' VAL . 61.1 t -65.02 -52.22 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.769 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.05 -19.2 64.09 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.202 -0.936 . . . . 0.0 109.596 179.87 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.85 -23.84 36.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.556 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.427 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 21.2 p -99.89 -13.22 19.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.789 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.02 -28.31 19.16 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.128 -0.982 . . . . 0.0 109.759 -179.836 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 14.9 mttt -75.88 -8.7 57.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.904 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -105.4 -47.37 3.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.103 -0.998 . . . . 0.0 109.63 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.481 HD11 ' CH2' ' A' ' 130' ' ' TRP . 57.8 mt -71.9 -35.4 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.218 -0.926 . . . . 0.0 109.635 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.03 33.82 3.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.678 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.14 -75.99 0.2 Allowed Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.2 p -103.73 -37.47 7.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -1.16 . . . . 0.0 109.597 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 16.0 p-10 -71.61 -20.54 61.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.61 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.461 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 19.9 t30 57.55 25.29 11.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.627 179.956 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.06 19.94 24.91 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.34 -59.52 3.12 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -1.146 . . . . 0.0 109.56 179.959 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.467 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -67.02 -12.46 60.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.4 HG21 ' CG2' ' A' ' 17' ' ' ILE . 37.5 t -84.82 -41.25 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.149 -1.206 . . . . 0.0 109.868 -179.819 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.439 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -74.33 -36.73 49.42 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.306 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.467 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 9.7 ptpt -73.2 -26.55 61.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.109 -1.23 . . . . 0.0 110.207 -179.459 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.453 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pt-20 -95.42 -20.65 18.91 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.066 -1.021 . . . . 0.0 109.993 -179.746 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 37.3 t -88.19 -66.73 0.89 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 110.085 -179.577 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.517 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.6 m-85 -48.06 -31.53 5.59 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.048 -179.546 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.468 HG22 ' CG1' ' A' ' 55' ' ' VAL . 0.0 OUTLIER -56.17 -51.18 68.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.083 -1.011 . . . . 0.0 109.348 179.705 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 6.2 mttp -59.61 -48.64 80.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.285 -0.884 . . . . 0.0 109.533 179.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.516 ' CG ' HD22 ' A' ' 106' ' ' LEU . 5.8 t80 -52.63 -47.77 66.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.453 179.863 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.515 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 21.5 mt -58.93 -44.01 91.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.288 -0.882 . . . . 0.0 109.607 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -68.73 -60.98 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.47 -23.05 9.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -0.921 . . . . 0.0 109.589 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.413 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 28.5 m-70 -126.24 102.37 7.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.278 -0.889 . . . . 0.0 109.716 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.4 m170 -85.64 6.86 25.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.329 -0.857 . . . . 0.0 109.9 179.699 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -95.09 -18.12 21.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.128 -0.983 . . . . 0.0 109.427 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.462 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 38.7 mmm -107.03 -19.45 13.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.754 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.39 -46.34 37.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.036 -1.04 . . . . 0.0 109.562 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.3 -26.05 60.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.099 179.478 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.52 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 27.9 t -70.62 -33.75 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.431 -0.793 . . . . 0.0 109.342 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.513 ' CE1' HMB2 ' A' ' 148' ' ' HEM . 10.2 m-85 -78.98 -31.17 44.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.48 26.88 4.07 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.511 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 10.0 m-85 -124.02 166.85 15.02 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -1.156 . . . . 0.0 109.706 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.0 t -104.92 -11.16 16.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.855 . . . . 0.0 109.444 179.359 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.9 -164.82 31.84 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.57 30.33 2.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -1.186 . . . . 0.0 109.629 179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.65 27.7 5.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -115.62 142.13 28.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.253 -0.904 . . . . 0.0 109.632 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -66.22 -17.8 54.99 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.054 1.555 . . . . 0.0 110.111 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -53.37 -39.84 60.0 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.515 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 94.4 t -54.98 -34.86 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.401 -1.058 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.455 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.89 -27.93 62.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.28 -0.887 . . . . 0.0 109.449 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.54 -31.99 60.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.521 HD21 ' C1A' ' A' ' 148' ' ' HEM . 2.0 mt -81.97 -62.55 1.6 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.307 -0.871 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.517 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.68 -51.56 27.84 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.953 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -51.92 -37.18 51.68 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -1.145 . . . . 0.0 109.412 179.879 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -81.27 -27.69 35.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.512 179.856 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 46.5 t -77.84 -49.64 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.303 -0.873 . . . . 0.0 109.704 -179.909 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -47.51 -51.25 21.23 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.714 179.796 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.73 -47.14 20.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.251 -0.906 . . . . 0.0 110.089 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -52.76 -53.72 44.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.099 -1.001 . . . . 0.0 109.356 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.515 HD12 ' CE2' ' A' ' 134' ' ' TYR . 55.9 mt -55.49 -34.43 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.174 -0.954 . . . . 0.0 109.074 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.48 -54.07 31.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.751 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.8 t -60.98 -24.93 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -1.121 . . . . 0.0 109.27 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.66 -27.93 25.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.355 -0.84 . . . . 0.0 109.555 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.463 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 46.2 t -68.13 -9.75 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.219 -0.925 . . . . 0.0 109.78 179.833 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.7 t -92.26 29.93 1.57 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.046 -1.034 . . . . 0.0 109.763 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.487 ' O ' ' N ' ' A' ' 74' ' ' GLY . 9.4 m-70 -155.27 -91.93 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.817 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.403 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 9.2 mt 64.4 -69.63 0.09 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.331 -0.856 . . . . 0.0 109.691 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -56.12 -39.72 81.32 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.476 ' OD2' ' CG ' ' A' ' 72' ' ' HIS . 8.1 p-10 -95.88 95.93 8.59 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.296 -1.12 . . . . 0.0 109.476 179.838 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -92.64 31.14 1.4 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.228 -0.92 . . . . 0.0 109.644 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -102.1 -20.62 12.18 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.436 ' O ' ' N ' ' A' ' 81' ' ' ALA . 9.2 ttmm -126.22 -45.91 1.67 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -1.137 . . . . 0.0 109.706 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.449 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 18.3 tmm? -48.53 -36.35 15.17 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.229 -0.92 . . . . 0.0 109.603 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 96.1 t -77.59 -20.59 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.414 179.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.436 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -57.42 -52.4 65.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 109.444 179.88 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.73 -50.65 41.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.429 179.75 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.462 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.8 OUTLIER -56.34 -56.51 20.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 109.313 179.737 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.483 ' CG ' ' CB ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -53.54 -24.44 13.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.205 179.555 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.416 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -77.9 -44.13 27.97 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.407 -0.808 . . . . 0.0 109.479 179.78 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.454 ' CG1' HD13 ' A' ' 141' ' ' LEU . 21.0 t -53.17 -35.35 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.472 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -60.66 -48.36 86.63 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.468 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 64.9 t -57.65 -18.82 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.423 -1.045 . . . . 0.0 109.432 179.332 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.1 OUTLIER -86.72 -46.1 10.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.134 -0.978 . . . . 0.0 109.087 179.617 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.483 ' HA ' ' CE2' ' A' ' 93' ' ' TYR . 14.3 m80 -56.39 -37.5 70.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 109.564 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -60.96 -16.68 45.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.298 -0.876 . . . . 0.0 109.935 -179.863 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -119.97 40.76 2.11 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.7 m-30 -90.42 -172.12 3.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 109.53 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.9 -28.67 37.08 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.906 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.52 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.6 OUTLIER -79.95 -47.94 14.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.478 -1.013 . . . . 0.0 109.18 179.78 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.471 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.7 OUTLIER 75.13 -48.51 0.63 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.623 -0.673 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 97' ' ' HIS . 25.1 m170 -68.05 59.44 0.07 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.802 -1.186 . . . . 0.0 110.466 -179.516 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.405 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 56.1 mt -90.41 156.96 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.069 -1.019 . . . . 0.0 109.027 179.488 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.499 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -137.94 138.93 39.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.056 -1.027 . . . . 0.0 110.055 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -81.15 -3.69 52.95 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -0.873 . . . . 0.0 109.883 179.693 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 43.1 mm-40 -81.38 -22.25 38.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.006 -1.059 . . . . 0.0 109.489 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.499 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 55.0 m-85 -79.96 -15.09 57.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.309 -0.869 . . . . 0.0 109.891 -179.816 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.56 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 5.2 m-85 -62.93 -61.55 2.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.242 -0.911 . . . . 0.0 110.063 -179.847 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.481 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.4 OUTLIER -44.85 -58.83 4.86 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 110.746 -179.46 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 9.9 Cg_endo -57.45 -45.95 30.91 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.682 1.359 . . . . 0.0 110.003 -179.569 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.516 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.3 tm? -65.91 -20.09 66.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.301 179.789 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.4 ' HA2' ' CE1' ' A' ' 134' ' ' TYR . . . -86.29 -49.04 4.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.54 -45.49 92.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.2 -1.176 . . . . 0.0 109.537 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.9 m -61.56 -28.97 69.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.494 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.456 ' CD1' ' OH ' ' A' ' 134' ' ' TYR . 3.7 tt -67.23 -40.03 86.31 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.204 -0.935 . . . . 0.0 109.369 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.412 HD21 ' HB2' ' A' ' 130' ' ' TRP . 12.7 mt -54.17 -36.32 63.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.163 -0.961 . . . . 0.0 109.047 179.763 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.8 t -67.01 -30.72 70.9 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.459 179.711 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.444 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -79.96 -38.94 31.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 179.923 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 4.6 mmt -48.42 -42.91 33.49 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.228 -0.92 . . . . 0.0 109.618 179.959 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -50.67 -24.37 3.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.489 179.843 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.444 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 17.6 m170 -52.0 -53.1 45.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.959 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -72.44 -58.73 3.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.894 . . . . 0.0 109.5 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.466 HD11 ' CA ' ' A' ' 122' ' ' MET . 6.5 pt -102.58 60.79 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.587 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -69.57 -11.01 64.65 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.886 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -105.72 -30.03 4.75 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.861 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' A' ' 123' ' ' ASN . 12.7 mttm -93.05 -24.52 18.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.173 -1.192 . . . . 0.0 110.078 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.466 ' CA ' HD11 ' A' ' 118' ' ' ILE . 0.9 OUTLIER -64.17 79.55 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.088 -1.008 . . . . 0.0 109.432 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.46 ' N ' ' O ' ' A' ' 121' ' ' LYS . 8.5 p30 -81.54 -164.52 0.79 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 -179.839 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -70.74 -38.46 73.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.181 -0.95 . . . . 0.0 109.376 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.462 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -62.74 -33.43 75.12 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.293 -0.879 . . . . 0.0 109.234 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -67.25 -52.3 42.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.534 179.851 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.455 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 0.5 OUTLIER -71.04 -29.38 65.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.341 179.835 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.455 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 48.6 t0 -79.81 -32.15 40.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.302 -0.873 . . . . 0.0 109.362 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.468 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.08 -43.43 61.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.418 -0.801 . . . . 0.0 109.322 179.752 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.481 ' CH2' HD11 ' A' ' 17' ' ' ILE . 9.4 m0 -74.86 -25.8 59.23 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.257 -0.902 . . . . 0.0 108.716 179.489 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.48 -26.89 68.77 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.235 -0.916 . . . . 0.0 108.693 178.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.45 -40.98 9.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.51 -0.744 . . . . 0.0 109.14 179.517 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -73.6 -58.95 2.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.4 -0.812 . . . . 0.0 109.103 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.515 ' CE2' HD12 ' A' ' 66' ' ' ILE . 1.9 t80 -50.87 -28.07 8.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.33 -0.856 . . . . 0.0 108.997 179.381 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -73.02 -41.35 64.31 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.037 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -76.68 -29.06 56.16 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.483 -0.76 . . . . 0.0 109.059 179.42 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 42.1 mt -66.54 -61.59 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 108.738 179.532 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.3 p -66.35 -20.6 66.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.431 -0.793 . . . . 0.0 109.726 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.35 -26.98 50.17 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 -179.872 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.0 -19.32 54.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.25 -1.147 . . . . 0.0 109.723 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.462 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 10.3 tt -79.53 -6.94 58.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.061 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.42 ' O ' HG21 ' A' ' 142' ' ' ILE . 57.5 mt -86.78 9.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.002 -1.061 . . . . 0.0 110.122 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.483 ' CB ' ' CG ' ' A' ' 84' ' ' LYS . 7.2 m -83.08 -43.31 16.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.933 -1.104 . . . . 0.0 109.436 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.461 ' HA3' ' CG2' ' A' ' 88' ' ' VAL . . . -97.05 -21.24 21.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.509 ' O ' ' HG2' ' A' ' 146' ' ' GLN . 10.7 tp -52.51 -178.71 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -1.045 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.509 ' HG2' ' O ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 32.96 63.84 0.3 Allowed 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.698 0.761 . . . . 0.0 111.435 -179.497 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.679 179.479 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.56 ' CMC' ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.455 ' N ' ' CD2' ' A' ' 2' ' ' LEU . 4.5 mm? -67.36 153.52 43.5 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.258 -1.143 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 p -104.28 173.74 6.17 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.231 -0.918 . . . . 0.0 109.656 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -63.75 -22.08 66.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.629 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.66 -56.16 3.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.954 . . . . 0.0 109.545 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -58.23 -54.95 41.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.607 179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.403 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 10.1 ttp180 -50.8 -31.43 16.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 179.872 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.1 tp60 -80.18 -42.05 24.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.331 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.456 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 57.3 t -59.34 -25.07 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -0.911 . . . . 0.0 109.433 179.803 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.511 HG12 ' CD1' ' A' ' 130' ' ' TRP . 86.4 t -67.48 -52.39 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.55 -12.12 56.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.873 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.19 -26.65 21.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.138 -0.976 . . . . 0.0 109.891 -179.854 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.494 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 28.2 p -99.65 -7.7 25.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.107 -0.996 . . . . 0.0 109.893 179.948 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.55 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.18 -19.83 22.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.02 -1.05 . . . . 0.0 109.562 -179.759 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 45.1 mtpt -79.74 -15.01 58.31 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.715 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.28 -54.82 3.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.663 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.519 ' CG2' ' CG2' ' A' ' 26' ' ' VAL . 56.9 mt -65.87 -42.18 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.642 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.55 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -96.45 31.78 2.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.211 -0.93 . . . . 0.0 109.711 -179.855 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.97 -73.29 0.39 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.94 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.6 p -107.04 -26.26 11.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.257 -1.143 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.463 ' HB2' ' CB ' ' A' ' 24' ' ' ALA . 10.5 p-10 -81.01 -19.32 44.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.694 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.422 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 5.3 t30 58.39 22.16 9.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.651 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.408 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 101.73 31.09 5.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.463 ' CB ' ' HB2' ' A' ' 21' ' ' ASP . . . -84.1 -46.49 11.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.261 -1.14 . . . . 0.0 109.584 179.925 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.38 -1.78 86.61 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.91 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.519 ' CG2' ' CG2' ' A' ' 17' ' ' ILE . 21.2 t -88.2 -40.24 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.041 -1.27 . . . . 0.0 109.426 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.448 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.49 -53.91 4.51 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.545 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.466 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 18.2 ptpt -48.9 -31.7 7.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.101 -1.235 . . . . 0.0 109.673 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.456 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 24.5 pt-20 -91.62 -21.32 20.87 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.215 -0.928 . . . . 0.0 109.387 179.713 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.4 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 20.8 t -87.6 -64.58 1.13 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.346 -0.847 . . . . 0.0 109.767 -179.794 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.524 ' CE2' ' O ' ' A' ' 149' ' ' CMO . 10.5 m-85 -48.28 -34.29 10.18 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 109.955 -179.566 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.409 HG23 ' O ' ' A' ' 28' ' ' LYS . 0.2 OUTLIER -56.74 -54.73 42.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 109.273 179.659 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -55.28 -51.39 66.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 179.847 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.516 ' CD1' HD22 ' A' ' 106' ' ' LEU . 2.0 t80 -54.54 -51.7 64.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 109.54 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.469 HD11 ' CG2' ' A' ' 55' ' ' VAL . 16.3 mt -54.81 -45.85 74.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.667 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.9 -59.21 3.46 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.257 -0.902 . . . . 0.0 109.671 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.4 -22.41 53.85 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 0.0 109.624 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.412 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 38.9 m-70 -131.0 107.85 9.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 109.786 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 48.7 m170 -88.9 -12.53 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.364 -0.835 . . . . 0.0 109.753 179.748 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -73.69 -16.89 61.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.123 -0.986 . . . . 0.0 109.715 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.5 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 73.0 mmm -109.13 -16.25 14.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.165 -0.96 . . . . 0.0 109.882 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.466 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.58 -51.3 28.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.986 -1.071 . . . . 0.0 109.498 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.02 -28.14 64.18 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.127 179.526 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 38.8 t -66.02 -32.1 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.407 -0.808 . . . . 0.0 109.265 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.515 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 29.3 m-85 -82.48 -25.68 33.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.159 -0.963 . . . . 0.0 109.503 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.49 26.79 5.5 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.779 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.54 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.2 m-85 -123.43 167.93 13.21 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.37 -1.077 . . . . 0.0 109.888 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 t -109.91 19.17 19.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.385 -0.822 . . . . 0.0 109.282 179.508 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.37 -163.33 29.52 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -179.946 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.19 40.72 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -1.157 . . . . 0.0 109.732 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 20.9 t -139.74 21.02 2.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.687 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.21 139.02 20.06 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.678 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -61.21 -24.73 79.56 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 123.951 1.5 . . . . 0.0 110.089 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.54 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.25 -39.32 42.62 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' CD2' ' A' ' 47' ' ' PHE . 59.4 t -51.31 -36.28 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -1.129 . . . . 0.0 109.367 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -73.38 -10.22 59.51 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.354 -0.841 . . . . 0.0 109.591 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.412 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 59.5 m-20 -86.78 -57.03 3.13 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.13 -0.981 . . . . 0.0 109.551 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.507 HD21 ' C1A' ' A' ' 148' ' ' HEM . 10.0 mt -63.29 -61.06 2.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.512 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -47.95 -37.38 15.69 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.46 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -69.72 -59.88 2.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.107 -1.231 . . . . 0.0 109.507 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.405 ' HG2' ' O2D' ' A' ' 148' ' ' HEM . 10.2 mttt -57.51 -46.57 83.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.268 -0.895 . . . . 0.0 109.34 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.456 HG21 ' C ' ' A' ' 149' ' ' CMO . 51.4 t -56.66 -52.12 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.268 -0.895 . . . . 0.0 109.558 179.771 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.413 HD23 ' CA ' ' A' ' 27' ' ' GLY . 1.4 mm? -47.06 -46.04 22.08 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.182 -0.949 . . . . 0.0 109.753 179.875 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.19 -49.52 52.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.597 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 16.1 tp60 -50.2 -48.75 54.1 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.272 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.446 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 50.1 mt -57.15 -39.21 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.374 -0.829 . . . . 0.0 109.025 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.22 -53.23 41.25 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.944 -1.662 . . . . 0.0 108.944 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.8 t -59.08 -26.73 34.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -1.089 . . . . 0.0 109.35 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.418 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -84.62 -28.6 26.39 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.421 -0.799 . . . . 0.0 109.58 179.966 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.46 ' CG1' HG11 ' A' ' 10' ' ' VAL . 58.1 t -61.39 -15.78 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.922 . . . . 0.0 109.733 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -90.94 26.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.212 -0.93 . . . . 0.0 109.959 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.469 ' O ' ' N ' ' A' ' 74' ' ' GLY . 7.9 m-70 -155.72 -87.0 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.016 . . . . 0.0 109.81 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.42 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 21.2 mt 63.53 -72.45 0.05 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.455 -0.778 . . . . 0.0 110.009 -179.873 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -65.51 -26.21 71.77 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -91.09 48.51 1.52 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.546 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.456 ' HG2' ' N ' ' A' ' 77' ' ' GLY . 0.0 OUTLIER -56.92 -19.54 18.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.723 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.456 ' N ' ' HG2' ' A' ' 76' ' ' GLU . . . -51.93 -24.1 13.09 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.995 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.422 ' O ' ' N ' ' A' ' 81' ' ' ALA . 15.9 ttpt -123.66 -46.22 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -1.171 . . . . 0.0 109.712 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 37.2 ttp -48.99 -27.81 3.43 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.666 179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 47.9 t -81.19 -21.63 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 179.846 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.422 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -71.69 -28.7 63.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.427 179.908 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -81.48 -52.3 7.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.29 -0.881 . . . . 0.0 109.5 179.875 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.458 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 99.3 mmm -56.44 -39.81 73.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.186 -0.946 . . . . 0.0 108.975 179.683 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.411 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -52.02 -28.65 17.83 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.077 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.412 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -80.08 -33.09 39.13 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.552 -0.718 . . . . 0.0 109.097 179.324 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.402 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.9 t -69.62 -33.83 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.22 179.688 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.462 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -65.37 -39.61 95.94 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 91' ' ' LYS . 90.3 t -58.7 -28.08 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.268 -1.137 . . . . 0.0 109.213 179.657 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.516 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -73.69 -25.94 60.48 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.349 -0.844 . . . . 0.0 109.26 179.641 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.46 ' CB ' HD12 ' A' ' 98' ' ' ILE . 18.5 m80 -88.04 18.19 4.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.375 -0.828 . . . . 0.0 110.169 -179.085 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.403 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 1.6 tttt -79.35 -60.56 2.32 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.02 -1.05 . . . . 0.0 110.52 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.43 ' HA2' ' HB2' ' A' ' 96' ' ' LYS . . . -148.24 57.58 0.48 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -179.497 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.516 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-85 -86.62 -148.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.308 -1.113 . . . . 0.0 109.812 -179.864 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -45.24 -70.22 0.65 Allowed Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.522 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.7 OUTLIER -66.79 -50.4 62.79 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 108.802 179.559 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.477 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.0 OUTLIER 76.58 -34.58 0.23 Allowed 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.399 -0.813 . . . . 0.0 111.48 179.277 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.474 ' N ' ' HG3' ' A' ' 96' ' ' LYS . 14.2 m170 -87.1 60.52 6.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.466 -1.396 . . . . 0.0 109.554 179.854 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.46 HD12 ' CB ' ' A' ' 90' ' ' HIS . 83.6 mt -87.21 155.06 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.122 -0.986 . . . . 0.0 110.224 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -133.97 141.37 47.25 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.528 -0.732 . . . . 0.0 109.724 -179.941 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.471 ' CB ' HG22 ' A' ' 142' ' ' ILE . . . -82.1 -3.28 54.43 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.358 -0.839 . . . . 0.0 110.213 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.467 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 16.9 pt-20 -78.95 -23.49 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.909 -1.12 . . . . 0.0 109.54 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.5 ' CD2' ' HG3' ' A' ' 41' ' ' MET . 71.8 m-85 -80.33 -7.0 58.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.23 -0.918 . . . . 0.0 110.026 179.837 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.517 ' CE2' HMC1 ' A' ' 148' ' ' HEM . 3.2 m-85 -70.0 -66.91 0.53 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.115 -0.99 . . . . 0.0 110.092 -179.561 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.492 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.78 -60.02 3.48 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.494 -0.754 . . . . 0.0 110.743 -179.338 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.492 ' CD ' ' CB ' ' A' ' 104' ' ' GLU . 4.2 Cg_endo -52.87 -55.7 3.5 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.683 1.359 . . . . 0.0 109.995 -179.5 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.516 HD22 ' CD1' ' A' ' 34' ' ' PHE . 3.3 tm? -59.98 -19.76 54.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.283 179.745 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -75.33 -45.72 18.04 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.57 -46.79 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.134 -1.215 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.5 m -64.87 -17.64 64.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.251 -0.905 . . . . 0.0 109.407 179.584 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.515 ' CD2' ' CE ' ' A' ' 114' ' ' MET . 4.9 tt -74.63 -41.87 59.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.947 . . . . 0.0 109.685 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.24 -28.89 68.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.115 -0.991 . . . . 0.0 109.39 179.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.7 t -60.26 -46.15 90.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.334 -0.854 . . . . 0.0 109.64 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.465 ' HA ' ' CD2' ' A' ' 116' ' ' HIS . . . -66.29 -36.92 84.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.533 ' HG2' ' CZ3' ' A' ' 130' ' ' TRP . 0.0 OUTLIER -47.28 -42.69 21.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.316 -0.865 . . . . 0.0 109.85 179.904 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.458 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.97 -24.01 15.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.277 -0.889 . . . . 0.0 109.766 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.465 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.6 m170 -52.38 -55.16 23.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 109.842 -179.784 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.426 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 3.8 ttt85 -72.03 -66.09 0.69 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.188 -0.945 . . . . 0.0 109.833 -179.841 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.444 HG12 ' CD1' ' A' ' 17' ' ' ILE . 6.6 pt -94.57 58.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.114 -0.991 . . . . 0.0 109.748 -179.826 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.75 -39.49 95.26 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -85.92 -13.46 69.29 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.867 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.414 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.2 mttm -104.71 -20.84 13.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.07 -1.253 . . . . 0.0 109.883 -179.812 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.42 ' N ' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.47 90.45 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.213 179.71 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.474 ' ND2' ' HB2' ' A' ' 125' ' ' ALA . 9.1 p-10 -92.5 -172.61 3.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.224 -0.922 . . . . 0.0 110.029 -179.619 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -63.65 -48.99 75.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.46 -0.775 . . . . 0.0 110.308 -179.426 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.474 ' HB2' ' ND2' ' A' ' 123' ' ' ASN . . . -60.52 -24.88 65.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.428 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -75.18 -49.27 20.0 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.461 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.463 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 20.1 ptpt -73.04 -30.85 64.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -0.911 . . . . 0.0 109.74 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.463 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.5 t0 -76.71 -41.93 43.42 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.456 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -64.02 -43.28 96.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.368 -0.833 . . . . 0.0 109.376 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.533 ' CZ3' ' HG2' ' A' ' 114' ' ' MET . 6.8 m0 -75.6 -26.24 57.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.288 -0.882 . . . . 0.0 109.314 179.761 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -64.94 -26.4 68.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.454 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.409 ' HB3' HD12 ' A' ' 2' ' ' LEU . . . -96.82 -26.37 15.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.441 -0.787 . . . . 0.0 109.276 179.659 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.405 ' HB2' HG21 ' A' ' 10' ' ' VAL . . . -73.93 -57.69 3.8 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.364 -0.835 . . . . 0.0 109.449 179.819 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.492 ' CE2' ' HE1' ' A' ' 114' ' ' MET . 17.2 m-30 -50.36 -29.18 9.4 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.333 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.27 -43.95 69.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.372 -0.83 . . . . 0.0 109.08 179.554 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -75.16 -33.32 61.47 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.352 -0.843 . . . . 0.0 109.238 179.663 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.418 HG12 ' CB ' ' A' ' 69' ' ' ALA . 3.5 mt -67.9 -59.06 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.314 -0.866 . . . . 0.0 109.192 179.667 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.43 ' OG ' ' CMC' ' A' ' 148' ' ' HEM . 0.4 OUTLIER -68.2 -48.76 64.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.717 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -50.91 -28.59 17.4 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.189 -1.565 . . . . 0.0 109.189 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.06 3.21 31.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -1.132 . . . . 0.0 110.048 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.458 ' HB2' ' CE ' ' A' ' 83' ' ' MET . 7.2 tt -97.97 -24.38 15.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.933 -1.104 . . . . 0.0 109.804 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.523 ' CG2' ' NE2' ' A' ' 146' ' ' GLN . 6.8 mt -87.2 18.23 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.382 -179.446 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.411 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -77.96 -20.67 52.27 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.107 -0.996 . . . . 0.0 108.872 179.489 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.35 1.51 5.71 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.838 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.523 ' O ' ' CB ' ' A' ' 146' ' ' GLN . 0.2 OUTLIER -97.68 126.89 43.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.849 -1.383 . . . . 0.0 110.1 -179.825 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.523 ' CB ' ' O ' ' A' ' 145' ' ' LEU . 0.4 OUTLIER 160.6 48.3 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.856 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.642 -179.959 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.517 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.524 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.409 ' HB2' ' O ' ' A' ' 1' ' ' GLY . 12.3 mt 56.92 165.39 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.332 -1.099 . . . . 0.0 109.714 -180.0 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p -151.8 -179.91 7.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.546 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.43 -22.59 59.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.135 -0.978 . . . . 0.0 109.21 179.726 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.402 ' O ' ' CG2' ' A' ' 9' ' ' VAL . . . -86.4 -36.39 19.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.35 -0.844 . . . . 0.0 109.539 179.723 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -70.92 -48.5 53.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.217 -0.927 . . . . 0.0 109.509 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 13.9 ptm180 -56.31 -30.83 63.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.277 -0.889 . . . . 0.0 109.348 179.856 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.434 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 17.7 mm-40 -73.74 -41.73 62.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.436 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.464 ' CG1' ' O ' ' A' ' 125' ' ' ALA . 21.6 t -61.4 -22.54 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.481 HG12 ' CD1' ' A' ' 130' ' ' TRP . 66.4 t -73.37 -43.31 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 109.673 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.79 -8.03 54.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.288 -0.883 . . . . 0.0 110.016 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.5 m -94.23 -30.3 14.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.043 . . . . 0.0 109.826 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.509 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.2 p -92.91 -13.17 29.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.954 -179.835 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.04 -19.49 27.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.117 -0.989 . . . . 0.0 109.849 -179.741 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.2 mtpt -83.87 -4.06 58.38 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.928 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.66 -53.31 2.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.788 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.483 HD11 ' CH2' ' A' ' 130' ' ' TRP . 60.9 mt -66.16 -36.28 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.455 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.56 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -104.29 27.34 7.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.51 -69.52 1.07 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 p -107.21 -36.95 6.41 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -1.141 . . . . 0.0 109.59 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -71.79 -20.04 61.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.922 . . . . 0.0 109.667 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 17.5 t30 54.54 30.44 13.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.268 -0.895 . . . . 0.0 109.593 -179.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.75 59.99 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.4 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -68.59 -47.3 67.09 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.108 -1.231 . . . . 0.0 109.52 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.472 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.23 12.97 62.94 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.473 ' CG1' HD13 ' A' ' 63' ' ' LEU . 11.3 t -97.84 -32.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.139 -1.212 . . . . 0.0 109.116 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 31' ' ' PHE . . . -86.69 -44.24 5.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.489 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 7.7 ptpt -53.87 -35.41 61.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -1.195 . . . . 0.0 109.386 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.47 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.3 pt-20 -86.85 -26.83 23.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 109.366 179.714 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.411 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 30.4 t -85.11 -58.31 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.366 -0.834 . . . . 0.0 109.684 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.518 ' CZ ' ' HA2' ' A' ' 59' ' ' GLY . 3.4 m-85 -47.3 -32.57 4.82 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.333 -0.854 . . . . 0.0 109.915 -179.72 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.54 -49.22 78.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.158 179.669 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -52.28 64.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.571 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.508 ' CG ' HD22 ' A' ' 106' ' ' LEU . 6.8 t80 -52.4 -54.48 31.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.189 -0.944 . . . . 0.0 109.483 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.512 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 38.2 mt -55.7 -43.67 76.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.665 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 9.6 t -68.81 -65.43 0.7 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.732 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.449 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -52.67 -27.35 16.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.723 -179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.468 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 16.2 m-70 -123.06 106.72 11.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.914 . . . . 0.0 109.837 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -87.36 -20.83 26.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.429 -0.795 . . . . 0.0 109.294 179.542 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.4 p-10 -66.15 -17.9 65.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.371 179.478 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.51 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 84.6 mmm -106.14 -24.5 12.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.266 -0.896 . . . . 0.0 109.705 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.464 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.88 -46.14 42.18 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.078 -1.014 . . . . 0.0 109.61 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.75 -21.12 60.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.302 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.463 HG13 ' CMB' ' A' ' 148' ' ' HEM . 35.8 t -76.16 -40.83 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.299 -0.876 . . . . 0.0 109.412 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -67.26 -41.79 84.97 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 109.576 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.46 32.94 1.07 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.52 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.4 m-85 -125.04 173.15 8.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.225 -1.162 . . . . 0.0 109.629 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 17.6 t -111.51 19.38 18.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 109.371 179.547 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.11 -167.34 30.07 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.86 -23.0 39.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.203 -1.175 . . . . 0.0 109.66 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 12.5 m -84.74 51.24 2.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.923 . . . . 0.0 109.676 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -120.51 136.21 25.13 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.597 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -68.06 -33.45 25.42 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.97 1.511 . . . . 0.0 110.033 -179.906 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.52 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.41 -32.39 30.21 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.512 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 91.7 t -53.92 -41.61 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.268 -1.136 . . . . 0.0 109.501 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.489 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -74.5 -11.01 60.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.262 -0.899 . . . . 0.0 109.872 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.409 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 11.4 t0 -91.73 -33.3 15.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.111 -0.993 . . . . 0.0 109.375 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.519 HD21 ' C1A' ' A' ' 148' ' ' HEM . 1.6 mt -81.59 -64.25 1.22 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.348 -0.845 . . . . 0.0 110.201 -179.786 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.518 ' HA2' ' CZ ' ' A' ' 31' ' ' PHE . . . -56.09 -20.77 29.1 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.37 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -72.24 -40.76 67.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.109 -1.23 . . . . 0.0 109.761 -179.719 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.472 ' HB3' ' CGD' ' A' ' 148' ' ' HEM . 28.6 mttt -84.46 -43.67 14.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.601 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.449 HG21 ' C ' ' A' ' 149' ' ' CMO . 61.6 t -52.56 -47.18 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.128 -0.983 . . . . 0.0 109.48 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.473 HD13 ' CG1' ' A' ' 26' ' ' VAL . 0.8 OUTLIER -48.09 -47.85 33.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.108 -0.995 . . . . 0.0 109.773 179.81 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.409 ' HB2' ' O ' ' A' ' 61' ' ' LYS . . . -49.6 -49.38 47.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.912 . . . . 0.0 109.653 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -49.06 -54.96 13.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.135 -0.978 . . . . 0.0 109.378 179.849 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.459 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 83.7 mt -52.36 -35.32 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.313 -0.867 . . . . 0.0 109.05 179.554 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.85 -57.11 15.21 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.869 -1.693 . . . . 0.0 108.869 179.416 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.5 t -57.58 -25.91 25.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -1.135 . . . . 0.0 109.253 179.76 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.07 -19.58 34.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.391 -0.818 . . . . 0.0 109.5 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 53.0 t -75.47 -14.47 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.686 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.488 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -90.41 35.64 0.88 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.109 -0.994 . . . . 0.0 109.96 -179.824 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 71' ' ' SER . 6.0 m-70 -161.68 -84.75 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.063 -1.023 . . . . 0.0 109.918 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.439 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 42.2 mt 60.22 -77.67 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.599 -0.688 . . . . 0.0 109.97 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.476 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -67.19 -24.48 73.4 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.43 146.54 26.22 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -1.159 . . . . 0.0 109.668 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -140.45 62.45 1.49 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.912 . . . . 0.0 109.605 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -115.41 -18.52 6.16 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 22.9 ttpt -140.19 -40.62 0.43 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.079 -1.248 . . . . 0.0 109.923 -179.896 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 59.0 ttp -48.17 -49.07 33.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.19 -0.944 . . . . 0.0 109.772 -179.866 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.8 t -73.07 -14.63 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.872 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.78 -35.08 72.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.126 -0.983 . . . . 0.0 109.835 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.411 ' O ' HG23 ' A' ' 86' ' ' VAL . 10.7 tt0 -98.82 -40.97 7.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.666 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.418 ' HA ' HG23 ' A' ' 86' ' ' VAL . 1.7 mtp -62.18 -46.55 88.43 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.419 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 13.1 tttt -56.18 -39.27 72.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.172 -0.955 . . . . 0.0 109.172 179.65 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -63.19 -39.65 95.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.388 179.709 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.505 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 48.8 t -51.92 -47.96 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -52.94 -49.88 53.15 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.624 -1.791 . . . . 0.0 108.624 179.548 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.414 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.1 t -53.13 -34.75 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.389 -1.065 . . . . 0.0 109.249 179.462 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 24.6 mmm180 -69.56 -49.21 56.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.865 . . . . 0.0 109.416 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.475 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 10.7 m80 -61.63 -15.41 39.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.235 -0.916 . . . . 0.0 109.363 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.463 ' HG3' ' CB ' ' A' ' 147' ' ' SER . 4.8 ttmt -43.21 -33.49 0.94 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.466 -0.771 . . . . 0.0 110.917 -179.568 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.39 60.95 0.28 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.11 -1.519 . . . . 0.0 110.675 -179.502 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.9 m-30 -69.83 -166.0 0.1 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.014 -1.286 . . . . 0.0 109.257 178.64 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.31 -22.63 61.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.612 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.489 ' O ' ' CB ' ' A' ' 96' ' ' LYS . 0.2 OUTLIER -93.61 -44.06 8.38 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.381 -1.07 . . . . 0.0 109.321 -179.955 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.489 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 27.4 mttt 79.58 -32.14 0.14 Allowed 'General case' 0 N--CA 1.509 2.512 0 O-C-N 121.954 -0.467 . . . . 0.0 111.278 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.431 ' HB2' ' OD1' ' A' ' 95' ' ' ASN . 30.7 m170 -60.69 -99.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.518 -1.364 . . . . 0.0 109.99 -179.6 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.501 ' O ' ' CD ' ' A' ' 99' ' ' LYS . 6.1 mt 62.83 129.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.778 -1.201 . . . . 0.0 109.903 -179.546 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.518 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -145.4 143.35 30.03 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 122.237 1.018 . . . . 0.0 110.85 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.417 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -69.12 -19.61 64.04 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.047 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -64.9 -32.77 74.64 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.772 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.518 ' CD2' ' HB2' ' A' ' 99' ' ' LYS . 22.9 m-85 -81.26 -25.62 36.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.589 -0.694 . . . . 0.0 109.956 179.847 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.566 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 3.4 m-85 -53.46 -65.88 0.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.22 -0.925 . . . . 0.0 110.344 -179.382 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.487 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.6 mt-10 -46.53 -59.43 5.06 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.251 -0.906 . . . . 0.0 110.512 -179.194 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 41.0 Cg_exo -45.42 -55.06 3.78 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.712 1.375 . . . . 0.0 110.621 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.508 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.0 tm? -55.43 -39.13 69.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.34 -40.33 97.75 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.27 -55.07 27.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -1.162 . . . . 0.0 109.766 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.1 t -60.16 -27.43 67.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.202 -0.937 . . . . 0.0 109.703 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.437 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 3.2 tt -70.35 -38.92 74.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.205 -0.935 . . . . 0.0 109.589 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.08 -29.39 68.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.15 -0.969 . . . . 0.0 109.41 179.897 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 m -73.49 -29.7 62.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.784 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.467 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -80.68 -38.3 29.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.949 . . . . 0.0 109.569 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.503 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 1.9 mtt -50.1 -39.68 43.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.283 -0.885 . . . . 0.0 109.463 179.857 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.5 OUTLIER -51.67 -24.74 6.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.23 -0.919 . . . . 0.0 109.382 179.565 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.467 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 33.8 m170 -55.67 -49.67 72.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.327 -0.858 . . . . 0.0 109.829 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.438 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 2.9 ttt85 -70.1 -65.37 0.73 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.272 -0.892 . . . . 0.0 109.696 -179.837 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.457 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 13.5 pt -87.97 46.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 109.565 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.451 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.49 125.25 35.92 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 95.71 -30.44 8.39 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.743 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.401 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 19.2 mmtt -90.11 -28.71 18.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.227 -1.161 . . . . 0.0 109.166 179.682 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.457 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 1.2 ttt -71.37 107.38 4.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.437 -0.789 . . . . 0.0 109.359 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.4 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 10.0 p30 -109.72 -162.1 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.177 -0.952 . . . . 0.0 109.894 -179.776 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.43 ' HA ' ' HD3' ' A' ' 127' ' ' LYS . . . -67.55 -45.78 74.67 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.346 -0.847 . . . . 0.0 109.64 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.464 ' O ' ' CG1' ' A' ' 9' ' ' VAL . . . -57.62 -24.03 54.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -86.23 -57.06 3.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.8 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.43 ' HD3' ' HA ' ' A' ' 124' ' ' ALA . 0.1 OUTLIER -65.94 -27.33 68.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.153 -0.967 . . . . 0.0 109.692 -179.735 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.416 ' HB3' ' O ' ' A' ' 124' ' ' ALA . 32.1 t70 -80.55 -49.95 10.65 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.311 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -57.7 -50.47 73.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.394 -0.816 . . . . 0.0 109.282 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.509 ' CE2' ' OG1' ' A' ' 13' ' ' THR . 4.8 m0 -63.89 -30.96 71.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.237 -0.915 . . . . 0.0 108.877 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.98 -30.09 67.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 108.89 179.166 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.6 -28.52 23.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.392 -0.818 . . . . 0.0 109.194 179.501 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.85 -40.81 21.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.406 -0.809 . . . . 0.0 109.473 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.455 ' OH ' ' CE ' ' A' ' 114' ' ' MET . 1.8 m-85 -50.26 -32.01 15.65 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.45 -34.78 72.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.281 -0.887 . . . . 0.0 109.242 179.638 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.27 -39.68 39.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 0.0 109.371 179.692 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 54.5 mt -66.05 -58.12 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.274 -0.891 . . . . 0.0 109.145 179.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.11 -17.5 64.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.291 -0.881 . . . . 0.0 109.645 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 142' ' ' ILE . . . -68.25 -55.56 12.59 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.23 -28.19 4.38 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.505 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -74.82 -21.55 59.22 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -0.893 . . . . 0.0 109.536 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.443 HD12 HG22 ' A' ' 142' ' ' ILE . 91.0 mt -83.78 8.36 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.292 -0.88 . . . . 0.0 110.096 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.3 m -100.13 -46.0 5.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.04 -1.038 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.414 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -68.86 -31.55 72.94 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.475 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER -61.61 -148.35 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.414 179.869 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 22.9 mp0 52.92 43.37 31.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.01 -1.056 . . . . 0.0 109.762 179.845 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.463 ' CB ' ' HG3' ' A' ' 91' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.671 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.566 ' CMC' ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.449 ' C ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.4 mt -94.13 172.24 8.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.298 179.721 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -137.29 178.48 7.06 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.811 -1.18 . . . . 0.0 110.384 -179.802 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.81 -14.88 63.16 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.494 -0.754 . . . . 0.0 110.536 -179.506 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.82 -48.26 6.11 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.05 -1.032 . . . . 0.0 109.819 -179.679 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -66.67 -33.96 76.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.638 179.903 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 42.9 mtp180 -54.75 -41.82 70.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.644 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -74.73 -36.55 62.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.239 -0.913 . . . . 0.0 109.549 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 33.3 t -71.26 -35.8 59.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.151 -0.968 . . . . 0.0 108.987 179.628 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.446 HG12 ' CD1' ' A' ' 130' ' ' TRP . 41.9 t -67.46 -37.24 78.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.399 -0.813 . . . . 0.0 109.057 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.26 -16.29 56.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.345 -0.847 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.6 t -90.3 -22.72 21.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.891 -179.625 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.8 p -95.24 -12.28 26.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 110.028 -179.851 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.575 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.31 -15.07 27.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.042 -1.037 . . . . 0.0 109.973 -179.895 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mtpt -85.92 -2.0 57.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.73 -45.16 3.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.996 -1.065 . . . . 0.0 109.667 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.445 ' CG2' HG21 ' A' ' 26' ' ' VAL . 45.8 mt -72.47 -36.34 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.446 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.575 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -103.02 31.67 4.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.323 -0.86 . . . . 0.0 109.588 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.62 -78.73 0.1 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.54 -27.74 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 13.4 p-10 -80.01 -20.15 46.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 0.0 109.607 179.959 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.4 t30 56.16 27.7 11.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.875 . . . . 0.0 109.645 179.997 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.94 22.38 42.51 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.415 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -59.21 -52.37 65.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -1.161 . . . . 0.0 109.569 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.412 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -92.92 26.11 16.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.445 HG21 ' CG2' ' A' ' 17' ' ' ILE . 39.2 t -110.14 -22.73 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.29 -1.123 . . . . 0.0 108.887 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.405 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -100.15 -26.97 8.01 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 179.79 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.467 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 14.2 ptpt -70.19 -34.99 73.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.245 -1.15 . . . . 0.0 109.385 179.789 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.467 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -92.34 -8.9 43.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.157 -0.964 . . . . 0.0 109.839 179.678 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.6 t -93.25 -61.3 1.6 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.067 -1.021 . . . . 0.0 109.722 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.501 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.9 m-85 -55.64 -30.56 61.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.926 . . . . 0.0 109.768 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.437 ' CA ' HG12 ' A' ' 55' ' ' VAL . 17.8 m -58.35 -48.01 81.96 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.125 -0.984 . . . . 0.0 109.395 179.794 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.31 -41.33 98.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.317 -0.865 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.52 ' CG ' HD22 ' A' ' 106' ' ' LEU . 2.4 t80 -62.14 -44.67 96.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.251 -0.905 . . . . 0.0 109.43 179.84 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.5 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 15.7 mt -62.8 -45.53 92.22 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.2 p -66.28 -46.75 75.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.738 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 -21.4 62.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 33.7 m-70 -127.82 114.31 17.07 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.758 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -93.22 5.29 52.03 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.357 -0.839 . . . . 0.0 109.984 179.736 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -95.6 -22.18 17.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.044 -1.035 . . . . 0.0 109.486 179.811 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.512 ' HE2' ' CD2' ' A' ' 102' ' ' TYR . 0.4 OUTLIER -97.01 -22.45 16.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.309 -0.87 . . . . 0.0 109.615 179.977 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.43 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.16 -50.75 61.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.196 -0.94 . . . . 0.0 109.536 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -66.41 -21.39 66.22 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.895 . . . . 0.0 109.585 179.897 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.49 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 52.6 t -79.73 -55.98 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.5 ' CE1' ' C1B' ' A' ' 148' ' ' HEM . 33.7 m-85 -53.74 -40.9 66.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.79 31.78 1.41 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 -179.849 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.513 ' CD2' HG22 ' A' ' 55' ' ' VAL . 11.9 m-85 -125.36 -179.07 4.44 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -1.176 . . . . 0.0 109.749 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.9 t -123.99 19.17 9.25 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.417 -0.802 . . . . 0.0 109.299 179.481 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.44 -163.38 27.53 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.92 -19.08 55.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.698 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 8.5 t -85.41 50.13 1.89 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -128.62 117.8 19.84 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.615 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -59.28 -29.54 90.56 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.842 1.443 . . . . 0.0 110.108 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.96 -34.49 38.44 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.513 HG22 ' CD2' ' A' ' 47' ' ' PHE . 89.3 t -52.26 -31.47 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.274 -1.133 . . . . 0.0 109.636 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.456 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -77.36 -21.86 52.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.487 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.83 -45.55 16.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.9 . . . . 0.0 109.557 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.506 HD21 ' C1A' ' A' ' 148' ' ' HEM . 2.9 mt -68.25 -59.06 3.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -0.925 . . . . 0.0 109.535 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -51.17 -54.8 21.77 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.421 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -53.19 -37.61 62.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -1.17 . . . . 0.0 109.59 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 mttm -77.98 -25.79 48.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.435 ' CG2' ' O ' ' A' ' 58' ' ' LEU . 41.9 t -82.61 -40.91 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.418 ' HG ' ' HB ' ' A' ' 26' ' ' VAL . 1.6 mm? -50.11 -55.03 16.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.554 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -43.67 36.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.229 -0.919 . . . . 0.0 109.71 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.409 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 0.2 OUTLIER -51.59 -54.17 30.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 179.79 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 69.2 mt -55.48 -34.65 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.263 -0.898 . . . . 0.0 108.98 179.721 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.542 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.84 -55.15 18.23 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.5 t -57.79 -22.12 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.322 -1.105 . . . . 0.0 109.138 179.759 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.68 -31.17 21.18 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.392 -0.818 . . . . 0.0 109.461 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 53.0 t -69.24 -17.09 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 109.484 179.728 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -61.97 -37.93 86.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -0.941 . . . . 0.0 109.912 -179.832 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.409 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 22.5 m-70 -129.29 81.73 2.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 109.885 -179.815 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.435 ' CD1' HG13 ' A' ' 10' ' ' VAL . 53.5 mt -85.51 -36.39 20.55 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.892 . . . . 0.0 109.461 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -90.38 -24.52 28.57 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.686 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -86.95 120.1 27.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.348 -1.089 . . . . 0.0 109.472 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -110.22 44.19 1.27 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.231 -0.918 . . . . 0.0 109.706 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -128.16 17.12 5.98 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 3.2 ttmt -158.47 -50.12 0.06 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.162 -1.199 . . . . 0.0 109.934 179.942 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.409 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 49.5 ttp -49.11 -41.2 35.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 109.652 -179.807 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.455 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 60.0 t -77.29 -0.53 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 110.036 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.11 -24.12 26.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.04 -1.038 . . . . 0.0 109.595 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -106.77 -41.05 5.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.545 179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.444 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 10.1 mtp -67.98 -40.81 83.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.219 -0.926 . . . . 0.0 108.949 179.653 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 6.0 tttt -56.28 -28.56 59.12 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 179.009 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.405 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -78.49 -31.92 47.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.48 -0.763 . . . . 0.0 109.056 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.485 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 47.3 t -62.72 -41.78 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.245 -0.91 . . . . 0.0 109.06 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.418 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -54.06 -41.78 69.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.356 -1.898 . . . . 0.0 108.356 179.53 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 97.5 t -56.34 -46.54 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.426 -1.043 . . . . 0.0 109.252 179.475 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.508 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 10.4 mpt_? -52.05 -29.96 23.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.028 -1.045 . . . . 0.0 109.054 179.466 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.507 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 34.6 m80 -84.22 9.51 12.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.417 -0.802 . . . . 0.0 110.022 -179.894 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.469 ' CD ' ' HA ' ' A' ' 147' ' ' SER . 25.0 ttpt -104.36 -11.74 16.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.034 -1.041 . . . . 0.0 110.241 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.17 18.79 2.31 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.142 -1.504 . . . . 0.0 110.855 -179.242 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.508 ' CZ ' ' HB3' ' A' ' 89' ' ' ARG . 1.6 m-85 -58.9 -164.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.644 -1.504 . . . . 0.0 109.174 179.317 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.77 -31.21 40.83 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 179.625 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.495 ' O ' ' CB ' ' A' ' 96' ' ' LYS . 0.5 OUTLIER -81.14 -48.67 11.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.529 -0.983 . . . . 0.0 108.787 179.703 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.8 tmtt? 76.83 -19.3 0.43 Allowed 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.652 -0.655 . . . . 0.0 111.901 179.162 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.419 ' HB2' ' OD1' ' A' ' 95' ' ' ASN . 37.8 m170 -72.31 -95.82 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.443 -1.411 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.469 HG13 ' ND2' ' A' ' 95' ' ' ASN . 8.1 mt 61.71 148.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 120.858 -1.151 . . . . 0.0 110.511 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.425 ' HG3' ' O ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -156.88 149.66 23.63 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 121.943 0.878 . . . . 0.0 110.521 179.812 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.83 -7.29 55.18 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.681 179.613 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.567 ' CG ' ' CD2' ' A' ' 102' ' ' TYR . 12.0 pt-20 -71.38 -34.23 70.24 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.95 -1.094 . . . . 0.0 109.082 179.461 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.567 ' CD2' ' CG ' ' A' ' 101' ' ' GLU . 94.3 m-85 -80.3 -25.46 39.35 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 109.329 179.566 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.572 ' CE1' ' CHC' ' A' ' 148' ' ' HEM . 2.7 m-85 -48.12 -62.16 1.62 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.358 -0.839 . . . . 0.0 110.236 -179.798 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -51.97 -59.84 7.41 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.177 -0.952 . . . . 0.0 110.173 -179.366 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 36.1 Cg_exo -47.53 -59.69 1.15 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.586 1.309 . . . . 0.0 110.229 179.91 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.52 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -54.29 -22.57 12.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.91 . . . . 0.0 109.406 179.906 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.01 -44.09 9.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.96 -49.96 74.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -1.163 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 75.6 m -56.65 -31.29 64.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 109.603 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 2.6 tt -62.75 -43.83 97.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.602 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 12.7 mt -53.87 -39.19 65.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 13.5 t -62.3 -32.02 72.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.235 -0.915 . . . . 0.0 109.503 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.408 ' HB3' ' OE2' ' A' ' 29' ' ' GLU . . . -78.91 -39.73 34.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.41 179.758 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.547 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -48.72 -45.73 39.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -48.32 -29.31 3.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -0.927 . . . . 0.0 109.968 -179.838 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.419 ' CE1' ' OE1' ' A' ' 29' ' ' GLU . 17.5 m170 -49.9 -56.4 10.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.082 -1.011 . . . . 0.0 109.817 -179.826 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.8 ttt85 -69.77 -63.57 1.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.849 -179.82 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.457 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 4.7 pt -96.61 58.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.313 -0.867 . . . . 0.0 109.709 -179.789 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.36 -20.32 71.38 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.73 -21.1 17.21 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.865 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.457 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -100.62 -19.37 16.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -1.187 . . . . 0.0 109.884 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -66.95 79.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.051 -1.031 . . . . 0.0 109.799 -179.927 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.435 ' OD1' ' N ' ' A' ' 123' ' ' ASN . 15.7 p-10 -80.13 -171.97 3.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.172 179.589 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -70.12 -31.35 68.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.066 -1.021 . . . . 0.0 109.907 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.18 -23.69 61.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.038 -1.039 . . . . 0.0 109.024 179.668 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -74.88 -47.55 29.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 108.892 179.403 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.468 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 6.9 ptpt -71.79 -31.28 66.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.413 -0.805 . . . . 0.0 109.232 179.569 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.468 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.4 t70 -75.78 -48.52 21.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -58.55 -44.57 89.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.422 -0.799 . . . . 0.0 109.493 179.844 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.547 ' CZ3' ' CE ' ' A' ' 114' ' ' MET . 7.0 m0 -74.88 -26.17 59.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.245 179.838 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.12 -27.3 65.45 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.246 -0.909 . . . . 0.0 108.979 179.415 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -93.46 -23.06 18.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.192 179.502 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.436 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -79.81 -42.88 23.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.395 -0.816 . . . . 0.0 109.556 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -49.26 -33.32 12.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.207 -0.933 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.74 -25.15 49.02 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.229 -0.919 . . . . 0.0 108.938 179.412 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.436 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.7 t0 -85.95 -40.76 15.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.387 -0.821 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.405 ' O ' ' HE1' ' A' ' 83' ' ' MET . 1.6 mp -65.8 -59.6 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 108.824 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.501 ' OG ' ' CD2' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -64.6 -25.22 67.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.243 -0.911 . . . . 0.0 109.745 -179.85 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -55.68 -49.56 65.02 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.95 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.94 -17.75 64.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.234 -1.156 . . . . 0.0 109.845 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.485 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 5.1 tt -84.19 -33.38 24.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.15 -0.969 . . . . 0.0 109.738 -179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 138' ' ' SER . 50.6 mt -68.48 -9.25 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 110.065 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 67.6 m -70.51 -65.15 0.77 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.069 -1.019 . . . . 0.0 109.595 179.835 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.45 -7.37 64.09 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.474 ' O ' ' HG2' ' A' ' 146' ' ' GLN . 5.9 tt -83.86 176.82 8.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.08 -1.247 . . . . 0.0 109.48 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 55.48 29.74 13.84 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.607 -0.683 . . . . 0.0 110.295 179.907 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.469 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 7.7 p . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.024 -0.988 . . . . 0.0 109.698 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.572 ' CHC' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.499 ' O ' ' CE1' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 21.9 mt -51.22 165.78 0.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.357 -1.084 . . . . 0.0 109.964 -179.928 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.94 -174.02 2.37 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.459 ' HA ' ' CD ' ' A' ' 7' ' ' ARG . . . -79.8 -26.35 40.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.64 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -85.96 -32.37 21.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.9 . . . . 0.0 109.647 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.69 -47.74 18.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.459 ' CD ' ' HA ' ' A' ' 4' ' ' ALA . 8.3 ptm180 -52.54 -32.69 41.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.153 -0.967 . . . . 0.0 108.738 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.401 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 49.4 tp60 -71.16 -36.01 71.85 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 47.5 t -73.3 -31.74 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.391 -0.818 . . . . 0.0 108.942 179.196 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.511 HG11 ' CD1' ' A' ' 130' ' ' TRP . 41.9 t -70.03 -37.49 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.743 . . . . 0.0 109.357 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.08 -16.35 58.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.691 179.903 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.4 -27.22 21.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.925 . . . . 0.0 109.693 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.2 p -88.5 -14.2 38.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.79 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.54 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.34 -20.55 21.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.125 -0.985 . . . . 0.0 109.717 -179.767 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.5 mtpp -79.74 -0.05 32.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.839 179.694 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -113.32 -56.35 2.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.011 -1.055 . . . . 0.0 109.553 179.856 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.464 ' CG1' HG12 ' A' ' 118' ' ' ILE . 73.9 mt -62.54 -34.18 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.202 -0.936 . . . . 0.0 109.55 179.939 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.526 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.5 36.66 2.44 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.271 -0.893 . . . . 0.0 109.771 -179.889 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.86 -88.19 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.9 p -112.28 15.04 20.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -1.132 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 4.3 p-10 -122.1 -9.14 8.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.164 -0.96 . . . . 0.0 110.032 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.449 ' O ' ' ND2' ' A' ' 22' ' ' ASN . 9.0 t30 56.41 20.17 4.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.565 -179.711 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.06 34.32 30.45 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.719 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.402 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -56.39 -43.99 79.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -1.139 . . . . 0.0 109.62 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.476 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.96 -18.32 72.67 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.466 HG12 ' CD2' ' A' ' 63' ' ' LEU . 25.7 t -68.76 -31.86 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.551 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.411 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.23 -54.32 4.44 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.611 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.476 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.7 ptpt -55.19 -24.71 28.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -1.163 . . . . 0.0 110.108 -179.487 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 25' ' ' GLY . 23.1 pt-20 -98.23 -16.15 19.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.001 -1.062 . . . . 0.0 109.851 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.402 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 40.5 t -90.78 -60.19 1.98 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.186 -0.946 . . . . 0.0 110.014 -179.628 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CZ ' ' O ' ' A' ' 149' ' ' CMO . 10.5 m-85 -59.83 -32.0 70.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.218 -0.926 . . . . 0.0 110.167 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.457 ' OG1' ' CG1' ' A' ' 55' ' ' VAL . 16.6 m -60.65 -45.05 95.55 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.096 -1.002 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -64.7 -29.26 70.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 179.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' CG ' HD22 ' A' ' 106' ' ' LEU . 17.0 t80 -78.3 -49.58 13.39 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.279 -0.888 . . . . 0.0 109.458 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.504 HD21 ' CD2' ' A' ' 45' ' ' PHE . 13.3 mt -51.84 -46.43 64.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.333 -0.854 . . . . 0.0 109.687 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.3 t -61.82 -59.96 4.36 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 109.677 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.35 -23.04 66.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.24 -0.912 . . . . 0.0 109.73 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.451 ' N ' ' O ' ' A' ' 34' ' ' PHE . 25.5 m-70 -121.22 99.35 6.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 109.688 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -85.33 -19.79 30.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.309 -0.87 . . . . 0.0 109.531 179.936 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -69.28 -20.53 63.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.695 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.515 ' HE1' ' CD1' ' A' ' 102' ' ' TYR . 7.3 mmm -108.83 -16.83 14.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.201 -0.937 . . . . 0.0 109.824 -179.927 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.463 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -50.47 -41.0 52.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 0.0 109.378 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -76.47 -32.1 58.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.299 -0.876 . . . . 0.0 109.159 179.583 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 24.7 t -59.18 -56.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.384 -0.823 . . . . 0.0 109.245 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.522 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 62.4 m-85 -54.19 -31.03 51.77 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.21 29.68 3.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.873 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.522 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.5 m-85 -123.81 167.6 13.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 17.93 20.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.885 . . . . 0.0 109.422 179.625 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.74 -164.06 29.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.5 28.71 2.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -1.15 . . . . 0.0 109.618 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 99.5 p -126.91 28.1 5.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.08 137.44 22.44 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -65.67 -24.46 55.19 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.931 1.49 . . . . 0.0 110.095 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.52 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.22 -36.33 44.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' CD2' ' A' ' 47' ' ' PHE . 94.6 t -50.99 -39.9 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.299 -1.118 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.46 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -76.54 -1.25 26.42 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.292 -0.88 . . . . 0.0 109.831 179.714 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -96.47 -27.45 14.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.05 -1.031 . . . . 0.0 109.703 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.494 HD21 ' C1A' ' A' ' 148' ' ' HEM . 6.9 mt -86.65 -62.27 1.55 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.411 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -57.62 -24.67 53.65 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.46 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -66.53 -31.61 72.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.634 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.507 ' CB ' ' CGD' ' A' ' 148' ' ' HEM . 9.3 mtpt -101.82 -39.58 7.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.428 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.471 HG21 ' C1D' ' A' ' 148' ' ' HEM . 58.3 t -51.7 -53.77 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.27 -0.894 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.466 ' CD2' HG12 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -45.9 -44.5 14.63 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.321 -0.862 . . . . 0.0 110.42 -179.705 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.432 ' HA ' ' OD1' ' A' ' 22' ' ' ASN . . . -52.99 -30.02 32.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.025 . . . . 0.0 109.674 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 60.7 tp60 -69.49 -31.97 70.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 108.834 179.178 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.453 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 94.0 mt -72.97 -31.5 35.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.413 -0.804 . . . . 0.0 108.861 179.271 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.54 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.09 -48.37 40.12 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 179.551 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.1 t -63.66 -24.17 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.246 -1.149 . . . . 0.0 109.113 179.736 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.04 -26.46 25.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.468 -0.77 . . . . 0.0 109.481 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.453 ' CG2' ' O ' ' A' ' 66' ' ' ILE . 48.6 t -67.57 -13.71 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.212 -0.93 . . . . 0.0 109.718 179.842 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.418 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -81.09 -16.9 51.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.849 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.457 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 5.7 m-70 -128.76 66.99 1.41 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.177 -0.952 . . . . 0.0 109.672 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.452 ' CD1' HG12 ' A' ' 10' ' ' VAL . 65.2 mt -101.37 -26.87 13.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.305 -0.872 . . . . 0.0 109.534 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.79 -27.21 54.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.023 -1.631 . . . . 0.0 109.023 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -111.24 150.28 29.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -1.117 . . . . 0.0 109.506 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.402 ' O ' ' HG3' ' A' ' 76' ' ' GLU . 6.1 pt-20 -128.44 55.6 1.68 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.615 -179.991 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -131.02 15.98 5.31 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.402 ' O ' ' N ' ' A' ' 81' ' ' ALA . 13.7 ttpp -164.29 -42.75 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.076 -1.25 . . . . 0.0 109.735 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.457 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 11.8 tmm? -48.64 -41.28 30.71 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.211 -0.931 . . . . 0.0 109.567 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.411 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.6 t -73.13 -20.43 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.895 . . . . 0.0 109.421 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.402 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -57.3 -56.63 19.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 179.761 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.18 -53.2 53.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.355 -0.841 . . . . 0.0 109.233 179.664 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.401 ' HG3' ' O ' ' A' ' 79' ' ' MET . 0.5 OUTLIER -53.15 -57.05 11.79 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.68 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.443 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.86 -29.17 18.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.013 179.488 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -72.39 -42.82 64.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.43 -0.794 . . . . 0.0 109.133 179.608 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.405 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 16.7 t -62.27 -35.77 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.017 179.621 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.427 ' HA2' ' HB2' ' A' ' 145' ' ' LEU . . . -57.46 -44.2 93.75 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.591 -1.803 . . . . 0.0 108.591 179.612 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 90.2 t -54.96 -35.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.285 -1.127 . . . . 0.0 109.033 179.397 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 6.9 mpt_? -70.69 -30.79 67.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.387 -0.821 . . . . 0.0 109.163 179.55 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.525 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 27.5 m80 -80.04 2.85 22.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.346 -0.846 . . . . 0.0 109.974 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.3 ttmt -101.07 14.01 33.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.057 -1.027 . . . . 0.0 110.011 -179.539 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -169.41 31.51 0.16 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.231 -1.462 . . . . 0.0 110.543 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.525 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.9 m-85 -74.08 -163.82 0.2 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.739 -1.448 . . . . 0.0 109.688 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -65.29 -53.45 32.78 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.521 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.518 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 14.6 p-10 -67.37 -33.67 75.69 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -1.164 . . . . 0.0 109.849 -179.729 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 mttt 55.27 21.19 3.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.241 -0.912 . . . . 0.0 109.633 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -128.3 48.66 2.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.49 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.514 HD12 ' CD2' ' A' ' 90' ' ' HIS . 61.9 mt -86.33 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.771 -179.883 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.471 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 4.8 mptt -141.73 143.52 33.56 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.325 -0.859 . . . . 0.0 109.766 -179.895 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.19 6.93 17.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.851 179.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.26 -21.12 21.24 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.178 -0.951 . . . . 0.0 108.779 179.723 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.515 ' CD1' ' HE1' ' A' ' 41' ' ' MET . 61.5 m-85 -85.16 -13.16 50.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.559 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 4.3 m-85 -61.07 -61.2 2.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.164 -0.96 . . . . 0.0 110.038 -179.818 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.489 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -49.44 -56.94 13.53 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.881 -179.612 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.489 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -50.94 -62.0 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.684 1.36 . . . . 0.0 109.929 179.741 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.51 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.0 tm? -57.99 -25.86 61.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.29 -0.881 . . . . 0.0 109.46 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -72.97 -39.55 54.04 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.985 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.43 -50.0 71.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.217 -1.167 . . . . 0.0 109.479 179.863 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 9.0 m -57.3 -20.64 29.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 109.482 179.832 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 1.1 tt -69.18 -46.17 68.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.746 -179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.409 HD21 ' HB2' ' A' ' 130' ' ' TRP . 12.4 mt -58.56 -30.5 67.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.142 -0.974 . . . . 0.0 109.442 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.3 m -73.45 -40.87 63.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.246 -0.909 . . . . 0.0 109.671 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.408 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -74.46 -31.01 62.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.235 -0.915 . . . . 0.0 109.653 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.503 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.8 mmt -60.06 -43.05 95.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.2 OUTLIER -49.81 -25.37 3.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.778 -179.884 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.408 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 15.9 m170 -53.76 -56.21 19.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.204 -0.935 . . . . 0.0 109.797 -179.862 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.412 ' HD2' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -64.59 -58.64 5.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.153 -0.967 . . . . 0.0 109.749 -179.877 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.464 HG12 ' CG1' ' A' ' 17' ' ' ILE . 5.3 pt -103.04 59.59 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.922 . . . . 0.0 109.737 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.77 -27.72 73.58 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.932 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -95.69 -17.59 35.35 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.408 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 5.4 mptt -101.7 -23.37 14.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 109.758 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.463 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.3 OUTLIER -71.29 83.9 0.77 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.138 -0.977 . . . . 0.0 109.581 179.937 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.43 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.3 p30 -81.39 -167.88 1.64 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.327 -0.858 . . . . 0.0 109.54 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -65.95 -47.81 73.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.43 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -56.96 -31.68 65.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.395 179.768 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -66.63 -53.03 38.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.822 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 2.5 ptpt -70.01 -26.6 64.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.263 179.727 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.464 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 38.7 t0 -82.53 -36.18 26.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 109.426 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.407 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -67.02 -43.26 83.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.758 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.511 ' CD1' HG11 ' A' ' 10' ' ' VAL . 12.1 m0 -76.7 -29.13 56.13 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.238 -0.913 . . . . 0.0 109.062 179.903 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.467 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -50.68 -43.05 57.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.319 -0.863 . . . . 0.0 109.098 179.43 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.13 -17.32 35.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.419 -0.801 . . . . 0.0 109.228 179.33 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.409 ' O ' HD13 ' A' ' 137' ' ' ILE . . . -88.01 -61.57 1.69 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.246 -0.909 . . . . 0.0 109.704 179.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.505 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.1 OUTLIER -50.47 -27.01 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.07 -1.019 . . . . 0.0 109.144 -179.825 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.23 -31.56 30.2 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.305 -0.872 . . . . 0.0 108.795 179.17 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -82.1 -37.83 25.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.448 -0.783 . . . . 0.0 109.405 179.729 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.465 ' N ' HD12 ' A' ' 137' ' ' ILE . 1.6 mp -65.86 -58.4 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 108.776 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -29.87 70.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.445 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -70.5 -35.63 68.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.48 -23.94 66.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -1.176 . . . . 0.0 109.614 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.411 HD23 ' HB2' ' A' ' 145' ' ' LEU . 8.7 tt -74.55 -17.3 60.76 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.254 -0.904 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.445 ' CD1' ' HA2' ' A' ' 139' ' ' GLY . 58.7 mt -76.39 -0.96 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 110.101 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.443 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 19.5 m -66.91 -32.9 74.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.991 -1.068 . . . . 0.0 109.051 179.669 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.4 -10.98 8.33 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.62 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.495 ' CD2' ' CZ ' ' A' ' 103' ' ' PHE . 19.2 tp -93.31 91.57 7.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.041 -1.27 . . . . 0.0 109.571 -179.904 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 6.7 mm-40 -120.04 -11.48 9.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.013 -1.054 . . . . 0.0 109.633 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.559 ' CMC' ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.507 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 mt -58.57 166.78 1.67 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.291 -1.123 . . . . 0.0 109.819 179.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 p -123.3 -170.16 2.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 179.748 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.28 -27.88 42.29 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.892 . . . . 0.0 109.967 -179.668 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -85.23 -30.38 23.91 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -0.957 . . . . 0.0 109.796 -179.895 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 42.1 mt-30 -78.29 -52.27 8.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.169 -0.957 . . . . 0.0 109.887 -179.856 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.98 -29.37 12.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.97 -1.081 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -70.71 -45.21 65.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 0.0 108.778 179.353 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.447 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 44.8 t -62.12 -31.25 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.364 -0.835 . . . . 0.0 108.859 179.27 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.419 HG13 ' CD1' ' A' ' 73' ' ' LEU . 98.6 t -66.03 -50.13 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.512 -0.743 . . . . 0.0 109.4 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.11 61.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.9 m -83.45 -25.05 31.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.105 -0.997 . . . . 0.0 109.744 -179.919 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.477 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 38.2 p -100.22 -10.18 21.64 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.92 . . . . 0.0 110.043 -179.907 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.12 -25.8 19.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.027 -1.046 . . . . 0.0 109.609 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.9 mtpp -76.05 -12.8 60.19 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.224 -0.923 . . . . 0.0 109.641 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.454 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.4 OUTLIER -103.02 -52.67 3.0 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.466 HD11 ' CH2' ' A' ' 130' ' ' TRP . 44.1 mt -65.14 -34.78 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.271 -0.893 . . . . 0.0 109.581 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -107.91 35.24 3.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.719 -179.948 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.1 -84.14 0.03 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 78.3 p -97.51 -23.41 16.04 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.307 -1.114 . . . . 0.0 109.617 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -83.34 -21.45 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.449 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 9.9 t30 56.79 20.57 5.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.92 . . . . 0.0 109.61 179.998 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.2 20.94 11.39 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.49 -47.52 69.8 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.414 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -93.34 31.63 6.26 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.427 HG13 ' CD1' ' A' ' 63' ' ' LEU . 41.9 t -119.05 -35.91 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.297 -1.12 . . . . 0.0 108.942 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.458 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -90.26 -41.17 5.58 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.766 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.467 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.3 ptpt -61.08 -30.63 70.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 109.587 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.467 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -90.41 -25.16 20.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.124 -0.985 . . . . 0.0 109.422 179.798 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 41.4 t -85.54 -50.63 7.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.353 -0.842 . . . . 0.0 109.574 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 5.0 m-30 -55.2 -37.56 67.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.585 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 98.6 m -55.82 -45.89 78.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.901 . . . . 0.0 109.347 179.772 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.402 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 13.6 mttp -66.59 -47.63 72.12 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.403 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.516 ' CG ' HD22 ' A' ' 106' ' ' LEU . 4.3 t80 -55.7 -49.94 71.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.297 179.794 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.5 HD23 ' CG ' ' A' ' 45' ' ' PHE . 32.3 mt -59.48 -45.1 92.63 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.89 -61.68 2.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.691 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.401 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -58.04 -28.64 64.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.694 -179.906 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.51 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 9.4 m-70 -118.0 103.38 9.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.718 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -85.61 -21.45 28.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.34 -0.85 . . . . 0.0 109.345 179.634 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.2 p-10 -68.23 -20.49 64.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.912 . . . . 0.0 109.275 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.476 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 92.2 mmm -103.26 -22.35 13.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.581 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.443 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -51.17 -44.45 61.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.031 -1.043 . . . . 0.0 109.338 179.825 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.68 -23.38 59.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.346 -0.846 . . . . 0.0 109.136 179.565 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.51 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 29.2 t -73.44 -39.96 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.423 -0.798 . . . . 0.0 109.202 179.733 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.524 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -68.89 -38.95 79.97 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.573 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.404 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 117.66 28.22 2.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.882 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.3 m-85 -122.31 172.23 8.47 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.199 -1.177 . . . . 0.0 109.692 -179.981 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 11.7 t -111.13 19.22 18.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.316 -0.865 . . . . 0.0 109.351 179.493 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.95 -164.0 29.87 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.79 5.82 41.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -1.162 . . . . 0.0 110.073 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 15.2 t -110.09 42.27 1.56 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.001 -1.062 . . . . 0.0 109.548 179.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.85 131.54 23.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 0.0 109.624 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -61.34 -20.47 68.36 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 123.81 1.426 . . . . 0.0 109.949 -179.949 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.9 -35.95 88.52 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.508 HG22 ' CD2' ' A' ' 47' ' ' PHE . 58.9 t -54.56 -22.78 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -1.095 . . . . 0.0 109.468 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.466 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -86.47 -19.44 29.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.319 -0.863 . . . . 0.0 109.571 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.409 ' O ' ' HB2' ' A' ' 61' ' ' LYS . 0.3 OUTLIER -88.11 -26.45 22.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.296 -0.878 . . . . 0.0 109.588 -179.994 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.472 HD21 ' C1A' ' A' ' 148' ' ' HEM . 2.7 mt -86.44 -66.58 0.89 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.188 -0.945 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.553 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -49.46 -37.06 25.1 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.434 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -72.45 -22.32 61.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.151 -1.205 . . . . 0.0 109.946 -179.698 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 4.7 mttp -94.55 -21.9 18.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.122 -0.986 . . . . 0.0 109.827 -179.868 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.463 HG21 ' C ' ' A' ' 149' ' ' CMO . 23.3 t -83.71 -46.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.938 . . . . 0.0 109.889 -179.784 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.427 ' CD1' HG13 ' A' ' 26' ' ' VAL . 2.9 mm? -47.86 -46.88 31.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -51.91 25.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.194 -0.941 . . . . 0.0 109.992 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -50.65 -42.98 57.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.07 -1.019 . . . . 0.0 109.438 -179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 39.8 mt -61.34 -38.36 79.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.312 -0.868 . . . . 0.0 109.238 179.621 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.539 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.73 -50.97 57.62 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.873 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.4 t -61.22 -29.96 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.083 -1.245 . . . . 0.0 109.467 -179.823 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.447 ' O ' ' CD2' ' A' ' 73' ' ' LEU . . . -84.72 -14.52 48.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.424 -0.798 . . . . 0.0 110.094 -179.42 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.475 ' HA ' ' CD1' ' A' ' 73' ' ' LEU . 41.6 t -84.64 -43.36 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.027 -1.046 . . . . 0.0 110.091 -179.409 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.35 -24.75 2.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.987 -1.07 . . . . 0.0 109.33 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.562 ' CG ' ' CB ' ' A' ' 76' ' ' GLU . 3.2 m-70 -93.83 -114.08 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.532 -0.73 . . . . 0.0 109.946 -179.787 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.475 ' CD1' ' HA ' ' A' ' 70' ' ' VAL . 16.5 mt 66.15 -57.42 0.36 Allowed 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.027 -1.045 . . . . 0.0 110.392 -179.289 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -58.01 -45.43 93.81 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -179.133 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.404 ' O ' ' N ' ' A' ' 77' ' ' GLY . 35.1 m-20 -140.18 -41.13 0.43 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.853 -1.38 . . . . 0.0 111.695 -179.085 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.562 ' CB ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -68.51 51.54 0.07 Allowed 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.325 -0.859 . . . . 0.0 111.284 -178.007 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.45 ' O ' ' CG2' ' A' ' 80' ' ' VAL . . . -65.37 -17.17 63.78 Favored Glycine 0 N--CA 1.475 1.236 0 N-CA-C 105.911 -2.876 . . . . 0.0 105.911 176.246 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 15.8 ttmt -49.9 -38.58 36.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.564 -0.963 . . . . 0.0 108.852 178.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.463 ' CG ' ' O ' ' A' ' 76' ' ' GLU . 0.0 OUTLIER -50.36 -25.81 4.24 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.16 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.45 ' CG2' ' O ' ' A' ' 77' ' ' GLY . 53.5 t -51.21 -31.11 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.076 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.24 -35.61 76.3 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -61.27 -52.97 62.49 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.215 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.41 ' HE1' ' O ' ' A' ' 137' ' ' ILE . 86.5 mmm -56.96 -38.56 73.13 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.255 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -35.74 40.96 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -67.89 -32.37 72.81 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.508 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 48.6 t -59.38 -51.95 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 108.785 179.432 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.416 ' O ' HD11 ' A' ' 145' ' ' LEU . . . -56.66 -52.94 47.42 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.061 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.417 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 63.3 t -51.75 -33.26 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.397 -1.061 . . . . 0.0 108.817 179.065 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.508 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.0 mmm180 -76.43 -49.75 15.88 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.189 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.552 ' ND1' ' CZ ' ' A' ' 93' ' ' TYR . 2.1 m80 -58.92 -21.24 57.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.464 -0.772 . . . . 0.0 109.115 179.332 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -66.72 -12.08 57.07 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.314 -0.866 . . . . 0.0 110.254 -179.704 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.31 53.49 0.6 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.634 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.552 ' CZ ' ' ND1' ' A' ' 90' ' ' HIS . 3.1 m-30 -89.23 -164.36 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.238 -1.154 . . . . 0.0 109.702 179.734 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.14 -51.14 19.33 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.51 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 17.1 p-10 -69.16 -32.36 71.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.14 -1.212 . . . . 0.0 109.828 -179.686 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.8 tttm 58.26 18.86 5.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.197 -0.939 . . . . 0.0 109.699 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 15.4 m170 -125.75 41.27 3.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.69 -179.935 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.508 HD13 ' CD2' ' A' ' 90' ' ' HIS . 36.4 mt -81.32 155.75 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.184 -0.947 . . . . 0.0 109.679 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.447 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.1 mptp? -136.58 145.58 45.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.884 -179.825 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -86.4 11.77 11.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.954 179.853 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.566 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 15.5 pt-20 -95.48 -24.21 16.76 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.107 -0.995 . . . . 0.0 109.557 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.566 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 88.7 m-85 -83.03 -7.39 59.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.928 179.722 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.493 ' CD2' HMC3 ' A' ' 148' ' ' HEM . 11.3 m-85 -66.87 -52.17 46.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.096 -1.002 . . . . 0.0 109.945 -179.739 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.495 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.5 tm-20 -56.54 -55.61 40.99 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.131 -0.98 . . . . 0.0 109.867 -179.685 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.83 -61.85 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 123.755 1.397 . . . . 0.0 109.83 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.516 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -55.75 -23.78 31.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.291 -0.88 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.99 -48.67 6.84 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.981 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.36 65.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -1.191 . . . . 0.0 109.414 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.0 m -75.28 -31.01 60.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.872 . . . . 0.0 109.518 179.893 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.451 ' CD2' ' OH ' ' A' ' 134' ' ' TYR . 1.0 OUTLIER -70.13 -30.16 67.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.41 179.905 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.413 HD21 ' HB2' ' A' ' 130' ' ' TRP . 11.1 mt -64.34 -32.11 73.59 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.348 179.767 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.4 OUTLIER -74.89 -26.2 59.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 109.54 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.405 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.77 -35.78 20.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.247 -0.908 . . . . 0.0 109.518 -179.885 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.485 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 2.8 mtt -49.44 -45.08 46.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 0.0 110.116 -179.717 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 119' ' ' GLY . 13.3 pt-20 -50.27 -25.69 3.98 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.153 -0.967 . . . . 0.0 109.907 -179.719 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.405 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 29.7 m170 -50.12 -39.92 44.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.635 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.447 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 3.2 ttt85 -80.17 -61.7 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.179 -0.951 . . . . 0.0 109.539 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.454 ' CG2' ' HB3' ' A' ' 16' ' ' ASP . 7.2 pt -89.35 44.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.236 -0.915 . . . . 0.0 109.521 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -51.62 123.07 18.15 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 102.12 -39.82 2.64 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.873 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.431 ' O ' ' N ' ' A' ' 123' ' ' ASN . 29.9 mttp -83.54 -29.5 27.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -1.14 . . . . 0.0 109.439 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.412 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.26 76.73 0.1 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.235 179.727 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.447 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 9.4 p30 -79.8 -167.67 1.33 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.311 -0.868 . . . . 0.0 109.875 -179.714 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.412 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.95 -45.9 87.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.839 . . . . 0.0 109.531 179.868 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.454 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -58.07 -33.46 69.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.283 -0.886 . . . . 0.0 109.283 179.832 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.01 -53.38 20.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.28 -0.888 . . . . 0.0 109.417 179.832 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.438 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.9 ptpt -70.47 -26.84 63.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.191 -0.943 . . . . 0.0 109.356 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.438 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.8 t70 -81.91 -39.81 23.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.357 179.557 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -62.37 -43.54 98.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.375 -0.828 . . . . 0.0 109.241 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.485 ' CE3' ' SD ' ' A' ' 114' ' ' MET . 9.0 m0 -75.57 -31.89 60.17 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.304 -0.873 . . . . 0.0 108.7 179.563 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.46 -30.84 61.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 108.631 178.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.11 -28.89 22.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.797 . . . . 0.0 109.101 179.477 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -82.93 -52.65 6.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.431 -0.793 . . . . 0.0 109.465 179.899 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.451 ' CZ ' HD12 ' A' ' 66' ' ' ILE . 0.1 OUTLIER -49.85 -30.05 9.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 0.0 109.376 179.85 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -78.73 -27.62 44.87 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.275 -0.891 . . . . 0.0 108.984 179.456 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' A' ' 133' ' ' ALA . 2.4 t0 -84.12 -39.86 18.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.435 -0.791 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.41 ' O ' ' HE1' ' A' ' 83' ' ' MET . 8.2 mt -67.7 -56.33 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.497 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 87.2 p -69.37 -36.7 77.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.334 -0.853 . . . . 0.0 109.607 -179.91 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.461 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -56.23 -23.11 39.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.942 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.03 59.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 0.0 109.998 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.508 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 0.2 OUTLIER -91.4 -19.45 22.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.109 -0.994 . . . . 0.0 109.811 -179.847 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.461 ' CD1' ' HA2' ' A' ' 139' ' ' GLY . 3.2 mp -80.06 3.37 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.218 -0.926 . . . . 0.0 110.115 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 23.4 m -100.8 -31.09 11.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.01 -1.057 . . . . 0.0 109.925 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -93.1 -21.47 30.14 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.465 HD13 ' N ' ' A' ' 91' ' ' LYS . 12.8 tp -77.46 -133.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.179 -1.189 . . . . 0.0 109.315 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 49.19 41.86 20.54 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.781 -1.199 . . . . 0.0 109.93 179.688 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.468 ' HA ' ' CG ' ' A' ' 91' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.637 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.519 HMB3 ' CE1' ' A' ' 45' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.473 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.468 ' CA ' ' OE1' ' A' ' 6' ' ' GLN . . . . . . . . 0 N--CA 1.49 2.262 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.459 ' CD1' ' C ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 42.6 34.88 0.6 Allowed 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.564 -0.962 . . . . 0.0 109.308 179.904 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.427 ' O ' ' CB ' ' A' ' 7' ' ' ARG . 2.0 p -90.36 -156.24 0.42 Allowed 'General case' 0 C--N 1.289 -2.05 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.11 -178.604 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -65.76 -10.61 38.67 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.425 -0.797 . . . . 0.0 110.208 -179.596 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -104.56 -54.13 2.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.015 -1.053 . . . . 0.0 110.187 -179.732 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.468 ' OE1' ' CA ' ' A' ' 1' ' ' GLY . 65.7 mt-30 -70.99 -50.5 33.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.967 -1.083 . . . . 0.0 109.43 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.432 ' HG2' ' HB2' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -53.06 -24.25 9.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.048 179.583 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 5.8 mp0 -83.16 -53.29 5.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.434 -0.791 . . . . 0.0 109.521 179.893 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -55.37 -33.99 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.399 -179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.499 HG12 ' CD1' ' A' ' 130' ' ' TRP . 93.8 t -57.33 -43.17 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.95 -10.12 59.16 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.271 -0.893 . . . . 0.0 109.896 179.836 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 t -93.56 -26.21 17.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.123 -0.986 . . . . 0.0 109.99 -179.718 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.484 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 20.6 p -95.74 -15.25 22.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -0.971 . . . . 0.0 109.965 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.567 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.49 -23.02 23.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.065 -1.022 . . . . 0.0 109.686 -179.933 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 73.4 mttt -81.6 1.67 32.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.934 . . . . 0.0 109.852 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.57 -48.51 2.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.128 -0.982 . . . . 0.0 109.263 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.442 ' CD1' ' CH2' ' A' ' 130' ' ' TRP . 42.0 mt -71.31 -28.76 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.432 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.567 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -109.33 34.42 3.77 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.235 -0.916 . . . . 0.0 109.603 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.15 -86.93 0.01 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.9 p -100.77 -24.46 14.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -1.145 . . . . 0.0 109.706 -179.99 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -81.02 -20.77 41.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.936 . . . . 0.0 109.699 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.8 t30 56.93 30.06 17.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.592 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.417 ' HA3' ' CD2' ' A' ' 63' ' ' LEU . . . 88.53 37.71 7.4 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.02 -49.63 12.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -1.144 . . . . 0.0 109.655 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.476 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -76.23 -23.55 70.88 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 -179.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.466 HG11 ' CD1' ' A' ' 63' ' ' LEU . 41.5 t -67.01 -27.2 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.334 -1.097 . . . . 0.0 109.817 -179.936 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.69 -50.79 4.07 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.476 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.2 ptpt -57.62 -24.17 55.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -1.203 . . . . 0.0 110.041 -179.556 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.428 ' O ' ' CD ' ' A' ' 33' ' ' LYS . 12.2 pt-20 -97.06 -28.39 14.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.036 -1.04 . . . . 0.0 109.768 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.407 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 37.1 t -83.99 -52.5 6.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 109.709 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 3.7 m-30 -60.45 -45.27 94.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.322 -0.861 . . . . 0.0 109.787 -179.806 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.428 ' CA ' HG12 ' A' ' 55' ' ' VAL . 21.1 m -52.07 -41.3 62.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.13 -0.981 . . . . 0.0 109.453 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.428 ' CD ' ' O ' ' A' ' 29' ' ' GLU . 8.1 mtpt -68.98 -48.18 63.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.564 179.918 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.512 ' CG ' HD22 ' A' ' 106' ' ' LEU . 9.0 t80 -58.91 -49.86 76.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.514 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.497 HD23 ' CG ' ' A' ' 45' ' ' PHE . 32.8 mt -57.35 -45.49 84.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 109.698 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.412 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 1.3 t -63.33 -59.83 4.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.194 -0.941 . . . . 0.0 109.758 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.442 ' HB3' ' CD2' ' A' ' 38' ' ' HIS . . . -59.95 -26.91 66.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.898 . . . . 0.0 109.724 -179.909 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.445 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 19.6 m-70 -119.69 104.32 10.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.771 -179.944 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 54.5 m170 -86.45 -21.93 26.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.604 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -67.66 -16.38 64.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -0.891 . . . . 0.0 109.525 179.644 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.47 ' CE ' HMB2 ' A' ' 148' ' ' HEM . 89.7 mmm -109.35 -24.41 11.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.464 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.14 -40.46 23.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -77.06 -21.34 54.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.376 179.728 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.516 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 39.6 t -75.09 -39.71 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 0.0 109.563 179.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.523 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 15.6 m-85 -68.08 -31.06 70.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.616 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.42 27.24 3.68 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 179.919 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.523 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.9 m-85 -122.77 171.41 9.2 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.29 -1.123 . . . . 0.0 109.653 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.9 t -111.14 23.47 14.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.212 179.58 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.84 -163.78 27.59 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.412 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -93.13 29.81 1.79 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 18.3 m -126.52 22.98 6.92 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 109.633 -179.956 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.41 137.94 19.58 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.236 -0.915 . . . . 0.0 109.615 179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -66.51 -24.14 49.39 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 123.919 1.484 . . . . 0.0 110.07 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -54.24 -31.66 50.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.901 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.521 HG22 ' CD2' ' A' ' 47' ' ' PHE . 97.5 t -53.66 -53.71 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.268 -1.136 . . . . 0.0 109.568 -179.946 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.458 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -63.07 -14.79 52.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.906 . . . . 0.0 109.769 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.52 -44.21 11.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.17 -0.956 . . . . 0.0 109.694 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.542 HD21 ' C1A' ' A' ' 148' ' ' HEM . 1.0 OUTLIER -70.22 -63.62 1.05 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.219 -0.926 . . . . 0.0 110.051 -179.8 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.54 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -51.9 -29.3 26.76 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.765 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.458 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -67.93 -40.65 83.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -1.203 . . . . 0.0 110.029 -179.708 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 43.4 mttm -80.85 -36.31 31.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 109.928 -179.77 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.451 HG21 ' C ' ' A' ' 149' ' ' CMO . 86.1 t -59.39 -53.98 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 0.0 109.903 -179.786 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.466 ' CD1' HG11 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -47.0 -38.72 11.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.195 -0.94 . . . . 0.0 109.833 -179.936 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.88 -49.32 63.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.625 179.925 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -52.8 -48.2 67.06 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.966 . . . . 0.0 109.437 179.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.457 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 98.8 mt -55.89 -32.98 33.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.296 -0.878 . . . . 0.0 109.165 179.662 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.538 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.99 -57.86 9.01 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 179.503 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.9 t -55.31 -26.17 18.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -1.111 . . . . 0.0 109.05 179.803 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -26.23 26.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.445 -0.784 . . . . 0.0 109.535 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.469 ' HA ' ' CD2' ' A' ' 73' ' ' LEU . 40.0 t -59.87 -19.36 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 179.859 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 34.0 t -88.7 10.14 21.81 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.221 -0.924 . . . . 0.0 110.203 -179.688 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.45 ' ND1' ' O ' ' A' ' 71' ' ' SER . 19.3 m-70 -147.76 50.73 1.05 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.972 -1.08 . . . . 0.0 109.82 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.469 ' CD2' ' HA ' ' A' ' 70' ' ' VAL . 3.7 mm? -74.34 -43.9 54.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.343 -0.848 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -89.81 -33.58 8.98 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.904 -1.678 . . . . 0.0 108.904 179.864 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -97.76 69.67 2.14 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.424 -1.045 . . . . 0.0 109.359 179.787 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -88.49 15.61 7.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.891 -179.931 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.47 -30.04 61.39 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 179.904 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.403 ' O ' ' N ' ' A' ' 81' ' ' ALA . 1.7 tppt? -120.06 -27.08 5.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.182 -1.187 . . . . 0.0 109.834 -179.947 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.422 ' HB2' ' HB3' ' A' ' 72' ' ' HIS . 3.9 tmm? -48.83 -41.96 34.68 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.083 -1.011 . . . . 0.0 109.453 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.463 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.4 t -67.72 -26.66 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.358 -0.839 . . . . 0.0 109.199 179.607 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.403 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -58.24 -48.07 81.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.291 -0.88 . . . . 0.0 109.365 179.756 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -78.19 -48.1 16.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.876 . . . . 0.0 109.286 179.67 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.415 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 2.7 mtp -57.22 -56.81 16.98 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.26 -0.9 . . . . 0.0 109.243 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -51.4 -32.86 27.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.19 -0.944 . . . . 0.0 108.856 179.372 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.421 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -65.58 -39.72 91.93 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.268 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.454 ' CG1' HD12 ' A' ' 141' ' ' LEU . 56.3 t -52.99 -50.22 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.291 -0.88 . . . . 0.0 109.18 179.502 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -50.5 -49.77 38.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 179.732 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.421 ' HB ' ' O ' ' A' ' 85' ' ' ALA . 91.5 t -49.71 -26.23 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.324 -1.104 . . . . 0.0 109.309 179.591 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.4 mmt180 -78.76 -48.52 14.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.381 -0.824 . . . . 0.0 108.872 179.452 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.415 ' HB3' HD12 ' A' ' 145' ' ' LEU . 13.3 m80 -55.5 -28.28 53.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.441 -0.787 . . . . 0.0 109.327 179.618 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.411 ' HG3' ' HA ' ' A' ' 147' ' ' SER . 0.3 OUTLIER -67.93 -10.05 50.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.319 -0.863 . . . . 0.0 110.04 -179.897 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -138.73 50.71 0.79 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.792 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.5 m-30 -101.59 -168.55 1.57 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.18 -1.188 . . . . 0.0 109.584 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.96 -49.47 16.72 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.516 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.7 OUTLIER -68.02 -51.03 51.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.439 -1.036 . . . . 0.0 109.221 179.796 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.479 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.7 tttt 74.64 -48.69 0.65 Allowed 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.528 -0.732 . . . . 0.0 110.844 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -67.81 61.22 0.07 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.958 -1.089 . . . . 0.0 110.248 -179.553 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 96' ' ' LYS . 65.9 mt -92.03 161.24 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.041 . . . . 0.0 109.462 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.491 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -139.8 139.38 36.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.102 -0.999 . . . . 0.0 110.017 -179.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.448 ' HB3' ' CD1' ' A' ' 142' ' ' ILE . . . -79.13 -5.9 55.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.421 -0.8 . . . . 0.0 109.621 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -70.67 -31.52 68.47 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.103 -0.998 . . . . 0.0 109.694 179.944 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.491 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 75.5 m-85 -82.79 4.93 23.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 110.529 -179.314 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.56 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 5.5 m-85 -77.09 -57.57 3.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.959 -1.088 . . . . 0.0 109.783 179.704 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -58.31 -50.83 85.91 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.851 -179.698 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' CD ' ' N ' ' A' ' 104' ' ' GLU . 24.8 Cg_exo -55.62 -57.49 1.56 Allowed 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.888 1.468 . . . . 0.0 109.768 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.512 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.2 tm? -57.49 -19.5 24.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.401 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.51 -51.08 4.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.953 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.72 -54.3 48.41 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.166 -1.196 . . . . 0.0 109.572 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.5 t -55.98 -25.17 42.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.407 ' HB2' ' O ' ' A' ' 106' ' ' LEU . 5.2 tt -67.39 -45.16 77.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.916 . . . . 0.0 109.734 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.452 HD21 ' CB ' ' A' ' 130' ' ' TRP . 13.8 mt -56.6 -31.86 64.68 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.653 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.52 -30.41 70.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.906 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.423 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -82.86 -34.21 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.893 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.405 ' CE ' ' OH ' ' A' ' 134' ' ' TYR . 5.9 mmt -46.39 -45.33 17.77 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.3 -0.875 . . . . 0.0 110.34 -179.713 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -50.32 -23.2 2.16 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.11 -0.993 . . . . 0.0 110.223 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.423 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -57.0 -46.88 81.96 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.051 -1.031 . . . . 0.0 109.703 -179.809 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.442 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 1.9 ttt85 -73.11 -55.8 5.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 109.815 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.485 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 5.3 pt -99.92 48.69 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.127 -0.983 . . . . 0.0 110.103 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.09 100.98 0.11 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 179.64 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.44 -45.33 1.14 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.485 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.3 mmtt -82.23 -24.1 35.02 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.251 -1.146 . . . . 0.0 109.154 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.419 ' HE1' HD22 ' A' ' 111' ' ' LEU . 0.0 OUTLIER -65.97 79.58 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.441 -0.787 . . . . 0.0 109.595 -179.992 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -88.22 -178.64 5.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.894 . . . . 0.0 110.186 -179.793 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -55.23 -34.73 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.874 -179.696 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.61 -14.4 62.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.668 179.896 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -90.43 -50.73 5.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.07 -1.019 . . . . 0.0 109.624 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.443 ' O ' ' CB ' ' A' ' 131' ' ' ALA . 15.1 ptpt -69.42 -27.77 65.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.262 179.776 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.437 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.0 t0 -79.07 -52.56 8.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.32 -0.862 . . . . 0.0 109.486 179.772 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -56.66 -54.34 47.22 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.374 -0.829 . . . . 0.0 109.765 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.499 ' CD1' HG12 ' A' ' 10' ' ' VAL . 4.1 m0 -63.46 -27.83 69.55 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.443 ' CB ' ' O ' ' A' ' 127' ' ' LYS . . . -68.39 -25.46 65.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.225 -0.922 . . . . 0.0 108.78 179.202 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.409 ' O ' HD23 ' A' ' 2' ' ' LEU . . . -86.22 -41.93 14.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.44 -0.787 . . . . 0.0 109.121 179.466 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.436 ' CB ' HD13 ' A' ' 73' ' ' LEU . . . -70.19 -56.12 7.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.515 -0.74 . . . . 0.0 109.781 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 134' ' ' TYR . 9.0 m-30 -47.39 -27.96 1.88 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.296 -0.877 . . . . 0.0 109.636 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.98 -43.18 65.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.258 -0.901 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.76 -36.57 59.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.341 -0.85 . . . . 0.0 109.325 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.411 ' CD1' ' O ' ' A' ' 133' ' ' ALA . 1.3 mp -66.64 -58.44 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 108.885 179.717 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 31.7 p -66.97 -24.08 66.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.251 -0.906 . . . . 0.0 109.62 179.882 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.32 -28.78 55.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.16 -22.86 60.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -1.138 . . . . 0.0 109.595 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.456 ' O ' ' CD2' ' A' ' 141' ' ' LEU . 3.8 tt -86.46 11.6 12.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 109.986 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.448 ' CD1' ' HB3' ' A' ' 100' ' ' ALA . 44.0 mm -100.29 19.29 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.074 -1.016 . . . . 0.0 109.683 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.451 ' CB ' ' HG3' ' A' ' 84' ' ' LYS . 4.4 m -108.11 -52.65 2.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.634 179.962 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.407 ' O ' ' HA ' ' A' ' 88' ' ' VAL . . . -75.96 -7.75 84.3 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.473 ' HB3' ' NE2' ' A' ' 146' ' ' GLN . 0.7 OUTLIER -94.96 -155.66 0.48 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.953 -1.322 . . . . 0.0 108.432 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.473 ' NE2' ' HB3' ' A' ' 145' ' ' LEU . 3.0 mp0 55.83 47.74 19.61 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.776 -1.202 . . . . 0.0 109.595 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.411 ' HA ' ' HG3' ' A' ' 91' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.65 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.56 ' CMC' ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.451 ' C ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.441 ' CD1' ' CD1' ' A' ' 73' ' ' LEU . 8.0 mt -83.96 175.36 9.62 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.317 -1.108 . . . . 0.0 109.512 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 p -124.69 -167.6 1.69 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.177 -0.952 . . . . 0.0 110.002 179.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.84 -16.01 54.85 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.208 -0.932 . . . . 0.0 109.98 -179.746 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -104.37 -42.83 5.36 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.059 -1.026 . . . . 0.0 109.726 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -64.81 -46.1 83.43 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.409 ' HG3' ' HB3' ' A' ' 73' ' ' LEU . 38.6 ttp180 -55.38 -34.27 64.17 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.206 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -73.87 -41.66 61.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.261 -0.899 . . . . 0.0 109.176 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.469 ' HB ' ' CB ' ' A' ' 129' ' ' ALA . 59.7 t -57.42 -29.85 34.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.336 -0.853 . . . . 0.0 109.426 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.406 HG11 HG12 ' A' ' 70' ' ' VAL . 91.9 t -66.03 -52.14 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 109.468 179.793 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.56 -9.75 51.4 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.307 -0.871 . . . . 0.0 109.988 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 p -92.94 -24.43 18.41 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.045 -1.035 . . . . 0.0 109.774 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.4 p -98.49 -7.76 27.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 110.065 -179.939 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -95.14 -23.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.093 . . . . 0.0 109.588 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.2 mttm -77.08 -2.49 34.4 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.206 -0.933 . . . . 0.0 109.852 179.756 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -114.02 -51.12 2.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.085 -1.009 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.463 HG13 ' CG2' ' A' ' 118' ' ' ILE . 56.3 mt -66.34 -31.52 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.919 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.566 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -108.77 34.03 3.9 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.315 -0.866 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.31 -85.0 0.02 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.8 p -95.68 -31.45 13.23 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -1.14 . . . . 0.0 109.58 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 21' ' ' ASP . 24.5 p-10 -75.51 -21.97 57.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.295 -0.878 . . . . 0.0 109.591 180.0 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.45 ' HA ' ' CB ' ' A' ' 18' ' ' ALA . 4.3 t30 56.57 21.85 6.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.207 -0.933 . . . . 0.0 109.523 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 98.82 21.67 15.55 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -71.04 -56.85 5.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -1.146 . . . . 0.0 109.637 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.46 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -70.85 -21.08 78.04 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.925 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.462 ' O ' ' CB ' ' A' ' 30' ' ' CYS . 46.6 t -70.65 -35.03 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.284 -1.127 . . . . 0.0 110.005 -179.778 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.02 -43.72 13.33 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 -179.308 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.46 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.8 ptpt -64.28 -26.39 68.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -1.217 . . . . 0.0 110.155 -179.385 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.412 ' HG2' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -100.68 -11.41 20.0 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.045 -1.034 . . . . 0.0 110.156 -179.73 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.462 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 34.1 t -93.05 -68.19 0.81 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 109.888 -179.797 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CD1' HD23 ' A' ' 106' ' ' LEU . 10.3 m-85 -50.32 -30.48 12.14 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 110.004 -179.604 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.44 ' CA ' HG12 ' A' ' 55' ' ' VAL . 15.7 m -54.33 -53.18 57.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.064 -1.023 . . . . 0.0 109.221 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.405 ' HD3' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -55.44 -48.56 74.26 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.932 . . . . 0.0 109.243 179.737 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.517 ' CG ' HD22 ' A' ' 106' ' ' LEU . 3.8 t80 -54.33 -49.65 69.23 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.322 -0.862 . . . . 0.0 109.255 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.49 ' CD1' ' CG2' ' A' ' 55' ' ' VAL . 24.2 mt -60.1 -46.09 90.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.642 179.866 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.439 ' OG ' ' N ' ' A' ' 37' ' ' ALA . 8.9 p -61.21 -54.41 44.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.732 -179.91 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.439 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -67.86 -27.09 66.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.226 -0.921 . . . . 0.0 109.62 -179.927 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.514 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 10.0 m-70 -117.51 107.37 14.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.754 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 56.3 m170 -88.41 -19.9 25.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.408 -0.808 . . . . 0.0 109.356 179.648 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -71.04 -11.29 60.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.71 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.558 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -107.61 -27.73 10.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.007 . . . . 0.0 109.943 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -46.99 -48.14 21.79 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.13 -0.981 . . . . 0.0 109.796 -179.825 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.6 -28.78 65.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.122 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.494 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 21.3 t -70.15 -38.4 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.273 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.533 ' CE1' ' CMB' ' A' ' 148' ' ' HEM . 9.8 m-85 -77.27 -29.93 54.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.243 -0.911 . . . . 0.0 109.612 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.14 29.51 3.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.374 -1.491 . . . . 0.0 109.374 179.825 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.514 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.0 m-85 -124.25 166.99 14.91 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -1.167 . . . . 0.0 109.91 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.2 t -104.29 -20.3 13.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.421 -0.8 . . . . 0.0 109.127 179.343 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.83 -164.69 24.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.816 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.15 35.84 1.26 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -1.179 . . . . 0.0 109.69 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 56.4 p -135.07 23.2 3.53 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 109.533 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.493 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.8 p-10 -107.69 138.79 20.11 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -60.33 -20.73 64.18 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.934 1.491 . . . . 0.0 109.995 -179.964 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.71 -44.75 54.95 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.49 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 80.3 t -51.45 -37.99 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.401 -1.058 . . . . 0.0 109.31 179.776 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.456 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -71.72 -24.45 61.8 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.28 -0.887 . . . . 0.0 109.251 179.602 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -79.33 -37.96 36.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.376 179.778 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.52 HD21 ' C1A' ' A' ' 148' ' ' HEM . 1.6 mt -77.19 -60.98 2.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.527 179.926 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.494 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.66 -46.65 38.42 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.46 -42.04 70.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.39 179.842 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.8 mttt -76.54 -29.17 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.262 -0.899 . . . . 0.0 109.354 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.413 HG21 ' C ' ' A' ' 149' ' ' CMO . 47.6 t -78.58 -49.95 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.417 ' O ' ' HB ' ' A' ' 66' ' ' ILE . 1.0 OUTLIER -48.43 -46.1 37.19 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.82 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.72 -49.93 69.58 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.303 -0.873 . . . . 0.0 109.564 179.939 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.402 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 8.1 tp-100 -50.9 -43.32 59.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 109.31 179.813 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.446 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 31.8 mm -57.6 -43.6 83.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.284 -0.885 . . . . 0.0 108.758 179.477 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.532 ' N ' ' CZ2' ' A' ' 14' ' ' TRP . . . -60.83 -55.16 31.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.775 -1.73 . . . . 0.0 108.775 179.371 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.3 t -54.03 -35.32 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.346 -1.09 . . . . 0.0 109.435 179.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -79.8 -30.38 40.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.88 . . . . 0.0 109.42 179.825 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.459 ' O ' ' CD2' ' A' ' 73' ' ' LEU . 48.9 t -68.68 -16.43 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.262 -0.899 . . . . 0.0 109.584 179.895 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.41 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.2 m -90.03 -0.05 57.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.172 -0.955 . . . . 0.0 110.199 -179.897 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.462 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 21.4 m-70 -140.02 50.85 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.983 -1.073 . . . . 0.0 109.767 -179.872 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.459 ' CD2' ' O ' ' A' ' 70' ' ' VAL . 4.3 mm? -58.71 -51.78 68.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.934 . . . . 0.0 109.465 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -92.39 -25.46 21.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.838 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.45 60.11 2.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.286 -1.126 . . . . 0.0 109.639 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.402 ' HA ' ' HB3' ' A' ' 79' ' ' MET . 0.0 OUTLIER -70.37 -7.12 40.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 110.033 179.96 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.02 -19.48 30.73 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.407 ' HA ' ' HB2' ' A' ' 81' ' ' ALA . 6.5 ttmm -130.28 -39.38 1.34 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -1.21 . . . . 0.0 110.004 -179.871 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' MET . . . . . 0.462 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 28.2 ttp -48.53 -54.83 12.89 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.116 -0.99 . . . . 0.0 109.829 -179.847 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 45.9 t -68.61 -11.64 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.964 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . 0.407 ' HB2' ' HA ' ' A' ' 78' ' ' LYS . . . -78.44 -37.41 43.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.03 -1.044 . . . . 0.0 109.44 179.904 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -88.65 -41.18 12.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.412 ' HA ' HG23 ' A' ' 86' ' ' VAL . 8.9 mtp -60.36 -41.04 92.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.94 . . . . 0.0 109.247 179.809 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.46 ' CE ' ' HB3' ' A' ' 143' ' ' SER . 0.0 OUTLIER -51.8 -42.04 62.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.784 179.171 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -61.28 -39.68 91.31 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.494 ' CG1' ' CD1' ' A' ' 141' ' ' LEU . 23.9 t -56.98 -51.86 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.277 -0.89 . . . . 0.0 108.774 179.496 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 145' ' ' LEU . . . -60.86 -53.59 43.95 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.655 -2.178 . . . . 0.0 107.655 178.826 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.457 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 78.7 t -48.8 -24.96 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.451 -1.029 . . . . 0.0 109.445 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.515 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 7.5 mmm180 -83.6 -43.85 15.22 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.021 -1.049 . . . . 0.0 108.729 179.238 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.505 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 19.5 m80 -58.75 -33.73 70.59 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.379 -0.825 . . . . 0.0 109.698 179.589 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -61.45 -15.78 40.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 110.434 -179.29 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.46 46.73 1.05 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.257 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.515 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.7 m-30 -87.28 -173.13 4.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.195 -1.179 . . . . 0.0 109.402 179.51 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.26 -26.42 52.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 179.668 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.494 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 0.6 OUTLIER -76.86 -55.23 5.67 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.559 -0.965 . . . . 0.0 109.101 179.704 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.48 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 10.3 tptp 77.09 -19.02 0.45 Allowed 'General case' 0 N--CA 1.508 2.469 0 O-C-N 121.765 -0.585 . . . . 0.0 111.472 179.871 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.409 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 8.2 m170 -94.05 44.01 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.601 -1.312 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.42 ' CD1' ' O ' ' A' ' 90' ' ' HIS . 36.3 mt -74.84 160.46 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.758 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.496 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -151.21 136.24 17.43 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.349 -0.845 . . . . 0.0 109.987 179.984 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.94 -5.52 44.26 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.573 -0.704 . . . . 0.0 109.506 179.301 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mm-40 -74.98 -30.66 61.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.07 -1.019 . . . . 0.0 109.439 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.558 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 36.0 m-85 -75.66 -23.54 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.299 -0.876 . . . . 0.0 109.889 -179.746 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.566 ' CE2' ' CMC' ' A' ' 148' ' ' HEM . 4.8 m-85 -54.39 -64.16 0.92 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.56 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.48 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.81 -58.55 5.25 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 110.856 -179.111 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 11.3 Cg_endo -59.49 -46.62 20.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.639 1.336 . . . . 0.0 109.63 -179.666 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.517 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.1 tm? -60.98 -27.29 68.19 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.216 -0.927 . . . . 0.0 108.841 179.414 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.402 ' HA3' ' CD2' ' A' ' 134' ' ' TYR . . . -81.34 -38.0 16.16 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 179.508 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.19 -60.13 4.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 0.0 109.345 179.782 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.0 m -52.42 -24.86 8.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.902 . . . . 0.0 109.18 179.67 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.401 HD23 ' HE1' ' A' ' 114' ' ' MET . 2.3 tt -66.51 -48.19 70.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.347 -0.846 . . . . 0.0 109.421 179.811 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.409 HD21 ' HB2' ' A' ' 130' ' ' TRP . 13.0 mt -57.65 -32.32 67.17 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.947 . . . . 0.0 109.216 179.729 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.4 m -73.82 -38.52 64.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.339 -0.85 . . . . 0.0 109.429 179.823 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.417 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -72.61 -35.71 67.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.292 -0.88 . . . . 0.0 109.387 179.791 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.401 ' HE1' HD23 ' A' ' 110' ' ' LEU . 4.2 mmt -51.39 -42.15 61.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.44 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.3 OUTLIER -50.7 -23.7 2.85 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.99 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.417 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 21.2 m170 -53.71 -26.71 24.29 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.882 . . . . 0.0 110.094 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.411 ' HG2' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -101.7 -73.31 0.66 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.026 -1.046 . . . . 0.0 109.877 -179.848 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.463 ' CG2' HG13 ' A' ' 17' ' ' ILE . 24.9 pt -65.33 -33.83 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.875 -1.14 . . . . 0.0 109.169 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.44 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . 45.43 -108.64 0.23 Allowed Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.08 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.32 -35.88 10.16 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -179.47 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.456 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 40.3 mttt -68.06 -22.25 64.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.155 -1.203 . . . . 0.0 109.699 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.453 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -74.99 72.42 2.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.068 -1.02 . . . . 0.0 109.111 179.443 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.417 ' OD1' ' N ' ' A' ' 123' ' ' ASN . 15.0 p-10 -73.43 -175.88 2.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.275 -0.891 . . . . 0.0 109.882 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -59.08 -45.99 89.42 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 109.302 179.86 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.464 ' O ' ' CB ' ' A' ' 129' ' ' ALA . . . -60.12 -33.0 71.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.315 -0.865 . . . . 0.0 109.074 179.662 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -66.98 -51.99 48.32 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.272 -0.893 . . . . 0.0 109.429 179.698 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.463 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 14.4 ptpt -71.61 -28.96 64.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.251 -0.906 . . . . 0.0 109.546 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.463 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 39.3 t0 -80.07 -43.39 21.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.331 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.469 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -56.28 -46.1 79.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.325 -0.86 . . . . 0.0 109.213 179.675 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.464 ' CZ2' ' CD1' ' A' ' 14' ' ' TRP . 13.1 m0 -74.63 -32.39 62.28 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.258 -0.901 . . . . 0.0 108.581 179.585 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.54 -26.02 53.68 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.92 -30.66 14.04 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.315 -0.866 . . . . 0.0 109.063 179.476 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.408 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -83.08 -54.38 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.493 -0.754 . . . . 0.0 109.412 179.845 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.56 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -48.87 -27.31 2.96 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.362 -179.938 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.56 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -80.98 -32.08 34.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 108.776 179.335 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.408 ' N ' ' O ' ' A' ' 133' ' ' ALA . 3.1 m-20 -81.7 -35.67 29.54 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.431 -0.793 . . . . 0.0 109.272 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 137' ' ' ILE . 1.4 mp -66.39 -60.53 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.207 -0.933 . . . . 0.0 108.545 179.409 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.14 -12.06 46.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.95 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -75.78 -46.25 14.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.969 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.55 -28.73 68.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -1.142 . . . . 0.0 109.702 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.494 ' CD1' ' CG1' ' A' ' 86' ' ' VAL . 1.7 tt -71.64 -22.09 61.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.298 -0.876 . . . . 0.0 109.667 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 86.9 mt -78.12 1.34 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.177 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.46 ' HB3' ' CE ' ' A' ' 84' ' ' LYS . 68.2 m -81.35 -44.6 17.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.045 . . . . 0.0 109.718 -179.974 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 88' ' ' VAL . . . -110.85 11.12 29.78 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.88 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 0.3 OUTLIER -72.06 -36.31 69.54 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.027 -1.278 . . . . 0.0 110.014 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.413 ' O ' ' CG ' ' A' ' 146' ' ' GLN . 0.0 OUTLIER -108.36 64.91 0.62 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.411 ' O ' ' HE2' ' A' ' 91' ' ' LYS . 1.2 t . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.68 -179.869 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.566 ' CMC' ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.413 ' C ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.7 mt -79.34 171.36 15.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.292 -1.122 . . . . 0.0 109.692 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 p -118.67 -169.93 1.81 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.635 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.63 -13.33 56.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.786 179.859 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -98.48 -31.53 11.94 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.158 -0.964 . . . . 0.0 109.82 -179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -81.31 -43.01 19.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 109.911 -179.765 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.456 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 12.4 ptm180 -53.78 -35.0 60.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.617 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.456 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 6.8 mm-40 -71.96 -47.74 50.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.921 . . . . 0.0 109.541 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 125' ' ' ALA . 33.1 t -60.09 -27.09 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.257 -0.902 . . . . 0.0 109.461 179.954 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.487 HG12 ' CD1' ' A' ' 130' ' ' TRP . 54.9 t -70.63 -49.11 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.287 -0.883 . . . . 0.0 109.475 179.899 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.9 -16.25 62.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.866 . . . . 0.0 109.795 -179.988 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.59 -26.16 26.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.705 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.407 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 20.7 p -95.15 -9.61 32.98 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.197 -0.94 . . . . 0.0 109.959 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.57 ' CE3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.61 -17.25 24.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.026 -1.046 . . . . 0.0 109.963 -179.882 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.4 mtpt -80.06 -13.71 59.09 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.121 -0.987 . . . . 0.0 109.585 179.658 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.408 ' O ' ' NE ' ' A' ' 117' ' ' ARG . 68.2 m-20 -98.62 -55.43 2.74 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.561 179.802 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.421 HG12 ' HB3' ' A' ' 117' ' ' ARG . 30.8 mt -65.39 -28.74 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.211 -0.931 . . . . 0.0 109.12 179.698 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.57 ' CB ' ' CE3' ' A' ' 14' ' ' TRP . . . -111.42 36.56 3.18 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 179.806 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.55 -86.77 0.02 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.7 p -104.98 9.76 34.4 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -1.17 . . . . 0.0 109.94 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.407 ' OD1' ' HA ' ' A' ' 18' ' ' ALA . 2.3 p30 -119.3 -12.41 9.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.1 -1.0 . . . . 0.0 109.848 179.907 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.441 ' O ' HD11 ' A' ' 63' ' ' LEU . 14.8 t-20 64.03 13.03 7.4 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.234 -0.916 . . . . 0.0 109.838 -179.758 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.465 ' HA2' ' CG2' ' A' ' 26' ' ' VAL . . . 96.3 16.28 38.2 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.918 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.415 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -48.35 -38.19 18.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.221 -1.164 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.41 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -87.29 14.53 57.43 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.465 ' CG2' ' HA2' ' A' ' 23' ' ' GLY . 15.7 t -102.21 -29.44 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.075 -1.25 . . . . 0.0 109.558 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -92.26 -37.08 6.03 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.657 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.468 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.7 ptpt -64.07 -31.7 72.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.172 -1.193 . . . . 0.0 109.549 -179.857 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.468 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 19.6 pt-20 -94.46 -19.13 20.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.125 -0.985 . . . . 0.0 109.642 179.882 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.459 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 35.4 t -89.25 -53.6 4.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.867 -179.78 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 15.9 m-85 -63.41 -34.85 78.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 109.774 -179.688 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.457 ' CA ' HG12 ' A' ' 55' ' ' VAL . 12.4 m -58.71 -36.05 73.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.09 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.81 -42.22 50.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.874 . . . . 0.0 109.291 179.571 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.512 ' CG ' HD22 ' A' ' 106' ' ' LEU . 12.7 t80 -63.07 -47.41 83.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -0.887 . . . . 0.0 109.313 179.661 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.504 HD21 ' CD2' ' A' ' 45' ' ' PHE . 22.0 mt -57.16 -43.69 82.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.876 . . . . 0.0 109.739 179.925 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 3.6 t -68.76 -63.52 1.04 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 109.706 -179.923 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.56 -24.45 8.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.262 -0.899 . . . . 0.0 109.7 -179.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.417 ' CD2' ' N ' ' A' ' 38' ' ' HIS . 25.6 m-70 -125.49 104.29 8.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.805 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -86.71 -5.23 59.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.389 -0.819 . . . . 0.0 109.855 179.661 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -82.16 -21.99 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.099 -1.001 . . . . 0.0 109.535 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' MET . . . . . 0.452 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 88.4 mmm -101.12 -23.88 14.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.244 -0.91 . . . . 0.0 109.692 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.437 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.62 -38.13 20.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.226 -0.921 . . . . 0.0 109.632 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.67 -28.56 60.89 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.422 179.76 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.509 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 52.5 t -67.17 -59.69 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.514 179.844 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.508 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 68.1 m-85 -50.79 -42.08 57.72 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.236 -0.915 . . . . 0.0 109.586 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.07 35.84 0.92 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.735 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.508 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.36 166.79 15.34 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.119 -1.224 . . . . 0.0 109.762 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.6 t -111.2 21.62 16.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.411 -0.805 . . . . 0.0 109.117 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 146.08 177.59 20.87 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -179.788 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -68.79 -13.78 62.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -1.181 . . . . 0.0 109.828 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 71.9 p -87.85 45.55 1.29 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.103 -0.998 . . . . 0.0 109.688 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.52 132.45 24.26 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -69.23 -22.17 34.89 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 123.874 1.46 . . . . 0.0 110.083 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.501 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -57.39 -26.93 57.48 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.458 ' CG2' HD11 ' A' ' 35' ' ' LEU . 87.1 t -58.33 -51.94 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.179 -1.189 . . . . 0.0 109.637 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.454 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -58.21 -22.6 52.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.928 . . . . 0.0 109.552 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.96 -60.31 2.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.874 . . . . 0.0 109.604 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.474 HD21 ' C1A' ' A' ' 148' ' ' HEM . 0.5 OUTLIER -55.88 -59.04 5.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.677 -179.949 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.516 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.54 -60.76 5.59 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.466 ' HA ' ' CD2' ' A' ' 63' ' ' LEU . . . -48.23 -33.97 9.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 0.0 109.654 179.788 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.406 ' O ' HMD3 ' A' ' 148' ' ' HEM . 47.0 mttt -77.76 -20.26 53.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.319 -0.863 . . . . 0.0 109.419 179.769 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.505 HG23 ' CZ ' ' A' ' 31' ' ' PHE . 49.4 t -81.24 -61.16 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.31 -0.869 . . . . 0.0 109.677 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.466 ' CD2' ' HA ' ' A' ' 60' ' ' ALA . 0.3 OUTLIER -46.07 -43.07 14.33 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.27 -0.894 . . . . 0.0 109.835 179.914 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.25 -40.23 33.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.96 -1.088 . . . . 0.0 109.477 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -65.83 -43.37 88.77 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.249 -0.907 . . . . 0.0 109.153 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.462 ' O ' ' CG2' ' A' ' 70' ' ' VAL . 33.9 mt -59.96 -40.13 82.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.412 -0.805 . . . . 0.0 109.182 179.68 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.537 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.04 -50.79 62.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.88 -30.53 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 109.334 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -82.81 -24.92 33.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.404 -0.81 . . . . 0.0 109.588 -179.963 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.463 ' CG1' HG11 ' A' ' 10' ' ' VAL . 46.2 t -69.8 -9.06 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.855 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.509 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 24.9 p -91.39 30.9 1.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.058 -1.027 . . . . 0.0 109.938 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.509 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.5 m-70 -160.69 -89.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.633 179.875 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.422 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 15.0 mt 63.73 -71.76 0.06 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.367 -0.833 . . . . 0.0 109.985 179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -62.06 -29.24 72.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 179.823 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -92.39 88.36 6.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.294 -1.121 . . . . 0.0 109.507 179.842 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -89.31 44.32 1.2 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.662 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -119.95 -7.51 9.43 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -143.29 -44.97 0.29 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.054 -1.263 . . . . 0.0 109.902 -179.874 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.4 tmm? -48.8 -34.38 12.26 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.113 -0.992 . . . . 0.0 109.781 -179.877 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.414 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 46.7 t -80.33 -19.6 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.612 179.931 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.41 -40.59 97.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.593 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -87.0 -45.6 10.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.537 179.912 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.5 mtp -59.48 -56.92 15.91 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.257 179.765 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.414 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -52.43 -27.04 14.36 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.236 -0.915 . . . . 0.0 109.091 179.546 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -71.04 -35.93 72.14 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.707 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.419 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 16.5 t -58.72 -38.77 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.221 -0.924 . . . . 0.0 109.226 179.868 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.411 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -55.86 -47.75 77.09 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.531 -1.827 . . . . 0.0 108.531 179.588 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 79.7 t -55.13 -36.13 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.32 -1.106 . . . . 0.0 108.955 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . 0.507 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mpt_? -69.01 -52.33 29.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 108.991 179.398 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' HIS . . . . . 0.503 ' CE1' ' OH ' ' A' ' 93' ' ' TYR . 16.9 m80 -56.35 -29.22 61.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.836 . . . . 0.0 109.288 179.581 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.45 ' HG3' ' CA ' ' A' ' 147' ' ' SER . 5.9 ttmt -66.23 -13.07 59.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.285 -0.884 . . . . 0.0 110.06 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.25 47.66 1.01 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.936 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.507 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -91.42 -169.29 2.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.346 -1.091 . . . . 0.0 109.817 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.26 -52.82 7.3 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.647 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.509 ' ND2' ' CG1' ' A' ' 44' ' ' VAL . 11.9 p-10 -61.49 -31.65 71.64 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.128 -1.219 . . . . 0.0 109.486 -179.798 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.5 tttt 60.42 32.94 20.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -0.864 . . . . 0.0 110.147 179.595 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.406 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 54.3 m170 -129.24 -85.31 0.55 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.186 -0.946 . . . . 0.0 109.092 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.478 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 17.7 mt 60.13 151.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.806 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.517 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -147.16 131.65 17.69 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 179.743 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.09 -12.51 61.54 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.647 -0.658 . . . . 0.0 109.461 179.5 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.414 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 1.0 OUTLIER -73.23 -19.75 61.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.092 -1.005 . . . . 0.0 109.255 179.517 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.517 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 34.4 m-85 -88.48 -22.42 23.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.501 ' CE1' ' HHC' ' A' ' 148' ' ' HEM . 3.2 m-85 -54.39 -58.91 5.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.068 -179.703 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.497 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -54.3 -58.0 15.85 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.112 -0.993 . . . . 0.0 110.097 -179.498 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.497 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.7 Cg_exo -49.18 -59.83 1.09 Allowed 'Trans proline' 0 C--N 1.309 -1.533 0 O-C-N 123.62 1.326 . . . . 0.0 110.095 179.89 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.512 HD22 ' CG ' ' A' ' 34' ' ' PHE . 3.3 tm? -53.71 -27.28 27.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.555 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.06 -45.96 9.79 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 -179.976 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -60.64 -52.87 63.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.625 -179.986 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 17.3 m -57.66 -27.74 63.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.656 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.457 ' CD2' ' HE2' ' A' ' 114' ' ' MET . 4.1 tt -67.37 -43.08 82.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.215 -0.928 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.439 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.8 mt -56.51 -34.24 66.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.537 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.402 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 10.6 t -64.12 -34.44 78.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.721 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -81.57 -28.44 33.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.233 -0.917 . . . . 0.0 109.782 -179.732 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 114' ' ' MET . . . . . 0.474 ' HE3' ' CZ3' ' A' ' 130' ' ' TRP . 5.8 mmt -51.47 -35.51 40.17 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.96 . . . . 0.0 110.291 -179.563 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 7.1 pt-20 -64.85 -12.28 46.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.086 -1.009 . . . . 0.0 110.164 -179.548 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 116' ' ' HIS . . . . . 0.427 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 14.7 m170 -67.59 -27.15 66.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.943 -1.098 . . . . 0.0 109.52 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.421 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -94.16 -64.45 1.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.791 179.976 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 119' ' ' GLY . 24.3 pt -84.3 -34.85 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.641 -179.898 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.478 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 42.39 -94.94 0.01 OUTLIER Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -44.03 -48.22 7.98 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -179.146 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.448 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -67.32 -22.64 65.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.116 -1.226 . . . . 0.0 109.895 -179.877 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 122' ' ' MET . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -71.1 96.55 1.36 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.086 -1.008 . . . . 0.0 109.098 179.51 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.434 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 8.5 p30 -100.36 -161.52 0.87 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.265 -0.897 . . . . 0.0 110.062 -179.5 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.409 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -72.86 -45.58 57.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.354 -0.841 . . . . 0.0 109.655 -179.945 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . 0.434 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -62.47 -30.41 71.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.196 -0.94 . . . . 0.0 109.036 179.731 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.47 -50.23 47.36 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.446 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 18.8 ptpt -72.1 -27.55 62.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 179.774 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 128' ' ' ASP . . . . . 0.446 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 62.2 t0 -80.44 -41.3 24.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.168 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -63.91 -45.71 88.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 109.152 179.55 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.492 ' CE3' ' OH ' ' A' ' 134' ' ' TYR . 5.0 m0 -73.02 -25.73 61.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.368 -0.833 . . . . 0.0 109.138 179.544 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -65.43 -34.08 77.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.289 -0.882 . . . . 0.0 108.926 179.218 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.47 -20.76 24.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.372 -0.83 . . . . 0.0 109.333 179.564 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -79.39 -53.39 6.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.525 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.492 ' OH ' ' CE3' ' A' ' 130' ' ' TRP . 10.4 m-30 -53.0 -28.4 23.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.334 179.929 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.9 -48.58 52.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.053 179.465 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.89 -34.31 66.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.322 -0.861 . . . . 0.0 109.225 179.642 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 64.1 mt -66.73 -59.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.348 -0.845 . . . . 0.0 109.16 179.743 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.2 p -67.87 -25.98 65.79 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.677 -179.931 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -68.87 -46.57 59.59 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -179.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.51 -26.89 45.41 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -1.172 . . . . 0.0 109.66 179.975 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.417 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.1 tt -77.29 -16.35 59.01 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.203 -0.936 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.9 mt -76.5 -0.73 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.14 -0.975 . . . . 0.0 110.151 -179.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.0 m -84.37 -43.96 14.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.037 -1.04 . . . . 0.0 109.632 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -85.53 -16.55 63.85 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.945 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.478 ' O ' ' CB ' ' A' ' 146' ' ' GLN . 6.8 tp -86.23 -173.65 4.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.195 -1.179 . . . . 0.0 108.943 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 146' ' ' GLN . . . . . 0.478 ' CB ' ' O ' ' A' ' 145' ' ' LEU . 4.8 mm-40 75.27 63.88 0.06 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.366 -0.834 . . . . 0.0 109.262 -179.564 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.45 ' CA ' ' HG3' ' A' ' 91' ' ' LYS . 5.4 p . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.635 179.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 148' ' ' HEM . . . . . 0.501 ' HHC' ' CE1' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 149' ' ' CMO . . . . . 0.508 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.895 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.474 ' O ' HG23 ' A' ' 10' ' ' VAL . 76.9 mt-30 -70.27 -47.35 61.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.305 -0.872 . . . . 0.0 109.212 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 31.8 mtp180 -53.98 -36.01 62.44 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.247 -0.908 . . . . 0.0 109.193 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -74.59 -40.38 61.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.309 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 5' ' ' ALA . 61.0 t -66.06 -23.71 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.284 -0.885 . . . . 0.0 109.192 179.606 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.645 HG23 ' HB1' ' A' ' 129' ' ' ALA . 50.9 t -76.74 -44.89 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -0.853 . . . . 0.0 109.338 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.412 ' O ' ' HG3' ' A' ' 15' ' ' LYS . . . -74.04 -15.96 61.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.764 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -86.21 -24.16 26.19 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.149 -0.969 . . . . 0.0 109.816 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.507 HG21 ' HB1' ' A' ' 126' ' ' ALA . 3.6 p -95.16 -10.96 29.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.214 -0.929 . . . . 0.0 109.8 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.686 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.8 -28.73 17.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 0.0 109.863 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.412 ' HG3' ' O ' ' A' ' 11' ' ' ALA . 10.6 mtmt -74.57 -12.73 60.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 109.812 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.415 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 1.7 m-20 -101.52 -55.05 2.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -0.988 . . . . 0.0 109.528 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.921 HD12 ' CH2' ' A' ' 130' ' ' TRP . 86.0 mt -67.5 -35.5 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.271 -0.893 . . . . 0.0 109.593 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.637 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -105.59 33.73 3.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.285 -0.884 . . . . 0.0 109.728 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -84.58 0.03 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 p -101.08 -18.81 16.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.703 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.7 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.4 p-10 -85.51 -16.99 37.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.207 -0.933 . . . . 0.0 109.902 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.598 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.4 t30 62.39 17.0 9.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.263 -0.898 . . . . 0.0 109.676 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.88 29.65 5.75 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.7 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -70.88 -46.99 61.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -1.174 . . . . 0.0 109.546 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.441 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.85 38.19 3.19 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.579 HG11 HD11 ' A' ' 63' ' ' LEU . 34.6 t -124.01 -43.12 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.233 -1.157 . . . . 0.0 108.64 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.488 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -88.81 -32.0 11.77 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.54 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.531 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 15.5 ptpt -62.19 -35.57 79.25 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.232 -1.158 . . . . 0.0 109.124 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.837 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 17.2 pt-20 -86.42 -21.08 27.32 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -0.972 . . . . 0.0 109.31 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 38.5 t -87.98 -59.38 2.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.398 -0.814 . . . . 0.0 109.692 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.2 m-85 -53.67 -42.99 68.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.275 -0.891 . . . . 0.0 109.669 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.778 ' OG1' HG11 ' A' ' 55' ' ' VAL . 17.8 m -52.02 -50.25 61.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.15 -0.969 . . . . 0.0 109.252 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.427 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 0.2 OUTLIER -62.5 -44.73 95.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.26 179.649 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.707 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.9 t80 -57.81 -46.66 84.36 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.35 -0.844 . . . . 0.0 109.206 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.705 ' CD1' HG22 ' A' ' 55' ' ' VAL . 11.1 mt -59.26 -44.34 92.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.715 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.613 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 46.8 t -66.7 -64.32 0.88 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.204 -0.935 . . . . 0.0 109.749 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.39 -26.57 20.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.218 -0.926 . . . . 0.0 109.827 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 16.3 m80 -123.79 104.92 9.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.857 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.6 m170 -85.99 8.24 21.3 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.428 -0.795 . . . . 0.0 109.758 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -98.54 -11.66 21.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.129 -0.982 . . . . 0.0 109.623 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.562 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -105.84 -11.77 16.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.209 -0.932 . . . . 0.0 110.081 -179.793 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.438 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -58.46 -60.26 4.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.938 -1.101 . . . . 0.0 109.26 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.81 -28.24 63.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.088 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' ND2' ' A' ' 95' ' ' ASN . 28.5 t -68.85 -47.77 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.376 -0.828 . . . . 0.0 109.088 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.53 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -71.19 -37.08 72.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.557 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.77 34.23 1.57 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.4 m-85 -125.92 168.61 13.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -1.162 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.0 t -105.92 -13.68 15.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.406 -0.809 . . . . 0.0 109.479 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.77 -162.97 28.28 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.613 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -83.49 -19.55 35.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.297 -1.119 . . . . 0.0 109.778 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 14.9 p -87.76 52.15 2.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -0.902 . . . . 0.0 109.739 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -127.12 133.77 25.42 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.923 . . . . 0.0 109.581 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -67.23 -29.01 39.69 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.908 1.478 . . . . 0.0 110.063 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.27 -38.28 40.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.778 HG11 ' OG1' ' A' ' 32' ' ' THR . 94.4 t -51.2 -46.78 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -1.095 . . . . 0.0 109.421 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.496 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -64.2 -17.12 63.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.902 . . . . 0.0 109.494 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.83 -47.38 15.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.819 ' O ' HG23 ' A' ' 62' ' ' VAL . 9.6 mt -73.23 -60.69 2.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.178 -0.951 . . . . 0.0 109.476 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.715 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -47.65 -31.19 7.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.496 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -78.38 -60.54 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -1.148 . . . . 0.0 109.438 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -52.43 -39.2 60.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.286 -0.884 . . . . 0.0 109.493 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.819 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.3 t -64.63 -48.32 85.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.715 HD23 ' O ' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -47.78 -44.74 28.69 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.184 -0.947 . . . . 0.0 109.636 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 67' ' ' GLY . . . -49.2 -52.74 24.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.409 -0.807 . . . . 0.0 109.778 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.1 tp60 -49.82 -44.02 49.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.095 -1.003 . . . . 0.0 109.268 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.972 ' O ' HG23 ' A' ' 70' ' ' VAL . 82.7 mt -63.2 -28.04 44.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.336 -0.852 . . . . 0.0 108.851 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.561 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -71.41 -55.22 7.84 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.44 -24.48 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.238 -1.154 . . . . 0.0 109.116 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.41 ' O ' HD22 ' A' ' 73' ' ' LEU . . . -86.09 -18.09 33.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.413 -0.805 . . . . 0.0 109.57 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.972 HG23 ' O ' ' A' ' 66' ' ' ILE . 41.0 t -75.07 -16.04 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.511 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 74.6 m -88.45 11.06 18.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.129 -0.982 . . . . 0.0 110.143 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.8 m-70 -161.73 61.37 0.25 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.048 -1.033 . . . . 0.0 109.926 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.56 HD11 ' HB1' ' A' ' 133' ' ' ALA . 3.1 mm? . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.483 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.418 ' HG2' ' O ' ' A' ' 72' ' ' HIS . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.664 HG13 ' HB1' ' A' ' 140' ' ' ALA . 71.6 t -84.1 -17.01 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.39 -0.819 . . . . 0.0 109.405 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -39.39 70.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.493 ' O ' HG23 ' A' ' 86' ' ' VAL . 12.3 tt0 -69.91 -48.17 59.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.243 -0.911 . . . . 0.0 109.331 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.58 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.7 OUTLIER -58.68 -46.78 86.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 109.214 179.7 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.469 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.9 mttt -52.92 -34.78 56.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.246 -0.909 . . . . 0.0 109.148 179.571 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.42 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -69.3 -42.98 74.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.339 -0.851 . . . . 0.0 109.391 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.2 t -50.97 -40.15 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.302 -0.874 . . . . 0.0 109.338 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.463 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -58.05 -50.48 65.73 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.777 HG23 ' HA3' ' A' ' 144' ' ' GLY . 97.6 t -54.62 -35.88 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -1.034 . . . . 0.0 108.95 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 1.5 mpt_? -66.08 -45.02 82.75 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.359 -0.838 . . . . 0.0 108.97 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.684 ' O ' HD12 ' A' ' 98' ' ' ILE . 16.5 m80 -64.71 -12.2 44.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.441 -0.787 . . . . 0.0 109.766 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.445 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -74.27 -8.48 56.37 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.032 -1.042 . . . . 0.0 110.426 -179.657 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -152.04 57.75 0.43 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.792 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.5 m-30 -88.35 -169.74 2.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.265 -1.138 . . . . 0.0 109.728 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.52 -8.77 87.12 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.02 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.0 p-10 -112.22 -23.75 10.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.862 -1.375 . . . . 0.0 109.975 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 51.33 28.43 4.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.134 -0.978 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.821 ' HB2' HG22 ' A' ' 44' ' ' VAL . 38.4 m170 -129.32 38.42 3.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.792 HD11 ' CD2' ' A' ' 93' ' ' TYR . 51.2 mt -87.72 154.6 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.065 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.429 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.86 149.83 27.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.129 -0.982 . . . . 0.0 110.159 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.672 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -80.17 -8.83 59.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.358 -0.839 . . . . 0.0 109.588 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 105' ' ' PRO . 14.5 pt-20 -68.62 -30.24 68.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.1 -1.0 . . . . 0.0 109.336 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.562 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 70.4 m-85 -82.47 -21.24 35.65 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.312 -0.867 . . . . 0.0 109.737 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.8 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.2 m-85 -57.66 -68.83 0.2 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.389 -0.819 . . . . 0.0 110.465 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.505 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 8.4 mt-10 -43.62 -60.21 2.78 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.45 -0.781 . . . . 0.0 111.022 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.538 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.3 Cg_endo -56.5 -50.59 11.41 Favored 'Trans proline' 0 C--N 1.304 -1.802 0 O-C-N 123.756 1.398 . . . . 0.0 110.052 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.933 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -65.52 -19.67 66.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.158 -0.963 . . . . 0.0 109.333 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -79.99 -44.9 8.68 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.52 -47.07 77.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.217 -1.167 . . . . 0.0 109.337 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 48.7 m -63.66 -16.77 61.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.32 -0.862 . . . . 0.0 109.508 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.493 HD22 ' CE2' ' A' ' 134' ' ' TYR . 6.3 tt -75.41 -40.24 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.673 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.882 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.8 mt -63.12 -30.06 71.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.937 . . . . 0.0 109.718 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 1.4 t -73.2 -20.9 60.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 109.639 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.837 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -88.29 -31.25 19.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.582 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.585 ' SD ' HD23 ' A' ' 111' ' ' LEU . 1.0 OUTLIER -55.6 -35.75 66.17 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.853 . . . . 0.0 109.992 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 20.8 pt-20 -57.75 -22.54 47.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.117 -0.989 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.405 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 0.4 OUTLIER -56.98 -40.56 76.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.211 -0.931 . . . . 0.0 109.355 179.796 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.47 ' HD3' HG23 ' A' ' 17' ' ' ILE . 11.2 ttt85 -77.59 -62.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.543 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.507 HG12 HD11 ' A' ' 17' ' ' ILE . 8.7 pt -91.69 43.26 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.459 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -52.99 124.46 27.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 101.06 -37.06 3.78 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 26.4 mmtt -89.12 -24.52 22.22 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 109.293 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.435 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -72.12 86.9 1.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.323 -0.861 . . . . 0.0 109.586 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.87 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.1 p-10 -83.66 -171.98 3.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.348 -0.845 . . . . 0.0 109.859 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.441 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -64.15 -42.58 96.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.299 -0.876 . . . . 0.0 109.778 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.87 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -61.09 -29.96 70.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.128 -0.983 . . . . 0.0 109.334 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.507 ' HB1' HG21 ' A' ' 13' ' ' THR . . . -69.93 -50.35 42.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.527 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 11.5 ptpt -71.79 -28.37 63.57 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.9 t0 -76.51 -49.28 16.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.267 -0.896 . . . . 0.0 109.332 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.645 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -56.53 -45.25 81.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.391 -0.818 . . . . 0.0 109.261 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.921 ' CH2' HD12 ' A' ' 17' ' ' ILE . 5.4 m0 -73.54 -32.07 64.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.36 -0.838 . . . . 0.0 109.134 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.604 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.03 -24.69 67.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.291 -0.88 . . . . 0.0 109.185 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.23 -26.97 16.41 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.386 -0.821 . . . . 0.0 109.265 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.56 ' HB1' HD11 ' A' ' 73' ' ' LEU . . . -81.68 -44.46 17.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.325 -0.859 . . . . 0.0 109.577 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.729 ' CZ ' HG21 ' A' ' 66' ' ' ILE . 2.8 m-85 -57.45 -27.61 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.943 . . . . 0.0 109.493 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.45 -46.32 89.07 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.355 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -74.58 -28.28 60.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.33 -0.857 . . . . 0.0 109.587 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.67 HD12 ' HA ' ' A' ' 134' ' ' TYR . 81.4 mt -68.62 -60.24 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.453 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.404 ' O ' HG12 ' A' ' 142' ' ' ILE . 45.2 p -67.52 -48.76 66.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.382 -0.824 . . . . 0.0 109.774 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.64 -29.85 26.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.664 ' HB1' HG13 ' A' ' 80' ' ' VAL . . . -78.85 -17.55 55.45 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.157 -1.202 . . . . 0.0 109.825 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.8 HD22 ' CE2' ' A' ' 103' ' ' PHE . 9.3 tt -89.57 -23.44 21.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 109.82 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.672 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.0 mm -70.7 -16.71 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.219 -0.925 . . . . 0.0 109.82 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.469 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.5 OUTLIER -61.39 -68.01 0.35 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -0.966 . . . . 0.0 109.175 179.808 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.777 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -66.04 -19.37 67.84 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.483 ' CB ' ' HA ' ' A' ' 142' ' ' ILE . 24.6 tp . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.316 -1.108 . . . . 0.0 109.597 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 121.153 0.501 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -70.82 -40.96 72.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.06 -1.025 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -51.04 -52.73 40.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.113 -0.992 . . . . 0.0 109.297 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 60.1 mm-40 -49.72 -41.73 44.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.926 . . . . 0.0 109.268 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.7 t -71.25 -29.91 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -0.883 . . . . 0.0 108.88 179.25 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.849 HG12 HG13 ' A' ' 70' ' ' VAL . 41.5 t -78.59 -43.73 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.494 -0.754 . . . . 0.0 109.051 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.71 -13.19 60.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.443 -0.786 . . . . 0.0 109.78 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.5 m -92.13 -27.65 17.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 110.094 -179.645 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -87.73 -14.53 39.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.166 -0.959 . . . . 0.0 109.843 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -86.2 -18.4 32.27 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -0.95 . . . . 0.0 109.781 -179.802 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -80.28 1.97 26.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.142 -0.974 . . . . 0.0 109.784 179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -114.22 -53.95 2.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.103 -0.998 . . . . 0.0 109.333 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.895 HD12 ' CH2' ' A' ' 130' ' ' TRP . 54.7 mt -63.94 -35.19 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.468 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.4 38.27 2.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.912 . . . . 0.0 109.791 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.83 -88.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.1 p -109.41 17.38 21.51 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.305 -1.115 . . . . 0.0 109.683 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.439 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 2.9 p-10 -125.88 -3.93 7.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.578 HD21 ' HB2' ' A' ' 64' ' ' ALA . 6.4 t30 57.15 19.25 4.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.293 -0.88 . . . . 0.0 109.452 -179.576 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.48 27.22 30.63 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HD2' ' A' ' 28' ' ' LYS . . . -52.56 -38.26 59.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.348 -1.089 . . . . 0.0 109.698 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.43 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.44 18.97 38.67 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.875 HG21 ' CG2' ' A' ' 17' ' ' ILE . 25.5 t -117.3 -14.22 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.136 -1.214 . . . . 0.0 109.46 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.461 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -110.03 -29.46 3.77 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.015 -1.634 . . . . 0.0 109.015 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.487 ' HB2' ' CB ' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -77.8 -28.47 50.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.187 -1.184 . . . . 0.0 109.458 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.619 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 1.6 pm0 -95.38 -16.0 22.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.633 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.406 ' HB2' ' OE2' ' A' ' 29' ' ' GLU . 37.0 t -87.98 -62.49 1.48 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -0.925 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.659 ' O ' HD12 ' A' ' 35' ' ' LEU . 10.8 m-85 -50.27 -30.96 12.94 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.143 -0.973 . . . . 0.0 109.694 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.579 ' OG1' HG11 ' A' ' 55' ' ' VAL . 52.6 m -61.64 -30.97 71.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.418 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 6.7 mmtt -74.57 -47.44 32.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.283 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.689 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.1 t80 -57.85 -46.16 85.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.419 -0.801 . . . . 0.0 109.535 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.701 HD13 HG22 ' A' ' 55' ' ' VAL . 6.8 mt -60.3 -46.89 88.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -0.882 . . . . 0.0 109.775 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.481 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 54.3 p -65.14 -49.9 68.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.284 -0.885 . . . . 0.0 109.769 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.45 -25.9 63.41 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.192 -0.943 . . . . 0.0 109.765 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.447 ' N ' ' O ' ' A' ' 34' ' ' PHE . 22.9 m80 -126.14 117.76 23.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.204 -0.935 . . . . 0.0 109.866 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.2 m170 -94.75 -15.33 23.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.455 -0.778 . . . . 0.0 109.56 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -71.59 -7.62 48.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.17 -0.956 . . . . 0.0 109.882 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.567 ' SD ' HG11 ' A' ' 44' ' ' VAL . 4.9 mmt -118.77 -12.08 9.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.012 -1.055 . . . . 0.0 110.115 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.458 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -56.53 -53.53 56.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.943 -1.098 . . . . 0.0 109.254 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -64.25 -27.9 69.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.102 179.559 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.022 HG13 ' ND2' ' A' ' 95' ' ' ASN . 13.0 t -67.95 -53.38 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.417 -0.802 . . . . 0.0 109.171 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 38.9 m-85 -61.93 -19.02 62.28 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 29.66 6.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 14.1 m-85 -126.37 168.84 13.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -1.138 . . . . 0.0 109.941 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.5 t -114.67 20.11 15.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.452 -0.78 . . . . 0.0 109.166 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.78 -163.74 28.24 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -98.93 39.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -1.17 . . . . 0.0 109.645 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 16.1 m -140.53 22.94 2.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 109.675 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -110.43 145.67 32.71 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.24 -0.913 . . . . 0.0 109.692 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -77.57 56.15 5.46 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.972 1.511 . . . . 0.0 110.169 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -135.06 -38.4 0.19 Allowed Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.701 HG22 HD13 ' A' ' 35' ' ' LEU . 47.5 t -50.0 -26.65 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.242 -1.152 . . . . 0.0 109.596 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.512 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -81.1 -7.81 59.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.292 -0.88 . . . . 0.0 110.002 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -91.73 -31.37 15.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.067 -1.021 . . . . 0.0 109.747 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.877 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.1 mt -83.04 -64.09 1.24 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.115 -0.991 . . . . 0.0 109.697 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.461 ' HA3' ' CA ' ' A' ' 27' ' ' GLY . . . -51.39 -44.81 53.16 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.512 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -53.49 -39.15 64.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.225 -1.162 . . . . 0.0 109.611 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -89.63 -32.31 17.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.252 -0.905 . . . . 0.0 109.633 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.877 HG23 ' O ' ' A' ' 58' ' ' LEU . 57.7 t -65.27 -47.95 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.566 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.691 HD11 ' CG1' ' A' ' 26' ' ' VAL . 2.9 mm? -47.3 -45.27 24.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.198 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.578 ' HB2' HD21 ' A' ' 22' ' ' ASN . . . -53.65 -39.95 65.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.175 -0.953 . . . . 0.0 110.077 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.463 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 6.8 tp-100 -59.78 -39.54 85.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.964 -1.085 . . . . 0.0 108.903 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 1.029 HD13 HG21 ' A' ' 137' ' ' ILE . 26.7 mm -62.44 -42.14 94.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.405 -0.809 . . . . 0.0 108.9 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.546 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.6 -51.32 55.06 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.562 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 64' ' ' ALA . 46.6 t -58.47 -26.8 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.318 -1.107 . . . . 0.0 109.411 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.83 -28.19 26.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.32 -0.863 . . . . 0.0 109.704 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.849 HG13 HG12 ' A' ' 10' ' ' VAL . 54.1 t -75.83 -23.33 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.2 p -63.57 -13.48 42.05 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 110.034 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.437 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 15.4 m-70 -124.01 -77.53 0.59 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.106 -0.996 . . . . 0.0 109.957 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.49 HD23 ' SD ' ' A' ' 79' ' ' MET . 53.5 mt . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.672 -0.643 . . . . 0.0 109.734 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.49 ' SD ' HD23 ' A' ' 73' ' ' LEU . 4.7 ttp . . . . . 0 N--CA 1.495 1.783 0 CA-C-O 121.281 0.562 . . . . 0.0 109.694 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.554 HG12 ' HE3' ' A' ' 84' ' ' LYS . 42.8 t -65.39 -15.41 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.218 -0.926 . . . . 0.0 109.61 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.06 -52.22 20.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.973 . . . . 0.0 109.377 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.596 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.4 mt-10 -71.25 -41.05 70.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.477 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 2.1 mtp -58.8 -48.58 80.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.305 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.601 ' O ' HG23 ' A' ' 88' ' ' VAL . 11.1 mttt -50.8 -38.57 49.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.151 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.412 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -66.83 -44.55 80.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.401 -0.812 . . . . 0.0 109.408 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.625 ' HB ' HD12 ' A' ' 141' ' ' LEU . 14.4 t -58.23 -37.94 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.157 -0.964 . . . . 0.0 109.264 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.458 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -63.34 -49.08 73.36 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 84' ' ' LYS . 57.4 t -51.44 -38.45 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -1.059 . . . . 0.0 109.453 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.551 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 2.8 mpt_? -59.22 -25.62 64.15 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -0.944 . . . . 0.0 109.336 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.479 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 11.5 m-70 -87.38 16.32 5.49 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.397 -0.814 . . . . 0.0 109.643 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.439 ' O ' ' HG3' ' A' ' 96' ' ' LYS . 23.3 ttmt -75.27 -67.48 0.65 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.941 -1.1 . . . . 0.0 110.167 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.4 ' HA2' ' HG3' ' A' ' 96' ' ' LYS . . . -145.7 56.07 0.53 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.551 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -82.46 -100.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 110.342 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -96.48 -57.28 1.13 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.022 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -84.37 -28.45 26.98 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.415 -1.05 . . . . 0.0 108.594 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.511 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 14.6 tttm 64.41 -48.99 0.3 Allowed 'General case' 0 N--CA 1.505 2.283 0 O-C-N 121.75 -0.594 . . . . 0.0 112.271 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.469 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 64.2 m170 -50.0 -97.21 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.628 -1.295 . . . . 0.0 111.234 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.511 ' CG1' ' ND2' ' A' ' 95' ' ' ASN . 14.9 mt 65.4 154.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 121.035 -1.04 . . . . 0.0 109.572 -178.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.435 ' HE3' ' HB3' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -158.32 150.75 22.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.268 -0.895 . . . . 0.0 109.828 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.821 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -77.82 -10.21 59.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.569 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.0 mt-10 -67.68 -35.77 79.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 109.597 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.482 ' HB3' ' CE2' ' A' ' 34' ' ' PHE . 76.5 m-85 -81.15 -16.48 52.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.344 -0.847 . . . . 0.0 110.146 -179.416 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.824 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -58.32 -57.49 12.66 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.158 -0.963 . . . . 0.0 109.973 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.518 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -53.75 -58.05 14.84 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 109.755 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.518 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 39.7 Cg_exo -50.81 -62.17 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.628 1.33 . . . . 0.0 109.76 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.954 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -53.77 -24.75 16.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -0.895 . . . . 0.0 109.241 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -74.68 -51.49 8.04 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.096 -1.601 . . . . 0.0 109.096 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -54.22 -55.43 28.17 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -1.169 . . . . 0.0 109.456 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 54.9 m -53.33 -22.76 7.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.349 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.4 tt -65.88 -48.51 71.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.314 -0.866 . . . . 0.0 109.632 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.697 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -57.54 -36.56 71.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.184 -0.948 . . . . 0.0 109.544 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -67.44 -33.81 75.9 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.595 179.966 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.619 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -81.69 -25.73 35.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -0.924 . . . . 0.0 109.663 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.534 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.9 mmt -58.45 -47.73 83.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.918 . . . . 0.0 110.205 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.449 ' O ' ' N ' ' A' ' 119' ' ' GLY . 6.4 pt-20 -50.05 -23.54 2.14 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.068 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.428 ' NE2' ' HA ' ' A' ' 113' ' ' ALA . 19.1 m170 -50.2 -40.73 48.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.993 -1.067 . . . . 0.0 109.783 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -87.17 -56.14 3.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.7 -179.873 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.541 HG12 HD11 ' A' ' 17' ' ' ILE . 5.7 pt -104.34 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.143 -0.973 . . . . 0.0 109.633 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -63.15 -20.11 62.41 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.51 -29.23 10.28 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.443 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.2 mppt? -94.26 -23.44 17.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -1.189 . . . . 0.0 109.803 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.488 ' SD ' HD11 ' A' ' 118' ' ' ILE . 3.8 tpt -63.89 86.35 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.18 -0.95 . . . . 0.0 109.616 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.826 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.2 p-10 -87.14 -168.73 2.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.414 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.29 -39.98 74.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -0.932 . . . . 0.0 109.628 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.826 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -65.05 -31.11 72.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.095 -1.003 . . . . 0.0 108.98 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.458 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -66.27 -50.8 62.48 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.107 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.492 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 17.5 ptpt -70.53 -27.67 64.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.913 . . . . 0.0 109.124 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.482 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.1 t0 -79.33 -32.57 43.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.374 -0.829 . . . . 0.0 108.953 179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.7 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -72.42 -47.69 47.15 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.433 -0.792 . . . . 0.0 109.126 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.895 ' CH2' HD12 ' A' ' 17' ' ' ILE . 12.5 m0 -71.54 -21.54 61.88 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.269 -0.895 . . . . 0.0 108.976 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.492 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -53.24 -34.3 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -0.889 . . . . 0.0 109.038 179.075 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -97.22 -15.4 20.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.417 -0.802 . . . . 0.0 109.494 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.647 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -81.51 -67.79 0.75 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.252 -0.905 . . . . 0.0 109.854 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.514 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.4 OUTLIER -55.31 -21.25 14.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.032 -1.043 . . . . 0.0 109.268 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -80.92 -49.56 10.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.299 -0.876 . . . . 0.0 108.944 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -73.21 -26.45 61.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.399 -0.813 . . . . 0.0 109.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 1.029 HG21 HD13 ' A' ' 66' ' ' ILE . 43.9 mt -67.88 -61.21 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 109.183 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.402 ' O ' HG12 ' A' ' 142' ' ' ILE . 0.7 OUTLIER -62.89 -14.2 43.51 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.346 -0.846 . . . . 0.0 109.907 -179.819 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.43 -36.01 24.69 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.67 -27.9 66.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -1.184 . . . . 0.0 109.916 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.824 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.8 tt -74.39 -5.61 43.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.194 -0.941 . . . . 0.0 110.138 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.821 HD12 ' HB2' ' A' ' 100' ' ' ALA . 49.8 mm -90.66 18.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.98 -1.075 . . . . 0.0 109.843 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.445 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 5.8 m -95.25 -63.41 1.17 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.947 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.12 -22.52 74.35 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.479 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.354 -1.086 . . . . 0.0 109.535 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.767 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.296 0.569 . . . . 0.0 109.599 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.489 ' O ' HG23 ' A' ' 10' ' ' VAL . 36.6 mt-30 -65.13 -51.39 61.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.366 -0.834 . . . . 0.0 109.552 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -53.43 -32.3 49.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.08 -1.013 . . . . 0.0 108.921 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 47.8 tp60 -71.48 -44.07 65.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.166 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 5' ' ' ALA . 30.0 t -65.12 -30.65 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.291 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.807 HG12 HG13 ' A' ' 70' ' ' VAL . 84.8 t -70.04 -41.75 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.369 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.8 -14.67 60.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -0.869 . . . . 0.0 109.764 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.1 -33.25 19.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.509 HG21 ' HB1' ' A' ' 126' ' ' ALA . 12.1 p -85.55 -15.73 41.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.739 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -86.99 -18.98 29.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.811 -179.893 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.8 mtpp -80.99 0.32 36.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.194 -0.941 . . . . 0.0 109.898 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -115.83 -53.65 2.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.081 -1.012 . . . . 0.0 109.439 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.945 HD12 ' CH2' ' A' ' 130' ' ' TRP . 64.7 mt -67.3 -32.78 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.552 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -103.07 31.92 4.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.872 . . . . 0.0 109.647 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.7 -86.39 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.0 p -95.25 -35.71 11.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.752 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.711 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 2.9 p30 -71.24 -17.12 62.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.26 -0.9 . . . . 0.0 109.81 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.552 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 0.2 OUTLIER 58.31 24.8 11.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.133 -0.979 . . . . 0.0 109.455 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.577 ' CA ' HD22 ' A' ' 63' ' ' LEU . . . 92.78 32.95 7.69 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.711 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -81.11 -66.34 0.9 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -1.108 . . . . 0.0 109.816 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 29' ' ' GLU . . . -52.74 -22.98 13.0 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.793 HG12 HD11 ' A' ' 63' ' ' LEU . 38.5 t -74.82 -32.21 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.846 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.01 -55.48 2.93 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.42 ' HB3' ' HA ' ' A' ' 56' ' ' ALA . 6.6 ptpp? -57.31 -19.63 23.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.187 -1.184 . . . . 0.0 110.053 -179.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.65 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -98.35 -30.42 12.59 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.972 -1.08 . . . . 0.0 109.579 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.3 t -82.32 -55.48 4.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.34 -0.85 . . . . 0.0 109.538 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.524 ' O ' HD12 ' A' ' 35' ' ' LEU . 12.2 m-85 -54.55 -37.44 65.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.357 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.884 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.56 -54.72 37.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.213 -0.929 . . . . 0.0 109.232 179.624 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -57.11 -47.82 80.15 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.212 -0.93 . . . . 0.0 109.335 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.741 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.4 t80 -55.07 -52.24 63.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.3 -0.875 . . . . 0.0 109.28 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.893 HD13 HG22 ' A' ' 55' ' ' VAL . 6.8 mt -59.3 -41.14 88.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.255 -0.903 . . . . 0.0 109.664 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.426 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 20.6 t -63.1 -61.19 2.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.657 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -63.37 -26.72 68.88 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.236 -0.915 . . . . 0.0 109.684 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -118.9 107.53 13.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.691 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -88.34 -24.29 23.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 109.362 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 40' ' ' ASP . 25.5 p-10 -65.39 -19.16 65.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.408 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.544 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -95.21 -17.6 21.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.292 -0.88 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.439 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -57.43 -62.78 1.54 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.975 . . . . 0.0 109.38 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.56 -26.38 43.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.882 HG13 ' OD1' ' A' ' 95' ' ' ASN . 21.1 t -73.63 -48.76 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 109.239 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.522 ' CD2' HD21 ' A' ' 35' ' ' LEU . 27.1 m-85 -68.26 -26.9 65.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.22 -0.925 . . . . 0.0 109.549 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 108.66 27.49 4.92 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.528 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.3 m-85 -123.74 167.29 14.22 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.176 . . . . 0.0 109.868 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 t -102.81 -20.93 14.13 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.421 -0.799 . . . . 0.0 109.203 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.9 -163.91 23.72 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.426 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -94.73 34.11 1.38 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.298 -1.119 . . . . 0.0 109.698 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 24.4 p -133.0 21.23 4.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.68 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -106.64 139.48 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.607 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.6 -16.96 57.94 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.954 1.502 . . . . 0.0 110.105 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.528 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -56.27 -39.8 83.05 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.893 HG22 HD13 ' A' ' 35' ' ' LEU . 84.1 t -51.04 -37.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -1.098 . . . . 0.0 109.38 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.456 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -73.74 -6.6 47.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.305 -0.872 . . . . 0.0 109.721 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -91.62 -27.16 18.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.011 . . . . 0.0 109.57 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.825 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -91.43 -64.0 1.18 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.175 -0.953 . . . . 0.0 109.627 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.522 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.18 -41.94 39.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -62.84 -23.85 67.5 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -1.149 . . . . 0.0 109.691 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.73 -28.37 12.51 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.679 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.825 HG23 ' O ' ' A' ' 58' ' ' LEU . 59.6 t -67.22 -56.49 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.287 -0.883 . . . . 0.0 109.848 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.793 HD11 HG12 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -48.2 -38.4 18.19 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.961 . . . . 0.0 109.616 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.44 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -50.44 -42.21 53.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.449 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.446 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 5.7 tp-100 -62.7 -36.17 82.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.232 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.865 ' O ' HG23 ' A' ' 70' ' ' VAL . 41.6 mt -66.92 -37.07 78.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.355 -0.841 . . . . 0.0 109.186 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.81 -48.27 56.18 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 179.492 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 64' ' ' ALA . 61.6 t -61.42 -27.99 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.357 -1.084 . . . . 0.0 109.43 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.86 -32.98 24.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.319 -0.863 . . . . 0.0 109.503 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 66' ' ' ILE . 56.5 t -66.58 -22.67 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 41.3 m -67.31 -12.36 59.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.948 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.425 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 14.0 m-70 -122.85 -83.92 0.66 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.123 -0.986 . . . . 0.0 109.918 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.649 HD11 ' HA ' ' A' ' 70' ' ' VAL . 35.1 mt . . . . . 0 N--CA 1.494 1.773 0 O-C-N 121.65 -0.657 . . . . 0.0 109.676 -179.589 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.411 ' SD ' HD23 ' A' ' 73' ' ' LEU . 5.5 ttp . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.293 0.568 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.453 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.2 t -72.14 -29.41 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.01 -41.91 97.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.253 -0.904 . . . . 0.0 109.435 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.682 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.5 mt-10 -71.98 -50.8 25.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.513 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.444 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.2 OUTLIER -62.47 -38.66 90.69 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 109.149 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.453 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -60.06 -38.04 81.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.265 -0.897 . . . . 0.0 109.099 179.44 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -67.92 -41.34 82.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.258 -0.901 . . . . 0.0 109.21 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.682 HG23 ' O ' ' A' ' 82' ' ' GLU . 30.8 t -55.48 -50.52 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.328 -0.857 . . . . 0.0 109.119 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.524 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -56.55 -53.58 42.47 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 84' ' ' LYS . 79.1 t -53.85 -34.24 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.438 -1.037 . . . . 0.0 108.947 179.355 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mmm180 -72.13 -48.72 41.54 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.413 -0.804 . . . . 0.0 109.051 179.449 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.707 ' O ' HD12 ' A' ' 98' ' ' ILE . 14.5 m80 -56.48 -27.38 56.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.04 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.416 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -66.46 -12.07 55.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 110.289 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -136.08 49.85 0.87 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.701 ' CD2' HD11 ' A' ' 98' ' ' ILE . 4.3 m-30 -89.61 -168.71 2.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -1.174 . . . . 0.0 109.795 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -78.6 -52.19 5.2 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.882 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.3 -29.41 70.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -1.186 . . . . 0.0 109.657 -179.762 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 12.0 mtmm 53.54 29.36 8.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.671 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -136.29 45.31 2.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.284 -0.885 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.707 HD12 ' O ' ' A' ' 90' ' ' HIS . 62.2 mt -87.55 154.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.298 -0.876 . . . . 0.0 109.727 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -144.12 148.35 34.96 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.282 -0.886 . . . . 0.0 110.104 -179.84 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.523 ' HB2' HG23 ' A' ' 142' ' ' ILE . . . -83.68 -3.56 57.86 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.698 -0.627 . . . . 0.0 109.609 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 8.8 pt-20 -74.95 -29.16 60.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.074 -1.016 . . . . 0.0 109.477 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.544 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 59.8 m-85 -81.78 -22.1 37.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.726 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.879 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.0 m-85 -54.03 -63.46 1.14 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.221 -0.924 . . . . 0.0 110.263 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.511 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -48.98 -58.41 8.69 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.132 -0.98 . . . . 0.0 110.13 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.511 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.6 Cg_exo -49.85 -62.53 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.598 1.315 . . . . 0.0 110.026 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.964 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.59 -22.02 12.12 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.255 -0.903 . . . . 0.0 109.547 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.66 -50.36 5.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.44 95.19 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.133 -1.216 . . . . 0.0 109.557 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.4 t -66.62 -21.36 66.12 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.859 HD22 ' OH ' ' A' ' 134' ' ' TYR . 2.7 tt -71.96 -41.97 67.12 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 109.626 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.925 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.3 mt -58.97 -30.25 67.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 0.0 109.573 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 3.6 m -68.64 -33.99 74.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.713 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.65 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -81.47 -33.46 31.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.259 -0.9 . . . . 0.0 109.782 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.494 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -45.89 -47.55 16.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.313 -0.867 . . . . 0.0 110.341 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.457 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 18.8 pt-20 -51.94 -22.48 3.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 0.0 110.015 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 24.0 m170 -53.7 -30.7 44.98 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.012 -1.055 . . . . 0.0 109.81 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -95.42 -68.9 0.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.133 -0.979 . . . . 0.0 109.93 -179.775 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.495 HG23 HG12 ' A' ' 17' ' ' ILE . 33.2 pt -75.11 -36.85 39.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.025 -1.047 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.487 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 39.52 -96.84 0.01 OUTLIER Glycine 0 N--CA 1.498 2.828 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.54 -42.45 10.09 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 3.3 mtpt -72.42 -21.9 61.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.112 -1.228 . . . . 0.0 109.771 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.45 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.23 90.53 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.157 -0.964 . . . . 0.0 109.57 179.829 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.801 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 17.8 p-10 -84.94 -179.88 7.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.566 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 127' ' ' LYS . . . -64.01 -40.25 95.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.801 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -63.98 -30.51 71.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.191 -0.943 . . . . 0.0 109.196 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.787 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -67.03 -50.5 61.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.406 -0.809 . . . . 0.0 109.322 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.541 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.0 ptpt -71.88 -30.02 64.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.289 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.427 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 59.5 t0 -77.13 -44.02 31.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.2 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.412 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -63.82 -41.62 97.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.48 -0.763 . . . . 0.0 109.065 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.945 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.5 m0 -75.25 -25.01 57.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.32 -0.863 . . . . 0.0 109.012 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.541 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.43 -37.2 80.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -0.886 . . . . 0.0 108.987 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -78.83 -24.58 44.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.324 -0.86 . . . . 0.0 109.297 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -83.27 -50.41 8.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.359 -0.838 . . . . 0.0 109.543 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.859 ' OH ' HD22 ' A' ' 110' ' ' LEU . 3.7 m-85 -50.35 -31.68 15.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.18 -0.95 . . . . 0.0 109.306 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.94 -35.68 57.11 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.341 -0.849 . . . . 0.0 108.986 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.83 -36.12 37.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.385 -0.822 . . . . 0.0 109.287 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.786 HD13 HG23 ' A' ' 66' ' ' ILE . 58.6 mt -66.58 -58.96 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.88 . . . . 0.0 109.087 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.0 p -67.3 -19.81 65.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.386 -0.821 . . . . 0.0 109.644 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.427 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -72.1 -42.65 50.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.86 -23.03 65.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -1.146 . . . . 0.0 109.673 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.879 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.6 tt -80.34 -34.07 36.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.682 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.523 HG23 ' HB2' ' A' ' 100' ' ' ALA . 43.4 mt -73.79 -3.45 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 110.145 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.6 m -68.77 -59.43 3.1 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.011 -1.056 . . . . 0.0 109.621 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -88.38 4.4 85.28 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.569 HD12 HD21 ' A' ' 141' ' ' LEU . 4.4 tt . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.056 -1.261 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.678 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.326 0.584 . . . . 0.0 109.572 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 83.8 mt-30 -81.86 -52.08 7.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.427 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -49.61 -30.96 9.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.223 -0.923 . . . . 0.0 109.521 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.427 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 6.3 mm-40 -72.1 -42.91 65.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.266 -0.896 . . . . 0.0 109.278 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 5' ' ' ALA . 42.9 t -63.25 -32.15 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.274 -0.891 . . . . 0.0 109.243 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.973 HG12 HG13 ' A' ' 70' ' ' VAL . 70.7 t -66.12 -45.99 88.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.368 -0.833 . . . . 0.0 109.344 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.71 -10.56 59.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 109.821 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.3 p -92.88 -24.29 18.51 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.138 -0.976 . . . . 0.0 109.979 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.503 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 18.3 p -97.55 -8.98 27.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.092 -1.005 . . . . 0.0 109.959 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.694 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.6 -20.15 22.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.018 -1.051 . . . . 0.0 109.569 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -80.8 3.22 23.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.97 -56.49 2.1 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.066 -1.022 . . . . 0.0 109.512 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.882 HD12 ' CH2' ' A' ' 130' ' ' TRP . 51.2 mt -62.35 -30.26 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.51 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.907 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -107.42 32.41 4.69 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -0.91 . . . . 0.0 109.618 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -69.41 1.21 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 84.5 p -109.99 -29.96 8.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.281 -1.129 . . . . 0.0 109.663 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.815 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.8 p-10 -78.78 -20.2 50.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.896 . . . . 0.0 109.67 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.907 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.8 t30 57.61 28.41 15.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.185 -0.947 . . . . 0.0 109.516 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.412 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 93.51 25.39 18.59 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.815 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -73.2 -47.08 46.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.252 -1.146 . . . . 0.0 109.592 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.479 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.28 17.86 45.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.801 -1.319 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.657 HG13 ' SD ' ' A' ' 114' ' ' MET . 21.2 t -109.48 -25.81 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.25 179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.5 ' HA3' HD23 ' A' ' 63' ' ' LEU . . . -94.43 -43.19 3.76 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.479 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.3 OUTLIER -62.19 -31.49 72.01 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.096 -1.238 . . . . 0.0 109.577 -179.837 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.89 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 14.5 pt-20 -89.38 -15.99 32.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.929 . . . . 0.0 109.618 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 15.8 t -90.15 -63.14 1.32 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.482 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 16.8 m-85 -47.54 -33.95 7.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.496 ' OG1' HG11 ' A' ' 55' ' ' VAL . 51.5 m -55.39 -40.75 71.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.172 -0.955 . . . . 0.0 109.421 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.41 -49.41 27.22 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.264 -0.897 . . . . 0.0 109.456 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.713 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.9 t80 -52.06 -46.51 65.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.339 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.656 ' CD1' HG22 ' A' ' 55' ' ' VAL . 17.6 mt -58.07 -47.12 84.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.529 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.515 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 6.4 t -65.35 -55.83 15.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.569 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.54 -24.47 66.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -124.9 103.88 8.29 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.269 -0.894 . . . . 0.0 109.722 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.5 m170 -86.29 -18.99 30.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.366 -0.834 . . . . 0.0 109.454 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -71.96 -9.66 58.68 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.283 -0.885 . . . . 0.0 109.893 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.437 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 29.7 mmm -119.38 -15.8 9.05 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 110.079 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.459 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.03 -47.7 44.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.041 . . . . 0.0 109.424 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.25 -31.6 64.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.331 -0.855 . . . . 0.0 109.093 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.034 HG13 ' ND2' ' A' ' 95' ' ' ASN . 15.9 t -60.51 -37.31 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.408 -0.808 . . . . 0.0 109.141 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.518 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.2 m-85 -76.86 -18.46 58.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.764 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 102.44 23.46 8.93 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 9.8 m-85 -122.49 167.33 13.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -1.137 . . . . 0.0 109.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 12.5 t -112.62 21.3 15.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 109.233 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.95 -172.42 25.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.515 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -74.95 -6.86 51.57 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -1.167 . . . . 0.0 109.976 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 62.2 p -94.3 43.41 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.056 -1.028 . . . . 0.0 109.73 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -123.77 129.18 24.91 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.649 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -67.97 -28.93 34.98 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.776 1.408 . . . . 0.0 110.022 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.457 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.49 -30.15 33.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.656 HG22 ' CD1' ' A' ' 35' ' ' LEU . 95.5 t -50.93 -32.78 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -1.116 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.487 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -80.72 -6.22 58.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.312 -0.867 . . . . 0.0 109.809 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.22 -27.15 20.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.104 -0.998 . . . . 0.0 109.596 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.902 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.4 mt -89.78 -65.81 0.98 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.713 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.482 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.94 -42.16 29.61 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -56.19 -45.36 79.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.166 -1.196 . . . . 0.0 109.361 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 39.6 mttp -80.79 -38.17 28.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.386 -0.821 . . . . 0.0 109.403 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.902 HG23 ' O ' ' A' ' 58' ' ' LEU . 42.3 t -59.79 -50.18 81.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 0.0 109.619 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.535 HD11 HG11 ' A' ' 26' ' ' VAL . 1.2 mm? -47.12 -46.63 23.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.255 -0.903 . . . . 0.0 109.85 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.94 -51.07 43.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.814 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.7 tp60 -50.28 -53.77 26.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.124 -0.985 . . . . 0.0 109.438 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.933 ' O ' HG23 ' A' ' 70' ' ' VAL . 45.0 mt -51.27 -39.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 109.27 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.16 -56.09 24.15 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -57.3 -25.73 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.346 -1.09 . . . . 0.0 109.428 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.57 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -85.38 -30.46 23.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.376 -0.827 . . . . 0.0 109.632 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.973 HG13 HG12 ' A' ' 10' ' ' VAL . 74.1 t -66.77 -17.11 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -0.936 . . . . 0.0 109.838 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.464 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 40.9 t -90.21 21.09 3.95 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.155 -0.966 . . . . 0.0 109.975 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.469 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 10.3 m-70 -157.9 44.12 0.32 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.058 -1.026 . . . . 0.0 109.881 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.519 ' CD2' ' HA ' ' A' ' 70' ' ' VAL . 3.6 mm? . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.95 . . . . 0.0 109.413 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.469 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 21.7 ttp . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.252 0.549 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 27.1 t -70.53 -21.95 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.511 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.18 -42.94 83.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.207 -0.933 . . . . 0.0 109.285 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.589 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.8 mt-10 -78.98 -48.39 14.56 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.269 -0.894 . . . . 0.0 109.322 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.52 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.6 OUTLIER -57.39 -52.03 66.99 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -0.885 . . . . 0.0 109.27 179.677 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.838 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -51.12 -34.18 29.72 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 108.909 179.398 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.38 -39.69 71.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.362 -0.836 . . . . 0.0 108.951 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 82' ' ' GLU . 53.1 t -61.79 -49.94 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.333 -0.854 . . . . 0.0 109.118 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.485 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -55.16 -38.0 65.8 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.838 HG23 ' O ' ' A' ' 84' ' ' LYS . 95.6 t -60.08 -18.94 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.3 -1.117 . . . . 0.0 109.447 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.524 ' HB3' ' CE2' ' A' ' 93' ' ' TYR . 0.5 OUTLIER -82.63 -19.04 39.06 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.264 -0.898 . . . . 0.0 109.127 179.7 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.554 ' HB3' HD12 ' A' ' 98' ' ' ILE . 4.0 m80 -89.98 19.3 4.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.433 ' O ' ' HD3' ' A' ' 96' ' ' LYS . 2.4 mtmt -80.44 -59.14 2.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.164 -0.96 . . . . 0.0 110.776 -178.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.433 ' HA2' ' HD3' ' A' ' 96' ' ' LYS . . . -148.51 56.77 0.48 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.524 ' CE2' ' HB3' ' A' ' 89' ' ' ARG . 2.7 m-30 -82.46 -103.17 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 110.012 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -102.16 -62.68 0.74 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.034 ' ND2' HG13 ' A' ' 44' ' ' VAL . 2.0 t30 -68.21 -41.27 81.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.462 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 0.3 OUTLIER 65.66 -57.63 0.32 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.124 0.487 . . . . 0.0 109.852 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 95' ' ' ASN . 2.3 m-70 -62.93 79.53 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.215 -0.928 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.554 HD12 ' HB3' ' A' ' 90' ' ' HIS . 31.8 mt -109.18 158.85 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 109.233 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.523 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.6 mptp? -140.49 139.61 35.15 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.068 -1.02 . . . . 0.0 110.288 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.458 ' CB ' HG12 ' A' ' 142' ' ' ILE . . . -78.55 -2.63 39.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.835 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -76.1 -26.43 56.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.996 -1.065 . . . . 0.0 109.439 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.523 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 83.9 m-85 -85.24 10.13 13.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.384 -0.823 . . . . 0.0 110.076 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.686 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.3 m-85 -83.35 -61.28 1.89 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 109.671 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.506 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -51.01 -57.57 13.31 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.441 -0.787 . . . . 0.0 110.644 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 5.2 Cg_endo -54.01 -43.76 55.35 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.59 1.311 . . . . 0.0 110.142 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.861 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.5 tm? -64.12 -17.03 63.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.179 -0.951 . . . . 0.0 109.542 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.74 -36.98 12.37 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.29 -59.62 4.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.196 -1.179 . . . . 0.0 109.63 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.7 t -60.29 -18.9 52.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.27 -0.894 . . . . 0.0 109.565 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.926 HD21 ' HE2' ' A' ' 114' ' ' MET . 3.2 tt -76.76 -36.57 56.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.253 -0.905 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.577 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -63.85 -28.77 70.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.189 -0.944 . . . . 0.0 109.435 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -34.43 78.2 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.312 -0.868 . . . . 0.0 109.6 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.89 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -75.58 -38.22 59.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.926 ' HE2' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.34 -44.19 23.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.297 -0.877 . . . . 0.0 110.017 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.477 ' HG2' ' CB ' ' A' ' 122' ' ' MET . 0.6 OUTLIER -52.42 -22.08 4.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.307 -0.871 . . . . 0.0 109.962 -179.771 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.411 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 21.1 m170 -56.53 -35.86 68.58 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.146 -0.972 . . . . 0.0 110.247 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.507 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -90.8 -86.86 0.2 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.011 -1.056 . . . . 0.0 110.176 -179.583 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 119' ' ' GLY . 34.9 pt -56.61 -36.31 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.811 -1.18 . . . . 0.0 109.608 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.483 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.77 -98.99 0.01 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.519 -1.033 . . . . 0.0 110.519 179.154 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.35 -44.77 8.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.469 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 44.3 mttt -68.28 -25.77 65.32 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.074 -1.25 . . . . 0.0 110.032 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.477 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.0 OUTLIER -65.52 80.6 0.06 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.982 -1.073 . . . . 0.0 108.845 179.384 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.668 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 12.2 p-10 -82.12 -174.29 5.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.297 -0.877 . . . . 0.0 110.13 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.464 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -62.26 -45.31 93.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.376 -0.828 . . . . 0.0 109.897 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.668 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -62.6 -30.93 71.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.146 -0.971 . . . . 0.0 109.575 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -68.74 -44.76 73.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 109.264 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.577 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 1.6 ptpt -75.19 -29.83 60.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.375 -0.828 . . . . 0.0 109.664 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.486 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 44.2 t0 -79.22 -46.12 18.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.391 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.556 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -57.55 -47.79 81.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.42 -0.8 . . . . 0.0 109.308 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.882 ' CH2' HD12 ' A' ' 17' ' ' ILE . 7.3 m0 -71.92 -29.7 64.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.4 -0.812 . . . . 0.0 109.371 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.577 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -63.78 -25.92 68.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.235 -0.916 . . . . 0.0 108.974 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.48 ' O ' ' HB3' ' A' ' 135' ' ' ALA . . . -101.05 -24.95 14.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.421 -0.8 . . . . 0.0 109.169 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.54 ' HB2' HG21 ' A' ' 10' ' ' VAL . . . -67.44 -51.89 46.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.287 -0.883 . . . . 0.0 109.334 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.51 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 21.3 m-85 -52.76 -29.04 25.03 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 109.231 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' A' ' 132' ' ' ALA . . . -60.84 -46.41 90.68 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 108.835 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.82 -44.34 56.04 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 109.169 179.439 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.57 HG12 ' HB1' ' A' ' 69' ' ' ALA . 18.1 mt -64.3 -57.75 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.256 -0.903 . . . . 0.0 108.93 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.549 ' O ' HD12 ' A' ' 142' ' ' ILE . 2.0 p -67.87 -25.74 65.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.217 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.437 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -73.4 -46.59 25.5 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.25 -22.47 66.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -1.122 . . . . 0.0 109.712 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.686 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.4 tt -69.22 -33.46 73.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.665 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 138' ' ' SER . 3.9 mt -82.9 10.01 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.2 -0.937 . . . . 0.0 110.318 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.469 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 75.7 m -73.97 -22.6 59.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.996 -1.065 . . . . 0.0 108.887 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -127.77 1.42 6.86 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.832 ' O ' HD13 ' A' ' 145' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.718 0 O-C-N 120.85 -1.382 . . . . 0.0 110.015 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.781 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.231 0.539 . . . . 0.0 109.819 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -68.62 -58.49 4.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.717 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.521 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -50.15 -24.57 2.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.221 -0.924 . . . . 0.0 109.895 -179.773 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.521 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 50.1 tp60 -80.66 -41.39 23.88 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 109.493 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.781 HG23 ' O ' ' A' ' 5' ' ' ALA . 67.1 t -62.09 -24.54 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.9 HG12 HG13 ' A' ' 70' ' ' VAL . 89.1 t -66.84 -45.05 88.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.39 -0.819 . . . . 0.0 109.661 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.55 -11.35 60.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.296 -0.877 . . . . 0.0 110.193 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 m -92.7 -22.94 19.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.005 -1.06 . . . . 0.0 109.804 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.3 p -96.71 -10.52 26.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.249 -0.907 . . . . 0.0 110.131 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.767 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.74 -20.83 21.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.078 -1.014 . . . . 0.0 109.892 -179.801 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -79.19 -13.04 59.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.947 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -102.27 -47.87 4.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.089 -1.007 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.879 HD12 ' CH2' ' A' ' 130' ' ' TRP . 34.8 mt -70.81 -31.55 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -0.924 . . . . 0.0 109.745 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.856 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -106.96 33.88 3.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.915 . . . . 0.0 109.716 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.64 -71.82 0.62 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 76.5 p -110.65 -27.91 8.71 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.657 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.66 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.2 p-10 -79.01 -20.24 49.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 0.0 109.658 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.856 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 27.0 t30 55.67 24.09 6.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.584 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.17 24.57 12.47 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.66 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -66.1 -55.08 18.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -1.137 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -86.14 11.43 62.91 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.507 HG11 HD11 ' A' ' 63' ' ' LEU . 37.8 t -97.99 -29.65 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.115 -1.227 . . . . 0.0 109.338 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.458 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -89.91 -45.16 4.6 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.47 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 11.3 ptpt -56.19 -31.89 63.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.158 -1.201 . . . . 0.0 109.569 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.533 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 24.3 pt-20 -92.3 -16.67 25.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.929 . . . . 0.0 109.722 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.434 ' SG ' HD12 ' A' ' 110' ' ' LEU . 36.6 t -85.27 -67.67 0.78 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.205 -0.934 . . . . 0.0 109.809 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.601 ' HB3' HG13 ' A' ' 55' ' ' VAL . 10.4 m-85 -48.35 -29.13 3.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.247 -0.908 . . . . 0.0 109.935 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.426 ' N ' HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.06 -59.06 5.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.201 -0.937 . . . . 0.0 109.488 179.935 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 3.9 mttp -55.9 -53.15 60.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.261 -0.899 . . . . 0.0 109.717 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.679 ' CG ' HD23 ' A' ' 106' ' ' LEU . 8.9 t80 -49.34 -53.09 23.95 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.224 -0.922 . . . . 0.0 109.734 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.79 ' CD1' HG22 ' A' ' 55' ' ' VAL . 20.1 mt -54.23 -46.35 72.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.229 -0.919 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.08 -59.84 3.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.185 -0.947 . . . . 0.0 109.713 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.24 -23.66 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.669 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 25.0 m80 -120.79 95.83 4.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.688 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.5 m170 -82.76 6.03 19.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.244 -0.91 . . . . 0.0 110.02 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -97.48 -20.38 17.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.099 -1.001 . . . . 0.0 109.523 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.53 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 65.4 mmm -104.85 -19.84 13.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -0.896 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.458 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.08 -35.62 16.49 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 109.43 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.4 -27.54 46.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.304 -0.873 . . . . 0.0 109.099 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.103 HG22 ' ND2' ' A' ' 95' ' ' ASN . 32.3 t -66.71 -60.74 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.526 ' CD2' HD21 ' A' ' 35' ' ' LEU . 67.4 m-85 -51.29 -28.3 11.64 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.291 -0.881 . . . . 0.0 109.504 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.409 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.3 24.85 4.92 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 8.7 m-85 -121.86 166.24 14.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 110.066 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.8 t -106.0 -19.78 13.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.422 -0.799 . . . . 0.0 108.892 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.65 -162.5 19.64 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.88 15.5 23.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -1.118 . . . . 0.0 109.798 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 19.5 m -109.18 25.12 12.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.118 -0.989 . . . . 0.0 109.497 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.418 ' OD2' ' HB3' ' A' ' 47' ' ' PHE . 0.9 OUTLIER -118.87 140.59 28.79 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.33 -0.856 . . . . 0.0 109.543 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -69.55 -13.36 35.09 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.957 1.504 . . . . 0.0 110.509 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.537 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.49 -40.62 39.6 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.79 HG22 ' CD1' ' A' ' 35' ' ' LEU . 39.2 t -50.05 -45.92 23.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.321 -1.105 . . . . 0.0 109.55 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -61.8 -16.65 51.65 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.3 -36.64 39.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.915 . . . . 0.0 109.645 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.948 ' O ' HG23 ' A' ' 62' ' ' VAL . 11.5 mt -87.07 -60.03 2.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.157 -0.964 . . . . 0.0 109.638 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.458 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -46.9 -48.9 18.35 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.419 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -56.39 -38.58 71.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -1.166 . . . . 0.0 109.695 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -83.86 -29.9 26.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.663 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 58' ' ' LEU . 38.7 t -71.61 -47.87 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.305 -0.872 . . . . 0.0 109.652 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.507 HD11 HG11 ' A' ' 26' ' ' VAL . 1.9 mm? -48.99 -50.27 36.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 109.656 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.97 -44.97 20.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.363 -0.836 . . . . 0.0 110.017 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.406 ' HG3' ' SD ' ' A' ' 83' ' ' MET . 28.8 tp60 -57.72 -52.69 64.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.127 -0.983 . . . . 0.0 109.332 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.959 ' O ' HG23 ' A' ' 70' ' ' VAL . 96.1 mt -53.89 -36.65 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.184 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.51 -55.38 27.7 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.31 -23.17 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -1.141 . . . . 0.0 109.17 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.88 -23.24 25.31 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.413 -0.805 . . . . 0.0 109.579 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.3 t -72.76 -21.31 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.898 . . . . 0.0 109.757 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.442 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 53.9 m -88.67 39.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.154 -0.966 . . . . 0.0 109.975 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.451 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 16.2 m-70 -151.13 -62.1 0.18 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.097 -1.002 . . . . 0.0 109.908 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.545 HD22 ' H ' ' A' ' 73' ' ' LEU . 4.4 mm? . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.191 0.519 . . . . 0.0 110.638 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.451 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 41.4 ttp . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.289 0.566 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.421 ' HA ' ' HB1' ' A' ' 140' ' ' ALA . 90.6 t -83.26 -17.52 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.593 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.77 -30.6 45.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.578 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.471 ' HG3' ' N ' ' A' ' 83' ' ' MET . 23.9 pt-20 -86.17 -42.65 13.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.669 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.545 ' HE1' HD12 ' A' ' 141' ' ' LEU . 92.0 mmm -63.93 -35.29 80.17 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.011 -1.056 . . . . 0.0 108.845 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.874 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -52.62 -37.23 57.99 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.029 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.438 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -69.06 -27.36 65.56 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -74.88 -46.56 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.816 . . . . 0.0 108.962 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.446 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -63.93 -34.7 90.63 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.874 HG23 ' O ' ' A' ' 84' ' ' LYS . 53.3 t -58.9 -37.2 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.356 -1.085 . . . . 0.0 109.206 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.438 ' HG2' ' O ' ' A' ' 85' ' ' ALA . 17.3 mmm180 -64.76 -31.13 72.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.01 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.747 ' HB2' HD12 ' A' ' 145' ' ' LEU . 52.5 m80 -77.38 -2.6 35.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.427 -0.796 . . . . 0.0 109.897 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.8 ttmt -98.07 64.38 1.67 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.077 -1.014 . . . . 0.0 109.638 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.416 ' O ' ' O ' ' A' ' 93' ' ' TYR . . . 147.28 2.6 0.5 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.314 -1.422 . . . . 0.0 111.772 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.554 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.8 m-85 -56.13 -167.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.38 -1.659 . . . . 0.0 110.022 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.55 -40.17 13.3 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.103 ' ND2' HG22 ' A' ' 44' ' ' VAL . 2.2 t-20 -59.38 -47.23 86.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.457 -1.025 . . . . 0.0 108.479 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.8 tttt 59.96 13.89 3.97 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.494 -0.754 . . . . 0.0 110.928 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.488 ' HB2' ' ND2' ' A' ' 95' ' ' ASN . 14.2 m-70 -131.6 44.08 2.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.046 -1.034 . . . . 0.0 108.923 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.587 HD12 ' O ' ' A' ' 90' ' ' HIS . 67.8 mt -78.97 154.96 4.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.46 -0.775 . . . . 0.0 110.01 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.467 ' CE ' ' O ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -145.34 148.83 33.83 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.81 0.814 . . . . 0.0 110.084 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.7 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -81.9 -16.99 48.76 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.555 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -60.82 -27.01 67.74 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.002 -1.061 . . . . 0.0 109.208 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.555 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 93.4 m-85 -83.41 -20.23 34.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.18 -0.95 . . . . 0.0 110.246 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.723 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.4 m-85 -59.38 -65.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.101 -0.999 . . . . 0.0 110.206 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -44.42 -60.13 3.21 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 110.872 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.522 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.1 Cg_endo -59.7 -26.56 82.56 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 123.827 1.435 . . . . 0.0 110.343 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.813 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.4 tm? -79.4 -19.18 50.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.113 -0.992 . . . . 0.0 109.444 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.93 -38.7 9.11 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.1 -54.11 48.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -1.171 . . . . 0.0 109.673 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.8 m -57.46 -26.16 60.79 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -0.905 . . . . 0.0 109.598 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.541 HD22 ' OH ' ' A' ' 134' ' ' TYR . 8.7 tt -69.41 -39.71 77.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.54 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.874 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.5 mt -58.71 -33.37 70.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.222 -0.924 . . . . 0.0 109.643 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.9 t -67.37 -27.92 67.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.18 -0.95 . . . . 0.0 109.66 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.533 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -83.28 -36.5 24.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.704 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.525 ' HE2' HD21 ' A' ' 110' ' ' LEU . 5.2 mmt -49.52 -42.86 44.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 109.864 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -51.99 -22.67 4.18 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.232 -0.918 . . . . 0.0 109.954 -179.72 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -68.59 -22.53 64.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.947 . . . . 0.0 110.004 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.497 ' CB ' HG23 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -93.29 -50.03 5.67 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.861 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.602 HD11 ' SD ' ' A' ' 122' ' ' MET . 13.2 pt -104.42 -36.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.151 -0.968 . . . . 0.0 109.439 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 122' ' ' MET . . . 42.81 -94.27 0.01 OUTLIER Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.036 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.67 -42.03 10.22 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -76.68 -17.38 59.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.04 -1.271 . . . . 0.0 109.697 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.602 ' SD ' HD11 ' A' ' 118' ' ' ILE . 4.8 tpt -72.52 92.48 1.49 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.137 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.791 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 8.3 p-10 -93.5 176.86 6.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 109.826 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.482 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -54.76 -50.1 69.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 109.759 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.791 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -54.7 -24.7 23.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.242 -0.911 . . . . 0.0 109.715 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.483 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.71 -51.24 11.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.956 . . . . 0.0 109.521 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 19.6 ptpt -71.66 -28.22 63.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.258 -0.901 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.453 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 35.7 t0 -78.89 -38.56 37.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.481 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -69.96 -45.71 66.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.449 -0.782 . . . . 0.0 109.444 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.879 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -72.97 -21.82 60.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.366 -0.834 . . . . 0.0 109.295 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.652 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -76.22 -23.94 54.61 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.155 -0.966 . . . . 0.0 109.091 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -99.03 -23.4 15.3 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.411 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.437 ' HB2' HG21 ' A' ' 10' ' ' VAL . . . -82.21 -37.35 26.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.39 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.541 ' OH ' HD22 ' A' ' 110' ' ' LEU . 4.8 m-30 -49.37 -27.87 4.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.285 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.4 -29.5 53.13 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 108.913 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.1 t0 -80.08 -44.2 20.45 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.431 -0.793 . . . . 0.0 109.205 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.453 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.0 mt -65.28 -55.48 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.076 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.69 -41.82 74.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.478 -0.764 . . . . 0.0 109.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.34 -52.17 33.55 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.421 ' HB1' ' HA ' ' A' ' 80' ' ' VAL . . . -53.68 -28.75 35.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -1.175 . . . . 0.0 109.791 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.899 HD23 ' O ' ' A' ' 141' ' ' LEU . 9.4 tt -71.47 -10.03 59.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.199 -0.938 . . . . 0.0 110.049 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.7 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.1 mm -91.01 38.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.039 -1.038 . . . . 0.0 109.919 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.43 ' HB3' ' HG2' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -115.52 -28.68 6.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.374 -0.829 . . . . 0.0 109.228 179.671 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.4 20.68 4.93 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.029 -1.629 . . . . 0.0 109.029 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.747 HD12 ' HB2' ' A' ' 90' ' ' HIS . 2.6 tt . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.277 -1.131 . . . . 0.0 109.794 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -74.78 -48.23 26.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.212 -0.93 . . . . 0.0 109.246 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.629 ' HG2' HD12 ' A' ' 73' ' ' LEU . 7.7 tmm_? -54.28 -42.93 70.58 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.046 -1.034 . . . . 0.0 108.765 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -52.14 -38.29 57.04 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.18 -0.95 . . . . 0.0 108.603 179.227 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 125' ' ' ALA . 44.8 t -72.71 -26.45 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.032 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 1.069 HG12 HG13 ' A' ' 70' ' ' VAL . 78.0 t -75.69 -45.68 38.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.515 -0.741 . . . . 0.0 109.153 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.59 -13.06 60.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 0.0 109.748 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 t -92.12 -28.57 17.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.125 -0.985 . . . . 0.0 109.829 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.4 HG21 ' HB1' ' A' ' 126' ' ' ALA . 7.2 p -90.83 -11.88 38.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.156 -0.965 . . . . 0.0 109.963 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.44 -21.73 21.77 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.073 -1.017 . . . . 0.0 109.532 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.7 mtpp -76.66 -3.61 38.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.226 -0.921 . . . . 0.0 109.679 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -109.51 -55.78 2.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.093 -1.005 . . . . 0.0 109.519 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.907 HD12 ' CH2' ' A' ' 130' ' ' TRP . 23.6 mt -60.55 -40.51 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.283 -0.886 . . . . 0.0 109.592 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.813 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -97.33 33.33 2.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.694 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.19 -80.04 0.07 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 54.2 p -112.02 12.98 20.7 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.22 -1.165 . . . . 0.0 109.829 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.744 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.4 p-10 -119.15 -17.07 9.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.086 -1.009 . . . . 0.0 109.791 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.813 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 25.3 t-20 55.88 29.26 13.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.671 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.415 ' HA3' ' CG ' ' A' ' 63' ' ' LEU . . . 90.88 23.28 30.72 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.744 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -61.45 -48.52 80.76 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.402 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -90.79 20.15 40.84 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.67 HG12 HD21 ' A' ' 63' ' ' LEU . 22.7 t -114.12 -17.69 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -1.123 . . . . 0.0 109.069 179.565 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -105.92 -25.57 6.43 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.5 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.3 ptpt -75.91 -33.43 59.9 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.288 -1.125 . . . . 0.0 109.558 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.84 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 1.1 pm0 -94.78 -13.88 25.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.181 -0.95 . . . . 0.0 109.722 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.415 ' HB2' ' OE2' ' A' ' 29' ' ' GLU . 32.0 t -88.33 -59.81 2.13 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -0.96 . . . . 0.0 109.562 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.525 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.1 m-85 -56.48 -29.17 61.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.153 -0.967 . . . . 0.0 109.533 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.69 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -54.66 -60.42 3.38 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.657 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.5 -50.62 62.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.704 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -50.68 -48.2 58.57 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.226 -0.921 . . . . 0.0 109.306 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.656 ' CD1' HG22 ' A' ' 55' ' ' VAL . 19.0 mt -58.26 -43.67 88.03 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.551 ' OG ' ' HB2' ' A' ' 50' ' ' ALA . 55.9 m -67.01 -69.1 0.33 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -0.936 . . . . 0.0 109.877 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.42 ' HB3' ' ND1' ' A' ' 38' ' ' HIS . . . -50.87 -24.19 3.38 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.25 -0.906 . . . . 0.0 109.921 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.42 ' ND1' ' HB3' ' A' ' 37' ' ' ALA . 11.6 m80 -128.17 106.69 9.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.141 -0.974 . . . . 0.0 109.957 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.6 m170 -85.64 -19.76 30.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.558 -0.714 . . . . 0.0 109.283 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -70.55 -16.23 62.85 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.311 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.473 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -101.61 -15.44 17.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.792 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.455 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.84 -66.31 0.55 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.006 . . . . 0.0 109.246 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -53.17 -24.62 11.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.92 . . . . 0.0 109.123 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.81 HG13 ' OD1' ' A' ' 95' ' ' ASN . 2.5 t -71.37 -56.25 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.7 m-85 -60.59 -24.96 65.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.335 -0.853 . . . . 0.0 109.528 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.53 26.81 5.75 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.2 m-85 -123.65 168.23 12.93 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.247 -1.149 . . . . 0.0 109.814 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -106.77 -18.16 14.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.24 -175.67 47.58 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB2' ' OG ' ' A' ' 36' ' ' SER . . . -63.66 -13.55 43.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.853 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.17 44.11 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -130.37 123.77 20.74 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.176 -0.952 . . . . 0.0 109.592 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -66.3 -22.94 52.42 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.886 1.466 . . . . 0.0 110.087 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.51 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.99 -29.93 28.97 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.69 HG11 HG23 ' A' ' 32' ' ' THR . 49.0 t -57.69 -42.69 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -1.165 . . . . 0.0 109.476 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -68.58 -19.53 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.243 -0.91 . . . . 0.0 109.553 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.68 -37.92 24.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.912 . . . . 0.0 109.426 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.591 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.2 mt -76.0 -65.99 0.84 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.925 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.525 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -47.34 -47.18 22.19 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -57.8 -38.14 75.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -1.171 . . . . 0.0 109.618 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -77.01 -28.42 54.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.918 . . . . 0.0 109.605 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 58' ' ' LEU . 47.8 t -80.45 -41.28 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 109.572 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.67 HD21 HG12 ' A' ' 26' ' ' VAL . 0.7 OUTLIER -47.71 -49.96 26.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.903 . . . . 0.0 109.906 179.895 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.579 ' HB2' ' OD1' ' A' ' 22' ' ' ASN . . . -49.38 -50.91 38.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.122 -0.986 . . . . 0.0 109.828 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 34.1 tp60 -49.1 -47.67 45.02 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.07 -1.019 . . . . 0.0 109.34 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.707 ' O ' HG23 ' A' ' 70' ' ' VAL . 24.3 mm -56.51 -45.71 82.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.362 -0.836 . . . . 0.0 108.963 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA3' ' CZ3' ' A' ' 14' ' ' TRP . . . -61.46 -51.02 60.57 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.7 t -57.57 -31.36 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -1.065 . . . . 0.0 109.705 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.615 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -82.21 -33.86 29.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.537 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.069 HG13 HG12 ' A' ' 10' ' ' VAL . 56.1 t -65.89 -18.95 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -75.05 -15.39 60.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 22.4 m-70 -115.46 -88.96 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.784 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.817 HD11 ' HA ' ' A' ' 70' ' ' VAL . 19.3 mt . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.425 -0.797 . . . . 0.0 109.975 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 31.0 ttp . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.298 0.571 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.423 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 38.8 t -76.28 -25.2 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.321 -0.862 . . . . 0.0 109.321 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.28 -44.69 84.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.361 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.668 ' O ' HG23 ' A' ' 86' ' ' VAL . 13.2 mt-10 -83.94 -44.58 14.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.37 -0.831 . . . . 0.0 109.309 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.643 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.0 OUTLIER -58.38 -58.57 7.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.306 179.777 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.423 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -52.05 -31.44 30.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.175 -0.953 . . . . 0.0 108.97 179.563 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.543 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -66.8 -45.51 78.14 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.36 -0.838 . . . . 0.0 109.023 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.668 HG23 ' O ' ' A' ' 82' ' ' GLU . 31.5 t -51.01 -47.68 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.307 -0.871 . . . . 0.0 109.193 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -53.65 -51.39 48.85 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 85.8 t -53.99 -35.34 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.321 -1.105 . . . . 0.0 109.006 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.526 ' HB3' ' CE1' ' A' ' 93' ' ' TYR . 5.4 mmm180 -70.6 -55.1 9.61 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.382 -0.823 . . . . 0.0 109.09 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.615 ' O ' HD12 ' A' ' 98' ' ' ILE . 12.4 m80 -52.31 -29.75 25.0 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.893 . . . . 0.0 108.971 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 ttmt -68.0 -9.97 49.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.486 -0.759 . . . . 0.0 110.124 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.55 51.36 0.7 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.526 ' CE1' ' HB3' ' A' ' 89' ' ' ARG . 3.2 m-30 -106.41 -167.02 1.24 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.176 -1.191 . . . . 0.0 109.66 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.0 -38.13 93.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.81 ' OD1' HG13 ' A' ' 44' ' ' VAL . 1.3 t-20 -78.96 -44.6 22.11 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.469 -1.018 . . . . 0.0 109.403 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.451 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.8 OUTLIER 71.94 -54.78 0.68 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 179.615 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.681 ' HB2' HD22 ' A' ' 95' ' ' ASN . 9.1 m170 -48.67 -87.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.097 -1.002 . . . . 0.0 109.944 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.615 HD12 ' O ' ' A' ' 90' ' ' HIS . 54.1 mt 59.48 156.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.714 . . . . 0.0 109.938 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.532 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.59 144.15 25.08 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 -179.841 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.41 -8.64 59.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.713 -0.617 . . . . 0.0 109.545 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -75.72 -21.54 57.44 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.101 -0.999 . . . . 0.0 109.375 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.532 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -84.94 -15.32 44.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.304 -0.872 . . . . 0.0 109.853 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.722 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.7 m-85 -63.26 -65.88 0.62 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.207 -0.933 . . . . 0.0 110.248 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.5 -59.0 3.71 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.516 -0.74 . . . . 0.0 111.087 -179.317 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 4.9 Cg_endo -52.59 -55.79 3.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.671 1.353 . . . . 0.0 110.06 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.957 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -58.66 -21.2 53.52 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.338 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.98 -47.95 17.51 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.74 -53.88 53.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.161 -1.199 . . . . 0.0 109.562 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.8 m -54.98 -25.27 28.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.204 -0.935 . . . . 0.0 109.564 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.796 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -64.66 -37.04 86.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.666 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.74 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -64.7 -42.55 95.2 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -65.1 -23.14 67.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.749 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.84 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.24 -38.65 18.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.95 . . . . 0.0 109.693 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.796 ' SD ' HD23 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -53.16 -44.69 68.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.815 -179.861 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.481 ' HG2' ' CB ' ' A' ' 122' ' ' MET . 12.2 mt-10 -47.47 -28.35 2.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.243 -0.911 . . . . 0.0 109.668 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.464 ' N ' ' CD2' ' A' ' 116' ' ' HIS . 15.7 m170 -57.81 -27.07 62.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -0.997 . . . . 0.0 109.817 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.442 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -90.25 -65.59 1.0 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.252 -0.905 . . . . 0.0 109.871 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.741 HG23 HG12 ' A' ' 17' ' ' ILE . 41.8 pt -87.51 -37.48 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 109.496 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.503 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 40.91 -93.47 0.01 OUTLIER Glycine 0 N--CA 1.497 2.76 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -42.9 -41.43 4.54 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.496 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 34.6 mmtt -76.23 -28.24 57.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.13 -1.218 . . . . 0.0 109.748 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.481 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -59.21 102.01 0.12 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.173 -0.955 . . . . 0.0 109.317 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.731 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 9.2 p-10 -98.62 -178.7 4.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.244 -0.91 . . . . 0.0 109.772 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.05 -43.27 99.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 109.761 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.731 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -65.03 -24.38 67.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.094 -1.004 . . . . 0.0 109.306 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.505 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -72.67 -48.71 36.89 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.325 -0.859 . . . . 0.0 109.432 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.513 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.8 ptpt -73.39 -29.75 62.82 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.258 -0.901 . . . . 0.0 109.671 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.513 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 12.5 t0 -75.15 -38.34 61.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.192 -0.942 . . . . 0.0 109.273 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.633 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -66.63 -43.88 83.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -0.825 . . . . 0.0 109.104 179.559 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.907 ' CH2' HD12 ' A' ' 17' ' ' ILE . 11.1 m0 -73.58 -32.75 64.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.312 -0.868 . . . . 0.0 109.192 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.539 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -47.64 -27.68 2.01 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.271 -0.893 . . . . 0.0 109.414 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -108.69 -14.72 14.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.399 -0.813 . . . . 0.0 109.665 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.674 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -73.49 -69.13 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.957 . . . . 0.0 110.153 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.599 ' HA ' HD12 ' A' ' 137' ' ' ILE . 11.6 p90 -58.31 -20.14 40.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.844 -1.16 . . . . 0.0 109.127 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.423 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -73.61 -40.85 63.51 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.241 -0.912 . . . . 0.0 108.893 179.315 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.63 -30.52 56.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.352 -0.843 . . . . 0.0 109.055 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.643 HG23 ' SD ' ' A' ' 83' ' ' MET . 58.5 mt -68.28 -59.99 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.401 -0.812 . . . . 0.0 109.151 179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -57.56 -18.77 21.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.347 -0.846 . . . . 0.0 109.714 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.74 -52.2 21.31 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.47 -25.82 17.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.27 -1.135 . . . . 0.0 109.744 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.829 HD23 ' O ' ' A' ' 141' ' ' LEU . 7.3 tt -74.05 -11.58 60.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -0.912 . . . . 0.0 110.016 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.673 HG22 ' O ' ' A' ' 142' ' ' ILE . 98.3 mt -91.53 21.47 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.081 -1.012 . . . . 0.0 109.714 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -109.6 -20.35 12.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.156 -0.965 . . . . 0.0 109.83 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.14 -22.63 3.78 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.489 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 3.4 tp . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.11 -1.23 . . . . 0.0 109.77 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.959 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.16 0.505 . . . . 0.0 110.044 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.517 ' O ' HG23 ' A' ' 10' ' ' VAL . 37.8 mt-30 -60.98 -56.34 22.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.671 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.58 ' HA ' HD12 ' A' ' 73' ' ' LEU . 9.7 ttp180 -51.86 -26.22 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.141 -0.975 . . . . 0.0 109.598 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 39.3 tp60 -85.27 -49.35 8.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 5' ' ' ALA . 41.5 t -52.05 -28.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.267 -0.896 . . . . 0.0 109.687 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.892 HG11 HD11 ' A' ' 73' ' ' LEU . 84.8 t -64.99 -53.68 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.898 . . . . 0.0 109.624 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.83 -17.6 64.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.3 -32.6 38.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.181 -0.949 . . . . 0.0 109.698 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.428 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 41.0 p -94.54 -11.57 29.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.66 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.06 -18.09 31.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.047 -1.033 . . . . 0.0 109.873 -179.825 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -85.65 -15.64 41.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.167 -0.958 . . . . 0.0 109.608 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -96.64 -53.83 3.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.51 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.98 HD12 ' CH2' ' A' ' 130' ' ' TRP . 62.0 mt -68.49 -43.12 84.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.285 -0.884 . . . . 0.0 109.508 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.594 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -100.43 34.99 2.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.375 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.73 -86.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.3 p -106.95 13.59 27.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.238 -1.154 . . . . 0.0 110.066 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.444 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 3.2 p30 -122.59 -9.84 8.41 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.121 -0.987 . . . . 0.0 110.177 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.615 HD21 ' HB2' ' A' ' 64' ' ' ALA . 6.7 t30 57.06 18.36 3.99 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.271 -0.893 . . . . 0.0 109.584 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.425 ' O ' ' HB ' ' A' ' 26' ' ' VAL . . . 85.76 32.63 17.9 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.25 -47.81 80.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.189 -1.183 . . . . 0.0 109.18 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.44 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -85.72 9.48 68.26 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.466 HG21 ' CG2' ' A' ' 17' ' ' ILE . 9.2 t -95.48 -39.27 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.135 -1.215 . . . . 0.0 109.353 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -81.89 -51.81 4.35 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.9 ptpt -50.39 -30.97 13.57 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.202 -1.175 . . . . 0.0 109.604 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.761 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 22.3 pt-20 -89.48 -22.43 22.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.444 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.7 t -86.98 -39.6 15.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.343 -0.848 . . . . 0.0 109.645 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 10.1 m-85 -75.37 -42.21 54.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.879 . . . . 0.0 109.857 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.613 ' OG1' HG11 ' A' ' 55' ' ' VAL . 20.4 m -51.69 -49.05 63.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.089 -1.007 . . . . 0.0 109.394 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.9 . . . . 0.0 109.434 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.737 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.6 t80 -65.09 -46.76 79.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.676 HD13 HG22 ' A' ' 55' ' ' VAL . 10.8 mt -59.94 -47.6 85.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.418 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 3.0 t -61.17 -57.78 11.05 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.173 -0.954 . . . . 0.0 109.783 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.91 -27.28 68.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.183 -0.948 . . . . 0.0 109.841 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 19.9 m80 -121.93 105.61 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 109.781 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -87.2 -18.96 29.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.378 -0.826 . . . . 0.0 109.405 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -68.85 -19.08 64.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.905 . . . . 0.0 109.509 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.42 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 73.9 mmm -106.51 -23.61 12.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.288 -0.883 . . . . 0.0 109.712 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.46 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.96 -42.92 39.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.117 -0.989 . . . . 0.0 109.57 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.78 -28.19 60.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.31 -0.868 . . . . 0.0 109.255 179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.866 HG13 ' OD1' ' A' ' 95' ' ' ASN . 38.0 t -66.37 -49.46 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.332 -0.855 . . . . 0.0 109.424 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 50.6 m-85 -62.06 -30.93 71.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.739 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.19 31.68 2.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.041 -1.623 . . . . 0.0 109.041 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.0 m-85 -125.79 173.07 9.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.36 -1.082 . . . . 0.0 109.746 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.61 20.9 13.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.865 . . . . 0.0 109.301 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.54 -161.95 27.35 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.453 ' HB1' HG23 ' A' ' 32' ' ' THR . . . -92.5 29.46 1.72 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -1.134 . . . . 0.0 109.66 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.3 p -125.92 26.79 6.51 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.73 138.43 22.09 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.614 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -69.29 -25.43 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.962 1.507 . . . . 0.0 110.069 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' A' ' 57' ' ' ASP . . . -57.61 -31.49 63.7 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.676 HG22 HD13 ' A' ' 35' ' ' LEU . 70.2 t -53.85 -34.87 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.269 -1.136 . . . . 0.0 109.532 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.563 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.25 -7.48 58.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.316 -0.865 . . . . 0.0 109.856 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.403 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 7.7 m-20 -88.81 -38.77 14.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.72 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.63 ' O ' HG23 ' A' ' 62' ' ' VAL . 8.9 mt -74.81 -63.63 1.21 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 0.0 109.514 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.844 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -49.77 -34.57 21.99 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.563 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -68.04 -49.62 60.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.235 -1.156 . . . . 0.0 109.467 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -71.69 -44.07 64.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.376 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.63 HG23 ' O ' ' A' ' 58' ' ' LEU . 83.6 t -55.96 -51.47 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.629 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.844 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -46.45 -49.53 18.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.238 -0.913 . . . . 0.0 110.169 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.615 ' HB2' HD21 ' A' ' 22' ' ' ASN . . . -54.25 -39.01 66.43 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.089 -1.007 . . . . 0.0 109.907 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 23.5 tp60 -56.74 -39.49 74.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.992 -1.067 . . . . 0.0 108.931 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.986 ' O ' HG23 ' A' ' 70' ' ' VAL . 89.9 mt -66.98 -34.85 72.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.423 -0.798 . . . . 0.0 108.863 179.354 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.57 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.07 -51.34 45.75 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.74 -27.6 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.267 -1.137 . . . . 0.0 108.796 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.7 -27.38 27.07 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.634 -0.666 . . . . 0.0 109.507 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.986 HG23 ' O ' ' A' ' 66' ' ' ILE . 40.9 t -58.81 -17.28 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.32 -0.862 . . . . 0.0 109.7 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.441 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 1.2 t -56.15 -43.49 78.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.926 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.441 ' ND1' ' O ' ' A' ' 71' ' ' SER . 33.4 m-70 -138.73 102.73 4.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 0.0 109.979 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.936 HD21 ' HA ' ' A' ' 70' ' ' VAL . 36.1 mt . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.28 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.511 ' SD ' HG23 ' A' ' 80' ' ' VAL . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.199 0.524 . . . . 0.0 109.667 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.511 HG23 ' SD ' ' A' ' 79' ' ' MET . 75.4 t -63.8 -15.56 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.712 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -80.01 -12.95 59.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.124 -0.985 . . . . 0.0 109.875 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.428 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.6 tp10 -99.44 -48.13 4.89 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.71 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.407 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 97.6 mmm -59.78 -44.91 93.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.152 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.679 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.04 -30.55 15.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.209 -0.932 . . . . 0.0 108.786 179.238 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -82.45 -36.38 26.63 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.498 -0.751 . . . . 0.0 109.112 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.443 ' CG1' HD12 ' A' ' 141' ' ' LEU . 89.2 t -59.22 -51.59 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.277 -0.889 . . . . 0.0 109.334 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.481 ' N ' ' HG ' ' A' ' 141' ' ' LEU . . . -53.06 -48.65 58.09 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.629 -1.789 . . . . 0.0 108.629 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 84' ' ' LYS . 99.0 t -47.38 -27.94 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.49 -1.006 . . . . 0.0 109.645 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.521 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 17.5 mmt180 -70.27 -42.72 71.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.128 -0.983 . . . . 0.0 108.804 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.477 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 12.3 m80 -65.56 -12.42 52.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.438 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 0.2 OUTLIER -68.1 -13.21 62.03 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.327 -0.858 . . . . 0.0 110.399 -179.667 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.75 58.99 0.38 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.462 -1.352 . . . . 0.0 110.098 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.521 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 3.6 m-30 -92.32 -172.46 3.11 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.158 -1.201 . . . . 0.0 109.241 179.212 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.36 -34.77 90.8 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.507 -1.837 . . . . 0.0 108.507 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.866 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -82.94 -58.94 2.66 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.541 -0.976 . . . . 0.0 108.924 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.483 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 3.0 pttt 79.45 -19.82 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.774 -0.579 . . . . 0.0 111.02 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.623 ' HB2' HD22 ' A' ' 95' ' ' ASN . 5.7 m170 -92.24 40.64 1.05 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.666 -1.271 . . . . 0.0 109.44 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.456 HD13 ' CD2' ' A' ' 90' ' ' HIS . 65.3 mt -72.77 164.27 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.363 -0.836 . . . . 0.0 109.754 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.438 ' N ' HG22 ' A' ' 98' ' ' ILE . 0.1 OUTLIER -145.07 141.79 29.15 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.349 -0.844 . . . . 0.0 109.889 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.97 5.28 16.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 46.4 mm-40 -83.99 -32.63 24.86 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.99 -1.069 . . . . 0.0 109.463 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.439 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 95.6 m-85 -75.72 -10.73 59.68 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.275 -0.891 . . . . 0.0 109.958 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.843 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.1 m-85 -62.93 -61.31 2.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.157 -0.964 . . . . 0.0 110.176 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -50.22 -55.58 24.07 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 109.881 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 32.3 Cg_exo -51.05 -62.68 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 123.712 1.375 . . . . 0.0 109.934 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.962 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.75 -24.45 35.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.54 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.74 -45.51 12.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.64 -38.59 87.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -1.188 . . . . 0.0 109.652 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -20.49 64.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.531 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.493 HD22 ' HE2' ' A' ' 134' ' ' TYR . 1.9 tt -74.58 -39.69 62.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.695 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.811 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -62.73 -30.06 71.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.258 -0.901 . . . . 0.0 109.558 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.7 t -72.53 -25.27 61.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.289 -0.882 . . . . 0.0 109.764 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.761 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.06 -38.76 18.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.244 -0.91 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.648 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.9 mmt -46.66 -45.07 19.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.33 -0.856 . . . . 0.0 110.055 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -49.21 -25.2 2.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 109.611 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.471 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 26.5 m170 -57.46 -37.43 72.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.574 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.51 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 2.1 ttt85 -83.89 -70.41 0.57 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.699 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.476 HG23 HG12 ' A' ' 17' ' ' ILE . 14.1 pt -82.44 53.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.173 -0.954 . . . . 0.0 109.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -59.43 123.78 34.4 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.32 -36.81 3.82 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.425 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 15.6 mtpt -84.58 -30.73 24.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.27 -1.135 . . . . 0.0 109.399 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.37 81.63 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.329 -0.857 . . . . 0.0 109.446 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.583 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.1 p30 -86.8 -168.68 2.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.754 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.446 ' O ' ' CB ' ' A' ' 128' ' ' ASP . . . -64.3 -46.21 84.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.489 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.782 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.28 -24.38 54.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.276 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.48 -58.36 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.548 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.2 OUTLIER -68.49 -25.85 65.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.588 -179.823 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 124' ' ' ALA . 25.0 t70 -80.75 -39.71 26.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.543 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.93 -41.82 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.848 . . . . 0.0 109.279 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.98 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.8 m0 -73.74 -24.52 59.9 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.163 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.548 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -74.04 -24.52 59.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.192 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.58 -40.58 12.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.858 . . . . 0.0 109.458 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.783 ' CB ' HD13 ' A' ' 73' ' ' LEU . . . -70.97 -45.58 63.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.399 -0.813 . . . . 0.0 109.537 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.493 ' HE2' HD22 ' A' ' 110' ' ' LEU . 3.2 m-85 -50.08 -32.15 14.93 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.908 . . . . 0.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.88 -37.11 70.21 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.19 -0.944 . . . . 0.0 108.866 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.17 -33.0 44.42 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.38 -0.825 . . . . 0.0 109.231 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.761 HD13 HG23 ' A' ' 66' ' ' ILE . 24.9 mt -65.77 -60.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.334 -0.854 . . . . 0.0 108.833 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.413 ' O ' HG13 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -66.93 -37.39 84.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.589 -0.694 . . . . 0.0 109.669 -179.775 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -52.44 -44.9 59.16 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.31 -18.36 64.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.21 -1.171 . . . . 0.0 109.82 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.843 HD22 ' CE2' ' A' ' 103' ' ' PHE . 6.7 tt -87.73 -23.77 24.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 109.78 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.493 HD12 ' HA2' ' A' ' 139' ' ' GLY . 50.9 mt -82.68 8.03 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 0.0 110.275 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -86.95 -35.92 18.61 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.008 -1.058 . . . . 0.0 109.502 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.417 ' O ' ' HD3' ' A' ' 91' ' ' LYS . . . -104.43 5.85 45.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.477 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 1.5 tt . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.075 -1.25 . . . . 0.0 109.19 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.228 0.537 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -84.98 -46.21 11.44 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.218 -0.926 . . . . 0.0 109.735 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.466 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 4.3 ptm180 -51.7 -32.06 28.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.466 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 5.5 mm100 -70.2 -47.62 60.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.215 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.765 HG11 ' O ' ' A' ' 125' ' ' ALA . 80.9 t -56.44 -30.75 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.285 -0.884 . . . . 0.0 109.176 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.884 HG12 HG13 ' A' ' 70' ' ' VAL . 83.1 t -64.14 -55.02 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -0.836 . . . . 0.0 109.221 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.9 -14.04 62.64 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.613 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.5 m -84.44 -27.18 27.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.15 -0.969 . . . . 0.0 109.724 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.471 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 25.3 p -98.94 -7.2 27.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.152 -0.967 . . . . 0.0 109.69 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -89.27 -21.48 23.18 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.151 -0.968 . . . . 0.0 109.646 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.3 mtpm? -79.31 2.31 21.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 110.092 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -116.45 -54.4 2.46 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.06 -1.025 . . . . 0.0 109.525 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.808 HD12 ' CH2' ' A' ' 130' ' ' TRP . 43.2 mt -66.49 -32.25 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.292 -0.88 . . . . 0.0 109.518 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.651 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -105.92 35.39 2.92 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.713 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.7 -81.57 0.05 OUTLIER Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 p -108.78 -34.86 6.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -1.128 . . . . 0.0 109.58 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.516 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 37.8 p30 -75.91 -15.05 60.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.909 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.651 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.8 t30 63.18 16.0 9.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.147 -0.971 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.474 ' O ' HD12 ' A' ' 63' ' ' LEU . . . 100.11 17.36 25.21 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.516 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -50.07 -36.81 30.76 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.094 -1.239 . . . . 0.0 109.774 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.454 ' HA2' ' CE ' ' A' ' 28' ' ' LYS . . . -92.97 13.61 67.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 30' ' ' CYS . 54.5 t -95.4 -28.3 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.045 -1.268 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.438 ' HA2' ' HB3' ' A' ' 30' ' ' CYS . . . -91.47 -44.52 4.28 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.475 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 10.8 ptpt -51.61 -33.66 34.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.195 -1.179 . . . . 0.0 109.089 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.87 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 19.0 pt-20 -91.44 -29.41 17.05 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.218 -0.926 . . . . 0.0 109.243 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.438 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 18.0 t -84.83 -68.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 110.065 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.608 ' HZ ' HG11 ' A' ' 62' ' ' VAL . 22.1 m-85 -45.94 -32.6 2.8 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.564 -178.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.725 ' OG1' HG11 ' A' ' 55' ' ' VAL . 5.6 m -59.04 -52.16 66.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.929 -1.107 . . . . 0.0 109.124 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 36.3 mttt -55.44 -48.21 74.8 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.069 -1.019 . . . . 0.0 109.311 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.515 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.9 t80 -54.83 -54.48 41.74 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.31 -0.869 . . . . 0.0 109.336 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.745 ' CD1' HG22 ' A' ' 55' ' ' VAL . 46.0 mt -55.39 -43.29 75.05 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.64 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -68.17 0.37 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.679 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.37 -30.09 37.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.214 -0.929 . . . . 0.0 109.626 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.403 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 9.2 m80 -115.2 99.84 7.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.754 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -82.3 -14.4 55.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.453 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -74.21 -13.78 60.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.152 -0.968 . . . . 0.0 109.62 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.474 ' SD ' HG11 ' A' ' 44' ' ' VAL . 2.6 mmt -104.83 -27.34 11.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.13 -0.981 . . . . 0.0 109.91 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.664 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -48.24 -41.53 27.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.037 -1.039 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.43 -26.02 59.81 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -0.85 . . . . 0.0 108.782 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.874 HG13 ' OD1' ' A' ' 95' ' ' ASN . 2.9 t -72.61 -47.34 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.832 ' HD2' HD13 ' A' ' 58' ' ' LEU . 25.0 m-85 -65.61 -32.74 74.49 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.874 . . . . 0.0 109.47 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.14 27.94 3.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.544 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.6 m-85 -123.21 172.95 8.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.21 -1.17 . . . . 0.0 109.828 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.56 19.51 16.78 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.371 -0.83 . . . . 0.0 109.215 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 151.83 -163.8 30.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB1' HG23 ' A' ' 32' ' ' THR . . . -98.74 36.24 1.7 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -1.171 . . . . 0.0 109.704 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 67.3 p -147.46 28.94 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.613 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 54' ' ' GLY . 0.4 OUTLIER -108.15 143.62 27.76 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.639 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -65.95 70.27 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.998 1.525 . . . . 0.0 110.059 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.524 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -155.19 -43.56 0.02 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.745 HG22 ' CD1' ' A' ' 35' ' ' LEU . 61.6 t -53.0 -40.1 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.357 -1.084 . . . . 0.0 109.496 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.62 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -63.93 -20.31 65.76 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.487 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.55 -57.76 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.301 -0.875 . . . . 0.0 109.236 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.832 HD13 ' HD2' ' A' ' 45' ' ' PHE . 0.4 OUTLIER -57.56 -63.3 1.28 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.462 -0.774 . . . . 0.0 110.28 -179.85 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.585 ' O ' HD13 ' A' ' 63' ' ' LEU . . . -54.59 -21.7 22.24 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.203 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.674 ' HA ' HD11 ' A' ' 63' ' ' LEU . . . -83.94 -6.12 59.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.126 -1.22 . . . . 0.0 110.684 -179.28 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 56.9 mttt -113.19 -12.3 13.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.972 -1.08 . . . . 0.0 110.002 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.608 HG11 ' HZ ' ' A' ' 31' ' ' PHE . 93.4 t -83.2 -25.65 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.099 -1.001 . . . . 0.0 110.68 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.674 HD11 ' HA ' ' A' ' 60' ' ' ALA . 0.0 OUTLIER -70.28 -4.8 23.66 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.706 -1.246 . . . . 0.0 110.697 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.479 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -85.16 -42.45 14.72 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.834 -1.166 . . . . 0.0 109.559 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.435 ' OE1' HG21 ' A' ' 86' ' ' VAL . 2.8 mm-40 -56.57 -47.99 78.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.107 -0.996 . . . . 0.0 108.807 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.919 ' O ' HG23 ' A' ' 70' ' ' VAL . 80.1 mt -57.32 -34.69 46.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.252 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.582 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.85 -57.26 12.66 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.1 t -57.33 -23.7 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.267 -1.137 . . . . 0.0 109.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.45 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -86.71 -27.88 23.43 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.447 -0.783 . . . . 0.0 109.582 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.919 HG23 ' O ' ' A' ' 66' ' ' ILE . 54.5 t -70.46 -12.39 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.181 -0.949 . . . . 0.0 109.826 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.0 t -82.58 6.63 17.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.033 . . . . 0.0 110.061 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.471 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 23.9 m-70 -140.08 -88.88 0.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.004 -1.06 . . . . 0.0 109.685 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.572 HD11 ' HA ' ' A' ' 70' ' ' VAL . 29.8 mt . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.468 -0.77 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.471 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 17.2 tmm? . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.266 0.555 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.424 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 69.3 t -71.04 -20.27 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.63 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.29 74.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.712 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.471 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 17.5 mt-10 -76.7 -53.45 7.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.574 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.8 mtp -53.31 -41.07 65.28 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.201 -0.937 . . . . 0.0 109.435 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.525 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.7 OUTLIER -52.17 -31.88 33.43 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.175 -0.953 . . . . 0.0 108.723 179.24 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.3 -36.75 71.74 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.665 ' CG1' HD11 ' A' ' 141' ' ' LEU . 45.5 t -56.89 -51.75 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.199 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -51.8 -46.75 54.38 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.856 -1.698 . . . . 0.0 108.856 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 84' ' ' LYS . 60.8 t -50.41 -25.75 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -1.173 . . . . 0.0 109.292 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.474 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 0.2 OUTLIER -81.3 -53.3 6.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.325 -0.859 . . . . 0.0 108.743 179.352 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.672 ' HB2' HD13 ' A' ' 145' ' ' LEU . 21.1 m80 -54.72 -21.91 12.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.053 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 91' ' ' LYS . 34.0 ttpt -67.69 -12.93 61.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.448 -0.782 . . . . 0.0 110.243 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.07 55.58 0.55 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.512 ' OH ' ' CE1' ' A' ' 90' ' ' HIS . 3.8 m-30 -89.59 -100.23 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.322 -1.105 . . . . 0.0 109.645 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.44 -50.05 0.02 OUTLIER Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.066 -2.013 . . . . 0.0 108.066 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.874 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.1 OUTLIER -67.17 -30.44 70.41 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.489 -1.006 . . . . 0.0 108.521 178.934 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 43.5 mttt 51.98 22.24 1.75 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.636 -0.665 . . . . 0.0 109.805 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.2 m170 -128.64 49.48 2.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.338 -0.851 . . . . 0.0 109.149 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.469 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 76.3 mt -84.93 158.74 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.857 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.511 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -142.02 144.91 33.87 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.356 -0.84 . . . . 0.0 109.983 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.708 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -80.98 -15.86 55.07 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.679 -0.638 . . . . 0.0 109.36 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 54.3 mm-40 -67.86 -22.38 65.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.128 -0.983 . . . . 0.0 109.471 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.511 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -86.32 -26.39 24.93 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 109.79 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.812 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.7 m-85 -51.28 -59.06 4.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.23 -0.919 . . . . 0.0 110.281 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.506 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -54.65 -58.78 12.67 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.203 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.506 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.4 Cg_exo -48.25 -53.13 7.18 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 O-C-N 123.639 1.337 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.93 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -59.48 -18.0 36.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -0.941 . . . . 0.0 109.858 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -83.99 -42.56 7.56 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.71 -57.78 9.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.078 -1.248 . . . . 0.0 109.684 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.5 t -60.66 -16.25 37.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.778 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.981 HD21 ' CE ' ' A' ' 114' ' ' MET . 3.2 tt -78.53 -36.42 44.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.075 -1.016 . . . . 0.0 109.715 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.837 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -64.36 -28.78 69.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.069 -1.019 . . . . 0.0 109.423 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.427 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 14.1 t -66.63 -35.22 79.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.699 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.87 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -80.29 -31.63 38.22 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.655 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.981 ' CE ' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.35 -38.09 12.34 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.019 -179.92 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.471 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.9 OUTLIER -62.65 -14.0 38.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.074 -1.017 . . . . 0.0 109.705 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.545 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.9 m170 -53.9 -37.54 63.88 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.911 -1.118 . . . . 0.0 109.443 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.475 ' HB3' HG12 ' A' ' 17' ' ' ILE . 1.1 ttt85 -89.81 -51.62 5.4 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.2 -0.938 . . . . 0.0 109.82 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.435 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 2.8 pt -110.04 48.73 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.161 -0.962 . . . . 0.0 109.897 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -59.57 -18.29 44.08 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.17 -30.61 9.14 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.7 mtpp -94.47 -25.81 16.73 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.164 -1.198 . . . . 0.0 109.537 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 1.8 tpt -61.09 96.73 0.05 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.889 . . . . 0.0 109.431 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -106.14 -162.54 0.87 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.744 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -67.08 -46.25 74.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.355 -0.841 . . . . 0.0 110.134 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.765 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -63.58 -21.55 66.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.074 -1.016 . . . . 0.0 109.779 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.4 -47.15 14.83 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.177 -0.952 . . . . 0.0 109.563 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.573 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 17.6 ptpt -74.02 -30.68 62.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -0.891 . . . . 0.0 109.685 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.454 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -73.94 -53.34 10.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.93 . . . . 0.0 109.738 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.549 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -55.09 -43.41 73.97 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.35 -0.844 . . . . 0.0 109.71 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.837 ' HB3' HD21 ' A' ' 111' ' ' LEU . 7.5 m0 -76.09 -27.15 57.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.245 -0.909 . . . . 0.0 109.565 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.573 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.26 -30.42 68.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.169 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.78 -26.39 21.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.38 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -82.06 -48.38 11.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.517 ' CE2' ' HE2' ' A' ' 114' ' ' MET . 9.1 m-30 -52.42 -31.01 32.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.293 -0.88 . . . . 0.0 109.337 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.75 -46.39 63.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -0.875 . . . . 0.0 109.219 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -73.91 -30.53 62.64 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.312 -0.867 . . . . 0.0 109.221 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.663 HD13 HG23 ' A' ' 66' ' ' ILE . 59.4 mt -67.98 -60.78 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.314 -0.866 . . . . 0.0 108.973 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 3.6 m -66.96 -31.47 72.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.487 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.16 -38.41 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.17 -23.74 66.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -1.141 . . . . 0.0 109.528 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.849 HD23 ' O ' ' A' ' 141' ' ' LEU . 10.0 tt -76.34 -2.39 31.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 110.116 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.708 HD12 ' HB2' ' A' ' 100' ' ' ALA . 40.6 mm -92.15 31.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.961 -1.087 . . . . 0.0 109.902 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.465 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -108.73 -34.23 6.75 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.283 -0.885 . . . . 0.0 109.381 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.79 21.89 7.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.672 HD13 ' HB2' ' A' ' 90' ' ' HIS . 14.3 tp . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.345 -1.091 . . . . 0.0 110.004 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.861 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.257 0.551 . . . . 0.0 109.683 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -71.24 -55.45 8.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 2.8 ptm180 -50.92 -32.36 20.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.447 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.458 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 9.4 tp-100 -70.29 -39.01 75.13 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.294 -0.879 . . . . 0.0 109.349 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.861 HG23 ' O ' ' A' ' 5' ' ' ALA . 22.0 t -69.38 -27.63 35.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.453 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 1.055 HG12 HG13 ' A' ' 70' ' ' VAL . 97.2 t -71.95 -37.96 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.596 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.98 -14.75 60.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.855 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 t -90.87 -25.62 19.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -93.56 -12.41 29.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 109.952 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.739 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.21 -24.31 21.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.084 -1.01 . . . . 0.0 109.788 -179.842 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -75.23 -8.37 56.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.406 ' HB3' HG21 ' A' ' 118' ' ' ILE . 1.8 m-20 -103.7 -54.06 2.65 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.085 -1.009 . . . . 0.0 109.68 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.917 HD12 ' CH2' ' A' ' 130' ' ' TRP . 46.4 mt -65.79 -36.67 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.246 -0.909 . . . . 0.0 109.712 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.939 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.69 33.56 3.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.778 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.09 -66.98 2.36 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 88.3 p -115.61 -19.64 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -1.134 . . . . 0.0 109.558 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.809 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 7.5 p-10 -87.17 -19.08 28.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.894 . . . . 0.0 109.654 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.939 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.2 t30 58.57 22.89 10.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.05 23.69 10.4 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.809 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -70.45 -43.43 69.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -1.159 . . . . 0.0 109.603 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.423 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -88.39 14.46 59.44 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.624 HG11 HD11 ' A' ' 63' ' ' LEU . 44.0 t -108.64 -26.15 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -1.228 . . . . 0.0 109.317 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -97.36 -36.86 4.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.478 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.0 ptpt -66.41 -29.07 69.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.176 -1.191 . . . . 0.0 109.554 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.478 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 13.1 pt-20 -93.86 -20.34 20.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -0.935 . . . . 0.0 109.675 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.0 t -88.25 -59.86 2.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.234 -0.916 . . . . 0.0 109.866 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.8 m-85 -54.48 -30.11 52.16 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 109.81 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.96 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -55.32 -58.47 7.57 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.162 -0.961 . . . . 0.0 109.336 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -54.31 -45.29 72.55 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.878 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.788 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -56.36 -59.09 5.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.962 . . . . 0.0 109.286 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.838 ' CD1' HG22 ' A' ' 55' ' ' VAL . 26.6 mt -51.15 -43.71 61.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 109.632 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.467 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 2.6 t -68.82 -71.27 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.911 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -49.52 -29.89 7.52 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.888 . . . . 0.0 109.787 -179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 11.9 m80 -117.85 107.49 14.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.266 -0.896 . . . . 0.0 109.944 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -86.59 -25.4 24.98 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.475 -0.765 . . . . 0.0 108.967 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -66.97 -21.62 65.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.229 -0.919 . . . . 0.0 108.931 179.117 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.494 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -94.99 -27.63 15.55 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.413 -0.805 . . . . 0.0 109.55 179.846 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.437 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.06 -45.0 64.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.064 -1.023 . . . . 0.0 109.248 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.4 84.51 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.341 -0.849 . . . . 0.0 109.184 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.98 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.7 t -62.96 -60.24 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.31 -0.868 . . . . 0.0 109.156 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HD1' HD13 ' A' ' 58' ' ' LEU . 62.0 m-85 -61.54 -31.97 72.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.192 -0.942 . . . . 0.0 109.009 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.06 -138.59 15.08 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.517 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 2.0 m-85 61.64 162.6 0.07 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.211 -1.17 . . . . 0.0 109.915 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 32.2 t -106.71 23.36 14.42 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.42 -161.06 31.45 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.467 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -92.32 -21.4 20.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.711 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.6 p -90.8 56.89 3.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.147 -0.97 . . . . 0.0 109.669 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.47 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -120.1 139.99 29.23 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.208 -0.933 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 15.8 Cg_exo -62.11 -31.59 83.28 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.98 1.516 . . . . 0.0 110.067 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -37.25 40.04 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.96 HG11 HG23 ' A' ' 32' ' ' THR . 93.4 t -50.2 -37.49 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -1.103 . . . . 0.0 109.445 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -75.65 -21.47 57.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.881 . . . . 0.0 109.299 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -81.41 -40.03 24.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.486 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.823 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 mt -74.93 -59.59 2.67 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.516 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.5 -48.48 42.05 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.448 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -59.59 -48.41 81.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -1.106 . . . . 0.0 109.468 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -62.93 -33.24 74.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.883 . . . . 0.0 109.461 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 58' ' ' LEU . 55.1 t -75.08 -49.47 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.323 -0.861 . . . . 0.0 109.527 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.624 HD11 HG11 ' A' ' 26' ' ' VAL . 2.0 mm? -48.68 -46.23 40.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.14 -49.31 32.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.785 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -53.72 -51.58 62.84 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.277 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.953 ' O ' HG23 ' A' ' 70' ' ' VAL . 61.0 mt -53.91 -39.21 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.339 -0.85 . . . . 0.0 109.131 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.558 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -59.52 -54.5 37.19 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -60.19 -29.98 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -1.147 . . . . 0.0 109.268 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.543 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -83.56 -5.58 59.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.406 -0.809 . . . . 0.0 109.989 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.055 HG13 HG12 ' A' ' 10' ' ' VAL . 42.2 t -90.56 -16.37 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.99 -1.069 . . . . 0.0 109.954 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.27 16.52 5.16 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.157 -0.964 . . . . 0.0 110.101 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -137.8 -86.59 0.28 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.305 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.462 HD11 HG11 ' A' ' 10' ' ' VAL . 68.1 mt . . . . . 0 N--CA 1.496 1.831 0 O-C-N 121.302 -0.873 . . . . 0.0 110.035 179.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 24.3 t -75.83 -22.87 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.599 -0.84 . . . . 0.0 109.117 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.17 -22.2 27.13 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.24 -0.912 . . . . 0.0 109.137 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.859 ' O ' HG23 ' A' ' 86' ' ' VAL . 33.6 mt-10 -90.98 -37.55 13.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.339 -0.851 . . . . 0.0 109.541 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.634 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.0 OUTLIER -67.11 -51.8 49.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.124 -0.985 . . . . 0.0 109.07 179.667 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.79 -31.33 66.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.258 -0.901 . . . . 0.0 108.752 179.232 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -67.33 -42.6 83.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 109.006 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.859 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.8 t -53.83 -44.62 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 108.83 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.402 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -58.98 -51.46 59.1 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.738 HG23 ' HA3' ' A' ' 144' ' ' GLY . 55.1 t -58.22 -23.08 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.341 -1.094 . . . . 0.0 109.023 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -86.64 -50.06 7.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.391 -0.818 . . . . 0.0 109.074 179.713 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.542 ' HB3' HD13 ' A' ' 98' ' ' ILE . 2.9 m80 -48.42 -44.55 35.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.755 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.441 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -58.94 -17.94 29.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.179 -0.951 . . . . 0.0 109.822 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.25 37.86 3.39 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.467 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.2 m-30 -93.76 -166.01 1.43 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -1.107 . . . . 0.0 109.519 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.51 -33.86 24.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.98 ' ND2' HG13 ' A' ' 44' ' ' VAL . 2.2 t30 -69.41 -59.0 3.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.486 -1.008 . . . . 0.0 109.299 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 76.13 -12.97 0.95 Allowed 'General case' 0 N--CA 1.507 2.42 0 O-C-N 121.572 -0.705 . . . . 0.0 111.491 179.589 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.3 m170 -99.78 41.94 1.13 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.633 -1.292 . . . . 0.0 109.018 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.542 HD13 ' HB3' ' A' ' 90' ' ' HIS . 57.3 mt -76.07 152.35 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.404 -0.81 . . . . 0.0 110.46 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.457 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 8.5 mttp -142.2 138.9 31.83 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 121.661 0.743 . . . . 0.0 109.809 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.592 ' HB2' HG23 ' A' ' 142' ' ' ILE . . . -75.42 -6.8 51.91 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.713 -0.617 . . . . 0.0 109.511 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 6.0 pt-20 -74.12 -26.63 60.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.09 -1.006 . . . . 0.0 109.301 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.494 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 33.3 m-85 -81.63 -21.25 38.35 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.865 . . . . 0.0 109.724 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.815 ' HE2' HD22 ' A' ' 141' ' ' LEU . 3.3 m-85 -55.84 -63.0 1.32 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.334 -0.854 . . . . 0.0 110.289 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.51 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.7 mt-10 -48.91 -57.82 10.25 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.165 -0.959 . . . . 0.0 110.129 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.51 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -49.62 -63.18 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.632 1.333 . . . . 0.0 110.05 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.964 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -55.1 -24.9 27.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.292 -0.88 . . . . 0.0 109.43 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.1 -48.74 5.9 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.85 95.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.124 -1.221 . . . . 0.0 109.646 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 58.4 m -65.33 -19.14 65.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 0.0 109.606 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.828 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.5 tt -73.89 -38.78 64.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.617 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.926 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -60.53 -35.75 76.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 109.619 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 9.3 t -65.13 -33.83 76.95 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.666 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -81.16 -35.11 31.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.206 -0.934 . . . . 0.0 109.794 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.491 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 0.6 OUTLIER -54.71 -28.85 50.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.812 -179.867 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.45 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -68.48 -13.88 62.62 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.253 -0.904 . . . . 0.0 109.244 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.407 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 24.2 m170 -65.56 -45.18 84.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.085 -1.009 . . . . 0.0 109.772 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.417 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -74.54 -47.95 29.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.506 HG12 HD11 ' A' ' 17' ' ' ILE . 4.5 pt -114.32 54.99 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.274 -0.891 . . . . 0.0 109.633 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -66.27 -18.18 66.98 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -97.63 -26.35 9.97 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.438 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.5 mmtt -96.14 -25.43 15.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.262 -1.14 . . . . 0.0 109.621 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -64.23 104.67 0.78 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.25 -0.906 . . . . 0.0 109.545 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.456 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 5.0 p-10 -106.29 -171.08 1.83 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.379 -0.825 . . . . 0.0 109.537 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.99 -55.31 26.89 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.844 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.456 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -54.23 -26.54 29.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.132 -0.98 . . . . 0.0 109.439 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -71.45 -54.59 10.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -0.973 . . . . 0.0 109.359 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.3 ptpt -70.04 -25.2 63.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.346 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.459 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.6 t0 -81.71 -34.56 30.52 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -0.853 . . . . 0.0 109.326 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.406 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.21 -41.47 63.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.353 -0.842 . . . . 0.0 109.371 179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.926 ' HB3' HD21 ' A' ' 111' ' ' LEU . 8.5 m0 -75.47 -24.38 56.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 109.242 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -71.88 -29.4 64.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.26 -34.32 16.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.66 -43.49 69.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.373 -0.829 . . . . 0.0 109.393 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.828 ' OH ' HD22 ' A' ' 110' ' ' LEU . 3.1 m-85 -52.02 -28.89 18.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.4 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.63 -31.15 59.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.318 -0.864 . . . . 0.0 109.458 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.18 -39.67 22.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.472 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.634 HG23 ' SD ' ' A' ' 83' ' ' MET . 76.0 mt -66.38 -57.56 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.255 -0.903 . . . . 0.0 109.35 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 1.5 p -68.65 -27.1 65.69 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.857 . . . . 0.0 109.653 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.674 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -65.28 -53.59 31.94 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.06 -16.46 31.6 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.248 -1.148 . . . . 0.0 109.859 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.815 HD22 ' HE2' ' A' ' 103' ' ' PHE . 8.1 tt -89.89 -39.18 13.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.836 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.674 HD12 ' HA2' ' A' ' 139' ' ' GLY . 11.2 mt -66.09 -11.17 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.135 -0.978 . . . . 0.0 110.002 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.02 -59.35 4.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.091 -1.006 . . . . 0.0 109.228 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.738 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -82.09 4.25 76.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.517 ' HB3' ' HA ' ' A' ' 142' ' ' ILE . 51.7 tp . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.004 -1.292 . . . . 0.0 109.382 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.827 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.464 ' O ' HG23 ' A' ' 10' ' ' VAL . 33.8 mt-30 -81.7 -53.03 6.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.182 -0.949 . . . . 0.0 109.819 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.27 -27.96 10.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.149 -0.969 . . . . 0.0 109.606 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -77.45 -44.27 29.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.89 . . . . 0.0 109.284 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.827 HG23 ' O ' ' A' ' 5' ' ' ALA . 46.3 t -62.98 -25.06 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.293 -0.88 . . . . 0.0 109.184 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.969 HG12 HG13 ' A' ' 70' ' ' VAL . 86.5 t -72.56 -46.93 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.416 -0.802 . . . . 0.0 109.358 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.68 -11.33 60.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.331 -0.856 . . . . 0.0 109.854 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.6 m -91.63 -21.23 20.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 109.694 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.464 HG21 ' HB1' ' A' ' 126' ' ' ALA . 12.1 p -101.87 -9.26 20.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.27 -0.894 . . . . 0.0 109.963 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.676 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.63 -19.9 23.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.097 -1.002 . . . . 0.0 109.771 -179.857 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -81.62 -10.7 59.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.223 -0.923 . . . . 0.0 109.933 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.62 -54.44 2.58 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.062 -1.024 . . . . 0.0 109.656 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.965 HD12 ' CH2' ' A' ' 130' ' ' TRP . 59.5 mt -66.04 -35.38 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 0.0 109.623 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.716 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.45 31.1 4.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.668 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.28 -70.46 0.95 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.8 p -107.5 -37.13 6.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.215 -1.167 . . . . 0.0 109.751 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.589 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.6 p-10 -72.42 -19.73 61.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.261 -0.899 . . . . 0.0 109.714 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.716 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.9 t30 56.8 26.21 11.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.209 -0.932 . . . . 0.0 109.657 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.16 23.91 23.56 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.97 -49.58 60.81 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 0.0 109.579 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.45 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -87.83 13.08 61.86 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.586 HG11 HD11 ' A' ' 63' ' ' LEU . 17.2 t -98.68 -30.59 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.094 -1.239 . . . . 0.0 109.241 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.452 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -90.06 -43.37 5.05 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.474 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.2 ptpt -56.07 -33.23 64.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.17 -1.194 . . . . 0.0 109.559 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.853 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 11.0 pt-20 -89.6 -18.57 26.31 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.958 . . . . 0.0 109.686 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.23 -61.52 1.68 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.511 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.6 m-85 -51.64 -31.82 26.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.185 -0.947 . . . . 0.0 109.885 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.892 HG23 HG11 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -56.03 -55.57 31.3 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.188 -0.945 . . . . 0.0 109.594 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -57.45 -49.11 77.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.316 -0.865 . . . . 0.0 109.678 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.683 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.3 t80 -50.91 -51.17 54.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.185 -0.947 . . . . 0.0 109.609 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.713 ' CD1' HG22 ' A' ' 55' ' ' VAL . 12.8 mt -56.41 -46.13 80.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.868 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.607 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 13.5 t -60.75 -57.59 12.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.194 -0.941 . . . . 0.0 109.83 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.32 -21.84 66.27 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.4 ' O ' ' O ' ' A' ' 35' ' ' LEU . 15.2 m80 -122.76 105.95 10.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.833 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -87.02 -21.13 26.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.436 -0.79 . . . . 0.0 109.264 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -73.27 -20.24 60.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.491 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -96.65 -18.6 19.6 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 109.629 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.446 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -59.88 -57.53 12.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.472 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.73 -23.31 63.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -0.932 . . . . 0.0 109.345 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.95 HG13 ' ND2' ' A' ' 95' ' ' ASN . 49.5 t -75.05 -57.08 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.342 -0.849 . . . . 0.0 109.504 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.529 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -55.77 -35.25 66.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.95 . . . . 0.0 109.514 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.39 28.08 2.91 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.529 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 9.3 m-85 -123.14 -168.66 1.8 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 109.784 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.1 t -133.62 21.43 3.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.507 -0.746 . . . . 0.0 109.123 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 139.84 -161.72 26.28 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.607 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -91.44 36.74 0.94 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.232 -1.158 . . . . 0.0 109.724 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.7 m -132.68 19.04 4.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.628 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -107.13 133.84 20.14 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.575 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.38 -19.87 55.26 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.947 1.498 . . . . 0.0 109.974 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.506 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.61 -27.63 64.06 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.892 HG11 HG23 ' A' ' 32' ' ' THR . 99.3 t -57.18 -35.19 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -1.167 . . . . 0.0 109.405 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.708 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.34 -3.83 48.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.89 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.97 -29.97 14.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.046 -1.034 . . . . 0.0 109.397 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.798 ' O ' HG23 ' A' ' 62' ' ' VAL . 7.1 mt -86.02 -63.56 1.3 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.161 -0.962 . . . . 0.0 109.524 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.652 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -54.49 -28.83 45.91 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -63.1 -53.04 59.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.149 -1.207 . . . . 0.0 109.518 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.435 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 11.3 mtpt -76.25 -43.54 41.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.281 -0.887 . . . . 0.0 109.321 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.798 HG23 ' O ' ' A' ' 58' ' ' LEU . 63.0 t -50.16 -49.14 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.308 -0.87 . . . . 0.0 109.591 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.652 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -47.51 -45.68 26.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.144 -0.973 . . . . 0.0 109.729 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -48.67 -50.9 31.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.244 -0.91 . . . . 0.0 109.903 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.1 tp60 -49.9 -49.21 50.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.139 -0.976 . . . . 0.0 109.491 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.912 ' O ' HG23 ' A' ' 70' ' ' VAL . 71.1 mt -56.2 -35.83 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.325 -0.86 . . . . 0.0 109.138 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.84 -54.9 25.4 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.156 -1.578 . . . . 0.0 109.156 179.742 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.0 t -59.57 -24.48 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.9 -25.46 26.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.307 -0.871 . . . . 0.0 109.534 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.969 HG13 HG12 ' A' ' 10' ' ' VAL . 55.1 t -73.66 -18.38 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 109.665 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -89.35 15.3 9.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -0.93 . . . . 0.0 109.927 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.465 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 14.0 m-70 -155.97 45.59 0.45 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.076 -1.015 . . . . 0.0 109.899 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.505 HD11 HG11 ' A' ' 10' ' ' VAL . 69.3 mt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.465 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 39.8 ttp . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 121.263 0.554 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.427 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 58.1 t -66.86 -19.23 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.226 -0.921 . . . . 0.0 109.456 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.8 -36.32 75.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 0.0 109.434 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.441 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 22.3 tp10 -81.58 -49.81 10.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.437 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.4 mtp -53.04 -45.68 68.13 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.277 -0.889 . . . . 0.0 109.362 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.759 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.4 -37.53 48.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 109.086 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.45 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -65.33 -35.35 80.71 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.404 -0.81 . . . . 0.0 109.153 179.467 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.527 HG12 HD11 ' A' ' 141' ' ' LEU . 28.9 t -62.4 -53.09 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.318 -0.864 . . . . 0.0 109.216 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -53.12 -42.2 61.67 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 84' ' ' LYS . 97.7 t -52.63 -27.89 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -1.136 . . . . 0.0 109.345 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.47 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 2.0 mmm180 -78.96 -51.22 9.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.094 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.705 ' HB2' HD13 ' A' ' 145' ' ' LEU . 43.2 m80 -54.0 -22.35 10.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.387 -0.821 . . . . 0.0 109.127 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.4 ttmt -64.99 -11.33 37.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.478 -0.764 . . . . 0.0 110.281 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.76 55.63 0.52 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CE2' ' CD2' ' A' ' 90' ' ' HIS . 4.4 m-30 -90.44 -170.15 2.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.306 -1.114 . . . . 0.0 109.661 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.11 -53.35 10.8 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.95 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.5 p-10 -62.06 -30.08 70.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.166 -1.196 . . . . 0.0 109.68 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.9 mtmt 60.62 35.62 19.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 109.942 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.414 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 4.8 m-70 -132.97 -83.98 0.47 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.06 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.668 HD12 ' O ' ' A' ' 90' ' ' HIS . 22.6 mt 60.06 153.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 110.387 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.554 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -152.71 135.09 15.09 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.626 0.727 . . . . 0.0 109.725 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.733 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -72.95 -6.32 44.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.735 -0.603 . . . . 0.0 109.544 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.462 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.8 mm-40 -76.36 -24.07 54.17 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.028 -1.045 . . . . 0.0 109.115 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.554 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 73.0 m-85 -85.95 -26.52 25.46 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.328 -0.858 . . . . 0.0 109.732 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.67 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.1 m-85 -50.82 -59.03 4.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 110.278 -179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -54.71 -59.07 11.47 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.289 -179.355 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.5 Cg_exo -47.94 -55.69 3.79 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.712 1.375 . . . . 0.0 110.308 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.934 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.99 -21.42 21.08 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.933 . . . . 0.0 109.652 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.61 -48.31 10.71 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.58 -47.46 85.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -1.164 . . . . 0.0 109.826 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.04 -25.12 65.09 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.689 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.3 tt -69.44 -40.72 77.05 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.688 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.742 HD21 ' HB3' ' A' ' 130' ' ' TRP . 14.8 mt -59.17 -32.78 70.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.228 -0.92 . . . . 0.0 109.677 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.9 p -66.83 -29.8 69.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 109.901 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.853 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -83.33 -38.82 21.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.176 -0.952 . . . . 0.0 109.845 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.614 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.2 mmt -48.45 -46.54 37.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 110.033 -179.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.455 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -47.96 -25.95 1.56 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 -179.633 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.448 ' ND1' ' OE1' ' A' ' 29' ' ' GLU . 18.3 m170 -54.65 -45.78 73.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.065 -1.022 . . . . 0.0 110.029 -179.644 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.46 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 7.0 ttt85 -78.17 -60.37 2.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.202 -0.936 . . . . 0.0 110.033 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.489 HG12 HD11 ' A' ' 17' ' ' ILE . 4.5 pt -104.7 52.36 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.172 -0.955 . . . . 0.0 109.82 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.455 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -63.5 -20.09 63.17 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -91.78 -24.29 25.85 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.446 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 25.1 mttt -100.01 -21.23 15.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.183 . . . . 0.0 109.711 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.433 ' SD ' HD11 ' A' ' 118' ' ' ILE . 5.0 tpt -60.94 98.37 0.07 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.562 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.745 ' OD1' ' HB2' ' A' ' 126' ' ' ALA . 14.5 p-10 -96.36 -174.37 3.04 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.28 -0.887 . . . . 0.0 109.667 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.18 79.81 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.679 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -69.26 -27.21 65.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -0.906 . . . . 0.0 109.355 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.745 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -71.93 -45.41 61.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.597 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 5.0 ptpt -74.54 -27.92 60.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.119 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.469 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -81.88 -36.56 28.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.357 -0.84 . . . . 0.0 109.115 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.466 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -68.7 -47.37 66.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.365 -0.835 . . . . 0.0 109.134 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.965 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.5 m0 -70.13 -25.77 63.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.337 -0.852 . . . . 0.0 108.985 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.597 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.95 -34.88 74.0 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -81.91 -28.78 32.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.282 -0.886 . . . . 0.0 109.423 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -78.59 -47.75 16.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.335 -0.853 . . . . 0.0 109.62 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.689 ' OH ' HD22 ' A' ' 110' ' ' LEU . 4.3 m-85 -49.5 -29.17 6.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.02 61.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.373 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -80.32 -36.48 34.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.479 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.614 HD13 HG23 ' A' ' 66' ' ' ILE . 65.3 mt -66.69 -58.12 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.293 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.406 ' O ' HG12 ' A' ' 142' ' ' ILE . 1.8 p -64.74 -23.73 67.34 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -0.876 . . . . 0.0 109.597 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -73.42 -39.33 51.03 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.18 -31.09 70.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -1.16 . . . . 0.0 109.654 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.917 HD23 ' O ' ' A' ' 141' ' ' LEU . 8.5 tt -73.24 -6.53 46.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.225 -0.922 . . . . 0.0 110.028 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.733 HD12 ' HB2' ' A' ' 100' ' ' ALA . 45.7 mm -88.67 16.59 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 109.936 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.43 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 4.8 t -95.93 -43.08 7.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.62 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -107.94 16.07 36.58 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.705 HD13 ' HB2' ' A' ' 90' ' ' HIS . 11.3 tp . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.162 -1.199 . . . . 0.0 109.585 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.72 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 121.586 0.708 . . . . 0.0 109.106 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.714 ' O ' HG23 ' A' ' 10' ' ' VAL . 28.1 mt-30 -70.05 -26.44 64.02 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.521 -179.138 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.8 tmm_? -77.21 -41.03 42.96 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.188 -1.005 . . . . 0.0 108.829 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -56.76 -29.37 62.53 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 5' ' ' ALA . 14.2 t -81.65 -29.53 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.915 HG12 HG13 ' A' ' 70' ' ' VAL . 53.1 t -76.92 -37.59 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.565 -0.709 . . . . 0.0 109.311 179.611 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.2 -11.4 59.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.323 -0.861 . . . . 0.0 109.937 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -92.67 -34.01 14.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.808 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.0 p -83.58 -15.96 47.17 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.276 -0.89 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.713 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.15 -23.58 24.79 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.119 -0.988 . . . . 0.0 109.483 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.1 mtpt -75.78 -5.36 45.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.811 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.435 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.7 OUTLIER -110.76 -58.83 2.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.053 -1.029 . . . . 0.0 109.592 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.959 HD12 ' CH2' ' A' ' 130' ' ' TRP . 26.5 mt -56.94 -35.12 46.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.699 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.97 34.8 3.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.282 -0.886 . . . . 0.0 109.67 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.14 -72.26 0.56 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.7 p -112.05 -31.01 7.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.221 -1.164 . . . . 0.0 109.618 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.719 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.6 p-10 -76.45 -16.79 59.59 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -0.908 . . . . 0.0 109.792 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.699 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 31.4 t30 60.47 24.96 14.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.228 -0.92 . . . . 0.0 109.554 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.21 38.4 5.69 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.719 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -83.32 -39.36 20.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.636 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.449 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -89.32 17.19 53.42 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.645 HG21 ' CG2' ' A' ' 17' ' ' ILE . 28.5 t -105.96 -40.22 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -1.209 . . . . 0.0 109.378 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.481 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -86.78 -40.14 7.29 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.494 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.0 ptpt -59.87 -30.16 68.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -1.188 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.748 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 8.5 pt-20 -93.19 -22.21 19.19 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.7 t -88.21 -62.38 1.5 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.966 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.513 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 23.0 m-85 -50.54 -35.81 31.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.332 -0.855 . . . . 0.0 110.179 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.702 ' OG1' HG11 ' A' ' 55' ' ' VAL . 18.6 m -53.14 -54.78 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.985 -1.072 . . . . 0.0 109.2 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.79 -43.02 85.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.156 -0.965 . . . . 0.0 108.944 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.657 ' HB2' HD23 ' A' ' 106' ' ' LEU . 90.4 t80 -55.32 -63.26 1.22 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -0.806 . . . . 0.0 109.1 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.782 HD13 HG22 ' A' ' 55' ' ' VAL . 5.7 mt -47.82 -43.89 28.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.435 -0.79 . . . . 0.0 109.71 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.89 -63.43 1.21 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.574 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -59.12 -24.35 62.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 16.5 m80 -118.62 99.12 6.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.288 -0.882 . . . . 0.0 109.648 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -83.88 -19.95 33.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.593 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -70.0 -11.23 60.72 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.256 -0.903 . . . . 0.0 109.895 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.444 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 83.0 mmm -113.34 -21.6 10.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.111 -0.993 . . . . 0.0 109.888 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.494 ' HA ' HD23 ' A' ' 35' ' ' LEU . . . -48.81 -46.56 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.024 -1.047 . . . . 0.0 109.592 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.61 -21.22 61.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.254 -0.904 . . . . 0.0 109.312 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.996 HG13 ' ND2' ' A' ' 95' ' ' ASN . 7.1 t -77.28 -38.48 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.316 -0.865 . . . . 0.0 109.278 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.509 ' CG ' HD21 ' A' ' 35' ' ' LEU . 12.8 m-85 -70.47 -27.61 64.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.85 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 111.96 20.97 6.53 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 6.1 m-85 -119.75 164.88 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.282 -1.128 . . . . 0.0 109.801 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.28 -15.33 20.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.446 -0.784 . . . . 0.0 109.213 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.417 ' O ' ' OD2' ' A' ' 52' ' ' ASP . . . -164.57 -155.3 8.33 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.454 ' O ' HG23 ' A' ' 32' ' ' THR . . . -104.98 -0.21 27.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.438 -1.036 . . . . 0.0 110.079 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.0 t -107.24 51.9 0.73 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.949 -1.094 . . . . 0.0 109.861 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.712 ' OD1' HG23 ' A' ' 55' ' ' VAL . 0.6 OUTLIER -131.23 149.25 73.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.255 -0.903 . . . . 0.0 109.674 179.799 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 10.0 Cg_exo -65.8 -24.31 54.43 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.973 1.512 . . . . 0.0 110.296 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.53 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -48.45 -35.87 16.33 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.782 HG22 HD13 ' A' ' 35' ' ' LEU . 57.5 t -61.26 -35.61 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -1.109 . . . . 0.0 109.445 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.39 -11.26 60.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.34 -31.2 16.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.606 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.764 ' O ' HG23 ' A' ' 62' ' ' VAL . 7.8 mt -88.42 -62.68 1.44 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.973 . . . . 0.0 109.725 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.617 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -50.15 -33.52 22.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -71.81 -43.83 64.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -1.18 . . . . 0.0 109.718 -179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.8 mtpp -74.95 -36.99 62.09 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.764 HG23 ' O ' ' A' ' 58' ' ' LEU . 61.1 t -61.8 -47.65 92.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.819 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.617 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.6 mm? -47.28 -46.31 24.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.16 -0.962 . . . . 0.0 109.899 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -47.44 -48.4 26.59 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.417 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 17.9 tp60 -52.64 -49.69 64.65 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.101 -0.999 . . . . 0.0 109.407 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.907 ' O ' HG23 ' A' ' 70' ' ' VAL . 72.2 mt -58.1 -27.64 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.256 -0.902 . . . . 0.0 109.195 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.557 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.78 -54.88 8.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -60.67 -21.26 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.25 -1.147 . . . . 0.0 109.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.59 -25.15 23.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.915 HG13 HG12 ' A' ' 10' ' ' VAL . 41.4 t -73.08 -11.74 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.248 -0.907 . . . . 0.0 109.731 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -92.36 25.4 2.98 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 109.592 179.977 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.454 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 28.0 m-70 -142.68 -75.34 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.525 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.9 mm? . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.711 -0.618 . . . . 0.0 110.297 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.454 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 5.6 tmm? . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.342 0.591 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.829 HG22 ' HB1' ' A' ' 140' ' ' ALA . 73.0 t -79.58 -18.77 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.693 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -48.82 -51.43 29.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.788 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.517 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.0 OUTLIER -76.52 -45.36 31.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.467 ' HB2' ' HA ' ' A' ' 80' ' ' VAL . 1.6 mtp -54.78 -53.44 55.18 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.428 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -51.12 -33.05 24.74 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.935 . . . . 0.0 109.202 179.696 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -68.89 -42.99 76.21 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.371 -0.831 . . . . 0.0 109.295 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 82' ' ' GLU . 14.4 t -58.99 -41.45 83.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.133 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -55.77 -48.86 69.26 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 78.1 t -52.71 -40.24 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.247 -1.149 . . . . 0.0 108.901 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -64.28 -50.94 65.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.398 -0.814 . . . . 0.0 109.01 179.273 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.65 ' O ' HD12 ' A' ' 98' ' ' ILE . 12.0 m-70 -55.5 -38.7 69.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.314 -0.866 . . . . 0.0 109.316 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.409 ' HB2' HD12 ' A' ' 145' ' ' LEU . 10.0 ttpp -62.72 -15.8 54.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.304 -0.872 . . . . 0.0 109.982 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -124.06 43.28 1.43 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -88.13 -171.68 3.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.3 -1.118 . . . . 0.0 109.683 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.75 -44.6 7.16 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.996 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.1 p-10 -64.92 -33.22 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -1.134 . . . . 0.0 109.593 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.7 tttt 55.12 20.23 3.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.212 -0.93 . . . . 0.0 109.809 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 8.9 m-70 -129.6 55.84 1.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.33 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.65 HD12 ' O ' ' A' ' 90' ' ' HIS . 73.4 mt -90.32 156.3 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.327 -0.858 . . . . 0.0 110.193 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.534 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 2.7 mptt -143.34 131.6 22.01 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.486 -0.759 . . . . 0.0 109.665 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.754 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -73.25 -9.02 58.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.458 -0.777 . . . . 0.0 109.795 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.6 -23.2 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.567 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 73.7 m-85 -84.9 -15.84 43.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.125 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.759 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.6 m-85 -60.61 -68.75 0.27 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.195 -0.941 . . . . 0.0 110.368 -179.483 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.49 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.8 OUTLIER -44.37 -59.06 4.22 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.403 -0.811 . . . . 0.0 111.096 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.8 Cg_endo -55.06 -55.4 3.22 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.629 1.331 . . . . 0.0 110.034 -179.39 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.901 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -62.78 -18.57 62.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' CE1' ' A' ' 134' ' ' TYR . . . -85.39 -39.85 8.15 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.16 45.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.231 -1.158 . . . . 0.0 109.489 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -21.5 11.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.59 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -67.58 -41.29 84.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.735 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.833 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.6 mt -60.65 -41.44 94.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.143 -0.973 . . . . 0.0 109.562 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.3 t -64.31 -29.94 71.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.852 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.748 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -83.37 -36.34 24.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.195 -0.941 . . . . 0.0 109.641 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.59 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.1 mtt -48.79 -35.89 15.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 110.3 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.439 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.7 OUTLIER -58.42 -23.19 56.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.116 -0.99 . . . . 0.0 109.66 -179.506 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.414 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 1.2 m80 -54.72 -49.14 71.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.133 -0.98 . . . . 0.0 109.56 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.481 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.1 OUTLIER -67.22 -62.61 1.34 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -0.929 . . . . 0.0 109.504 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.522 HG23 HG12 ' A' ' 17' ' ' ILE . 13.9 pt -92.03 47.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.262 -0.899 . . . . 0.0 109.431 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.91 125.47 37.25 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.42 -36.08 4.3 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.484 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.9 mmtp -87.46 -28.45 22.08 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.128 -1.219 . . . . 0.0 109.318 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -68.92 104.2 2.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.356 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.558 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 6.8 p30 -103.38 -170.14 1.74 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.37 -0.831 . . . . 0.0 109.992 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.424 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -62.32 -41.25 98.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.558 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -64.29 -25.15 67.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.747 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -79.07 -46.69 17.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.144 -0.973 . . . . 0.0 109.884 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.507 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.3 ptpt -74.11 -25.65 59.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.097 -1.002 . . . . 0.0 109.461 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.487 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 26.3 t0 -83.73 -43.11 15.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.323 -0.86 . . . . 0.0 109.195 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.475 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -60.98 -46.11 92.06 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.436 -0.79 . . . . 0.0 108.996 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.959 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -70.34 -31.0 68.09 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.54 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -55.89 -25.18 41.47 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.538 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.4 -32.84 15.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.494 -0.753 . . . . 0.0 109.151 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.839 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -81.59 -63.63 1.35 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.465 -0.772 . . . . 0.0 109.723 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.54 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.84 -25.37 4.41 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.947 . . . . 0.0 109.081 -179.979 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 131' ' ' ALA . . . -77.52 -47.73 18.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -0.9 . . . . 0.0 109.031 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.41 -29.28 62.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.385 -0.822 . . . . 0.0 109.205 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.839 HD12 ' C ' ' A' ' 133' ' ' ALA . 5.4 mt -66.99 -59.65 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.336 -0.852 . . . . 0.0 108.909 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 31.1 p -60.07 -26.54 66.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.556 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -77.55 -25.08 63.8 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.829 ' HB1' HG22 ' A' ' 80' ' ' VAL . . . -73.25 -29.82 63.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -1.12 . . . . 0.0 109.562 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 141' ' ' LEU . 10.4 tt -75.1 -10.76 59.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.913 . . . . 0.0 109.864 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.754 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.5 mm -92.41 37.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.132 -0.98 . . . . 0.0 109.697 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 21.5 m -116.74 -23.29 8.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.679 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.57 -8.49 6.91 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.631 HD13 ' HB2' ' A' ' 90' ' ' HIS . 26.3 tp . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.073 -1.251 . . . . 0.0 109.558 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.856 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.29 0.567 . . . . 0.0 109.655 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.406 ' O ' HG23 ' A' ' 10' ' ' VAL . 48.3 mt-30 -70.22 -47.14 62.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 109.58 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.54 -29.33 58.75 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.159 -0.963 . . . . 0.0 109.24 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -80.52 -37.79 30.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.371 -0.83 . . . . 0.0 108.86 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.7 t -72.5 -32.22 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.463 -0.773 . . . . 0.0 108.993 179.372 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.806 HG23 ' HB1' ' A' ' 129' ' ' ALA . 55.4 t -71.31 -37.89 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.468 -0.77 . . . . 0.0 109.272 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.62 -13.02 60.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.846 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 t -92.24 -24.27 19.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.139 -0.976 . . . . 0.0 109.961 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.427 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 16.7 p -91.28 -17.75 25.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.196 -0.94 . . . . 0.0 109.976 -179.718 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.744 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -84.35 -19.38 33.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 109.762 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.6 mtpt -83.46 1.83 39.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.998 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -118.04 -54.71 2.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.45 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.93 HD12 ' CH2' ' A' ' 130' ' ' TRP . 81.3 mt -66.51 -33.09 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.275 -0.89 . . . . 0.0 109.467 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.716 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.67 33.08 3.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.575 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.65 -87.84 0.01 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.6 p -101.0 -21.44 15.04 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.671 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 18.0 p-10 -81.63 -23.16 37.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.594 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.716 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 23.5 t30 57.09 29.36 16.41 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.692 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 90.68 38.66 6.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.671 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -80.82 -58.2 3.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.266 -1.138 . . . . 0.0 109.643 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -73.18 -22.2 79.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.881 HG11 HD21 ' A' ' 63' ' ' LEU . 23.5 t -66.04 -29.19 46.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -1.103 . . . . 0.0 109.544 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.444 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -80.11 -56.38 3.27 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.497 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 14.6 ptpt -54.28 -24.95 20.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.177 -1.19 . . . . 0.0 110.175 -179.355 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.658 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 18.8 pt-20 -97.75 -18.43 18.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.99 -1.069 . . . . 0.0 109.899 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.438 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 35.5 t -89.16 -68.84 0.75 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -0.937 . . . . 0.0 109.785 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.591 ' HB3' HG13 ' A' ' 55' ' ' VAL . 12.9 m-85 -48.17 -31.26 5.48 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.21 -0.931 . . . . 0.0 109.83 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.663 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.55 -54.02 46.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.931 . . . . 0.0 109.61 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.441 ' HA ' ' OG ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -60.49 -38.65 84.97 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.877 -179.887 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.674 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.1 t80 -59.11 -52.64 64.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.167 -0.958 . . . . 0.0 109.705 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.64 ' CD1' HG22 ' A' ' 55' ' ' VAL . 4.2 mt -58.86 -48.79 80.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.239 -0.913 . . . . 0.0 109.842 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.663 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 3.3 p -56.0 -52.68 63.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.731 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.424 ' H ' ' HG ' ' A' ' 36' ' ' SER . . . -72.53 -25.13 61.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 0.0 109.713 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.417 ' N ' ' O ' ' A' ' 34' ' ' PHE . 19.7 m80 -120.35 109.04 14.87 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.767 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -89.86 -21.55 22.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.408 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -71.07 -21.15 62.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.336 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.511 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -96.64 -13.87 22.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.885 . . . . 0.0 109.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.02 -64.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.095 -1.003 . . . . 0.0 109.514 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -54.79 -25.23 26.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.277 -0.89 . . . . 0.0 109.369 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.894 HG13 ' OD1' ' A' ' 95' ' ' ASN . 39.0 t -75.97 -43.69 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 41' ' ' MET . 18.1 m-85 -73.35 -18.44 61.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.911 . . . . 0.0 109.67 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.415 ' O ' ' CD1' ' A' ' 47' ' ' PHE . . . 95.03 26.47 12.49 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.498 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 15.1 m-85 -126.9 -177.1 3.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -1.128 . . . . 0.0 109.982 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.99 16.21 7.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.461 -0.774 . . . . 0.0 109.415 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 144.84 -163.42 27.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -79.7 -17.79 52.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.308 -1.113 . . . . 0.0 109.826 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -85.14 49.92 1.84 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.932 . . . . 0.0 109.665 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.32 122.9 15.14 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.611 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -65.83 -25.9 52.67 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.872 1.459 . . . . 0.0 110.077 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.498 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.89 -33.4 43.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.663 HG11 HG23 ' A' ' 32' ' ' THR . 97.6 t -52.01 -33.62 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -1.142 . . . . 0.0 109.298 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.701 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.1 -4.29 34.71 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.289 -0.882 . . . . 0.0 109.578 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -90.18 -36.02 15.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.122 -0.986 . . . . 0.0 109.791 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.727 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.6 mt -83.99 -62.16 1.64 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.032 -1.042 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.444 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.46 -28.36 28.34 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -64.72 -53.67 43.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.062 -1.257 . . . . 0.0 109.756 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.608 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 9.7 mttm -79.56 -43.75 22.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.727 HG23 ' O ' ' A' ' 58' ' ' LEU . 94.8 t -46.8 -58.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.389 -0.819 . . . . 0.0 110.229 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.881 HD21 HG11 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -46.43 -38.84 9.59 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.205 -0.934 . . . . 0.0 109.987 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.608 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.47 -42.15 61.4 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.935 . . . . 0.0 109.521 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 62' ' ' VAL . 13.8 mm-40 -60.67 -42.12 96.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.172 -0.955 . . . . 0.0 109.321 179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.938 ' O ' HG23 ' A' ' 70' ' ' VAL . 88.9 mt -61.13 -33.49 56.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.24 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.547 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.38 -53.66 24.04 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.921 -1.672 . . . . 0.0 108.921 179.621 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.4 t -59.84 -24.24 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.315 -1.109 . . . . 0.0 109.207 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.09 -30.33 22.66 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.408 -0.807 . . . . 0.0 109.578 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.938 HG23 ' O ' ' A' ' 66' ' ' ILE . 48.2 t -63.5 -21.21 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.495 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.08 44.0 1.16 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.179 -0.951 . . . . 0.0 109.874 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 4.3 m-70 -152.15 -84.07 0.08 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.129 -0.982 . . . . 0.0 110.311 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.77 HD22 ' N ' ' A' ' 73' ' ' LEU . 2.6 mm? . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.774 -0.579 . . . . 0.0 110.559 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 3.1 tmm? . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.227 0.536 . . . . 0.0 109.774 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.4 t -73.81 -8.07 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.922 . . . . 0.0 110.071 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -77.74 -32.09 52.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.989 -1.069 . . . . 0.0 109.712 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.479 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.5 mt-10 -99.34 -41.45 7.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.925 . . . . 0.0 109.639 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.47 ' SD ' HG23 ' A' ' 137' ' ' ILE . 2.4 mtp -62.53 -47.79 82.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.188 -0.945 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.453 ' HG2' ' HB2' ' A' ' 143' ' ' SER . 0.1 OUTLIER -54.96 -35.73 64.58 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.255 -0.903 . . . . 0.0 109.279 179.694 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -64.23 -35.39 80.65 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.229 -0.919 . . . . 0.0 109.266 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 82' ' ' GLU . 28.6 t -55.08 -48.96 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.352 -0.843 . . . . 0.0 109.42 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -51.99 -50.42 44.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.859 HG23 ' HA3' ' A' ' 144' ' ' GLY . 97.0 t -48.68 -25.3 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.327 -1.102 . . . . 0.0 109.596 179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.505 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.2 mmt180 -77.08 -44.67 29.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.179 -0.951 . . . . 0.0 109.127 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.469 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 17.7 m80 -58.78 -19.87 44.7 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.349 -0.845 . . . . 0.0 109.196 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.432 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 25.5 ttpt -68.04 -15.09 63.45 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.419 -0.801 . . . . 0.0 109.851 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.91 50.51 0.81 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.8 m-30 -94.23 -172.41 2.8 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.237 -1.155 . . . . 0.0 109.328 179.707 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.74 -40.3 53.27 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.894 ' OD1' HG13 ' A' ' 44' ' ' VAL . 1.7 t-20 -78.39 -44.68 24.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.464 -1.021 . . . . 0.0 109.001 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 71.93 -54.24 0.68 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.396 -0.815 . . . . 0.0 110.314 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 28.9 m170 -66.69 69.2 0.07 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.974 . . . . 0.0 110.115 -179.551 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.456 ' N ' ' O ' ' A' ' 96' ' ' LYS . 84.5 mt -100.61 161.76 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.93 . . . . 0.0 109.329 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.487 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -136.92 142.54 42.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.139 -0.975 . . . . 0.0 109.726 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.16 -0.41 51.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.878 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.526 ' HG2' ' CD1' ' A' ' 102' ' ' TYR . 7.6 pt-20 -78.74 -28.43 44.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.104 -0.998 . . . . 0.0 109.676 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.526 ' CD1' ' HG2' ' A' ' 101' ' ' GLU . 92.8 m-85 -78.03 -13.52 59.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 109.845 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.899 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -57.9 -64.57 0.86 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.203 -0.936 . . . . 0.0 110.192 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.487 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.3 mt-10 -51.38 -55.87 25.35 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.169 -0.957 . . . . 0.0 110.208 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 33.6 Cg_exo -49.42 -54.27 5.71 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.69 1.363 . . . . 0.0 110.19 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.911 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.1 tm? -57.05 -19.46 19.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.223 -0.923 . . . . 0.0 109.599 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.53 -39.82 20.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.63 -57.14 12.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.243 -1.151 . . . . 0.0 109.614 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.2 m -56.91 -23.23 43.48 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.608 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.698 HD22 ' OH ' ' A' ' 134' ' ' TYR . 4.4 tt -70.38 -43.77 69.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.558 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.622 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.2 mt -57.06 -30.43 64.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.503 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.4 t -66.65 -39.01 88.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.208 -0.933 . . . . 0.0 109.633 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.658 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -75.15 -39.82 60.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.668 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.61 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.2 mmt -48.05 -40.31 22.59 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.203 -0.936 . . . . 0.0 109.874 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -54.11 -24.57 18.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.264 -0.897 . . . . 0.0 109.746 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.406 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -49.65 -53.08 26.36 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.184 -0.947 . . . . 0.0 109.697 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.19 -72.55 0.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.153 -0.967 . . . . 0.0 109.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.628 HG12 HD11 ' A' ' 17' ' ' ILE . 3.1 pt -86.42 56.32 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.916 . . . . 0.0 109.657 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -68.35 -23.69 74.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -94.77 -21.7 25.45 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 59.2 mttt -100.64 -21.47 15.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.627 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.489 ' CA ' HD12 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.16 80.43 0.13 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.327 -0.858 . . . . 0.0 109.632 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.558 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.9 p30 -83.79 -163.93 0.84 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.612 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -71.46 -42.17 68.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.708 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -62.67 -24.02 67.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.18 -52.8 8.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.595 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.557 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.5 ptpt -67.46 -33.2 74.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.918 . . . . 0.0 109.363 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.466 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.0 t70 -73.17 -55.42 6.49 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.413 179.774 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.806 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -51.23 -43.42 61.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.405 -0.809 . . . . 0.0 109.373 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.93 ' CH2' HD12 ' A' ' 17' ' ' ILE . 2.8 m0 -75.74 -29.34 58.85 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.351 -0.843 . . . . 0.0 109.107 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.557 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.07 -27.85 65.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.183 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.31 -26.63 21.02 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.305 -0.872 . . . . 0.0 109.28 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.418 ' O ' ' CD1' ' A' ' 137' ' ' ILE . . . -79.49 -45.22 19.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.415 -0.803 . . . . 0.0 109.503 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.778 ' HE1' HD13 ' A' ' 66' ' ' ILE . 5.8 m-85 -48.99 -31.61 7.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.08 -36.41 69.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.29 -0.881 . . . . 0.0 109.39 179.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.57 -40.37 29.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.524 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.47 HG23 ' SD ' ' A' ' 83' ' ' MET . 1.9 mp -67.42 -56.68 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.864 . . . . 0.0 109.139 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.6 p -68.26 -26.58 65.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.739 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -71.02 -35.78 64.56 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.48 -21.69 66.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.189 -1.183 . . . . 0.0 109.763 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.899 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.2 tt -82.32 -12.62 57.87 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -0.945 . . . . 0.0 109.944 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 142' ' ' ILE . 36.5 mt -79.61 3.26 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.138 -0.976 . . . . 0.0 110.157 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.453 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 9.5 m -89.92 -45.06 9.48 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.015 -1.053 . . . . 0.0 109.632 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.859 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -82.56 -28.58 38.81 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.493 HD12 ' HA2' ' A' ' 87' ' ' GLY . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.378 -1.072 . . . . 0.0 109.609 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.82 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.198 0.523 . . . . 0.0 109.785 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.467 ' O ' HG23 ' A' ' 10' ' ' VAL . 76.8 mt-30 -62.02 -52.83 62.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.539 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.616 ' HA ' HD12 ' A' ' 73' ' ' LEU . 7.5 ptm180 -50.47 -33.9 22.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.34 179.751 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.468 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 56.6 tp60 -75.57 -46.62 30.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.82 HG23 ' O ' ' A' ' 5' ' ' ALA . 40.7 t -60.54 -34.85 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.178 179.516 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.776 HG12 HG13 ' A' ' 70' ' ' VAL . 69.8 t -64.66 -48.73 83.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.36 -0.838 . . . . 0.0 109.343 179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.35 -11.53 60.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 109.675 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -91.17 -25.51 19.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.135 -0.978 . . . . 0.0 109.717 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 p -98.01 -11.75 22.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.183 -0.948 . . . . 0.0 109.809 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.552 ' CE3' ' HB3' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.8 -28.39 20.48 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.082 -1.011 . . . . 0.0 109.657 -179.882 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -70.76 -15.26 62.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.414 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -99.55 -61.52 1.36 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.644 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.972 HD12 ' CH2' ' A' ' 130' ' ' TRP . 55.8 mt -57.9 -39.13 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.711 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.723 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.64 36.09 2.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.702 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.8 -82.5 0.06 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.0 p -97.93 -26.24 14.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 0.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.651 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 4.2 p30 -80.75 -23.8 39.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.639 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.723 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 27.2 t30 56.92 22.07 6.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.528 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 101.97 23.44 9.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.651 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -69.57 -54.31 14.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 109.619 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.453 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -85.93 10.98 63.59 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.85 HG12 HD11 ' A' ' 63' ' ' LEU . 35.8 t -104.84 -22.66 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.241 . . . . 0.0 109.202 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -98.95 -35.43 4.83 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.454 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 15.0 ptpt -68.88 -27.04 65.44 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.189 -1.183 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.449 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 17.5 pt-20 -100.82 -5.97 25.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 110.087 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.5 t -95.99 -67.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.054 -1.029 . . . . 0.0 109.978 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -47.18 -29.78 2.53 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.206 -0.934 . . . . 0.0 110.149 -179.387 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.548 HG22 ' HB1' ' A' ' 50' ' ' ALA . 0.2 OUTLIER -52.74 -63.25 1.2 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.074 -1.016 . . . . 0.0 109.207 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -50.35 -47.49 55.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.341 -0.849 . . . . 0.0 109.242 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.73 ' CG ' HD23 ' A' ' 106' ' ' LEU . 7.8 t80 -56.46 -51.26 69.1 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.18 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.862 ' CD1' HG22 ' A' ' 55' ' ' VAL . 19.5 mt -58.32 -44.7 88.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.496 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.576 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 0.2 OUTLIER -67.67 -62.95 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.344 -0.848 . . . . 0.0 109.612 179.965 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.8 -24.48 9.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.626 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.4 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 20.3 m80 -125.0 101.74 7.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.299 -0.876 . . . . 0.0 109.738 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -84.51 -17.48 38.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.398 -0.814 . . . . 0.0 109.503 179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -67.87 -16.11 63.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.774 ' HE3' HG11 ' A' ' 44' ' ' VAL . 89.6 mmm -120.04 -15.02 8.82 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 110.019 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.431 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.04 -44.84 41.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.913 -1.117 . . . . 0.0 109.525 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.0 -29.75 60.97 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.322 -0.861 . . . . 0.0 109.26 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.041 HG13 ' ND2' ' A' ' 95' ' ' ASN . 2.4 t -60.89 -27.99 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.342 -0.849 . . . . 0.0 109.173 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.543 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 8.3 m-85 -82.64 -27.8 31.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.103 -0.998 . . . . 0.0 109.683 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.448 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.84 20.26 6.51 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.543 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 3.6 m-85 -117.88 172.84 7.12 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.231 -1.159 . . . . 0.0 109.653 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.6 t -115.28 22.09 13.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.331 -0.856 . . . . 0.0 109.029 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.45 -170.8 28.93 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.576 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -85.86 11.28 11.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -1.168 . . . . 0.0 109.97 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.04 20.3 18.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.994 . . . . 0.0 109.557 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.404 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -101.31 136.42 19.67 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.54 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -68.03 -17.01 45.97 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.916 1.482 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.0 -36.88 61.38 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.862 HG22 ' CD1' ' A' ' 35' ' ' LEU . 61.2 t -51.71 -33.27 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.238 -1.154 . . . . 0.0 109.449 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.66 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.28 -13.77 59.45 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.252 -0.905 . . . . 0.0 109.787 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -90.21 -23.14 21.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.184 -0.947 . . . . 0.0 109.494 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.673 ' O ' HG23 ' A' ' 62' ' ' VAL . 3.4 mt -90.89 -66.43 0.93 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.902 . . . . 0.0 109.906 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.93 -30.89 38.27 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -1.217 . . . . 0.0 109.479 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.544 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 17.0 mttt -94.34 -38.44 10.98 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.42 -0.8 . . . . 0.0 109.485 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 58' ' ' LEU . 91.4 t -51.43 -57.99 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.38 -0.825 . . . . 0.0 109.794 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.85 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.31 -45.0 24.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.227 -0.921 . . . . 0.0 109.677 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.544 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -47.66 -40.74 20.67 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.687 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 35.2 tp60 -64.79 -41.28 95.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.195 -0.941 . . . . 0.0 109.164 179.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.795 ' O ' HG23 ' A' ' 70' ' ' VAL . 59.4 mt -60.79 -37.31 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -0.843 . . . . 0.0 109.144 179.519 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.76 29.68 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.2 t -58.04 -24.81 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -1.125 . . . . 0.0 109.17 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.0 -34.21 22.4 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.418 -0.801 . . . . 0.0 109.433 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.795 HG23 ' O ' ' A' ' 66' ' ' ILE . 50.7 t -63.95 -19.33 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -0.899 . . . . 0.0 109.425 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 24.1 m -62.2 -41.93 98.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.196 -0.94 . . . . 0.0 109.667 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 71' ' ' SER . 8.7 m-70 -131.02 84.48 2.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.724 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.624 HD11 HG11 ' A' ' 10' ' ' VAL . 42.1 mt . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 109.6 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.7 tmm? . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.272 0.558 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.401 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 54.8 t -76.86 -22.51 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.258 -0.901 . . . . 0.0 109.605 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.47 -17.89 61.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.851 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -92.57 -49.84 5.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 109.761 -179.875 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.466 ' HE2' ' O ' ' A' ' 137' ' ' ILE . 95.8 mmm -60.74 -45.91 92.49 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.067 -1.021 . . . . 0.0 109.156 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.796 ' O ' HG23 ' A' ' 88' ' ' VAL . 2.0 mttt -51.73 -31.17 25.34 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.128 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.448 ' O ' ' CG ' ' A' ' 89' ' ' ARG . . . -79.47 -32.02 42.53 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.462 -0.774 . . . . 0.0 108.956 179.164 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 82' ' ' GLU . 45.2 t -69.86 -41.69 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.127 -0.983 . . . . 0.0 109.273 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.49 92.69 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.931 -1.667 . . . . 0.0 108.931 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.796 HG23 ' O ' ' A' ' 84' ' ' LYS . 97.0 t -59.25 -29.4 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -1.191 . . . . 0.0 109.178 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.478 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.9 OUTLIER -76.63 -45.7 28.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -0.871 . . . . 0.0 109.316 179.773 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.798 ' O ' HD12 ' A' ' 98' ' ' ILE . 22.0 m80 -59.18 -20.67 55.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.088 179.428 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 ttpt -70.23 -9.54 56.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.89 . . . . 0.0 110.188 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.4 54.57 0.55 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.885 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.9 m-30 -88.8 -168.99 2.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -1.167 . . . . 0.0 109.613 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -76.49 -36.46 38.48 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.041 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.7 p-10 -79.67 -24.66 41.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.046 -1.267 . . . . 0.0 110.009 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 ttmm 51.41 26.79 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.153 -0.967 . . . . 0.0 109.499 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.413 ' H ' ' ND2' ' A' ' 95' ' ' ASN . 6.0 m80 -134.28 42.97 2.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.42 -0.8 . . . . 0.0 109.323 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.885 HD11 ' CD2' ' A' ' 93' ' ' TYR . 58.9 mt -86.03 156.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 110.061 -179.633 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.472 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.28 143.69 25.08 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.706 0.765 . . . . 0.0 109.882 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.1 -6.37 56.3 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.717 -0.614 . . . . 0.0 109.622 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.422 ' HG2' ' HB3' ' A' ' 99' ' ' LYS . 15.7 pt-20 -72.95 -28.73 62.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.091 -1.006 . . . . 0.0 109.359 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.54 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 44.8 m-85 -79.93 -20.42 45.72 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.593 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.5 m-85 -57.37 -68.13 0.26 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.338 -0.851 . . . . 0.0 110.555 -179.332 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 3.4 mt-10 -43.24 -59.96 2.81 Favored Pre-proline 0 N--CA 1.495 1.808 0 O-C-N 121.516 -0.74 . . . . 0.0 111.016 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 8.8 Cg_endo -55.99 -42.52 65.93 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.732 1.385 . . . . 0.0 110.199 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.737 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.9 tm? -66.75 -27.18 67.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.475 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.36 -38.8 37.8 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.45 -48.42 72.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -1.127 . . . . 0.0 109.539 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.2 m -62.31 -26.46 68.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.548 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.424 HD22 ' CE2' ' A' ' 134' ' ' TYR . 8.3 tt -70.42 -40.22 73.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 109.563 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.938 HD21 ' HB3' ' A' ' 130' ' ' TRP . 13.0 mt -58.96 -32.04 69.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.426 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.53 -27.75 64.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.282 -0.886 . . . . 0.0 109.523 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.421 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -84.18 -35.07 23.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.224 -0.922 . . . . 0.0 109.689 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.661 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.3 mmt -46.93 -50.4 18.95 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.285 -0.884 . . . . 0.0 110.227 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.475 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 8.5 pt-20 -47.23 -24.76 0.78 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 110.276 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 19.8 m170 -53.65 -31.33 47.08 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.709 -1.244 . . . . 0.0 109.651 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -91.89 -68.39 0.8 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.19 -0.944 . . . . 0.0 110.127 -179.655 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.499 HG23 HG12 ' A' ' 17' ' ' ILE . 18.3 pt -78.21 -34.16 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.116 -0.99 . . . . 0.0 109.756 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.475 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . 41.2 -98.73 0.01 OUTLIER Glycine 0 N--CA 1.498 2.794 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.61 -39.46 10.56 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.491 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.6 OUTLIER -73.29 -18.13 61.24 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.044 -1.268 . . . . 0.0 109.919 -179.806 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.449 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -79.45 107.06 11.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 179.571 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.686 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.4 p-10 -111.61 -171.23 1.8 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.926 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.451 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.47 -49.0 79.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.424 -0.798 . . . . 0.0 109.963 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.722 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.83 -20.72 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.516 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -85.44 -55.73 3.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.311 -0.868 . . . . 0.0 109.791 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.451 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -69.69 -24.78 63.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.781 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -80.04 -45.35 18.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.236 -0.915 . . . . 0.0 109.524 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -65.25 -45.89 82.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.391 -0.818 . . . . 0.0 109.391 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.972 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.7 m0 -66.41 -29.4 69.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -0.864 . . . . 0.0 109.34 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.448 ' N ' HD11 ' A' ' 111' ' ' LEU . . . -69.64 -28.06 65.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 108.932 179.327 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.81 -31.72 15.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.44 -0.787 . . . . 0.0 109.359 179.614 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.06 -39.78 68.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.398 -0.814 . . . . 0.0 109.206 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.424 ' CE2' HD22 ' A' ' 110' ' ' LEU . 5.3 m-30 -52.64 -30.89 34.05 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.342 -0.849 . . . . 0.0 109.064 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.58 -35.07 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.336 -0.852 . . . . 0.0 109.242 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -77.89 -39.07 44.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.33 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.636 HD13 HG23 ' A' ' 66' ' ' ILE . 12.2 mt -65.82 -58.48 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.297 -0.877 . . . . 0.0 109.109 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.429 ' O ' ' HB3' ' A' ' 141' ' ' LEU . 0.1 OUTLIER -68.51 -28.25 66.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -58.38 -52.72 51.09 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.04 -23.28 13.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.259 -1.142 . . . . 0.0 109.535 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.649 HD23 ' O ' ' A' ' 141' ' ' LEU . 10.5 tt -81.73 -18.12 45.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.703 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.714 HG22 ' O ' ' A' ' 142' ' ' ILE . 69.3 mt -89.88 37.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.78 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 60.7 m -117.84 -36.15 3.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.073 -1.017 . . . . 0.0 109.688 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -105.12 -18.01 12.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' LEU . . . . . . . . . . . . . 4.9 tp . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.123 -1.221 . . . . 0.0 109.581 -179.902 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.603 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 46.9 mt-30 -81.35 -46.86 14.05 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.131 -0.981 . . . . 0.0 109.621 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.453 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -54.84 -31.66 59.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.089 -1.007 . . . . 0.0 109.468 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.453 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 27.7 mm100 -70.78 -37.43 73.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 109.336 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 5' ' ' ALA . 47.3 t -69.71 -29.18 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.931 HG12 HG13 ' A' ' 70' ' ' VAL . 63.8 t -70.73 -43.76 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.309 -0.869 . . . . 0.0 109.291 179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.61 -12.79 60.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.319 -0.863 . . . . 0.0 109.771 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.0 t -91.89 -27.79 17.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 p -90.93 -13.85 32.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.141 -0.974 . . . . 0.0 110.032 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -88.44 -15.07 36.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.068 -1.02 . . . . 0.0 109.865 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.42 -0.58 55.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.947 . . . . 0.0 109.924 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -113.3 -49.67 2.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.034 -1.041 . . . . 0.0 109.602 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.946 HD12 ' CH2' ' A' ' 130' ' ' TRP . 58.5 mt -69.43 -36.19 70.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.251 -0.906 . . . . 0.0 109.575 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.14 33.17 3.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 109.72 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -61.81 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 p -120.39 -36.74 3.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -1.123 . . . . 0.0 109.594 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 2.0 p30 -71.26 -19.15 62.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.261 -0.899 . . . . 0.0 109.665 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.849 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 28.4 t30 57.53 19.65 5.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -0.929 . . . . 0.0 109.635 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.411 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 105.46 19.36 10.58 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.774 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -64.91 -52.39 56.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -1.181 . . . . 0.0 109.596 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.23 -22.73 75.65 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.69 HG21 ' CG2' ' A' ' 17' ' ' ILE . 15.5 t -71.09 -41.01 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -1.086 . . . . 0.0 109.855 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.401 ' HA3' ' C ' ' A' ' 59' ' ' GLY . . . -74.93 -57.19 4.53 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.269 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.482 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 15.8 ptpt -47.39 -31.3 3.93 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.208 -1.172 . . . . 0.0 110.228 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.82 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 23.4 pt-20 -95.79 -17.81 20.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.058 -1.026 . . . . 0.0 109.939 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 29.3 t -83.54 -68.11 0.74 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.948 . . . . 0.0 109.8 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.521 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.8 m-85 -50.32 -32.04 16.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.808 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -51.95 -55.05 22.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.1 -1.0 . . . . 0.0 109.165 179.718 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -57.68 -48.6 79.07 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.32 -0.862 . . . . 0.0 109.268 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.694 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.1 t80 -55.04 -49.05 72.54 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.195 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.712 ' CD1' HG22 ' A' ' 55' ' ' VAL . 23.2 mt -59.83 -41.57 91.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.854 . . . . 0.0 109.725 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.79 -63.34 1.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.935 . . . . 0.0 109.818 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.25 -21.36 48.12 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.203 -0.936 . . . . 0.0 109.886 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.404 ' O ' ' O ' ' A' ' 35' ' ' LEU . 16.9 m80 -126.74 106.71 9.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.922 . . . . 0.0 109.933 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 5.5 m170 -85.88 -20.44 29.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.535 -0.728 . . . . 0.0 109.249 179.292 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -73.05 -20.29 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.248 -0.908 . . . . 0.0 109.098 179.34 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.485 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -91.86 -20.43 21.46 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -0.866 . . . . 0.0 109.537 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.444 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.26 -56.48 20.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.302 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.61 63.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.288 -0.882 . . . . 0.0 109.255 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.035 HG13 ' ND2' ' A' ' 95' ' ' ASN . 22.4 t -71.4 -58.45 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.288 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.536 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 39.7 m-85 -57.2 -40.69 77.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.58 35.18 1.1 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.0 m-85 -125.62 169.0 12.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 109.858 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 t -112.34 18.07 18.85 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.351 -0.843 . . . . 0.0 109.372 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.3 -164.05 29.28 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.43 25.31 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -1.155 . . . . 0.0 109.716 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 37.6 m -124.78 31.04 5.77 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.623 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.54 135.45 21.9 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 109.642 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -64.07 -18.21 62.71 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.929 1.489 . . . . 0.0 109.972 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.62 -39.08 94.65 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.808 HG11 HG23 ' A' ' 32' ' ' THR . 65.6 t -52.09 -38.56 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.322 -1.105 . . . . 0.0 109.411 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.01 -12.22 60.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 0.0 109.659 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -92.76 -35.5 13.4 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.972 . . . . 0.0 109.662 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.869 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.9 mt -79.43 -61.16 2.09 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.241 -0.912 . . . . 0.0 109.873 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.864 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -55.61 -36.47 64.8 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.585 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -60.85 -52.63 64.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.09 -1.241 . . . . 0.0 109.365 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.6 mttt -67.5 -41.99 83.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.308 -0.87 . . . . 0.0 109.183 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.869 HG23 ' O ' ' A' ' 58' ' ' LEU . 63.3 t -56.42 -44.51 80.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.175 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -48.17 -46.07 34.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.416 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -50.65 -49.46 56.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.107 -0.995 . . . . 0.0 109.33 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -52.99 -37.66 61.55 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -0.892 . . . . 0.0 109.088 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.915 ' O ' HG23 ' A' ' 70' ' ' VAL . 34.7 mm -67.87 -35.75 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 109.063 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.56 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.43 -47.22 44.06 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.514 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.559 HG11 ' OE1' ' A' ' 82' ' ' GLU . 43.9 t -62.45 -25.43 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.361 -1.082 . . . . 0.0 109.439 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.83 -30.7 24.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.931 HG13 HG12 ' A' ' 10' ' ' VAL . 53.8 t -62.68 -37.23 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.488 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.2 p -51.39 -69.28 0.12 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.923 . . . . 0.0 109.348 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.444 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 9.0 m-70 -90.82 45.32 1.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 109.192 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.777 ' CD2' HG11 ' A' ' 10' ' ' VAL . 30.4 tp . . . . . 0 C--N 1.305 -1.356 0 O-C-N 121.244 -0.91 . . . . 0.0 109.526 -179.722 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.444 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 8.3 tmm? . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.61 HG12 ' HE2' ' A' ' 84' ' ' LYS . 37.9 t -62.01 -24.46 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.857 . . . . 0.0 109.108 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.65 -52.86 55.11 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.266 -0.896 . . . . 0.0 109.23 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.559 ' OE1' HG11 ' A' ' 68' ' ' VAL . 5.8 tt0 -66.91 -46.16 75.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.113 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.472 ' SD ' HG23 ' A' ' 137' ' ' ILE . 1.6 mtp -52.61 -48.91 66.01 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.623 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.61 ' HE2' HG12 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -52.63 -34.22 50.27 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.182 -0.949 . . . . 0.0 108.894 179.389 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -66.58 -15.87 63.75 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.613 ' CG1' HD11 ' A' ' 141' ' ' LEU . 11.3 t -85.81 -32.52 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.033 -1.042 . . . . 0.0 108.624 179.315 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.479 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -71.26 -43.32 55.6 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 179.176 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.422 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 96.3 t -55.65 -25.93 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.38 -1.07 . . . . 0.0 108.62 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.509 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.3 OUTLIER -76.06 -49.53 17.25 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 108.996 179.301 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.866 ' HB2' HD13 ' A' ' 145' ' ' LEU . 24.5 m80 -62.04 -21.71 65.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.379 -0.826 . . . . 0.0 109.01 179.553 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.422 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.2 OUTLIER -63.58 -14.13 48.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.396 -0.815 . . . . 0.0 109.972 -179.884 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.47 53.46 0.58 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.509 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.9 m-30 -91.31 -173.2 3.53 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -1.168 . . . . 0.0 109.349 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.45 -25.51 54.0 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 179.731 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.035 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.2 t30 -82.34 -45.49 14.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.463 -1.022 . . . . 0.0 109.179 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 9.0 ttpt 72.3 -53.75 0.69 Allowed 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.464 -0.773 . . . . 0.0 110.224 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 38.1 m170 -65.61 73.07 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.119 -0.988 . . . . 0.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.462 ' N ' ' O ' ' A' ' 96' ' ' LYS . 48.8 mt -104.81 155.03 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.521 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.53 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.7 mptp? -138.72 149.76 45.43 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.231 -0.918 . . . . 0.0 109.948 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.706 ' HB1' HG12 ' A' ' 142' ' ' ILE . . . -87.45 -18.79 29.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.527 -0.733 . . . . 0.0 109.628 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.459 ' HG2' ' HB3' ' A' ' 99' ' ' LYS . 17.7 pt-20 -67.22 -19.64 65.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.53 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 52.6 m-85 -82.06 -21.41 36.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.249 -0.907 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.412 ' HB2' ' O ' ' A' ' 100' ' ' ALA . 4.5 m-85 -60.42 -64.56 0.91 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.294 -0.879 . . . . 0.0 110.205 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.495 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.77 -58.75 4.2 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.462 -0.774 . . . . 0.0 110.987 -179.328 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.519 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 7.4 Cg_endo -55.06 -47.29 27.26 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 123.63 1.332 . . . . 0.0 110.082 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.878 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -61.75 -22.43 65.39 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.151 -0.968 . . . . 0.0 109.428 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.98 -48.24 11.89 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.79 -51.26 70.75 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 109.595 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 m -58.9 -18.77 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.658 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.769 HD23 ' SD ' ' A' ' 114' ' ' MET . 1.2 tt -75.71 -31.14 59.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.178 -0.951 . . . . 0.0 109.722 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.871 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.2 mt -71.29 -29.03 64.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 0.0 109.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.13 -34.29 70.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.916 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.82 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -80.89 -29.55 35.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.719 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.769 ' SD ' HD23 ' A' ' 110' ' ' LEU . 2.7 mtt -61.72 -34.16 75.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.896 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.448 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -61.49 -17.85 56.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.174 -0.954 . . . . 0.0 109.409 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -57.94 -49.14 77.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.721 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.1 ttt85 -74.25 -65.68 0.82 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.698 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.663 HG12 HD11 ' A' ' 17' ' ' ILE . 7.0 pt -92.31 53.19 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.258 -0.901 . . . . 0.0 109.726 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.448 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.49 -15.12 61.1 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.39 -30.95 6.68 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.71 -26.02 17.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -1.16 . . . . 0.0 109.791 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.423 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -60.19 97.67 0.05 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 -179.903 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.58 HD21 ' HB3' ' A' ' 125' ' ' ALA . 15.7 p-10 -106.42 -171.5 1.91 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.437 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.15 -49.48 77.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.388 -0.82 . . . . 0.0 109.952 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.58 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -58.4 -26.22 62.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.05 -1.031 . . . . 0.0 109.321 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.424 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -76.95 -54.01 7.11 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.231 -0.918 . . . . 0.0 109.849 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.498 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 6.3 ptmm? -70.9 -29.29 65.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.058 -1.026 . . . . 0.0 109.792 -179.75 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -77.85 -42.03 34.91 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -0.93 . . . . 0.0 109.607 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.456 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -65.53 -50.16 66.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.407 179.787 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.946 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.0 m0 -64.55 -28.77 69.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.299 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.23 -28.81 69.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.188 -0.945 . . . . 0.0 109.064 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -90.58 -24.32 20.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.395 -0.816 . . . . 0.0 109.373 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.489 ' HB2' HD21 ' A' ' 73' ' ' LEU . . . -77.47 -62.8 1.54 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.355 -0.841 . . . . 0.0 109.685 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.568 ' CE1' ' CG2' ' A' ' 66' ' ' ILE . 16.2 m-30 -52.0 -26.19 10.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.228 -0.92 . . . . 0.0 109.577 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.67 -44.85 69.64 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.208 -0.932 . . . . 0.0 108.904 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -75.41 -32.27 60.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.407 -0.808 . . . . 0.0 109.281 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.554 HG12 ' HB1' ' A' ' 69' ' ' ALA . 49.1 mt -67.46 -59.29 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.321 -0.862 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.442 ' O ' ' CD1' ' A' ' 142' ' ' ILE . 2.4 p -67.25 -13.72 62.24 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.312 -0.868 . . . . 0.0 109.805 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -84.96 -21.74 54.69 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.453 ' O ' ' NZ ' ' A' ' 84' ' ' LYS . . . -86.24 -10.36 54.78 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 110.054 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.881 HD23 ' O ' ' A' ' 141' ' ' LEU . 3.0 tt -89.14 17.24 6.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.029 -1.045 . . . . 0.0 109.882 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.706 HG12 ' HB1' ' A' ' 100' ' ' ALA . 1.9 mp -107.52 7.15 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.099 -1.001 . . . . 0.0 110.121 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.401 ' HB2' ' NZ ' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -96.77 -34.48 11.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.945 -1.097 . . . . 0.0 109.63 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.83 11.1 27.52 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.866 HD13 ' HB2' ' A' ' 90' ' ' HIS . 11.4 tp . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.106 -1.232 . . . . 0.0 109.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.552 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.295 0.569 . . . . 0.0 109.596 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.427 ' O ' HG23 ' A' ' 10' ' ' VAL . 42.8 mt-30 -64.34 -44.57 91.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.219 -0.926 . . . . 0.0 109.69 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -48.68 -50.55 32.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.512 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -59.0 -48.38 81.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 0.0 109.057 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.711 HG11 ' O ' ' A' ' 125' ' ' ALA . 48.6 t -59.83 -36.11 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 0.0 109.145 179.517 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 1.058 HG12 HG13 ' A' ' 70' ' ' VAL . 65.7 t -72.14 -46.47 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.36 -0.837 . . . . 0.0 109.116 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.03 -18.01 61.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.53 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.8 t -87.12 -25.44 24.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.2 p -91.08 -17.19 26.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.851 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.02 -15.67 37.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.923 . . . . 0.0 109.841 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -84.45 -14.34 49.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.113 -0.992 . . . . 0.0 109.596 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.452 ' OD1' HG22 ' A' ' 118' ' ' ILE . 1.8 t70 -98.84 -51.25 3.94 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.156 -0.965 . . . . 0.0 109.614 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.956 HD12 ' CH2' ' A' ' 130' ' ' TRP . 62.2 mt -69.11 -36.41 73.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.249 -0.907 . . . . 0.0 109.585 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.855 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.27 33.16 3.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.692 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.2 -81.75 0.05 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.8 p -102.04 -17.49 16.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -1.149 . . . . 0.0 109.725 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.84 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 5.5 p-10 -89.02 -19.65 25.38 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.218 -0.926 . . . . 0.0 109.656 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.855 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.0 t30 59.32 24.57 13.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.238 -0.914 . . . . 0.0 109.674 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.94 22.69 14.93 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.027 -1.629 . . . . 0.0 109.027 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.84 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -71.12 -43.63 67.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.295 -1.12 . . . . 0.0 109.71 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.433 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.91 22.84 20.04 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.65 ' CG1' HD21 ' A' ' 110' ' ' LEU . 16.9 t -115.14 -34.23 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -1.194 . . . . 0.0 109.057 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.477 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -92.57 -39.39 5.31 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.473 ' HB2' ' CB ' ' A' ' 56' ' ' ALA . 2.5 ptmt -63.85 -30.01 71.14 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -1.225 . . . . 0.0 109.381 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.661 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 6.5 pt-20 -92.59 -22.2 19.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.442 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 37.8 t -85.47 -51.44 6.52 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.294 -0.879 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.696 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.7 m-85 -53.63 -32.27 50.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.668 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 16.6 m -62.36 -28.38 69.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.968 . . . . 0.0 109.222 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.3 mmtt -81.65 -40.11 23.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.897 ' CG ' HD23 ' A' ' 106' ' ' LEU . 1.5 t80 -65.84 -55.55 16.51 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.265 -0.897 . . . . 0.0 109.362 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.755 ' CD1' HG22 ' A' ' 55' ' ' VAL . 25.3 mt -50.08 -44.62 52.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 0.0 109.722 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.518 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 40.1 p -66.36 -68.29 0.38 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.181 -0.949 . . . . 0.0 109.647 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.434 ' H ' ' HG ' ' A' ' 36' ' ' SER . . . -52.5 -27.17 15.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.403 ' N ' ' O ' ' A' ' 34' ' ' PHE . 18.5 m80 -120.06 101.41 7.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -0.86 . . . . 0.0 109.756 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -83.63 -19.01 36.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.404 -0.81 . . . . 0.0 109.371 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -72.51 -13.02 61.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.597 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.479 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -105.6 -14.94 15.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.938 -179.826 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.06 -65.23 0.61 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.005 -1.06 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.42 -20.91 48.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.035 HG13 ' ND2' ' A' ' 95' ' ' ASN . 38.7 t -77.95 -39.0 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.288 -0.883 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.533 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.3 m-85 -74.39 -21.65 59.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.231 -0.918 . . . . 0.0 109.531 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.92 25.21 7.28 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.533 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.7 m-85 -123.76 175.85 6.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -1.112 . . . . 0.0 109.802 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.57 18.4 15.04 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.392 -0.817 . . . . 0.0 109.352 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 147.97 -163.87 28.87 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.518 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -93.09 31.8 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.64 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.1 t -130.46 25.58 5.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.629 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.04 138.18 20.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -66.67 -22.77 49.97 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.994 1.523 . . . . 0.0 109.976 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.508 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.97 -31.67 58.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.755 HG22 ' CD1' ' A' ' 35' ' ' LEU . 92.9 t -54.19 -35.9 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.22 -1.164 . . . . 0.0 109.379 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.473 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . . . -78.53 -5.16 51.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 0.0 109.809 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.417 ' OD2' ' HA2' ' A' ' 54' ' ' GLY . 37.0 m-20 -93.55 -27.45 16.62 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.03 -1.044 . . . . 0.0 109.558 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.862 ' O ' HG23 ' A' ' 62' ' ' VAL . 6.4 mt -88.13 -63.97 1.22 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.073 -1.017 . . . . 0.0 109.354 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.477 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -51.19 -37.07 37.27 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -67.32 -34.34 77.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.859 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 0.0 OUTLIER -87.06 -34.49 19.15 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 109.785 -179.82 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.862 HG23 ' O ' ' A' ' 58' ' ' LEU . 24.4 t -67.24 -47.46 81.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.935 . . . . 0.0 109.719 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.8 mm? -47.89 -46.99 32.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.79 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.78 -48.08 20.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.257 -0.902 . . . . 0.0 109.973 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -55.4 -53.3 58.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.111 -0.993 . . . . 0.0 109.42 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 1.007 ' O ' HG23 ' A' ' 70' ' ' VAL . 52.2 mt -51.77 -38.47 22.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.362 -0.836 . . . . 0.0 109.176 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.574 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.06 -55.69 28.84 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.773 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.465 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 98.9 t -59.94 -29.2 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -1.126 . . . . 0.0 109.758 -179.592 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.53 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.76 -10.64 57.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 110.075 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.058 HG13 HG12 ' A' ' 10' ' ' VAL . 42.1 t -71.53 -42.32 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.012 -1.055 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.31 -12.49 59.96 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.056 -1.027 . . . . 0.0 110.032 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.483 ' N ' ' ND1' ' A' ' 72' ' ' HIS . 9.0 m80 -110.99 52.6 0.73 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.145 -0.972 . . . . 0.0 109.998 -179.306 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.537 ' CD1' HG11 ' A' ' 10' ' ' VAL . 90.0 mt . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.936 . . . . 0.0 109.168 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.438 ' HG2' ' HB3' ' A' ' 72' ' ' HIS . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.48 -30.51 46.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.364 -0.835 . . . . 0.0 108.747 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.77 -42.09 97.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.355 -0.841 . . . . 0.0 108.864 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.43 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.6 OUTLIER -61.59 -53.06 61.26 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.368 -0.833 . . . . 0.0 108.931 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 80.5 mmm -57.72 -40.41 79.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.278 -0.888 . . . . 0.0 108.829 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.88 -35.73 46.19 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.243 -0.911 . . . . 0.0 108.606 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.426 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -74.18 -36.06 64.03 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG12 HD11 ' A' ' 141' ' ' LEU . 49.0 t -56.92 -43.89 81.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.306 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.498 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -67.21 -51.38 38.78 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 179.173 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.559 HG23 ' HA3' ' A' ' 144' ' ' GLY . 53.1 t -58.76 -22.39 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.497 -1.002 . . . . 0.0 109.197 179.234 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.7 mmm180 -75.41 -41.59 55.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 109.13 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.539 ' HA ' ' CG ' ' A' ' 93' ' ' TYR . 4.8 m80 -60.31 -28.74 68.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.087 179.335 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 2.0 ttmt -52.44 -26.28 12.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 110.308 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -130.23 45.28 1.15 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.586 -1.292 . . . . 0.0 110.132 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.539 ' CG ' ' HA ' ' A' ' 90' ' ' HIS . 3.2 m-30 -86.01 -170.7 3.22 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.081 -1.246 . . . . 0.0 109.503 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.5 -48.15 45.88 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.035 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -72.95 -44.69 60.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.472 -1.017 . . . . 0.0 109.163 179.777 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.477 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 6.4 tttp 72.55 -54.1 0.69 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.354 -0.841 . . . . 0.0 110.145 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -62.91 78.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.188 -0.945 . . . . 0.0 109.871 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.454 ' N ' ' O ' ' A' ' 96' ' ' LYS . 71.4 mt -113.46 163.27 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.125 -0.984 . . . . 0.0 109.69 -179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.443 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -140.86 135.38 31.3 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.791 179.784 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.67 ' HB1' HG12 ' A' ' 142' ' ' ILE . . . -79.14 1.29 24.9 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.275 -0.89 . . . . 0.0 109.84 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.525 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -80.45 -26.43 38.34 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 109.545 179.88 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.525 ' CD1' ' HG3' ' A' ' 101' ' ' GLU . 93.3 m-85 -78.03 -10.33 59.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.185 -0.947 . . . . 0.0 109.703 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.946 ' CE2' HD22 ' A' ' 141' ' ' LEU . 6.5 m-85 -62.51 -60.71 3.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 110.066 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.0 mt-10 -52.54 -55.72 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.203 -0.936 . . . . 0.0 110.004 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.97 -62.42 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.69 1.363 . . . . 0.0 109.768 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.954 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.83 -23.38 30.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.36 -0.838 . . . . 0.0 109.314 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.2 -48.17 9.97 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.41 -33.53 74.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.137 -1.213 . . . . 0.0 109.585 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.73 -27.86 63.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.216 -0.928 . . . . 0.0 109.5 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 1.008 HD22 ' OH ' ' A' ' 134' ' ' TYR . 2.2 tt -69.67 -35.6 75.29 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.818 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.6 mt -59.73 -34.17 72.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 t -68.72 -33.03 73.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.669 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.661 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -76.37 -39.93 52.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.635 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.498 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 4.2 mtt -50.06 -38.58 38.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.17 -22.52 6.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.194 -0.941 . . . . 0.0 109.561 179.779 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.424 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -57.52 -47.75 81.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.4 ttt85 -73.06 -61.93 1.64 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.723 HD11 ' SD ' ' A' ' 122' ' ' MET . 14.6 pt -97.27 55.88 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.331 -0.855 . . . . 0.0 109.63 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -62.17 -14.44 46.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -107.73 -27.44 5.18 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 6.2 mttm -93.92 -13.44 27.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -1.212 . . . . 0.0 110.146 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.723 ' SD ' HD11 ' A' ' 118' ' ' ILE . 4.0 tpt -71.99 98.23 2.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.509 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.649 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 4.0 p30 -104.6 169.16 8.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.447 -0.783 . . . . 0.0 109.514 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -49.16 -51.75 30.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.25 -0.906 . . . . 0.0 109.625 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.711 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -53.03 -26.72 16.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -0.931 . . . . 0.0 109.441 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -75.69 -58.01 3.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.566 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.564 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.1 ptpt -63.68 -29.29 70.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.147 -0.97 . . . . 0.0 109.286 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.47 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 43.0 t0 -77.32 -43.04 34.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.411 -0.806 . . . . 0.0 109.407 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.767 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -65.34 -39.61 92.59 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 109.212 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.956 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.4 m0 -77.52 -28.32 52.01 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.353 -0.842 . . . . 0.0 108.986 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.564 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -66.34 -30.29 70.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.323 -0.861 . . . . 0.0 109.026 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.45 -34.06 20.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.393 -0.817 . . . . 0.0 109.167 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -74.07 -36.78 64.34 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.441 -0.787 . . . . 0.0 109.13 179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 1.008 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.9 OUTLIER -57.65 -23.74 52.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.386 -0.821 . . . . 0.0 109.39 179.728 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.4 -32.01 42.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.547 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -80.86 -35.38 32.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.599 HD13 HG23 ' A' ' 66' ' ' ILE . 45.5 mt -74.62 -54.21 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.206 -0.934 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 12.2 p -71.0 -40.98 71.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 109.577 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.496 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -57.49 -47.53 87.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.86 -26.27 9.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.244 -1.151 . . . . 0.0 109.586 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.946 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.5 tt -84.98 -18.62 33.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.773 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.67 HG12 ' HB1' ' A' ' 100' ' ' ALA . 76.5 mt -83.04 7.0 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 110.108 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.1 m -101.81 -27.6 12.92 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.056 -1.028 . . . . 0.0 109.62 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.559 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -100.07 -25.03 9.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.526 HD13 HD21 ' A' ' 141' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.287 -1.125 . . . . 0.0 109.561 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.956 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.253 0.549 . . . . 0.0 109.613 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.553 ' O ' HG23 ' A' ' 10' ' ' VAL . 96.4 mt-30 -66.62 -54.02 27.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.794 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.489 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 1.2 ttp180 -50.06 -32.44 15.57 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.207 -0.933 . . . . 0.0 109.571 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 30.9 mm-40 -75.83 -43.85 43.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.332 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.956 HG23 ' O ' ' A' ' 5' ' ' ALA . 24.5 t -61.67 -32.8 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.93 HG12 HG13 ' A' ' 70' ' ' VAL . 91.6 t -62.18 -45.63 98.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.4 179.698 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.6 -15.24 60.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 0.0 109.686 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -84.34 -24.04 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 109.694 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 35.5 p -100.5 -12.54 19.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.868 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.77 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -89.83 -27.65 19.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.102 -0.999 . . . . 0.0 109.81 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.7 mtpp -74.74 -9.87 58.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.167 -0.958 . . . . 0.0 109.708 179.592 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.582 ' HB3' HG21 ' A' ' 118' ' ' ILE . 0.3 OUTLIER -102.31 -61.29 1.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.59 179.925 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.947 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.5 mt -57.74 -41.1 78.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 109.625 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.795 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -101.39 34.48 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.75 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.69 -69.11 1.32 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 p -113.94 -25.3 8.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 109.518 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 17.7 p-10 -80.65 -19.3 45.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.679 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.795 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 20.3 t30 60.32 21.34 10.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.262 -0.899 . . . . 0.0 109.641 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.81 20.39 31.47 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -65.5 -50.88 63.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.218 -1.166 . . . . 0.0 109.532 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.469 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.94 -5.0 86.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.695 HG21 ' CG2' ' A' ' 17' ' ' ILE . 43.5 t -87.47 -33.08 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.996 -1.296 . . . . 0.0 109.724 -179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.97 -41.01 9.87 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.469 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.3 ptpt -63.67 -31.87 73.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -1.18 . . . . 0.0 109.826 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.45 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 15.8 pt-20 -89.58 -14.71 34.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.167 -0.958 . . . . 0.0 110.083 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.674 ' SG ' HD12 ' A' ' 110' ' ' LEU . 42.2 t -91.58 -63.66 1.22 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.137 -0.977 . . . . 0.0 109.999 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.518 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 14.3 m-85 -54.19 -37.34 64.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.226 -0.922 . . . . 0.0 109.907 -179.53 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.807 ' OG1' HG11 ' A' ' 55' ' ' VAL . 8.7 m -53.18 -32.88 50.15 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.051 -1.031 . . . . 0.0 108.907 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.435 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 3.9 mmtt -76.14 -47.48 24.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.34 -0.85 . . . . 0.0 109.067 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.574 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.1 t80 -61.41 -49.64 76.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.854 ' CD1' HG22 ' A' ' 55' ' ' VAL . 70.2 mt -54.83 -44.22 73.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.129 -0.982 . . . . 0.0 109.401 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.532 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 82.7 p -73.48 -66.09 0.74 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.366 -0.834 . . . . 0.0 109.982 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.456 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -49.61 -30.08 8.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.205 -0.934 . . . . 0.0 109.702 -179.724 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 25.9 m80 -123.63 110.12 14.6 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.264 -0.898 . . . . 0.0 109.785 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -88.93 -18.66 27.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.502 -0.748 . . . . 0.0 109.31 179.444 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -66.51 -21.1 66.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.264 -0.897 . . . . 0.0 109.227 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.536 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 88.6 mmm -107.91 -23.94 11.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 109.75 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.37 -34.29 15.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.865 -1.147 . . . . 0.0 109.136 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.67 -36.75 70.73 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.354 -0.841 . . . . 0.0 109.118 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.87 HG13 ' OD1' ' A' ' 95' ' ' ASN . 20.4 t -58.41 -63.7 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.034 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.589 ' CD2' HD21 ' A' ' 35' ' ' LEU . 84.4 m-85 -56.42 -27.59 56.97 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.319 -0.863 . . . . 0.0 109.1 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 42' ' ' ALA . . . 108.99 -138.45 14.76 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 1.7 m-85 61.04 170.65 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.105 -1.232 . . . . 0.0 109.83 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.4 t -115.01 25.79 10.63 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.67 -163.94 27.51 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.532 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -89.25 16.36 7.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.165 -1.197 . . . . 0.0 109.901 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.99 35.29 4.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.116 -0.99 . . . . 0.0 109.691 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.463 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 2.8 t70 -114.43 137.37 22.58 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.616 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -62.75 -24.46 74.65 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.92 1.484 . . . . 0.0 110.067 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.538 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -40.7 47.22 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.854 HG22 ' CD1' ' A' ' 35' ' ' LEU . 67.3 t -49.95 -34.03 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -1.143 . . . . 0.0 109.474 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.514 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -75.72 -20.66 58.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.777 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -86.37 -46.81 9.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.639 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.774 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.9 OUTLIER -64.59 -62.76 1.39 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.204 -0.935 . . . . 0.0 109.581 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.518 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.97 -47.44 40.14 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.514 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -57.41 -40.21 77.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -1.185 . . . . 0.0 109.587 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -74.55 -24.37 58.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.774 HG23 ' O ' ' A' ' 58' ' ' LEU . 51.2 t -81.9 -49.14 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.901 . . . . 0.0 109.641 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.8 HD21 HD11 ' A' ' 110' ' ' LEU . 2.5 mm? -48.15 -46.6 34.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.926 . . . . 0.0 109.751 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.8 -50.86 59.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.256 -0.902 . . . . 0.0 109.821 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 33.5 tp60 -48.75 -51.25 29.97 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.087 -1.008 . . . . 0.0 109.577 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.937 ' O ' HG23 ' A' ' 70' ' ' VAL . 96.7 mt -56.46 -30.97 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.223 -0.923 . . . . 0.0 109.043 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.565 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -68.66 -56.9 8.71 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.8 t -57.8 -20.71 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.247 -1.149 . . . . 0.0 109.243 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.02 -34.1 18.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.675 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.937 HG23 ' O ' ' A' ' 66' ' ' ILE . 55.1 t -60.84 -15.89 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.202 -0.936 . . . . 0.0 109.887 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.501 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 23.9 m -91.55 16.14 11.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.182 -0.949 . . . . 0.0 110.29 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.9 m-70 -160.95 40.82 0.16 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.926 -1.109 . . . . 0.0 110.37 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.871 HD11 HG11 ' A' ' 10' ' ' VAL . 22.7 mt . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.013 -1.055 . . . . 0.0 109.479 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.46 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 14.7 ttp . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.291 0.567 . . . . 0.0 109.694 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.45 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.5 t -70.39 -23.1 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.222 -0.924 . . . . 0.0 109.284 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.76 -37.03 73.37 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.214 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.443 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.0 OUTLIER -81.39 -49.12 11.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.264 179.681 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.564 ' CE ' HD12 ' A' ' 141' ' ' LEU . 3.1 mtp -59.47 -46.17 89.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.233 -0.917 . . . . 0.0 109.103 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.659 ' O ' HG23 ' A' ' 88' ' ' VAL . 3.8 tptp -53.49 -33.4 54.2 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 108.915 179.426 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.423 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -70.9 -33.43 70.55 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.401 -0.812 . . . . 0.0 109.248 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.723 ' CG1' HD11 ' A' ' 141' ' ' LEU . 44.4 t -62.66 -52.25 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 109.237 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -52.35 -42.55 56.71 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 84' ' ' LYS . 95.7 t -51.8 -26.6 7.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.346 -1.091 . . . . 0.0 109.231 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.444 ' HB2' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -80.91 -24.76 38.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.273 -0.892 . . . . 0.0 108.848 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.738 ' O ' HD12 ' A' ' 98' ' ' ILE . 41.4 m80 -82.1 -4.67 57.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.528 -0.732 . . . . 0.0 109.894 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HD2' ' HA ' ' A' ' 88' ' ' VAL . 8.9 ptmm? -81.8 -8.64 59.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.796 -1.19 . . . . 0.0 110.357 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -164.33 59.42 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.153 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.755 ' HD2' HD11 ' A' ' 98' ' ' ILE . 0.9 OUTLIER -84.21 -163.5 0.8 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.267 . . . . 0.0 109.25 179.021 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.9 -26.48 74.31 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 -179.328 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.917 ' H ' HD21 ' A' ' 95' ' ' ASN . 0.0 OUTLIER -91.79 -32.88 15.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.258 . . . . 0.0 109.933 -179.668 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 56.85 30.93 18.72 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.129 -0.982 . . . . 0.0 109.649 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 3.9 m-70 -137.44 47.44 2.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.159 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.755 HD11 ' HD2' ' A' ' 93' ' ' TYR . 59.7 mt -89.9 159.78 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.286 -0.884 . . . . 0.0 110.576 -179.172 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.494 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -152.27 142.17 22.08 Favored 'General case' 0 N--CA 1.487 1.424 0 CA-C-O 121.636 0.732 . . . . 0.0 109.684 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.749 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -78.98 -3.02 42.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.647 -0.658 . . . . 0.0 109.62 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -73.11 -33.19 65.42 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.975 -1.078 . . . . 0.0 109.488 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.564 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 85.9 m-85 -78.46 -15.58 58.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.244 -0.91 . . . . 0.0 110.125 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.635 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.6 m-85 -59.66 -63.4 1.31 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.163 -0.961 . . . . 0.0 110.248 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.484 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.4 mt-10 -45.49 -58.43 5.95 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.427 -0.796 . . . . 0.0 110.797 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.564 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.2 Cg_endo -59.99 -46.1 20.89 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.748 1.394 . . . . 0.0 109.923 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.919 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -67.11 -20.02 65.72 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 109.25 179.709 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -84.47 -47.38 5.45 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.55 -28.26 66.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -1.114 . . . . 0.0 109.354 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.89 -34.74 69.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.3 -0.875 . . . . 0.0 109.482 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.977 HD13 ' OH ' ' A' ' 134' ' ' TYR . 2.5 tt -65.38 -34.43 78.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.198 -0.938 . . . . 0.0 109.425 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.684 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.2 mt -58.51 -35.48 72.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.097 -1.002 . . . . 0.0 109.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.421 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 21.2 t -70.09 -26.31 63.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.429 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.502 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.93 -33.15 21.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.679 ' SD ' HD23 ' A' ' 110' ' ' LEU . 0.8 OUTLIER -53.87 -44.26 70.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.995 -179.675 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.452 ' O ' ' N ' ' A' ' 119' ' ' GLY . 8.1 pt-20 -51.77 -23.01 4.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.23 -0.919 . . . . 0.0 109.818 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.502 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 20.9 m170 -48.97 -41.44 34.17 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.165 -0.959 . . . . 0.0 109.71 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.3 ttt85 -83.48 -55.77 4.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.432 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.582 HG21 ' HB3' ' A' ' 16' ' ' ASP . 3.9 pt -106.64 59.23 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.302 -0.874 . . . . 0.0 109.558 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -67.48 -29.29 73.94 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.75 -18.2 56.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.1 mttt -105.04 -20.36 13.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.067 -1.255 . . . . 0.0 110.102 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.412 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -73.01 80.99 1.21 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.421 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.541 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.2 p30 -82.29 -162.17 0.53 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -0.853 . . . . 0.0 109.706 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.41 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -69.13 -43.13 74.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.469 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.541 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -60.76 -32.25 71.56 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.171 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -68.42 -53.03 26.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.462 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.473 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.3 ptpt -70.45 -29.03 65.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.193 -0.942 . . . . 0.0 109.379 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.473 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 24.2 t0 -80.42 -40.72 25.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.329 -0.857 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -61.66 -42.91 99.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.947 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.2 m0 -75.4 -34.24 61.04 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.3 -0.875 . . . . 0.0 108.846 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.43 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -55.85 -23.48 31.07 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.163 -0.961 . . . . 0.0 108.764 178.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -92.39 -46.28 7.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.43 -0.794 . . . . 0.0 109.308 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.34 -54.08 10.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.263 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.977 ' OH ' HD13 ' A' ' 110' ' ' LEU . 1.3 t80 -49.78 -30.46 9.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.215 179.608 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -74.61 -38.33 62.6 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.309 -0.869 . . . . 0.0 108.877 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.38 -31.69 48.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.399 -0.813 . . . . 0.0 109.27 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.73 HD13 HG23 ' A' ' 66' ' ' ILE . 54.9 mt -66.8 -60.53 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.258 -0.901 . . . . 0.0 108.909 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.421 ' O ' HG12 ' A' ' 142' ' ' ILE . 26.4 p -66.98 -18.09 65.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -0.795 . . . . 0.0 109.765 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -75.31 -45.81 17.79 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.13 -22.0 65.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.222 -1.163 . . . . 0.0 109.808 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.723 HD11 ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -77.87 -13.9 59.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 0.0 109.957 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.749 HD12 ' CB ' ' A' ' 100' ' ' ALA . 37.1 mm -79.68 -12.99 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.438 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 27.5 m -68.54 -64.67 0.82 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.103 -0.998 . . . . 0.0 109.733 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.56 -11.28 68.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.472 ' HB3' ' HA ' ' A' ' 142' ' ' ILE . 9.7 tt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.036 -1.273 . . . . 0.0 109.301 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.964 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.232 0.539 . . . . 0.0 109.73 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.665 ' O ' HG23 ' A' ' 10' ' ' VAL . 75.8 mt-30 -58.38 -55.74 31.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 109.661 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.825 ' HG2' HD12 ' A' ' 73' ' ' LEU . 3.0 ttp180 -49.11 -37.9 23.1 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.286 -0.884 . . . . 0.0 109.625 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -74.28 -40.59 62.21 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.381 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.964 HG23 ' O ' ' A' ' 5' ' ' ALA . 39.5 t -65.0 -24.85 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.89 . . . . 0.0 109.449 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 1.052 HG12 HG13 ' A' ' 70' ' ' VAL . 97.4 t -70.02 -34.72 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.236 -0.915 . . . . 0.0 109.559 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.09 -13.16 59.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -0.901 . . . . 0.0 109.913 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.74 -19.6 22.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.14 -0.975 . . . . 0.0 109.845 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.43 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.5 p -101.29 -14.83 17.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.126 -0.984 . . . . 0.0 109.956 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.717 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.03 -32.42 20.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.687 -179.776 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.2 mtpt -69.71 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.606 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.9 m-20 -99.24 -60.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.118 -0.989 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.918 HD12 ' CH2' ' A' ' 130' ' ' TRP . 66.3 mt -61.17 -41.15 88.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.262 -0.899 . . . . 0.0 109.538 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.681 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -96.34 31.67 2.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.293 -0.879 . . . . 0.0 109.511 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.48 -69.9 1.11 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.6 p -110.29 -32.66 6.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -1.163 . . . . 0.0 109.613 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.65 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 5.0 p-10 -74.93 -18.98 60.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.905 . . . . 0.0 109.638 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.681 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.6 t30 59.39 21.08 9.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 109.597 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.483 ' O ' HD13 ' A' ' 63' ' ' LEU . . . 97.89 34.68 5.36 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.65 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -85.36 -56.34 3.57 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.229 -1.16 . . . . 0.0 109.576 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -66.53 -14.74 62.87 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.777 HG12 HD11 ' A' ' 63' ' ' LEU . 37.8 t -89.18 -11.59 10.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -1.185 . . . . 0.0 109.942 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.506 ' CA ' ' CD1' ' A' ' 63' ' ' LEU . . . -100.06 -41.77 2.76 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.482 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -74.74 -22.15 58.96 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.119 -1.224 . . . . 0.0 110.003 -179.512 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.447 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 22.3 pt-20 -92.38 -21.96 19.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.116 -0.99 . . . . 0.0 109.701 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.4 t -87.18 -68.0 0.78 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.254 -0.903 . . . . 0.0 110.083 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.534 ' HZ ' HG11 ' A' ' 62' ' ' VAL . 29.2 m-85 -46.62 -33.43 4.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.292 -0.88 . . . . 0.0 110.246 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.666 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.79 -52.11 61.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.067 -1.02 . . . . 0.0 109.384 179.699 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -65.18 -46.03 82.45 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.281 -0.887 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.714 ' CG ' HD23 ' A' ' 106' ' ' LEU . 9.4 t80 -49.53 -49.43 46.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.228 -0.92 . . . . 0.0 109.544 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.764 ' CD1' HG22 ' A' ' 55' ' ' VAL . 14.1 mt -57.99 -46.75 84.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.491 ' O ' ' CD2' ' A' ' 39' ' ' HIS . 0.4 OUTLIER -64.56 -62.15 1.76 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.923 . . . . 0.0 109.525 179.907 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.48 -27.15 23.66 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.222 -0.924 . . . . 0.0 109.524 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 20.7 m80 -120.49 97.27 5.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.491 ' CD2' ' O ' ' A' ' 36' ' ' SER . 64.4 m170 -83.08 4.15 27.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.016 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.6 p-10 -94.95 -13.4 25.38 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.081 -1.012 . . . . 0.0 109.942 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' VAL . 98.0 mmm -112.85 -19.25 12.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.086 -1.009 . . . . 0.0 109.966 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.46 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -47.64 -40.34 19.44 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.181 -0.949 . . . . 0.0 109.859 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.154 -0.966 . . . . 0.0 109.509 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.13 HG22 ' ND2' ' A' ' 95' ' ' ASN . 45.9 t -81.2 -34.64 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.557 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.522 ' HB3' ' CD2' ' A' ' 47' ' ' PHE . 24.0 m-85 -76.88 -11.66 59.85 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 110.124 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.4 25.47 25.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.522 ' CD2' ' HB3' ' A' ' 45' ' ' PHE . 14.0 m-85 -125.58 168.64 13.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.912 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.99 -17.39 14.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.416 -0.802 . . . . 0.0 109.202 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.98 -161.6 23.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.99 28.34 3.58 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.325 -1.103 . . . . 0.0 109.713 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 72.1 p -118.02 -16.36 9.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.257 -0.902 . . . . 0.0 109.795 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.1 p-10 -73.07 142.74 82.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.213 -0.93 . . . . 0.0 109.706 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -72.89 -17.38 25.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.976 1.514 . . . . 0.0 110.19 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.5 -38.54 35.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.764 HG22 ' CD1' ' A' ' 35' ' ' LEU . 63.2 t -51.09 -35.92 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.449 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -71.15 -7.15 44.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.27 -0.894 . . . . 0.0 109.691 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.76 -28.26 18.38 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.065 -1.022 . . . . 0.0 109.648 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.968 ' O ' HG23 ' A' ' 62' ' ' VAL . 11.5 mt -88.73 -63.74 1.25 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.071 -1.018 . . . . 0.0 109.681 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.521 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -50.29 -46.99 43.79 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.3 -24.46 19.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -1.156 . . . . 0.0 109.662 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.26 -23.79 12.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.717 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.968 HG23 ' O ' ' A' ' 58' ' ' LEU . 43.4 t -73.23 -56.72 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.983 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.777 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.22 -41.13 17.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.141 -0.974 . . . . 0.0 109.851 -179.927 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.98 -43.19 50.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.515 ' NE2' ' SD ' ' A' ' 83' ' ' MET . 47.6 tp60 -62.69 -41.5 99.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.083 -1.011 . . . . 0.0 109.195 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.909 ' O ' HG23 ' A' ' 70' ' ' VAL . 63.0 mt -57.95 -36.18 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.278 -0.889 . . . . 0.0 108.83 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.88 -59.63 8.86 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 108.689 -1.765 . . . . 0.0 108.689 179.294 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 74.3 t -54.35 -26.16 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.276 -1.132 . . . . 0.0 109.04 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.94 -28.88 25.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.41 -0.806 . . . . 0.0 109.594 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.052 HG13 HG12 ' A' ' 10' ' ' VAL . 52.5 t -68.8 -9.64 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.499 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 18.3 t -93.2 33.57 1.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.007 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.499 ' CG ' ' O ' ' A' ' 71' ' ' SER . 9.1 m-70 -160.25 -87.41 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.189 -0.944 . . . . 0.0 109.731 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.825 HD12 ' HG2' ' A' ' 7' ' ' ARG . 24.3 mt . . . . . 0 N--CA 1.496 1.859 0 O-C-N 121.482 -0.762 . . . . 0.0 110.037 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 64.4 ttp . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.228 0.537 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.404 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 98.0 t -60.1 -18.19 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.24 -0.912 . . . . 0.0 109.421 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -80.8 -21.28 41.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.295 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.42 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.0 OUTLIER -91.91 -47.39 7.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.544 179.864 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.515 ' SD ' ' NE2' ' A' ' 65' ' ' GLN . 99.2 mmm -62.15 -41.08 97.93 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.027 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.863 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.4 OUTLIER -52.98 -32.61 47.17 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.052 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.424 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -76.31 -33.25 59.03 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.077 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.558 HG12 HD11 ' A' ' 141' ' ' LEU . 71.3 t -65.05 -53.12 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.076 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.419 ' HA3' ' HB2' ' A' ' 145' ' ' LEU . . . -53.51 -39.84 60.93 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.863 HG23 ' O ' ' A' ' 84' ' ' LYS . 85.7 t -53.98 -28.34 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -1.113 . . . . 0.0 109.266 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.8 mmt180 -75.19 -48.9 21.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 0.0 108.959 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.605 ' O ' HD12 ' A' ' 98' ' ' ILE . 36.1 m-70 -57.64 -22.37 45.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.306 -0.871 . . . . 0.0 108.912 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.4 -9.82 59.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.414 -0.804 . . . . 0.0 109.941 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.76 50.39 0.75 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.6 m-30 -92.1 -174.11 3.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -1.15 . . . . 0.0 109.512 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.89 -28.48 41.86 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.13 ' ND2' HG22 ' A' ' 44' ' ' VAL . 0.4 OUTLIER -83.76 -46.17 12.54 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.579 -0.953 . . . . 0.0 108.923 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.6 mtpt 72.72 -49.96 0.7 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.56 -0.713 . . . . 0.0 110.76 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.3 m170 -66.46 63.14 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.01 -1.056 . . . . 0.0 110.596 -179.233 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.605 HD12 ' O ' ' A' ' 90' ' ' HIS . 96.7 mt -94.08 159.15 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.089 -1.007 . . . . 0.0 109.235 179.431 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.441 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -139.63 141.78 37.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.17 -0.956 . . . . 0.0 109.852 -179.929 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.86 8.24 18.12 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.855 . . . . 0.0 109.685 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -85.09 -29.9 24.5 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.151 -0.968 . . . . 0.0 108.697 179.784 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.443 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 93.5 m-85 -79.09 -17.01 55.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.32 -0.862 . . . . 0.0 109.636 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.796 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.0 m-85 -56.6 -60.14 3.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.23 -0.919 . . . . 0.0 110.169 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.499 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.4 mt-10 -52.82 -57.41 16.15 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.148 -0.97 . . . . 0.0 110.066 -179.453 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.499 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 34.7 Cg_exo -48.88 -58.88 1.49 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 O-C-N 123.626 1.329 . . . . 0.0 110.13 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.821 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.94 -28.89 54.64 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.388 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.26 -50.12 13.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.42 -37.49 87.72 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -1.128 . . . . 0.0 109.503 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 t -68.48 -35.25 77.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.326 -0.859 . . . . 0.0 109.576 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.937 HD22 ' OH ' ' A' ' 134' ' ' TYR . 3.8 tt -67.02 -31.57 72.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.398 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.911 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -61.43 -33.35 73.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.161 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.418 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 2.7 t -72.93 -26.77 61.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.398 179.68 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.623 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -85.46 -22.75 28.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.487 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.6 mtt -65.0 -36.43 84.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.351 -0.843 . . . . 0.0 109.882 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' N ' ' A' ' 119' ' ' GLY . 12.5 pt-20 -58.53 -18.47 29.73 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.464 179.871 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.623 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 1.0 OUTLIER -56.04 -36.12 67.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.223 -0.923 . . . . 0.0 109.483 179.771 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HD2' HG23 ' A' ' 118' ' ' ILE . 0.1 OUTLIER -89.72 -42.37 11.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.309 -0.87 . . . . 0.0 109.362 179.778 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.478 HG12 HD11 ' A' ' 17' ' ' ILE . 3.1 pt -119.03 57.01 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.865 . . . . 0.0 109.473 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -64.57 -18.67 63.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.31 -28.53 8.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.462 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.8 mttt -94.44 -17.51 22.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.184 -1.186 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.455 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -76.54 86.2 3.24 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.109 -0.995 . . . . 0.0 109.371 179.762 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.517 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 8.9 p30 -93.61 -163.2 1.02 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.845 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.456 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -68.44 -44.57 74.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -0.856 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.517 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -61.54 -26.06 67.69 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.112 -0.992 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.99 -52.57 8.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.314 -0.866 . . . . 0.0 109.792 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.456 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 9.7 ptmm? -71.74 -25.69 62.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.215 -0.928 . . . . 0.0 109.906 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -84.32 -36.32 22.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.112 -0.992 . . . . 0.0 109.745 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.95 -43.18 72.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.361 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.918 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.5 m0 -71.41 -36.72 71.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.281 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.425 ' N ' HD11 ' A' ' 111' ' ' LEU . . . -60.97 -33.9 73.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.119 179.506 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.66 -30.78 36.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.32 -0.862 . . . . 0.0 109.277 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.528 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -81.13 -40.19 24.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.354 -0.841 . . . . 0.0 109.288 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.937 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.8 OUTLIER -50.26 -34.75 24.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.264 179.642 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.38 -28.26 62.9 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.083 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -83.43 -39.25 20.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.381 -0.824 . . . . 0.0 109.337 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.528 HD12 ' C ' ' A' ' 133' ' ' ALA . 4.6 mt -65.95 -58.25 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.149 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -68.66 -19.7 64.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.403 -0.81 . . . . 0.0 109.63 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -65.96 -57.73 10.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.33 -26.36 3.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 0.0 109.756 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.859 HD23 ' O ' ' A' ' 141' ' ' LEU . 7.5 tt -74.41 -12.47 60.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.97 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.669 HG22 ' O ' ' A' ' 142' ' ' ILE . 75.6 mt -91.37 21.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.089 -1.007 . . . . 0.0 109.763 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.4 t -105.82 -32.87 8.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.167 -0.958 . . . . 0.0 109.691 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -121.46 16.39 9.1 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.541 HD12 ' HB2' ' A' ' 90' ' ' HIS . 4.5 tt . . . . . 0 N--CA 1.491 1.584 0 O-C-N 121.109 -1.23 . . . . 0.0 110.126 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.653 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.231 0.539 . . . . 0.0 109.547 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.602 ' O ' HG23 ' A' ' 10' ' ' VAL . 82.9 mt-30 -60.14 -44.25 95.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.472 ' CG ' ' HB3' ' A' ' 73' ' ' LEU . 5.6 ttp180 -57.17 -29.27 63.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.506 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -82.89 -34.26 26.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.829 . . . . 0.0 109.45 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.653 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.8 t -67.62 -19.57 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.177 -0.952 . . . . 0.0 109.589 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.703 HG12 HG13 ' A' ' 70' ' ' VAL . 93.0 t -73.82 -47.1 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -0.947 . . . . 0.0 109.627 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.26 -13.98 62.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.935 . . . . 0.0 109.841 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.63 -21.65 20.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.184 -0.948 . . . . 0.0 109.9 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -97.67 -12.76 22.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.141 -0.974 . . . . 0.0 110.023 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.03 -28.06 17.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.037 -1.039 . . . . 0.0 109.726 -179.884 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -73.26 -10.92 60.26 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.852 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -104.06 -46.71 4.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.108 -0.995 . . . . 0.0 109.62 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.958 HD12 ' CH2' ' A' ' 130' ' ' TRP . 40.5 mt -70.23 -39.58 77.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.276 -0.89 . . . . 0.0 109.685 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.899 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.1 34.42 2.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.552 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.51 -65.47 3.53 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 26.6 p -111.96 -33.67 6.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.236 -1.155 . . . . 0.0 109.714 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.512 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.7 p-10 -76.63 -18.3 58.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.739 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.899 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 4.3 t30 57.77 20.47 6.51 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.6 21.52 19.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.512 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.02 -54.3 23.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.299 -1.118 . . . . 0.0 109.566 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.471 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.48 2.02 74.22 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.515 HG21 ' CG2' ' A' ' 17' ' ' ILE . 36.9 t -91.94 -40.31 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.053 -1.263 . . . . 0.0 109.529 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.44 -50.54 5.67 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.658 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.473 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 6.4 ptpt -52.7 -30.29 31.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.148 -1.207 . . . . 0.0 109.784 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.473 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.5 pt-20 -91.96 -22.7 19.87 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 109.847 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.4 t -83.14 -65.4 1.01 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.183 -0.948 . . . . 0.0 109.989 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.504 ' O ' HD12 ' A' ' 35' ' ' LEU . 11.3 m-85 -48.46 -29.32 3.98 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 110.024 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.803 ' OG1' HG11 ' A' ' 55' ' ' VAL . 19.5 m -62.98 -60.95 2.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 109.649 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -50.02 -38.02 35.6 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.583 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CD2' HD23 ' A' ' 106' ' ' LEU . 13.2 t80 -69.09 -54.91 12.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.552 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.808 HD13 HG22 ' A' ' 55' ' ' VAL . 12.4 mt -50.57 -44.11 56.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.625 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.671 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 18.9 p -65.73 -51.45 59.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.234 -0.916 . . . . 0.0 109.719 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.4 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -67.32 -19.42 65.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.239 -0.913 . . . . 0.0 109.755 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.439 ' CE1' ' CE1' ' A' ' 34' ' ' PHE . 33.9 m80 -124.51 101.33 7.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.955 . . . . 0.0 109.721 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -86.35 3.53 43.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 110.04 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -93.39 -20.37 20.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.032 -1.043 . . . . 0.0 109.534 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.484 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 88.1 mmm -104.68 -23.29 13.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.703 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.456 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.26 -34.14 14.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.096 -1.003 . . . . 0.0 109.614 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.12 -22.48 48.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.35 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.928 HG13 ' ND2' ' A' ' 95' ' ' ASN . 46.8 t -74.35 -58.3 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -0.868 . . . . 0.0 109.49 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.649 ' CD2' HD21 ' A' ' 35' ' ' LEU . 68.1 m-85 -52.47 -31.21 33.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.567 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.62 2.89 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.542 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.02 166.96 14.84 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.304 -1.115 . . . . 0.0 109.761 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.0 t -105.36 -21.07 13.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.39 -0.819 . . . . 0.0 109.114 179.308 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -169.43 -163.63 23.79 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.671 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -93.29 29.01 2.02 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.196 -1.179 . . . . 0.0 109.615 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.53 27.78 6.42 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.603 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.625 ' OD2' HG23 ' A' ' 55' ' ' VAL . 7.9 p-10 -116.52 141.09 27.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.88 . . . . 0.0 109.708 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -67.41 -22.58 45.24 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 124.01 1.531 . . . . 0.0 110.135 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.83 -38.58 37.67 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.808 HG22 HD13 ' A' ' 35' ' ' LEU . 88.4 t -50.8 -39.7 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -1.092 . . . . 0.0 109.428 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.439 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.02 -20.53 61.68 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.306 -0.871 . . . . 0.0 109.256 179.572 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -74.3 -37.29 63.69 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.48 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.895 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -85.42 -56.16 3.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -0.95 . . . . 0.0 109.555 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -48.52 -49.07 27.54 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.41 -39.41 87.29 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -1.174 . . . . 0.0 109.74 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.3 mttt -77.83 -30.26 51.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.274 -0.891 . . . . 0.0 109.646 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.6 t -76.19 -51.86 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.593 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.456 HD13 HD12 ' A' ' 66' ' ' ILE . 2.1 mm? -48.93 -47.29 43.68 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.66 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.485 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -49.16 -42.95 41.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.52 ' NE2' ' SD ' ' A' ' 83' ' ' MET . 47.3 tp60 -58.33 -43.66 88.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 109.384 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.871 ' O ' HG23 ' A' ' 70' ' ' VAL . 40.7 mt -59.58 -38.7 76.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.264 -0.898 . . . . 0.0 109.033 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.556 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.44 -53.43 28.76 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.279 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.517 HG11 ' OE2' ' A' ' 82' ' ' GLU . 51.8 t -54.06 -31.16 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.317 -1.108 . . . . 0.0 108.962 179.534 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.407 ' O ' ' CD2' ' A' ' 73' ' ' LEU . . . -82.35 -31.46 29.79 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.385 -0.822 . . . . 0.0 109.27 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.871 HG23 ' O ' ' A' ' 66' ' ' ILE . 52.1 t -69.96 -15.3 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.332 -0.855 . . . . 0.0 109.629 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.6 m -85.21 10.86 11.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.039 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -126.27 -72.96 0.63 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.07 -1.019 . . . . 0.0 109.685 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.495 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 3.7 mm? . . . . . 0 N--CA 1.493 1.683 0 O-C-N 121.848 -0.533 . . . . 0.0 110.642 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 ttp . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 121.209 0.528 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.429 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 99.0 t -62.9 -22.72 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.284 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -77.43 -21.04 53.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.291 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.517 ' OE2' HG11 ' A' ' 68' ' ' VAL . 27.0 tt0 -90.06 -49.18 6.73 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.331 -0.856 . . . . 0.0 109.529 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.602 ' HE1' HD12 ' A' ' 141' ' ' LEU . 93.6 mmm -60.9 -40.28 92.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.125 -0.985 . . . . 0.0 109.008 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.744 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.3 OUTLIER -53.04 -31.22 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.243 -0.911 . . . . 0.0 108.556 179.175 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.418 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -75.79 -31.36 59.44 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.201 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.594 HG12 HD11 ' A' ' 141' ' ' LEU . 53.9 t -65.37 -50.33 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.096 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.559 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -54.43 -41.95 73.75 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.744 HG23 ' O ' ' A' ' 84' ' ' LYS . 88.2 t -51.36 -25.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.333 -1.098 . . . . 0.0 109.021 179.415 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.452 ' HB3' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -78.35 -33.33 49.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.364 -0.835 . . . . 0.0 108.904 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.651 ' HB2' HD12 ' A' ' 145' ' ' LEU . 30.9 m80 -80.86 4.7 18.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.398 -0.813 . . . . 0.0 109.611 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.433 ' O ' ' HG2' ' A' ' 91' ' ' LYS . 5.8 ttpp -88.63 -10.24 49.3 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.096 -1.003 . . . . 0.0 110.137 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -160.42 43.95 0.42 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.014 -1.565 . . . . 0.0 111.045 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.542 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.6 m-85 -75.17 -165.18 0.37 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.68 -1.483 . . . . 0.0 109.195 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.3 -36.75 55.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.42 -1.872 . . . . 0.0 108.42 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.928 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.7 t30 -72.16 -58.51 3.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.574 -0.956 . . . . 0.0 109.07 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.485 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 1.9 tttp 76.5 -15.67 0.7 Allowed 'General case' 0 N--CA 1.506 2.358 0 O-C-N 121.637 -0.664 . . . . 0.0 111.391 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.435 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 65.9 m170 -98.73 44.01 1.04 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.598 -1.314 . . . . 0.0 109.119 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.527 HD12 ' O ' ' A' ' 90' ' ' HIS . 71.6 mt -75.22 159.04 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.331 -0.856 . . . . 0.0 109.878 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.451 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -142.49 141.98 32.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.377 -0.827 . . . . 0.0 109.948 -179.971 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.36 2.15 26.02 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.468 -0.77 . . . . 0.0 109.565 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mt-10 -77.61 -34.53 53.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 109.55 179.837 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.484 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 61.6 m-85 -80.42 -0.05 35.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.37 -0.831 . . . . 0.0 110.361 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.458 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.0 m-85 -70.48 -55.37 9.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.012 -1.055 . . . . 0.0 109.75 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.486 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.2 tt0 -59.61 -52.11 76.31 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.185 -0.947 . . . . 0.0 109.746 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.486 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.3 Cg_exo -54.32 -56.13 2.78 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 123.819 1.431 . . . . 0.0 109.843 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.734 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -55.31 -31.12 61.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' O ' ' CB ' ' A' ' 110' ' ' LEU . . . -76.06 -48.09 10.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.59 10.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.263 -1.139 . . . . 0.0 109.421 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.9 t -55.19 -21.51 14.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.271 -0.893 . . . . 0.0 109.298 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.45 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.0 OUTLIER -69.27 -48.84 60.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.329 -0.857 . . . . 0.0 109.532 179.88 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.631 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.5 mt -55.04 -34.66 63.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.098 -1.001 . . . . 0.0 109.159 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.15 -31.67 70.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.324 179.657 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.497 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -81.43 -38.41 26.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.409 179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.468 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.5 mmt -50.38 -45.03 55.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.234 -0.916 . . . . 0.0 109.518 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -49.66 -24.71 2.37 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.888 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.497 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 18.8 m170 -58.49 -50.87 72.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.958 . . . . 0.0 109.495 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.479 ' HD2' HG23 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.56 -52.43 38.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.474 179.898 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 6.1 pt -116.64 65.37 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.25 -0.906 . . . . 0.0 109.707 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -66.48 -10.4 53.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -106.28 -39.55 2.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.507 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 8.7 mmmt -82.24 -25.75 33.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.029 -1.277 . . . . 0.0 109.97 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.437 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.55 84.17 0.1 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.997 -1.065 . . . . 0.0 109.164 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.813 HD21 ' HB3' ' A' ' 125' ' ' ALA . 18.7 p-10 -88.15 -171.46 3.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.373 -0.829 . . . . 0.0 109.792 -179.633 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.419 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -61.05 -45.2 95.75 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.276 -0.89 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.813 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -60.95 -30.13 70.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.382 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.99 -49.15 54.45 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.921 . . . . 0.0 109.475 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.521 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.7 OUTLIER -72.41 -30.67 64.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 109.558 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 25.5 t0 -78.88 -35.15 44.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.241 -0.912 . . . . 0.0 109.279 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.442 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -66.59 -47.37 72.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.322 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.958 ' CH2' HD12 ' A' ' 17' ' ' ILE . 13.9 m0 -72.56 -27.38 62.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.163 -0.96 . . . . 0.0 108.716 179.538 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -63.75 -15.12 57.79 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.349 -0.845 . . . . 0.0 108.957 178.743 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -110.98 -29.26 7.98 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.163 -0.96 . . . . 0.0 109.095 179.588 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.492 ' O ' HD12 ' A' ' 137' ' ' ILE . . . -83.19 -45.46 13.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.436 -0.79 . . . . 0.0 109.559 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.548 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -58.52 -18.58 30.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 109.25 179.914 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.548 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -84.35 -33.13 23.92 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.222 -0.924 . . . . 0.0 108.512 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.58 -36.42 38.19 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.492 HD12 ' O ' ' A' ' 133' ' ' ALA . 4.1 mt -64.56 -61.44 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.443 ' OG ' ' CD2' ' A' ' 103' ' ' PHE . 4.0 t -66.5 -22.4 66.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.583 -0.698 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.96 -52.99 25.23 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.16 -24.61 4.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -1.186 . . . . 0.0 109.436 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.715 HD23 ' O ' ' A' ' 141' ' ' LEU . 5.8 tt -74.25 -22.62 59.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.648 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.492 HG22 ' O ' ' A' ' 142' ' ' ILE . 69.4 mt -81.81 6.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.177 -0.952 . . . . 0.0 110.193 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.2 t -95.46 -36.13 11.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.005 -1.059 . . . . 0.0 109.71 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.15 14.29 28.48 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.651 HD12 ' HB2' ' A' ' 90' ' ' HIS . 4.6 tt . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.061 -1.258 . . . . 0.0 110.055 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.73 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.262 0.553 . . . . 0.0 109.587 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -62.37 -57.71 10.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 110.127 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -28.22 5.35 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.011 -1.055 . . . . 0.0 109.6 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.7 tp60 -78.6 -39.83 36.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.423 -0.798 . . . . 0.0 108.924 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 5' ' ' ALA . 90.0 t -66.7 -33.67 64.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.043 179.336 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.919 HG12 HG13 ' A' ' 70' ' ' VAL . 84.0 t -69.31 -47.51 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.432 -0.793 . . . . 0.0 109.372 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.62 -13.92 62.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.306 -0.871 . . . . 0.0 109.754 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.5 t -90.73 -26.09 19.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.144 -0.972 . . . . 0.0 109.791 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.4 p -97.29 -10.24 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 110.031 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.653 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -92.48 -19.52 21.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.03 -1.044 . . . . 0.0 109.839 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.3 mtpp -81.94 -11.8 58.7 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.915 . . . . 0.0 109.748 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.403 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -103.49 -55.63 2.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.656 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.973 HD12 ' CH2' ' A' ' 130' ' ' TRP . 61.0 mt -64.36 -36.64 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.609 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.82 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -101.85 33.7 2.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.626 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.4 -85.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.8 p -97.96 -23.94 15.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.301 -1.117 . . . . 0.0 109.678 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.689 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 11.6 p-10 -82.34 -19.88 38.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.655 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.82 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 18.5 t30 56.38 25.12 9.15 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.262 -0.899 . . . . 0.0 109.621 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.45 24.94 12.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.689 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -69.91 -52.55 23.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -1.143 . . . . 0.0 109.648 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.03 -12.98 83.08 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.553 HG21 ' CG2' ' A' ' 17' ' ' ILE . 30.7 t -82.03 -36.05 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.129 -1.218 . . . . 0.0 109.873 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.442 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -78.05 -41.32 18.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.477 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 17.4 ptpt -66.1 -29.55 69.89 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.137 -1.214 . . . . 0.0 110.125 -179.578 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.717 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 22.5 pt-20 -92.5 -20.98 20.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.176 -0.952 . . . . 0.0 109.881 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.1 t -82.8 -60.14 2.27 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.522 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 21.0 m-85 -57.5 -32.27 66.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.888 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.691 HG23 HG11 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -52.3 -53.66 41.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.178 -0.951 . . . . 0.0 109.392 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -59.69 -50.59 73.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.309 -0.869 . . . . 0.0 109.562 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.72 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.5 t80 -50.63 -47.26 58.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.738 ' CD1' HG22 ' A' ' 55' ' ' VAL . 17.6 mt -61.14 -45.37 94.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.509 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 29.8 p -67.38 -55.15 14.94 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.224 -0.922 . . . . 0.0 109.817 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.413 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -61.28 -26.53 67.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.189 -0.945 . . . . 0.0 109.708 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.401 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 24.2 m80 -124.49 110.55 14.63 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.224 -0.922 . . . . 0.0 109.881 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -89.47 -8.87 51.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.472 -0.767 . . . . 0.0 109.697 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -81.94 -16.37 50.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.066 -1.021 . . . . 0.0 109.568 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.55 ' HE3' ' CG ' ' A' ' 102' ' ' TYR . 3.9 mmt -104.65 -17.12 14.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.19 -0.944 . . . . 0.0 109.789 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.441 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -54.12 -51.87 62.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.047 -1.033 . . . . 0.0 109.267 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.7 -27.44 68.34 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 109.227 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.963 HG13 ' ND2' ' A' ' 95' ' ' ASN . 9.1 t -69.54 -55.45 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.354 -0.841 . . . . 0.0 109.04 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.524 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.5 m-85 -57.44 -28.77 63.62 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.286 -0.884 . . . . 0.0 109.58 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.65 29.62 4.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 12.6 m-85 -126.06 172.24 10.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.75 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.8 t -115.83 19.68 15.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.339 -0.85 . . . . 0.0 109.289 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.92 -164.18 28.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.509 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -92.96 26.32 2.84 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.171 -1.194 . . . . 0.0 109.648 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 26.6 m -121.52 28.59 7.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.626 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.14 135.41 23.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.252 -0.905 . . . . 0.0 109.569 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.2 -21.0 55.78 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.916 1.482 . . . . 0.0 110.061 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.512 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.52 -36.36 47.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.738 HG22 ' CD1' ' A' ' 35' ' ' LEU . 59.8 t -53.45 -42.22 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.266 -1.137 . . . . 0.0 109.456 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.432 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -67.86 -21.15 65.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.407 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.12 -37.25 29.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.289 -0.882 . . . . 0.0 109.524 179.89 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.739 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.7 mt -75.81 -61.56 1.88 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.522 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.72 -50.66 30.87 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.432 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.12 -37.27 64.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.278 -1.13 . . . . 0.0 109.493 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 25.2 mttt -80.24 -26.38 39.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.508 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 58' ' ' LEU . 59.9 t -82.17 -49.06 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.188 -0.945 . . . . 0.0 109.556 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 63' ' ' LEU . 2.2 mm? -47.83 -46.8 31.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.25 -0.906 . . . . 0.0 109.657 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.64 -52.32 31.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.925 . . . . 0.0 109.85 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.446 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 6.3 tp-100 -50.89 -45.92 60.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.053 -1.03 . . . . 0.0 109.346 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.935 ' O ' HG23 ' A' ' 70' ' ' VAL . 42.1 mt -57.53 -39.06 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.298 -0.876 . . . . 0.0 109.097 179.417 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.556 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.99 -54.19 32.21 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.6 t -56.8 -29.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -1.113 . . . . 0.0 109.466 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.424 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -83.26 -31.31 27.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.345 -0.847 . . . . 0.0 109.659 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.935 HG23 ' O ' ' A' ' 66' ' ' ILE . 51.5 t -61.57 -18.03 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.21 -0.931 . . . . 0.0 109.672 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.436 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -89.33 -1.29 58.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.163 -0.96 . . . . 0.0 110.131 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.464 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 18.9 m-70 -135.84 52.47 1.99 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.989 -1.069 . . . . 0.0 109.954 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.422 HD11 ' HA ' ' A' ' 70' ' ' VAL . 34.9 mt . . . . . 0 N--CA 1.492 1.648 0 O-C-N 121.123 -0.986 . . . . 0.0 109.442 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.464 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 52.6 ttp . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.472 ' O ' HG12 ' A' ' 80' ' ' VAL . 95.8 t -76.97 -0.65 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 110.012 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.76 -31.12 26.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.04 -1.038 . . . . 0.0 109.366 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.495 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 3.1 tp10 -94.74 -44.59 7.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.416 ' HG2' ' OE1' ' A' ' 65' ' ' GLN . 3.4 mtp -55.12 -50.03 70.27 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.228 -0.92 . . . . 0.0 109.35 179.786 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.478 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.3 mtpt -50.38 -40.71 50.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.151 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.495 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -57.66 -34.14 69.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.372 -0.83 . . . . 0.0 109.274 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.412 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 4.0 t -68.0 -35.13 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.139 -0.976 . . . . 0.0 109.024 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.594 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -64.16 -49.45 66.55 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.735 -1.746 . . . . 0.0 108.735 179.611 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.465 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 83.9 t -55.94 -19.7 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.371 -1.076 . . . . 0.0 109.575 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.523 ' HD3' ' N ' ' A' ' 89' ' ' ARG . 0.0 OUTLIER -84.67 -45.15 12.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.802 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.599 ' CD2' HD13 ' A' ' 98' ' ' ILE . 3.7 m80 -64.12 -10.52 23.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.44 -0.788 . . . . 0.0 110.637 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.465 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -82.25 7.4 13.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.83 -1.169 . . . . 0.0 110.335 -179.817 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.93 51.96 0.31 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.517 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.3 m-30 -91.85 -168.61 2.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -1.156 . . . . 0.0 109.912 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -63.5 -19.75 62.77 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.963 ' ND2' HG13 ' A' ' 44' ' ' VAL . 10.3 p-10 -105.06 -26.05 12.28 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.056 -1.261 . . . . 0.0 110.062 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.6 mttt 49.49 29.86 3.13 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.141 -0.974 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -137.34 29.43 2.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.297 -0.877 . . . . 0.0 109.693 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.599 HD13 ' CD2' ' A' ' 90' ' ' HIS . 35.6 mt -72.51 158.99 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.181 -0.949 . . . . 0.0 109.684 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.64 174.06 10.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.817 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.551 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -100.88 -19.17 16.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.532 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -68.21 -20.61 64.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.224 -0.922 . . . . 0.0 109.563 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.55 ' CG ' ' HE3' ' A' ' 41' ' ' MET . 46.7 m-85 -80.17 -22.06 42.37 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.201 -0.937 . . . . 0.0 109.675 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.712 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -58.99 -62.59 1.77 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.328 -0.858 . . . . 0.0 110.244 -179.295 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.1 mt-10 -45.06 -58.69 5.22 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.848 . . . . 0.0 110.867 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.539 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.6 Cg_endo -56.49 -47.95 21.41 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.665 1.35 . . . . 0.0 110.213 -179.413 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.952 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -65.78 -20.54 66.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.165 -0.959 . . . . 0.0 109.459 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.64 -42.78 9.71 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.18 -49.33 74.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -1.212 . . . . 0.0 109.538 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.68 -18.16 52.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.649 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.794 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.7 OUTLIER -73.86 -35.29 64.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.929 . . . . 0.0 109.76 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.768 HD21 ' HB3' ' A' ' 130' ' ' TRP . 14.3 mt -68.36 -32.49 72.61 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.673 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 m -71.66 -22.4 61.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.717 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -87.13 -39.29 15.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.794 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.6 mtt -56.41 -36.33 68.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.323 -0.86 . . . . 0.0 109.863 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.456 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -54.37 -21.25 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.168 -0.957 . . . . 0.0 109.533 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -65.27 -23.75 67.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 109.905 -179.775 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.507 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 4.5 ttt85 -94.07 -69.6 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.101 -0.999 . . . . 0.0 109.861 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.558 HG23 HG12 ' A' ' 17' ' ' ILE . 16.5 pt -78.28 -32.9 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.205 -0.934 . . . . 0.0 109.61 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.465 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.09 -97.23 0.01 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -46.64 -45.11 17.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.494 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 2.8 mptt -69.67 -11.61 60.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.456 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -84.33 79.79 9.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.087 -1.008 . . . . 0.0 109.383 179.556 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.579 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.4 p30 -80.52 -165.81 0.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.606 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.424 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -69.68 -44.56 70.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.92 . . . . 0.0 109.441 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.579 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -57.67 -36.6 72.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.191 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -61.05 -53.53 55.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.303 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.615 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 14.8 ptpt -70.48 -29.66 66.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.323 -0.861 . . . . 0.0 109.427 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.7 t70 -74.48 -50.34 18.68 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.324 -0.86 . . . . 0.0 109.34 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.589 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -59.67 -43.34 94.03 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.256 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.973 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.9 m0 -73.99 -23.1 59.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.267 -0.896 . . . . 0.0 109.022 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.615 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.48 -26.82 65.67 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.301 -0.874 . . . . 0.0 108.662 178.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.54 -24.16 17.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.449 -0.782 . . . . 0.0 109.1 179.476 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.607 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -70.58 -59.52 2.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.6 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.531 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 12.1 m-85 -51.76 -27.91 13.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.16 -0.963 . . . . 0.0 109.271 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.92 -53.37 32.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.122 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -70.26 -35.77 74.0 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.22 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.607 HD12 ' C ' ' A' ' 133' ' ' ALA . 29.1 mt -68.85 -57.23 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.351 -0.843 . . . . 0.0 109.469 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.2 p -68.91 -27.91 66.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.771 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -68.37 -47.6 56.79 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -56.61 -30.06 62.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.207 -1.172 . . . . 0.0 109.715 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.712 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.2 tt -68.72 -18.77 64.3 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.729 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.551 HD12 ' CB ' ' A' ' 100' ' ' ALA . 39.5 mm -76.47 -3.81 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 0.0 110.043 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.478 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 3.1 m -81.95 -49.01 10.77 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.445 179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.454 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -83.94 -8.36 84.24 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.594 HD12 ' HA2' ' A' ' 87' ' ' GLY . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.07 -1.253 . . . . 0.0 109.14 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.834 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.598 ' O ' HG23 ' A' ' 10' ' ' VAL . 83.9 mt-30 -71.34 -49.21 44.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.292 -0.88 . . . . 0.0 109.669 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -48.64 -31.14 6.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.224 -0.923 . . . . 0.0 109.769 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 42.4 mm-40 -80.87 -49.14 11.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.907 . . . . 0.0 109.648 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.834 HG23 ' O ' ' A' ' 5' ' ' ALA . 36.9 t -53.91 -26.82 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.184 -0.948 . . . . 0.0 109.507 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.911 HG12 HG13 ' A' ' 70' ' ' VAL . 99.0 t -68.41 -54.65 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.519 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.74 -16.09 62.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.816 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 t -86.79 -27.33 23.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.184 -0.947 . . . . 0.0 109.78 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 p -93.79 -12.54 28.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.886 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.644 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.37 -28.53 17.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.088 -1.007 . . . . 0.0 109.684 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -70.83 -13.79 62.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -0.891 . . . . 0.0 109.788 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -101.68 -53.74 2.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.984 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.954 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.2 mt -63.77 -36.61 77.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.262 -0.899 . . . . 0.0 109.603 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.899 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.13 25.65 8.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.311 -0.868 . . . . 0.0 109.728 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.23 -80.41 0.14 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.9 p -98.21 55.15 1.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -1.129 . . . . 0.0 109.563 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.42 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 7.3 p-10 -177.18 -33.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.356 -0.84 . . . . 0.0 109.915 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.899 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 20.6 t30 63.72 37.79 9.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.483 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 78.47 29.06 54.1 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.42 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -75.97 -52.17 10.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.665 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.475 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.75 -22.99 68.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.829 HG12 HD11 ' A' ' 63' ' ' LEU . 48.5 t -67.54 -19.79 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.307 -1.113 . . . . 0.0 109.757 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -91.9 -46.81 3.55 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.475 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.2 ptpt -63.38 -20.81 65.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.153 -1.204 . . . . 0.0 109.787 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.426 ' O ' ' HD2' ' A' ' 33' ' ' LYS . 11.0 pt-20 -99.11 -26.53 14.18 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.4 t -85.09 -51.84 6.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.261 -0.899 . . . . 0.0 109.636 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.635 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.1 m-85 -60.08 -46.04 90.91 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.241 -0.912 . . . . 0.0 109.937 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.638 ' OG1' HG11 ' A' ' 55' ' ' VAL . 53.1 m -49.63 -35.78 22.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.144 -0.972 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.426 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 1.4 mttm -75.79 -43.77 44.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.4 179.694 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.897 ' CG ' HD23 ' A' ' 106' ' ' LEU . 6.6 t80 -60.99 -53.19 60.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.294 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.942 ' CD1' HG22 ' A' ' 55' ' ' VAL . 31.1 mt -57.02 -42.35 80.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.875 . . . . 0.0 109.617 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 43.4 t -65.58 -59.29 4.11 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -0.935 . . . . 0.0 109.582 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.8 -26.47 68.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.189 -0.944 . . . . 0.0 109.631 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 17.8 m80 -120.94 108.5 13.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.74 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -88.66 -21.31 24.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.42 -0.8 . . . . 0.0 109.306 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -68.11 -13.51 62.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.548 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.553 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -104.6 -16.55 14.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.921 -179.814 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.483 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -53.13 -66.26 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.066 -1.021 . . . . 0.0 109.634 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.84 -21.89 44.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.606 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.069 HG13 ' ND2' ' A' ' 95' ' ' ASN . 31.8 t -76.76 -37.16 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.533 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.2 m-85 -76.77 -27.21 55.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.93 . . . . 0.0 109.497 -179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.97 27.2 4.37 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.533 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -123.66 173.33 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -1.147 . . . . 0.0 109.909 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.2 t -109.37 -15.93 14.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.432 -0.792 . . . . 0.0 109.199 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.64 -164.57 29.03 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.26 32.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -1.193 . . . . 0.0 109.617 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 25.8 t -134.89 26.68 3.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.289 -0.882 . . . . 0.0 109.618 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.622 ' OD2' HG23 ' A' ' 55' ' ' VAL . 5.2 p-10 -104.39 150.12 38.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.213 -0.929 . . . . 0.0 109.715 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -74.99 -1.93 11.87 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.042 1.549 . . . . 0.0 110.439 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -77.48 -35.58 36.51 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.942 HG22 ' CD1' ' A' ' 35' ' ' LEU . 77.3 t -51.36 -44.34 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -1.116 . . . . 0.0 109.538 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -71.86 -7.22 47.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -0.855 . . . . 0.0 109.938 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.36 -30.0 14.72 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.687 ' O ' HG23 ' A' ' 62' ' ' VAL . 3.9 mt -84.66 -61.44 1.79 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 109.702 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -51.51 -30.57 27.06 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.469 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -63.51 -52.8 59.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.152 -1.204 . . . . 0.0 109.704 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.601 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 5.5 mttp -73.41 -41.75 62.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.687 HG23 ' O ' ' A' ' 58' ' ' LEU . 87.1 t -50.95 -63.67 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.818 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.829 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -46.84 -40.66 14.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.214 -0.929 . . . . 0.0 109.887 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.601 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.58 -38.69 55.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -0.94 . . . . 0.0 109.422 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.408 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 17.5 tp60 -65.08 -39.87 93.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.313 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.954 ' O ' HG23 ' A' ' 70' ' ' VAL . 67.5 mt -62.46 -34.98 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.074 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.563 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.73 29.84 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.5 t -59.9 -24.24 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -1.119 . . . . 0.0 109.165 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.94 -24.49 26.54 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.443 -0.786 . . . . 0.0 109.425 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.954 HG23 ' O ' ' A' ' 66' ' ' ILE . 52.0 t -68.02 -17.23 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.232 -0.918 . . . . 0.0 109.609 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.504 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.8 OUTLIER -89.65 41.62 1.05 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.146 -0.971 . . . . 0.0 109.703 179.954 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.1 m-70 -161.26 -73.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.588 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.513 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.4 mm? . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.68 -0.638 . . . . 0.0 110.448 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.401 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 58.1 ttp . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.273 0.558 . . . . 0.0 109.549 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.607 HG12 ' HB2' ' A' ' 84' ' ' LYS . 47.5 t -74.53 -22.46 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.201 -0.937 . . . . 0.0 109.519 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.52 -58.44 6.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.698 ' O ' HG23 ' A' ' 86' ' ' VAL . 31.4 mt-10 -74.84 -44.11 50.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.473 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 0.6 OUTLIER -57.84 -57.58 12.15 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.607 ' HB2' HG12 ' A' ' 80' ' ' VAL . 34.5 tttt -51.49 -32.07 26.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.203 179.722 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.479 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -68.94 -43.99 73.96 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 109.311 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.698 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.4 t -54.89 -40.29 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.201 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 90' ' ' HIS . . . -53.58 -49.23 58.32 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.544 HG13 ' CD ' ' A' ' 91' ' ' LYS . 72.8 t -53.59 -49.29 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.305 -1.115 . . . . 0.0 109.084 179.533 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.518 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -49.68 -37.55 29.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.189 -0.944 . . . . 0.0 109.658 179.703 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.64 ' O ' HD12 ' A' ' 98' ' ' ILE . 12.2 m-70 -71.4 -3.69 22.2 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.544 ' CD ' HG13 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -78.96 -11.58 60.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.732 -1.23 . . . . 0.0 110.24 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -151.85 57.73 0.43 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -87.57 -170.73 3.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -1.133 . . . . 0.0 109.534 179.614 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.66 -29.54 67.22 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.703 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.069 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.9 p-10 -99.24 -32.89 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -1.183 . . . . 0.0 109.505 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.456 ' O ' ' CD ' ' A' ' 96' ' ' LYS . 0.0 OUTLIER 67.74 7.36 5.65 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.414 -0.804 . . . . 0.0 110.397 179.612 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.419 ' O ' ' O ' ' A' ' 98' ' ' ILE . 0.8 OUTLIER -95.86 -87.84 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.012 -1.055 . . . . 0.0 108.981 178.964 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.64 HD12 ' O ' ' A' ' 90' ' ' HIS . 15.3 mt 58.65 152.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.363 -0.836 . . . . 0.0 110.694 179.342 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.543 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.48 135.5 14.72 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 121.727 0.775 . . . . 0.0 109.807 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.719 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -72.23 -7.31 48.61 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.658 -0.651 . . . . 0.0 109.532 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.448 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 5.8 pt-20 -75.54 -23.74 56.66 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.086 179.355 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.553 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 25.5 m-85 -85.41 -20.38 29.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.854 . . . . 0.0 109.631 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.931 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.5 m-85 -55.95 -61.05 2.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.26 -0.9 . . . . 0.0 110.045 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -52.37 -57.62 14.77 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.066 -1.021 . . . . 0.0 109.839 -179.66 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.9 Cg_exo -50.72 -63.57 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.667 1.351 . . . . 0.0 109.886 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.897 HD23 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -56.54 -26.76 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.295 -0.878 . . . . 0.0 109.342 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -75.62 -46.05 15.86 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.71 -51.86 66.68 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -1.193 . . . . 0.0 109.273 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 t -56.33 -22.25 29.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.875 . . . . 0.0 109.247 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.51 HD23 ' CG ' ' A' ' 114' ' ' MET . 4.4 tt -67.46 -48.61 66.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.585 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.731 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.6 mt -54.36 -31.68 55.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.137 -0.977 . . . . 0.0 109.398 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -65.84 -49.47 68.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.657 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.518 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -71.45 -32.52 68.42 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.601 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.51 ' CG ' HD23 ' A' ' 110' ' ' LEU . 3.4 mmt -47.57 -38.57 14.59 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.265 -0.897 . . . . 0.0 110.023 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.421 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -63.77 -16.92 62.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.565 -179.776 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.518 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 1.6 m-70 -60.78 -43.97 97.39 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.082 -1.011 . . . . 0.0 109.779 -179.781 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.431 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -72.81 -59.37 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.781 -179.7 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.703 HD11 ' SD ' ' A' ' 122' ' ' MET . 12.3 pt -94.0 40.53 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -0.941 . . . . 0.0 109.876 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.421 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -53.46 117.07 6.52 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 112.73 -31.34 6.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.529 -1.829 . . . . 0.0 108.529 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -98.98 -24.87 14.76 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.339 -1.095 . . . . 0.0 109.13 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.703 ' SD ' HD11 ' A' ' 118' ' ' ILE . 6.5 tpt -67.56 96.34 0.52 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.025 179.428 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.461 ' O ' ' HB3' ' A' ' 126' ' ' ALA . 12.5 p-10 -100.73 -172.11 2.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 0.0 109.621 -179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.436 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -58.71 -52.93 63.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.881 . . . . 0.0 110.045 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.713 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -54.63 -24.91 23.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.157 -0.965 . . . . 0.0 109.418 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.16 -54.06 7.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.353 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.595 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 16.7 ptpt -70.0 -30.22 67.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.919 . . . . 0.0 109.358 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.477 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 63.4 t0 -76.91 -38.3 53.75 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.4 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -66.91 -43.87 82.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.402 -0.811 . . . . 0.0 109.347 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.954 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.9 m0 -75.34 -33.01 61.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.251 -0.905 . . . . 0.0 109.011 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.595 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -52.41 -39.2 60.64 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 108.984 179.205 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.71 -23.0 24.3 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.391 -0.818 . . . . 0.0 108.985 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.693 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -83.45 -63.17 1.41 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 109.518 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.535 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -51.59 -23.97 4.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.182 -0.949 . . . . 0.0 109.098 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.81 -36.78 56.69 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.266 -0.896 . . . . 0.0 109.012 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -78.95 -38.73 36.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.409 -0.807 . . . . 0.0 109.235 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 133' ' ' ALA . 1.4 mp -62.42 -54.89 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.343 -0.848 . . . . 0.0 108.802 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.411 ' O ' HG12 ' A' ' 142' ' ' ILE . 83.6 p -68.44 -17.7 64.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -0.885 . . . . 0.0 109.659 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.39 -35.21 20.97 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.46 -25.5 63.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -1.151 . . . . 0.0 109.621 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.931 HD22 ' CE2' ' A' ' 103' ' ' PHE . 9.9 tt -74.04 -16.49 61.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 109.831 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.719 HD12 ' HB2' ' A' ' 100' ' ' ALA . 51.2 mm -88.19 15.42 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.996 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.6 t -93.25 -45.16 7.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -83.94 -23.3 52.94 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.129 -1.589 . . . . 0.0 109.129 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.478 HD12 ' HB2' ' A' ' 90' ' ' HIS . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.258 -1.142 . . . . 0.0 109.579 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.779 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.193 0.521 . . . . 0.0 109.663 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.758 ' O ' HG23 ' A' ' 10' ' ' VAL . 52.0 mt-30 -66.47 -48.0 71.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.16 -0.963 . . . . 0.0 109.345 179.815 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.609 ' HG2' HD12 ' A' ' 73' ' ' LEU . 3.0 ttp180 -60.84 -24.04 65.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.3 tp60 -83.02 -49.26 9.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.444 -0.785 . . . . 0.0 109.186 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.779 HG23 ' O ' ' A' ' 5' ' ' ALA . 86.3 t -51.56 -27.43 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.404 -0.81 . . . . 0.0 109.498 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.944 HG12 HG13 ' A' ' 70' ' ' VAL . 61.1 t -65.02 -52.22 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.769 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.05 -19.2 64.09 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.202 -0.936 . . . . 0.0 109.596 179.87 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.85 -23.84 36.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.556 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.417 HG21 ' CB ' ' A' ' 126' ' ' ALA . 21.2 p -99.89 -13.22 19.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.789 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.708 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.02 -28.31 19.16 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.128 -0.982 . . . . 0.0 109.759 -179.836 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 14.9 mttt -75.88 -8.7 57.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.904 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -105.4 -47.37 3.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.103 -0.998 . . . . 0.0 109.63 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.967 HD12 ' CH2' ' A' ' 130' ' ' TRP . 57.8 mt -71.9 -35.4 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.218 -0.926 . . . . 0.0 109.635 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.883 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -105.03 33.82 3.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.678 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.14 -75.99 0.2 Allowed Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.2 p -103.73 -37.47 7.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -1.16 . . . . 0.0 109.597 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.694 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 16.0 p-10 -71.61 -20.54 61.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.61 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.883 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.9 t30 57.55 25.29 11.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.627 179.956 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.06 19.94 24.91 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.694 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -68.34 -59.52 3.12 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -1.146 . . . . 0.0 109.56 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -67.02 -12.46 60.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.49 HG21 ' CG2' ' A' ' 17' ' ' ILE . 37.5 t -84.82 -41.25 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.149 -1.206 . . . . 0.0 109.868 -179.819 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.447 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -74.33 -36.73 49.42 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.306 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.477 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 9.7 ptpt -73.2 -26.55 61.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.109 -1.23 . . . . 0.0 110.207 -179.459 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.453 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pt-20 -95.42 -20.65 18.91 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.066 -1.021 . . . . 0.0 109.993 -179.746 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.542 ' SG ' HD12 ' A' ' 110' ' ' LEU . 37.3 t -88.19 -66.73 0.89 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 110.085 -179.577 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.526 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.6 m-85 -48.06 -31.53 5.59 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.048 -179.546 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.943 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -56.17 -51.18 68.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.083 -1.011 . . . . 0.0 109.348 179.705 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.414 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 6.2 mttp -59.61 -48.64 80.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.285 -0.884 . . . . 0.0 109.533 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.732 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.8 t80 -52.63 -47.77 66.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.453 179.863 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.831 ' CD1' HG22 ' A' ' 55' ' ' VAL . 21.5 mt -58.93 -44.01 91.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.288 -0.882 . . . . 0.0 109.607 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.5 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -68.73 -60.98 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 -179.957 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.47 -23.05 9.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -0.921 . . . . 0.0 109.589 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.403 ' O ' ' O ' ' A' ' 35' ' ' LEU . 33.9 m80 -126.24 102.37 7.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.278 -0.889 . . . . 0.0 109.716 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.4 m170 -85.64 6.86 25.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.329 -0.857 . . . . 0.0 109.9 179.699 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -95.09 -18.12 21.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.128 -0.983 . . . . 0.0 109.427 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.436 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 38.7 mmm -107.03 -19.45 13.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.754 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.39 -46.34 37.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.036 -1.04 . . . . 0.0 109.562 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.3 -26.05 60.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.099 179.478 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.009 HG13 ' ND2' ' A' ' 95' ' ' ASN . 27.9 t -70.62 -33.75 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.431 -0.793 . . . . 0.0 109.342 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 10.2 m-85 -78.98 -31.17 44.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.48 26.88 4.07 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.878 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.514 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.0 m-85 -124.02 166.85 15.02 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -1.156 . . . . 0.0 109.706 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.0 t -104.92 -11.16 16.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.855 . . . . 0.0 109.444 179.359 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.9 -164.82 31.84 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.5 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -95.57 30.33 2.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -1.186 . . . . 0.0 109.629 179.938 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.65 27.7 5.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.433 ' OD2' HG23 ' A' ' 55' ' ' VAL . 8.1 p-10 -115.62 142.13 28.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.253 -0.904 . . . . 0.0 109.632 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -66.22 -17.8 54.99 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.054 1.555 . . . . 0.0 110.111 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.506 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -53.37 -39.84 60.0 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.943 HG11 HG23 ' A' ' 32' ' ' THR . 94.4 t -54.98 -34.86 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.401 -1.058 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.455 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -72.89 -27.93 62.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.28 -0.887 . . . . 0.0 109.449 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.54 -31.99 60.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.838 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.0 mt -81.97 -62.55 1.6 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.307 -0.871 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.526 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.68 -51.56 27.84 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -51.92 -37.18 51.68 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -1.145 . . . . 0.0 109.412 179.879 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -81.27 -27.69 35.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.512 179.856 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.838 HG23 ' O ' ' A' ' 58' ' ' LEU . 46.5 t -77.84 -49.64 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.303 -0.873 . . . . 0.0 109.704 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.454 HD13 ' HA ' ' A' ' 63' ' ' LEU . 3.6 mm? -47.51 -51.25 21.23 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.714 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.73 -47.14 20.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.251 -0.906 . . . . 0.0 110.089 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -52.76 -53.72 44.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.099 -1.001 . . . . 0.0 109.356 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.909 ' O ' HG23 ' A' ' 70' ' ' VAL . 55.9 mt -55.49 -34.43 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.174 -0.954 . . . . 0.0 109.074 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.552 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.48 -54.07 31.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.751 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.8 t -60.98 -24.93 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -1.121 . . . . 0.0 109.27 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -85.66 -27.93 25.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.355 -0.84 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.944 HG13 HG12 ' A' ' 10' ' ' VAL . 46.2 t -68.13 -9.75 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.219 -0.925 . . . . 0.0 109.78 179.833 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.7 t -92.26 29.93 1.57 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.046 -1.034 . . . . 0.0 109.763 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 9.4 m-70 -155.27 -91.93 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.817 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.609 HD12 ' HG2' ' A' ' 7' ' ' ARG . 9.2 mt . . . . . 0 N--CA 1.496 1.858 0 O-C-N 121.331 -0.856 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 18.3 tmm? . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.303 0.573 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 96.1 t -77.59 -20.59 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.414 179.827 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.42 -52.4 65.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 109.444 179.88 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -69.73 -50.65 41.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.429 179.75 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.484 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.8 OUTLIER -56.34 -56.51 20.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 109.313 179.737 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.488 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -53.54 -24.44 13.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.205 179.555 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.545 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -77.9 -44.13 27.97 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.407 -0.808 . . . . 0.0 109.479 179.78 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.0 t -53.17 -35.35 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.474 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -60.66 -48.36 86.63 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.8 HG23 ' HA3' ' A' ' 144' ' ' GLY . 64.9 t -57.65 -18.82 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.423 -1.045 . . . . 0.0 109.432 179.332 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.1 OUTLIER -86.72 -46.1 10.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.134 -0.978 . . . . 0.0 109.087 179.617 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.521 ' O ' HD12 ' A' ' 98' ' ' ILE . 14.3 m80 -56.39 -37.5 70.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 109.564 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -60.96 -16.68 45.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.298 -0.876 . . . . 0.0 109.935 -179.863 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -119.97 40.76 2.11 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.7 m-30 -90.42 -172.12 3.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 109.53 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.9 -28.67 37.08 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.906 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.009 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -79.95 -47.94 14.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.478 -1.013 . . . . 0.0 109.18 179.78 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.471 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.7 OUTLIER 75.13 -48.51 0.63 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.623 -0.673 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -68.05 59.44 0.07 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.802 -1.186 . . . . 0.0 110.466 -179.516 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.521 HD12 ' O ' ' A' ' 90' ' ' HIS . 56.1 mt -90.41 156.96 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.069 -1.019 . . . . 0.0 109.027 179.488 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.521 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -137.94 138.93 39.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.056 -1.027 . . . . 0.0 110.055 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -81.15 -3.69 52.95 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -0.873 . . . . 0.0 109.883 179.693 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 43.1 mm-40 -81.38 -22.25 38.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.006 -1.059 . . . . 0.0 109.489 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.531 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 55.0 m-85 -79.96 -15.09 57.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.309 -0.869 . . . . 0.0 109.891 -179.816 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.889 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.2 m-85 -62.93 -61.55 2.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.242 -0.911 . . . . 0.0 110.063 -179.847 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.489 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.4 OUTLIER -44.85 -58.83 4.86 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 110.746 -179.46 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.9 Cg_endo -57.45 -45.95 30.91 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.682 1.359 . . . . 0.0 110.003 -179.569 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.936 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -65.91 -20.09 66.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.301 179.789 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.407 ' HA2' ' CE1' ' A' ' 134' ' ' TYR . . . -86.29 -49.04 4.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.54 -45.49 92.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.2 -1.176 . . . . 0.0 109.537 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.9 m -61.56 -28.97 69.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.494 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.967 HD13 ' OH ' ' A' ' 134' ' ' TYR . 3.7 tt -67.23 -40.03 86.31 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.204 -0.935 . . . . 0.0 109.369 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.656 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.7 mt -54.17 -36.32 63.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.163 -0.961 . . . . 0.0 109.047 179.763 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.8 t -67.01 -30.72 70.9 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.459 179.711 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.444 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -79.96 -38.94 31.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 179.923 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.486 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.6 mmt -48.42 -42.91 33.49 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.228 -0.92 . . . . 0.0 109.618 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -50.67 -24.37 3.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.489 179.843 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.444 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 17.6 m170 -52.0 -53.1 45.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.959 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -72.44 -58.73 3.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.894 . . . . 0.0 109.5 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.608 HD11 ' SD ' ' A' ' 122' ' ' MET . 6.5 pt -102.58 60.79 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.587 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -69.57 -11.01 64.65 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.886 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -105.72 -30.03 4.75 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.861 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 12.7 mttm -93.05 -24.52 18.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.173 -1.192 . . . . 0.0 110.078 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.608 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.9 OUTLIER -64.17 79.55 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.088 -1.008 . . . . 0.0 109.432 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.668 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 8.5 p30 -81.54 -164.52 0.79 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 -179.839 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.409 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.74 -38.46 73.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.181 -0.95 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.668 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -62.74 -33.43 75.12 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.293 -0.879 . . . . 0.0 109.234 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.417 ' CB ' HG21 ' A' ' 13' ' ' THR . . . -67.25 -52.3 42.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.534 179.851 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.523 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.5 OUTLIER -71.04 -29.38 65.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.341 179.835 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.467 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 48.6 t0 -79.81 -32.15 40.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.302 -0.873 . . . . 0.0 109.362 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.08 -43.43 61.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.418 -0.801 . . . . 0.0 109.322 179.752 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.967 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.4 m0 -74.86 -25.8 59.23 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.257 -0.902 . . . . 0.0 108.716 179.489 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -62.48 -26.89 68.77 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.235 -0.916 . . . . 0.0 108.693 178.911 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.45 -40.98 9.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.51 -0.744 . . . . 0.0 109.14 179.517 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -73.6 -58.95 2.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.4 -0.812 . . . . 0.0 109.103 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.967 ' OH ' HD13 ' A' ' 110' ' ' LEU . 1.9 t80 -50.87 -28.07 8.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.33 -0.856 . . . . 0.0 108.997 179.381 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.407 ' HB2' ' O ' ' A' ' 131' ' ' ALA . . . -73.02 -41.35 64.31 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.037 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -76.68 -29.06 56.16 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.483 -0.76 . . . . 0.0 109.059 179.42 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.841 HD13 HG23 ' A' ' 66' ' ' ILE . 42.1 mt -66.54 -61.59 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 108.738 179.532 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.3 p -66.35 -20.6 66.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.431 -0.793 . . . . 0.0 109.726 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.35 -26.98 50.17 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 -179.872 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.0 -19.32 54.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.25 -1.147 . . . . 0.0 109.723 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.889 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.3 tt -79.53 -6.94 58.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.061 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.48 HG22 ' O ' ' A' ' 142' ' ' ILE . 57.5 mt -86.78 9.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.002 -1.061 . . . . 0.0 110.122 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.488 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 7.2 m -83.08 -43.31 16.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.933 -1.104 . . . . 0.0 109.436 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.8 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -97.05 -21.24 21.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.487 HD13 ' HB2' ' A' ' 90' ' ' HIS . 10.7 tp . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.423 -1.045 . . . . 0.0 109.53 179.928 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.848 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.257 0.551 . . . . 0.0 109.545 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.522 ' O ' HG23 ' A' ' 10' ' ' VAL . 3.6 mt-30 -58.23 -54.95 41.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.607 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.726 ' HG2' HD12 ' A' ' 73' ' ' LEU . 10.1 ttp180 -50.8 -31.43 16.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 179.872 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.1 tp60 -80.18 -42.05 24.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.331 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.848 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.3 t -59.34 -25.07 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -0.911 . . . . 0.0 109.433 179.803 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 1.021 HG12 HG13 ' A' ' 70' ' ' VAL . 86.4 t -67.48 -52.39 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.55 -12.12 56.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.873 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.19 -26.65 21.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.138 -0.976 . . . . 0.0 109.891 -179.854 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.443 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 28.2 p -99.65 -7.7 25.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.107 -0.996 . . . . 0.0 109.893 179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.687 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.18 -19.83 22.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.02 -1.05 . . . . 0.0 109.562 -179.759 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 45.1 mtpt -79.74 -15.01 58.31 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.715 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.28 -54.82 3.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.663 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.878 HD12 ' CH2' ' A' ' 130' ' ' TRP . 56.9 mt -65.87 -42.18 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.642 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.889 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -96.45 31.78 2.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.211 -0.93 . . . . 0.0 109.711 -179.855 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.97 -73.29 0.39 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.94 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.6 p -107.04 -26.26 11.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.257 -1.143 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.808 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.5 p-10 -81.01 -19.32 44.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.694 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.889 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 5.3 t30 58.39 22.16 9.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.651 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.411 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 101.73 31.09 5.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.808 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -84.1 -46.49 11.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.261 -1.14 . . . . 0.0 109.584 179.925 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.476 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.38 -1.78 86.61 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.91 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.698 HG11 HD11 ' A' ' 63' ' ' LEU . 21.2 t -88.2 -40.24 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.041 -1.27 . . . . 0.0 109.426 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.49 -53.91 4.51 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.545 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.476 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 18.2 ptpt -48.9 -31.7 7.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.101 -1.235 . . . . 0.0 109.673 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.611 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 24.5 pt-20 -91.62 -21.32 20.87 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.215 -0.928 . . . . 0.0 109.387 179.713 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.422 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 20.8 t -87.6 -64.58 1.13 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.346 -0.847 . . . . 0.0 109.767 -179.794 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.554 ' HB3' HG13 ' A' ' 55' ' ' VAL . 10.5 m-85 -48.28 -34.29 10.18 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 109.955 -179.566 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.891 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -56.74 -54.73 42.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 109.273 179.659 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -55.28 -51.39 66.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 179.847 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.873 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -54.54 -51.7 64.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 109.54 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.707 ' CD1' HG22 ' A' ' 55' ' ' VAL . 16.3 mt -54.81 -45.85 74.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.667 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.9 -59.21 3.46 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.257 -0.902 . . . . 0.0 109.671 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.4 -22.41 53.85 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 0.0 109.624 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 47.5 m80 -131.0 107.85 9.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 109.786 -179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -88.9 -12.53 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.364 -0.835 . . . . 0.0 109.753 179.748 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -73.69 -16.89 61.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.123 -0.986 . . . . 0.0 109.715 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.515 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 73.0 mmm -109.13 -16.25 14.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.165 -0.96 . . . . 0.0 109.882 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.469 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.58 -51.3 28.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.986 -1.071 . . . . 0.0 109.498 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.02 -28.14 64.18 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.127 179.526 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.914 HG13 ' OD1' ' A' ' 95' ' ' ASN . 38.8 t -66.02 -32.1 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.407 -0.808 . . . . 0.0 109.265 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.537 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 29.3 m-85 -82.48 -25.68 33.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.159 -0.963 . . . . 0.0 109.503 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.49 26.79 5.5 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.779 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.2 m-85 -123.43 167.93 13.21 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.37 -1.077 . . . . 0.0 109.888 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 t -109.91 19.17 19.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.385 -0.822 . . . . 0.0 109.282 179.508 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.37 -163.33 29.52 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -179.946 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.19 40.72 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -1.157 . . . . 0.0 109.732 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 20.9 t -139.74 21.02 2.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.687 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.21 139.02 20.06 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.678 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -61.21 -24.73 79.56 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 123.951 1.5 . . . . 0.0 110.089 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.534 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.25 -39.32 42.62 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.891 HG11 HG23 ' A' ' 32' ' ' THR . 59.4 t -51.31 -36.28 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -1.129 . . . . 0.0 109.367 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.581 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -73.38 -10.22 59.51 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.354 -0.841 . . . . 0.0 109.591 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.41 ' OD2' ' HA2' ' A' ' 54' ' ' GLY . 59.5 m-20 -86.78 -57.03 3.13 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.13 -0.981 . . . . 0.0 109.551 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.772 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -63.29 -61.06 2.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.782 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -47.95 -37.38 15.69 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.581 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -69.72 -59.88 2.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.107 -1.231 . . . . 0.0 109.507 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -57.51 -46.57 83.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.268 -0.895 . . . . 0.0 109.34 179.749 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 58' ' ' LEU . 51.4 t -56.66 -52.12 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.268 -0.895 . . . . 0.0 109.558 179.771 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.782 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.4 mm? -47.06 -46.04 22.08 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.182 -0.949 . . . . 0.0 109.753 179.875 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.19 -49.52 52.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.597 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 16.1 tp60 -50.2 -48.75 54.1 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.272 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.987 ' O ' HG23 ' A' ' 70' ' ' VAL . 50.1 mt -57.15 -39.21 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.374 -0.829 . . . . 0.0 109.025 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.22 -53.23 41.25 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.944 -1.662 . . . . 0.0 108.944 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.8 t -59.08 -26.73 34.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -1.089 . . . . 0.0 109.35 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.436 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -84.62 -28.6 26.39 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.421 -0.799 . . . . 0.0 109.58 179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.021 HG13 HG12 ' A' ' 10' ' ' VAL . 58.1 t -61.39 -15.78 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.922 . . . . 0.0 109.733 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -90.94 26.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.212 -0.93 . . . . 0.0 109.959 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.412 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 7.9 m-70 -155.72 -87.0 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.016 . . . . 0.0 109.81 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.726 HD12 ' HG2' ' A' ' 7' ' ' ARG . 21.2 mt . . . . . 0 N--CA 1.495 1.815 0 O-C-N 121.455 -0.778 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 37.2 ttp . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.3 0.571 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 47.9 t -81.19 -21.63 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 179.846 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -28.7 63.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.427 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.424 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.6 OUTLIER -81.48 -52.3 7.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.29 -0.881 . . . . 0.0 109.5 179.875 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.474 ' HE3' ' HB2' ' A' ' 141' ' ' LEU . 99.3 mmm -56.44 -39.81 73.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.186 -0.946 . . . . 0.0 108.975 179.683 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.52 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -52.02 -28.65 17.83 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.077 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -80.08 -33.09 39.13 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.552 -0.718 . . . . 0.0 109.097 179.324 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.9 t -69.62 -33.83 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.22 179.688 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.478 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -65.37 -39.61 95.94 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 84' ' ' LYS . 90.3 t -58.7 -28.08 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.268 -1.137 . . . . 0.0 109.213 179.657 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.525 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -73.69 -25.94 60.48 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.349 -0.844 . . . . 0.0 109.26 179.641 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.535 ' CA ' HD12 ' A' ' 98' ' ' ILE . 18.5 m80 -88.04 18.19 4.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.375 -0.828 . . . . 0.0 110.169 -179.085 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.411 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 1.6 tttt -79.35 -60.56 2.32 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.02 -1.05 . . . . 0.0 110.52 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.44 ' HA2' ' HB2' ' A' ' 96' ' ' LYS . . . -148.24 57.58 0.48 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -179.497 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.525 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -86.62 -148.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.308 -1.113 . . . . 0.0 109.812 -179.864 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -45.24 -70.22 0.65 Allowed Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.914 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.4 OUTLIER -66.79 -50.4 62.79 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 108.802 179.559 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.484 ' HG3' ' N ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER 76.58 -34.58 0.23 Allowed 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.399 -0.813 . . . . 0.0 111.48 179.277 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.484 ' N ' ' HG3' ' A' ' 96' ' ' LYS . 14.2 m170 -87.1 60.52 6.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.466 -1.396 . . . . 0.0 109.554 179.854 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.535 HD12 ' CA ' ' A' ' 90' ' ' HIS . 83.6 mt -87.21 155.06 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.122 -0.986 . . . . 0.0 110.224 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.446 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -133.97 141.37 47.25 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.528 -0.732 . . . . 0.0 109.724 -179.941 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.1 -3.28 54.43 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.358 -0.839 . . . . 0.0 110.213 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.467 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 16.9 pt-20 -78.95 -23.49 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.909 -1.12 . . . . 0.0 109.54 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.521 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 71.8 m-85 -80.33 -7.0 58.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.23 -0.918 . . . . 0.0 110.026 179.837 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.755 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -70.0 -66.91 0.53 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.115 -0.99 . . . . 0.0 110.092 -179.561 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.492 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.78 -60.02 3.48 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.494 -0.754 . . . . 0.0 110.743 -179.338 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.521 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 4.2 Cg_endo -52.87 -55.7 3.5 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.683 1.359 . . . . 0.0 109.995 -179.5 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.942 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -59.98 -19.76 54.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.283 179.745 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.418 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -75.33 -45.72 18.04 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.57 -46.79 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.134 -1.215 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.5 m -64.87 -17.64 64.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.251 -0.905 . . . . 0.0 109.407 179.584 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.889 HD21 ' CE ' ' A' ' 114' ' ' MET . 4.9 tt -74.63 -41.87 59.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.947 . . . . 0.0 109.685 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.738 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -60.24 -28.89 68.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.115 -0.991 . . . . 0.0 109.39 179.636 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.7 t -60.26 -46.15 90.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.334 -0.854 . . . . 0.0 109.64 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.611 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -66.29 -36.92 84.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.889 ' CE ' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.28 -42.69 21.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.316 -0.865 . . . . 0.0 109.85 179.904 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.458 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.97 -24.01 15.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.277 -0.889 . . . . 0.0 109.766 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.513 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.6 m170 -52.38 -55.16 23.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 109.842 -179.784 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.463 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 3.8 ttt85 -72.03 -66.09 0.69 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.188 -0.945 . . . . 0.0 109.833 -179.841 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.687 HG12 HD11 ' A' ' 17' ' ' ILE . 6.6 pt -94.57 58.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.114 -0.991 . . . . 0.0 109.748 -179.826 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.75 -39.49 95.26 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -85.92 -13.46 69.29 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.867 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.443 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.2 mttm -104.71 -20.84 13.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.07 -1.253 . . . . 0.0 109.883 -179.812 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.47 90.45 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.213 179.71 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.54 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 9.1 p-10 -92.5 -172.61 3.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.224 -0.922 . . . . 0.0 110.029 -179.619 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.422 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.65 -48.99 75.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.46 -0.775 . . . . 0.0 110.308 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.63 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -60.52 -24.88 65.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.428 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -75.18 -49.27 20.0 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.461 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.534 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 20.1 ptpt -73.04 -30.85 64.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -0.911 . . . . 0.0 109.74 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.5 t0 -76.71 -41.93 43.42 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.465 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -64.02 -43.28 96.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.368 -0.833 . . . . 0.0 109.376 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.878 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -75.6 -26.24 57.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.288 -0.882 . . . . 0.0 109.314 179.761 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.534 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -64.94 -26.4 68.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.454 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -96.82 -26.37 15.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.441 -0.787 . . . . 0.0 109.276 179.659 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.844 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -73.93 -57.69 3.8 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.364 -0.835 . . . . 0.0 109.449 179.819 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.497 ' CE2' ' HE2' ' A' ' 114' ' ' MET . 17.2 m-30 -50.36 -29.18 9.4 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.333 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.27 -43.95 69.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.372 -0.83 . . . . 0.0 109.08 179.554 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -75.16 -33.32 61.47 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.352 -0.843 . . . . 0.0 109.238 179.663 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.844 HD12 ' C ' ' A' ' 133' ' ' ALA . 3.5 mt -67.9 -59.06 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.314 -0.866 . . . . 0.0 109.192 179.667 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.2 -48.76 64.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.717 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -50.91 -28.59 17.4 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.189 -1.565 . . . . 0.0 109.189 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.06 3.21 31.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -1.132 . . . . 0.0 110.048 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.755 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.2 tt -97.97 -24.38 15.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.933 -1.104 . . . . 0.0 109.804 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.635 HG22 ' O ' ' A' ' 142' ' ' ILE . 6.8 mt -87.2 18.23 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.382 -179.446 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -77.96 -20.67 52.27 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.107 -0.996 . . . . 0.0 108.872 179.489 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.35 1.51 5.71 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.838 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.904 ' O ' HD13 ' A' ' 145' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.681 0 O-C-N 120.849 -1.383 . . . . 0.0 110.1 -179.825 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.901 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.301 0.572 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.548 ' O ' HG23 ' A' ' 10' ' ' VAL . 40.5 mt-30 -70.92 -48.5 53.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.217 -0.927 . . . . 0.0 109.509 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.453 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 13.9 ptm180 -56.31 -30.83 63.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.277 -0.889 . . . . 0.0 109.348 179.856 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.453 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 17.7 mm-40 -73.74 -41.73 62.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.436 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 5' ' ' ALA . 21.6 t -61.4 -22.54 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.867 HG12 HG13 ' A' ' 70' ' ' VAL . 66.4 t -73.37 -43.31 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 109.673 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.79 -8.03 54.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.288 -0.883 . . . . 0.0 110.016 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.5 m -94.23 -30.3 14.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.043 . . . . 0.0 109.826 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.429 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.2 p -92.91 -13.17 29.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.954 -179.835 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.822 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -88.04 -19.49 27.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.117 -0.989 . . . . 0.0 109.849 -179.741 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.2 mtpt -83.87 -4.06 58.38 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.928 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.66 -53.31 2.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.788 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.959 HD12 ' CH2' ' A' ' 130' ' ' TRP . 60.9 mt -66.16 -36.28 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.455 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.823 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.29 27.34 7.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.51 -69.52 1.07 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 p -107.21 -36.95 6.41 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -1.141 . . . . 0.0 109.59 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -71.79 -20.04 61.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.922 . . . . 0.0 109.667 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.823 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 17.5 t30 54.54 30.44 13.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.268 -0.895 . . . . 0.0 109.593 -179.955 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.75 59.99 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.59 -47.3 67.09 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.108 -1.231 . . . . 0.0 109.52 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.23 12.97 62.94 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.52 HG11 HD11 ' A' ' 63' ' ' LEU . 11.3 t -97.84 -32.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.139 -1.212 . . . . 0.0 109.116 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 31' ' ' PHE . . . -86.69 -44.24 5.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.495 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.7 ptpt -53.87 -35.41 61.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -1.195 . . . . 0.0 109.386 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.495 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.3 pt-20 -86.85 -26.83 23.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 109.366 179.714 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.416 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 30.4 t -85.11 -58.31 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.366 -0.834 . . . . 0.0 109.684 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.677 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.4 m-85 -47.3 -32.57 4.82 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.333 -0.854 . . . . 0.0 109.915 -179.72 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.677 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -60.54 -49.22 78.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.158 179.669 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -52.28 64.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.571 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.703 ' CG ' HD23 ' A' ' 106' ' ' LEU . 6.8 t80 -52.4 -54.48 31.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.189 -0.944 . . . . 0.0 109.483 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.918 ' CD1' HG22 ' A' ' 55' ' ' VAL . 38.2 mt -55.7 -43.67 76.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.665 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.572 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 9.6 t -68.81 -65.43 0.7 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.732 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.67 -27.35 16.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.723 -179.937 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.404 ' O ' ' O ' ' A' ' 35' ' ' LEU . 16.3 m80 -123.06 106.72 11.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.914 . . . . 0.0 109.837 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -87.36 -20.83 26.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.429 -0.795 . . . . 0.0 109.294 179.542 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.411 ' OD1' ' HG2' ' A' ' 41' ' ' MET . 16.4 p-10 -66.15 -17.9 65.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.371 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.51 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 84.6 mmm -106.14 -24.5 12.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.266 -0.896 . . . . 0.0 109.705 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.463 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.88 -46.14 42.18 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.078 -1.014 . . . . 0.0 109.61 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.75 -21.12 60.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.302 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.945 HG13 ' CG ' ' A' ' 95' ' ' ASN . 35.8 t -76.16 -40.83 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.299 -0.876 . . . . 0.0 109.412 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.536 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -67.26 -41.79 84.97 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 109.576 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.46 32.94 1.07 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.4 m-85 -125.04 173.15 8.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.225 -1.162 . . . . 0.0 109.629 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 17.6 t -111.51 19.38 18.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 109.371 179.547 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.11 -167.34 30.07 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.572 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -80.86 -23.0 39.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.203 -1.175 . . . . 0.0 109.66 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 12.5 m -84.74 51.24 2.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.923 . . . . 0.0 109.676 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -120.51 136.21 25.13 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.597 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -68.06 -33.45 25.42 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.97 1.511 . . . . 0.0 110.033 -179.906 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.41 -32.39 30.21 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.918 HG22 ' CD1' ' A' ' 35' ' ' LEU . 91.7 t -53.92 -41.61 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.268 -1.136 . . . . 0.0 109.501 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.706 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.5 -11.01 60.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.262 -0.899 . . . . 0.0 109.872 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.401 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 11.4 t0 -91.73 -33.3 15.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.111 -0.993 . . . . 0.0 109.375 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.516 ' HB3' ' CE2' ' A' ' 31' ' ' PHE . 1.6 mt -81.59 -64.25 1.22 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.348 -0.845 . . . . 0.0 110.201 -179.786 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.61 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -56.09 -20.77 29.1 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.37 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.706 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -72.24 -40.76 67.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.109 -1.23 . . . . 0.0 109.761 -179.719 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.401 ' HG3' ' O ' ' A' ' 57' ' ' ASP . 28.6 mttt -84.46 -43.67 14.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.601 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 58' ' ' LEU . 61.6 t -52.56 -47.18 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.128 -0.983 . . . . 0.0 109.48 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -48.09 -47.85 33.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.108 -0.995 . . . . 0.0 109.773 179.81 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.6 -49.38 47.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.912 . . . . 0.0 109.653 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -49.06 -54.96 13.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.135 -0.978 . . . . 0.0 109.378 179.849 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.947 ' O ' HG23 ' A' ' 70' ' ' VAL . 83.7 mt -52.36 -35.32 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.313 -0.867 . . . . 0.0 109.05 179.554 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.85 -57.11 15.21 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.869 -1.693 . . . . 0.0 108.869 179.416 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.5 t -57.58 -25.91 25.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -1.135 . . . . 0.0 109.253 179.76 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.438 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.07 -19.58 34.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.391 -0.818 . . . . 0.0 109.5 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.947 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.0 t -75.47 -14.47 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.686 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.488 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -90.41 35.64 0.88 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.109 -0.994 . . . . 0.0 109.96 -179.824 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 71' ' ' SER . 6.0 m-70 -161.68 -84.75 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.063 -1.023 . . . . 0.0 109.918 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 42.2 mt . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.599 -0.688 . . . . 0.0 109.97 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 59.0 ttp . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.249 0.547 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.8 t -73.07 -14.63 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.872 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.78 -35.08 72.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.126 -0.983 . . . . 0.0 109.835 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.63 ' O ' HG23 ' A' ' 86' ' ' VAL . 10.7 tt0 -98.82 -40.97 7.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.666 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.7 mtp -62.18 -46.55 88.43 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.419 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 13.1 tttt -56.18 -39.27 72.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.172 -0.955 . . . . 0.0 109.172 179.65 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -63.19 -39.65 95.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.388 179.709 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.837 ' CG1' HD11 ' A' ' 141' ' ' LEU . 48.8 t -51.92 -47.96 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.525 ' O ' HD12 ' A' ' 145' ' ' LEU . . . -52.94 -49.88 53.15 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.624 -1.791 . . . . 0.0 108.624 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.647 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.1 t -53.13 -34.75 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.389 -1.065 . . . . 0.0 109.249 179.462 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 24.6 mmm180 -69.56 -49.21 56.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.865 . . . . 0.0 109.416 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.582 ' HB2' HD12 ' A' ' 145' ' ' LEU . 10.7 m80 -61.63 -15.41 39.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.235 -0.916 . . . . 0.0 109.363 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.405 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 4.8 ttmt -43.21 -33.49 0.94 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.466 -0.771 . . . . 0.0 110.917 -179.568 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.39 60.95 0.28 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.11 -1.519 . . . . 0.0 110.675 -179.502 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.9 m-30 -69.83 -166.0 0.1 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.014 -1.286 . . . . 0.0 109.257 178.64 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.31 -22.63 61.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.612 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.945 ' CG ' HG13 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -93.61 -44.06 8.38 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.381 -1.07 . . . . 0.0 109.321 -179.955 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.489 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 27.4 mttt 79.58 -32.14 0.14 Allowed 'General case' 0 N--CA 1.509 2.512 0 O-C-N 121.954 -0.467 . . . . 0.0 111.278 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.433 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 30.7 m170 -60.69 -99.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.518 -1.364 . . . . 0.0 109.99 -179.6 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.556 HD12 ' O ' ' A' ' 90' ' ' HIS . 6.1 mt 62.83 129.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.778 -1.201 . . . . 0.0 109.903 -179.546 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.514 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -145.4 143.35 30.03 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 122.237 1.018 . . . . 0.0 110.85 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.477 ' HB1' HD13 ' A' ' 142' ' ' ILE . . . -69.12 -19.61 64.04 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.047 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -64.9 -32.77 74.64 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.772 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.514 ' CD2' ' HB2' ' A' ' 99' ' ' LYS . 22.9 m-85 -81.26 -25.62 36.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.589 -0.694 . . . . 0.0 109.956 179.847 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.538 ' CZ ' HD22 ' A' ' 141' ' ' LEU . 3.4 m-85 -53.46 -65.88 0.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.22 -0.925 . . . . 0.0 110.344 -179.382 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.6 mt-10 -46.53 -59.43 5.06 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.251 -0.906 . . . . 0.0 110.512 -179.194 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 41.0 Cg_exo -45.42 -55.06 3.78 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.712 1.375 . . . . 0.0 110.621 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.706 ' C ' HD13 ' A' ' 106' ' ' LEU . 3.0 tm? -55.43 -39.13 69.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.34 -40.33 97.75 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.27 -55.07 27.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -1.162 . . . . 0.0 109.766 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.1 t -60.16 -27.43 67.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.202 -0.937 . . . . 0.0 109.703 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.857 HD22 ' OH ' ' A' ' 134' ' ' TYR . 3.2 tt -70.35 -38.92 74.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.205 -0.935 . . . . 0.0 109.589 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.857 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -60.08 -29.39 68.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.15 -0.969 . . . . 0.0 109.41 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 m -73.49 -29.7 62.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.784 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.467 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -80.68 -38.3 29.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.949 . . . . 0.0 109.569 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.597 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.9 mtt -50.1 -39.68 43.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.283 -0.885 . . . . 0.0 109.463 179.857 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.5 OUTLIER -51.67 -24.74 6.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.23 -0.919 . . . . 0.0 109.382 179.565 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.467 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 33.8 m170 -55.67 -49.67 72.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.327 -0.858 . . . . 0.0 109.829 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.438 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 2.9 ttt85 -70.1 -65.37 0.73 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.272 -0.892 . . . . 0.0 109.696 -179.837 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 13.5 pt -87.97 46.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 109.565 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.451 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.49 125.25 35.92 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 95.71 -30.44 8.39 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.743 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.431 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 19.2 mmtt -90.11 -28.71 18.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.227 -1.161 . . . . 0.0 109.166 179.682 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.448 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 1.2 ttt -71.37 107.38 4.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.437 -0.789 . . . . 0.0 109.359 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.507 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 10.0 p30 -109.72 -162.1 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.177 -0.952 . . . . 0.0 109.894 -179.776 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.431 ' O ' ' HB3' ' A' ' 128' ' ' ASP . . . -67.55 -45.78 74.67 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.346 -0.847 . . . . 0.0 109.64 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.798 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.62 -24.03 54.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -86.23 -57.06 3.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.8 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -65.94 -27.33 68.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.153 -0.967 . . . . 0.0 109.692 -179.735 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.431 ' HB3' ' O ' ' A' ' 124' ' ' ALA . 32.1 t70 -80.55 -49.95 10.65 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.311 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -57.7 -50.47 73.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.394 -0.816 . . . . 0.0 109.282 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.959 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.8 m0 -63.89 -30.96 71.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.237 -0.915 . . . . 0.0 108.877 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.98 -30.09 67.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 108.89 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.6 -28.52 23.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.392 -0.818 . . . . 0.0 109.194 179.501 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.85 -40.81 21.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.406 -0.809 . . . . 0.0 109.473 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.857 ' OH ' HD22 ' A' ' 110' ' ' LEU . 1.8 m-85 -50.26 -32.01 15.65 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.45 -34.78 72.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.281 -0.887 . . . . 0.0 109.242 179.638 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.27 -39.68 39.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 0.0 109.371 179.692 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.677 HD13 HG23 ' A' ' 66' ' ' ILE . 54.5 mt -66.05 -58.12 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.274 -0.891 . . . . 0.0 109.145 179.669 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.11 -17.5 64.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.291 -0.881 . . . . 0.0 109.645 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 142' ' ' ILE . . . -68.25 -55.56 12.59 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.23 -28.19 4.38 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.837 HD11 ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -74.82 -21.55 59.22 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -0.893 . . . . 0.0 109.536 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.575 HG22 ' O ' ' A' ' 142' ' ' ILE . 91.0 mt -83.78 8.36 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.292 -0.88 . . . . 0.0 110.096 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.3 m -100.13 -46.0 5.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.04 -1.038 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.647 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -68.86 -31.55 72.94 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.582 HD12 ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.414 179.869 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.581 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.193 0.521 . . . . 0.0 109.819 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.434 ' O ' HG23 ' A' ' 10' ' ' VAL . 73.6 mt-30 -66.67 -33.96 76.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.638 179.903 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 42.9 mtp180 -54.75 -41.82 70.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.644 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -74.73 -36.55 62.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.239 -0.913 . . . . 0.0 109.549 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 5' ' ' ALA . 33.3 t -71.26 -35.8 59.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.151 -0.968 . . . . 0.0 108.987 179.628 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.777 HG23 ' HB1' ' A' ' 129' ' ' ALA . 41.9 t -67.46 -37.24 78.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.399 -0.813 . . . . 0.0 109.057 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.26 -16.29 56.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.345 -0.847 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.6 t -90.3 -22.72 21.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.891 -179.625 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.8 p -95.24 -12.28 26.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 110.028 -179.851 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.575 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.31 -15.07 27.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.042 -1.037 . . . . 0.0 109.973 -179.895 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mtpt -85.92 -2.0 57.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.73 -45.16 3.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.996 -1.065 . . . . 0.0 109.667 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.948 HD12 ' CH2' ' A' ' 130' ' ' TRP . 45.8 mt -72.47 -36.34 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.446 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.677 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -103.02 31.67 4.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.323 -0.86 . . . . 0.0 109.588 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.62 -78.73 0.1 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.54 -27.74 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.434 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 13.4 p-10 -80.01 -20.15 46.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 0.0 109.607 179.959 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.677 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 21.4 t30 56.16 27.7 11.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.875 . . . . 0.0 109.645 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.94 22.38 42.51 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -59.21 -52.37 65.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -1.161 . . . . 0.0 109.569 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.425 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -92.92 26.11 16.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.696 HG11 HD11 ' A' ' 63' ' ' LEU . 39.2 t -110.14 -22.73 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.29 -1.123 . . . . 0.0 108.887 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.412 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -100.15 -26.97 8.01 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 179.79 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.485 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 14.2 ptpt -70.19 -34.99 73.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.245 -1.15 . . . . 0.0 109.385 179.789 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.737 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -92.34 -8.9 43.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.157 -0.964 . . . . 0.0 109.839 179.678 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.6 t -93.25 -61.3 1.6 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.067 -1.021 . . . . 0.0 109.722 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.509 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.9 m-85 -55.64 -30.56 61.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.926 . . . . 0.0 109.768 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.759 ' OG1' HG11 ' A' ' 55' ' ' VAL . 17.8 m -58.35 -48.01 81.96 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.125 -0.984 . . . . 0.0 109.395 179.794 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.31 -41.33 98.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.317 -0.865 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.643 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.4 t80 -62.14 -44.67 96.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.251 -0.905 . . . . 0.0 109.43 179.84 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.793 ' CD1' HG22 ' A' ' 55' ' ' VAL . 15.7 mt -62.8 -45.53 92.22 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.642 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 3.2 p -66.28 -46.75 75.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.738 -179.934 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 -21.4 62.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -127.82 114.31 17.07 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.758 -179.912 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -93.22 5.29 52.03 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.357 -0.839 . . . . 0.0 109.984 179.736 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -95.6 -22.18 17.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.044 -1.035 . . . . 0.0 109.486 179.811 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.482 ' SD ' ' CG ' ' A' ' 102' ' ' TYR . 0.4 OUTLIER -97.01 -22.45 16.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.309 -0.87 . . . . 0.0 109.615 179.977 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.415 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.16 -50.75 61.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.196 -0.94 . . . . 0.0 109.536 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -66.41 -21.39 66.22 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.895 . . . . 0.0 109.585 179.897 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.944 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.6 t -79.73 -55.98 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.517 ' CD2' HD21 ' A' ' 35' ' ' LEU . 33.7 m-85 -53.74 -40.9 66.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.79 31.78 1.41 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 -179.849 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.504 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.9 m-85 -125.36 -179.07 4.44 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -1.176 . . . . 0.0 109.749 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.9 t -123.99 19.17 9.25 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.417 -0.802 . . . . 0.0 109.299 179.481 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.44 -163.38 27.53 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.642 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -77.92 -19.08 55.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.698 -180.0 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 8.5 t -85.41 50.13 1.89 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -128.62 117.8 19.84 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.615 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -59.28 -29.54 90.56 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.842 1.443 . . . . 0.0 110.108 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.504 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.96 -34.49 38.44 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.793 HG22 ' CD1' ' A' ' 35' ' ' LEU . 89.3 t -52.26 -31.47 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.274 -1.133 . . . . 0.0 109.636 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.427 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -77.36 -21.86 52.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.487 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.83 -45.55 16.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.9 . . . . 0.0 109.557 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.956 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.9 mt -68.25 -59.06 3.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -0.925 . . . . 0.0 109.535 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.509 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -51.17 -54.8 21.77 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.421 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -53.19 -37.61 62.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -1.17 . . . . 0.0 109.59 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 mttm -77.98 -25.79 48.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.956 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.9 t -82.61 -40.91 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.696 HD11 HG11 ' A' ' 26' ' ' VAL . 1.6 mm? -50.11 -55.03 16.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.554 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -43.67 36.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.229 -0.919 . . . . 0.0 109.71 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.414 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 0.2 OUTLIER -51.59 -54.17 30.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 179.79 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.78 ' O ' HG23 ' A' ' 70' ' ' VAL . 69.2 mt -55.48 -34.65 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.263 -0.898 . . . . 0.0 108.98 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.567 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.84 -55.15 18.23 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.5 t -57.79 -22.12 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.322 -1.105 . . . . 0.0 109.138 179.759 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.68 -31.17 21.18 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.392 -0.818 . . . . 0.0 109.461 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.78 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.0 t -69.24 -17.09 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 109.484 179.728 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -61.97 -37.93 86.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -0.941 . . . . 0.0 109.912 -179.832 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.437 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 22.5 m-70 -129.29 81.73 2.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 109.885 -179.815 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.611 HD11 HG11 ' A' ' 10' ' ' VAL . 53.5 mt . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.892 . . . . 0.0 109.461 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.437 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 49.5 ttp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.287 0.565 . . . . 0.0 109.652 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.455 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 60.0 t -77.29 -0.53 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 110.036 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.11 -24.12 26.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.04 -1.038 . . . . 0.0 109.595 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.564 ' O ' HG23 ' A' ' 86' ' ' VAL . 4.6 tt0 -106.77 -41.05 5.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.545 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.638 ' HE2' HD12 ' A' ' 141' ' ' LEU . 10.1 mtp -67.98 -40.81 83.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.219 -0.926 . . . . 0.0 108.949 179.653 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 6.0 tttt -56.28 -28.56 59.12 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 179.009 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.425 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -78.49 -31.92 47.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.48 -0.763 . . . . 0.0 109.056 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.936 ' CG1' HD11 ' A' ' 141' ' ' LEU . 47.3 t -62.72 -41.78 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.245 -0.91 . . . . 0.0 109.06 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 141' ' ' LEU . . . -54.06 -41.78 69.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.356 -1.898 . . . . 0.0 108.356 179.53 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.442 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 97.5 t -56.34 -46.54 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.426 -1.043 . . . . 0.0 109.252 179.475 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.518 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 10.4 mpt_? -52.05 -29.96 23.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.028 -1.045 . . . . 0.0 109.054 179.466 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.503 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 34.6 m80 -84.22 9.51 12.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.417 -0.802 . . . . 0.0 110.022 -179.894 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 25.0 ttpt -104.36 -11.74 16.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.034 -1.041 . . . . 0.0 110.241 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.17 18.79 2.31 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.142 -1.504 . . . . 0.0 110.855 -179.242 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CZ ' ' HB3' ' A' ' 89' ' ' ARG . 1.6 m-85 -58.9 -164.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.644 -1.504 . . . . 0.0 109.174 179.317 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.77 -31.21 40.83 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 179.625 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.944 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -81.14 -48.67 11.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.529 -0.983 . . . . 0.0 108.787 179.703 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.8 tmtt? 76.83 -19.3 0.43 Allowed 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.652 -0.655 . . . . 0.0 111.901 179.162 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.414 ' HB2' ' OD1' ' A' ' 95' ' ' ASN . 37.8 m170 -72.31 -95.82 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.443 -1.411 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.496 HG13 ' ND2' ' A' ' 95' ' ' ASN . 8.1 mt 61.71 148.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 120.858 -1.151 . . . . 0.0 110.511 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -156.88 149.66 23.63 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 121.943 0.878 . . . . 0.0 110.521 179.812 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.4 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -76.83 -7.29 55.18 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.681 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.567 ' CG ' ' CD2' ' A' ' 102' ' ' TYR . 12.0 pt-20 -71.38 -34.23 70.24 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.95 -1.094 . . . . 0.0 109.082 179.461 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.567 ' CD2' ' CG ' ' A' ' 101' ' ' GLU . 94.3 m-85 -80.3 -25.46 39.35 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 109.329 179.566 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.481 ' CD2' ' OG ' ' A' ' 138' ' ' SER . 2.7 m-85 -48.12 -62.16 1.62 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.358 -0.839 . . . . 0.0 110.236 -179.798 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.513 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -51.97 -59.84 7.41 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.177 -0.952 . . . . 0.0 110.173 -179.366 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.513 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 36.1 Cg_exo -47.53 -59.69 1.15 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.586 1.309 . . . . 0.0 110.229 179.91 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.922 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.29 -22.57 12.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.91 . . . . 0.0 109.406 179.906 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.01 -44.09 9.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.96 -49.96 74.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -1.163 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 75.6 m -56.65 -31.29 64.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 109.603 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 2.6 tt -62.75 -43.83 97.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.602 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.71 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.7 mt -53.87 -39.19 65.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 13.5 t -62.3 -32.02 72.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.235 -0.915 . . . . 0.0 109.503 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.737 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -78.91 -39.73 34.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.41 179.758 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.547 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -48.72 -45.73 39.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -48.32 -29.31 3.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -0.927 . . . . 0.0 109.968 -179.838 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.419 ' CE1' ' OE1' ' A' ' 29' ' ' GLU . 17.5 m170 -49.9 -56.4 10.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.082 -1.011 . . . . 0.0 109.817 -179.826 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.8 ttt85 -69.77 -63.57 1.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.849 -179.82 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.532 HG12 HD11 ' A' ' 17' ' ' ILE . 4.7 pt -96.61 58.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.313 -0.867 . . . . 0.0 109.709 -179.789 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.36 -20.32 71.38 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.73 -21.1 17.21 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.865 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.494 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -100.62 -19.37 16.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -1.187 . . . . 0.0 109.884 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.406 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.95 79.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.051 -1.031 . . . . 0.0 109.799 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.742 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 15.7 p-10 -80.13 -171.97 3.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.172 179.589 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.452 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.12 -31.35 68.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.066 -1.021 . . . . 0.0 109.907 -179.81 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.742 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -72.18 -23.69 61.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.038 -1.039 . . . . 0.0 109.024 179.668 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.476 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -74.88 -47.55 29.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 108.892 179.403 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 6.9 ptpt -71.79 -31.28 66.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.413 -0.805 . . . . 0.0 109.232 179.569 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.477 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.4 t70 -75.78 -48.52 21.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.777 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -58.55 -44.57 89.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.422 -0.799 . . . . 0.0 109.493 179.844 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.948 ' CH2' HD12 ' A' ' 17' ' ' ILE . 7.0 m0 -74.88 -26.17 59.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.245 179.838 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.611 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.12 -27.3 65.45 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.246 -0.909 . . . . 0.0 108.979 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.414 ' HB3' ' OE1' ' A' ' 6' ' ' GLN . . . -93.46 -23.06 18.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.192 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.629 ' O ' HD12 ' A' ' 137' ' ' ILE . . . -79.81 -42.88 23.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.395 -0.816 . . . . 0.0 109.556 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -49.26 -33.32 12.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.207 -0.933 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.74 -25.15 49.02 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.229 -0.919 . . . . 0.0 108.938 179.412 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.436 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.7 t0 -85.95 -40.76 15.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.387 -0.821 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.629 HD12 ' O ' ' A' ' 133' ' ' ALA . 1.6 mp -65.8 -59.6 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 108.824 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.481 ' OG ' ' CD2' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -64.6 -25.22 67.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.243 -0.911 . . . . 0.0 109.745 -179.85 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.572 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -55.68 -49.56 65.02 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.94 -17.75 64.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.234 -1.156 . . . . 0.0 109.845 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.936 HD11 ' CG1' ' A' ' 86' ' ' VAL . 5.1 tt -84.19 -33.38 24.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.15 -0.969 . . . . 0.0 109.738 -179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.572 HD12 ' HA2' ' A' ' 139' ' ' GLY . 50.6 mt -68.48 -9.25 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 110.065 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 67.6 m -70.51 -65.15 0.77 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.069 -1.019 . . . . 0.0 109.595 179.835 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.45 -7.37 64.09 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.487 HD12 ' HB2' ' A' ' 90' ' ' HIS . 5.9 tt . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.08 -1.247 . . . . 0.0 109.48 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.765 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.161 0.505 . . . . 0.0 109.647 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.408 ' NE2' ' OD1' ' A' ' 128' ' ' ASP . 1.7 mt-30 -77.69 -47.74 18.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.42 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 8.3 ptm180 -52.54 -32.69 41.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.153 -0.967 . . . . 0.0 108.738 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.42 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 49.4 tp60 -71.16 -36.01 71.85 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 5' ' ' ALA . 47.5 t -73.3 -31.74 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.391 -0.818 . . . . 0.0 108.942 179.196 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.758 HG12 HG13 ' A' ' 70' ' ' VAL . 41.9 t -70.03 -37.49 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.743 . . . . 0.0 109.357 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.08 -16.35 58.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.691 179.903 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.4 -27.22 21.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.925 . . . . 0.0 109.693 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.2 p -88.5 -14.2 38.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.79 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.562 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.34 -20.55 21.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.125 -0.985 . . . . 0.0 109.717 -179.767 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.5 mtpp -79.74 -0.05 32.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.839 179.694 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -113.32 -56.35 2.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.011 -1.055 . . . . 0.0 109.553 179.856 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.94 HD12 ' CH2' ' A' ' 130' ' ' TRP . 73.9 mt -62.54 -34.18 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.202 -0.936 . . . . 0.0 109.55 179.939 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.526 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.5 36.66 2.44 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.271 -0.893 . . . . 0.0 109.771 -179.889 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.86 -88.19 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.9 p -112.28 15.04 20.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -1.132 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.423 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 4.3 p-10 -122.1 -9.14 8.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.164 -0.96 . . . . 0.0 110.032 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.601 ' ND2' ' HB2' ' A' ' 64' ' ' ALA . 9.0 t30 56.41 20.17 4.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.565 -179.711 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.586 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 80.06 34.32 30.45 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.719 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.405 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -56.39 -43.99 79.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -1.139 . . . . 0.0 109.62 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.486 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.96 -18.32 72.67 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.91 HG11 HD21 ' A' ' 63' ' ' LEU . 25.7 t -68.76 -31.86 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.551 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.23 -54.32 4.44 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.611 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.486 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.7 ptpt -55.19 -24.71 28.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -1.163 . . . . 0.0 110.108 -179.487 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.783 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 23.1 pt-20 -98.23 -16.15 19.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.001 -1.062 . . . . 0.0 109.851 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.426 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 40.5 t -90.78 -60.19 1.98 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.186 -0.946 . . . . 0.0 110.014 -179.628 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -59.83 -32.0 70.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.218 -0.926 . . . . 0.0 110.167 -179.412 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.859 ' OG1' HG11 ' A' ' 55' ' ' VAL . 16.6 m -60.65 -45.05 95.55 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.096 -1.002 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.422 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 3.3 mttm -64.7 -29.26 70.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 179.91 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.652 ' CG ' HD23 ' A' ' 106' ' ' LEU . 17.0 t80 -78.3 -49.58 13.39 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.279 -0.888 . . . . 0.0 109.458 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.691 HD13 HG22 ' A' ' 55' ' ' VAL . 13.3 mt -51.84 -46.43 64.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.333 -0.854 . . . . 0.0 109.687 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.476 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 7.3 t -61.82 -59.96 4.36 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 109.677 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.35 -23.04 66.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.24 -0.912 . . . . 0.0 109.73 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.451 ' N ' ' O ' ' A' ' 34' ' ' PHE . 29.8 m80 -121.22 99.35 6.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 109.688 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -85.33 -19.79 30.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.309 -0.87 . . . . 0.0 109.531 179.936 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -69.28 -20.53 63.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.695 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.435 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 7.3 mmm -108.83 -16.83 14.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.201 -0.937 . . . . 0.0 109.824 -179.927 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.469 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -50.47 -41.0 52.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 0.0 109.378 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -76.47 -32.1 58.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.299 -0.876 . . . . 0.0 109.159 179.583 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.03 HG13 ' ND2' ' A' ' 95' ' ' ASN . 24.7 t -59.18 -56.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.384 -0.823 . . . . 0.0 109.245 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.546 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 62.4 m-85 -54.19 -31.03 51.77 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.21 29.68 3.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.873 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.546 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.5 m-85 -123.81 167.6 13.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 17.93 20.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.885 . . . . 0.0 109.422 179.625 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.74 -164.06 29.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.476 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -93.5 28.71 2.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -1.15 . . . . 0.0 109.618 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 99.5 p -126.91 28.1 5.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.08 137.44 22.44 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -65.67 -24.46 55.19 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.931 1.49 . . . . 0.0 110.095 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.22 -36.33 44.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.859 HG11 ' OG1' ' A' ' 32' ' ' THR . 94.6 t -50.99 -39.9 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.299 -1.118 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.71 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -76.54 -1.25 26.42 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.292 -0.88 . . . . 0.0 109.831 179.714 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -96.47 -27.45 14.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.05 -1.031 . . . . 0.0 109.703 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.787 ' O ' HG23 ' A' ' 62' ' ' VAL . 6.9 mt -86.65 -62.27 1.55 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.426 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -57.62 -24.67 53.65 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.71 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -66.53 -31.61 72.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.634 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.3 mtpt -101.82 -39.58 7.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.428 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.787 HG23 ' O ' ' A' ' 58' ' ' LEU . 58.3 t -51.7 -53.77 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.27 -0.894 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.91 HD21 HG11 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -45.9 -44.5 14.63 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.321 -0.862 . . . . 0.0 110.42 -179.705 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.601 ' HB2' ' ND2' ' A' ' 22' ' ' ASN . . . -52.99 -30.02 32.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.025 . . . . 0.0 109.674 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 11.5 tp-100 -69.49 -31.97 70.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 108.834 179.178 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 70' ' ' VAL . 94.0 mt -72.97 -31.5 35.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.413 -0.804 . . . . 0.0 108.861 179.271 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.562 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.09 -48.37 40.12 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 179.551 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.1 t -63.66 -24.17 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.246 -1.149 . . . . 0.0 109.113 179.736 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.04 -26.46 25.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.468 -0.77 . . . . 0.0 109.481 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 66' ' ' ILE . 48.6 t -67.57 -13.71 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.212 -0.93 . . . . 0.0 109.718 179.842 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.418 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -81.09 -16.9 51.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.849 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 5.7 m-70 -128.76 66.99 1.41 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.177 -0.952 . . . . 0.0 109.672 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.631 HD11 ' HA ' ' A' ' 70' ' ' VAL . 65.2 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.305 -0.872 . . . . 0.0 109.534 179.892 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 11.8 tmm? . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.324 0.583 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.411 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.6 t -73.13 -20.43 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.895 . . . . 0.0 109.421 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.3 -56.63 19.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 179.761 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.61 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -64.18 -53.2 53.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.355 -0.841 . . . . 0.0 109.233 179.664 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.418 ' HG3' ' O ' ' A' ' 79' ' ' MET . 0.5 OUTLIER -53.15 -57.05 11.79 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.68 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.467 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.86 -29.17 18.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.013 179.488 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -72.39 -42.82 64.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.43 -0.794 . . . . 0.0 109.133 179.608 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 82' ' ' GLU . 16.7 t -62.27 -35.77 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.017 179.621 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.466 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -57.46 -44.2 93.75 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.591 -1.803 . . . . 0.0 108.591 179.612 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 90.2 t -54.96 -35.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.285 -1.127 . . . . 0.0 109.033 179.397 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 6.9 mpt_? -70.69 -30.79 67.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.387 -0.821 . . . . 0.0 109.163 179.55 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.768 ' CB ' HD13 ' A' ' 145' ' ' LEU . 27.5 m80 -80.04 2.85 22.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.346 -0.846 . . . . 0.0 109.974 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.3 ttmt -101.07 14.01 33.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.057 -1.027 . . . . 0.0 110.011 -179.539 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -169.41 31.51 0.16 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.231 -1.462 . . . . 0.0 110.543 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.53 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.9 m-85 -74.08 -163.82 0.2 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.739 -1.448 . . . . 0.0 109.688 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -65.29 -53.45 32.78 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.521 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.03 ' ND2' HG13 ' A' ' 44' ' ' VAL . 14.6 p-10 -67.37 -33.67 75.69 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -1.164 . . . . 0.0 109.849 -179.729 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 mttt 55.27 21.19 3.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.241 -0.912 . . . . 0.0 109.633 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -128.3 48.66 2.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.49 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.727 HD13 ' CD2' ' A' ' 90' ' ' HIS . 61.9 mt -86.33 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.771 -179.883 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.494 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 4.8 mptt -141.73 143.52 33.56 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.325 -0.859 . . . . 0.0 109.766 -179.895 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.659 ' CB ' HG23 ' A' ' 142' ' ' ILE . . . -83.19 6.93 17.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.851 179.69 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.26 -21.12 21.24 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.178 -0.951 . . . . 0.0 108.779 179.723 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.494 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 61.5 m-85 -85.16 -13.16 50.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.642 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.3 m-85 -61.07 -61.2 2.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.164 -0.96 . . . . 0.0 110.038 -179.818 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -49.44 -56.94 13.53 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.881 -179.612 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -50.94 -62.0 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.684 1.36 . . . . 0.0 109.929 179.741 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.778 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -57.99 -25.86 61.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.29 -0.881 . . . . 0.0 109.46 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.498 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -72.97 -39.55 54.04 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.985 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.43 -50.0 71.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.217 -1.167 . . . . 0.0 109.479 179.863 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 9.0 m -57.3 -20.64 29.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 109.482 179.832 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.456 HD23 ' HG3' ' A' ' 114' ' ' MET . 1.1 tt -69.18 -46.17 68.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.746 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.736 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.4 mt -58.56 -30.5 67.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.142 -0.974 . . . . 0.0 109.442 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.3 m -73.45 -40.87 63.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.246 -0.909 . . . . 0.0 109.671 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.783 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -74.46 -31.01 62.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.235 -0.915 . . . . 0.0 109.653 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.503 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.8 mmt -60.06 -43.05 95.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.2 OUTLIER -49.81 -25.37 3.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.778 -179.884 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -53.76 -56.21 19.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.204 -0.935 . . . . 0.0 109.797 -179.862 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.405 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -64.59 -58.64 5.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.153 -0.967 . . . . 0.0 109.749 -179.877 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.526 HG12 HD11 ' A' ' 17' ' ' ILE . 5.3 pt -103.04 59.59 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.922 . . . . 0.0 109.737 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.77 -27.72 73.58 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.932 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -95.69 -17.59 35.35 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 5.4 mptt -101.7 -23.37 14.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 109.758 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.456 ' CA ' HD12 ' A' ' 118' ' ' ILE . 0.3 OUTLIER -71.29 83.9 0.77 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.138 -0.977 . . . . 0.0 109.581 179.937 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.574 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.3 p30 -81.39 -167.88 1.64 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.327 -0.858 . . . . 0.0 109.54 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -65.95 -47.81 73.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.574 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -56.96 -31.68 65.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.395 179.768 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -66.63 -53.03 38.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.822 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.521 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 2.5 ptpt -70.01 -26.6 64.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.263 179.727 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.476 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 38.7 t0 -82.53 -36.18 26.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 109.426 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.61 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -67.02 -43.26 83.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.758 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.94 ' CH2' HD12 ' A' ' 17' ' ' ILE . 12.1 m0 -76.7 -29.13 56.13 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.238 -0.913 . . . . 0.0 109.062 179.903 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -50.68 -43.05 57.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.319 -0.863 . . . . 0.0 109.098 179.43 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.13 -17.32 35.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.419 -0.801 . . . . 0.0 109.228 179.33 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.711 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -88.01 -61.57 1.69 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.246 -0.909 . . . . 0.0 109.704 179.938 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.502 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.47 -27.01 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.07 -1.019 . . . . 0.0 109.144 -179.825 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.23 -31.56 30.2 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.305 -0.872 . . . . 0.0 108.795 179.17 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -82.1 -37.83 25.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.448 -0.783 . . . . 0.0 109.405 179.729 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.45 ' N ' HD12 ' A' ' 137' ' ' ILE . 1.6 mp -65.86 -58.4 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 108.776 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -29.87 70.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.492 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -70.5 -35.63 68.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.48 -23.94 66.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -1.176 . . . . 0.0 109.614 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 141' ' ' LEU . 8.7 tt -74.55 -17.3 60.76 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.254 -0.904 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.659 HG23 ' CB ' ' A' ' 100' ' ' ALA . 58.7 mt -76.39 -0.96 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 110.101 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.467 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 19.5 m -66.91 -32.9 74.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.991 -1.068 . . . . 0.0 109.051 179.669 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.4 -10.98 8.33 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.62 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.768 HD13 ' CB ' ' A' ' 90' ' ' HIS . 19.2 tp . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.041 -1.27 . . . . 0.0 109.571 -179.904 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.603 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.244 0.545 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.424 ' O ' HG23 ' A' ' 10' ' ' VAL . 42.1 mt-30 -78.29 -52.27 8.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.169 -0.957 . . . . 0.0 109.887 -179.856 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.98 -29.37 12.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.97 -1.081 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -70.71 -45.21 65.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 0.0 108.778 179.353 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 5' ' ' ALA . 44.8 t -62.12 -31.25 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.364 -0.835 . . . . 0.0 108.859 179.27 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 1.048 HG12 HG13 ' A' ' 70' ' ' VAL . 98.6 t -66.03 -50.13 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.512 -0.743 . . . . 0.0 109.4 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.11 61.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.9 m -83.45 -25.05 31.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.105 -0.997 . . . . 0.0 109.744 -179.919 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.452 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 38.2 p -100.22 -10.18 21.64 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.92 . . . . 0.0 110.043 -179.907 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.12 -25.8 19.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.027 -1.046 . . . . 0.0 109.609 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.9 mtpp -76.05 -12.8 60.19 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.224 -0.923 . . . . 0.0 109.641 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.468 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.4 OUTLIER -103.02 -52.67 3.0 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.949 HD12 ' CH2' ' A' ' 130' ' ' TRP . 44.1 mt -65.14 -34.78 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.271 -0.893 . . . . 0.0 109.581 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.891 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -107.91 35.24 3.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.719 -179.948 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.1 -84.14 0.03 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 78.3 p -97.51 -23.41 16.04 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.307 -1.114 . . . . 0.0 109.617 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.629 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 12.3 p-10 -83.34 -21.45 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.891 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 9.9 t30 56.79 20.57 5.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.92 . . . . 0.0 109.61 179.998 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.2 20.94 11.39 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.629 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.49 -47.52 69.8 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.567 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -93.34 31.63 6.26 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.517 ' CG1' HD21 ' A' ' 110' ' ' LEU . 41.9 t -119.05 -35.91 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.297 -1.12 . . . . 0.0 108.942 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.462 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -90.26 -41.17 5.58 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.766 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.481 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.3 ptpt -61.08 -30.63 70.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 109.587 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.79 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -90.41 -25.16 20.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.124 -0.985 . . . . 0.0 109.422 179.798 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 41.4 t -85.54 -50.63 7.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.353 -0.842 . . . . 0.0 109.574 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 5.0 m-30 -55.2 -37.56 67.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.585 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.574 ' OG1' HG11 ' A' ' 55' ' ' VAL . 98.6 m -55.82 -45.89 78.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.901 . . . . 0.0 109.347 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.411 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 13.6 mttp -66.59 -47.63 72.12 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.403 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.532 ' CG ' HD23 ' A' ' 106' ' ' LEU . 4.3 t80 -55.7 -49.94 71.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.297 179.794 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.732 ' CD1' HG22 ' A' ' 55' ' ' VAL . 32.3 mt -59.48 -45.1 92.63 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.89 -61.68 2.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.691 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.04 -28.64 64.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.694 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 7.7 m80 -118.0 103.38 9.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.718 179.938 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -85.61 -21.45 28.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.34 -0.85 . . . . 0.0 109.345 179.634 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.2 p-10 -68.23 -20.49 64.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.912 . . . . 0.0 109.275 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.49 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 92.2 mmm -103.26 -22.35 13.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.581 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -51.17 -44.45 61.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.031 -1.043 . . . . 0.0 109.338 179.825 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.68 -23.38 59.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.346 -0.846 . . . . 0.0 109.136 179.565 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.047 HG13 ' ND2' ' A' ' 95' ' ' ASN . 29.2 t -73.44 -39.96 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.423 -0.798 . . . . 0.0 109.202 179.733 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.542 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -68.89 -38.95 79.97 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.573 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.404 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 117.66 28.22 2.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.882 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.542 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.3 m-85 -122.31 172.23 8.47 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.199 -1.177 . . . . 0.0 109.692 -179.981 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 11.7 t -111.13 19.22 18.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.316 -0.865 . . . . 0.0 109.351 179.493 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.95 -164.0 29.87 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.79 5.82 41.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -1.162 . . . . 0.0 110.073 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 15.2 t -110.09 42.27 1.56 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.001 -1.062 . . . . 0.0 109.548 179.976 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.414 ' HA ' ' HD3' ' A' ' 53' ' ' PRO . 0.4 OUTLIER -115.85 131.54 23.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 0.0 109.624 -179.979 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 16.9 Cg_exo -61.34 -20.47 68.36 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 123.81 1.426 . . . . 0.0 109.949 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.9 -35.95 88.52 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.732 HG22 ' CD1' ' A' ' 35' ' ' LEU . 58.9 t -54.56 -22.78 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -1.095 . . . . 0.0 109.468 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.457 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -86.47 -19.44 29.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.319 -0.863 . . . . 0.0 109.571 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.406 ' O ' ' HB2' ' A' ' 61' ' ' LYS . 0.3 OUTLIER -88.11 -26.45 22.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.296 -0.878 . . . . 0.0 109.588 -179.994 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.714 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.7 mt -86.44 -66.58 0.89 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.188 -0.945 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.553 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -49.46 -37.06 25.1 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.439 ' HB3' ' O ' ' A' ' 56' ' ' ALA . . . -72.45 -22.32 61.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.151 -1.205 . . . . 0.0 109.946 -179.698 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.406 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 4.7 mttp -94.55 -21.9 18.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.122 -0.986 . . . . 0.0 109.827 -179.868 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 58' ' ' LEU . 23.3 t -83.71 -46.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.938 . . . . 0.0 109.889 -179.784 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.671 HD21 HD11 ' A' ' 110' ' ' LEU . 2.9 mm? -47.86 -46.88 31.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -51.91 25.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.194 -0.941 . . . . 0.0 109.992 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -50.65 -42.98 57.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.07 -1.019 . . . . 0.0 109.438 -179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.881 ' O ' HG23 ' A' ' 70' ' ' VAL . 39.8 mt -61.34 -38.36 79.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.312 -0.868 . . . . 0.0 109.238 179.621 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.566 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.73 -50.97 57.62 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.873 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.4 t -61.22 -29.96 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.083 -1.245 . . . . 0.0 109.467 -179.823 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.607 ' O ' HD21 ' A' ' 73' ' ' LEU . . . -84.72 -14.52 48.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.424 -0.798 . . . . 0.0 110.094 -179.42 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.048 HG13 HG12 ' A' ' 10' ' ' VAL . 41.6 t -84.64 -43.36 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.027 -1.046 . . . . 0.0 110.091 -179.409 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.35 -24.75 2.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.987 -1.07 . . . . 0.0 109.33 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.443 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 3.2 m-70 -93.83 -114.08 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.532 -0.73 . . . . 0.0 109.946 -179.787 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.799 HD11 ' HA ' ' A' ' 70' ' ' VAL . 16.5 mt . . . . . 0 N--CA 1.5 2.056 0 O-C-N 121.027 -1.045 . . . . 0.0 110.392 -179.289 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.5 t -51.21 -31.11 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.076 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.24 -35.61 76.3 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.964 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.434 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.3 OUTLIER -61.27 -52.97 62.49 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.215 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.556 ' CE ' HD12 ' A' ' 141' ' ' LEU . 86.5 mmm -56.96 -38.56 73.13 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.255 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -35.74 40.96 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.921 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.434 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -67.89 -32.37 72.81 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 1.044 HG11 HD11 ' A' ' 141' ' ' LEU . 48.6 t -59.38 -51.95 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 108.785 179.432 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.47 ' O ' HD12 ' A' ' 145' ' ' LEU . . . -56.66 -52.94 47.42 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.061 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.764 HG23 ' HA3' ' A' ' 144' ' ' GLY . 63.3 t -51.75 -33.26 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.397 -1.061 . . . . 0.0 108.817 179.065 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.508 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.0 mmm180 -76.43 -49.75 15.88 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.189 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.582 ' HB2' HD13 ' A' ' 145' ' ' LEU . 2.1 m80 -58.92 -21.24 57.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.464 -0.772 . . . . 0.0 109.115 179.332 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.434 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -66.72 -12.08 57.07 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.314 -0.866 . . . . 0.0 110.254 -179.704 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.31 53.49 0.6 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.634 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.552 ' CZ ' ' ND1' ' A' ' 90' ' ' HIS . 3.1 m-30 -89.23 -164.36 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.238 -1.154 . . . . 0.0 109.702 179.734 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.14 -51.14 19.33 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.047 ' ND2' HG13 ' A' ' 44' ' ' VAL . 17.1 p-10 -69.16 -32.36 71.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.14 -1.212 . . . . 0.0 109.828 -179.686 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.8 tttm 58.26 18.86 5.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.197 -0.939 . . . . 0.0 109.699 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -125.75 41.27 3.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.69 -179.935 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.566 HD13 ' CD2' ' A' ' 90' ' ' HIS . 36.4 mt -81.32 155.75 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.184 -0.947 . . . . 0.0 109.679 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.473 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.1 mptp? -136.58 145.58 45.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.884 -179.825 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.782 ' HB1' ' CG1' ' A' ' 142' ' ' ILE . . . -86.4 11.77 11.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.954 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.566 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 15.5 pt-20 -95.48 -24.21 16.76 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.107 -0.995 . . . . 0.0 109.557 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.566 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 88.7 m-85 -83.03 -7.39 59.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.928 179.722 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.736 ' CZ ' HD22 ' A' ' 141' ' ' LEU . 11.3 m-85 -66.87 -52.17 46.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.096 -1.002 . . . . 0.0 109.945 -179.739 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.504 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.5 tm-20 -56.54 -55.61 40.99 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.131 -0.98 . . . . 0.0 109.867 -179.685 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.83 -61.85 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 123.755 1.397 . . . . 0.0 109.83 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.925 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.75 -23.78 31.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.291 -0.88 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.99 -48.67 6.84 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.36 65.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -1.191 . . . . 0.0 109.414 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.0 m -75.28 -31.01 60.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.872 . . . . 0.0 109.518 179.893 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.813 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.0 OUTLIER -70.13 -30.16 67.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.41 179.905 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.696 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.1 mt -64.34 -32.11 73.59 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.348 179.767 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.4 OUTLIER -74.89 -26.2 59.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 109.54 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.79 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.77 -35.78 20.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.247 -0.908 . . . . 0.0 109.518 -179.885 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.512 ' HE3' HD22 ' A' ' 110' ' ' LEU . 2.8 mtt -49.44 -45.08 46.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 0.0 110.116 -179.717 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' SER . 13.3 pt-20 -50.27 -25.69 3.98 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.153 -0.967 . . . . 0.0 109.907 -179.719 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.405 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 29.7 m170 -50.12 -39.92 44.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.635 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.447 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 3.2 ttt85 -80.17 -61.7 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.179 -0.951 . . . . 0.0 109.539 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.468 ' CG2' ' HB3' ' A' ' 16' ' ' ASP . 7.2 pt -89.35 44.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.236 -0.915 . . . . 0.0 109.521 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -51.62 123.07 18.15 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 102.12 -39.82 2.64 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.873 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.431 ' O ' ' N ' ' A' ' 123' ' ' ASN . 29.9 mttp -83.54 -29.5 27.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -1.14 . . . . 0.0 109.439 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.407 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.26 76.73 0.1 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.235 179.727 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.581 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.4 p30 -79.8 -167.67 1.33 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.311 -0.868 . . . . 0.0 109.875 -179.714 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.469 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.95 -45.9 87.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.839 . . . . 0.0 109.531 179.868 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.581 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -58.07 -33.46 69.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.283 -0.886 . . . . 0.0 109.283 179.832 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.01 -53.38 20.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.28 -0.888 . . . . 0.0 109.417 179.832 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.503 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 11.9 ptpt -70.47 -26.84 63.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.191 -0.943 . . . . 0.0 109.356 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.447 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.8 t70 -81.91 -39.81 23.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.357 179.557 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -62.37 -43.54 98.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.375 -0.828 . . . . 0.0 109.241 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.949 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.0 m0 -75.57 -31.89 60.17 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.304 -0.873 . . . . 0.0 108.7 179.563 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.503 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -55.46 -30.84 61.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 108.631 178.867 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.11 -28.89 22.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.797 . . . . 0.0 109.101 179.477 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -82.93 -52.65 6.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.431 -0.793 . . . . 0.0 109.465 179.899 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.813 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.1 OUTLIER -49.85 -30.05 9.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 0.0 109.376 179.85 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -78.73 -27.62 44.87 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.275 -0.891 . . . . 0.0 108.984 179.456 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' A' ' 133' ' ' ALA . 2.4 t0 -84.12 -39.86 18.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.435 -0.791 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.558 HD13 HG23 ' A' ' 66' ' ' ILE . 8.2 mt -67.7 -56.33 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.497 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.556 ' O ' HD12 ' A' ' 142' ' ' ILE . 87.2 p -69.37 -36.7 77.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.334 -0.853 . . . . 0.0 109.607 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.558 ' HA2' HD13 ' A' ' 142' ' ' ILE . . . -56.23 -23.11 39.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.942 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.03 59.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 0.0 109.998 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.044 HD11 HG11 ' A' ' 86' ' ' VAL . 0.2 OUTLIER -91.4 -19.45 22.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.109 -0.994 . . . . 0.0 109.811 -179.847 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.782 ' CG1' ' HB1' ' A' ' 100' ' ' ALA . 3.2 mp -80.06 3.37 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.218 -0.926 . . . . 0.0 110.115 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 23.4 m -100.8 -31.09 11.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.01 -1.057 . . . . 0.0 109.925 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.764 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -93.1 -21.47 30.14 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.609 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.582 HD13 ' HB2' ' A' ' 90' ' ' HIS . 12.8 tp . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.179 -1.189 . . . . 0.0 109.315 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.852 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 120.941 0.4 . . . . 0.0 110.187 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.817 ' O ' HG23 ' A' ' 10' ' ' VAL . 65.7 mt-30 -70.99 -50.5 33.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.967 -1.083 . . . . 0.0 109.43 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.475 ' HG2' ' HB2' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -53.06 -24.25 9.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.048 179.583 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 5.8 mp0 -83.16 -53.29 5.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.434 -0.791 . . . . 0.0 109.521 179.893 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 5' ' ' ALA . 21.2 t -55.37 -33.99 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.817 HG23 ' O ' ' A' ' 6' ' ' GLN . 93.8 t -57.33 -43.17 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.95 -10.12 59.16 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.271 -0.893 . . . . 0.0 109.896 179.836 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 t -93.56 -26.21 17.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.123 -0.986 . . . . 0.0 109.99 -179.718 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.449 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 20.6 p -95.74 -15.25 22.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -0.971 . . . . 0.0 109.965 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.799 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -88.49 -23.02 23.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.065 -1.022 . . . . 0.0 109.686 -179.933 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 73.4 mttt -81.6 1.67 32.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.934 . . . . 0.0 109.852 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.57 -48.51 2.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.128 -0.982 . . . . 0.0 109.263 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.994 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.0 mt -71.31 -28.76 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.432 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.696 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -109.33 34.42 3.77 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.235 -0.916 . . . . 0.0 109.603 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.15 -86.93 0.01 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.9 p -100.77 -24.46 14.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -1.145 . . . . 0.0 109.706 -179.99 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.647 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.7 p-10 -81.02 -20.77 41.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.936 . . . . 0.0 109.699 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.696 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 28.8 t30 56.93 30.06 17.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.592 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.828 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 88.53 37.71 7.4 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.647 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -79.02 -49.63 12.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -1.144 . . . . 0.0 109.655 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.487 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -76.23 -23.55 70.88 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 -179.921 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.005 HG12 HD11 ' A' ' 63' ' ' LEU . 41.5 t -67.01 -27.2 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.334 -1.097 . . . . 0.0 109.817 -179.936 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.4 ' HA3' ' C ' ' A' ' 59' ' ' GLY . . . -84.69 -50.79 4.07 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.487 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.2 ptpt -57.62 -24.17 55.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -1.203 . . . . 0.0 110.041 -179.556 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.428 ' O ' ' CD ' ' A' ' 33' ' ' LYS . 12.2 pt-20 -97.06 -28.39 14.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.036 -1.04 . . . . 0.0 109.768 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.407 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 37.1 t -83.99 -52.5 6.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 109.709 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 3.7 m-30 -60.45 -45.27 94.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.322 -0.861 . . . . 0.0 109.787 -179.806 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.748 ' OG1' HG11 ' A' ' 55' ' ' VAL . 21.1 m -52.07 -41.3 62.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.13 -0.981 . . . . 0.0 109.453 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.428 ' CD ' ' O ' ' A' ' 29' ' ' GLU . 8.1 mtpt -68.98 -48.18 63.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.564 179.918 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.73 ' CG ' HD23 ' A' ' 106' ' ' LEU . 9.0 t80 -58.91 -49.86 76.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.514 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.711 ' CD1' HG22 ' A' ' 55' ' ' VAL . 32.8 mt -57.35 -45.49 84.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 109.698 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.531 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 1.3 t -63.33 -59.83 4.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.194 -0.941 . . . . 0.0 109.758 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -59.95 -26.91 66.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.898 . . . . 0.0 109.724 -179.909 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -119.69 104.32 10.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.771 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 54.5 m170 -86.45 -21.93 26.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.604 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -67.66 -16.38 64.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -0.891 . . . . 0.0 109.525 179.644 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.429 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 89.7 mmm -109.35 -24.41 11.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.521 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -48.14 -40.46 23.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -77.06 -21.34 54.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.376 179.728 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.055 HG22 ' ND2' ' A' ' 95' ' ' ASN . 39.6 t -75.09 -39.71 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 0.0 109.563 179.981 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.543 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 15.6 m-85 -68.08 -31.06 70.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.616 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.406 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.42 27.24 3.68 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.543 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.9 m-85 -122.77 171.41 9.2 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.29 -1.123 . . . . 0.0 109.653 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.9 t -111.14 23.47 14.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.212 179.58 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.84 -163.78 27.59 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -93.13 29.81 1.79 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 18.3 m -126.52 22.98 6.92 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 109.633 -179.956 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.41 137.94 19.58 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.236 -0.915 . . . . 0.0 109.615 179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -66.51 -24.14 49.39 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 123.919 1.484 . . . . 0.0 110.07 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -54.24 -31.66 50.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.901 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.748 HG11 ' OG1' ' A' ' 32' ' ' THR . 97.5 t -53.66 -53.71 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.268 -1.136 . . . . 0.0 109.568 -179.946 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.721 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -63.07 -14.79 52.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.906 . . . . 0.0 109.769 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.52 -44.21 11.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.17 -0.956 . . . . 0.0 109.694 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.488 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.0 OUTLIER -70.22 -63.62 1.05 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.219 -0.926 . . . . 0.0 110.051 -179.8 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.54 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -51.9 -29.3 26.76 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.765 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.721 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -67.93 -40.65 83.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -1.203 . . . . 0.0 110.029 -179.708 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 43.4 mttm -80.85 -36.31 31.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 109.928 -179.77 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 58' ' ' LEU . 86.1 t -59.39 -53.98 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 0.0 109.903 -179.786 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 1.005 HD11 HG12 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -47.0 -38.72 11.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.195 -0.94 . . . . 0.0 109.833 -179.936 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.88 -49.32 63.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.625 179.925 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.407 ' OE1' HG21 ' A' ' 86' ' ' VAL . 14.0 tp60 -52.8 -48.2 67.06 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.966 . . . . 0.0 109.437 179.855 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.984 ' O ' HG23 ' A' ' 70' ' ' VAL . 98.8 mt -55.89 -32.98 33.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.296 -0.878 . . . . 0.0 109.165 179.662 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.567 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.99 -57.86 9.01 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 179.503 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.9 t -55.31 -26.17 18.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -1.111 . . . . 0.0 109.05 179.803 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -26.23 26.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.445 -0.784 . . . . 0.0 109.535 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.984 HG23 ' O ' ' A' ' 66' ' ' ILE . 40.0 t -59.87 -19.36 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 179.859 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 34.0 t -88.7 10.14 21.81 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.221 -0.924 . . . . 0.0 110.203 -179.688 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.46 ' HB3' ' HB2' ' A' ' 79' ' ' MET . 19.3 m-70 -147.76 50.73 1.05 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.972 -1.08 . . . . 0.0 109.82 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.796 HD11 ' HB1' ' A' ' 133' ' ' ALA . 3.7 mm? . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.343 -0.848 . . . . 0.0 109.494 179.811 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.46 ' HB2' ' HB3' ' A' ' 72' ' ' HIS . 3.9 tmm? . . . . . 0 N--CA 1.493 1.689 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.463 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.4 t -67.72 -26.66 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.358 -0.839 . . . . 0.0 109.199 179.607 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.24 -48.07 81.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.291 -0.88 . . . . 0.0 109.365 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.59 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.6 OUTLIER -78.19 -48.1 16.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.876 . . . . 0.0 109.286 179.67 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.476 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 2.7 mtp -57.22 -56.81 16.98 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.26 -0.9 . . . . 0.0 109.243 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.475 ' HG3' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.4 -32.86 27.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.19 -0.944 . . . . 0.0 108.856 179.372 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.59 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -65.58 -39.72 91.93 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.268 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.893 ' CG1' HD11 ' A' ' 141' ' ' LEU . 56.3 t -52.99 -50.22 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.291 -0.88 . . . . 0.0 109.18 179.502 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -50.5 -49.77 38.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 179.732 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.685 HG23 ' HA3' ' A' ' 144' ' ' GLY . 91.5 t -49.71 -26.23 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.324 -1.104 . . . . 0.0 109.309 179.591 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.4 mmt180 -78.76 -48.52 14.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.381 -0.824 . . . . 0.0 108.872 179.452 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.579 ' HB2' HD13 ' A' ' 145' ' ' LEU . 13.3 m80 -55.5 -28.28 53.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.441 -0.787 . . . . 0.0 109.327 179.618 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -67.93 -10.05 50.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.319 -0.863 . . . . 0.0 110.04 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -138.73 50.71 0.79 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.792 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.5 m-30 -101.59 -168.55 1.57 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.18 -1.188 . . . . 0.0 109.584 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.96 -49.47 16.72 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 1.055 ' ND2' HG22 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -68.02 -51.03 51.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.439 -1.036 . . . . 0.0 109.221 179.796 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.479 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.7 tttt 74.64 -48.69 0.65 Allowed 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.528 -0.732 . . . . 0.0 110.844 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -67.81 61.22 0.07 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.958 -1.089 . . . . 0.0 110.248 -179.553 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 96' ' ' LYS . 65.9 mt -92.03 161.24 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.041 . . . . 0.0 109.462 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.513 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -139.8 139.38 36.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.102 -0.999 . . . . 0.0 110.017 -179.798 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 1.055 ' HB1' HD12 ' A' ' 142' ' ' ILE . . . -79.13 -5.9 55.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.421 -0.8 . . . . 0.0 109.621 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -70.67 -31.52 68.47 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.103 -0.998 . . . . 0.0 109.694 179.944 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.513 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 75.5 m-85 -82.79 4.93 23.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 110.529 -179.314 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.566 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.5 m-85 -77.09 -57.57 3.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.959 -1.088 . . . . 0.0 109.783 179.704 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -58.31 -50.83 85.91 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.851 -179.698 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' CD ' ' N ' ' A' ' 104' ' ' GLU . 24.8 Cg_exo -55.62 -57.49 1.56 Allowed 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.888 1.468 . . . . 0.0 109.768 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.929 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -57.49 -19.5 24.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.401 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.51 -51.08 4.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.953 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.72 -54.3 48.41 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.166 -1.196 . . . . 0.0 109.572 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.5 t -55.98 -25.17 42.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' A' ' 106' ' ' LEU . 5.2 tt -67.39 -45.16 77.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.916 . . . . 0.0 109.734 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.911 HD21 ' HB3' ' A' ' 130' ' ' TRP . 13.8 mt -56.6 -31.86 64.68 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.653 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.52 -30.41 70.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.906 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -82.86 -34.21 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.893 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.414 ' HE1' HD21 ' A' ' 110' ' ' LEU . 5.9 mmt -46.39 -45.33 17.77 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.3 -0.875 . . . . 0.0 110.34 -179.713 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -50.32 -23.2 2.16 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.11 -0.993 . . . . 0.0 110.223 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.411 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -57.0 -46.88 81.96 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.051 -1.031 . . . . 0.0 109.703 -179.809 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.467 ' HD3' HG23 ' A' ' 17' ' ' ILE . 1.9 ttt85 -73.11 -55.8 5.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 109.815 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 5.3 pt -99.92 48.69 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.127 -0.983 . . . . 0.0 110.103 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.09 100.98 0.11 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 179.64 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.44 -45.33 1.14 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.513 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.3 mmtt -82.23 -24.1 35.02 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.251 -1.146 . . . . 0.0 109.154 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.97 79.58 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.441 -0.787 . . . . 0.0 109.595 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.501 HD22 ' HB3' ' A' ' 125' ' ' ALA . 19.7 p-10 -88.22 -178.64 5.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.894 . . . . 0.0 110.186 -179.793 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -55.23 -34.73 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.874 -179.696 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.752 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -68.61 -14.4 62.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.668 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -90.43 -50.73 5.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.07 -1.019 . . . . 0.0 109.624 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.724 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.1 ptpt -69.42 -27.77 65.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.262 179.776 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.45 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.0 t0 -79.07 -52.56 8.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.32 -0.862 . . . . 0.0 109.486 179.772 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -56.66 -54.34 47.22 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.374 -0.829 . . . . 0.0 109.765 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.994 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.1 m0 -63.46 -27.83 69.55 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.724 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.39 -25.46 65.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.225 -0.922 . . . . 0.0 108.78 179.202 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.22 -41.93 14.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.44 -0.787 . . . . 0.0 109.121 179.466 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.796 ' HB1' HD11 ' A' ' 73' ' ' LEU . . . -70.19 -56.12 7.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.515 -0.74 . . . . 0.0 109.781 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 134' ' ' TYR . 9.0 m-30 -47.39 -27.96 1.88 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.296 -0.877 . . . . 0.0 109.636 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.98 -43.18 65.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.258 -0.901 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.76 -36.57 59.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.341 -0.85 . . . . 0.0 109.325 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.717 HD12 ' O ' ' A' ' 133' ' ' ALA . 1.3 mp -66.64 -58.44 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 108.885 179.717 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.405 ' O ' HG12 ' A' ' 142' ' ' ILE . 31.7 p -66.97 -24.08 66.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.251 -0.906 . . . . 0.0 109.62 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.32 -28.78 55.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.16 -22.86 60.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -1.138 . . . . 0.0 109.595 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.901 HD23 ' O ' ' A' ' 141' ' ' LEU . 3.8 tt -86.46 11.6 12.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 109.986 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 1.055 HD12 ' HB1' ' A' ' 100' ' ' ALA . 44.0 mm -100.29 19.29 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.074 -1.016 . . . . 0.0 109.683 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.475 ' CB ' ' HG3' ' A' ' 84' ' ' LYS . 4.4 m -108.11 -52.65 2.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.634 179.962 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.685 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -75.96 -7.75 84.3 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.579 HD13 ' HB2' ' A' ' 90' ' ' HIS . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.465 0 O-C-N 120.953 -1.322 . . . . 0.0 108.432 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.784 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.28 0.562 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.429 ' O ' HG23 ' A' ' 10' ' ' VAL . 1.5 mt-30 -64.81 -46.1 83.43 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.439 ' HG3' ' HB3' ' A' ' 73' ' ' LEU . 38.6 ttp180 -55.38 -34.27 64.17 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.206 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -73.87 -41.66 61.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.261 -0.899 . . . . 0.0 109.176 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.784 HG23 ' O ' ' A' ' 5' ' ' ALA . 59.7 t -57.42 -29.85 34.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.336 -0.853 . . . . 0.0 109.426 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 1.046 HG12 HG13 ' A' ' 70' ' ' VAL . 91.9 t -66.03 -52.14 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 109.468 179.793 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.56 -9.75 51.4 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.307 -0.871 . . . . 0.0 109.988 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 p -92.94 -24.43 18.41 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.045 -1.035 . . . . 0.0 109.774 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.4 p -98.49 -7.76 27.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 110.065 -179.939 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.596 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -95.14 -23.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.093 . . . . 0.0 109.588 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.2 mttm -77.08 -2.49 34.4 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.206 -0.933 . . . . 0.0 109.852 179.756 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -114.02 -51.12 2.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.085 -1.009 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.951 HD12 ' CH2' ' A' ' 130' ' ' TRP . 56.3 mt -66.34 -31.52 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.919 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.888 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -108.77 34.03 3.9 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.315 -0.866 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.31 -85.0 0.02 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.8 p -95.68 -31.45 13.23 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -1.14 . . . . 0.0 109.58 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.543 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 24.5 p-10 -75.51 -21.97 57.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.295 -0.878 . . . . 0.0 109.591 180.0 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.888 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 4.3 t30 56.57 21.85 6.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.207 -0.933 . . . . 0.0 109.523 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 98.82 21.67 15.55 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.543 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -71.04 -56.85 5.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -1.146 . . . . 0.0 109.637 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.47 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -70.85 -21.08 78.04 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.925 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.631 HG11 HD11 ' A' ' 63' ' ' LEU . 46.6 t -70.65 -35.03 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.284 -1.127 . . . . 0.0 110.005 -179.778 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.02 -43.72 13.33 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 -179.308 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.47 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.8 ptpt -64.28 -26.39 68.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -1.217 . . . . 0.0 110.155 -179.385 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.763 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -100.68 -11.41 20.0 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.045 -1.034 . . . . 0.0 110.156 -179.73 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.462 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 34.1 t -93.05 -68.19 0.81 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 109.888 -179.797 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.528 ' CZ ' HG11 ' A' ' 62' ' ' VAL . 10.3 m-85 -50.32 -30.48 12.14 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 110.004 -179.604 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.771 ' OG1' HG11 ' A' ' 55' ' ' VAL . 15.7 m -54.33 -53.18 57.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.064 -1.023 . . . . 0.0 109.221 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.425 ' HD3' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -55.44 -48.56 74.26 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.932 . . . . 0.0 109.243 179.737 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.6 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.8 t80 -54.33 -49.65 69.23 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.322 -0.862 . . . . 0.0 109.255 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.832 ' CD1' HG22 ' A' ' 55' ' ' VAL . 24.2 mt -60.1 -46.09 90.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.642 179.866 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.439 ' OG ' ' N ' ' A' ' 37' ' ' ALA . 8.9 p -61.21 -54.41 44.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.732 -179.91 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.439 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -67.86 -27.09 66.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.226 -0.921 . . . . 0.0 109.62 -179.927 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.403 ' N ' ' O ' ' A' ' 34' ' ' PHE . 7.8 m80 -117.51 107.37 14.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.754 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 56.3 m170 -88.41 -19.9 25.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.408 -0.808 . . . . 0.0 109.356 179.648 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -71.04 -11.29 60.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.71 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.558 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -107.61 -27.73 10.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.007 . . . . 0.0 109.943 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.475 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -46.99 -48.14 21.79 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.13 -0.981 . . . . 0.0 109.796 -179.825 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.6 -28.78 65.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.122 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.984 HG13 ' ND2' ' A' ' 95' ' ' ASN . 21.3 t -70.15 -38.4 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.273 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.534 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 9.8 m-85 -77.27 -29.93 54.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.243 -0.911 . . . . 0.0 109.612 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.14 29.51 3.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.374 -1.491 . . . . 0.0 109.374 179.825 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.534 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.0 m-85 -124.25 166.99 14.91 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -1.167 . . . . 0.0 109.91 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.2 t -104.29 -20.3 13.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.421 -0.8 . . . . 0.0 109.127 179.343 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.83 -164.69 24.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.816 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.42 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -95.15 35.84 1.26 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -1.179 . . . . 0.0 109.69 -179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 56.4 p -135.07 23.2 3.53 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 109.533 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.493 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.8 p-10 -107.69 138.79 20.11 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -60.33 -20.73 64.18 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.934 1.491 . . . . 0.0 109.995 -179.964 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.71 -44.75 54.95 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.832 HG22 ' CD1' ' A' ' 35' ' ' LEU . 80.3 t -51.45 -37.99 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.401 -1.058 . . . . 0.0 109.31 179.776 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.508 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -71.72 -24.45 61.8 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.28 -0.887 . . . . 0.0 109.251 179.602 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -79.33 -37.96 36.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.376 179.778 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.741 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 mt -77.19 -60.98 2.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.527 179.926 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.498 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.66 -46.65 38.42 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.508 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -54.46 -42.04 70.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.39 179.842 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.8 mttt -76.54 -29.17 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.262 -0.899 . . . . 0.0 109.354 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' O ' ' A' ' 58' ' ' LEU . 47.6 t -78.58 -49.95 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.631 HD11 HG11 ' A' ' 26' ' ' VAL . 1.0 OUTLIER -48.43 -46.1 37.19 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.82 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.72 -49.93 69.58 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.303 -0.873 . . . . 0.0 109.564 179.939 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.426 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 8.1 tp-100 -50.9 -43.32 59.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 109.31 179.813 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.853 ' O ' HG23 ' A' ' 70' ' ' VAL . 31.8 mm -57.6 -43.6 83.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.284 -0.885 . . . . 0.0 108.758 179.477 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.548 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.83 -55.16 31.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.775 -1.73 . . . . 0.0 108.775 179.371 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.3 t -54.03 -35.32 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.346 -1.09 . . . . 0.0 109.435 179.833 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.599 ' HB1' HG13 ' A' ' 137' ' ' ILE . . . -79.8 -30.38 40.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.88 . . . . 0.0 109.42 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.046 HG13 HG12 ' A' ' 10' ' ' VAL . 48.9 t -68.68 -16.43 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.262 -0.899 . . . . 0.0 109.584 179.895 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.41 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.2 m -90.03 -0.05 57.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.172 -0.955 . . . . 0.0 110.199 -179.897 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.472 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 21.4 m-70 -140.02 50.85 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.983 -1.073 . . . . 0.0 109.767 -179.872 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.622 HD21 ' HA ' ' A' ' 70' ' ' VAL . 4.3 mm? . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.934 . . . . 0.0 109.465 179.967 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.472 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 28.2 ttp . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.258 0.551 . . . . 0.0 109.829 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 45.9 t -68.61 -11.64 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.964 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.44 -37.41 43.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.03 -1.044 . . . . 0.0 109.44 179.904 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -88.65 -41.18 12.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.468 ' HE2' HD12 ' A' ' 141' ' ' LEU . 8.9 mtp -60.36 -41.04 92.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.94 . . . . 0.0 109.247 179.809 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.554 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.8 -42.04 62.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.784 179.171 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.437 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -61.28 -39.68 91.31 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.992 ' CG1' HD11 ' A' ' 141' ' ' LEU . 23.9 t -56.98 -51.86 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.277 -0.89 . . . . 0.0 108.774 179.496 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 145' ' ' LEU . . . -60.86 -53.59 43.95 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.655 -2.178 . . . . 0.0 107.655 178.826 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 84' ' ' LYS . 78.7 t -48.8 -24.96 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.451 -1.029 . . . . 0.0 109.445 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.515 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 7.5 mmm180 -83.6 -43.85 15.22 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.021 -1.049 . . . . 0.0 108.729 179.238 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.696 ' O ' HD12 ' A' ' 98' ' ' ILE . 19.5 m80 -58.75 -33.73 70.59 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.379 -0.825 . . . . 0.0 109.698 179.589 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -61.45 -15.78 40.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 110.434 -179.29 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.46 46.73 1.05 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.257 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.515 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.7 m-30 -87.28 -173.13 4.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.195 -1.179 . . . . 0.0 109.402 179.51 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.26 -26.42 52.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 179.668 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.984 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -76.86 -55.23 5.67 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.559 -0.965 . . . . 0.0 109.101 179.704 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.481 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 10.3 tptp 77.09 -19.02 0.45 Allowed 'General case' 0 N--CA 1.508 2.469 0 O-C-N 121.765 -0.585 . . . . 0.0 111.472 179.871 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.409 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 8.2 m170 -94.05 44.01 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.601 -1.312 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.696 HD12 ' O ' ' A' ' 90' ' ' HIS . 36.3 mt -74.84 160.46 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.758 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.515 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -151.21 136.24 17.43 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.349 -0.845 . . . . 0.0 109.987 179.984 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.94 -5.52 44.26 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.573 -0.704 . . . . 0.0 109.506 179.301 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mm-40 -74.98 -30.66 61.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.07 -1.019 . . . . 0.0 109.439 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.561 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 36.0 m-85 -75.66 -23.54 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.299 -0.876 . . . . 0.0 109.889 -179.746 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -54.39 -64.16 0.92 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.56 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.81 -58.55 5.25 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 110.856 -179.111 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.561 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.3 Cg_endo -59.49 -46.62 20.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.639 1.336 . . . . 0.0 109.63 -179.666 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.786 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.1 tm? -60.98 -27.29 68.19 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.216 -0.927 . . . . 0.0 108.841 179.414 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -81.34 -38.0 16.16 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 179.508 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.19 -60.13 4.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 0.0 109.345 179.782 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.0 m -52.42 -24.86 8.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.902 . . . . 0.0 109.18 179.67 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.421 ' HB3' ' O ' ' A' ' 107' ' ' GLY . 2.3 tt -66.51 -48.19 70.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.347 -0.846 . . . . 0.0 109.421 179.811 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.804 HD21 ' CB ' ' A' ' 130' ' ' TRP . 13.0 mt -57.65 -32.32 67.17 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.947 . . . . 0.0 109.216 179.729 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.4 m -73.82 -38.52 64.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.339 -0.85 . . . . 0.0 109.429 179.823 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.763 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -72.61 -35.71 67.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.292 -0.88 . . . . 0.0 109.387 179.791 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.705 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.2 mmt -51.39 -42.15 61.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.44 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.3 OUTLIER -50.7 -23.7 2.85 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.99 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 21.2 m170 -53.71 -26.71 24.29 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.882 . . . . 0.0 110.094 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.7 -73.31 0.66 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.026 -1.046 . . . . 0.0 109.877 -179.848 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.61 HG23 ' CG1' ' A' ' 17' ' ' ILE . 24.9 pt -65.33 -33.83 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.875 -1.14 . . . . 0.0 109.169 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.448 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 45.43 -108.64 0.23 Allowed Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.08 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.32 -35.88 10.16 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -179.47 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.497 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 40.3 mttt -68.06 -22.25 64.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.155 -1.203 . . . . 0.0 109.699 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.445 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -74.99 72.42 2.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.068 -1.02 . . . . 0.0 109.111 179.443 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.758 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 15.0 p-10 -73.43 -175.88 2.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.275 -0.891 . . . . 0.0 109.882 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.422 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -59.08 -45.99 89.42 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 109.302 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.758 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -60.12 -33.0 71.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.315 -0.865 . . . . 0.0 109.074 179.662 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.55 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -66.98 -51.99 48.32 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.272 -0.893 . . . . 0.0 109.429 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 14.4 ptpt -71.61 -28.96 64.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.251 -0.906 . . . . 0.0 109.546 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.476 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 39.3 t0 -80.07 -43.39 21.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.331 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.476 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -56.28 -46.1 79.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.325 -0.86 . . . . 0.0 109.213 179.675 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.951 ' CH2' HD12 ' A' ' 17' ' ' ILE . 13.1 m0 -74.63 -32.39 62.28 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.258 -0.901 . . . . 0.0 108.581 179.585 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -56.54 -26.02 53.68 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.962 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.92 -30.66 14.04 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.315 -0.866 . . . . 0.0 109.063 179.476 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.434 ' C ' HD13 ' A' ' 137' ' ' ILE . . . -83.08 -54.38 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.493 -0.754 . . . . 0.0 109.412 179.845 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.56 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -48.87 -27.31 2.96 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.362 -179.938 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.56 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -80.98 -32.08 34.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 108.776 179.335 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.408 ' N ' ' O ' ' A' ' 133' ' ' ALA . 3.1 m-20 -81.7 -35.67 29.54 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.431 -0.793 . . . . 0.0 109.272 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.664 HG21 HD13 ' A' ' 66' ' ' ILE . 1.4 mp -66.39 -60.53 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.207 -0.933 . . . . 0.0 108.545 179.409 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.14 -12.06 46.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.95 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.676 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -75.78 -46.25 14.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.55 -28.73 68.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -1.142 . . . . 0.0 109.702 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.992 HD11 ' CG1' ' A' ' 86' ' ' VAL . 1.7 tt -71.64 -22.09 61.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.298 -0.876 . . . . 0.0 109.667 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.676 HD12 ' HA2' ' A' ' 139' ' ' GLY . 86.9 mt -78.12 1.34 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.177 -179.826 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 143' ' ' SER . . . . . 0.479 ' HB3' ' CE ' ' A' ' 84' ' ' LYS . 68.2 m -81.35 -44.6 17.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.045 . . . . 0.0 109.718 -179.974 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 88' ' ' VAL . . . -110.85 11.12 29.78 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.88 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.432 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.027 -1.278 . . . . 0.0 110.014 -179.83 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.636 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.26 0.552 . . . . 0.0 109.82 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.516 ' O ' HG23 ' A' ' 10' ' ' VAL . 24.6 mt-30 -81.31 -43.01 19.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 109.911 -179.765 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.473 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 12.4 ptm180 -53.78 -35.0 60.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.617 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.473 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 6.8 mm-40 -71.96 -47.74 50.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.921 . . . . 0.0 109.541 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 5' ' ' ALA . 33.1 t -60.09 -27.09 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.257 -0.902 . . . . 0.0 109.461 179.954 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.857 HG12 HG13 ' A' ' 70' ' ' VAL . 54.9 t -70.63 -49.11 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.287 -0.883 . . . . 0.0 109.475 179.899 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.9 -16.25 62.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.866 . . . . 0.0 109.795 -179.988 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.59 -26.16 26.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.705 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -95.15 -9.61 32.98 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.197 -0.94 . . . . 0.0 109.959 -179.992 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.77 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.61 -17.25 24.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.026 -1.046 . . . . 0.0 109.963 -179.882 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.4 mtpt -80.06 -13.71 59.09 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.121 -0.987 . . . . 0.0 109.585 179.658 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.408 ' O ' ' NE ' ' A' ' 117' ' ' ARG . 68.2 m-20 -98.62 -55.43 2.74 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.561 179.802 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.918 HD12 ' CH2' ' A' ' 130' ' ' TRP . 30.8 mt -65.39 -28.74 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.211 -0.931 . . . . 0.0 109.12 179.698 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.77 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -111.42 36.56 3.18 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 179.806 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.55 -86.77 0.02 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.7 p -104.98 9.76 34.4 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -1.17 . . . . 0.0 109.94 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.437 ' OD1' ' HA ' ' A' ' 18' ' ' ALA . 2.3 p30 -119.3 -12.41 9.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.1 -1.0 . . . . 0.0 109.848 179.907 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.674 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 14.8 t-20 64.03 13.03 7.4 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.234 -0.916 . . . . 0.0 109.838 -179.758 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.73 ' C ' HD13 ' A' ' 63' ' ' LEU . . . 96.3 16.28 38.2 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.918 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.421 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -48.35 -38.19 18.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.221 -1.164 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.29 14.53 57.43 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.552 ' HB ' HD22 ' A' ' 63' ' ' LEU . 15.7 t -102.21 -29.44 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.075 -1.25 . . . . 0.0 109.558 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -92.26 -37.08 6.03 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.657 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.484 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.7 ptpt -64.07 -31.7 72.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.172 -1.193 . . . . 0.0 109.549 -179.857 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.484 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 19.6 pt-20 -94.46 -19.13 20.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.125 -0.985 . . . . 0.0 109.642 179.882 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.527 ' SG ' HD12 ' A' ' 110' ' ' LEU . 35.4 t -89.25 -53.6 4.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.867 -179.78 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.902 ' CZ ' HG21 ' A' ' 62' ' ' VAL . 15.9 m-85 -63.41 -34.85 78.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 109.774 -179.688 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.796 ' OG1' HG11 ' A' ' 55' ' ' VAL . 12.4 m -58.71 -36.05 73.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.09 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.81 -42.22 50.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.874 . . . . 0.0 109.291 179.571 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.693 ' CG ' HD23 ' A' ' 106' ' ' LEU . 12.7 t80 -63.07 -47.41 83.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -0.887 . . . . 0.0 109.313 179.661 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.82 ' CD1' HG22 ' A' ' 55' ' ' VAL . 22.0 mt -57.16 -43.69 82.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.876 . . . . 0.0 109.739 179.925 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.404 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 3.6 t -68.76 -63.52 1.04 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 109.706 -179.923 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.56 -24.45 8.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.262 -0.899 . . . . 0.0 109.7 -179.956 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.404 ' O ' ' O ' ' A' ' 35' ' ' LEU . 29.7 m80 -125.49 104.29 8.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.805 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -86.71 -5.23 59.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.389 -0.819 . . . . 0.0 109.855 179.661 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -82.16 -21.99 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.099 -1.001 . . . . 0.0 109.535 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 41' ' ' MET . . . . . 0.421 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 88.4 mmm -101.12 -23.88 14.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.244 -0.91 . . . . 0.0 109.692 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.427 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.62 -38.13 20.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.226 -0.921 . . . . 0.0 109.632 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.67 -28.56 60.89 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.422 179.76 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.77 HG13 ' OD1' ' A' ' 95' ' ' ASN . 52.5 t -67.17 -59.69 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.514 179.844 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.637 ' CD2' HD21 ' A' ' 35' ' ' LEU . 68.1 m-85 -50.79 -42.08 57.72 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.236 -0.915 . . . . 0.0 109.586 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.07 35.84 0.92 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.735 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.36 166.79 15.34 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.119 -1.224 . . . . 0.0 109.762 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.6 t -111.2 21.62 16.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.411 -0.805 . . . . 0.0 109.117 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 146.08 177.59 20.87 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -179.788 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -68.79 -13.78 62.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -1.181 . . . . 0.0 109.828 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 71.9 p -87.85 45.55 1.29 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.103 -0.998 . . . . 0.0 109.688 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.52 132.45 24.26 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -69.23 -22.17 34.89 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 123.874 1.46 . . . . 0.0 110.083 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.492 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -57.39 -26.93 57.48 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.82 HG22 ' CD1' ' A' ' 35' ' ' LEU . 87.1 t -58.33 -51.94 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.179 -1.189 . . . . 0.0 109.637 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -58.21 -22.6 52.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.928 . . . . 0.0 109.552 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.96 -60.31 2.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.874 . . . . 0.0 109.604 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.815 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.5 OUTLIER -55.88 -59.04 5.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.677 -179.949 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.524 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.54 -60.76 5.59 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.867 ' HA ' HD21 ' A' ' 63' ' ' LEU . . . -48.23 -33.97 9.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 0.0 109.654 179.788 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -77.76 -20.26 53.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.319 -0.863 . . . . 0.0 109.419 179.769 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.902 HG21 ' CZ ' ' A' ' 31' ' ' PHE . 49.4 t -81.24 -61.16 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.31 -0.869 . . . . 0.0 109.677 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.867 HD21 ' HA ' ' A' ' 60' ' ' ALA . 0.3 OUTLIER -46.07 -43.07 14.33 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.27 -0.894 . . . . 0.0 109.835 179.914 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.25 -40.23 33.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.96 -1.088 . . . . 0.0 109.477 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -65.83 -43.37 88.77 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.249 -0.907 . . . . 0.0 109.153 179.484 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.91 ' O ' HG23 ' A' ' 70' ' ' VAL . 33.9 mt -59.96 -40.13 82.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.412 -0.805 . . . . 0.0 109.182 179.68 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.565 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.04 -50.79 62.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.88 -30.53 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 109.334 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -82.81 -24.92 33.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.404 -0.81 . . . . 0.0 109.588 -179.963 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.91 HG23 ' O ' ' A' ' 66' ' ' ILE . 46.2 t -69.8 -9.06 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.855 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.509 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 24.9 p -91.39 30.9 1.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.058 -1.027 . . . . 0.0 109.938 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.509 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.5 m-70 -160.69 -89.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.633 179.875 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.411 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 15.0 mt . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.367 -0.833 . . . . 0.0 109.985 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.4 tmm? . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.191 0.519 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.431 ' O ' ' HB3' ' A' ' 84' ' ' LYS . 46.7 t -80.33 -19.6 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.612 179.931 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.41 -40.59 97.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.593 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.573 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 1.2 tp10 -87.0 -45.6 10.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.537 179.912 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.5 mtp -59.48 -56.92 15.91 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.257 179.765 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.431 ' HB3' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -52.43 -27.04 14.36 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.236 -0.915 . . . . 0.0 109.091 179.546 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.573 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.04 -35.93 72.14 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.707 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 82' ' ' GLU . 16.5 t -58.72 -38.77 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.221 -0.924 . . . . 0.0 109.226 179.868 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.421 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -55.86 -47.75 77.09 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.531 -1.827 . . . . 0.0 108.531 179.588 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.561 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.7 t -55.13 -36.13 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.32 -1.106 . . . . 0.0 108.955 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.507 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mpt_? -69.01 -52.33 29.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 108.991 179.398 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 90' ' ' HIS . . . . . 0.62 ' HB2' HD13 ' A' ' 145' ' ' LEU . 16.9 m80 -56.35 -29.22 61.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.836 . . . . 0.0 109.288 179.581 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 ttmt -66.23 -13.07 59.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.285 -0.884 . . . . 0.0 110.06 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.25 47.66 1.01 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.936 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.507 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -91.42 -169.29 2.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.346 -1.091 . . . . 0.0 109.817 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.26 -52.82 7.3 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.647 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.77 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -61.49 -31.65 71.64 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.128 -1.219 . . . . 0.0 109.486 -179.798 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.438 ' H ' ' ND2' ' A' ' 95' ' ' ASN . 9.5 tttt 60.42 32.94 20.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -0.864 . . . . 0.0 110.147 179.595 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 97' ' ' HIS . . . . . 0.414 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 6.2 m-70 -129.24 -85.31 0.55 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.186 -0.946 . . . . 0.0 109.092 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 90' ' ' HIS . 17.7 mt 60.13 151.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.806 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.542 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -147.16 131.65 17.69 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 179.743 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.09 -12.51 61.54 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.647 -0.658 . . . . 0.0 109.461 179.5 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.421 ' O ' ' HG2' ' A' ' 105' ' ' PRO . 1.0 OUTLIER -73.23 -19.75 61.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.092 -1.005 . . . . 0.0 109.255 179.517 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.542 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 34.4 m-85 -88.48 -22.42 23.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.829 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -54.39 -58.91 5.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.068 -179.703 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.509 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -54.3 -58.0 15.85 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.112 -0.993 . . . . 0.0 110.097 -179.498 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.509 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.7 Cg_exo -49.18 -59.83 1.09 Allowed 'Trans proline' 0 C--N 1.309 -1.533 0 O-C-N 123.62 1.326 . . . . 0.0 110.095 179.89 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.826 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -53.71 -27.28 27.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.555 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.06 -45.96 9.79 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 -179.976 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -60.64 -52.87 63.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.625 -179.986 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 17.3 m -57.66 -27.74 63.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.656 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.527 HD12 ' SG ' ' A' ' 30' ' ' CYS . 4.1 tt -67.37 -43.08 82.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.215 -0.928 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.913 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.8 mt -56.51 -34.24 66.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.537 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 10.6 t -64.12 -34.44 78.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.721 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 113' ' ' ALA . . . . . 0.417 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -81.57 -28.44 33.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.233 -0.917 . . . . 0.0 109.782 -179.732 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 114' ' ' MET . . . . . 0.471 ' HE2' ' OH ' ' A' ' 134' ' ' TYR . 5.8 mmt -51.47 -35.51 40.17 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.96 . . . . 0.0 110.291 -179.563 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 7.1 pt-20 -64.85 -12.28 46.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.086 -1.009 . . . . 0.0 110.164 -179.548 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 116' ' ' HIS . . . . . 0.417 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 0.5 OUTLIER -67.59 -27.15 66.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.943 -1.098 . . . . 0.0 109.52 179.917 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.436 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -94.16 -64.45 1.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.791 179.976 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.511 HG23 HG12 ' A' ' 17' ' ' ILE . 24.3 pt -84.3 -34.85 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.641 -179.898 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 119' ' ' GLY . . . . . 0.49 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 42.39 -94.94 0.01 OUTLIER Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -44.03 -48.22 7.98 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -179.146 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.486 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -67.32 -22.64 65.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.116 -1.226 . . . . 0.0 109.895 -179.877 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 122' ' ' MET . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -71.1 96.55 1.36 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.086 -1.008 . . . . 0.0 109.098 179.51 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.434 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 8.5 p30 -100.36 -161.52 0.87 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.265 -0.897 . . . . 0.0 110.062 -179.5 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.47 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -72.86 -45.58 57.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.354 -0.841 . . . . 0.0 109.655 -179.945 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 125' ' ' ALA . . . . . 0.434 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -62.47 -30.41 71.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.196 -0.94 . . . . 0.0 109.036 179.731 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.47 -50.23 47.36 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.624 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.8 ptpt -72.1 -27.55 62.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 179.774 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 128' ' ' ASP . . . . . 0.462 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 62.2 t0 -80.44 -41.3 24.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.168 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.505 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -63.91 -45.71 88.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 109.152 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.918 ' CH2' HD12 ' A' ' 17' ' ' ILE . 5.0 m0 -73.02 -25.73 61.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.368 -0.833 . . . . 0.0 109.138 179.544 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.624 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.43 -34.08 77.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.289 -0.882 . . . . 0.0 108.926 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.47 -20.76 24.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.372 -0.83 . . . . 0.0 109.333 179.564 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -79.39 -53.39 6.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.525 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.488 ' OH ' ' CE3' ' A' ' 130' ' ' TRP . 10.4 m-30 -53.0 -28.4 23.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.334 179.929 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.9 -48.58 52.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.053 179.465 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.89 -34.31 66.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.322 -0.861 . . . . 0.0 109.225 179.642 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.759 HD13 HG23 ' A' ' 66' ' ' ILE . 64.1 mt -66.73 -59.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.348 -0.845 . . . . 0.0 109.16 179.743 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.403 ' O ' HG13 ' A' ' 142' ' ' ILE . 2.2 p -67.87 -25.98 65.79 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.677 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.43 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -68.87 -46.57 59.59 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -179.952 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.51 -26.89 45.41 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -1.172 . . . . 0.0 109.66 179.975 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.829 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.1 tt -77.29 -16.35 59.01 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.203 -0.936 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.442 HG22 ' O ' ' A' ' 142' ' ' ILE . 60.9 mt -76.5 -0.73 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.14 -0.975 . . . . 0.0 110.151 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.0 m -84.37 -43.96 14.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.037 -1.04 . . . . 0.0 109.632 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.561 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -85.53 -16.55 63.85 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.62 HD13 ' HB2' ' A' ' 90' ' ' HIS . 6.8 tp . . . . . 0 N--CA 1.488 1.43 0 O-C-N 121.195 -1.179 . . . . 0.0 108.943 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.847 ' CD1' HD12 ' A' ' 73' ' ' LEU . 12.0 mt -128.86 165.39 21.11 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.127 -1.219 . . . . 0.0 109.747 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.59 168.4 15.79 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.249 -0.907 . . . . 0.0 109.905 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -63.31 -40.5 97.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.333 -0.855 . . . . 0.0 109.403 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.895 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -63.3 -41.97 99.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.318 -0.864 . . . . 0.0 109.307 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.474 ' O ' HG23 ' A' ' 10' ' ' VAL . 76.9 mt-30 -70.27 -47.35 61.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.305 -0.872 . . . . 0.0 109.212 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 31.8 mtp180 -53.98 -36.01 62.44 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.247 -0.908 . . . . 0.0 109.193 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -74.59 -40.38 61.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.309 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 5' ' ' ALA . 61.0 t -66.06 -23.71 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.284 -0.885 . . . . 0.0 109.192 179.606 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.645 HG23 ' HB1' ' A' ' 129' ' ' ALA . 50.9 t -76.74 -44.89 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -0.853 . . . . 0.0 109.338 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.412 ' O ' ' HG3' ' A' ' 15' ' ' LYS . . . -74.04 -15.96 61.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.764 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -86.21 -24.16 26.19 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.149 -0.969 . . . . 0.0 109.816 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.507 HG21 ' HB1' ' A' ' 126' ' ' ALA . 3.6 p -95.16 -10.96 29.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.214 -0.929 . . . . 0.0 109.8 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.686 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.8 -28.73 17.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 0.0 109.863 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.412 ' HG3' ' O ' ' A' ' 11' ' ' ALA . 10.6 mtmt -74.57 -12.73 60.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 109.812 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.415 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 1.7 m-20 -101.52 -55.05 2.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -0.988 . . . . 0.0 109.528 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.921 HD12 ' CH2' ' A' ' 130' ' ' TRP . 86.0 mt -67.5 -35.5 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.271 -0.893 . . . . 0.0 109.593 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.637 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -105.59 33.73 3.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.285 -0.884 . . . . 0.0 109.728 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -84.58 0.03 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 p -101.08 -18.81 16.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.703 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.7 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.4 p-10 -85.51 -16.99 37.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.207 -0.933 . . . . 0.0 109.902 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.598 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.4 t30 62.39 17.0 9.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.263 -0.898 . . . . 0.0 109.676 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.88 29.65 5.75 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.7 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -70.88 -46.99 61.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -1.174 . . . . 0.0 109.546 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.441 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.85 38.19 3.19 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.579 HG11 HD11 ' A' ' 63' ' ' LEU . 34.6 t -124.01 -43.12 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.233 -1.157 . . . . 0.0 108.64 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.488 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -88.81 -32.0 11.77 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.54 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.531 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 15.5 ptpt -62.19 -35.57 79.25 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.232 -1.158 . . . . 0.0 109.124 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.837 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 17.2 pt-20 -86.42 -21.08 27.32 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -0.972 . . . . 0.0 109.31 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 38.5 t -87.98 -59.38 2.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.398 -0.814 . . . . 0.0 109.692 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.2 m-85 -53.67 -42.99 68.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.275 -0.891 . . . . 0.0 109.669 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.778 ' OG1' HG11 ' A' ' 55' ' ' VAL . 17.8 m -52.02 -50.25 61.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.15 -0.969 . . . . 0.0 109.252 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.427 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 0.2 OUTLIER -62.5 -44.73 95.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.26 179.649 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.707 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.9 t80 -57.81 -46.66 84.36 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.35 -0.844 . . . . 0.0 109.206 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.705 ' CD1' HG22 ' A' ' 55' ' ' VAL . 11.1 mt -59.26 -44.34 92.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.715 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.613 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 46.8 t -66.7 -64.32 0.88 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.204 -0.935 . . . . 0.0 109.749 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.39 -26.57 20.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.218 -0.926 . . . . 0.0 109.827 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 16.3 m80 -123.79 104.92 9.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.857 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.6 m170 -85.99 8.24 21.3 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.428 -0.795 . . . . 0.0 109.758 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -98.54 -11.66 21.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.129 -0.982 . . . . 0.0 109.623 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.571 ' HE2' HG11 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -105.84 -11.77 16.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.209 -0.932 . . . . 0.0 110.081 -179.793 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.438 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -58.46 -60.26 4.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.938 -1.101 . . . . 0.0 109.26 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.81 -28.24 63.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.088 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' ND2' ' A' ' 95' ' ' ASN . 28.5 t -68.85 -47.77 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.376 -0.828 . . . . 0.0 109.088 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.768 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 35.5 m-85 -71.19 -37.08 72.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.557 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.77 34.23 1.57 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.4 m-85 -125.92 168.61 13.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -1.162 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.0 t -105.92 -13.68 15.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.406 -0.809 . . . . 0.0 109.479 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.77 -162.97 28.28 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.613 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -83.49 -19.55 35.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.297 -1.119 . . . . 0.0 109.778 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 14.9 p -87.76 52.15 2.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -0.902 . . . . 0.0 109.739 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -127.12 133.77 25.42 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.923 . . . . 0.0 109.581 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -67.23 -29.01 39.69 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.908 1.478 . . . . 0.0 110.063 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.27 -38.28 40.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.778 HG11 ' OG1' ' A' ' 32' ' ' THR . 94.4 t -51.2 -46.78 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -1.095 . . . . 0.0 109.421 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.496 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -64.2 -17.12 63.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.902 . . . . 0.0 109.494 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.83 -47.38 15.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.819 ' O ' HG23 ' A' ' 62' ' ' VAL . 9.6 mt -73.23 -60.69 2.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.178 -0.951 . . . . 0.0 109.476 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.715 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -47.65 -31.19 7.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.496 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -78.38 -60.54 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -1.148 . . . . 0.0 109.438 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -52.43 -39.2 60.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.286 -0.884 . . . . 0.0 109.493 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.819 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.3 t -64.63 -48.32 85.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.715 HD23 ' O ' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -47.78 -44.74 28.69 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.184 -0.947 . . . . 0.0 109.636 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 67' ' ' GLY . . . -49.2 -52.74 24.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.409 -0.807 . . . . 0.0 109.778 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.1 tp60 -49.82 -44.02 49.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.095 -1.003 . . . . 0.0 109.268 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.972 ' O ' HG23 ' A' ' 70' ' ' VAL . 82.7 mt -63.2 -28.04 44.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.336 -0.852 . . . . 0.0 108.851 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.561 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -71.41 -55.22 7.84 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.44 -24.48 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.238 -1.154 . . . . 0.0 109.116 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.41 ' O ' HD22 ' A' ' 73' ' ' LEU . . . -86.09 -18.09 33.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.413 -0.805 . . . . 0.0 109.57 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.972 HG23 ' O ' ' A' ' 66' ' ' ILE . 41.0 t -75.07 -16.04 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.511 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 74.6 m -88.45 11.06 18.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.129 -0.982 . . . . 0.0 110.143 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.8 m-70 -161.73 61.37 0.25 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.048 -1.033 . . . . 0.0 109.926 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.847 HD12 ' CD1' ' A' ' 2' ' ' LEU . 3.1 mm? -75.17 -42.9 54.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -78.37 -26.57 59.23 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.64 87.68 6.0 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -1.162 . . . . 0.0 109.663 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.436 ' HB2' HG21 ' A' ' 80' ' ' VAL . 3.7 pm0 -94.96 43.32 1.09 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 109.474 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -113.65 -21.36 5.78 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -126.04 -57.93 1.4 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -1.196 . . . . 0.0 110.031 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.418 ' HG2' ' O ' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -50.83 -24.6 3.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.052 -1.03 . . . . 0.0 109.284 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.664 HG13 ' HB1' ' A' ' 140' ' ' ALA . 71.6 t -84.1 -17.01 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.39 -0.819 . . . . 0.0 109.405 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -39.39 70.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.493 ' O ' HG23 ' A' ' 86' ' ' VAL . 12.3 tt0 -69.91 -48.17 59.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.243 -0.911 . . . . 0.0 109.331 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.58 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.7 OUTLIER -58.68 -46.78 86.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 109.214 179.7 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.469 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.9 mttt -52.92 -34.78 56.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.246 -0.909 . . . . 0.0 109.148 179.571 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.42 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -69.3 -42.98 74.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.339 -0.851 . . . . 0.0 109.391 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.2 t -50.97 -40.15 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.302 -0.874 . . . . 0.0 109.338 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.463 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -58.05 -50.48 65.73 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.777 HG23 ' HA3' ' A' ' 144' ' ' GLY . 97.6 t -54.62 -35.88 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -1.034 . . . . 0.0 108.95 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 1.5 mpt_? -66.08 -45.02 82.75 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.359 -0.838 . . . . 0.0 108.97 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.684 ' O ' HD12 ' A' ' 98' ' ' ILE . 16.5 m80 -64.71 -12.2 44.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.441 -0.787 . . . . 0.0 109.766 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.459 ' HG3' ' N ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -74.27 -8.48 56.37 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.032 -1.042 . . . . 0.0 110.426 -179.657 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -152.04 57.75 0.43 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.792 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.5 m-30 -88.35 -169.74 2.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.265 -1.138 . . . . 0.0 109.728 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.52 -8.77 87.12 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.02 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.0 p-10 -112.22 -23.75 10.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.862 -1.375 . . . . 0.0 109.975 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 51.33 28.43 4.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.134 -0.978 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.821 ' HB2' HG22 ' A' ' 44' ' ' VAL . 38.4 m170 -129.32 38.42 3.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.792 HD11 ' CD2' ' A' ' 93' ' ' TYR . 51.2 mt -87.72 154.6 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.065 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.429 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.86 149.83 27.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.129 -0.982 . . . . 0.0 110.159 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.672 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -80.17 -8.83 59.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.358 -0.839 . . . . 0.0 109.588 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 105' ' ' PRO . 14.5 pt-20 -68.62 -30.24 68.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.1 -1.0 . . . . 0.0 109.336 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.562 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 70.4 m-85 -82.47 -21.24 35.65 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.312 -0.867 . . . . 0.0 109.737 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.8 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.2 m-85 -57.66 -68.83 0.2 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.389 -0.819 . . . . 0.0 110.465 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.505 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 8.4 mt-10 -43.62 -60.21 2.78 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.45 -0.781 . . . . 0.0 111.022 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.538 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.3 Cg_endo -56.5 -50.59 11.41 Favored 'Trans proline' 0 C--N 1.304 -1.802 0 O-C-N 123.756 1.398 . . . . 0.0 110.052 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.933 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -65.52 -19.67 66.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.158 -0.963 . . . . 0.0 109.333 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -79.99 -44.9 8.68 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.52 -47.07 77.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.217 -1.167 . . . . 0.0 109.337 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 48.7 m -63.66 -16.77 61.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.32 -0.862 . . . . 0.0 109.508 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.493 HD22 ' CE2' ' A' ' 134' ' ' TYR . 6.3 tt -75.41 -40.24 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.673 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.882 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.8 mt -63.12 -30.06 71.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.937 . . . . 0.0 109.718 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 1.4 t -73.2 -20.9 60.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 109.639 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.837 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -88.29 -31.25 19.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.582 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.585 ' SD ' HD23 ' A' ' 111' ' ' LEU . 1.0 OUTLIER -55.6 -35.75 66.17 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.853 . . . . 0.0 109.992 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 20.8 pt-20 -57.75 -22.54 47.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.117 -0.989 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.405 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 0.4 OUTLIER -56.98 -40.56 76.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.211 -0.931 . . . . 0.0 109.355 179.796 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.47 ' HD3' HG23 ' A' ' 17' ' ' ILE . 11.2 ttt85 -77.59 -62.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.543 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.507 HG12 HD11 ' A' ' 17' ' ' ILE . 8.7 pt -91.69 43.26 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.459 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -52.99 124.46 27.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 101.06 -37.06 3.78 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 26.4 mmtt -89.12 -24.52 22.22 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 109.293 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.435 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -72.12 86.9 1.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.323 -0.861 . . . . 0.0 109.586 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.87 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.1 p-10 -83.66 -171.98 3.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.348 -0.845 . . . . 0.0 109.859 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.441 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -64.15 -42.58 96.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.299 -0.876 . . . . 0.0 109.778 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.87 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -61.09 -29.96 70.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.128 -0.983 . . . . 0.0 109.334 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.507 ' HB1' HG21 ' A' ' 13' ' ' THR . . . -69.93 -50.35 42.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.527 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 11.5 ptpt -71.79 -28.37 63.57 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.9 t0 -76.51 -49.28 16.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.267 -0.896 . . . . 0.0 109.332 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.645 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -56.53 -45.25 81.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.391 -0.818 . . . . 0.0 109.261 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.921 ' CH2' HD12 ' A' ' 17' ' ' ILE . 5.4 m0 -73.54 -32.07 64.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.36 -0.838 . . . . 0.0 109.134 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.604 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.03 -24.69 67.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.291 -0.88 . . . . 0.0 109.185 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.23 -26.97 16.41 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.386 -0.821 . . . . 0.0 109.265 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.56 ' HB1' HD11 ' A' ' 73' ' ' LEU . . . -81.68 -44.46 17.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.325 -0.859 . . . . 0.0 109.577 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.729 ' CZ ' HG21 ' A' ' 66' ' ' ILE . 2.8 m-85 -57.45 -27.61 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.943 . . . . 0.0 109.493 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.45 -46.32 89.07 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.355 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -74.58 -28.28 60.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.33 -0.857 . . . . 0.0 109.587 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.67 HD12 ' HA ' ' A' ' 134' ' ' TYR . 81.4 mt -68.62 -60.24 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.453 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.404 ' O ' HG12 ' A' ' 142' ' ' ILE . 45.2 p -67.52 -48.76 66.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.382 -0.824 . . . . 0.0 109.774 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.64 -29.85 26.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.664 ' HB1' HG13 ' A' ' 80' ' ' VAL . . . -78.85 -17.55 55.45 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.157 -1.202 . . . . 0.0 109.825 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.8 HD22 ' CE2' ' A' ' 103' ' ' PHE . 9.3 tt -89.57 -23.44 21.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 109.82 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.672 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.0 mm -70.7 -16.71 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.219 -0.925 . . . . 0.0 109.82 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.469 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.5 OUTLIER -61.39 -68.01 0.35 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -0.966 . . . . 0.0 109.175 179.808 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.777 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -66.04 -19.37 67.84 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.483 ' CB ' ' HA ' ' A' ' 142' ' ' ILE . 24.6 tp -58.75 170.28 0.83 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.316 -1.108 . . . . 0.0 109.597 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.482 ' HG2' ' O ' ' A' ' 145' ' ' LEU . 0.3 OUTLIER 36.33 46.83 0.44 Allowed 'General case' 0 N--CA 1.502 2.138 0 CA-C-O 121.336 0.589 . . . . 0.0 111.044 -179.86 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.459 ' N ' ' HG3' ' A' ' 91' ' ' LYS . 4.0 t . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.659 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.768 HMA3 ' HA ' ' A' ' 45' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.638 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.883 HD13 HD13 ' A' ' 73' ' ' LEU . 10.8 mt -61.02 176.95 0.37 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -1.116 . . . . 0.0 109.404 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.402 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 77.7 p -134.27 -159.81 1.0 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.917 . . . . 0.0 109.775 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.79 -27.74 20.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.544 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.29 -34.98 15.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.373 -0.829 . . . . 0.0 109.684 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.402 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 27.9 mt-30 -70.82 -40.96 72.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.06 -1.025 . . . . 0.0 109.527 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.46 ' NH2' ' HA3' ' A' ' 74' ' ' GLY . 11.0 ttm180 -51.04 -52.73 40.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.113 -0.992 . . . . 0.0 109.297 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 60.1 mm-40 -49.72 -41.73 44.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.926 . . . . 0.0 109.268 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.7 t -71.25 -29.91 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -0.883 . . . . 0.0 108.88 179.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.849 HG12 HG13 ' A' ' 70' ' ' VAL . 41.5 t -78.59 -43.73 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.494 -0.754 . . . . 0.0 109.051 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.71 -13.19 60.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.443 -0.786 . . . . 0.0 109.78 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.5 m -92.13 -27.65 17.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 110.094 -179.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -87.73 -14.53 39.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.166 -0.959 . . . . 0.0 109.843 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -86.2 -18.4 32.27 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -0.95 . . . . 0.0 109.781 -179.802 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -80.28 1.97 26.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.142 -0.974 . . . . 0.0 109.784 179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -114.22 -53.95 2.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.103 -0.998 . . . . 0.0 109.333 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.895 HD12 ' CH2' ' A' ' 130' ' ' TRP . 54.7 mt -63.94 -35.19 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.468 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.4 38.27 2.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.912 . . . . 0.0 109.791 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.83 -88.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.1 p -109.41 17.38 21.51 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.305 -1.115 . . . . 0.0 109.683 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.439 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 2.9 p-10 -125.88 -3.93 7.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.578 HD21 ' HB2' ' A' ' 64' ' ' ALA . 6.4 t30 57.15 19.25 4.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.293 -0.88 . . . . 0.0 109.452 -179.576 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.48 27.22 30.63 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HD2' ' A' ' 28' ' ' LYS . . . -52.56 -38.26 59.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.348 -1.089 . . . . 0.0 109.698 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.43 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.44 18.97 38.67 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.875 HG21 ' CG2' ' A' ' 17' ' ' ILE . 25.5 t -117.3 -14.22 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.136 -1.214 . . . . 0.0 109.46 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.461 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -110.03 -29.46 3.77 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.015 -1.634 . . . . 0.0 109.015 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.487 ' HB2' ' CB ' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -77.8 -28.47 50.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.187 -1.184 . . . . 0.0 109.458 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.619 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 1.6 pm0 -95.38 -16.0 22.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.633 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.406 ' HB2' ' OE2' ' A' ' 29' ' ' GLU . 37.0 t -87.98 -62.49 1.48 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -0.925 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.659 ' O ' HD12 ' A' ' 35' ' ' LEU . 10.8 m-85 -50.27 -30.96 12.94 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.143 -0.973 . . . . 0.0 109.694 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.579 ' OG1' HG11 ' A' ' 55' ' ' VAL . 52.6 m -61.64 -30.97 71.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.418 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 6.7 mmtt -74.57 -47.44 32.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.283 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.689 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.1 t80 -57.85 -46.16 85.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.419 -0.801 . . . . 0.0 109.535 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.701 HD13 HG22 ' A' ' 55' ' ' VAL . 6.8 mt -60.3 -46.89 88.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -0.882 . . . . 0.0 109.775 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.481 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 54.3 p -65.14 -49.9 68.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.284 -0.885 . . . . 0.0 109.769 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.45 -25.9 63.41 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.192 -0.943 . . . . 0.0 109.765 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.447 ' N ' ' O ' ' A' ' 34' ' ' PHE . 22.9 m80 -126.14 117.76 23.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.204 -0.935 . . . . 0.0 109.866 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.2 m170 -94.75 -15.33 23.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.455 -0.778 . . . . 0.0 109.56 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -71.59 -7.62 48.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.17 -0.956 . . . . 0.0 109.882 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.582 ' HE2' ' CD1' ' A' ' 102' ' ' TYR . 4.9 mmt -118.77 -12.08 9.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.012 -1.055 . . . . 0.0 110.115 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.458 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -56.53 -53.53 56.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.943 -1.098 . . . . 0.0 109.254 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -64.25 -27.9 69.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.102 179.559 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.022 HG13 ' ND2' ' A' ' 95' ' ' ASN . 13.0 t -67.95 -53.38 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.417 -0.802 . . . . 0.0 109.171 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 38.9 m-85 -61.93 -19.02 62.28 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 29.66 6.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 14.1 m-85 -126.37 168.84 13.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -1.138 . . . . 0.0 109.941 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.5 t -114.67 20.11 15.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.452 -0.78 . . . . 0.0 109.166 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.78 -163.74 28.24 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -98.93 39.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -1.17 . . . . 0.0 109.645 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 16.1 m -140.53 22.94 2.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 109.675 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -110.43 145.67 32.71 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.24 -0.913 . . . . 0.0 109.692 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -77.57 56.15 5.46 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.972 1.511 . . . . 0.0 110.169 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -135.06 -38.4 0.19 Allowed Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.701 HG22 HD13 ' A' ' 35' ' ' LEU . 47.5 t -50.0 -26.65 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.242 -1.152 . . . . 0.0 109.596 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.512 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -81.1 -7.81 59.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.292 -0.88 . . . . 0.0 110.002 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -91.73 -31.37 15.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.067 -1.021 . . . . 0.0 109.747 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.877 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.1 mt -83.04 -64.09 1.24 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.115 -0.991 . . . . 0.0 109.697 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.461 ' HA3' ' CA ' ' A' ' 27' ' ' GLY . . . -51.39 -44.81 53.16 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.512 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -53.49 -39.15 64.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.225 -1.162 . . . . 0.0 109.611 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.463 ' HD3' ' CGD' ' A' ' 148' ' ' HEM . 17.5 mttt -89.63 -32.31 17.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.252 -0.905 . . . . 0.0 109.633 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.877 HG23 ' O ' ' A' ' 58' ' ' LEU . 57.7 t -65.27 -47.95 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.566 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.691 HD11 ' CG1' ' A' ' 26' ' ' VAL . 2.9 mm? -47.3 -45.27 24.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.198 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.578 ' HB2' HD21 ' A' ' 22' ' ' ASN . . . -53.65 -39.95 65.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.175 -0.953 . . . . 0.0 110.077 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.463 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 6.8 tp-100 -59.78 -39.54 85.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.964 -1.085 . . . . 0.0 108.903 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 1.029 HD13 HG21 ' A' ' 137' ' ' ILE . 26.7 mm -62.44 -42.14 94.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.405 -0.809 . . . . 0.0 108.9 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.546 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.6 -51.32 55.06 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.562 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 64' ' ' ALA . 46.6 t -58.47 -26.8 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.318 -1.107 . . . . 0.0 109.411 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.83 -28.19 26.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.32 -0.863 . . . . 0.0 109.704 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.849 HG13 HG12 ' A' ' 10' ' ' VAL . 54.1 t -75.83 -23.33 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.2 p -63.57 -13.48 42.05 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 110.034 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.487 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.4 m-70 -124.01 -77.53 0.59 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.106 -0.996 . . . . 0.0 109.957 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.883 HD13 HD13 ' A' ' 2' ' ' LEU . 53.5 mt 59.78 -79.52 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.672 -0.643 . . . . 0.0 109.734 -179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -54.64 -29.81 49.63 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.37 125.29 43.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.319 -1.106 . . . . 0.0 109.527 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -114.35 41.62 2.26 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.583 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.55 -32.33 7.0 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.639 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 22.2 ttmt -128.51 -30.01 2.38 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -1.146 . . . . 0.0 110.386 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.49 ' SD ' HD23 ' A' ' 73' ' ' LEU . 4.7 ttp -47.23 -62.38 1.45 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.065 -1.022 . . . . 0.0 109.694 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.554 HG12 ' HE3' ' A' ' 84' ' ' LYS . 42.8 t -65.39 -15.41 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.218 -0.926 . . . . 0.0 109.61 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.639 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -71.06 -52.22 20.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.973 . . . . 0.0 109.377 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.596 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.4 mt-10 -71.25 -41.05 70.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.477 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 2.1 mtp -58.8 -48.58 80.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.305 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.601 ' O ' HG23 ' A' ' 88' ' ' VAL . 11.1 mttt -50.8 -38.57 49.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.151 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.412 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -66.83 -44.55 80.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.401 -0.812 . . . . 0.0 109.408 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.625 ' HB ' HD12 ' A' ' 141' ' ' LEU . 14.4 t -58.23 -37.94 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.157 -0.964 . . . . 0.0 109.264 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.458 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -63.34 -49.08 73.36 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 84' ' ' LYS . 57.4 t -51.44 -38.45 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -1.059 . . . . 0.0 109.453 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.551 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 2.8 mpt_? -59.22 -25.62 64.15 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -0.944 . . . . 0.0 109.336 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.536 ' CD2' HD13 ' A' ' 98' ' ' ILE . 4.5 m80 -87.38 16.32 5.49 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.397 -0.814 . . . . 0.0 109.643 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.439 ' O ' ' HG3' ' A' ' 96' ' ' LYS . 23.3 ttmt -75.27 -67.48 0.65 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.941 -1.1 . . . . 0.0 110.167 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.4 ' HA2' ' HG3' ' A' ' 96' ' ' LYS . . . -145.7 56.07 0.53 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.551 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -82.46 -100.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 110.342 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -96.48 -57.28 1.13 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.022 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -84.37 -28.45 26.98 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.415 -1.05 . . . . 0.0 108.594 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.511 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 14.6 tttm 64.41 -48.99 0.3 Allowed 'General case' 0 N--CA 1.505 2.283 0 O-C-N 121.75 -0.594 . . . . 0.0 112.271 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.469 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 64.2 m170 -50.0 -97.21 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.628 -1.295 . . . . 0.0 111.234 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.536 HD13 ' CD2' ' A' ' 90' ' ' HIS . 14.9 mt 65.4 154.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 121.035 -1.04 . . . . 0.0 109.572 -178.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.435 ' HE3' ' HB3' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -158.32 150.75 22.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.268 -0.895 . . . . 0.0 109.828 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.821 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -77.82 -10.21 59.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.569 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.0 mt-10 -67.68 -35.77 79.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 109.597 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.582 ' CD1' ' HE2' ' A' ' 41' ' ' MET . 76.5 m-85 -81.15 -16.48 52.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.344 -0.847 . . . . 0.0 110.146 -179.416 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.824 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -58.32 -57.49 12.66 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.158 -0.963 . . . . 0.0 109.973 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.518 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -53.75 -58.05 14.84 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 109.755 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.518 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 39.7 Cg_exo -50.81 -62.17 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.628 1.33 . . . . 0.0 109.76 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.954 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -53.77 -24.75 16.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -0.895 . . . . 0.0 109.241 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -74.68 -51.49 8.04 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.096 -1.601 . . . . 0.0 109.096 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -54.22 -55.43 28.17 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -1.169 . . . . 0.0 109.456 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 54.9 m -53.33 -22.76 7.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.349 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.4 tt -65.88 -48.51 71.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.314 -0.866 . . . . 0.0 109.632 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.697 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -57.54 -36.56 71.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.184 -0.948 . . . . 0.0 109.544 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -67.44 -33.81 75.9 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.595 179.966 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.619 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -81.69 -25.73 35.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -0.924 . . . . 0.0 109.663 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.534 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.9 mmt -58.45 -47.73 83.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.918 . . . . 0.0 110.205 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.449 ' O ' ' N ' ' A' ' 119' ' ' GLY . 6.4 pt-20 -50.05 -23.54 2.14 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.068 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.428 ' NE2' ' HA ' ' A' ' 113' ' ' ALA . 19.1 m170 -50.2 -40.73 48.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.993 -1.067 . . . . 0.0 109.783 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -87.17 -56.14 3.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.7 -179.873 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.541 HG12 HD11 ' A' ' 17' ' ' ILE . 5.7 pt -104.34 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.143 -0.973 . . . . 0.0 109.633 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -63.15 -20.11 62.41 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.51 -29.23 10.28 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.443 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.2 mppt? -94.26 -23.44 17.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -1.189 . . . . 0.0 109.803 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.488 ' SD ' HD11 ' A' ' 118' ' ' ILE . 3.8 tpt -63.89 86.35 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.18 -0.95 . . . . 0.0 109.616 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.826 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.2 p-10 -87.14 -168.73 2.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.414 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.29 -39.98 74.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -0.932 . . . . 0.0 109.628 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.826 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -65.05 -31.11 72.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.095 -1.003 . . . . 0.0 108.98 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.458 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -66.27 -50.8 62.48 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.107 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.492 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 17.5 ptpt -70.53 -27.67 64.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.913 . . . . 0.0 109.124 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.482 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.1 t0 -79.33 -32.57 43.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.374 -0.829 . . . . 0.0 108.953 179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.7 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -72.42 -47.69 47.15 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.433 -0.792 . . . . 0.0 109.126 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.895 ' CH2' HD12 ' A' ' 17' ' ' ILE . 12.5 m0 -71.54 -21.54 61.88 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.269 -0.895 . . . . 0.0 108.976 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.492 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -53.24 -34.3 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -0.889 . . . . 0.0 109.038 179.075 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -97.22 -15.4 20.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.417 -0.802 . . . . 0.0 109.494 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.647 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -81.51 -67.79 0.75 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.252 -0.905 . . . . 0.0 109.854 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.514 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.4 OUTLIER -55.31 -21.25 14.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.032 -1.043 . . . . 0.0 109.268 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -80.92 -49.56 10.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.299 -0.876 . . . . 0.0 108.944 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -73.21 -26.45 61.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.399 -0.813 . . . . 0.0 109.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 1.029 HG21 HD13 ' A' ' 66' ' ' ILE . 43.9 mt -67.88 -61.21 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 109.183 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.402 ' O ' HG12 ' A' ' 142' ' ' ILE . 0.7 OUTLIER -62.89 -14.2 43.51 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.346 -0.846 . . . . 0.0 109.907 -179.819 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.43 -36.01 24.69 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.67 -27.9 66.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -1.184 . . . . 0.0 109.916 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.824 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.8 tt -74.39 -5.61 43.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.194 -0.941 . . . . 0.0 110.138 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.821 HD12 ' HB2' ' A' ' 100' ' ' ALA . 49.8 mm -90.66 18.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.98 -1.075 . . . . 0.0 109.843 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.445 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 5.8 m -95.25 -63.41 1.17 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.947 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.12 -22.52 74.35 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.586 HD23 ' HG3' ' A' ' 146' ' ' GLN . 0.4 OUTLIER -56.4 -168.63 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.354 -1.086 . . . . 0.0 109.535 179.935 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.586 ' HG3' HD23 ' A' ' 145' ' ' LEU . 5.7 mt-30 55.63 92.75 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.416 ' HB3' ' HG3' ' A' ' 91' ' ' LYS . 19.2 p . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.625 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.781 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.536 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 7.8 mt -93.01 176.35 6.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -1.165 . . . . 0.0 109.875 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.08 -166.52 1.22 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.338 -0.851 . . . . 0.0 109.891 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -84.02 -23.38 30.97 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.141 -0.974 . . . . 0.0 109.796 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.767 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -94.38 -36.13 12.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.599 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.489 ' O ' HG23 ' A' ' 10' ' ' VAL . 36.6 mt-30 -65.13 -51.39 61.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.366 -0.834 . . . . 0.0 109.552 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.471 ' NH1' ' HA3' ' A' ' 74' ' ' GLY . 7.5 ptm180 -53.43 -32.3 49.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.08 -1.013 . . . . 0.0 108.921 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 47.8 tp60 -71.48 -44.07 65.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.166 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 5' ' ' ALA . 30.0 t -65.12 -30.65 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.291 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.807 HG12 HG13 ' A' ' 70' ' ' VAL . 84.8 t -70.04 -41.75 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.369 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.8 -14.67 60.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -0.869 . . . . 0.0 109.764 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.1 -33.25 19.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.509 HG21 ' HB1' ' A' ' 126' ' ' ALA . 12.1 p -85.55 -15.73 41.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.739 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -86.99 -18.98 29.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.811 -179.893 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.8 mtpp -80.99 0.32 36.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.194 -0.941 . . . . 0.0 109.898 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -115.83 -53.65 2.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.081 -1.012 . . . . 0.0 109.439 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.945 HD12 ' CH2' ' A' ' 130' ' ' TRP . 64.7 mt -67.3 -32.78 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.552 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -103.07 31.92 4.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.872 . . . . 0.0 109.647 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.7 -86.39 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.0 p -95.25 -35.71 11.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.752 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.711 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 2.9 p30 -71.24 -17.12 62.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.26 -0.9 . . . . 0.0 109.81 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.552 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 0.2 OUTLIER 58.31 24.8 11.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.133 -0.979 . . . . 0.0 109.455 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.577 ' CA ' HD22 ' A' ' 63' ' ' LEU . . . 92.78 32.95 7.69 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.711 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -81.11 -66.34 0.9 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -1.108 . . . . 0.0 109.816 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 29' ' ' GLU . . . -52.74 -22.98 13.0 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.793 HG12 HD11 ' A' ' 63' ' ' LEU . 38.5 t -74.82 -32.21 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.846 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.01 -55.48 2.93 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.42 ' HB3' ' HA ' ' A' ' 56' ' ' ALA . 6.6 ptpp? -57.31 -19.63 23.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.187 -1.184 . . . . 0.0 110.053 -179.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.65 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -98.35 -30.42 12.59 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.972 -1.08 . . . . 0.0 109.579 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.3 t -82.32 -55.48 4.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.34 -0.85 . . . . 0.0 109.538 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.524 ' O ' HD12 ' A' ' 35' ' ' LEU . 12.2 m-85 -54.55 -37.44 65.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.357 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.884 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.56 -54.72 37.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.213 -0.929 . . . . 0.0 109.232 179.624 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -57.11 -47.82 80.15 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.212 -0.93 . . . . 0.0 109.335 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.741 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.4 t80 -55.07 -52.24 63.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.3 -0.875 . . . . 0.0 109.28 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.893 HD13 HG22 ' A' ' 55' ' ' VAL . 6.8 mt -59.3 -41.14 88.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.255 -0.903 . . . . 0.0 109.664 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.426 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 20.6 t -63.1 -61.19 2.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.657 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -63.37 -26.72 68.88 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.236 -0.915 . . . . 0.0 109.684 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -118.9 107.53 13.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.691 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -88.34 -24.29 23.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 109.362 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 40' ' ' ASP . 25.5 p-10 -65.39 -19.16 65.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.408 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.544 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -95.21 -17.6 21.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.292 -0.88 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.439 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -57.43 -62.78 1.54 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.975 . . . . 0.0 109.38 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.56 -26.38 43.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.882 HG13 ' OD1' ' A' ' 95' ' ' ASN . 21.1 t -73.63 -48.76 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 109.239 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.522 ' CD2' HD21 ' A' ' 35' ' ' LEU . 27.1 m-85 -68.26 -26.9 65.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.22 -0.925 . . . . 0.0 109.549 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 108.66 27.49 4.92 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.528 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.3 m-85 -123.74 167.29 14.22 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.176 . . . . 0.0 109.868 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 t -102.81 -20.93 14.13 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.421 -0.799 . . . . 0.0 109.203 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.9 -163.91 23.72 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.426 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -94.73 34.11 1.38 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.298 -1.119 . . . . 0.0 109.698 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 24.4 p -133.0 21.23 4.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.68 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -106.64 139.48 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.607 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.6 -16.96 57.94 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.954 1.502 . . . . 0.0 110.105 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.528 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -56.27 -39.8 83.05 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.893 HG22 HD13 ' A' ' 35' ' ' LEU . 84.1 t -51.04 -37.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -1.098 . . . . 0.0 109.38 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.456 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -73.74 -6.6 47.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.305 -0.872 . . . . 0.0 109.721 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -91.62 -27.16 18.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.011 . . . . 0.0 109.57 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.825 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -91.43 -64.0 1.18 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.175 -0.953 . . . . 0.0 109.627 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.522 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.18 -41.94 39.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -62.84 -23.85 67.5 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -1.149 . . . . 0.0 109.691 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.73 -28.37 12.51 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.679 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.825 HG23 ' O ' ' A' ' 58' ' ' LEU . 59.6 t -67.22 -56.49 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.287 -0.883 . . . . 0.0 109.848 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.793 HD11 HG12 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -48.2 -38.4 18.19 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.961 . . . . 0.0 109.616 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.44 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -50.44 -42.21 53.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.449 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.446 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 5.7 tp-100 -62.7 -36.17 82.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.232 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.865 ' O ' HG23 ' A' ' 70' ' ' VAL . 41.6 mt -66.92 -37.07 78.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.355 -0.841 . . . . 0.0 109.186 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.81 -48.27 56.18 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 179.492 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 64' ' ' ALA . 61.6 t -61.42 -27.99 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.357 -1.084 . . . . 0.0 109.43 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.86 -32.98 24.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.319 -0.863 . . . . 0.0 109.503 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 66' ' ' ILE . 56.5 t -66.58 -22.67 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 41.3 m -67.31 -12.36 59.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.948 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.483 ' O ' ' N ' ' A' ' 74' ' ' GLY . 14.0 m-70 -122.85 -83.92 0.66 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.123 -0.986 . . . . 0.0 109.918 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.649 HD11 ' HA ' ' A' ' 70' ' ' VAL . 35.1 mt 60.85 -77.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.65 -0.657 . . . . 0.0 109.676 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.46 -29.84 40.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.796 -1.721 . . . . 0.0 108.796 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -87.56 160.44 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.381 -1.07 . . . . 0.0 109.372 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -148.73 67.29 1.05 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.654 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -126.3 -44.03 0.26 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.241 -1.544 . . . . 0.0 109.241 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 22.5 ttpp -122.04 -26.04 4.83 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 110.124 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.411 ' SD ' HD23 ' A' ' 73' ' ' LEU . 5.5 ttp -48.01 -50.65 26.95 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.064 -1.023 . . . . 0.0 109.726 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.453 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.2 t -72.14 -29.41 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.01 -41.91 97.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.253 -0.904 . . . . 0.0 109.435 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.682 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.5 mt-10 -71.98 -50.8 25.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.513 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.444 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.2 OUTLIER -62.47 -38.66 90.69 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 109.149 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.453 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -60.06 -38.04 81.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.265 -0.897 . . . . 0.0 109.099 179.44 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -67.92 -41.34 82.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.258 -0.901 . . . . 0.0 109.21 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.682 HG23 ' O ' ' A' ' 82' ' ' GLU . 30.8 t -55.48 -50.52 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.328 -0.857 . . . . 0.0 109.119 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.524 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -56.55 -53.58 42.47 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 84' ' ' LYS . 79.1 t -53.85 -34.24 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.438 -1.037 . . . . 0.0 108.947 179.355 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mmm180 -72.13 -48.72 41.54 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.413 -0.804 . . . . 0.0 109.051 179.449 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.707 ' O ' HD12 ' A' ' 98' ' ' ILE . 14.5 m80 -56.48 -27.38 56.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.04 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.487 ' HG3' ' CA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -66.46 -12.07 55.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 110.289 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -136.08 49.85 0.87 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.701 ' CD2' HD11 ' A' ' 98' ' ' ILE . 4.3 m-30 -89.61 -168.71 2.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -1.174 . . . . 0.0 109.795 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -78.6 -52.19 5.2 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.882 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -62.3 -29.41 70.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -1.186 . . . . 0.0 109.657 -179.762 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 12.0 mtmm 53.54 29.36 8.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.671 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 -136.29 45.31 2.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.284 -0.885 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.707 HD12 ' O ' ' A' ' 90' ' ' HIS . 62.2 mt -87.55 154.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.298 -0.876 . . . . 0.0 109.727 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -144.12 148.35 34.96 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.282 -0.886 . . . . 0.0 110.104 -179.84 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.523 ' HB2' HG23 ' A' ' 142' ' ' ILE . . . -83.68 -3.56 57.86 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.698 -0.627 . . . . 0.0 109.609 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 8.8 pt-20 -74.95 -29.16 60.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.074 -1.016 . . . . 0.0 109.477 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.544 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 59.8 m-85 -81.78 -22.1 37.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.726 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.879 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.0 m-85 -54.03 -63.46 1.14 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.221 -0.924 . . . . 0.0 110.263 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.511 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -48.98 -58.41 8.69 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.132 -0.98 . . . . 0.0 110.13 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.511 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.6 Cg_exo -49.85 -62.53 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.598 1.315 . . . . 0.0 110.026 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.964 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.59 -22.02 12.12 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.255 -0.903 . . . . 0.0 109.547 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.66 -50.36 5.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.44 95.19 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.133 -1.216 . . . . 0.0 109.557 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.4 t -66.62 -21.36 66.12 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.859 HD22 ' OH ' ' A' ' 134' ' ' TYR . 2.7 tt -71.96 -41.97 67.12 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 109.626 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.925 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.3 mt -58.97 -30.25 67.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 0.0 109.573 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 3.6 m -68.64 -33.99 74.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.713 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.65 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -81.47 -33.46 31.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.259 -0.9 . . . . 0.0 109.782 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.494 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -45.89 -47.55 16.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.313 -0.867 . . . . 0.0 110.341 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.457 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 18.8 pt-20 -51.94 -22.48 3.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 0.0 110.015 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 24.0 m170 -53.7 -30.7 44.98 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.012 -1.055 . . . . 0.0 109.81 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -95.42 -68.9 0.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.133 -0.979 . . . . 0.0 109.93 -179.775 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.495 HG23 HG12 ' A' ' 17' ' ' ILE . 33.2 pt -75.11 -36.85 39.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.025 -1.047 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.487 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 39.52 -96.84 0.01 OUTLIER Glycine 0 N--CA 1.498 2.828 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.54 -42.45 10.09 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 3.3 mtpt -72.42 -21.9 61.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.112 -1.228 . . . . 0.0 109.771 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.45 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.23 90.53 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.157 -0.964 . . . . 0.0 109.57 179.829 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.801 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 17.8 p-10 -84.94 -179.88 7.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.566 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 127' ' ' LYS . . . -64.01 -40.25 95.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.801 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -63.98 -30.51 71.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.191 -0.943 . . . . 0.0 109.196 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.787 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -67.03 -50.5 61.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.406 -0.809 . . . . 0.0 109.322 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.541 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.0 ptpt -71.88 -30.02 64.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.289 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.427 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 59.5 t0 -77.13 -44.02 31.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.2 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.412 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -63.82 -41.62 97.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.48 -0.763 . . . . 0.0 109.065 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.945 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.5 m0 -75.25 -25.01 57.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.32 -0.863 . . . . 0.0 109.012 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.541 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.43 -37.2 80.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -0.886 . . . . 0.0 108.987 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -78.83 -24.58 44.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.324 -0.86 . . . . 0.0 109.297 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -83.27 -50.41 8.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.359 -0.838 . . . . 0.0 109.543 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.859 ' OH ' HD22 ' A' ' 110' ' ' LEU . 3.7 m-85 -50.35 -31.68 15.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.18 -0.95 . . . . 0.0 109.306 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.94 -35.68 57.11 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.341 -0.849 . . . . 0.0 108.986 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.83 -36.12 37.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.385 -0.822 . . . . 0.0 109.287 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.786 HD13 HG23 ' A' ' 66' ' ' ILE . 58.6 mt -66.58 -58.96 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.88 . . . . 0.0 109.087 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.0 p -67.3 -19.81 65.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.386 -0.821 . . . . 0.0 109.644 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.427 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -72.1 -42.65 50.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.86 -23.03 65.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -1.146 . . . . 0.0 109.673 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.879 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.6 tt -80.34 -34.07 36.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.682 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.523 HG23 ' HB2' ' A' ' 100' ' ' ALA . 43.4 mt -73.79 -3.45 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 110.145 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.6 m -68.77 -59.43 3.1 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.011 -1.056 . . . . 0.0 109.621 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -88.38 4.4 85.28 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.663 HD23 ' N ' ' A' ' 146' ' ' GLN . 4.4 tt -78.02 178.75 7.26 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.056 -1.261 . . . . 0.0 109.48 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.663 ' N ' HD23 ' A' ' 145' ' ' LEU . 0.1 OUTLIER 41.69 39.22 1.11 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.655 -0.653 . . . . 0.0 110.606 -179.744 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.487 ' CA ' ' HG3' ' A' ' 91' ' ' LYS . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.748 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.556 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.564 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.704 HD11 ' HA ' ' A' ' 133' ' ' ALA . 11.6 mt -86.9 164.94 16.29 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -1.157 . . . . 0.0 109.796 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 p -142.22 -172.8 3.67 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 109.777 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -81.1 -25.52 36.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -0.886 . . . . 0.0 109.631 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.678 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -88.82 -23.54 22.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.572 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 83.8 mt-30 -81.86 -52.08 7.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.427 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -49.61 -30.96 9.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.223 -0.923 . . . . 0.0 109.521 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.427 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 6.3 mm-40 -72.1 -42.91 65.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.266 -0.896 . . . . 0.0 109.278 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 5' ' ' ALA . 42.9 t -63.25 -32.15 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.274 -0.891 . . . . 0.0 109.243 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.973 HG12 HG13 ' A' ' 70' ' ' VAL . 70.7 t -66.12 -45.99 88.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.368 -0.833 . . . . 0.0 109.344 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.71 -10.56 59.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 109.821 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.3 p -92.88 -24.29 18.51 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.138 -0.976 . . . . 0.0 109.979 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.503 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 18.3 p -97.55 -8.98 27.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.092 -1.005 . . . . 0.0 109.959 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.694 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.6 -20.15 22.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.018 -1.051 . . . . 0.0 109.569 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -80.8 3.22 23.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.97 -56.49 2.1 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.066 -1.022 . . . . 0.0 109.512 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.882 HD12 ' CH2' ' A' ' 130' ' ' TRP . 51.2 mt -62.35 -30.26 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.51 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.907 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -107.42 32.41 4.69 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -0.91 . . . . 0.0 109.618 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -69.41 1.21 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 84.5 p -109.99 -29.96 8.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.281 -1.129 . . . . 0.0 109.663 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.815 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.8 p-10 -78.78 -20.2 50.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.896 . . . . 0.0 109.67 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.907 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.8 t30 57.61 28.41 15.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.185 -0.947 . . . . 0.0 109.516 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.412 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 93.51 25.39 18.59 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.815 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -73.2 -47.08 46.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.252 -1.146 . . . . 0.0 109.592 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.479 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.28 17.86 45.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.801 -1.319 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.657 HG13 ' SD ' ' A' ' 114' ' ' MET . 21.2 t -109.48 -25.81 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.25 179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.5 ' HA3' HD23 ' A' ' 63' ' ' LEU . . . -94.43 -43.19 3.76 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.479 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.3 OUTLIER -62.19 -31.49 72.01 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.096 -1.238 . . . . 0.0 109.577 -179.837 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.89 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 14.5 pt-20 -89.38 -15.99 32.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.929 . . . . 0.0 109.618 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 15.8 t -90.15 -63.14 1.32 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.482 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 16.8 m-85 -47.54 -33.95 7.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.496 ' OG1' HG11 ' A' ' 55' ' ' VAL . 51.5 m -55.39 -40.75 71.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.172 -0.955 . . . . 0.0 109.421 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.41 -49.41 27.22 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.264 -0.897 . . . . 0.0 109.456 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.713 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.9 t80 -52.06 -46.51 65.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.339 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.656 ' CD1' HG22 ' A' ' 55' ' ' VAL . 17.6 mt -58.07 -47.12 84.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.529 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.515 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 6.4 t -65.35 -55.83 15.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.569 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.54 -24.47 66.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -124.9 103.88 8.29 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.269 -0.894 . . . . 0.0 109.722 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.5 m170 -86.29 -18.99 30.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.366 -0.834 . . . . 0.0 109.454 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -71.96 -9.66 58.68 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.283 -0.885 . . . . 0.0 109.893 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.621 ' HE1' HMB2 ' A' ' 148' ' ' HEM . 29.7 mmm -119.38 -15.8 9.05 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 110.079 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.459 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.03 -47.7 44.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.041 . . . . 0.0 109.424 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.25 -31.6 64.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.331 -0.855 . . . . 0.0 109.093 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.034 HG13 ' ND2' ' A' ' 95' ' ' ASN . 15.9 t -60.51 -37.31 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.408 -0.808 . . . . 0.0 109.141 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.548 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 33.2 m-85 -76.86 -18.46 58.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.764 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 102.44 23.46 8.93 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 9.8 m-85 -122.49 167.33 13.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -1.137 . . . . 0.0 109.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 12.5 t -112.62 21.3 15.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 109.233 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.95 -172.42 25.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.515 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -74.95 -6.86 51.57 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -1.167 . . . . 0.0 109.976 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 62.2 p -94.3 43.41 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.056 -1.028 . . . . 0.0 109.73 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -123.77 129.18 24.91 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.649 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -67.97 -28.93 34.98 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.776 1.408 . . . . 0.0 110.022 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.457 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.49 -30.15 33.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.656 HG22 ' CD1' ' A' ' 35' ' ' LEU . 95.5 t -50.93 -32.78 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -1.116 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.487 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -80.72 -6.22 58.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.312 -0.867 . . . . 0.0 109.809 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.22 -27.15 20.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.104 -0.998 . . . . 0.0 109.596 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.902 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.4 mt -89.78 -65.81 0.98 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.713 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.482 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.94 -42.16 29.61 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -56.19 -45.36 79.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.166 -1.196 . . . . 0.0 109.361 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 39.6 mttp -80.79 -38.17 28.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.386 -0.821 . . . . 0.0 109.403 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.902 HG23 ' O ' ' A' ' 58' ' ' LEU . 42.3 t -59.79 -50.18 81.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 0.0 109.619 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.535 HD11 HG11 ' A' ' 26' ' ' VAL . 1.2 mm? -47.12 -46.63 23.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.255 -0.903 . . . . 0.0 109.85 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.94 -51.07 43.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.814 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.7 tp60 -50.28 -53.77 26.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.124 -0.985 . . . . 0.0 109.438 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.933 ' O ' HG23 ' A' ' 70' ' ' VAL . 45.0 mt -51.27 -39.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 109.27 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.16 -56.09 24.15 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -57.3 -25.73 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.346 -1.09 . . . . 0.0 109.428 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.57 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -85.38 -30.46 23.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.376 -0.827 . . . . 0.0 109.632 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.973 HG13 HG12 ' A' ' 10' ' ' VAL . 74.1 t -66.77 -17.11 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -0.936 . . . . 0.0 109.838 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.464 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 40.9 t -90.21 21.09 3.95 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.155 -0.966 . . . . 0.0 109.975 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.469 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 10.3 m-70 -157.9 44.12 0.32 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.058 -1.026 . . . . 0.0 109.881 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.689 HD12 HD13 ' A' ' 2' ' ' LEU . 3.6 mm? -69.82 -44.27 70.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.95 . . . . 0.0 109.413 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -90.13 -22.92 33.75 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.75 103.18 13.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.302 -1.116 . . . . 0.0 109.554 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.09 40.48 1.33 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.62 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.04 19.58 53.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.525 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 7.4 ttpt -176.89 -35.11 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.238 -1.154 . . . . 0.0 109.706 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.469 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 21.7 ttp -47.53 -51.1 21.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.18 -0.95 . . . . 0.0 109.81 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 27.1 t -70.53 -21.95 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.511 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -67.18 -42.94 83.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.207 -0.933 . . . . 0.0 109.285 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.589 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.8 mt-10 -78.98 -48.39 14.56 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.269 -0.894 . . . . 0.0 109.322 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.52 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.6 OUTLIER -57.39 -52.03 66.99 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -0.885 . . . . 0.0 109.27 179.677 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.838 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -51.12 -34.18 29.72 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 108.909 179.398 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.38 -39.69 71.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.362 -0.836 . . . . 0.0 108.951 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 82' ' ' GLU . 53.1 t -61.79 -49.94 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.333 -0.854 . . . . 0.0 109.118 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.485 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -55.16 -38.0 65.8 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.838 HG23 ' O ' ' A' ' 84' ' ' LYS . 95.6 t -60.08 -18.94 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.3 -1.117 . . . . 0.0 109.447 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.524 ' HB3' ' CE2' ' A' ' 93' ' ' TYR . 0.5 OUTLIER -82.63 -19.04 39.06 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.264 -0.898 . . . . 0.0 109.127 179.7 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.554 ' HB3' HD12 ' A' ' 98' ' ' ILE . 4.0 m80 -89.98 19.3 4.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.433 ' O ' ' HD3' ' A' ' 96' ' ' LYS . 2.4 mtmt -80.44 -59.14 2.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.164 -0.96 . . . . 0.0 110.776 -178.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.433 ' HA2' ' HD3' ' A' ' 96' ' ' LYS . . . -148.51 56.77 0.48 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.524 ' CE2' ' HB3' ' A' ' 89' ' ' ARG . 2.7 m-30 -82.46 -103.17 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 110.012 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -102.16 -62.68 0.74 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.034 ' ND2' HG13 ' A' ' 44' ' ' VAL . 2.0 t30 -68.21 -41.27 81.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.462 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 0.3 OUTLIER 65.66 -57.63 0.32 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.124 0.487 . . . . 0.0 109.852 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 95' ' ' ASN . 2.3 m-70 -62.93 79.53 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.215 -0.928 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.554 HD12 ' HB3' ' A' ' 90' ' ' HIS . 31.8 mt -109.18 158.85 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 109.233 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.523 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.6 mptp? -140.49 139.61 35.15 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.068 -1.02 . . . . 0.0 110.288 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.458 ' CB ' HG12 ' A' ' 142' ' ' ILE . . . -78.55 -2.63 39.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.835 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -76.1 -26.43 56.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.996 -1.065 . . . . 0.0 109.439 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.532 ' CD1' ' HE2' ' A' ' 41' ' ' MET . 83.9 m-85 -85.24 10.13 13.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.384 -0.823 . . . . 0.0 110.076 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.686 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.3 m-85 -83.35 -61.28 1.89 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 109.671 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.506 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -51.01 -57.57 13.31 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.441 -0.787 . . . . 0.0 110.644 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 5.2 Cg_endo -54.01 -43.76 55.35 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.59 1.311 . . . . 0.0 110.142 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.861 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.5 tm? -64.12 -17.03 63.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.179 -0.951 . . . . 0.0 109.542 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.74 -36.98 12.37 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.29 -59.62 4.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.196 -1.179 . . . . 0.0 109.63 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.7 t -60.29 -18.9 52.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.27 -0.894 . . . . 0.0 109.565 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.926 HD21 ' HE2' ' A' ' 114' ' ' MET . 3.2 tt -76.76 -36.57 56.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.253 -0.905 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.577 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -63.85 -28.77 70.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.189 -0.944 . . . . 0.0 109.435 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -34.43 78.2 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.312 -0.868 . . . . 0.0 109.6 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.89 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -75.58 -38.22 59.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.926 ' HE2' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.34 -44.19 23.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.297 -0.877 . . . . 0.0 110.017 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.477 ' HG2' ' CB ' ' A' ' 122' ' ' MET . 0.6 OUTLIER -52.42 -22.08 4.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.307 -0.871 . . . . 0.0 109.962 -179.771 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.411 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 21.1 m170 -56.53 -35.86 68.58 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.146 -0.972 . . . . 0.0 110.247 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.507 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -90.8 -86.86 0.2 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.011 -1.056 . . . . 0.0 110.176 -179.583 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 119' ' ' GLY . 34.9 pt -56.61 -36.31 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.811 -1.18 . . . . 0.0 109.608 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.483 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.77 -98.99 0.01 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.519 -1.033 . . . . 0.0 110.519 179.154 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.35 -44.77 8.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.469 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 44.3 mttt -68.28 -25.77 65.32 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.074 -1.25 . . . . 0.0 110.032 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.477 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.0 OUTLIER -65.52 80.6 0.06 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.982 -1.073 . . . . 0.0 108.845 179.384 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.668 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 12.2 p-10 -82.12 -174.29 5.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.297 -0.877 . . . . 0.0 110.13 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.464 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -62.26 -45.31 93.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.376 -0.828 . . . . 0.0 109.897 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.668 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -62.6 -30.93 71.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.146 -0.971 . . . . 0.0 109.575 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -68.74 -44.76 73.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 109.264 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.577 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 1.6 ptpt -75.19 -29.83 60.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.375 -0.828 . . . . 0.0 109.664 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.486 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 44.2 t0 -79.22 -46.12 18.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.391 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.556 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -57.55 -47.79 81.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.42 -0.8 . . . . 0.0 109.308 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.882 ' CH2' HD12 ' A' ' 17' ' ' ILE . 7.3 m0 -71.92 -29.7 64.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.4 -0.812 . . . . 0.0 109.371 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.577 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -63.78 -25.92 68.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.235 -0.916 . . . . 0.0 108.974 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.48 ' O ' ' HB3' ' A' ' 135' ' ' ALA . . . -101.05 -24.95 14.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.421 -0.8 . . . . 0.0 109.169 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.704 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -67.44 -51.89 46.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.287 -0.883 . . . . 0.0 109.334 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.51 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 21.3 m-85 -52.76 -29.04 25.03 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 109.231 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' A' ' 132' ' ' ALA . . . -60.84 -46.41 90.68 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 108.835 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.82 -44.34 56.04 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 109.169 179.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.57 HG12 ' HB1' ' A' ' 69' ' ' ALA . 18.1 mt -64.3 -57.75 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.256 -0.903 . . . . 0.0 108.93 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.549 ' O ' HD12 ' A' ' 142' ' ' ILE . 2.0 p -67.87 -25.74 65.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.217 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.437 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -73.4 -46.59 25.5 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.25 -22.47 66.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -1.122 . . . . 0.0 109.712 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.686 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.4 tt -69.22 -33.46 73.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.665 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 138' ' ' SER . 3.9 mt -82.9 10.01 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.2 -0.937 . . . . 0.0 110.318 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.469 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 75.7 m -73.97 -22.6 59.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.996 -1.065 . . . . 0.0 108.887 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -127.77 1.42 6.86 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.976 HD22 ' N ' ' A' ' 146' ' ' GLN . 0.2 OUTLIER -100.37 129.6 46.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.85 -1.382 . . . . 0.0 110.015 -179.809 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.976 ' N ' HD22 ' A' ' 145' ' ' LEU . 1.6 mt-30 162.45 44.81 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 178.123 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.415 ' OXT' ' HD3' ' A' ' 91' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.567 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.648 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.469 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.809 HD13 HD12 ' A' ' 73' ' ' LEU . 11.9 mt 57.06 165.56 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.159 -1.201 . . . . 0.0 110.128 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.44 ' O ' ' HG2' ' A' ' 7' ' ' ARG . 6.6 p -128.04 -168.66 1.93 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.268 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.51 -16.22 56.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.218 -0.926 . . . . 0.0 110.191 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.781 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -101.03 -36.13 9.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.065 -1.022 . . . . 0.0 109.819 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -68.62 -58.49 4.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.717 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.521 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -50.15 -24.57 2.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.221 -0.924 . . . . 0.0 109.895 -179.773 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.521 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 50.1 tp60 -80.66 -41.39 23.88 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 109.493 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.781 HG23 ' O ' ' A' ' 5' ' ' ALA . 67.1 t -62.09 -24.54 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.9 HG12 HG13 ' A' ' 70' ' ' VAL . 89.1 t -66.84 -45.05 88.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.39 -0.819 . . . . 0.0 109.661 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.55 -11.35 60.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.296 -0.877 . . . . 0.0 110.193 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 m -92.7 -22.94 19.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.005 -1.06 . . . . 0.0 109.804 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.3 p -96.71 -10.52 26.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.249 -0.907 . . . . 0.0 110.131 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.767 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.74 -20.83 21.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.078 -1.014 . . . . 0.0 109.892 -179.801 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -79.19 -13.04 59.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.947 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -102.27 -47.87 4.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.089 -1.007 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.879 HD12 ' CH2' ' A' ' 130' ' ' TRP . 34.8 mt -70.81 -31.55 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -0.924 . . . . 0.0 109.745 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.856 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -106.96 33.88 3.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.915 . . . . 0.0 109.716 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.64 -71.82 0.62 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 76.5 p -110.65 -27.91 8.71 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.657 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.66 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.2 p-10 -79.01 -20.24 49.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 0.0 109.658 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.856 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 27.0 t30 55.67 24.09 6.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.584 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.17 24.57 12.47 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.66 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -66.1 -55.08 18.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -1.137 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -86.14 11.43 62.91 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.507 HG11 HD11 ' A' ' 63' ' ' LEU . 37.8 t -97.99 -29.65 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.115 -1.227 . . . . 0.0 109.338 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.458 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -89.91 -45.16 4.6 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.47 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 11.3 ptpt -56.19 -31.89 63.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.158 -1.201 . . . . 0.0 109.569 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.533 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 24.3 pt-20 -92.3 -16.67 25.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.929 . . . . 0.0 109.722 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.434 ' SG ' HD12 ' A' ' 110' ' ' LEU . 36.6 t -85.27 -67.67 0.78 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.205 -0.934 . . . . 0.0 109.809 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.601 ' HB3' HG13 ' A' ' 55' ' ' VAL . 10.4 m-85 -48.35 -29.13 3.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.247 -0.908 . . . . 0.0 109.935 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.426 ' N ' HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.06 -59.06 5.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.201 -0.937 . . . . 0.0 109.488 179.935 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 3.9 mttp -55.9 -53.15 60.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.261 -0.899 . . . . 0.0 109.717 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.679 ' CG ' HD23 ' A' ' 106' ' ' LEU . 8.9 t80 -49.34 -53.09 23.95 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.224 -0.922 . . . . 0.0 109.734 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.79 ' CD1' HG22 ' A' ' 55' ' ' VAL . 20.1 mt -54.23 -46.35 72.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.229 -0.919 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.08 -59.84 3.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.185 -0.947 . . . . 0.0 109.713 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.24 -23.66 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.669 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 25.0 m80 -120.79 95.83 4.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.688 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.5 m170 -82.76 6.03 19.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.244 -0.91 . . . . 0.0 110.02 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -97.48 -20.38 17.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.099 -1.001 . . . . 0.0 109.523 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.53 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 65.4 mmm -104.85 -19.84 13.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -0.896 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.458 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.08 -35.62 16.49 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 109.43 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.4 -27.54 46.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.304 -0.873 . . . . 0.0 109.099 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.103 HG22 ' ND2' ' A' ' 95' ' ' ASN . 32.3 t -66.71 -60.74 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.526 ' CD2' HD21 ' A' ' 35' ' ' LEU . 67.4 m-85 -51.29 -28.3 11.64 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.291 -0.881 . . . . 0.0 109.504 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.409 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.3 24.85 4.92 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 8.7 m-85 -121.86 166.24 14.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 110.066 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.8 t -106.0 -19.78 13.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.422 -0.799 . . . . 0.0 108.892 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.65 -162.5 19.64 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.88 15.5 23.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -1.118 . . . . 0.0 109.798 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 19.5 m -109.18 25.12 12.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.118 -0.989 . . . . 0.0 109.497 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.418 ' OD2' ' HB3' ' A' ' 47' ' ' PHE . 0.9 OUTLIER -118.87 140.59 28.79 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.33 -0.856 . . . . 0.0 109.543 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -69.55 -13.36 35.09 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.957 1.504 . . . . 0.0 110.509 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.537 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.49 -40.62 39.6 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.79 HG22 ' CD1' ' A' ' 35' ' ' LEU . 39.2 t -50.05 -45.92 23.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.321 -1.105 . . . . 0.0 109.55 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -61.8 -16.65 51.65 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.3 -36.64 39.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.915 . . . . 0.0 109.645 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.948 ' O ' HG23 ' A' ' 62' ' ' VAL . 11.5 mt -87.07 -60.03 2.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.157 -0.964 . . . . 0.0 109.638 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.458 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -46.9 -48.9 18.35 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.419 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -56.39 -38.58 71.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -1.166 . . . . 0.0 109.695 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -83.86 -29.9 26.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.663 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 58' ' ' LEU . 38.7 t -71.61 -47.87 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.305 -0.872 . . . . 0.0 109.652 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.507 HD11 HG11 ' A' ' 26' ' ' VAL . 1.9 mm? -48.99 -50.27 36.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 109.656 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.97 -44.97 20.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.363 -0.836 . . . . 0.0 110.017 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.406 ' HG3' ' SD ' ' A' ' 83' ' ' MET . 28.8 tp60 -57.72 -52.69 64.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.127 -0.983 . . . . 0.0 109.332 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.959 ' O ' HG23 ' A' ' 70' ' ' VAL . 96.1 mt -53.89 -36.65 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.184 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.51 -55.38 27.7 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.31 -23.17 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -1.141 . . . . 0.0 109.17 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.88 -23.24 25.31 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.413 -0.805 . . . . 0.0 109.579 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.3 t -72.76 -21.31 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.898 . . . . 0.0 109.757 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.442 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 53.9 m -88.67 39.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.154 -0.966 . . . . 0.0 109.975 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.523 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.2 m-70 -151.13 -62.1 0.18 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.097 -1.002 . . . . 0.0 109.908 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.809 HD12 HD13 ' A' ' 2' ' ' LEU . 4.4 mm? 42.37 -88.89 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.191 0.519 . . . . 0.0 110.638 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -56.45 -30.6 58.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.43 57.32 3.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -1.107 . . . . 0.0 109.537 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.505 ' O ' HG23 ' A' ' 80' ' ' VAL . 0.7 OUTLIER -65.41 -23.93 67.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.703 -179.914 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -60.0 -29.52 68.2 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.504 ' HE3' ' CE1' ' A' ' 72' ' ' HIS . 5.5 ttpp -104.11 -47.35 4.19 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.769 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.451 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 41.4 ttp -49.6 -28.56 5.88 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 76' ' ' GLU . 90.6 t -83.26 -17.52 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.593 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.41 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -78.77 -30.6 45.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.578 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.471 ' HG3' ' N ' ' A' ' 83' ' ' MET . 23.9 pt-20 -86.17 -42.65 13.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.669 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.545 ' HE1' HD12 ' A' ' 141' ' ' LEU . 92.0 mmm -63.93 -35.29 80.17 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.011 -1.056 . . . . 0.0 108.845 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.874 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -52.62 -37.23 57.99 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.029 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.438 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -69.06 -27.36 65.56 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -74.88 -46.56 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.816 . . . . 0.0 108.962 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.446 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -63.93 -34.7 90.63 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.874 HG23 ' O ' ' A' ' 84' ' ' LYS . 53.3 t -58.9 -37.2 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.356 -1.085 . . . . 0.0 109.206 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.438 ' HG2' ' O ' ' A' ' 85' ' ' ALA . 17.3 mmm180 -64.76 -31.13 72.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.01 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.747 ' HB2' HD12 ' A' ' 145' ' ' LEU . 52.5 m80 -77.38 -2.6 35.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.427 -0.796 . . . . 0.0 109.897 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.507 ' CG ' ' CB ' ' A' ' 147' ' ' SER . 6.8 ttmt -98.07 64.38 1.67 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.077 -1.014 . . . . 0.0 109.638 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.416 ' O ' ' O ' ' A' ' 93' ' ' TYR . . . 147.28 2.6 0.5 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.314 -1.422 . . . . 0.0 111.772 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.554 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.8 m-85 -56.13 -167.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.38 -1.659 . . . . 0.0 110.022 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.55 -40.17 13.3 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.103 ' ND2' HG22 ' A' ' 44' ' ' VAL . 2.2 t-20 -59.38 -47.23 86.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.457 -1.025 . . . . 0.0 108.479 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.8 tttt 59.96 13.89 3.97 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.494 -0.754 . . . . 0.0 110.928 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.488 ' HB2' ' ND2' ' A' ' 95' ' ' ASN . 14.2 m-70 -131.6 44.08 2.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.046 -1.034 . . . . 0.0 108.923 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.587 HD12 ' O ' ' A' ' 90' ' ' HIS . 67.8 mt -78.97 154.96 4.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.46 -0.775 . . . . 0.0 110.01 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.467 ' CE ' ' O ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -145.34 148.83 33.83 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.81 0.814 . . . . 0.0 110.084 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.7 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -81.9 -16.99 48.76 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.555 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -60.82 -27.01 67.74 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.002 -1.061 . . . . 0.0 109.208 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.555 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 93.4 m-85 -83.41 -20.23 34.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.18 -0.95 . . . . 0.0 110.246 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.924 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 5.4 m-85 -59.38 -65.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.101 -0.999 . . . . 0.0 110.206 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -44.42 -60.13 3.21 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 110.872 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.522 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.1 Cg_endo -59.7 -26.56 82.56 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 123.827 1.435 . . . . 0.0 110.343 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.813 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.4 tm? -79.4 -19.18 50.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.113 -0.992 . . . . 0.0 109.444 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.93 -38.7 9.11 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.1 -54.11 48.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -1.171 . . . . 0.0 109.673 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.8 m -57.46 -26.16 60.79 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -0.905 . . . . 0.0 109.598 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.541 HD22 ' OH ' ' A' ' 134' ' ' TYR . 8.7 tt -69.41 -39.71 77.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.54 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.874 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.5 mt -58.71 -33.37 70.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.222 -0.924 . . . . 0.0 109.643 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.9 t -67.37 -27.92 67.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.18 -0.95 . . . . 0.0 109.66 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.533 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -83.28 -36.5 24.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.704 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.525 ' HE2' HD21 ' A' ' 110' ' ' LEU . 5.2 mmt -49.52 -42.86 44.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 109.864 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -51.99 -22.67 4.18 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.232 -0.918 . . . . 0.0 109.954 -179.72 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -68.59 -22.53 64.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.947 . . . . 0.0 110.004 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.497 ' CB ' HG23 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -93.29 -50.03 5.67 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.861 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.602 HD11 ' SD ' ' A' ' 122' ' ' MET . 13.2 pt -104.42 -36.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.151 -0.968 . . . . 0.0 109.439 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 122' ' ' MET . . . 42.81 -94.27 0.01 OUTLIER Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.036 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.67 -42.03 10.22 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -76.68 -17.38 59.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.04 -1.271 . . . . 0.0 109.697 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.602 ' SD ' HD11 ' A' ' 118' ' ' ILE . 4.8 tpt -72.52 92.48 1.49 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.137 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.791 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 8.3 p-10 -93.5 176.86 6.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 109.826 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.482 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -54.76 -50.1 69.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 109.759 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.791 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -54.7 -24.7 23.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.242 -0.911 . . . . 0.0 109.715 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.483 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.71 -51.24 11.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.956 . . . . 0.0 109.521 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 19.6 ptpt -71.66 -28.22 63.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.258 -0.901 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.453 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 35.7 t0 -78.89 -38.56 37.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.481 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -69.96 -45.71 66.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.449 -0.782 . . . . 0.0 109.444 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.879 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -72.97 -21.82 60.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.366 -0.834 . . . . 0.0 109.295 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.652 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -76.22 -23.94 54.61 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.155 -0.966 . . . . 0.0 109.091 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -99.03 -23.4 15.3 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.411 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.636 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -82.21 -37.35 26.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.39 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.541 ' OH ' HD22 ' A' ' 110' ' ' LEU . 4.8 m-30 -49.37 -27.87 4.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.285 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.4 -29.5 53.13 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 108.913 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.1 t0 -80.08 -44.2 20.45 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.431 -0.793 . . . . 0.0 109.205 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.453 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.0 mt -65.28 -55.48 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.076 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.69 -41.82 74.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.478 -0.764 . . . . 0.0 109.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.34 -52.17 33.55 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.421 ' HB1' ' HA ' ' A' ' 80' ' ' VAL . . . -53.68 -28.75 35.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -1.175 . . . . 0.0 109.791 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.899 HD23 ' O ' ' A' ' 141' ' ' LEU . 9.4 tt -71.47 -10.03 59.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.199 -0.938 . . . . 0.0 110.049 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.7 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.1 mm -91.01 38.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.039 -1.038 . . . . 0.0 109.919 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.43 ' HB3' ' HG2' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -115.52 -28.68 6.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.374 -0.829 . . . . 0.0 109.228 179.671 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.4 20.68 4.93 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.029 -1.629 . . . . 0.0 109.029 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.747 HD12 ' HB2' ' A' ' 90' ' ' HIS . 2.6 tt -108.86 15.25 23.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -1.131 . . . . 0.0 109.794 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.457 HE22 ' C ' ' A' ' 142' ' ' ILE . 1.6 mp0 -113.19 68.73 0.68 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.997 -1.064 . . . . 0.0 109.668 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.507 ' CB ' ' CG ' ' A' ' 91' ' ' LYS . 4.8 p . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.655 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.924 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.508 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.867 HD11 ' HA ' ' A' ' 133' ' ' ALA . 11.7 mt 57.3 163.82 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.396 -1.061 . . . . 0.0 109.833 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.9 p -140.14 -158.33 0.85 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.924 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.07 -35.58 14.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.51 -0.744 . . . . 0.0 109.288 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -91.13 -21.5 21.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.873 . . . . 0.0 109.392 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -74.78 -48.23 26.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.212 -0.93 . . . . 0.0 109.246 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.629 ' HG2' HD12 ' A' ' 73' ' ' LEU . 7.7 tmm_? -54.28 -42.93 70.58 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.046 -1.034 . . . . 0.0 108.765 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -52.14 -38.29 57.04 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.18 -0.95 . . . . 0.0 108.603 179.227 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 125' ' ' ALA . 44.8 t -72.71 -26.45 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.032 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 1.069 HG12 HG13 ' A' ' 70' ' ' VAL . 78.0 t -75.69 -45.68 38.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.515 -0.741 . . . . 0.0 109.153 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.59 -13.06 60.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 0.0 109.748 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 t -92.12 -28.57 17.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.125 -0.985 . . . . 0.0 109.829 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.4 HG21 ' HB1' ' A' ' 126' ' ' ALA . 7.2 p -90.83 -11.88 38.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.156 -0.965 . . . . 0.0 109.963 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.44 -21.73 21.77 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.073 -1.017 . . . . 0.0 109.532 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.7 mtpp -76.66 -3.61 38.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.226 -0.921 . . . . 0.0 109.679 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -109.51 -55.78 2.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.093 -1.005 . . . . 0.0 109.519 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.907 HD12 ' CH2' ' A' ' 130' ' ' TRP . 23.6 mt -60.55 -40.51 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.283 -0.886 . . . . 0.0 109.592 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.813 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -97.33 33.33 2.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.694 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.19 -80.04 0.07 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 54.2 p -112.02 12.98 20.7 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.22 -1.165 . . . . 0.0 109.829 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.744 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.4 p-10 -119.15 -17.07 9.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.086 -1.009 . . . . 0.0 109.791 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.813 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 25.3 t-20 55.88 29.26 13.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.671 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.415 ' HA3' ' CG ' ' A' ' 63' ' ' LEU . . . 90.88 23.28 30.72 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.744 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -61.45 -48.52 80.76 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.402 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -90.79 20.15 40.84 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.67 HG12 HD21 ' A' ' 63' ' ' LEU . 22.7 t -114.12 -17.69 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -1.123 . . . . 0.0 109.069 179.565 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -105.92 -25.57 6.43 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.5 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.3 ptpt -75.91 -33.43 59.9 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.288 -1.125 . . . . 0.0 109.558 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.84 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 1.1 pm0 -94.78 -13.88 25.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.181 -0.95 . . . . 0.0 109.722 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.415 ' HB2' ' OE2' ' A' ' 29' ' ' GLU . 32.0 t -88.33 -59.81 2.13 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -0.96 . . . . 0.0 109.562 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.525 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.1 m-85 -56.48 -29.17 61.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.153 -0.967 . . . . 0.0 109.533 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.69 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -54.66 -60.42 3.38 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.657 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.5 -50.62 62.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.704 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -50.68 -48.2 58.57 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.226 -0.921 . . . . 0.0 109.306 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.656 ' CD1' HG22 ' A' ' 55' ' ' VAL . 19.0 mt -58.26 -43.67 88.03 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.551 ' OG ' ' HB2' ' A' ' 50' ' ' ALA . 55.9 m -67.01 -69.1 0.33 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -0.936 . . . . 0.0 109.877 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.42 ' HB3' ' ND1' ' A' ' 38' ' ' HIS . . . -50.87 -24.19 3.38 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.25 -0.906 . . . . 0.0 109.921 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.42 ' ND1' ' HB3' ' A' ' 37' ' ' ALA . 11.6 m80 -128.17 106.69 9.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.141 -0.974 . . . . 0.0 109.957 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.6 m170 -85.64 -19.76 30.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.558 -0.714 . . . . 0.0 109.283 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -70.55 -16.23 62.85 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.311 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.504 ' CE ' HMB2 ' A' ' 148' ' ' HEM . 0.0 OUTLIER -101.61 -15.44 17.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.792 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.455 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.84 -66.31 0.55 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.006 . . . . 0.0 109.246 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -53.17 -24.62 11.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.92 . . . . 0.0 109.123 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.81 HG13 ' OD1' ' A' ' 95' ' ' ASN . 2.5 t -71.37 -56.25 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.677 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 33.7 m-85 -60.59 -24.96 65.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.335 -0.853 . . . . 0.0 109.528 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.53 26.81 5.75 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.2 m-85 -123.65 168.23 12.93 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.247 -1.149 . . . . 0.0 109.814 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -106.77 -18.16 14.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.24 -175.67 47.58 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB2' ' OG ' ' A' ' 36' ' ' SER . . . -63.66 -13.55 43.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.853 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.17 44.11 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -130.37 123.77 20.74 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.176 -0.952 . . . . 0.0 109.592 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -66.3 -22.94 52.42 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.886 1.466 . . . . 0.0 110.087 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.51 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.99 -29.93 28.97 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.69 HG11 HG23 ' A' ' 32' ' ' THR . 49.0 t -57.69 -42.69 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -1.165 . . . . 0.0 109.476 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -68.58 -19.53 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.243 -0.91 . . . . 0.0 109.553 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.68 -37.92 24.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.912 . . . . 0.0 109.426 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.823 HD21 ' CHA' ' A' ' 148' ' ' HEM . 1.2 mt -76.0 -65.99 0.84 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.925 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.525 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -47.34 -47.18 22.19 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -57.8 -38.14 75.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -1.171 . . . . 0.0 109.618 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -77.01 -28.42 54.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.918 . . . . 0.0 109.605 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.912 HG22 ' C1D' ' A' ' 148' ' ' HEM . 47.8 t -80.45 -41.28 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 109.572 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.67 HD21 HG12 ' A' ' 26' ' ' VAL . 0.7 OUTLIER -47.71 -49.96 26.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.903 . . . . 0.0 109.906 179.895 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.579 ' HB2' ' OD1' ' A' ' 22' ' ' ASN . . . -49.38 -50.91 38.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.122 -0.986 . . . . 0.0 109.828 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 34.1 tp60 -49.1 -47.67 45.02 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.07 -1.019 . . . . 0.0 109.34 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.707 ' O ' HG23 ' A' ' 70' ' ' VAL . 24.3 mm -56.51 -45.71 82.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.362 -0.836 . . . . 0.0 108.963 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA3' ' CZ3' ' A' ' 14' ' ' TRP . . . -61.46 -51.02 60.57 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.7 t -57.57 -31.36 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -1.065 . . . . 0.0 109.705 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.615 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -82.21 -33.86 29.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.537 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.069 HG13 HG12 ' A' ' 10' ' ' VAL . 56.1 t -65.89 -18.95 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -75.05 -15.39 60.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.474 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.4 m-70 -115.46 -88.96 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.784 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.817 HD11 ' HA ' ' A' ' 70' ' ' VAL . 19.3 mt 63.63 -71.86 0.06 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.425 -0.797 . . . . 0.0 109.975 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -60.35 -28.05 66.52 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -93.78 140.52 29.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -1.111 . . . . 0.0 109.571 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.74 58.11 1.77 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.2 -0.937 . . . . 0.0 109.633 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -138.06 16.97 3.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.476 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 17.0 ttpt -168.4 -42.59 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 109.906 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 31.0 ttp -47.98 -38.77 17.66 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.129 -0.982 . . . . 0.0 109.565 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.423 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 38.8 t -76.28 -25.2 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.321 -0.862 . . . . 0.0 109.321 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -57.28 -44.69 84.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.361 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.668 ' O ' HG23 ' A' ' 86' ' ' VAL . 13.2 mt-10 -83.94 -44.58 14.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.37 -0.831 . . . . 0.0 109.309 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.643 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.0 OUTLIER -58.38 -58.57 7.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.306 179.777 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.423 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -52.05 -31.44 30.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.175 -0.953 . . . . 0.0 108.97 179.563 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.543 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -66.8 -45.51 78.14 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.36 -0.838 . . . . 0.0 109.023 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.668 HG23 ' O ' ' A' ' 82' ' ' GLU . 31.5 t -51.01 -47.68 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.307 -0.871 . . . . 0.0 109.193 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -53.65 -51.39 48.85 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 85.8 t -53.99 -35.34 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.321 -1.105 . . . . 0.0 109.006 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.526 ' HB3' ' CE1' ' A' ' 93' ' ' TYR . 5.4 mmm180 -70.6 -55.1 9.61 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.382 -0.823 . . . . 0.0 109.09 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.615 ' O ' HD12 ' A' ' 98' ' ' ILE . 12.4 m80 -52.31 -29.75 25.0 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.893 . . . . 0.0 108.971 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.462 ' HA ' ' CB ' ' A' ' 147' ' ' SER . 1.6 ttmt -68.0 -9.97 49.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.486 -0.759 . . . . 0.0 110.124 -179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.55 51.36 0.7 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.526 ' CE1' ' HB3' ' A' ' 89' ' ' ARG . 3.2 m-30 -106.41 -167.02 1.24 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.176 -1.191 . . . . 0.0 109.66 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.0 -38.13 93.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.81 ' OD1' HG13 ' A' ' 44' ' ' VAL . 1.3 t-20 -78.96 -44.6 22.11 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.469 -1.018 . . . . 0.0 109.403 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.451 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.8 OUTLIER 71.94 -54.78 0.68 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 179.615 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.681 ' HB2' HD22 ' A' ' 95' ' ' ASN . 9.1 m170 -48.67 -87.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.097 -1.002 . . . . 0.0 109.944 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.615 HD12 ' O ' ' A' ' 90' ' ' HIS . 54.1 mt 59.48 156.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.714 . . . . 0.0 109.938 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.532 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.59 144.15 25.08 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 -179.841 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.41 -8.64 59.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.713 -0.617 . . . . 0.0 109.545 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -75.72 -21.54 57.44 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.101 -0.999 . . . . 0.0 109.375 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.532 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -84.94 -15.32 44.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.304 -0.872 . . . . 0.0 109.853 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.722 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.7 m-85 -63.26 -65.88 0.62 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.207 -0.933 . . . . 0.0 110.248 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.5 -59.0 3.71 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.516 -0.74 . . . . 0.0 111.087 -179.317 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 4.9 Cg_endo -52.59 -55.79 3.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.671 1.353 . . . . 0.0 110.06 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.957 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -58.66 -21.2 53.52 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.338 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.98 -47.95 17.51 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.74 -53.88 53.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.161 -1.199 . . . . 0.0 109.562 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.8 m -54.98 -25.27 28.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.204 -0.935 . . . . 0.0 109.564 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.796 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -64.66 -37.04 86.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.666 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.74 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -64.7 -42.55 95.2 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -65.1 -23.14 67.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.749 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.84 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.24 -38.65 18.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.95 . . . . 0.0 109.693 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.796 ' SD ' HD23 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -53.16 -44.69 68.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.815 -179.861 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.481 ' HG2' ' CB ' ' A' ' 122' ' ' MET . 12.2 mt-10 -47.47 -28.35 2.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.243 -0.911 . . . . 0.0 109.668 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.464 ' N ' ' CD2' ' A' ' 116' ' ' HIS . 15.7 m170 -57.81 -27.07 62.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -0.997 . . . . 0.0 109.817 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.442 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -90.25 -65.59 1.0 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.252 -0.905 . . . . 0.0 109.871 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.741 HG23 HG12 ' A' ' 17' ' ' ILE . 41.8 pt -87.51 -37.48 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 109.496 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.503 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 40.91 -93.47 0.01 OUTLIER Glycine 0 N--CA 1.497 2.76 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -42.9 -41.43 4.54 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.496 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 34.6 mmtt -76.23 -28.24 57.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.13 -1.218 . . . . 0.0 109.748 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.481 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -59.21 102.01 0.12 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.173 -0.955 . . . . 0.0 109.317 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.731 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 9.2 p-10 -98.62 -178.7 4.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.244 -0.91 . . . . 0.0 109.772 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.05 -43.27 99.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 109.761 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.731 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -65.03 -24.38 67.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.094 -1.004 . . . . 0.0 109.306 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.505 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -72.67 -48.71 36.89 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.325 -0.859 . . . . 0.0 109.432 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.513 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.8 ptpt -73.39 -29.75 62.82 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.258 -0.901 . . . . 0.0 109.671 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.513 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 12.5 t0 -75.15 -38.34 61.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.192 -0.942 . . . . 0.0 109.273 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.633 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -66.63 -43.88 83.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -0.825 . . . . 0.0 109.104 179.559 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.907 ' CH2' HD12 ' A' ' 17' ' ' ILE . 11.1 m0 -73.58 -32.75 64.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.312 -0.868 . . . . 0.0 109.192 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.539 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -47.64 -27.68 2.01 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.271 -0.893 . . . . 0.0 109.414 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -108.69 -14.72 14.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.399 -0.813 . . . . 0.0 109.665 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.867 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -73.49 -69.13 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.957 . . . . 0.0 110.153 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.599 ' HA ' HD12 ' A' ' 137' ' ' ILE . 11.6 p90 -58.31 -20.14 40.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.844 -1.16 . . . . 0.0 109.127 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.423 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -73.61 -40.85 63.51 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.241 -0.912 . . . . 0.0 108.893 179.315 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.63 -30.52 56.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.352 -0.843 . . . . 0.0 109.055 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.643 HG23 ' SD ' ' A' ' 83' ' ' MET . 58.5 mt -68.28 -59.99 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.401 -0.812 . . . . 0.0 109.151 179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -57.56 -18.77 21.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.347 -0.846 . . . . 0.0 109.714 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.74 -52.2 21.31 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.47 -25.82 17.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.27 -1.135 . . . . 0.0 109.744 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.829 HD23 ' O ' ' A' ' 141' ' ' LEU . 7.3 tt -74.05 -11.58 60.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -0.912 . . . . 0.0 110.016 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.673 HG22 ' O ' ' A' ' 142' ' ' ILE . 98.3 mt -91.53 21.47 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.081 -1.012 . . . . 0.0 109.714 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -109.6 -20.35 12.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.156 -0.965 . . . . 0.0 109.83 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.14 -22.63 3.78 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.489 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 3.4 tp -62.74 -98.49 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.11 -1.23 . . . . 0.0 109.77 -179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 47.35 33.56 2.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.945 -1.097 . . . . 0.0 110.121 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.462 ' CB ' ' HA ' ' A' ' 91' ' ' LYS . 3.6 p . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.061 -1.024 . . . . 0.0 109.678 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.912 ' C1D' HG22 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.501 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.465 ' HA ' HD13 ' A' ' 2' ' ' LEU . 4.5 mm? -92.07 145.32 24.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.266 -1.138 . . . . 0.0 109.996 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 p -115.95 -166.34 1.13 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.368 -0.832 . . . . 0.0 109.52 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.1 -33.13 59.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.266 -0.896 . . . . 0.0 110.173 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.959 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -81.02 -47.11 14.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.143 -0.973 . . . . 0.0 110.044 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.517 ' O ' HG23 ' A' ' 10' ' ' VAL . 37.8 mt-30 -60.98 -56.34 22.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.671 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.58 ' HA ' HD12 ' A' ' 73' ' ' LEU . 9.7 ttp180 -51.86 -26.22 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.141 -0.975 . . . . 0.0 109.598 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 39.3 tp60 -85.27 -49.35 8.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 5' ' ' ALA . 41.5 t -52.05 -28.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.267 -0.896 . . . . 0.0 109.687 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.892 HG11 HD11 ' A' ' 73' ' ' LEU . 84.8 t -64.99 -53.68 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.898 . . . . 0.0 109.624 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.83 -17.6 64.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.3 -32.6 38.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.181 -0.949 . . . . 0.0 109.698 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.428 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 41.0 p -94.54 -11.57 29.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.66 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.06 -18.09 31.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.047 -1.033 . . . . 0.0 109.873 -179.825 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -85.65 -15.64 41.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.167 -0.958 . . . . 0.0 109.608 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -96.64 -53.83 3.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.51 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.98 HD12 ' CH2' ' A' ' 130' ' ' TRP . 62.0 mt -68.49 -43.12 84.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.285 -0.884 . . . . 0.0 109.508 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.594 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -100.43 34.99 2.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.375 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.73 -86.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.3 p -106.95 13.59 27.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.238 -1.154 . . . . 0.0 110.066 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.444 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 3.2 p30 -122.59 -9.84 8.41 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.121 -0.987 . . . . 0.0 110.177 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.615 HD21 ' HB2' ' A' ' 64' ' ' ALA . 6.7 t30 57.06 18.36 3.99 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.271 -0.893 . . . . 0.0 109.584 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.425 ' O ' ' HB ' ' A' ' 26' ' ' VAL . . . 85.76 32.63 17.9 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.25 -47.81 80.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.189 -1.183 . . . . 0.0 109.18 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.44 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -85.72 9.48 68.26 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.466 HG21 ' CG2' ' A' ' 17' ' ' ILE . 9.2 t -95.48 -39.27 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.135 -1.215 . . . . 0.0 109.353 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -81.89 -51.81 4.35 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.9 ptpt -50.39 -30.97 13.57 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.202 -1.175 . . . . 0.0 109.604 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.761 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 22.3 pt-20 -89.48 -22.43 22.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.444 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.7 t -86.98 -39.6 15.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.343 -0.848 . . . . 0.0 109.645 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.509 ' CE2' ' O ' ' A' ' 149' ' ' CMO . 10.1 m-85 -75.37 -42.21 54.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.879 . . . . 0.0 109.857 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.613 ' OG1' HG11 ' A' ' 55' ' ' VAL . 20.4 m -51.69 -49.05 63.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.089 -1.007 . . . . 0.0 109.394 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.9 . . . . 0.0 109.434 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.737 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.6 t80 -65.09 -46.76 79.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.676 HD13 HG22 ' A' ' 55' ' ' VAL . 10.8 mt -59.94 -47.6 85.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.418 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 3.0 t -61.17 -57.78 11.05 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.173 -0.954 . . . . 0.0 109.783 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.91 -27.28 68.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.183 -0.948 . . . . 0.0 109.841 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 19.9 m80 -121.93 105.61 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 109.781 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -87.2 -18.96 29.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.378 -0.826 . . . . 0.0 109.405 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -68.85 -19.08 64.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.905 . . . . 0.0 109.509 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.437 ' HE3' ' CMB' ' A' ' 148' ' ' HEM . 73.9 mmm -106.51 -23.61 12.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.288 -0.883 . . . . 0.0 109.712 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.46 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.96 -42.92 39.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.117 -0.989 . . . . 0.0 109.57 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.78 -28.19 60.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.31 -0.868 . . . . 0.0 109.255 179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.866 HG13 ' OD1' ' A' ' 95' ' ' ASN . 38.0 t -66.37 -49.46 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.332 -0.855 . . . . 0.0 109.424 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 50.6 m-85 -62.06 -30.93 71.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.739 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.19 31.68 2.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.041 -1.623 . . . . 0.0 109.041 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.0 m-85 -125.79 173.07 9.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.36 -1.082 . . . . 0.0 109.746 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.61 20.9 13.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.865 . . . . 0.0 109.301 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.54 -161.95 27.35 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.453 ' HB1' HG23 ' A' ' 32' ' ' THR . . . -92.5 29.46 1.72 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -1.134 . . . . 0.0 109.66 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.3 p -125.92 26.79 6.51 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.73 138.43 22.09 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.614 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -69.29 -25.43 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.962 1.507 . . . . 0.0 110.069 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' A' ' 57' ' ' ASP . . . -57.61 -31.49 63.7 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.676 HG22 HD13 ' A' ' 35' ' ' LEU . 70.2 t -53.85 -34.87 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.269 -1.136 . . . . 0.0 109.532 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.563 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.25 -7.48 58.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.316 -0.865 . . . . 0.0 109.856 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.403 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 7.7 m-20 -88.81 -38.77 14.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.72 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.63 ' O ' HG23 ' A' ' 62' ' ' VAL . 8.9 mt -74.81 -63.63 1.21 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 0.0 109.514 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.844 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -49.77 -34.57 21.99 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.563 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -68.04 -49.62 60.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.235 -1.156 . . . . 0.0 109.467 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.408 ' HD3' ' O2D' ' A' ' 148' ' ' HEM . 7.8 mttt -71.69 -44.07 64.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.376 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.644 HG21 ' O ' ' A' ' 149' ' ' CMO . 83.6 t -55.96 -51.47 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.629 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.844 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -46.45 -49.53 18.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.238 -0.913 . . . . 0.0 110.169 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.615 ' HB2' HD21 ' A' ' 22' ' ' ASN . . . -54.25 -39.01 66.43 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.089 -1.007 . . . . 0.0 109.907 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 23.5 tp60 -56.74 -39.49 74.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.992 -1.067 . . . . 0.0 108.931 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.986 ' O ' HG23 ' A' ' 70' ' ' VAL . 89.9 mt -66.98 -34.85 72.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.423 -0.798 . . . . 0.0 108.863 179.354 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.57 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.07 -51.34 45.75 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.74 -27.6 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.267 -1.137 . . . . 0.0 108.796 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.7 -27.38 27.07 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.634 -0.666 . . . . 0.0 109.507 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.986 HG23 ' O ' ' A' ' 66' ' ' ILE . 40.9 t -58.81 -17.28 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.32 -0.862 . . . . 0.0 109.7 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.441 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 1.2 t -56.15 -43.49 78.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.926 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.441 ' ND1' ' O ' ' A' ' 71' ' ' SER . 33.4 m-70 -138.73 102.73 4.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 0.0 109.979 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.936 HD21 ' HA ' ' A' ' 70' ' ' VAL . 36.1 mt -95.55 -37.15 11.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.28 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.61 -21.11 35.23 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.021 -1.631 . . . . 0.0 109.021 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -81.86 -172.43 3.9 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -1.189 . . . . 0.0 109.694 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -166.12 51.53 0.09 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.515 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -99.48 -54.63 1.07 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.504 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 32.1 ttpt -124.33 -31.7 3.26 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.249 -1.148 . . . . 0.0 109.941 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.511 ' SD ' HG23 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -47.66 -62.96 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.181 -0.949 . . . . 0.0 109.667 -179.944 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.511 HG23 ' SD ' ' A' ' 79' ' ' MET . 75.4 t -63.8 -15.56 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.712 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.504 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -80.01 -12.95 59.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.124 -0.985 . . . . 0.0 109.875 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.428 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.6 tp10 -99.44 -48.13 4.89 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.71 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.407 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 97.6 mmm -59.78 -44.91 93.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.152 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.679 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.04 -30.55 15.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.209 -0.932 . . . . 0.0 108.786 179.238 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -82.45 -36.38 26.63 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.498 -0.751 . . . . 0.0 109.112 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.443 ' CG1' HD12 ' A' ' 141' ' ' LEU . 89.2 t -59.22 -51.59 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.277 -0.889 . . . . 0.0 109.334 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.481 ' N ' ' HG ' ' A' ' 141' ' ' LEU . . . -53.06 -48.65 58.09 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.629 -1.789 . . . . 0.0 108.629 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 84' ' ' LYS . 99.0 t -47.38 -27.94 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.49 -1.006 . . . . 0.0 109.645 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.521 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 17.5 mmt180 -70.27 -42.72 71.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.128 -0.983 . . . . 0.0 108.804 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.477 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 12.3 m80 -65.56 -12.42 52.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.458 ' HD2' ' CB ' ' A' ' 147' ' ' SER . 0.2 OUTLIER -68.1 -13.21 62.03 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.327 -0.858 . . . . 0.0 110.399 -179.667 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.75 58.99 0.38 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.462 -1.352 . . . . 0.0 110.098 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.521 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 3.6 m-30 -92.32 -172.46 3.11 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.158 -1.201 . . . . 0.0 109.241 179.212 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.36 -34.77 90.8 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.507 -1.837 . . . . 0.0 108.507 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.866 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -82.94 -58.94 2.66 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.541 -0.976 . . . . 0.0 108.924 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.483 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 3.0 pttt 79.45 -19.82 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.774 -0.579 . . . . 0.0 111.02 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.623 ' HB2' HD22 ' A' ' 95' ' ' ASN . 5.7 m170 -92.24 40.64 1.05 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.666 -1.271 . . . . 0.0 109.44 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.456 HD13 ' CD2' ' A' ' 90' ' ' HIS . 65.3 mt -72.77 164.27 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.363 -0.836 . . . . 0.0 109.754 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.438 ' N ' HG22 ' A' ' 98' ' ' ILE . 0.1 OUTLIER -145.07 141.79 29.15 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.349 -0.844 . . . . 0.0 109.889 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.97 5.28 16.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 46.4 mm-40 -83.99 -32.63 24.86 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.99 -1.069 . . . . 0.0 109.463 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.464 ' CB ' HBB1 ' A' ' 148' ' ' HEM . 95.6 m-85 -75.72 -10.73 59.68 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.275 -0.891 . . . . 0.0 109.958 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.843 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.1 m-85 -62.93 -61.31 2.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.157 -0.964 . . . . 0.0 110.176 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -50.22 -55.58 24.07 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 109.881 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 32.3 Cg_exo -51.05 -62.68 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 123.712 1.375 . . . . 0.0 109.934 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.962 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.75 -24.45 35.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.54 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.74 -45.51 12.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.64 -38.59 87.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -1.188 . . . . 0.0 109.652 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -20.49 64.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.531 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.493 HD22 ' HE2' ' A' ' 134' ' ' TYR . 1.9 tt -74.58 -39.69 62.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.695 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.811 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -62.73 -30.06 71.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.258 -0.901 . . . . 0.0 109.558 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.7 t -72.53 -25.27 61.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.289 -0.882 . . . . 0.0 109.764 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.761 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.06 -38.76 18.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.244 -0.91 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.648 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.9 mmt -46.66 -45.07 19.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.33 -0.856 . . . . 0.0 110.055 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -49.21 -25.2 2.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 109.611 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.471 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 26.5 m170 -57.46 -37.43 72.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.574 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.51 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 2.1 ttt85 -83.89 -70.41 0.57 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.699 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.476 HG23 HG12 ' A' ' 17' ' ' ILE . 14.1 pt -82.44 53.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.173 -0.954 . . . . 0.0 109.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -59.43 123.78 34.4 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.32 -36.81 3.82 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.425 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 15.6 mtpt -84.58 -30.73 24.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.27 -1.135 . . . . 0.0 109.399 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.37 81.63 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.329 -0.857 . . . . 0.0 109.446 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.583 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.1 p30 -86.8 -168.68 2.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.754 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.446 ' O ' ' CB ' ' A' ' 128' ' ' ASP . . . -64.3 -46.21 84.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.489 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.782 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.28 -24.38 54.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.276 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.48 -58.36 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.548 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.2 OUTLIER -68.49 -25.85 65.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.588 -179.823 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 124' ' ' ALA . 25.0 t70 -80.75 -39.71 26.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.543 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.93 -41.82 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.848 . . . . 0.0 109.279 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.98 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.8 m0 -73.74 -24.52 59.9 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.163 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.548 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -74.04 -24.52 59.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.192 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.58 -40.58 12.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.858 . . . . 0.0 109.458 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.783 ' CB ' HD13 ' A' ' 73' ' ' LEU . . . -70.97 -45.58 63.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.399 -0.813 . . . . 0.0 109.537 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.493 ' HE2' HD22 ' A' ' 110' ' ' LEU . 3.2 m-85 -50.08 -32.15 14.93 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.908 . . . . 0.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.88 -37.11 70.21 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.19 -0.944 . . . . 0.0 108.866 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.17 -33.0 44.42 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.38 -0.825 . . . . 0.0 109.231 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.761 HD13 HG23 ' A' ' 66' ' ' ILE . 24.9 mt -65.77 -60.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.334 -0.854 . . . . 0.0 108.833 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.413 ' O ' HG13 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -66.93 -37.39 84.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.589 -0.694 . . . . 0.0 109.669 -179.775 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -52.44 -44.9 59.16 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.31 -18.36 64.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.21 -1.171 . . . . 0.0 109.82 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.843 HD22 ' CE2' ' A' ' 103' ' ' PHE . 6.7 tt -87.73 -23.77 24.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 109.78 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.493 HD12 ' HA2' ' A' ' 139' ' ' GLY . 50.9 mt -82.68 8.03 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 0.0 110.275 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -86.95 -35.92 18.61 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.008 -1.058 . . . . 0.0 109.502 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.417 ' O ' ' HD3' ' A' ' 91' ' ' LYS . . . -104.43 5.85 45.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.913 HD23 ' HG3' ' A' ' 146' ' ' GLN . 1.5 tt -91.84 -175.59 4.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.075 -1.25 . . . . 0.0 109.19 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.913 ' HG3' HD23 ' A' ' 145' ' ' LEU . 36.9 mt-30 56.48 83.93 0.09 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.142 -0.974 . . . . 0.0 110.12 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.458 ' CB ' ' HD2' ' A' ' 91' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.63 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.701 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.644 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.722 HD11 ' HA ' ' A' ' 133' ' ' ALA . 12.9 mt -94.67 159.45 15.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -1.142 . . . . 0.0 109.639 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.401 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 1.2 p -133.25 -179.2 5.36 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.641 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -75.49 -28.4 59.19 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.647 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.61 -24.61 29.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.904 . . . . 0.0 109.584 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.401 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 29.9 mt-30 -84.98 -46.21 11.44 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.218 -0.926 . . . . 0.0 109.735 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.466 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 4.3 ptm180 -51.7 -32.06 28.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.466 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 5.5 mm100 -70.2 -47.62 60.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.215 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.765 HG11 ' O ' ' A' ' 125' ' ' ALA . 80.9 t -56.44 -30.75 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.285 -0.884 . . . . 0.0 109.176 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.884 HG12 HG13 ' A' ' 70' ' ' VAL . 83.1 t -64.14 -55.02 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -0.836 . . . . 0.0 109.221 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.9 -14.04 62.64 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.613 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.5 m -84.44 -27.18 27.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.15 -0.969 . . . . 0.0 109.724 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.471 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 25.3 p -98.94 -7.2 27.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.152 -0.967 . . . . 0.0 109.69 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -89.27 -21.48 23.18 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.151 -0.968 . . . . 0.0 109.646 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.3 mtpm? -79.31 2.31 21.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 110.092 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -116.45 -54.4 2.46 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.06 -1.025 . . . . 0.0 109.525 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.808 HD12 ' CH2' ' A' ' 130' ' ' TRP . 43.2 mt -66.49 -32.25 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.292 -0.88 . . . . 0.0 109.518 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.651 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -105.92 35.39 2.92 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.713 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.7 -81.57 0.05 OUTLIER Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 p -108.78 -34.86 6.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -1.128 . . . . 0.0 109.58 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.516 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 37.8 p30 -75.91 -15.05 60.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.909 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.651 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.8 t30 63.18 16.0 9.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.147 -0.971 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.474 ' O ' HD12 ' A' ' 63' ' ' LEU . . . 100.11 17.36 25.21 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.516 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -50.07 -36.81 30.76 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.094 -1.239 . . . . 0.0 109.774 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.454 ' HA2' ' CE ' ' A' ' 28' ' ' LYS . . . -92.97 13.61 67.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 30' ' ' CYS . 54.5 t -95.4 -28.3 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.045 -1.268 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.438 ' HA2' ' HB3' ' A' ' 30' ' ' CYS . . . -91.47 -44.52 4.28 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.475 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 10.8 ptpt -51.61 -33.66 34.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.195 -1.179 . . . . 0.0 109.089 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.87 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 19.0 pt-20 -91.44 -29.41 17.05 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.218 -0.926 . . . . 0.0 109.243 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.438 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 18.0 t -84.83 -68.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 110.065 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.608 ' HZ ' HG11 ' A' ' 62' ' ' VAL . 22.1 m-85 -45.94 -32.6 2.8 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.564 -178.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.725 ' OG1' HG11 ' A' ' 55' ' ' VAL . 5.6 m -59.04 -52.16 66.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.929 -1.107 . . . . 0.0 109.124 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 36.3 mttt -55.44 -48.21 74.8 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.069 -1.019 . . . . 0.0 109.311 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.515 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.9 t80 -54.83 -54.48 41.74 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.31 -0.869 . . . . 0.0 109.336 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.745 ' CD1' HG22 ' A' ' 55' ' ' VAL . 46.0 mt -55.39 -43.29 75.05 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.64 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -68.17 0.37 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.679 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.37 -30.09 37.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.214 -0.929 . . . . 0.0 109.626 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.403 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 9.2 m80 -115.2 99.84 7.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.754 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -82.3 -14.4 55.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.453 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -74.21 -13.78 60.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.152 -0.968 . . . . 0.0 109.62 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.895 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 2.6 mmt -104.83 -27.34 11.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.13 -0.981 . . . . 0.0 109.91 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.664 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -48.24 -41.53 27.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.037 -1.039 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.43 -26.02 59.81 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -0.85 . . . . 0.0 108.782 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.874 HG13 ' OD1' ' A' ' 95' ' ' ASN . 2.9 t -72.61 -47.34 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.832 ' HD2' HD13 ' A' ' 58' ' ' LEU . 25.0 m-85 -65.61 -32.74 74.49 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.874 . . . . 0.0 109.47 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.14 27.94 3.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.544 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.6 m-85 -123.21 172.95 8.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.21 -1.17 . . . . 0.0 109.828 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.56 19.51 16.78 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.371 -0.83 . . . . 0.0 109.215 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 151.83 -163.8 30.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB1' HG23 ' A' ' 32' ' ' THR . . . -98.74 36.24 1.7 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -1.171 . . . . 0.0 109.704 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 67.3 p -147.46 28.94 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.613 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 54' ' ' GLY . 0.4 OUTLIER -108.15 143.62 27.76 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.639 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -65.95 70.27 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.998 1.525 . . . . 0.0 110.059 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.524 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -155.19 -43.56 0.02 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.745 HG22 ' CD1' ' A' ' 35' ' ' LEU . 61.6 t -53.0 -40.1 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.357 -1.084 . . . . 0.0 109.496 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.62 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -63.93 -20.31 65.76 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.487 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.55 -57.76 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.301 -0.875 . . . . 0.0 109.236 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.909 HD21 ' C1A' ' A' ' 148' ' ' HEM . 0.4 OUTLIER -57.56 -63.3 1.28 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.462 -0.774 . . . . 0.0 110.28 -179.85 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.585 ' O ' HD13 ' A' ' 63' ' ' LEU . . . -54.59 -21.7 22.24 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.203 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.674 ' HA ' HD11 ' A' ' 63' ' ' LEU . . . -83.94 -6.12 59.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.126 -1.22 . . . . 0.0 110.684 -179.28 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 56.9 mttt -113.19 -12.3 13.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.972 -1.08 . . . . 0.0 110.002 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.723 HG21 ' O ' ' A' ' 149' ' ' CMO . 93.4 t -83.2 -25.65 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.099 -1.001 . . . . 0.0 110.68 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.674 HD11 ' HA ' ' A' ' 60' ' ' ALA . 0.0 OUTLIER -70.28 -4.8 23.66 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.706 -1.246 . . . . 0.0 110.697 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.479 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -85.16 -42.45 14.72 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.834 -1.166 . . . . 0.0 109.559 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.435 ' OE1' HG21 ' A' ' 86' ' ' VAL . 2.8 mm-40 -56.57 -47.99 78.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.107 -0.996 . . . . 0.0 108.807 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.919 ' O ' HG23 ' A' ' 70' ' ' VAL . 80.1 mt -57.32 -34.69 46.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.252 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.582 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.85 -57.26 12.66 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.1 t -57.33 -23.7 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.267 -1.137 . . . . 0.0 109.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.45 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -86.71 -27.88 23.43 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.447 -0.783 . . . . 0.0 109.582 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.919 HG23 ' O ' ' A' ' 66' ' ' ILE . 54.5 t -70.46 -12.39 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.181 -0.949 . . . . 0.0 109.826 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.0 t -82.58 6.63 17.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.033 . . . . 0.0 110.061 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' GLY . 23.9 m-70 -140.08 -88.88 0.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.004 -1.06 . . . . 0.0 109.685 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.572 HD11 ' HA ' ' A' ' 70' ' ' VAL . 29.8 mt 62.29 -74.23 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.468 -0.77 . . . . 0.0 109.823 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.488 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.77 -30.69 44.62 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -101.68 91.51 4.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -1.083 . . . . 0.0 109.443 179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -89.76 42.92 1.12 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.646 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -113.6 -17.43 7.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.501 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 8.4 ttmt -134.53 -41.19 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.15 -1.206 . . . . 0.0 109.894 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.471 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 17.2 tmm? -48.91 -42.71 37.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.955 . . . . 0.0 109.741 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.424 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 69.3 t -71.04 -20.27 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.63 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -68.06 -33.29 74.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.712 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.471 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 17.5 mt-10 -76.7 -53.45 7.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.574 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.8 mtp -53.31 -41.07 65.28 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.201 -0.937 . . . . 0.0 109.435 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.525 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.7 OUTLIER -52.17 -31.88 33.43 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.175 -0.953 . . . . 0.0 108.723 179.24 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.3 -36.75 71.74 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.665 ' CG1' HD11 ' A' ' 141' ' ' LEU . 45.5 t -56.89 -51.75 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.199 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -51.8 -46.75 54.38 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.856 -1.698 . . . . 0.0 108.856 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 84' ' ' LYS . 60.8 t -50.41 -25.75 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -1.173 . . . . 0.0 109.292 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.474 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 0.2 OUTLIER -81.3 -53.3 6.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.325 -0.859 . . . . 0.0 108.743 179.352 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.672 ' HB2' HD13 ' A' ' 145' ' ' LEU . 21.1 m80 -54.72 -21.91 12.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.053 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.511 ' CD ' ' HA ' ' A' ' 147' ' ' SER . 34.0 ttpt -67.69 -12.93 61.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.448 -0.782 . . . . 0.0 110.243 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.07 55.58 0.55 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.56 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.512 ' OH ' ' CE1' ' A' ' 90' ' ' HIS . 3.8 m-30 -89.59 -100.23 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.322 -1.105 . . . . 0.0 109.645 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.44 -50.05 0.02 OUTLIER Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.066 -2.013 . . . . 0.0 108.066 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.874 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.1 OUTLIER -67.17 -30.44 70.41 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.489 -1.006 . . . . 0.0 108.521 178.934 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 43.5 mttt 51.98 22.24 1.75 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.636 -0.665 . . . . 0.0 109.805 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.2 m170 -128.64 49.48 2.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.338 -0.851 . . . . 0.0 109.149 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.469 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 76.3 mt -84.93 158.74 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.857 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.511 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -142.02 144.91 33.87 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.356 -0.84 . . . . 0.0 109.983 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.708 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -80.98 -15.86 55.07 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.679 -0.638 . . . . 0.0 109.36 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 54.3 mm-40 -67.86 -22.38 65.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.128 -0.983 . . . . 0.0 109.471 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.511 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -86.32 -26.39 24.93 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 109.79 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.812 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.7 m-85 -51.28 -59.06 4.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.23 -0.919 . . . . 0.0 110.281 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.506 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -54.65 -58.78 12.67 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.203 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.506 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.4 Cg_exo -48.25 -53.13 7.18 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 O-C-N 123.639 1.337 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.93 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -59.48 -18.0 36.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -0.941 . . . . 0.0 109.858 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -83.99 -42.56 7.56 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.71 -57.78 9.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.078 -1.248 . . . . 0.0 109.684 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.5 t -60.66 -16.25 37.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.778 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.981 HD21 ' CE ' ' A' ' 114' ' ' MET . 3.2 tt -78.53 -36.42 44.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.075 -1.016 . . . . 0.0 109.715 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.837 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -64.36 -28.78 69.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.069 -1.019 . . . . 0.0 109.423 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.427 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 14.1 t -66.63 -35.22 79.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.699 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.87 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -80.29 -31.63 38.22 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.655 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.981 ' CE ' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.35 -38.09 12.34 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.019 -179.92 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.471 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.9 OUTLIER -62.65 -14.0 38.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.074 -1.017 . . . . 0.0 109.705 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.545 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.9 m170 -53.9 -37.54 63.88 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.911 -1.118 . . . . 0.0 109.443 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.475 ' HB3' HG12 ' A' ' 17' ' ' ILE . 1.1 ttt85 -89.81 -51.62 5.4 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.2 -0.938 . . . . 0.0 109.82 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.435 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 2.8 pt -110.04 48.73 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.161 -0.962 . . . . 0.0 109.897 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -59.57 -18.29 44.08 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.17 -30.61 9.14 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.7 mtpp -94.47 -25.81 16.73 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.164 -1.198 . . . . 0.0 109.537 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 1.8 tpt -61.09 96.73 0.05 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.889 . . . . 0.0 109.431 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -106.14 -162.54 0.87 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.744 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -67.08 -46.25 74.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.355 -0.841 . . . . 0.0 110.134 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.765 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -63.58 -21.55 66.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.074 -1.016 . . . . 0.0 109.779 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.4 -47.15 14.83 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.177 -0.952 . . . . 0.0 109.563 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.573 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 17.6 ptpt -74.02 -30.68 62.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -0.891 . . . . 0.0 109.685 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.454 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -73.94 -53.34 10.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.93 . . . . 0.0 109.738 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.549 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -55.09 -43.41 73.97 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.35 -0.844 . . . . 0.0 109.71 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.837 ' HB3' HD21 ' A' ' 111' ' ' LEU . 7.5 m0 -76.09 -27.15 57.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.245 -0.909 . . . . 0.0 109.565 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.573 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.26 -30.42 68.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.169 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.78 -26.39 21.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.38 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.722 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -82.06 -48.38 11.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.482 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.517 ' CE2' ' HE2' ' A' ' 114' ' ' MET . 9.1 m-30 -52.42 -31.01 32.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.293 -0.88 . . . . 0.0 109.337 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.75 -46.39 63.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -0.875 . . . . 0.0 109.219 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -73.91 -30.53 62.64 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.312 -0.867 . . . . 0.0 109.221 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.663 HD13 HG23 ' A' ' 66' ' ' ILE . 59.4 mt -67.98 -60.78 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.314 -0.866 . . . . 0.0 108.973 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 3.6 m -66.96 -31.47 72.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.487 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.16 -38.41 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.17 -23.74 66.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -1.141 . . . . 0.0 109.528 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.849 HD23 ' O ' ' A' ' 141' ' ' LEU . 10.0 tt -76.34 -2.39 31.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 110.116 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.708 HD12 ' HB2' ' A' ' 100' ' ' ALA . 40.6 mm -92.15 31.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.961 -1.087 . . . . 0.0 109.902 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.465 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -108.73 -34.23 6.75 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.283 -0.885 . . . . 0.0 109.381 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.79 21.89 7.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.672 HD13 ' HB2' ' A' ' 90' ' ' HIS . 14.3 tp -100.89 2.39 40.86 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.345 -1.091 . . . . 0.0 110.004 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -111.25 67.2 0.64 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.85 -1.156 . . . . 0.0 109.836 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.511 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 3.4 m . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.661 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.909 ' C1A' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.723 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.852 HD11 ' HA ' ' A' ' 133' ' ' ALA . 65.4 mt -74.93 -168.48 0.75 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -1.149 . . . . 0.0 109.485 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.404 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 0.7 OUTLIER -93.63 172.61 8.15 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.216 -0.928 . . . . 0.0 109.6 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -71.16 -19.2 62.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.861 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -94.51 -32.85 13.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.166 -0.959 . . . . 0.0 109.683 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.404 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 57.8 mt-30 -71.24 -55.45 8.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.708 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 2.8 ptm180 -50.92 -32.36 20.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.447 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.458 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 9.4 tp-100 -70.29 -39.01 75.13 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.294 -0.879 . . . . 0.0 109.349 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.861 HG23 ' O ' ' A' ' 5' ' ' ALA . 22.0 t -69.38 -27.63 35.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.453 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 1.055 HG12 HG13 ' A' ' 70' ' ' VAL . 97.2 t -71.95 -37.96 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.596 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.98 -14.75 60.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.855 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 t -90.87 -25.62 19.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -93.56 -12.41 29.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 109.952 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.739 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.21 -24.31 21.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.084 -1.01 . . . . 0.0 109.788 -179.842 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -75.23 -8.37 56.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.406 ' HB3' HG21 ' A' ' 118' ' ' ILE . 1.8 m-20 -103.7 -54.06 2.65 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.085 -1.009 . . . . 0.0 109.68 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.917 HD12 ' CH2' ' A' ' 130' ' ' TRP . 46.4 mt -65.79 -36.67 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.246 -0.909 . . . . 0.0 109.712 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.939 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.69 33.56 3.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.778 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.09 -66.98 2.36 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 88.3 p -115.61 -19.64 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -1.134 . . . . 0.0 109.558 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.809 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 7.5 p-10 -87.17 -19.08 28.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.894 . . . . 0.0 109.654 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.939 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.2 t30 58.57 22.89 10.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.05 23.69 10.4 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.809 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -70.45 -43.43 69.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -1.159 . . . . 0.0 109.603 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.423 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -88.39 14.46 59.44 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.624 HG11 HD11 ' A' ' 63' ' ' LEU . 44.0 t -108.64 -26.15 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -1.228 . . . . 0.0 109.317 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -97.36 -36.86 4.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.478 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.0 ptpt -66.41 -29.07 69.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.176 -1.191 . . . . 0.0 109.554 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.478 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 13.1 pt-20 -93.86 -20.34 20.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -0.935 . . . . 0.0 109.675 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.0 t -88.25 -59.86 2.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.234 -0.916 . . . . 0.0 109.866 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.8 m-85 -54.48 -30.11 52.16 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 109.81 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.96 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -55.32 -58.47 7.57 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.162 -0.961 . . . . 0.0 109.336 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -54.31 -45.29 72.55 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.878 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.788 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -56.36 -59.09 5.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.962 . . . . 0.0 109.286 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.838 ' CD1' HG22 ' A' ' 55' ' ' VAL . 26.6 mt -51.15 -43.71 61.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 109.632 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.467 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 2.6 t -68.82 -71.27 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.911 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -49.52 -29.89 7.52 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.888 . . . . 0.0 109.787 -179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 11.9 m80 -117.85 107.49 14.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.266 -0.896 . . . . 0.0 109.944 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -86.59 -25.4 24.98 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.475 -0.765 . . . . 0.0 108.967 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -66.97 -21.62 65.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.229 -0.919 . . . . 0.0 108.931 179.117 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.494 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -94.99 -27.63 15.55 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.413 -0.805 . . . . 0.0 109.55 179.846 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.437 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.06 -45.0 64.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.064 -1.023 . . . . 0.0 109.248 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.4 84.51 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.341 -0.849 . . . . 0.0 109.184 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.98 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.7 t -62.96 -60.24 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.31 -0.868 . . . . 0.0 109.156 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.526 ' CE1' ' C1B' ' A' ' 148' ' ' HEM . 62.0 m-85 -61.54 -31.97 72.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.192 -0.942 . . . . 0.0 109.009 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.06 -138.59 15.08 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.517 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 2.0 m-85 61.64 162.6 0.07 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.211 -1.17 . . . . 0.0 109.915 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 32.2 t -106.71 23.36 14.42 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.42 -161.06 31.45 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.467 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -92.32 -21.4 20.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.711 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.6 p -90.8 56.89 3.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.147 -0.97 . . . . 0.0 109.669 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.47 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -120.1 139.99 29.23 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.208 -0.933 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 15.8 Cg_exo -62.11 -31.59 83.28 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.98 1.516 . . . . 0.0 110.067 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -37.25 40.04 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.96 HG11 HG23 ' A' ' 32' ' ' THR . 93.4 t -50.2 -37.49 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -1.103 . . . . 0.0 109.445 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -75.65 -21.47 57.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.881 . . . . 0.0 109.299 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -81.41 -40.03 24.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.486 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.823 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 mt -74.93 -59.59 2.67 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.516 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.5 -48.48 42.05 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.448 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -59.59 -48.41 81.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -1.106 . . . . 0.0 109.468 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -62.93 -33.24 74.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.883 . . . . 0.0 109.461 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 58' ' ' LEU . 55.1 t -75.08 -49.47 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.323 -0.861 . . . . 0.0 109.527 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.624 HD11 HG11 ' A' ' 26' ' ' VAL . 2.0 mm? -48.68 -46.23 40.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.14 -49.31 32.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.785 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -53.72 -51.58 62.84 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.277 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.953 ' O ' HG23 ' A' ' 70' ' ' VAL . 61.0 mt -53.91 -39.21 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.339 -0.85 . . . . 0.0 109.131 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.558 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -59.52 -54.5 37.19 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -60.19 -29.98 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -1.147 . . . . 0.0 109.268 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.543 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -83.56 -5.58 59.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.406 -0.809 . . . . 0.0 109.989 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.055 HG13 HG12 ' A' ' 10' ' ' VAL . 42.2 t -90.56 -16.37 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.99 -1.069 . . . . 0.0 109.954 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.27 16.52 5.16 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.157 -0.964 . . . . 0.0 110.101 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.534 ' CD2' ' HA3' ' A' ' 77' ' ' GLY . 36.6 m-70 -137.8 -86.59 0.28 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.305 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.602 ' HB3' HD12 ' A' ' 2' ' ' LEU . 68.1 mt 45.35 34.47 1.52 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.302 -0.873 . . . . 0.0 110.035 179.712 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -165.4 -47.73 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -107.96 -175.0 2.66 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.59 -0.947 . . . . 0.0 108.862 179.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -72.96 -42.99 62.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.025 -1.047 . . . . 0.0 108.789 179.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.534 ' HA3' ' CD2' ' A' ' 72' ' ' HIS . . . 44.9 26.34 1.16 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 28.5 ttmt 50.25 20.56 0.66 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.242 -1.152 . . . . 0.0 110.134 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.35 -28.18 15.69 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.999 -1.063 . . . . 0.0 108.593 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 24.3 t -75.83 -22.87 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.599 -0.84 . . . . 0.0 109.117 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.17 -22.2 27.13 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.24 -0.912 . . . . 0.0 109.137 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.859 ' O ' HG23 ' A' ' 86' ' ' VAL . 33.6 mt-10 -90.98 -37.55 13.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.339 -0.851 . . . . 0.0 109.541 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.634 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.0 OUTLIER -67.11 -51.8 49.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.124 -0.985 . . . . 0.0 109.07 179.667 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.79 -31.33 66.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.258 -0.901 . . . . 0.0 108.752 179.232 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -67.33 -42.6 83.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 109.006 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.859 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.8 t -53.83 -44.62 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 108.83 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.402 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -58.98 -51.46 59.1 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.738 HG23 ' HA3' ' A' ' 144' ' ' GLY . 55.1 t -58.22 -23.08 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.341 -1.094 . . . . 0.0 109.023 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -86.64 -50.06 7.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.391 -0.818 . . . . 0.0 109.074 179.713 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.542 ' HB3' HD13 ' A' ' 98' ' ' ILE . 2.9 m80 -48.42 -44.55 35.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.755 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.441 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -58.94 -17.94 29.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.179 -0.951 . . . . 0.0 109.822 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.25 37.86 3.39 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.542 ' CD2' HBA1 ' A' ' 148' ' ' HEM . 3.2 m-30 -93.76 -166.01 1.43 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -1.107 . . . . 0.0 109.519 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.51 -33.86 24.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.98 ' ND2' HG13 ' A' ' 44' ' ' VAL . 2.2 t30 -69.41 -59.0 3.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.486 -1.008 . . . . 0.0 109.299 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 76.13 -12.97 0.95 Allowed 'General case' 0 N--CA 1.507 2.42 0 O-C-N 121.572 -0.705 . . . . 0.0 111.491 179.589 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.3 m170 -99.78 41.94 1.13 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.633 -1.292 . . . . 0.0 109.018 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.542 HD13 ' HB3' ' A' ' 90' ' ' HIS . 57.3 mt -76.07 152.35 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.404 -0.81 . . . . 0.0 110.46 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.457 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 8.5 mttp -142.2 138.9 31.83 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 121.661 0.743 . . . . 0.0 109.809 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.592 ' HB2' HG23 ' A' ' 142' ' ' ILE . . . -75.42 -6.8 51.91 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.713 -0.617 . . . . 0.0 109.511 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 6.0 pt-20 -74.12 -26.63 60.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.09 -1.006 . . . . 0.0 109.301 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.494 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 33.3 m-85 -81.63 -21.25 38.35 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.865 . . . . 0.0 109.724 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.815 ' HE2' HD22 ' A' ' 141' ' ' LEU . 3.3 m-85 -55.84 -63.0 1.32 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.334 -0.854 . . . . 0.0 110.289 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.51 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.7 mt-10 -48.91 -57.82 10.25 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.165 -0.959 . . . . 0.0 110.129 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.51 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -49.62 -63.18 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.632 1.333 . . . . 0.0 110.05 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.964 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -55.1 -24.9 27.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.292 -0.88 . . . . 0.0 109.43 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.1 -48.74 5.9 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.85 95.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.124 -1.221 . . . . 0.0 109.646 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 58.4 m -65.33 -19.14 65.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 0.0 109.606 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.828 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.5 tt -73.89 -38.78 64.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.617 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.926 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -60.53 -35.75 76.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 109.619 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 9.3 t -65.13 -33.83 76.95 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.666 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -81.16 -35.11 31.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.206 -0.934 . . . . 0.0 109.794 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.491 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 0.6 OUTLIER -54.71 -28.85 50.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.812 -179.867 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.45 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -68.48 -13.88 62.62 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.253 -0.904 . . . . 0.0 109.244 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.407 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 24.2 m170 -65.56 -45.18 84.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.085 -1.009 . . . . 0.0 109.772 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.417 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -74.54 -47.95 29.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.506 HG12 HD11 ' A' ' 17' ' ' ILE . 4.5 pt -114.32 54.99 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.274 -0.891 . . . . 0.0 109.633 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -66.27 -18.18 66.98 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -97.63 -26.35 9.97 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.438 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.5 mmtt -96.14 -25.43 15.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.262 -1.14 . . . . 0.0 109.621 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -64.23 104.67 0.78 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.25 -0.906 . . . . 0.0 109.545 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.456 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 5.0 p-10 -106.29 -171.08 1.83 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.379 -0.825 . . . . 0.0 109.537 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.99 -55.31 26.89 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.844 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.456 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -54.23 -26.54 29.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.132 -0.98 . . . . 0.0 109.439 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -71.45 -54.59 10.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -0.973 . . . . 0.0 109.359 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.3 ptpt -70.04 -25.2 63.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.346 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.459 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.6 t0 -81.71 -34.56 30.52 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -0.853 . . . . 0.0 109.326 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.406 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.21 -41.47 63.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.353 -0.842 . . . . 0.0 109.371 179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.926 ' HB3' HD21 ' A' ' 111' ' ' LEU . 8.5 m0 -75.47 -24.38 56.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 109.242 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -71.88 -29.4 64.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.64 ' C ' HD21 ' A' ' 2' ' ' LEU . . . -89.26 -34.32 16.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.852 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -70.66 -43.49 69.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.373 -0.829 . . . . 0.0 109.393 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.828 ' OH ' HD22 ' A' ' 110' ' ' LEU . 3.1 m-85 -52.02 -28.89 18.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.4 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.63 -31.15 59.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.318 -0.864 . . . . 0.0 109.458 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.18 -39.67 22.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.472 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.634 HG23 ' SD ' ' A' ' 83' ' ' MET . 76.0 mt -66.38 -57.56 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.255 -0.903 . . . . 0.0 109.35 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 1.5 p -68.65 -27.1 65.69 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.857 . . . . 0.0 109.653 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.674 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -65.28 -53.59 31.94 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.06 -16.46 31.6 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.248 -1.148 . . . . 0.0 109.859 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.815 HD22 ' HE2' ' A' ' 103' ' ' PHE . 8.1 tt -89.89 -39.18 13.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.836 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.674 HD12 ' HA2' ' A' ' 139' ' ' GLY . 11.2 mt -66.09 -11.17 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.135 -0.978 . . . . 0.0 110.002 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.02 -59.35 4.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.091 -1.006 . . . . 0.0 109.228 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.738 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -82.09 4.25 76.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.517 ' HB3' ' HA ' ' A' ' 142' ' ' ILE . 51.7 tp -82.94 171.35 13.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.004 -1.292 . . . . 0.0 109.382 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.467 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 57.91 71.7 0.56 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.294 -0.879 . . . . 0.0 109.608 -179.724 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.431 ' HB2' ' CG ' ' A' ' 91' ' ' LYS . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.613 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.891 HMB1 HG11 ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.595 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.412 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.604 HD11 ' HA ' ' A' ' 133' ' ' ALA . 11.9 mt -149.69 158.77 44.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.15 -1.206 . . . . 0.0 109.456 179.741 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.6 p -134.58 -171.82 2.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.264 -0.898 . . . . 0.0 109.621 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.98 -20.06 50.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.935 . . . . 0.0 109.557 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.827 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -88.31 -32.12 18.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.227 -0.921 . . . . 0.0 109.581 179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.464 ' O ' HG23 ' A' ' 10' ' ' VAL . 33.8 mt-30 -81.7 -53.03 6.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.182 -0.949 . . . . 0.0 109.819 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.27 -27.96 10.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.149 -0.969 . . . . 0.0 109.606 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -77.45 -44.27 29.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.89 . . . . 0.0 109.284 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.827 HG23 ' O ' ' A' ' 5' ' ' ALA . 46.3 t -62.98 -25.06 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.293 -0.88 . . . . 0.0 109.184 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.969 HG12 HG13 ' A' ' 70' ' ' VAL . 86.5 t -72.56 -46.93 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.416 -0.802 . . . . 0.0 109.358 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.68 -11.33 60.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.331 -0.856 . . . . 0.0 109.854 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.6 m -91.63 -21.23 20.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 109.694 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.464 HG21 ' HB1' ' A' ' 126' ' ' ALA . 12.1 p -101.87 -9.26 20.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.27 -0.894 . . . . 0.0 109.963 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.676 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.63 -19.9 23.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.097 -1.002 . . . . 0.0 109.771 -179.857 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -81.62 -10.7 59.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.223 -0.923 . . . . 0.0 109.933 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.62 -54.44 2.58 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.062 -1.024 . . . . 0.0 109.656 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.965 HD12 ' CH2' ' A' ' 130' ' ' TRP . 59.5 mt -66.04 -35.38 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 0.0 109.623 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.716 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.45 31.1 4.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.668 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.28 -70.46 0.95 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.8 p -107.5 -37.13 6.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.215 -1.167 . . . . 0.0 109.751 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.589 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.6 p-10 -72.42 -19.73 61.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.261 -0.899 . . . . 0.0 109.714 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.716 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.9 t30 56.8 26.21 11.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.209 -0.932 . . . . 0.0 109.657 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.16 23.91 23.56 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.97 -49.58 60.81 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 0.0 109.579 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.45 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -87.83 13.08 61.86 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.586 HG11 HD11 ' A' ' 63' ' ' LEU . 17.2 t -98.68 -30.59 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.094 -1.239 . . . . 0.0 109.241 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.452 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -90.06 -43.37 5.05 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.474 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.2 ptpt -56.07 -33.23 64.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.17 -1.194 . . . . 0.0 109.559 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.853 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 11.0 pt-20 -89.6 -18.57 26.31 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.958 . . . . 0.0 109.686 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.23 -61.52 1.68 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.511 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.6 m-85 -51.64 -31.82 26.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.185 -0.947 . . . . 0.0 109.885 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.892 HG23 HG11 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -56.03 -55.57 31.3 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.188 -0.945 . . . . 0.0 109.594 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -57.45 -49.11 77.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.316 -0.865 . . . . 0.0 109.678 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.683 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.3 t80 -50.91 -51.17 54.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.185 -0.947 . . . . 0.0 109.609 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.713 ' CD1' HG22 ' A' ' 55' ' ' VAL . 12.8 mt -56.41 -46.13 80.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.868 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.607 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 13.5 t -60.75 -57.59 12.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.194 -0.941 . . . . 0.0 109.83 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.32 -21.84 66.27 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.4 ' O ' ' O ' ' A' ' 35' ' ' LEU . 15.2 m80 -122.76 105.95 10.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.833 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -87.02 -21.13 26.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.436 -0.79 . . . . 0.0 109.264 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -73.27 -20.24 60.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.644 ' HE1' HMB2 ' A' ' 148' ' ' HEM . 0.0 OUTLIER -96.65 -18.6 19.6 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 109.629 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.446 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -59.88 -57.53 12.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.472 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.73 -23.31 63.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -0.932 . . . . 0.0 109.345 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.95 HG13 ' ND2' ' A' ' 95' ' ' ASN . 49.5 t -75.05 -57.08 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.342 -0.849 . . . . 0.0 109.504 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.529 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -55.77 -35.25 66.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.95 . . . . 0.0 109.514 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.39 28.08 2.91 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.529 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 9.3 m-85 -123.14 -168.66 1.8 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 109.784 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.1 t -133.62 21.43 3.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.507 -0.746 . . . . 0.0 109.123 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 139.84 -161.72 26.28 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.607 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -91.44 36.74 0.94 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.232 -1.158 . . . . 0.0 109.724 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.7 m -132.68 19.04 4.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.628 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -107.13 133.84 20.14 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.575 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.38 -19.87 55.26 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.947 1.498 . . . . 0.0 109.974 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.506 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.61 -27.63 64.06 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.892 HG11 HG23 ' A' ' 32' ' ' THR . 99.3 t -57.18 -35.19 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -1.167 . . . . 0.0 109.405 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.708 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.34 -3.83 48.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.89 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.97 -29.97 14.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.046 -1.034 . . . . 0.0 109.397 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.798 ' O ' HG23 ' A' ' 62' ' ' VAL . 7.1 mt -86.02 -63.56 1.3 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.161 -0.962 . . . . 0.0 109.524 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.652 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -54.49 -28.83 45.91 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -63.1 -53.04 59.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.149 -1.207 . . . . 0.0 109.518 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.5 ' HB3' ' CGD' ' A' ' 148' ' ' HEM . 11.3 mtpt -76.25 -43.54 41.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.281 -0.887 . . . . 0.0 109.321 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.798 HG23 ' O ' ' A' ' 58' ' ' LEU . 63.0 t -50.16 -49.14 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.308 -0.87 . . . . 0.0 109.591 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.652 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -47.51 -45.68 26.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.144 -0.973 . . . . 0.0 109.729 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -48.67 -50.9 31.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.244 -0.91 . . . . 0.0 109.903 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.1 tp60 -49.9 -49.21 50.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.139 -0.976 . . . . 0.0 109.491 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.912 ' O ' HG23 ' A' ' 70' ' ' VAL . 71.1 mt -56.2 -35.83 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.325 -0.86 . . . . 0.0 109.138 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.84 -54.9 25.4 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.156 -1.578 . . . . 0.0 109.156 179.742 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.0 t -59.57 -24.48 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.9 -25.46 26.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.307 -0.871 . . . . 0.0 109.534 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.969 HG13 HG12 ' A' ' 10' ' ' VAL . 55.1 t -73.66 -18.38 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 109.665 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -89.35 15.3 9.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -0.93 . . . . 0.0 109.927 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.465 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 14.0 m-70 -155.97 45.59 0.45 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.076 -1.015 . . . . 0.0 109.899 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.505 HD11 HG11 ' A' ' 10' ' ' VAL . 69.3 mt -82.79 -27.79 30.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.54 -23.55 60.21 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -126.7 119.0 25.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.252 -1.146 . . . . 0.0 109.576 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -106.34 39.73 1.76 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.217 -0.927 . . . . 0.0 109.624 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -88.36 -21.7 43.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.618 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 2.8 ttpt -131.14 -37.97 1.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -1.169 . . . . 0.0 109.847 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.465 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 39.8 ttp -47.93 -53.16 16.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 109.627 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.427 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 58.1 t -66.86 -19.23 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.226 -0.921 . . . . 0.0 109.456 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.618 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -69.8 -36.32 75.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 0.0 109.434 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.441 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 22.3 tp10 -81.58 -49.81 10.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.437 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.4 mtp -53.04 -45.68 68.13 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.277 -0.889 . . . . 0.0 109.362 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.759 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.4 -37.53 48.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 109.086 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.45 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -65.33 -35.35 80.71 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.404 -0.81 . . . . 0.0 109.153 179.467 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.527 HG12 HD11 ' A' ' 141' ' ' LEU . 28.9 t -62.4 -53.09 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.318 -0.864 . . . . 0.0 109.216 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -53.12 -42.2 61.67 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 84' ' ' LYS . 97.7 t -52.63 -27.89 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -1.136 . . . . 0.0 109.345 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.47 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 2.0 mmm180 -78.96 -51.22 9.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.094 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.705 ' HB2' HD13 ' A' ' 145' ' ' LEU . 43.2 m80 -54.0 -22.35 10.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.387 -0.821 . . . . 0.0 109.127 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.509 ' CG ' ' CB ' ' A' ' 147' ' ' SER . 14.4 ttmt -64.99 -11.33 37.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.478 -0.764 . . . . 0.0 110.281 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.76 55.63 0.52 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CE2' ' CD2' ' A' ' 90' ' ' HIS . 4.4 m-30 -90.44 -170.15 2.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.306 -1.114 . . . . 0.0 109.661 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.11 -53.35 10.8 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.95 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.5 p-10 -62.06 -30.08 70.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.166 -1.196 . . . . 0.0 109.68 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.9 mtmt 60.62 35.62 19.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 109.942 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.414 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 4.8 m-70 -132.97 -83.98 0.47 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.06 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.668 HD12 ' O ' ' A' ' 90' ' ' HIS . 22.6 mt 60.06 153.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 110.387 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.554 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -152.71 135.09 15.09 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.626 0.727 . . . . 0.0 109.725 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.733 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -72.95 -6.32 44.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.735 -0.603 . . . . 0.0 109.544 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.462 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.8 mm-40 -76.36 -24.07 54.17 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.028 -1.045 . . . . 0.0 109.115 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.554 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 73.0 m-85 -85.95 -26.52 25.46 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.328 -0.858 . . . . 0.0 109.732 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.735 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 4.1 m-85 -50.82 -59.03 4.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 110.278 -179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -54.71 -59.07 11.47 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.289 -179.355 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.5 Cg_exo -47.94 -55.69 3.79 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.712 1.375 . . . . 0.0 110.308 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.934 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.99 -21.42 21.08 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.933 . . . . 0.0 109.652 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.61 -48.31 10.71 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.58 -47.46 85.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -1.164 . . . . 0.0 109.826 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.04 -25.12 65.09 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.689 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.3 tt -69.44 -40.72 77.05 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.688 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.742 HD21 ' HB3' ' A' ' 130' ' ' TRP . 14.8 mt -59.17 -32.78 70.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.228 -0.92 . . . . 0.0 109.677 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.9 p -66.83 -29.8 69.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 109.901 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.853 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -83.33 -38.82 21.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.176 -0.952 . . . . 0.0 109.845 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.614 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.2 mmt -48.45 -46.54 37.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 110.033 -179.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.455 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -47.96 -25.95 1.56 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 -179.633 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.448 ' ND1' ' OE1' ' A' ' 29' ' ' GLU . 18.3 m170 -54.65 -45.78 73.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.065 -1.022 . . . . 0.0 110.029 -179.644 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.46 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 7.0 ttt85 -78.17 -60.37 2.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.202 -0.936 . . . . 0.0 110.033 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.489 HG12 HD11 ' A' ' 17' ' ' ILE . 4.5 pt -104.7 52.36 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.172 -0.955 . . . . 0.0 109.82 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.455 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -63.5 -20.09 63.17 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -91.78 -24.29 25.85 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.446 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 25.1 mttt -100.01 -21.23 15.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.183 . . . . 0.0 109.711 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.433 ' SD ' HD11 ' A' ' 118' ' ' ILE . 5.0 tpt -60.94 98.37 0.07 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.562 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.745 ' OD1' ' HB2' ' A' ' 126' ' ' ALA . 14.5 p-10 -96.36 -174.37 3.04 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.28 -0.887 . . . . 0.0 109.667 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.18 79.81 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.679 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -69.26 -27.21 65.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -0.906 . . . . 0.0 109.355 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.745 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -71.93 -45.41 61.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.597 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 5.0 ptpt -74.54 -27.92 60.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.119 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.469 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -81.88 -36.56 28.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.357 -0.84 . . . . 0.0 109.115 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.466 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -68.7 -47.37 66.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.365 -0.835 . . . . 0.0 109.134 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.965 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.5 m0 -70.13 -25.77 63.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.337 -0.852 . . . . 0.0 108.985 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.597 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.95 -34.88 74.0 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -81.91 -28.78 32.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.282 -0.886 . . . . 0.0 109.423 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -78.59 -47.75 16.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.335 -0.853 . . . . 0.0 109.62 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.689 ' OH ' HD22 ' A' ' 110' ' ' LEU . 4.3 m-85 -49.5 -29.17 6.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.02 61.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.373 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -80.32 -36.48 34.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.479 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.614 HD13 HG23 ' A' ' 66' ' ' ILE . 65.3 mt -66.69 -58.12 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.293 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.406 ' O ' HG12 ' A' ' 142' ' ' ILE . 1.8 p -64.74 -23.73 67.34 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -0.876 . . . . 0.0 109.597 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -73.42 -39.33 51.03 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.18 -31.09 70.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -1.16 . . . . 0.0 109.654 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.917 HD23 ' O ' ' A' ' 141' ' ' LEU . 8.5 tt -73.24 -6.53 46.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.225 -0.922 . . . . 0.0 110.028 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.733 HD12 ' HB2' ' A' ' 100' ' ' ALA . 45.7 mm -88.67 16.59 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 109.936 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.43 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 4.8 t -95.93 -43.08 7.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.62 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -107.94 16.07 36.58 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.705 HD13 ' HB2' ' A' ' 90' ' ' HIS . 11.3 tp -105.92 16.28 25.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.162 -1.199 . . . . 0.0 109.585 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -99.13 62.54 1.28 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.916 -1.115 . . . . 0.0 109.754 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.509 ' CB ' ' CG ' ' A' ' 91' ' ' LYS . 9.2 p . . . . . 0 N--CA 1.493 1.686 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.866 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.735 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.489 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.96 HD21 ' HB3' ' A' ' 132' ' ' ALA . 9.1 mt -152.66 176.42 11.76 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -1.17 . . . . 0.0 111.464 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.527 ' HA ' ' CB ' ' A' ' 7' ' ' ARG . 3.1 p 68.63 -178.71 0.22 Allowed 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 122.46 1.124 . . . . 0.0 111.573 178.691 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.709 ' O ' ' HB2' ' A' ' 5' ' ' ALA . . . 38.51 27.68 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.357 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.72 ' O ' HG23 ' A' ' 9' ' ' VAL . . . 164.51 -62.26 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.456 -0.777 . . . . 0.0 109.106 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.714 ' O ' HG23 ' A' ' 10' ' ' VAL . 28.1 mt-30 -70.05 -26.44 64.02 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.521 -179.138 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.527 ' CB ' ' HA ' ' A' ' 3' ' ' SER . 2.8 tmm_? -77.21 -41.03 42.96 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.188 -1.005 . . . . 0.0 108.829 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -56.76 -29.37 62.53 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 5' ' ' ALA . 14.2 t -81.65 -29.53 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.915 HG12 HG13 ' A' ' 70' ' ' VAL . 53.1 t -76.92 -37.59 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.565 -0.709 . . . . 0.0 109.311 179.611 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.2 -11.4 59.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.323 -0.861 . . . . 0.0 109.937 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -92.67 -34.01 14.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.808 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.0 p -83.58 -15.96 47.17 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.276 -0.89 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.713 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.15 -23.58 24.79 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.119 -0.988 . . . . 0.0 109.483 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.1 mtpt -75.78 -5.36 45.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.811 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.435 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.7 OUTLIER -110.76 -58.83 2.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.053 -1.029 . . . . 0.0 109.592 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.959 HD12 ' CH2' ' A' ' 130' ' ' TRP . 26.5 mt -56.94 -35.12 46.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.699 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.97 34.8 3.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.282 -0.886 . . . . 0.0 109.67 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.14 -72.26 0.56 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.7 p -112.05 -31.01 7.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.221 -1.164 . . . . 0.0 109.618 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.719 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.6 p-10 -76.45 -16.79 59.59 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -0.908 . . . . 0.0 109.792 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.699 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 31.4 t30 60.47 24.96 14.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.228 -0.92 . . . . 0.0 109.554 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.21 38.4 5.69 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.719 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -83.32 -39.36 20.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.636 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.449 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -89.32 17.19 53.42 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.645 HG21 ' CG2' ' A' ' 17' ' ' ILE . 28.5 t -105.96 -40.22 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -1.209 . . . . 0.0 109.378 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.481 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -86.78 -40.14 7.29 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.494 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.0 ptpt -59.87 -30.16 68.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -1.188 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.748 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 8.5 pt-20 -93.19 -22.21 19.19 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.7 t -88.21 -62.38 1.5 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.966 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.513 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 23.0 m-85 -50.54 -35.81 31.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.332 -0.855 . . . . 0.0 110.179 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.702 ' OG1' HG11 ' A' ' 55' ' ' VAL . 18.6 m -53.14 -54.78 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.985 -1.072 . . . . 0.0 109.2 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.79 -43.02 85.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.156 -0.965 . . . . 0.0 108.944 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.657 ' HB2' HD23 ' A' ' 106' ' ' LEU . 90.4 t80 -55.32 -63.26 1.22 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -0.806 . . . . 0.0 109.1 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.782 HD13 HG22 ' A' ' 55' ' ' VAL . 5.7 mt -47.82 -43.89 28.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.435 -0.79 . . . . 0.0 109.71 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.89 -63.43 1.21 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.574 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -59.12 -24.35 62.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 16.5 m80 -118.62 99.12 6.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.288 -0.882 . . . . 0.0 109.648 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -83.88 -19.95 33.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.593 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -70.0 -11.23 60.72 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.256 -0.903 . . . . 0.0 109.895 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.581 ' HE3' HMB1 ' A' ' 148' ' ' HEM . 83.0 mmm -113.34 -21.6 10.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.111 -0.993 . . . . 0.0 109.888 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.494 ' HA ' HD23 ' A' ' 35' ' ' LEU . . . -48.81 -46.56 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.024 -1.047 . . . . 0.0 109.592 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.61 -21.22 61.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.254 -0.904 . . . . 0.0 109.312 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.996 HG13 ' ND2' ' A' ' 95' ' ' ASN . 7.1 t -77.28 -38.48 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.316 -0.865 . . . . 0.0 109.278 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.509 ' CG ' HD21 ' A' ' 35' ' ' LEU . 12.8 m-85 -70.47 -27.61 64.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.85 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 111.96 20.97 6.53 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 6.1 m-85 -119.75 164.88 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.282 -1.128 . . . . 0.0 109.801 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.28 -15.33 20.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.446 -0.784 . . . . 0.0 109.213 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.417 ' O ' ' OD2' ' A' ' 52' ' ' ASP . . . -164.57 -155.3 8.33 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.454 ' O ' HG23 ' A' ' 32' ' ' THR . . . -104.98 -0.21 27.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.438 -1.036 . . . . 0.0 110.079 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.0 t -107.24 51.9 0.73 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.949 -1.094 . . . . 0.0 109.861 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.712 ' OD1' HG23 ' A' ' 55' ' ' VAL . 0.6 OUTLIER -131.23 149.25 73.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.255 -0.903 . . . . 0.0 109.674 179.799 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 10.0 Cg_exo -65.8 -24.31 54.43 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.973 1.512 . . . . 0.0 110.296 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.53 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -48.45 -35.87 16.33 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.782 HG22 HD13 ' A' ' 35' ' ' LEU . 57.5 t -61.26 -35.61 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -1.109 . . . . 0.0 109.445 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.39 -11.26 60.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.34 -31.2 16.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.606 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.764 ' O ' HG23 ' A' ' 62' ' ' VAL . 7.8 mt -88.42 -62.68 1.44 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.973 . . . . 0.0 109.725 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.617 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -50.15 -33.52 22.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -71.81 -43.83 64.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -1.18 . . . . 0.0 109.718 -179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.8 mtpp -74.95 -36.99 62.09 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.764 HG23 ' O ' ' A' ' 58' ' ' LEU . 61.1 t -61.8 -47.65 92.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.819 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.617 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.6 mm? -47.28 -46.31 24.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.16 -0.962 . . . . 0.0 109.899 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -47.44 -48.4 26.59 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.417 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 17.9 tp60 -52.64 -49.69 64.65 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.101 -0.999 . . . . 0.0 109.407 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.907 ' O ' HG23 ' A' ' 70' ' ' VAL . 72.2 mt -58.1 -27.64 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.256 -0.902 . . . . 0.0 109.195 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.557 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.78 -54.88 8.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -60.67 -21.26 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.25 -1.147 . . . . 0.0 109.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.59 -25.15 23.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.915 HG13 HG12 ' A' ' 10' ' ' VAL . 41.4 t -73.08 -11.74 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.248 -0.907 . . . . 0.0 109.731 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -92.36 25.4 2.98 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 109.592 179.977 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.518 ' O ' ' N ' ' A' ' 74' ' ' GLY . 28.0 m-70 -142.68 -75.34 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.525 ' CD2' ' N ' ' A' ' 73' ' ' LEU . 2.9 mm? 51.2 -85.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.711 -0.618 . . . . 0.0 110.297 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.52 -28.05 35.77 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -76.72 63.47 2.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -1.135 . . . . 0.0 109.461 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -69.84 82.67 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.526 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 173.7 -33.27 0.11 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 108.851 -1.699 . . . . 0.0 108.851 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.434 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 11.7 ttpt -109.06 -34.6 6.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 109.472 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.454 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 5.6 tmm? -52.92 -36.28 59.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.279 -0.888 . . . . 0.0 109.55 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.829 HG22 ' HB1' ' A' ' 140' ' ' ALA . 73.0 t -79.58 -18.77 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.693 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.434 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -48.82 -51.43 29.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.788 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.517 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.0 OUTLIER -76.52 -45.36 31.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.467 ' HB2' ' HA ' ' A' ' 80' ' ' VAL . 1.6 mtp -54.78 -53.44 55.18 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.428 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -51.12 -33.05 24.74 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.935 . . . . 0.0 109.202 179.696 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -68.89 -42.99 76.21 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.371 -0.831 . . . . 0.0 109.295 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 82' ' ' GLU . 14.4 t -58.99 -41.45 83.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.133 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -55.77 -48.86 69.26 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 78.1 t -52.71 -40.24 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.247 -1.149 . . . . 0.0 108.901 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -64.28 -50.94 65.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.398 -0.814 . . . . 0.0 109.01 179.273 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.65 ' O ' HD12 ' A' ' 98' ' ' ILE . 25.4 m80 -55.5 -38.7 69.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.314 -0.866 . . . . 0.0 109.316 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.449 ' HA ' ' CB ' ' A' ' 147' ' ' SER . 10.0 ttpp -62.72 -15.8 54.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.304 -0.872 . . . . 0.0 109.982 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -124.06 43.28 1.43 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -88.13 -171.68 3.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.3 -1.118 . . . . 0.0 109.683 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.75 -44.6 7.16 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.996 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.1 p-10 -64.92 -33.22 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -1.134 . . . . 0.0 109.593 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.7 tttt 55.12 20.23 3.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.212 -0.93 . . . . 0.0 109.809 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 8.9 m-70 -129.6 55.84 1.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.33 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.65 HD12 ' O ' ' A' ' 90' ' ' HIS . 73.4 mt -90.32 156.3 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.327 -0.858 . . . . 0.0 110.193 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.534 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 2.7 mptt -143.34 131.6 22.01 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.486 -0.759 . . . . 0.0 109.665 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.754 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -73.25 -9.02 58.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.458 -0.777 . . . . 0.0 109.795 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.6 -23.2 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.567 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 73.7 m-85 -84.9 -15.84 43.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.125 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.759 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.6 m-85 -60.61 -68.75 0.27 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.195 -0.941 . . . . 0.0 110.368 -179.483 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.49 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.8 OUTLIER -44.37 -59.06 4.22 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.403 -0.811 . . . . 0.0 111.096 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.8 Cg_endo -55.06 -55.4 3.22 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.629 1.331 . . . . 0.0 110.034 -179.39 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.901 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -62.78 -18.57 62.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' CE1' ' A' ' 134' ' ' TYR . . . -85.39 -39.85 8.15 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.16 45.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.231 -1.158 . . . . 0.0 109.489 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -21.5 11.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.59 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -67.58 -41.29 84.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.735 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.833 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.6 mt -60.65 -41.44 94.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.143 -0.973 . . . . 0.0 109.562 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.3 t -64.31 -29.94 71.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.852 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.748 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -83.37 -36.34 24.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.195 -0.941 . . . . 0.0 109.641 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.59 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.1 mtt -48.79 -35.89 15.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 110.3 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.439 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.7 OUTLIER -58.42 -23.19 56.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.116 -0.99 . . . . 0.0 109.66 -179.506 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.414 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 1.2 m80 -54.72 -49.14 71.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.133 -0.98 . . . . 0.0 109.56 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.481 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.1 OUTLIER -67.22 -62.61 1.34 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -0.929 . . . . 0.0 109.504 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.522 HG23 HG12 ' A' ' 17' ' ' ILE . 13.9 pt -92.03 47.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.262 -0.899 . . . . 0.0 109.431 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.91 125.47 37.25 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.42 -36.08 4.3 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.484 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.9 mmtp -87.46 -28.45 22.08 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.128 -1.219 . . . . 0.0 109.318 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -68.92 104.2 2.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.356 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.558 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 6.8 p30 -103.38 -170.14 1.74 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.37 -0.831 . . . . 0.0 109.992 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.424 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -62.32 -41.25 98.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.558 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -64.29 -25.15 67.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.747 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -79.07 -46.69 17.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.144 -0.973 . . . . 0.0 109.884 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.507 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.3 ptpt -74.11 -25.65 59.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.097 -1.002 . . . . 0.0 109.461 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.487 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 26.3 t0 -83.73 -43.11 15.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.323 -0.86 . . . . 0.0 109.195 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.475 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -60.98 -46.11 92.06 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.436 -0.79 . . . . 0.0 108.996 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.959 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -70.34 -31.0 68.09 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.54 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -55.89 -25.18 41.47 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.538 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.96 ' HB3' HD21 ' A' ' 2' ' ' LEU . . . -91.4 -32.84 15.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.494 -0.753 . . . . 0.0 109.151 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.839 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -81.59 -63.63 1.35 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.465 -0.772 . . . . 0.0 109.723 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.54 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.84 -25.37 4.41 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.947 . . . . 0.0 109.081 -179.979 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 131' ' ' ALA . . . -77.52 -47.73 18.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -0.9 . . . . 0.0 109.031 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.41 -29.28 62.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.385 -0.822 . . . . 0.0 109.205 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.839 HD12 ' C ' ' A' ' 133' ' ' ALA . 5.4 mt -66.99 -59.65 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.336 -0.852 . . . . 0.0 108.909 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 31.1 p -60.07 -26.54 66.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.556 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -77.55 -25.08 63.8 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.829 ' HB1' HG22 ' A' ' 80' ' ' VAL . . . -73.25 -29.82 63.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -1.12 . . . . 0.0 109.562 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 141' ' ' LEU . 10.4 tt -75.1 -10.76 59.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.913 . . . . 0.0 109.864 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.754 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.5 mm -92.41 37.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.132 -0.98 . . . . 0.0 109.697 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 21.5 m -116.74 -23.29 8.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.679 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.57 -8.49 6.91 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.631 HD13 ' HB2' ' A' ' 90' ' ' HIS . 26.3 tp -72.32 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.073 -1.251 . . . . 0.0 109.558 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.485 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 2.6 mp0 47.3 37.24 5.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.001 -1.062 . . . . 0.0 110.074 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.612 ' OG ' HD11 ' A' ' 145' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.494 1.739 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.817 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.616 ' C1D' HG22 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.626 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.759 HD12 HD12 ' A' ' 73' ' ' LEU . 17.6 mt 52.3 -178.17 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.321 -1.105 . . . . 0.0 109.619 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.3 p -133.86 -168.55 2.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 110.03 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.59 -22.24 40.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.446 -0.784 . . . . 0.0 109.95 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.856 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -93.39 -34.26 13.53 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.916 . . . . 0.0 109.655 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.406 ' O ' HG23 ' A' ' 10' ' ' VAL . 48.3 mt-30 -70.22 -47.14 62.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 109.58 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.54 -29.33 58.75 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.159 -0.963 . . . . 0.0 109.24 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -80.52 -37.79 30.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.371 -0.83 . . . . 0.0 108.86 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.7 t -72.5 -32.22 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.463 -0.773 . . . . 0.0 108.993 179.372 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.806 HG23 ' HB1' ' A' ' 129' ' ' ALA . 55.4 t -71.31 -37.89 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.468 -0.77 . . . . 0.0 109.272 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.62 -13.02 60.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.846 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 t -92.24 -24.27 19.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.139 -0.976 . . . . 0.0 109.961 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.427 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 16.7 p -91.28 -17.75 25.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.196 -0.94 . . . . 0.0 109.976 -179.718 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.744 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -84.35 -19.38 33.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 109.762 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.6 mtpt -83.46 1.83 39.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.998 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -118.04 -54.71 2.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.45 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.93 HD12 ' CH2' ' A' ' 130' ' ' TRP . 81.3 mt -66.51 -33.09 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.275 -0.89 . . . . 0.0 109.467 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.716 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.67 33.08 3.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.575 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.65 -87.84 0.01 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.6 p -101.0 -21.44 15.04 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.671 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 18.0 p-10 -81.63 -23.16 37.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.594 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.716 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 23.5 t30 57.09 29.36 16.41 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.692 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 90.68 38.66 6.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.671 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -80.82 -58.2 3.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.266 -1.138 . . . . 0.0 109.643 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -73.18 -22.2 79.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.881 HG11 HD21 ' A' ' 63' ' ' LEU . 23.5 t -66.04 -29.19 46.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -1.103 . . . . 0.0 109.544 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.444 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -80.11 -56.38 3.27 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.497 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 14.6 ptpt -54.28 -24.95 20.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.177 -1.19 . . . . 0.0 110.175 -179.355 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.658 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 18.8 pt-20 -97.75 -18.43 18.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.99 -1.069 . . . . 0.0 109.899 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.438 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 35.5 t -89.16 -68.84 0.75 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -0.937 . . . . 0.0 109.785 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.591 ' HB3' HG13 ' A' ' 55' ' ' VAL . 12.9 m-85 -48.17 -31.26 5.48 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.21 -0.931 . . . . 0.0 109.83 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.663 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.55 -54.02 46.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.931 . . . . 0.0 109.61 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.441 ' HA ' ' OG ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -60.49 -38.65 84.97 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.877 -179.887 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.674 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.1 t80 -59.11 -52.64 64.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.167 -0.958 . . . . 0.0 109.705 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.64 ' CD1' HG22 ' A' ' 55' ' ' VAL . 4.2 mt -58.86 -48.79 80.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.239 -0.913 . . . . 0.0 109.842 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.663 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 3.3 p -56.0 -52.68 63.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.731 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.424 ' H ' ' HG ' ' A' ' 36' ' ' SER . . . -72.53 -25.13 61.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 0.0 109.713 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.417 ' N ' ' O ' ' A' ' 34' ' ' PHE . 19.7 m80 -120.35 109.04 14.87 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.767 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -89.86 -21.55 22.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.408 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -71.07 -21.15 62.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.336 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.511 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -96.64 -13.87 22.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.885 . . . . 0.0 109.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.02 -64.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.095 -1.003 . . . . 0.0 109.514 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -54.79 -25.23 26.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.277 -0.89 . . . . 0.0 109.369 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.894 HG13 ' OD1' ' A' ' 95' ' ' ASN . 39.0 t -75.97 -43.69 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 41' ' ' MET . 18.1 m-85 -73.35 -18.44 61.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.911 . . . . 0.0 109.67 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.415 ' O ' ' CD1' ' A' ' 47' ' ' PHE . . . 95.03 26.47 12.49 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.498 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 15.1 m-85 -126.9 -177.1 3.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -1.128 . . . . 0.0 109.982 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.99 16.21 7.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.461 -0.774 . . . . 0.0 109.415 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 144.84 -163.42 27.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -79.7 -17.79 52.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.308 -1.113 . . . . 0.0 109.826 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -85.14 49.92 1.84 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.932 . . . . 0.0 109.665 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.32 122.9 15.14 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.611 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -65.83 -25.9 52.67 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.872 1.459 . . . . 0.0 110.077 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.498 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.89 -33.4 43.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.663 HG11 HG23 ' A' ' 32' ' ' THR . 97.6 t -52.01 -33.62 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -1.142 . . . . 0.0 109.298 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.701 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.1 -4.29 34.71 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.289 -0.882 . . . . 0.0 109.578 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -90.18 -36.02 15.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.122 -0.986 . . . . 0.0 109.791 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.727 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.6 mt -83.99 -62.16 1.64 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.032 -1.042 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.444 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.46 -28.36 28.34 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -64.72 -53.67 43.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.062 -1.257 . . . . 0.0 109.756 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.608 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 9.7 mttm -79.56 -43.75 22.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.778 HG21 ' O ' ' A' ' 149' ' ' CMO . 94.8 t -46.8 -58.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.389 -0.819 . . . . 0.0 110.229 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.881 HD21 HG11 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -46.43 -38.84 9.59 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.205 -0.934 . . . . 0.0 109.987 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.608 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.47 -42.15 61.4 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.935 . . . . 0.0 109.521 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 62' ' ' VAL . 13.8 mm-40 -60.67 -42.12 96.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.172 -0.955 . . . . 0.0 109.321 179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.938 ' O ' HG23 ' A' ' 70' ' ' VAL . 88.9 mt -61.13 -33.49 56.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.24 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.547 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.38 -53.66 24.04 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.921 -1.672 . . . . 0.0 108.921 179.621 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.4 t -59.84 -24.24 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.315 -1.109 . . . . 0.0 109.207 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.09 -30.33 22.66 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.408 -0.807 . . . . 0.0 109.578 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.938 HG23 ' O ' ' A' ' 66' ' ' ILE . 48.2 t -63.5 -21.21 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.495 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.08 44.0 1.16 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.179 -0.951 . . . . 0.0 109.874 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.529 ' O ' ' N ' ' A' ' 74' ' ' GLY . 4.3 m-70 -152.15 -84.07 0.08 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.129 -0.982 . . . . 0.0 110.311 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.77 HD22 ' N ' ' A' ' 73' ' ' LEU . 2.6 mm? 44.59 -87.7 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.774 -0.579 . . . . 0.0 110.559 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -48.3 -27.01 5.25 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -106.41 84.11 1.97 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.265 -1.138 . . . . 0.0 109.512 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -89.55 44.36 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.633 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -119.11 -12.71 6.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.51 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 0.0 OUTLIER -130.14 -38.02 1.43 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.07 -1.253 . . . . 0.0 109.876 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 3.1 tmm? -49.78 -44.95 49.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -0.939 . . . . 0.0 109.774 -179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.4 t -73.81 -8.07 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.922 . . . . 0.0 110.071 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.51 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -77.74 -32.09 52.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.989 -1.069 . . . . 0.0 109.712 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.479 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.5 mt-10 -99.34 -41.45 7.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.925 . . . . 0.0 109.639 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.47 ' SD ' HG23 ' A' ' 137' ' ' ILE . 2.4 mtp -62.53 -47.79 82.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.188 -0.945 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.453 ' HG2' ' HB2' ' A' ' 143' ' ' SER . 0.1 OUTLIER -54.96 -35.73 64.58 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.255 -0.903 . . . . 0.0 109.279 179.694 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -64.23 -35.39 80.65 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.229 -0.919 . . . . 0.0 109.266 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 82' ' ' GLU . 28.6 t -55.08 -48.96 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.352 -0.843 . . . . 0.0 109.42 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -51.99 -50.42 44.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.859 HG23 ' HA3' ' A' ' 144' ' ' GLY . 97.0 t -48.68 -25.3 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.327 -1.102 . . . . 0.0 109.596 179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.505 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.2 mmt180 -77.08 -44.67 29.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.179 -0.951 . . . . 0.0 109.127 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.469 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 17.7 m80 -58.78 -19.87 44.7 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.349 -0.845 . . . . 0.0 109.196 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.477 ' HD3' ' HA ' ' A' ' 147' ' ' SER . 25.5 ttpt -68.04 -15.09 63.45 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.419 -0.801 . . . . 0.0 109.851 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.91 50.51 0.81 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.514 ' CD2' HBA1 ' A' ' 148' ' ' HEM . 4.8 m-30 -94.23 -172.41 2.8 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.237 -1.155 . . . . 0.0 109.328 179.707 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.74 -40.3 53.27 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.894 ' OD1' HG13 ' A' ' 44' ' ' VAL . 1.7 t-20 -78.39 -44.68 24.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.464 -1.021 . . . . 0.0 109.001 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 71.93 -54.24 0.68 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.396 -0.815 . . . . 0.0 110.314 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 28.9 m170 -66.69 69.2 0.07 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.974 . . . . 0.0 110.115 -179.551 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.456 ' N ' ' O ' ' A' ' 96' ' ' LYS . 84.5 mt -100.61 161.76 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.93 . . . . 0.0 109.329 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.487 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -136.92 142.54 42.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.139 -0.975 . . . . 0.0 109.726 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.16 -0.41 51.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.878 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.526 ' HG2' ' CD1' ' A' ' 102' ' ' TYR . 7.6 pt-20 -78.74 -28.43 44.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.104 -0.998 . . . . 0.0 109.676 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.526 ' CD1' ' HG2' ' A' ' 101' ' ' GLU . 92.8 m-85 -78.03 -13.52 59.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 109.845 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.899 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -57.9 -64.57 0.86 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.203 -0.936 . . . . 0.0 110.192 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.487 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.3 mt-10 -51.38 -55.87 25.35 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.169 -0.957 . . . . 0.0 110.208 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 33.6 Cg_exo -49.42 -54.27 5.71 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.69 1.363 . . . . 0.0 110.19 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.911 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.1 tm? -57.05 -19.46 19.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.223 -0.923 . . . . 0.0 109.599 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.53 -39.82 20.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.63 -57.14 12.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.243 -1.151 . . . . 0.0 109.614 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.2 m -56.91 -23.23 43.48 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.608 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.698 HD22 ' OH ' ' A' ' 134' ' ' TYR . 4.4 tt -70.38 -43.77 69.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.558 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.622 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.2 mt -57.06 -30.43 64.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.503 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.4 t -66.65 -39.01 88.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.208 -0.933 . . . . 0.0 109.633 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.658 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -75.15 -39.82 60.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.668 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.61 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.2 mmt -48.05 -40.31 22.59 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.203 -0.936 . . . . 0.0 109.874 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -54.11 -24.57 18.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.264 -0.897 . . . . 0.0 109.746 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.406 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -49.65 -53.08 26.36 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.184 -0.947 . . . . 0.0 109.697 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.19 -72.55 0.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.153 -0.967 . . . . 0.0 109.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.628 HG12 HD11 ' A' ' 17' ' ' ILE . 3.1 pt -86.42 56.32 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.916 . . . . 0.0 109.657 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -68.35 -23.69 74.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -94.77 -21.7 25.45 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 59.2 mttt -100.64 -21.47 15.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.627 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.489 ' CA ' HD12 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.16 80.43 0.13 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.327 -0.858 . . . . 0.0 109.632 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.558 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.9 p30 -83.79 -163.93 0.84 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.612 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -71.46 -42.17 68.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.708 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -62.67 -24.02 67.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.18 -52.8 8.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.595 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.557 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.5 ptpt -67.46 -33.2 74.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.918 . . . . 0.0 109.363 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.466 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.0 t70 -73.17 -55.42 6.49 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.413 179.774 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.806 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -51.23 -43.42 61.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.405 -0.809 . . . . 0.0 109.373 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.93 ' CH2' HD12 ' A' ' 17' ' ' ILE . 2.8 m0 -75.74 -29.34 58.85 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.351 -0.843 . . . . 0.0 109.107 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.557 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.07 -27.85 65.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.183 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.31 -26.63 21.02 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.305 -0.872 . . . . 0.0 109.28 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.526 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -79.49 -45.22 19.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.415 -0.803 . . . . 0.0 109.503 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.778 ' HE1' HD13 ' A' ' 66' ' ' ILE . 5.8 m-85 -48.99 -31.61 7.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.08 -36.41 69.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.29 -0.881 . . . . 0.0 109.39 179.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.57 -40.37 29.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.524 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.47 HG23 ' SD ' ' A' ' 83' ' ' MET . 1.9 mp -67.42 -56.68 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.864 . . . . 0.0 109.139 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.6 p -68.26 -26.58 65.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.739 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -71.02 -35.78 64.56 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.48 -21.69 66.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.189 -1.183 . . . . 0.0 109.763 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.899 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.2 tt -82.32 -12.62 57.87 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -0.945 . . . . 0.0 109.944 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 142' ' ' ILE . 36.5 mt -79.61 3.26 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.138 -0.976 . . . . 0.0 110.157 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.453 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 9.5 m -89.92 -45.06 9.48 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.015 -1.053 . . . . 0.0 109.632 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.859 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -82.56 -28.58 38.81 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.493 HD12 ' HA2' ' A' ' 87' ' ' GLY . 0.3 OUTLIER -58.83 -163.54 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -1.072 . . . . 0.0 109.609 179.94 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.488 ' H ' HD23 ' A' ' 145' ' ' LEU . 0.7 OUTLIER 27.92 59.95 0.11 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-O 121.517 0.675 . . . . 0.0 111.789 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.477 ' HA ' ' HD3' ' A' ' 91' ' ' LYS . 21.7 m . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.08 -1.012 . . . . 0.0 109.653 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.889 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.778 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.774 HD21 ' HA ' ' A' ' 133' ' ' ALA . 4.3 mm? -84.92 144.19 28.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.31 -1.112 . . . . 0.0 109.65 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.412 ' OG ' ' CG ' ' A' ' 6' ' ' GLN . 0.7 OUTLIER -88.2 178.23 6.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.573 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -72.39 -18.61 61.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.223 -0.923 . . . . 0.0 109.792 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.82 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -98.87 -40.05 8.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.785 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.467 ' O ' HG23 ' A' ' 10' ' ' VAL . 76.8 mt-30 -62.02 -52.83 62.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.539 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.616 ' HA ' HD12 ' A' ' 73' ' ' LEU . 7.5 ptm180 -50.47 -33.9 22.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.34 179.751 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.468 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 56.6 tp60 -75.57 -46.62 30.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.82 HG23 ' O ' ' A' ' 5' ' ' ALA . 40.7 t -60.54 -34.85 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.178 179.516 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.776 HG12 HG13 ' A' ' 70' ' ' VAL . 69.8 t -64.66 -48.73 83.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.36 -0.838 . . . . 0.0 109.343 179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.35 -11.53 60.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 109.675 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -91.17 -25.51 19.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.135 -0.978 . . . . 0.0 109.717 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 p -98.01 -11.75 22.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.183 -0.948 . . . . 0.0 109.809 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.552 ' CE3' ' HB3' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.8 -28.39 20.48 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.082 -1.011 . . . . 0.0 109.657 -179.882 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -70.76 -15.26 62.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.414 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -99.55 -61.52 1.36 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.644 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.972 HD12 ' CH2' ' A' ' 130' ' ' TRP . 55.8 mt -57.9 -39.13 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.711 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.723 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.64 36.09 2.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.702 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.8 -82.5 0.06 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.0 p -97.93 -26.24 14.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 0.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.651 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 4.2 p30 -80.75 -23.8 39.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.639 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.723 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 27.2 t30 56.92 22.07 6.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.528 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 101.97 23.44 9.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.651 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -69.57 -54.31 14.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 109.619 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.453 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -85.93 10.98 63.59 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.85 HG12 HD11 ' A' ' 63' ' ' LEU . 35.8 t -104.84 -22.66 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.241 . . . . 0.0 109.202 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -98.95 -35.43 4.83 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.454 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 15.0 ptpt -68.88 -27.04 65.44 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.189 -1.183 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.449 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 17.5 pt-20 -100.82 -5.97 25.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 110.087 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.5 t -95.99 -67.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.054 -1.029 . . . . 0.0 109.978 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -47.18 -29.78 2.53 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.206 -0.934 . . . . 0.0 110.149 -179.387 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.548 HG22 ' HB1' ' A' ' 50' ' ' ALA . 0.2 OUTLIER -52.74 -63.25 1.2 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.074 -1.016 . . . . 0.0 109.207 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -50.35 -47.49 55.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.341 -0.849 . . . . 0.0 109.242 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.73 ' CG ' HD23 ' A' ' 106' ' ' LEU . 7.8 t80 -56.46 -51.26 69.1 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.18 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.862 ' CD1' HG22 ' A' ' 55' ' ' VAL . 19.5 mt -58.32 -44.7 88.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.496 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.576 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 0.2 OUTLIER -67.67 -62.95 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.344 -0.848 . . . . 0.0 109.612 179.965 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.8 -24.48 9.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.626 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.4 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 20.3 m80 -125.0 101.74 7.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.299 -0.876 . . . . 0.0 109.738 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -84.51 -17.48 38.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.398 -0.814 . . . . 0.0 109.503 179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -67.87 -16.11 63.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.783 ' HE3' HG11 ' A' ' 44' ' ' VAL . 89.6 mmm -120.04 -15.02 8.82 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 110.019 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.431 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.04 -44.84 41.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.913 -1.117 . . . . 0.0 109.525 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.0 -29.75 60.97 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.322 -0.861 . . . . 0.0 109.26 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.041 HG13 ' ND2' ' A' ' 95' ' ' ASN . 2.4 t -60.89 -27.99 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.342 -0.849 . . . . 0.0 109.173 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.581 ' CE1' HMB2 ' A' ' 148' ' ' HEM . 8.3 m-85 -82.64 -27.8 31.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.103 -0.998 . . . . 0.0 109.683 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.448 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.84 20.26 6.51 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.543 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 3.6 m-85 -117.88 172.84 7.12 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.231 -1.159 . . . . 0.0 109.653 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.6 t -115.28 22.09 13.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.331 -0.856 . . . . 0.0 109.029 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.45 -170.8 28.93 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.576 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -85.86 11.28 11.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -1.168 . . . . 0.0 109.97 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.04 20.3 18.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.994 . . . . 0.0 109.557 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.404 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -101.31 136.42 19.67 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.54 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -68.03 -17.01 45.97 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.916 1.482 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.0 -36.88 61.38 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.862 HG22 ' CD1' ' A' ' 35' ' ' LEU . 61.2 t -51.71 -33.27 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.238 -1.154 . . . . 0.0 109.449 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.66 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.28 -13.77 59.45 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.252 -0.905 . . . . 0.0 109.787 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -90.21 -23.14 21.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.184 -0.947 . . . . 0.0 109.494 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.75 HD21 ' CHA' ' A' ' 148' ' ' HEM . 3.4 mt -90.89 -66.43 0.93 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.902 . . . . 0.0 109.906 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.93 -30.89 38.27 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -1.217 . . . . 0.0 109.479 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.544 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 17.0 mttt -94.34 -38.44 10.98 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.42 -0.8 . . . . 0.0 109.485 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 58' ' ' LEU . 91.4 t -51.43 -57.99 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.38 -0.825 . . . . 0.0 109.794 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.85 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.31 -45.0 24.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.227 -0.921 . . . . 0.0 109.677 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.544 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -47.66 -40.74 20.67 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.687 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 35.2 tp60 -64.79 -41.28 95.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.195 -0.941 . . . . 0.0 109.164 179.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.795 ' O ' HG23 ' A' ' 70' ' ' VAL . 59.4 mt -60.79 -37.31 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -0.843 . . . . 0.0 109.144 179.519 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.76 29.68 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.2 t -58.04 -24.81 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -1.125 . . . . 0.0 109.17 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.0 -34.21 22.4 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.418 -0.801 . . . . 0.0 109.433 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.795 HG23 ' O ' ' A' ' 66' ' ' ILE . 50.7 t -63.95 -19.33 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -0.899 . . . . 0.0 109.425 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 24.1 m -62.2 -41.93 98.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.196 -0.94 . . . . 0.0 109.667 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 71' ' ' SER . 8.7 m-70 -131.02 84.48 2.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.724 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.624 HD11 HG11 ' A' ' 10' ' ' VAL . 42.1 mt -81.64 -46.58 14.16 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 109.6 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.8 -22.64 61.28 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.66 118.38 29.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -1.141 . . . . 0.0 109.65 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.551 ' HB3' HG21 ' A' ' 80' ' ' VAL . 25.1 mt-10 -114.41 49.07 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.62 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -105.84 -19.83 9.92 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.6 tttt -138.59 -45.24 0.49 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -1.181 . . . . 0.0 109.826 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -49.35 -33.12 12.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.947 . . . . 0.0 109.753 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.551 HG21 ' HB3' ' A' ' 76' ' ' GLU . 54.8 t -76.86 -22.51 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.258 -0.901 . . . . 0.0 109.605 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.47 -17.89 61.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.851 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -92.57 -49.84 5.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 109.761 -179.875 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.466 ' HE2' ' O ' ' A' ' 137' ' ' ILE . 95.8 mmm -60.74 -45.91 92.49 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.067 -1.021 . . . . 0.0 109.156 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.796 ' O ' HG23 ' A' ' 88' ' ' VAL . 2.0 mttt -51.73 -31.17 25.34 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.128 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.448 ' O ' ' CG ' ' A' ' 89' ' ' ARG . . . -79.47 -32.02 42.53 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.462 -0.774 . . . . 0.0 108.956 179.164 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 82' ' ' GLU . 45.2 t -69.86 -41.69 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.127 -0.983 . . . . 0.0 109.273 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.49 92.69 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.931 -1.667 . . . . 0.0 108.931 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.796 HG23 ' O ' ' A' ' 84' ' ' LYS . 97.0 t -59.25 -29.4 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -1.191 . . . . 0.0 109.178 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.478 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.9 OUTLIER -76.63 -45.7 28.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -0.871 . . . . 0.0 109.316 179.773 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.798 ' O ' HD12 ' A' ' 98' ' ' ILE . 22.0 m80 -59.18 -20.67 55.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.088 179.428 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.482 ' HG3' ' HA ' ' A' ' 147' ' ' SER . 8.1 ttpt -70.23 -9.54 56.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.89 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.4 54.57 0.55 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.885 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.9 m-30 -88.8 -168.99 2.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -1.167 . . . . 0.0 109.613 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -76.49 -36.46 38.48 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.041 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.7 p-10 -79.67 -24.66 41.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.046 -1.267 . . . . 0.0 110.009 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 ttmm 51.41 26.79 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.153 -0.967 . . . . 0.0 109.499 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.413 ' H ' ' ND2' ' A' ' 95' ' ' ASN . 6.0 m80 -134.28 42.97 2.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.42 -0.8 . . . . 0.0 109.323 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.885 HD11 ' CD2' ' A' ' 93' ' ' TYR . 58.9 mt -86.03 156.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 110.061 -179.633 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.472 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.28 143.69 25.08 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.706 0.765 . . . . 0.0 109.882 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.1 -6.37 56.3 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.717 -0.614 . . . . 0.0 109.622 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.422 ' HG2' ' HB3' ' A' ' 99' ' ' LYS . 15.7 pt-20 -72.95 -28.73 62.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.091 -1.006 . . . . 0.0 109.359 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.54 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 44.8 m-85 -79.93 -20.42 45.72 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.84 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 5.5 m-85 -57.37 -68.13 0.26 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.338 -0.851 . . . . 0.0 110.555 -179.332 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 3.4 mt-10 -43.24 -59.96 2.81 Favored Pre-proline 0 N--CA 1.495 1.808 0 O-C-N 121.516 -0.74 . . . . 0.0 111.016 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 8.8 Cg_endo -55.99 -42.52 65.93 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.732 1.385 . . . . 0.0 110.199 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.737 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.9 tm? -66.75 -27.18 67.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.475 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.36 -38.8 37.8 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.45 -48.42 72.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -1.127 . . . . 0.0 109.539 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.2 m -62.31 -26.46 68.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.548 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.424 HD22 ' CE2' ' A' ' 134' ' ' TYR . 8.3 tt -70.42 -40.22 73.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 109.563 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.938 HD21 ' HB3' ' A' ' 130' ' ' TRP . 13.0 mt -58.96 -32.04 69.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.426 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.53 -27.75 64.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.282 -0.886 . . . . 0.0 109.523 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.421 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -84.18 -35.07 23.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.224 -0.922 . . . . 0.0 109.689 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.661 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.3 mmt -46.93 -50.4 18.95 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.285 -0.884 . . . . 0.0 110.227 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.475 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 8.5 pt-20 -47.23 -24.76 0.78 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 110.276 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 19.8 m170 -53.65 -31.33 47.08 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.709 -1.244 . . . . 0.0 109.651 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -91.89 -68.39 0.8 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.19 -0.944 . . . . 0.0 110.127 -179.655 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.499 HG23 HG12 ' A' ' 17' ' ' ILE . 18.3 pt -78.21 -34.16 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.116 -0.99 . . . . 0.0 109.756 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.475 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . 41.2 -98.73 0.01 OUTLIER Glycine 0 N--CA 1.498 2.794 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.61 -39.46 10.56 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.491 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.6 OUTLIER -73.29 -18.13 61.24 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.044 -1.268 . . . . 0.0 109.919 -179.806 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.449 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -79.45 107.06 11.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 179.571 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.686 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.4 p-10 -111.61 -171.23 1.8 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.926 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.451 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.47 -49.0 79.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.424 -0.798 . . . . 0.0 109.963 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.722 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.83 -20.72 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.516 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -85.44 -55.73 3.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.311 -0.868 . . . . 0.0 109.791 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.451 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -69.69 -24.78 63.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.781 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -80.04 -45.35 18.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.236 -0.915 . . . . 0.0 109.524 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -65.25 -45.89 82.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.391 -0.818 . . . . 0.0 109.391 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.972 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.7 m0 -66.41 -29.4 69.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -0.864 . . . . 0.0 109.34 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.448 ' N ' HD11 ' A' ' 111' ' ' LEU . . . -69.64 -28.06 65.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 108.932 179.327 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.81 -31.72 15.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.44 -0.787 . . . . 0.0 109.359 179.614 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.774 ' HA ' HD21 ' A' ' 2' ' ' LEU . . . -72.06 -39.78 68.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.398 -0.814 . . . . 0.0 109.206 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.424 ' CE2' HD22 ' A' ' 110' ' ' LEU . 5.3 m-30 -52.64 -30.89 34.05 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.342 -0.849 . . . . 0.0 109.064 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.58 -35.07 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.336 -0.852 . . . . 0.0 109.242 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -77.89 -39.07 44.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.33 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.636 HD13 HG23 ' A' ' 66' ' ' ILE . 12.2 mt -65.82 -58.48 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.297 -0.877 . . . . 0.0 109.109 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.429 ' O ' ' HB3' ' A' ' 141' ' ' LEU . 0.1 OUTLIER -68.51 -28.25 66.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -58.38 -52.72 51.09 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.04 -23.28 13.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.259 -1.142 . . . . 0.0 109.535 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.649 HD23 ' O ' ' A' ' 141' ' ' LEU . 10.5 tt -81.73 -18.12 45.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.703 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.714 HG22 ' O ' ' A' ' 142' ' ' ILE . 69.3 mt -89.88 37.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.78 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 60.7 m -117.84 -36.15 3.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.073 -1.017 . . . . 0.0 109.688 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -105.12 -18.01 12.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.443 ' HG ' ' N ' ' A' ' 146' ' ' GLN . 4.9 tp -65.31 -102.47 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.123 -1.221 . . . . 0.0 109.581 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.443 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 1.4 mp0 47.2 28.44 0.99 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.835 -1.166 . . . . 0.0 110.012 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.482 ' HA ' ' HG3' ' A' ' 91' ' ' LYS . 3.1 m . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.95 -1.024 . . . . 0.0 109.589 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.84 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.478 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.411 ' O ' ' O ' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.889 HD11 HD11 ' A' ' 73' ' ' LEU . 12.3 mt 53.81 174.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.277 -1.131 . . . . 0.0 109.644 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.3 p -159.48 -157.88 0.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.183 -0.948 . . . . 0.0 109.964 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.93 -31.79 18.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.539 -0.726 . . . . 0.0 109.408 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.603 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -94.22 -16.43 23.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.343 -0.848 . . . . 0.0 109.61 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 46.9 mt-30 -81.35 -46.86 14.05 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.131 -0.981 . . . . 0.0 109.621 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.453 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -54.84 -31.66 59.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.089 -1.007 . . . . 0.0 109.468 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.453 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 27.7 mm100 -70.78 -37.43 73.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 109.336 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 5' ' ' ALA . 47.3 t -69.71 -29.18 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.931 HG12 HG13 ' A' ' 70' ' ' VAL . 63.8 t -70.73 -43.76 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.309 -0.869 . . . . 0.0 109.291 179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.61 -12.79 60.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.319 -0.863 . . . . 0.0 109.771 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.0 t -91.89 -27.79 17.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 p -90.93 -13.85 32.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.141 -0.974 . . . . 0.0 110.032 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -88.44 -15.07 36.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.068 -1.02 . . . . 0.0 109.865 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.42 -0.58 55.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.947 . . . . 0.0 109.924 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -113.3 -49.67 2.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.034 -1.041 . . . . 0.0 109.602 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.946 HD12 ' CH2' ' A' ' 130' ' ' TRP . 58.5 mt -69.43 -36.19 70.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.251 -0.906 . . . . 0.0 109.575 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.14 33.17 3.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 109.72 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -61.81 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 p -120.39 -36.74 3.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -1.123 . . . . 0.0 109.594 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 2.0 p30 -71.26 -19.15 62.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.261 -0.899 . . . . 0.0 109.665 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.849 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 28.4 t30 57.53 19.65 5.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -0.929 . . . . 0.0 109.635 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.411 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 105.46 19.36 10.58 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.774 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -64.91 -52.39 56.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -1.181 . . . . 0.0 109.596 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.23 -22.73 75.65 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.69 HG21 ' CG2' ' A' ' 17' ' ' ILE . 15.5 t -71.09 -41.01 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -1.086 . . . . 0.0 109.855 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.401 ' HA3' ' C ' ' A' ' 59' ' ' GLY . . . -74.93 -57.19 4.53 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.269 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.482 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 15.8 ptpt -47.39 -31.3 3.93 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.208 -1.172 . . . . 0.0 110.228 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.82 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 23.4 pt-20 -95.79 -17.81 20.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.058 -1.026 . . . . 0.0 109.939 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 29.3 t -83.54 -68.11 0.74 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.948 . . . . 0.0 109.8 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.521 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.8 m-85 -50.32 -32.04 16.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.808 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -51.95 -55.05 22.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.1 -1.0 . . . . 0.0 109.165 179.718 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -57.68 -48.6 79.07 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.32 -0.862 . . . . 0.0 109.268 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.694 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.1 t80 -55.04 -49.05 72.54 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.195 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.712 ' CD1' HG22 ' A' ' 55' ' ' VAL . 23.2 mt -59.83 -41.57 91.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.854 . . . . 0.0 109.725 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.79 -63.34 1.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.935 . . . . 0.0 109.818 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.25 -21.36 48.12 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.203 -0.936 . . . . 0.0 109.886 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.404 ' O ' ' O ' ' A' ' 35' ' ' LEU . 16.9 m80 -126.74 106.71 9.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.922 . . . . 0.0 109.933 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 5.5 m170 -85.88 -20.44 29.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.535 -0.728 . . . . 0.0 109.249 179.292 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -73.05 -20.29 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.248 -0.908 . . . . 0.0 109.098 179.34 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.564 ' HE1' HMB2 ' A' ' 148' ' ' HEM . 0.2 OUTLIER -91.86 -20.43 21.46 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -0.866 . . . . 0.0 109.537 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.444 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.26 -56.48 20.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.302 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.61 63.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.288 -0.882 . . . . 0.0 109.255 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.035 HG13 ' ND2' ' A' ' 95' ' ' ASN . 22.4 t -71.4 -58.45 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.288 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.536 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 39.7 m-85 -57.2 -40.69 77.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.58 35.18 1.1 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.0 m-85 -125.62 169.0 12.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 109.858 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 t -112.34 18.07 18.85 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.351 -0.843 . . . . 0.0 109.372 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.3 -164.05 29.28 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.43 25.31 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -1.155 . . . . 0.0 109.716 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 37.6 m -124.78 31.04 5.77 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.623 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.54 135.45 21.9 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 109.642 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -64.07 -18.21 62.71 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.929 1.489 . . . . 0.0 109.972 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.62 -39.08 94.65 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.808 HG11 HG23 ' A' ' 32' ' ' THR . 65.6 t -52.09 -38.56 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.322 -1.105 . . . . 0.0 109.411 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.01 -12.22 60.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 0.0 109.659 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -92.76 -35.5 13.4 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.972 . . . . 0.0 109.662 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.869 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.9 mt -79.43 -61.16 2.09 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.241 -0.912 . . . . 0.0 109.873 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.864 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -55.61 -36.47 64.8 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.585 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -60.85 -52.63 64.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.09 -1.241 . . . . 0.0 109.365 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.478 ' HB2' ' CGD' ' A' ' 148' ' ' HEM . 16.6 mttt -67.5 -41.99 83.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.308 -0.87 . . . . 0.0 109.183 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.869 HG23 ' O ' ' A' ' 58' ' ' LEU . 63.3 t -56.42 -44.51 80.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.175 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -48.17 -46.07 34.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.416 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -50.65 -49.46 56.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.107 -0.995 . . . . 0.0 109.33 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -52.99 -37.66 61.55 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -0.892 . . . . 0.0 109.088 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.915 ' O ' HG23 ' A' ' 70' ' ' VAL . 34.7 mm -67.87 -35.75 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 109.063 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.56 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.43 -47.22 44.06 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.514 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.559 HG11 ' OE1' ' A' ' 82' ' ' GLU . 43.9 t -62.45 -25.43 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.361 -1.082 . . . . 0.0 109.439 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.83 -30.7 24.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.931 HG13 HG12 ' A' ' 10' ' ' VAL . 53.8 t -62.68 -37.23 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.488 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.2 p -51.39 -69.28 0.12 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.923 . . . . 0.0 109.348 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.444 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 9.0 m-70 -90.82 45.32 1.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 109.192 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.889 HD11 HD11 ' A' ' 2' ' ' LEU . 30.4 tp -86.59 -16.53 36.49 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.244 -0.91 . . . . 0.0 109.526 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.7 -28.35 47.33 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.62 -157.12 0.59 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.327 -1.102 . . . . 0.0 109.543 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -173.36 46.38 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.913 . . . . 0.0 109.64 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -127.22 17.58 6.22 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.581 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 33.0 ttpt -163.25 -46.94 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.052 -1.264 . . . . 0.0 109.87 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.444 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 8.3 tmm? -48.25 -44.08 33.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.129 -0.982 . . . . 0.0 109.473 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.61 HG12 ' HE2' ' A' ' 84' ' ' LYS . 37.9 t -62.01 -24.46 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.857 . . . . 0.0 109.108 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.581 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -64.65 -52.86 55.11 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.266 -0.896 . . . . 0.0 109.23 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.559 ' OE1' HG11 ' A' ' 68' ' ' VAL . 5.8 tt0 -66.91 -46.16 75.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.113 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.472 ' SD ' HG23 ' A' ' 137' ' ' ILE . 1.6 mtp -52.61 -48.91 66.01 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.623 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.61 ' HE2' HG12 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -52.63 -34.22 50.27 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.182 -0.949 . . . . 0.0 108.894 179.389 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -66.58 -15.87 63.75 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.613 ' CG1' HD11 ' A' ' 141' ' ' LEU . 11.3 t -85.81 -32.52 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.033 -1.042 . . . . 0.0 108.624 179.315 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.479 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -71.26 -43.32 55.6 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 179.176 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.422 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 96.3 t -55.65 -25.93 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.38 -1.07 . . . . 0.0 108.62 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.509 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.3 OUTLIER -76.06 -49.53 17.25 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 108.996 179.301 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.866 ' HB2' HD13 ' A' ' 145' ' ' LEU . 24.5 m80 -62.04 -21.71 65.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.379 -0.826 . . . . 0.0 109.01 179.553 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.487 ' HG3' ' CB ' ' A' ' 147' ' ' SER . 0.2 OUTLIER -63.58 -14.13 48.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.396 -0.815 . . . . 0.0 109.972 -179.884 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.47 53.46 0.58 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.509 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.9 m-30 -91.31 -173.2 3.53 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -1.168 . . . . 0.0 109.349 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.45 -25.51 54.0 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 179.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.035 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.2 t30 -82.34 -45.49 14.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.463 -1.022 . . . . 0.0 109.179 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 9.0 ttpt 72.3 -53.75 0.69 Allowed 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.464 -0.773 . . . . 0.0 110.224 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 38.1 m170 -65.61 73.07 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.119 -0.988 . . . . 0.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.462 ' N ' ' O ' ' A' ' 96' ' ' LYS . 48.8 mt -104.81 155.03 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.521 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.53 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.7 mptp? -138.72 149.76 45.43 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.231 -0.918 . . . . 0.0 109.948 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.706 ' HB1' HG12 ' A' ' 142' ' ' ILE . . . -87.45 -18.79 29.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.527 -0.733 . . . . 0.0 109.628 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.459 ' HG2' ' HB3' ' A' ' 99' ' ' LYS . 17.7 pt-20 -67.22 -19.64 65.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.53 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 52.6 m-85 -82.06 -21.41 36.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.249 -0.907 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.842 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 4.5 m-85 -60.42 -64.56 0.91 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.294 -0.879 . . . . 0.0 110.205 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.495 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.77 -58.75 4.2 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.462 -0.774 . . . . 0.0 110.987 -179.328 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.519 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 7.4 Cg_endo -55.06 -47.29 27.26 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 123.63 1.332 . . . . 0.0 110.082 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.878 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -61.75 -22.43 65.39 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.151 -0.968 . . . . 0.0 109.428 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.98 -48.24 11.89 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.79 -51.26 70.75 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 109.595 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 m -58.9 -18.77 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.658 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.769 HD23 ' SD ' ' A' ' 114' ' ' MET . 1.2 tt -75.71 -31.14 59.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.178 -0.951 . . . . 0.0 109.722 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.871 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.2 mt -71.29 -29.03 64.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 0.0 109.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.13 -34.29 70.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.916 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.82 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -80.89 -29.55 35.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.719 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.769 ' SD ' HD23 ' A' ' 110' ' ' LEU . 2.7 mtt -61.72 -34.16 75.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.896 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.448 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -61.49 -17.85 56.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.174 -0.954 . . . . 0.0 109.409 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -57.94 -49.14 77.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.721 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.1 ttt85 -74.25 -65.68 0.82 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.698 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.663 HG12 HD11 ' A' ' 17' ' ' ILE . 7.0 pt -92.31 53.19 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.258 -0.901 . . . . 0.0 109.726 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.448 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.49 -15.12 61.1 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.39 -30.95 6.68 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.71 -26.02 17.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -1.16 . . . . 0.0 109.791 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.423 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -60.19 97.67 0.05 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 -179.903 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.58 HD21 ' HB3' ' A' ' 125' ' ' ALA . 15.7 p-10 -106.42 -171.5 1.91 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.437 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.15 -49.48 77.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.388 -0.82 . . . . 0.0 109.952 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.58 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -58.4 -26.22 62.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.05 -1.031 . . . . 0.0 109.321 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.424 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -76.95 -54.01 7.11 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.231 -0.918 . . . . 0.0 109.849 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.498 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 6.3 ptmm? -70.9 -29.29 65.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.058 -1.026 . . . . 0.0 109.792 -179.75 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -77.85 -42.03 34.91 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -0.93 . . . . 0.0 109.607 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.456 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -65.53 -50.16 66.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.407 179.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.946 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.0 m0 -64.55 -28.77 69.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.299 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.23 -28.81 69.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.188 -0.945 . . . . 0.0 109.064 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.503 ' HB1' ' H ' ' A' ' 2' ' ' LEU . . . -90.58 -24.32 20.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.395 -0.816 . . . . 0.0 109.373 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.554 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -77.47 -62.8 1.54 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.355 -0.841 . . . . 0.0 109.685 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.568 ' CE1' ' CG2' ' A' ' 66' ' ' ILE . 16.2 m-30 -52.0 -26.19 10.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.228 -0.92 . . . . 0.0 109.577 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.67 -44.85 69.64 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.208 -0.932 . . . . 0.0 108.904 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -75.41 -32.27 60.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.407 -0.808 . . . . 0.0 109.281 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.554 HG12 ' HB1' ' A' ' 69' ' ' ALA . 49.1 mt -67.46 -59.29 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.321 -0.862 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.442 ' O ' ' CD1' ' A' ' 142' ' ' ILE . 2.4 p -67.25 -13.72 62.24 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.312 -0.868 . . . . 0.0 109.805 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -84.96 -21.74 54.69 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.453 ' O ' ' NZ ' ' A' ' 84' ' ' LYS . . . -86.24 -10.36 54.78 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 110.054 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.881 HD23 ' O ' ' A' ' 141' ' ' LEU . 3.0 tt -89.14 17.24 6.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.029 -1.045 . . . . 0.0 109.882 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.706 HG12 ' HB1' ' A' ' 100' ' ' ALA . 1.9 mp -107.52 7.15 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.099 -1.001 . . . . 0.0 110.121 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.401 ' HB2' ' NZ ' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -96.77 -34.48 11.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.945 -1.097 . . . . 0.0 109.63 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.83 11.1 27.52 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.866 HD13 ' HB2' ' A' ' 90' ' ' HIS . 11.4 tp -98.43 -11.66 22.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.106 -1.232 . . . . 0.0 109.863 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -98.34 62.21 1.46 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.044 -1.035 . . . . 0.0 109.725 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.487 ' CB ' ' HG3' ' A' ' 91' ' ' LYS . 2.7 m . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.696 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.842 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.504 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.435 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.463 HD21 ' HA ' ' A' ' 133' ' ' ALA . 4.3 mm? 57.96 160.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.521 -0.987 . . . . 0.0 109.747 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -141.68 168.05 20.68 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.154 -0.966 . . . . 0.0 109.876 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -64.63 -28.16 69.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.365 -0.835 . . . . 0.0 109.601 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.552 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -82.21 -42.25 19.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.596 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.427 ' O ' HG23 ' A' ' 10' ' ' VAL . 42.8 mt-30 -64.34 -44.57 91.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.219 -0.926 . . . . 0.0 109.69 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.478 ' NH1' ' HA3' ' A' ' 74' ' ' GLY . 73.7 mtp180 -48.68 -50.55 32.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.512 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -59.0 -48.38 81.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 0.0 109.057 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.711 HG11 ' O ' ' A' ' 125' ' ' ALA . 48.6 t -59.83 -36.11 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 0.0 109.145 179.517 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 1.058 HG12 HG13 ' A' ' 70' ' ' VAL . 65.7 t -72.14 -46.47 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.36 -0.837 . . . . 0.0 109.116 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.03 -18.01 61.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.53 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.8 t -87.12 -25.44 24.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.2 p -91.08 -17.19 26.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.851 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.02 -15.67 37.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.923 . . . . 0.0 109.841 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -84.45 -14.34 49.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.113 -0.992 . . . . 0.0 109.596 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.452 ' OD1' HG22 ' A' ' 118' ' ' ILE . 1.8 t70 -98.84 -51.25 3.94 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.156 -0.965 . . . . 0.0 109.614 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.956 HD12 ' CH2' ' A' ' 130' ' ' TRP . 62.2 mt -69.11 -36.41 73.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.249 -0.907 . . . . 0.0 109.585 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.855 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.27 33.16 3.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.692 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.2 -81.75 0.05 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.8 p -102.04 -17.49 16.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -1.149 . . . . 0.0 109.725 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.84 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 5.5 p-10 -89.02 -19.65 25.38 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.218 -0.926 . . . . 0.0 109.656 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.855 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.0 t30 59.32 24.57 13.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.238 -0.914 . . . . 0.0 109.674 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.94 22.69 14.93 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.027 -1.629 . . . . 0.0 109.027 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.84 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -71.12 -43.63 67.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.295 -1.12 . . . . 0.0 109.71 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.433 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.91 22.84 20.04 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.65 ' CG1' HD21 ' A' ' 110' ' ' LEU . 16.9 t -115.14 -34.23 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -1.194 . . . . 0.0 109.057 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.477 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -92.57 -39.39 5.31 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.473 ' HB2' ' CB ' ' A' ' 56' ' ' ALA . 2.5 ptmt -63.85 -30.01 71.14 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -1.225 . . . . 0.0 109.381 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.661 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 6.5 pt-20 -92.59 -22.2 19.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.442 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 37.8 t -85.47 -51.44 6.52 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.294 -0.879 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.696 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.7 m-85 -53.63 -32.27 50.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.668 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 16.6 m -62.36 -28.38 69.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.968 . . . . 0.0 109.222 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.3 mmtt -81.65 -40.11 23.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.897 ' CG ' HD23 ' A' ' 106' ' ' LEU . 1.5 t80 -65.84 -55.55 16.51 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.265 -0.897 . . . . 0.0 109.362 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.755 ' CD1' HG22 ' A' ' 55' ' ' VAL . 25.3 mt -50.08 -44.62 52.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 0.0 109.722 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.518 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 40.1 p -66.36 -68.29 0.38 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.181 -0.949 . . . . 0.0 109.647 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.434 ' H ' ' HG ' ' A' ' 36' ' ' SER . . . -52.5 -27.17 15.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.403 ' N ' ' O ' ' A' ' 34' ' ' PHE . 18.5 m80 -120.06 101.41 7.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -0.86 . . . . 0.0 109.756 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -83.63 -19.01 36.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.404 -0.81 . . . . 0.0 109.371 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -72.51 -13.02 61.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.597 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.496 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 0.2 OUTLIER -105.6 -14.94 15.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.938 -179.826 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.06 -65.23 0.61 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.005 -1.06 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.42 -20.91 48.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.035 HG13 ' ND2' ' A' ' 95' ' ' ASN . 38.7 t -77.95 -39.0 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.288 -0.883 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.533 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.3 m-85 -74.39 -21.65 59.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.231 -0.918 . . . . 0.0 109.531 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.92 25.21 7.28 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.533 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.7 m-85 -123.76 175.85 6.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -1.112 . . . . 0.0 109.802 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.57 18.4 15.04 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.392 -0.817 . . . . 0.0 109.352 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 147.97 -163.87 28.87 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.518 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -93.09 31.8 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.64 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.1 t -130.46 25.58 5.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.629 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.04 138.18 20.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -66.67 -22.77 49.97 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.994 1.523 . . . . 0.0 109.976 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.508 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.97 -31.67 58.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.755 HG22 ' CD1' ' A' ' 35' ' ' LEU . 92.9 t -54.19 -35.9 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.22 -1.164 . . . . 0.0 109.379 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.473 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . . . -78.53 -5.16 51.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 0.0 109.809 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.417 ' OD2' ' HA2' ' A' ' 54' ' ' GLY . 37.0 m-20 -93.55 -27.45 16.62 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.03 -1.044 . . . . 0.0 109.558 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.862 ' O ' HG23 ' A' ' 62' ' ' VAL . 6.4 mt -88.13 -63.97 1.22 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.073 -1.017 . . . . 0.0 109.354 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.477 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -51.19 -37.07 37.27 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -67.32 -34.34 77.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.859 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 0.0 OUTLIER -87.06 -34.49 19.15 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 109.785 -179.82 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.862 HG23 ' O ' ' A' ' 58' ' ' LEU . 24.4 t -67.24 -47.46 81.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.935 . . . . 0.0 109.719 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.8 mm? -47.89 -46.99 32.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.79 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.78 -48.08 20.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.257 -0.902 . . . . 0.0 109.973 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -55.4 -53.3 58.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.111 -0.993 . . . . 0.0 109.42 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 1.007 ' O ' HG23 ' A' ' 70' ' ' VAL . 52.2 mt -51.77 -38.47 22.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.362 -0.836 . . . . 0.0 109.176 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.574 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.06 -55.69 28.84 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.773 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.465 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 98.9 t -59.94 -29.2 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -1.126 . . . . 0.0 109.758 -179.592 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.53 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.76 -10.64 57.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 110.075 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.058 HG13 HG12 ' A' ' 10' ' ' VAL . 42.1 t -71.53 -42.32 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.012 -1.055 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.31 -12.49 59.96 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.056 -1.027 . . . . 0.0 110.032 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.483 ' N ' ' ND1' ' A' ' 72' ' ' HIS . 9.0 m80 -110.99 52.6 0.73 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.145 -0.972 . . . . 0.0 109.998 -179.306 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.537 ' CD1' HG11 ' A' ' 10' ' ' VAL . 90.0 mt -102.7 -35.14 8.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.936 . . . . 0.0 109.168 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.478 ' HA3' ' NH1' ' A' ' 7' ' ' ARG . . . -74.68 -48.05 13.75 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.732 -1.747 . . . . 0.0 108.732 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -136.51 -131.68 0.14 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.475 -1.015 . . . . 0.0 108.907 179.432 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.453 ' HB3' ' HB3' ' A' ' 72' ' ' HIS . 1.4 mt-10 50.75 31.35 5.84 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 120.961 -1.087 . . . . 0.0 108.8 -179.69 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.414 ' O ' ' HB ' ' A' ' 80' ' ' VAL . . . -47.59 -26.04 3.6 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 25.5 ttpt -55.44 -34.98 64.94 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.585 -0.95 . . . . 0.0 108.874 178.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.438 ' HG2' ' HB3' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -57.46 -29.08 63.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.156 -0.965 . . . . 0.0 108.884 179.551 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.414 ' HB ' ' O ' ' A' ' 77' ' ' GLY . 57.7 t -60.48 -30.51 46.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.364 -0.835 . . . . 0.0 108.747 179.236 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.77 -42.09 97.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.355 -0.841 . . . . 0.0 108.864 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.43 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.6 OUTLIER -61.59 -53.06 61.26 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.368 -0.833 . . . . 0.0 108.931 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 80.5 mmm -57.72 -40.41 79.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.278 -0.888 . . . . 0.0 108.829 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.88 -35.73 46.19 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.243 -0.911 . . . . 0.0 108.606 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.426 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -74.18 -36.06 64.03 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG12 HD11 ' A' ' 141' ' ' LEU . 49.0 t -56.92 -43.89 81.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.306 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.498 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -67.21 -51.38 38.78 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 179.173 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.559 HG23 ' HA3' ' A' ' 144' ' ' GLY . 53.1 t -58.76 -22.39 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.497 -1.002 . . . . 0.0 109.197 179.234 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.7 mmm180 -75.41 -41.59 55.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 109.13 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.539 ' HA ' ' CG ' ' A' ' 93' ' ' TYR . 4.8 m80 -60.31 -28.74 68.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.087 179.335 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.515 ' HG3' ' HA ' ' A' ' 147' ' ' SER . 2.0 ttmt -52.44 -26.28 12.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 110.308 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -130.23 45.28 1.15 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.586 -1.292 . . . . 0.0 110.132 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.539 ' CG ' ' HA ' ' A' ' 90' ' ' HIS . 3.2 m-30 -86.01 -170.7 3.22 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.081 -1.246 . . . . 0.0 109.503 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.5 -48.15 45.88 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.035 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -72.95 -44.69 60.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.472 -1.017 . . . . 0.0 109.163 179.777 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.477 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 6.4 tttp 72.55 -54.1 0.69 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.354 -0.841 . . . . 0.0 110.145 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -62.91 78.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.188 -0.945 . . . . 0.0 109.871 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.454 ' N ' ' O ' ' A' ' 96' ' ' LYS . 71.4 mt -113.46 163.27 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.125 -0.984 . . . . 0.0 109.69 -179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.443 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -140.86 135.38 31.3 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.791 179.784 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.67 ' HB1' HG12 ' A' ' 142' ' ' ILE . . . -79.14 1.29 24.9 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.275 -0.89 . . . . 0.0 109.84 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.525 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -80.45 -26.43 38.34 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 109.545 179.88 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.525 ' CD1' ' HG3' ' A' ' 101' ' ' GLU . 93.3 m-85 -78.03 -10.33 59.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.185 -0.947 . . . . 0.0 109.703 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.946 ' CE2' HD22 ' A' ' 141' ' ' LEU . 6.5 m-85 -62.51 -60.71 3.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 110.066 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.0 mt-10 -52.54 -55.72 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.203 -0.936 . . . . 0.0 110.004 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.97 -62.42 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.69 1.363 . . . . 0.0 109.768 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.954 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.83 -23.38 30.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.36 -0.838 . . . . 0.0 109.314 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.2 -48.17 9.97 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.41 -33.53 74.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.137 -1.213 . . . . 0.0 109.585 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.73 -27.86 63.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.216 -0.928 . . . . 0.0 109.5 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 1.008 HD22 ' OH ' ' A' ' 134' ' ' TYR . 2.2 tt -69.67 -35.6 75.29 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.818 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.6 mt -59.73 -34.17 72.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 t -68.72 -33.03 73.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.669 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.661 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -76.37 -39.93 52.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.635 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.498 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 4.2 mtt -50.06 -38.58 38.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.17 -22.52 6.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.194 -0.941 . . . . 0.0 109.561 179.779 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.424 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -57.52 -47.75 81.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.4 ttt85 -73.06 -61.93 1.64 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.723 HD11 ' SD ' ' A' ' 122' ' ' MET . 14.6 pt -97.27 55.88 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.331 -0.855 . . . . 0.0 109.63 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -62.17 -14.44 46.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -107.73 -27.44 5.18 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 6.2 mttm -93.92 -13.44 27.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -1.212 . . . . 0.0 110.146 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.723 ' SD ' HD11 ' A' ' 118' ' ' ILE . 4.0 tpt -71.99 98.23 2.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.509 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.649 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 4.0 p30 -104.6 169.16 8.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.447 -0.783 . . . . 0.0 109.514 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -49.16 -51.75 30.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.25 -0.906 . . . . 0.0 109.625 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.711 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -53.03 -26.72 16.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -0.931 . . . . 0.0 109.441 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -75.69 -58.01 3.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.566 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.564 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.1 ptpt -63.68 -29.29 70.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.147 -0.97 . . . . 0.0 109.286 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.47 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 43.0 t0 -77.32 -43.04 34.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.411 -0.806 . . . . 0.0 109.407 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.767 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -65.34 -39.61 92.59 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 109.212 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.956 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.4 m0 -77.52 -28.32 52.01 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.353 -0.842 . . . . 0.0 108.986 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.564 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -66.34 -30.29 70.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.323 -0.861 . . . . 0.0 109.026 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.439 ' O ' HD21 ' A' ' 2' ' ' LEU . . . -86.45 -34.06 20.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.393 -0.817 . . . . 0.0 109.167 179.594 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.463 ' HA ' HD21 ' A' ' 2' ' ' LEU . . . -74.07 -36.78 64.34 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.441 -0.787 . . . . 0.0 109.13 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 1.008 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.9 OUTLIER -57.65 -23.74 52.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.386 -0.821 . . . . 0.0 109.39 179.728 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.4 -32.01 42.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.547 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -80.86 -35.38 32.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.599 HD13 HG23 ' A' ' 66' ' ' ILE . 45.5 mt -74.62 -54.21 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.206 -0.934 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 12.2 p -71.0 -40.98 71.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 109.577 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.496 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -57.49 -47.53 87.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.86 -26.27 9.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.244 -1.151 . . . . 0.0 109.586 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.946 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.5 tt -84.98 -18.62 33.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.773 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.67 HG12 ' HB1' ' A' ' 100' ' ' ALA . 76.5 mt -83.04 7.0 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 110.108 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.1 m -101.81 -27.6 12.92 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.056 -1.028 . . . . 0.0 109.62 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.559 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -100.07 -25.03 9.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.526 HD13 HD21 ' A' ' 141' ' ' LEU . 0.5 OUTLIER -63.85 -142.12 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.287 -1.125 . . . . 0.0 109.561 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.484 ' H ' HD23 ' A' ' 145' ' ' LEU . 3.3 mt-30 55.73 53.67 9.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.141 -0.974 . . . . 0.0 110.283 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.515 ' HA ' ' HG3' ' A' ' 91' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.016 -1.052 . . . . 0.0 109.607 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.854 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.65 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.412 ' C ' HD22 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.573 ' N ' HD22 ' A' ' 2' ' ' LEU . 4.4 mm? -95.21 166.96 11.65 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.264 -1.139 . . . . 0.0 109.71 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.434 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -99.49 167.39 10.64 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 109.638 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.29 -22.91 65.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.287 -0.883 . . . . 0.0 109.667 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.956 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -88.58 -48.08 7.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.553 ' O ' HG23 ' A' ' 10' ' ' VAL . 96.4 mt-30 -66.62 -54.02 27.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.794 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.489 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 1.2 ttp180 -50.06 -32.44 15.57 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.207 -0.933 . . . . 0.0 109.571 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 30.9 mm-40 -75.83 -43.85 43.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.332 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.956 HG23 ' O ' ' A' ' 5' ' ' ALA . 24.5 t -61.67 -32.8 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.93 HG12 HG13 ' A' ' 70' ' ' VAL . 91.6 t -62.18 -45.63 98.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.4 179.698 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.6 -15.24 60.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 0.0 109.686 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -84.34 -24.04 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 109.694 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 35.5 p -100.5 -12.54 19.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.868 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.77 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -89.83 -27.65 19.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.102 -0.999 . . . . 0.0 109.81 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.7 mtpp -74.74 -9.87 58.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.167 -0.958 . . . . 0.0 109.708 179.592 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.582 ' HB3' HG21 ' A' ' 118' ' ' ILE . 0.3 OUTLIER -102.31 -61.29 1.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.59 179.925 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.947 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.5 mt -57.74 -41.1 78.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 109.625 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.795 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -101.39 34.48 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.75 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.69 -69.11 1.32 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 p -113.94 -25.3 8.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 109.518 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 17.7 p-10 -80.65 -19.3 45.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.679 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.795 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 20.3 t30 60.32 21.34 10.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.262 -0.899 . . . . 0.0 109.641 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.81 20.39 31.47 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -65.5 -50.88 63.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.218 -1.166 . . . . 0.0 109.532 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.94 -5.0 86.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.695 HG21 ' CG2' ' A' ' 17' ' ' ILE . 43.5 t -87.47 -33.08 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.996 -1.296 . . . . 0.0 109.724 -179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.97 -41.01 9.87 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.469 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.3 ptpt -63.67 -31.87 73.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -1.18 . . . . 0.0 109.826 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.45 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 15.8 pt-20 -89.58 -14.71 34.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.167 -0.958 . . . . 0.0 110.083 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.674 ' SG ' HD12 ' A' ' 110' ' ' LEU . 42.2 t -91.58 -63.66 1.22 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.137 -0.977 . . . . 0.0 109.999 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.518 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 14.3 m-85 -54.19 -37.34 64.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.226 -0.922 . . . . 0.0 109.907 -179.53 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.807 ' OG1' HG11 ' A' ' 55' ' ' VAL . 8.7 m -53.18 -32.88 50.15 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.051 -1.031 . . . . 0.0 108.907 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.435 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 3.9 mmtt -76.14 -47.48 24.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.34 -0.85 . . . . 0.0 109.067 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.574 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.1 t80 -61.41 -49.64 76.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.854 ' CD1' HG22 ' A' ' 55' ' ' VAL . 70.2 mt -54.83 -44.22 73.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.129 -0.982 . . . . 0.0 109.401 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.532 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 82.7 p -73.48 -66.09 0.74 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.366 -0.834 . . . . 0.0 109.982 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.456 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -49.61 -30.08 8.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.205 -0.934 . . . . 0.0 109.702 -179.724 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 25.9 m80 -123.63 110.12 14.6 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.264 -0.898 . . . . 0.0 109.785 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -88.93 -18.66 27.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.502 -0.748 . . . . 0.0 109.31 179.444 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -66.51 -21.1 66.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.264 -0.897 . . . . 0.0 109.227 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.536 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 88.6 mmm -107.91 -23.94 11.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 109.75 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.37 -34.29 15.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.865 -1.147 . . . . 0.0 109.136 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.67 -36.75 70.73 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.354 -0.841 . . . . 0.0 109.118 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.87 HG13 ' OD1' ' A' ' 95' ' ' ASN . 20.4 t -58.41 -63.7 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.034 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.613 ' CE1' ' C1B' ' A' ' 148' ' ' HEM . 84.4 m-85 -56.42 -27.59 56.97 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.319 -0.863 . . . . 0.0 109.1 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 42' ' ' ALA . . . 108.99 -138.45 14.76 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 1.7 m-85 61.04 170.65 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.105 -1.232 . . . . 0.0 109.83 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.4 t -115.01 25.79 10.63 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.67 -163.94 27.51 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.532 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -89.25 16.36 7.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.165 -1.197 . . . . 0.0 109.901 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.99 35.29 4.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.116 -0.99 . . . . 0.0 109.691 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.463 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 2.8 t70 -114.43 137.37 22.58 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.616 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -62.75 -24.46 74.65 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.92 1.484 . . . . 0.0 110.067 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.538 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -40.7 47.22 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.854 HG22 ' CD1' ' A' ' 35' ' ' LEU . 67.3 t -49.95 -34.03 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -1.143 . . . . 0.0 109.474 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.514 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -75.72 -20.66 58.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.777 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -86.37 -46.81 9.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.639 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.774 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.9 OUTLIER -64.59 -62.76 1.39 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.204 -0.935 . . . . 0.0 109.581 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.518 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.97 -47.44 40.14 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.514 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -57.41 -40.21 77.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -1.185 . . . . 0.0 109.587 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -74.55 -24.37 58.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.774 HG23 ' O ' ' A' ' 58' ' ' LEU . 51.2 t -81.9 -49.14 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.901 . . . . 0.0 109.641 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.8 HD21 HD11 ' A' ' 110' ' ' LEU . 2.5 mm? -48.15 -46.6 34.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.926 . . . . 0.0 109.751 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.8 -50.86 59.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.256 -0.902 . . . . 0.0 109.821 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 33.5 tp60 -48.75 -51.25 29.97 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.087 -1.008 . . . . 0.0 109.577 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.937 ' O ' HG23 ' A' ' 70' ' ' VAL . 96.7 mt -56.46 -30.97 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.223 -0.923 . . . . 0.0 109.043 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.565 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -68.66 -56.9 8.71 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.8 t -57.8 -20.71 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.247 -1.149 . . . . 0.0 109.243 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.02 -34.1 18.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.675 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.937 HG23 ' O ' ' A' ' 66' ' ' ILE . 55.1 t -60.84 -15.89 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.202 -0.936 . . . . 0.0 109.887 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.501 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 23.9 m -91.55 16.14 11.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.182 -0.949 . . . . 0.0 110.29 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.9 m-70 -160.95 40.82 0.16 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.926 -1.109 . . . . 0.0 110.37 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.871 HD11 HG11 ' A' ' 10' ' ' VAL . 22.7 mt -68.69 -37.67 79.72 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.013 -1.055 . . . . 0.0 109.479 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.63 -26.22 36.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -103.64 96.64 6.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -1.112 . . . . 0.0 109.583 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.83 33.47 1.67 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.518 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -82.35 -24.97 52.93 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.466 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 5.2 ttpt -133.14 -37.62 0.98 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.251 -1.147 . . . . 0.0 109.967 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.46 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 14.7 ttp -47.84 -48.19 31.06 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.19 -0.944 . . . . 0.0 109.694 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.45 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.5 t -70.39 -23.1 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.222 -0.924 . . . . 0.0 109.284 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -70.76 -37.03 73.37 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.214 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.443 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.0 OUTLIER -81.39 -49.12 11.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.264 179.681 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.564 ' CE ' HD12 ' A' ' 141' ' ' LEU . 3.1 mtp -59.47 -46.17 89.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.233 -0.917 . . . . 0.0 109.103 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.659 ' O ' HG23 ' A' ' 88' ' ' VAL . 3.8 tptp -53.49 -33.4 54.2 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 108.915 179.426 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.423 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -70.9 -33.43 70.55 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.401 -0.812 . . . . 0.0 109.248 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.723 ' CG1' HD11 ' A' ' 141' ' ' LEU . 44.4 t -62.66 -52.25 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 109.237 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -52.35 -42.55 56.71 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 84' ' ' LYS . 95.7 t -51.8 -26.6 7.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.346 -1.091 . . . . 0.0 109.231 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.444 ' HB2' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -80.91 -24.76 38.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.273 -0.892 . . . . 0.0 108.848 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.738 ' O ' HD12 ' A' ' 98' ' ' ILE . 41.4 m80 -82.1 -4.67 57.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.528 -0.732 . . . . 0.0 109.894 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HD2' ' HA ' ' A' ' 88' ' ' VAL . 8.9 ptmm? -81.8 -8.64 59.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.796 -1.19 . . . . 0.0 110.357 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -164.33 59.42 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.153 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.755 ' HD2' HD11 ' A' ' 98' ' ' ILE . 0.9 OUTLIER -84.21 -163.5 0.8 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.267 . . . . 0.0 109.25 179.021 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.9 -26.48 74.31 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 -179.328 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.917 ' H ' HD21 ' A' ' 95' ' ' ASN . 0.0 OUTLIER -91.79 -32.88 15.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.258 . . . . 0.0 109.933 -179.668 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 56.85 30.93 18.72 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.129 -0.982 . . . . 0.0 109.649 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 3.9 m-70 -137.44 47.44 2.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.159 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.755 HD11 ' HD2' ' A' ' 93' ' ' TYR . 59.7 mt -89.9 159.78 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.286 -0.884 . . . . 0.0 110.576 -179.172 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.494 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -152.27 142.17 22.08 Favored 'General case' 0 N--CA 1.487 1.424 0 CA-C-O 121.636 0.732 . . . . 0.0 109.684 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.749 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -78.98 -3.02 42.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.647 -0.658 . . . . 0.0 109.62 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -73.11 -33.19 65.42 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.975 -1.078 . . . . 0.0 109.488 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.564 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 85.9 m-85 -78.46 -15.58 58.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.244 -0.91 . . . . 0.0 110.125 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.764 ' CE2' HMC1 ' A' ' 148' ' ' HEM . 4.6 m-85 -59.66 -63.4 1.31 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.163 -0.961 . . . . 0.0 110.248 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.484 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.4 mt-10 -45.49 -58.43 5.95 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.427 -0.796 . . . . 0.0 110.797 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.564 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.2 Cg_endo -59.99 -46.1 20.89 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.748 1.394 . . . . 0.0 109.923 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.919 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -67.11 -20.02 65.72 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 109.25 179.709 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -84.47 -47.38 5.45 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.55 -28.26 66.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -1.114 . . . . 0.0 109.354 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.89 -34.74 69.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.3 -0.875 . . . . 0.0 109.482 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.977 HD13 ' OH ' ' A' ' 134' ' ' TYR . 2.5 tt -65.38 -34.43 78.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.198 -0.938 . . . . 0.0 109.425 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.684 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.2 mt -58.51 -35.48 72.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.097 -1.002 . . . . 0.0 109.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.421 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 21.2 t -70.09 -26.31 63.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.429 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.502 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.93 -33.15 21.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.679 ' SD ' HD23 ' A' ' 110' ' ' LEU . 0.8 OUTLIER -53.87 -44.26 70.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.995 -179.675 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.452 ' O ' ' N ' ' A' ' 119' ' ' GLY . 8.1 pt-20 -51.77 -23.01 4.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.23 -0.919 . . . . 0.0 109.818 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.502 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 20.9 m170 -48.97 -41.44 34.17 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.165 -0.959 . . . . 0.0 109.71 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.3 ttt85 -83.48 -55.77 4.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.432 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.582 HG21 ' HB3' ' A' ' 16' ' ' ASP . 3.9 pt -106.64 59.23 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.302 -0.874 . . . . 0.0 109.558 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -67.48 -29.29 73.94 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.75 -18.2 56.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.1 mttt -105.04 -20.36 13.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.067 -1.255 . . . . 0.0 110.102 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.412 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -73.01 80.99 1.21 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.421 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.541 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.2 p30 -82.29 -162.17 0.53 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -0.853 . . . . 0.0 109.706 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.41 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -69.13 -43.13 74.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.469 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.541 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -60.76 -32.25 71.56 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.171 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -68.42 -53.03 26.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.462 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.473 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.3 ptpt -70.45 -29.03 65.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.193 -0.942 . . . . 0.0 109.379 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.473 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 24.2 t0 -80.42 -40.72 25.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.329 -0.857 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -61.66 -42.91 99.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.947 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.2 m0 -75.4 -34.24 61.04 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.3 -0.875 . . . . 0.0 108.846 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.43 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -55.85 -23.48 31.07 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.163 -0.961 . . . . 0.0 108.764 178.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -92.39 -46.28 7.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.43 -0.794 . . . . 0.0 109.308 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.34 -54.08 10.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.263 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.977 ' OH ' HD13 ' A' ' 110' ' ' LEU . 1.3 t80 -49.78 -30.46 9.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.215 179.608 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -74.61 -38.33 62.6 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.309 -0.869 . . . . 0.0 108.877 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.38 -31.69 48.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.399 -0.813 . . . . 0.0 109.27 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.73 HD13 HG23 ' A' ' 66' ' ' ILE . 54.9 mt -66.8 -60.53 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.258 -0.901 . . . . 0.0 108.909 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.421 ' O ' HG12 ' A' ' 142' ' ' ILE . 26.4 p -66.98 -18.09 65.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -0.795 . . . . 0.0 109.765 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -75.31 -45.81 17.79 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.13 -22.0 65.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.222 -1.163 . . . . 0.0 109.808 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.723 HD11 ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -77.87 -13.9 59.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 0.0 109.957 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.749 HD12 ' CB ' ' A' ' 100' ' ' ALA . 37.1 mm -79.68 -12.99 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.438 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 27.5 m -68.54 -64.67 0.82 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.103 -0.998 . . . . 0.0 109.733 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.56 -11.28 68.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.821 HD23 ' N ' ' A' ' 146' ' ' GLN . 9.7 tt -86.27 173.71 9.57 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.036 -1.273 . . . . 0.0 109.301 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.821 ' N ' HD23 ' A' ' 145' ' ' LEU . 0.0 OUTLIER 63.36 29.15 15.69 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.684 -0.635 . . . . 0.0 110.226 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.428 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 9.9 p . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.787 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.764 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.628 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.582 HD21 ' O ' ' A' ' 132' ' ' ALA . 4.1 mm? 60.02 141.71 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.627 -0.925 . . . . 0.0 110.153 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.437 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -130.71 168.75 16.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.064 -1.023 . . . . 0.0 109.766 179.913 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.73 -38.67 72.69 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -0.891 . . . . 0.0 109.695 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.964 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -69.29 -56.55 7.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.27 -0.894 . . . . 0.0 109.73 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.665 ' O ' HG23 ' A' ' 10' ' ' VAL . 30.0 mt-30 -58.38 -55.74 31.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 109.661 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.825 ' HG2' HD12 ' A' ' 73' ' ' LEU . 3.0 ttp180 -49.11 -37.9 23.1 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.286 -0.884 . . . . 0.0 109.625 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -74.28 -40.59 62.21 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.381 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.964 HG23 ' O ' ' A' ' 5' ' ' ALA . 39.5 t -65.0 -24.85 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.89 . . . . 0.0 109.449 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 1.052 HG12 HG13 ' A' ' 70' ' ' VAL . 97.4 t -70.02 -34.72 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.236 -0.915 . . . . 0.0 109.559 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.09 -13.16 59.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -0.901 . . . . 0.0 109.913 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.74 -19.6 22.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.14 -0.975 . . . . 0.0 109.845 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.43 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.5 p -101.29 -14.83 17.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.126 -0.984 . . . . 0.0 109.956 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.717 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.03 -32.42 20.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.687 -179.776 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.2 mtpt -69.71 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.606 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.9 m-20 -99.24 -60.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.118 -0.989 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.918 HD12 ' CH2' ' A' ' 130' ' ' TRP . 66.3 mt -61.17 -41.15 88.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.262 -0.899 . . . . 0.0 109.538 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.681 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -96.34 31.67 2.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.293 -0.879 . . . . 0.0 109.511 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.48 -69.9 1.11 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.6 p -110.29 -32.66 6.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -1.163 . . . . 0.0 109.613 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.65 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 5.0 p-10 -74.93 -18.98 60.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.905 . . . . 0.0 109.638 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.681 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.6 t30 59.39 21.08 9.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 109.597 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.483 ' O ' HD13 ' A' ' 63' ' ' LEU . . . 97.89 34.68 5.36 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.65 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -85.36 -56.34 3.57 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.229 -1.16 . . . . 0.0 109.576 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -66.53 -14.74 62.87 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.777 HG12 HD11 ' A' ' 63' ' ' LEU . 37.8 t -89.18 -11.59 10.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -1.185 . . . . 0.0 109.942 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.506 ' CA ' ' CD1' ' A' ' 63' ' ' LEU . . . -100.06 -41.77 2.76 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.482 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -74.74 -22.15 58.96 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.119 -1.224 . . . . 0.0 110.003 -179.512 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.447 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 22.3 pt-20 -92.38 -21.96 19.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.116 -0.99 . . . . 0.0 109.701 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.4 t -87.18 -68.0 0.78 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.254 -0.903 . . . . 0.0 110.083 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.534 ' HZ ' HG11 ' A' ' 62' ' ' VAL . 29.2 m-85 -46.62 -33.43 4.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.292 -0.88 . . . . 0.0 110.246 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.666 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.79 -52.11 61.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.067 -1.02 . . . . 0.0 109.384 179.699 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -65.18 -46.03 82.45 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.281 -0.887 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.714 ' CG ' HD23 ' A' ' 106' ' ' LEU . 9.4 t80 -49.53 -49.43 46.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.228 -0.92 . . . . 0.0 109.544 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.764 ' CD1' HG22 ' A' ' 55' ' ' VAL . 14.1 mt -57.99 -46.75 84.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.491 ' O ' ' CD2' ' A' ' 39' ' ' HIS . 0.4 OUTLIER -64.56 -62.15 1.76 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.923 . . . . 0.0 109.525 179.907 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.48 -27.15 23.66 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.222 -0.924 . . . . 0.0 109.524 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 20.7 m80 -120.49 97.27 5.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.491 ' CD2' ' O ' ' A' ' 36' ' ' SER . 64.4 m170 -83.08 4.15 27.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.016 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.6 p-10 -94.95 -13.4 25.38 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.081 -1.012 . . . . 0.0 109.942 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' VAL . 98.0 mmm -112.85 -19.25 12.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.086 -1.009 . . . . 0.0 109.966 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.46 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -47.64 -40.34 19.44 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.181 -0.949 . . . . 0.0 109.859 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.154 -0.966 . . . . 0.0 109.509 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.13 HG22 ' ND2' ' A' ' 95' ' ' ASN . 45.9 t -81.2 -34.64 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.557 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.56 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 24.0 m-85 -76.88 -11.66 59.85 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 110.124 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.4 25.47 25.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.522 ' CD2' ' HB3' ' A' ' 45' ' ' PHE . 14.0 m-85 -125.58 168.64 13.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.912 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.99 -17.39 14.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.416 -0.802 . . . . 0.0 109.202 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.98 -161.6 23.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.99 28.34 3.58 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.325 -1.103 . . . . 0.0 109.713 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 72.1 p -118.02 -16.36 9.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.257 -0.902 . . . . 0.0 109.795 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.1 p-10 -73.07 142.74 82.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.213 -0.93 . . . . 0.0 109.706 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -72.89 -17.38 25.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.976 1.514 . . . . 0.0 110.19 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.5 -38.54 35.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.764 HG22 ' CD1' ' A' ' 35' ' ' LEU . 63.2 t -51.09 -35.92 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.449 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -71.15 -7.15 44.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.27 -0.894 . . . . 0.0 109.691 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.76 -28.26 18.38 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.065 -1.022 . . . . 0.0 109.648 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.968 ' O ' HG23 ' A' ' 62' ' ' VAL . 11.5 mt -88.73 -63.74 1.25 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.071 -1.018 . . . . 0.0 109.681 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.521 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -50.29 -46.99 43.79 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.3 -24.46 19.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -1.156 . . . . 0.0 109.662 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.26 -23.79 12.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.717 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.968 HG23 ' O ' ' A' ' 58' ' ' LEU . 43.4 t -73.23 -56.72 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.983 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.777 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.22 -41.13 17.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.141 -0.974 . . . . 0.0 109.851 -179.927 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.98 -43.19 50.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.515 ' NE2' ' SD ' ' A' ' 83' ' ' MET . 47.6 tp60 -62.69 -41.5 99.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.083 -1.011 . . . . 0.0 109.195 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.909 ' O ' HG23 ' A' ' 70' ' ' VAL . 63.0 mt -57.95 -36.18 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.278 -0.889 . . . . 0.0 108.83 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.88 -59.63 8.86 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 108.689 -1.765 . . . . 0.0 108.689 179.294 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 74.3 t -54.35 -26.16 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.276 -1.132 . . . . 0.0 109.04 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.94 -28.88 25.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.41 -0.806 . . . . 0.0 109.594 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.052 HG13 HG12 ' A' ' 10' ' ' VAL . 52.5 t -68.8 -9.64 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.499 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 18.3 t -93.2 33.57 1.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.007 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.499 ' CG ' ' O ' ' A' ' 71' ' ' SER . 9.1 m-70 -160.25 -87.41 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.189 -0.944 . . . . 0.0 109.731 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.825 HD12 ' HG2' ' A' ' 7' ' ' ARG . 24.3 mt 63.33 -72.07 0.05 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.482 -0.762 . . . . 0.0 110.037 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -75.97 -20.67 77.5 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.208 -1.557 . . . . 0.0 109.208 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -107.12 95.95 6.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.239 -1.154 . . . . 0.0 109.635 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -92.76 35.3 1.04 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.531 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.1 63.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.599 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 12.5 ttpp -140.54 -39.3 0.43 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.274 . . . . 0.0 110.099 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 64.4 ttp -47.78 -56.32 7.66 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.148 -0.97 . . . . 0.0 109.683 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.404 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 98.0 t -60.1 -18.19 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.24 -0.912 . . . . 0.0 109.421 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.599 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -80.8 -21.28 41.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.295 179.714 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.42 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.0 OUTLIER -91.91 -47.39 7.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.544 179.864 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.515 ' SD ' ' NE2' ' A' ' 65' ' ' GLN . 99.2 mmm -62.15 -41.08 97.93 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.027 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.863 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.4 OUTLIER -52.98 -32.61 47.17 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.052 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.424 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -76.31 -33.25 59.03 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.077 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.558 HG12 HD11 ' A' ' 141' ' ' LEU . 71.3 t -65.05 -53.12 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.076 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.419 ' HA3' ' HB2' ' A' ' 145' ' ' LEU . . . -53.51 -39.84 60.93 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.863 HG23 ' O ' ' A' ' 84' ' ' LYS . 85.7 t -53.98 -28.34 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -1.113 . . . . 0.0 109.266 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.8 mmt180 -75.19 -48.9 21.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 0.0 108.959 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.605 ' O ' HD12 ' A' ' 98' ' ' ILE . 54.1 m80 -57.64 -22.37 45.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.306 -0.871 . . . . 0.0 108.912 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.457 ' CG ' ' HA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -72.4 -9.82 59.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.414 -0.804 . . . . 0.0 109.941 179.86 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.76 50.39 0.75 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.6 m-30 -92.1 -174.11 3.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -1.15 . . . . 0.0 109.512 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.89 -28.48 41.86 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.13 ' ND2' HG22 ' A' ' 44' ' ' VAL . 0.4 OUTLIER -83.76 -46.17 12.54 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.579 -0.953 . . . . 0.0 108.923 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.6 mtpt 72.72 -49.96 0.7 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.56 -0.713 . . . . 0.0 110.76 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.3 m170 -66.46 63.14 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.01 -1.056 . . . . 0.0 110.596 -179.233 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.605 HD12 ' O ' ' A' ' 90' ' ' HIS . 96.7 mt -94.08 159.15 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.089 -1.007 . . . . 0.0 109.235 179.431 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.441 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -139.63 141.78 37.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.17 -0.956 . . . . 0.0 109.852 -179.929 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.86 8.24 18.12 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.855 . . . . 0.0 109.685 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -85.09 -29.9 24.5 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.151 -0.968 . . . . 0.0 108.697 179.784 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.468 ' CB ' HBB1 ' A' ' 148' ' ' HEM . 93.5 m-85 -79.09 -17.01 55.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.32 -0.862 . . . . 0.0 109.636 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.796 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.0 m-85 -56.6 -60.14 3.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.23 -0.919 . . . . 0.0 110.169 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.499 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.4 mt-10 -52.82 -57.41 16.15 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.148 -0.97 . . . . 0.0 110.066 -179.453 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.499 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 34.7 Cg_exo -48.88 -58.88 1.49 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 O-C-N 123.626 1.329 . . . . 0.0 110.13 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.821 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.94 -28.89 54.64 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.388 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.26 -50.12 13.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.42 -37.49 87.72 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -1.128 . . . . 0.0 109.503 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 t -68.48 -35.25 77.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.326 -0.859 . . . . 0.0 109.576 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.937 HD22 ' OH ' ' A' ' 134' ' ' TYR . 3.8 tt -67.02 -31.57 72.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.398 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.911 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -61.43 -33.35 73.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.161 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.418 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 2.7 t -72.93 -26.77 61.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.398 179.68 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.623 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -85.46 -22.75 28.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.487 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.6 mtt -65.0 -36.43 84.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.351 -0.843 . . . . 0.0 109.882 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' N ' ' A' ' 119' ' ' GLY . 12.5 pt-20 -58.53 -18.47 29.73 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.464 179.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.623 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 1.0 OUTLIER -56.04 -36.12 67.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.223 -0.923 . . . . 0.0 109.483 179.771 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HD2' HG23 ' A' ' 118' ' ' ILE . 0.1 OUTLIER -89.72 -42.37 11.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.309 -0.87 . . . . 0.0 109.362 179.778 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.478 HG12 HD11 ' A' ' 17' ' ' ILE . 3.1 pt -119.03 57.01 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.865 . . . . 0.0 109.473 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -64.57 -18.67 63.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.31 -28.53 8.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.462 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.8 mttt -94.44 -17.51 22.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.184 -1.186 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.455 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -76.54 86.2 3.24 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.109 -0.995 . . . . 0.0 109.371 179.762 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.517 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 8.9 p30 -93.61 -163.2 1.02 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.845 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.456 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -68.44 -44.57 74.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -0.856 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.517 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -61.54 -26.06 67.69 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.112 -0.992 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.99 -52.57 8.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.314 -0.866 . . . . 0.0 109.792 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.456 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 9.7 ptmm? -71.74 -25.69 62.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.215 -0.928 . . . . 0.0 109.906 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -84.32 -36.32 22.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.112 -0.992 . . . . 0.0 109.745 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.95 -43.18 72.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.361 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.918 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.5 m0 -71.41 -36.72 71.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.281 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.425 ' N ' HD11 ' A' ' 111' ' ' LEU . . . -60.97 -33.9 73.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.119 179.506 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.582 ' O ' HD21 ' A' ' 2' ' ' LEU . . . -80.66 -30.78 36.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.32 -0.862 . . . . 0.0 109.277 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.528 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -81.13 -40.19 24.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.354 -0.841 . . . . 0.0 109.288 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.937 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.8 OUTLIER -50.26 -34.75 24.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.264 179.642 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.38 -28.26 62.9 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.083 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -83.43 -39.25 20.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.381 -0.824 . . . . 0.0 109.337 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.528 HD12 ' C ' ' A' ' 133' ' ' ALA . 4.6 mt -65.95 -58.25 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.149 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -68.66 -19.7 64.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.403 -0.81 . . . . 0.0 109.63 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -65.96 -57.73 10.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.33 -26.36 3.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 0.0 109.756 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.859 HD23 ' O ' ' A' ' 141' ' ' LEU . 7.5 tt -74.41 -12.47 60.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.97 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.669 HG22 ' O ' ' A' ' 142' ' ' ILE . 75.6 mt -91.37 21.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.089 -1.007 . . . . 0.0 109.763 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.4 t -105.82 -32.87 8.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.167 -0.958 . . . . 0.0 109.691 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -121.46 16.39 9.1 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.541 HD12 ' HB2' ' A' ' 90' ' ' HIS . 4.5 tt -98.71 2.12 46.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.109 -1.23 . . . . 0.0 110.126 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -113.22 68.12 0.67 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.038 -1.039 . . . . 0.0 109.682 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.457 ' HA ' ' CG ' ' A' ' 91' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.623 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.447 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.588 HD13 HD12 ' A' ' 73' ' ' LEU . 11.6 mt -60.22 163.55 4.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.195 -1.179 . . . . 0.0 109.766 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 p -136.49 -172.55 3.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 109.542 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -10.14 59.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.936 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.653 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -107.57 -50.11 3.13 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.142 -0.974 . . . . 0.0 109.547 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.602 ' O ' HG23 ' A' ' 10' ' ' VAL . 82.9 mt-30 -60.14 -44.25 95.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.472 ' CG ' ' HB3' ' A' ' 73' ' ' LEU . 5.6 ttp180 -57.17 -29.27 63.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.506 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -82.89 -34.26 26.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.829 . . . . 0.0 109.45 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.653 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.8 t -67.62 -19.57 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.177 -0.952 . . . . 0.0 109.589 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.703 HG12 HG13 ' A' ' 70' ' ' VAL . 93.0 t -73.82 -47.1 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -0.947 . . . . 0.0 109.627 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.26 -13.98 62.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.935 . . . . 0.0 109.841 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.63 -21.65 20.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.184 -0.948 . . . . 0.0 109.9 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -97.67 -12.76 22.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.141 -0.974 . . . . 0.0 110.023 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.03 -28.06 17.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.037 -1.039 . . . . 0.0 109.726 -179.884 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -73.26 -10.92 60.26 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.852 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -104.06 -46.71 4.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.108 -0.995 . . . . 0.0 109.62 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.958 HD12 ' CH2' ' A' ' 130' ' ' TRP . 40.5 mt -70.23 -39.58 77.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.276 -0.89 . . . . 0.0 109.685 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.899 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.1 34.42 2.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.552 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.51 -65.47 3.53 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 26.6 p -111.96 -33.67 6.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.236 -1.155 . . . . 0.0 109.714 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.512 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.7 p-10 -76.63 -18.3 58.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.739 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.899 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 4.3 t30 57.77 20.47 6.51 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.6 21.52 19.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.512 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.02 -54.3 23.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.299 -1.118 . . . . 0.0 109.566 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.471 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.48 2.02 74.22 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.515 HG21 ' CG2' ' A' ' 17' ' ' ILE . 36.9 t -91.94 -40.31 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.053 -1.263 . . . . 0.0 109.529 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.44 -50.54 5.67 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.658 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.473 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 6.4 ptpt -52.7 -30.29 31.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.148 -1.207 . . . . 0.0 109.784 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.473 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.5 pt-20 -91.96 -22.7 19.87 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 109.847 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.4 t -83.14 -65.4 1.01 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.183 -0.948 . . . . 0.0 109.989 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.504 ' O ' HD12 ' A' ' 35' ' ' LEU . 11.3 m-85 -48.46 -29.32 3.98 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 110.024 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.803 ' OG1' HG11 ' A' ' 55' ' ' VAL . 19.5 m -62.98 -60.95 2.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 109.649 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -50.02 -38.02 35.6 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.583 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CD2' HD23 ' A' ' 106' ' ' LEU . 13.2 t80 -69.09 -54.91 12.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.552 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.808 HD13 HG22 ' A' ' 55' ' ' VAL . 12.4 mt -50.57 -44.11 56.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.625 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.671 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 18.9 p -65.73 -51.45 59.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.234 -0.916 . . . . 0.0 109.719 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.4 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -67.32 -19.42 65.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.239 -0.913 . . . . 0.0 109.755 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.439 ' CE1' ' CE1' ' A' ' 34' ' ' PHE . 33.9 m80 -124.51 101.33 7.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.955 . . . . 0.0 109.721 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -86.35 3.53 43.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 110.04 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -93.39 -20.37 20.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.032 -1.043 . . . . 0.0 109.534 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.556 ' HE1' ' CD2' ' A' ' 102' ' ' TYR . 88.1 mmm -104.68 -23.29 13.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.703 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.456 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.26 -34.14 14.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.096 -1.003 . . . . 0.0 109.614 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.12 -22.48 48.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.35 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.928 HG13 ' ND2' ' A' ' 95' ' ' ASN . 46.8 t -74.35 -58.3 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -0.868 . . . . 0.0 109.49 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.649 ' CD2' HD21 ' A' ' 35' ' ' LEU . 68.1 m-85 -52.47 -31.21 33.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.567 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.62 2.89 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.542 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.02 166.96 14.84 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.304 -1.115 . . . . 0.0 109.761 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.0 t -105.36 -21.07 13.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.39 -0.819 . . . . 0.0 109.114 179.308 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -169.43 -163.63 23.79 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.671 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -93.29 29.01 2.02 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.196 -1.179 . . . . 0.0 109.615 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.53 27.78 6.42 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.603 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.625 ' OD2' HG23 ' A' ' 55' ' ' VAL . 7.9 p-10 -116.52 141.09 27.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.88 . . . . 0.0 109.708 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -67.41 -22.58 45.24 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 124.01 1.531 . . . . 0.0 110.135 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.83 -38.58 37.67 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.808 HG22 HD13 ' A' ' 35' ' ' LEU . 88.4 t -50.8 -39.7 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -1.092 . . . . 0.0 109.428 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.439 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.02 -20.53 61.68 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.306 -0.871 . . . . 0.0 109.256 179.572 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -74.3 -37.29 63.69 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.48 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.895 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -85.42 -56.16 3.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -0.95 . . . . 0.0 109.555 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -48.52 -49.07 27.54 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.41 -39.41 87.29 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -1.174 . . . . 0.0 109.74 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.3 mttt -77.83 -30.26 51.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.274 -0.891 . . . . 0.0 109.646 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.6 t -76.19 -51.86 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.593 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.456 HD13 HD12 ' A' ' 66' ' ' ILE . 2.1 mm? -48.93 -47.29 43.68 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.66 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.485 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -49.16 -42.95 41.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.52 ' NE2' ' SD ' ' A' ' 83' ' ' MET . 47.3 tp60 -58.33 -43.66 88.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 109.384 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.871 ' O ' HG23 ' A' ' 70' ' ' VAL . 40.7 mt -59.58 -38.7 76.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.264 -0.898 . . . . 0.0 109.033 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.556 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.44 -53.43 28.76 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.279 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.517 HG11 ' OE2' ' A' ' 82' ' ' GLU . 51.8 t -54.06 -31.16 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.317 -1.108 . . . . 0.0 108.962 179.534 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.407 ' O ' ' CD2' ' A' ' 73' ' ' LEU . . . -82.35 -31.46 29.79 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.385 -0.822 . . . . 0.0 109.27 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.871 HG23 ' O ' ' A' ' 66' ' ' ILE . 52.1 t -69.96 -15.3 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.332 -0.855 . . . . 0.0 109.629 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.6 m -85.21 10.86 11.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.039 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.528 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.1 m-70 -126.27 -72.96 0.63 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.07 -1.019 . . . . 0.0 109.685 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.588 HD12 HD13 ' A' ' 2' ' ' LEU . 3.7 mm? 42.73 -88.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.848 -0.533 . . . . 0.0 110.642 179.669 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -50.29 -27.06 10.36 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -115.15 86.75 2.51 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -1.094 . . . . 0.0 109.406 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' A' ' 79' ' ' MET . 0.6 OUTLIER -90.95 20.2 5.03 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.774 -179.883 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.77 -28.44 73.5 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.468 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 17.9 ttpp -123.09 -29.96 3.82 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.181 -1.187 . . . . 0.0 110.083 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.457 ' HB3' ' HA ' ' A' ' 76' ' ' GLU . 10.7 ttp -47.76 -57.99 4.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.154 -0.966 . . . . 0.0 109.672 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.429 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 99.0 t -62.9 -22.72 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.284 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.468 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -77.43 -21.04 53.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.291 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.517 ' OE2' HG11 ' A' ' 68' ' ' VAL . 27.0 tt0 -90.06 -49.18 6.73 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.331 -0.856 . . . . 0.0 109.529 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.602 ' HE1' HD12 ' A' ' 141' ' ' LEU . 93.6 mmm -60.9 -40.28 92.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.125 -0.985 . . . . 0.0 109.008 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.744 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.3 OUTLIER -53.04 -31.22 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.243 -0.911 . . . . 0.0 108.556 179.175 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.418 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -75.79 -31.36 59.44 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.201 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.594 HG12 HD11 ' A' ' 141' ' ' LEU . 53.9 t -65.37 -50.33 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.096 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.559 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -54.43 -41.95 73.75 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.744 HG23 ' O ' ' A' ' 84' ' ' LYS . 88.2 t -51.36 -25.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.333 -1.098 . . . . 0.0 109.021 179.415 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.452 ' HB3' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -78.35 -33.33 49.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.364 -0.835 . . . . 0.0 108.904 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.651 ' HB2' HD12 ' A' ' 145' ' ' LEU . 30.9 m80 -80.86 4.7 18.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.398 -0.813 . . . . 0.0 109.611 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.497 ' CD ' ' HA ' ' A' ' 147' ' ' SER . 5.8 ttpp -88.63 -10.24 49.3 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.096 -1.003 . . . . 0.0 110.137 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -160.42 43.95 0.42 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.014 -1.565 . . . . 0.0 111.045 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.542 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.6 m-85 -75.17 -165.18 0.37 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.68 -1.483 . . . . 0.0 109.195 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.3 -36.75 55.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.42 -1.872 . . . . 0.0 108.42 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.928 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.7 t30 -72.16 -58.51 3.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.574 -0.956 . . . . 0.0 109.07 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.485 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 1.9 tttp 76.5 -15.67 0.7 Allowed 'General case' 0 N--CA 1.506 2.358 0 O-C-N 121.637 -0.664 . . . . 0.0 111.391 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.435 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 65.9 m170 -98.73 44.01 1.04 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.598 -1.314 . . . . 0.0 109.119 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.527 HD12 ' O ' ' A' ' 90' ' ' HIS . 71.6 mt -75.22 159.04 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.331 -0.856 . . . . 0.0 109.878 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.451 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -142.49 141.98 32.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.377 -0.827 . . . . 0.0 109.948 -179.971 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.36 2.15 26.02 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.468 -0.77 . . . . 0.0 109.565 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mt-10 -77.61 -34.53 53.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 109.55 179.837 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.556 ' CD2' ' HE1' ' A' ' 41' ' ' MET . 61.6 m-85 -80.42 -0.05 35.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.37 -0.831 . . . . 0.0 110.361 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.458 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.0 m-85 -70.48 -55.37 9.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.012 -1.055 . . . . 0.0 109.75 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.486 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.2 tt0 -59.61 -52.11 76.31 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.185 -0.947 . . . . 0.0 109.746 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.486 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.3 Cg_exo -54.32 -56.13 2.78 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 123.819 1.431 . . . . 0.0 109.843 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.734 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -55.31 -31.12 61.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' O ' ' CB ' ' A' ' 110' ' ' LEU . . . -76.06 -48.09 10.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.59 10.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.263 -1.139 . . . . 0.0 109.421 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.9 t -55.19 -21.51 14.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.271 -0.893 . . . . 0.0 109.298 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.45 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.0 OUTLIER -69.27 -48.84 60.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.329 -0.857 . . . . 0.0 109.532 179.88 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.631 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.5 mt -55.04 -34.66 63.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.098 -1.001 . . . . 0.0 109.159 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.15 -31.67 70.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.324 179.657 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.497 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -81.43 -38.41 26.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.409 179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.468 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.5 mmt -50.38 -45.03 55.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.234 -0.916 . . . . 0.0 109.518 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -49.66 -24.71 2.37 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.888 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.497 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 18.8 m170 -58.49 -50.87 72.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.958 . . . . 0.0 109.495 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.479 ' HD2' HG23 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.56 -52.43 38.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.474 179.898 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 6.1 pt -116.64 65.37 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.25 -0.906 . . . . 0.0 109.707 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -66.48 -10.4 53.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -106.28 -39.55 2.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.507 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 8.7 mmmt -82.24 -25.75 33.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.029 -1.277 . . . . 0.0 109.97 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.437 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.55 84.17 0.1 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.997 -1.065 . . . . 0.0 109.164 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.813 HD21 ' HB3' ' A' ' 125' ' ' ALA . 18.7 p-10 -88.15 -171.46 3.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.373 -0.829 . . . . 0.0 109.792 -179.633 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.419 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -61.05 -45.2 95.75 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.276 -0.89 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.813 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -60.95 -30.13 70.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.382 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.99 -49.15 54.45 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.921 . . . . 0.0 109.475 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.521 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.7 OUTLIER -72.41 -30.67 64.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 109.558 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 25.5 t0 -78.88 -35.15 44.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.241 -0.912 . . . . 0.0 109.279 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.442 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -66.59 -47.37 72.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.322 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.958 ' CH2' HD12 ' A' ' 17' ' ' ILE . 13.9 m0 -72.56 -27.38 62.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.163 -0.96 . . . . 0.0 108.716 179.538 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -63.75 -15.12 57.79 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.349 -0.845 . . . . 0.0 108.957 178.743 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -110.98 -29.26 7.98 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.163 -0.96 . . . . 0.0 109.095 179.588 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.492 ' O ' HD12 ' A' ' 137' ' ' ILE . . . -83.19 -45.46 13.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.436 -0.79 . . . . 0.0 109.559 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.548 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -58.52 -18.58 30.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 109.25 179.914 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.548 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -84.35 -33.13 23.92 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.222 -0.924 . . . . 0.0 108.512 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.58 -36.42 38.19 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.492 HD12 ' O ' ' A' ' 133' ' ' ALA . 4.1 mt -64.56 -61.44 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.541 ' OG ' HMC2 ' A' ' 148' ' ' HEM . 4.0 t -66.5 -22.4 66.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.583 -0.698 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.96 -52.99 25.23 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.16 -24.61 4.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -1.186 . . . . 0.0 109.436 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.715 HD23 ' O ' ' A' ' 141' ' ' LEU . 5.8 tt -74.25 -22.62 59.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.648 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.492 HG22 ' O ' ' A' ' 142' ' ' ILE . 69.4 mt -81.81 6.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.177 -0.952 . . . . 0.0 110.193 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.2 t -95.46 -36.13 11.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.005 -1.059 . . . . 0.0 109.71 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.15 14.29 28.48 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.651 HD12 ' HB2' ' A' ' 90' ' ' HIS . 4.6 tt -100.12 3.76 44.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.061 -1.258 . . . . 0.0 110.055 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -107.3 65.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.015 -1.053 . . . . 0.0 109.671 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.497 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 4.6 p . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.602 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.578 HMA2 ' CGA' ' A' ' 148' ' ' HEM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.598 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.493 ' N ' HD22 ' A' ' 2' ' ' LEU . 4.5 mm? -76.73 160.6 29.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -1.174 . . . . 0.0 109.64 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 p -102.28 -170.15 1.77 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.251 -0.906 . . . . 0.0 109.672 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.53 -30.16 57.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.029 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.73 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -85.08 -44.49 12.96 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.082 -1.011 . . . . 0.0 109.587 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' A' ' 2' ' ' LEU . 37.1 mt-30 -62.37 -57.71 10.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 110.127 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -28.22 5.35 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.011 -1.055 . . . . 0.0 109.6 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.7 tp60 -78.6 -39.83 36.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.423 -0.798 . . . . 0.0 108.924 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 5' ' ' ALA . 90.0 t -66.7 -33.67 64.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.043 179.336 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.919 HG12 HG13 ' A' ' 70' ' ' VAL . 84.0 t -69.31 -47.51 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.432 -0.793 . . . . 0.0 109.372 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.62 -13.92 62.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.306 -0.871 . . . . 0.0 109.754 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.5 t -90.73 -26.09 19.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.144 -0.972 . . . . 0.0 109.791 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.4 p -97.29 -10.24 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 110.031 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.653 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -92.48 -19.52 21.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.03 -1.044 . . . . 0.0 109.839 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.3 mtpp -81.94 -11.8 58.7 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.915 . . . . 0.0 109.748 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.403 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -103.49 -55.63 2.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.656 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.973 HD12 ' CH2' ' A' ' 130' ' ' TRP . 61.0 mt -64.36 -36.64 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.609 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.82 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -101.85 33.7 2.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.626 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.4 -85.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.8 p -97.96 -23.94 15.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.301 -1.117 . . . . 0.0 109.678 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.689 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 11.6 p-10 -82.34 -19.88 38.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.655 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.82 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 18.5 t30 56.38 25.12 9.15 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.262 -0.899 . . . . 0.0 109.621 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.45 24.94 12.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.689 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -69.91 -52.55 23.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -1.143 . . . . 0.0 109.648 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.03 -12.98 83.08 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.553 HG21 ' CG2' ' A' ' 17' ' ' ILE . 30.7 t -82.03 -36.05 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.129 -1.218 . . . . 0.0 109.873 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.442 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -78.05 -41.32 18.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.477 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 17.4 ptpt -66.1 -29.55 69.89 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.137 -1.214 . . . . 0.0 110.125 -179.578 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.717 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 22.5 pt-20 -92.5 -20.98 20.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.176 -0.952 . . . . 0.0 109.881 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.1 t -82.8 -60.14 2.27 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.522 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 21.0 m-85 -57.5 -32.27 66.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.888 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.691 HG23 HG11 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -52.3 -53.66 41.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.178 -0.951 . . . . 0.0 109.392 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -59.69 -50.59 73.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.309 -0.869 . . . . 0.0 109.562 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.72 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.5 t80 -50.63 -47.26 58.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.738 ' CD1' HG22 ' A' ' 55' ' ' VAL . 17.6 mt -61.14 -45.37 94.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.509 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 29.8 p -67.38 -55.15 14.94 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.224 -0.922 . . . . 0.0 109.817 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.413 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -61.28 -26.53 67.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.189 -0.945 . . . . 0.0 109.708 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.401 ' HB2' ' O ' ' A' ' 34' ' ' PHE . 24.2 m80 -124.49 110.55 14.63 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.224 -0.922 . . . . 0.0 109.881 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -89.47 -8.87 51.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.472 -0.767 . . . . 0.0 109.697 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -81.94 -16.37 50.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.066 -1.021 . . . . 0.0 109.568 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.593 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 3.9 mmt -104.65 -17.12 14.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.19 -0.944 . . . . 0.0 109.789 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.441 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -54.12 -51.87 62.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.047 -1.033 . . . . 0.0 109.267 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.7 -27.44 68.34 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 109.227 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.963 HG13 ' ND2' ' A' ' 95' ' ' ASN . 9.1 t -69.54 -55.45 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.354 -0.841 . . . . 0.0 109.04 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.53 ' HA ' HMA1 ' A' ' 148' ' ' HEM . 33.5 m-85 -57.44 -28.77 63.62 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.286 -0.884 . . . . 0.0 109.58 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.65 29.62 4.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 12.6 m-85 -126.06 172.24 10.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.75 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.8 t -115.83 19.68 15.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.339 -0.85 . . . . 0.0 109.289 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.92 -164.18 28.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.509 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -92.96 26.32 2.84 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.171 -1.194 . . . . 0.0 109.648 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 26.6 m -121.52 28.59 7.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.626 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.14 135.41 23.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.252 -0.905 . . . . 0.0 109.569 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.2 -21.0 55.78 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.916 1.482 . . . . 0.0 110.061 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.512 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.52 -36.36 47.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.738 HG22 ' CD1' ' A' ' 35' ' ' LEU . 59.8 t -53.45 -42.22 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.266 -1.137 . . . . 0.0 109.456 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.432 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -67.86 -21.15 65.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.407 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.12 -37.25 29.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.289 -0.882 . . . . 0.0 109.524 179.89 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.774 HD21 ' CHA' ' A' ' 148' ' ' HEM . 1.7 mt -75.81 -61.56 1.88 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.522 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.72 -50.66 30.87 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.432 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.12 -37.27 64.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.278 -1.13 . . . . 0.0 109.493 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 25.2 mttt -80.24 -26.38 39.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.508 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 58' ' ' LEU . 59.9 t -82.17 -49.06 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.188 -0.945 . . . . 0.0 109.556 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 63' ' ' LEU . 2.2 mm? -47.83 -46.8 31.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.25 -0.906 . . . . 0.0 109.657 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.64 -52.32 31.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.925 . . . . 0.0 109.85 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.446 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 6.3 tp-100 -50.89 -45.92 60.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.053 -1.03 . . . . 0.0 109.346 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.935 ' O ' HG23 ' A' ' 70' ' ' VAL . 42.1 mt -57.53 -39.06 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.298 -0.876 . . . . 0.0 109.097 179.417 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.556 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.99 -54.19 32.21 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.6 t -56.8 -29.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -1.113 . . . . 0.0 109.466 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.424 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -83.26 -31.31 27.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.345 -0.847 . . . . 0.0 109.659 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.935 HG23 ' O ' ' A' ' 66' ' ' ILE . 51.5 t -61.57 -18.03 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.21 -0.931 . . . . 0.0 109.672 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.436 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -89.33 -1.29 58.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.163 -0.96 . . . . 0.0 110.131 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.464 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 18.9 m-70 -135.84 52.47 1.99 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.989 -1.069 . . . . 0.0 109.954 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.422 HD11 ' HA ' ' A' ' 70' ' ' VAL . 34.9 mt -93.18 -34.59 13.54 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -0.986 . . . . 0.0 109.442 179.774 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -73.68 -26.75 68.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -126.43 92.97 3.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.368 -1.078 . . . . 0.0 109.337 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -91.72 34.89 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.829 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -85.48 -20.41 56.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.413 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 1.3 tppt? -125.15 -33.71 2.84 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -1.169 . . . . 0.0 109.911 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.464 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 52.6 ttp -50.26 -36.43 31.29 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.17 -0.956 . . . . 0.0 109.512 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.472 ' O ' HG12 ' A' ' 80' ' ' VAL . 95.8 t -76.97 -0.65 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 110.012 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -83.76 -31.12 26.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.04 -1.038 . . . . 0.0 109.366 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.495 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 3.1 tp10 -94.74 -44.59 7.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.416 ' HG2' ' OE1' ' A' ' 65' ' ' GLN . 3.4 mtp -55.12 -50.03 70.27 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.228 -0.92 . . . . 0.0 109.35 179.786 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.478 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.3 mtpt -50.38 -40.71 50.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.151 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.495 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -57.66 -34.14 69.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.372 -0.83 . . . . 0.0 109.274 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.412 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 4.0 t -68.0 -35.13 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.139 -0.976 . . . . 0.0 109.024 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.594 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -64.16 -49.45 66.55 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.735 -1.746 . . . . 0.0 108.735 179.611 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.465 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 83.9 t -55.94 -19.7 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.371 -1.076 . . . . 0.0 109.575 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.523 ' HD3' ' N ' ' A' ' 89' ' ' ARG . 0.0 OUTLIER -84.67 -45.15 12.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.802 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.599 ' CD2' HD13 ' A' ' 98' ' ' ILE . 3.7 m80 -64.12 -10.52 23.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.44 -0.788 . . . . 0.0 110.637 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.488 ' CG ' ' HB2' ' A' ' 147' ' ' SER . 0.0 OUTLIER -82.25 7.4 13.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.83 -1.169 . . . . 0.0 110.335 -179.817 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.93 51.96 0.31 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.517 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.3 m-30 -91.85 -168.61 2.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -1.156 . . . . 0.0 109.912 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -63.5 -19.75 62.77 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.963 ' ND2' HG13 ' A' ' 44' ' ' VAL . 10.3 p-10 -105.06 -26.05 12.28 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.056 -1.261 . . . . 0.0 110.062 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.6 mttt 49.49 29.86 3.13 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.141 -0.974 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -137.34 29.43 2.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.297 -0.877 . . . . 0.0 109.693 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.599 HD13 ' CD2' ' A' ' 90' ' ' HIS . 35.6 mt -72.51 158.99 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.181 -0.949 . . . . 0.0 109.684 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.64 174.06 10.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.817 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.551 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -100.88 -19.17 16.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.532 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -68.21 -20.61 64.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.224 -0.922 . . . . 0.0 109.563 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.539 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 46.7 m-85 -80.17 -22.06 42.37 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.201 -0.937 . . . . 0.0 109.675 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.712 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -58.99 -62.59 1.77 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.328 -0.858 . . . . 0.0 110.244 -179.295 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.1 mt-10 -45.06 -58.69 5.22 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.848 . . . . 0.0 110.867 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.539 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.6 Cg_endo -56.49 -47.95 21.41 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.665 1.35 . . . . 0.0 110.213 -179.413 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.952 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -65.78 -20.54 66.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.165 -0.959 . . . . 0.0 109.459 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.64 -42.78 9.71 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.18 -49.33 74.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -1.212 . . . . 0.0 109.538 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.68 -18.16 52.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.649 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.794 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.7 OUTLIER -73.86 -35.29 64.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.929 . . . . 0.0 109.76 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.768 HD21 ' HB3' ' A' ' 130' ' ' TRP . 14.3 mt -68.36 -32.49 72.61 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.673 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 m -71.66 -22.4 61.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.717 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -87.13 -39.29 15.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.794 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.6 mtt -56.41 -36.33 68.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.323 -0.86 . . . . 0.0 109.863 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.456 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -54.37 -21.25 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.168 -0.957 . . . . 0.0 109.533 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -65.27 -23.75 67.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 109.905 -179.775 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.507 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 4.5 ttt85 -94.07 -69.6 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.101 -0.999 . . . . 0.0 109.861 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.558 HG23 HG12 ' A' ' 17' ' ' ILE . 16.5 pt -78.28 -32.9 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.205 -0.934 . . . . 0.0 109.61 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.465 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.09 -97.23 0.01 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -46.64 -45.11 17.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.494 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 2.8 mptt -69.67 -11.61 60.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.456 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -84.33 79.79 9.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.087 -1.008 . . . . 0.0 109.383 179.556 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.579 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.4 p30 -80.52 -165.81 0.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.606 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.424 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -69.68 -44.56 70.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.92 . . . . 0.0 109.441 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.579 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -57.67 -36.6 72.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.191 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -61.05 -53.53 55.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.303 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.615 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 14.8 ptpt -70.48 -29.66 66.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.323 -0.861 . . . . 0.0 109.427 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.7 t70 -74.48 -50.34 18.68 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.324 -0.86 . . . . 0.0 109.34 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.589 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -59.67 -43.34 94.03 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.256 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.973 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.9 m0 -73.99 -23.1 59.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.267 -0.896 . . . . 0.0 109.022 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.615 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.48 -26.82 65.67 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.301 -0.874 . . . . 0.0 108.662 178.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.54 -24.16 17.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.449 -0.782 . . . . 0.0 109.1 179.476 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.607 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -70.58 -59.52 2.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.6 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.531 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 12.1 m-85 -51.76 -27.91 13.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.16 -0.963 . . . . 0.0 109.271 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.92 -53.37 32.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.122 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -70.26 -35.77 74.0 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.22 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.607 HD12 ' C ' ' A' ' 133' ' ' ALA . 29.1 mt -68.85 -57.23 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.351 -0.843 . . . . 0.0 109.469 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.2 p -68.91 -27.91 66.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.771 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -68.37 -47.6 56.79 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -56.61 -30.06 62.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.207 -1.172 . . . . 0.0 109.715 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.712 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.2 tt -68.72 -18.77 64.3 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.729 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.551 HD12 ' CB ' ' A' ' 100' ' ' ALA . 39.5 mm -76.47 -3.81 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 0.0 110.043 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.478 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 3.1 m -81.95 -49.01 10.77 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.445 179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.454 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -83.94 -8.36 84.24 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.594 HD12 ' HA2' ' A' ' 87' ' ' GLY . 0.4 OUTLIER -79.66 -171.26 2.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.07 -1.253 . . . . 0.0 109.14 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.499 ' NE2' ' O ' ' A' ' 142' ' ' ILE . 0.0 OUTLIER 55.17 72.75 0.46 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.119 -0.988 . . . . 0.0 109.588 -179.758 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.488 ' HB2' ' CG ' ' A' ' 91' ' ' LYS . 1.7 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.651 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.774 ' CHA' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.672 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.621 ' HG ' HD12 ' A' ' 73' ' ' LEU . 4.4 mm? 55.64 170.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -1.145 . . . . 0.0 109.65 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.6 173.13 11.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.22 -0.925 . . . . 0.0 109.704 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -68.1 -28.11 67.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.329 -0.857 . . . . 0.0 109.572 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.834 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -82.33 -41.82 19.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.435 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.598 ' O ' HG23 ' A' ' 10' ' ' VAL . 83.9 mt-30 -71.34 -49.21 44.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.292 -0.88 . . . . 0.0 109.669 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -48.64 -31.14 6.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.224 -0.923 . . . . 0.0 109.769 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 42.4 mm-40 -80.87 -49.14 11.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.907 . . . . 0.0 109.648 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.834 HG23 ' O ' ' A' ' 5' ' ' ALA . 36.9 t -53.91 -26.82 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.184 -0.948 . . . . 0.0 109.507 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.911 HG12 HG13 ' A' ' 70' ' ' VAL . 99.0 t -68.41 -54.65 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.519 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.74 -16.09 62.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.816 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 t -86.79 -27.33 23.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.184 -0.947 . . . . 0.0 109.78 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 p -93.79 -12.54 28.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.886 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.644 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.37 -28.53 17.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.088 -1.007 . . . . 0.0 109.684 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -70.83 -13.79 62.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -0.891 . . . . 0.0 109.788 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -101.68 -53.74 2.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.984 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.954 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.2 mt -63.77 -36.61 77.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.262 -0.899 . . . . 0.0 109.603 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.899 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.13 25.65 8.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.311 -0.868 . . . . 0.0 109.728 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.23 -80.41 0.14 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.9 p -98.21 55.15 1.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -1.129 . . . . 0.0 109.563 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.42 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 7.3 p-10 -177.18 -33.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.356 -0.84 . . . . 0.0 109.915 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.899 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 20.6 t30 63.72 37.79 9.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.483 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 78.47 29.06 54.1 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.42 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -75.97 -52.17 10.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.665 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.475 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.75 -22.99 68.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.829 HG12 HD11 ' A' ' 63' ' ' LEU . 48.5 t -67.54 -19.79 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.307 -1.113 . . . . 0.0 109.757 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -91.9 -46.81 3.55 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.475 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.2 ptpt -63.38 -20.81 65.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.153 -1.204 . . . . 0.0 109.787 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.426 ' O ' ' HD2' ' A' ' 33' ' ' LYS . 11.0 pt-20 -99.11 -26.53 14.18 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.4 t -85.09 -51.84 6.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.261 -0.899 . . . . 0.0 109.636 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.635 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.1 m-85 -60.08 -46.04 90.91 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.241 -0.912 . . . . 0.0 109.937 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.638 ' OG1' HG11 ' A' ' 55' ' ' VAL . 53.1 m -49.63 -35.78 22.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.144 -0.972 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.426 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 1.4 mttm -75.79 -43.77 44.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.4 179.694 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.897 ' CG ' HD23 ' A' ' 106' ' ' LEU . 6.6 t80 -60.99 -53.19 60.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.294 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.942 ' CD1' HG22 ' A' ' 55' ' ' VAL . 31.1 mt -57.02 -42.35 80.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.875 . . . . 0.0 109.617 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 43.4 t -65.58 -59.29 4.11 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -0.935 . . . . 0.0 109.582 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.8 -26.47 68.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.189 -0.944 . . . . 0.0 109.631 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 17.8 m80 -120.94 108.5 13.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.74 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -88.66 -21.31 24.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.42 -0.8 . . . . 0.0 109.306 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -68.11 -13.51 62.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.548 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.553 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -104.6 -16.55 14.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.921 -179.814 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.483 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -53.13 -66.26 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.066 -1.021 . . . . 0.0 109.634 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.84 -21.89 44.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.606 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.069 HG13 ' ND2' ' A' ' 95' ' ' ASN . 31.8 t -76.76 -37.16 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.635 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 5.2 m-85 -76.77 -27.21 55.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.93 . . . . 0.0 109.497 -179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.97 27.2 4.37 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.533 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -123.66 173.33 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -1.147 . . . . 0.0 109.909 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.2 t -109.37 -15.93 14.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.432 -0.792 . . . . 0.0 109.199 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.64 -164.57 29.03 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.26 32.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -1.193 . . . . 0.0 109.617 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 25.8 t -134.89 26.68 3.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.289 -0.882 . . . . 0.0 109.618 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.622 ' OD2' HG23 ' A' ' 55' ' ' VAL . 5.2 p-10 -104.39 150.12 38.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.213 -0.929 . . . . 0.0 109.715 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -74.99 -1.93 11.87 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.042 1.549 . . . . 0.0 110.439 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -77.48 -35.58 36.51 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.942 HG22 ' CD1' ' A' ' 35' ' ' LEU . 77.3 t -51.36 -44.34 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -1.116 . . . . 0.0 109.538 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -71.86 -7.22 47.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -0.855 . . . . 0.0 109.938 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.36 -30.0 14.72 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.687 ' O ' HG23 ' A' ' 62' ' ' VAL . 3.9 mt -84.66 -61.44 1.79 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 109.702 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -51.51 -30.57 27.06 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.469 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -63.51 -52.8 59.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.152 -1.204 . . . . 0.0 109.704 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.601 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 5.5 mttp -73.41 -41.75 62.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.687 HG23 ' O ' ' A' ' 58' ' ' LEU . 87.1 t -50.95 -63.67 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.818 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.829 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -46.84 -40.66 14.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.214 -0.929 . . . . 0.0 109.887 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.601 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.58 -38.69 55.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -0.94 . . . . 0.0 109.422 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.408 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 17.5 tp60 -65.08 -39.87 93.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.313 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.954 ' O ' HG23 ' A' ' 70' ' ' VAL . 67.5 mt -62.46 -34.98 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.074 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.563 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.73 29.84 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.5 t -59.9 -24.24 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -1.119 . . . . 0.0 109.165 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.94 -24.49 26.54 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.443 -0.786 . . . . 0.0 109.425 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.954 HG23 ' O ' ' A' ' 66' ' ' ILE . 52.0 t -68.02 -17.23 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.232 -0.918 . . . . 0.0 109.609 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.504 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.8 OUTLIER -89.65 41.62 1.05 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.146 -0.971 . . . . 0.0 109.703 179.954 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' GLY . 8.1 m-70 -161.26 -73.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.588 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.621 HD12 ' HG ' ' A' ' 2' ' ' LEU . 2.4 mm? 50.76 -86.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.68 -0.638 . . . . 0.0 110.448 179.499 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -58.65 -21.85 51.37 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.47 75.56 1.97 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -1.135 . . . . 0.0 109.581 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -85.21 10.02 13.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.927 . . . . 0.0 109.977 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -79.23 -23.92 62.31 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.086 -1.605 . . . . 0.0 109.086 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 4.9 ttpt -122.07 -38.5 2.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.285 -1.127 . . . . 0.0 109.627 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.401 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 58.1 ttp -50.04 -38.55 38.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.607 HG12 ' HB2' ' A' ' 84' ' ' LYS . 47.5 t -74.53 -22.46 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.201 -0.937 . . . . 0.0 109.519 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.499 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -52.52 -58.44 6.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.52 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.698 ' O ' HG23 ' A' ' 86' ' ' VAL . 31.4 mt-10 -74.84 -44.11 50.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.473 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 0.6 OUTLIER -57.84 -57.58 12.15 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.607 ' HB2' HG12 ' A' ' 80' ' ' VAL . 34.5 tttt -51.49 -32.07 26.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.203 179.722 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.479 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -68.94 -43.99 73.96 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 109.311 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.698 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.4 t -54.89 -40.29 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.201 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 90' ' ' HIS . . . -53.58 -49.23 58.32 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.544 HG13 ' CD ' ' A' ' 91' ' ' LYS . 72.8 t -53.59 -49.29 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.305 -1.115 . . . . 0.0 109.084 179.533 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.518 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -49.68 -37.55 29.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.189 -0.944 . . . . 0.0 109.658 179.703 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.64 ' O ' HD12 ' A' ' 98' ' ' ILE . 22.9 m80 -71.4 -3.69 22.2 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.544 ' CD ' HG13 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -78.96 -11.58 60.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.732 -1.23 . . . . 0.0 110.24 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -151.85 57.73 0.43 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -87.57 -170.73 3.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -1.133 . . . . 0.0 109.534 179.614 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.66 -29.54 67.22 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.703 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.069 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.9 p-10 -99.24 -32.89 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -1.183 . . . . 0.0 109.505 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.456 ' O ' ' CD ' ' A' ' 96' ' ' LYS . 0.0 OUTLIER 67.74 7.36 5.65 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.414 -0.804 . . . . 0.0 110.397 179.612 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.419 ' O ' ' O ' ' A' ' 98' ' ' ILE . 0.8 OUTLIER -95.86 -87.84 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.012 -1.055 . . . . 0.0 108.981 178.964 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.64 HD12 ' O ' ' A' ' 90' ' ' HIS . 15.3 mt 58.65 152.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.363 -0.836 . . . . 0.0 110.694 179.342 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.543 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.48 135.5 14.72 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 121.727 0.775 . . . . 0.0 109.807 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.719 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -72.23 -7.31 48.61 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.658 -0.651 . . . . 0.0 109.532 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.448 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 5.8 pt-20 -75.54 -23.74 56.66 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.086 179.355 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.553 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 25.5 m-85 -85.41 -20.38 29.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.854 . . . . 0.0 109.631 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.931 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.5 m-85 -55.95 -61.05 2.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.26 -0.9 . . . . 0.0 110.045 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -52.37 -57.62 14.77 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.066 -1.021 . . . . 0.0 109.839 -179.66 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.9 Cg_exo -50.72 -63.57 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.667 1.351 . . . . 0.0 109.886 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.897 HD23 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -56.54 -26.76 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.295 -0.878 . . . . 0.0 109.342 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -75.62 -46.05 15.86 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.71 -51.86 66.68 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -1.193 . . . . 0.0 109.273 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 t -56.33 -22.25 29.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.875 . . . . 0.0 109.247 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.51 HD23 ' CG ' ' A' ' 114' ' ' MET . 4.4 tt -67.46 -48.61 66.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.585 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.731 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.6 mt -54.36 -31.68 55.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.137 -0.977 . . . . 0.0 109.398 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -65.84 -49.47 68.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.657 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.518 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -71.45 -32.52 68.42 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.601 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.51 ' CG ' HD23 ' A' ' 110' ' ' LEU . 3.4 mmt -47.57 -38.57 14.59 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.265 -0.897 . . . . 0.0 110.023 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.421 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -63.77 -16.92 62.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.565 -179.776 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.518 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 1.6 m-70 -60.78 -43.97 97.39 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.082 -1.011 . . . . 0.0 109.779 -179.781 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.431 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -72.81 -59.37 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.781 -179.7 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.703 HD11 ' SD ' ' A' ' 122' ' ' MET . 12.3 pt -94.0 40.53 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -0.941 . . . . 0.0 109.876 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.421 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -53.46 117.07 6.52 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 112.73 -31.34 6.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.529 -1.829 . . . . 0.0 108.529 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -98.98 -24.87 14.76 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.339 -1.095 . . . . 0.0 109.13 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.703 ' SD ' HD11 ' A' ' 118' ' ' ILE . 6.5 tpt -67.56 96.34 0.52 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.025 179.428 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.461 ' O ' ' HB3' ' A' ' 126' ' ' ALA . 12.5 p-10 -100.73 -172.11 2.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 0.0 109.621 -179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.436 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -58.71 -52.93 63.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.881 . . . . 0.0 110.045 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.713 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -54.63 -24.91 23.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.157 -0.965 . . . . 0.0 109.418 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.16 -54.06 7.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.353 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.595 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 16.7 ptpt -70.0 -30.22 67.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.919 . . . . 0.0 109.358 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.477 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 63.4 t0 -76.91 -38.3 53.75 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.4 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -66.91 -43.87 82.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.402 -0.811 . . . . 0.0 109.347 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.954 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.9 m0 -75.34 -33.01 61.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.251 -0.905 . . . . 0.0 109.011 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.595 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -52.41 -39.2 60.64 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 108.984 179.205 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.586 ' O ' HD21 ' A' ' 2' ' ' LEU . . . -87.71 -23.0 24.3 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.391 -0.818 . . . . 0.0 108.985 179.321 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.693 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -83.45 -63.17 1.41 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 109.518 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.535 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -51.59 -23.97 4.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.182 -0.949 . . . . 0.0 109.098 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.81 -36.78 56.69 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.266 -0.896 . . . . 0.0 109.012 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -78.95 -38.73 36.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.409 -0.807 . . . . 0.0 109.235 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 133' ' ' ALA . 1.4 mp -62.42 -54.89 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.343 -0.848 . . . . 0.0 108.802 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.411 ' O ' HG12 ' A' ' 142' ' ' ILE . 83.6 p -68.44 -17.7 64.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -0.885 . . . . 0.0 109.659 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.39 -35.21 20.97 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.46 -25.5 63.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -1.151 . . . . 0.0 109.621 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.931 HD22 ' CE2' ' A' ' 103' ' ' PHE . 9.9 tt -74.04 -16.49 61.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 109.831 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.719 HD12 ' HB2' ' A' ' 100' ' ' ALA . 51.2 mm -88.19 15.42 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.996 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.6 t -93.25 -45.16 7.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -83.94 -23.3 52.94 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.129 -1.589 . . . . 0.0 109.129 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.606 HD23 ' HG3' ' A' ' 146' ' ' GLN . 0.3 OUTLIER -56.3 -169.06 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -1.142 . . . . 0.0 109.579 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.606 ' HG3' HD23 ' A' ' 145' ' ' LEU . 7.5 mt-30 54.8 66.72 1.16 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.257 -0.902 . . . . 0.0 109.681 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.423 ' OXT' ' CE ' ' A' ' 91' ' ' LYS . 16.0 p . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.682 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.741 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.661 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 mt -143.59 161.46 38.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.321 -1.105 . . . . 0.0 109.758 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.417 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.5 OUTLIER -140.69 -171.35 3.21 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.308 -0.87 . . . . 0.0 109.817 -179.818 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.71 -35.63 57.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.883 . . . . 0.0 109.853 -179.717 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.779 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -76.17 -41.86 48.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.328 -0.858 . . . . 0.0 109.663 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.758 ' O ' HG23 ' A' ' 10' ' ' VAL . 52.0 mt-30 -66.47 -48.0 71.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.16 -0.963 . . . . 0.0 109.345 179.815 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.609 ' HG2' HD12 ' A' ' 73' ' ' LEU . 3.0 ttp180 -60.84 -24.04 65.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.3 tp60 -83.02 -49.26 9.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.444 -0.785 . . . . 0.0 109.186 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.779 HG23 ' O ' ' A' ' 5' ' ' ALA . 86.3 t -51.56 -27.43 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.404 -0.81 . . . . 0.0 109.498 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.944 HG12 HG13 ' A' ' 70' ' ' VAL . 61.1 t -65.02 -52.22 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.769 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.05 -19.2 64.09 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.202 -0.936 . . . . 0.0 109.596 179.87 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.85 -23.84 36.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.556 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.417 HG21 ' CB ' ' A' ' 126' ' ' ALA . 21.2 p -99.89 -13.22 19.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.789 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.708 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.02 -28.31 19.16 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.128 -0.982 . . . . 0.0 109.759 -179.836 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 14.9 mttt -75.88 -8.7 57.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.904 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -105.4 -47.37 3.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.103 -0.998 . . . . 0.0 109.63 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.967 HD12 ' CH2' ' A' ' 130' ' ' TRP . 57.8 mt -71.9 -35.4 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.218 -0.926 . . . . 0.0 109.635 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.883 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -105.03 33.82 3.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.678 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.14 -75.99 0.2 Allowed Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.2 p -103.73 -37.47 7.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -1.16 . . . . 0.0 109.597 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.694 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 16.0 p-10 -71.61 -20.54 61.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.61 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.883 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.9 t30 57.55 25.29 11.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.627 179.956 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.06 19.94 24.91 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.694 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -68.34 -59.52 3.12 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -1.146 . . . . 0.0 109.56 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -67.02 -12.46 60.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.49 HG21 ' CG2' ' A' ' 17' ' ' ILE . 37.5 t -84.82 -41.25 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.149 -1.206 . . . . 0.0 109.868 -179.819 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.447 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -74.33 -36.73 49.42 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.306 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.477 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 9.7 ptpt -73.2 -26.55 61.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.109 -1.23 . . . . 0.0 110.207 -179.459 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.453 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pt-20 -95.42 -20.65 18.91 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.066 -1.021 . . . . 0.0 109.993 -179.746 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.542 ' SG ' HD12 ' A' ' 110' ' ' LEU . 37.3 t -88.19 -66.73 0.89 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 110.085 -179.577 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.526 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.6 m-85 -48.06 -31.53 5.59 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.048 -179.546 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.943 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -56.17 -51.18 68.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.083 -1.011 . . . . 0.0 109.348 179.705 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.414 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 6.2 mttp -59.61 -48.64 80.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.285 -0.884 . . . . 0.0 109.533 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.732 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.8 t80 -52.63 -47.77 66.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.453 179.863 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.831 ' CD1' HG22 ' A' ' 55' ' ' VAL . 21.5 mt -58.93 -44.01 91.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.288 -0.882 . . . . 0.0 109.607 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.5 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -68.73 -60.98 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 -179.957 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -53.47 -23.05 9.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -0.921 . . . . 0.0 109.589 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.403 ' O ' ' O ' ' A' ' 35' ' ' LEU . 33.9 m80 -126.24 102.37 7.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.278 -0.889 . . . . 0.0 109.716 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.4 m170 -85.64 6.86 25.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.329 -0.857 . . . . 0.0 109.9 179.699 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -95.09 -18.12 21.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.128 -0.983 . . . . 0.0 109.427 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.482 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 38.7 mmm -107.03 -19.45 13.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.754 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.39 -46.34 37.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.036 -1.04 . . . . 0.0 109.562 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.3 -26.05 60.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.099 179.478 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.009 HG13 ' ND2' ' A' ' 95' ' ' ASN . 27.9 t -70.62 -33.75 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.431 -0.793 . . . . 0.0 109.342 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.546 ' CE1' HMB2 ' A' ' 148' ' ' HEM . 10.2 m-85 -78.98 -31.17 44.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.48 26.88 4.07 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.878 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.514 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.0 m-85 -124.02 166.85 15.02 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -1.156 . . . . 0.0 109.706 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.0 t -104.92 -11.16 16.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.855 . . . . 0.0 109.444 179.359 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.9 -164.82 31.84 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.5 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -95.57 30.33 2.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -1.186 . . . . 0.0 109.629 179.938 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.65 27.7 5.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.433 ' OD2' HG23 ' A' ' 55' ' ' VAL . 8.1 p-10 -115.62 142.13 28.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.253 -0.904 . . . . 0.0 109.632 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -66.22 -17.8 54.99 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.054 1.555 . . . . 0.0 110.111 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.506 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -53.37 -39.84 60.0 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.943 HG11 HG23 ' A' ' 32' ' ' THR . 94.4 t -54.98 -34.86 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.401 -1.058 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.455 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -72.89 -27.93 62.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.28 -0.887 . . . . 0.0 109.449 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.54 -31.99 60.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.838 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.0 mt -81.97 -62.55 1.6 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.307 -0.871 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.526 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.68 -51.56 27.84 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -51.92 -37.18 51.68 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -1.145 . . . . 0.0 109.412 179.879 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -81.27 -27.69 35.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.512 179.856 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.838 HG23 ' O ' ' A' ' 58' ' ' LEU . 46.5 t -77.84 -49.64 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.303 -0.873 . . . . 0.0 109.704 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.454 HD13 ' HA ' ' A' ' 63' ' ' LEU . 3.6 mm? -47.51 -51.25 21.23 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.714 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.73 -47.14 20.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.251 -0.906 . . . . 0.0 110.089 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -52.76 -53.72 44.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.099 -1.001 . . . . 0.0 109.356 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.909 ' O ' HG23 ' A' ' 70' ' ' VAL . 55.9 mt -55.49 -34.43 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.174 -0.954 . . . . 0.0 109.074 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.552 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.48 -54.07 31.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.751 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.8 t -60.98 -24.93 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -1.121 . . . . 0.0 109.27 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -85.66 -27.93 25.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.355 -0.84 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.944 HG13 HG12 ' A' ' 10' ' ' VAL . 46.2 t -68.13 -9.75 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.219 -0.925 . . . . 0.0 109.78 179.833 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.7 t -92.26 29.93 1.57 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.046 -1.034 . . . . 0.0 109.763 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.487 ' O ' ' N ' ' A' ' 74' ' ' GLY . 9.4 m-70 -155.27 -91.93 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.817 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.609 HD12 ' HG2' ' A' ' 7' ' ' ARG . 9.2 mt 64.4 -69.63 0.09 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.331 -0.856 . . . . 0.0 109.691 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -56.12 -39.72 81.32 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.476 ' OD2' ' CG ' ' A' ' 72' ' ' HIS . 8.1 p-10 -95.88 95.93 8.59 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.296 -1.12 . . . . 0.0 109.476 179.838 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -92.64 31.14 1.4 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.228 -0.92 . . . . 0.0 109.644 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -102.1 -20.62 12.18 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.462 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 9.2 ttmm -126.22 -45.91 1.67 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -1.137 . . . . 0.0 109.706 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 18.3 tmm? -48.53 -36.35 15.17 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.229 -0.92 . . . . 0.0 109.603 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 96.1 t -77.59 -20.59 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.414 179.827 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -57.42 -52.4 65.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 109.444 179.88 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -69.73 -50.65 41.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.429 179.75 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.484 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.8 OUTLIER -56.34 -56.51 20.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 109.313 179.737 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.488 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -53.54 -24.44 13.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.205 179.555 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.545 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -77.9 -44.13 27.97 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.407 -0.808 . . . . 0.0 109.479 179.78 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.0 t -53.17 -35.35 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.474 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -60.66 -48.36 86.63 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.8 HG23 ' HA3' ' A' ' 144' ' ' GLY . 64.9 t -57.65 -18.82 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.423 -1.045 . . . . 0.0 109.432 179.332 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.1 OUTLIER -86.72 -46.1 10.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.134 -0.978 . . . . 0.0 109.087 179.617 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.521 ' O ' HD12 ' A' ' 98' ' ' ILE . 14.3 m80 -56.39 -37.5 70.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 109.564 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -60.96 -16.68 45.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.298 -0.876 . . . . 0.0 109.935 -179.863 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -119.97 40.76 2.11 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.7 m-30 -90.42 -172.12 3.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 109.53 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.9 -28.67 37.08 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.906 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.009 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -79.95 -47.94 14.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.478 -1.013 . . . . 0.0 109.18 179.78 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.471 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.7 OUTLIER 75.13 -48.51 0.63 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.623 -0.673 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -68.05 59.44 0.07 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.802 -1.186 . . . . 0.0 110.466 -179.516 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.521 HD12 ' O ' ' A' ' 90' ' ' HIS . 56.1 mt -90.41 156.96 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.069 -1.019 . . . . 0.0 109.027 179.488 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.521 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -137.94 138.93 39.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.056 -1.027 . . . . 0.0 110.055 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -81.15 -3.69 52.95 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -0.873 . . . . 0.0 109.883 179.693 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 43.1 mm-40 -81.38 -22.25 38.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.006 -1.059 . . . . 0.0 109.489 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.531 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 55.0 m-85 -79.96 -15.09 57.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.309 -0.869 . . . . 0.0 109.891 -179.816 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.917 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 5.2 m-85 -62.93 -61.55 2.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.242 -0.911 . . . . 0.0 110.063 -179.847 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.489 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.4 OUTLIER -44.85 -58.83 4.86 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 110.746 -179.46 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.9 Cg_endo -57.45 -45.95 30.91 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.682 1.359 . . . . 0.0 110.003 -179.569 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.936 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -65.91 -20.09 66.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.301 179.789 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.407 ' HA2' ' CE1' ' A' ' 134' ' ' TYR . . . -86.29 -49.04 4.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.54 -45.49 92.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.2 -1.176 . . . . 0.0 109.537 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.9 m -61.56 -28.97 69.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.494 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.967 HD13 ' OH ' ' A' ' 134' ' ' TYR . 3.7 tt -67.23 -40.03 86.31 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.204 -0.935 . . . . 0.0 109.369 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.656 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.7 mt -54.17 -36.32 63.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.163 -0.961 . . . . 0.0 109.047 179.763 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.8 t -67.01 -30.72 70.9 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.459 179.711 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.444 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -79.96 -38.94 31.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 179.923 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.486 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.6 mmt -48.42 -42.91 33.49 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.228 -0.92 . . . . 0.0 109.618 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -50.67 -24.37 3.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.489 179.843 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.444 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 17.6 m170 -52.0 -53.1 45.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.959 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -72.44 -58.73 3.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.894 . . . . 0.0 109.5 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.608 HD11 ' SD ' ' A' ' 122' ' ' MET . 6.5 pt -102.58 60.79 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.587 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -69.57 -11.01 64.65 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.886 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -105.72 -30.03 4.75 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.861 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 12.7 mttm -93.05 -24.52 18.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.173 -1.192 . . . . 0.0 110.078 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.608 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.9 OUTLIER -64.17 79.55 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.088 -1.008 . . . . 0.0 109.432 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.668 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 8.5 p30 -81.54 -164.52 0.79 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 -179.839 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.409 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.74 -38.46 73.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.181 -0.95 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.668 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -62.74 -33.43 75.12 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.293 -0.879 . . . . 0.0 109.234 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.417 ' CB ' HG21 ' A' ' 13' ' ' THR . . . -67.25 -52.3 42.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.534 179.851 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.523 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.5 OUTLIER -71.04 -29.38 65.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.341 179.835 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.467 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 48.6 t0 -79.81 -32.15 40.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.302 -0.873 . . . . 0.0 109.362 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.08 -43.43 61.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.418 -0.801 . . . . 0.0 109.322 179.752 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.967 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.4 m0 -74.86 -25.8 59.23 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.257 -0.902 . . . . 0.0 108.716 179.489 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -62.48 -26.89 68.77 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.235 -0.916 . . . . 0.0 108.693 178.911 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.45 -40.98 9.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.51 -0.744 . . . . 0.0 109.14 179.517 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -73.6 -58.95 2.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.4 -0.812 . . . . 0.0 109.103 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.967 ' OH ' HD13 ' A' ' 110' ' ' LEU . 1.9 t80 -50.87 -28.07 8.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.33 -0.856 . . . . 0.0 108.997 179.381 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.407 ' HB2' ' O ' ' A' ' 131' ' ' ALA . . . -73.02 -41.35 64.31 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.037 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -76.68 -29.06 56.16 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.483 -0.76 . . . . 0.0 109.059 179.42 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.841 HD13 HG23 ' A' ' 66' ' ' ILE . 42.1 mt -66.54 -61.59 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 108.738 179.532 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.3 p -66.35 -20.6 66.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.431 -0.793 . . . . 0.0 109.726 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.35 -26.98 50.17 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 -179.872 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.0 -19.32 54.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.25 -1.147 . . . . 0.0 109.723 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.889 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.3 tt -79.53 -6.94 58.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.061 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.48 HG22 ' O ' ' A' ' 142' ' ' ILE . 57.5 mt -86.78 9.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.002 -1.061 . . . . 0.0 110.122 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.488 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 7.2 m -83.08 -43.31 16.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.933 -1.104 . . . . 0.0 109.436 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.8 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -97.05 -21.24 21.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.517 ' O ' ' HG2' ' A' ' 146' ' ' GLN . 10.7 tp -52.51 -178.71 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -1.045 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.517 ' HG2' ' O ' ' A' ' 145' ' ' LEU . 3.9 pm0 32.96 63.84 0.3 Allowed 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.698 0.761 . . . . 0.0 111.435 -179.497 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.679 179.479 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.917 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.541 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.538 ' N ' HD22 ' A' ' 2' ' ' LEU . 4.5 mm? -67.36 153.52 43.5 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.258 -1.143 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 1.2 p -104.28 173.74 6.17 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.231 -0.918 . . . . 0.0 109.656 179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -63.75 -22.08 66.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.629 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.848 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -91.66 -56.16 3.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.954 . . . . 0.0 109.545 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.522 ' O ' HG23 ' A' ' 10' ' ' VAL . 3.6 mt-30 -58.23 -54.95 41.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.607 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.726 ' HG2' HD12 ' A' ' 73' ' ' LEU . 10.1 ttp180 -50.8 -31.43 16.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 179.872 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.1 tp60 -80.18 -42.05 24.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.331 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.848 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.3 t -59.34 -25.07 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -0.911 . . . . 0.0 109.433 179.803 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 1.021 HG12 HG13 ' A' ' 70' ' ' VAL . 86.4 t -67.48 -52.39 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.55 -12.12 56.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.873 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.19 -26.65 21.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.138 -0.976 . . . . 0.0 109.891 -179.854 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.443 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 28.2 p -99.65 -7.7 25.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.107 -0.996 . . . . 0.0 109.893 179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.687 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.18 -19.83 22.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.02 -1.05 . . . . 0.0 109.562 -179.759 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 45.1 mtpt -79.74 -15.01 58.31 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.715 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.28 -54.82 3.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.663 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.878 HD12 ' CH2' ' A' ' 130' ' ' TRP . 56.9 mt -65.87 -42.18 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.642 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.889 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -96.45 31.78 2.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.211 -0.93 . . . . 0.0 109.711 -179.855 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.97 -73.29 0.39 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.94 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.6 p -107.04 -26.26 11.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.257 -1.143 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.808 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.5 p-10 -81.01 -19.32 44.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.694 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.889 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 5.3 t30 58.39 22.16 9.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.651 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.411 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 101.73 31.09 5.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.808 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -84.1 -46.49 11.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.261 -1.14 . . . . 0.0 109.584 179.925 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.476 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.38 -1.78 86.61 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.91 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.698 HG11 HD11 ' A' ' 63' ' ' LEU . 21.2 t -88.2 -40.24 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.041 -1.27 . . . . 0.0 109.426 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.49 -53.91 4.51 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.545 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.476 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 18.2 ptpt -48.9 -31.7 7.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.101 -1.235 . . . . 0.0 109.673 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.611 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 24.5 pt-20 -91.62 -21.32 20.87 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.215 -0.928 . . . . 0.0 109.387 179.713 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.422 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 20.8 t -87.6 -64.58 1.13 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.346 -0.847 . . . . 0.0 109.767 -179.794 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.554 ' HB3' HG13 ' A' ' 55' ' ' VAL . 10.5 m-85 -48.28 -34.29 10.18 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 109.955 -179.566 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.891 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -56.74 -54.73 42.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 109.273 179.659 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -55.28 -51.39 66.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 179.847 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.873 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -54.54 -51.7 64.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 109.54 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.707 ' CD1' HG22 ' A' ' 55' ' ' VAL . 16.3 mt -54.81 -45.85 74.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.667 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.9 -59.21 3.46 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.257 -0.902 . . . . 0.0 109.671 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.4 -22.41 53.85 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 0.0 109.624 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 47.5 m80 -131.0 107.85 9.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 109.786 -179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -88.9 -12.53 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.364 -0.835 . . . . 0.0 109.753 179.748 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -73.69 -16.89 61.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.123 -0.986 . . . . 0.0 109.715 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.571 ' HE2' ' CG ' ' A' ' 102' ' ' TYR . 73.0 mmm -109.13 -16.25 14.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.165 -0.96 . . . . 0.0 109.882 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.469 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.58 -51.3 28.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.986 -1.071 . . . . 0.0 109.498 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.02 -28.14 64.18 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.127 179.526 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.914 HG13 ' OD1' ' A' ' 95' ' ' ASN . 38.8 t -66.02 -32.1 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.407 -0.808 . . . . 0.0 109.265 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.537 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 29.3 m-85 -82.48 -25.68 33.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.159 -0.963 . . . . 0.0 109.503 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.49 26.79 5.5 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.779 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.2 m-85 -123.43 167.93 13.21 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.37 -1.077 . . . . 0.0 109.888 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 t -109.91 19.17 19.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.385 -0.822 . . . . 0.0 109.282 179.508 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.37 -163.33 29.52 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -179.946 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.19 40.72 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -1.157 . . . . 0.0 109.732 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 20.9 t -139.74 21.02 2.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.687 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.21 139.02 20.06 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.678 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -61.21 -24.73 79.56 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 123.951 1.5 . . . . 0.0 110.089 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.534 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.25 -39.32 42.62 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.891 HG11 HG23 ' A' ' 32' ' ' THR . 59.4 t -51.31 -36.28 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -1.129 . . . . 0.0 109.367 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.581 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -73.38 -10.22 59.51 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.354 -0.841 . . . . 0.0 109.591 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.41 ' OD2' ' HA2' ' A' ' 54' ' ' GLY . 59.5 m-20 -86.78 -57.03 3.13 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.13 -0.981 . . . . 0.0 109.551 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.772 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -63.29 -61.06 2.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.782 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -47.95 -37.38 15.69 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.581 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -69.72 -59.88 2.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.107 -1.231 . . . . 0.0 109.507 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HD3' ' O1D' ' A' ' 148' ' ' HEM . 10.2 mttt -57.51 -46.57 83.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.268 -0.895 . . . . 0.0 109.34 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 58' ' ' LEU . 51.4 t -56.66 -52.12 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.268 -0.895 . . . . 0.0 109.558 179.771 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.782 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.4 mm? -47.06 -46.04 22.08 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.182 -0.949 . . . . 0.0 109.753 179.875 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.19 -49.52 52.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.597 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 16.1 tp60 -50.2 -48.75 54.1 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.272 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.987 ' O ' HG23 ' A' ' 70' ' ' VAL . 50.1 mt -57.15 -39.21 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.374 -0.829 . . . . 0.0 109.025 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.22 -53.23 41.25 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.944 -1.662 . . . . 0.0 108.944 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.8 t -59.08 -26.73 34.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -1.089 . . . . 0.0 109.35 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.436 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -84.62 -28.6 26.39 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.421 -0.799 . . . . 0.0 109.58 179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.021 HG13 HG12 ' A' ' 10' ' ' VAL . 58.1 t -61.39 -15.78 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.922 . . . . 0.0 109.733 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -90.94 26.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.212 -0.93 . . . . 0.0 109.959 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.469 ' O ' ' N ' ' A' ' 74' ' ' GLY . 7.9 m-70 -155.72 -87.0 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.016 . . . . 0.0 109.81 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.726 HD12 ' HG2' ' A' ' 7' ' ' ARG . 21.2 mt 63.53 -72.45 0.05 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.455 -0.778 . . . . 0.0 110.009 -179.873 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -65.51 -26.21 71.77 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -91.09 48.51 1.52 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.546 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.451 ' HG2' ' N ' ' A' ' 77' ' ' GLY . 0.0 OUTLIER -56.92 -19.54 18.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.723 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.451 ' N ' ' HG2' ' A' ' 76' ' ' GLU . . . -51.93 -24.1 13.09 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.995 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.422 ' O ' ' N ' ' A' ' 81' ' ' ALA . 15.9 ttpt -123.66 -46.22 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -1.171 . . . . 0.0 109.712 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 37.2 ttp -48.99 -27.81 3.43 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.666 179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 76' ' ' GLU . 47.9 t -81.19 -21.63 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 179.846 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.422 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -71.69 -28.7 63.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.427 179.908 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.424 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.6 OUTLIER -81.48 -52.3 7.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.29 -0.881 . . . . 0.0 109.5 179.875 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.474 ' HE3' ' HB2' ' A' ' 141' ' ' LEU . 99.3 mmm -56.44 -39.81 73.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.186 -0.946 . . . . 0.0 108.975 179.683 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.52 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -52.02 -28.65 17.83 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.077 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -80.08 -33.09 39.13 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.552 -0.718 . . . . 0.0 109.097 179.324 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.9 t -69.62 -33.83 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.22 179.688 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.478 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -65.37 -39.61 95.94 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 84' ' ' LYS . 90.3 t -58.7 -28.08 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.268 -1.137 . . . . 0.0 109.213 179.657 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.525 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -73.69 -25.94 60.48 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.349 -0.844 . . . . 0.0 109.26 179.641 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.535 ' CA ' HD12 ' A' ' 98' ' ' ILE . 18.5 m80 -88.04 18.19 4.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.375 -0.828 . . . . 0.0 110.169 -179.085 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.411 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 1.6 tttt -79.35 -60.56 2.32 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.02 -1.05 . . . . 0.0 110.52 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.44 ' HA2' ' HB2' ' A' ' 96' ' ' LYS . . . -148.24 57.58 0.48 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -179.497 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.525 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -86.62 -148.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.308 -1.113 . . . . 0.0 109.812 -179.864 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -45.24 -70.22 0.65 Allowed Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.914 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.4 OUTLIER -66.79 -50.4 62.79 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 108.802 179.559 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.484 ' HG3' ' N ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER 76.58 -34.58 0.23 Allowed 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.399 -0.813 . . . . 0.0 111.48 179.277 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.484 ' N ' ' HG3' ' A' ' 96' ' ' LYS . 14.2 m170 -87.1 60.52 6.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.466 -1.396 . . . . 0.0 109.554 179.854 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.535 HD12 ' CA ' ' A' ' 90' ' ' HIS . 83.6 mt -87.21 155.06 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.122 -0.986 . . . . 0.0 110.224 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.446 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -133.97 141.37 47.25 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.528 -0.732 . . . . 0.0 109.724 -179.941 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.1 -3.28 54.43 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.358 -0.839 . . . . 0.0 110.213 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.467 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 16.9 pt-20 -78.95 -23.49 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.909 -1.12 . . . . 0.0 109.54 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.571 ' CG ' ' HE2' ' A' ' 41' ' ' MET . 71.8 m-85 -80.33 -7.0 58.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.23 -0.918 . . . . 0.0 110.026 179.837 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.755 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -70.0 -66.91 0.53 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.115 -0.99 . . . . 0.0 110.092 -179.561 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.492 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.78 -60.02 3.48 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.494 -0.754 . . . . 0.0 110.743 -179.338 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.521 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 4.2 Cg_endo -52.87 -55.7 3.5 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.683 1.359 . . . . 0.0 109.995 -179.5 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.942 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -59.98 -19.76 54.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.283 179.745 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.418 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -75.33 -45.72 18.04 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.57 -46.79 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.134 -1.215 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.5 m -64.87 -17.64 64.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.251 -0.905 . . . . 0.0 109.407 179.584 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.889 HD21 ' CE ' ' A' ' 114' ' ' MET . 4.9 tt -74.63 -41.87 59.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.947 . . . . 0.0 109.685 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.738 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -60.24 -28.89 68.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.115 -0.991 . . . . 0.0 109.39 179.636 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.7 t -60.26 -46.15 90.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.334 -0.854 . . . . 0.0 109.64 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.611 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -66.29 -36.92 84.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.889 ' CE ' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.28 -42.69 21.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.316 -0.865 . . . . 0.0 109.85 179.904 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.458 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.97 -24.01 15.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.277 -0.889 . . . . 0.0 109.766 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.513 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.6 m170 -52.38 -55.16 23.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 109.842 -179.784 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.463 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 3.8 ttt85 -72.03 -66.09 0.69 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.188 -0.945 . . . . 0.0 109.833 -179.841 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.687 HG12 HD11 ' A' ' 17' ' ' ILE . 6.6 pt -94.57 58.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.114 -0.991 . . . . 0.0 109.748 -179.826 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.75 -39.49 95.26 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -85.92 -13.46 69.29 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.867 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.443 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.2 mttm -104.71 -20.84 13.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.07 -1.253 . . . . 0.0 109.883 -179.812 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.47 90.45 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.213 179.71 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.54 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 9.1 p-10 -92.5 -172.61 3.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.224 -0.922 . . . . 0.0 110.029 -179.619 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.422 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.65 -48.99 75.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.46 -0.775 . . . . 0.0 110.308 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.63 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -60.52 -24.88 65.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.428 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -75.18 -49.27 20.0 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.461 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.534 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 20.1 ptpt -73.04 -30.85 64.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -0.911 . . . . 0.0 109.74 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.5 t0 -76.71 -41.93 43.42 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.465 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -64.02 -43.28 96.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.368 -0.833 . . . . 0.0 109.376 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.878 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -75.6 -26.24 57.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.288 -0.882 . . . . 0.0 109.314 179.761 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.534 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -64.94 -26.4 68.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.454 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -96.82 -26.37 15.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.441 -0.787 . . . . 0.0 109.276 179.659 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.844 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -73.93 -57.69 3.8 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.364 -0.835 . . . . 0.0 109.449 179.819 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.497 ' CE2' ' HE2' ' A' ' 114' ' ' MET . 17.2 m-30 -50.36 -29.18 9.4 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.333 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.27 -43.95 69.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.372 -0.83 . . . . 0.0 109.08 179.554 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -75.16 -33.32 61.47 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.352 -0.843 . . . . 0.0 109.238 179.663 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.844 HD12 ' C ' ' A' ' 133' ' ' ALA . 3.5 mt -67.9 -59.06 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.314 -0.866 . . . . 0.0 109.192 179.667 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.62 ' OG ' HMC2 ' A' ' 148' ' ' HEM . 0.4 OUTLIER -68.2 -48.76 64.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.717 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -50.91 -28.59 17.4 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.189 -1.565 . . . . 0.0 109.189 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.06 3.21 31.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -1.132 . . . . 0.0 110.048 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.755 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.2 tt -97.97 -24.38 15.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.933 -1.104 . . . . 0.0 109.804 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.635 HG22 ' O ' ' A' ' 142' ' ' ILE . 6.8 mt -87.2 18.23 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.382 -179.446 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -77.96 -20.67 52.27 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.107 -0.996 . . . . 0.0 108.872 179.489 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.35 1.51 5.71 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.838 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.939 HD22 ' N ' ' A' ' 146' ' ' GLN . 0.2 OUTLIER -97.68 126.89 43.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.849 -1.383 . . . . 0.0 110.1 -179.825 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.939 ' N ' HD22 ' A' ' 145' ' ' LEU . 1.2 mt-30 160.6 48.3 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.856 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.642 -179.959 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.654 ' C1D' HG22 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.756 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.411 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.454 ' HA ' HD23 ' A' ' 2' ' ' LEU . 12.3 mt 56.92 165.39 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.332 -1.099 . . . . 0.0 109.714 -180.0 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p -151.8 -179.91 7.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.546 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.43 -22.59 59.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.135 -0.978 . . . . 0.0 109.21 179.726 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.901 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -86.4 -36.39 19.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.35 -0.844 . . . . 0.0 109.539 179.723 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.548 ' O ' HG23 ' A' ' 10' ' ' VAL . 40.5 mt-30 -70.92 -48.5 53.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.217 -0.927 . . . . 0.0 109.509 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.453 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 13.9 ptm180 -56.31 -30.83 63.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.277 -0.889 . . . . 0.0 109.348 179.856 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.453 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 17.7 mm-40 -73.74 -41.73 62.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.436 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 5' ' ' ALA . 21.6 t -61.4 -22.54 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.867 HG12 HG13 ' A' ' 70' ' ' VAL . 66.4 t -73.37 -43.31 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 109.673 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.79 -8.03 54.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.288 -0.883 . . . . 0.0 110.016 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.5 m -94.23 -30.3 14.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.043 . . . . 0.0 109.826 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.429 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.2 p -92.91 -13.17 29.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.954 -179.835 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.822 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -88.04 -19.49 27.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.117 -0.989 . . . . 0.0 109.849 -179.741 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.2 mtpt -83.87 -4.06 58.38 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.928 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.66 -53.31 2.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.788 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.959 HD12 ' CH2' ' A' ' 130' ' ' TRP . 60.9 mt -66.16 -36.28 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.455 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.823 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.29 27.34 7.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.51 -69.52 1.07 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 p -107.21 -36.95 6.41 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -1.141 . . . . 0.0 109.59 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -71.79 -20.04 61.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.922 . . . . 0.0 109.667 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.823 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 17.5 t30 54.54 30.44 13.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.268 -0.895 . . . . 0.0 109.593 -179.955 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.75 59.99 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.59 -47.3 67.09 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.108 -1.231 . . . . 0.0 109.52 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.23 12.97 62.94 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.52 HG11 HD11 ' A' ' 63' ' ' LEU . 11.3 t -97.84 -32.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.139 -1.212 . . . . 0.0 109.116 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 31' ' ' PHE . . . -86.69 -44.24 5.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.495 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.7 ptpt -53.87 -35.41 61.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -1.195 . . . . 0.0 109.386 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.495 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.3 pt-20 -86.85 -26.83 23.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 109.366 179.714 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.416 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 30.4 t -85.11 -58.31 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.366 -0.834 . . . . 0.0 109.684 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.677 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.4 m-85 -47.3 -32.57 4.82 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.333 -0.854 . . . . 0.0 109.915 -179.72 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.677 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -60.54 -49.22 78.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.158 179.669 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -52.28 64.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.571 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.703 ' CG ' HD23 ' A' ' 106' ' ' LEU . 6.8 t80 -52.4 -54.48 31.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.189 -0.944 . . . . 0.0 109.483 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.918 ' CD1' HG22 ' A' ' 55' ' ' VAL . 38.2 mt -55.7 -43.67 76.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.665 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.572 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 9.6 t -68.81 -65.43 0.7 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.732 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.67 -27.35 16.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.723 -179.937 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.404 ' O ' ' O ' ' A' ' 35' ' ' LEU . 16.3 m80 -123.06 106.72 11.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.914 . . . . 0.0 109.837 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -87.36 -20.83 26.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.429 -0.795 . . . . 0.0 109.294 179.542 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.411 ' OD1' ' HG2' ' A' ' 41' ' ' MET . 16.4 p-10 -66.15 -17.9 65.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.371 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.51 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 84.6 mmm -106.14 -24.5 12.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.266 -0.896 . . . . 0.0 109.705 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.463 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.88 -46.14 42.18 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.078 -1.014 . . . . 0.0 109.61 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.75 -21.12 60.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.302 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.945 HG13 ' CG ' ' A' ' 95' ' ' ASN . 35.8 t -76.16 -40.83 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.299 -0.876 . . . . 0.0 109.412 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.733 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 11.2 m-85 -67.26 -41.79 84.97 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 109.576 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.46 32.94 1.07 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.4 m-85 -125.04 173.15 8.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.225 -1.162 . . . . 0.0 109.629 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 17.6 t -111.51 19.38 18.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 109.371 179.547 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.11 -167.34 30.07 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.572 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -80.86 -23.0 39.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.203 -1.175 . . . . 0.0 109.66 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 12.5 m -84.74 51.24 2.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.923 . . . . 0.0 109.676 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -120.51 136.21 25.13 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.597 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -68.06 -33.45 25.42 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.97 1.511 . . . . 0.0 110.033 -179.906 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.41 -32.39 30.21 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.918 HG22 ' CD1' ' A' ' 35' ' ' LEU . 91.7 t -53.92 -41.61 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.268 -1.136 . . . . 0.0 109.501 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.706 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.5 -11.01 60.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.262 -0.899 . . . . 0.0 109.872 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.401 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 11.4 t0 -91.73 -33.3 15.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.111 -0.993 . . . . 0.0 109.375 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.516 ' HB3' ' CE2' ' A' ' 31' ' ' PHE . 1.6 mt -81.59 -64.25 1.22 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.348 -0.845 . . . . 0.0 110.201 -179.786 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.61 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -56.09 -20.77 29.1 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.37 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.706 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -72.24 -40.76 67.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.109 -1.23 . . . . 0.0 109.761 -179.719 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.502 ' HB3' ' CGD' ' A' ' 148' ' ' HEM . 28.6 mttt -84.46 -43.67 14.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.601 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.562 HG21 ' O ' ' A' ' 149' ' ' CMO . 61.6 t -52.56 -47.18 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.128 -0.983 . . . . 0.0 109.48 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -48.09 -47.85 33.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.108 -0.995 . . . . 0.0 109.773 179.81 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.6 -49.38 47.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.912 . . . . 0.0 109.653 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -49.06 -54.96 13.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.135 -0.978 . . . . 0.0 109.378 179.849 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.947 ' O ' HG23 ' A' ' 70' ' ' VAL . 83.7 mt -52.36 -35.32 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.313 -0.867 . . . . 0.0 109.05 179.554 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.85 -57.11 15.21 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.869 -1.693 . . . . 0.0 108.869 179.416 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.5 t -57.58 -25.91 25.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -1.135 . . . . 0.0 109.253 179.76 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.438 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.07 -19.58 34.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.391 -0.818 . . . . 0.0 109.5 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.947 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.0 t -75.47 -14.47 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.686 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.488 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -90.41 35.64 0.88 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.109 -0.994 . . . . 0.0 109.96 -179.824 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 71' ' ' SER . 6.0 m-70 -161.68 -84.75 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.063 -1.023 . . . . 0.0 109.918 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 42.2 mt 60.22 -77.67 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.599 -0.688 . . . . 0.0 109.97 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.476 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -67.19 -24.48 73.4 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.43 146.54 26.22 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -1.159 . . . . 0.0 109.668 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -140.45 62.45 1.49 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.912 . . . . 0.0 109.605 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -115.41 -18.52 6.16 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.527 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 22.9 ttpt -140.19 -40.62 0.43 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.079 -1.248 . . . . 0.0 109.923 -179.896 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 59.0 ttp -48.17 -49.07 33.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.19 -0.944 . . . . 0.0 109.772 -179.866 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.8 t -73.07 -14.63 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.872 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -70.78 -35.08 72.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.126 -0.983 . . . . 0.0 109.835 -179.811 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.63 ' O ' HG23 ' A' ' 86' ' ' VAL . 10.7 tt0 -98.82 -40.97 7.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.666 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.7 mtp -62.18 -46.55 88.43 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.419 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 13.1 tttt -56.18 -39.27 72.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.172 -0.955 . . . . 0.0 109.172 179.65 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -63.19 -39.65 95.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.388 179.709 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.837 ' CG1' HD11 ' A' ' 141' ' ' LEU . 48.8 t -51.92 -47.96 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.525 ' O ' HD12 ' A' ' 145' ' ' LEU . . . -52.94 -49.88 53.15 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.624 -1.791 . . . . 0.0 108.624 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.647 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.1 t -53.13 -34.75 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.389 -1.065 . . . . 0.0 109.249 179.462 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 24.6 mmm180 -69.56 -49.21 56.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.865 . . . . 0.0 109.416 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.582 ' HB2' HD12 ' A' ' 145' ' ' LEU . 10.7 m80 -61.63 -15.41 39.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.235 -0.916 . . . . 0.0 109.363 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.472 ' HG3' ' CB ' ' A' ' 147' ' ' SER . 4.8 ttmt -43.21 -33.49 0.94 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.466 -0.771 . . . . 0.0 110.917 -179.568 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.39 60.95 0.28 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.11 -1.519 . . . . 0.0 110.675 -179.502 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.9 m-30 -69.83 -166.0 0.1 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.014 -1.286 . . . . 0.0 109.257 178.64 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.31 -22.63 61.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.612 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.945 ' CG ' HG13 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -93.61 -44.06 8.38 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.381 -1.07 . . . . 0.0 109.321 -179.955 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.489 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 27.4 mttt 79.58 -32.14 0.14 Allowed 'General case' 0 N--CA 1.509 2.512 0 O-C-N 121.954 -0.467 . . . . 0.0 111.278 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.433 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 30.7 m170 -60.69 -99.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.518 -1.364 . . . . 0.0 109.99 -179.6 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.556 HD12 ' O ' ' A' ' 90' ' ' HIS . 6.1 mt 62.83 129.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.778 -1.201 . . . . 0.0 109.903 -179.546 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.514 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -145.4 143.35 30.03 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 122.237 1.018 . . . . 0.0 110.85 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.477 ' HB1' HD13 ' A' ' 142' ' ' ILE . . . -69.12 -19.61 64.04 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.047 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -64.9 -32.77 74.64 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.772 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.514 ' CD2' ' HB2' ' A' ' 99' ' ' LYS . 22.9 m-85 -81.26 -25.62 36.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.589 -0.694 . . . . 0.0 109.956 179.847 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.782 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 3.4 m-85 -53.46 -65.88 0.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.22 -0.925 . . . . 0.0 110.344 -179.382 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.6 mt-10 -46.53 -59.43 5.06 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.251 -0.906 . . . . 0.0 110.512 -179.194 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 41.0 Cg_exo -45.42 -55.06 3.78 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.712 1.375 . . . . 0.0 110.621 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.706 ' C ' HD13 ' A' ' 106' ' ' LEU . 3.0 tm? -55.43 -39.13 69.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.34 -40.33 97.75 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.27 -55.07 27.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -1.162 . . . . 0.0 109.766 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.1 t -60.16 -27.43 67.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.202 -0.937 . . . . 0.0 109.703 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.857 HD22 ' OH ' ' A' ' 134' ' ' TYR . 3.2 tt -70.35 -38.92 74.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.205 -0.935 . . . . 0.0 109.589 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.857 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -60.08 -29.39 68.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.15 -0.969 . . . . 0.0 109.41 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 m -73.49 -29.7 62.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.784 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.467 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -80.68 -38.3 29.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.949 . . . . 0.0 109.569 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.597 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.9 mtt -50.1 -39.68 43.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.283 -0.885 . . . . 0.0 109.463 179.857 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.5 OUTLIER -51.67 -24.74 6.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.23 -0.919 . . . . 0.0 109.382 179.565 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.467 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 33.8 m170 -55.67 -49.67 72.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.327 -0.858 . . . . 0.0 109.829 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.438 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 2.9 ttt85 -70.1 -65.37 0.73 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.272 -0.892 . . . . 0.0 109.696 -179.837 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 13.5 pt -87.97 46.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 109.565 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.451 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.49 125.25 35.92 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 95.71 -30.44 8.39 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.743 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.431 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 19.2 mmtt -90.11 -28.71 18.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.227 -1.161 . . . . 0.0 109.166 179.682 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.448 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 1.2 ttt -71.37 107.38 4.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.437 -0.789 . . . . 0.0 109.359 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.507 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 10.0 p30 -109.72 -162.1 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.177 -0.952 . . . . 0.0 109.894 -179.776 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.431 ' O ' ' HB3' ' A' ' 128' ' ' ASP . . . -67.55 -45.78 74.67 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.346 -0.847 . . . . 0.0 109.64 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.798 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.62 -24.03 54.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -86.23 -57.06 3.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.8 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -65.94 -27.33 68.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.153 -0.967 . . . . 0.0 109.692 -179.735 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.431 ' HB3' ' O ' ' A' ' 124' ' ' ALA . 32.1 t70 -80.55 -49.95 10.65 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.311 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -57.7 -50.47 73.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.394 -0.816 . . . . 0.0 109.282 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.959 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.8 m0 -63.89 -30.96 71.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.237 -0.915 . . . . 0.0 108.877 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.98 -30.09 67.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 108.89 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.6 -28.52 23.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.392 -0.818 . . . . 0.0 109.194 179.501 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.85 -40.81 21.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.406 -0.809 . . . . 0.0 109.473 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.857 ' OH ' HD22 ' A' ' 110' ' ' LEU . 1.8 m-85 -50.26 -32.01 15.65 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.45 -34.78 72.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.281 -0.887 . . . . 0.0 109.242 179.638 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.27 -39.68 39.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 0.0 109.371 179.692 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.677 HD13 HG23 ' A' ' 66' ' ' ILE . 54.5 mt -66.05 -58.12 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.274 -0.891 . . . . 0.0 109.145 179.669 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.11 -17.5 64.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.291 -0.881 . . . . 0.0 109.645 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 142' ' ' ILE . . . -68.25 -55.56 12.59 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.23 -28.19 4.38 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.837 HD11 ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -74.82 -21.55 59.22 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -0.893 . . . . 0.0 109.536 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.575 HG22 ' O ' ' A' ' 142' ' ' ILE . 91.0 mt -83.78 8.36 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.292 -0.88 . . . . 0.0 110.096 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.3 m -100.13 -46.0 5.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.04 -1.038 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.647 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -68.86 -31.55 72.94 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.582 HD12 ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER -61.61 -148.35 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.414 179.869 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.51 ' H ' HD23 ' A' ' 145' ' ' LEU . 22.9 mp0 52.92 43.37 31.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.01 -1.056 . . . . 0.0 109.762 179.845 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.472 ' CB ' ' HG3' ' A' ' 91' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.671 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.782 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.562 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.502 HD11 ' CB ' ' A' ' 133' ' ' ALA . 15.4 mt -94.13 172.24 8.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.298 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -137.29 178.48 7.06 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.811 -1.18 . . . . 0.0 110.384 -179.802 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.81 -14.88 63.16 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.494 -0.754 . . . . 0.0 110.536 -179.506 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.581 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -94.82 -48.26 6.11 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.05 -1.032 . . . . 0.0 109.819 -179.679 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.434 ' O ' HG23 ' A' ' 10' ' ' VAL . 73.6 mt-30 -66.67 -33.96 76.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.638 179.903 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 42.9 mtp180 -54.75 -41.82 70.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.644 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -74.73 -36.55 62.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.239 -0.913 . . . . 0.0 109.549 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 5' ' ' ALA . 33.3 t -71.26 -35.8 59.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.151 -0.968 . . . . 0.0 108.987 179.628 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.777 HG23 ' HB1' ' A' ' 129' ' ' ALA . 41.9 t -67.46 -37.24 78.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.399 -0.813 . . . . 0.0 109.057 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.26 -16.29 56.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.345 -0.847 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.6 t -90.3 -22.72 21.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.891 -179.625 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.8 p -95.24 -12.28 26.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 110.028 -179.851 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.575 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.31 -15.07 27.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.042 -1.037 . . . . 0.0 109.973 -179.895 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mtpt -85.92 -2.0 57.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.73 -45.16 3.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.996 -1.065 . . . . 0.0 109.667 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.948 HD12 ' CH2' ' A' ' 130' ' ' TRP . 45.8 mt -72.47 -36.34 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.446 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.677 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -103.02 31.67 4.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.323 -0.86 . . . . 0.0 109.588 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.62 -78.73 0.1 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.54 -27.74 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.434 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 13.4 p-10 -80.01 -20.15 46.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 0.0 109.607 179.959 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.677 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 21.4 t30 56.16 27.7 11.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.875 . . . . 0.0 109.645 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.94 22.38 42.51 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -59.21 -52.37 65.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -1.161 . . . . 0.0 109.569 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.425 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -92.92 26.11 16.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.696 HG11 HD11 ' A' ' 63' ' ' LEU . 39.2 t -110.14 -22.73 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.29 -1.123 . . . . 0.0 108.887 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.412 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -100.15 -26.97 8.01 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 179.79 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.485 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 14.2 ptpt -70.19 -34.99 73.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.245 -1.15 . . . . 0.0 109.385 179.789 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.737 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -92.34 -8.9 43.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.157 -0.964 . . . . 0.0 109.839 179.678 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.6 t -93.25 -61.3 1.6 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.067 -1.021 . . . . 0.0 109.722 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.509 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.9 m-85 -55.64 -30.56 61.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.926 . . . . 0.0 109.768 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.759 ' OG1' HG11 ' A' ' 55' ' ' VAL . 17.8 m -58.35 -48.01 81.96 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.125 -0.984 . . . . 0.0 109.395 179.794 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.31 -41.33 98.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.317 -0.865 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.643 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.4 t80 -62.14 -44.67 96.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.251 -0.905 . . . . 0.0 109.43 179.84 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.793 ' CD1' HG22 ' A' ' 55' ' ' VAL . 15.7 mt -62.8 -45.53 92.22 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.642 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 3.2 p -66.28 -46.75 75.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.738 -179.934 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 -21.4 62.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -127.82 114.31 17.07 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.758 -179.912 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -93.22 5.29 52.03 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.357 -0.839 . . . . 0.0 109.984 179.736 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -95.6 -22.18 17.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.044 -1.035 . . . . 0.0 109.486 179.811 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.619 ' CE ' HMB2 ' A' ' 148' ' ' HEM . 0.4 OUTLIER -97.01 -22.45 16.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.309 -0.87 . . . . 0.0 109.615 179.977 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.415 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.16 -50.75 61.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.196 -0.94 . . . . 0.0 109.536 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -66.41 -21.39 66.22 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.895 . . . . 0.0 109.585 179.897 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.944 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.6 t -79.73 -55.98 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.517 ' CD2' HD21 ' A' ' 35' ' ' LEU . 33.7 m-85 -53.74 -40.9 66.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.79 31.78 1.41 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 -179.849 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.504 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.9 m-85 -125.36 -179.07 4.44 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -1.176 . . . . 0.0 109.749 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.9 t -123.99 19.17 9.25 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.417 -0.802 . . . . 0.0 109.299 179.481 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.44 -163.38 27.53 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.642 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -77.92 -19.08 55.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.698 -180.0 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 8.5 t -85.41 50.13 1.89 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -128.62 117.8 19.84 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.615 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -59.28 -29.54 90.56 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.842 1.443 . . . . 0.0 110.108 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.504 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.96 -34.49 38.44 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.793 HG22 ' CD1' ' A' ' 35' ' ' LEU . 89.3 t -52.26 -31.47 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.274 -1.133 . . . . 0.0 109.636 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.427 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -77.36 -21.86 52.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.487 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.83 -45.55 16.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.9 . . . . 0.0 109.557 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.956 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.9 mt -68.25 -59.06 3.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -0.925 . . . . 0.0 109.535 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.509 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -51.17 -54.8 21.77 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.421 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -53.19 -37.61 62.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -1.17 . . . . 0.0 109.59 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 mttm -77.98 -25.79 48.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.956 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.9 t -82.61 -40.91 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.696 HD11 HG11 ' A' ' 26' ' ' VAL . 1.6 mm? -50.11 -55.03 16.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.554 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -43.67 36.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.229 -0.919 . . . . 0.0 109.71 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.414 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 0.2 OUTLIER -51.59 -54.17 30.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 179.79 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.78 ' O ' HG23 ' A' ' 70' ' ' VAL . 69.2 mt -55.48 -34.65 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.263 -0.898 . . . . 0.0 108.98 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.567 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.84 -55.15 18.23 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.5 t -57.79 -22.12 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.322 -1.105 . . . . 0.0 109.138 179.759 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.68 -31.17 21.18 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.392 -0.818 . . . . 0.0 109.461 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.78 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.0 t -69.24 -17.09 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 109.484 179.728 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -61.97 -37.93 86.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -0.941 . . . . 0.0 109.912 -179.832 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.437 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 22.5 m-70 -129.29 81.73 2.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 109.885 -179.815 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.611 HD11 HG11 ' A' ' 10' ' ' VAL . 53.5 mt -85.51 -36.39 20.55 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.892 . . . . 0.0 109.461 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -90.38 -24.52 28.57 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.686 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -86.95 120.1 27.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.348 -1.089 . . . . 0.0 109.472 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -110.22 44.19 1.27 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.231 -0.918 . . . . 0.0 109.706 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -128.16 17.12 5.98 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 3.2 ttmt -158.47 -50.12 0.06 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.162 -1.199 . . . . 0.0 109.934 179.942 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.437 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 49.5 ttp -49.11 -41.2 35.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 109.652 -179.807 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.455 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 60.0 t -77.29 -0.53 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 110.036 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -86.11 -24.12 26.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.04 -1.038 . . . . 0.0 109.595 -179.975 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.564 ' O ' HG23 ' A' ' 86' ' ' VAL . 4.6 tt0 -106.77 -41.05 5.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.545 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.638 ' HE2' HD12 ' A' ' 141' ' ' LEU . 10.1 mtp -67.98 -40.81 83.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.219 -0.926 . . . . 0.0 108.949 179.653 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 6.0 tttt -56.28 -28.56 59.12 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 179.009 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.425 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -78.49 -31.92 47.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.48 -0.763 . . . . 0.0 109.056 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.936 ' CG1' HD11 ' A' ' 141' ' ' LEU . 47.3 t -62.72 -41.78 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.245 -0.91 . . . . 0.0 109.06 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 141' ' ' LEU . . . -54.06 -41.78 69.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.356 -1.898 . . . . 0.0 108.356 179.53 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.442 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 97.5 t -56.34 -46.54 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.426 -1.043 . . . . 0.0 109.252 179.475 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.518 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 10.4 mpt_? -52.05 -29.96 23.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.028 -1.045 . . . . 0.0 109.054 179.466 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.503 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 34.6 m80 -84.22 9.51 12.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.417 -0.802 . . . . 0.0 110.022 -179.894 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 25.0 ttpt -104.36 -11.74 16.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.034 -1.041 . . . . 0.0 110.241 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.17 18.79 2.31 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.142 -1.504 . . . . 0.0 110.855 -179.242 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CZ ' ' HB3' ' A' ' 89' ' ' ARG . 1.6 m-85 -58.9 -164.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.644 -1.504 . . . . 0.0 109.174 179.317 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.77 -31.21 40.83 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 179.625 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.944 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -81.14 -48.67 11.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.529 -0.983 . . . . 0.0 108.787 179.703 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.8 tmtt? 76.83 -19.3 0.43 Allowed 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.652 -0.655 . . . . 0.0 111.901 179.162 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.414 ' HB2' ' OD1' ' A' ' 95' ' ' ASN . 37.8 m170 -72.31 -95.82 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.443 -1.411 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.496 HG13 ' ND2' ' A' ' 95' ' ' ASN . 8.1 mt 61.71 148.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 120.858 -1.151 . . . . 0.0 110.511 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -156.88 149.66 23.63 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 121.943 0.878 . . . . 0.0 110.521 179.812 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.4 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -76.83 -7.29 55.18 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.681 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.567 ' CG ' ' CD2' ' A' ' 102' ' ' TYR . 12.0 pt-20 -71.38 -34.23 70.24 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.95 -1.094 . . . . 0.0 109.082 179.461 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.567 ' CD2' ' CG ' ' A' ' 101' ' ' GLU . 94.3 m-85 -80.3 -25.46 39.35 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 109.329 179.566 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.572 ' CE1' ' CHC' ' A' ' 148' ' ' HEM . 2.7 m-85 -48.12 -62.16 1.62 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.358 -0.839 . . . . 0.0 110.236 -179.798 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.513 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -51.97 -59.84 7.41 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.177 -0.952 . . . . 0.0 110.173 -179.366 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.513 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 36.1 Cg_exo -47.53 -59.69 1.15 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.586 1.309 . . . . 0.0 110.229 179.91 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.922 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.29 -22.57 12.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.91 . . . . 0.0 109.406 179.906 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.01 -44.09 9.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.96 -49.96 74.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -1.163 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 75.6 m -56.65 -31.29 64.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 109.603 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 2.6 tt -62.75 -43.83 97.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.602 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.71 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.7 mt -53.87 -39.19 65.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 13.5 t -62.3 -32.02 72.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.235 -0.915 . . . . 0.0 109.503 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.737 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -78.91 -39.73 34.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.41 179.758 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.547 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -48.72 -45.73 39.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -48.32 -29.31 3.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -0.927 . . . . 0.0 109.968 -179.838 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.419 ' CE1' ' OE1' ' A' ' 29' ' ' GLU . 17.5 m170 -49.9 -56.4 10.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.082 -1.011 . . . . 0.0 109.817 -179.826 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.8 ttt85 -69.77 -63.57 1.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.849 -179.82 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.532 HG12 HD11 ' A' ' 17' ' ' ILE . 4.7 pt -96.61 58.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.313 -0.867 . . . . 0.0 109.709 -179.789 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.36 -20.32 71.38 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.73 -21.1 17.21 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.865 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.494 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -100.62 -19.37 16.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -1.187 . . . . 0.0 109.884 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.406 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.95 79.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.051 -1.031 . . . . 0.0 109.799 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.742 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 15.7 p-10 -80.13 -171.97 3.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.172 179.589 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.452 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.12 -31.35 68.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.066 -1.021 . . . . 0.0 109.907 -179.81 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.742 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -72.18 -23.69 61.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.038 -1.039 . . . . 0.0 109.024 179.668 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.476 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -74.88 -47.55 29.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 108.892 179.403 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 6.9 ptpt -71.79 -31.28 66.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.413 -0.805 . . . . 0.0 109.232 179.569 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.477 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.4 t70 -75.78 -48.52 21.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.777 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -58.55 -44.57 89.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.422 -0.799 . . . . 0.0 109.493 179.844 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.948 ' CH2' HD12 ' A' ' 17' ' ' ILE . 7.0 m0 -74.88 -26.17 59.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.245 179.838 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.611 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.12 -27.3 65.45 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.246 -0.909 . . . . 0.0 108.979 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.414 ' HB3' ' OE1' ' A' ' 6' ' ' GLN . . . -93.46 -23.06 18.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.192 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.629 ' O ' HD12 ' A' ' 137' ' ' ILE . . . -79.81 -42.88 23.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.395 -0.816 . . . . 0.0 109.556 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -49.26 -33.32 12.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.207 -0.933 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.74 -25.15 49.02 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.229 -0.919 . . . . 0.0 108.938 179.412 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.436 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.7 t0 -85.95 -40.76 15.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.387 -0.821 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.629 HD12 ' O ' ' A' ' 133' ' ' ALA . 1.6 mp -65.8 -59.6 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 108.824 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.78 ' OG ' HMC2 ' A' ' 148' ' ' HEM . 0.1 OUTLIER -64.6 -25.22 67.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.243 -0.911 . . . . 0.0 109.745 -179.85 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.572 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -55.68 -49.56 65.02 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.94 -17.75 64.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.234 -1.156 . . . . 0.0 109.845 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.936 HD11 ' CG1' ' A' ' 86' ' ' VAL . 5.1 tt -84.19 -33.38 24.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.15 -0.969 . . . . 0.0 109.738 -179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.572 HD12 ' HA2' ' A' ' 139' ' ' GLY . 50.6 mt -68.48 -9.25 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 110.065 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 67.6 m -70.51 -65.15 0.77 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.069 -1.019 . . . . 0.0 109.595 179.835 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.45 -7.37 64.09 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.676 HD23 ' N ' ' A' ' 146' ' ' GLN . 5.9 tt -83.86 176.82 8.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.08 -1.247 . . . . 0.0 109.48 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.676 ' N ' HD23 ' A' ' 145' ' ' LEU . 0.0 OUTLIER 55.48 29.74 13.84 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.607 -0.683 . . . . 0.0 110.295 179.907 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.439 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 7.7 p . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.024 -0.988 . . . . 0.0 109.698 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.78 HMC2 ' OG ' ' A' ' 138' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.499 ' O ' ' CE1' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.444 HD11 ' HA ' ' A' ' 133' ' ' ALA . 21.9 mt -51.22 165.78 0.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.357 -1.084 . . . . 0.0 109.964 -179.928 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.94 -174.02 2.37 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.491 ' HA ' ' CD ' ' A' ' 7' ' ' ARG . . . -79.8 -26.35 40.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.64 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.765 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -85.96 -32.37 21.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.9 . . . . 0.0 109.647 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.408 ' NE2' ' OD1' ' A' ' 128' ' ' ASP . 1.7 mt-30 -77.69 -47.74 18.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.491 ' CD ' ' HA ' ' A' ' 4' ' ' ALA . 8.3 ptm180 -52.54 -32.69 41.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.153 -0.967 . . . . 0.0 108.738 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.42 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 49.4 tp60 -71.16 -36.01 71.85 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 5' ' ' ALA . 47.5 t -73.3 -31.74 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.391 -0.818 . . . . 0.0 108.942 179.196 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.758 HG12 HG13 ' A' ' 70' ' ' VAL . 41.9 t -70.03 -37.49 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.743 . . . . 0.0 109.357 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.08 -16.35 58.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.691 179.903 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.4 -27.22 21.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.925 . . . . 0.0 109.693 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.2 p -88.5 -14.2 38.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.79 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.562 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.34 -20.55 21.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.125 -0.985 . . . . 0.0 109.717 -179.767 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.5 mtpp -79.74 -0.05 32.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.839 179.694 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -113.32 -56.35 2.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.011 -1.055 . . . . 0.0 109.553 179.856 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.94 HD12 ' CH2' ' A' ' 130' ' ' TRP . 73.9 mt -62.54 -34.18 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.202 -0.936 . . . . 0.0 109.55 179.939 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.526 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.5 36.66 2.44 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.271 -0.893 . . . . 0.0 109.771 -179.889 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.86 -88.19 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.9 p -112.28 15.04 20.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -1.132 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.423 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 4.3 p-10 -122.1 -9.14 8.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.164 -0.96 . . . . 0.0 110.032 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.601 ' ND2' ' HB2' ' A' ' 64' ' ' ALA . 9.0 t30 56.41 20.17 4.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.565 -179.711 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.586 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 80.06 34.32 30.45 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.719 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.405 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -56.39 -43.99 79.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -1.139 . . . . 0.0 109.62 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.486 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.96 -18.32 72.67 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.91 HG11 HD21 ' A' ' 63' ' ' LEU . 25.7 t -68.76 -31.86 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.551 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.23 -54.32 4.44 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.611 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.486 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.7 ptpt -55.19 -24.71 28.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -1.163 . . . . 0.0 110.108 -179.487 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.783 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 23.1 pt-20 -98.23 -16.15 19.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.001 -1.062 . . . . 0.0 109.851 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.426 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 40.5 t -90.78 -60.19 1.98 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.186 -0.946 . . . . 0.0 110.014 -179.628 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CZ ' ' O ' ' A' ' 149' ' ' CMO . 10.5 m-85 -59.83 -32.0 70.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.218 -0.926 . . . . 0.0 110.167 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.859 ' OG1' HG11 ' A' ' 55' ' ' VAL . 16.6 m -60.65 -45.05 95.55 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.096 -1.002 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.422 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 3.3 mttm -64.7 -29.26 70.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 179.91 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.652 ' CG ' HD23 ' A' ' 106' ' ' LEU . 17.0 t80 -78.3 -49.58 13.39 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.279 -0.888 . . . . 0.0 109.458 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.691 HD13 HG22 ' A' ' 55' ' ' VAL . 13.3 mt -51.84 -46.43 64.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.333 -0.854 . . . . 0.0 109.687 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.476 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 7.3 t -61.82 -59.96 4.36 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 109.677 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.35 -23.04 66.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.24 -0.912 . . . . 0.0 109.73 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.451 ' N ' ' O ' ' A' ' 34' ' ' PHE . 29.8 m80 -121.22 99.35 6.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 109.688 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -85.33 -19.79 30.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.309 -0.87 . . . . 0.0 109.531 179.936 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -69.28 -20.53 63.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.695 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.518 ' HE2' ' CD1' ' A' ' 102' ' ' TYR . 7.3 mmm -108.83 -16.83 14.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.201 -0.937 . . . . 0.0 109.824 -179.927 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.469 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -50.47 -41.0 52.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 0.0 109.378 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -76.47 -32.1 58.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.299 -0.876 . . . . 0.0 109.159 179.583 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.03 HG13 ' ND2' ' A' ' 95' ' ' ASN . 24.7 t -59.18 -56.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.384 -0.823 . . . . 0.0 109.245 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.546 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 62.4 m-85 -54.19 -31.03 51.77 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.21 29.68 3.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.873 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.546 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.5 m-85 -123.81 167.6 13.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 17.93 20.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.885 . . . . 0.0 109.422 179.625 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.74 -164.06 29.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.476 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -93.5 28.71 2.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -1.15 . . . . 0.0 109.618 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 99.5 p -126.91 28.1 5.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.08 137.44 22.44 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -65.67 -24.46 55.19 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.931 1.49 . . . . 0.0 110.095 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.22 -36.33 44.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.859 HG11 ' OG1' ' A' ' 32' ' ' THR . 94.6 t -50.99 -39.9 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.299 -1.118 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.71 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -76.54 -1.25 26.42 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.292 -0.88 . . . . 0.0 109.831 179.714 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -96.47 -27.45 14.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.05 -1.031 . . . . 0.0 109.703 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.787 ' O ' HG23 ' A' ' 62' ' ' VAL . 6.9 mt -86.65 -62.27 1.55 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.426 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -57.62 -24.67 53.65 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.71 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -66.53 -31.61 72.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.634 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.507 ' CB ' ' CGD' ' A' ' 148' ' ' HEM . 9.3 mtpt -101.82 -39.58 7.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.428 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.787 HG23 ' O ' ' A' ' 58' ' ' LEU . 58.3 t -51.7 -53.77 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.27 -0.894 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.91 HD21 HG11 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -45.9 -44.5 14.63 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.321 -0.862 . . . . 0.0 110.42 -179.705 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.601 ' HB2' ' ND2' ' A' ' 22' ' ' ASN . . . -52.99 -30.02 32.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.025 . . . . 0.0 109.674 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 11.5 tp-100 -69.49 -31.97 70.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 108.834 179.178 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 70' ' ' VAL . 94.0 mt -72.97 -31.5 35.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.413 -0.804 . . . . 0.0 108.861 179.271 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.562 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.09 -48.37 40.12 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 179.551 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.1 t -63.66 -24.17 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.246 -1.149 . . . . 0.0 109.113 179.736 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.04 -26.46 25.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.468 -0.77 . . . . 0.0 109.481 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 66' ' ' ILE . 48.6 t -67.57 -13.71 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.212 -0.93 . . . . 0.0 109.718 179.842 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.418 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -81.09 -16.9 51.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.849 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 5.7 m-70 -128.76 66.99 1.41 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.177 -0.952 . . . . 0.0 109.672 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.631 HD11 ' HA ' ' A' ' 70' ' ' VAL . 65.2 mt -101.37 -26.87 13.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.305 -0.872 . . . . 0.0 109.534 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.79 -27.21 54.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.023 -1.631 . . . . 0.0 109.023 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -111.24 150.28 29.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -1.117 . . . . 0.0 109.506 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -128.44 55.6 1.68 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.615 -179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -131.02 15.98 5.31 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.566 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 13.7 ttpp -164.29 -42.75 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.076 -1.25 . . . . 0.0 109.735 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 11.8 tmm? -48.64 -41.28 30.71 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.211 -0.931 . . . . 0.0 109.567 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.411 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.6 t -73.13 -20.43 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.895 . . . . 0.0 109.421 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.566 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -57.3 -56.63 19.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 179.761 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.61 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -64.18 -53.2 53.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.355 -0.841 . . . . 0.0 109.233 179.664 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.418 ' HG3' ' O ' ' A' ' 79' ' ' MET . 0.5 OUTLIER -53.15 -57.05 11.79 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.68 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.467 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.86 -29.17 18.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.013 179.488 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -72.39 -42.82 64.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.43 -0.794 . . . . 0.0 109.133 179.608 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 82' ' ' GLU . 16.7 t -62.27 -35.77 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.017 179.621 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.466 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -57.46 -44.2 93.75 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.591 -1.803 . . . . 0.0 108.591 179.612 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 90.2 t -54.96 -35.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.285 -1.127 . . . . 0.0 109.033 179.397 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 6.9 mpt_? -70.69 -30.79 67.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.387 -0.821 . . . . 0.0 109.163 179.55 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.768 ' CB ' HD13 ' A' ' 145' ' ' LEU . 27.5 m80 -80.04 2.85 22.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.346 -0.846 . . . . 0.0 109.974 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.3 ttmt -101.07 14.01 33.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.057 -1.027 . . . . 0.0 110.011 -179.539 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -169.41 31.51 0.16 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.231 -1.462 . . . . 0.0 110.543 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.53 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.9 m-85 -74.08 -163.82 0.2 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.739 -1.448 . . . . 0.0 109.688 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -65.29 -53.45 32.78 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.521 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.03 ' ND2' HG13 ' A' ' 44' ' ' VAL . 14.6 p-10 -67.37 -33.67 75.69 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -1.164 . . . . 0.0 109.849 -179.729 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 mttt 55.27 21.19 3.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.241 -0.912 . . . . 0.0 109.633 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -128.3 48.66 2.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.49 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.727 HD13 ' CD2' ' A' ' 90' ' ' HIS . 61.9 mt -86.33 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.771 -179.883 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.494 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 4.8 mptt -141.73 143.52 33.56 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.325 -0.859 . . . . 0.0 109.766 -179.895 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.659 ' CB ' HG23 ' A' ' 142' ' ' ILE . . . -83.19 6.93 17.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.851 179.69 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.26 -21.12 21.24 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.178 -0.951 . . . . 0.0 108.779 179.723 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.518 ' CD1' ' HE2' ' A' ' 41' ' ' MET . 61.5 m-85 -85.16 -13.16 50.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.753 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 4.3 m-85 -61.07 -61.2 2.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.164 -0.96 . . . . 0.0 110.038 -179.818 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -49.44 -56.94 13.53 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.881 -179.612 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -50.94 -62.0 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.684 1.36 . . . . 0.0 109.929 179.741 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.778 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -57.99 -25.86 61.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.29 -0.881 . . . . 0.0 109.46 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.498 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -72.97 -39.55 54.04 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.985 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.43 -50.0 71.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.217 -1.167 . . . . 0.0 109.479 179.863 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 9.0 m -57.3 -20.64 29.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 109.482 179.832 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.456 HD23 ' HG3' ' A' ' 114' ' ' MET . 1.1 tt -69.18 -46.17 68.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.746 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.736 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.4 mt -58.56 -30.5 67.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.142 -0.974 . . . . 0.0 109.442 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.3 m -73.45 -40.87 63.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.246 -0.909 . . . . 0.0 109.671 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.783 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -74.46 -31.01 62.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.235 -0.915 . . . . 0.0 109.653 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.503 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.8 mmt -60.06 -43.05 95.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.2 OUTLIER -49.81 -25.37 3.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.778 -179.884 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -53.76 -56.21 19.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.204 -0.935 . . . . 0.0 109.797 -179.862 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.405 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -64.59 -58.64 5.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.153 -0.967 . . . . 0.0 109.749 -179.877 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.526 HG12 HD11 ' A' ' 17' ' ' ILE . 5.3 pt -103.04 59.59 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.922 . . . . 0.0 109.737 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.77 -27.72 73.58 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.932 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -95.69 -17.59 35.35 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 5.4 mptt -101.7 -23.37 14.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 109.758 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.456 ' CA ' HD12 ' A' ' 118' ' ' ILE . 0.3 OUTLIER -71.29 83.9 0.77 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.138 -0.977 . . . . 0.0 109.581 179.937 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.574 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.3 p30 -81.39 -167.88 1.64 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.327 -0.858 . . . . 0.0 109.54 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -65.95 -47.81 73.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.574 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -56.96 -31.68 65.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.395 179.768 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -66.63 -53.03 38.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.822 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.521 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 2.5 ptpt -70.01 -26.6 64.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.263 179.727 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.476 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 38.7 t0 -82.53 -36.18 26.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 109.426 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.61 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -67.02 -43.26 83.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.758 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.94 ' CH2' HD12 ' A' ' 17' ' ' ILE . 12.1 m0 -76.7 -29.13 56.13 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.238 -0.913 . . . . 0.0 109.062 179.903 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -50.68 -43.05 57.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.319 -0.863 . . . . 0.0 109.098 179.43 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.13 -17.32 35.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.419 -0.801 . . . . 0.0 109.228 179.33 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.711 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -88.01 -61.57 1.69 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.246 -0.909 . . . . 0.0 109.704 179.938 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.502 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.47 -27.01 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.07 -1.019 . . . . 0.0 109.144 -179.825 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.23 -31.56 30.2 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.305 -0.872 . . . . 0.0 108.795 179.17 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -82.1 -37.83 25.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.448 -0.783 . . . . 0.0 109.405 179.729 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.45 ' N ' HD12 ' A' ' 137' ' ' ILE . 1.6 mp -65.86 -58.4 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 108.776 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -29.87 70.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.492 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -70.5 -35.63 68.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.48 -23.94 66.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -1.176 . . . . 0.0 109.614 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 141' ' ' LEU . 8.7 tt -74.55 -17.3 60.76 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.254 -0.904 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.659 HG23 ' CB ' ' A' ' 100' ' ' ALA . 58.7 mt -76.39 -0.96 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 110.101 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.467 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 19.5 m -66.91 -32.9 74.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.991 -1.068 . . . . 0.0 109.051 179.669 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.4 -10.98 8.33 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.62 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.768 HD13 ' CB ' ' A' ' 90' ' ' HIS . 19.2 tp -93.31 91.57 7.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.041 -1.27 . . . . 0.0 109.571 -179.904 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 6.7 mm-40 -120.04 -11.48 9.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.013 -1.054 . . . . 0.0 109.633 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.753 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.507 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 mt -58.57 166.78 1.67 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.291 -1.123 . . . . 0.0 109.819 179.983 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 p -123.3 -170.16 2.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 179.748 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.28 -27.88 42.29 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.892 . . . . 0.0 109.967 -179.668 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.603 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -85.23 -30.38 23.91 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -0.957 . . . . 0.0 109.796 -179.895 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.424 ' O ' HG23 ' A' ' 10' ' ' VAL . 42.1 mt-30 -78.29 -52.27 8.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.169 -0.957 . . . . 0.0 109.887 -179.856 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.98 -29.37 12.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.97 -1.081 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -70.71 -45.21 65.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 0.0 108.778 179.353 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 5' ' ' ALA . 44.8 t -62.12 -31.25 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.364 -0.835 . . . . 0.0 108.859 179.27 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 1.048 HG12 HG13 ' A' ' 70' ' ' VAL . 98.6 t -66.03 -50.13 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.512 -0.743 . . . . 0.0 109.4 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.11 61.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.9 m -83.45 -25.05 31.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.105 -0.997 . . . . 0.0 109.744 -179.919 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.452 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 38.2 p -100.22 -10.18 21.64 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.92 . . . . 0.0 110.043 -179.907 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.12 -25.8 19.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.027 -1.046 . . . . 0.0 109.609 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.9 mtpp -76.05 -12.8 60.19 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.224 -0.923 . . . . 0.0 109.641 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.468 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.4 OUTLIER -103.02 -52.67 3.0 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.949 HD12 ' CH2' ' A' ' 130' ' ' TRP . 44.1 mt -65.14 -34.78 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.271 -0.893 . . . . 0.0 109.581 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.891 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -107.91 35.24 3.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.719 -179.948 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.1 -84.14 0.03 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 78.3 p -97.51 -23.41 16.04 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.307 -1.114 . . . . 0.0 109.617 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.629 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 12.3 p-10 -83.34 -21.45 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.891 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 9.9 t30 56.79 20.57 5.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.92 . . . . 0.0 109.61 179.998 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.2 20.94 11.39 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.629 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.49 -47.52 69.8 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.567 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -93.34 31.63 6.26 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.517 ' CG1' HD21 ' A' ' 110' ' ' LEU . 41.9 t -119.05 -35.91 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.297 -1.12 . . . . 0.0 108.942 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.462 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -90.26 -41.17 5.58 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.766 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.481 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.3 ptpt -61.08 -30.63 70.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 109.587 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.79 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -90.41 -25.16 20.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.124 -0.985 . . . . 0.0 109.422 179.798 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 41.4 t -85.54 -50.63 7.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.353 -0.842 . . . . 0.0 109.574 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 5.0 m-30 -55.2 -37.56 67.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.585 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.574 ' OG1' HG11 ' A' ' 55' ' ' VAL . 98.6 m -55.82 -45.89 78.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.901 . . . . 0.0 109.347 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.411 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 13.6 mttp -66.59 -47.63 72.12 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.403 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.532 ' CG ' HD23 ' A' ' 106' ' ' LEU . 4.3 t80 -55.7 -49.94 71.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.297 179.794 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.732 ' CD1' HG22 ' A' ' 55' ' ' VAL . 32.3 mt -59.48 -45.1 92.63 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.89 -61.68 2.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.691 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -58.04 -28.64 64.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.694 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 7.7 m80 -118.0 103.38 9.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.718 179.938 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -85.61 -21.45 28.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.34 -0.85 . . . . 0.0 109.345 179.634 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.2 p-10 -68.23 -20.49 64.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.912 . . . . 0.0 109.275 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.504 ' HE3' ' CMB' ' A' ' 148' ' ' HEM . 92.2 mmm -103.26 -22.35 13.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.581 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -51.17 -44.45 61.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.031 -1.043 . . . . 0.0 109.338 179.825 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.68 -23.38 59.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.346 -0.846 . . . . 0.0 109.136 179.565 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.047 HG13 ' ND2' ' A' ' 95' ' ' ASN . 29.2 t -73.44 -39.96 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.423 -0.798 . . . . 0.0 109.202 179.733 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.542 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -68.89 -38.95 79.97 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.573 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.404 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 117.66 28.22 2.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.882 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.542 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.3 m-85 -122.31 172.23 8.47 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.199 -1.177 . . . . 0.0 109.692 -179.981 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 11.7 t -111.13 19.22 18.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.316 -0.865 . . . . 0.0 109.351 179.493 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.95 -164.0 29.87 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.79 5.82 41.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -1.162 . . . . 0.0 110.073 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 15.2 t -110.09 42.27 1.56 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.001 -1.062 . . . . 0.0 109.548 179.976 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.414 ' HA ' ' HD3' ' A' ' 53' ' ' PRO . 0.4 OUTLIER -115.85 131.54 23.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 0.0 109.624 -179.979 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 16.9 Cg_exo -61.34 -20.47 68.36 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 123.81 1.426 . . . . 0.0 109.949 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.9 -35.95 88.52 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.732 HG22 ' CD1' ' A' ' 35' ' ' LEU . 58.9 t -54.56 -22.78 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -1.095 . . . . 0.0 109.468 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.457 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -86.47 -19.44 29.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.319 -0.863 . . . . 0.0 109.571 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.406 ' O ' ' HB2' ' A' ' 61' ' ' LYS . 0.3 OUTLIER -88.11 -26.45 22.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.296 -0.878 . . . . 0.0 109.588 -179.994 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.782 HD21 ' CHA' ' A' ' 148' ' ' HEM . 2.7 mt -86.44 -66.58 0.89 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.188 -0.945 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.553 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -49.46 -37.06 25.1 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.439 ' HB3' ' O ' ' A' ' 56' ' ' ALA . . . -72.45 -22.32 61.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.151 -1.205 . . . . 0.0 109.946 -179.698 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.406 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 4.7 mttp -94.55 -21.9 18.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.122 -0.986 . . . . 0.0 109.827 -179.868 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 58' ' ' LEU . 23.3 t -83.71 -46.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.938 . . . . 0.0 109.889 -179.784 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.671 HD21 HD11 ' A' ' 110' ' ' LEU . 2.9 mm? -47.86 -46.88 31.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -51.91 25.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.194 -0.941 . . . . 0.0 109.992 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -50.65 -42.98 57.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.07 -1.019 . . . . 0.0 109.438 -179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.881 ' O ' HG23 ' A' ' 70' ' ' VAL . 39.8 mt -61.34 -38.36 79.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.312 -0.868 . . . . 0.0 109.238 179.621 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.566 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.73 -50.97 57.62 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.873 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.4 t -61.22 -29.96 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.083 -1.245 . . . . 0.0 109.467 -179.823 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.607 ' O ' HD21 ' A' ' 73' ' ' LEU . . . -84.72 -14.52 48.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.424 -0.798 . . . . 0.0 110.094 -179.42 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.048 HG13 HG12 ' A' ' 10' ' ' VAL . 41.6 t -84.64 -43.36 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.027 -1.046 . . . . 0.0 110.091 -179.409 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.35 -24.75 2.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.987 -1.07 . . . . 0.0 109.33 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.562 ' CG ' ' CB ' ' A' ' 76' ' ' GLU . 3.2 m-70 -93.83 -114.08 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.532 -0.73 . . . . 0.0 109.946 -179.787 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.799 HD11 ' HA ' ' A' ' 70' ' ' VAL . 16.5 mt 66.15 -57.42 0.36 Allowed 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.027 -1.045 . . . . 0.0 110.392 -179.289 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.468 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -58.01 -45.43 93.81 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -179.133 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.472 ' O ' ' N ' ' A' ' 77' ' ' GLY . 35.1 m-20 -140.18 -41.13 0.43 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.853 -1.38 . . . . 0.0 111.695 -179.085 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.562 ' CB ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -68.51 51.54 0.07 Allowed 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.325 -0.859 . . . . 0.0 111.284 -178.007 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 80' ' ' VAL . . . -65.37 -17.17 63.78 Favored Glycine 0 N--CA 1.475 1.236 0 N-CA-C 105.911 -2.876 . . . . 0.0 105.911 176.246 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 15.8 ttmt -49.9 -38.58 36.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.564 -0.963 . . . . 0.0 108.852 178.965 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.463 ' CG ' ' O ' ' A' ' 76' ' ' GLU . 0.0 OUTLIER -50.36 -25.81 4.24 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.16 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 77' ' ' GLY . 53.5 t -51.21 -31.11 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.076 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.24 -35.61 76.3 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.964 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.434 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.3 OUTLIER -61.27 -52.97 62.49 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.215 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.556 ' CE ' HD12 ' A' ' 141' ' ' LEU . 86.5 mmm -56.96 -38.56 73.13 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.255 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -35.74 40.96 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.921 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.434 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -67.89 -32.37 72.81 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 1.044 HG11 HD11 ' A' ' 141' ' ' LEU . 48.6 t -59.38 -51.95 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 108.785 179.432 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.47 ' O ' HD12 ' A' ' 145' ' ' LEU . . . -56.66 -52.94 47.42 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.061 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.764 HG23 ' HA3' ' A' ' 144' ' ' GLY . 63.3 t -51.75 -33.26 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.397 -1.061 . . . . 0.0 108.817 179.065 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.508 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.0 mmm180 -76.43 -49.75 15.88 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.189 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.582 ' HB2' HD13 ' A' ' 145' ' ' LEU . 2.1 m80 -58.92 -21.24 57.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.464 -0.772 . . . . 0.0 109.115 179.332 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.501 ' CG ' ' HA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -66.72 -12.08 57.07 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.314 -0.866 . . . . 0.0 110.254 -179.704 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.31 53.49 0.6 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.634 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.552 ' CZ ' ' ND1' ' A' ' 90' ' ' HIS . 3.1 m-30 -89.23 -164.36 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.238 -1.154 . . . . 0.0 109.702 179.734 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.14 -51.14 19.33 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.047 ' ND2' HG13 ' A' ' 44' ' ' VAL . 17.1 p-10 -69.16 -32.36 71.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.14 -1.212 . . . . 0.0 109.828 -179.686 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.8 tttm 58.26 18.86 5.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.197 -0.939 . . . . 0.0 109.699 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -125.75 41.27 3.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.69 -179.935 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.566 HD13 ' CD2' ' A' ' 90' ' ' HIS . 36.4 mt -81.32 155.75 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.184 -0.947 . . . . 0.0 109.679 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.473 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.1 mptp? -136.58 145.58 45.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.884 -179.825 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.782 ' HB1' ' CG1' ' A' ' 142' ' ' ILE . . . -86.4 11.77 11.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.954 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.566 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 15.5 pt-20 -95.48 -24.21 16.76 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.107 -0.995 . . . . 0.0 109.557 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.566 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 88.7 m-85 -83.03 -7.39 59.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.928 179.722 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.857 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 11.3 m-85 -66.87 -52.17 46.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.096 -1.002 . . . . 0.0 109.945 -179.739 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.504 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.5 tm-20 -56.54 -55.61 40.99 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.131 -0.98 . . . . 0.0 109.867 -179.685 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.83 -61.85 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 123.755 1.397 . . . . 0.0 109.83 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.925 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.75 -23.78 31.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.291 -0.88 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.99 -48.67 6.84 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.36 65.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -1.191 . . . . 0.0 109.414 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.0 m -75.28 -31.01 60.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.872 . . . . 0.0 109.518 179.893 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.813 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.0 OUTLIER -70.13 -30.16 67.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.41 179.905 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.696 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.1 mt -64.34 -32.11 73.59 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.348 179.767 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.4 OUTLIER -74.89 -26.2 59.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 109.54 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.79 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.77 -35.78 20.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.247 -0.908 . . . . 0.0 109.518 -179.885 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.512 ' HE3' HD22 ' A' ' 110' ' ' LEU . 2.8 mtt -49.44 -45.08 46.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 0.0 110.116 -179.717 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' SER . 13.3 pt-20 -50.27 -25.69 3.98 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.153 -0.967 . . . . 0.0 109.907 -179.719 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.405 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 29.7 m170 -50.12 -39.92 44.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.635 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.447 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 3.2 ttt85 -80.17 -61.7 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.179 -0.951 . . . . 0.0 109.539 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.468 ' CG2' ' HB3' ' A' ' 16' ' ' ASP . 7.2 pt -89.35 44.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.236 -0.915 . . . . 0.0 109.521 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -51.62 123.07 18.15 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 102.12 -39.82 2.64 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.873 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.431 ' O ' ' N ' ' A' ' 123' ' ' ASN . 29.9 mttp -83.54 -29.5 27.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -1.14 . . . . 0.0 109.439 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.407 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.26 76.73 0.1 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.235 179.727 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.581 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.4 p30 -79.8 -167.67 1.33 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.311 -0.868 . . . . 0.0 109.875 -179.714 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.469 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.95 -45.9 87.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.839 . . . . 0.0 109.531 179.868 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.581 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -58.07 -33.46 69.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.283 -0.886 . . . . 0.0 109.283 179.832 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.01 -53.38 20.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.28 -0.888 . . . . 0.0 109.417 179.832 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.503 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 11.9 ptpt -70.47 -26.84 63.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.191 -0.943 . . . . 0.0 109.356 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.447 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.8 t70 -81.91 -39.81 23.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.357 179.557 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -62.37 -43.54 98.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.375 -0.828 . . . . 0.0 109.241 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.949 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.0 m0 -75.57 -31.89 60.17 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.304 -0.873 . . . . 0.0 108.7 179.563 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.503 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -55.46 -30.84 61.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 108.631 178.867 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.11 -28.89 22.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.797 . . . . 0.0 109.101 179.477 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -82.93 -52.65 6.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.431 -0.793 . . . . 0.0 109.465 179.899 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.813 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.1 OUTLIER -49.85 -30.05 9.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 0.0 109.376 179.85 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -78.73 -27.62 44.87 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.275 -0.891 . . . . 0.0 108.984 179.456 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' A' ' 133' ' ' ALA . 2.4 t0 -84.12 -39.86 18.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.435 -0.791 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.558 HD13 HG23 ' A' ' 66' ' ' ILE . 8.2 mt -67.7 -56.33 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.497 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.556 ' O ' HD12 ' A' ' 142' ' ' ILE . 87.2 p -69.37 -36.7 77.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.334 -0.853 . . . . 0.0 109.607 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.558 ' HA2' HD13 ' A' ' 142' ' ' ILE . . . -56.23 -23.11 39.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.942 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.03 59.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 0.0 109.998 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.044 HD11 HG11 ' A' ' 86' ' ' VAL . 0.2 OUTLIER -91.4 -19.45 22.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.109 -0.994 . . . . 0.0 109.811 -179.847 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.782 ' CG1' ' HB1' ' A' ' 100' ' ' ALA . 3.2 mp -80.06 3.37 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.218 -0.926 . . . . 0.0 110.115 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 23.4 m -100.8 -31.09 11.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.01 -1.057 . . . . 0.0 109.925 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.764 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -93.1 -21.47 30.14 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.609 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.582 HD13 ' HB2' ' A' ' 90' ' ' HIS . 12.8 tp -77.46 -133.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.179 -1.189 . . . . 0.0 109.315 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.477 HE21 ' HA ' ' A' ' 146' ' ' GLN . 0.5 OUTLIER 49.19 41.86 20.54 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.781 -1.199 . . . . 0.0 109.93 179.688 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.501 ' HA ' ' CG ' ' A' ' 91' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.637 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.857 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.488 ' C ' HD22 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.904 ' C ' HD12 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.262 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.904 HD12 ' C ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 42.6 34.88 0.6 Allowed 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.564 -0.962 . . . . 0.0 109.308 179.904 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.44 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 2.0 p -90.36 -156.24 0.42 Allowed 'General case' 0 C--N 1.289 -2.05 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.11 -178.604 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -65.76 -10.61 38.67 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.425 -0.797 . . . . 0.0 110.208 -179.596 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.852 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -104.56 -54.13 2.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.015 -1.053 . . . . 0.0 110.187 -179.732 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.817 ' O ' HG23 ' A' ' 10' ' ' VAL . 65.7 mt-30 -70.99 -50.5 33.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.967 -1.083 . . . . 0.0 109.43 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.475 ' HG2' ' HB2' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -53.06 -24.25 9.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.048 179.583 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 5.8 mp0 -83.16 -53.29 5.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.434 -0.791 . . . . 0.0 109.521 179.893 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 5' ' ' ALA . 21.2 t -55.37 -33.99 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.817 HG23 ' O ' ' A' ' 6' ' ' GLN . 93.8 t -57.33 -43.17 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.95 -10.12 59.16 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.271 -0.893 . . . . 0.0 109.896 179.836 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 t -93.56 -26.21 17.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.123 -0.986 . . . . 0.0 109.99 -179.718 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.449 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 20.6 p -95.74 -15.25 22.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -0.971 . . . . 0.0 109.965 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.799 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -88.49 -23.02 23.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.065 -1.022 . . . . 0.0 109.686 -179.933 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 73.4 mttt -81.6 1.67 32.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.934 . . . . 0.0 109.852 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.57 -48.51 2.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.128 -0.982 . . . . 0.0 109.263 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.994 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.0 mt -71.31 -28.76 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.432 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.696 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -109.33 34.42 3.77 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.235 -0.916 . . . . 0.0 109.603 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.15 -86.93 0.01 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.9 p -100.77 -24.46 14.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -1.145 . . . . 0.0 109.706 -179.99 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.647 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.7 p-10 -81.02 -20.77 41.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.936 . . . . 0.0 109.699 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.696 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 28.8 t30 56.93 30.06 17.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.592 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.828 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 88.53 37.71 7.4 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.647 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -79.02 -49.63 12.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -1.144 . . . . 0.0 109.655 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.487 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -76.23 -23.55 70.88 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 -179.921 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.005 HG12 HD11 ' A' ' 63' ' ' LEU . 41.5 t -67.01 -27.2 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.334 -1.097 . . . . 0.0 109.817 -179.936 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.4 ' HA3' ' C ' ' A' ' 59' ' ' GLY . . . -84.69 -50.79 4.07 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.487 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.2 ptpt -57.62 -24.17 55.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -1.203 . . . . 0.0 110.041 -179.556 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.428 ' O ' ' CD ' ' A' ' 33' ' ' LYS . 12.2 pt-20 -97.06 -28.39 14.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.036 -1.04 . . . . 0.0 109.768 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.407 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 37.1 t -83.99 -52.5 6.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 109.709 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 3.7 m-30 -60.45 -45.27 94.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.322 -0.861 . . . . 0.0 109.787 -179.806 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.748 ' OG1' HG11 ' A' ' 55' ' ' VAL . 21.1 m -52.07 -41.3 62.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.13 -0.981 . . . . 0.0 109.453 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.428 ' CD ' ' O ' ' A' ' 29' ' ' GLU . 8.1 mtpt -68.98 -48.18 63.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.564 179.918 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.73 ' CG ' HD23 ' A' ' 106' ' ' LEU . 9.0 t80 -58.91 -49.86 76.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.514 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.711 ' CD1' HG22 ' A' ' 55' ' ' VAL . 32.8 mt -57.35 -45.49 84.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 109.698 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.531 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 1.3 t -63.33 -59.83 4.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.194 -0.941 . . . . 0.0 109.758 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -59.95 -26.91 66.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.898 . . . . 0.0 109.724 -179.909 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -119.69 104.32 10.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.771 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 54.5 m170 -86.45 -21.93 26.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.604 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -67.66 -16.38 64.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -0.891 . . . . 0.0 109.525 179.644 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.44 ' HE3' ' CMB' ' A' ' 148' ' ' HEM . 89.7 mmm -109.35 -24.41 11.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.521 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -48.14 -40.46 23.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -77.06 -21.34 54.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.376 179.728 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.055 HG22 ' ND2' ' A' ' 95' ' ' ASN . 39.6 t -75.09 -39.71 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 0.0 109.563 179.981 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.655 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 15.6 m-85 -68.08 -31.06 70.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.616 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.42 27.24 3.68 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.543 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.9 m-85 -122.77 171.41 9.2 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.29 -1.123 . . . . 0.0 109.653 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.9 t -111.14 23.47 14.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.212 179.58 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.84 -163.78 27.59 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -93.13 29.81 1.79 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 18.3 m -126.52 22.98 6.92 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 109.633 -179.956 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.41 137.94 19.58 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.236 -0.915 . . . . 0.0 109.615 179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -66.51 -24.14 49.39 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 123.919 1.484 . . . . 0.0 110.07 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -54.24 -31.66 50.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.901 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.748 HG11 ' OG1' ' A' ' 32' ' ' THR . 97.5 t -53.66 -53.71 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.268 -1.136 . . . . 0.0 109.568 -179.946 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.721 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -63.07 -14.79 52.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.906 . . . . 0.0 109.769 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.52 -44.21 11.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.17 -0.956 . . . . 0.0 109.694 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.504 HD21 ' CHA' ' A' ' 148' ' ' HEM . 1.0 OUTLIER -70.22 -63.62 1.05 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.219 -0.926 . . . . 0.0 110.051 -179.8 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.54 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -51.9 -29.3 26.76 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.765 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.721 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -67.93 -40.65 83.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -1.203 . . . . 0.0 110.029 -179.708 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 43.4 mttm -80.85 -36.31 31.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 109.928 -179.77 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.753 HG21 ' O ' ' A' ' 149' ' ' CMO . 86.1 t -59.39 -53.98 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 0.0 109.903 -179.786 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 1.005 HD11 HG12 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -47.0 -38.72 11.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.195 -0.94 . . . . 0.0 109.833 -179.936 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.88 -49.32 63.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.625 179.925 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.407 ' OE1' HG21 ' A' ' 86' ' ' VAL . 14.0 tp60 -52.8 -48.2 67.06 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.966 . . . . 0.0 109.437 179.855 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.984 ' O ' HG23 ' A' ' 70' ' ' VAL . 98.8 mt -55.89 -32.98 33.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.296 -0.878 . . . . 0.0 109.165 179.662 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.567 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.99 -57.86 9.01 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 179.503 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.9 t -55.31 -26.17 18.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -1.111 . . . . 0.0 109.05 179.803 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -26.23 26.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.445 -0.784 . . . . 0.0 109.535 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.984 HG23 ' O ' ' A' ' 66' ' ' ILE . 40.0 t -59.87 -19.36 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 179.859 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 34.0 t -88.7 10.14 21.81 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.221 -0.924 . . . . 0.0 110.203 -179.688 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.46 ' HB3' ' HB2' ' A' ' 79' ' ' MET . 19.3 m-70 -147.76 50.73 1.05 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.972 -1.08 . . . . 0.0 109.82 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.796 HD11 ' HB1' ' A' ' 133' ' ' ALA . 3.7 mm? -74.34 -43.9 54.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.343 -0.848 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -89.81 -33.58 8.98 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.904 -1.678 . . . . 0.0 108.904 179.864 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -97.76 69.67 2.14 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.424 -1.045 . . . . 0.0 109.359 179.787 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -88.49 15.61 7.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.891 -179.931 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.47 -30.04 61.39 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 179.904 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.558 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 1.7 tppt? -120.06 -27.08 5.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.182 -1.187 . . . . 0.0 109.834 -179.947 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.46 ' HB2' ' HB3' ' A' ' 72' ' ' HIS . 3.9 tmm? -48.83 -41.96 34.68 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.083 -1.011 . . . . 0.0 109.453 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.463 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.4 t -67.72 -26.66 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.358 -0.839 . . . . 0.0 109.199 179.607 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -58.24 -48.07 81.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.291 -0.88 . . . . 0.0 109.365 179.756 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.59 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.6 OUTLIER -78.19 -48.1 16.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.876 . . . . 0.0 109.286 179.67 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.476 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 2.7 mtp -57.22 -56.81 16.98 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.26 -0.9 . . . . 0.0 109.243 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.475 ' HG3' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.4 -32.86 27.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.19 -0.944 . . . . 0.0 108.856 179.372 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.59 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -65.58 -39.72 91.93 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.268 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.893 ' CG1' HD11 ' A' ' 141' ' ' LEU . 56.3 t -52.99 -50.22 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.291 -0.88 . . . . 0.0 109.18 179.502 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -50.5 -49.77 38.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 179.732 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.685 HG23 ' HA3' ' A' ' 144' ' ' GLY . 91.5 t -49.71 -26.23 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.324 -1.104 . . . . 0.0 109.309 179.591 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.4 mmt180 -78.76 -48.52 14.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.381 -0.824 . . . . 0.0 108.872 179.452 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.579 ' HB2' HD13 ' A' ' 145' ' ' LEU . 13.3 m80 -55.5 -28.28 53.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.441 -0.787 . . . . 0.0 109.327 179.618 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.493 ' HG3' ' HA ' ' A' ' 147' ' ' SER . 0.3 OUTLIER -67.93 -10.05 50.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.319 -0.863 . . . . 0.0 110.04 -179.897 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -138.73 50.71 0.79 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.792 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.5 m-30 -101.59 -168.55 1.57 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.18 -1.188 . . . . 0.0 109.584 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.96 -49.47 16.72 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 1.055 ' ND2' HG22 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -68.02 -51.03 51.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.439 -1.036 . . . . 0.0 109.221 179.796 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.479 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.7 tttt 74.64 -48.69 0.65 Allowed 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.528 -0.732 . . . . 0.0 110.844 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -67.81 61.22 0.07 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.958 -1.089 . . . . 0.0 110.248 -179.553 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 96' ' ' LYS . 65.9 mt -92.03 161.24 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.041 . . . . 0.0 109.462 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.513 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -139.8 139.38 36.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.102 -0.999 . . . . 0.0 110.017 -179.798 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 1.055 ' HB1' HD12 ' A' ' 142' ' ' ILE . . . -79.13 -5.9 55.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.421 -0.8 . . . . 0.0 109.621 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -70.67 -31.52 68.47 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.103 -0.998 . . . . 0.0 109.694 179.944 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.513 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 75.5 m-85 -82.79 4.93 23.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 110.529 -179.314 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.824 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 5.5 m-85 -77.09 -57.57 3.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.959 -1.088 . . . . 0.0 109.783 179.704 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -58.31 -50.83 85.91 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.851 -179.698 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' CD ' ' N ' ' A' ' 104' ' ' GLU . 24.8 Cg_exo -55.62 -57.49 1.56 Allowed 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.888 1.468 . . . . 0.0 109.768 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.929 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -57.49 -19.5 24.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.401 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.51 -51.08 4.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.953 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.72 -54.3 48.41 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.166 -1.196 . . . . 0.0 109.572 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.5 t -55.98 -25.17 42.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' A' ' 106' ' ' LEU . 5.2 tt -67.39 -45.16 77.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.916 . . . . 0.0 109.734 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.911 HD21 ' HB3' ' A' ' 130' ' ' TRP . 13.8 mt -56.6 -31.86 64.68 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.653 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.52 -30.41 70.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.906 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -82.86 -34.21 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.893 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.414 ' HE1' HD21 ' A' ' 110' ' ' LEU . 5.9 mmt -46.39 -45.33 17.77 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.3 -0.875 . . . . 0.0 110.34 -179.713 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -50.32 -23.2 2.16 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.11 -0.993 . . . . 0.0 110.223 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.411 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -57.0 -46.88 81.96 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.051 -1.031 . . . . 0.0 109.703 -179.809 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.467 ' HD3' HG23 ' A' ' 17' ' ' ILE . 1.9 ttt85 -73.11 -55.8 5.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 109.815 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 5.3 pt -99.92 48.69 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.127 -0.983 . . . . 0.0 110.103 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.09 100.98 0.11 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 179.64 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.44 -45.33 1.14 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.513 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.3 mmtt -82.23 -24.1 35.02 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.251 -1.146 . . . . 0.0 109.154 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.97 79.58 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.441 -0.787 . . . . 0.0 109.595 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.501 HD22 ' HB3' ' A' ' 125' ' ' ALA . 19.7 p-10 -88.22 -178.64 5.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.894 . . . . 0.0 110.186 -179.793 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -55.23 -34.73 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.874 -179.696 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.752 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -68.61 -14.4 62.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.668 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -90.43 -50.73 5.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.07 -1.019 . . . . 0.0 109.624 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.724 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.1 ptpt -69.42 -27.77 65.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.262 179.776 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.45 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.0 t0 -79.07 -52.56 8.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.32 -0.862 . . . . 0.0 109.486 179.772 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -56.66 -54.34 47.22 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.374 -0.829 . . . . 0.0 109.765 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.994 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.1 m0 -63.46 -27.83 69.55 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.724 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.39 -25.46 65.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.225 -0.922 . . . . 0.0 108.78 179.202 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.22 -41.93 14.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.44 -0.787 . . . . 0.0 109.121 179.466 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.796 ' HB1' HD11 ' A' ' 73' ' ' LEU . . . -70.19 -56.12 7.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.515 -0.74 . . . . 0.0 109.781 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 134' ' ' TYR . 9.0 m-30 -47.39 -27.96 1.88 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.296 -0.877 . . . . 0.0 109.636 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.98 -43.18 65.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.258 -0.901 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.76 -36.57 59.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.341 -0.85 . . . . 0.0 109.325 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.717 HD12 ' O ' ' A' ' 133' ' ' ALA . 1.3 mp -66.64 -58.44 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 108.885 179.717 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.405 ' O ' HG12 ' A' ' 142' ' ' ILE . 31.7 p -66.97 -24.08 66.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.251 -0.906 . . . . 0.0 109.62 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.32 -28.78 55.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.16 -22.86 60.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -1.138 . . . . 0.0 109.595 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.901 HD23 ' O ' ' A' ' 141' ' ' LEU . 3.8 tt -86.46 11.6 12.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 109.986 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 1.055 HD12 ' HB1' ' A' ' 100' ' ' ALA . 44.0 mm -100.29 19.29 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.074 -1.016 . . . . 0.0 109.683 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.475 ' CB ' ' HG3' ' A' ' 84' ' ' LYS . 4.4 m -108.11 -52.65 2.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.634 179.962 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.685 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -75.96 -7.75 84.3 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.579 HD13 ' HB2' ' A' ' 90' ' ' HIS . 0.7 OUTLIER -94.96 -155.66 0.48 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.953 -1.322 . . . . 0.0 108.432 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.417 ' HB2' ' O ' ' A' ' 145' ' ' LEU . 2.1 mp0 55.83 47.74 19.61 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.776 -1.202 . . . . 0.0 109.595 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.493 ' HA ' ' HG3' ' A' ' 91' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.65 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.824 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.753 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.937 ' CD1' HD12 ' A' ' 73' ' ' LEU . 8.0 mt -83.96 175.36 9.62 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.317 -1.108 . . . . 0.0 109.512 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 p -124.69 -167.6 1.69 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.177 -0.952 . . . . 0.0 110.002 179.862 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.84 -16.01 54.85 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.208 -0.932 . . . . 0.0 109.98 -179.746 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.784 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -104.37 -42.83 5.36 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.059 -1.026 . . . . 0.0 109.726 -179.705 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.429 ' O ' HG23 ' A' ' 10' ' ' VAL . 1.5 mt-30 -64.81 -46.1 83.43 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.439 ' HG3' ' HB3' ' A' ' 73' ' ' LEU . 38.6 ttp180 -55.38 -34.27 64.17 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.206 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -73.87 -41.66 61.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.261 -0.899 . . . . 0.0 109.176 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.784 HG23 ' O ' ' A' ' 5' ' ' ALA . 59.7 t -57.42 -29.85 34.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.336 -0.853 . . . . 0.0 109.426 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 1.046 HG12 HG13 ' A' ' 70' ' ' VAL . 91.9 t -66.03 -52.14 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 109.468 179.793 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.56 -9.75 51.4 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.307 -0.871 . . . . 0.0 109.988 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 p -92.94 -24.43 18.41 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.045 -1.035 . . . . 0.0 109.774 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.4 p -98.49 -7.76 27.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 110.065 -179.939 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.596 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -95.14 -23.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.093 . . . . 0.0 109.588 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.2 mttm -77.08 -2.49 34.4 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.206 -0.933 . . . . 0.0 109.852 179.756 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -114.02 -51.12 2.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.085 -1.009 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.951 HD12 ' CH2' ' A' ' 130' ' ' TRP . 56.3 mt -66.34 -31.52 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.919 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.888 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -108.77 34.03 3.9 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.315 -0.866 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.31 -85.0 0.02 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.8 p -95.68 -31.45 13.23 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -1.14 . . . . 0.0 109.58 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.543 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 24.5 p-10 -75.51 -21.97 57.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.295 -0.878 . . . . 0.0 109.591 180.0 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.888 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 4.3 t30 56.57 21.85 6.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.207 -0.933 . . . . 0.0 109.523 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 98.82 21.67 15.55 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.543 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -71.04 -56.85 5.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -1.146 . . . . 0.0 109.637 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.47 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -70.85 -21.08 78.04 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.925 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.631 HG11 HD11 ' A' ' 63' ' ' LEU . 46.6 t -70.65 -35.03 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.284 -1.127 . . . . 0.0 110.005 -179.778 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.02 -43.72 13.33 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 -179.308 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.47 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.8 ptpt -64.28 -26.39 68.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -1.217 . . . . 0.0 110.155 -179.385 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.763 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -100.68 -11.41 20.0 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.045 -1.034 . . . . 0.0 110.156 -179.73 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.462 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 34.1 t -93.05 -68.19 0.81 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 109.888 -179.797 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.528 ' CZ ' HG11 ' A' ' 62' ' ' VAL . 10.3 m-85 -50.32 -30.48 12.14 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 110.004 -179.604 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.771 ' OG1' HG11 ' A' ' 55' ' ' VAL . 15.7 m -54.33 -53.18 57.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.064 -1.023 . . . . 0.0 109.221 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.425 ' HD3' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -55.44 -48.56 74.26 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.932 . . . . 0.0 109.243 179.737 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.6 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.8 t80 -54.33 -49.65 69.23 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.322 -0.862 . . . . 0.0 109.255 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.832 ' CD1' HG22 ' A' ' 55' ' ' VAL . 24.2 mt -60.1 -46.09 90.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.642 179.866 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.439 ' OG ' ' N ' ' A' ' 37' ' ' ALA . 8.9 p -61.21 -54.41 44.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.732 -179.91 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.439 ' N ' ' OG ' ' A' ' 36' ' ' SER . . . -67.86 -27.09 66.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.226 -0.921 . . . . 0.0 109.62 -179.927 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.403 ' N ' ' O ' ' A' ' 34' ' ' PHE . 7.8 m80 -117.51 107.37 14.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.754 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 56.3 m170 -88.41 -19.9 25.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.408 -0.808 . . . . 0.0 109.356 179.648 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -71.04 -11.29 60.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.71 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.558 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -107.61 -27.73 10.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.007 . . . . 0.0 109.943 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.475 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -46.99 -48.14 21.79 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.13 -0.981 . . . . 0.0 109.796 -179.825 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.6 -28.78 65.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.122 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.984 HG13 ' ND2' ' A' ' 95' ' ' ASN . 21.3 t -70.15 -38.4 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.273 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.608 ' CE1' HMB2 ' A' ' 148' ' ' HEM . 9.8 m-85 -77.27 -29.93 54.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.243 -0.911 . . . . 0.0 109.612 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.14 29.51 3.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.374 -1.491 . . . . 0.0 109.374 179.825 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.534 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.0 m-85 -124.25 166.99 14.91 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -1.167 . . . . 0.0 109.91 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.2 t -104.29 -20.3 13.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.421 -0.8 . . . . 0.0 109.127 179.343 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.83 -164.69 24.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.816 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.42 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -95.15 35.84 1.26 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -1.179 . . . . 0.0 109.69 -179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 56.4 p -135.07 23.2 3.53 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 109.533 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.493 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.8 p-10 -107.69 138.79 20.11 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -60.33 -20.73 64.18 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.934 1.491 . . . . 0.0 109.995 -179.964 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.71 -44.75 54.95 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.832 HG22 ' CD1' ' A' ' 35' ' ' LEU . 80.3 t -51.45 -37.99 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.401 -1.058 . . . . 0.0 109.31 179.776 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.508 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -71.72 -24.45 61.8 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.28 -0.887 . . . . 0.0 109.251 179.602 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -79.33 -37.96 36.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.376 179.778 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.793 HD21 ' CHA' ' A' ' 148' ' ' HEM . 1.6 mt -77.19 -60.98 2.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.527 179.926 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.498 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.66 -46.65 38.42 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.508 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -54.46 -42.04 70.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.39 179.842 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.8 mttt -76.54 -29.17 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.262 -0.899 . . . . 0.0 109.354 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' O ' ' A' ' 58' ' ' LEU . 47.6 t -78.58 -49.95 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.631 HD11 HG11 ' A' ' 26' ' ' VAL . 1.0 OUTLIER -48.43 -46.1 37.19 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.82 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.72 -49.93 69.58 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.303 -0.873 . . . . 0.0 109.564 179.939 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.426 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 8.1 tp-100 -50.9 -43.32 59.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 109.31 179.813 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.853 ' O ' HG23 ' A' ' 70' ' ' VAL . 31.8 mm -57.6 -43.6 83.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.284 -0.885 . . . . 0.0 108.758 179.477 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.548 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.83 -55.16 31.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.775 -1.73 . . . . 0.0 108.775 179.371 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.3 t -54.03 -35.32 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.346 -1.09 . . . . 0.0 109.435 179.833 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.599 ' HB1' HG13 ' A' ' 137' ' ' ILE . . . -79.8 -30.38 40.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.88 . . . . 0.0 109.42 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.046 HG13 HG12 ' A' ' 10' ' ' VAL . 48.9 t -68.68 -16.43 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.262 -0.899 . . . . 0.0 109.584 179.895 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.41 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.2 m -90.03 -0.05 57.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.172 -0.955 . . . . 0.0 110.199 -179.897 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.472 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 21.4 m-70 -140.02 50.85 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.983 -1.073 . . . . 0.0 109.767 -179.872 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.937 HD12 ' CD1' ' A' ' 2' ' ' LEU . 4.3 mm? -58.71 -51.78 68.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.934 . . . . 0.0 109.465 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -92.39 -25.46 21.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.838 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.45 60.11 2.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.286 -1.126 . . . . 0.0 109.639 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.445 ' HA ' ' HB3' ' A' ' 79' ' ' MET . 0.0 OUTLIER -70.37 -7.12 40.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 110.033 179.96 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.02 -19.48 30.73 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.556 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 6.5 ttmm -130.28 -39.38 1.34 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -1.21 . . . . 0.0 110.004 -179.871 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.472 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 28.2 ttp -48.53 -54.83 12.89 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.116 -0.99 . . . . 0.0 109.829 -179.847 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 45.9 t -68.61 -11.64 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.964 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.556 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -78.44 -37.41 43.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.03 -1.044 . . . . 0.0 109.44 179.904 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -88.65 -41.18 12.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.468 ' HE2' HD12 ' A' ' 141' ' ' LEU . 8.9 mtp -60.36 -41.04 92.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.94 . . . . 0.0 109.247 179.809 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.554 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.8 -42.04 62.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.784 179.171 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.437 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -61.28 -39.68 91.31 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.992 ' CG1' HD11 ' A' ' 141' ' ' LEU . 23.9 t -56.98 -51.86 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.277 -0.89 . . . . 0.0 108.774 179.496 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 145' ' ' LEU . . . -60.86 -53.59 43.95 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.655 -2.178 . . . . 0.0 107.655 178.826 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 84' ' ' LYS . 78.7 t -48.8 -24.96 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.451 -1.029 . . . . 0.0 109.445 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.515 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 7.5 mmm180 -83.6 -43.85 15.22 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.021 -1.049 . . . . 0.0 108.729 179.238 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.696 ' O ' HD12 ' A' ' 98' ' ' ILE . 19.5 m80 -58.75 -33.73 70.59 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.379 -0.825 . . . . 0.0 109.698 179.589 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -61.45 -15.78 40.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 110.434 -179.29 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.46 46.73 1.05 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.257 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.515 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.7 m-30 -87.28 -173.13 4.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.195 -1.179 . . . . 0.0 109.402 179.51 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.26 -26.42 52.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 179.668 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.984 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -76.86 -55.23 5.67 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.559 -0.965 . . . . 0.0 109.101 179.704 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.481 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 10.3 tptp 77.09 -19.02 0.45 Allowed 'General case' 0 N--CA 1.508 2.469 0 O-C-N 121.765 -0.585 . . . . 0.0 111.472 179.871 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.409 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 8.2 m170 -94.05 44.01 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.601 -1.312 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.696 HD12 ' O ' ' A' ' 90' ' ' HIS . 36.3 mt -74.84 160.46 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.758 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.515 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -151.21 136.24 17.43 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.349 -0.845 . . . . 0.0 109.987 179.984 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.94 -5.52 44.26 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.573 -0.704 . . . . 0.0 109.506 179.301 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mm-40 -74.98 -30.66 61.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.07 -1.019 . . . . 0.0 109.439 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.561 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 36.0 m-85 -75.66 -23.54 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.299 -0.876 . . . . 0.0 109.889 -179.746 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.818 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 4.8 m-85 -54.39 -64.16 0.92 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.56 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.81 -58.55 5.25 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 110.856 -179.111 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.561 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.3 Cg_endo -59.49 -46.62 20.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.639 1.336 . . . . 0.0 109.63 -179.666 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.786 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.1 tm? -60.98 -27.29 68.19 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.216 -0.927 . . . . 0.0 108.841 179.414 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -81.34 -38.0 16.16 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 179.508 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.19 -60.13 4.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 0.0 109.345 179.782 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.0 m -52.42 -24.86 8.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.902 . . . . 0.0 109.18 179.67 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.421 ' HB3' ' O ' ' A' ' 107' ' ' GLY . 2.3 tt -66.51 -48.19 70.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.347 -0.846 . . . . 0.0 109.421 179.811 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.804 HD21 ' CB ' ' A' ' 130' ' ' TRP . 13.0 mt -57.65 -32.32 67.17 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.947 . . . . 0.0 109.216 179.729 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.4 m -73.82 -38.52 64.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.339 -0.85 . . . . 0.0 109.429 179.823 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.763 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -72.61 -35.71 67.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.292 -0.88 . . . . 0.0 109.387 179.791 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.705 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.2 mmt -51.39 -42.15 61.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.44 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.3 OUTLIER -50.7 -23.7 2.85 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.99 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 21.2 m170 -53.71 -26.71 24.29 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.882 . . . . 0.0 110.094 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.7 -73.31 0.66 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.026 -1.046 . . . . 0.0 109.877 -179.848 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.61 HG23 ' CG1' ' A' ' 17' ' ' ILE . 24.9 pt -65.33 -33.83 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.875 -1.14 . . . . 0.0 109.169 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.448 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 45.43 -108.64 0.23 Allowed Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.08 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.32 -35.88 10.16 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -179.47 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.497 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 40.3 mttt -68.06 -22.25 64.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.155 -1.203 . . . . 0.0 109.699 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.445 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -74.99 72.42 2.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.068 -1.02 . . . . 0.0 109.111 179.443 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.758 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 15.0 p-10 -73.43 -175.88 2.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.275 -0.891 . . . . 0.0 109.882 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.422 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -59.08 -45.99 89.42 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 109.302 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.758 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -60.12 -33.0 71.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.315 -0.865 . . . . 0.0 109.074 179.662 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.55 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -66.98 -51.99 48.32 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.272 -0.893 . . . . 0.0 109.429 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 14.4 ptpt -71.61 -28.96 64.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.251 -0.906 . . . . 0.0 109.546 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.476 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 39.3 t0 -80.07 -43.39 21.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.331 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.476 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -56.28 -46.1 79.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.325 -0.86 . . . . 0.0 109.213 179.675 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.951 ' CH2' HD12 ' A' ' 17' ' ' ILE . 13.1 m0 -74.63 -32.39 62.28 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.258 -0.901 . . . . 0.0 108.581 179.585 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -56.54 -26.02 53.68 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.962 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.92 -30.66 14.04 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.315 -0.866 . . . . 0.0 109.063 179.476 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.434 ' C ' HD13 ' A' ' 137' ' ' ILE . . . -83.08 -54.38 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.493 -0.754 . . . . 0.0 109.412 179.845 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.56 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -48.87 -27.31 2.96 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.362 -179.938 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.56 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -80.98 -32.08 34.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 108.776 179.335 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.408 ' N ' ' O ' ' A' ' 133' ' ' ALA . 3.1 m-20 -81.7 -35.67 29.54 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.431 -0.793 . . . . 0.0 109.272 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.664 HG21 HD13 ' A' ' 66' ' ' ILE . 1.4 mp -66.39 -60.53 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.207 -0.933 . . . . 0.0 108.545 179.409 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.14 -12.06 46.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.95 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.676 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -75.78 -46.25 14.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.55 -28.73 68.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -1.142 . . . . 0.0 109.702 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.992 HD11 ' CG1' ' A' ' 86' ' ' VAL . 1.7 tt -71.64 -22.09 61.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.298 -0.876 . . . . 0.0 109.667 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.676 HD12 ' HA2' ' A' ' 139' ' ' GLY . 86.9 mt -78.12 1.34 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.177 -179.826 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.479 ' HB3' ' CE ' ' A' ' 84' ' ' LYS . 68.2 m -81.35 -44.6 17.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.045 . . . . 0.0 109.718 -179.974 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 88' ' ' VAL . . . -110.85 11.12 29.78 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.88 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.432 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 0.3 OUTLIER -72.06 -36.31 69.54 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.027 -1.278 . . . . 0.0 110.014 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.413 ' O ' ' CG ' ' A' ' 146' ' ' GLN . 1.2 pt20 -108.36 64.91 0.62 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 -179.956 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 1.2 t . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.68 -179.869 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.818 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.614 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.677 HD13 HD13 ' A' ' 73' ' ' LEU . 15.7 mt -79.34 171.36 15.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.292 -1.122 . . . . 0.0 109.692 -179.912 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 p -118.67 -169.93 1.81 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.635 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.63 -13.33 56.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.786 179.859 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.636 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -98.48 -31.53 11.94 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.158 -0.964 . . . . 0.0 109.82 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.516 ' O ' HG23 ' A' ' 10' ' ' VAL . 24.6 mt-30 -81.31 -43.01 19.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 109.911 -179.765 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.473 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 12.4 ptm180 -53.78 -35.0 60.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.617 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.473 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 6.8 mm-40 -71.96 -47.74 50.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.921 . . . . 0.0 109.541 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 5' ' ' ALA . 33.1 t -60.09 -27.09 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.257 -0.902 . . . . 0.0 109.461 179.954 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.857 HG12 HG13 ' A' ' 70' ' ' VAL . 54.9 t -70.63 -49.11 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.287 -0.883 . . . . 0.0 109.475 179.899 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.9 -16.25 62.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.866 . . . . 0.0 109.795 -179.988 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.59 -26.16 26.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.705 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -95.15 -9.61 32.98 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.197 -0.94 . . . . 0.0 109.959 -179.992 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.77 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.61 -17.25 24.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.026 -1.046 . . . . 0.0 109.963 -179.882 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.4 mtpt -80.06 -13.71 59.09 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.121 -0.987 . . . . 0.0 109.585 179.658 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.408 ' O ' ' NE ' ' A' ' 117' ' ' ARG . 68.2 m-20 -98.62 -55.43 2.74 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.561 179.802 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.918 HD12 ' CH2' ' A' ' 130' ' ' TRP . 30.8 mt -65.39 -28.74 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.211 -0.931 . . . . 0.0 109.12 179.698 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.77 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -111.42 36.56 3.18 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 179.806 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.55 -86.77 0.02 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.7 p -104.98 9.76 34.4 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -1.17 . . . . 0.0 109.94 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.437 ' OD1' ' HA ' ' A' ' 18' ' ' ALA . 2.3 p30 -119.3 -12.41 9.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.1 -1.0 . . . . 0.0 109.848 179.907 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.674 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 14.8 t-20 64.03 13.03 7.4 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.234 -0.916 . . . . 0.0 109.838 -179.758 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.73 ' C ' HD13 ' A' ' 63' ' ' LEU . . . 96.3 16.28 38.2 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.918 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.421 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -48.35 -38.19 18.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.221 -1.164 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.29 14.53 57.43 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.552 ' HB ' HD22 ' A' ' 63' ' ' LEU . 15.7 t -102.21 -29.44 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.075 -1.25 . . . . 0.0 109.558 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -92.26 -37.08 6.03 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.657 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.484 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.7 ptpt -64.07 -31.7 72.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.172 -1.193 . . . . 0.0 109.549 -179.857 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.484 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 19.6 pt-20 -94.46 -19.13 20.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.125 -0.985 . . . . 0.0 109.642 179.882 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.527 ' SG ' HD12 ' A' ' 110' ' ' LEU . 35.4 t -89.25 -53.6 4.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.867 -179.78 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.902 ' CZ ' HG21 ' A' ' 62' ' ' VAL . 15.9 m-85 -63.41 -34.85 78.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 109.774 -179.688 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.796 ' OG1' HG11 ' A' ' 55' ' ' VAL . 12.4 m -58.71 -36.05 73.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.09 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.81 -42.22 50.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.874 . . . . 0.0 109.291 179.571 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.693 ' CG ' HD23 ' A' ' 106' ' ' LEU . 12.7 t80 -63.07 -47.41 83.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -0.887 . . . . 0.0 109.313 179.661 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.82 ' CD1' HG22 ' A' ' 55' ' ' VAL . 22.0 mt -57.16 -43.69 82.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.876 . . . . 0.0 109.739 179.925 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.404 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 3.6 t -68.76 -63.52 1.04 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 109.706 -179.923 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -52.56 -24.45 8.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.262 -0.899 . . . . 0.0 109.7 -179.956 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.404 ' O ' ' O ' ' A' ' 35' ' ' LEU . 29.7 m80 -125.49 104.29 8.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.805 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -86.71 -5.23 59.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.389 -0.819 . . . . 0.0 109.855 179.661 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -82.16 -21.99 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.099 -1.001 . . . . 0.0 109.535 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 41' ' ' MET . . . . . 0.457 ' CE ' HMB2 ' A' ' 148' ' ' HEM . 88.4 mmm -101.12 -23.88 14.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.244 -0.91 . . . . 0.0 109.692 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.427 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.62 -38.13 20.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.226 -0.921 . . . . 0.0 109.632 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.67 -28.56 60.89 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.422 179.76 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.77 HG13 ' OD1' ' A' ' 95' ' ' ASN . 52.5 t -67.17 -59.69 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.514 179.844 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.637 ' CD2' HD21 ' A' ' 35' ' ' LEU . 68.1 m-85 -50.79 -42.08 57.72 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.236 -0.915 . . . . 0.0 109.586 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.07 35.84 0.92 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.735 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.36 166.79 15.34 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.119 -1.224 . . . . 0.0 109.762 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.6 t -111.2 21.62 16.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.411 -0.805 . . . . 0.0 109.117 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 146.08 177.59 20.87 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -179.788 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -68.79 -13.78 62.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -1.181 . . . . 0.0 109.828 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 71.9 p -87.85 45.55 1.29 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.103 -0.998 . . . . 0.0 109.688 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.52 132.45 24.26 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -69.23 -22.17 34.89 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 123.874 1.46 . . . . 0.0 110.083 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.492 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -57.39 -26.93 57.48 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.82 HG22 ' CD1' ' A' ' 35' ' ' LEU . 87.1 t -58.33 -51.94 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.179 -1.189 . . . . 0.0 109.637 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -58.21 -22.6 52.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.928 . . . . 0.0 109.552 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.96 -60.31 2.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.874 . . . . 0.0 109.604 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.878 HD21 ' C1A' ' A' ' 148' ' ' HEM . 0.5 OUTLIER -55.88 -59.04 5.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.677 -179.949 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.524 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.54 -60.76 5.59 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.867 ' HA ' HD21 ' A' ' 63' ' ' LEU . . . -48.23 -33.97 9.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 0.0 109.654 179.788 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -77.76 -20.26 53.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.319 -0.863 . . . . 0.0 109.419 179.769 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.902 HG21 ' CZ ' ' A' ' 31' ' ' PHE . 49.4 t -81.24 -61.16 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.31 -0.869 . . . . 0.0 109.677 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.867 HD21 ' HA ' ' A' ' 60' ' ' ALA . 0.3 OUTLIER -46.07 -43.07 14.33 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.27 -0.894 . . . . 0.0 109.835 179.914 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.25 -40.23 33.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.96 -1.088 . . . . 0.0 109.477 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -65.83 -43.37 88.77 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.249 -0.907 . . . . 0.0 109.153 179.484 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.91 ' O ' HG23 ' A' ' 70' ' ' VAL . 33.9 mt -59.96 -40.13 82.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.412 -0.805 . . . . 0.0 109.182 179.68 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.565 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.04 -50.79 62.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.88 -30.53 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 109.334 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -82.81 -24.92 33.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.404 -0.81 . . . . 0.0 109.588 -179.963 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.91 HG23 ' O ' ' A' ' 66' ' ' ILE . 46.2 t -69.8 -9.06 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.855 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.509 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 24.9 p -91.39 30.9 1.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.058 -1.027 . . . . 0.0 109.938 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.509 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.5 m-70 -160.69 -89.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.633 179.875 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.677 HD13 HD13 ' A' ' 2' ' ' LEU . 15.0 mt 63.73 -71.76 0.06 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.367 -0.833 . . . . 0.0 109.985 179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.465 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -62.06 -29.24 72.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 179.823 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -92.39 88.36 6.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.294 -1.121 . . . . 0.0 109.507 179.842 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -89.31 44.32 1.2 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.662 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -119.95 -7.51 9.43 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.4 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 34.0 ttmt -143.29 -44.97 0.29 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.054 -1.263 . . . . 0.0 109.902 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.4 tmm? -48.8 -34.38 12.26 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.113 -0.992 . . . . 0.0 109.781 -179.877 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.431 ' O ' ' HB3' ' A' ' 84' ' ' LYS . 46.7 t -80.33 -19.6 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.612 179.931 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.4 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -62.41 -40.59 97.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.593 179.958 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.573 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 1.2 tp10 -87.0 -45.6 10.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.537 179.912 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.5 mtp -59.48 -56.92 15.91 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.257 179.765 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.431 ' HB3' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -52.43 -27.04 14.36 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.236 -0.915 . . . . 0.0 109.091 179.546 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.573 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.04 -35.93 72.14 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.707 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 82' ' ' GLU . 16.5 t -58.72 -38.77 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.221 -0.924 . . . . 0.0 109.226 179.868 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.421 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -55.86 -47.75 77.09 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.531 -1.827 . . . . 0.0 108.531 179.588 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.561 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.7 t -55.13 -36.13 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.32 -1.106 . . . . 0.0 108.955 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.507 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mpt_? -69.01 -52.33 29.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 108.991 179.398 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 90' ' ' HIS . . . . . 0.62 ' HB2' HD13 ' A' ' 145' ' ' LEU . 16.9 m80 -56.35 -29.22 61.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.836 . . . . 0.0 109.288 179.581 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HG3' ' CA ' ' A' ' 147' ' ' SER . 5.9 ttmt -66.23 -13.07 59.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.285 -0.884 . . . . 0.0 110.06 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.25 47.66 1.01 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.936 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.507 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -91.42 -169.29 2.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.346 -1.091 . . . . 0.0 109.817 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.26 -52.82 7.3 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.647 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.77 ' OD1' HG13 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -61.49 -31.65 71.64 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.128 -1.219 . . . . 0.0 109.486 -179.798 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.438 ' H ' ' ND2' ' A' ' 95' ' ' ASN . 9.5 tttt 60.42 32.94 20.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -0.864 . . . . 0.0 110.147 179.595 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.414 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 6.2 m-70 -129.24 -85.31 0.55 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.186 -0.946 . . . . 0.0 109.092 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 90' ' ' HIS . 17.7 mt 60.13 151.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.806 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.542 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -147.16 131.65 17.69 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 179.743 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.09 -12.51 61.54 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.647 -0.658 . . . . 0.0 109.461 179.5 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.421 ' O ' ' HG2' ' A' ' 105' ' ' PRO . 1.0 OUTLIER -73.23 -19.75 61.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.092 -1.005 . . . . 0.0 109.255 179.517 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.542 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 34.4 m-85 -88.48 -22.42 23.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.829 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -54.39 -58.91 5.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.068 -179.703 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.509 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -54.3 -58.0 15.85 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.112 -0.993 . . . . 0.0 110.097 -179.498 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.509 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.7 Cg_exo -49.18 -59.83 1.09 Allowed 'Trans proline' 0 C--N 1.309 -1.533 0 O-C-N 123.62 1.326 . . . . 0.0 110.095 179.89 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.826 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -53.71 -27.28 27.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.555 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.06 -45.96 9.79 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 -179.976 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -60.64 -52.87 63.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.625 -179.986 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 17.3 m -57.66 -27.74 63.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.656 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.527 HD12 ' SG ' ' A' ' 30' ' ' CYS . 4.1 tt -67.37 -43.08 82.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.215 -0.928 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.913 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.8 mt -56.51 -34.24 66.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.537 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 10.6 t -64.12 -34.44 78.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.721 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 113' ' ' ALA . . . . . 0.417 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -81.57 -28.44 33.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.233 -0.917 . . . . 0.0 109.782 -179.732 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.471 ' HE2' ' OH ' ' A' ' 134' ' ' TYR . 5.8 mmt -51.47 -35.51 40.17 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.96 . . . . 0.0 110.291 -179.563 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 7.1 pt-20 -64.85 -12.28 46.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.086 -1.009 . . . . 0.0 110.164 -179.548 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 116' ' ' HIS . . . . . 0.417 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 0.5 OUTLIER -67.59 -27.15 66.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.943 -1.098 . . . . 0.0 109.52 179.917 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.436 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -94.16 -64.45 1.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.791 179.976 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.511 HG23 HG12 ' A' ' 17' ' ' ILE . 24.3 pt -84.3 -34.85 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.641 -179.898 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.49 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 42.39 -94.94 0.01 OUTLIER Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -44.03 -48.22 7.98 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -179.146 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.486 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -67.32 -22.64 65.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.116 -1.226 . . . . 0.0 109.895 -179.877 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 122' ' ' MET . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -71.1 96.55 1.36 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.086 -1.008 . . . . 0.0 109.098 179.51 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.434 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 8.5 p30 -100.36 -161.52 0.87 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.265 -0.897 . . . . 0.0 110.062 -179.5 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.47 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -72.86 -45.58 57.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.354 -0.841 . . . . 0.0 109.655 -179.945 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 125' ' ' ALA . . . . . 0.434 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -62.47 -30.41 71.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.196 -0.94 . . . . 0.0 109.036 179.731 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.47 -50.23 47.36 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.624 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.8 ptpt -72.1 -27.55 62.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 179.774 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 128' ' ' ASP . . . . . 0.462 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 62.2 t0 -80.44 -41.3 24.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.168 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.505 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -63.91 -45.71 88.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 109.152 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.918 ' CH2' HD12 ' A' ' 17' ' ' ILE . 5.0 m0 -73.02 -25.73 61.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.368 -0.833 . . . . 0.0 109.138 179.544 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.624 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.43 -34.08 77.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.289 -0.882 . . . . 0.0 108.926 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.47 -20.76 24.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.372 -0.83 . . . . 0.0 109.333 179.564 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.538 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -79.39 -53.39 6.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.525 179.946 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.488 ' OH ' ' CE3' ' A' ' 130' ' ' TRP . 10.4 m-30 -53.0 -28.4 23.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.334 179.929 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.9 -48.58 52.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.053 179.465 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.89 -34.31 66.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.322 -0.861 . . . . 0.0 109.225 179.642 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.759 HD13 HG23 ' A' ' 66' ' ' ILE . 64.1 mt -66.73 -59.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.348 -0.845 . . . . 0.0 109.16 179.743 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.403 ' O ' HG13 ' A' ' 142' ' ' ILE . 2.2 p -67.87 -25.98 65.79 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.677 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.43 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -68.87 -46.57 59.59 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -179.952 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.51 -26.89 45.41 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -1.172 . . . . 0.0 109.66 179.975 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.829 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.1 tt -77.29 -16.35 59.01 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.203 -0.936 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.442 HG22 ' O ' ' A' ' 142' ' ' ILE . 60.9 mt -76.5 -0.73 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.14 -0.975 . . . . 0.0 110.151 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.0 m -84.37 -43.96 14.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.037 -1.04 . . . . 0.0 109.632 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.561 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -85.53 -16.55 63.85 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.62 HD13 ' HB2' ' A' ' 90' ' ' HIS . 6.8 tp -86.23 -173.65 4.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.195 -1.179 . . . . 0.0 108.943 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 146' ' ' GLN . . . . . 0.478 ' CB ' ' O ' ' A' ' 145' ' ' LEU . 4.8 mm-40 75.27 63.88 0.06 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.366 -0.834 . . . . 0.0 109.262 -179.564 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.474 ' CA ' ' HG3' ' A' ' 91' ' ' LYS . 5.4 p . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.635 179.98 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 148' ' ' HEM . . . . . 0.878 ' C1A' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 149' ' ' CMO . . . . . 0.734 ' O ' HD22 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.895 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.474 ' O ' HG23 ' A' ' 10' ' ' VAL . 76.9 mt-30 -70.27 -47.35 61.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.305 -0.872 . . . . 0.0 109.212 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 31.8 mtp180 -53.98 -36.01 62.44 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.247 -0.908 . . . . 0.0 109.193 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -74.59 -40.38 61.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.309 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 5' ' ' ALA . 61.0 t -66.06 -23.71 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.284 -0.885 . . . . 0.0 109.192 179.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.645 HG23 ' HB1' ' A' ' 129' ' ' ALA . 50.9 t -76.74 -44.89 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -0.853 . . . . 0.0 109.338 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.412 ' O ' ' HG3' ' A' ' 15' ' ' LYS . . . -74.04 -15.96 61.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.764 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -86.21 -24.16 26.19 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.149 -0.969 . . . . 0.0 109.816 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.507 HG21 ' HB1' ' A' ' 126' ' ' ALA . 3.6 p -95.16 -10.96 29.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.214 -0.929 . . . . 0.0 109.8 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.686 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.8 -28.73 17.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 0.0 109.863 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.412 ' HG3' ' O ' ' A' ' 11' ' ' ALA . 10.6 mtmt -74.57 -12.73 60.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 109.812 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.415 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 1.7 m-20 -101.52 -55.05 2.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -0.988 . . . . 0.0 109.528 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.921 HD12 ' CH2' ' A' ' 130' ' ' TRP . 86.0 mt -67.5 -35.5 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.271 -0.893 . . . . 0.0 109.593 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.637 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -105.59 33.73 3.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.285 -0.884 . . . . 0.0 109.728 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -84.58 0.03 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 p -101.08 -18.81 16.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.703 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.7 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.4 p-10 -85.51 -16.99 37.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.207 -0.933 . . . . 0.0 109.902 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.598 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.4 t30 62.39 17.0 9.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.263 -0.898 . . . . 0.0 109.676 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.88 29.65 5.75 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.7 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -70.88 -46.99 61.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -1.174 . . . . 0.0 109.546 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.441 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.85 38.19 3.19 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.579 HG11 HD11 ' A' ' 63' ' ' LEU . 34.6 t -124.01 -43.12 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.233 -1.157 . . . . 0.0 108.64 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.488 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -88.81 -32.0 11.77 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.54 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.531 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 15.5 ptpt -62.19 -35.57 79.25 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.232 -1.158 . . . . 0.0 109.124 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.837 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 17.2 pt-20 -86.42 -21.08 27.32 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -0.972 . . . . 0.0 109.31 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 38.5 t -87.98 -59.38 2.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.398 -0.814 . . . . 0.0 109.692 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.2 m-85 -53.67 -42.99 68.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.275 -0.891 . . . . 0.0 109.669 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.778 ' OG1' HG11 ' A' ' 55' ' ' VAL . 17.8 m -52.02 -50.25 61.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.15 -0.969 . . . . 0.0 109.252 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.427 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 0.2 OUTLIER -62.5 -44.73 95.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.26 179.649 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.707 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.9 t80 -57.81 -46.66 84.36 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.35 -0.844 . . . . 0.0 109.206 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.705 ' CD1' HG22 ' A' ' 55' ' ' VAL . 11.1 mt -59.26 -44.34 92.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.715 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.613 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 46.8 t -66.7 -64.32 0.88 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.204 -0.935 . . . . 0.0 109.749 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.648 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -53.39 -26.57 20.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.218 -0.926 . . . . 0.0 109.827 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.648 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 16.2 m-70 -123.79 104.92 9.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.857 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.6 m170 -85.99 8.24 21.3 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.428 -0.795 . . . . 0.0 109.758 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -98.54 -11.66 21.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.129 -0.982 . . . . 0.0 109.623 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.562 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -105.84 -11.77 16.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.209 -0.932 . . . . 0.0 110.081 -179.793 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.438 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -58.46 -60.26 4.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.938 -1.101 . . . . 0.0 109.26 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.81 -28.24 63.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.088 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' ND2' ' A' ' 95' ' ' ASN . 28.5 t -68.85 -47.77 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.376 -0.828 . . . . 0.0 109.088 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.53 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -71.19 -37.08 72.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.557 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.77 34.23 1.57 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.4 m-85 -125.92 168.61 13.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -1.162 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.0 t -105.92 -13.68 15.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.406 -0.809 . . . . 0.0 109.479 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.77 -162.97 28.28 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.613 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -83.49 -19.55 35.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.297 -1.119 . . . . 0.0 109.778 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 14.9 p -87.76 52.15 2.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -0.902 . . . . 0.0 109.739 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -127.12 133.77 25.42 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.923 . . . . 0.0 109.581 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -67.23 -29.01 39.69 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.908 1.478 . . . . 0.0 110.063 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.27 -38.28 40.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.778 HG11 ' OG1' ' A' ' 32' ' ' THR . 94.4 t -51.2 -46.78 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -1.095 . . . . 0.0 109.421 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.496 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -64.2 -17.12 63.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.902 . . . . 0.0 109.494 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.83 -47.38 15.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.819 ' O ' HG23 ' A' ' 62' ' ' VAL . 9.6 mt -73.23 -60.69 2.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.178 -0.951 . . . . 0.0 109.476 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.715 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -47.65 -31.19 7.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.496 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -78.38 -60.54 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -1.148 . . . . 0.0 109.438 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -52.43 -39.2 60.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.286 -0.884 . . . . 0.0 109.493 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.819 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.3 t -64.63 -48.32 85.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.715 HD23 ' O ' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -47.78 -44.74 28.69 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.184 -0.947 . . . . 0.0 109.636 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 67' ' ' GLY . . . -49.2 -52.74 24.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.409 -0.807 . . . . 0.0 109.778 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.1 tp60 -49.82 -44.02 49.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.095 -1.003 . . . . 0.0 109.268 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.972 ' O ' HG23 ' A' ' 70' ' ' VAL . 82.7 mt -63.2 -28.04 44.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.336 -0.852 . . . . 0.0 108.851 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.561 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -71.41 -55.22 7.84 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.44 -24.48 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.238 -1.154 . . . . 0.0 109.116 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.41 ' O ' HD22 ' A' ' 73' ' ' LEU . . . -86.09 -18.09 33.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.413 -0.805 . . . . 0.0 109.57 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.972 HG23 ' O ' ' A' ' 66' ' ' ILE . 41.0 t -75.07 -16.04 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.511 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 74.6 m -88.45 11.06 18.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.129 -0.982 . . . . 0.0 110.143 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.8 m-70 -161.73 61.37 0.25 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.048 -1.033 . . . . 0.0 109.926 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.56 HD11 ' HB1' ' A' ' 133' ' ' ALA . 3.1 mm? . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.483 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.418 ' HG2' ' O ' ' A' ' 72' ' ' HIS . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.664 HG13 ' HB1' ' A' ' 140' ' ' ALA . 71.6 t -84.1 -17.01 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.39 -0.819 . . . . 0.0 109.405 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -39.39 70.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.493 ' O ' HG23 ' A' ' 86' ' ' VAL . 12.3 tt0 -69.91 -48.17 59.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.243 -0.911 . . . . 0.0 109.331 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.58 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.7 OUTLIER -58.68 -46.78 86.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 109.214 179.7 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.469 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.9 mttt -52.92 -34.78 56.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.246 -0.909 . . . . 0.0 109.148 179.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.42 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -69.3 -42.98 74.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.339 -0.851 . . . . 0.0 109.391 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.2 t -50.97 -40.15 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.302 -0.874 . . . . 0.0 109.338 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.463 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -58.05 -50.48 65.73 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.777 HG23 ' HA3' ' A' ' 144' ' ' GLY . 97.6 t -54.62 -35.88 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -1.034 . . . . 0.0 108.95 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 1.5 mpt_? -66.08 -45.02 82.75 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.359 -0.838 . . . . 0.0 108.97 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.684 ' O ' HD12 ' A' ' 98' ' ' ILE . 16.5 m80 -64.71 -12.2 44.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.441 -0.787 . . . . 0.0 109.766 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.445 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -74.27 -8.48 56.37 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.032 -1.042 . . . . 0.0 110.426 -179.657 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -152.04 57.75 0.43 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.792 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.5 m-30 -88.35 -169.74 2.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.265 -1.138 . . . . 0.0 109.728 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.52 -8.77 87.12 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.02 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.0 p-10 -112.22 -23.75 10.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.862 -1.375 . . . . 0.0 109.975 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 51.33 28.43 4.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.134 -0.978 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.821 ' HB2' HG22 ' A' ' 44' ' ' VAL . 38.4 m170 -129.32 38.42 3.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.792 HD11 ' CD2' ' A' ' 93' ' ' TYR . 51.2 mt -87.72 154.6 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.065 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.429 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.86 149.83 27.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.129 -0.982 . . . . 0.0 110.159 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.672 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -80.17 -8.83 59.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.358 -0.839 . . . . 0.0 109.588 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 105' ' ' PRO . 14.5 pt-20 -68.62 -30.24 68.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.1 -1.0 . . . . 0.0 109.336 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.562 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 70.4 m-85 -82.47 -21.24 35.65 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.312 -0.867 . . . . 0.0 109.737 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.8 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.2 m-85 -57.66 -68.83 0.2 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.389 -0.819 . . . . 0.0 110.465 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.505 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 8.4 mt-10 -43.62 -60.21 2.78 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.45 -0.781 . . . . 0.0 111.022 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.538 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.3 Cg_endo -56.5 -50.59 11.41 Favored 'Trans proline' 0 C--N 1.304 -1.802 0 O-C-N 123.756 1.398 . . . . 0.0 110.052 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.933 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -65.52 -19.67 66.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.158 -0.963 . . . . 0.0 109.333 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -79.99 -44.9 8.68 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.52 -47.07 77.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.217 -1.167 . . . . 0.0 109.337 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 48.7 m -63.66 -16.77 61.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.32 -0.862 . . . . 0.0 109.508 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.493 HD22 ' CE2' ' A' ' 134' ' ' TYR . 6.3 tt -75.41 -40.24 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.673 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.882 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.8 mt -63.12 -30.06 71.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.937 . . . . 0.0 109.718 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 1.4 t -73.2 -20.9 60.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 109.639 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.837 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -88.29 -31.25 19.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.582 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.585 ' SD ' HD23 ' A' ' 111' ' ' LEU . 1.0 OUTLIER -55.6 -35.75 66.17 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.853 . . . . 0.0 109.992 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 20.8 pt-20 -57.75 -22.54 47.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.117 -0.989 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.405 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -56.98 -40.56 76.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.211 -0.931 . . . . 0.0 109.355 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.47 ' HD3' HG23 ' A' ' 17' ' ' ILE . 11.2 ttt85 -77.59 -62.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.543 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.507 HG12 HD11 ' A' ' 17' ' ' ILE . 8.7 pt -91.69 43.26 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.459 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -52.99 124.46 27.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 101.06 -37.06 3.78 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 26.4 mmtt -89.12 -24.52 22.22 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 109.293 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.435 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -72.12 86.9 1.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.323 -0.861 . . . . 0.0 109.586 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.87 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.1 p-10 -83.66 -171.98 3.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.348 -0.845 . . . . 0.0 109.859 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.441 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -64.15 -42.58 96.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.299 -0.876 . . . . 0.0 109.778 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.87 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -61.09 -29.96 70.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.128 -0.983 . . . . 0.0 109.334 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.507 ' HB1' HG21 ' A' ' 13' ' ' THR . . . -69.93 -50.35 42.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.527 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 11.5 ptpt -71.79 -28.37 63.57 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.9 t0 -76.51 -49.28 16.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.267 -0.896 . . . . 0.0 109.332 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.645 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -56.53 -45.25 81.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.391 -0.818 . . . . 0.0 109.261 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.921 ' CH2' HD12 ' A' ' 17' ' ' ILE . 5.4 m0 -73.54 -32.07 64.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.36 -0.838 . . . . 0.0 109.134 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.604 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.03 -24.69 67.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.291 -0.88 . . . . 0.0 109.185 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.23 -26.97 16.41 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.386 -0.821 . . . . 0.0 109.265 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.56 ' HB1' HD11 ' A' ' 73' ' ' LEU . . . -81.68 -44.46 17.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.325 -0.859 . . . . 0.0 109.577 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.729 ' CZ ' HG21 ' A' ' 66' ' ' ILE . 2.8 m-85 -57.45 -27.61 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.943 . . . . 0.0 109.493 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.45 -46.32 89.07 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.355 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -74.58 -28.28 60.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.33 -0.857 . . . . 0.0 109.587 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.67 HD12 ' HA ' ' A' ' 134' ' ' TYR . 81.4 mt -68.62 -60.24 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.453 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.404 ' O ' HG12 ' A' ' 142' ' ' ILE . 45.2 p -67.52 -48.76 66.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.382 -0.824 . . . . 0.0 109.774 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.64 -29.85 26.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.664 ' HB1' HG13 ' A' ' 80' ' ' VAL . . . -78.85 -17.55 55.45 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.157 -1.202 . . . . 0.0 109.825 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.8 HD22 ' CE2' ' A' ' 103' ' ' PHE . 9.3 tt -89.57 -23.44 21.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 109.82 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.672 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.0 mm -70.7 -16.71 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.219 -0.925 . . . . 0.0 109.82 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.469 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.5 OUTLIER -61.39 -68.01 0.35 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -0.966 . . . . 0.0 109.175 179.808 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.777 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -66.04 -19.37 67.84 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.483 ' CB ' ' HA ' ' A' ' 142' ' ' ILE . 24.6 tp . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.316 -1.108 . . . . 0.0 109.597 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 121.153 0.501 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -70.82 -40.96 72.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.06 -1.025 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -51.04 -52.73 40.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.113 -0.992 . . . . 0.0 109.297 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 60.1 mm-40 -49.72 -41.73 44.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.926 . . . . 0.0 109.268 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.7 t -71.25 -29.91 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -0.883 . . . . 0.0 108.88 179.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.849 HG12 HG13 ' A' ' 70' ' ' VAL . 41.5 t -78.59 -43.73 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.494 -0.754 . . . . 0.0 109.051 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.71 -13.19 60.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.443 -0.786 . . . . 0.0 109.78 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.5 m -92.13 -27.65 17.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 110.094 -179.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -87.73 -14.53 39.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.166 -0.959 . . . . 0.0 109.843 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -86.2 -18.4 32.27 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -0.95 . . . . 0.0 109.781 -179.802 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -80.28 1.97 26.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.142 -0.974 . . . . 0.0 109.784 179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -114.22 -53.95 2.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.103 -0.998 . . . . 0.0 109.333 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.895 HD12 ' CH2' ' A' ' 130' ' ' TRP . 54.7 mt -63.94 -35.19 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.468 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.4 38.27 2.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.912 . . . . 0.0 109.791 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.83 -88.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.1 p -109.41 17.38 21.51 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.305 -1.115 . . . . 0.0 109.683 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.439 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 2.9 p-10 -125.88 -3.93 7.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.578 HD21 ' HB2' ' A' ' 64' ' ' ALA . 6.4 t30 57.15 19.25 4.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.293 -0.88 . . . . 0.0 109.452 -179.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.48 27.22 30.63 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HD2' ' A' ' 28' ' ' LYS . . . -52.56 -38.26 59.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.348 -1.089 . . . . 0.0 109.698 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.43 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.44 18.97 38.67 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.875 HG21 ' CG2' ' A' ' 17' ' ' ILE . 25.5 t -117.3 -14.22 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.136 -1.214 . . . . 0.0 109.46 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.461 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -110.03 -29.46 3.77 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.015 -1.634 . . . . 0.0 109.015 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.487 ' HB2' ' CB ' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -77.8 -28.47 50.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.187 -1.184 . . . . 0.0 109.458 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.619 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 1.6 pm0 -95.38 -16.0 22.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.633 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.406 ' HB2' ' OE2' ' A' ' 29' ' ' GLU . 37.0 t -87.98 -62.49 1.48 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -0.925 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.659 ' O ' HD12 ' A' ' 35' ' ' LEU . 10.8 m-85 -50.27 -30.96 12.94 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.143 -0.973 . . . . 0.0 109.694 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.579 ' OG1' HG11 ' A' ' 55' ' ' VAL . 52.6 m -61.64 -30.97 71.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.418 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 6.7 mmtt -74.57 -47.44 32.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.283 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.689 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.1 t80 -57.85 -46.16 85.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.419 -0.801 . . . . 0.0 109.535 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.701 HD13 HG22 ' A' ' 55' ' ' VAL . 6.8 mt -60.3 -46.89 88.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -0.882 . . . . 0.0 109.775 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.481 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 54.3 p -65.14 -49.9 68.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.284 -0.885 . . . . 0.0 109.769 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.63 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -70.45 -25.9 63.41 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.192 -0.943 . . . . 0.0 109.765 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.63 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 21.3 m-70 -126.14 117.76 23.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.204 -0.935 . . . . 0.0 109.866 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.2 m170 -94.75 -15.33 23.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.455 -0.778 . . . . 0.0 109.56 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -71.59 -7.62 48.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.17 -0.956 . . . . 0.0 109.882 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.567 ' SD ' HG11 ' A' ' 44' ' ' VAL . 4.9 mmt -118.77 -12.08 9.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.012 -1.055 . . . . 0.0 110.115 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.458 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -56.53 -53.53 56.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.943 -1.098 . . . . 0.0 109.254 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -64.25 -27.9 69.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.102 179.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.022 HG13 ' ND2' ' A' ' 95' ' ' ASN . 13.0 t -67.95 -53.38 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.417 -0.802 . . . . 0.0 109.171 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 38.9 m-85 -61.93 -19.02 62.28 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 29.66 6.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 14.1 m-85 -126.37 168.84 13.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -1.138 . . . . 0.0 109.941 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.5 t -114.67 20.11 15.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.452 -0.78 . . . . 0.0 109.166 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.78 -163.74 28.24 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -98.93 39.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -1.17 . . . . 0.0 109.645 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 16.1 m -140.53 22.94 2.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 109.675 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -110.43 145.67 32.71 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.24 -0.913 . . . . 0.0 109.692 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -77.57 56.15 5.46 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.972 1.511 . . . . 0.0 110.169 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -135.06 -38.4 0.19 Allowed Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.701 HG22 HD13 ' A' ' 35' ' ' LEU . 47.5 t -50.0 -26.65 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.242 -1.152 . . . . 0.0 109.596 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.512 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -81.1 -7.81 59.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.292 -0.88 . . . . 0.0 110.002 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -91.73 -31.37 15.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.067 -1.021 . . . . 0.0 109.747 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.877 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.1 mt -83.04 -64.09 1.24 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.115 -0.991 . . . . 0.0 109.697 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.461 ' HA3' ' CA ' ' A' ' 27' ' ' GLY . . . -51.39 -44.81 53.16 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.512 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -53.49 -39.15 64.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.225 -1.162 . . . . 0.0 109.611 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -89.63 -32.31 17.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.252 -0.905 . . . . 0.0 109.633 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.877 HG23 ' O ' ' A' ' 58' ' ' LEU . 57.7 t -65.27 -47.95 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.566 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.691 HD11 ' CG1' ' A' ' 26' ' ' VAL . 2.9 mm? -47.3 -45.27 24.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.198 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.578 ' HB2' HD21 ' A' ' 22' ' ' ASN . . . -53.65 -39.95 65.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.175 -0.953 . . . . 0.0 110.077 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.463 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 6.8 tp-100 -59.78 -39.54 85.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.964 -1.085 . . . . 0.0 108.903 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 1.029 HD13 HG21 ' A' ' 137' ' ' ILE . 26.7 mm -62.44 -42.14 94.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.405 -0.809 . . . . 0.0 108.9 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.546 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.6 -51.32 55.06 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.562 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 64' ' ' ALA . 46.6 t -58.47 -26.8 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.318 -1.107 . . . . 0.0 109.411 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.83 -28.19 26.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.32 -0.863 . . . . 0.0 109.704 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.849 HG13 HG12 ' A' ' 10' ' ' VAL . 54.1 t -75.83 -23.33 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.2 p -63.57 -13.48 42.05 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 110.034 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.437 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 15.4 m-70 -124.01 -77.53 0.59 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.106 -0.996 . . . . 0.0 109.957 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.49 HD23 ' SD ' ' A' ' 79' ' ' MET . 53.5 mt . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.672 -0.643 . . . . 0.0 109.734 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.49 ' SD ' HD23 ' A' ' 73' ' ' LEU . 4.7 ttp . . . . . 0 N--CA 1.495 1.783 0 CA-C-O 121.281 0.562 . . . . 0.0 109.694 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.554 HG12 ' HE3' ' A' ' 84' ' ' LYS . 42.8 t -65.39 -15.41 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.218 -0.926 . . . . 0.0 109.61 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.06 -52.22 20.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.973 . . . . 0.0 109.377 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.596 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.4 mt-10 -71.25 -41.05 70.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.477 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 2.1 mtp -58.8 -48.58 80.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.305 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.601 ' O ' HG23 ' A' ' 88' ' ' VAL . 11.1 mttt -50.8 -38.57 49.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.151 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.412 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -66.83 -44.55 80.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.401 -0.812 . . . . 0.0 109.408 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.625 ' HB ' HD12 ' A' ' 141' ' ' LEU . 14.4 t -58.23 -37.94 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.157 -0.964 . . . . 0.0 109.264 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.458 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -63.34 -49.08 73.36 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 84' ' ' LYS . 57.4 t -51.44 -38.45 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -1.059 . . . . 0.0 109.453 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.551 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 2.8 mpt_? -59.22 -25.62 64.15 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -0.944 . . . . 0.0 109.336 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.536 ' CD2' HD13 ' A' ' 98' ' ' ILE . 4.5 m80 -87.38 16.32 5.49 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.397 -0.814 . . . . 0.0 109.643 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.439 ' O ' ' HG3' ' A' ' 96' ' ' LYS . 23.3 ttmt -75.27 -67.48 0.65 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.941 -1.1 . . . . 0.0 110.167 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.4 ' HA2' ' HG3' ' A' ' 96' ' ' LYS . . . -145.7 56.07 0.53 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.551 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -82.46 -100.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 110.342 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -96.48 -57.28 1.13 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.022 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -84.37 -28.45 26.98 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.415 -1.05 . . . . 0.0 108.594 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.511 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 14.6 tttm 64.41 -48.99 0.3 Allowed 'General case' 0 N--CA 1.505 2.283 0 O-C-N 121.75 -0.594 . . . . 0.0 112.271 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.469 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 64.2 m170 -50.0 -97.21 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.628 -1.295 . . . . 0.0 111.234 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.536 HD13 ' CD2' ' A' ' 90' ' ' HIS . 14.9 mt 65.4 154.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 121.035 -1.04 . . . . 0.0 109.572 -178.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.435 ' HE3' ' HB3' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -158.32 150.75 22.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.268 -0.895 . . . . 0.0 109.828 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.821 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -77.82 -10.21 59.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.569 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.0 mt-10 -67.68 -35.77 79.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 109.597 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.482 ' HB3' ' CE2' ' A' ' 34' ' ' PHE . 76.5 m-85 -81.15 -16.48 52.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.344 -0.847 . . . . 0.0 110.146 -179.416 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.824 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -58.32 -57.49 12.66 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.158 -0.963 . . . . 0.0 109.973 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.518 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -53.75 -58.05 14.84 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 109.755 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.518 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 39.7 Cg_exo -50.81 -62.17 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.628 1.33 . . . . 0.0 109.76 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.954 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -53.77 -24.75 16.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -0.895 . . . . 0.0 109.241 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -74.68 -51.49 8.04 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.096 -1.601 . . . . 0.0 109.096 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -54.22 -55.43 28.17 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -1.169 . . . . 0.0 109.456 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 54.9 m -53.33 -22.76 7.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.349 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.4 tt -65.88 -48.51 71.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.314 -0.866 . . . . 0.0 109.632 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.697 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -57.54 -36.56 71.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.184 -0.948 . . . . 0.0 109.544 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -67.44 -33.81 75.9 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.595 179.966 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.619 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -81.69 -25.73 35.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -0.924 . . . . 0.0 109.663 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.534 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.9 mmt -58.45 -47.73 83.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.918 . . . . 0.0 110.205 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.449 ' O ' ' N ' ' A' ' 119' ' ' GLY . 6.4 pt-20 -50.05 -23.54 2.14 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.068 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.428 ' NE2' ' HA ' ' A' ' 113' ' ' ALA . 19.1 m170 -50.2 -40.73 48.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.993 -1.067 . . . . 0.0 109.783 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -87.17 -56.14 3.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.7 -179.873 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.541 HG12 HD11 ' A' ' 17' ' ' ILE . 5.7 pt -104.34 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.143 -0.973 . . . . 0.0 109.633 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -63.15 -20.11 62.41 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.51 -29.23 10.28 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.443 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.2 mppt? -94.26 -23.44 17.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -1.189 . . . . 0.0 109.803 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.488 ' SD ' HD11 ' A' ' 118' ' ' ILE . 3.8 tpt -63.89 86.35 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.18 -0.95 . . . . 0.0 109.616 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.826 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.2 p-10 -87.14 -168.73 2.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.414 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.29 -39.98 74.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -0.932 . . . . 0.0 109.628 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.826 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -65.05 -31.11 72.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.095 -1.003 . . . . 0.0 108.98 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.458 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -66.27 -50.8 62.48 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.107 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.492 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 17.5 ptpt -70.53 -27.67 64.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.913 . . . . 0.0 109.124 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.482 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.1 t0 -79.33 -32.57 43.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.374 -0.829 . . . . 0.0 108.953 179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.7 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -72.42 -47.69 47.15 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.433 -0.792 . . . . 0.0 109.126 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.895 ' CH2' HD12 ' A' ' 17' ' ' ILE . 12.5 m0 -71.54 -21.54 61.88 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.269 -0.895 . . . . 0.0 108.976 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.492 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -53.24 -34.3 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -0.889 . . . . 0.0 109.038 179.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -97.22 -15.4 20.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.417 -0.802 . . . . 0.0 109.494 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.647 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -81.51 -67.79 0.75 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.252 -0.905 . . . . 0.0 109.854 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.514 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.4 OUTLIER -55.31 -21.25 14.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.032 -1.043 . . . . 0.0 109.268 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -80.92 -49.56 10.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.299 -0.876 . . . . 0.0 108.944 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -73.21 -26.45 61.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.399 -0.813 . . . . 0.0 109.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 1.029 HG21 HD13 ' A' ' 66' ' ' ILE . 43.9 mt -67.88 -61.21 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 109.183 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.402 ' O ' HG12 ' A' ' 142' ' ' ILE . 0.7 OUTLIER -62.89 -14.2 43.51 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.346 -0.846 . . . . 0.0 109.907 -179.819 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.43 -36.01 24.69 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.67 -27.9 66.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -1.184 . . . . 0.0 109.916 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.824 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.8 tt -74.39 -5.61 43.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.194 -0.941 . . . . 0.0 110.138 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.821 HD12 ' HB2' ' A' ' 100' ' ' ALA . 49.8 mm -90.66 18.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.98 -1.075 . . . . 0.0 109.843 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.445 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 5.8 m -95.25 -63.41 1.17 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.947 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.12 -22.52 74.35 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.479 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.354 -1.086 . . . . 0.0 109.535 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.767 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.296 0.569 . . . . 0.0 109.599 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.489 ' O ' HG23 ' A' ' 10' ' ' VAL . 36.6 mt-30 -65.13 -51.39 61.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.366 -0.834 . . . . 0.0 109.552 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 7.5 ptm180 -53.43 -32.3 49.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.08 -1.013 . . . . 0.0 108.921 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 47.8 tp60 -71.48 -44.07 65.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.166 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 5' ' ' ALA . 30.0 t -65.12 -30.65 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.291 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.807 HG12 HG13 ' A' ' 70' ' ' VAL . 84.8 t -70.04 -41.75 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.369 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.8 -14.67 60.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -0.869 . . . . 0.0 109.764 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.1 -33.25 19.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.509 HG21 ' HB1' ' A' ' 126' ' ' ALA . 12.1 p -85.55 -15.73 41.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.739 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -86.99 -18.98 29.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.811 -179.893 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.8 mtpp -80.99 0.32 36.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.194 -0.941 . . . . 0.0 109.898 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -115.83 -53.65 2.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.081 -1.012 . . . . 0.0 109.439 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.945 HD12 ' CH2' ' A' ' 130' ' ' TRP . 64.7 mt -67.3 -32.78 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.552 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -103.07 31.92 4.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.872 . . . . 0.0 109.647 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.7 -86.39 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.0 p -95.25 -35.71 11.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.752 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.711 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 2.9 p30 -71.24 -17.12 62.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.26 -0.9 . . . . 0.0 109.81 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.552 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 0.2 OUTLIER 58.31 24.8 11.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.133 -0.979 . . . . 0.0 109.455 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.577 ' CA ' HD22 ' A' ' 63' ' ' LEU . . . 92.78 32.95 7.69 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.711 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -81.11 -66.34 0.9 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -1.108 . . . . 0.0 109.816 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 29' ' ' GLU . . . -52.74 -22.98 13.0 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.793 HG12 HD11 ' A' ' 63' ' ' LEU . 38.5 t -74.82 -32.21 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.846 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.01 -55.48 2.93 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.42 ' HB3' ' HA ' ' A' ' 56' ' ' ALA . 6.6 ptpp? -57.31 -19.63 23.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.187 -1.184 . . . . 0.0 110.053 -179.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.65 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -98.35 -30.42 12.59 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.972 -1.08 . . . . 0.0 109.579 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.3 t -82.32 -55.48 4.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.34 -0.85 . . . . 0.0 109.538 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.524 ' O ' HD12 ' A' ' 35' ' ' LEU . 12.2 m-85 -54.55 -37.44 65.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.357 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.884 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.56 -54.72 37.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.213 -0.929 . . . . 0.0 109.232 179.624 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -57.11 -47.82 80.15 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.212 -0.93 . . . . 0.0 109.335 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.741 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.4 t80 -55.07 -52.24 63.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.3 -0.875 . . . . 0.0 109.28 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.893 HD13 HG22 ' A' ' 55' ' ' VAL . 6.8 mt -59.3 -41.14 88.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.255 -0.903 . . . . 0.0 109.664 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.426 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 20.6 t -63.1 -61.19 2.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.657 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.622 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -63.37 -26.72 68.88 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.236 -0.915 . . . . 0.0 109.684 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.622 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 12.1 m-70 -118.9 107.53 13.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.691 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -88.34 -24.29 23.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 109.362 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 40' ' ' ASP . 25.5 p-10 -65.39 -19.16 65.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.408 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.544 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -95.21 -17.6 21.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.292 -0.88 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.439 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -57.43 -62.78 1.54 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.975 . . . . 0.0 109.38 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.56 -26.38 43.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.025 HG13 ' ND2' ' A' ' 95' ' ' ASN . 21.1 t -73.63 -48.76 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 109.239 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.522 ' CD2' HD21 ' A' ' 35' ' ' LEU . 27.1 m-85 -68.26 -26.9 65.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.22 -0.925 . . . . 0.0 109.549 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 108.66 27.49 4.92 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.528 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.3 m-85 -123.74 167.29 14.22 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.176 . . . . 0.0 109.868 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 t -102.81 -20.93 14.13 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.421 -0.799 . . . . 0.0 109.203 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.9 -163.91 23.72 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.426 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -94.73 34.11 1.38 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.298 -1.119 . . . . 0.0 109.698 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 24.4 p -133.0 21.23 4.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.68 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -106.64 139.48 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.607 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.6 -16.96 57.94 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.954 1.502 . . . . 0.0 110.105 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.528 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -56.27 -39.8 83.05 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.893 HG22 HD13 ' A' ' 35' ' ' LEU . 84.1 t -51.04 -37.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -1.098 . . . . 0.0 109.38 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.456 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -73.74 -6.6 47.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.305 -0.872 . . . . 0.0 109.721 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -91.62 -27.16 18.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.011 . . . . 0.0 109.57 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.825 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -91.43 -64.0 1.18 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.175 -0.953 . . . . 0.0 109.627 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.522 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.18 -41.94 39.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -62.84 -23.85 67.5 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -1.149 . . . . 0.0 109.691 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.73 -28.37 12.51 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.679 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.825 HG23 ' O ' ' A' ' 58' ' ' LEU . 59.6 t -67.22 -56.49 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.287 -0.883 . . . . 0.0 109.848 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.793 HD11 HG12 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -48.2 -38.4 18.19 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.961 . . . . 0.0 109.616 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.44 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -50.44 -42.21 53.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.449 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.446 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 5.7 tp-100 -62.7 -36.17 82.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.232 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.865 ' O ' HG23 ' A' ' 70' ' ' VAL . 41.6 mt -66.92 -37.07 78.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.355 -0.841 . . . . 0.0 109.186 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.81 -48.27 56.18 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 179.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 64' ' ' ALA . 61.6 t -61.42 -27.99 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.357 -1.084 . . . . 0.0 109.43 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.86 -32.98 24.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.319 -0.863 . . . . 0.0 109.503 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 66' ' ' ILE . 56.5 t -66.58 -22.67 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 41.3 m -67.31 -12.36 59.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.948 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.425 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 14.0 m-70 -122.85 -83.92 0.66 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.123 -0.986 . . . . 0.0 109.918 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.649 HD11 ' HA ' ' A' ' 70' ' ' VAL . 35.1 mt . . . . . 0 N--CA 1.494 1.773 0 O-C-N 121.65 -0.657 . . . . 0.0 109.676 -179.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.411 ' SD ' HD23 ' A' ' 73' ' ' LEU . 5.5 ttp . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.293 0.568 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.453 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.2 t -72.14 -29.41 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.01 -41.91 97.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.253 -0.904 . . . . 0.0 109.435 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.682 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.5 mt-10 -71.98 -50.8 25.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.513 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.444 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.2 OUTLIER -62.47 -38.66 90.69 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 109.149 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.453 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -60.06 -38.04 81.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.265 -0.897 . . . . 0.0 109.099 179.44 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -67.92 -41.34 82.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.258 -0.901 . . . . 0.0 109.21 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.682 HG23 ' O ' ' A' ' 82' ' ' GLU . 30.8 t -55.48 -50.52 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.328 -0.857 . . . . 0.0 109.119 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.524 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -56.55 -53.58 42.47 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 84' ' ' LYS . 79.1 t -53.85 -34.24 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.438 -1.037 . . . . 0.0 108.947 179.355 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mmm180 -72.13 -48.72 41.54 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.413 -0.804 . . . . 0.0 109.051 179.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.707 ' O ' HD12 ' A' ' 98' ' ' ILE . 14.5 m80 -56.48 -27.38 56.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.04 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.416 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -66.46 -12.07 55.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 110.289 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -136.08 49.85 0.87 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.701 ' CD2' HD11 ' A' ' 98' ' ' ILE . 4.3 m-30 -89.61 -168.71 2.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -1.174 . . . . 0.0 109.795 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -78.6 -52.19 5.2 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.025 ' ND2' HG13 ' A' ' 44' ' ' VAL . 17.8 p-10 -62.3 -29.41 70.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -1.186 . . . . 0.0 109.657 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.435 ' O ' ' CD2' ' A' ' 97' ' ' HIS . 12.0 mtmm 53.54 29.36 8.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.671 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.435 ' CD2' ' O ' ' A' ' 96' ' ' LYS . 39.0 m170 -136.29 45.31 2.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.284 -0.885 . . . . 0.0 109.57 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.707 HD12 ' O ' ' A' ' 90' ' ' HIS . 62.2 mt -87.55 154.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.298 -0.876 . . . . 0.0 109.727 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -144.12 148.35 34.96 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.282 -0.886 . . . . 0.0 110.104 -179.84 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.523 ' HB2' HG23 ' A' ' 142' ' ' ILE . . . -83.68 -3.56 57.86 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.698 -0.627 . . . . 0.0 109.609 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 8.8 pt-20 -74.95 -29.16 60.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.074 -1.016 . . . . 0.0 109.477 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.544 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 59.8 m-85 -81.78 -22.1 37.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.726 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.879 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.0 m-85 -54.03 -63.46 1.14 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.221 -0.924 . . . . 0.0 110.263 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.511 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -48.98 -58.41 8.69 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.132 -0.98 . . . . 0.0 110.13 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.511 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.6 Cg_exo -49.85 -62.53 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.598 1.315 . . . . 0.0 110.026 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.964 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.59 -22.02 12.12 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.255 -0.903 . . . . 0.0 109.547 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.66 -50.36 5.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.44 95.19 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.133 -1.216 . . . . 0.0 109.557 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.4 t -66.62 -21.36 66.12 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.859 HD22 ' OH ' ' A' ' 134' ' ' TYR . 2.7 tt -71.96 -41.97 67.12 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 109.626 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.925 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.3 mt -58.97 -30.25 67.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 0.0 109.573 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 3.6 m -68.64 -33.99 74.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.713 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.65 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -81.47 -33.46 31.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.259 -0.9 . . . . 0.0 109.782 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.494 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -45.89 -47.55 16.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.313 -0.867 . . . . 0.0 110.341 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.457 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 18.8 pt-20 -51.94 -22.48 3.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 0.0 110.015 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 24.0 m170 -53.7 -30.7 44.98 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.012 -1.055 . . . . 0.0 109.81 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -95.42 -68.9 0.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.133 -0.979 . . . . 0.0 109.93 -179.775 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.495 HG23 ' CG1' ' A' ' 17' ' ' ILE . 33.2 pt -75.11 -36.85 39.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.025 -1.047 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.487 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 39.52 -96.84 0.01 OUTLIER Glycine 0 N--CA 1.498 2.828 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.54 -42.45 10.09 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 3.3 mtpt -72.42 -21.9 61.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.112 -1.228 . . . . 0.0 109.771 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.45 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.23 90.53 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.157 -0.964 . . . . 0.0 109.57 179.829 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.801 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 17.8 p-10 -84.94 -179.88 7.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.566 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 127' ' ' LYS . . . -64.01 -40.25 95.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.801 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -63.98 -30.51 71.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.191 -0.943 . . . . 0.0 109.196 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.787 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -67.03 -50.5 61.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.406 -0.809 . . . . 0.0 109.322 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.541 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.0 ptpt -71.88 -30.02 64.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.289 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.427 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 59.5 t0 -77.13 -44.02 31.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.2 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.412 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -63.82 -41.62 97.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.48 -0.763 . . . . 0.0 109.065 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.945 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.5 m0 -75.25 -25.01 57.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.32 -0.863 . . . . 0.0 109.012 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.541 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.43 -37.2 80.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -0.886 . . . . 0.0 108.987 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -78.83 -24.58 44.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.324 -0.86 . . . . 0.0 109.297 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -83.27 -50.41 8.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.359 -0.838 . . . . 0.0 109.543 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.859 ' OH ' HD22 ' A' ' 110' ' ' LEU . 3.7 m-85 -50.35 -31.68 15.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.18 -0.95 . . . . 0.0 109.306 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.94 -35.68 57.11 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.341 -0.849 . . . . 0.0 108.986 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.83 -36.12 37.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.385 -0.822 . . . . 0.0 109.287 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.786 HD13 HG23 ' A' ' 66' ' ' ILE . 58.6 mt -66.58 -58.96 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.88 . . . . 0.0 109.087 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.0 p -67.3 -19.81 65.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.386 -0.821 . . . . 0.0 109.644 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.427 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -72.1 -42.65 50.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.86 -23.03 65.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -1.146 . . . . 0.0 109.673 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.879 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.6 tt -80.34 -34.07 36.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.682 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.523 HG23 ' HB2' ' A' ' 100' ' ' ALA . 43.4 mt -73.79 -3.45 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 110.145 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.6 m -68.77 -59.43 3.1 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.011 -1.056 . . . . 0.0 109.621 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -88.38 4.4 85.28 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.569 HD12 HD21 ' A' ' 141' ' ' LEU . 4.4 tt . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.056 -1.261 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.678 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.326 0.584 . . . . 0.0 109.572 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 83.8 mt-30 -81.86 -52.08 7.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.427 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -49.61 -30.96 9.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.223 -0.923 . . . . 0.0 109.521 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.427 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 6.3 mm-40 -72.1 -42.91 65.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.266 -0.896 . . . . 0.0 109.278 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 5' ' ' ALA . 42.9 t -63.25 -32.15 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.274 -0.891 . . . . 0.0 109.243 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.973 HG12 HG13 ' A' ' 70' ' ' VAL . 70.7 t -66.12 -45.99 88.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.368 -0.833 . . . . 0.0 109.344 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.71 -10.56 59.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 109.821 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.3 p -92.88 -24.29 18.51 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.138 -0.976 . . . . 0.0 109.979 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.503 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 18.3 p -97.55 -8.98 27.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.092 -1.005 . . . . 0.0 109.959 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.694 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.6 -20.15 22.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.018 -1.051 . . . . 0.0 109.569 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -80.8 3.22 23.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.97 -56.49 2.1 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.066 -1.022 . . . . 0.0 109.512 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.882 HD12 ' CH2' ' A' ' 130' ' ' TRP . 51.2 mt -62.35 -30.26 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.51 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.907 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -107.42 32.41 4.69 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -0.91 . . . . 0.0 109.618 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -69.41 1.21 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 84.5 p -109.99 -29.96 8.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.281 -1.129 . . . . 0.0 109.663 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.815 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.8 p-10 -78.78 -20.2 50.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.896 . . . . 0.0 109.67 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.907 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.8 t30 57.61 28.41 15.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.185 -0.947 . . . . 0.0 109.516 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.412 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 93.51 25.39 18.59 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.815 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -73.2 -47.08 46.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.252 -1.146 . . . . 0.0 109.592 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.479 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.28 17.86 45.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.801 -1.319 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.657 HG13 ' SD ' ' A' ' 114' ' ' MET . 21.2 t -109.48 -25.81 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.25 179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.5 ' HA3' HD23 ' A' ' 63' ' ' LEU . . . -94.43 -43.19 3.76 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.479 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.3 OUTLIER -62.19 -31.49 72.01 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.096 -1.238 . . . . 0.0 109.577 -179.837 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.89 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 14.5 pt-20 -89.38 -15.99 32.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.929 . . . . 0.0 109.618 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 15.8 t -90.15 -63.14 1.32 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.482 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 16.8 m-85 -47.54 -33.95 7.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.496 ' OG1' HG11 ' A' ' 55' ' ' VAL . 51.5 m -55.39 -40.75 71.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.172 -0.955 . . . . 0.0 109.421 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.41 -49.41 27.22 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.264 -0.897 . . . . 0.0 109.456 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.713 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.9 t80 -52.06 -46.51 65.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.339 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.656 ' CD1' HG22 ' A' ' 55' ' ' VAL . 17.6 mt -58.07 -47.12 84.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.529 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.515 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 6.4 t -65.35 -55.83 15.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.569 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -61.54 -24.47 66.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.657 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 17.2 m-70 -124.9 103.88 8.29 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.269 -0.894 . . . . 0.0 109.722 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.5 m170 -86.29 -18.99 30.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.366 -0.834 . . . . 0.0 109.454 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -71.96 -9.66 58.68 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.283 -0.885 . . . . 0.0 109.893 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.437 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 29.7 mmm -119.38 -15.8 9.05 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 110.079 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.459 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.03 -47.7 44.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.041 . . . . 0.0 109.424 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.25 -31.6 64.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.331 -0.855 . . . . 0.0 109.093 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.034 HG13 ' ND2' ' A' ' 95' ' ' ASN . 15.9 t -60.51 -37.31 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.408 -0.808 . . . . 0.0 109.141 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.518 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.2 m-85 -76.86 -18.46 58.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.764 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 102.44 23.46 8.93 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 9.8 m-85 -122.49 167.33 13.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -1.137 . . . . 0.0 109.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 12.5 t -112.62 21.3 15.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 109.233 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.95 -172.42 25.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.515 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -74.95 -6.86 51.57 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -1.167 . . . . 0.0 109.976 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 62.2 p -94.3 43.41 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.056 -1.028 . . . . 0.0 109.73 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -123.77 129.18 24.91 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.649 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -67.97 -28.93 34.98 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.776 1.408 . . . . 0.0 110.022 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.457 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.49 -30.15 33.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.656 HG22 ' CD1' ' A' ' 35' ' ' LEU . 95.5 t -50.93 -32.78 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -1.116 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.487 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -80.72 -6.22 58.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.312 -0.867 . . . . 0.0 109.809 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.22 -27.15 20.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.104 -0.998 . . . . 0.0 109.596 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.902 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.4 mt -89.78 -65.81 0.98 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.713 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.482 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.94 -42.16 29.61 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -56.19 -45.36 79.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.166 -1.196 . . . . 0.0 109.361 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 39.6 mttp -80.79 -38.17 28.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.386 -0.821 . . . . 0.0 109.403 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.902 HG23 ' O ' ' A' ' 58' ' ' LEU . 42.3 t -59.79 -50.18 81.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 0.0 109.619 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.535 HD11 HG11 ' A' ' 26' ' ' VAL . 1.2 mm? -47.12 -46.63 23.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.255 -0.903 . . . . 0.0 109.85 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.94 -51.07 43.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.814 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.7 tp60 -50.28 -53.77 26.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.124 -0.985 . . . . 0.0 109.438 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.933 ' O ' HG23 ' A' ' 70' ' ' VAL . 45.0 mt -51.27 -39.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 109.27 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.16 -56.09 24.15 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -57.3 -25.73 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.346 -1.09 . . . . 0.0 109.428 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.57 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -85.38 -30.46 23.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.376 -0.827 . . . . 0.0 109.632 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.973 HG13 HG12 ' A' ' 10' ' ' VAL . 74.1 t -66.77 -17.11 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -0.936 . . . . 0.0 109.838 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.464 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 40.9 t -90.21 21.09 3.95 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.155 -0.966 . . . . 0.0 109.975 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.469 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 10.3 m-70 -157.9 44.12 0.32 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.058 -1.026 . . . . 0.0 109.881 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.519 ' CD2' ' HA ' ' A' ' 70' ' ' VAL . 3.6 mm? . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.95 . . . . 0.0 109.413 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.469 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 21.7 ttp . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.252 0.549 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 27.1 t -70.53 -21.95 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.511 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.18 -42.94 83.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.207 -0.933 . . . . 0.0 109.285 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.589 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.8 mt-10 -78.98 -48.39 14.56 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.269 -0.894 . . . . 0.0 109.322 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.52 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.6 OUTLIER -57.39 -52.03 66.99 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -0.885 . . . . 0.0 109.27 179.677 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.838 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -51.12 -34.18 29.72 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 108.909 179.398 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.38 -39.69 71.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.362 -0.836 . . . . 0.0 108.951 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 82' ' ' GLU . 53.1 t -61.79 -49.94 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.333 -0.854 . . . . 0.0 109.118 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.485 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -55.16 -38.0 65.8 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.838 HG23 ' O ' ' A' ' 84' ' ' LYS . 95.6 t -60.08 -18.94 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.3 -1.117 . . . . 0.0 109.447 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.524 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.5 OUTLIER -82.63 -19.04 39.06 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.264 -0.898 . . . . 0.0 109.127 179.7 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.554 ' HB3' HD12 ' A' ' 98' ' ' ILE . 4.0 m80 -89.98 19.3 4.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.433 ' O ' ' HD3' ' A' ' 96' ' ' LYS . 2.4 mtmt -80.44 -59.14 2.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.164 -0.96 . . . . 0.0 110.776 -178.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.433 ' HA2' ' HD3' ' A' ' 96' ' ' LYS . . . -148.51 56.77 0.48 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.524 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -82.46 -103.17 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 110.012 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -102.16 -62.68 0.74 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.034 ' ND2' HG13 ' A' ' 44' ' ' VAL . 2.0 t30 -68.21 -41.27 81.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.462 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 0.3 OUTLIER 65.66 -57.63 0.32 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.124 0.487 . . . . 0.0 109.852 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 95' ' ' ASN . 44.1 m170 -62.93 79.53 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.215 -0.928 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.554 HD12 ' HB3' ' A' ' 90' ' ' HIS . 31.8 mt -109.18 158.85 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 109.233 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.523 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.6 mptp? -140.49 139.61 35.15 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.068 -1.02 . . . . 0.0 110.288 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.458 ' CB ' HG12 ' A' ' 142' ' ' ILE . . . -78.55 -2.63 39.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.835 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -76.1 -26.43 56.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.996 -1.065 . . . . 0.0 109.439 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.523 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 83.9 m-85 -85.24 10.13 13.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.384 -0.823 . . . . 0.0 110.076 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.686 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.3 m-85 -83.35 -61.28 1.89 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 109.671 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.506 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -51.01 -57.57 13.31 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.441 -0.787 . . . . 0.0 110.644 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 5.2 Cg_endo -54.01 -43.76 55.35 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.59 1.311 . . . . 0.0 110.142 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.861 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.5 tm? -64.12 -17.03 63.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.179 -0.951 . . . . 0.0 109.542 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.74 -36.98 12.37 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.29 -59.62 4.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.196 -1.179 . . . . 0.0 109.63 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.7 t -60.29 -18.9 52.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.27 -0.894 . . . . 0.0 109.565 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.926 HD21 ' HE2' ' A' ' 114' ' ' MET . 3.2 tt -76.76 -36.57 56.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.253 -0.905 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.577 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -63.85 -28.77 70.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.189 -0.944 . . . . 0.0 109.435 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -34.43 78.2 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.312 -0.868 . . . . 0.0 109.6 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.89 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -75.58 -38.22 59.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.926 ' HE2' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.34 -44.19 23.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.297 -0.877 . . . . 0.0 110.017 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.477 ' HG2' ' CB ' ' A' ' 122' ' ' MET . 0.6 OUTLIER -52.42 -22.08 4.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.307 -0.871 . . . . 0.0 109.962 -179.771 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.411 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 21.1 m170 -56.53 -35.86 68.58 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.146 -0.972 . . . . 0.0 110.247 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.507 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -90.8 -86.86 0.2 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.011 -1.056 . . . . 0.0 110.176 -179.583 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 119' ' ' GLY . 34.9 pt -56.61 -36.31 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.811 -1.18 . . . . 0.0 109.608 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.483 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.77 -98.99 0.01 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.519 -1.033 . . . . 0.0 110.519 179.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.35 -44.77 8.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.469 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 44.3 mttt -68.28 -25.77 65.32 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.074 -1.25 . . . . 0.0 110.032 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.477 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.0 OUTLIER -65.52 80.6 0.06 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.982 -1.073 . . . . 0.0 108.845 179.384 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.668 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 12.2 p-10 -82.12 -174.29 5.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.297 -0.877 . . . . 0.0 110.13 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.464 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -62.26 -45.31 93.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.376 -0.828 . . . . 0.0 109.897 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.668 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -62.6 -30.93 71.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.146 -0.971 . . . . 0.0 109.575 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -68.74 -44.76 73.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 109.264 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.577 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 1.6 ptpt -75.19 -29.83 60.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.375 -0.828 . . . . 0.0 109.664 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.486 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 44.2 t0 -79.22 -46.12 18.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.391 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.556 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -57.55 -47.79 81.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.42 -0.8 . . . . 0.0 109.308 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.882 ' CH2' HD12 ' A' ' 17' ' ' ILE . 7.3 m0 -71.92 -29.7 64.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.4 -0.812 . . . . 0.0 109.371 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.577 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -63.78 -25.92 68.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.235 -0.916 . . . . 0.0 108.974 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.48 ' O ' ' HB3' ' A' ' 135' ' ' ALA . . . -101.05 -24.95 14.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.421 -0.8 . . . . 0.0 109.169 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.54 ' HB2' HG21 ' A' ' 10' ' ' VAL . . . -67.44 -51.89 46.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.287 -0.883 . . . . 0.0 109.334 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.51 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 21.3 m-85 -52.76 -29.04 25.03 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 109.231 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' A' ' 132' ' ' ALA . . . -60.84 -46.41 90.68 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 108.835 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.82 -44.34 56.04 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 109.169 179.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.57 HG12 ' HB1' ' A' ' 69' ' ' ALA . 18.1 mt -64.3 -57.75 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.256 -0.903 . . . . 0.0 108.93 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.549 ' O ' HD12 ' A' ' 142' ' ' ILE . 2.0 p -67.87 -25.74 65.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.217 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.437 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -73.4 -46.59 25.5 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.25 -22.47 66.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -1.122 . . . . 0.0 109.712 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.686 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.4 tt -69.22 -33.46 73.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.665 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 138' ' ' SER . 3.9 mt -82.9 10.01 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.2 -0.937 . . . . 0.0 110.318 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.469 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 75.7 m -73.97 -22.6 59.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.996 -1.065 . . . . 0.0 108.887 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -127.77 1.42 6.86 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.832 HD13 ' O ' ' A' ' 145' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.718 0 O-C-N 120.85 -1.382 . . . . 0.0 110.015 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.781 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.231 0.539 . . . . 0.0 109.819 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -68.62 -58.49 4.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.717 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.521 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -50.15 -24.57 2.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.221 -0.924 . . . . 0.0 109.895 -179.773 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.521 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 50.1 tp60 -80.66 -41.39 23.88 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 109.493 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.781 HG23 ' O ' ' A' ' 5' ' ' ALA . 67.1 t -62.09 -24.54 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.9 HG12 HG13 ' A' ' 70' ' ' VAL . 89.1 t -66.84 -45.05 88.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.39 -0.819 . . . . 0.0 109.661 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.55 -11.35 60.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.296 -0.877 . . . . 0.0 110.193 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 m -92.7 -22.94 19.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.005 -1.06 . . . . 0.0 109.804 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.3 p -96.71 -10.52 26.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.249 -0.907 . . . . 0.0 110.131 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.767 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.74 -20.83 21.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.078 -1.014 . . . . 0.0 109.892 -179.801 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -79.19 -13.04 59.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.947 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -102.27 -47.87 4.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.089 -1.007 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.879 HD12 ' CH2' ' A' ' 130' ' ' TRP . 34.8 mt -70.81 -31.55 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -0.924 . . . . 0.0 109.745 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.856 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -106.96 33.88 3.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.915 . . . . 0.0 109.716 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.64 -71.82 0.62 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 76.5 p -110.65 -27.91 8.71 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.657 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.66 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.2 p-10 -79.01 -20.24 49.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 0.0 109.658 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.856 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 27.0 t30 55.67 24.09 6.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.584 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.17 24.57 12.47 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.66 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -66.1 -55.08 18.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -1.137 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -86.14 11.43 62.91 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.507 HG11 HD11 ' A' ' 63' ' ' LEU . 37.8 t -97.99 -29.65 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.115 -1.227 . . . . 0.0 109.338 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.458 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -89.91 -45.16 4.6 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.47 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 11.3 ptpt -56.19 -31.89 63.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.158 -1.201 . . . . 0.0 109.569 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.533 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 24.3 pt-20 -92.3 -16.67 25.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.929 . . . . 0.0 109.722 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.434 ' SG ' HD12 ' A' ' 110' ' ' LEU . 36.6 t -85.27 -67.67 0.78 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.205 -0.934 . . . . 0.0 109.809 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.601 ' HB3' HG13 ' A' ' 55' ' ' VAL . 10.4 m-85 -48.35 -29.13 3.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.247 -0.908 . . . . 0.0 109.935 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.426 ' N ' HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.06 -59.06 5.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.201 -0.937 . . . . 0.0 109.488 179.935 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 3.9 mttp -55.9 -53.15 60.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.261 -0.899 . . . . 0.0 109.717 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.679 ' CG ' HD23 ' A' ' 106' ' ' LEU . 8.9 t80 -49.34 -53.09 23.95 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.224 -0.922 . . . . 0.0 109.734 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.79 ' CD1' HG22 ' A' ' 55' ' ' VAL . 20.1 mt -54.23 -46.35 72.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.229 -0.919 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.08 -59.84 3.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.185 -0.947 . . . . 0.0 109.713 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.604 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -58.24 -23.66 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.669 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.604 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 22.2 m-70 -120.79 95.83 4.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.688 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.5 m170 -82.76 6.03 19.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.244 -0.91 . . . . 0.0 110.02 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -97.48 -20.38 17.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.099 -1.001 . . . . 0.0 109.523 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.53 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 65.4 mmm -104.85 -19.84 13.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -0.896 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.458 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.08 -35.62 16.49 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 109.43 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.4 -27.54 46.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.304 -0.873 . . . . 0.0 109.099 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.969 HG22 ' OD1' ' A' ' 95' ' ' ASN . 32.3 t -66.71 -60.74 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.526 ' CD2' HD21 ' A' ' 35' ' ' LEU . 67.4 m-85 -51.29 -28.3 11.64 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.291 -0.881 . . . . 0.0 109.504 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.409 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.3 24.85 4.92 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 8.7 m-85 -121.86 166.24 14.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 110.066 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.8 t -106.0 -19.78 13.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.422 -0.799 . . . . 0.0 108.892 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.65 -162.5 19.64 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.88 15.5 23.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -1.118 . . . . 0.0 109.798 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 19.5 m -109.18 25.12 12.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.118 -0.989 . . . . 0.0 109.497 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.418 ' OD2' ' HB3' ' A' ' 47' ' ' PHE . 0.9 OUTLIER -118.87 140.59 28.79 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.33 -0.856 . . . . 0.0 109.543 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -69.55 -13.36 35.09 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.957 1.504 . . . . 0.0 110.509 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.537 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.49 -40.62 39.6 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.79 HG22 ' CD1' ' A' ' 35' ' ' LEU . 39.2 t -50.05 -45.92 23.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.321 -1.105 . . . . 0.0 109.55 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -61.8 -16.65 51.65 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.3 -36.64 39.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.915 . . . . 0.0 109.645 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.948 ' O ' HG23 ' A' ' 62' ' ' VAL . 11.5 mt -87.07 -60.03 2.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.157 -0.964 . . . . 0.0 109.638 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.458 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -46.9 -48.9 18.35 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.419 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -56.39 -38.58 71.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -1.166 . . . . 0.0 109.695 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -83.86 -29.9 26.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.663 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 58' ' ' LEU . 38.7 t -71.61 -47.87 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.305 -0.872 . . . . 0.0 109.652 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.507 HD11 HG11 ' A' ' 26' ' ' VAL . 1.9 mm? -48.99 -50.27 36.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 109.656 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.97 -44.97 20.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.363 -0.836 . . . . 0.0 110.017 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.406 ' HG3' ' SD ' ' A' ' 83' ' ' MET . 28.8 tp60 -57.72 -52.69 64.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.127 -0.983 . . . . 0.0 109.332 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.959 ' O ' HG23 ' A' ' 70' ' ' VAL . 96.1 mt -53.89 -36.65 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.184 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.51 -55.38 27.7 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.31 -23.17 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -1.141 . . . . 0.0 109.17 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.88 -23.24 25.31 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.413 -0.805 . . . . 0.0 109.579 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.3 t -72.76 -21.31 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.898 . . . . 0.0 109.757 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.442 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 53.9 m -88.67 39.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.154 -0.966 . . . . 0.0 109.975 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.451 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 16.2 m-70 -151.13 -62.1 0.18 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.097 -1.002 . . . . 0.0 109.908 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.545 ' H ' HD22 ' A' ' 73' ' ' LEU . 4.4 mm? . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.191 0.519 . . . . 0.0 110.638 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.451 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 41.4 ttp . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.289 0.566 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.421 ' HA ' ' HB1' ' A' ' 140' ' ' ALA . 90.6 t -83.26 -17.52 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.593 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.77 -30.6 45.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.578 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.471 ' HG3' ' N ' ' A' ' 83' ' ' MET . 23.9 pt-20 -86.17 -42.65 13.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.669 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.545 ' HE1' HD12 ' A' ' 141' ' ' LEU . 92.0 mmm -63.93 -35.29 80.17 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.011 -1.056 . . . . 0.0 108.845 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.874 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -52.62 -37.23 57.99 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.029 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.438 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -69.06 -27.36 65.56 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -74.88 -46.56 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.816 . . . . 0.0 108.962 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.446 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -63.93 -34.7 90.63 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.874 HG23 ' O ' ' A' ' 84' ' ' LYS . 53.3 t -58.9 -37.2 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.356 -1.085 . . . . 0.0 109.206 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.438 ' HG2' ' O ' ' A' ' 85' ' ' ALA . 17.3 mmm180 -64.76 -31.13 72.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.01 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.747 ' HB2' HD12 ' A' ' 145' ' ' LEU . 52.5 m80 -77.38 -2.6 35.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.427 -0.796 . . . . 0.0 109.897 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.8 ttmt -98.07 64.38 1.67 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.077 -1.014 . . . . 0.0 109.638 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.416 ' O ' ' O ' ' A' ' 93' ' ' TYR . . . 147.28 2.6 0.5 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.314 -1.422 . . . . 0.0 111.772 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.554 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.8 m-85 -56.13 -167.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.38 -1.659 . . . . 0.0 110.022 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.55 -40.17 13.3 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.969 ' OD1' HG22 ' A' ' 44' ' ' VAL . 3.7 t30 -59.38 -47.23 86.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.457 -1.025 . . . . 0.0 108.479 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.8 tttt 59.96 13.89 3.97 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.494 -0.754 . . . . 0.0 110.928 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.467 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 14.2 m-70 -131.6 44.08 2.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.046 -1.034 . . . . 0.0 108.923 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.587 HD12 ' O ' ' A' ' 90' ' ' HIS . 67.8 mt -78.97 154.96 4.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.46 -0.775 . . . . 0.0 110.01 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.467 ' CE ' ' O ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -145.34 148.83 33.83 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.81 0.814 . . . . 0.0 110.084 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.7 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -81.9 -16.99 48.76 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.555 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -60.82 -27.01 67.74 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.002 -1.061 . . . . 0.0 109.208 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.555 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 93.4 m-85 -83.41 -20.23 34.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.18 -0.95 . . . . 0.0 110.246 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.723 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.4 m-85 -59.38 -65.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.101 -0.999 . . . . 0.0 110.206 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -44.42 -60.13 3.21 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 110.872 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.522 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.1 Cg_endo -59.7 -26.56 82.56 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 123.827 1.435 . . . . 0.0 110.343 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.813 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.4 tm? -79.4 -19.18 50.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.113 -0.992 . . . . 0.0 109.444 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.93 -38.7 9.11 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.1 -54.11 48.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -1.171 . . . . 0.0 109.673 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.8 m -57.46 -26.16 60.79 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -0.905 . . . . 0.0 109.598 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.541 HD22 ' OH ' ' A' ' 134' ' ' TYR . 8.7 tt -69.41 -39.71 77.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.54 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.874 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.5 mt -58.71 -33.37 70.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.222 -0.924 . . . . 0.0 109.643 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.9 t -67.37 -27.92 67.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.18 -0.95 . . . . 0.0 109.66 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.533 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -83.28 -36.5 24.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.704 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.525 ' HE2' HD21 ' A' ' 110' ' ' LEU . 5.2 mmt -49.52 -42.86 44.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 109.864 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -51.99 -22.67 4.18 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.232 -0.918 . . . . 0.0 109.954 -179.72 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.444 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 15.7 m170 -68.59 -22.53 64.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.947 . . . . 0.0 110.004 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.497 ' CB ' HG23 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -93.29 -50.03 5.67 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.861 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.602 HD11 ' SD ' ' A' ' 122' ' ' MET . 13.2 pt -104.42 -36.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.151 -0.968 . . . . 0.0 109.439 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 122' ' ' MET . . . 42.81 -94.27 0.01 OUTLIER Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.67 -42.03 10.22 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -76.68 -17.38 59.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.04 -1.271 . . . . 0.0 109.697 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.602 ' SD ' HD11 ' A' ' 118' ' ' ILE . 4.8 tpt -72.52 92.48 1.49 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.137 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.791 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 8.3 p-10 -93.5 176.86 6.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 109.826 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.482 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -54.76 -50.1 69.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 109.759 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.791 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -54.7 -24.7 23.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.242 -0.911 . . . . 0.0 109.715 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.483 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.71 -51.24 11.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.956 . . . . 0.0 109.521 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 19.6 ptpt -71.66 -28.22 63.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.258 -0.901 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.453 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 35.7 t0 -78.89 -38.56 37.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.481 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -69.96 -45.71 66.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.449 -0.782 . . . . 0.0 109.444 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.879 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -72.97 -21.82 60.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.366 -0.834 . . . . 0.0 109.295 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.652 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -76.22 -23.94 54.61 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.155 -0.966 . . . . 0.0 109.091 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -99.03 -23.4 15.3 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.411 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.437 ' HB2' HG21 ' A' ' 10' ' ' VAL . . . -82.21 -37.35 26.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.39 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.541 ' OH ' HD22 ' A' ' 110' ' ' LEU . 4.8 m-30 -49.37 -27.87 4.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.285 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.4 -29.5 53.13 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 108.913 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.1 t0 -80.08 -44.2 20.45 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.431 -0.793 . . . . 0.0 109.205 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.453 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.0 mt -65.28 -55.48 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.076 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.69 -41.82 74.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.478 -0.764 . . . . 0.0 109.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.34 -52.17 33.55 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.421 ' HB1' ' HA ' ' A' ' 80' ' ' VAL . . . -53.68 -28.75 35.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -1.175 . . . . 0.0 109.791 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.899 ' O ' HD23 ' A' ' 141' ' ' LEU . 9.4 tt -71.47 -10.03 59.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.199 -0.938 . . . . 0.0 110.049 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.7 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.1 mm -91.01 38.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.039 -1.038 . . . . 0.0 109.919 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.43 ' HB3' ' HG2' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -115.52 -28.68 6.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.374 -0.829 . . . . 0.0 109.228 179.671 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.4 20.68 4.93 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.029 -1.629 . . . . 0.0 109.029 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.747 HD12 ' HB2' ' A' ' 90' ' ' HIS . 2.6 tt . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.277 -1.131 . . . . 0.0 109.794 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -74.78 -48.23 26.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.212 -0.93 . . . . 0.0 109.246 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.629 ' HG2' HD12 ' A' ' 73' ' ' LEU . 7.7 tmm_? -54.28 -42.93 70.58 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.046 -1.034 . . . . 0.0 108.765 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -52.14 -38.29 57.04 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.18 -0.95 . . . . 0.0 108.603 179.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 125' ' ' ALA . 44.8 t -72.71 -26.45 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 1.069 HG12 HG13 ' A' ' 70' ' ' VAL . 78.0 t -75.69 -45.68 38.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.515 -0.741 . . . . 0.0 109.153 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.59 -13.06 60.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 0.0 109.748 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 t -92.12 -28.57 17.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.125 -0.985 . . . . 0.0 109.829 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.4 HG21 ' HB1' ' A' ' 126' ' ' ALA . 7.2 p -90.83 -11.88 38.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.156 -0.965 . . . . 0.0 109.963 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.44 -21.73 21.77 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.073 -1.017 . . . . 0.0 109.532 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.7 mtpp -76.66 -3.61 38.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.226 -0.921 . . . . 0.0 109.679 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -109.51 -55.78 2.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.093 -1.005 . . . . 0.0 109.519 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.907 HD12 ' CH2' ' A' ' 130' ' ' TRP . 23.6 mt -60.55 -40.51 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.283 -0.886 . . . . 0.0 109.592 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.813 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -97.33 33.33 2.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.694 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.19 -80.04 0.07 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 54.2 p -112.02 12.98 20.7 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.22 -1.165 . . . . 0.0 109.829 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.744 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.4 p-10 -119.15 -17.07 9.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.086 -1.009 . . . . 0.0 109.791 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.813 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 25.3 t-20 55.88 29.26 13.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.671 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.415 ' HA3' ' CG ' ' A' ' 63' ' ' LEU . . . 90.88 23.28 30.72 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.744 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -61.45 -48.52 80.76 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.402 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -90.79 20.15 40.84 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.67 HG12 HD21 ' A' ' 63' ' ' LEU . 22.7 t -114.12 -17.69 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -1.123 . . . . 0.0 109.069 179.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -105.92 -25.57 6.43 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.5 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.3 ptpt -75.91 -33.43 59.9 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.288 -1.125 . . . . 0.0 109.558 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.84 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 1.1 pm0 -94.78 -13.88 25.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.181 -0.95 . . . . 0.0 109.722 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.415 ' HB2' ' OE2' ' A' ' 29' ' ' GLU . 32.0 t -88.33 -59.81 2.13 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -0.96 . . . . 0.0 109.562 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.525 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.1 m-85 -56.48 -29.17 61.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.153 -0.967 . . . . 0.0 109.533 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.69 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -54.66 -60.42 3.38 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.657 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.5 -50.62 62.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.704 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -50.68 -48.2 58.57 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.226 -0.921 . . . . 0.0 109.306 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.656 ' CD1' HG22 ' A' ' 55' ' ' VAL . 19.0 mt -58.26 -43.67 88.03 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.551 ' OG ' ' HB2' ' A' ' 50' ' ' ALA . 55.9 m -67.01 -69.1 0.33 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -0.936 . . . . 0.0 109.877 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.662 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -50.87 -24.19 3.38 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.25 -0.906 . . . . 0.0 109.921 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.662 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 12.3 m-70 -128.17 106.69 9.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.141 -0.974 . . . . 0.0 109.957 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.6 m170 -85.64 -19.76 30.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.558 -0.714 . . . . 0.0 109.283 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -70.55 -16.23 62.85 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.311 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.473 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -101.61 -15.44 17.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.792 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.455 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.84 -66.31 0.55 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.006 . . . . 0.0 109.246 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -53.17 -24.62 11.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.92 . . . . 0.0 109.123 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.944 HG13 ' ND2' ' A' ' 95' ' ' ASN . 2.5 t -71.37 -56.25 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.7 m-85 -60.59 -24.96 65.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.335 -0.853 . . . . 0.0 109.528 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.53 26.81 5.75 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.2 m-85 -123.65 168.23 12.93 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.247 -1.149 . . . . 0.0 109.814 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -106.77 -18.16 14.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.24 -175.67 47.58 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB2' ' OG ' ' A' ' 36' ' ' SER . . . -63.66 -13.55 43.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.853 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.17 44.11 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -130.37 123.77 20.74 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.176 -0.952 . . . . 0.0 109.592 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -66.3 -22.94 52.42 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.886 1.466 . . . . 0.0 110.087 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.51 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.99 -29.93 28.97 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.69 HG11 HG23 ' A' ' 32' ' ' THR . 49.0 t -57.69 -42.69 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -1.165 . . . . 0.0 109.476 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -68.58 -19.53 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.243 -0.91 . . . . 0.0 109.553 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.68 -37.92 24.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.912 . . . . 0.0 109.426 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.591 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.2 mt -76.0 -65.99 0.84 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.925 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.525 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -47.34 -47.18 22.19 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -57.8 -38.14 75.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -1.171 . . . . 0.0 109.618 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -77.01 -28.42 54.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.918 . . . . 0.0 109.605 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 58' ' ' LEU . 47.8 t -80.45 -41.28 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 109.572 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.67 HD21 HG12 ' A' ' 26' ' ' VAL . 0.7 OUTLIER -47.71 -49.96 26.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.903 . . . . 0.0 109.906 179.895 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.579 ' HB2' ' OD1' ' A' ' 22' ' ' ASN . . . -49.38 -50.91 38.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.122 -0.986 . . . . 0.0 109.828 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 34.1 tp60 -49.1 -47.67 45.02 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.07 -1.019 . . . . 0.0 109.34 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.707 ' O ' HG23 ' A' ' 70' ' ' VAL . 24.3 mm -56.51 -45.71 82.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.362 -0.836 . . . . 0.0 108.963 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA3' ' CZ3' ' A' ' 14' ' ' TRP . . . -61.46 -51.02 60.57 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.7 t -57.57 -31.36 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -1.065 . . . . 0.0 109.705 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.615 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -82.21 -33.86 29.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.537 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.069 HG13 HG12 ' A' ' 10' ' ' VAL . 56.1 t -65.89 -18.95 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -75.05 -15.39 60.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 22.4 m-70 -115.46 -88.96 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.784 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.817 HD11 ' HA ' ' A' ' 70' ' ' VAL . 19.3 mt . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.425 -0.797 . . . . 0.0 109.975 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 31.0 ttp . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.298 0.571 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.423 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 38.8 t -76.28 -25.2 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.321 -0.862 . . . . 0.0 109.321 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.28 -44.69 84.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.361 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.668 ' O ' HG23 ' A' ' 86' ' ' VAL . 13.2 mt-10 -83.94 -44.58 14.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.37 -0.831 . . . . 0.0 109.309 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.643 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.0 OUTLIER -58.38 -58.57 7.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.306 179.777 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.423 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -52.05 -31.44 30.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.175 -0.953 . . . . 0.0 108.97 179.563 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.543 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -66.8 -45.51 78.14 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.36 -0.838 . . . . 0.0 109.023 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.668 HG23 ' O ' ' A' ' 82' ' ' GLU . 31.5 t -51.01 -47.68 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.307 -0.871 . . . . 0.0 109.193 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -53.65 -51.39 48.85 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 85.8 t -53.99 -35.34 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.321 -1.105 . . . . 0.0 109.006 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.526 ' HB3' ' CE1' ' A' ' 93' ' ' TYR . 5.4 mmm180 -70.6 -55.1 9.61 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.382 -0.823 . . . . 0.0 109.09 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.615 ' O ' HD12 ' A' ' 98' ' ' ILE . 12.4 m80 -52.31 -29.75 25.0 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.893 . . . . 0.0 108.971 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 ttmt -68.0 -9.97 49.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.486 -0.759 . . . . 0.0 110.124 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.55 51.36 0.7 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.526 ' CE1' ' HB3' ' A' ' 89' ' ' ARG . 3.2 m-30 -106.41 -167.02 1.24 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.176 -1.191 . . . . 0.0 109.66 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.0 -38.13 93.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.944 ' ND2' HG13 ' A' ' 44' ' ' VAL . 10.7 t30 -78.96 -44.6 22.11 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.469 -1.018 . . . . 0.0 109.403 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.451 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.8 OUTLIER 71.94 -54.78 0.68 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 179.615 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.458 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 9.1 m170 -48.67 -87.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.097 -1.002 . . . . 0.0 109.944 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.615 HD12 ' O ' ' A' ' 90' ' ' HIS . 54.1 mt 59.48 156.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.714 . . . . 0.0 109.938 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.532 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.59 144.15 25.08 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 -179.841 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.41 -8.64 59.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.713 -0.617 . . . . 0.0 109.545 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -75.72 -21.54 57.44 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.101 -0.999 . . . . 0.0 109.375 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.532 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -84.94 -15.32 44.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.304 -0.872 . . . . 0.0 109.853 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.722 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.7 m-85 -63.26 -65.88 0.62 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.207 -0.933 . . . . 0.0 110.248 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.5 -59.0 3.71 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.516 -0.74 . . . . 0.0 111.087 -179.317 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 4.9 Cg_endo -52.59 -55.79 3.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.671 1.353 . . . . 0.0 110.06 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.957 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -58.66 -21.2 53.52 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.338 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.98 -47.95 17.51 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.74 -53.88 53.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.161 -1.199 . . . . 0.0 109.562 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.8 m -54.98 -25.27 28.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.204 -0.935 . . . . 0.0 109.564 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.796 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -64.66 -37.04 86.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.666 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.74 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -64.7 -42.55 95.2 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -65.1 -23.14 67.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.749 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.84 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.24 -38.65 18.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.95 . . . . 0.0 109.693 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.796 ' SD ' HD23 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -53.16 -44.69 68.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.815 -179.861 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.481 ' HG2' ' CB ' ' A' ' 122' ' ' MET . 12.2 mt-10 -47.47 -28.35 2.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.243 -0.911 . . . . 0.0 109.668 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.464 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 15.7 m170 -57.81 -27.07 62.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -0.997 . . . . 0.0 109.817 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.442 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -90.25 -65.59 1.0 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.252 -0.905 . . . . 0.0 109.871 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.741 HG23 HG12 ' A' ' 17' ' ' ILE . 41.8 pt -87.51 -37.48 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 109.496 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.503 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 40.91 -93.47 0.01 OUTLIER Glycine 0 N--CA 1.497 2.76 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -42.9 -41.43 4.54 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.496 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 34.6 mmtt -76.23 -28.24 57.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.13 -1.218 . . . . 0.0 109.748 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.481 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -59.21 102.01 0.12 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.173 -0.955 . . . . 0.0 109.317 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.731 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 9.2 p-10 -98.62 -178.7 4.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.244 -0.91 . . . . 0.0 109.772 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.05 -43.27 99.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 109.761 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.731 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -65.03 -24.38 67.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.094 -1.004 . . . . 0.0 109.306 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.505 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -72.67 -48.71 36.89 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.325 -0.859 . . . . 0.0 109.432 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.513 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.8 ptpt -73.39 -29.75 62.82 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.258 -0.901 . . . . 0.0 109.671 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.513 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 12.5 t0 -75.15 -38.34 61.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.192 -0.942 . . . . 0.0 109.273 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.633 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -66.63 -43.88 83.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -0.825 . . . . 0.0 109.104 179.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.907 ' CH2' HD12 ' A' ' 17' ' ' ILE . 11.1 m0 -73.58 -32.75 64.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.312 -0.868 . . . . 0.0 109.192 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.539 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -47.64 -27.68 2.01 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.271 -0.893 . . . . 0.0 109.414 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -108.69 -14.72 14.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.399 -0.813 . . . . 0.0 109.665 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.674 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -73.49 -69.13 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.957 . . . . 0.0 110.153 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.599 ' HA ' HD12 ' A' ' 137' ' ' ILE . 11.6 p90 -58.31 -20.14 40.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.844 -1.16 . . . . 0.0 109.127 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.423 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -73.61 -40.85 63.51 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.241 -0.912 . . . . 0.0 108.893 179.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.63 -30.52 56.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.352 -0.843 . . . . 0.0 109.055 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.643 HG23 ' SD ' ' A' ' 83' ' ' MET . 58.5 mt -68.28 -59.99 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.401 -0.812 . . . . 0.0 109.151 179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -57.56 -18.77 21.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.347 -0.846 . . . . 0.0 109.714 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.74 -52.2 21.31 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.47 -25.82 17.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.27 -1.135 . . . . 0.0 109.744 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.829 ' O ' HD23 ' A' ' 141' ' ' LEU . 7.3 tt -74.05 -11.58 60.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -0.912 . . . . 0.0 110.016 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.673 ' O ' HG22 ' A' ' 142' ' ' ILE . 98.3 mt -91.53 21.47 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.081 -1.012 . . . . 0.0 109.714 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -109.6 -20.35 12.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.156 -0.965 . . . . 0.0 109.83 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.14 -22.63 3.78 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.489 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 3.4 tp . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.11 -1.23 . . . . 0.0 109.77 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.959 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.16 0.505 . . . . 0.0 110.044 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.517 ' O ' HG23 ' A' ' 10' ' ' VAL . 37.8 mt-30 -60.98 -56.34 22.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.671 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.58 ' HA ' HD12 ' A' ' 73' ' ' LEU . 9.7 ttp180 -51.86 -26.22 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.141 -0.975 . . . . 0.0 109.598 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 39.3 tp60 -85.27 -49.35 8.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 5' ' ' ALA . 41.5 t -52.05 -28.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.267 -0.896 . . . . 0.0 109.687 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.892 HG11 HD11 ' A' ' 73' ' ' LEU . 84.8 t -64.99 -53.68 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.898 . . . . 0.0 109.624 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.83 -17.6 64.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.3 -32.6 38.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.181 -0.949 . . . . 0.0 109.698 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.428 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 41.0 p -94.54 -11.57 29.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.66 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.06 -18.09 31.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.047 -1.033 . . . . 0.0 109.873 -179.825 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -85.65 -15.64 41.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.167 -0.958 . . . . 0.0 109.608 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -96.64 -53.83 3.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.51 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.98 HD12 ' CH2' ' A' ' 130' ' ' TRP . 62.0 mt -68.49 -43.12 84.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.285 -0.884 . . . . 0.0 109.508 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.594 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -100.43 34.99 2.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.375 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.73 -86.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.3 p -106.95 13.59 27.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.238 -1.154 . . . . 0.0 110.066 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.444 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 3.2 p30 -122.59 -9.84 8.41 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.121 -0.987 . . . . 0.0 110.177 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.615 HD21 ' HB2' ' A' ' 64' ' ' ALA . 6.7 t30 57.06 18.36 3.99 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.271 -0.893 . . . . 0.0 109.584 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.425 ' O ' ' HB ' ' A' ' 26' ' ' VAL . . . 85.76 32.63 17.9 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.25 -47.81 80.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.189 -1.183 . . . . 0.0 109.18 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.44 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -85.72 9.48 68.26 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.466 HG21 ' CG2' ' A' ' 17' ' ' ILE . 9.2 t -95.48 -39.27 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.135 -1.215 . . . . 0.0 109.353 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -81.89 -51.81 4.35 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.9 ptpt -50.39 -30.97 13.57 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.202 -1.175 . . . . 0.0 109.604 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.761 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 22.3 pt-20 -89.48 -22.43 22.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.444 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.7 t -86.98 -39.6 15.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.343 -0.848 . . . . 0.0 109.645 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 10.1 m-85 -75.37 -42.21 54.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.879 . . . . 0.0 109.857 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.613 ' OG1' HG11 ' A' ' 55' ' ' VAL . 20.4 m -51.69 -49.05 63.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.089 -1.007 . . . . 0.0 109.394 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.9 . . . . 0.0 109.434 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.737 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.6 t80 -65.09 -46.76 79.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.676 HD13 HG22 ' A' ' 55' ' ' VAL . 10.8 mt -59.94 -47.6 85.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.418 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 3.0 t -61.17 -57.78 11.05 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.173 -0.954 . . . . 0.0 109.783 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.645 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -61.91 -27.28 68.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.183 -0.948 . . . . 0.0 109.841 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.645 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 18.8 m-70 -121.93 105.61 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 109.781 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -87.2 -18.96 29.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.378 -0.826 . . . . 0.0 109.405 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -68.85 -19.08 64.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.905 . . . . 0.0 109.509 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.42 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 73.9 mmm -106.51 -23.61 12.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.288 -0.883 . . . . 0.0 109.712 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.46 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.96 -42.92 39.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.117 -0.989 . . . . 0.0 109.57 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.78 -28.19 60.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.31 -0.868 . . . . 0.0 109.255 179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.016 HG13 ' ND2' ' A' ' 95' ' ' ASN . 38.0 t -66.37 -49.46 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.332 -0.855 . . . . 0.0 109.424 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 50.6 m-85 -62.06 -30.93 71.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.739 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.19 31.68 2.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.041 -1.623 . . . . 0.0 109.041 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.0 m-85 -125.79 173.07 9.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.36 -1.082 . . . . 0.0 109.746 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.61 20.9 13.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.865 . . . . 0.0 109.301 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.54 -161.95 27.35 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.453 ' HB1' HG23 ' A' ' 32' ' ' THR . . . -92.5 29.46 1.72 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -1.134 . . . . 0.0 109.66 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.3 p -125.92 26.79 6.51 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.73 138.43 22.09 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.614 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -69.29 -25.43 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.962 1.507 . . . . 0.0 110.069 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' A' ' 57' ' ' ASP . . . -57.61 -31.49 63.7 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.676 HG22 HD13 ' A' ' 35' ' ' LEU . 70.2 t -53.85 -34.87 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.269 -1.136 . . . . 0.0 109.532 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.563 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.25 -7.48 58.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.316 -0.865 . . . . 0.0 109.856 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.403 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 7.7 m-20 -88.81 -38.77 14.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.72 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.63 ' O ' HG23 ' A' ' 62' ' ' VAL . 8.9 mt -74.81 -63.63 1.21 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 0.0 109.514 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.844 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -49.77 -34.57 21.99 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.563 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -68.04 -49.62 60.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.235 -1.156 . . . . 0.0 109.467 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -71.69 -44.07 64.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.376 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.63 HG23 ' O ' ' A' ' 58' ' ' LEU . 83.6 t -55.96 -51.47 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.629 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.844 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -46.45 -49.53 18.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.238 -0.913 . . . . 0.0 110.169 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.615 ' HB2' HD21 ' A' ' 22' ' ' ASN . . . -54.25 -39.01 66.43 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.089 -1.007 . . . . 0.0 109.907 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 23.5 tp60 -56.74 -39.49 74.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.992 -1.067 . . . . 0.0 108.931 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.986 ' O ' HG23 ' A' ' 70' ' ' VAL . 89.9 mt -66.98 -34.85 72.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.423 -0.798 . . . . 0.0 108.863 179.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.57 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.07 -51.34 45.75 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.74 -27.6 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.267 -1.137 . . . . 0.0 108.796 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.7 -27.38 27.07 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.634 -0.666 . . . . 0.0 109.507 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.986 HG23 ' O ' ' A' ' 66' ' ' ILE . 40.9 t -58.81 -17.28 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.32 -0.862 . . . . 0.0 109.7 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.441 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 1.2 t -56.15 -43.49 78.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.926 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.441 ' ND1' ' O ' ' A' ' 71' ' ' SER . 33.4 m-70 -138.73 102.73 4.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 0.0 109.979 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.936 HD21 ' HA ' ' A' ' 70' ' ' VAL . 36.1 mt . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.28 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.511 ' SD ' HG23 ' A' ' 80' ' ' VAL . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.199 0.524 . . . . 0.0 109.667 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.511 HG23 ' SD ' ' A' ' 79' ' ' MET . 75.4 t -63.8 -15.56 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.712 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -80.01 -12.95 59.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.124 -0.985 . . . . 0.0 109.875 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.428 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.6 tp10 -99.44 -48.13 4.89 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.71 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.407 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 97.6 mmm -59.78 -44.91 93.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.152 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.679 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.04 -30.55 15.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.209 -0.932 . . . . 0.0 108.786 179.238 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -82.45 -36.38 26.63 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.498 -0.751 . . . . 0.0 109.112 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.443 ' CG1' HD12 ' A' ' 141' ' ' LEU . 89.2 t -59.22 -51.59 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.277 -0.889 . . . . 0.0 109.334 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.481 ' N ' ' HG ' ' A' ' 141' ' ' LEU . . . -53.06 -48.65 58.09 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.629 -1.789 . . . . 0.0 108.629 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 84' ' ' LYS . 99.0 t -47.38 -27.94 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.49 -1.006 . . . . 0.0 109.645 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.521 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 17.5 mmt180 -70.27 -42.72 71.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.128 -0.983 . . . . 0.0 108.804 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.477 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 12.3 m80 -65.56 -12.42 52.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.438 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 0.2 OUTLIER -68.1 -13.21 62.03 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.327 -0.858 . . . . 0.0 110.399 -179.667 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.75 58.99 0.38 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.462 -1.352 . . . . 0.0 110.098 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.521 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 3.6 m-30 -92.32 -172.46 3.11 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.158 -1.201 . . . . 0.0 109.241 179.212 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.36 -34.77 90.8 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.507 -1.837 . . . . 0.0 108.507 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.016 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.8 OUTLIER -82.94 -58.94 2.66 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.541 -0.976 . . . . 0.0 108.924 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.483 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 3.0 pttt 79.45 -19.82 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.774 -0.579 . . . . 0.0 111.02 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.406 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 5.7 m170 -92.24 40.64 1.05 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.666 -1.271 . . . . 0.0 109.44 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.456 HD13 ' CD2' ' A' ' 90' ' ' HIS . 65.3 mt -72.77 164.27 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.363 -0.836 . . . . 0.0 109.754 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.438 ' N ' HG22 ' A' ' 98' ' ' ILE . 0.1 OUTLIER -145.07 141.79 29.15 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.349 -0.844 . . . . 0.0 109.889 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.97 5.28 16.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 46.4 mm-40 -83.99 -32.63 24.86 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.99 -1.069 . . . . 0.0 109.463 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.439 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 95.6 m-85 -75.72 -10.73 59.68 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.275 -0.891 . . . . 0.0 109.958 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.843 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.1 m-85 -62.93 -61.31 2.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.157 -0.964 . . . . 0.0 110.176 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -50.22 -55.58 24.07 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 109.881 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 32.3 Cg_exo -51.05 -62.68 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 123.712 1.375 . . . . 0.0 109.934 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.962 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.75 -24.45 35.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.54 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.74 -45.51 12.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.64 -38.59 87.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -1.188 . . . . 0.0 109.652 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -20.49 64.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.531 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.493 HD22 ' HE2' ' A' ' 134' ' ' TYR . 1.9 tt -74.58 -39.69 62.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.695 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.811 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -62.73 -30.06 71.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.258 -0.901 . . . . 0.0 109.558 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.7 t -72.53 -25.27 61.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.289 -0.882 . . . . 0.0 109.764 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.761 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.06 -38.76 18.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.244 -0.91 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.648 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.9 mmt -46.66 -45.07 19.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.33 -0.856 . . . . 0.0 110.055 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -49.21 -25.2 2.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 109.611 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.471 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 26.5 m170 -57.46 -37.43 72.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.574 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.51 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 2.1 ttt85 -83.89 -70.41 0.57 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.699 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.476 HG23 HG12 ' A' ' 17' ' ' ILE . 14.1 pt -82.44 53.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.173 -0.954 . . . . 0.0 109.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -59.43 123.78 34.4 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.32 -36.81 3.82 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.425 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 15.6 mtpt -84.58 -30.73 24.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.27 -1.135 . . . . 0.0 109.399 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.37 81.63 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.329 -0.857 . . . . 0.0 109.446 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.583 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.1 p30 -86.8 -168.68 2.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.754 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.446 ' O ' ' CB ' ' A' ' 128' ' ' ASP . . . -64.3 -46.21 84.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.489 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.782 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.28 -24.38 54.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.276 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.48 -58.36 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.548 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.2 OUTLIER -68.49 -25.85 65.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.588 -179.823 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 124' ' ' ALA . 25.0 t70 -80.75 -39.71 26.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.543 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.93 -41.82 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.848 . . . . 0.0 109.279 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.98 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.8 m0 -73.74 -24.52 59.9 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.163 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.548 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -74.04 -24.52 59.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.192 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.58 -40.58 12.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.858 . . . . 0.0 109.458 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.783 ' CB ' HD13 ' A' ' 73' ' ' LEU . . . -70.97 -45.58 63.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.399 -0.813 . . . . 0.0 109.537 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.493 ' HE2' HD22 ' A' ' 110' ' ' LEU . 3.2 m-85 -50.08 -32.15 14.93 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.908 . . . . 0.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.88 -37.11 70.21 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.19 -0.944 . . . . 0.0 108.866 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.17 -33.0 44.42 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.38 -0.825 . . . . 0.0 109.231 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.761 HD13 HG23 ' A' ' 66' ' ' ILE . 24.9 mt -65.77 -60.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.334 -0.854 . . . . 0.0 108.833 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.413 ' O ' HG13 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -66.93 -37.39 84.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.589 -0.694 . . . . 0.0 109.669 -179.775 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -52.44 -44.9 59.16 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.31 -18.36 64.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.21 -1.171 . . . . 0.0 109.82 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.843 HD22 ' CE2' ' A' ' 103' ' ' PHE . 6.7 tt -87.73 -23.77 24.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 109.78 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.493 HD12 ' HA2' ' A' ' 139' ' ' GLY . 50.9 mt -82.68 8.03 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 0.0 110.275 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -86.95 -35.92 18.61 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.008 -1.058 . . . . 0.0 109.502 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.417 ' O ' ' HD3' ' A' ' 91' ' ' LYS . . . -104.43 5.85 45.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.477 ' CD1' ' HB2' ' A' ' 90' ' ' HIS . 1.5 tt . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.075 -1.25 . . . . 0.0 109.19 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.228 0.537 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -84.98 -46.21 11.44 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.218 -0.926 . . . . 0.0 109.735 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.466 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 4.3 ptm180 -51.7 -32.06 28.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.466 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 5.5 mm100 -70.2 -47.62 60.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.215 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.765 HG11 ' O ' ' A' ' 125' ' ' ALA . 80.9 t -56.44 -30.75 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.285 -0.884 . . . . 0.0 109.176 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.884 HG12 HG13 ' A' ' 70' ' ' VAL . 83.1 t -64.14 -55.02 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -0.836 . . . . 0.0 109.221 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.9 -14.04 62.64 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.613 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.5 m -84.44 -27.18 27.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.15 -0.969 . . . . 0.0 109.724 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.471 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 25.3 p -98.94 -7.2 27.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.152 -0.967 . . . . 0.0 109.69 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -89.27 -21.48 23.18 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.151 -0.968 . . . . 0.0 109.646 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.3 mtpm? -79.31 2.31 21.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 110.092 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -116.45 -54.4 2.46 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.06 -1.025 . . . . 0.0 109.525 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.808 HD12 ' CH2' ' A' ' 130' ' ' TRP . 43.2 mt -66.49 -32.25 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.292 -0.88 . . . . 0.0 109.518 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.651 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -105.92 35.39 2.92 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.713 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.7 -81.57 0.05 OUTLIER Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 p -108.78 -34.86 6.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -1.128 . . . . 0.0 109.58 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.516 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 37.8 p30 -75.91 -15.05 60.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.909 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.651 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.8 t30 63.18 16.0 9.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.147 -0.971 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.474 ' O ' HD12 ' A' ' 63' ' ' LEU . . . 100.11 17.36 25.21 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.516 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -50.07 -36.81 30.76 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.094 -1.239 . . . . 0.0 109.774 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.454 ' HA2' ' CE ' ' A' ' 28' ' ' LYS . . . -92.97 13.61 67.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 30' ' ' CYS . 54.5 t -95.4 -28.3 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.045 -1.268 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.438 ' HA2' ' HB3' ' A' ' 30' ' ' CYS . . . -91.47 -44.52 4.28 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.475 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 10.8 ptpt -51.61 -33.66 34.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.195 -1.179 . . . . 0.0 109.089 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.87 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 19.0 pt-20 -91.44 -29.41 17.05 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.218 -0.926 . . . . 0.0 109.243 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.438 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 18.0 t -84.83 -68.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 110.065 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.608 ' HZ ' HG11 ' A' ' 62' ' ' VAL . 22.1 m-85 -45.94 -32.6 2.8 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.564 -178.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.725 ' OG1' HG11 ' A' ' 55' ' ' VAL . 5.6 m -59.04 -52.16 66.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.929 -1.107 . . . . 0.0 109.124 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 36.3 mttt -55.44 -48.21 74.8 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.069 -1.019 . . . . 0.0 109.311 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.515 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.9 t80 -54.83 -54.48 41.74 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.31 -0.869 . . . . 0.0 109.336 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.745 ' CD1' HG22 ' A' ' 55' ' ' VAL . 46.0 mt -55.39 -43.29 75.05 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.64 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -68.17 0.37 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.679 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.645 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -53.37 -30.09 37.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.214 -0.929 . . . . 0.0 109.626 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.645 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 10.8 m-70 -115.2 99.84 7.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.754 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 24.7 m170 -82.3 -14.4 55.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.453 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -74.21 -13.78 60.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.152 -0.968 . . . . 0.0 109.62 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.474 ' SD ' HG11 ' A' ' 44' ' ' VAL . 2.6 mmt -104.83 -27.34 11.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.13 -0.981 . . . . 0.0 109.91 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.664 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -48.24 -41.53 27.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.037 -1.039 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.43 -26.02 59.81 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -0.85 . . . . 0.0 108.782 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.008 HG13 ' ND2' ' A' ' 95' ' ' ASN . 2.9 t -72.61 -47.34 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.832 ' HD2' HD13 ' A' ' 58' ' ' LEU . 25.0 m-85 -65.61 -32.74 74.49 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.874 . . . . 0.0 109.47 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.14 27.94 3.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.544 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.6 m-85 -123.21 172.95 8.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.21 -1.17 . . . . 0.0 109.828 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.56 19.51 16.78 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.371 -0.83 . . . . 0.0 109.215 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 151.83 -163.8 30.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB1' HG23 ' A' ' 32' ' ' THR . . . -98.74 36.24 1.7 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -1.171 . . . . 0.0 109.704 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 67.3 p -147.46 28.94 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.613 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 54' ' ' GLY . 0.4 OUTLIER -108.15 143.62 27.76 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.639 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -65.95 70.27 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.998 1.525 . . . . 0.0 110.059 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.524 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -155.19 -43.56 0.02 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.745 HG22 ' CD1' ' A' ' 35' ' ' LEU . 61.6 t -53.0 -40.1 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.357 -1.084 . . . . 0.0 109.496 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.62 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -63.93 -20.31 65.76 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.487 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.55 -57.76 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.301 -0.875 . . . . 0.0 109.236 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.832 HD13 ' HD2' ' A' ' 45' ' ' PHE . 0.4 OUTLIER -57.56 -63.3 1.28 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.462 -0.774 . . . . 0.0 110.28 -179.85 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.585 ' O ' HD13 ' A' ' 63' ' ' LEU . . . -54.59 -21.7 22.24 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.203 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.674 ' HA ' HD11 ' A' ' 63' ' ' LEU . . . -83.94 -6.12 59.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.126 -1.22 . . . . 0.0 110.684 -179.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 56.9 mttt -113.19 -12.3 13.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.972 -1.08 . . . . 0.0 110.002 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.608 HG11 ' HZ ' ' A' ' 31' ' ' PHE . 93.4 t -83.2 -25.65 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.099 -1.001 . . . . 0.0 110.68 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.674 HD11 ' HA ' ' A' ' 60' ' ' ALA . 0.0 OUTLIER -70.28 -4.8 23.66 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.706 -1.246 . . . . 0.0 110.697 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.479 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -85.16 -42.45 14.72 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.834 -1.166 . . . . 0.0 109.559 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.435 ' OE1' HG21 ' A' ' 86' ' ' VAL . 2.8 mm-40 -56.57 -47.99 78.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.107 -0.996 . . . . 0.0 108.807 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.919 ' O ' HG23 ' A' ' 70' ' ' VAL . 80.1 mt -57.32 -34.69 46.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.582 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.85 -57.26 12.66 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.1 t -57.33 -23.7 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.267 -1.137 . . . . 0.0 109.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.45 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -86.71 -27.88 23.43 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.447 -0.783 . . . . 0.0 109.582 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.919 HG23 ' O ' ' A' ' 66' ' ' ILE . 54.5 t -70.46 -12.39 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.181 -0.949 . . . . 0.0 109.826 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.0 t -82.58 6.63 17.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.033 . . . . 0.0 110.061 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.471 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 23.9 m-70 -140.08 -88.88 0.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.004 -1.06 . . . . 0.0 109.685 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.572 HD11 ' HA ' ' A' ' 70' ' ' VAL . 29.8 mt . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.468 -0.77 . . . . 0.0 109.823 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.471 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 17.2 tmm? . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.266 0.555 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.424 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 69.3 t -71.04 -20.27 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.63 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.29 74.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.712 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.471 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 17.5 mt-10 -76.7 -53.45 7.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.574 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.8 mtp -53.31 -41.07 65.28 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.201 -0.937 . . . . 0.0 109.435 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.525 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.7 OUTLIER -52.17 -31.88 33.43 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.175 -0.953 . . . . 0.0 108.723 179.24 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.3 -36.75 71.74 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.665 ' CG1' HD11 ' A' ' 141' ' ' LEU . 45.5 t -56.89 -51.75 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.199 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -51.8 -46.75 54.38 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.856 -1.698 . . . . 0.0 108.856 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 84' ' ' LYS . 60.8 t -50.41 -25.75 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -1.173 . . . . 0.0 109.292 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.474 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 0.2 OUTLIER -81.3 -53.3 6.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.325 -0.859 . . . . 0.0 108.743 179.352 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.672 ' HB2' HD13 ' A' ' 145' ' ' LEU . 21.1 m80 -54.72 -21.91 12.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.053 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 91' ' ' LYS . 34.0 ttpt -67.69 -12.93 61.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.448 -0.782 . . . . 0.0 110.243 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.07 55.58 0.55 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.512 ' OH ' ' CE1' ' A' ' 90' ' ' HIS . 3.8 m-30 -89.59 -100.23 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.322 -1.105 . . . . 0.0 109.645 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.44 -50.05 0.02 OUTLIER Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.066 -2.013 . . . . 0.0 108.066 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.008 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.8 p-10 -67.17 -30.44 70.41 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.489 -1.006 . . . . 0.0 108.521 178.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 43.5 mttt 51.98 22.24 1.75 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.636 -0.665 . . . . 0.0 109.805 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.2 m170 -128.64 49.48 2.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.338 -0.851 . . . . 0.0 109.149 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.469 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 76.3 mt -84.93 158.74 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.857 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.511 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -142.02 144.91 33.87 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.356 -0.84 . . . . 0.0 109.983 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.708 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -80.98 -15.86 55.07 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.679 -0.638 . . . . 0.0 109.36 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 54.3 mm-40 -67.86 -22.38 65.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.128 -0.983 . . . . 0.0 109.471 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.511 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -86.32 -26.39 24.93 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 109.79 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.812 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.7 m-85 -51.28 -59.06 4.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.23 -0.919 . . . . 0.0 110.281 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.506 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -54.65 -58.78 12.67 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.203 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.506 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.4 Cg_exo -48.25 -53.13 7.18 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 O-C-N 123.639 1.337 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.93 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -59.48 -18.0 36.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -0.941 . . . . 0.0 109.858 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -83.99 -42.56 7.56 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.71 -57.78 9.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.078 -1.248 . . . . 0.0 109.684 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.5 t -60.66 -16.25 37.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.778 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.981 HD21 ' CE ' ' A' ' 114' ' ' MET . 3.2 tt -78.53 -36.42 44.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.075 -1.016 . . . . 0.0 109.715 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.837 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -64.36 -28.78 69.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.069 -1.019 . . . . 0.0 109.423 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.427 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 14.1 t -66.63 -35.22 79.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.699 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.87 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -80.29 -31.63 38.22 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.655 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.981 ' CE ' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.35 -38.09 12.34 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.019 -179.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.471 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.9 OUTLIER -62.65 -14.0 38.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.074 -1.017 . . . . 0.0 109.705 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.545 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.9 m170 -53.9 -37.54 63.88 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.911 -1.118 . . . . 0.0 109.443 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.475 ' HB3' HG12 ' A' ' 17' ' ' ILE . 1.1 ttt85 -89.81 -51.62 5.4 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.2 -0.938 . . . . 0.0 109.82 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.435 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 2.8 pt -110.04 48.73 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.161 -0.962 . . . . 0.0 109.897 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -59.57 -18.29 44.08 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.17 -30.61 9.14 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.7 mtpp -94.47 -25.81 16.73 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.164 -1.198 . . . . 0.0 109.537 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 1.8 tpt -61.09 96.73 0.05 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.889 . . . . 0.0 109.431 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -106.14 -162.54 0.87 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.744 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -67.08 -46.25 74.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.355 -0.841 . . . . 0.0 110.134 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.765 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -63.58 -21.55 66.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.074 -1.016 . . . . 0.0 109.779 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.4 -47.15 14.83 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.177 -0.952 . . . . 0.0 109.563 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.573 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 17.6 ptpt -74.02 -30.68 62.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -0.891 . . . . 0.0 109.685 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.454 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -73.94 -53.34 10.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.93 . . . . 0.0 109.738 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.549 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -55.09 -43.41 73.97 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.35 -0.844 . . . . 0.0 109.71 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.837 ' HB3' HD21 ' A' ' 111' ' ' LEU . 7.5 m0 -76.09 -27.15 57.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.245 -0.909 . . . . 0.0 109.565 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.573 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.26 -30.42 68.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.169 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.78 -26.39 21.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.38 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -82.06 -48.38 11.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.517 ' CE2' ' HE2' ' A' ' 114' ' ' MET . 9.1 m-30 -52.42 -31.01 32.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.293 -0.88 . . . . 0.0 109.337 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.75 -46.39 63.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -0.875 . . . . 0.0 109.219 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -73.91 -30.53 62.64 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.312 -0.867 . . . . 0.0 109.221 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.663 HD13 HG23 ' A' ' 66' ' ' ILE . 59.4 mt -67.98 -60.78 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.314 -0.866 . . . . 0.0 108.973 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 3.6 m -66.96 -31.47 72.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.487 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.16 -38.41 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.17 -23.74 66.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -1.141 . . . . 0.0 109.528 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.849 ' O ' HD23 ' A' ' 141' ' ' LEU . 10.0 tt -76.34 -2.39 31.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 110.116 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.708 HD12 ' HB2' ' A' ' 100' ' ' ALA . 40.6 mm -92.15 31.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.961 -1.087 . . . . 0.0 109.902 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.465 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -108.73 -34.23 6.75 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.283 -0.885 . . . . 0.0 109.381 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.79 21.89 7.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.672 HD13 ' HB2' ' A' ' 90' ' ' HIS . 14.3 tp . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.345 -1.091 . . . . 0.0 110.004 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.861 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.257 0.551 . . . . 0.0 109.683 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 57.8 mt-30 -71.24 -55.45 8.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 2.8 ptm180 -50.92 -32.36 20.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.447 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.458 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 9.4 tp-100 -70.29 -39.01 75.13 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.294 -0.879 . . . . 0.0 109.349 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.861 HG23 ' O ' ' A' ' 5' ' ' ALA . 22.0 t -69.38 -27.63 35.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.453 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 1.055 HG12 HG13 ' A' ' 70' ' ' VAL . 97.2 t -71.95 -37.96 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.596 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.98 -14.75 60.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.855 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 t -90.87 -25.62 19.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -93.56 -12.41 29.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 109.952 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.739 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.21 -24.31 21.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.084 -1.01 . . . . 0.0 109.788 -179.842 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -75.23 -8.37 56.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.406 ' HB3' HG21 ' A' ' 118' ' ' ILE . 1.8 m-20 -103.7 -54.06 2.65 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.085 -1.009 . . . . 0.0 109.68 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.917 HD12 ' CH2' ' A' ' 130' ' ' TRP . 46.4 mt -65.79 -36.67 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.246 -0.909 . . . . 0.0 109.712 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.939 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.69 33.56 3.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.778 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.09 -66.98 2.36 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 88.3 p -115.61 -19.64 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -1.134 . . . . 0.0 109.558 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.809 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 7.5 p-10 -87.17 -19.08 28.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.894 . . . . 0.0 109.654 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.939 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.2 t30 58.57 22.89 10.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.05 23.69 10.4 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.809 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -70.45 -43.43 69.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -1.159 . . . . 0.0 109.603 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.423 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -88.39 14.46 59.44 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.624 HG11 HD11 ' A' ' 63' ' ' LEU . 44.0 t -108.64 -26.15 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -1.228 . . . . 0.0 109.317 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -97.36 -36.86 4.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.478 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.0 ptpt -66.41 -29.07 69.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.176 -1.191 . . . . 0.0 109.554 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.478 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 13.1 pt-20 -93.86 -20.34 20.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -0.935 . . . . 0.0 109.675 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.0 t -88.25 -59.86 2.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.234 -0.916 . . . . 0.0 109.866 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.8 m-85 -54.48 -30.11 52.16 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 109.81 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.96 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -55.32 -58.47 7.57 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.162 -0.961 . . . . 0.0 109.336 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -54.31 -45.29 72.55 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.878 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.788 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -56.36 -59.09 5.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.962 . . . . 0.0 109.286 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.838 ' CD1' HG22 ' A' ' 55' ' ' VAL . 26.6 mt -51.15 -43.71 61.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 109.632 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.467 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 2.6 t -68.82 -71.27 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.911 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -49.52 -29.89 7.52 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.888 . . . . 0.0 109.787 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.657 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 12.9 m-70 -117.85 107.49 14.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.266 -0.896 . . . . 0.0 109.944 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -86.59 -25.4 24.98 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.475 -0.765 . . . . 0.0 108.967 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -66.97 -21.62 65.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.229 -0.919 . . . . 0.0 108.931 179.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.494 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -94.99 -27.63 15.55 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.413 -0.805 . . . . 0.0 109.55 179.846 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.437 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.06 -45.0 64.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.064 -1.023 . . . . 0.0 109.248 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.4 84.51 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.341 -0.849 . . . . 0.0 109.184 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.98 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.7 t -62.96 -60.24 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.31 -0.868 . . . . 0.0 109.156 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HD1' HD13 ' A' ' 58' ' ' LEU . 62.0 m-85 -61.54 -31.97 72.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.192 -0.942 . . . . 0.0 109.009 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.06 -138.59 15.08 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.517 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 2.0 m-85 61.64 162.6 0.07 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.211 -1.17 . . . . 0.0 109.915 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 32.2 t -106.71 23.36 14.42 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.42 -161.06 31.45 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.467 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -92.32 -21.4 20.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.711 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.6 p -90.8 56.89 3.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.147 -0.97 . . . . 0.0 109.669 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.47 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -120.1 139.99 29.23 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.208 -0.933 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 15.8 Cg_exo -62.11 -31.59 83.28 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.98 1.516 . . . . 0.0 110.067 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -37.25 40.04 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.96 HG11 HG23 ' A' ' 32' ' ' THR . 93.4 t -50.2 -37.49 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -1.103 . . . . 0.0 109.445 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -75.65 -21.47 57.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.881 . . . . 0.0 109.299 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -81.41 -40.03 24.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.486 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.823 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 mt -74.93 -59.59 2.67 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.516 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.5 -48.48 42.05 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.448 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -59.59 -48.41 81.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -1.106 . . . . 0.0 109.468 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -62.93 -33.24 74.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.883 . . . . 0.0 109.461 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 58' ' ' LEU . 55.1 t -75.08 -49.47 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.323 -0.861 . . . . 0.0 109.527 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.624 HD11 HG11 ' A' ' 26' ' ' VAL . 2.0 mm? -48.68 -46.23 40.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.14 -49.31 32.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.785 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -53.72 -51.58 62.84 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.277 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.953 ' O ' HG23 ' A' ' 70' ' ' VAL . 61.0 mt -53.91 -39.21 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.339 -0.85 . . . . 0.0 109.131 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.558 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -59.52 -54.5 37.19 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -60.19 -29.98 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -1.147 . . . . 0.0 109.268 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.543 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -83.56 -5.58 59.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.406 -0.809 . . . . 0.0 109.989 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.055 HG13 HG12 ' A' ' 10' ' ' VAL . 42.2 t -90.56 -16.37 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.99 -1.069 . . . . 0.0 109.954 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.27 16.52 5.16 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.157 -0.964 . . . . 0.0 110.101 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -137.8 -86.59 0.28 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.305 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.462 HD11 HG11 ' A' ' 10' ' ' VAL . 68.1 mt . . . . . 0 N--CA 1.496 1.831 0 O-C-N 121.302 -0.873 . . . . 0.0 110.035 179.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 24.3 t -75.83 -22.87 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.599 -0.84 . . . . 0.0 109.117 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.17 -22.2 27.13 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.24 -0.912 . . . . 0.0 109.137 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.859 ' O ' HG23 ' A' ' 86' ' ' VAL . 33.6 mt-10 -90.98 -37.55 13.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.339 -0.851 . . . . 0.0 109.541 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.634 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.0 OUTLIER -67.11 -51.8 49.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.124 -0.985 . . . . 0.0 109.07 179.667 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.79 -31.33 66.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.258 -0.901 . . . . 0.0 108.752 179.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -67.33 -42.6 83.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 109.006 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.859 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.8 t -53.83 -44.62 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 108.83 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.402 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -58.98 -51.46 59.1 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.738 HG23 ' HA3' ' A' ' 144' ' ' GLY . 55.1 t -58.22 -23.08 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.341 -1.094 . . . . 0.0 109.023 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -86.64 -50.06 7.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.391 -0.818 . . . . 0.0 109.074 179.713 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.542 ' HB3' HD13 ' A' ' 98' ' ' ILE . 2.9 m80 -48.42 -44.55 35.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.755 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.441 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -58.94 -17.94 29.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.179 -0.951 . . . . 0.0 109.822 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.25 37.86 3.39 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.467 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.2 m-30 -93.76 -166.01 1.43 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -1.107 . . . . 0.0 109.519 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.51 -33.86 24.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.98 ' ND2' HG13 ' A' ' 44' ' ' VAL . 2.2 t30 -69.41 -59.0 3.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.486 -1.008 . . . . 0.0 109.299 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 76.13 -12.97 0.95 Allowed 'General case' 0 N--CA 1.507 2.42 0 O-C-N 121.572 -0.705 . . . . 0.0 111.491 179.589 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.3 m170 -99.78 41.94 1.13 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.633 -1.292 . . . . 0.0 109.018 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.542 HD13 ' HB3' ' A' ' 90' ' ' HIS . 57.3 mt -76.07 152.35 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.404 -0.81 . . . . 0.0 110.46 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.457 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 8.5 mttp -142.2 138.9 31.83 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 121.661 0.743 . . . . 0.0 109.809 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.592 ' HB2' HG23 ' A' ' 142' ' ' ILE . . . -75.42 -6.8 51.91 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.713 -0.617 . . . . 0.0 109.511 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 6.0 pt-20 -74.12 -26.63 60.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.09 -1.006 . . . . 0.0 109.301 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.494 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 33.3 m-85 -81.63 -21.25 38.35 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.865 . . . . 0.0 109.724 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.815 ' HE2' HD22 ' A' ' 141' ' ' LEU . 3.3 m-85 -55.84 -63.0 1.32 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.334 -0.854 . . . . 0.0 110.289 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.51 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.7 mt-10 -48.91 -57.82 10.25 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.165 -0.959 . . . . 0.0 110.129 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.51 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -49.62 -63.18 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.632 1.333 . . . . 0.0 110.05 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.964 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -55.1 -24.9 27.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.292 -0.88 . . . . 0.0 109.43 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.1 -48.74 5.9 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.85 95.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.124 -1.221 . . . . 0.0 109.646 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 58.4 m -65.33 -19.14 65.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 0.0 109.606 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.828 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.5 tt -73.89 -38.78 64.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.617 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.926 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -60.53 -35.75 76.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 109.619 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 9.3 t -65.13 -33.83 76.95 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.666 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -81.16 -35.11 31.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.206 -0.934 . . . . 0.0 109.794 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.491 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 0.6 OUTLIER -54.71 -28.85 50.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.812 -179.867 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.45 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -68.48 -13.88 62.62 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.253 -0.904 . . . . 0.0 109.244 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.407 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 24.2 m170 -65.56 -45.18 84.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.085 -1.009 . . . . 0.0 109.772 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.417 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -74.54 -47.95 29.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.506 HG12 HD11 ' A' ' 17' ' ' ILE . 4.5 pt -114.32 54.99 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.274 -0.891 . . . . 0.0 109.633 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -66.27 -18.18 66.98 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -97.63 -26.35 9.97 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.438 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.5 mmtt -96.14 -25.43 15.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.262 -1.14 . . . . 0.0 109.621 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -64.23 104.67 0.78 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.25 -0.906 . . . . 0.0 109.545 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.456 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 5.0 p-10 -106.29 -171.08 1.83 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.379 -0.825 . . . . 0.0 109.537 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.99 -55.31 26.89 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.844 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.456 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -54.23 -26.54 29.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.132 -0.98 . . . . 0.0 109.439 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -71.45 -54.59 10.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -0.973 . . . . 0.0 109.359 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.3 ptpt -70.04 -25.2 63.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.346 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.459 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.6 t0 -81.71 -34.56 30.52 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -0.853 . . . . 0.0 109.326 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.406 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.21 -41.47 63.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.353 -0.842 . . . . 0.0 109.371 179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.926 ' HB3' HD21 ' A' ' 111' ' ' LEU . 8.5 m0 -75.47 -24.38 56.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 109.242 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -71.88 -29.4 64.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.26 -34.32 16.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.66 -43.49 69.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.373 -0.829 . . . . 0.0 109.393 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.828 ' OH ' HD22 ' A' ' 110' ' ' LEU . 3.1 m-85 -52.02 -28.89 18.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.4 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.63 -31.15 59.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.318 -0.864 . . . . 0.0 109.458 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.18 -39.67 22.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.472 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.634 HG23 ' SD ' ' A' ' 83' ' ' MET . 76.0 mt -66.38 -57.56 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.255 -0.903 . . . . 0.0 109.35 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 1.5 p -68.65 -27.1 65.69 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.857 . . . . 0.0 109.653 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.674 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -65.28 -53.59 31.94 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.06 -16.46 31.6 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.248 -1.148 . . . . 0.0 109.859 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.815 HD22 ' HE2' ' A' ' 103' ' ' PHE . 8.1 tt -89.89 -39.18 13.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.836 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.674 HD12 ' HA2' ' A' ' 139' ' ' GLY . 11.2 mt -66.09 -11.17 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.135 -0.978 . . . . 0.0 110.002 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.02 -59.35 4.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.091 -1.006 . . . . 0.0 109.228 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.738 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -82.09 4.25 76.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.517 ' HB3' ' HA ' ' A' ' 142' ' ' ILE . 51.7 tp . . . . . 0 N--CA 1.49 1.546 0 O-C-N 121.004 -1.292 . . . . 0.0 109.382 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.827 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.464 ' O ' HG23 ' A' ' 10' ' ' VAL . 21.9 mt-30 -81.7 -53.03 6.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.182 -0.949 . . . . 0.0 109.819 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.27 -27.96 10.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.149 -0.969 . . . . 0.0 109.606 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -77.45 -44.27 29.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.89 . . . . 0.0 109.284 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.827 HG23 ' O ' ' A' ' 5' ' ' ALA . 46.3 t -62.98 -25.06 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.293 -0.88 . . . . 0.0 109.184 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.969 HG12 HG13 ' A' ' 70' ' ' VAL . 86.5 t -72.56 -46.93 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.416 -0.802 . . . . 0.0 109.358 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.68 -11.33 60.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.331 -0.856 . . . . 0.0 109.854 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.6 m -91.63 -21.23 20.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 109.694 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.464 HG21 ' HB1' ' A' ' 126' ' ' ALA . 12.1 p -101.87 -9.26 20.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.27 -0.894 . . . . 0.0 109.963 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.676 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.63 -19.9 23.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.097 -1.002 . . . . 0.0 109.771 -179.857 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -81.62 -10.7 59.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.223 -0.923 . . . . 0.0 109.933 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.62 -54.44 2.58 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.062 -1.024 . . . . 0.0 109.656 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.965 HD12 ' CH2' ' A' ' 130' ' ' TRP . 59.5 mt -66.04 -35.38 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 0.0 109.623 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.716 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.45 31.1 4.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.668 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.28 -70.46 0.95 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.8 p -107.5 -37.13 6.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.215 -1.167 . . . . 0.0 109.751 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.589 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.6 p-10 -72.42 -19.73 61.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.261 -0.899 . . . . 0.0 109.714 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.716 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.9 t30 56.8 26.21 11.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.209 -0.932 . . . . 0.0 109.657 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.16 23.91 23.56 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.97 -49.58 60.81 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 0.0 109.579 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.45 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -87.83 13.08 61.86 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.586 HG11 HD11 ' A' ' 63' ' ' LEU . 17.2 t -98.68 -30.59 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.094 -1.239 . . . . 0.0 109.241 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.452 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -90.06 -43.37 5.05 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.474 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.2 ptpt -56.07 -33.23 64.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.17 -1.194 . . . . 0.0 109.559 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.853 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 11.0 pt-20 -89.6 -18.57 26.31 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.958 . . . . 0.0 109.686 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.23 -61.52 1.68 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.511 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.6 m-85 -51.64 -31.82 26.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.185 -0.947 . . . . 0.0 109.885 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.892 HG23 HG11 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -56.03 -55.57 31.3 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.188 -0.945 . . . . 0.0 109.594 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -57.45 -49.11 77.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.316 -0.865 . . . . 0.0 109.678 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.683 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.3 t80 -50.91 -51.17 54.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.185 -0.947 . . . . 0.0 109.609 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.713 ' CD1' HG22 ' A' ' 55' ' ' VAL . 12.8 mt -56.41 -46.13 80.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.868 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.607 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 13.5 t -60.75 -57.59 12.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.194 -0.941 . . . . 0.0 109.83 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.619 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -66.32 -21.84 66.27 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.757 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.619 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 15.3 m-70 -122.76 105.95 10.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.833 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -87.02 -21.13 26.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.436 -0.79 . . . . 0.0 109.264 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -73.27 -20.24 60.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.491 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -96.65 -18.6 19.6 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 109.629 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.446 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -59.88 -57.53 12.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.472 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.73 -23.31 63.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -0.932 . . . . 0.0 109.345 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.95 HG13 ' ND2' ' A' ' 95' ' ' ASN . 49.5 t -75.05 -57.08 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.342 -0.849 . . . . 0.0 109.504 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.529 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -55.77 -35.25 66.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.95 . . . . 0.0 109.514 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.39 28.08 2.91 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.529 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 9.3 m-85 -123.14 -168.66 1.8 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 109.784 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.1 t -133.62 21.43 3.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.507 -0.746 . . . . 0.0 109.123 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 139.84 -161.72 26.28 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.607 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -91.44 36.74 0.94 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.232 -1.158 . . . . 0.0 109.724 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.7 m -132.68 19.04 4.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.628 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -107.13 133.84 20.14 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.575 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.38 -19.87 55.26 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.947 1.498 . . . . 0.0 109.974 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.506 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.61 -27.63 64.06 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.892 HG11 HG23 ' A' ' 32' ' ' THR . 99.3 t -57.18 -35.19 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -1.167 . . . . 0.0 109.405 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.708 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.34 -3.83 48.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.89 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.97 -29.97 14.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.046 -1.034 . . . . 0.0 109.397 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.798 ' O ' HG23 ' A' ' 62' ' ' VAL . 7.1 mt -86.02 -63.56 1.3 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.161 -0.962 . . . . 0.0 109.524 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.652 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -54.49 -28.83 45.91 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -63.1 -53.04 59.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.149 -1.207 . . . . 0.0 109.518 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.435 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 11.3 mtpt -76.25 -43.54 41.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.281 -0.887 . . . . 0.0 109.321 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.798 HG23 ' O ' ' A' ' 58' ' ' LEU . 63.0 t -50.16 -49.14 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.308 -0.87 . . . . 0.0 109.591 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.652 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -47.51 -45.68 26.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.144 -0.973 . . . . 0.0 109.729 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -48.67 -50.9 31.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.244 -0.91 . . . . 0.0 109.903 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.1 tp60 -49.9 -49.21 50.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.139 -0.976 . . . . 0.0 109.491 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.912 ' O ' HG23 ' A' ' 70' ' ' VAL . 71.1 mt -56.2 -35.83 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.325 -0.86 . . . . 0.0 109.138 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.84 -54.9 25.4 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.156 -1.578 . . . . 0.0 109.156 179.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.0 t -59.57 -24.48 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.9 -25.46 26.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.307 -0.871 . . . . 0.0 109.534 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.969 HG13 HG12 ' A' ' 10' ' ' VAL . 55.1 t -73.66 -18.38 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 109.665 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -89.35 15.3 9.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -0.93 . . . . 0.0 109.927 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.465 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 14.0 m-70 -155.97 45.59 0.45 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.076 -1.015 . . . . 0.0 109.899 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.505 HD11 HG11 ' A' ' 10' ' ' VAL . 69.3 mt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.465 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 39.8 ttp . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 121.263 0.554 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.427 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 58.1 t -66.86 -19.23 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.226 -0.921 . . . . 0.0 109.456 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.8 -36.32 75.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 0.0 109.434 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.441 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 22.3 tp10 -81.58 -49.81 10.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.437 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.4 mtp -53.04 -45.68 68.13 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.277 -0.889 . . . . 0.0 109.362 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.759 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.4 -37.53 48.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 109.086 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.45 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -65.33 -35.35 80.71 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.404 -0.81 . . . . 0.0 109.153 179.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.527 HG12 HD11 ' A' ' 141' ' ' LEU . 28.9 t -62.4 -53.09 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.318 -0.864 . . . . 0.0 109.216 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -53.12 -42.2 61.67 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 84' ' ' LYS . 97.7 t -52.63 -27.89 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -1.136 . . . . 0.0 109.345 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.47 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 2.0 mmm180 -78.96 -51.22 9.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.094 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.705 ' HB2' HD13 ' A' ' 145' ' ' LEU . 43.2 m80 -54.0 -22.35 10.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.387 -0.821 . . . . 0.0 109.127 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.4 ttmt -64.99 -11.33 37.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.478 -0.764 . . . . 0.0 110.281 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.76 55.63 0.52 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CE2' ' CD2' ' A' ' 90' ' ' HIS . 4.4 m-30 -90.44 -170.15 2.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.306 -1.114 . . . . 0.0 109.661 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.11 -53.35 10.8 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.95 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.5 p-10 -62.06 -30.08 70.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.166 -1.196 . . . . 0.0 109.68 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.9 mtmt 60.62 35.62 19.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 109.942 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.414 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 47.5 m170 -132.97 -83.98 0.47 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.06 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.668 HD12 ' O ' ' A' ' 90' ' ' HIS . 22.6 mt 60.06 153.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 110.387 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.554 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -152.71 135.09 15.09 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.626 0.727 . . . . 0.0 109.725 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.733 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -72.95 -6.32 44.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.735 -0.603 . . . . 0.0 109.544 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.462 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.8 mm-40 -76.36 -24.07 54.17 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.028 -1.045 . . . . 0.0 109.115 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.554 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 73.0 m-85 -85.95 -26.52 25.46 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.328 -0.858 . . . . 0.0 109.732 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.67 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.1 m-85 -50.82 -59.03 4.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 110.278 -179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -54.71 -59.07 11.47 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.289 -179.355 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.5 Cg_exo -47.94 -55.69 3.79 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.712 1.375 . . . . 0.0 110.308 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.934 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.99 -21.42 21.08 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.933 . . . . 0.0 109.652 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.61 -48.31 10.71 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.58 -47.46 85.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -1.164 . . . . 0.0 109.826 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.04 -25.12 65.09 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.689 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.3 tt -69.44 -40.72 77.05 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.688 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.742 HD21 ' HB3' ' A' ' 130' ' ' TRP . 14.8 mt -59.17 -32.78 70.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.228 -0.92 . . . . 0.0 109.677 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.9 p -66.83 -29.8 69.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 109.901 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.853 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -83.33 -38.82 21.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.176 -0.952 . . . . 0.0 109.845 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.614 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.2 mmt -48.45 -46.54 37.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 110.033 -179.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.455 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -47.96 -25.95 1.56 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 -179.633 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.448 ' ND1' ' OE1' ' A' ' 29' ' ' GLU . 18.3 m170 -54.65 -45.78 73.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.065 -1.022 . . . . 0.0 110.029 -179.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.46 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 7.0 ttt85 -78.17 -60.37 2.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.202 -0.936 . . . . 0.0 110.033 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.489 HG12 HD11 ' A' ' 17' ' ' ILE . 4.5 pt -104.7 52.36 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.172 -0.955 . . . . 0.0 109.82 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.455 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -63.5 -20.09 63.17 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -91.78 -24.29 25.85 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.446 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 25.1 mttt -100.01 -21.23 15.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.183 . . . . 0.0 109.711 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.433 ' SD ' HD11 ' A' ' 118' ' ' ILE . 5.0 tpt -60.94 98.37 0.07 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.562 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.745 ' OD1' ' HB2' ' A' ' 126' ' ' ALA . 14.5 p-10 -96.36 -174.37 3.04 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.28 -0.887 . . . . 0.0 109.667 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.18 79.81 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.679 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -69.26 -27.21 65.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -0.906 . . . . 0.0 109.355 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.745 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -71.93 -45.41 61.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.597 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 5.0 ptpt -74.54 -27.92 60.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.119 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.469 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -81.88 -36.56 28.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.357 -0.84 . . . . 0.0 109.115 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.466 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -68.7 -47.37 66.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.365 -0.835 . . . . 0.0 109.134 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.965 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.5 m0 -70.13 -25.77 63.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.337 -0.852 . . . . 0.0 108.985 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.597 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.95 -34.88 74.0 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -81.91 -28.78 32.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.282 -0.886 . . . . 0.0 109.423 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -78.59 -47.75 16.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.335 -0.853 . . . . 0.0 109.62 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.689 ' OH ' HD22 ' A' ' 110' ' ' LEU . 4.3 m-85 -49.5 -29.17 6.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.02 61.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.373 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -80.32 -36.48 34.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.479 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.614 HD13 HG23 ' A' ' 66' ' ' ILE . 65.3 mt -66.69 -58.12 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.293 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.406 ' O ' HG12 ' A' ' 142' ' ' ILE . 1.8 p -64.74 -23.73 67.34 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -0.876 . . . . 0.0 109.597 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -73.42 -39.33 51.03 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.18 -31.09 70.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -1.16 . . . . 0.0 109.654 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.917 ' O ' HD23 ' A' ' 141' ' ' LEU . 8.5 tt -73.24 -6.53 46.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.225 -0.922 . . . . 0.0 110.028 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.733 HD12 ' HB2' ' A' ' 100' ' ' ALA . 45.7 mm -88.67 16.59 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 109.936 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.43 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 4.8 t -95.93 -43.08 7.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.62 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -107.94 16.07 36.58 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.705 HD13 ' HB2' ' A' ' 90' ' ' HIS . 11.3 tp . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.162 -1.199 . . . . 0.0 109.585 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.72 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 121.586 0.708 . . . . 0.0 109.106 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.714 ' O ' HG23 ' A' ' 10' ' ' VAL . 28.1 mt-30 -70.05 -26.44 64.02 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.521 -179.138 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.8 tmm_? -77.21 -41.03 42.96 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.188 -1.005 . . . . 0.0 108.829 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -56.76 -29.37 62.53 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 5' ' ' ALA . 14.2 t -81.65 -29.53 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.915 HG12 HG13 ' A' ' 70' ' ' VAL . 53.1 t -76.92 -37.59 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.565 -0.709 . . . . 0.0 109.311 179.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.2 -11.4 59.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.323 -0.861 . . . . 0.0 109.937 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -92.67 -34.01 14.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.808 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.0 p -83.58 -15.96 47.17 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.276 -0.89 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.713 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.15 -23.58 24.79 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.119 -0.988 . . . . 0.0 109.483 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.1 mtpt -75.78 -5.36 45.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.811 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.435 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.7 OUTLIER -110.76 -58.83 2.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.053 -1.029 . . . . 0.0 109.592 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.959 HD12 ' CH2' ' A' ' 130' ' ' TRP . 26.5 mt -56.94 -35.12 46.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.699 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.97 34.8 3.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.282 -0.886 . . . . 0.0 109.67 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.14 -72.26 0.56 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.7 p -112.05 -31.01 7.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.221 -1.164 . . . . 0.0 109.618 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.719 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.6 p-10 -76.45 -16.79 59.59 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -0.908 . . . . 0.0 109.792 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.699 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 31.4 t30 60.47 24.96 14.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.228 -0.92 . . . . 0.0 109.554 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.21 38.4 5.69 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.719 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -83.32 -39.36 20.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.636 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.449 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -89.32 17.19 53.42 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.645 HG21 ' CG2' ' A' ' 17' ' ' ILE . 28.5 t -105.96 -40.22 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -1.209 . . . . 0.0 109.378 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.481 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -86.78 -40.14 7.29 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.494 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.0 ptpt -59.87 -30.16 68.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -1.188 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.748 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 8.5 pt-20 -93.19 -22.21 19.19 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.7 t -88.21 -62.38 1.5 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.966 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.513 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 23.0 m-85 -50.54 -35.81 31.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.332 -0.855 . . . . 0.0 110.179 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.702 ' OG1' HG11 ' A' ' 55' ' ' VAL . 18.6 m -53.14 -54.78 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.985 -1.072 . . . . 0.0 109.2 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.79 -43.02 85.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.156 -0.965 . . . . 0.0 108.944 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.657 ' HB2' HD23 ' A' ' 106' ' ' LEU . 90.4 t80 -55.32 -63.26 1.22 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -0.806 . . . . 0.0 109.1 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.782 HD13 HG22 ' A' ' 55' ' ' VAL . 5.7 mt -47.82 -43.89 28.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.435 -0.79 . . . . 0.0 109.71 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.89 -63.43 1.21 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.574 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.581 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -59.12 -24.35 62.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.581 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 16.1 m-70 -118.62 99.12 6.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.288 -0.882 . . . . 0.0 109.648 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.4 m170 -83.88 -19.95 33.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.593 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -70.0 -11.23 60.72 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.256 -0.903 . . . . 0.0 109.895 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.444 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 83.0 mmm -113.34 -21.6 10.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.111 -0.993 . . . . 0.0 109.888 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.494 ' HA ' HD23 ' A' ' 35' ' ' LEU . . . -48.81 -46.56 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.024 -1.047 . . . . 0.0 109.592 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.61 -21.22 61.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.254 -0.904 . . . . 0.0 109.312 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.996 HG13 ' ND2' ' A' ' 95' ' ' ASN . 7.1 t -77.28 -38.48 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.316 -0.865 . . . . 0.0 109.278 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.509 ' CG ' HD21 ' A' ' 35' ' ' LEU . 12.8 m-85 -70.47 -27.61 64.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.85 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 111.96 20.97 6.53 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 6.1 m-85 -119.75 164.88 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.282 -1.128 . . . . 0.0 109.801 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.28 -15.33 20.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.446 -0.784 . . . . 0.0 109.213 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.417 ' O ' ' OD2' ' A' ' 52' ' ' ASP . . . -164.57 -155.3 8.33 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.454 ' O ' HG23 ' A' ' 32' ' ' THR . . . -104.98 -0.21 27.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.438 -1.036 . . . . 0.0 110.079 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.0 t -107.24 51.9 0.73 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.949 -1.094 . . . . 0.0 109.861 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.712 ' OD1' HG23 ' A' ' 55' ' ' VAL . 0.6 OUTLIER -131.23 149.25 73.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.255 -0.903 . . . . 0.0 109.674 179.799 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 10.0 Cg_exo -65.8 -24.31 54.43 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.973 1.512 . . . . 0.0 110.296 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.53 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -48.45 -35.87 16.33 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.782 HG22 HD13 ' A' ' 35' ' ' LEU . 57.5 t -61.26 -35.61 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -1.109 . . . . 0.0 109.445 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.448 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.39 -11.26 60.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.34 -31.2 16.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.606 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.764 ' O ' HG23 ' A' ' 62' ' ' VAL . 7.8 mt -88.42 -62.68 1.44 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.973 . . . . 0.0 109.725 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.617 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -50.15 -33.52 22.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -71.81 -43.83 64.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -1.18 . . . . 0.0 109.718 -179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.8 mtpp -74.95 -36.99 62.09 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.764 HG23 ' O ' ' A' ' 58' ' ' LEU . 61.1 t -61.8 -47.65 92.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.819 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.617 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.6 mm? -47.28 -46.31 24.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.16 -0.962 . . . . 0.0 109.899 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -47.44 -48.4 26.59 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.417 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 17.9 tp60 -52.64 -49.69 64.65 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.101 -0.999 . . . . 0.0 109.407 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.907 ' O ' HG23 ' A' ' 70' ' ' VAL . 72.2 mt -58.1 -27.64 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.256 -0.902 . . . . 0.0 109.195 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.557 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.78 -54.88 8.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -60.67 -21.26 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.25 -1.147 . . . . 0.0 109.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.59 -25.15 23.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.915 HG13 HG12 ' A' ' 10' ' ' VAL . 41.4 t -73.08 -11.74 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.248 -0.907 . . . . 0.0 109.731 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -92.36 25.4 2.98 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 109.592 179.977 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.454 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 28.0 m-70 -142.68 -75.34 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.525 ' N ' ' CD2' ' A' ' 73' ' ' LEU . 2.9 mm? . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.711 -0.618 . . . . 0.0 110.297 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.454 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 5.6 tmm? . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.342 0.591 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.829 HG22 ' HB1' ' A' ' 140' ' ' ALA . 73.0 t -79.58 -18.77 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.693 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -48.82 -51.43 29.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.788 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.517 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.0 OUTLIER -76.52 -45.36 31.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.467 ' HB2' ' HA ' ' A' ' 80' ' ' VAL . 1.6 mtp -54.78 -53.44 55.18 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.428 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -51.12 -33.05 24.74 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.935 . . . . 0.0 109.202 179.696 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -68.89 -42.99 76.21 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.371 -0.831 . . . . 0.0 109.295 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 82' ' ' GLU . 14.4 t -58.99 -41.45 83.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.133 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -55.77 -48.86 69.26 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 78.1 t -52.71 -40.24 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.247 -1.149 . . . . 0.0 108.901 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -64.28 -50.94 65.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.398 -0.814 . . . . 0.0 109.01 179.273 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.65 ' O ' HD12 ' A' ' 98' ' ' ILE . 25.4 m80 -55.5 -38.7 69.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.314 -0.866 . . . . 0.0 109.316 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.409 ' HB2' HD12 ' A' ' 145' ' ' LEU . 10.0 ttpp -62.72 -15.8 54.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.304 -0.872 . . . . 0.0 109.982 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -124.06 43.28 1.43 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -88.13 -171.68 3.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.3 -1.118 . . . . 0.0 109.683 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.75 -44.6 7.16 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.996 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.1 p-10 -64.92 -33.22 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -1.134 . . . . 0.0 109.593 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.7 tttt 55.12 20.23 3.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.212 -0.93 . . . . 0.0 109.809 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -129.6 55.84 1.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.33 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.65 HD12 ' O ' ' A' ' 90' ' ' HIS . 73.4 mt -90.32 156.3 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.327 -0.858 . . . . 0.0 110.193 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.534 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 2.7 mptt -143.34 131.6 22.01 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.486 -0.759 . . . . 0.0 109.665 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.754 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -73.25 -9.02 58.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.458 -0.777 . . . . 0.0 109.795 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.6 -23.2 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.567 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 73.7 m-85 -84.9 -15.84 43.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.125 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.759 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.6 m-85 -60.61 -68.75 0.27 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.195 -0.941 . . . . 0.0 110.368 -179.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.49 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.8 OUTLIER -44.37 -59.06 4.22 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.403 -0.811 . . . . 0.0 111.096 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.8 Cg_endo -55.06 -55.4 3.22 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.629 1.331 . . . . 0.0 110.034 -179.39 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.901 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -62.78 -18.57 62.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' CE1' ' A' ' 134' ' ' TYR . . . -85.39 -39.85 8.15 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.16 45.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.231 -1.158 . . . . 0.0 109.489 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -21.5 11.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.59 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -67.58 -41.29 84.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.735 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.833 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.6 mt -60.65 -41.44 94.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.143 -0.973 . . . . 0.0 109.562 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.3 t -64.31 -29.94 71.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.852 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.748 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -83.37 -36.34 24.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.195 -0.941 . . . . 0.0 109.641 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.59 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.1 mtt -48.79 -35.89 15.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 110.3 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.439 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.7 OUTLIER -58.42 -23.19 56.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.116 -0.99 . . . . 0.0 109.66 -179.506 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.414 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 9.6 m170 -54.72 -49.14 71.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.133 -0.98 . . . . 0.0 109.56 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.481 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.1 OUTLIER -67.22 -62.61 1.34 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -0.929 . . . . 0.0 109.504 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.522 HG23 HG12 ' A' ' 17' ' ' ILE . 13.9 pt -92.03 47.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.262 -0.899 . . . . 0.0 109.431 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.91 125.47 37.25 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.42 -36.08 4.3 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.484 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.9 mmtp -87.46 -28.45 22.08 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.128 -1.219 . . . . 0.0 109.318 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -68.92 104.2 2.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.356 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.558 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 6.8 p30 -103.38 -170.14 1.74 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.37 -0.831 . . . . 0.0 109.992 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.424 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -62.32 -41.25 98.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.558 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -64.29 -25.15 67.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.747 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -79.07 -46.69 17.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.144 -0.973 . . . . 0.0 109.884 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.507 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.3 ptpt -74.11 -25.65 59.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.097 -1.002 . . . . 0.0 109.461 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.487 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 26.3 t0 -83.73 -43.11 15.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.323 -0.86 . . . . 0.0 109.195 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.475 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -60.98 -46.11 92.06 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.436 -0.79 . . . . 0.0 108.996 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.959 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -70.34 -31.0 68.09 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.54 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -55.89 -25.18 41.47 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.538 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.4 -32.84 15.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.494 -0.753 . . . . 0.0 109.151 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.839 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -81.59 -63.63 1.35 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.465 -0.772 . . . . 0.0 109.723 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.54 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.84 -25.37 4.41 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.947 . . . . 0.0 109.081 -179.979 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 131' ' ' ALA . . . -77.52 -47.73 18.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -0.9 . . . . 0.0 109.031 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.41 -29.28 62.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.385 -0.822 . . . . 0.0 109.205 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.839 HD12 ' C ' ' A' ' 133' ' ' ALA . 5.4 mt -66.99 -59.65 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.336 -0.852 . . . . 0.0 108.909 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 31.1 p -60.07 -26.54 66.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.556 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -77.55 -25.08 63.8 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.829 ' HB1' HG22 ' A' ' 80' ' ' VAL . . . -73.25 -29.82 63.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -1.12 . . . . 0.0 109.562 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.855 ' O ' HD23 ' A' ' 141' ' ' LEU . 10.4 tt -75.1 -10.76 59.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.913 . . . . 0.0 109.864 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.754 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.5 mm -92.41 37.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.132 -0.98 . . . . 0.0 109.697 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 21.5 m -116.74 -23.29 8.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.679 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.57 -8.49 6.91 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.631 HD13 ' HB2' ' A' ' 90' ' ' HIS . 26.3 tp . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.073 -1.251 . . . . 0.0 109.558 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.856 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.29 0.567 . . . . 0.0 109.655 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.406 ' O ' HG23 ' A' ' 10' ' ' VAL . 48.3 mt-30 -70.22 -47.14 62.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 109.58 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.54 -29.33 58.75 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.159 -0.963 . . . . 0.0 109.24 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -80.52 -37.79 30.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.371 -0.83 . . . . 0.0 108.86 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.7 t -72.5 -32.22 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.463 -0.773 . . . . 0.0 108.993 179.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.806 HG23 ' HB1' ' A' ' 129' ' ' ALA . 55.4 t -71.31 -37.89 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.468 -0.77 . . . . 0.0 109.272 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.62 -13.02 60.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.846 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 t -92.24 -24.27 19.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.139 -0.976 . . . . 0.0 109.961 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.427 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 16.7 p -91.28 -17.75 25.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.196 -0.94 . . . . 0.0 109.976 -179.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.744 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -84.35 -19.38 33.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 109.762 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.6 mtpt -83.46 1.83 39.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.998 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -118.04 -54.71 2.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.45 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.93 HD12 ' CH2' ' A' ' 130' ' ' TRP . 81.3 mt -66.51 -33.09 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.275 -0.89 . . . . 0.0 109.467 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.716 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.67 33.08 3.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.575 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.65 -87.84 0.01 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.6 p -101.0 -21.44 15.04 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.671 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 18.0 p-10 -81.63 -23.16 37.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.594 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.716 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 23.5 t30 57.09 29.36 16.41 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.692 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 90.68 38.66 6.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.671 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -80.82 -58.2 3.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.266 -1.138 . . . . 0.0 109.643 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -73.18 -22.2 79.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.881 HG11 HD21 ' A' ' 63' ' ' LEU . 23.5 t -66.04 -29.19 46.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -1.103 . . . . 0.0 109.544 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.444 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -80.11 -56.38 3.27 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.497 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 14.6 ptpt -54.28 -24.95 20.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.177 -1.19 . . . . 0.0 110.175 -179.355 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.658 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 18.8 pt-20 -97.75 -18.43 18.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.99 -1.069 . . . . 0.0 109.899 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.438 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 35.5 t -89.16 -68.84 0.75 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -0.937 . . . . 0.0 109.785 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.591 ' HB3' HG13 ' A' ' 55' ' ' VAL . 12.9 m-85 -48.17 -31.26 5.48 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.21 -0.931 . . . . 0.0 109.83 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.663 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.55 -54.02 46.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.931 . . . . 0.0 109.61 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.441 ' HA ' ' OG ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -60.49 -38.65 84.97 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.877 -179.887 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.674 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.1 t80 -59.11 -52.64 64.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.167 -0.958 . . . . 0.0 109.705 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.64 ' CD1' HG22 ' A' ' 55' ' ' VAL . 4.2 mt -58.86 -48.79 80.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.239 -0.913 . . . . 0.0 109.842 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.663 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 3.3 p -56.0 -52.68 63.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.731 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.635 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -72.53 -25.13 61.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 0.0 109.713 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.635 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 18.6 m-70 -120.35 109.04 14.87 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.767 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -89.86 -21.55 22.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.408 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -71.07 -21.15 62.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.336 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.511 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -96.64 -13.87 22.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.885 . . . . 0.0 109.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.02 -64.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.095 -1.003 . . . . 0.0 109.514 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -54.79 -25.23 26.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.277 -0.89 . . . . 0.0 109.369 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.044 HG13 ' ND2' ' A' ' 95' ' ' ASN . 39.0 t -75.97 -43.69 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 41' ' ' MET . 18.1 m-85 -73.35 -18.44 61.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.911 . . . . 0.0 109.67 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.415 ' O ' ' CD1' ' A' ' 47' ' ' PHE . . . 95.03 26.47 12.49 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.498 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 15.1 m-85 -126.9 -177.1 3.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -1.128 . . . . 0.0 109.982 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.99 16.21 7.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.461 -0.774 . . . . 0.0 109.415 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 144.84 -163.42 27.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -79.7 -17.79 52.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.308 -1.113 . . . . 0.0 109.826 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -85.14 49.92 1.84 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.932 . . . . 0.0 109.665 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.32 122.9 15.14 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.611 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -65.83 -25.9 52.67 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.872 1.459 . . . . 0.0 110.077 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.498 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.89 -33.4 43.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.663 HG11 HG23 ' A' ' 32' ' ' THR . 97.6 t -52.01 -33.62 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -1.142 . . . . 0.0 109.298 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.701 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.1 -4.29 34.71 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.289 -0.882 . . . . 0.0 109.578 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -90.18 -36.02 15.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.122 -0.986 . . . . 0.0 109.791 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.727 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.6 mt -83.99 -62.16 1.64 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.032 -1.042 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.444 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.46 -28.36 28.34 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -64.72 -53.67 43.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.062 -1.257 . . . . 0.0 109.756 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.608 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 9.7 mttm -79.56 -43.75 22.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.727 HG23 ' O ' ' A' ' 58' ' ' LEU . 94.8 t -46.8 -58.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.389 -0.819 . . . . 0.0 110.229 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.881 HD21 HG11 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -46.43 -38.84 9.59 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.205 -0.934 . . . . 0.0 109.987 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.608 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.47 -42.15 61.4 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.935 . . . . 0.0 109.521 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 62' ' ' VAL . 3.2 mm100 -60.67 -42.12 96.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.172 -0.955 . . . . 0.0 109.321 179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.938 ' O ' HG23 ' A' ' 70' ' ' VAL . 88.9 mt -61.13 -33.49 56.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.24 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.547 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.38 -53.66 24.04 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.921 -1.672 . . . . 0.0 108.921 179.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.4 t -59.84 -24.24 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.315 -1.109 . . . . 0.0 109.207 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.09 -30.33 22.66 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.408 -0.807 . . . . 0.0 109.578 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.938 HG23 ' O ' ' A' ' 66' ' ' ILE . 48.2 t -63.5 -21.21 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.495 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.08 44.0 1.16 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.179 -0.951 . . . . 0.0 109.874 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 4.3 m-70 -152.15 -84.07 0.08 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.129 -0.982 . . . . 0.0 110.311 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.77 HD22 ' N ' ' A' ' 73' ' ' LEU . 2.6 mm? . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.774 -0.579 . . . . 0.0 110.559 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 3.1 tmm? . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.227 0.536 . . . . 0.0 109.774 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.4 t -73.81 -8.07 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.922 . . . . 0.0 110.071 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -77.74 -32.09 52.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.989 -1.069 . . . . 0.0 109.712 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.479 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.5 mt-10 -99.34 -41.45 7.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.925 . . . . 0.0 109.639 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.47 ' SD ' HG23 ' A' ' 137' ' ' ILE . 2.4 mtp -62.53 -47.79 82.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.188 -0.945 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.453 ' HG2' ' HB2' ' A' ' 143' ' ' SER . 0.1 OUTLIER -54.96 -35.73 64.58 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.255 -0.903 . . . . 0.0 109.279 179.694 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -64.23 -35.39 80.65 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.229 -0.919 . . . . 0.0 109.266 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 82' ' ' GLU . 28.6 t -55.08 -48.96 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.352 -0.843 . . . . 0.0 109.42 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -51.99 -50.42 44.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.859 HG23 ' HA3' ' A' ' 144' ' ' GLY . 97.0 t -48.68 -25.3 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.327 -1.102 . . . . 0.0 109.596 179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.505 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.2 mmt180 -77.08 -44.67 29.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.179 -0.951 . . . . 0.0 109.127 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.469 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 17.7 m80 -58.78 -19.87 44.7 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.349 -0.845 . . . . 0.0 109.196 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.432 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 25.5 ttpt -68.04 -15.09 63.45 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.419 -0.801 . . . . 0.0 109.851 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.91 50.51 0.81 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.8 m-30 -94.23 -172.41 2.8 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.237 -1.155 . . . . 0.0 109.328 179.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.74 -40.3 53.27 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.044 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.7 t30 -78.39 -44.68 24.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.464 -1.021 . . . . 0.0 109.001 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 71.93 -54.24 0.68 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.396 -0.815 . . . . 0.0 110.314 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 28.9 m170 -66.69 69.2 0.07 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.974 . . . . 0.0 110.115 -179.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.456 ' N ' ' O ' ' A' ' 96' ' ' LYS . 84.5 mt -100.61 161.76 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.93 . . . . 0.0 109.329 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.487 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -136.92 142.54 42.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.139 -0.975 . . . . 0.0 109.726 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.16 -0.41 51.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.878 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.526 ' HG2' ' CD1' ' A' ' 102' ' ' TYR . 7.6 pt-20 -78.74 -28.43 44.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.104 -0.998 . . . . 0.0 109.676 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.526 ' CD1' ' HG2' ' A' ' 101' ' ' GLU . 92.8 m-85 -78.03 -13.52 59.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 109.845 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.899 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -57.9 -64.57 0.86 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.203 -0.936 . . . . 0.0 110.192 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.487 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.3 mt-10 -51.38 -55.87 25.35 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.169 -0.957 . . . . 0.0 110.208 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 33.6 Cg_exo -49.42 -54.27 5.71 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.69 1.363 . . . . 0.0 110.19 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.911 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.1 tm? -57.05 -19.46 19.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.223 -0.923 . . . . 0.0 109.599 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.53 -39.82 20.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.63 -57.14 12.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.243 -1.151 . . . . 0.0 109.614 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.2 m -56.91 -23.23 43.48 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.608 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.698 HD22 ' OH ' ' A' ' 134' ' ' TYR . 4.4 tt -70.38 -43.77 69.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.558 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.622 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.2 mt -57.06 -30.43 64.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.503 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.4 t -66.65 -39.01 88.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.208 -0.933 . . . . 0.0 109.633 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.658 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -75.15 -39.82 60.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.668 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.61 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.2 mmt -48.05 -40.31 22.59 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.203 -0.936 . . . . 0.0 109.874 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -54.11 -24.57 18.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.264 -0.897 . . . . 0.0 109.746 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.406 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -49.65 -53.08 26.36 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.184 -0.947 . . . . 0.0 109.697 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.19 -72.55 0.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.153 -0.967 . . . . 0.0 109.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.628 HG12 HD11 ' A' ' 17' ' ' ILE . 3.1 pt -86.42 56.32 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.916 . . . . 0.0 109.657 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -68.35 -23.69 74.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -94.77 -21.7 25.45 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 59.2 mttt -100.64 -21.47 15.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.627 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.489 ' CA ' HD12 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.16 80.43 0.13 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.327 -0.858 . . . . 0.0 109.632 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.558 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.9 p30 -83.79 -163.93 0.84 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.612 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -71.46 -42.17 68.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.708 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -62.67 -24.02 67.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.18 -52.8 8.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.595 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.557 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.5 ptpt -67.46 -33.2 74.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.918 . . . . 0.0 109.363 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.466 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.0 t70 -73.17 -55.42 6.49 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.413 179.774 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.806 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -51.23 -43.42 61.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.405 -0.809 . . . . 0.0 109.373 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.93 ' CH2' HD12 ' A' ' 17' ' ' ILE . 2.8 m0 -75.74 -29.34 58.85 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.351 -0.843 . . . . 0.0 109.107 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.557 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.07 -27.85 65.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.183 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.31 -26.63 21.02 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.305 -0.872 . . . . 0.0 109.28 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.418 ' O ' ' CD1' ' A' ' 137' ' ' ILE . . . -79.49 -45.22 19.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.415 -0.803 . . . . 0.0 109.503 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.778 ' HE1' HD13 ' A' ' 66' ' ' ILE . 5.8 m-85 -48.99 -31.61 7.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.08 -36.41 69.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.29 -0.881 . . . . 0.0 109.39 179.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.57 -40.37 29.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.524 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.47 HG23 ' SD ' ' A' ' 83' ' ' MET . 1.9 mp -67.42 -56.68 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.864 . . . . 0.0 109.139 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.6 p -68.26 -26.58 65.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.739 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -71.02 -35.78 64.56 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.48 -21.69 66.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.189 -1.183 . . . . 0.0 109.763 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.899 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.2 tt -82.32 -12.62 57.87 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -0.945 . . . . 0.0 109.944 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 142' ' ' ILE . 36.5 mt -79.61 3.26 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.138 -0.976 . . . . 0.0 110.157 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.453 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 9.5 m -89.92 -45.06 9.48 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.015 -1.053 . . . . 0.0 109.632 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.859 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -82.56 -28.58 38.81 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.493 HD12 ' HA2' ' A' ' 87' ' ' GLY . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.378 -1.072 . . . . 0.0 109.609 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.82 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.198 0.523 . . . . 0.0 109.785 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.467 ' O ' HG23 ' A' ' 10' ' ' VAL . 76.8 mt-30 -62.02 -52.83 62.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.539 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.616 ' HA ' HD12 ' A' ' 73' ' ' LEU . 7.5 ptm180 -50.47 -33.9 22.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.34 179.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.468 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 56.6 tp60 -75.57 -46.62 30.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.82 HG23 ' O ' ' A' ' 5' ' ' ALA . 40.7 t -60.54 -34.85 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.178 179.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.776 HG12 HG13 ' A' ' 70' ' ' VAL . 69.8 t -64.66 -48.73 83.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.36 -0.838 . . . . 0.0 109.343 179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.35 -11.53 60.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 109.675 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -91.17 -25.51 19.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.135 -0.978 . . . . 0.0 109.717 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 p -98.01 -11.75 22.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.183 -0.948 . . . . 0.0 109.809 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.552 ' CE3' ' HB3' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.8 -28.39 20.48 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.082 -1.011 . . . . 0.0 109.657 -179.882 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -70.76 -15.26 62.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.414 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -99.55 -61.52 1.36 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.644 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.972 HD12 ' CH2' ' A' ' 130' ' ' TRP . 55.8 mt -57.9 -39.13 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.711 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.723 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.64 36.09 2.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.702 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.8 -82.5 0.06 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.0 p -97.93 -26.24 14.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 0.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.651 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 4.2 p30 -80.75 -23.8 39.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.639 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.723 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 27.2 t30 56.92 22.07 6.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.528 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 101.97 23.44 9.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.651 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -69.57 -54.31 14.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 109.619 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.453 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -85.93 10.98 63.59 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.85 HG12 HD11 ' A' ' 63' ' ' LEU . 35.8 t -104.84 -22.66 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.241 . . . . 0.0 109.202 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -98.95 -35.43 4.83 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.454 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 15.0 ptpt -68.88 -27.04 65.44 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.189 -1.183 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.449 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 17.5 pt-20 -100.82 -5.97 25.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 110.087 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.5 t -95.99 -67.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.054 -1.029 . . . . 0.0 109.978 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -47.18 -29.78 2.53 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.206 -0.934 . . . . 0.0 110.149 -179.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.548 HG22 ' HB1' ' A' ' 50' ' ' ALA . 0.2 OUTLIER -52.74 -63.25 1.2 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.074 -1.016 . . . . 0.0 109.207 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -50.35 -47.49 55.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.341 -0.849 . . . . 0.0 109.242 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.73 ' CG ' HD23 ' A' ' 106' ' ' LEU . 7.8 t80 -56.46 -51.26 69.1 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.18 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.862 ' CD1' HG22 ' A' ' 55' ' ' VAL . 19.5 mt -58.32 -44.7 88.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.496 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.576 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 0.2 OUTLIER -67.67 -62.95 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.344 -0.848 . . . . 0.0 109.612 179.965 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.637 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -52.8 -24.48 9.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.626 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.637 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 19.0 m-70 -125.0 101.74 7.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.299 -0.876 . . . . 0.0 109.738 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -84.51 -17.48 38.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.398 -0.814 . . . . 0.0 109.503 179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -67.87 -16.11 63.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.774 ' HE3' HG11 ' A' ' 44' ' ' VAL . 89.6 mmm -120.04 -15.02 8.82 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 110.019 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.431 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.04 -44.84 41.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.913 -1.117 . . . . 0.0 109.525 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.0 -29.75 60.97 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.322 -0.861 . . . . 0.0 109.26 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.041 HG13 ' ND2' ' A' ' 95' ' ' ASN . 2.4 t -60.89 -27.99 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.342 -0.849 . . . . 0.0 109.173 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.543 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 8.3 m-85 -82.64 -27.8 31.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.103 -0.998 . . . . 0.0 109.683 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.448 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.84 20.26 6.51 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.543 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 3.6 m-85 -117.88 172.84 7.12 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.231 -1.159 . . . . 0.0 109.653 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.6 t -115.28 22.09 13.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.331 -0.856 . . . . 0.0 109.029 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.45 -170.8 28.93 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.576 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -85.86 11.28 11.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -1.168 . . . . 0.0 109.97 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.04 20.3 18.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.994 . . . . 0.0 109.557 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.404 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -101.31 136.42 19.67 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.54 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -68.03 -17.01 45.97 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.916 1.482 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.0 -36.88 61.38 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.862 HG22 ' CD1' ' A' ' 35' ' ' LEU . 61.2 t -51.71 -33.27 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.238 -1.154 . . . . 0.0 109.449 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.66 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.28 -13.77 59.45 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.252 -0.905 . . . . 0.0 109.787 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -90.21 -23.14 21.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.184 -0.947 . . . . 0.0 109.494 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.673 ' O ' HG23 ' A' ' 62' ' ' VAL . 3.4 mt -90.89 -66.43 0.93 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.902 . . . . 0.0 109.906 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.93 -30.89 38.27 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -1.217 . . . . 0.0 109.479 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.544 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 17.0 mttt -94.34 -38.44 10.98 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.42 -0.8 . . . . 0.0 109.485 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 58' ' ' LEU . 91.4 t -51.43 -57.99 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.38 -0.825 . . . . 0.0 109.794 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.85 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.31 -45.0 24.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.227 -0.921 . . . . 0.0 109.677 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.544 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -47.66 -40.74 20.67 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.687 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 35.2 tp60 -64.79 -41.28 95.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.195 -0.941 . . . . 0.0 109.164 179.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.795 ' O ' HG23 ' A' ' 70' ' ' VAL . 59.4 mt -60.79 -37.31 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -0.843 . . . . 0.0 109.144 179.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.76 29.68 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.2 t -58.04 -24.81 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -1.125 . . . . 0.0 109.17 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.0 -34.21 22.4 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.418 -0.801 . . . . 0.0 109.433 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.795 HG23 ' O ' ' A' ' 66' ' ' ILE . 50.7 t -63.95 -19.33 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -0.899 . . . . 0.0 109.425 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 24.1 m -62.2 -41.93 98.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.196 -0.94 . . . . 0.0 109.667 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 71' ' ' SER . 8.7 m-70 -131.02 84.48 2.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.724 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.624 HD11 HG11 ' A' ' 10' ' ' VAL . 42.1 mt . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 109.6 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.7 tmm? . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.272 0.558 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.401 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 54.8 t -76.86 -22.51 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.258 -0.901 . . . . 0.0 109.605 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.47 -17.89 61.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.851 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -92.57 -49.84 5.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 109.761 -179.875 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.466 ' HE2' ' O ' ' A' ' 137' ' ' ILE . 95.8 mmm -60.74 -45.91 92.49 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.067 -1.021 . . . . 0.0 109.156 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.796 ' O ' HG23 ' A' ' 88' ' ' VAL . 2.0 mttt -51.73 -31.17 25.34 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.128 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.448 ' O ' ' CG ' ' A' ' 89' ' ' ARG . . . -79.47 -32.02 42.53 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.462 -0.774 . . . . 0.0 108.956 179.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 82' ' ' GLU . 45.2 t -69.86 -41.69 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.127 -0.983 . . . . 0.0 109.273 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.49 92.69 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.931 -1.667 . . . . 0.0 108.931 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.796 HG23 ' O ' ' A' ' 84' ' ' LYS . 97.0 t -59.25 -29.4 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -1.191 . . . . 0.0 109.178 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.478 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.9 OUTLIER -76.63 -45.7 28.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -0.871 . . . . 0.0 109.316 179.773 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.798 ' O ' HD12 ' A' ' 98' ' ' ILE . 22.0 m80 -59.18 -20.67 55.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.088 179.428 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 ttpt -70.23 -9.54 56.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.89 . . . . 0.0 110.188 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.4 54.57 0.55 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.885 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.9 m-30 -88.8 -168.99 2.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -1.167 . . . . 0.0 109.613 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -76.49 -36.46 38.48 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.041 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.7 p-10 -79.67 -24.66 41.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.046 -1.267 . . . . 0.0 110.009 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 ttmm 51.41 26.79 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.153 -0.967 . . . . 0.0 109.499 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.413 ' H ' ' ND2' ' A' ' 95' ' ' ASN . 4.6 m-70 -134.28 42.97 2.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.42 -0.8 . . . . 0.0 109.323 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.885 HD11 ' CD2' ' A' ' 93' ' ' TYR . 58.9 mt -86.03 156.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 110.061 -179.633 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.472 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.28 143.69 25.08 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.706 0.765 . . . . 0.0 109.882 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.1 -6.37 56.3 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.717 -0.614 . . . . 0.0 109.622 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.422 ' HG2' ' HB3' ' A' ' 99' ' ' LYS . 15.7 pt-20 -72.95 -28.73 62.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.091 -1.006 . . . . 0.0 109.359 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.54 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 44.8 m-85 -79.93 -20.42 45.72 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.593 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.5 m-85 -57.37 -68.13 0.26 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.338 -0.851 . . . . 0.0 110.555 -179.332 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 3.4 mt-10 -43.24 -59.96 2.81 Favored Pre-proline 0 N--CA 1.495 1.808 0 O-C-N 121.516 -0.74 . . . . 0.0 111.016 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 8.8 Cg_endo -55.99 -42.52 65.93 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.732 1.385 . . . . 0.0 110.199 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.737 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.9 tm? -66.75 -27.18 67.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.475 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.36 -38.8 37.8 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.45 -48.42 72.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -1.127 . . . . 0.0 109.539 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.2 m -62.31 -26.46 68.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.548 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.424 HD22 ' CE2' ' A' ' 134' ' ' TYR . 8.3 tt -70.42 -40.22 73.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 109.563 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.938 HD21 ' HB3' ' A' ' 130' ' ' TRP . 13.0 mt -58.96 -32.04 69.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.426 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.53 -27.75 64.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.282 -0.886 . . . . 0.0 109.523 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.421 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -84.18 -35.07 23.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.224 -0.922 . . . . 0.0 109.689 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.661 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.3 mmt -46.93 -50.4 18.95 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.285 -0.884 . . . . 0.0 110.227 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.475 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 8.5 pt-20 -47.23 -24.76 0.78 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 110.276 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 19.8 m170 -53.65 -31.33 47.08 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.709 -1.244 . . . . 0.0 109.651 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -91.89 -68.39 0.8 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.19 -0.944 . . . . 0.0 110.127 -179.655 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.499 HG23 HG12 ' A' ' 17' ' ' ILE . 18.3 pt -78.21 -34.16 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.116 -0.99 . . . . 0.0 109.756 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.475 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . 41.2 -98.73 0.01 OUTLIER Glycine 0 N--CA 1.498 2.794 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.61 -39.46 10.56 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.491 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.6 OUTLIER -73.29 -18.13 61.24 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.044 -1.268 . . . . 0.0 109.919 -179.806 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.449 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -79.45 107.06 11.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 179.571 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.686 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.4 p-10 -111.61 -171.23 1.8 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.926 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.451 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.47 -49.0 79.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.424 -0.798 . . . . 0.0 109.963 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.722 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.83 -20.72 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.516 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -85.44 -55.73 3.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.311 -0.868 . . . . 0.0 109.791 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.451 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -69.69 -24.78 63.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.781 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -80.04 -45.35 18.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.236 -0.915 . . . . 0.0 109.524 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -65.25 -45.89 82.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.391 -0.818 . . . . 0.0 109.391 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.972 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.7 m0 -66.41 -29.4 69.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -0.864 . . . . 0.0 109.34 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.448 ' N ' HD11 ' A' ' 111' ' ' LEU . . . -69.64 -28.06 65.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 108.932 179.327 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.81 -31.72 15.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.44 -0.787 . . . . 0.0 109.359 179.614 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.06 -39.78 68.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.398 -0.814 . . . . 0.0 109.206 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.424 ' CE2' HD22 ' A' ' 110' ' ' LEU . 5.3 m-30 -52.64 -30.89 34.05 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.342 -0.849 . . . . 0.0 109.064 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.58 -35.07 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.336 -0.852 . . . . 0.0 109.242 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -77.89 -39.07 44.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.33 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.636 HD13 HG23 ' A' ' 66' ' ' ILE . 12.2 mt -65.82 -58.48 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.297 -0.877 . . . . 0.0 109.109 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.429 ' O ' ' HB3' ' A' ' 141' ' ' LEU . 0.1 OUTLIER -68.51 -28.25 66.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -58.38 -52.72 51.09 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.04 -23.28 13.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.259 -1.142 . . . . 0.0 109.535 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.649 ' O ' HD23 ' A' ' 141' ' ' LEU . 10.5 tt -81.73 -18.12 45.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.703 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.714 ' O ' HG22 ' A' ' 142' ' ' ILE . 69.3 mt -89.88 37.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.78 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 60.7 m -117.84 -36.15 3.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.073 -1.017 . . . . 0.0 109.688 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -105.12 -18.01 12.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . . . . . . . . . 4.9 tp . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.123 -1.221 . . . . 0.0 109.581 -179.902 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.603 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 46.9 mt-30 -81.35 -46.86 14.05 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.131 -0.981 . . . . 0.0 109.621 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.453 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -54.84 -31.66 59.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.089 -1.007 . . . . 0.0 109.468 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.453 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 27.7 mm100 -70.78 -37.43 73.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 109.336 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 5' ' ' ALA . 47.3 t -69.71 -29.18 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.931 HG12 HG13 ' A' ' 70' ' ' VAL . 63.8 t -70.73 -43.76 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.309 -0.869 . . . . 0.0 109.291 179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.61 -12.79 60.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.319 -0.863 . . . . 0.0 109.771 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.0 t -91.89 -27.79 17.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 p -90.93 -13.85 32.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.141 -0.974 . . . . 0.0 110.032 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -88.44 -15.07 36.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.068 -1.02 . . . . 0.0 109.865 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.42 -0.58 55.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.947 . . . . 0.0 109.924 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -113.3 -49.67 2.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.034 -1.041 . . . . 0.0 109.602 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.946 HD12 ' CH2' ' A' ' 130' ' ' TRP . 58.5 mt -69.43 -36.19 70.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.251 -0.906 . . . . 0.0 109.575 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.14 33.17 3.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 109.72 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -61.81 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 p -120.39 -36.74 3.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -1.123 . . . . 0.0 109.594 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 2.0 p30 -71.26 -19.15 62.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.261 -0.899 . . . . 0.0 109.665 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.849 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 28.4 t30 57.53 19.65 5.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -0.929 . . . . 0.0 109.635 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.411 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 105.46 19.36 10.58 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.774 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -64.91 -52.39 56.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -1.181 . . . . 0.0 109.596 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.23 -22.73 75.65 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.69 HG21 ' CG2' ' A' ' 17' ' ' ILE . 15.5 t -71.09 -41.01 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -1.086 . . . . 0.0 109.855 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.401 ' HA3' ' C ' ' A' ' 59' ' ' GLY . . . -74.93 -57.19 4.53 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.482 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 15.8 ptpt -47.39 -31.3 3.93 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.208 -1.172 . . . . 0.0 110.228 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.82 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 23.4 pt-20 -95.79 -17.81 20.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.058 -1.026 . . . . 0.0 109.939 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 29.3 t -83.54 -68.11 0.74 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.948 . . . . 0.0 109.8 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.521 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.8 m-85 -50.32 -32.04 16.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.808 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -51.95 -55.05 22.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.1 -1.0 . . . . 0.0 109.165 179.718 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -57.68 -48.6 79.07 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.32 -0.862 . . . . 0.0 109.268 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.694 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.1 t80 -55.04 -49.05 72.54 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.195 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.712 ' CD1' HG22 ' A' ' 55' ' ' VAL . 23.2 mt -59.83 -41.57 91.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.854 . . . . 0.0 109.725 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.79 -63.34 1.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.935 . . . . 0.0 109.818 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.6 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -58.25 -21.36 48.12 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.203 -0.936 . . . . 0.0 109.886 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.6 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 16.5 m-70 -126.74 106.71 9.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.922 . . . . 0.0 109.933 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 5.5 m170 -85.88 -20.44 29.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.535 -0.728 . . . . 0.0 109.249 179.292 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -73.05 -20.29 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.248 -0.908 . . . . 0.0 109.098 179.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.485 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -91.86 -20.43 21.46 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -0.866 . . . . 0.0 109.537 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.444 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.26 -56.48 20.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.302 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.61 63.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.288 -0.882 . . . . 0.0 109.255 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.035 HG13 ' ND2' ' A' ' 95' ' ' ASN . 22.4 t -71.4 -58.45 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.288 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.536 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 39.7 m-85 -57.2 -40.69 77.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.58 35.18 1.1 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.0 m-85 -125.62 169.0 12.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 109.858 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 t -112.34 18.07 18.85 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.351 -0.843 . . . . 0.0 109.372 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.3 -164.05 29.28 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.43 25.31 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -1.155 . . . . 0.0 109.716 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 37.6 m -124.78 31.04 5.77 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.623 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.54 135.45 21.9 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 109.642 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -64.07 -18.21 62.71 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.929 1.489 . . . . 0.0 109.972 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.62 -39.08 94.65 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.808 HG11 HG23 ' A' ' 32' ' ' THR . 65.6 t -52.09 -38.56 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.322 -1.105 . . . . 0.0 109.411 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.01 -12.22 60.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 0.0 109.659 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -92.76 -35.5 13.4 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.972 . . . . 0.0 109.662 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.869 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.9 mt -79.43 -61.16 2.09 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.241 -0.912 . . . . 0.0 109.873 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.864 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -55.61 -36.47 64.8 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.585 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -60.85 -52.63 64.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.09 -1.241 . . . . 0.0 109.365 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 16.6 mttt -67.5 -41.99 83.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.308 -0.87 . . . . 0.0 109.183 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.869 HG23 ' O ' ' A' ' 58' ' ' LEU . 63.3 t -56.42 -44.51 80.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.175 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -48.17 -46.07 34.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.416 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -50.65 -49.46 56.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.107 -0.995 . . . . 0.0 109.33 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -52.99 -37.66 61.55 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -0.892 . . . . 0.0 109.088 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.915 ' O ' HG23 ' A' ' 70' ' ' VAL . 34.7 mm -67.87 -35.75 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 109.063 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.56 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.43 -47.22 44.06 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.559 HG11 ' OE1' ' A' ' 82' ' ' GLU . 43.9 t -62.45 -25.43 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.361 -1.082 . . . . 0.0 109.439 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.83 -30.7 24.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.931 HG13 HG12 ' A' ' 10' ' ' VAL . 53.8 t -62.68 -37.23 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.488 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.2 p -51.39 -69.28 0.12 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.923 . . . . 0.0 109.348 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.444 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 9.0 m-70 -90.82 45.32 1.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 109.192 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.777 ' CD2' HG11 ' A' ' 10' ' ' VAL . 30.4 tp . . . . . 0 C--N 1.305 -1.356 0 O-C-N 121.244 -0.91 . . . . 0.0 109.526 -179.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.444 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 8.3 tmm? . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.61 HG12 ' HE2' ' A' ' 84' ' ' LYS . 37.9 t -62.01 -24.46 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.857 . . . . 0.0 109.108 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.65 -52.86 55.11 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.266 -0.896 . . . . 0.0 109.23 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.559 ' OE1' HG11 ' A' ' 68' ' ' VAL . 5.8 tt0 -66.91 -46.16 75.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.113 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.472 ' SD ' HG23 ' A' ' 137' ' ' ILE . 1.6 mtp -52.61 -48.91 66.01 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.61 ' HE2' HG12 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -52.63 -34.22 50.27 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.182 -0.949 . . . . 0.0 108.894 179.389 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -66.58 -15.87 63.75 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.613 ' CG1' HD11 ' A' ' 141' ' ' LEU . 11.3 t -85.81 -32.52 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.033 -1.042 . . . . 0.0 108.624 179.315 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.479 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -71.26 -43.32 55.6 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 179.176 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.422 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 96.3 t -55.65 -25.93 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.38 -1.07 . . . . 0.0 108.62 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.509 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.3 OUTLIER -76.06 -49.53 17.25 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 108.996 179.301 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.866 ' HB2' HD13 ' A' ' 145' ' ' LEU . 24.5 m80 -62.04 -21.71 65.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.379 -0.826 . . . . 0.0 109.01 179.553 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.422 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.2 OUTLIER -63.58 -14.13 48.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.396 -0.815 . . . . 0.0 109.972 -179.884 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.47 53.46 0.58 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.509 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.9 m-30 -91.31 -173.2 3.53 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -1.168 . . . . 0.0 109.349 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.45 -25.51 54.0 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 179.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.035 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.2 t30 -82.34 -45.49 14.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.463 -1.022 . . . . 0.0 109.179 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 9.0 ttpt 72.3 -53.75 0.69 Allowed 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.464 -0.773 . . . . 0.0 110.224 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 38.1 m170 -65.61 73.07 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.119 -0.988 . . . . 0.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.462 ' N ' ' O ' ' A' ' 96' ' ' LYS . 48.8 mt -104.81 155.03 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.521 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.53 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.7 mptp? -138.72 149.76 45.43 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.231 -0.918 . . . . 0.0 109.948 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.706 ' HB1' HG12 ' A' ' 142' ' ' ILE . . . -87.45 -18.79 29.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.527 -0.733 . . . . 0.0 109.628 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.459 ' HG2' ' HB3' ' A' ' 99' ' ' LYS . 17.7 pt-20 -67.22 -19.64 65.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.53 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 52.6 m-85 -82.06 -21.41 36.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.249 -0.907 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.412 ' HB2' ' O ' ' A' ' 100' ' ' ALA . 4.5 m-85 -60.42 -64.56 0.91 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.294 -0.879 . . . . 0.0 110.205 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.495 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.77 -58.75 4.2 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.462 -0.774 . . . . 0.0 110.987 -179.328 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.519 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 7.4 Cg_endo -55.06 -47.29 27.26 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 123.63 1.332 . . . . 0.0 110.082 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.878 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -61.75 -22.43 65.39 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.151 -0.968 . . . . 0.0 109.428 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.98 -48.24 11.89 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.79 -51.26 70.75 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 109.595 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 m -58.9 -18.77 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.658 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.769 HD23 ' SD ' ' A' ' 114' ' ' MET . 1.2 tt -75.71 -31.14 59.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.178 -0.951 . . . . 0.0 109.722 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.871 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.2 mt -71.29 -29.03 64.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 0.0 109.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.13 -34.29 70.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.916 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.82 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -80.89 -29.55 35.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.719 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.769 ' SD ' HD23 ' A' ' 110' ' ' LEU . 2.7 mtt -61.72 -34.16 75.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.896 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.448 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -61.49 -17.85 56.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.174 -0.954 . . . . 0.0 109.409 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -57.94 -49.14 77.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.721 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.1 ttt85 -74.25 -65.68 0.82 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.698 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.663 HG12 HD11 ' A' ' 17' ' ' ILE . 7.0 pt -92.31 53.19 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.258 -0.901 . . . . 0.0 109.726 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.448 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.49 -15.12 61.1 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.39 -30.95 6.68 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.71 -26.02 17.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -1.16 . . . . 0.0 109.791 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.423 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -60.19 97.67 0.05 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 -179.903 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.58 HD21 ' HB3' ' A' ' 125' ' ' ALA . 15.7 p-10 -106.42 -171.5 1.91 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.437 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.15 -49.48 77.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.388 -0.82 . . . . 0.0 109.952 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.58 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -58.4 -26.22 62.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.05 -1.031 . . . . 0.0 109.321 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.424 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -76.95 -54.01 7.11 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.231 -0.918 . . . . 0.0 109.849 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.498 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 6.3 ptmm? -70.9 -29.29 65.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.058 -1.026 . . . . 0.0 109.792 -179.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -77.85 -42.03 34.91 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -0.93 . . . . 0.0 109.607 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.456 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -65.53 -50.16 66.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.407 179.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.946 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.0 m0 -64.55 -28.77 69.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.299 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.23 -28.81 69.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.188 -0.945 . . . . 0.0 109.064 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -90.58 -24.32 20.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.395 -0.816 . . . . 0.0 109.373 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.489 ' HB2' HD21 ' A' ' 73' ' ' LEU . . . -77.47 -62.8 1.54 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.355 -0.841 . . . . 0.0 109.685 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.568 ' CE1' ' CG2' ' A' ' 66' ' ' ILE . 16.2 m-30 -52.0 -26.19 10.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.228 -0.92 . . . . 0.0 109.577 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.67 -44.85 69.64 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.208 -0.932 . . . . 0.0 108.904 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -75.41 -32.27 60.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.407 -0.808 . . . . 0.0 109.281 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.554 HG12 ' HB1' ' A' ' 69' ' ' ALA . 49.1 mt -67.46 -59.29 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.321 -0.862 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.442 ' O ' ' CD1' ' A' ' 142' ' ' ILE . 2.4 p -67.25 -13.72 62.24 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.312 -0.868 . . . . 0.0 109.805 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -84.96 -21.74 54.69 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.453 ' O ' ' NZ ' ' A' ' 84' ' ' LYS . . . -86.24 -10.36 54.78 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 110.054 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.881 ' O ' HD23 ' A' ' 141' ' ' LEU . 3.0 tt -89.14 17.24 6.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.029 -1.045 . . . . 0.0 109.882 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.706 HG12 ' HB1' ' A' ' 100' ' ' ALA . 1.9 mp -107.52 7.15 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.099 -1.001 . . . . 0.0 110.121 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.401 ' HB2' ' NZ ' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -96.77 -34.48 11.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.945 -1.097 . . . . 0.0 109.63 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.83 11.1 27.52 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.866 HD13 ' HB2' ' A' ' 90' ' ' HIS . 11.4 tp . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.106 -1.232 . . . . 0.0 109.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.552 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.295 0.569 . . . . 0.0 109.596 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.427 ' O ' HG23 ' A' ' 10' ' ' VAL . 42.8 mt-30 -64.34 -44.57 91.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.219 -0.926 . . . . 0.0 109.69 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -48.68 -50.55 32.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.512 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -59.0 -48.38 81.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 0.0 109.057 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.711 HG11 ' O ' ' A' ' 125' ' ' ALA . 48.6 t -59.83 -36.11 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 0.0 109.145 179.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 1.058 HG12 HG13 ' A' ' 70' ' ' VAL . 65.7 t -72.14 -46.47 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.36 -0.837 . . . . 0.0 109.116 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.03 -18.01 61.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.53 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.8 t -87.12 -25.44 24.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.2 p -91.08 -17.19 26.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.851 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.02 -15.67 37.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.923 . . . . 0.0 109.841 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -84.45 -14.34 49.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.113 -0.992 . . . . 0.0 109.596 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.452 ' OD1' HG22 ' A' ' 118' ' ' ILE . 1.8 t70 -98.84 -51.25 3.94 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.156 -0.965 . . . . 0.0 109.614 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.956 HD12 ' CH2' ' A' ' 130' ' ' TRP . 62.2 mt -69.11 -36.41 73.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.249 -0.907 . . . . 0.0 109.585 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.855 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.27 33.16 3.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.692 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.2 -81.75 0.05 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.8 p -102.04 -17.49 16.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -1.149 . . . . 0.0 109.725 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.84 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 5.5 p-10 -89.02 -19.65 25.38 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.218 -0.926 . . . . 0.0 109.656 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.855 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.0 t30 59.32 24.57 13.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.238 -0.914 . . . . 0.0 109.674 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.94 22.69 14.93 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.027 -1.629 . . . . 0.0 109.027 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.84 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -71.12 -43.63 67.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.295 -1.12 . . . . 0.0 109.71 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.433 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.91 22.84 20.04 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.65 ' CG1' HD21 ' A' ' 110' ' ' LEU . 16.9 t -115.14 -34.23 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -1.194 . . . . 0.0 109.057 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.477 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -92.57 -39.39 5.31 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.473 ' HB2' ' CB ' ' A' ' 56' ' ' ALA . 2.5 ptmt -63.85 -30.01 71.14 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -1.225 . . . . 0.0 109.381 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.661 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 6.5 pt-20 -92.59 -22.2 19.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.442 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 37.8 t -85.47 -51.44 6.52 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.294 -0.879 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.696 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.7 m-85 -53.63 -32.27 50.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.668 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 16.6 m -62.36 -28.38 69.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.968 . . . . 0.0 109.222 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.3 mmtt -81.65 -40.11 23.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.897 ' CG ' HD23 ' A' ' 106' ' ' LEU . 1.5 t80 -65.84 -55.55 16.51 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.265 -0.897 . . . . 0.0 109.362 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.755 ' CD1' HG22 ' A' ' 55' ' ' VAL . 25.3 mt -50.08 -44.62 52.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 0.0 109.722 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.518 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 40.1 p -66.36 -68.29 0.38 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.181 -0.949 . . . . 0.0 109.647 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.654 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -52.5 -27.17 15.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.654 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 17.7 m-70 -120.06 101.41 7.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -0.86 . . . . 0.0 109.756 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -83.63 -19.01 36.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.404 -0.81 . . . . 0.0 109.371 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -72.51 -13.02 61.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.597 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.479 ' SD ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -105.6 -14.94 15.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.938 -179.826 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.06 -65.23 0.61 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.005 -1.06 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.42 -20.91 48.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.035 HG13 ' ND2' ' A' ' 95' ' ' ASN . 38.7 t -77.95 -39.0 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.288 -0.883 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.533 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.3 m-85 -74.39 -21.65 59.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.231 -0.918 . . . . 0.0 109.531 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.92 25.21 7.28 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.533 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.7 m-85 -123.76 175.85 6.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -1.112 . . . . 0.0 109.802 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.57 18.4 15.04 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.392 -0.817 . . . . 0.0 109.352 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 147.97 -163.87 28.87 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.518 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -93.09 31.8 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.64 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.1 t -130.46 25.58 5.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.629 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.04 138.18 20.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -66.67 -22.77 49.97 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.994 1.523 . . . . 0.0 109.976 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.508 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.97 -31.67 58.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.755 HG22 ' CD1' ' A' ' 35' ' ' LEU . 92.9 t -54.19 -35.9 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.22 -1.164 . . . . 0.0 109.379 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.473 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . . . -78.53 -5.16 51.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 0.0 109.809 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.417 ' OD2' ' HA2' ' A' ' 54' ' ' GLY . 37.0 m-20 -93.55 -27.45 16.62 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.03 -1.044 . . . . 0.0 109.558 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.862 ' O ' HG23 ' A' ' 62' ' ' VAL . 6.4 mt -88.13 -63.97 1.22 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.073 -1.017 . . . . 0.0 109.354 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.477 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -51.19 -37.07 37.27 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -67.32 -34.34 77.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.859 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 0.0 OUTLIER -87.06 -34.49 19.15 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 109.785 -179.82 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.862 HG23 ' O ' ' A' ' 58' ' ' LEU . 24.4 t -67.24 -47.46 81.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.935 . . . . 0.0 109.719 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.8 mm? -47.89 -46.99 32.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.79 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.78 -48.08 20.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.257 -0.902 . . . . 0.0 109.973 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -55.4 -53.3 58.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.111 -0.993 . . . . 0.0 109.42 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 1.007 ' O ' HG23 ' A' ' 70' ' ' VAL . 52.2 mt -51.77 -38.47 22.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.362 -0.836 . . . . 0.0 109.176 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.574 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.06 -55.69 28.84 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.465 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 98.9 t -59.94 -29.2 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -1.126 . . . . 0.0 109.758 -179.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.53 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.76 -10.64 57.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 110.075 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.058 HG13 HG12 ' A' ' 10' ' ' VAL . 42.1 t -71.53 -42.32 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.012 -1.055 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.31 -12.49 59.96 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.056 -1.027 . . . . 0.0 110.032 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.483 ' ND1' ' N ' ' A' ' 72' ' ' HIS . 9.0 m80 -110.99 52.6 0.73 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.145 -0.972 . . . . 0.0 109.998 -179.306 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.537 ' CD1' HG11 ' A' ' 10' ' ' VAL . 90.0 mt . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.936 . . . . 0.0 109.168 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.438 ' HG2' ' HB3' ' A' ' 72' ' ' HIS . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.48 -30.51 46.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.364 -0.835 . . . . 0.0 108.747 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.77 -42.09 97.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.355 -0.841 . . . . 0.0 108.864 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.43 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.6 OUTLIER -61.59 -53.06 61.26 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.368 -0.833 . . . . 0.0 108.931 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 80.5 mmm -57.72 -40.41 79.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.278 -0.888 . . . . 0.0 108.829 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.88 -35.73 46.19 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.243 -0.911 . . . . 0.0 108.606 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.426 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -74.18 -36.06 64.03 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG12 HD11 ' A' ' 141' ' ' LEU . 49.0 t -56.92 -43.89 81.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.306 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.498 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -67.21 -51.38 38.78 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 179.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.559 HG23 ' HA3' ' A' ' 144' ' ' GLY . 53.1 t -58.76 -22.39 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.497 -1.002 . . . . 0.0 109.197 179.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.7 mmm180 -75.41 -41.59 55.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 109.13 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.539 ' HA ' ' CG ' ' A' ' 93' ' ' TYR . 4.8 m80 -60.31 -28.74 68.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.087 179.335 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 2.0 ttmt -52.44 -26.28 12.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 110.308 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -130.23 45.28 1.15 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.586 -1.292 . . . . 0.0 110.132 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.539 ' CG ' ' HA ' ' A' ' 90' ' ' HIS . 3.2 m-30 -86.01 -170.7 3.22 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.081 -1.246 . . . . 0.0 109.503 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.5 -48.15 45.88 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.035 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -72.95 -44.69 60.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.472 -1.017 . . . . 0.0 109.163 179.777 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.477 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 6.4 tttp 72.55 -54.1 0.69 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.354 -0.841 . . . . 0.0 110.145 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -62.91 78.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.188 -0.945 . . . . 0.0 109.871 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.454 ' N ' ' O ' ' A' ' 96' ' ' LYS . 71.4 mt -113.46 163.27 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.125 -0.984 . . . . 0.0 109.69 -179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.443 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -140.86 135.38 31.3 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.791 179.784 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.67 ' HB1' HG12 ' A' ' 142' ' ' ILE . . . -79.14 1.29 24.9 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.275 -0.89 . . . . 0.0 109.84 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.525 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -80.45 -26.43 38.34 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 109.545 179.88 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.525 ' CD1' ' HG3' ' A' ' 101' ' ' GLU . 93.3 m-85 -78.03 -10.33 59.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.185 -0.947 . . . . 0.0 109.703 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.946 ' CE2' HD22 ' A' ' 141' ' ' LEU . 6.5 m-85 -62.51 -60.71 3.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 110.066 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.0 mt-10 -52.54 -55.72 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.203 -0.936 . . . . 0.0 110.004 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.97 -62.42 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.69 1.363 . . . . 0.0 109.768 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.954 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.83 -23.38 30.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.36 -0.838 . . . . 0.0 109.314 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.2 -48.17 9.97 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.41 -33.53 74.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.137 -1.213 . . . . 0.0 109.585 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.73 -27.86 63.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.216 -0.928 . . . . 0.0 109.5 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 1.008 HD22 ' OH ' ' A' ' 134' ' ' TYR . 2.2 tt -69.67 -35.6 75.29 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.818 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.6 mt -59.73 -34.17 72.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 t -68.72 -33.03 73.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.669 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.661 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -76.37 -39.93 52.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.635 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.498 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 4.2 mtt -50.06 -38.58 38.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.17 -22.52 6.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.194 -0.941 . . . . 0.0 109.561 179.779 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.424 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -57.52 -47.75 81.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.4 ttt85 -73.06 -61.93 1.64 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.723 HD11 ' SD ' ' A' ' 122' ' ' MET . 14.6 pt -97.27 55.88 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.331 -0.855 . . . . 0.0 109.63 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -62.17 -14.44 46.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -107.73 -27.44 5.18 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 6.2 mttm -93.92 -13.44 27.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -1.212 . . . . 0.0 110.146 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.723 ' SD ' HD11 ' A' ' 118' ' ' ILE . 4.0 tpt -71.99 98.23 2.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.509 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.799 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 2.4 p-10 -104.6 169.16 8.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.447 -0.783 . . . . 0.0 109.514 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -49.16 -51.75 30.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.25 -0.906 . . . . 0.0 109.625 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.799 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -53.03 -26.72 16.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -0.931 . . . . 0.0 109.441 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -75.69 -58.01 3.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.566 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.564 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.1 ptpt -63.68 -29.29 70.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.147 -0.97 . . . . 0.0 109.286 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.47 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 43.0 t0 -77.32 -43.04 34.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.411 -0.806 . . . . 0.0 109.407 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.767 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -65.34 -39.61 92.59 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 109.212 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.956 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.4 m0 -77.52 -28.32 52.01 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.353 -0.842 . . . . 0.0 108.986 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.564 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -66.34 -30.29 70.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.323 -0.861 . . . . 0.0 109.026 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.45 -34.06 20.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.393 -0.817 . . . . 0.0 109.167 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -74.07 -36.78 64.34 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.441 -0.787 . . . . 0.0 109.13 179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 1.008 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.9 OUTLIER -57.65 -23.74 52.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.386 -0.821 . . . . 0.0 109.39 179.728 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.4 -32.01 42.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.547 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -80.86 -35.38 32.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.599 HD13 HG23 ' A' ' 66' ' ' ILE . 45.5 mt -74.62 -54.21 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.206 -0.934 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 12.2 p -71.0 -40.98 71.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 109.577 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.496 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -57.49 -47.53 87.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.86 -26.27 9.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.244 -1.151 . . . . 0.0 109.586 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.946 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.5 tt -84.98 -18.62 33.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.773 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.67 HG12 ' HB1' ' A' ' 100' ' ' ALA . 76.5 mt -83.04 7.0 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 110.108 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.1 m -101.81 -27.6 12.92 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.056 -1.028 . . . . 0.0 109.62 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.559 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -100.07 -25.03 9.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.526 HD13 HD21 ' A' ' 141' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.287 -1.125 . . . . 0.0 109.561 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.956 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.253 0.549 . . . . 0.0 109.613 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.553 ' O ' HG23 ' A' ' 10' ' ' VAL . 96.4 mt-30 -66.62 -54.02 27.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.794 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.489 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 1.2 ttp180 -50.06 -32.44 15.57 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.207 -0.933 . . . . 0.0 109.571 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 30.9 mm-40 -75.83 -43.85 43.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.332 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.956 HG23 ' O ' ' A' ' 5' ' ' ALA . 24.5 t -61.67 -32.8 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.93 HG12 HG13 ' A' ' 70' ' ' VAL . 91.6 t -62.18 -45.63 98.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.4 179.698 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.6 -15.24 60.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 0.0 109.686 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -84.34 -24.04 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 109.694 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 35.5 p -100.5 -12.54 19.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.868 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.77 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -89.83 -27.65 19.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.102 -0.999 . . . . 0.0 109.81 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.7 mtpp -74.74 -9.87 58.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.167 -0.958 . . . . 0.0 109.708 179.592 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.582 ' HB3' HG21 ' A' ' 118' ' ' ILE . 0.3 OUTLIER -102.31 -61.29 1.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.59 179.925 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.947 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.5 mt -57.74 -41.1 78.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 109.625 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.795 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -101.39 34.48 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.75 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.69 -69.11 1.32 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 p -113.94 -25.3 8.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 109.518 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 17.7 p-10 -80.65 -19.3 45.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.679 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.795 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 20.3 t30 60.32 21.34 10.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.262 -0.899 . . . . 0.0 109.641 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.81 20.39 31.47 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -65.5 -50.88 63.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.218 -1.166 . . . . 0.0 109.532 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.469 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.94 -5.0 86.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.695 HG21 ' CG2' ' A' ' 17' ' ' ILE . 43.5 t -87.47 -33.08 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.996 -1.296 . . . . 0.0 109.724 -179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.97 -41.01 9.87 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.469 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.3 ptpt -63.67 -31.87 73.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -1.18 . . . . 0.0 109.826 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.45 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 15.8 pt-20 -89.58 -14.71 34.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.167 -0.958 . . . . 0.0 110.083 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.674 ' SG ' HD12 ' A' ' 110' ' ' LEU . 42.2 t -91.58 -63.66 1.22 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.137 -0.977 . . . . 0.0 109.999 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.518 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 14.3 m-85 -54.19 -37.34 64.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.226 -0.922 . . . . 0.0 109.907 -179.53 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.807 ' OG1' HG11 ' A' ' 55' ' ' VAL . 8.7 m -53.18 -32.88 50.15 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.051 -1.031 . . . . 0.0 108.907 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.435 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 3.9 mmtt -76.14 -47.48 24.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.34 -0.85 . . . . 0.0 109.067 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.574 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.1 t80 -61.41 -49.64 76.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.854 ' CD1' HG22 ' A' ' 55' ' ' VAL . 70.2 mt -54.83 -44.22 73.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.129 -0.982 . . . . 0.0 109.401 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.532 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 82.7 p -73.48 -66.09 0.74 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.366 -0.834 . . . . 0.0 109.982 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.642 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -49.61 -30.08 8.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.205 -0.934 . . . . 0.0 109.702 -179.724 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.642 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 23.0 m-70 -123.63 110.12 14.6 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.264 -0.898 . . . . 0.0 109.785 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -88.93 -18.66 27.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.502 -0.748 . . . . 0.0 109.31 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -66.51 -21.1 66.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.264 -0.897 . . . . 0.0 109.227 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.536 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 88.6 mmm -107.91 -23.94 11.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 109.75 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.37 -34.29 15.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.865 -1.147 . . . . 0.0 109.136 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.67 -36.75 70.73 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.354 -0.841 . . . . 0.0 109.118 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.004 HG13 ' ND2' ' A' ' 95' ' ' ASN . 20.4 t -58.41 -63.7 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.034 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.589 ' CD2' HD21 ' A' ' 35' ' ' LEU . 84.4 m-85 -56.42 -27.59 56.97 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.319 -0.863 . . . . 0.0 109.1 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 42' ' ' ALA . . . 108.99 -138.45 14.76 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 1.7 m-85 61.04 170.65 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.105 -1.232 . . . . 0.0 109.83 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.4 t -115.01 25.79 10.63 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.67 -163.94 27.51 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.532 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -89.25 16.36 7.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.165 -1.197 . . . . 0.0 109.901 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.99 35.29 4.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.116 -0.99 . . . . 0.0 109.691 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.463 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 2.8 t70 -114.43 137.37 22.58 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.616 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -62.75 -24.46 74.65 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.92 1.484 . . . . 0.0 110.067 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.538 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -40.7 47.22 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.854 HG22 ' CD1' ' A' ' 35' ' ' LEU . 67.3 t -49.95 -34.03 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -1.143 . . . . 0.0 109.474 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.514 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -75.72 -20.66 58.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.777 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -86.37 -46.81 9.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.639 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.774 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.9 OUTLIER -64.59 -62.76 1.39 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.204 -0.935 . . . . 0.0 109.581 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.518 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.97 -47.44 40.14 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.514 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -57.41 -40.21 77.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -1.185 . . . . 0.0 109.587 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -74.55 -24.37 58.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.774 HG23 ' O ' ' A' ' 58' ' ' LEU . 51.2 t -81.9 -49.14 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.901 . . . . 0.0 109.641 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.8 HD21 HD11 ' A' ' 110' ' ' LEU . 2.5 mm? -48.15 -46.6 34.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.926 . . . . 0.0 109.751 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.8 -50.86 59.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.256 -0.902 . . . . 0.0 109.821 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 33.5 tp60 -48.75 -51.25 29.97 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.087 -1.008 . . . . 0.0 109.577 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.937 ' O ' HG23 ' A' ' 70' ' ' VAL . 96.7 mt -56.46 -30.97 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.223 -0.923 . . . . 0.0 109.043 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.565 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -68.66 -56.9 8.71 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.8 t -57.8 -20.71 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.247 -1.149 . . . . 0.0 109.243 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.02 -34.1 18.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.675 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.937 HG23 ' O ' ' A' ' 66' ' ' ILE . 55.1 t -60.84 -15.89 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.202 -0.936 . . . . 0.0 109.887 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.501 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 23.9 m -91.55 16.14 11.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.182 -0.949 . . . . 0.0 110.29 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.9 m-70 -160.95 40.82 0.16 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.926 -1.109 . . . . 0.0 110.37 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.871 HD11 HG11 ' A' ' 10' ' ' VAL . 22.7 mt . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.013 -1.055 . . . . 0.0 109.479 179.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.46 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 14.7 ttp . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.291 0.567 . . . . 0.0 109.694 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.45 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.5 t -70.39 -23.1 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.222 -0.924 . . . . 0.0 109.284 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.76 -37.03 73.37 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.214 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.443 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.0 OUTLIER -81.39 -49.12 11.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.264 179.681 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.564 ' CE ' HD12 ' A' ' 141' ' ' LEU . 3.1 mtp -59.47 -46.17 89.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.233 -0.917 . . . . 0.0 109.103 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.659 ' O ' HG23 ' A' ' 88' ' ' VAL . 3.8 tptp -53.49 -33.4 54.2 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 108.915 179.426 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.423 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -70.9 -33.43 70.55 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.401 -0.812 . . . . 0.0 109.248 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.723 ' CG1' HD11 ' A' ' 141' ' ' LEU . 44.4 t -62.66 -52.25 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 109.237 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -52.35 -42.55 56.71 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 84' ' ' LYS . 95.7 t -51.8 -26.6 7.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.346 -1.091 . . . . 0.0 109.231 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.444 ' HB2' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -80.91 -24.76 38.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.273 -0.892 . . . . 0.0 108.848 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.738 ' O ' HD12 ' A' ' 98' ' ' ILE . 41.4 m80 -82.1 -4.67 57.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.528 -0.732 . . . . 0.0 109.894 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HD2' ' HA ' ' A' ' 88' ' ' VAL . 8.9 ptmm? -81.8 -8.64 59.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.796 -1.19 . . . . 0.0 110.357 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -164.33 59.42 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.153 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.755 ' HD2' HD11 ' A' ' 98' ' ' ILE . 0.9 OUTLIER -84.21 -163.5 0.8 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.267 . . . . 0.0 109.25 179.021 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.9 -26.48 74.31 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 -179.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.004 ' ND2' HG13 ' A' ' 44' ' ' VAL . 18.7 p-10 -91.79 -32.88 15.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.258 . . . . 0.0 109.933 -179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.441 ' O ' ' CD2' ' A' ' 97' ' ' HIS . 0.0 OUTLIER 56.85 30.93 18.72 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.129 -0.982 . . . . 0.0 109.649 179.894 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.441 ' CD2' ' O ' ' A' ' 96' ' ' LYS . 38.2 m170 -137.44 47.44 2.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.159 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.755 HD11 ' HD2' ' A' ' 93' ' ' TYR . 59.7 mt -89.9 159.78 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.286 -0.884 . . . . 0.0 110.576 -179.172 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.494 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -152.27 142.17 22.08 Favored 'General case' 0 N--CA 1.487 1.424 0 CA-C-O 121.636 0.732 . . . . 0.0 109.684 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.749 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -78.98 -3.02 42.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.647 -0.658 . . . . 0.0 109.62 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -73.11 -33.19 65.42 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.975 -1.078 . . . . 0.0 109.488 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.564 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 85.9 m-85 -78.46 -15.58 58.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.244 -0.91 . . . . 0.0 110.125 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.635 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.6 m-85 -59.66 -63.4 1.31 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.163 -0.961 . . . . 0.0 110.248 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.484 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.4 mt-10 -45.49 -58.43 5.95 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.427 -0.796 . . . . 0.0 110.797 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.564 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.2 Cg_endo -59.99 -46.1 20.89 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.748 1.394 . . . . 0.0 109.923 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.919 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -67.11 -20.02 65.72 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 109.25 179.709 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -84.47 -47.38 5.45 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.55 -28.26 66.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -1.114 . . . . 0.0 109.354 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.89 -34.74 69.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.3 -0.875 . . . . 0.0 109.482 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.977 HD13 ' OH ' ' A' ' 134' ' ' TYR . 2.5 tt -65.38 -34.43 78.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.198 -0.938 . . . . 0.0 109.425 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.684 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.2 mt -58.51 -35.48 72.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.097 -1.002 . . . . 0.0 109.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.421 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 21.2 t -70.09 -26.31 63.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.429 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.502 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.93 -33.15 21.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.679 ' SD ' HD23 ' A' ' 110' ' ' LEU . 0.8 OUTLIER -53.87 -44.26 70.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.995 -179.675 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.452 ' O ' ' N ' ' A' ' 119' ' ' GLY . 8.1 pt-20 -51.77 -23.01 4.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.23 -0.919 . . . . 0.0 109.818 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.502 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 20.9 m170 -48.97 -41.44 34.17 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.165 -0.959 . . . . 0.0 109.71 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.3 ttt85 -83.48 -55.77 4.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.432 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.582 HG21 ' HB3' ' A' ' 16' ' ' ASP . 3.9 pt -106.64 59.23 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.302 -0.874 . . . . 0.0 109.558 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -67.48 -29.29 73.94 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.75 -18.2 56.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.1 mttt -105.04 -20.36 13.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.067 -1.255 . . . . 0.0 110.102 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.412 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -73.01 80.99 1.21 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.421 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.541 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.2 p30 -82.29 -162.17 0.53 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -0.853 . . . . 0.0 109.706 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.41 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -69.13 -43.13 74.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.469 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.541 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -60.76 -32.25 71.56 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.171 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -68.42 -53.03 26.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.462 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.473 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.3 ptpt -70.45 -29.03 65.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.193 -0.942 . . . . 0.0 109.379 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.473 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 24.2 t0 -80.42 -40.72 25.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.329 -0.857 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -61.66 -42.91 99.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.947 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.2 m0 -75.4 -34.24 61.04 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.3 -0.875 . . . . 0.0 108.846 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.43 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -55.85 -23.48 31.07 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.163 -0.961 . . . . 0.0 108.764 178.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -92.39 -46.28 7.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.43 -0.794 . . . . 0.0 109.308 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.34 -54.08 10.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.263 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.977 ' OH ' HD13 ' A' ' 110' ' ' LEU . 1.3 t80 -49.78 -30.46 9.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.215 179.608 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -74.61 -38.33 62.6 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.309 -0.869 . . . . 0.0 108.877 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.38 -31.69 48.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.399 -0.813 . . . . 0.0 109.27 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.73 HD13 HG23 ' A' ' 66' ' ' ILE . 54.9 mt -66.8 -60.53 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.258 -0.901 . . . . 0.0 108.909 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.421 ' O ' HG12 ' A' ' 142' ' ' ILE . 26.4 p -66.98 -18.09 65.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -0.795 . . . . 0.0 109.765 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -75.31 -45.81 17.79 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.13 -22.0 65.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.222 -1.163 . . . . 0.0 109.808 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.723 HD11 ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -77.87 -13.9 59.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 0.0 109.957 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.749 HD12 ' CB ' ' A' ' 100' ' ' ALA . 37.1 mm -79.68 -12.99 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.438 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 27.5 m -68.54 -64.67 0.82 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.103 -0.998 . . . . 0.0 109.733 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.56 -11.28 68.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.472 ' HB3' ' HA ' ' A' ' 142' ' ' ILE . 9.7 tt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.036 -1.273 . . . . 0.0 109.301 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.964 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.232 0.539 . . . . 0.0 109.73 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.665 ' O ' HG23 ' A' ' 10' ' ' VAL . 75.8 mt-30 -58.38 -55.74 31.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 109.661 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.825 ' HG2' HD12 ' A' ' 73' ' ' LEU . 3.0 ttp180 -49.11 -37.9 23.1 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.286 -0.884 . . . . 0.0 109.625 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -74.28 -40.59 62.21 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.381 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.964 HG23 ' O ' ' A' ' 5' ' ' ALA . 39.5 t -65.0 -24.85 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.89 . . . . 0.0 109.449 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 1.052 HG12 HG13 ' A' ' 70' ' ' VAL . 97.4 t -70.02 -34.72 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.236 -0.915 . . . . 0.0 109.559 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.09 -13.16 59.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -0.901 . . . . 0.0 109.913 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.74 -19.6 22.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.14 -0.975 . . . . 0.0 109.845 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.43 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.5 p -101.29 -14.83 17.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.126 -0.984 . . . . 0.0 109.956 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.717 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.03 -32.42 20.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.687 -179.776 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.2 mtpt -69.71 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.606 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.9 m-20 -99.24 -60.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.118 -0.989 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.918 HD12 ' CH2' ' A' ' 130' ' ' TRP . 66.3 mt -61.17 -41.15 88.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.262 -0.899 . . . . 0.0 109.538 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.681 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -96.34 31.67 2.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.293 -0.879 . . . . 0.0 109.511 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.48 -69.9 1.11 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.6 p -110.29 -32.66 6.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -1.163 . . . . 0.0 109.613 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.65 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 5.0 p-10 -74.93 -18.98 60.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.905 . . . . 0.0 109.638 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.681 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.6 t30 59.39 21.08 9.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 109.597 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.483 ' O ' HD13 ' A' ' 63' ' ' LEU . . . 97.89 34.68 5.36 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.65 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -85.36 -56.34 3.57 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.229 -1.16 . . . . 0.0 109.576 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -66.53 -14.74 62.87 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.777 HG12 HD11 ' A' ' 63' ' ' LEU . 37.8 t -89.18 -11.59 10.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -1.185 . . . . 0.0 109.942 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.506 ' CA ' ' CD1' ' A' ' 63' ' ' LEU . . . -100.06 -41.77 2.76 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.482 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -74.74 -22.15 58.96 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.119 -1.224 . . . . 0.0 110.003 -179.512 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.447 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 22.3 pt-20 -92.38 -21.96 19.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.116 -0.99 . . . . 0.0 109.701 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.4 t -87.18 -68.0 0.78 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.254 -0.903 . . . . 0.0 110.083 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.534 ' HZ ' HG11 ' A' ' 62' ' ' VAL . 29.2 m-85 -46.62 -33.43 4.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.292 -0.88 . . . . 0.0 110.246 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.666 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.79 -52.11 61.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.067 -1.02 . . . . 0.0 109.384 179.699 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -65.18 -46.03 82.45 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.281 -0.887 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.714 ' CG ' HD23 ' A' ' 106' ' ' LEU . 9.4 t80 -49.53 -49.43 46.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.228 -0.92 . . . . 0.0 109.544 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.764 ' CD1' HG22 ' A' ' 55' ' ' VAL . 14.1 mt -57.99 -46.75 84.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.491 ' O ' ' CD2' ' A' ' 39' ' ' HIS . 0.4 OUTLIER -64.56 -62.15 1.76 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.923 . . . . 0.0 109.525 179.907 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.631 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -53.48 -27.15 23.66 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.222 -0.924 . . . . 0.0 109.524 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.631 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 18.9 m-70 -120.49 97.27 5.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.491 ' CD2' ' O ' ' A' ' 36' ' ' SER . 64.4 m170 -83.08 4.15 27.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.016 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.6 p-10 -94.95 -13.4 25.38 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.081 -1.012 . . . . 0.0 109.942 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' VAL . 98.0 mmm -112.85 -19.25 12.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.086 -1.009 . . . . 0.0 109.966 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.46 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -47.64 -40.34 19.44 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.181 -0.949 . . . . 0.0 109.859 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.154 -0.966 . . . . 0.0 109.509 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.012 HG13 ' ND2' ' A' ' 95' ' ' ASN . 45.9 t -81.2 -34.64 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.557 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.522 ' HB3' ' CD2' ' A' ' 47' ' ' PHE . 24.0 m-85 -76.88 -11.66 59.85 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 110.124 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.4 25.47 25.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.522 ' CD2' ' HB3' ' A' ' 45' ' ' PHE . 14.0 m-85 -125.58 168.64 13.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.912 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.99 -17.39 14.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.416 -0.802 . . . . 0.0 109.202 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.98 -161.6 23.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.99 28.34 3.58 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.325 -1.103 . . . . 0.0 109.713 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 72.1 p -118.02 -16.36 9.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.257 -0.902 . . . . 0.0 109.795 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.1 p-10 -73.07 142.74 82.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.213 -0.93 . . . . 0.0 109.706 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -72.89 -17.38 25.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.976 1.514 . . . . 0.0 110.19 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.5 -38.54 35.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.764 HG22 ' CD1' ' A' ' 35' ' ' LEU . 63.2 t -51.09 -35.92 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.449 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -71.15 -7.15 44.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.27 -0.894 . . . . 0.0 109.691 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.76 -28.26 18.38 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.065 -1.022 . . . . 0.0 109.648 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.968 ' O ' HG23 ' A' ' 62' ' ' VAL . 11.5 mt -88.73 -63.74 1.25 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.071 -1.018 . . . . 0.0 109.681 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.521 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -50.29 -46.99 43.79 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.3 -24.46 19.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -1.156 . . . . 0.0 109.662 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.26 -23.79 12.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.717 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.968 HG23 ' O ' ' A' ' 58' ' ' LEU . 43.4 t -73.23 -56.72 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.983 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.777 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.22 -41.13 17.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.141 -0.974 . . . . 0.0 109.851 -179.927 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.98 -43.19 50.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.458 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 7.2 tp-100 -62.69 -41.5 99.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.083 -1.011 . . . . 0.0 109.195 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.909 ' O ' HG23 ' A' ' 70' ' ' VAL . 63.0 mt -57.95 -36.18 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.278 -0.889 . . . . 0.0 108.83 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.88 -59.63 8.86 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 108.689 -1.765 . . . . 0.0 108.689 179.294 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 74.3 t -54.35 -26.16 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.276 -1.132 . . . . 0.0 109.04 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.94 -28.88 25.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.41 -0.806 . . . . 0.0 109.594 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.052 HG13 HG12 ' A' ' 10' ' ' VAL . 52.5 t -68.8 -9.64 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.499 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 18.3 t -93.2 33.57 1.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.007 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.499 ' CG ' ' O ' ' A' ' 71' ' ' SER . 9.1 m-70 -160.25 -87.41 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.189 -0.944 . . . . 0.0 109.731 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.825 HD12 ' HG2' ' A' ' 7' ' ' ARG . 24.3 mt . . . . . 0 N--CA 1.496 1.859 0 O-C-N 121.482 -0.762 . . . . 0.0 110.037 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 64.4 ttp . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.228 0.537 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.404 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 98.0 t -60.1 -18.19 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.24 -0.912 . . . . 0.0 109.421 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -80.8 -21.28 41.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.295 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.42 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.0 OUTLIER -91.91 -47.39 7.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.544 179.864 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.498 ' HE1' HD12 ' A' ' 141' ' ' LEU . 99.2 mmm -62.15 -41.08 97.93 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.027 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.863 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.4 OUTLIER -52.98 -32.61 47.17 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.052 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.424 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -76.31 -33.25 59.03 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.077 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.558 HG12 HD11 ' A' ' 141' ' ' LEU . 71.3 t -65.05 -53.12 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.076 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.419 ' HA3' ' HB2' ' A' ' 145' ' ' LEU . . . -53.51 -39.84 60.93 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.863 HG23 ' O ' ' A' ' 84' ' ' LYS . 85.7 t -53.98 -28.34 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -1.113 . . . . 0.0 109.266 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.8 mmt180 -75.19 -48.9 21.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 0.0 108.959 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.605 ' O ' HD12 ' A' ' 98' ' ' ILE . 54.1 m80 -57.64 -22.37 45.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.306 -0.871 . . . . 0.0 108.912 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.4 -9.82 59.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.414 -0.804 . . . . 0.0 109.941 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.76 50.39 0.75 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.6 m-30 -92.1 -174.11 3.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -1.15 . . . . 0.0 109.512 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.89 -28.48 41.86 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.012 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -83.76 -46.17 12.54 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.579 -0.953 . . . . 0.0 108.923 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.6 mtpt 72.72 -49.96 0.7 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.56 -0.713 . . . . 0.0 110.76 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.3 m170 -66.46 63.14 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.01 -1.056 . . . . 0.0 110.596 -179.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.605 HD12 ' O ' ' A' ' 90' ' ' HIS . 96.7 mt -94.08 159.15 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.089 -1.007 . . . . 0.0 109.235 179.431 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.441 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -139.63 141.78 37.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.17 -0.956 . . . . 0.0 109.852 -179.929 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.86 8.24 18.12 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.855 . . . . 0.0 109.685 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -85.09 -29.9 24.5 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.151 -0.968 . . . . 0.0 108.697 179.784 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.443 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 93.5 m-85 -79.09 -17.01 55.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.32 -0.862 . . . . 0.0 109.636 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.796 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.0 m-85 -56.6 -60.14 3.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.23 -0.919 . . . . 0.0 110.169 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.499 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.4 mt-10 -52.82 -57.41 16.15 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.148 -0.97 . . . . 0.0 110.066 -179.453 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.499 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 34.7 Cg_exo -48.88 -58.88 1.49 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 O-C-N 123.626 1.329 . . . . 0.0 110.13 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.821 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.94 -28.89 54.64 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.388 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.26 -50.12 13.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.42 -37.49 87.72 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -1.128 . . . . 0.0 109.503 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 t -68.48 -35.25 77.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.326 -0.859 . . . . 0.0 109.576 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.937 HD22 ' OH ' ' A' ' 134' ' ' TYR . 3.8 tt -67.02 -31.57 72.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.398 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.911 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -61.43 -33.35 73.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.161 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.418 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 2.7 t -72.93 -26.77 61.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.398 179.68 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.494 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -85.46 -22.75 28.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.487 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.6 mtt -65.0 -36.43 84.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.351 -0.843 . . . . 0.0 109.882 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' N ' ' A' ' 119' ' ' GLY . 12.5 pt-20 -58.53 -18.47 29.73 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.464 179.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.494 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 28.4 m170 -56.04 -36.12 67.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.223 -0.923 . . . . 0.0 109.483 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HD2' HG23 ' A' ' 118' ' ' ILE . 0.1 OUTLIER -89.72 -42.37 11.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.309 -0.87 . . . . 0.0 109.362 179.778 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.478 HG12 HD11 ' A' ' 17' ' ' ILE . 3.1 pt -119.03 57.01 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.865 . . . . 0.0 109.473 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -64.57 -18.67 63.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.31 -28.53 8.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.462 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.8 mttt -94.44 -17.51 22.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.184 -1.186 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.455 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -76.54 86.2 3.24 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.109 -0.995 . . . . 0.0 109.371 179.762 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.517 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 8.9 p30 -93.61 -163.2 1.02 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.845 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.456 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -68.44 -44.57 74.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -0.856 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.517 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -61.54 -26.06 67.69 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.112 -0.992 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.99 -52.57 8.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.314 -0.866 . . . . 0.0 109.792 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.456 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 9.7 ptmm? -71.74 -25.69 62.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.215 -0.928 . . . . 0.0 109.906 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -84.32 -36.32 22.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.112 -0.992 . . . . 0.0 109.745 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.95 -43.18 72.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.361 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.918 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.5 m0 -71.41 -36.72 71.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.281 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.425 ' N ' HD11 ' A' ' 111' ' ' LEU . . . -60.97 -33.9 73.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.119 179.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.66 -30.78 36.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.32 -0.862 . . . . 0.0 109.277 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.528 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -81.13 -40.19 24.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.354 -0.841 . . . . 0.0 109.288 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.937 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.8 OUTLIER -50.26 -34.75 24.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.264 179.642 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.38 -28.26 62.9 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.083 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -83.43 -39.25 20.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.381 -0.824 . . . . 0.0 109.337 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.528 HD12 ' C ' ' A' ' 133' ' ' ALA . 4.6 mt -65.95 -58.25 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.149 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -68.66 -19.7 64.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.403 -0.81 . . . . 0.0 109.63 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -65.96 -57.73 10.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.33 -26.36 3.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 0.0 109.756 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.859 ' O ' HD23 ' A' ' 141' ' ' LEU . 7.5 tt -74.41 -12.47 60.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.97 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.669 ' O ' HG22 ' A' ' 142' ' ' ILE . 75.6 mt -91.37 21.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.089 -1.007 . . . . 0.0 109.763 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.4 t -105.82 -32.87 8.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.167 -0.958 . . . . 0.0 109.691 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -121.46 16.39 9.1 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.541 HD12 ' HB2' ' A' ' 90' ' ' HIS . 4.5 tt . . . . . 0 N--CA 1.491 1.584 0 O-C-N 121.109 -1.23 . . . . 0.0 110.126 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.653 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.231 0.539 . . . . 0.0 109.547 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.602 ' O ' HG23 ' A' ' 10' ' ' VAL . 82.9 mt-30 -60.14 -44.25 95.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.472 ' CG ' ' HB3' ' A' ' 73' ' ' LEU . 5.6 ttp180 -57.17 -29.27 63.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.506 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -82.89 -34.26 26.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.829 . . . . 0.0 109.45 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.653 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.8 t -67.62 -19.57 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.177 -0.952 . . . . 0.0 109.589 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.703 HG12 HG13 ' A' ' 70' ' ' VAL . 93.0 t -73.82 -47.1 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -0.947 . . . . 0.0 109.627 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.26 -13.98 62.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.935 . . . . 0.0 109.841 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.63 -21.65 20.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.184 -0.948 . . . . 0.0 109.9 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -97.67 -12.76 22.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.141 -0.974 . . . . 0.0 110.023 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.03 -28.06 17.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.037 -1.039 . . . . 0.0 109.726 -179.884 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -73.26 -10.92 60.26 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.852 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -104.06 -46.71 4.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.108 -0.995 . . . . 0.0 109.62 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.958 HD12 ' CH2' ' A' ' 130' ' ' TRP . 40.5 mt -70.23 -39.58 77.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.276 -0.89 . . . . 0.0 109.685 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.899 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.1 34.42 2.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.552 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.51 -65.47 3.53 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 26.6 p -111.96 -33.67 6.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.236 -1.155 . . . . 0.0 109.714 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.512 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.7 p-10 -76.63 -18.3 58.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.739 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.899 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 4.3 t30 57.77 20.47 6.51 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.6 21.52 19.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.512 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.02 -54.3 23.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.299 -1.118 . . . . 0.0 109.566 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.471 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.48 2.02 74.22 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.515 HG21 ' CG2' ' A' ' 17' ' ' ILE . 36.9 t -91.94 -40.31 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.053 -1.263 . . . . 0.0 109.529 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.44 -50.54 5.67 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.658 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.473 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 6.4 ptpt -52.7 -30.29 31.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.148 -1.207 . . . . 0.0 109.784 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.473 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.5 pt-20 -91.96 -22.7 19.87 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 109.847 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.4 t -83.14 -65.4 1.01 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.183 -0.948 . . . . 0.0 109.989 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.504 ' O ' HD12 ' A' ' 35' ' ' LEU . 11.3 m-85 -48.46 -29.32 3.98 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 110.024 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.803 ' OG1' HG11 ' A' ' 55' ' ' VAL . 19.5 m -62.98 -60.95 2.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 109.649 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -50.02 -38.02 35.6 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.583 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CD2' HD23 ' A' ' 106' ' ' LEU . 13.2 t80 -69.09 -54.91 12.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.552 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.808 HD13 HG22 ' A' ' 55' ' ' VAL . 12.4 mt -50.57 -44.11 56.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.625 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.671 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 18.9 p -65.73 -51.45 59.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.234 -0.916 . . . . 0.0 109.719 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.567 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -67.32 -19.42 65.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.239 -0.913 . . . . 0.0 109.755 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.567 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 27.8 m-70 -124.51 101.33 7.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.955 . . . . 0.0 109.721 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -86.35 3.53 43.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 110.04 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -93.39 -20.37 20.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.032 -1.043 . . . . 0.0 109.534 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.484 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 88.1 mmm -104.68 -23.29 13.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.703 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.456 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.26 -34.14 14.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.096 -1.003 . . . . 0.0 109.614 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.12 -22.48 48.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.35 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.928 HG13 ' ND2' ' A' ' 95' ' ' ASN . 46.8 t -74.35 -58.3 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -0.868 . . . . 0.0 109.49 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.649 ' CD2' HD21 ' A' ' 35' ' ' LEU . 68.1 m-85 -52.47 -31.21 33.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.567 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.62 2.89 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.542 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.02 166.96 14.84 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.304 -1.115 . . . . 0.0 109.761 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.0 t -105.36 -21.07 13.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.39 -0.819 . . . . 0.0 109.114 179.308 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -169.43 -163.63 23.79 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.671 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -93.29 29.01 2.02 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.196 -1.179 . . . . 0.0 109.615 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.53 27.78 6.42 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.603 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.625 ' OD2' HG23 ' A' ' 55' ' ' VAL . 7.9 p-10 -116.52 141.09 27.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.88 . . . . 0.0 109.708 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -67.41 -22.58 45.24 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 124.01 1.531 . . . . 0.0 110.135 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.83 -38.58 37.67 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.808 HG22 HD13 ' A' ' 35' ' ' LEU . 88.4 t -50.8 -39.7 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -1.092 . . . . 0.0 109.428 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.439 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.02 -20.53 61.68 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.306 -0.871 . . . . 0.0 109.256 179.572 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -74.3 -37.29 63.69 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.48 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.895 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -85.42 -56.16 3.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -0.95 . . . . 0.0 109.555 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -48.52 -49.07 27.54 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.41 -39.41 87.29 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -1.174 . . . . 0.0 109.74 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.3 mttt -77.83 -30.26 51.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.274 -0.891 . . . . 0.0 109.646 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.6 t -76.19 -51.86 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.593 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.456 HD13 HD12 ' A' ' 66' ' ' ILE . 2.1 mm? -48.93 -47.29 43.68 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.66 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.485 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -49.16 -42.95 41.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.455 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 7.4 tp-100 -58.33 -43.66 88.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 109.384 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.871 ' O ' HG23 ' A' ' 70' ' ' VAL . 40.7 mt -59.58 -38.7 76.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.264 -0.898 . . . . 0.0 109.033 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.556 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.44 -53.43 28.76 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.279 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.517 HG11 ' OE2' ' A' ' 82' ' ' GLU . 51.8 t -54.06 -31.16 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.317 -1.108 . . . . 0.0 108.962 179.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.407 ' O ' ' CD2' ' A' ' 73' ' ' LEU . . . -82.35 -31.46 29.79 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.385 -0.822 . . . . 0.0 109.27 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.871 HG23 ' O ' ' A' ' 66' ' ' ILE . 52.1 t -69.96 -15.3 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.332 -0.855 . . . . 0.0 109.629 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.6 m -85.21 10.86 11.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.039 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -126.27 -72.96 0.63 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.07 -1.019 . . . . 0.0 109.685 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.495 ' N ' ' CD2' ' A' ' 73' ' ' LEU . 3.7 mm? . . . . . 0 N--CA 1.493 1.683 0 O-C-N 121.848 -0.533 . . . . 0.0 110.642 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 ttp . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 121.209 0.528 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.429 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 99.0 t -62.9 -22.72 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.284 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -77.43 -21.04 53.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.291 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.517 ' OE2' HG11 ' A' ' 68' ' ' VAL . 27.0 tt0 -90.06 -49.18 6.73 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.331 -0.856 . . . . 0.0 109.529 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.602 ' HE1' HD12 ' A' ' 141' ' ' LEU . 93.6 mmm -60.9 -40.28 92.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.125 -0.985 . . . . 0.0 109.008 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.744 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.3 OUTLIER -53.04 -31.22 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.243 -0.911 . . . . 0.0 108.556 179.175 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.418 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -75.79 -31.36 59.44 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.201 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.594 HG12 HD11 ' A' ' 141' ' ' LEU . 53.9 t -65.37 -50.33 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.096 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.559 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -54.43 -41.95 73.75 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.744 HG23 ' O ' ' A' ' 84' ' ' LYS . 88.2 t -51.36 -25.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.333 -1.098 . . . . 0.0 109.021 179.415 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.452 ' HB3' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -78.35 -33.33 49.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.364 -0.835 . . . . 0.0 108.904 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.651 ' HB2' HD12 ' A' ' 145' ' ' LEU . 30.9 m80 -80.86 4.7 18.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.398 -0.813 . . . . 0.0 109.611 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.433 ' O ' ' HG2' ' A' ' 91' ' ' LYS . 5.8 ttpp -88.63 -10.24 49.3 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.096 -1.003 . . . . 0.0 110.137 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -160.42 43.95 0.42 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.014 -1.565 . . . . 0.0 111.045 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.542 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.6 m-85 -75.17 -165.18 0.37 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.68 -1.483 . . . . 0.0 109.195 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.3 -36.75 55.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.42 -1.872 . . . . 0.0 108.42 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.928 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.7 t30 -72.16 -58.51 3.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.574 -0.956 . . . . 0.0 109.07 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.485 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 1.9 tttp 76.5 -15.67 0.7 Allowed 'General case' 0 N--CA 1.506 2.358 0 O-C-N 121.637 -0.664 . . . . 0.0 111.391 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.435 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 65.9 m170 -98.73 44.01 1.04 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.598 -1.314 . . . . 0.0 109.119 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.527 HD12 ' O ' ' A' ' 90' ' ' HIS . 71.6 mt -75.22 159.04 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.331 -0.856 . . . . 0.0 109.878 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.451 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -142.49 141.98 32.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.377 -0.827 . . . . 0.0 109.948 -179.971 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.36 2.15 26.02 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.468 -0.77 . . . . 0.0 109.565 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mt-10 -77.61 -34.53 53.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 109.55 179.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.484 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 61.6 m-85 -80.42 -0.05 35.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.37 -0.831 . . . . 0.0 110.361 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.458 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.0 m-85 -70.48 -55.37 9.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.012 -1.055 . . . . 0.0 109.75 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.486 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.2 tt0 -59.61 -52.11 76.31 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.185 -0.947 . . . . 0.0 109.746 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.486 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.3 Cg_exo -54.32 -56.13 2.78 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 123.819 1.431 . . . . 0.0 109.843 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.734 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -55.31 -31.12 61.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' O ' ' CB ' ' A' ' 110' ' ' LEU . . . -76.06 -48.09 10.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.59 10.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.263 -1.139 . . . . 0.0 109.421 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.9 t -55.19 -21.51 14.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.271 -0.893 . . . . 0.0 109.298 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.45 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.0 OUTLIER -69.27 -48.84 60.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.329 -0.857 . . . . 0.0 109.532 179.88 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.631 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.5 mt -55.04 -34.66 63.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.098 -1.001 . . . . 0.0 109.159 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.15 -31.67 70.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.324 179.657 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.497 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -81.43 -38.41 26.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.409 179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.468 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.5 mmt -50.38 -45.03 55.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.234 -0.916 . . . . 0.0 109.518 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -49.66 -24.71 2.37 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.888 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.497 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 18.8 m170 -58.49 -50.87 72.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.958 . . . . 0.0 109.495 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.479 ' HD2' HG23 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.56 -52.43 38.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.474 179.898 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 6.1 pt -116.64 65.37 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.25 -0.906 . . . . 0.0 109.707 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -66.48 -10.4 53.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -106.28 -39.55 2.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.507 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 8.7 mmmt -82.24 -25.75 33.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.029 -1.277 . . . . 0.0 109.97 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.437 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.55 84.17 0.1 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.997 -1.065 . . . . 0.0 109.164 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.813 HD21 ' HB3' ' A' ' 125' ' ' ALA . 18.7 p-10 -88.15 -171.46 3.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.373 -0.829 . . . . 0.0 109.792 -179.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.419 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -61.05 -45.2 95.75 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.276 -0.89 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.813 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -60.95 -30.13 70.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.382 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.99 -49.15 54.45 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.921 . . . . 0.0 109.475 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.521 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.7 OUTLIER -72.41 -30.67 64.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 109.558 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 25.5 t0 -78.88 -35.15 44.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.241 -0.912 . . . . 0.0 109.279 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.442 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -66.59 -47.37 72.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.322 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.958 ' CH2' HD12 ' A' ' 17' ' ' ILE . 13.9 m0 -72.56 -27.38 62.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.163 -0.96 . . . . 0.0 108.716 179.538 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -63.75 -15.12 57.79 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.349 -0.845 . . . . 0.0 108.957 178.743 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -110.98 -29.26 7.98 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.163 -0.96 . . . . 0.0 109.095 179.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.492 ' O ' HD12 ' A' ' 137' ' ' ILE . . . -83.19 -45.46 13.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.436 -0.79 . . . . 0.0 109.559 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.548 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -58.52 -18.58 30.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 109.25 179.914 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.548 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -84.35 -33.13 23.92 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.222 -0.924 . . . . 0.0 108.512 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.58 -36.42 38.19 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.492 HD12 ' O ' ' A' ' 133' ' ' ALA . 4.1 mt -64.56 -61.44 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.443 ' OG ' ' CD2' ' A' ' 103' ' ' PHE . 4.0 t -66.5 -22.4 66.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.583 -0.698 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.96 -52.99 25.23 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.16 -24.61 4.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -1.186 . . . . 0.0 109.436 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.715 ' O ' HD23 ' A' ' 141' ' ' LEU . 5.8 tt -74.25 -22.62 59.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.648 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.492 ' O ' HG22 ' A' ' 142' ' ' ILE . 69.4 mt -81.81 6.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.177 -0.952 . . . . 0.0 110.193 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.2 t -95.46 -36.13 11.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.005 -1.059 . . . . 0.0 109.71 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.15 14.29 28.48 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.651 HD12 ' HB2' ' A' ' 90' ' ' HIS . 4.6 tt . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.061 -1.258 . . . . 0.0 110.055 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.73 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.262 0.553 . . . . 0.0 109.587 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -62.37 -57.71 10.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 110.127 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -28.22 5.35 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.011 -1.055 . . . . 0.0 109.6 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.7 tp60 -78.6 -39.83 36.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.423 -0.798 . . . . 0.0 108.924 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 5' ' ' ALA . 90.0 t -66.7 -33.67 64.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.043 179.336 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.919 HG12 HG13 ' A' ' 70' ' ' VAL . 84.0 t -69.31 -47.51 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.432 -0.793 . . . . 0.0 109.372 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.62 -13.92 62.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.306 -0.871 . . . . 0.0 109.754 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.5 t -90.73 -26.09 19.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.144 -0.972 . . . . 0.0 109.791 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.4 p -97.29 -10.24 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 110.031 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.653 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -92.48 -19.52 21.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.03 -1.044 . . . . 0.0 109.839 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.3 mtpp -81.94 -11.8 58.7 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.915 . . . . 0.0 109.748 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.403 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -103.49 -55.63 2.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.656 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.973 HD12 ' CH2' ' A' ' 130' ' ' TRP . 61.0 mt -64.36 -36.64 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.609 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.82 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -101.85 33.7 2.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.626 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.4 -85.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.8 p -97.96 -23.94 15.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.301 -1.117 . . . . 0.0 109.678 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.689 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 11.6 p-10 -82.34 -19.88 38.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.655 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.82 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 18.5 t30 56.38 25.12 9.15 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.262 -0.899 . . . . 0.0 109.621 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.45 24.94 12.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.689 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -69.91 -52.55 23.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -1.143 . . . . 0.0 109.648 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.03 -12.98 83.08 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.553 HG21 ' CG2' ' A' ' 17' ' ' ILE . 30.7 t -82.03 -36.05 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.129 -1.218 . . . . 0.0 109.873 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.442 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -78.05 -41.32 18.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.477 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 17.4 ptpt -66.1 -29.55 69.89 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.137 -1.214 . . . . 0.0 110.125 -179.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.717 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 22.5 pt-20 -92.5 -20.98 20.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.176 -0.952 . . . . 0.0 109.881 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.1 t -82.8 -60.14 2.27 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.522 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 21.0 m-85 -57.5 -32.27 66.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.888 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.691 HG23 HG11 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -52.3 -53.66 41.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.178 -0.951 . . . . 0.0 109.392 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -59.69 -50.59 73.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.309 -0.869 . . . . 0.0 109.562 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.72 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.5 t80 -50.63 -47.26 58.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.738 ' CD1' HG22 ' A' ' 55' ' ' VAL . 17.6 mt -61.14 -45.37 94.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.509 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 29.8 p -67.38 -55.15 14.94 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.224 -0.922 . . . . 0.0 109.817 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.628 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -61.28 -26.53 67.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.189 -0.945 . . . . 0.0 109.708 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.628 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 21.9 m-70 -124.49 110.55 14.63 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.224 -0.922 . . . . 0.0 109.881 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -89.47 -8.87 51.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.472 -0.767 . . . . 0.0 109.697 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -81.94 -16.37 50.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.066 -1.021 . . . . 0.0 109.568 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.55 ' HE3' ' CG ' ' A' ' 102' ' ' TYR . 3.9 mmt -104.65 -17.12 14.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.19 -0.944 . . . . 0.0 109.789 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.441 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -54.12 -51.87 62.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.047 -1.033 . . . . 0.0 109.267 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.7 -27.44 68.34 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 109.227 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.963 HG13 ' ND2' ' A' ' 95' ' ' ASN . 9.1 t -69.54 -55.45 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.354 -0.841 . . . . 0.0 109.04 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.524 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 33.5 m-85 -57.44 -28.77 63.62 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.286 -0.884 . . . . 0.0 109.58 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.65 29.62 4.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 12.6 m-85 -126.06 172.24 10.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.75 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.8 t -115.83 19.68 15.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.339 -0.85 . . . . 0.0 109.289 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.92 -164.18 28.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.509 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -92.96 26.32 2.84 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.171 -1.194 . . . . 0.0 109.648 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 26.6 m -121.52 28.59 7.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.626 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.14 135.41 23.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.252 -0.905 . . . . 0.0 109.569 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.2 -21.0 55.78 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.916 1.482 . . . . 0.0 110.061 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.512 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.52 -36.36 47.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.738 HG22 ' CD1' ' A' ' 35' ' ' LEU . 59.8 t -53.45 -42.22 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.266 -1.137 . . . . 0.0 109.456 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.432 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -67.86 -21.15 65.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.407 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.12 -37.25 29.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.289 -0.882 . . . . 0.0 109.524 179.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.739 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.7 mt -75.81 -61.56 1.88 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.522 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.72 -50.66 30.87 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.432 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.12 -37.27 64.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.278 -1.13 . . . . 0.0 109.493 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 25.2 mttt -80.24 -26.38 39.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.508 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 58' ' ' LEU . 59.9 t -82.17 -49.06 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.188 -0.945 . . . . 0.0 109.556 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 63' ' ' LEU . 2.2 mm? -47.83 -46.8 31.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.25 -0.906 . . . . 0.0 109.657 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.64 -52.32 31.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.925 . . . . 0.0 109.85 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.446 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 6.3 tp-100 -50.89 -45.92 60.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.053 -1.03 . . . . 0.0 109.346 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.935 ' O ' HG23 ' A' ' 70' ' ' VAL . 42.1 mt -57.53 -39.06 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.298 -0.876 . . . . 0.0 109.097 179.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.556 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.99 -54.19 32.21 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.6 t -56.8 -29.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -1.113 . . . . 0.0 109.466 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.424 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -83.26 -31.31 27.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.345 -0.847 . . . . 0.0 109.659 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.935 HG23 ' O ' ' A' ' 66' ' ' ILE . 51.5 t -61.57 -18.03 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.21 -0.931 . . . . 0.0 109.672 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.436 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -89.33 -1.29 58.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.163 -0.96 . . . . 0.0 110.131 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.464 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 18.9 m-70 -135.84 52.47 1.99 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.989 -1.069 . . . . 0.0 109.954 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.422 HD11 ' HA ' ' A' ' 70' ' ' VAL . 34.9 mt . . . . . 0 N--CA 1.492 1.648 0 O-C-N 121.123 -0.986 . . . . 0.0 109.442 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.464 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 52.6 ttp . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.472 ' O ' HG12 ' A' ' 80' ' ' VAL . 95.8 t -76.97 -0.65 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 110.012 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.76 -31.12 26.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.04 -1.038 . . . . 0.0 109.366 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.495 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 3.1 tp10 -94.74 -44.59 7.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.416 ' HG2' ' OE1' ' A' ' 65' ' ' GLN . 3.4 mtp -55.12 -50.03 70.27 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.228 -0.92 . . . . 0.0 109.35 179.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.478 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.3 mtpt -50.38 -40.71 50.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.151 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.495 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -57.66 -34.14 69.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.372 -0.83 . . . . 0.0 109.274 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.412 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 4.0 t -68.0 -35.13 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.139 -0.976 . . . . 0.0 109.024 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.594 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -64.16 -49.45 66.55 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.735 -1.746 . . . . 0.0 108.735 179.611 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.465 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 83.9 t -55.94 -19.7 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.371 -1.076 . . . . 0.0 109.575 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.523 ' HD3' ' N ' ' A' ' 89' ' ' ARG . 0.0 OUTLIER -84.67 -45.15 12.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.802 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.599 ' CD2' HD13 ' A' ' 98' ' ' ILE . 3.7 m80 -64.12 -10.52 23.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.44 -0.788 . . . . 0.0 110.637 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.465 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -82.25 7.4 13.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.83 -1.169 . . . . 0.0 110.335 -179.817 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.93 51.96 0.31 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.517 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.3 m-30 -91.85 -168.61 2.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -1.156 . . . . 0.0 109.912 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -63.5 -19.75 62.77 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.963 ' ND2' HG13 ' A' ' 44' ' ' VAL . 10.3 p-10 -105.06 -26.05 12.28 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.056 -1.261 . . . . 0.0 110.062 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.6 mttt 49.49 29.86 3.13 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.141 -0.974 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.5 m170 -137.34 29.43 2.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.297 -0.877 . . . . 0.0 109.693 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.599 HD13 ' CD2' ' A' ' 90' ' ' HIS . 35.6 mt -72.51 158.99 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.181 -0.949 . . . . 0.0 109.684 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.64 174.06 10.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.817 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.551 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -100.88 -19.17 16.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.532 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -68.21 -20.61 64.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.224 -0.922 . . . . 0.0 109.563 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.55 ' CG ' ' HE3' ' A' ' 41' ' ' MET . 46.7 m-85 -80.17 -22.06 42.37 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.201 -0.937 . . . . 0.0 109.675 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.712 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -58.99 -62.59 1.77 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.328 -0.858 . . . . 0.0 110.244 -179.295 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.1 mt-10 -45.06 -58.69 5.22 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.848 . . . . 0.0 110.867 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.539 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.6 Cg_endo -56.49 -47.95 21.41 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.665 1.35 . . . . 0.0 110.213 -179.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.952 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -65.78 -20.54 66.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.165 -0.959 . . . . 0.0 109.459 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.64 -42.78 9.71 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.18 -49.33 74.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -1.212 . . . . 0.0 109.538 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.68 -18.16 52.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.649 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.794 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.7 OUTLIER -73.86 -35.29 64.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.929 . . . . 0.0 109.76 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.768 HD21 ' HB3' ' A' ' 130' ' ' TRP . 14.3 mt -68.36 -32.49 72.61 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.673 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 m -71.66 -22.4 61.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.717 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -87.13 -39.29 15.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.794 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.6 mtt -56.41 -36.33 68.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.323 -0.86 . . . . 0.0 109.863 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.456 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -54.37 -21.25 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.168 -0.957 . . . . 0.0 109.533 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 17.6 m170 -65.27 -23.75 67.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 109.905 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.507 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 4.5 ttt85 -94.07 -69.6 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.101 -0.999 . . . . 0.0 109.861 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.558 HG23 HG12 ' A' ' 17' ' ' ILE . 16.5 pt -78.28 -32.9 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.205 -0.934 . . . . 0.0 109.61 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.465 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.09 -97.23 0.01 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -46.64 -45.11 17.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.494 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 2.8 mptt -69.67 -11.61 60.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.456 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -84.33 79.79 9.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.087 -1.008 . . . . 0.0 109.383 179.556 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.579 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.4 p30 -80.52 -165.81 0.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.606 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.424 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -69.68 -44.56 70.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.92 . . . . 0.0 109.441 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.579 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -57.67 -36.6 72.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.191 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -61.05 -53.53 55.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.303 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.615 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 14.8 ptpt -70.48 -29.66 66.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.323 -0.861 . . . . 0.0 109.427 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.7 t70 -74.48 -50.34 18.68 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.324 -0.86 . . . . 0.0 109.34 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.589 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -59.67 -43.34 94.03 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.256 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.973 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.9 m0 -73.99 -23.1 59.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.267 -0.896 . . . . 0.0 109.022 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.615 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.48 -26.82 65.67 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.301 -0.874 . . . . 0.0 108.662 178.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.54 -24.16 17.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.449 -0.782 . . . . 0.0 109.1 179.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.607 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -70.58 -59.52 2.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.6 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.531 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 12.1 m-85 -51.76 -27.91 13.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.16 -0.963 . . . . 0.0 109.271 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.92 -53.37 32.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.122 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -70.26 -35.77 74.0 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.22 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.607 HD12 ' C ' ' A' ' 133' ' ' ALA . 29.1 mt -68.85 -57.23 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.351 -0.843 . . . . 0.0 109.469 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.2 p -68.91 -27.91 66.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.771 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -68.37 -47.6 56.79 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -56.61 -30.06 62.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.207 -1.172 . . . . 0.0 109.715 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.712 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.2 tt -68.72 -18.77 64.3 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.729 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.551 HD12 ' CB ' ' A' ' 100' ' ' ALA . 39.5 mm -76.47 -3.81 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 0.0 110.043 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.478 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 3.1 m -81.95 -49.01 10.77 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.445 179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.454 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -83.94 -8.36 84.24 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.594 HD12 ' HA2' ' A' ' 87' ' ' GLY . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.07 -1.253 . . . . 0.0 109.14 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.834 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.598 ' O ' HG23 ' A' ' 10' ' ' VAL . 83.9 mt-30 -71.34 -49.21 44.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.292 -0.88 . . . . 0.0 109.669 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -48.64 -31.14 6.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.224 -0.923 . . . . 0.0 109.769 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 42.4 mm-40 -80.87 -49.14 11.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.907 . . . . 0.0 109.648 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.834 HG23 ' O ' ' A' ' 5' ' ' ALA . 36.9 t -53.91 -26.82 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.184 -0.948 . . . . 0.0 109.507 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.911 HG12 HG13 ' A' ' 70' ' ' VAL . 99.0 t -68.41 -54.65 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.519 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.74 -16.09 62.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.816 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 t -86.79 -27.33 23.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.184 -0.947 . . . . 0.0 109.78 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 p -93.79 -12.54 28.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.886 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.644 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.37 -28.53 17.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.088 -1.007 . . . . 0.0 109.684 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -70.83 -13.79 62.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -0.891 . . . . 0.0 109.788 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -101.68 -53.74 2.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.984 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.954 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.2 mt -63.77 -36.61 77.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.262 -0.899 . . . . 0.0 109.603 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.899 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.13 25.65 8.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.311 -0.868 . . . . 0.0 109.728 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.23 -80.41 0.14 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.9 p -98.21 55.15 1.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -1.129 . . . . 0.0 109.563 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.42 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 7.3 p-10 -177.18 -33.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.356 -0.84 . . . . 0.0 109.915 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.899 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 20.6 t30 63.72 37.79 9.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.483 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 78.47 29.06 54.1 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.42 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -75.97 -52.17 10.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.665 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.475 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.75 -22.99 68.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.829 HG12 HD11 ' A' ' 63' ' ' LEU . 48.5 t -67.54 -19.79 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.307 -1.113 . . . . 0.0 109.757 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -91.9 -46.81 3.55 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.475 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.2 ptpt -63.38 -20.81 65.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.153 -1.204 . . . . 0.0 109.787 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.426 ' O ' ' HD2' ' A' ' 33' ' ' LYS . 11.0 pt-20 -99.11 -26.53 14.18 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.4 t -85.09 -51.84 6.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.261 -0.899 . . . . 0.0 109.636 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.635 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.1 m-85 -60.08 -46.04 90.91 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.241 -0.912 . . . . 0.0 109.937 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.638 ' OG1' HG11 ' A' ' 55' ' ' VAL . 53.1 m -49.63 -35.78 22.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.144 -0.972 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.426 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 1.4 mttm -75.79 -43.77 44.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.4 179.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.897 ' CG ' HD23 ' A' ' 106' ' ' LEU . 6.6 t80 -60.99 -53.19 60.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.294 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.942 ' CD1' HG22 ' A' ' 55' ' ' VAL . 31.1 mt -57.02 -42.35 80.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.875 . . . . 0.0 109.617 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 43.4 t -65.58 -59.29 4.11 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -0.935 . . . . 0.0 109.582 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.646 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -62.8 -26.47 68.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.189 -0.944 . . . . 0.0 109.631 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.646 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 17.2 m-70 -120.94 108.5 13.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.74 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -88.66 -21.31 24.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.42 -0.8 . . . . 0.0 109.306 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -68.11 -13.51 62.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.548 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.553 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -104.6 -16.55 14.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.921 -179.814 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.483 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -53.13 -66.26 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.066 -1.021 . . . . 0.0 109.634 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.84 -21.89 44.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.606 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.069 HG13 ' ND2' ' A' ' 95' ' ' ASN . 31.8 t -76.76 -37.16 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.533 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.2 m-85 -76.77 -27.21 55.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.93 . . . . 0.0 109.497 -179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.97 27.2 4.37 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.533 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -123.66 173.33 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -1.147 . . . . 0.0 109.909 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.2 t -109.37 -15.93 14.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.432 -0.792 . . . . 0.0 109.199 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.64 -164.57 29.03 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.26 32.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -1.193 . . . . 0.0 109.617 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 25.8 t -134.89 26.68 3.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.289 -0.882 . . . . 0.0 109.618 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.622 ' OD2' HG23 ' A' ' 55' ' ' VAL . 5.2 p-10 -104.39 150.12 38.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.213 -0.929 . . . . 0.0 109.715 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -74.99 -1.93 11.87 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.042 1.549 . . . . 0.0 110.439 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -77.48 -35.58 36.51 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.942 HG22 ' CD1' ' A' ' 35' ' ' LEU . 77.3 t -51.36 -44.34 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -1.116 . . . . 0.0 109.538 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -71.86 -7.22 47.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -0.855 . . . . 0.0 109.938 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.36 -30.0 14.72 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.687 ' O ' HG23 ' A' ' 62' ' ' VAL . 3.9 mt -84.66 -61.44 1.79 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 109.702 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -51.51 -30.57 27.06 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.469 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -63.51 -52.8 59.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.152 -1.204 . . . . 0.0 109.704 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.601 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 5.5 mttp -73.41 -41.75 62.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.687 HG23 ' O ' ' A' ' 58' ' ' LEU . 87.1 t -50.95 -63.67 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.818 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.829 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -46.84 -40.66 14.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.214 -0.929 . . . . 0.0 109.887 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.601 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.58 -38.69 55.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -0.94 . . . . 0.0 109.422 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.408 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 17.5 tp60 -65.08 -39.87 93.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.313 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.954 ' O ' HG23 ' A' ' 70' ' ' VAL . 67.5 mt -62.46 -34.98 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.074 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.563 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.73 29.84 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.5 t -59.9 -24.24 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -1.119 . . . . 0.0 109.165 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.94 -24.49 26.54 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.443 -0.786 . . . . 0.0 109.425 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.954 HG23 ' O ' ' A' ' 66' ' ' ILE . 52.0 t -68.02 -17.23 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.232 -0.918 . . . . 0.0 109.609 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.504 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.8 OUTLIER -89.65 41.62 1.05 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.146 -0.971 . . . . 0.0 109.703 179.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.504 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.1 m-70 -161.26 -73.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.588 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.513 ' N ' ' CD2' ' A' ' 73' ' ' LEU . 2.4 mm? . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.68 -0.638 . . . . 0.0 110.448 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.401 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 58.1 ttp . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.273 0.558 . . . . 0.0 109.549 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.607 HG12 ' HB2' ' A' ' 84' ' ' LYS . 47.5 t -74.53 -22.46 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.201 -0.937 . . . . 0.0 109.519 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.52 -58.44 6.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.698 ' O ' HG23 ' A' ' 86' ' ' VAL . 31.4 mt-10 -74.84 -44.11 50.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.473 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 0.6 OUTLIER -57.84 -57.58 12.15 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.607 ' HB2' HG12 ' A' ' 80' ' ' VAL . 34.5 tttt -51.49 -32.07 26.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.203 179.722 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.479 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -68.94 -43.99 73.96 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 109.311 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.698 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.4 t -54.89 -40.29 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.201 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 90' ' ' HIS . . . -53.58 -49.23 58.32 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.544 HG13 ' CD ' ' A' ' 91' ' ' LYS . 72.8 t -53.59 -49.29 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.305 -1.115 . . . . 0.0 109.084 179.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.518 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -49.68 -37.55 29.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.189 -0.944 . . . . 0.0 109.658 179.703 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.64 ' O ' HD12 ' A' ' 98' ' ' ILE . 22.9 m80 -71.4 -3.69 22.2 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.544 ' CD ' HG13 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -78.96 -11.58 60.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.732 -1.23 . . . . 0.0 110.24 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -151.85 57.73 0.43 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -87.57 -170.73 3.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -1.133 . . . . 0.0 109.534 179.614 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.66 -29.54 67.22 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.069 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.9 p-10 -99.24 -32.89 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -1.183 . . . . 0.0 109.505 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.456 ' CD ' ' O ' ' A' ' 96' ' ' LYS . 0.0 OUTLIER 67.74 7.36 5.65 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.414 -0.804 . . . . 0.0 110.397 179.612 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.419 ' O ' ' O ' ' A' ' 98' ' ' ILE . 3.1 m170 -95.86 -87.84 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.012 -1.055 . . . . 0.0 108.981 178.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.64 HD12 ' O ' ' A' ' 90' ' ' HIS . 15.3 mt 58.65 152.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.363 -0.836 . . . . 0.0 110.694 179.342 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.543 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.48 135.5 14.72 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 121.727 0.775 . . . . 0.0 109.807 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.719 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -72.23 -7.31 48.61 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.658 -0.651 . . . . 0.0 109.532 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.448 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 5.8 pt-20 -75.54 -23.74 56.66 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.086 179.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.553 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 25.5 m-85 -85.41 -20.38 29.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.854 . . . . 0.0 109.631 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.931 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.5 m-85 -55.95 -61.05 2.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.26 -0.9 . . . . 0.0 110.045 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -52.37 -57.62 14.77 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.066 -1.021 . . . . 0.0 109.839 -179.66 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.9 Cg_exo -50.72 -63.57 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.667 1.351 . . . . 0.0 109.886 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.897 HD23 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -56.54 -26.76 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.295 -0.878 . . . . 0.0 109.342 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -75.62 -46.05 15.86 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.71 -51.86 66.68 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -1.193 . . . . 0.0 109.273 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 t -56.33 -22.25 29.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.875 . . . . 0.0 109.247 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.51 HD23 ' CG ' ' A' ' 114' ' ' MET . 4.4 tt -67.46 -48.61 66.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.585 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.731 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.6 mt -54.36 -31.68 55.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.137 -0.977 . . . . 0.0 109.398 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -65.84 -49.47 68.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.657 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.48 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -71.45 -32.52 68.42 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.601 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.51 ' CG ' HD23 ' A' ' 110' ' ' LEU . 3.4 mmt -47.57 -38.57 14.59 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.265 -0.897 . . . . 0.0 110.023 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.421 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -63.77 -16.92 62.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.565 -179.776 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.48 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 37.0 m170 -60.78 -43.97 97.39 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.082 -1.011 . . . . 0.0 109.779 -179.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.431 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -72.81 -59.37 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.781 -179.7 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.703 HD11 ' SD ' ' A' ' 122' ' ' MET . 12.3 pt -94.0 40.53 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -0.941 . . . . 0.0 109.876 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.421 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -53.46 117.07 6.52 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 112.73 -31.34 6.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.529 -1.829 . . . . 0.0 108.529 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -98.98 -24.87 14.76 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.339 -1.095 . . . . 0.0 109.13 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.703 ' SD ' HD11 ' A' ' 118' ' ' ILE . 6.5 tpt -67.56 96.34 0.52 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.025 179.428 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.461 ' O ' ' HB3' ' A' ' 126' ' ' ALA . 12.5 p-10 -100.73 -172.11 2.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 0.0 109.621 -179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.436 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -58.71 -52.93 63.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.881 . . . . 0.0 110.045 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.713 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -54.63 -24.91 23.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.157 -0.965 . . . . 0.0 109.418 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.16 -54.06 7.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.353 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.595 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 16.7 ptpt -70.0 -30.22 67.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.919 . . . . 0.0 109.358 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.477 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 63.4 t0 -76.91 -38.3 53.75 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.4 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -66.91 -43.87 82.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.402 -0.811 . . . . 0.0 109.347 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.954 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.9 m0 -75.34 -33.01 61.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.251 -0.905 . . . . 0.0 109.011 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.595 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -52.41 -39.2 60.64 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 108.984 179.205 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.71 -23.0 24.3 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.391 -0.818 . . . . 0.0 108.985 179.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.693 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -83.45 -63.17 1.41 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 109.518 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.535 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -51.59 -23.97 4.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.182 -0.949 . . . . 0.0 109.098 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.81 -36.78 56.69 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.266 -0.896 . . . . 0.0 109.012 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -78.95 -38.73 36.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.409 -0.807 . . . . 0.0 109.235 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 133' ' ' ALA . 1.4 mp -62.42 -54.89 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.343 -0.848 . . . . 0.0 108.802 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.411 ' O ' HG12 ' A' ' 142' ' ' ILE . 83.6 p -68.44 -17.7 64.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -0.885 . . . . 0.0 109.659 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.39 -35.21 20.97 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.46 -25.5 63.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -1.151 . . . . 0.0 109.621 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.931 HD22 ' CE2' ' A' ' 103' ' ' PHE . 9.9 tt -74.04 -16.49 61.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 109.831 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.719 HD12 ' HB2' ' A' ' 100' ' ' ALA . 51.2 mm -88.19 15.42 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.996 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.6 t -93.25 -45.16 7.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -83.94 -23.3 52.94 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.129 -1.589 . . . . 0.0 109.129 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.478 HD12 ' HB2' ' A' ' 90' ' ' HIS . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.258 -1.142 . . . . 0.0 109.579 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.779 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.193 0.521 . . . . 0.0 109.663 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.758 ' O ' HG23 ' A' ' 10' ' ' VAL . 52.0 mt-30 -66.47 -48.0 71.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.16 -0.963 . . . . 0.0 109.345 179.815 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.609 ' HG2' HD12 ' A' ' 73' ' ' LEU . 3.0 ttp180 -60.84 -24.04 65.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.3 tp60 -83.02 -49.26 9.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.444 -0.785 . . . . 0.0 109.186 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.779 HG23 ' O ' ' A' ' 5' ' ' ALA . 86.3 t -51.56 -27.43 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.404 -0.81 . . . . 0.0 109.498 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.944 HG12 HG13 ' A' ' 70' ' ' VAL . 61.1 t -65.02 -52.22 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.769 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.05 -19.2 64.09 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.202 -0.936 . . . . 0.0 109.596 179.87 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.85 -23.84 36.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.556 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.417 HG21 ' CB ' ' A' ' 126' ' ' ALA . 21.2 p -99.89 -13.22 19.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.789 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.708 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.02 -28.31 19.16 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.128 -0.982 . . . . 0.0 109.759 -179.836 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 14.9 mttt -75.88 -8.7 57.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.904 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -105.4 -47.37 3.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.103 -0.998 . . . . 0.0 109.63 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.967 HD12 ' CH2' ' A' ' 130' ' ' TRP . 57.8 mt -71.9 -35.4 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.218 -0.926 . . . . 0.0 109.635 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.883 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -105.03 33.82 3.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.678 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.14 -75.99 0.2 Allowed Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.2 p -103.73 -37.47 7.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -1.16 . . . . 0.0 109.597 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.694 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 16.0 p-10 -71.61 -20.54 61.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.61 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.883 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.9 t30 57.55 25.29 11.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.627 179.956 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.06 19.94 24.91 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.694 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -68.34 -59.52 3.12 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -1.146 . . . . 0.0 109.56 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -67.02 -12.46 60.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.49 HG21 ' CG2' ' A' ' 17' ' ' ILE . 37.5 t -84.82 -41.25 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.149 -1.206 . . . . 0.0 109.868 -179.819 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.447 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -74.33 -36.73 49.42 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.306 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.477 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 9.7 ptpt -73.2 -26.55 61.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.109 -1.23 . . . . 0.0 110.207 -179.459 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.453 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pt-20 -95.42 -20.65 18.91 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.066 -1.021 . . . . 0.0 109.993 -179.746 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.542 ' SG ' HD12 ' A' ' 110' ' ' LEU . 37.3 t -88.19 -66.73 0.89 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 110.085 -179.577 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.526 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.6 m-85 -48.06 -31.53 5.59 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.048 -179.546 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.943 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -56.17 -51.18 68.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.083 -1.011 . . . . 0.0 109.348 179.705 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.414 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 6.2 mttp -59.61 -48.64 80.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.285 -0.884 . . . . 0.0 109.533 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.732 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.8 t80 -52.63 -47.77 66.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.453 179.863 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.831 ' CD1' HG22 ' A' ' 55' ' ' VAL . 21.5 mt -58.93 -44.01 91.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.288 -0.882 . . . . 0.0 109.607 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.5 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -68.73 -60.98 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 -179.957 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.598 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -53.47 -23.05 9.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -0.921 . . . . 0.0 109.589 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.598 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 28.5 m-70 -126.24 102.37 7.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.278 -0.889 . . . . 0.0 109.716 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.4 m170 -85.64 6.86 25.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.329 -0.857 . . . . 0.0 109.9 179.699 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -95.09 -18.12 21.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.128 -0.983 . . . . 0.0 109.427 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.436 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 38.7 mmm -107.03 -19.45 13.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.754 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.39 -46.34 37.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.036 -1.04 . . . . 0.0 109.562 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.3 -26.05 60.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.099 179.478 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.009 HG13 ' ND2' ' A' ' 95' ' ' ASN . 27.9 t -70.62 -33.75 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.431 -0.793 . . . . 0.0 109.342 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.514 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 10.2 m-85 -78.98 -31.17 44.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.48 26.88 4.07 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.514 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.0 m-85 -124.02 166.85 15.02 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -1.156 . . . . 0.0 109.706 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.0 t -104.92 -11.16 16.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.855 . . . . 0.0 109.444 179.359 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.9 -164.82 31.84 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.5 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -95.57 30.33 2.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -1.186 . . . . 0.0 109.629 179.938 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.65 27.7 5.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.433 ' OD2' HG23 ' A' ' 55' ' ' VAL . 8.1 p-10 -115.62 142.13 28.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.253 -0.904 . . . . 0.0 109.632 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -66.22 -17.8 54.99 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.054 1.555 . . . . 0.0 110.111 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.506 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -53.37 -39.84 60.0 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.943 HG11 HG23 ' A' ' 32' ' ' THR . 94.4 t -54.98 -34.86 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.401 -1.058 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.455 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -72.89 -27.93 62.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.28 -0.887 . . . . 0.0 109.449 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.54 -31.99 60.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.838 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.0 mt -81.97 -62.55 1.6 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.307 -0.871 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.526 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.68 -51.56 27.84 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -51.92 -37.18 51.68 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -1.145 . . . . 0.0 109.412 179.879 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -81.27 -27.69 35.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.512 179.856 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.838 HG23 ' O ' ' A' ' 58' ' ' LEU . 46.5 t -77.84 -49.64 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.303 -0.873 . . . . 0.0 109.704 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.454 ' HA ' HD13 ' A' ' 63' ' ' LEU . 3.6 mm? -47.51 -51.25 21.23 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.714 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.73 -47.14 20.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.251 -0.906 . . . . 0.0 110.089 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -52.76 -53.72 44.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.099 -1.001 . . . . 0.0 109.356 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.909 ' O ' HG23 ' A' ' 70' ' ' VAL . 55.9 mt -55.49 -34.43 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.174 -0.954 . . . . 0.0 109.074 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.552 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.48 -54.07 31.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.751 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.8 t -60.98 -24.93 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -1.121 . . . . 0.0 109.27 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -85.66 -27.93 25.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.355 -0.84 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.944 HG13 HG12 ' A' ' 10' ' ' VAL . 46.2 t -68.13 -9.75 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.219 -0.925 . . . . 0.0 109.78 179.833 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.7 t -92.26 29.93 1.57 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.046 -1.034 . . . . 0.0 109.763 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 9.4 m-70 -155.27 -91.93 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.817 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.609 HD12 ' HG2' ' A' ' 7' ' ' ARG . 9.2 mt . . . . . 0 N--CA 1.496 1.858 0 O-C-N 121.331 -0.856 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 18.3 tmm? . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.303 0.573 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 96.1 t -77.59 -20.59 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.414 179.827 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.42 -52.4 65.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 109.444 179.88 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -69.73 -50.65 41.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.429 179.75 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.484 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.8 OUTLIER -56.34 -56.51 20.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 109.313 179.737 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.488 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -53.54 -24.44 13.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.205 179.555 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.545 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -77.9 -44.13 27.97 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.407 -0.808 . . . . 0.0 109.479 179.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.0 t -53.17 -35.35 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.474 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -60.66 -48.36 86.63 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.8 HG23 ' HA3' ' A' ' 144' ' ' GLY . 64.9 t -57.65 -18.82 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.423 -1.045 . . . . 0.0 109.432 179.332 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.1 OUTLIER -86.72 -46.1 10.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.134 -0.978 . . . . 0.0 109.087 179.617 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.521 ' O ' HD12 ' A' ' 98' ' ' ILE . 14.3 m80 -56.39 -37.5 70.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 109.564 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -60.96 -16.68 45.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.298 -0.876 . . . . 0.0 109.935 -179.863 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -119.97 40.76 2.11 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.7 m-30 -90.42 -172.12 3.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 109.53 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.9 -28.67 37.08 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.906 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.009 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -79.95 -47.94 14.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.478 -1.013 . . . . 0.0 109.18 179.78 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.471 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.7 OUTLIER 75.13 -48.51 0.63 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.623 -0.673 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 97' ' ' HIS . 25.1 m170 -68.05 59.44 0.07 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.802 -1.186 . . . . 0.0 110.466 -179.516 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.521 HD12 ' O ' ' A' ' 90' ' ' HIS . 56.1 mt -90.41 156.96 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.069 -1.019 . . . . 0.0 109.027 179.488 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.521 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -137.94 138.93 39.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.056 -1.027 . . . . 0.0 110.055 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -81.15 -3.69 52.95 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -0.873 . . . . 0.0 109.883 179.693 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 43.1 mm-40 -81.38 -22.25 38.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.006 -1.059 . . . . 0.0 109.489 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.531 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 55.0 m-85 -79.96 -15.09 57.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.309 -0.869 . . . . 0.0 109.891 -179.816 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.889 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.2 m-85 -62.93 -61.55 2.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.242 -0.911 . . . . 0.0 110.063 -179.847 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.489 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.4 OUTLIER -44.85 -58.83 4.86 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 110.746 -179.46 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.9 Cg_endo -57.45 -45.95 30.91 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.682 1.359 . . . . 0.0 110.003 -179.569 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.936 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -65.91 -20.09 66.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.301 179.789 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.407 ' HA2' ' CE1' ' A' ' 134' ' ' TYR . . . -86.29 -49.04 4.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.54 -45.49 92.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.2 -1.176 . . . . 0.0 109.537 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.9 m -61.56 -28.97 69.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.494 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.967 HD13 ' OH ' ' A' ' 134' ' ' TYR . 3.7 tt -67.23 -40.03 86.31 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.204 -0.935 . . . . 0.0 109.369 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.656 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.7 mt -54.17 -36.32 63.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.163 -0.961 . . . . 0.0 109.047 179.763 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.8 t -67.01 -30.72 70.9 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.459 179.711 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.444 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -79.96 -38.94 31.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 179.923 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.486 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.6 mmt -48.42 -42.91 33.49 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.228 -0.92 . . . . 0.0 109.618 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -50.67 -24.37 3.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.489 179.843 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.444 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 17.6 m170 -52.0 -53.1 45.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.959 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -72.44 -58.73 3.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.894 . . . . 0.0 109.5 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.608 HD11 ' SD ' ' A' ' 122' ' ' MET . 6.5 pt -102.58 60.79 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.587 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -69.57 -11.01 64.65 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.886 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -105.72 -30.03 4.75 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.861 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 12.7 mttm -93.05 -24.52 18.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.173 -1.192 . . . . 0.0 110.078 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.608 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.9 OUTLIER -64.17 79.55 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.088 -1.008 . . . . 0.0 109.432 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.668 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 8.5 p30 -81.54 -164.52 0.79 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 -179.839 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.409 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.74 -38.46 73.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.181 -0.95 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.668 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -62.74 -33.43 75.12 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.293 -0.879 . . . . 0.0 109.234 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.417 ' CB ' HG21 ' A' ' 13' ' ' THR . . . -67.25 -52.3 42.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.534 179.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.523 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.5 OUTLIER -71.04 -29.38 65.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.341 179.835 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.467 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 48.6 t0 -79.81 -32.15 40.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.302 -0.873 . . . . 0.0 109.362 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.08 -43.43 61.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.418 -0.801 . . . . 0.0 109.322 179.752 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.967 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.4 m0 -74.86 -25.8 59.23 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.257 -0.902 . . . . 0.0 108.716 179.489 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -62.48 -26.89 68.77 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.235 -0.916 . . . . 0.0 108.693 178.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.45 -40.98 9.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.51 -0.744 . . . . 0.0 109.14 179.517 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -73.6 -58.95 2.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.4 -0.812 . . . . 0.0 109.103 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.967 ' OH ' HD13 ' A' ' 110' ' ' LEU . 1.9 t80 -50.87 -28.07 8.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.33 -0.856 . . . . 0.0 108.997 179.381 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.407 ' HB2' ' O ' ' A' ' 131' ' ' ALA . . . -73.02 -41.35 64.31 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.037 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -76.68 -29.06 56.16 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.483 -0.76 . . . . 0.0 109.059 179.42 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.841 HD13 HG23 ' A' ' 66' ' ' ILE . 42.1 mt -66.54 -61.59 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 108.738 179.532 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.3 p -66.35 -20.6 66.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.431 -0.793 . . . . 0.0 109.726 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.35 -26.98 50.17 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 -179.872 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.0 -19.32 54.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.25 -1.147 . . . . 0.0 109.723 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.889 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.3 tt -79.53 -6.94 58.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.061 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.48 ' O ' HG22 ' A' ' 142' ' ' ILE . 57.5 mt -86.78 9.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.002 -1.061 . . . . 0.0 110.122 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.488 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 7.2 m -83.08 -43.31 16.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.933 -1.104 . . . . 0.0 109.436 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.8 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -97.05 -21.24 21.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.487 HD13 ' HB2' ' A' ' 90' ' ' HIS . 10.7 tp . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.423 -1.045 . . . . 0.0 109.53 179.928 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.848 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.257 0.551 . . . . 0.0 109.545 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.522 ' O ' HG23 ' A' ' 10' ' ' VAL . 3.6 mt-30 -58.23 -54.95 41.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.607 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.726 ' HG2' HD12 ' A' ' 73' ' ' LEU . 10.1 ttp180 -50.8 -31.43 16.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 179.872 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.1 tp60 -80.18 -42.05 24.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.331 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.848 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.3 t -59.34 -25.07 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -0.911 . . . . 0.0 109.433 179.803 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 1.021 HG12 HG13 ' A' ' 70' ' ' VAL . 86.4 t -67.48 -52.39 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.55 -12.12 56.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.873 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.19 -26.65 21.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.138 -0.976 . . . . 0.0 109.891 -179.854 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.443 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 28.2 p -99.65 -7.7 25.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.107 -0.996 . . . . 0.0 109.893 179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.687 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.18 -19.83 22.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.02 -1.05 . . . . 0.0 109.562 -179.759 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 45.1 mtpt -79.74 -15.01 58.31 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.715 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.28 -54.82 3.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.663 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.878 HD12 ' CH2' ' A' ' 130' ' ' TRP . 56.9 mt -65.87 -42.18 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.642 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.889 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -96.45 31.78 2.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.211 -0.93 . . . . 0.0 109.711 -179.855 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.97 -73.29 0.39 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.94 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.6 p -107.04 -26.26 11.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.257 -1.143 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.808 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.5 p-10 -81.01 -19.32 44.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.694 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.889 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 5.3 t30 58.39 22.16 9.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.651 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.411 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 101.73 31.09 5.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.808 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -84.1 -46.49 11.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.261 -1.14 . . . . 0.0 109.584 179.925 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.476 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.38 -1.78 86.61 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.91 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.698 HG11 HD11 ' A' ' 63' ' ' LEU . 21.2 t -88.2 -40.24 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.041 -1.27 . . . . 0.0 109.426 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.49 -53.91 4.51 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.545 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.476 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 18.2 ptpt -48.9 -31.7 7.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.101 -1.235 . . . . 0.0 109.673 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.611 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 24.5 pt-20 -91.62 -21.32 20.87 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.215 -0.928 . . . . 0.0 109.387 179.713 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.422 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 20.8 t -87.6 -64.58 1.13 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.346 -0.847 . . . . 0.0 109.767 -179.794 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.554 ' HB3' HG13 ' A' ' 55' ' ' VAL . 10.5 m-85 -48.28 -34.29 10.18 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 109.955 -179.566 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.891 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -56.74 -54.73 42.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 109.273 179.659 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -55.28 -51.39 66.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 179.847 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.873 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -54.54 -51.7 64.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 109.54 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.707 ' CD1' HG22 ' A' ' 55' ' ' VAL . 16.3 mt -54.81 -45.85 74.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.667 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.9 -59.21 3.46 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.257 -0.902 . . . . 0.0 109.671 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.582 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -58.4 -22.41 53.85 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 0.0 109.624 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.582 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 38.9 m-70 -131.0 107.85 9.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 109.786 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 48.7 m170 -88.9 -12.53 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.364 -0.835 . . . . 0.0 109.753 179.748 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -73.69 -16.89 61.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.123 -0.986 . . . . 0.0 109.715 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.515 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 73.0 mmm -109.13 -16.25 14.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.165 -0.96 . . . . 0.0 109.882 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.469 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.58 -51.3 28.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.986 -1.071 . . . . 0.0 109.498 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.02 -28.14 64.18 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.127 179.526 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.064 HG13 ' ND2' ' A' ' 95' ' ' ASN . 38.8 t -66.02 -32.1 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.407 -0.808 . . . . 0.0 109.265 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.537 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 29.3 m-85 -82.48 -25.68 33.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.159 -0.963 . . . . 0.0 109.503 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.49 26.79 5.5 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.779 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.2 m-85 -123.43 167.93 13.21 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.37 -1.077 . . . . 0.0 109.888 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 t -109.91 19.17 19.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.385 -0.822 . . . . 0.0 109.282 179.508 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.37 -163.33 29.52 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -179.946 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.19 40.72 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -1.157 . . . . 0.0 109.732 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 20.9 t -139.74 21.02 2.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.687 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.21 139.02 20.06 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.678 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -61.21 -24.73 79.56 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 123.951 1.5 . . . . 0.0 110.089 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.534 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.25 -39.32 42.62 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.891 HG11 HG23 ' A' ' 32' ' ' THR . 59.4 t -51.31 -36.28 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -1.129 . . . . 0.0 109.367 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.581 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -73.38 -10.22 59.51 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.354 -0.841 . . . . 0.0 109.591 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.41 ' OD2' ' HA2' ' A' ' 54' ' ' GLY . 59.5 m-20 -86.78 -57.03 3.13 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.13 -0.981 . . . . 0.0 109.551 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.772 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -63.29 -61.06 2.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.782 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -47.95 -37.38 15.69 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.581 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -69.72 -59.88 2.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.107 -1.231 . . . . 0.0 109.507 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -57.51 -46.57 83.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.268 -0.895 . . . . 0.0 109.34 179.749 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 58' ' ' LEU . 51.4 t -56.66 -52.12 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.268 -0.895 . . . . 0.0 109.558 179.771 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.782 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.4 mm? -47.06 -46.04 22.08 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.182 -0.949 . . . . 0.0 109.753 179.875 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.19 -49.52 52.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.597 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 16.1 tp60 -50.2 -48.75 54.1 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.272 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.987 ' O ' HG23 ' A' ' 70' ' ' VAL . 50.1 mt -57.15 -39.21 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.374 -0.829 . . . . 0.0 109.025 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.22 -53.23 41.25 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.944 -1.662 . . . . 0.0 108.944 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.8 t -59.08 -26.73 34.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -1.089 . . . . 0.0 109.35 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.436 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -84.62 -28.6 26.39 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.421 -0.799 . . . . 0.0 109.58 179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.021 HG13 HG12 ' A' ' 10' ' ' VAL . 58.1 t -61.39 -15.78 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.922 . . . . 0.0 109.733 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -90.94 26.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.212 -0.93 . . . . 0.0 109.959 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.412 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 7.9 m-70 -155.72 -87.0 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.016 . . . . 0.0 109.81 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.726 HD12 ' HG2' ' A' ' 7' ' ' ARG . 21.2 mt . . . . . 0 N--CA 1.495 1.815 0 O-C-N 121.455 -0.778 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 37.2 ttp . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.3 0.571 . . . . 0.0 109.666 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 47.9 t -81.19 -21.63 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 179.846 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -28.7 63.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.427 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.424 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.6 OUTLIER -81.48 -52.3 7.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.29 -0.881 . . . . 0.0 109.5 179.875 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.474 ' HE3' ' HB2' ' A' ' 141' ' ' LEU . 99.3 mmm -56.44 -39.81 73.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.186 -0.946 . . . . 0.0 108.975 179.683 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.52 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -52.02 -28.65 17.83 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.077 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -80.08 -33.09 39.13 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.552 -0.718 . . . . 0.0 109.097 179.324 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.9 t -69.62 -33.83 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.22 179.688 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.478 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -65.37 -39.61 95.94 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 84' ' ' LYS . 90.3 t -58.7 -28.08 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.268 -1.137 . . . . 0.0 109.213 179.657 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.525 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -73.69 -25.94 60.48 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.349 -0.844 . . . . 0.0 109.26 179.641 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.535 ' CA ' HD12 ' A' ' 98' ' ' ILE . 18.5 m80 -88.04 18.19 4.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.375 -0.828 . . . . 0.0 110.169 -179.085 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.411 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 1.6 tttt -79.35 -60.56 2.32 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.02 -1.05 . . . . 0.0 110.52 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.44 ' HA2' ' HB2' ' A' ' 96' ' ' LYS . . . -148.24 57.58 0.48 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -179.497 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.525 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -86.62 -148.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.308 -1.113 . . . . 0.0 109.812 -179.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -45.24 -70.22 0.65 Allowed Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.064 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -66.79 -50.4 62.79 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 108.802 179.559 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.484 ' HG3' ' N ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER 76.58 -34.58 0.23 Allowed 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.399 -0.813 . . . . 0.0 111.48 179.277 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.484 ' N ' ' HG3' ' A' ' 96' ' ' LYS . 14.2 m170 -87.1 60.52 6.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.466 -1.396 . . . . 0.0 109.554 179.854 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.535 HD12 ' CA ' ' A' ' 90' ' ' HIS . 83.6 mt -87.21 155.06 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.122 -0.986 . . . . 0.0 110.224 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.446 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -133.97 141.37 47.25 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.528 -0.732 . . . . 0.0 109.724 -179.941 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.1 -3.28 54.43 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.358 -0.839 . . . . 0.0 110.213 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.467 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 16.9 pt-20 -78.95 -23.49 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.909 -1.12 . . . . 0.0 109.54 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.521 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 71.8 m-85 -80.33 -7.0 58.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.23 -0.918 . . . . 0.0 110.026 179.837 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.755 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -70.0 -66.91 0.53 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.115 -0.99 . . . . 0.0 110.092 -179.561 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.492 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.78 -60.02 3.48 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.494 -0.754 . . . . 0.0 110.743 -179.338 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.521 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 4.2 Cg_endo -52.87 -55.7 3.5 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.683 1.359 . . . . 0.0 109.995 -179.5 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.942 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -59.98 -19.76 54.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.283 179.745 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.418 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -75.33 -45.72 18.04 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.57 -46.79 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.134 -1.215 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.5 m -64.87 -17.64 64.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.251 -0.905 . . . . 0.0 109.407 179.584 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.889 HD21 ' CE ' ' A' ' 114' ' ' MET . 4.9 tt -74.63 -41.87 59.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.947 . . . . 0.0 109.685 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.738 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -60.24 -28.89 68.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.115 -0.991 . . . . 0.0 109.39 179.636 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.7 t -60.26 -46.15 90.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.334 -0.854 . . . . 0.0 109.64 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.611 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -66.29 -36.92 84.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.889 ' CE ' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.28 -42.69 21.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.316 -0.865 . . . . 0.0 109.85 179.904 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.458 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.97 -24.01 15.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.277 -0.889 . . . . 0.0 109.766 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.513 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.6 m170 -52.38 -55.16 23.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 109.842 -179.784 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.463 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 3.8 ttt85 -72.03 -66.09 0.69 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.188 -0.945 . . . . 0.0 109.833 -179.841 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.687 HG12 HD11 ' A' ' 17' ' ' ILE . 6.6 pt -94.57 58.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.114 -0.991 . . . . 0.0 109.748 -179.826 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.75 -39.49 95.26 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -85.92 -13.46 69.29 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.867 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.443 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.2 mttm -104.71 -20.84 13.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.07 -1.253 . . . . 0.0 109.883 -179.812 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.47 90.45 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.213 179.71 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.54 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 9.1 p-10 -92.5 -172.61 3.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.224 -0.922 . . . . 0.0 110.029 -179.619 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.422 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.65 -48.99 75.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.46 -0.775 . . . . 0.0 110.308 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.63 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -60.52 -24.88 65.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.428 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -75.18 -49.27 20.0 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.461 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.534 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 20.1 ptpt -73.04 -30.85 64.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -0.911 . . . . 0.0 109.74 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.5 t0 -76.71 -41.93 43.42 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.465 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -64.02 -43.28 96.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.368 -0.833 . . . . 0.0 109.376 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.878 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -75.6 -26.24 57.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.288 -0.882 . . . . 0.0 109.314 179.761 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.534 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -64.94 -26.4 68.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.454 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -96.82 -26.37 15.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.441 -0.787 . . . . 0.0 109.276 179.659 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.844 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -73.93 -57.69 3.8 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.364 -0.835 . . . . 0.0 109.449 179.819 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.497 ' CE2' ' HE2' ' A' ' 114' ' ' MET . 17.2 m-30 -50.36 -29.18 9.4 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.333 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.27 -43.95 69.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.372 -0.83 . . . . 0.0 109.08 179.554 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -75.16 -33.32 61.47 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.352 -0.843 . . . . 0.0 109.238 179.663 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.844 HD12 ' C ' ' A' ' 133' ' ' ALA . 3.5 mt -67.9 -59.06 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.314 -0.866 . . . . 0.0 109.192 179.667 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.2 -48.76 64.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.717 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -50.91 -28.59 17.4 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.189 -1.565 . . . . 0.0 109.189 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.06 3.21 31.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -1.132 . . . . 0.0 110.048 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.755 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.2 tt -97.97 -24.38 15.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.933 -1.104 . . . . 0.0 109.804 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.635 ' O ' HG22 ' A' ' 142' ' ' ILE . 6.8 mt -87.2 18.23 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.382 -179.446 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -77.96 -20.67 52.27 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.107 -0.996 . . . . 0.0 108.872 179.489 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.35 1.51 5.71 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.838 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.904 HD13 ' O ' ' A' ' 145' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.681 0 O-C-N 120.849 -1.383 . . . . 0.0 110.1 -179.825 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.901 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.301 0.572 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.548 ' O ' HG23 ' A' ' 10' ' ' VAL . 40.5 mt-30 -70.92 -48.5 53.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.217 -0.927 . . . . 0.0 109.509 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.453 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 13.9 ptm180 -56.31 -30.83 63.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.277 -0.889 . . . . 0.0 109.348 179.856 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.453 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 17.7 mm-40 -73.74 -41.73 62.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.436 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 5' ' ' ALA . 21.6 t -61.4 -22.54 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.867 HG12 HG13 ' A' ' 70' ' ' VAL . 66.4 t -73.37 -43.31 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 109.673 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.79 -8.03 54.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.288 -0.883 . . . . 0.0 110.016 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.5 m -94.23 -30.3 14.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.043 . . . . 0.0 109.826 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.429 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.2 p -92.91 -13.17 29.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.954 -179.835 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.822 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -88.04 -19.49 27.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.117 -0.989 . . . . 0.0 109.849 -179.741 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.2 mtpt -83.87 -4.06 58.38 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.928 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.66 -53.31 2.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.788 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.959 HD12 ' CH2' ' A' ' 130' ' ' TRP . 60.9 mt -66.16 -36.28 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.455 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.823 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.29 27.34 7.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.51 -69.52 1.07 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 p -107.21 -36.95 6.41 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -1.141 . . . . 0.0 109.59 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -71.79 -20.04 61.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.922 . . . . 0.0 109.667 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.823 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 17.5 t30 54.54 30.44 13.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.268 -0.895 . . . . 0.0 109.593 -179.955 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.75 59.99 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.59 -47.3 67.09 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.108 -1.231 . . . . 0.0 109.52 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.23 12.97 62.94 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.52 HG11 HD11 ' A' ' 63' ' ' LEU . 11.3 t -97.84 -32.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.139 -1.212 . . . . 0.0 109.116 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 31' ' ' PHE . . . -86.69 -44.24 5.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.495 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.7 ptpt -53.87 -35.41 61.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -1.195 . . . . 0.0 109.386 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.495 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.3 pt-20 -86.85 -26.83 23.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 109.366 179.714 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.416 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 30.4 t -85.11 -58.31 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.366 -0.834 . . . . 0.0 109.684 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.677 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.4 m-85 -47.3 -32.57 4.82 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.333 -0.854 . . . . 0.0 109.915 -179.72 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.677 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -60.54 -49.22 78.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.158 179.669 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -52.28 64.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.571 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.703 ' CG ' HD23 ' A' ' 106' ' ' LEU . 6.8 t80 -52.4 -54.48 31.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.189 -0.944 . . . . 0.0 109.483 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.918 ' CD1' HG22 ' A' ' 55' ' ' VAL . 38.2 mt -55.7 -43.67 76.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.665 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.572 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 9.6 t -68.81 -65.43 0.7 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.732 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.655 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -52.67 -27.35 16.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.723 -179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.655 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 16.2 m-70 -123.06 106.72 11.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.914 . . . . 0.0 109.837 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -87.36 -20.83 26.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.429 -0.795 . . . . 0.0 109.294 179.542 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.411 ' OD1' ' HG2' ' A' ' 41' ' ' MET . 16.4 p-10 -66.15 -17.9 65.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.371 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.51 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 84.6 mmm -106.14 -24.5 12.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.266 -0.896 . . . . 0.0 109.705 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.463 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.88 -46.14 42.18 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.078 -1.014 . . . . 0.0 109.61 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.75 -21.12 60.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.302 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.945 HG13 ' CG ' ' A' ' 95' ' ' ASN . 35.8 t -76.16 -40.83 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.299 -0.876 . . . . 0.0 109.412 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.536 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -67.26 -41.79 84.97 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 109.576 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.46 32.94 1.07 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.4 m-85 -125.04 173.15 8.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.225 -1.162 . . . . 0.0 109.629 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 17.6 t -111.51 19.38 18.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 109.371 179.547 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.11 -167.34 30.07 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.572 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -80.86 -23.0 39.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.203 -1.175 . . . . 0.0 109.66 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 12.5 m -84.74 51.24 2.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.923 . . . . 0.0 109.676 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -120.51 136.21 25.13 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.597 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -68.06 -33.45 25.42 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.97 1.511 . . . . 0.0 110.033 -179.906 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.41 -32.39 30.21 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.918 HG22 ' CD1' ' A' ' 35' ' ' LEU . 91.7 t -53.92 -41.61 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.268 -1.136 . . . . 0.0 109.501 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.706 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.5 -11.01 60.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.262 -0.899 . . . . 0.0 109.872 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.401 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 11.4 t0 -91.73 -33.3 15.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.111 -0.993 . . . . 0.0 109.375 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.516 ' HB3' ' CE2' ' A' ' 31' ' ' PHE . 1.6 mt -81.59 -64.25 1.22 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.348 -0.845 . . . . 0.0 110.201 -179.786 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.61 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -56.09 -20.77 29.1 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.37 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.706 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -72.24 -40.76 67.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.109 -1.23 . . . . 0.0 109.761 -179.719 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.401 ' HG3' ' O ' ' A' ' 57' ' ' ASP . 28.6 mttt -84.46 -43.67 14.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.601 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 58' ' ' LEU . 61.6 t -52.56 -47.18 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.128 -0.983 . . . . 0.0 109.48 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -48.09 -47.85 33.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.108 -0.995 . . . . 0.0 109.773 179.81 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.6 -49.38 47.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.912 . . . . 0.0 109.653 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -49.06 -54.96 13.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.135 -0.978 . . . . 0.0 109.378 179.849 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.947 ' O ' HG23 ' A' ' 70' ' ' VAL . 83.7 mt -52.36 -35.32 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.313 -0.867 . . . . 0.0 109.05 179.554 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.85 -57.11 15.21 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.869 -1.693 . . . . 0.0 108.869 179.416 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.5 t -57.58 -25.91 25.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -1.135 . . . . 0.0 109.253 179.76 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.438 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.07 -19.58 34.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.391 -0.818 . . . . 0.0 109.5 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.947 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.0 t -75.47 -14.47 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.686 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.488 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -90.41 35.64 0.88 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.109 -0.994 . . . . 0.0 109.96 -179.824 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 71' ' ' SER . 6.0 m-70 -161.68 -84.75 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.063 -1.023 . . . . 0.0 109.918 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 42.2 mt . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.599 -0.688 . . . . 0.0 109.97 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 59.0 ttp . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.249 0.547 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.8 t -73.07 -14.63 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.872 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.78 -35.08 72.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.126 -0.983 . . . . 0.0 109.835 -179.811 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.63 ' O ' HG23 ' A' ' 86' ' ' VAL . 10.7 tt0 -98.82 -40.97 7.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.666 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.7 mtp -62.18 -46.55 88.43 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.419 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 13.1 tttt -56.18 -39.27 72.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.172 -0.955 . . . . 0.0 109.172 179.65 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -63.19 -39.65 95.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.388 179.709 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.837 ' CG1' HD11 ' A' ' 141' ' ' LEU . 48.8 t -51.92 -47.96 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.525 ' O ' HD12 ' A' ' 145' ' ' LEU . . . -52.94 -49.88 53.15 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.624 -1.791 . . . . 0.0 108.624 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.647 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.1 t -53.13 -34.75 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.389 -1.065 . . . . 0.0 109.249 179.462 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 24.6 mmm180 -69.56 -49.21 56.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.865 . . . . 0.0 109.416 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.582 ' HB2' HD12 ' A' ' 145' ' ' LEU . 10.7 m80 -61.63 -15.41 39.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.235 -0.916 . . . . 0.0 109.363 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.405 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 4.8 ttmt -43.21 -33.49 0.94 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.466 -0.771 . . . . 0.0 110.917 -179.568 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.39 60.95 0.28 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.11 -1.519 . . . . 0.0 110.675 -179.502 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.9 m-30 -69.83 -166.0 0.1 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.014 -1.286 . . . . 0.0 109.257 178.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.31 -22.63 61.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.612 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.945 ' CG ' HG13 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -93.61 -44.06 8.38 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.381 -1.07 . . . . 0.0 109.321 -179.955 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.489 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 27.4 mttt 79.58 -32.14 0.14 Allowed 'General case' 0 N--CA 1.509 2.512 0 O-C-N 121.954 -0.467 . . . . 0.0 111.278 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.433 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 30.7 m170 -60.69 -99.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.518 -1.364 . . . . 0.0 109.99 -179.6 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.556 HD12 ' O ' ' A' ' 90' ' ' HIS . 6.1 mt 62.83 129.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.778 -1.201 . . . . 0.0 109.903 -179.546 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.514 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -145.4 143.35 30.03 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 122.237 1.018 . . . . 0.0 110.85 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.477 ' HB1' HD13 ' A' ' 142' ' ' ILE . . . -69.12 -19.61 64.04 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.047 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -64.9 -32.77 74.64 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.772 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.514 ' CD2' ' HB2' ' A' ' 99' ' ' LYS . 22.9 m-85 -81.26 -25.62 36.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.589 -0.694 . . . . 0.0 109.956 179.847 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.538 ' CZ ' HD22 ' A' ' 141' ' ' LEU . 3.4 m-85 -53.46 -65.88 0.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.22 -0.925 . . . . 0.0 110.344 -179.382 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.6 mt-10 -46.53 -59.43 5.06 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.251 -0.906 . . . . 0.0 110.512 -179.194 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 41.0 Cg_exo -45.42 -55.06 3.78 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.712 1.375 . . . . 0.0 110.621 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.706 HD13 ' C ' ' A' ' 106' ' ' LEU . 3.0 tm? -55.43 -39.13 69.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.34 -40.33 97.75 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.27 -55.07 27.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -1.162 . . . . 0.0 109.766 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.1 t -60.16 -27.43 67.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.202 -0.937 . . . . 0.0 109.703 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.857 HD22 ' OH ' ' A' ' 134' ' ' TYR . 3.2 tt -70.35 -38.92 74.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.205 -0.935 . . . . 0.0 109.589 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.857 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -60.08 -29.39 68.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.15 -0.969 . . . . 0.0 109.41 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 m -73.49 -29.7 62.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.784 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.467 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -80.68 -38.3 29.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.949 . . . . 0.0 109.569 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.597 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.9 mtt -50.1 -39.68 43.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.283 -0.885 . . . . 0.0 109.463 179.857 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.5 OUTLIER -51.67 -24.74 6.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.23 -0.919 . . . . 0.0 109.382 179.565 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.467 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 33.8 m170 -55.67 -49.67 72.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.327 -0.858 . . . . 0.0 109.829 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.438 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 2.9 ttt85 -70.1 -65.37 0.73 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.272 -0.892 . . . . 0.0 109.696 -179.837 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 13.5 pt -87.97 46.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 109.565 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.451 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.49 125.25 35.92 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 95.71 -30.44 8.39 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.743 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.431 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 19.2 mmtt -90.11 -28.71 18.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.227 -1.161 . . . . 0.0 109.166 179.682 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.448 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 1.2 ttt -71.37 107.38 4.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.437 -0.789 . . . . 0.0 109.359 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.507 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 10.0 p30 -109.72 -162.1 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.177 -0.952 . . . . 0.0 109.894 -179.776 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.431 ' O ' ' HB3' ' A' ' 128' ' ' ASP . . . -67.55 -45.78 74.67 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.346 -0.847 . . . . 0.0 109.64 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.798 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.62 -24.03 54.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -86.23 -57.06 3.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.8 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -65.94 -27.33 68.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.153 -0.967 . . . . 0.0 109.692 -179.735 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.431 ' HB3' ' O ' ' A' ' 124' ' ' ALA . 32.1 t70 -80.55 -49.95 10.65 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.311 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -57.7 -50.47 73.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.394 -0.816 . . . . 0.0 109.282 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.959 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.8 m0 -63.89 -30.96 71.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.237 -0.915 . . . . 0.0 108.877 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.98 -30.09 67.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 108.89 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.6 -28.52 23.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.392 -0.818 . . . . 0.0 109.194 179.501 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.85 -40.81 21.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.406 -0.809 . . . . 0.0 109.473 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.857 ' OH ' HD22 ' A' ' 110' ' ' LEU . 1.8 m-85 -50.26 -32.01 15.65 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.45 -34.78 72.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.281 -0.887 . . . . 0.0 109.242 179.638 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.27 -39.68 39.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 0.0 109.371 179.692 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.677 HD13 HG23 ' A' ' 66' ' ' ILE . 54.5 mt -66.05 -58.12 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.274 -0.891 . . . . 0.0 109.145 179.669 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.11 -17.5 64.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.291 -0.881 . . . . 0.0 109.645 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 142' ' ' ILE . . . -68.25 -55.56 12.59 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.23 -28.19 4.38 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.837 HD11 ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -74.82 -21.55 59.22 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -0.893 . . . . 0.0 109.536 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.575 ' O ' HG22 ' A' ' 142' ' ' ILE . 91.0 mt -83.78 8.36 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.292 -0.88 . . . . 0.0 110.096 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.3 m -100.13 -46.0 5.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.04 -1.038 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.647 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -68.86 -31.55 72.94 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.582 HD12 ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.414 179.869 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.581 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.193 0.521 . . . . 0.0 109.819 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.434 ' O ' HG23 ' A' ' 10' ' ' VAL . 73.6 mt-30 -66.67 -33.96 76.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.638 179.903 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 42.9 mtp180 -54.75 -41.82 70.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.644 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -74.73 -36.55 62.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.239 -0.913 . . . . 0.0 109.549 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 5' ' ' ALA . 33.3 t -71.26 -35.8 59.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.151 -0.968 . . . . 0.0 108.987 179.628 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.777 HG23 ' HB1' ' A' ' 129' ' ' ALA . 41.9 t -67.46 -37.24 78.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.399 -0.813 . . . . 0.0 109.057 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.26 -16.29 56.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.345 -0.847 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.6 t -90.3 -22.72 21.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.891 -179.625 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.8 p -95.24 -12.28 26.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 110.028 -179.851 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.575 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.31 -15.07 27.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.042 -1.037 . . . . 0.0 109.973 -179.895 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mtpt -85.92 -2.0 57.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.73 -45.16 3.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.996 -1.065 . . . . 0.0 109.667 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.948 HD12 ' CH2' ' A' ' 130' ' ' TRP . 45.8 mt -72.47 -36.34 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.446 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.677 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -103.02 31.67 4.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.323 -0.86 . . . . 0.0 109.588 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.62 -78.73 0.1 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.54 -27.74 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.434 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 13.4 p-10 -80.01 -20.15 46.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 0.0 109.607 179.959 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.677 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 21.4 t30 56.16 27.7 11.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.875 . . . . 0.0 109.645 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.94 22.38 42.51 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -59.21 -52.37 65.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -1.161 . . . . 0.0 109.569 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.425 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -92.92 26.11 16.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.696 HG11 HD11 ' A' ' 63' ' ' LEU . 39.2 t -110.14 -22.73 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.29 -1.123 . . . . 0.0 108.887 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.412 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -100.15 -26.97 8.01 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 179.79 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.485 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 14.2 ptpt -70.19 -34.99 73.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.245 -1.15 . . . . 0.0 109.385 179.789 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.737 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -92.34 -8.9 43.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.157 -0.964 . . . . 0.0 109.839 179.678 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.6 t -93.25 -61.3 1.6 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.067 -1.021 . . . . 0.0 109.722 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.509 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.9 m-85 -55.64 -30.56 61.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.926 . . . . 0.0 109.768 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.759 ' OG1' HG11 ' A' ' 55' ' ' VAL . 17.8 m -58.35 -48.01 81.96 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.125 -0.984 . . . . 0.0 109.395 179.794 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.31 -41.33 98.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.317 -0.865 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.643 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.4 t80 -62.14 -44.67 96.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.251 -0.905 . . . . 0.0 109.43 179.84 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.793 ' CD1' HG22 ' A' ' 55' ' ' VAL . 15.7 mt -62.8 -45.53 92.22 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.642 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 3.2 p -66.28 -46.75 75.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.738 -179.934 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.587 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -70.71 -21.4 62.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.753 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.587 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 33.7 m-70 -127.82 114.31 17.07 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.758 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -93.22 5.29 52.03 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.357 -0.839 . . . . 0.0 109.984 179.736 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -95.6 -22.18 17.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.044 -1.035 . . . . 0.0 109.486 179.811 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.482 ' SD ' ' CG ' ' A' ' 102' ' ' TYR . 0.4 OUTLIER -97.01 -22.45 16.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.309 -0.87 . . . . 0.0 109.615 179.977 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.415 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.16 -50.75 61.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.196 -0.94 . . . . 0.0 109.536 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -66.41 -21.39 66.22 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.895 . . . . 0.0 109.585 179.897 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.944 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.6 t -79.73 -55.98 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.517 ' CD2' HD21 ' A' ' 35' ' ' LEU . 33.7 m-85 -53.74 -40.9 66.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.79 31.78 1.41 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 -179.849 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.504 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.9 m-85 -125.36 -179.07 4.44 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -1.176 . . . . 0.0 109.749 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.9 t -123.99 19.17 9.25 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.417 -0.802 . . . . 0.0 109.299 179.481 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.44 -163.38 27.53 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.642 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -77.92 -19.08 55.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.698 -180.0 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 8.5 t -85.41 50.13 1.89 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -128.62 117.8 19.84 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.615 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -59.28 -29.54 90.56 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.842 1.443 . . . . 0.0 110.108 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.504 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.96 -34.49 38.44 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.793 HG22 ' CD1' ' A' ' 35' ' ' LEU . 89.3 t -52.26 -31.47 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.274 -1.133 . . . . 0.0 109.636 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.427 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -77.36 -21.86 52.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.487 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.83 -45.55 16.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.9 . . . . 0.0 109.557 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.956 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.9 mt -68.25 -59.06 3.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -0.925 . . . . 0.0 109.535 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.509 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -51.17 -54.8 21.77 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.421 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -53.19 -37.61 62.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -1.17 . . . . 0.0 109.59 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 mttm -77.98 -25.79 48.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.956 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.9 t -82.61 -40.91 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.696 HD11 HG11 ' A' ' 26' ' ' VAL . 1.6 mm? -50.11 -55.03 16.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.554 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -43.67 36.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.229 -0.919 . . . . 0.0 109.71 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.414 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 0.2 OUTLIER -51.59 -54.17 30.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 179.79 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.78 ' O ' HG23 ' A' ' 70' ' ' VAL . 69.2 mt -55.48 -34.65 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.263 -0.898 . . . . 0.0 108.98 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.567 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.84 -55.15 18.23 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.5 t -57.79 -22.12 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.322 -1.105 . . . . 0.0 109.138 179.759 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.68 -31.17 21.18 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.392 -0.818 . . . . 0.0 109.461 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.78 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.0 t -69.24 -17.09 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 109.484 179.728 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -61.97 -37.93 86.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -0.941 . . . . 0.0 109.912 -179.832 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.437 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 22.5 m-70 -129.29 81.73 2.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 109.885 -179.815 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.611 HD11 HG11 ' A' ' 10' ' ' VAL . 53.5 mt . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.892 . . . . 0.0 109.461 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.437 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 49.5 ttp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 121.287 0.565 . . . . 0.0 109.652 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.455 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 60.0 t -77.29 -0.53 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 110.036 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.11 -24.12 26.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.04 -1.038 . . . . 0.0 109.595 -179.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.564 ' O ' HG23 ' A' ' 86' ' ' VAL . 4.6 tt0 -106.77 -41.05 5.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.545 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.638 ' HE2' HD12 ' A' ' 141' ' ' LEU . 10.1 mtp -67.98 -40.81 83.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.219 -0.926 . . . . 0.0 108.949 179.653 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 6.0 tttt -56.28 -28.56 59.12 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 179.009 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.425 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -78.49 -31.92 47.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.48 -0.763 . . . . 0.0 109.056 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.936 ' CG1' HD11 ' A' ' 141' ' ' LEU . 47.3 t -62.72 -41.78 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.245 -0.91 . . . . 0.0 109.06 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 141' ' ' LEU . . . -54.06 -41.78 69.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.356 -1.898 . . . . 0.0 108.356 179.53 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.442 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 97.5 t -56.34 -46.54 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.426 -1.043 . . . . 0.0 109.252 179.475 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.518 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 10.4 mpt_? -52.05 -29.96 23.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.028 -1.045 . . . . 0.0 109.054 179.466 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.503 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 34.6 m80 -84.22 9.51 12.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.417 -0.802 . . . . 0.0 110.022 -179.894 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 25.0 ttpt -104.36 -11.74 16.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.034 -1.041 . . . . 0.0 110.241 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.17 18.79 2.31 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.142 -1.504 . . . . 0.0 110.855 -179.242 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CZ ' ' HB3' ' A' ' 89' ' ' ARG . 1.6 m-85 -58.9 -164.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.644 -1.504 . . . . 0.0 109.174 179.317 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.77 -31.21 40.83 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 179.625 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.944 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -81.14 -48.67 11.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.529 -0.983 . . . . 0.0 108.787 179.703 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.8 tmtt? 76.83 -19.3 0.43 Allowed 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.652 -0.655 . . . . 0.0 111.901 179.162 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.414 ' HB2' ' OD1' ' A' ' 95' ' ' ASN . 37.8 m170 -72.31 -95.82 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.443 -1.411 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.496 HG13 ' ND2' ' A' ' 95' ' ' ASN . 8.1 mt 61.71 148.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 120.858 -1.151 . . . . 0.0 110.511 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -156.88 149.66 23.63 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 121.943 0.878 . . . . 0.0 110.521 179.812 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.4 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -76.83 -7.29 55.18 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.681 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.567 ' CG ' ' CD2' ' A' ' 102' ' ' TYR . 12.0 pt-20 -71.38 -34.23 70.24 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.95 -1.094 . . . . 0.0 109.082 179.461 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.567 ' CD2' ' CG ' ' A' ' 101' ' ' GLU . 94.3 m-85 -80.3 -25.46 39.35 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 109.329 179.566 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.481 ' CD2' ' OG ' ' A' ' 138' ' ' SER . 2.7 m-85 -48.12 -62.16 1.62 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.358 -0.839 . . . . 0.0 110.236 -179.798 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.513 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -51.97 -59.84 7.41 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.177 -0.952 . . . . 0.0 110.173 -179.366 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.513 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 36.1 Cg_exo -47.53 -59.69 1.15 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.586 1.309 . . . . 0.0 110.229 179.91 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.922 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.29 -22.57 12.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.91 . . . . 0.0 109.406 179.906 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.01 -44.09 9.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.96 -49.96 74.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -1.163 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 75.6 m -56.65 -31.29 64.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 109.603 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 2.6 tt -62.75 -43.83 97.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.602 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.71 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.7 mt -53.87 -39.19 65.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 13.5 t -62.3 -32.02 72.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.235 -0.915 . . . . 0.0 109.503 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.737 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -78.91 -39.73 34.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.41 179.758 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.547 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -48.72 -45.73 39.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -48.32 -29.31 3.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -0.927 . . . . 0.0 109.968 -179.838 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.419 ' CE1' ' OE1' ' A' ' 29' ' ' GLU . 17.5 m170 -49.9 -56.4 10.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.082 -1.011 . . . . 0.0 109.817 -179.826 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.8 ttt85 -69.77 -63.57 1.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.849 -179.82 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.532 HG12 HD11 ' A' ' 17' ' ' ILE . 4.7 pt -96.61 58.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.313 -0.867 . . . . 0.0 109.709 -179.789 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.36 -20.32 71.38 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.73 -21.1 17.21 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.865 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.494 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -100.62 -19.37 16.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -1.187 . . . . 0.0 109.884 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.406 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.95 79.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.051 -1.031 . . . . 0.0 109.799 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.742 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 15.7 p-10 -80.13 -171.97 3.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.172 179.589 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.452 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.12 -31.35 68.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.066 -1.021 . . . . 0.0 109.907 -179.81 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.742 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -72.18 -23.69 61.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.038 -1.039 . . . . 0.0 109.024 179.668 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.476 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -74.88 -47.55 29.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 108.892 179.403 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 6.9 ptpt -71.79 -31.28 66.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.413 -0.805 . . . . 0.0 109.232 179.569 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.477 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.4 t70 -75.78 -48.52 21.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.777 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -58.55 -44.57 89.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.422 -0.799 . . . . 0.0 109.493 179.844 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.948 ' CH2' HD12 ' A' ' 17' ' ' ILE . 7.0 m0 -74.88 -26.17 59.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.245 179.838 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.611 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.12 -27.3 65.45 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.246 -0.909 . . . . 0.0 108.979 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.414 ' HB3' ' OE1' ' A' ' 6' ' ' GLN . . . -93.46 -23.06 18.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.192 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.629 ' O ' HD12 ' A' ' 137' ' ' ILE . . . -79.81 -42.88 23.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.395 -0.816 . . . . 0.0 109.556 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -49.26 -33.32 12.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.207 -0.933 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.74 -25.15 49.02 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.229 -0.919 . . . . 0.0 108.938 179.412 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.436 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.7 t0 -85.95 -40.76 15.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.387 -0.821 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.629 HD12 ' O ' ' A' ' 133' ' ' ALA . 1.6 mp -65.8 -59.6 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 108.824 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.481 ' OG ' ' CD2' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -64.6 -25.22 67.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.243 -0.911 . . . . 0.0 109.745 -179.85 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.572 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -55.68 -49.56 65.02 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.94 -17.75 64.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.234 -1.156 . . . . 0.0 109.845 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.936 HD11 ' CG1' ' A' ' 86' ' ' VAL . 5.1 tt -84.19 -33.38 24.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.15 -0.969 . . . . 0.0 109.738 -179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.572 HD12 ' HA2' ' A' ' 139' ' ' GLY . 50.6 mt -68.48 -9.25 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 110.065 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 67.6 m -70.51 -65.15 0.77 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.069 -1.019 . . . . 0.0 109.595 179.835 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.45 -7.37 64.09 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.487 HD12 ' HB2' ' A' ' 90' ' ' HIS . 5.9 tt . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.08 -1.247 . . . . 0.0 109.48 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.765 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.161 0.505 . . . . 0.0 109.647 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.69 -47.74 18.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.42 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 8.3 ptm180 -52.54 -32.69 41.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.153 -0.967 . . . . 0.0 108.738 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.42 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 49.4 tp60 -71.16 -36.01 71.85 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 5' ' ' ALA . 47.5 t -73.3 -31.74 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.391 -0.818 . . . . 0.0 108.942 179.196 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.758 HG12 HG13 ' A' ' 70' ' ' VAL . 41.9 t -70.03 -37.49 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.743 . . . . 0.0 109.357 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.08 -16.35 58.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.691 179.903 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.4 -27.22 21.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.925 . . . . 0.0 109.693 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.2 p -88.5 -14.2 38.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.79 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.562 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.34 -20.55 21.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.125 -0.985 . . . . 0.0 109.717 -179.767 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.5 mtpp -79.74 -0.05 32.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.839 179.694 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -113.32 -56.35 2.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.011 -1.055 . . . . 0.0 109.553 179.856 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.94 HD12 ' CH2' ' A' ' 130' ' ' TRP . 73.9 mt -62.54 -34.18 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.202 -0.936 . . . . 0.0 109.55 179.939 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.526 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.5 36.66 2.44 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.271 -0.893 . . . . 0.0 109.771 -179.889 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.86 -88.19 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.9 p -112.28 15.04 20.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -1.132 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.423 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 4.3 p-10 -122.1 -9.14 8.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.164 -0.96 . . . . 0.0 110.032 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.601 ' ND2' ' HB2' ' A' ' 64' ' ' ALA . 9.0 t30 56.41 20.17 4.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.565 -179.711 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.586 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 80.06 34.32 30.45 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.719 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.405 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -56.39 -43.99 79.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -1.139 . . . . 0.0 109.62 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.486 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.96 -18.32 72.67 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.91 HG11 HD21 ' A' ' 63' ' ' LEU . 25.7 t -68.76 -31.86 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.551 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.23 -54.32 4.44 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.611 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.486 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.7 ptpt -55.19 -24.71 28.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -1.163 . . . . 0.0 110.108 -179.487 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.783 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 23.1 pt-20 -98.23 -16.15 19.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.001 -1.062 . . . . 0.0 109.851 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.426 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 40.5 t -90.78 -60.19 1.98 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.186 -0.946 . . . . 0.0 110.014 -179.628 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -59.83 -32.0 70.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.218 -0.926 . . . . 0.0 110.167 -179.412 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.859 ' OG1' HG11 ' A' ' 55' ' ' VAL . 16.6 m -60.65 -45.05 95.55 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.096 -1.002 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.422 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 3.3 mttm -64.7 -29.26 70.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 179.91 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.652 ' CG ' HD23 ' A' ' 106' ' ' LEU . 17.0 t80 -78.3 -49.58 13.39 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.279 -0.888 . . . . 0.0 109.458 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.691 HD13 HG22 ' A' ' 55' ' ' VAL . 13.3 mt -51.84 -46.43 64.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.333 -0.854 . . . . 0.0 109.687 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.476 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 7.3 t -61.82 -59.96 4.36 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 109.677 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.593 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -62.35 -23.04 66.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.24 -0.912 . . . . 0.0 109.73 -179.919 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.593 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 25.5 m-70 -121.22 99.35 6.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 109.688 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -85.33 -19.79 30.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.309 -0.87 . . . . 0.0 109.531 179.936 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -69.28 -20.53 63.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.695 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.435 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 7.3 mmm -108.83 -16.83 14.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.201 -0.937 . . . . 0.0 109.824 -179.927 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.469 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -50.47 -41.0 52.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 0.0 109.378 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -76.47 -32.1 58.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.299 -0.876 . . . . 0.0 109.159 179.583 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.03 HG13 ' ND2' ' A' ' 95' ' ' ASN . 24.7 t -59.18 -56.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.384 -0.823 . . . . 0.0 109.245 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.546 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 62.4 m-85 -54.19 -31.03 51.77 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.21 29.68 3.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.873 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.546 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.5 m-85 -123.81 167.6 13.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 17.93 20.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.885 . . . . 0.0 109.422 179.625 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.74 -164.06 29.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.476 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -93.5 28.71 2.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -1.15 . . . . 0.0 109.618 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 99.5 p -126.91 28.1 5.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.08 137.44 22.44 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -65.67 -24.46 55.19 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.931 1.49 . . . . 0.0 110.095 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.22 -36.33 44.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.859 HG11 ' OG1' ' A' ' 32' ' ' THR . 94.6 t -50.99 -39.9 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.299 -1.118 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.71 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -76.54 -1.25 26.42 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.292 -0.88 . . . . 0.0 109.831 179.714 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -96.47 -27.45 14.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.05 -1.031 . . . . 0.0 109.703 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.787 ' O ' HG23 ' A' ' 62' ' ' VAL . 6.9 mt -86.65 -62.27 1.55 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.426 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -57.62 -24.67 53.65 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.71 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -66.53 -31.61 72.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.634 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.3 mtpt -101.82 -39.58 7.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.428 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.787 HG23 ' O ' ' A' ' 58' ' ' LEU . 58.3 t -51.7 -53.77 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.27 -0.894 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.91 HD21 HG11 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -45.9 -44.5 14.63 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.321 -0.862 . . . . 0.0 110.42 -179.705 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.601 ' HB2' ' ND2' ' A' ' 22' ' ' ASN . . . -52.99 -30.02 32.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.025 . . . . 0.0 109.674 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 60.7 tp60 -69.49 -31.97 70.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 108.834 179.178 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 70' ' ' VAL . 94.0 mt -72.97 -31.5 35.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.413 -0.804 . . . . 0.0 108.861 179.271 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.562 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.09 -48.37 40.12 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 179.551 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.1 t -63.66 -24.17 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.246 -1.149 . . . . 0.0 109.113 179.736 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.04 -26.46 25.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.468 -0.77 . . . . 0.0 109.481 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 66' ' ' ILE . 48.6 t -67.57 -13.71 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.212 -0.93 . . . . 0.0 109.718 179.842 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.418 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -81.09 -16.9 51.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.849 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 5.7 m-70 -128.76 66.99 1.41 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.177 -0.952 . . . . 0.0 109.672 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.631 HD11 ' HA ' ' A' ' 70' ' ' VAL . 65.2 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.305 -0.872 . . . . 0.0 109.534 179.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 11.8 tmm? . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.324 0.583 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.411 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.6 t -73.13 -20.43 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.895 . . . . 0.0 109.421 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.3 -56.63 19.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 179.761 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.61 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -64.18 -53.2 53.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.355 -0.841 . . . . 0.0 109.233 179.664 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.418 ' HG3' ' O ' ' A' ' 79' ' ' MET . 0.5 OUTLIER -53.15 -57.05 11.79 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.68 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.467 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.86 -29.17 18.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.013 179.488 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -72.39 -42.82 64.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.43 -0.794 . . . . 0.0 109.133 179.608 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 82' ' ' GLU . 16.7 t -62.27 -35.77 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.017 179.621 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.466 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -57.46 -44.2 93.75 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.591 -1.803 . . . . 0.0 108.591 179.612 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 90.2 t -54.96 -35.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.285 -1.127 . . . . 0.0 109.033 179.397 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 6.9 mpt_? -70.69 -30.79 67.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.387 -0.821 . . . . 0.0 109.163 179.55 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.768 ' CB ' HD13 ' A' ' 145' ' ' LEU . 27.5 m80 -80.04 2.85 22.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.346 -0.846 . . . . 0.0 109.974 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.3 ttmt -101.07 14.01 33.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.057 -1.027 . . . . 0.0 110.011 -179.539 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -169.41 31.51 0.16 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.231 -1.462 . . . . 0.0 110.543 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.53 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.9 m-85 -74.08 -163.82 0.2 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.739 -1.448 . . . . 0.0 109.688 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -65.29 -53.45 32.78 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.521 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.03 ' ND2' HG13 ' A' ' 44' ' ' VAL . 14.6 p-10 -67.37 -33.67 75.69 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -1.164 . . . . 0.0 109.849 -179.729 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 mttt 55.27 21.19 3.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.241 -0.912 . . . . 0.0 109.633 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -128.3 48.66 2.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.49 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.727 HD13 ' CD2' ' A' ' 90' ' ' HIS . 61.9 mt -86.33 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.771 -179.883 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.494 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 4.8 mptt -141.73 143.52 33.56 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.325 -0.859 . . . . 0.0 109.766 -179.895 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.659 ' CB ' HG23 ' A' ' 142' ' ' ILE . . . -83.19 6.93 17.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.851 179.69 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.26 -21.12 21.24 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.178 -0.951 . . . . 0.0 108.779 179.723 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.494 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 61.5 m-85 -85.16 -13.16 50.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.642 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.3 m-85 -61.07 -61.2 2.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.164 -0.96 . . . . 0.0 110.038 -179.818 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -49.44 -56.94 13.53 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.881 -179.612 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -50.94 -62.0 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.684 1.36 . . . . 0.0 109.929 179.741 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.778 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -57.99 -25.86 61.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.29 -0.881 . . . . 0.0 109.46 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.498 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -72.97 -39.55 54.04 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.985 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.43 -50.0 71.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.217 -1.167 . . . . 0.0 109.479 179.863 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 9.0 m -57.3 -20.64 29.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 109.482 179.832 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.456 HD23 ' HG3' ' A' ' 114' ' ' MET . 1.1 tt -69.18 -46.17 68.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.746 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.736 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.4 mt -58.56 -30.5 67.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.142 -0.974 . . . . 0.0 109.442 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.3 m -73.45 -40.87 63.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.246 -0.909 . . . . 0.0 109.671 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.783 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -74.46 -31.01 62.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.235 -0.915 . . . . 0.0 109.653 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.503 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.8 mmt -60.06 -43.05 95.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.2 OUTLIER -49.81 -25.37 3.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.778 -179.884 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -53.76 -56.21 19.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.204 -0.935 . . . . 0.0 109.797 -179.862 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.405 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -64.59 -58.64 5.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.153 -0.967 . . . . 0.0 109.749 -179.877 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.526 HG12 HD11 ' A' ' 17' ' ' ILE . 5.3 pt -103.04 59.59 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.922 . . . . 0.0 109.737 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.77 -27.72 73.58 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.932 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -95.69 -17.59 35.35 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 5.4 mptt -101.7 -23.37 14.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 109.758 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.456 ' CA ' HD12 ' A' ' 118' ' ' ILE . 0.3 OUTLIER -71.29 83.9 0.77 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.138 -0.977 . . . . 0.0 109.581 179.937 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.574 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.3 p30 -81.39 -167.88 1.64 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.327 -0.858 . . . . 0.0 109.54 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -65.95 -47.81 73.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.574 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -56.96 -31.68 65.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.395 179.768 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -66.63 -53.03 38.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.822 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.521 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 2.5 ptpt -70.01 -26.6 64.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.263 179.727 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.476 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 38.7 t0 -82.53 -36.18 26.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 109.426 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.61 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -67.02 -43.26 83.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.758 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.94 ' CH2' HD12 ' A' ' 17' ' ' ILE . 12.1 m0 -76.7 -29.13 56.13 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.238 -0.913 . . . . 0.0 109.062 179.903 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -50.68 -43.05 57.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.319 -0.863 . . . . 0.0 109.098 179.43 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.13 -17.32 35.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.419 -0.801 . . . . 0.0 109.228 179.33 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.711 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -88.01 -61.57 1.69 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.246 -0.909 . . . . 0.0 109.704 179.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.502 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.47 -27.01 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.07 -1.019 . . . . 0.0 109.144 -179.825 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.23 -31.56 30.2 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.305 -0.872 . . . . 0.0 108.795 179.17 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -82.1 -37.83 25.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.448 -0.783 . . . . 0.0 109.405 179.729 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.45 HD12 ' N ' ' A' ' 137' ' ' ILE . 1.6 mp -65.86 -58.4 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 108.776 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -29.87 70.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.492 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -70.5 -35.63 68.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.48 -23.94 66.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -1.176 . . . . 0.0 109.614 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.667 ' O ' HD23 ' A' ' 141' ' ' LEU . 8.7 tt -74.55 -17.3 60.76 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.254 -0.904 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.659 HG23 ' CB ' ' A' ' 100' ' ' ALA . 58.7 mt -76.39 -0.96 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 110.101 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.467 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 19.5 m -66.91 -32.9 74.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.991 -1.068 . . . . 0.0 109.051 179.669 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.4 -10.98 8.33 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.62 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.768 HD13 ' CB ' ' A' ' 90' ' ' HIS . 19.2 tp . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.041 -1.27 . . . . 0.0 109.571 -179.904 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.603 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.244 0.545 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.424 ' O ' HG23 ' A' ' 10' ' ' VAL . 42.1 mt-30 -78.29 -52.27 8.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.169 -0.957 . . . . 0.0 109.887 -179.856 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.98 -29.37 12.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.97 -1.081 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -70.71 -45.21 65.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 0.0 108.778 179.353 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 5' ' ' ALA . 44.8 t -62.12 -31.25 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.364 -0.835 . . . . 0.0 108.859 179.27 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 1.048 HG12 HG13 ' A' ' 70' ' ' VAL . 98.6 t -66.03 -50.13 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.512 -0.743 . . . . 0.0 109.4 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.11 61.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.9 m -83.45 -25.05 31.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.105 -0.997 . . . . 0.0 109.744 -179.919 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.452 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 38.2 p -100.22 -10.18 21.64 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.92 . . . . 0.0 110.043 -179.907 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.12 -25.8 19.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.027 -1.046 . . . . 0.0 109.609 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.9 mtpp -76.05 -12.8 60.19 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.224 -0.923 . . . . 0.0 109.641 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.468 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.4 OUTLIER -103.02 -52.67 3.0 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.949 HD12 ' CH2' ' A' ' 130' ' ' TRP . 44.1 mt -65.14 -34.78 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.271 -0.893 . . . . 0.0 109.581 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.891 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -107.91 35.24 3.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.719 -179.948 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.1 -84.14 0.03 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 78.3 p -97.51 -23.41 16.04 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.307 -1.114 . . . . 0.0 109.617 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.629 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 12.3 p-10 -83.34 -21.45 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.891 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 9.9 t30 56.79 20.57 5.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.92 . . . . 0.0 109.61 179.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.2 20.94 11.39 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.629 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.49 -47.52 69.8 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.567 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -93.34 31.63 6.26 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.517 ' CG1' HD21 ' A' ' 110' ' ' LEU . 41.9 t -119.05 -35.91 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.297 -1.12 . . . . 0.0 108.942 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.462 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -90.26 -41.17 5.58 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.766 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.481 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.3 ptpt -61.08 -30.63 70.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 109.587 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.79 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -90.41 -25.16 20.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.124 -0.985 . . . . 0.0 109.422 179.798 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 41.4 t -85.54 -50.63 7.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.353 -0.842 . . . . 0.0 109.574 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 5.0 m-30 -55.2 -37.56 67.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.585 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.574 ' OG1' HG11 ' A' ' 55' ' ' VAL . 98.6 m -55.82 -45.89 78.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.901 . . . . 0.0 109.347 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.411 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 13.6 mttp -66.59 -47.63 72.12 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.403 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.532 ' CG ' HD23 ' A' ' 106' ' ' LEU . 4.3 t80 -55.7 -49.94 71.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.297 179.794 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.732 ' CD1' HG22 ' A' ' 55' ' ' VAL . 32.3 mt -59.48 -45.1 92.63 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.89 -61.68 2.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.691 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -58.04 -28.64 64.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.694 -179.906 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.657 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 9.4 m-70 -118.0 103.38 9.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.718 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -85.61 -21.45 28.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.34 -0.85 . . . . 0.0 109.345 179.634 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.2 p-10 -68.23 -20.49 64.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.912 . . . . 0.0 109.275 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.49 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 92.2 mmm -103.26 -22.35 13.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.581 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -51.17 -44.45 61.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.031 -1.043 . . . . 0.0 109.338 179.825 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.68 -23.38 59.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.346 -0.846 . . . . 0.0 109.136 179.565 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.047 HG13 ' ND2' ' A' ' 95' ' ' ASN . 29.2 t -73.44 -39.96 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.423 -0.798 . . . . 0.0 109.202 179.733 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.542 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -68.89 -38.95 79.97 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.573 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.404 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 117.66 28.22 2.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.882 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.542 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.3 m-85 -122.31 172.23 8.47 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.199 -1.177 . . . . 0.0 109.692 -179.981 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 11.7 t -111.13 19.22 18.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.316 -0.865 . . . . 0.0 109.351 179.493 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.95 -164.0 29.87 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.79 5.82 41.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -1.162 . . . . 0.0 110.073 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 15.2 t -110.09 42.27 1.56 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.001 -1.062 . . . . 0.0 109.548 179.976 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.414 ' HA ' ' HD3' ' A' ' 53' ' ' PRO . 0.4 OUTLIER -115.85 131.54 23.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 0.0 109.624 -179.979 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 16.9 Cg_exo -61.34 -20.47 68.36 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 123.81 1.426 . . . . 0.0 109.949 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.9 -35.95 88.52 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.732 HG22 ' CD1' ' A' ' 35' ' ' LEU . 58.9 t -54.56 -22.78 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -1.095 . . . . 0.0 109.468 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.457 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -86.47 -19.44 29.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.319 -0.863 . . . . 0.0 109.571 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.406 ' O ' ' HB2' ' A' ' 61' ' ' LYS . 0.3 OUTLIER -88.11 -26.45 22.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.296 -0.878 . . . . 0.0 109.588 -179.994 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.714 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.7 mt -86.44 -66.58 0.89 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.188 -0.945 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.553 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -49.46 -37.06 25.1 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.439 ' HB3' ' O ' ' A' ' 56' ' ' ALA . . . -72.45 -22.32 61.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.151 -1.205 . . . . 0.0 109.946 -179.698 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.406 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 4.7 mttp -94.55 -21.9 18.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.122 -0.986 . . . . 0.0 109.827 -179.868 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 58' ' ' LEU . 23.3 t -83.71 -46.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.938 . . . . 0.0 109.889 -179.784 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.671 HD21 HD11 ' A' ' 110' ' ' LEU . 2.9 mm? -47.86 -46.88 31.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -51.91 25.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.194 -0.941 . . . . 0.0 109.992 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -50.65 -42.98 57.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.07 -1.019 . . . . 0.0 109.438 -179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.881 ' O ' HG23 ' A' ' 70' ' ' VAL . 39.8 mt -61.34 -38.36 79.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.312 -0.868 . . . . 0.0 109.238 179.621 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.566 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.73 -50.97 57.62 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.873 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.4 t -61.22 -29.96 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.083 -1.245 . . . . 0.0 109.467 -179.823 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.607 ' O ' HD21 ' A' ' 73' ' ' LEU . . . -84.72 -14.52 48.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.424 -0.798 . . . . 0.0 110.094 -179.42 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.048 HG13 HG12 ' A' ' 10' ' ' VAL . 41.6 t -84.64 -43.36 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.027 -1.046 . . . . 0.0 110.091 -179.409 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.35 -24.75 2.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.987 -1.07 . . . . 0.0 109.33 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.443 ' O ' ' HB2' ' A' ' 73' ' ' LEU . 3.2 m-70 -93.83 -114.08 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.532 -0.73 . . . . 0.0 109.946 -179.787 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.799 HD11 ' HA ' ' A' ' 70' ' ' VAL . 16.5 mt . . . . . 0 N--CA 1.5 2.056 0 O-C-N 121.027 -1.045 . . . . 0.0 110.392 -179.289 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.5 t -51.21 -31.11 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.076 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.24 -35.61 76.3 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.434 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.3 OUTLIER -61.27 -52.97 62.49 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.215 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.556 ' CE ' HD12 ' A' ' 141' ' ' LEU . 86.5 mmm -56.96 -38.56 73.13 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.255 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -35.74 40.96 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.434 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -67.89 -32.37 72.81 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 1.044 HG11 HD11 ' A' ' 141' ' ' LEU . 48.6 t -59.38 -51.95 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 108.785 179.432 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.47 ' O ' HD12 ' A' ' 145' ' ' LEU . . . -56.66 -52.94 47.42 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.061 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.764 HG23 ' HA3' ' A' ' 144' ' ' GLY . 63.3 t -51.75 -33.26 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.397 -1.061 . . . . 0.0 108.817 179.065 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.508 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.0 mmm180 -76.43 -49.75 15.88 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.189 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.582 ' HB2' HD13 ' A' ' 145' ' ' LEU . 2.1 m80 -58.92 -21.24 57.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.464 -0.772 . . . . 0.0 109.115 179.332 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.434 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -66.72 -12.08 57.07 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.314 -0.866 . . . . 0.0 110.254 -179.704 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.31 53.49 0.6 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.634 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.552 ' CZ ' ' ND1' ' A' ' 90' ' ' HIS . 3.1 m-30 -89.23 -164.36 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.238 -1.154 . . . . 0.0 109.702 179.734 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.14 -51.14 19.33 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.047 ' ND2' HG13 ' A' ' 44' ' ' VAL . 17.1 p-10 -69.16 -32.36 71.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.14 -1.212 . . . . 0.0 109.828 -179.686 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.8 tttm 58.26 18.86 5.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.197 -0.939 . . . . 0.0 109.699 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 15.4 m170 -125.75 41.27 3.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.69 -179.935 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.566 HD13 ' CD2' ' A' ' 90' ' ' HIS . 36.4 mt -81.32 155.75 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.184 -0.947 . . . . 0.0 109.679 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.473 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.1 mptp? -136.58 145.58 45.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.884 -179.825 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.782 ' HB1' ' CG1' ' A' ' 142' ' ' ILE . . . -86.4 11.77 11.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.954 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.566 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 15.5 pt-20 -95.48 -24.21 16.76 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.107 -0.995 . . . . 0.0 109.557 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.566 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 88.7 m-85 -83.03 -7.39 59.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.928 179.722 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.736 ' CZ ' HD22 ' A' ' 141' ' ' LEU . 11.3 m-85 -66.87 -52.17 46.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.096 -1.002 . . . . 0.0 109.945 -179.739 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.504 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.5 tm-20 -56.54 -55.61 40.99 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.131 -0.98 . . . . 0.0 109.867 -179.685 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.83 -61.85 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 123.755 1.397 . . . . 0.0 109.83 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.925 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.75 -23.78 31.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.291 -0.88 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.99 -48.67 6.84 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.36 65.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -1.191 . . . . 0.0 109.414 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.0 m -75.28 -31.01 60.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.872 . . . . 0.0 109.518 179.893 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.813 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.0 OUTLIER -70.13 -30.16 67.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.41 179.905 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.696 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.1 mt -64.34 -32.11 73.59 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.348 179.767 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.4 OUTLIER -74.89 -26.2 59.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 109.54 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.79 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.77 -35.78 20.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.247 -0.908 . . . . 0.0 109.518 -179.885 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.512 ' HE3' HD22 ' A' ' 110' ' ' LEU . 2.8 mtt -49.44 -45.08 46.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 0.0 110.116 -179.717 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' SER . 13.3 pt-20 -50.27 -25.69 3.98 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.153 -0.967 . . . . 0.0 109.907 -179.719 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.405 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 29.7 m170 -50.12 -39.92 44.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.635 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.447 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 3.2 ttt85 -80.17 -61.7 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.179 -0.951 . . . . 0.0 109.539 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.468 ' CG2' ' HB3' ' A' ' 16' ' ' ASP . 7.2 pt -89.35 44.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.236 -0.915 . . . . 0.0 109.521 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -51.62 123.07 18.15 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 102.12 -39.82 2.64 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.873 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.431 ' O ' ' N ' ' A' ' 123' ' ' ASN . 29.9 mttp -83.54 -29.5 27.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -1.14 . . . . 0.0 109.439 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.407 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.26 76.73 0.1 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.235 179.727 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.581 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.4 p30 -79.8 -167.67 1.33 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.311 -0.868 . . . . 0.0 109.875 -179.714 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.469 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.95 -45.9 87.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.839 . . . . 0.0 109.531 179.868 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.581 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -58.07 -33.46 69.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.283 -0.886 . . . . 0.0 109.283 179.832 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.01 -53.38 20.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.28 -0.888 . . . . 0.0 109.417 179.832 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.503 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 11.9 ptpt -70.47 -26.84 63.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.191 -0.943 . . . . 0.0 109.356 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.447 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.8 t70 -81.91 -39.81 23.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.357 179.557 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -62.37 -43.54 98.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.375 -0.828 . . . . 0.0 109.241 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.949 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.0 m0 -75.57 -31.89 60.17 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.304 -0.873 . . . . 0.0 108.7 179.563 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.503 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -55.46 -30.84 61.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 108.631 178.867 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.11 -28.89 22.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.797 . . . . 0.0 109.101 179.477 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -82.93 -52.65 6.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.431 -0.793 . . . . 0.0 109.465 179.899 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.813 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.1 OUTLIER -49.85 -30.05 9.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 0.0 109.376 179.85 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -78.73 -27.62 44.87 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.275 -0.891 . . . . 0.0 108.984 179.456 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' A' ' 133' ' ' ALA . 2.4 t0 -84.12 -39.86 18.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.435 -0.791 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.558 HD13 HG23 ' A' ' 66' ' ' ILE . 8.2 mt -67.7 -56.33 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.497 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.556 ' O ' HD12 ' A' ' 142' ' ' ILE . 87.2 p -69.37 -36.7 77.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.334 -0.853 . . . . 0.0 109.607 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.558 ' HA2' HD13 ' A' ' 142' ' ' ILE . . . -56.23 -23.11 39.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.942 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.03 59.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 0.0 109.998 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.044 HD11 HG11 ' A' ' 86' ' ' VAL . 0.2 OUTLIER -91.4 -19.45 22.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.109 -0.994 . . . . 0.0 109.811 -179.847 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.782 ' CG1' ' HB1' ' A' ' 100' ' ' ALA . 3.2 mp -80.06 3.37 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.218 -0.926 . . . . 0.0 110.115 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 23.4 m -100.8 -31.09 11.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.01 -1.057 . . . . 0.0 109.925 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.764 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -93.1 -21.47 30.14 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.609 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.582 HD13 ' HB2' ' A' ' 90' ' ' HIS . 12.8 tp . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.179 -1.189 . . . . 0.0 109.315 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.852 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 120.941 0.4 . . . . 0.0 110.187 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.817 ' O ' HG23 ' A' ' 10' ' ' VAL . 65.7 mt-30 -70.99 -50.5 33.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.967 -1.083 . . . . 0.0 109.43 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.475 ' HG2' ' HB2' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -53.06 -24.25 9.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.048 179.583 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 5.8 mp0 -83.16 -53.29 5.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.434 -0.791 . . . . 0.0 109.521 179.893 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 5' ' ' ALA . 21.2 t -55.37 -33.99 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.817 HG23 ' O ' ' A' ' 6' ' ' GLN . 93.8 t -57.33 -43.17 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.95 -10.12 59.16 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.271 -0.893 . . . . 0.0 109.896 179.836 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 t -93.56 -26.21 17.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.123 -0.986 . . . . 0.0 109.99 -179.718 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.449 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 20.6 p -95.74 -15.25 22.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -0.971 . . . . 0.0 109.965 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.799 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -88.49 -23.02 23.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.065 -1.022 . . . . 0.0 109.686 -179.933 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 73.4 mttt -81.6 1.67 32.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.934 . . . . 0.0 109.852 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.57 -48.51 2.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.128 -0.982 . . . . 0.0 109.263 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.994 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.0 mt -71.31 -28.76 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.432 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.696 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -109.33 34.42 3.77 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.235 -0.916 . . . . 0.0 109.603 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.15 -86.93 0.01 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.9 p -100.77 -24.46 14.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -1.145 . . . . 0.0 109.706 -179.99 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.647 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.7 p-10 -81.02 -20.77 41.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.936 . . . . 0.0 109.699 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.696 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 28.8 t30 56.93 30.06 17.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.592 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.828 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 88.53 37.71 7.4 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.647 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -79.02 -49.63 12.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -1.144 . . . . 0.0 109.655 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.487 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -76.23 -23.55 70.88 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 -179.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.005 HG12 HD11 ' A' ' 63' ' ' LEU . 41.5 t -67.01 -27.2 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.334 -1.097 . . . . 0.0 109.817 -179.936 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.4 ' HA3' ' C ' ' A' ' 59' ' ' GLY . . . -84.69 -50.79 4.07 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.487 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.2 ptpt -57.62 -24.17 55.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -1.203 . . . . 0.0 110.041 -179.556 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.428 ' O ' ' CD ' ' A' ' 33' ' ' LYS . 12.2 pt-20 -97.06 -28.39 14.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.036 -1.04 . . . . 0.0 109.768 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.407 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 37.1 t -83.99 -52.5 6.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 109.709 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 3.7 m-30 -60.45 -45.27 94.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.322 -0.861 . . . . 0.0 109.787 -179.806 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.748 ' OG1' HG11 ' A' ' 55' ' ' VAL . 21.1 m -52.07 -41.3 62.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.13 -0.981 . . . . 0.0 109.453 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.428 ' CD ' ' O ' ' A' ' 29' ' ' GLU . 8.1 mtpt -68.98 -48.18 63.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.564 179.918 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.73 ' CG ' HD23 ' A' ' 106' ' ' LEU . 9.0 t80 -58.91 -49.86 76.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.514 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.711 ' CD1' HG22 ' A' ' 55' ' ' VAL . 32.8 mt -57.35 -45.49 84.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 109.698 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.531 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 1.3 t -63.33 -59.83 4.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.194 -0.941 . . . . 0.0 109.758 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.641 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -59.95 -26.91 66.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.898 . . . . 0.0 109.724 -179.909 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.641 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 19.6 m-70 -119.69 104.32 10.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.771 -179.944 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 54.5 m170 -86.45 -21.93 26.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.604 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -67.66 -16.38 64.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -0.891 . . . . 0.0 109.525 179.644 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.429 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 89.7 mmm -109.35 -24.41 11.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.521 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -48.14 -40.46 23.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -77.06 -21.34 54.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.376 179.728 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.067 HG13 ' ND2' ' A' ' 95' ' ' ASN . 39.6 t -75.09 -39.71 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 0.0 109.563 179.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.543 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 15.6 m-85 -68.08 -31.06 70.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.616 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.406 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.42 27.24 3.68 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.543 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.9 m-85 -122.77 171.41 9.2 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.29 -1.123 . . . . 0.0 109.653 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.9 t -111.14 23.47 14.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.212 179.58 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.84 -163.78 27.59 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -93.13 29.81 1.79 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 18.3 m -126.52 22.98 6.92 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 109.633 -179.956 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.41 137.94 19.58 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.236 -0.915 . . . . 0.0 109.615 179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -66.51 -24.14 49.39 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 123.919 1.484 . . . . 0.0 110.07 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -54.24 -31.66 50.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.901 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.748 HG11 ' OG1' ' A' ' 32' ' ' THR . 97.5 t -53.66 -53.71 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.268 -1.136 . . . . 0.0 109.568 -179.946 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.721 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -63.07 -14.79 52.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.906 . . . . 0.0 109.769 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.52 -44.21 11.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.17 -0.956 . . . . 0.0 109.694 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.488 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.0 OUTLIER -70.22 -63.62 1.05 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.219 -0.926 . . . . 0.0 110.051 -179.8 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.54 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -51.9 -29.3 26.76 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.765 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.721 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -67.93 -40.65 83.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -1.203 . . . . 0.0 110.029 -179.708 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 43.4 mttm -80.85 -36.31 31.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 109.928 -179.77 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 58' ' ' LEU . 86.1 t -59.39 -53.98 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 0.0 109.903 -179.786 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 1.005 HD11 HG12 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -47.0 -38.72 11.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.195 -0.94 . . . . 0.0 109.833 -179.936 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.88 -49.32 63.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.625 179.925 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.407 ' OE1' HG21 ' A' ' 86' ' ' VAL . 14.0 tp60 -52.8 -48.2 67.06 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.966 . . . . 0.0 109.437 179.855 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.984 ' O ' HG23 ' A' ' 70' ' ' VAL . 98.8 mt -55.89 -32.98 33.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.296 -0.878 . . . . 0.0 109.165 179.662 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.567 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.99 -57.86 9.01 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 179.503 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.9 t -55.31 -26.17 18.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -1.111 . . . . 0.0 109.05 179.803 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -26.23 26.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.445 -0.784 . . . . 0.0 109.535 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.984 HG23 ' O ' ' A' ' 66' ' ' ILE . 40.0 t -59.87 -19.36 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 179.859 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 34.0 t -88.7 10.14 21.81 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.221 -0.924 . . . . 0.0 110.203 -179.688 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.46 ' HB3' ' HB2' ' A' ' 79' ' ' MET . 19.3 m-70 -147.76 50.73 1.05 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.972 -1.08 . . . . 0.0 109.82 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.796 HD11 ' HB1' ' A' ' 133' ' ' ALA . 3.7 mm? . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.343 -0.848 . . . . 0.0 109.494 179.811 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.46 ' HB2' ' HB3' ' A' ' 72' ' ' HIS . 3.9 tmm? . . . . . 0 N--CA 1.493 1.689 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.463 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.4 t -67.72 -26.66 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.358 -0.839 . . . . 0.0 109.199 179.607 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.24 -48.07 81.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.291 -0.88 . . . . 0.0 109.365 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.59 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.6 OUTLIER -78.19 -48.1 16.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.876 . . . . 0.0 109.286 179.67 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.476 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 2.7 mtp -57.22 -56.81 16.98 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.26 -0.9 . . . . 0.0 109.243 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.475 ' HG3' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.4 -32.86 27.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.19 -0.944 . . . . 0.0 108.856 179.372 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.59 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -65.58 -39.72 91.93 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.268 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.893 ' CG1' HD11 ' A' ' 141' ' ' LEU . 56.3 t -52.99 -50.22 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.291 -0.88 . . . . 0.0 109.18 179.502 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -50.5 -49.77 38.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 179.732 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.685 HG23 ' HA3' ' A' ' 144' ' ' GLY . 91.5 t -49.71 -26.23 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.324 -1.104 . . . . 0.0 109.309 179.591 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.4 mmt180 -78.76 -48.52 14.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.381 -0.824 . . . . 0.0 108.872 179.452 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.579 ' HB2' HD13 ' A' ' 145' ' ' LEU . 13.3 m80 -55.5 -28.28 53.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.441 -0.787 . . . . 0.0 109.327 179.618 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -67.93 -10.05 50.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.319 -0.863 . . . . 0.0 110.04 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -138.73 50.71 0.79 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.792 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.5 m-30 -101.59 -168.55 1.57 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.18 -1.188 . . . . 0.0 109.584 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.96 -49.47 16.72 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 1.067 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -68.02 -51.03 51.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.439 -1.036 . . . . 0.0 109.221 179.796 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.479 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.7 tttt 74.64 -48.69 0.65 Allowed 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.528 -0.732 . . . . 0.0 110.844 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -67.81 61.22 0.07 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.958 -1.089 . . . . 0.0 110.248 -179.553 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 96' ' ' LYS . 65.9 mt -92.03 161.24 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.041 . . . . 0.0 109.462 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.513 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -139.8 139.38 36.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.102 -0.999 . . . . 0.0 110.017 -179.798 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 1.055 ' HB1' HD12 ' A' ' 142' ' ' ILE . . . -79.13 -5.9 55.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.421 -0.8 . . . . 0.0 109.621 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -70.67 -31.52 68.47 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.103 -0.998 . . . . 0.0 109.694 179.944 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.513 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 75.5 m-85 -82.79 4.93 23.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 110.529 -179.314 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.566 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.5 m-85 -77.09 -57.57 3.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.959 -1.088 . . . . 0.0 109.783 179.704 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -58.31 -50.83 85.91 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.851 -179.698 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' CD ' ' N ' ' A' ' 104' ' ' GLU . 24.8 Cg_exo -55.62 -57.49 1.56 Allowed 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.888 1.468 . . . . 0.0 109.768 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.929 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -57.49 -19.5 24.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.401 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.51 -51.08 4.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.953 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.72 -54.3 48.41 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.166 -1.196 . . . . 0.0 109.572 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.5 t -55.98 -25.17 42.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' A' ' 106' ' ' LEU . 5.2 tt -67.39 -45.16 77.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.916 . . . . 0.0 109.734 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.911 HD21 ' HB3' ' A' ' 130' ' ' TRP . 13.8 mt -56.6 -31.86 64.68 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.653 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.52 -30.41 70.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.906 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -82.86 -34.21 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.893 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.414 ' HE1' HD21 ' A' ' 110' ' ' LEU . 5.9 mmt -46.39 -45.33 17.77 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.3 -0.875 . . . . 0.0 110.34 -179.713 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -50.32 -23.2 2.16 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.11 -0.993 . . . . 0.0 110.223 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.411 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -57.0 -46.88 81.96 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.051 -1.031 . . . . 0.0 109.703 -179.809 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.467 ' HD3' HG23 ' A' ' 17' ' ' ILE . 1.9 ttt85 -73.11 -55.8 5.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 109.815 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 5.3 pt -99.92 48.69 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.127 -0.983 . . . . 0.0 110.103 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.09 100.98 0.11 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 179.64 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.44 -45.33 1.14 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.513 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.3 mmtt -82.23 -24.1 35.02 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.251 -1.146 . . . . 0.0 109.154 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.97 79.58 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.441 -0.787 . . . . 0.0 109.595 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.712 HD21 ' HB3' ' A' ' 125' ' ' ALA . 0.1 OUTLIER -88.22 -178.64 5.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.894 . . . . 0.0 110.186 -179.793 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -55.23 -34.73 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.874 -179.696 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.752 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -68.61 -14.4 62.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.668 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -90.43 -50.73 5.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.07 -1.019 . . . . 0.0 109.624 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.724 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.1 ptpt -69.42 -27.77 65.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.262 179.776 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.45 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.0 t0 -79.07 -52.56 8.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.32 -0.862 . . . . 0.0 109.486 179.772 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -56.66 -54.34 47.22 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.374 -0.829 . . . . 0.0 109.765 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.994 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.1 m0 -63.46 -27.83 69.55 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.724 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.39 -25.46 65.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.225 -0.922 . . . . 0.0 108.78 179.202 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.22 -41.93 14.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.44 -0.787 . . . . 0.0 109.121 179.466 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.796 ' HB1' HD11 ' A' ' 73' ' ' LEU . . . -70.19 -56.12 7.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.515 -0.74 . . . . 0.0 109.781 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 134' ' ' TYR . 9.0 m-30 -47.39 -27.96 1.88 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.296 -0.877 . . . . 0.0 109.636 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.98 -43.18 65.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.258 -0.901 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.76 -36.57 59.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.341 -0.85 . . . . 0.0 109.325 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.717 HD12 ' O ' ' A' ' 133' ' ' ALA . 1.3 mp -66.64 -58.44 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 108.885 179.717 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.405 ' O ' HG12 ' A' ' 142' ' ' ILE . 31.7 p -66.97 -24.08 66.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.251 -0.906 . . . . 0.0 109.62 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.32 -28.78 55.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.16 -22.86 60.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -1.138 . . . . 0.0 109.595 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.901 ' O ' HD23 ' A' ' 141' ' ' LEU . 3.8 tt -86.46 11.6 12.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 109.986 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 1.055 HD12 ' HB1' ' A' ' 100' ' ' ALA . 44.0 mm -100.29 19.29 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.074 -1.016 . . . . 0.0 109.683 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.475 ' CB ' ' HG3' ' A' ' 84' ' ' LYS . 4.4 m -108.11 -52.65 2.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.634 179.962 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.685 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -75.96 -7.75 84.3 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.579 HD13 ' HB2' ' A' ' 90' ' ' HIS . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.465 0 O-C-N 120.953 -1.322 . . . . 0.0 108.432 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.784 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.28 0.562 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.429 ' O ' HG23 ' A' ' 10' ' ' VAL . 1.5 mt-30 -64.81 -46.1 83.43 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.439 ' HG3' ' HB3' ' A' ' 73' ' ' LEU . 38.6 ttp180 -55.38 -34.27 64.17 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.206 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -73.87 -41.66 61.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.261 -0.899 . . . . 0.0 109.176 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.784 HG23 ' O ' ' A' ' 5' ' ' ALA . 59.7 t -57.42 -29.85 34.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.336 -0.853 . . . . 0.0 109.426 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 1.046 HG12 HG13 ' A' ' 70' ' ' VAL . 91.9 t -66.03 -52.14 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 109.468 179.793 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.56 -9.75 51.4 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.307 -0.871 . . . . 0.0 109.988 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 p -92.94 -24.43 18.41 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.045 -1.035 . . . . 0.0 109.774 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.4 p -98.49 -7.76 27.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 110.065 -179.939 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.596 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -95.14 -23.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.093 . . . . 0.0 109.588 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.2 mttm -77.08 -2.49 34.4 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.206 -0.933 . . . . 0.0 109.852 179.756 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -114.02 -51.12 2.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.085 -1.009 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.951 HD12 ' CH2' ' A' ' 130' ' ' TRP . 56.3 mt -66.34 -31.52 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.919 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.888 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -108.77 34.03 3.9 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.315 -0.866 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.31 -85.0 0.02 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.8 p -95.68 -31.45 13.23 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -1.14 . . . . 0.0 109.58 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.543 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 24.5 p-10 -75.51 -21.97 57.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.295 -0.878 . . . . 0.0 109.591 180.0 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.888 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 4.3 t30 56.57 21.85 6.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.207 -0.933 . . . . 0.0 109.523 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 98.82 21.67 15.55 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.543 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -71.04 -56.85 5.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -1.146 . . . . 0.0 109.637 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.47 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -70.85 -21.08 78.04 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.925 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.631 HG11 HD11 ' A' ' 63' ' ' LEU . 46.6 t -70.65 -35.03 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.284 -1.127 . . . . 0.0 110.005 -179.778 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.02 -43.72 13.33 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 -179.308 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.47 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.8 ptpt -64.28 -26.39 68.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -1.217 . . . . 0.0 110.155 -179.385 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.763 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -100.68 -11.41 20.0 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.045 -1.034 . . . . 0.0 110.156 -179.73 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.462 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 34.1 t -93.05 -68.19 0.81 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 109.888 -179.797 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.528 ' CZ ' HG11 ' A' ' 62' ' ' VAL . 10.3 m-85 -50.32 -30.48 12.14 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 110.004 -179.604 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.771 ' OG1' HG11 ' A' ' 55' ' ' VAL . 15.7 m -54.33 -53.18 57.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.064 -1.023 . . . . 0.0 109.221 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.425 ' HD3' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -55.44 -48.56 74.26 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.932 . . . . 0.0 109.243 179.737 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.6 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.8 t80 -54.33 -49.65 69.23 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.322 -0.862 . . . . 0.0 109.255 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.832 ' CD1' HG22 ' A' ' 55' ' ' VAL . 24.2 mt -60.1 -46.09 90.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.642 179.866 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.439 ' OG ' ' N ' ' A' ' 37' ' ' ALA . 8.9 p -61.21 -54.41 44.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.732 -179.91 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.664 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -67.86 -27.09 66.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.226 -0.921 . . . . 0.0 109.62 -179.927 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.664 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 10.0 m-70 -117.51 107.37 14.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.754 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 56.3 m170 -88.41 -19.9 25.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.408 -0.808 . . . . 0.0 109.356 179.648 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -71.04 -11.29 60.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.71 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.558 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -107.61 -27.73 10.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.007 . . . . 0.0 109.943 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.475 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -46.99 -48.14 21.79 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.13 -0.981 . . . . 0.0 109.796 -179.825 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.6 -28.78 65.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.122 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.984 HG13 ' ND2' ' A' ' 95' ' ' ASN . 21.3 t -70.15 -38.4 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.273 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.534 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 9.8 m-85 -77.27 -29.93 54.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.243 -0.911 . . . . 0.0 109.612 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.14 29.51 3.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.374 -1.491 . . . . 0.0 109.374 179.825 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.534 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.0 m-85 -124.25 166.99 14.91 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -1.167 . . . . 0.0 109.91 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.2 t -104.29 -20.3 13.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.421 -0.8 . . . . 0.0 109.127 179.343 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.83 -164.69 24.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.816 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.42 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -95.15 35.84 1.26 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -1.179 . . . . 0.0 109.69 -179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 56.4 p -135.07 23.2 3.53 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 109.533 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.493 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.8 p-10 -107.69 138.79 20.11 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -60.33 -20.73 64.18 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.934 1.491 . . . . 0.0 109.995 -179.964 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.71 -44.75 54.95 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.832 HG22 ' CD1' ' A' ' 35' ' ' LEU . 80.3 t -51.45 -37.99 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.401 -1.058 . . . . 0.0 109.31 179.776 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.508 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -71.72 -24.45 61.8 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.28 -0.887 . . . . 0.0 109.251 179.602 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -79.33 -37.96 36.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.376 179.778 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.741 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 mt -77.19 -60.98 2.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.527 179.926 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.498 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.66 -46.65 38.42 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.508 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -54.46 -42.04 70.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.39 179.842 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.8 mttt -76.54 -29.17 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.262 -0.899 . . . . 0.0 109.354 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' O ' ' A' ' 58' ' ' LEU . 47.6 t -78.58 -49.95 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.631 HD11 HG11 ' A' ' 26' ' ' VAL . 1.0 OUTLIER -48.43 -46.1 37.19 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.82 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.72 -49.93 69.58 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.303 -0.873 . . . . 0.0 109.564 179.939 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.426 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 8.1 tp-100 -50.9 -43.32 59.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 109.31 179.813 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.853 ' O ' HG23 ' A' ' 70' ' ' VAL . 31.8 mm -57.6 -43.6 83.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.284 -0.885 . . . . 0.0 108.758 179.477 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.548 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.83 -55.16 31.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.775 -1.73 . . . . 0.0 108.775 179.371 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.3 t -54.03 -35.32 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.346 -1.09 . . . . 0.0 109.435 179.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.599 ' HB1' HG13 ' A' ' 137' ' ' ILE . . . -79.8 -30.38 40.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.88 . . . . 0.0 109.42 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.046 HG13 HG12 ' A' ' 10' ' ' VAL . 48.9 t -68.68 -16.43 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.262 -0.899 . . . . 0.0 109.584 179.895 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.41 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.2 m -90.03 -0.05 57.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.172 -0.955 . . . . 0.0 110.199 -179.897 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.472 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 21.4 m-70 -140.02 50.85 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.983 -1.073 . . . . 0.0 109.767 -179.872 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.622 HD21 ' HA ' ' A' ' 70' ' ' VAL . 4.3 mm? . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.934 . . . . 0.0 109.465 179.967 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.472 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 28.2 ttp . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.258 0.551 . . . . 0.0 109.829 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 45.9 t -68.61 -11.64 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.964 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.44 -37.41 43.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.03 -1.044 . . . . 0.0 109.44 179.904 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -88.65 -41.18 12.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.468 ' HE2' HD12 ' A' ' 141' ' ' LEU . 8.9 mtp -60.36 -41.04 92.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.94 . . . . 0.0 109.247 179.809 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.554 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.8 -42.04 62.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.784 179.171 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.437 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -61.28 -39.68 91.31 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.992 ' CG1' HD11 ' A' ' 141' ' ' LEU . 23.9 t -56.98 -51.86 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.277 -0.89 . . . . 0.0 108.774 179.496 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 145' ' ' LEU . . . -60.86 -53.59 43.95 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.655 -2.178 . . . . 0.0 107.655 178.826 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 84' ' ' LYS . 78.7 t -48.8 -24.96 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.451 -1.029 . . . . 0.0 109.445 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.515 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 7.5 mmm180 -83.6 -43.85 15.22 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.021 -1.049 . . . . 0.0 108.729 179.238 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.696 ' O ' HD12 ' A' ' 98' ' ' ILE . 19.5 m80 -58.75 -33.73 70.59 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.379 -0.825 . . . . 0.0 109.698 179.589 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -61.45 -15.78 40.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 110.434 -179.29 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.46 46.73 1.05 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.257 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.515 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.7 m-30 -87.28 -173.13 4.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.195 -1.179 . . . . 0.0 109.402 179.51 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.26 -26.42 52.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 179.668 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.984 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -76.86 -55.23 5.67 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.559 -0.965 . . . . 0.0 109.101 179.704 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.481 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 10.3 tptp 77.09 -19.02 0.45 Allowed 'General case' 0 N--CA 1.508 2.469 0 O-C-N 121.765 -0.585 . . . . 0.0 111.472 179.871 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.409 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 8.2 m170 -94.05 44.01 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.601 -1.312 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.696 HD12 ' O ' ' A' ' 90' ' ' HIS . 36.3 mt -74.84 160.46 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.758 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.515 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -151.21 136.24 17.43 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.349 -0.845 . . . . 0.0 109.987 179.984 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.94 -5.52 44.26 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.573 -0.704 . . . . 0.0 109.506 179.301 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mm-40 -74.98 -30.66 61.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.07 -1.019 . . . . 0.0 109.439 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.561 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 36.0 m-85 -75.66 -23.54 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.299 -0.876 . . . . 0.0 109.889 -179.746 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -54.39 -64.16 0.92 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.56 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.81 -58.55 5.25 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 110.856 -179.111 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.561 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.3 Cg_endo -59.49 -46.62 20.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.639 1.336 . . . . 0.0 109.63 -179.666 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.786 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.1 tm? -60.98 -27.29 68.19 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.216 -0.927 . . . . 0.0 108.841 179.414 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -81.34 -38.0 16.16 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 179.508 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.19 -60.13 4.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 0.0 109.345 179.782 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.0 m -52.42 -24.86 8.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.902 . . . . 0.0 109.18 179.67 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.421 ' HB3' ' O ' ' A' ' 107' ' ' GLY . 2.3 tt -66.51 -48.19 70.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.347 -0.846 . . . . 0.0 109.421 179.811 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.804 HD21 ' CB ' ' A' ' 130' ' ' TRP . 13.0 mt -57.65 -32.32 67.17 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.947 . . . . 0.0 109.216 179.729 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.4 m -73.82 -38.52 64.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.339 -0.85 . . . . 0.0 109.429 179.823 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.763 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -72.61 -35.71 67.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.292 -0.88 . . . . 0.0 109.387 179.791 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.705 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.2 mmt -51.39 -42.15 61.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.44 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.3 OUTLIER -50.7 -23.7 2.85 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.99 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 21.2 m170 -53.71 -26.71 24.29 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.882 . . . . 0.0 110.094 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.7 -73.31 0.66 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.026 -1.046 . . . . 0.0 109.877 -179.848 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.61 HG23 ' CG1' ' A' ' 17' ' ' ILE . 24.9 pt -65.33 -33.83 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.875 -1.14 . . . . 0.0 109.169 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.448 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 45.43 -108.64 0.23 Allowed Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.08 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.32 -35.88 10.16 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -179.47 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.497 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 40.3 mttt -68.06 -22.25 64.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.155 -1.203 . . . . 0.0 109.699 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.445 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -74.99 72.42 2.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.068 -1.02 . . . . 0.0 109.111 179.443 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.758 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 15.0 p-10 -73.43 -175.88 2.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.275 -0.891 . . . . 0.0 109.882 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.422 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -59.08 -45.99 89.42 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 109.302 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.758 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -60.12 -33.0 71.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.315 -0.865 . . . . 0.0 109.074 179.662 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.55 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -66.98 -51.99 48.32 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.272 -0.893 . . . . 0.0 109.429 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 14.4 ptpt -71.61 -28.96 64.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.251 -0.906 . . . . 0.0 109.546 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.476 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 39.3 t0 -80.07 -43.39 21.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.331 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.476 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -56.28 -46.1 79.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.325 -0.86 . . . . 0.0 109.213 179.675 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.951 ' CH2' HD12 ' A' ' 17' ' ' ILE . 13.1 m0 -74.63 -32.39 62.28 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.258 -0.901 . . . . 0.0 108.581 179.585 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -56.54 -26.02 53.68 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.962 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.92 -30.66 14.04 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.315 -0.866 . . . . 0.0 109.063 179.476 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.434 ' C ' HD13 ' A' ' 137' ' ' ILE . . . -83.08 -54.38 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.493 -0.754 . . . . 0.0 109.412 179.845 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.56 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -48.87 -27.31 2.96 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.362 -179.938 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.56 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -80.98 -32.08 34.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 108.776 179.335 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.408 ' N ' ' O ' ' A' ' 133' ' ' ALA . 3.1 m-20 -81.7 -35.67 29.54 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.431 -0.793 . . . . 0.0 109.272 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.664 HG21 HD13 ' A' ' 66' ' ' ILE . 1.4 mp -66.39 -60.53 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.207 -0.933 . . . . 0.0 108.545 179.409 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.14 -12.06 46.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.95 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.676 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -75.78 -46.25 14.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.55 -28.73 68.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -1.142 . . . . 0.0 109.702 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.992 HD11 ' CG1' ' A' ' 86' ' ' VAL . 1.7 tt -71.64 -22.09 61.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.298 -0.876 . . . . 0.0 109.667 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.676 HD12 ' HA2' ' A' ' 139' ' ' GLY . 86.9 mt -78.12 1.34 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.177 -179.826 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . 0.479 ' HB3' ' CE ' ' A' ' 84' ' ' LYS . 68.2 m -81.35 -44.6 17.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.045 . . . . 0.0 109.718 -179.974 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 88' ' ' VAL . . . -110.85 11.12 29.78 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.88 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.432 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.027 -1.278 . . . . 0.0 110.014 -179.83 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.636 ' O ' HG23 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.26 0.552 . . . . 0.0 109.82 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.516 ' O ' HG23 ' A' ' 10' ' ' VAL . 24.6 mt-30 -81.31 -43.01 19.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 109.911 -179.765 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.473 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 12.4 ptm180 -53.78 -35.0 60.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.617 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.473 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 6.8 mm-40 -71.96 -47.74 50.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.921 . . . . 0.0 109.541 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 5' ' ' ALA . 33.1 t -60.09 -27.09 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.257 -0.902 . . . . 0.0 109.461 179.954 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.857 HG12 HG13 ' A' ' 70' ' ' VAL . 54.9 t -70.63 -49.11 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.287 -0.883 . . . . 0.0 109.475 179.899 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.9 -16.25 62.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.866 . . . . 0.0 109.795 -179.988 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.59 -26.16 26.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.705 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -95.15 -9.61 32.98 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.197 -0.94 . . . . 0.0 109.959 -179.992 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.77 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.61 -17.25 24.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.026 -1.046 . . . . 0.0 109.963 -179.882 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.4 mtpt -80.06 -13.71 59.09 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.121 -0.987 . . . . 0.0 109.585 179.658 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.408 ' O ' ' NE ' ' A' ' 117' ' ' ARG . 68.2 m-20 -98.62 -55.43 2.74 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.561 179.802 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.918 HD12 ' CH2' ' A' ' 130' ' ' TRP . 30.8 mt -65.39 -28.74 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.211 -0.931 . . . . 0.0 109.12 179.698 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.77 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -111.42 36.56 3.18 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 179.806 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.55 -86.77 0.02 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.7 p -104.98 9.76 34.4 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -1.17 . . . . 0.0 109.94 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.437 ' OD1' ' HA ' ' A' ' 18' ' ' ALA . 2.3 p30 -119.3 -12.41 9.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.1 -1.0 . . . . 0.0 109.848 179.907 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.674 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 14.8 t-20 64.03 13.03 7.4 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.234 -0.916 . . . . 0.0 109.838 -179.758 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.73 ' C ' HD13 ' A' ' 63' ' ' LEU . . . 96.3 16.28 38.2 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.918 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.421 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -48.35 -38.19 18.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.221 -1.164 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.29 14.53 57.43 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.552 ' HB ' HD22 ' A' ' 63' ' ' LEU . 15.7 t -102.21 -29.44 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.075 -1.25 . . . . 0.0 109.558 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -92.26 -37.08 6.03 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.657 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.484 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.7 ptpt -64.07 -31.7 72.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.172 -1.193 . . . . 0.0 109.549 -179.857 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.484 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 19.6 pt-20 -94.46 -19.13 20.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.125 -0.985 . . . . 0.0 109.642 179.882 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.527 ' SG ' HD12 ' A' ' 110' ' ' LEU . 35.4 t -89.25 -53.6 4.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.867 -179.78 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.902 ' CZ ' HG21 ' A' ' 62' ' ' VAL . 15.9 m-85 -63.41 -34.85 78.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 109.774 -179.688 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.796 ' OG1' HG11 ' A' ' 55' ' ' VAL . 12.4 m -58.71 -36.05 73.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.09 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.81 -42.22 50.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.874 . . . . 0.0 109.291 179.571 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.693 ' CG ' HD23 ' A' ' 106' ' ' LEU . 12.7 t80 -63.07 -47.41 83.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -0.887 . . . . 0.0 109.313 179.661 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.82 ' CD1' HG22 ' A' ' 55' ' ' VAL . 22.0 mt -57.16 -43.69 82.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.876 . . . . 0.0 109.739 179.925 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.404 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 3.6 t -68.76 -63.52 1.04 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 109.706 -179.923 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.614 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -52.56 -24.45 8.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.262 -0.899 . . . . 0.0 109.7 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.614 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 25.6 m-70 -125.49 104.29 8.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.805 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -86.71 -5.23 59.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.389 -0.819 . . . . 0.0 109.855 179.661 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -82.16 -21.99 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.099 -1.001 . . . . 0.0 109.535 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' MET . . . . . 0.421 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 88.4 mmm -101.12 -23.88 14.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.244 -0.91 . . . . 0.0 109.692 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.427 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.62 -38.13 20.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.226 -0.921 . . . . 0.0 109.632 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.67 -28.56 60.89 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.422 179.76 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.91 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.5 t -67.17 -59.69 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.514 179.844 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.637 ' CD2' HD21 ' A' ' 35' ' ' LEU . 68.1 m-85 -50.79 -42.08 57.72 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.236 -0.915 . . . . 0.0 109.586 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.07 35.84 0.92 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.735 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.36 166.79 15.34 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.119 -1.224 . . . . 0.0 109.762 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.6 t -111.2 21.62 16.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.411 -0.805 . . . . 0.0 109.117 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 146.08 177.59 20.87 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -179.788 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -68.79 -13.78 62.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -1.181 . . . . 0.0 109.828 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 71.9 p -87.85 45.55 1.29 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.103 -0.998 . . . . 0.0 109.688 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.52 132.45 24.26 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -69.23 -22.17 34.89 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 123.874 1.46 . . . . 0.0 110.083 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.492 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -57.39 -26.93 57.48 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.82 HG22 ' CD1' ' A' ' 35' ' ' LEU . 87.1 t -58.33 -51.94 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.179 -1.189 . . . . 0.0 109.637 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -58.21 -22.6 52.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.928 . . . . 0.0 109.552 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.96 -60.31 2.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.874 . . . . 0.0 109.604 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.815 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.5 OUTLIER -55.88 -59.04 5.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.677 -179.949 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.524 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.54 -60.76 5.59 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.867 ' HA ' HD21 ' A' ' 63' ' ' LEU . . . -48.23 -33.97 9.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 0.0 109.654 179.788 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -77.76 -20.26 53.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.319 -0.863 . . . . 0.0 109.419 179.769 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.902 HG21 ' CZ ' ' A' ' 31' ' ' PHE . 49.4 t -81.24 -61.16 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.31 -0.869 . . . . 0.0 109.677 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.867 HD21 ' HA ' ' A' ' 60' ' ' ALA . 0.3 OUTLIER -46.07 -43.07 14.33 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.27 -0.894 . . . . 0.0 109.835 179.914 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.25 -40.23 33.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.96 -1.088 . . . . 0.0 109.477 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -65.83 -43.37 88.77 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.249 -0.907 . . . . 0.0 109.153 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.91 ' O ' HG23 ' A' ' 70' ' ' VAL . 33.9 mt -59.96 -40.13 82.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.412 -0.805 . . . . 0.0 109.182 179.68 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.565 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.04 -50.79 62.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.88 -30.53 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 109.334 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -82.81 -24.92 33.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.404 -0.81 . . . . 0.0 109.588 -179.963 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.91 HG23 ' O ' ' A' ' 66' ' ' ILE . 46.2 t -69.8 -9.06 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.855 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.509 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 24.9 p -91.39 30.9 1.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.058 -1.027 . . . . 0.0 109.938 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.509 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.5 m-70 -160.69 -89.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.633 179.875 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.411 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 15.0 mt . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.367 -0.833 . . . . 0.0 109.985 179.977 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.4 tmm? . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.191 0.519 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.431 ' O ' ' HB3' ' A' ' 84' ' ' LYS . 46.7 t -80.33 -19.6 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.612 179.931 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.41 -40.59 97.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.593 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.573 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 1.2 tp10 -87.0 -45.6 10.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.537 179.912 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.5 mtp -59.48 -56.92 15.91 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.257 179.765 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.431 ' HB3' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -52.43 -27.04 14.36 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.236 -0.915 . . . . 0.0 109.091 179.546 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.573 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.04 -35.93 72.14 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.707 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 82' ' ' GLU . 16.5 t -58.72 -38.77 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.221 -0.924 . . . . 0.0 109.226 179.868 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.421 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -55.86 -47.75 77.09 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.531 -1.827 . . . . 0.0 108.531 179.588 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.561 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.7 t -55.13 -36.13 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.32 -1.106 . . . . 0.0 108.955 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.507 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mpt_? -69.01 -52.33 29.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 108.991 179.398 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' HIS . . . . . 0.62 ' HB2' HD13 ' A' ' 145' ' ' LEU . 16.9 m80 -56.35 -29.22 61.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.836 . . . . 0.0 109.288 179.581 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 ttmt -66.23 -13.07 59.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.285 -0.884 . . . . 0.0 110.06 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.25 47.66 1.01 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.936 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.507 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -91.42 -169.29 2.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.346 -1.091 . . . . 0.0 109.817 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.26 -52.82 7.3 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.647 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.91 ' ND2' HG13 ' A' ' 44' ' ' VAL . 11.9 p-10 -61.49 -31.65 71.64 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.128 -1.219 . . . . 0.0 109.486 -179.798 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.5 tttt 60.42 32.94 20.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -0.864 . . . . 0.0 110.147 179.595 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' HIS . . . . . 0.414 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 54.3 m170 -129.24 -85.31 0.55 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.186 -0.946 . . . . 0.0 109.092 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 90' ' ' HIS . 17.7 mt 60.13 151.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.806 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.542 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -147.16 131.65 17.69 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 179.743 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.09 -12.51 61.54 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.647 -0.658 . . . . 0.0 109.461 179.5 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.421 ' O ' ' HG2' ' A' ' 105' ' ' PRO . 1.0 OUTLIER -73.23 -19.75 61.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.092 -1.005 . . . . 0.0 109.255 179.517 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.542 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 34.4 m-85 -88.48 -22.42 23.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.829 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -54.39 -58.91 5.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.068 -179.703 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.509 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -54.3 -58.0 15.85 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.112 -0.993 . . . . 0.0 110.097 -179.498 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.509 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.7 Cg_exo -49.18 -59.83 1.09 Allowed 'Trans proline' 0 C--N 1.309 -1.533 0 O-C-N 123.62 1.326 . . . . 0.0 110.095 179.89 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.826 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -53.71 -27.28 27.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.555 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.06 -45.96 9.79 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 -179.976 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -60.64 -52.87 63.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.625 -179.986 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 17.3 m -57.66 -27.74 63.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.656 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.527 HD12 ' SG ' ' A' ' 30' ' ' CYS . 4.1 tt -67.37 -43.08 82.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.215 -0.928 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.913 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.8 mt -56.51 -34.24 66.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.537 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 10.6 t -64.12 -34.44 78.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.721 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 113' ' ' ALA . . . . . 0.417 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -81.57 -28.44 33.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.233 -0.917 . . . . 0.0 109.782 -179.732 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 114' ' ' MET . . . . . 0.471 ' HE2' ' OH ' ' A' ' 134' ' ' TYR . 5.8 mmt -51.47 -35.51 40.17 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.96 . . . . 0.0 110.291 -179.563 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 7.1 pt-20 -64.85 -12.28 46.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.086 -1.009 . . . . 0.0 110.164 -179.548 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 116' ' ' HIS . . . . . 0.417 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 14.7 m170 -67.59 -27.15 66.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.943 -1.098 . . . . 0.0 109.52 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.436 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -94.16 -64.45 1.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.791 179.976 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.511 HG23 HG12 ' A' ' 17' ' ' ILE . 24.3 pt -84.3 -34.85 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.641 -179.898 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . 0.49 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 42.39 -94.94 0.01 OUTLIER Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -44.03 -48.22 7.98 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -179.146 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.486 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -67.32 -22.64 65.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.116 -1.226 . . . . 0.0 109.895 -179.877 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 122' ' ' MET . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -71.1 96.55 1.36 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.086 -1.008 . . . . 0.0 109.098 179.51 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.434 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 8.5 p30 -100.36 -161.52 0.87 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.265 -0.897 . . . . 0.0 110.062 -179.5 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.47 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -72.86 -45.58 57.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.354 -0.841 . . . . 0.0 109.655 -179.945 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . 0.434 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -62.47 -30.41 71.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.196 -0.94 . . . . 0.0 109.036 179.731 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.47 -50.23 47.36 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.624 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.8 ptpt -72.1 -27.55 62.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 179.774 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 128' ' ' ASP . . . . . 0.462 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 62.2 t0 -80.44 -41.3 24.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.168 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.505 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -63.91 -45.71 88.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 109.152 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.918 ' CH2' HD12 ' A' ' 17' ' ' ILE . 5.0 m0 -73.02 -25.73 61.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.368 -0.833 . . . . 0.0 109.138 179.544 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.624 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.43 -34.08 77.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.289 -0.882 . . . . 0.0 108.926 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.47 -20.76 24.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.372 -0.83 . . . . 0.0 109.333 179.564 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -79.39 -53.39 6.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.525 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.488 ' OH ' ' CE3' ' A' ' 130' ' ' TRP . 10.4 m-30 -53.0 -28.4 23.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.334 179.929 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.9 -48.58 52.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.053 179.465 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.89 -34.31 66.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.322 -0.861 . . . . 0.0 109.225 179.642 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.759 HD13 HG23 ' A' ' 66' ' ' ILE . 64.1 mt -66.73 -59.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.348 -0.845 . . . . 0.0 109.16 179.743 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.403 ' O ' HG13 ' A' ' 142' ' ' ILE . 2.2 p -67.87 -25.98 65.79 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.677 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.43 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -68.87 -46.57 59.59 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -179.952 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.51 -26.89 45.41 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -1.172 . . . . 0.0 109.66 179.975 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.829 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.1 tt -77.29 -16.35 59.01 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.203 -0.936 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.442 ' O ' HG22 ' A' ' 142' ' ' ILE . 60.9 mt -76.5 -0.73 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.14 -0.975 . . . . 0.0 110.151 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.0 m -84.37 -43.96 14.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.037 -1.04 . . . . 0.0 109.632 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.561 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -85.53 -16.55 63.85 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.62 HD13 ' HB2' ' A' ' 90' ' ' HIS . 6.8 tp . . . . . 0 N--CA 1.488 1.43 0 O-C-N 121.195 -1.179 . . . . 0.0 108.943 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.847 ' CD1' HD12 ' A' ' 73' ' ' LEU . 12.0 mt -128.86 165.39 21.11 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.127 -1.219 . . . . 0.0 109.747 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -128.59 168.4 15.79 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.249 -0.907 . . . . 0.0 109.905 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -63.31 -40.5 97.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.333 -0.855 . . . . 0.0 109.403 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.895 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -63.3 -41.97 99.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.318 -0.864 . . . . 0.0 109.307 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.474 ' O ' HG23 ' A' ' 10' ' ' VAL . 76.9 mt-30 -70.27 -47.35 61.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.305 -0.872 . . . . 0.0 109.212 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 31.8 mtp180 -53.98 -36.01 62.44 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.247 -0.908 . . . . 0.0 109.193 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -74.59 -40.38 61.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.358 -0.839 . . . . 0.0 109.309 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 5' ' ' ALA . 61.0 t -66.06 -23.71 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.284 -0.885 . . . . 0.0 109.192 179.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.645 HG23 ' HB1' ' A' ' 129' ' ' ALA . 50.9 t -76.74 -44.89 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -0.853 . . . . 0.0 109.338 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.412 ' O ' ' HG3' ' A' ' 15' ' ' LYS . . . -74.04 -15.96 61.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.764 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.8 p -86.21 -24.16 26.19 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.149 -0.969 . . . . 0.0 109.816 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.507 HG21 ' HB1' ' A' ' 126' ' ' ALA . 3.6 p -95.16 -10.96 29.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.214 -0.929 . . . . 0.0 109.8 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.686 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.8 -28.73 17.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 0.0 109.863 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.412 ' HG3' ' O ' ' A' ' 11' ' ' ALA . 10.6 mtmt -74.57 -12.73 60.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 109.812 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.415 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 1.7 m-20 -101.52 -55.05 2.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -0.988 . . . . 0.0 109.528 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.921 HD12 ' CH2' ' A' ' 130' ' ' TRP . 86.0 mt -67.5 -35.5 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.271 -0.893 . . . . 0.0 109.593 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.637 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -105.59 33.73 3.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.285 -0.884 . . . . 0.0 109.728 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -84.58 0.03 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 p -101.08 -18.81 16.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.703 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.7 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.4 p-10 -85.51 -16.99 37.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.207 -0.933 . . . . 0.0 109.902 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.598 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.4 t30 62.39 17.0 9.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.263 -0.898 . . . . 0.0 109.676 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.88 29.65 5.75 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.7 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -70.88 -46.99 61.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -1.174 . . . . 0.0 109.546 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.441 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.85 38.19 3.19 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.579 HG11 HD11 ' A' ' 63' ' ' LEU . 34.6 t -124.01 -43.12 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.233 -1.157 . . . . 0.0 108.64 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.488 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -88.81 -32.0 11.77 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 179.54 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.531 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 15.5 ptpt -62.19 -35.57 79.25 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.232 -1.158 . . . . 0.0 109.124 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.837 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 17.2 pt-20 -86.42 -21.08 27.32 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.145 -0.972 . . . . 0.0 109.31 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 38.5 t -87.98 -59.38 2.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.398 -0.814 . . . . 0.0 109.692 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.515 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.2 m-85 -53.67 -42.99 68.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.275 -0.891 . . . . 0.0 109.669 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.778 ' OG1' HG11 ' A' ' 55' ' ' VAL . 17.8 m -52.02 -50.25 61.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.15 -0.969 . . . . 0.0 109.252 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.427 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 0.2 OUTLIER -62.5 -44.73 95.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.26 179.649 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.707 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.9 t80 -57.81 -46.66 84.36 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.35 -0.844 . . . . 0.0 109.206 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.705 ' CD1' HG22 ' A' ' 55' ' ' VAL . 11.1 mt -59.26 -44.34 92.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.715 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.613 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 46.8 t -66.7 -64.32 0.88 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.204 -0.935 . . . . 0.0 109.749 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.648 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -53.39 -26.57 20.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.218 -0.926 . . . . 0.0 109.827 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.648 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 16.2 m-70 -123.79 104.92 9.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.857 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.6 m170 -85.99 8.24 21.3 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.428 -0.795 . . . . 0.0 109.758 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -98.54 -11.66 21.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.129 -0.982 . . . . 0.0 109.623 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.571 ' HE2' HG11 ' A' ' 44' ' ' VAL . 0.0 OUTLIER -105.84 -11.77 16.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.209 -0.932 . . . . 0.0 110.081 -179.793 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.438 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -58.46 -60.26 4.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.938 -1.101 . . . . 0.0 109.26 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.81 -28.24 63.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.088 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' ND2' ' A' ' 95' ' ' ASN . 28.5 t -68.85 -47.77 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.376 -0.828 . . . . 0.0 109.088 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.768 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 35.5 m-85 -71.19 -37.08 72.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.557 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 114.77 34.23 1.57 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.4 m-85 -125.92 168.61 13.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -1.162 . . . . 0.0 109.861 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.0 t -105.92 -13.68 15.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.406 -0.809 . . . . 0.0 109.479 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.77 -162.97 28.28 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.613 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -83.49 -19.55 35.57 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.297 -1.119 . . . . 0.0 109.778 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 14.9 p -87.76 52.15 2.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.257 -0.902 . . . . 0.0 109.739 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -127.12 133.77 25.42 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.923 . . . . 0.0 109.581 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -67.23 -29.01 39.69 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.908 1.478 . . . . 0.0 110.063 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.27 -38.28 40.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.778 HG11 ' OG1' ' A' ' 32' ' ' THR . 94.4 t -51.2 -46.78 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -1.095 . . . . 0.0 109.421 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.496 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -64.2 -17.12 63.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.902 . . . . 0.0 109.494 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.83 -47.38 15.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.819 ' O ' HG23 ' A' ' 62' ' ' VAL . 9.6 mt -73.23 -60.69 2.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.178 -0.951 . . . . 0.0 109.476 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.715 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -47.65 -31.19 7.07 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.496 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -78.38 -60.54 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -1.148 . . . . 0.0 109.438 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -52.43 -39.2 60.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.286 -0.884 . . . . 0.0 109.493 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.819 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.3 t -64.63 -48.32 85.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.715 HD23 ' O ' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -47.78 -44.74 28.69 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.184 -0.947 . . . . 0.0 109.636 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.401 ' O ' ' N ' ' A' ' 67' ' ' GLY . . . -49.2 -52.74 24.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.409 -0.807 . . . . 0.0 109.778 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.1 tp60 -49.82 -44.02 49.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.095 -1.003 . . . . 0.0 109.268 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.972 ' O ' HG23 ' A' ' 70' ' ' VAL . 82.7 mt -63.2 -28.04 44.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.336 -0.852 . . . . 0.0 108.851 179.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.561 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -71.41 -55.22 7.84 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.44 -24.48 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.238 -1.154 . . . . 0.0 109.116 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.41 ' O ' HD22 ' A' ' 73' ' ' LEU . . . -86.09 -18.09 33.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.413 -0.805 . . . . 0.0 109.57 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.972 HG23 ' O ' ' A' ' 66' ' ' ILE . 41.0 t -75.07 -16.04 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.511 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 74.6 m -88.45 11.06 18.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.129 -0.982 . . . . 0.0 110.143 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.8 m-70 -161.73 61.37 0.25 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.048 -1.033 . . . . 0.0 109.926 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.847 HD12 ' CD1' ' A' ' 2' ' ' LEU . 3.1 mm? -75.17 -42.9 54.94 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -78.37 -26.57 59.23 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.64 87.68 6.0 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.225 -1.162 . . . . 0.0 109.663 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.436 ' HB2' HG21 ' A' ' 80' ' ' VAL . 3.7 pm0 -94.96 43.32 1.09 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 109.474 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -113.65 -21.36 5.78 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -126.04 -57.93 1.4 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -1.196 . . . . 0.0 110.031 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.418 ' HG2' ' O ' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -50.83 -24.6 3.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.052 -1.03 . . . . 0.0 109.284 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.664 HG13 ' HB1' ' A' ' 140' ' ' ALA . 71.6 t -84.1 -17.01 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.39 -0.819 . . . . 0.0 109.405 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.69 -39.39 70.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.332 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.493 ' O ' HG23 ' A' ' 86' ' ' VAL . 12.3 tt0 -69.91 -48.17 59.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.243 -0.911 . . . . 0.0 109.331 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.58 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.7 OUTLIER -58.68 -46.78 86.47 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 109.214 179.7 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.469 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.9 mttt -52.92 -34.78 56.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.246 -0.909 . . . . 0.0 109.148 179.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.42 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -69.3 -42.98 74.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.339 -0.851 . . . . 0.0 109.391 179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.2 t -50.97 -40.15 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.302 -0.874 . . . . 0.0 109.338 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.463 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -58.05 -50.48 65.73 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.777 HG23 ' HA3' ' A' ' 144' ' ' GLY . 97.6 t -54.62 -35.88 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -1.034 . . . . 0.0 108.95 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 1.5 mpt_? -66.08 -45.02 82.75 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.359 -0.838 . . . . 0.0 108.97 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.684 ' O ' HD12 ' A' ' 98' ' ' ILE . 16.5 m80 -64.71 -12.2 44.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.441 -0.787 . . . . 0.0 109.766 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.459 ' HG3' ' N ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -74.27 -8.48 56.37 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.032 -1.042 . . . . 0.0 110.426 -179.657 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -152.04 57.75 0.43 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.792 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.5 m-30 -88.35 -169.74 2.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.265 -1.138 . . . . 0.0 109.728 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.52 -8.77 87.12 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -178.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.02 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.0 p-10 -112.22 -23.75 10.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.862 -1.375 . . . . 0.0 109.975 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 51.33 28.43 4.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.134 -0.978 . . . . 0.0 109.732 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.821 ' HB2' HG22 ' A' ' 44' ' ' VAL . 38.4 m170 -129.32 38.42 3.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.287 -0.883 . . . . 0.0 109.283 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.792 HD11 ' CD2' ' A' ' 93' ' ' TYR . 51.2 mt -87.72 154.6 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.233 -0.917 . . . . 0.0 110.065 -179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.429 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.86 149.83 27.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.129 -0.982 . . . . 0.0 110.159 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.672 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -80.17 -8.83 59.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.358 -0.839 . . . . 0.0 109.588 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 105' ' ' PRO . 14.5 pt-20 -68.62 -30.24 68.92 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.1 -1.0 . . . . 0.0 109.336 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.562 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 70.4 m-85 -82.47 -21.24 35.65 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.312 -0.867 . . . . 0.0 109.737 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.8 ' CE2' HD22 ' A' ' 141' ' ' LEU . 5.2 m-85 -57.66 -68.83 0.2 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.389 -0.819 . . . . 0.0 110.465 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.505 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 8.4 mt-10 -43.62 -60.21 2.78 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.45 -0.781 . . . . 0.0 111.022 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.538 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.3 Cg_endo -56.5 -50.59 11.41 Favored 'Trans proline' 0 C--N 1.304 -1.802 0 O-C-N 123.756 1.398 . . . . 0.0 110.052 -179.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.933 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -65.52 -19.67 66.02 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.158 -0.963 . . . . 0.0 109.333 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -79.99 -44.9 8.68 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.52 -47.07 77.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.217 -1.167 . . . . 0.0 109.337 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 48.7 m -63.66 -16.77 61.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.32 -0.862 . . . . 0.0 109.508 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.493 HD22 ' CE2' ' A' ' 134' ' ' TYR . 6.3 tt -75.41 -40.24 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.673 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.882 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.8 mt -63.12 -30.06 71.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.202 -0.937 . . . . 0.0 109.718 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 1.4 t -73.2 -20.9 60.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 109.639 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.837 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -88.29 -31.25 19.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.582 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.585 ' SD ' HD23 ' A' ' 111' ' ' LEU . 1.0 OUTLIER -55.6 -35.75 66.17 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.853 . . . . 0.0 109.992 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 20.8 pt-20 -57.75 -22.54 47.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.117 -0.989 . . . . 0.0 109.575 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.405 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -56.98 -40.56 76.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.211 -0.931 . . . . 0.0 109.355 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.47 ' HD3' HG23 ' A' ' 17' ' ' ILE . 11.2 ttt85 -77.59 -62.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 109.543 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.507 HG12 HD11 ' A' ' 17' ' ' ILE . 8.7 pt -91.69 43.26 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.459 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -52.99 124.46 27.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 101.06 -37.06 3.78 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 26.4 mmtt -89.12 -24.52 22.22 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 109.293 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.435 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -72.12 86.9 1.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.323 -0.861 . . . . 0.0 109.586 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.87 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.1 p-10 -83.66 -171.98 3.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.348 -0.845 . . . . 0.0 109.859 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.441 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -64.15 -42.58 96.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.299 -0.876 . . . . 0.0 109.778 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.87 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -61.09 -29.96 70.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.128 -0.983 . . . . 0.0 109.334 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.507 ' HB1' HG21 ' A' ' 13' ' ' THR . . . -69.93 -50.35 42.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.527 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 11.5 ptpt -71.79 -28.37 63.57 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.9 t0 -76.51 -49.28 16.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.267 -0.896 . . . . 0.0 109.332 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.645 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -56.53 -45.25 81.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.391 -0.818 . . . . 0.0 109.261 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.921 ' CH2' HD12 ' A' ' 17' ' ' ILE . 5.4 m0 -73.54 -32.07 64.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.36 -0.838 . . . . 0.0 109.134 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.604 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.03 -24.69 67.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.291 -0.88 . . . . 0.0 109.185 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.23 -26.97 16.41 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.386 -0.821 . . . . 0.0 109.265 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.56 ' HB1' HD11 ' A' ' 73' ' ' LEU . . . -81.68 -44.46 17.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.325 -0.859 . . . . 0.0 109.577 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.729 ' CZ ' HG21 ' A' ' 66' ' ' ILE . 2.8 m-85 -57.45 -27.61 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -0.943 . . . . 0.0 109.493 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -62.45 -46.32 89.07 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.185 -0.947 . . . . 0.0 109.355 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -74.58 -28.28 60.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.33 -0.857 . . . . 0.0 109.587 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.67 HD12 ' HA ' ' A' ' 134' ' ' TYR . 81.4 mt -68.62 -60.24 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.453 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.404 ' O ' HG12 ' A' ' 142' ' ' ILE . 45.2 p -67.52 -48.76 66.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.382 -0.824 . . . . 0.0 109.774 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.64 -29.85 26.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.664 ' HB1' HG13 ' A' ' 80' ' ' VAL . . . -78.85 -17.55 55.45 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.157 -1.202 . . . . 0.0 109.825 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.8 HD22 ' CE2' ' A' ' 103' ' ' PHE . 9.3 tt -89.57 -23.44 21.98 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 109.82 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.672 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.0 mm -70.7 -16.71 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.219 -0.925 . . . . 0.0 109.82 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.469 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.5 OUTLIER -61.39 -68.01 0.35 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -0.966 . . . . 0.0 109.175 179.808 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.777 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -66.04 -19.37 67.84 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.483 ' CB ' ' HA ' ' A' ' 142' ' ' ILE . 24.6 tp -58.75 170.28 0.83 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.316 -1.108 . . . . 0.0 109.597 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.482 ' HG2' ' O ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 36.33 46.83 0.44 Allowed 'General case' 0 N--CA 1.502 2.138 0 CA-C-O 121.336 0.589 . . . . 0.0 111.044 -179.86 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.459 ' N ' ' HG3' ' A' ' 91' ' ' LYS . 4.0 t . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.659 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.768 HMA3 ' HA ' ' A' ' 45' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.638 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.883 HD13 HD13 ' A' ' 73' ' ' LEU . 10.8 mt -61.02 176.95 0.37 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -1.116 . . . . 0.0 109.404 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.402 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 77.7 p -134.27 -159.81 1.0 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.917 . . . . 0.0 109.775 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.79 -27.74 20.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -0.853 . . . . 0.0 109.544 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.29 -34.98 15.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.373 -0.829 . . . . 0.0 109.684 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.402 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 27.9 mt-30 -70.82 -40.96 72.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.06 -1.025 . . . . 0.0 109.527 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.46 ' NH2' ' HA3' ' A' ' 74' ' ' GLY . 11.0 ttm180 -51.04 -52.73 40.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.113 -0.992 . . . . 0.0 109.297 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 60.1 mm-40 -49.72 -41.73 44.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.926 . . . . 0.0 109.268 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 23.7 t -71.25 -29.91 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -0.883 . . . . 0.0 108.88 179.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.849 HG12 HG13 ' A' ' 70' ' ' VAL . 41.5 t -78.59 -43.73 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.494 -0.754 . . . . 0.0 109.051 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.71 -13.19 60.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.443 -0.786 . . . . 0.0 109.78 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.5 m -92.13 -27.65 17.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.014 -1.054 . . . . 0.0 110.094 -179.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 p -87.73 -14.53 39.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.166 -0.959 . . . . 0.0 109.843 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.563 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -86.2 -18.4 32.27 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -0.95 . . . . 0.0 109.781 -179.802 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -80.28 1.97 26.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.142 -0.974 . . . . 0.0 109.784 179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -114.22 -53.95 2.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.103 -0.998 . . . . 0.0 109.333 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.895 HD12 ' CH2' ' A' ' 130' ' ' TRP . 54.7 mt -63.94 -35.19 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.468 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.563 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.4 38.27 2.01 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -0.912 . . . . 0.0 109.791 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.83 -88.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.1 p -109.41 17.38 21.51 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.305 -1.115 . . . . 0.0 109.683 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.439 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 2.9 p-10 -125.88 -3.93 7.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.578 HD21 ' HB2' ' A' ' 64' ' ' ALA . 6.4 t30 57.15 19.25 4.68 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.293 -0.88 . . . . 0.0 109.452 -179.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.48 27.22 30.63 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HD2' ' A' ' 28' ' ' LYS . . . -52.56 -38.26 59.52 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.348 -1.089 . . . . 0.0 109.698 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.43 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.44 18.97 38.67 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.875 HG21 ' CG2' ' A' ' 17' ' ' ILE . 25.5 t -117.3 -14.22 10.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.136 -1.214 . . . . 0.0 109.46 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.461 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -110.03 -29.46 3.77 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.015 -1.634 . . . . 0.0 109.015 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.487 ' HB2' ' CB ' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -77.8 -28.47 50.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.187 -1.184 . . . . 0.0 109.458 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.619 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 1.6 pm0 -95.38 -16.0 22.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.633 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.406 ' HB2' ' OE2' ' A' ' 29' ' ' GLU . 37.0 t -87.98 -62.49 1.48 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -0.925 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.659 ' O ' HD12 ' A' ' 35' ' ' LEU . 10.8 m-85 -50.27 -30.96 12.94 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.143 -0.973 . . . . 0.0 109.694 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.579 ' OG1' HG11 ' A' ' 55' ' ' VAL . 52.6 m -61.64 -30.97 71.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.418 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 6.7 mmtt -74.57 -47.44 32.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.283 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.689 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.1 t80 -57.85 -46.16 85.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.419 -0.801 . . . . 0.0 109.535 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.701 HD13 HG22 ' A' ' 55' ' ' VAL . 6.8 mt -60.3 -46.89 88.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -0.882 . . . . 0.0 109.775 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.481 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 54.3 p -65.14 -49.9 68.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.284 -0.885 . . . . 0.0 109.769 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.63 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -70.45 -25.9 63.41 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.192 -0.943 . . . . 0.0 109.765 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.63 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 21.3 m-70 -126.14 117.76 23.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.204 -0.935 . . . . 0.0 109.866 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.2 m170 -94.75 -15.33 23.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.455 -0.778 . . . . 0.0 109.56 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -71.59 -7.62 48.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.17 -0.956 . . . . 0.0 109.882 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.582 ' HE2' ' CD1' ' A' ' 102' ' ' TYR . 4.9 mmt -118.77 -12.08 9.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.012 -1.055 . . . . 0.0 110.115 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.458 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -56.53 -53.53 56.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.943 -1.098 . . . . 0.0 109.254 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -64.25 -27.9 69.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.102 179.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.022 HG13 ' ND2' ' A' ' 95' ' ' ASN . 13.0 t -67.95 -53.38 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.417 -0.802 . . . . 0.0 109.171 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 38.9 m-85 -61.93 -19.02 62.28 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.271 -0.893 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 100.21 29.66 6.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 14.1 m-85 -126.37 168.84 13.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -1.138 . . . . 0.0 109.941 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 20.5 t -114.67 20.11 15.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.452 -0.78 . . . . 0.0 109.166 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.78 -163.74 28.24 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -98.93 39.47 1.27 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -1.17 . . . . 0.0 109.645 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 16.1 m -140.53 22.94 2.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 109.675 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -110.43 145.67 32.71 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.24 -0.913 . . . . 0.0 109.692 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -77.57 56.15 5.46 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.972 1.511 . . . . 0.0 110.169 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -135.06 -38.4 0.19 Allowed Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.701 HG22 HD13 ' A' ' 35' ' ' LEU . 47.5 t -50.0 -26.65 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.242 -1.152 . . . . 0.0 109.596 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.512 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -81.1 -7.81 59.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.292 -0.88 . . . . 0.0 110.002 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -91.73 -31.37 15.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.067 -1.021 . . . . 0.0 109.747 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.877 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.1 mt -83.04 -64.09 1.24 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.115 -0.991 . . . . 0.0 109.697 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.461 ' HA3' ' CA ' ' A' ' 27' ' ' GLY . . . -51.39 -44.81 53.16 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.512 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -53.49 -39.15 64.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.225 -1.162 . . . . 0.0 109.611 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.463 ' HD3' ' CGD' ' A' ' 148' ' ' HEM . 17.5 mttt -89.63 -32.31 17.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.252 -0.905 . . . . 0.0 109.633 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.877 HG23 ' O ' ' A' ' 58' ' ' LEU . 57.7 t -65.27 -47.95 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.919 . . . . 0.0 109.566 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.691 HD11 ' CG1' ' A' ' 26' ' ' VAL . 2.9 mm? -47.3 -45.27 24.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.198 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.578 ' HB2' HD21 ' A' ' 22' ' ' ASN . . . -53.65 -39.95 65.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.175 -0.953 . . . . 0.0 110.077 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.463 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 6.8 tp-100 -59.78 -39.54 85.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.964 -1.085 . . . . 0.0 108.903 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 1.029 HD13 HG21 ' A' ' 137' ' ' ILE . 26.7 mm -62.44 -42.14 94.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.405 -0.809 . . . . 0.0 108.9 179.286 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.546 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.6 -51.32 55.06 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 179.562 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 64' ' ' ALA . 46.6 t -58.47 -26.8 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.318 -1.107 . . . . 0.0 109.411 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.83 -28.19 26.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.32 -0.863 . . . . 0.0 109.704 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.849 HG13 HG12 ' A' ' 10' ' ' VAL . 54.1 t -75.83 -23.33 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.215 -0.928 . . . . 0.0 109.565 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.2 p -63.57 -13.48 42.05 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 110.034 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.487 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.4 m-70 -124.01 -77.53 0.59 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.106 -0.996 . . . . 0.0 109.957 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.883 HD13 HD13 ' A' ' 2' ' ' LEU . 53.5 mt 59.78 -79.52 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.672 -0.643 . . . . 0.0 109.734 -179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -54.64 -29.81 49.63 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.37 125.29 43.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.319 -1.106 . . . . 0.0 109.527 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -114.35 41.62 2.26 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.2 -0.937 . . . . 0.0 109.583 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.55 -32.33 7.0 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.639 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 22.2 ttmt -128.51 -30.01 2.38 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -1.146 . . . . 0.0 110.386 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.49 ' SD ' HD23 ' A' ' 73' ' ' LEU . 4.7 ttp -47.23 -62.38 1.45 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.065 -1.022 . . . . 0.0 109.694 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.554 HG12 ' HE3' ' A' ' 84' ' ' LYS . 42.8 t -65.39 -15.41 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.218 -0.926 . . . . 0.0 109.61 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.639 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -71.06 -52.22 20.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.973 . . . . 0.0 109.377 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.596 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.4 mt-10 -71.25 -41.05 70.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.257 -0.902 . . . . 0.0 109.325 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.477 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 2.1 mtp -58.8 -48.58 80.79 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.234 -0.916 . . . . 0.0 109.305 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.601 ' O ' HG23 ' A' ' 88' ' ' VAL . 11.1 mttt -50.8 -38.57 49.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.151 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.412 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -66.83 -44.55 80.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.401 -0.812 . . . . 0.0 109.408 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.625 ' HB ' HD12 ' A' ' 141' ' ' LEU . 14.4 t -58.23 -37.94 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.157 -0.964 . . . . 0.0 109.264 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.458 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -63.34 -49.08 73.36 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 84' ' ' LYS . 57.4 t -51.44 -38.45 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -1.059 . . . . 0.0 109.453 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.551 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 2.8 mpt_? -59.22 -25.62 64.15 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -0.944 . . . . 0.0 109.336 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.536 ' CD2' HD13 ' A' ' 98' ' ' ILE . 4.5 m80 -87.38 16.32 5.49 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.397 -0.814 . . . . 0.0 109.643 -179.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.439 ' O ' ' HG3' ' A' ' 96' ' ' LYS . 23.3 ttmt -75.27 -67.48 0.65 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.941 -1.1 . . . . 0.0 110.167 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.4 ' HA2' ' HG3' ' A' ' 96' ' ' LYS . . . -145.7 56.07 0.53 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.551 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -82.46 -100.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.423 -1.045 . . . . 0.0 110.342 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -96.48 -57.28 1.13 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.022 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -84.37 -28.45 26.98 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.415 -1.05 . . . . 0.0 108.594 179.472 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.511 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 14.6 tttm 64.41 -48.99 0.3 Allowed 'General case' 0 N--CA 1.505 2.283 0 O-C-N 121.75 -0.594 . . . . 0.0 112.271 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.469 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 64.2 m170 -50.0 -97.21 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.628 -1.295 . . . . 0.0 111.234 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.536 HD13 ' CD2' ' A' ' 90' ' ' HIS . 14.9 mt 65.4 154.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 121.035 -1.04 . . . . 0.0 109.572 -178.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.435 ' HE3' ' HB3' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -158.32 150.75 22.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.268 -0.895 . . . . 0.0 109.828 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.821 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -77.82 -10.21 59.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.569 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.464 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.0 mt-10 -67.68 -35.77 79.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 109.597 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.582 ' CD1' ' HE2' ' A' ' 41' ' ' MET . 76.5 m-85 -81.15 -16.48 52.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.344 -0.847 . . . . 0.0 110.146 -179.416 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.824 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -58.32 -57.49 12.66 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.158 -0.963 . . . . 0.0 109.973 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.518 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -53.75 -58.05 14.84 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 109.755 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.518 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 39.7 Cg_exo -50.81 -62.17 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.628 1.33 . . . . 0.0 109.76 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.954 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -53.77 -24.75 16.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -0.895 . . . . 0.0 109.241 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -74.68 -51.49 8.04 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.096 -1.601 . . . . 0.0 109.096 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -54.22 -55.43 28.17 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -1.169 . . . . 0.0 109.456 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 54.9 m -53.33 -22.76 7.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.349 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.422 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.4 tt -65.88 -48.51 71.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.314 -0.866 . . . . 0.0 109.632 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.697 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -57.54 -36.56 71.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.184 -0.948 . . . . 0.0 109.544 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -67.44 -33.81 75.9 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 109.595 179.966 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.619 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -81.69 -25.73 35.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -0.924 . . . . 0.0 109.663 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.534 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.9 mmt -58.45 -47.73 83.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.918 . . . . 0.0 110.205 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.449 ' O ' ' N ' ' A' ' 119' ' ' GLY . 6.4 pt-20 -50.05 -23.54 2.14 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.068 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.428 ' NE2' ' HA ' ' A' ' 113' ' ' ALA . 19.1 m170 -50.2 -40.73 48.12 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.993 -1.067 . . . . 0.0 109.783 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -87.17 -56.14 3.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 109.7 -179.873 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.541 HG12 HD11 ' A' ' 17' ' ' ILE . 5.7 pt -104.34 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.143 -0.973 . . . . 0.0 109.633 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -63.15 -20.11 62.41 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.51 -29.23 10.28 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.443 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.2 mppt? -94.26 -23.44 17.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -1.189 . . . . 0.0 109.803 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.488 ' SD ' HD11 ' A' ' 118' ' ' ILE . 3.8 tpt -63.89 86.35 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.18 -0.95 . . . . 0.0 109.616 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.826 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.2 p-10 -87.14 -168.73 2.34 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -0.9 . . . . 0.0 109.521 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.414 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.29 -39.98 74.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -0.932 . . . . 0.0 109.628 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.826 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -65.05 -31.11 72.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.095 -1.003 . . . . 0.0 108.98 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.458 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -66.27 -50.8 62.48 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.107 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.492 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 17.5 ptpt -70.53 -27.67 64.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.913 . . . . 0.0 109.124 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.482 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.1 t0 -79.33 -32.57 43.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.374 -0.829 . . . . 0.0 108.953 179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.7 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -72.42 -47.69 47.15 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.433 -0.792 . . . . 0.0 109.126 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.895 ' CH2' HD12 ' A' ' 17' ' ' ILE . 12.5 m0 -71.54 -21.54 61.88 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.269 -0.895 . . . . 0.0 108.976 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.492 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -53.24 -34.3 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -0.889 . . . . 0.0 109.038 179.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -97.22 -15.4 20.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.417 -0.802 . . . . 0.0 109.494 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.647 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -81.51 -67.79 0.75 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.252 -0.905 . . . . 0.0 109.854 -179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.514 ' CE1' ' HA3' ' A' ' 107' ' ' GLY . 0.4 OUTLIER -55.31 -21.25 14.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.032 -1.043 . . . . 0.0 109.268 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -80.92 -49.56 10.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.299 -0.876 . . . . 0.0 108.944 179.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -73.21 -26.45 61.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.399 -0.813 . . . . 0.0 109.331 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 1.029 HG21 HD13 ' A' ' 66' ' ' ILE . 43.9 mt -67.88 -61.21 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 109.183 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.402 ' O ' HG12 ' A' ' 142' ' ' ILE . 0.7 OUTLIER -62.89 -14.2 43.51 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.346 -0.846 . . . . 0.0 109.907 -179.819 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.43 -36.01 24.69 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -68.67 -27.9 66.39 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -1.184 . . . . 0.0 109.916 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.824 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.8 tt -74.39 -5.61 43.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.194 -0.941 . . . . 0.0 110.138 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.821 HD12 ' HB2' ' A' ' 100' ' ' ALA . 49.8 mm -90.66 18.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.98 -1.075 . . . . 0.0 109.843 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.445 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 5.8 m -95.25 -63.41 1.17 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.947 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.12 -22.52 74.35 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.586 HD23 ' HG3' ' A' ' 146' ' ' GLN . 0.4 OUTLIER -56.4 -168.63 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.354 -1.086 . . . . 0.0 109.535 179.935 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.586 ' HG3' HD23 ' A' ' 145' ' ' LEU . 10.3 mt-30 55.63 92.75 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.211 -0.931 . . . . 0.0 109.676 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.416 ' HB3' ' HG3' ' A' ' 91' ' ' LYS . 19.2 p . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.625 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.781 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.536 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 7.8 mt -93.01 176.35 6.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.22 -1.165 . . . . 0.0 109.875 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.08 -166.52 1.22 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.338 -0.851 . . . . 0.0 109.891 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -84.02 -23.38 30.97 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.141 -0.974 . . . . 0.0 109.796 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.767 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -94.38 -36.13 12.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.599 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.489 ' O ' HG23 ' A' ' 10' ' ' VAL . 36.6 mt-30 -65.13 -51.39 61.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.366 -0.834 . . . . 0.0 109.552 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.471 ' NH1' ' HA3' ' A' ' 74' ' ' GLY . 7.5 ptm180 -53.43 -32.3 49.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.08 -1.013 . . . . 0.0 108.921 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 47.8 tp60 -71.48 -44.07 65.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.455 -0.778 . . . . 0.0 109.166 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 5' ' ' ALA . 30.0 t -65.12 -30.65 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.291 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.807 HG12 HG13 ' A' ' 70' ' ' VAL . 84.8 t -70.04 -41.75 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.369 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.8 -14.67 60.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -0.869 . . . . 0.0 109.764 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.1 -33.25 19.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.509 HG21 ' HB1' ' A' ' 126' ' ' ALA . 12.1 p -85.55 -15.73 41.73 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.739 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -86.99 -18.98 29.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -0.966 . . . . 0.0 109.811 -179.893 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.8 mtpp -80.99 0.32 36.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.194 -0.941 . . . . 0.0 109.898 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -115.83 -53.65 2.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.081 -1.012 . . . . 0.0 109.439 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.945 HD12 ' CH2' ' A' ' 130' ' ' TRP . 64.7 mt -67.3 -32.78 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.283 -0.886 . . . . 0.0 109.473 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.552 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -103.07 31.92 4.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.872 . . . . 0.0 109.647 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.7 -86.39 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.0 p -95.25 -35.71 11.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.244 -1.151 . . . . 0.0 109.752 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.711 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 2.9 p30 -71.24 -17.12 62.51 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.26 -0.9 . . . . 0.0 109.81 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.552 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 0.2 OUTLIER 58.31 24.8 11.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.133 -0.979 . . . . 0.0 109.455 -179.874 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.577 ' CA ' HD22 ' A' ' 63' ' ' LEU . . . 92.78 32.95 7.69 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.711 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -81.11 -66.34 0.9 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.316 -1.108 . . . . 0.0 109.816 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 29' ' ' GLU . . . -52.74 -22.98 13.0 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.793 HG12 HD11 ' A' ' 63' ' ' LEU . 38.5 t -74.82 -32.21 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.846 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -83.01 -55.48 2.93 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.42 ' HB3' ' HA ' ' A' ' 56' ' ' ALA . 6.6 ptpp? -57.31 -19.63 23.52 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.187 -1.184 . . . . 0.0 110.053 -179.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.65 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -98.35 -30.42 12.59 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.972 -1.08 . . . . 0.0 109.579 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.3 t -82.32 -55.48 4.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.34 -0.85 . . . . 0.0 109.538 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.524 ' O ' HD12 ' A' ' 35' ' ' LEU . 12.2 m-85 -54.55 -37.44 65.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.236 -0.915 . . . . 0.0 109.357 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.884 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.56 -54.72 37.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.213 -0.929 . . . . 0.0 109.232 179.624 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -57.11 -47.82 80.15 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.212 -0.93 . . . . 0.0 109.335 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.741 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.4 t80 -55.07 -52.24 63.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.3 -0.875 . . . . 0.0 109.28 179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.893 HD13 HG22 ' A' ' 55' ' ' VAL . 6.8 mt -59.3 -41.14 88.29 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.255 -0.903 . . . . 0.0 109.664 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.426 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 20.6 t -63.1 -61.19 2.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.28 -0.887 . . . . 0.0 109.657 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.622 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -63.37 -26.72 68.88 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.236 -0.915 . . . . 0.0 109.684 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.622 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 12.1 m-70 -118.9 107.53 13.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.691 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.2 m170 -88.34 -24.29 23.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 109.362 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 40' ' ' ASP . 25.5 p-10 -65.39 -19.16 65.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.408 179.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.544 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -95.21 -17.6 21.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.292 -0.88 . . . . 0.0 109.741 -179.998 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.439 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -57.43 -62.78 1.54 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.975 . . . . 0.0 109.38 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.56 -26.38 43.14 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.025 HG13 ' ND2' ' A' ' 95' ' ' ASN . 21.1 t -73.63 -48.76 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 109.239 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.522 ' CD2' HD21 ' A' ' 35' ' ' LEU . 27.1 m-85 -68.26 -26.9 65.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.22 -0.925 . . . . 0.0 109.549 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 108.66 27.49 4.92 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.528 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.3 m-85 -123.74 167.29 14.22 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.176 . . . . 0.0 109.868 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 t -102.81 -20.93 14.13 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.421 -0.799 . . . . 0.0 109.203 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.9 -163.91 23.72 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.095 -1.602 . . . . 0.0 109.095 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.426 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -94.73 34.11 1.38 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.298 -1.119 . . . . 0.0 109.698 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 24.4 p -133.0 21.23 4.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.68 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -106.64 139.48 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.607 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.6 -16.96 57.94 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.954 1.502 . . . . 0.0 110.105 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.528 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -56.27 -39.8 83.05 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.893 HG22 HD13 ' A' ' 35' ' ' LEU . 84.1 t -51.04 -37.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.334 -1.098 . . . . 0.0 109.38 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.456 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -73.74 -6.6 47.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.305 -0.872 . . . . 0.0 109.721 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -91.62 -27.16 18.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.011 . . . . 0.0 109.57 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.825 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -91.43 -64.0 1.18 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.175 -0.953 . . . . 0.0 109.627 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.522 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.18 -41.94 39.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -62.84 -23.85 67.5 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -1.149 . . . . 0.0 109.691 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.73 -28.37 12.51 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.679 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.825 HG23 ' O ' ' A' ' 58' ' ' LEU . 59.6 t -67.22 -56.49 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.287 -0.883 . . . . 0.0 109.848 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.793 HD11 HG12 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -48.2 -38.4 18.19 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.961 . . . . 0.0 109.616 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.44 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -50.44 -42.21 53.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.197 -0.939 . . . . 0.0 109.449 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.446 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 5.7 tp-100 -62.7 -36.17 82.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.232 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.865 ' O ' HG23 ' A' ' 70' ' ' VAL . 41.6 mt -66.92 -37.07 78.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.355 -0.841 . . . . 0.0 109.186 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.81 -48.27 56.18 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 179.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 64' ' ' ALA . 61.6 t -61.42 -27.99 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.357 -1.084 . . . . 0.0 109.43 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.86 -32.98 24.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.319 -0.863 . . . . 0.0 109.503 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 66' ' ' ILE . 56.5 t -66.58 -22.67 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.263 -0.898 . . . . 0.0 109.491 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 41.3 m -67.31 -12.36 59.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.948 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.483 ' O ' ' N ' ' A' ' 74' ' ' GLY . 14.0 m-70 -122.85 -83.92 0.66 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.123 -0.986 . . . . 0.0 109.918 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.649 HD11 ' HA ' ' A' ' 70' ' ' VAL . 35.1 mt 60.85 -77.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.65 -0.657 . . . . 0.0 109.676 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.46 -29.84 40.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.796 -1.721 . . . . 0.0 108.796 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -87.56 160.44 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.381 -1.07 . . . . 0.0 109.372 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -148.73 67.29 1.05 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.654 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -126.3 -44.03 0.26 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.241 -1.544 . . . . 0.0 109.241 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 22.5 ttpp -122.04 -26.04 4.83 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -1.159 . . . . 0.0 110.124 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.411 ' SD ' HD23 ' A' ' 73' ' ' LEU . 5.5 ttp -48.01 -50.65 26.95 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.064 -1.023 . . . . 0.0 109.726 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.453 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.2 t -72.14 -29.41 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 0.0 109.492 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.01 -41.91 97.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.253 -0.904 . . . . 0.0 109.435 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.682 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.5 mt-10 -71.98 -50.8 25.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.281 -0.887 . . . . 0.0 109.513 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.444 ' CE ' ' HB2' ' A' ' 141' ' ' LEU . 0.2 OUTLIER -62.47 -38.66 90.69 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 109.149 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.453 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -60.06 -38.04 81.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.265 -0.897 . . . . 0.0 109.099 179.44 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -67.92 -41.34 82.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.258 -0.901 . . . . 0.0 109.21 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.682 HG23 ' O ' ' A' ' 82' ' ' GLU . 30.8 t -55.48 -50.52 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.328 -0.857 . . . . 0.0 109.119 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.524 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -56.55 -53.58 42.47 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 84' ' ' LYS . 79.1 t -53.85 -34.24 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.438 -1.037 . . . . 0.0 108.947 179.355 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mmm180 -72.13 -48.72 41.54 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.413 -0.804 . . . . 0.0 109.051 179.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.707 ' O ' HD12 ' A' ' 98' ' ' ILE . 14.5 m80 -56.48 -27.38 56.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.329 -0.857 . . . . 0.0 109.04 179.394 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.487 ' HG3' ' CA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -66.46 -12.07 55.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 110.289 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -136.08 49.85 0.87 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.701 ' CD2' HD11 ' A' ' 98' ' ' ILE . 4.3 m-30 -89.61 -168.71 2.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -1.174 . . . . 0.0 109.795 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -78.6 -52.19 5.2 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.025 ' ND2' HG13 ' A' ' 44' ' ' VAL . 17.8 p-10 -62.3 -29.41 70.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.184 -1.186 . . . . 0.0 109.657 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.435 ' O ' ' CD2' ' A' ' 97' ' ' HIS . 12.0 mtmm 53.54 29.36 8.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.671 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.435 ' CD2' ' O ' ' A' ' 96' ' ' LYS . 39.0 m170 -136.29 45.31 2.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.284 -0.885 . . . . 0.0 109.57 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.707 HD12 ' O ' ' A' ' 90' ' ' HIS . 62.2 mt -87.55 154.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.298 -0.876 . . . . 0.0 109.727 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -144.12 148.35 34.96 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.282 -0.886 . . . . 0.0 110.104 -179.84 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.523 ' HB2' HG23 ' A' ' 142' ' ' ILE . . . -83.68 -3.56 57.86 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.698 -0.627 . . . . 0.0 109.609 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 8.8 pt-20 -74.95 -29.16 60.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.074 -1.016 . . . . 0.0 109.477 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.544 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 59.8 m-85 -81.78 -22.1 37.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.726 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.879 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.0 m-85 -54.03 -63.46 1.14 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.221 -0.924 . . . . 0.0 110.263 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.511 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -48.98 -58.41 8.69 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.132 -0.98 . . . . 0.0 110.13 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.511 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.6 Cg_exo -49.85 -62.53 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.598 1.315 . . . . 0.0 110.026 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.964 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.59 -22.02 12.12 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.255 -0.903 . . . . 0.0 109.547 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.66 -50.36 5.33 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.44 95.19 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.133 -1.216 . . . . 0.0 109.557 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.4 t -66.62 -21.36 66.12 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.269 -0.894 . . . . 0.0 109.495 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.859 HD22 ' OH ' ' A' ' 134' ' ' TYR . 2.7 tt -71.96 -41.97 67.12 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 109.626 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.925 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.3 mt -58.97 -30.25 67.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 0.0 109.573 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 3.6 m -68.64 -33.99 74.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.713 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.65 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -81.47 -33.46 31.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.259 -0.9 . . . . 0.0 109.782 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.494 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -45.89 -47.55 16.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.313 -0.867 . . . . 0.0 110.341 -179.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.457 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 18.8 pt-20 -51.94 -22.48 3.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 0.0 110.015 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 24.0 m170 -53.7 -30.7 44.98 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.012 -1.055 . . . . 0.0 109.81 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -95.42 -68.9 0.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.133 -0.979 . . . . 0.0 109.93 -179.775 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.495 HG23 ' CG1' ' A' ' 17' ' ' ILE . 33.2 pt -75.11 -36.85 39.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.025 -1.047 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.487 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 39.52 -96.84 0.01 OUTLIER Glycine 0 N--CA 1.498 2.828 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.54 -42.45 10.09 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 3.3 mtpt -72.42 -21.9 61.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.112 -1.228 . . . . 0.0 109.771 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.45 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.23 90.53 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.157 -0.964 . . . . 0.0 109.57 179.829 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.801 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 17.8 p-10 -84.94 -179.88 7.16 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.566 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 127' ' ' LYS . . . -64.01 -40.25 95.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.801 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -63.98 -30.51 71.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.191 -0.943 . . . . 0.0 109.196 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.787 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -67.03 -50.5 61.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.406 -0.809 . . . . 0.0 109.322 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.541 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.0 ptpt -71.88 -30.02 64.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.289 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.427 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 59.5 t0 -77.13 -44.02 31.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.2 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.412 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -63.82 -41.62 97.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.48 -0.763 . . . . 0.0 109.065 179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.945 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.5 m0 -75.25 -25.01 57.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.32 -0.863 . . . . 0.0 109.012 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.541 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.43 -37.2 80.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -0.886 . . . . 0.0 108.987 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -78.83 -24.58 44.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.324 -0.86 . . . . 0.0 109.297 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -83.27 -50.41 8.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.359 -0.838 . . . . 0.0 109.543 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.859 ' OH ' HD22 ' A' ' 110' ' ' LEU . 3.7 m-85 -50.35 -31.68 15.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.18 -0.95 . . . . 0.0 109.306 179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.94 -35.68 57.11 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.341 -0.849 . . . . 0.0 108.986 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.83 -36.12 37.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.385 -0.822 . . . . 0.0 109.287 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.786 HD13 HG23 ' A' ' 66' ' ' ILE . 58.6 mt -66.58 -58.96 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.291 -0.88 . . . . 0.0 109.087 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.0 p -67.3 -19.81 65.53 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.386 -0.821 . . . . 0.0 109.644 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.427 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -72.1 -42.65 50.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.86 -23.03 65.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -1.146 . . . . 0.0 109.673 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.879 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.6 tt -80.34 -34.07 36.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.682 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.523 HG23 ' HB2' ' A' ' 100' ' ' ALA . 43.4 mt -73.79 -3.45 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 110.145 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.6 m -68.77 -59.43 3.1 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.011 -1.056 . . . . 0.0 109.621 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -88.38 4.4 85.28 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.663 HD23 ' N ' ' A' ' 146' ' ' GLN . 4.4 tt -78.02 178.75 7.26 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.056 -1.261 . . . . 0.0 109.48 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.663 ' N ' HD23 ' A' ' 145' ' ' LEU . 0.0 OUTLIER 41.69 39.22 1.11 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.655 -0.653 . . . . 0.0 110.606 -179.744 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.487 ' CA ' ' HG3' ' A' ' 91' ' ' LYS . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.748 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.556 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.564 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.704 HD11 ' HA ' ' A' ' 133' ' ' ALA . 11.6 mt -86.9 164.94 16.29 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -1.157 . . . . 0.0 109.796 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.7 p -142.22 -172.8 3.67 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 109.777 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -81.1 -25.52 36.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -0.886 . . . . 0.0 109.631 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.678 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -88.82 -23.54 22.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.572 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 83.8 mt-30 -81.86 -52.08 7.46 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.427 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.1 OUTLIER -49.61 -30.96 9.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.223 -0.923 . . . . 0.0 109.521 179.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.427 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 6.3 mm-40 -72.1 -42.91 65.56 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.266 -0.896 . . . . 0.0 109.278 179.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 5' ' ' ALA . 42.9 t -63.25 -32.15 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.274 -0.891 . . . . 0.0 109.243 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.973 HG12 HG13 ' A' ' 70' ' ' VAL . 70.7 t -66.12 -45.99 88.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.368 -0.833 . . . . 0.0 109.344 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.71 -10.56 59.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 109.821 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.3 p -92.88 -24.29 18.51 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.138 -0.976 . . . . 0.0 109.979 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.503 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 18.3 p -97.55 -8.98 27.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.092 -1.005 . . . . 0.0 109.959 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.694 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.6 -20.15 22.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.018 -1.051 . . . . 0.0 109.569 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 40.9 mtpt -80.8 3.22 23.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.97 -56.49 2.1 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.066 -1.022 . . . . 0.0 109.512 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.882 HD12 ' CH2' ' A' ' 130' ' ' TRP . 51.2 mt -62.35 -30.26 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.51 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.907 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -107.42 32.41 4.69 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.243 -0.91 . . . . 0.0 109.618 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.85 -69.41 1.21 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 84.5 p -109.99 -29.96 8.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.281 -1.129 . . . . 0.0 109.663 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.815 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.8 p-10 -78.78 -20.2 50.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.896 . . . . 0.0 109.67 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.907 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.8 t30 57.61 28.41 15.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.185 -0.947 . . . . 0.0 109.516 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.412 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 93.51 25.39 18.59 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.815 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -73.2 -47.08 46.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.252 -1.146 . . . . 0.0 109.592 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.479 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.28 17.86 45.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.801 -1.319 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.657 HG13 ' SD ' ' A' ' 114' ' ' MET . 21.2 t -109.48 -25.81 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.25 179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.5 ' HA3' HD23 ' A' ' 63' ' ' LEU . . . -94.43 -43.19 3.76 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.479 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.3 OUTLIER -62.19 -31.49 72.01 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.096 -1.238 . . . . 0.0 109.577 -179.837 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.89 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 14.5 pt-20 -89.38 -15.99 32.02 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.929 . . . . 0.0 109.618 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 15.8 t -90.15 -63.14 1.32 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.482 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 16.8 m-85 -47.54 -33.95 7.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.496 ' OG1' HG11 ' A' ' 55' ' ' VAL . 51.5 m -55.39 -40.75 71.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.172 -0.955 . . . . 0.0 109.421 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.41 -49.41 27.22 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.264 -0.897 . . . . 0.0 109.456 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.713 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.9 t80 -52.06 -46.51 65.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.339 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.656 ' CD1' HG22 ' A' ' 55' ' ' VAL . 17.6 mt -58.07 -47.12 84.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.529 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.515 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 6.4 t -65.35 -55.83 15.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.569 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -61.54 -24.47 66.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.657 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 17.2 m-70 -124.9 103.88 8.29 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.269 -0.894 . . . . 0.0 109.722 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.5 m170 -86.29 -18.99 30.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.366 -0.834 . . . . 0.0 109.454 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -71.96 -9.66 58.68 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.283 -0.885 . . . . 0.0 109.893 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.621 ' HE1' HMB2 ' A' ' 148' ' ' HEM . 29.7 mmm -119.38 -15.8 9.05 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 110.079 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.459 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.03 -47.7 44.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.041 . . . . 0.0 109.424 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.25 -31.6 64.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.331 -0.855 . . . . 0.0 109.093 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.034 HG13 ' ND2' ' A' ' 95' ' ' ASN . 15.9 t -60.51 -37.31 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.408 -0.808 . . . . 0.0 109.141 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.548 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 33.2 m-85 -76.86 -18.46 58.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.764 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 102.44 23.46 8.93 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.518 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 9.8 m-85 -122.49 167.33 13.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -1.137 . . . . 0.0 109.722 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 12.5 t -112.62 21.3 15.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 109.233 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.95 -172.42 25.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.515 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -74.95 -6.86 51.57 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -1.167 . . . . 0.0 109.976 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 62.2 p -94.3 43.41 1.1 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.056 -1.028 . . . . 0.0 109.73 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -123.77 129.18 24.91 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.215 -0.928 . . . . 0.0 109.649 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -67.97 -28.93 34.98 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.776 1.408 . . . . 0.0 110.022 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.457 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.49 -30.15 33.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.656 HG22 ' CD1' ' A' ' 35' ' ' LEU . 95.5 t -50.93 -32.78 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.302 -1.116 . . . . 0.0 109.479 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.487 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -80.72 -6.22 58.14 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.312 -0.867 . . . . 0.0 109.809 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.22 -27.15 20.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.104 -0.998 . . . . 0.0 109.596 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.902 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.4 mt -89.78 -65.81 0.98 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.178 -0.951 . . . . 0.0 109.713 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.482 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.94 -42.16 29.61 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -56.19 -45.36 79.82 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.166 -1.196 . . . . 0.0 109.361 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 39.6 mttp -80.79 -38.17 28.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.386 -0.821 . . . . 0.0 109.403 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.902 HG23 ' O ' ' A' ' 58' ' ' LEU . 42.3 t -59.79 -50.18 81.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 0.0 109.619 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.535 HD11 HG11 ' A' ' 26' ' ' VAL . 1.2 mm? -47.12 -46.63 23.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.255 -0.903 . . . . 0.0 109.85 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.94 -51.07 43.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.814 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.7 tp60 -50.28 -53.77 26.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.124 -0.985 . . . . 0.0 109.438 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.933 ' O ' HG23 ' A' ' 70' ' ' VAL . 45.0 mt -51.27 -39.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 109.27 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.16 -56.09 24.15 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -57.3 -25.73 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.346 -1.09 . . . . 0.0 109.428 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.57 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -85.38 -30.46 23.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.376 -0.827 . . . . 0.0 109.632 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.973 HG13 HG12 ' A' ' 10' ' ' VAL . 74.1 t -66.77 -17.11 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -0.936 . . . . 0.0 109.838 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.464 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 40.9 t -90.21 21.09 3.95 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.155 -0.966 . . . . 0.0 109.975 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.469 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 10.3 m-70 -157.9 44.12 0.32 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.058 -1.026 . . . . 0.0 109.881 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.689 HD12 HD13 ' A' ' 2' ' ' LEU . 3.6 mm? -69.82 -44.27 70.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.95 . . . . 0.0 109.413 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -90.13 -22.92 33.75 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -103.75 103.18 13.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.302 -1.116 . . . . 0.0 109.554 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -102.09 40.48 1.33 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.62 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -95.04 19.58 53.39 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.525 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 7.4 ttpt -176.89 -35.11 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.238 -1.154 . . . . 0.0 109.706 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.469 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 21.7 ttp -47.53 -51.1 21.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.18 -0.95 . . . . 0.0 109.81 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 27.1 t -70.53 -21.95 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 109.511 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -67.18 -42.94 83.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.207 -0.933 . . . . 0.0 109.285 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.589 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.8 mt-10 -78.98 -48.39 14.56 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.269 -0.894 . . . . 0.0 109.322 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.52 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.6 OUTLIER -57.39 -52.03 66.99 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -0.885 . . . . 0.0 109.27 179.677 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.838 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -51.12 -34.18 29.72 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.167 -0.958 . . . . 0.0 108.909 179.398 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.38 -39.69 71.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.362 -0.836 . . . . 0.0 108.951 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 82' ' ' GLU . 53.1 t -61.79 -49.94 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.333 -0.854 . . . . 0.0 109.118 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.485 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -55.16 -38.0 65.8 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.838 HG23 ' O ' ' A' ' 84' ' ' LYS . 95.6 t -60.08 -18.94 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.3 -1.117 . . . . 0.0 109.447 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.524 ' HB3' ' CE2' ' A' ' 93' ' ' TYR . 0.5 OUTLIER -82.63 -19.04 39.06 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.264 -0.898 . . . . 0.0 109.127 179.7 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.554 ' HB3' HD12 ' A' ' 98' ' ' ILE . 4.0 m80 -89.98 19.3 4.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.433 ' O ' ' HD3' ' A' ' 96' ' ' LYS . 2.4 mtmt -80.44 -59.14 2.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.164 -0.96 . . . . 0.0 110.776 -178.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.433 ' HA2' ' HD3' ' A' ' 96' ' ' LYS . . . -148.51 56.77 0.48 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.524 ' CE2' ' HB3' ' A' ' 89' ' ' ARG . 2.7 m-30 -82.46 -103.17 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.365 -1.079 . . . . 0.0 110.012 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -102.16 -62.68 0.74 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.034 ' ND2' HG13 ' A' ' 44' ' ' VAL . 2.0 t30 -68.21 -41.27 81.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.462 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 0.3 OUTLIER 65.66 -57.63 0.32 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.124 0.487 . . . . 0.0 109.852 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.456 ' N ' ' O ' ' A' ' 95' ' ' ASN . 44.1 m170 -62.93 79.53 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.215 -0.928 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.554 HD12 ' HB3' ' A' ' 90' ' ' HIS . 31.8 mt -109.18 158.85 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 109.233 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.523 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.6 mptp? -140.49 139.61 35.15 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.068 -1.02 . . . . 0.0 110.288 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.458 ' CB ' HG12 ' A' ' 142' ' ' ILE . . . -78.55 -2.63 39.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.835 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -76.1 -26.43 56.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.996 -1.065 . . . . 0.0 109.439 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.532 ' CD1' ' HE2' ' A' ' 41' ' ' MET . 83.9 m-85 -85.24 10.13 13.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.384 -0.823 . . . . 0.0 110.076 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.686 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.3 m-85 -83.35 -61.28 1.89 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 109.671 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.506 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -51.01 -57.57 13.31 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.441 -0.787 . . . . 0.0 110.644 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 104' ' ' GLU . 5.2 Cg_endo -54.01 -43.76 55.35 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.59 1.311 . . . . 0.0 110.142 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.861 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.5 tm? -64.12 -17.03 63.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.179 -0.951 . . . . 0.0 109.542 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.74 -36.98 12.37 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.29 -59.62 4.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.196 -1.179 . . . . 0.0 109.63 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.7 t -60.29 -18.9 52.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.27 -0.894 . . . . 0.0 109.565 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.926 HD21 ' HE2' ' A' ' 114' ' ' MET . 3.2 tt -76.76 -36.57 56.98 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.253 -0.905 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.577 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -63.85 -28.77 70.08 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.189 -0.944 . . . . 0.0 109.435 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.66 -34.43 78.2 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.312 -0.868 . . . . 0.0 109.6 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.89 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -75.58 -38.22 59.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.193 -0.942 . . . . 0.0 109.47 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.926 ' HE2' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.34 -44.19 23.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.297 -0.877 . . . . 0.0 110.017 179.923 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.477 ' HG2' ' CB ' ' A' ' 122' ' ' MET . 0.6 OUTLIER -52.42 -22.08 4.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.307 -0.871 . . . . 0.0 109.962 -179.771 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.411 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 21.1 m170 -56.53 -35.86 68.58 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.146 -0.972 . . . . 0.0 110.247 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.507 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -90.8 -86.86 0.2 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.011 -1.056 . . . . 0.0 110.176 -179.583 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 119' ' ' GLY . 34.9 pt -56.61 -36.31 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.811 -1.18 . . . . 0.0 109.608 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.483 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.77 -98.99 0.01 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.519 -1.033 . . . . 0.0 110.519 179.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.35 -44.77 8.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.469 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 44.3 mttt -68.28 -25.77 65.32 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.074 -1.25 . . . . 0.0 110.032 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.477 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.0 OUTLIER -65.52 80.6 0.06 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.982 -1.073 . . . . 0.0 108.845 179.384 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.668 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 12.2 p-10 -82.12 -174.29 5.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.297 -0.877 . . . . 0.0 110.13 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.464 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -62.26 -45.31 93.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.376 -0.828 . . . . 0.0 109.897 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.668 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -62.6 -30.93 71.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.146 -0.971 . . . . 0.0 109.575 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -68.74 -44.76 73.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 109.264 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.577 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 1.6 ptpt -75.19 -29.83 60.49 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.375 -0.828 . . . . 0.0 109.664 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.486 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 44.2 t0 -79.22 -46.12 18.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.218 -0.926 . . . . 0.0 109.391 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.556 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -57.55 -47.79 81.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.42 -0.8 . . . . 0.0 109.308 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.882 ' CH2' HD12 ' A' ' 17' ' ' ILE . 7.3 m0 -71.92 -29.7 64.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.4 -0.812 . . . . 0.0 109.371 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.577 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -63.78 -25.92 68.4 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.235 -0.916 . . . . 0.0 108.974 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.48 ' O ' ' HB3' ' A' ' 135' ' ' ALA . . . -101.05 -24.95 14.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.421 -0.8 . . . . 0.0 109.169 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.704 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -67.44 -51.89 46.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.287 -0.883 . . . . 0.0 109.334 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.51 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 21.3 m-85 -52.76 -29.04 25.03 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.189 -0.945 . . . . 0.0 109.231 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' A' ' 132' ' ' ALA . . . -60.84 -46.41 90.68 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.156 -0.965 . . . . 0.0 108.835 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.82 -44.34 56.04 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 109.169 179.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.57 HG12 ' HB1' ' A' ' 69' ' ' ALA . 18.1 mt -64.3 -57.75 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.256 -0.903 . . . . 0.0 108.93 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.549 ' O ' HD12 ' A' ' 142' ' ' ILE . 2.0 p -67.87 -25.74 65.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.217 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.437 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -73.4 -46.59 25.5 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.25 -22.47 66.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -1.122 . . . . 0.0 109.712 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.686 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.4 tt -69.22 -33.46 73.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.665 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 138' ' ' SER . 3.9 mt -82.9 10.01 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.2 -0.937 . . . . 0.0 110.318 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.469 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 75.7 m -73.97 -22.6 59.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.996 -1.065 . . . . 0.0 108.887 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -127.77 1.42 6.86 Favored Glycine 0 N--CA 1.486 1.967 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.976 HD22 ' N ' ' A' ' 146' ' ' GLN . 0.2 OUTLIER -100.37 129.6 46.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.85 -1.382 . . . . 0.0 110.015 -179.809 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.976 ' N ' HD22 ' A' ' 145' ' ' LEU . 1.0 OUTLIER 162.45 44.81 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 178.123 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.415 ' OXT' ' HD3' ' A' ' 91' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.567 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.648 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.469 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.809 HD13 HD12 ' A' ' 73' ' ' LEU . 11.9 mt 57.06 165.56 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.159 -1.201 . . . . 0.0 110.128 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.44 ' O ' ' HG2' ' A' ' 7' ' ' ARG . 6.6 p -128.04 -168.66 1.93 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.268 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.51 -16.22 56.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.218 -0.926 . . . . 0.0 110.191 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.781 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -101.03 -36.13 9.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.065 -1.022 . . . . 0.0 109.819 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -68.62 -58.49 4.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.717 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.521 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -50.15 -24.57 2.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.221 -0.924 . . . . 0.0 109.895 -179.773 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.521 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 50.1 tp60 -80.66 -41.39 23.88 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.225 -0.922 . . . . 0.0 109.493 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.781 HG23 ' O ' ' A' ' 5' ' ' ALA . 67.1 t -62.09 -24.54 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.9 HG12 HG13 ' A' ' 70' ' ' VAL . 89.1 t -66.84 -45.05 88.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.39 -0.819 . . . . 0.0 109.661 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.55 -11.35 60.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.296 -0.877 . . . . 0.0 110.193 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 m -92.7 -22.94 19.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.005 -1.06 . . . . 0.0 109.804 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.3 p -96.71 -10.52 26.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.249 -0.907 . . . . 0.0 110.131 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.767 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.74 -20.83 21.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.078 -1.014 . . . . 0.0 109.892 -179.801 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -79.19 -13.04 59.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.26 -0.9 . . . . 0.0 109.947 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -102.27 -47.87 4.37 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.089 -1.007 . . . . 0.0 109.786 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.879 HD12 ' CH2' ' A' ' 130' ' ' TRP . 34.8 mt -70.81 -31.55 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -0.924 . . . . 0.0 109.745 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.856 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -106.96 33.88 3.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.915 . . . . 0.0 109.716 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.64 -71.82 0.62 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 76.5 p -110.65 -27.91 8.71 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.226 -1.161 . . . . 0.0 109.657 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.66 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.2 p-10 -79.01 -20.24 49.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 0.0 109.658 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.856 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 27.0 t30 55.67 24.09 6.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.584 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.17 24.57 12.47 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.66 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -66.1 -55.08 18.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -1.137 . . . . 0.0 109.64 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -86.14 11.43 62.91 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.507 HG11 HD11 ' A' ' 63' ' ' LEU . 37.8 t -97.99 -29.65 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.115 -1.227 . . . . 0.0 109.338 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.458 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -89.91 -45.16 4.6 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.47 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 11.3 ptpt -56.19 -31.89 63.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.158 -1.201 . . . . 0.0 109.569 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.533 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 24.3 pt-20 -92.3 -16.67 25.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.929 . . . . 0.0 109.722 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.434 ' SG ' HD12 ' A' ' 110' ' ' LEU . 36.6 t -85.27 -67.67 0.78 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.205 -0.934 . . . . 0.0 109.809 -179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.601 ' HB3' HG13 ' A' ' 55' ' ' VAL . 10.4 m-85 -48.35 -29.13 3.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.247 -0.908 . . . . 0.0 109.935 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.426 ' N ' HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.06 -59.06 5.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.201 -0.937 . . . . 0.0 109.488 179.935 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 3.9 mttp -55.9 -53.15 60.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.261 -0.899 . . . . 0.0 109.717 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.679 ' CG ' HD23 ' A' ' 106' ' ' LEU . 8.9 t80 -49.34 -53.09 23.95 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.224 -0.922 . . . . 0.0 109.734 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.79 ' CD1' HG22 ' A' ' 55' ' ' VAL . 20.1 mt -54.23 -46.35 72.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.229 -0.919 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.08 -59.84 3.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.185 -0.947 . . . . 0.0 109.713 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.604 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -58.24 -23.66 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.238 -0.914 . . . . 0.0 109.669 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.604 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 22.2 m-70 -120.79 95.83 4.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.688 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.5 m170 -82.76 6.03 19.48 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.244 -0.91 . . . . 0.0 110.02 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -97.48 -20.38 17.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.099 -1.001 . . . . 0.0 109.523 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.53 ' HG3' ' CD2' ' A' ' 102' ' ' TYR . 65.4 mmm -104.85 -19.84 13.76 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -0.896 . . . . 0.0 109.599 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.458 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.08 -35.62 16.49 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 109.43 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.4 -27.54 46.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.304 -0.873 . . . . 0.0 109.099 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.969 HG22 ' OD1' ' A' ' 95' ' ' ASN . 32.3 t -66.71 -60.74 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.345 -0.847 . . . . 0.0 109.188 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.526 ' CD2' HD21 ' A' ' 35' ' ' LEU . 67.4 m-85 -51.29 -28.3 11.64 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.291 -0.881 . . . . 0.0 109.504 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.409 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.3 24.85 4.92 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 8.7 m-85 -121.86 166.24 14.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 110.066 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 7.8 t -106.0 -19.78 13.63 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.422 -0.799 . . . . 0.0 108.892 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.65 -162.5 19.64 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.88 15.5 23.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.3 -1.118 . . . . 0.0 109.798 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 19.5 m -109.18 25.12 12.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.118 -0.989 . . . . 0.0 109.497 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.418 ' OD2' ' HB3' ' A' ' 47' ' ' PHE . 0.9 OUTLIER -118.87 140.59 28.79 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.33 -0.856 . . . . 0.0 109.543 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -69.55 -13.36 35.09 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 123.957 1.504 . . . . 0.0 110.509 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.537 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.49 -40.62 39.6 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.79 HG22 ' CD1' ' A' ' 35' ' ' LEU . 39.2 t -50.05 -45.92 23.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.321 -1.105 . . . . 0.0 109.55 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.419 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -61.8 -16.65 51.65 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.229 -0.92 . . . . 0.0 109.521 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.3 -36.64 39.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.235 -0.915 . . . . 0.0 109.645 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.948 ' O ' HG23 ' A' ' 62' ' ' VAL . 11.5 mt -87.07 -60.03 2.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.157 -0.964 . . . . 0.0 109.638 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.458 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -46.9 -48.9 18.35 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.419 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -56.39 -38.58 71.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -1.166 . . . . 0.0 109.695 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -83.86 -29.9 26.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.663 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 58' ' ' LEU . 38.7 t -71.61 -47.87 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.305 -0.872 . . . . 0.0 109.652 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.507 HD11 HG11 ' A' ' 26' ' ' VAL . 1.9 mm? -48.99 -50.27 36.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 109.656 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.97 -44.97 20.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.363 -0.836 . . . . 0.0 110.017 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.406 ' HG3' ' SD ' ' A' ' 83' ' ' MET . 28.8 tp60 -57.72 -52.69 64.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.127 -0.983 . . . . 0.0 109.332 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.959 ' O ' HG23 ' A' ' 70' ' ' VAL . 96.1 mt -53.89 -36.65 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.184 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.51 -55.38 27.7 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.31 -23.17 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -1.141 . . . . 0.0 109.17 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.88 -23.24 25.31 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.413 -0.805 . . . . 0.0 109.579 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.3 t -72.76 -21.31 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.898 . . . . 0.0 109.757 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.442 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 53.9 m -88.67 39.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.154 -0.966 . . . . 0.0 109.975 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.523 ' O ' ' N ' ' A' ' 74' ' ' GLY . 16.2 m-70 -151.13 -62.1 0.18 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.097 -1.002 . . . . 0.0 109.908 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.809 HD12 HD13 ' A' ' 2' ' ' LEU . 4.4 mm? 42.37 -88.89 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.191 0.519 . . . . 0.0 110.638 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -56.45 -30.6 58.92 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.43 57.32 3.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -1.107 . . . . 0.0 109.537 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.505 ' O ' HG23 ' A' ' 80' ' ' VAL . 0.7 OUTLIER -65.41 -23.93 67.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.703 -179.914 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -60.0 -29.52 68.2 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.504 ' HE3' ' CE1' ' A' ' 72' ' ' HIS . 5.5 ttpp -104.11 -47.35 4.19 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.769 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.451 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 41.4 ttp -49.6 -28.56 5.88 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 76' ' ' GLU . 90.6 t -83.26 -17.52 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.24 -0.912 . . . . 0.0 109.593 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.41 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -78.77 -30.6 45.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.578 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.471 ' HG3' ' N ' ' A' ' 83' ' ' MET . 23.9 pt-20 -86.17 -42.65 13.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -0.876 . . . . 0.0 109.669 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.545 ' HE1' HD12 ' A' ' 141' ' ' LEU . 92.0 mmm -63.93 -35.29 80.17 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.011 -1.056 . . . . 0.0 108.845 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.874 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -52.62 -37.23 57.99 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.029 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.438 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -69.06 -27.36 65.56 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -74.88 -46.56 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.816 . . . . 0.0 108.962 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.446 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -63.93 -34.7 90.63 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.874 HG23 ' O ' ' A' ' 84' ' ' LYS . 53.3 t -58.9 -37.2 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.356 -1.085 . . . . 0.0 109.206 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.438 ' HG2' ' O ' ' A' ' 85' ' ' ALA . 17.3 mmm180 -64.76 -31.13 72.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.01 179.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.747 ' HB2' HD12 ' A' ' 145' ' ' LEU . 52.5 m80 -77.38 -2.6 35.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.427 -0.796 . . . . 0.0 109.897 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.507 ' CG ' ' CB ' ' A' ' 147' ' ' SER . 6.8 ttmt -98.07 64.38 1.67 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.077 -1.014 . . . . 0.0 109.638 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.416 ' O ' ' O ' ' A' ' 93' ' ' TYR . . . 147.28 2.6 0.5 Allowed Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.314 -1.422 . . . . 0.0 111.772 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.554 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.8 m-85 -56.13 -167.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.38 -1.659 . . . . 0.0 110.022 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.55 -40.17 13.3 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.969 ' OD1' HG22 ' A' ' 44' ' ' VAL . 3.7 t30 -59.38 -47.23 86.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.457 -1.025 . . . . 0.0 108.479 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.8 tttt 59.96 13.89 3.97 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.494 -0.754 . . . . 0.0 110.928 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.467 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 14.2 m-70 -131.6 44.08 2.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.046 -1.034 . . . . 0.0 108.923 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.587 HD12 ' O ' ' A' ' 90' ' ' HIS . 67.8 mt -78.97 154.96 4.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.46 -0.775 . . . . 0.0 110.01 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.467 ' CE ' ' O ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER -145.34 148.83 33.83 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.81 0.814 . . . . 0.0 110.084 -179.818 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.7 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -81.9 -16.99 48.76 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.555 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -60.82 -27.01 67.74 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.002 -1.061 . . . . 0.0 109.208 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.555 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 93.4 m-85 -83.41 -20.23 34.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.18 -0.95 . . . . 0.0 110.246 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.924 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 5.4 m-85 -59.38 -65.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.101 -0.999 . . . . 0.0 110.206 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -44.42 -60.13 3.21 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 110.872 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.522 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.1 Cg_endo -59.7 -26.56 82.56 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 123.827 1.435 . . . . 0.0 110.343 -179.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.813 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.4 tm? -79.4 -19.18 50.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.113 -0.992 . . . . 0.0 109.444 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -84.93 -38.7 9.11 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.1 -54.11 48.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -1.171 . . . . 0.0 109.673 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.8 m -57.46 -26.16 60.79 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.252 -0.905 . . . . 0.0 109.598 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.541 HD22 ' OH ' ' A' ' 134' ' ' TYR . 8.7 tt -69.41 -39.71 77.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.54 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.874 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.5 mt -58.71 -33.37 70.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.222 -0.924 . . . . 0.0 109.643 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.9 t -67.37 -27.92 67.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.18 -0.95 . . . . 0.0 109.66 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.533 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -83.28 -36.5 24.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.704 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.525 ' HE2' HD21 ' A' ' 110' ' ' LEU . 5.2 mmt -49.52 -42.86 44.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 109.864 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -51.99 -22.67 4.18 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.232 -0.918 . . . . 0.0 109.954 -179.72 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.444 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 15.7 m170 -68.59 -22.53 64.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.947 . . . . 0.0 110.004 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.497 ' CB ' HG23 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -93.29 -50.03 5.67 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.861 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.602 HD11 ' SD ' ' A' ' 122' ' ' MET . 13.2 pt -104.42 -36.59 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.151 -0.968 . . . . 0.0 109.439 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 122' ' ' MET . . . 42.81 -94.27 0.01 OUTLIER Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -45.67 -42.03 10.22 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.109 -1.197 . . . . 0.0 110.109 -179.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -76.68 -17.38 59.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.04 -1.271 . . . . 0.0 109.697 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.602 ' SD ' HD11 ' A' ' 118' ' ' ILE . 4.8 tpt -72.52 92.48 1.49 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.137 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.791 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 8.3 p-10 -93.5 176.86 6.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 109.826 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.482 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -54.76 -50.1 69.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 109.759 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.791 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -54.7 -24.7 23.21 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.242 -0.911 . . . . 0.0 109.715 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.483 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.71 -51.24 11.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.956 . . . . 0.0 109.521 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 19.6 ptpt -71.66 -28.22 63.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.258 -0.901 . . . . 0.0 109.541 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.453 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 35.7 t0 -78.89 -38.56 37.28 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.481 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -69.96 -45.71 66.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.449 -0.782 . . . . 0.0 109.444 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.879 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -72.97 -21.82 60.8 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.366 -0.834 . . . . 0.0 109.295 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.652 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -76.22 -23.94 54.61 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.155 -0.966 . . . . 0.0 109.091 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -99.03 -23.4 15.3 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.411 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.636 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -82.21 -37.35 26.17 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.39 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.541 ' OH ' HD22 ' A' ' 110' ' ' LEU . 4.8 m-30 -49.37 -27.87 4.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.285 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.4 -29.5 53.13 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 108.913 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.1 t0 -80.08 -44.2 20.45 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.431 -0.793 . . . . 0.0 109.205 179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.453 ' O ' ' CE ' ' A' ' 83' ' ' MET . 4.0 mt -65.28 -55.48 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.207 -0.933 . . . . 0.0 109.076 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -69.69 -41.82 74.92 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.478 -0.764 . . . . 0.0 109.834 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -51.34 -52.17 33.55 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.421 ' HB1' ' HA ' ' A' ' 80' ' ' VAL . . . -53.68 -28.75 35.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -1.175 . . . . 0.0 109.791 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.899 ' O ' HD23 ' A' ' 141' ' ' LEU . 9.4 tt -71.47 -10.03 59.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.199 -0.938 . . . . 0.0 110.049 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.7 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.1 mm -91.01 38.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.039 -1.038 . . . . 0.0 109.919 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.43 ' HB3' ' HG2' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -115.52 -28.68 6.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.374 -0.829 . . . . 0.0 109.228 179.671 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.4 20.68 4.93 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.029 -1.629 . . . . 0.0 109.029 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.747 HD12 ' HB2' ' A' ' 90' ' ' HIS . 2.6 tt -108.86 15.25 23.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.277 -1.131 . . . . 0.0 109.794 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.585 HE21 HD23 ' A' ' 145' ' ' LEU . 7.1 mp0 -113.19 68.73 0.68 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.997 -1.064 . . . . 0.0 109.668 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.507 ' CB ' ' CG ' ' A' ' 91' ' ' LYS . 4.8 p . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.655 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.924 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.508 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.867 HD11 ' HA ' ' A' ' 133' ' ' ALA . 11.7 mt 57.3 163.82 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.396 -1.061 . . . . 0.0 109.833 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.9 p -140.14 -158.33 0.85 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.924 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.07 -35.58 14.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.51 -0.744 . . . . 0.0 109.288 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -91.13 -21.5 21.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.302 -0.873 . . . . 0.0 109.392 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -74.78 -48.23 26.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.212 -0.93 . . . . 0.0 109.246 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.629 ' HG2' HD12 ' A' ' 73' ' ' LEU . 7.7 tmm_? -54.28 -42.93 70.58 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.046 -1.034 . . . . 0.0 108.765 179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -52.14 -38.29 57.04 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.18 -0.95 . . . . 0.0 108.603 179.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 125' ' ' ALA . 44.8 t -72.71 -26.45 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 1.069 HG12 HG13 ' A' ' 70' ' ' VAL . 78.0 t -75.69 -45.68 38.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.515 -0.741 . . . . 0.0 109.153 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.59 -13.06 60.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 0.0 109.748 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 t -92.12 -28.57 17.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.125 -0.985 . . . . 0.0 109.829 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.4 HG21 ' HB1' ' A' ' 126' ' ' ALA . 7.2 p -90.83 -11.88 38.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.156 -0.965 . . . . 0.0 109.963 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.44 -21.73 21.77 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.073 -1.017 . . . . 0.0 109.532 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.7 mtpp -76.66 -3.61 38.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.226 -0.921 . . . . 0.0 109.679 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -109.51 -55.78 2.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.093 -1.005 . . . . 0.0 109.519 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.907 HD12 ' CH2' ' A' ' 130' ' ' TRP . 23.6 mt -60.55 -40.51 84.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.283 -0.886 . . . . 0.0 109.592 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.813 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -97.33 33.33 2.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.694 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.19 -80.04 0.07 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 54.2 p -112.02 12.98 20.7 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.22 -1.165 . . . . 0.0 109.829 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.744 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.4 p-10 -119.15 -17.07 9.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.086 -1.009 . . . . 0.0 109.791 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.813 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 25.3 t-20 55.88 29.26 13.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.671 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.415 ' HA3' ' CG ' ' A' ' 63' ' ' LEU . . . 90.88 23.28 30.72 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.744 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -61.45 -48.52 80.76 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.402 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -90.79 20.15 40.84 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.67 HG12 HD21 ' A' ' 63' ' ' LEU . 22.7 t -114.12 -17.69 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.291 -1.123 . . . . 0.0 109.069 179.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -105.92 -25.57 6.43 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.5 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.3 ptpt -75.91 -33.43 59.9 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.288 -1.125 . . . . 0.0 109.558 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.84 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 1.1 pm0 -94.78 -13.88 25.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.181 -0.95 . . . . 0.0 109.722 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.415 ' HB2' ' OE2' ' A' ' 29' ' ' GLU . 32.0 t -88.33 -59.81 2.13 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -0.96 . . . . 0.0 109.562 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.525 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.1 m-85 -56.48 -29.17 61.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.153 -0.967 . . . . 0.0 109.533 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.69 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -54.66 -60.42 3.38 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.657 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.5 -50.62 62.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.704 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -50.68 -48.2 58.57 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.226 -0.921 . . . . 0.0 109.306 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.656 ' CD1' HG22 ' A' ' 55' ' ' VAL . 19.0 mt -58.26 -43.67 88.03 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.551 ' OG ' ' HB2' ' A' ' 50' ' ' ALA . 55.9 m -67.01 -69.1 0.33 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -0.936 . . . . 0.0 109.877 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.662 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -50.87 -24.19 3.38 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.25 -0.906 . . . . 0.0 109.921 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.662 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 12.3 m-70 -128.17 106.69 9.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.141 -0.974 . . . . 0.0 109.957 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.6 m170 -85.64 -19.76 30.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.558 -0.714 . . . . 0.0 109.283 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -70.55 -16.23 62.85 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.311 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.504 ' CE ' HMB2 ' A' ' 148' ' ' HEM . 0.0 OUTLIER -101.61 -15.44 17.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.227 -0.921 . . . . 0.0 109.792 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.455 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.84 -66.31 0.55 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.006 . . . . 0.0 109.246 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -53.17 -24.62 11.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.92 . . . . 0.0 109.123 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.944 HG13 ' ND2' ' A' ' 95' ' ' ASN . 2.5 t -71.37 -56.25 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 179.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.677 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 33.7 m-85 -60.59 -24.96 65.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.335 -0.853 . . . . 0.0 109.528 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.53 26.81 5.75 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.2 m-85 -123.65 168.23 12.93 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.247 -1.149 . . . . 0.0 109.814 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -106.77 -18.16 14.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.24 -175.67 47.58 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.551 ' HB2' ' OG ' ' A' ' 36' ' ' SER . . . -63.66 -13.55 43.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.853 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.17 44.11 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 109.834 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -130.37 123.77 20.74 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.176 -0.952 . . . . 0.0 109.592 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -66.3 -22.94 52.42 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.886 1.466 . . . . 0.0 110.087 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.51 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.99 -29.93 28.97 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.69 HG11 HG23 ' A' ' 32' ' ' THR . 49.0 t -57.69 -42.69 82.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -1.165 . . . . 0.0 109.476 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -68.58 -19.53 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.243 -0.91 . . . . 0.0 109.553 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -82.68 -37.92 24.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.912 . . . . 0.0 109.426 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.823 HD21 ' CHA' ' A' ' 148' ' ' HEM . 1.2 mt -76.0 -65.99 0.84 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.925 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.525 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -47.34 -47.18 22.19 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 -179.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -57.8 -38.14 75.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -1.171 . . . . 0.0 109.618 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -77.01 -28.42 54.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.918 . . . . 0.0 109.605 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.912 HG22 ' C1D' ' A' ' 148' ' ' HEM . 47.8 t -80.45 -41.28 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 109.572 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.67 HD21 HG12 ' A' ' 26' ' ' VAL . 0.7 OUTLIER -47.71 -49.96 26.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.903 . . . . 0.0 109.906 179.895 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.579 ' HB2' ' OD1' ' A' ' 22' ' ' ASN . . . -49.38 -50.91 38.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.122 -0.986 . . . . 0.0 109.828 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 34.1 tp60 -49.1 -47.67 45.02 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.07 -1.019 . . . . 0.0 109.34 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.707 ' O ' HG23 ' A' ' 70' ' ' VAL . 24.3 mm -56.51 -45.71 82.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.362 -0.836 . . . . 0.0 108.963 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA3' ' CZ3' ' A' ' 14' ' ' TRP . . . -61.46 -51.02 60.57 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.7 t -57.57 -31.36 39.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -1.065 . . . . 0.0 109.705 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.615 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -82.21 -33.86 29.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.537 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.069 HG13 HG12 ' A' ' 10' ' ' VAL . 56.1 t -65.89 -18.95 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -75.05 -15.39 60.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.474 ' O ' ' N ' ' A' ' 74' ' ' GLY . 22.4 m-70 -115.46 -88.96 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.784 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.817 HD11 ' HA ' ' A' ' 70' ' ' VAL . 19.3 mt 63.63 -71.86 0.06 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.425 -0.797 . . . . 0.0 109.975 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -60.35 -28.05 66.52 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -93.78 140.52 29.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -1.111 . . . . 0.0 109.571 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.74 58.11 1.77 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.2 -0.937 . . . . 0.0 109.633 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -138.06 16.97 3.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.476 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 17.0 ttpt -168.4 -42.59 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 109.906 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 31.0 ttp -47.98 -38.77 17.66 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.129 -0.982 . . . . 0.0 109.565 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.423 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 38.8 t -76.28 -25.2 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.321 -0.862 . . . . 0.0 109.321 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -57.28 -44.69 84.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.361 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.668 ' O ' HG23 ' A' ' 86' ' ' VAL . 13.2 mt-10 -83.94 -44.58 14.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.37 -0.831 . . . . 0.0 109.309 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.643 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.0 OUTLIER -58.38 -58.57 7.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.306 179.777 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.423 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -52.05 -31.44 30.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.175 -0.953 . . . . 0.0 108.97 179.563 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.543 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -66.8 -45.51 78.14 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.36 -0.838 . . . . 0.0 109.023 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.668 HG23 ' O ' ' A' ' 82' ' ' GLU . 31.5 t -51.01 -47.68 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.307 -0.871 . . . . 0.0 109.193 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -53.65 -51.39 48.85 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 85.8 t -53.99 -35.34 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.321 -1.105 . . . . 0.0 109.006 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.526 ' HB3' ' CE1' ' A' ' 93' ' ' TYR . 5.4 mmm180 -70.6 -55.1 9.61 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.382 -0.823 . . . . 0.0 109.09 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.615 ' O ' HD12 ' A' ' 98' ' ' ILE . 12.4 m80 -52.31 -29.75 25.0 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.893 . . . . 0.0 108.971 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.462 ' HA ' ' CB ' ' A' ' 147' ' ' SER . 1.6 ttmt -68.0 -9.97 49.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.486 -0.759 . . . . 0.0 110.124 -179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.55 51.36 0.7 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.526 ' CE1' ' HB3' ' A' ' 89' ' ' ARG . 3.2 m-30 -106.41 -167.02 1.24 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.176 -1.191 . . . . 0.0 109.66 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.0 -38.13 93.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.944 ' ND2' HG13 ' A' ' 44' ' ' VAL . 10.7 t30 -78.96 -44.6 22.11 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.469 -1.018 . . . . 0.0 109.403 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.451 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.8 OUTLIER 71.94 -54.78 0.68 Allowed 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 179.615 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.458 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 9.1 m170 -48.67 -87.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.097 -1.002 . . . . 0.0 109.944 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.615 HD12 ' O ' ' A' ' 90' ' ' HIS . 54.1 mt 59.48 156.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.714 . . . . 0.0 109.938 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.532 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.59 144.15 25.08 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 -179.841 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.41 -8.64 59.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.713 -0.617 . . . . 0.0 109.545 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -75.72 -21.54 57.44 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.101 -0.999 . . . . 0.0 109.375 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.532 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -84.94 -15.32 44.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.304 -0.872 . . . . 0.0 109.853 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.722 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.7 m-85 -63.26 -65.88 0.62 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.207 -0.933 . . . . 0.0 110.248 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.5 -59.0 3.71 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.516 -0.74 . . . . 0.0 111.087 -179.317 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 4.9 Cg_endo -52.59 -55.79 3.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.671 1.353 . . . . 0.0 110.06 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.957 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -58.66 -21.2 53.52 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.338 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.98 -47.95 17.51 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.74 -53.88 53.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.161 -1.199 . . . . 0.0 109.562 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.8 m -54.98 -25.27 28.67 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.204 -0.935 . . . . 0.0 109.564 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.796 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -64.66 -37.04 86.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.226 -0.921 . . . . 0.0 109.666 -179.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.74 HD21 ' CB ' ' A' ' 130' ' ' TRP . 11.6 mt -64.7 -42.55 95.2 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.198 -0.939 . . . . 0.0 109.534 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -65.1 -23.14 67.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.749 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.84 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.24 -38.65 18.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.95 . . . . 0.0 109.693 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.796 ' SD ' HD23 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -53.16 -44.69 68.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.815 -179.861 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.481 ' HG2' ' CB ' ' A' ' 122' ' ' MET . 12.2 mt-10 -47.47 -28.35 2.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.243 -0.911 . . . . 0.0 109.668 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.464 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 15.7 m170 -57.81 -27.07 62.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.106 -0.997 . . . . 0.0 109.817 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.442 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.7 OUTLIER -90.25 -65.59 1.0 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.252 -0.905 . . . . 0.0 109.871 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.741 HG23 HG12 ' A' ' 17' ' ' ILE . 41.8 pt -87.51 -37.48 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.199 -0.938 . . . . 0.0 109.496 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.503 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 40.91 -93.47 0.01 OUTLIER Glycine 0 N--CA 1.497 2.76 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -42.9 -41.43 4.54 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.496 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 34.6 mmtt -76.23 -28.24 57.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.13 -1.218 . . . . 0.0 109.748 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.481 ' CB ' ' HG2' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -59.21 102.01 0.12 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.173 -0.955 . . . . 0.0 109.317 179.728 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.731 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 9.2 p-10 -98.62 -178.7 4.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.244 -0.91 . . . . 0.0 109.772 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.05 -43.27 99.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 109.761 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.731 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -65.03 -24.38 67.47 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.094 -1.004 . . . . 0.0 109.306 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.505 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -72.67 -48.71 36.89 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.325 -0.859 . . . . 0.0 109.432 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.513 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 11.8 ptpt -73.39 -29.75 62.82 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.258 -0.901 . . . . 0.0 109.671 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.513 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 12.5 t0 -75.15 -38.34 61.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.192 -0.942 . . . . 0.0 109.273 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.633 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -66.63 -43.88 83.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -0.825 . . . . 0.0 109.104 179.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.907 ' CH2' HD12 ' A' ' 17' ' ' ILE . 11.1 m0 -73.58 -32.75 64.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.312 -0.868 . . . . 0.0 109.192 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.539 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -47.64 -27.68 2.01 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.271 -0.893 . . . . 0.0 109.414 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -108.69 -14.72 14.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.399 -0.813 . . . . 0.0 109.665 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.867 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -73.49 -69.13 0.45 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.957 . . . . 0.0 110.153 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.599 ' HA ' HD12 ' A' ' 137' ' ' ILE . 11.6 p90 -58.31 -20.14 40.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.844 -1.16 . . . . 0.0 109.127 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.423 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -73.61 -40.85 63.51 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.241 -0.912 . . . . 0.0 108.893 179.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.63 -30.52 56.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.352 -0.843 . . . . 0.0 109.055 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.643 HG23 ' SD ' ' A' ' 83' ' ' MET . 58.5 mt -68.28 -59.99 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.401 -0.812 . . . . 0.0 109.151 179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -57.56 -18.77 21.2 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.347 -0.846 . . . . 0.0 109.714 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.74 -52.2 21.31 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -53.47 -25.82 17.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.27 -1.135 . . . . 0.0 109.744 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.829 ' O ' HD23 ' A' ' 141' ' ' LEU . 7.3 tt -74.05 -11.58 60.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -0.912 . . . . 0.0 110.016 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.673 ' O ' HG22 ' A' ' 142' ' ' ILE . 98.3 mt -91.53 21.47 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.081 -1.012 . . . . 0.0 109.714 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -109.6 -20.35 12.88 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.156 -0.965 . . . . 0.0 109.83 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.14 -22.63 3.78 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.489 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 3.4 tp -62.74 -98.49 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.11 -1.23 . . . . 0.0 109.77 -179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 47.35 33.56 2.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.945 -1.097 . . . . 0.0 110.121 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.462 ' CB ' ' HA ' ' A' ' 91' ' ' LYS . 3.6 p . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.061 -1.024 . . . . 0.0 109.678 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.912 ' C1D' HG22 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.501 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.465 HD13 ' HA ' ' A' ' 2' ' ' LEU . 4.5 mm? -92.07 145.32 24.61 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.266 -1.138 . . . . 0.0 109.996 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 p -115.95 -166.34 1.13 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.368 -0.832 . . . . 0.0 109.52 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.1 -33.13 59.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.266 -0.896 . . . . 0.0 110.173 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.959 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -81.02 -47.11 14.04 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.143 -0.973 . . . . 0.0 110.044 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.517 ' O ' HG23 ' A' ' 10' ' ' VAL . 37.8 mt-30 -60.98 -56.34 22.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.296 -0.878 . . . . 0.0 109.671 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.58 ' HA ' HD12 ' A' ' 73' ' ' LEU . 9.7 ttp180 -51.86 -26.22 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.141 -0.975 . . . . 0.0 109.598 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 39.3 tp60 -85.27 -49.35 8.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.564 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 5' ' ' ALA . 41.5 t -52.05 -28.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.267 -0.896 . . . . 0.0 109.687 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.892 HG11 HD11 ' A' ' 73' ' ' LEU . 84.8 t -64.99 -53.68 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.898 . . . . 0.0 109.624 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.83 -17.6 64.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.674 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.3 -32.6 38.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.181 -0.949 . . . . 0.0 109.698 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.428 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 41.0 p -94.54 -11.57 29.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.66 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.06 -18.09 31.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.047 -1.033 . . . . 0.0 109.873 -179.825 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -85.65 -15.64 41.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.167 -0.958 . . . . 0.0 109.608 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -96.64 -53.83 3.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.51 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.98 HD12 ' CH2' ' A' ' 130' ' ' TRP . 62.0 mt -68.49 -43.12 84.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.285 -0.884 . . . . 0.0 109.508 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.594 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -100.43 34.99 2.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.375 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.73 -86.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.3 p -106.95 13.59 27.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.238 -1.154 . . . . 0.0 110.066 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.444 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 3.2 p30 -122.59 -9.84 8.41 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.121 -0.987 . . . . 0.0 110.177 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.615 HD21 ' HB2' ' A' ' 64' ' ' ALA . 6.7 t30 57.06 18.36 3.99 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.271 -0.893 . . . . 0.0 109.584 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.425 ' O ' ' HB ' ' A' ' 26' ' ' VAL . . . 85.76 32.63 17.9 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.201 -1.56 . . . . 0.0 109.201 179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.25 -47.81 80.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.189 -1.183 . . . . 0.0 109.18 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.44 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -85.72 9.48 68.26 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.466 HG21 ' CG2' ' A' ' 17' ' ' ILE . 9.2 t -95.48 -39.27 9.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.135 -1.215 . . . . 0.0 109.353 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -81.89 -51.81 4.35 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.9 ptpt -50.39 -30.97 13.57 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.202 -1.175 . . . . 0.0 109.604 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.761 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 22.3 pt-20 -89.48 -22.43 22.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.444 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.7 t -86.98 -39.6 15.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.343 -0.848 . . . . 0.0 109.645 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.509 ' CE2' ' O ' ' A' ' 149' ' ' CMO . 10.1 m-85 -75.37 -42.21 54.55 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.879 . . . . 0.0 109.857 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.613 ' OG1' HG11 ' A' ' 55' ' ' VAL . 20.4 m -51.69 -49.05 63.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.089 -1.007 . . . . 0.0 109.394 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.9 . . . . 0.0 109.434 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.737 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.6 t80 -65.09 -46.76 79.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.676 HD13 HG22 ' A' ' 55' ' ' VAL . 10.8 mt -59.94 -47.6 85.14 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.833 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.418 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 3.0 t -61.17 -57.78 11.05 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.173 -0.954 . . . . 0.0 109.783 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.645 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -61.91 -27.28 68.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.183 -0.948 . . . . 0.0 109.841 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.645 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 18.8 m-70 -121.93 105.61 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.231 -0.918 . . . . 0.0 109.781 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -87.2 -18.96 29.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.378 -0.826 . . . . 0.0 109.405 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.1 p-10 -68.85 -19.08 64.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.905 . . . . 0.0 109.509 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.437 ' HE3' ' CMB' ' A' ' 148' ' ' HEM . 73.9 mmm -106.51 -23.61 12.43 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.288 -0.883 . . . . 0.0 109.712 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.46 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.96 -42.92 39.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.117 -0.989 . . . . 0.0 109.57 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.78 -28.19 60.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.31 -0.868 . . . . 0.0 109.255 179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.016 HG13 ' ND2' ' A' ' 95' ' ' ASN . 38.0 t -66.37 -49.46 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.332 -0.855 . . . . 0.0 109.424 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.535 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 50.6 m-85 -62.06 -30.93 71.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.739 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.19 31.68 2.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.041 -1.623 . . . . 0.0 109.041 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.0 m-85 -125.79 173.07 9.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.36 -1.082 . . . . 0.0 109.746 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.61 20.9 13.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.865 . . . . 0.0 109.301 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 142.54 -161.95 27.35 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.453 ' HB1' HG23 ' A' ' 32' ' ' THR . . . -92.5 29.46 1.72 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -1.134 . . . . 0.0 109.66 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.3 p -125.92 26.79 6.51 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.302 -0.874 . . . . 0.0 109.533 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.73 138.43 22.09 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.614 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -69.29 -25.43 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.962 1.507 . . . . 0.0 110.069 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' A' ' 57' ' ' ASP . . . -57.61 -31.49 63.7 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.676 HG22 HD13 ' A' ' 35' ' ' LEU . 70.2 t -53.85 -34.87 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.269 -1.136 . . . . 0.0 109.532 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.563 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.25 -7.48 58.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.316 -0.865 . . . . 0.0 109.856 179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.403 ' HB2' ' O ' ' A' ' 54' ' ' GLY . 7.7 m-20 -88.81 -38.77 14.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.72 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.63 ' O ' HG23 ' A' ' 62' ' ' VAL . 8.9 mt -74.81 -63.63 1.21 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 0.0 109.514 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.844 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -49.77 -34.57 21.99 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.563 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -68.04 -49.62 60.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.235 -1.156 . . . . 0.0 109.467 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.408 ' HD3' ' O2D' ' A' ' 148' ' ' HEM . 7.8 mttt -71.69 -44.07 64.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.263 -0.898 . . . . 0.0 109.376 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.644 HG21 ' O ' ' A' ' 149' ' ' CMO . 83.6 t -55.96 -51.47 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.629 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.844 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -46.45 -49.53 18.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.238 -0.913 . . . . 0.0 110.169 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.615 ' HB2' HD21 ' A' ' 22' ' ' ASN . . . -54.25 -39.01 66.43 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.089 -1.007 . . . . 0.0 109.907 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 23.5 tp60 -56.74 -39.49 74.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.992 -1.067 . . . . 0.0 108.931 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.986 ' O ' HG23 ' A' ' 70' ' ' VAL . 89.9 mt -66.98 -34.85 72.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.423 -0.798 . . . . 0.0 108.863 179.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.57 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.07 -51.34 45.75 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.74 -27.6 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.267 -1.137 . . . . 0.0 108.796 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.7 -27.38 27.07 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.634 -0.666 . . . . 0.0 109.507 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.986 HG23 ' O ' ' A' ' 66' ' ' ILE . 40.9 t -58.81 -17.28 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.32 -0.862 . . . . 0.0 109.7 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.441 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 1.2 t -56.15 -43.49 78.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.926 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.441 ' ND1' ' O ' ' A' ' 71' ' ' SER . 33.4 m-70 -138.73 102.73 4.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 0.0 109.979 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.936 HD21 ' HA ' ' A' ' 70' ' ' VAL . 36.1 mt -95.55 -37.15 11.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.28 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.61 -21.11 35.23 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.021 -1.631 . . . . 0.0 109.021 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -81.86 -172.43 3.9 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -1.189 . . . . 0.0 109.694 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -166.12 51.53 0.09 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -0.895 . . . . 0.0 109.515 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -99.48 -54.63 1.07 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.504 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 32.1 ttpt -124.33 -31.7 3.26 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.249 -1.148 . . . . 0.0 109.941 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.511 ' SD ' HG23 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -47.66 -62.96 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.181 -0.949 . . . . 0.0 109.667 -179.944 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.511 HG23 ' SD ' ' A' ' 79' ' ' MET . 75.4 t -63.8 -15.56 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.712 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.504 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -80.01 -12.95 59.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.124 -0.985 . . . . 0.0 109.875 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.428 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.6 tp10 -99.44 -48.13 4.89 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.71 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.407 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 97.6 mmm -59.78 -44.91 93.68 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.152 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.679 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.04 -30.55 15.85 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.209 -0.932 . . . . 0.0 108.786 179.238 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -82.45 -36.38 26.63 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.498 -0.751 . . . . 0.0 109.112 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.443 ' CG1' HD12 ' A' ' 141' ' ' LEU . 89.2 t -59.22 -51.59 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.277 -0.889 . . . . 0.0 109.334 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.481 ' N ' ' HG ' ' A' ' 141' ' ' LEU . . . -53.06 -48.65 58.09 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.629 -1.789 . . . . 0.0 108.629 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 84' ' ' LYS . 99.0 t -47.38 -27.94 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.49 -1.006 . . . . 0.0 109.645 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.521 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 17.5 mmt180 -70.27 -42.72 71.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.128 -0.983 . . . . 0.0 108.804 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.477 ' HB2' ' CD1' ' A' ' 145' ' ' LEU . 12.3 m80 -65.56 -12.42 52.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.476 -0.765 . . . . 0.0 109.472 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.458 ' HD2' ' CB ' ' A' ' 147' ' ' SER . 0.2 OUTLIER -68.1 -13.21 62.03 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.327 -0.858 . . . . 0.0 110.399 -179.667 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -155.75 58.99 0.38 Allowed Glycine 0 N--CA 1.491 2.367 0 C-N-CA 119.462 -1.352 . . . . 0.0 110.098 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.521 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 3.6 m-30 -92.32 -172.46 3.11 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.158 -1.201 . . . . 0.0 109.241 179.212 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.36 -34.77 90.8 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.507 -1.837 . . . . 0.0 108.507 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.016 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.8 OUTLIER -82.94 -58.94 2.66 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.541 -0.976 . . . . 0.0 108.924 179.666 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.483 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 3.0 pttt 79.45 -19.82 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.774 -0.579 . . . . 0.0 111.02 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.406 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 5.7 m170 -92.24 40.64 1.05 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.666 -1.271 . . . . 0.0 109.44 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.456 HD13 ' CD2' ' A' ' 90' ' ' HIS . 65.3 mt -72.77 164.27 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.363 -0.836 . . . . 0.0 109.754 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.438 ' N ' HG22 ' A' ' 98' ' ' ILE . 0.1 OUTLIER -145.07 141.79 29.15 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.349 -0.844 . . . . 0.0 109.889 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.97 5.28 16.81 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 46.4 mm-40 -83.99 -32.63 24.86 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.99 -1.069 . . . . 0.0 109.463 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.464 ' CB ' HBB1 ' A' ' 148' ' ' HEM . 95.6 m-85 -75.72 -10.73 59.68 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.275 -0.891 . . . . 0.0 109.958 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.843 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.1 m-85 -62.93 -61.31 2.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.157 -0.964 . . . . 0.0 110.176 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -50.22 -55.58 24.07 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 109.881 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 32.3 Cg_exo -51.05 -62.68 0.36 Allowed 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 123.712 1.375 . . . . 0.0 109.934 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.962 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.75 -24.45 35.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.54 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.74 -45.51 12.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.281 -1.527 . . . . 0.0 109.281 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.64 -38.59 87.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -1.188 . . . . 0.0 109.652 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -20.49 64.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.531 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.493 HD22 ' HE2' ' A' ' 134' ' ' TYR . 1.9 tt -74.58 -39.69 62.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.695 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.811 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -62.73 -30.06 71.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.258 -0.901 . . . . 0.0 109.558 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.7 t -72.53 -25.27 61.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.289 -0.882 . . . . 0.0 109.764 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.761 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.06 -38.76 18.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.244 -0.91 . . . . 0.0 109.699 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.648 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.9 mmt -46.66 -45.07 19.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.33 -0.856 . . . . 0.0 110.055 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -49.21 -25.2 2.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -0.931 . . . . 0.0 109.611 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.471 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 26.5 m170 -57.46 -37.43 72.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.574 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.51 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 2.1 ttt85 -83.89 -70.41 0.57 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.699 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.476 HG23 HG12 ' A' ' 17' ' ' ILE . 14.1 pt -82.44 53.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.173 -0.954 . . . . 0.0 109.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -59.43 123.78 34.4 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.32 -36.81 3.82 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.425 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 15.6 mtpt -84.58 -30.73 24.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.27 -1.135 . . . . 0.0 109.399 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.37 81.63 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.329 -0.857 . . . . 0.0 109.446 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.583 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.1 p30 -86.8 -168.68 2.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.754 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.446 ' O ' ' CB ' ' A' ' 128' ' ' ASP . . . -64.3 -46.21 84.6 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.489 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.782 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.28 -24.38 54.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.276 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.48 -58.36 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.548 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.2 OUTLIER -68.49 -25.85 65.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.248 -0.908 . . . . 0.0 109.588 -179.823 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 124' ' ' ALA . 25.0 t70 -80.75 -39.71 26.45 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 109.543 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.93 -41.82 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.344 -0.848 . . . . 0.0 109.279 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.98 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.8 m0 -73.74 -24.52 59.9 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.163 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.548 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -74.04 -24.52 59.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.192 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.58 -40.58 12.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.858 . . . . 0.0 109.458 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.783 ' CB ' HD13 ' A' ' 73' ' ' LEU . . . -70.97 -45.58 63.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.399 -0.813 . . . . 0.0 109.537 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.493 ' HE2' HD22 ' A' ' 110' ' ' LEU . 3.2 m-85 -50.08 -32.15 14.93 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.908 . . . . 0.0 109.432 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.88 -37.11 70.21 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.19 -0.944 . . . . 0.0 108.866 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -79.17 -33.0 44.42 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.38 -0.825 . . . . 0.0 109.231 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.761 HD13 HG23 ' A' ' 66' ' ' ILE . 24.9 mt -65.77 -60.68 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.334 -0.854 . . . . 0.0 108.833 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.413 ' O ' HG13 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -66.93 -37.39 84.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.589 -0.694 . . . . 0.0 109.669 -179.775 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -52.44 -44.9 59.16 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -64.31 -18.36 64.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.21 -1.171 . . . . 0.0 109.82 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.843 HD22 ' CE2' ' A' ' 103' ' ' PHE . 6.7 tt -87.73 -23.77 24.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 109.78 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.493 HD12 ' HA2' ' A' ' 139' ' ' GLY . 50.9 mt -82.68 8.03 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 0.0 110.275 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -86.95 -35.92 18.61 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.008 -1.058 . . . . 0.0 109.502 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.417 ' O ' ' HD3' ' A' ' 91' ' ' LYS . . . -104.43 5.85 45.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.913 HD23 ' HG3' ' A' ' 146' ' ' GLN . 1.5 tt -91.84 -175.59 4.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.075 -1.25 . . . . 0.0 109.19 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.913 ' HG3' HD23 ' A' ' 145' ' ' LEU . 17.6 mt-30 56.48 83.93 0.09 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.142 -0.974 . . . . 0.0 110.12 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.458 ' CB ' ' HD2' ' A' ' 91' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.63 179.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.701 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.644 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.722 HD11 ' HA ' ' A' ' 133' ' ' ALA . 12.9 mt -94.67 159.45 15.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -1.142 . . . . 0.0 109.639 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.401 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 1.2 p -133.25 -179.2 5.36 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.3 -0.875 . . . . 0.0 109.641 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -75.49 -28.4 59.19 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.647 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.61 -24.61 29.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.904 . . . . 0.0 109.584 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.401 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 29.9 mt-30 -84.98 -46.21 11.44 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.218 -0.926 . . . . 0.0 109.735 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.466 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 4.3 ptm180 -51.7 -32.06 28.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.212 -0.93 . . . . 0.0 109.408 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.466 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 5.5 mm100 -70.2 -47.62 60.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.215 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.765 HG11 ' O ' ' A' ' 125' ' ' ALA . 80.9 t -56.44 -30.75 31.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.285 -0.884 . . . . 0.0 109.176 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.884 HG12 HG13 ' A' ' 70' ' ' VAL . 83.1 t -64.14 -55.02 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -0.836 . . . . 0.0 109.221 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.9 -14.04 62.64 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.613 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.5 m -84.44 -27.18 27.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.15 -0.969 . . . . 0.0 109.724 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.471 ' OG1' ' CZ2' ' A' ' 130' ' ' TRP . 25.3 p -98.94 -7.2 27.42 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.152 -0.967 . . . . 0.0 109.69 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -89.27 -21.48 23.18 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.151 -0.968 . . . . 0.0 109.646 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.3 mtpm? -79.31 2.31 21.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 110.092 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -116.45 -54.4 2.46 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.06 -1.025 . . . . 0.0 109.525 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.808 HD12 ' CH2' ' A' ' 130' ' ' TRP . 43.2 mt -66.49 -32.25 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.292 -0.88 . . . . 0.0 109.518 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.651 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -105.92 35.39 2.92 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.713 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.7 -81.57 0.05 OUTLIER Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 p -108.78 -34.86 6.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -1.128 . . . . 0.0 109.58 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.516 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 37.8 p30 -75.91 -15.05 60.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.909 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.651 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.8 t30 63.18 16.0 9.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.147 -0.971 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.474 ' O ' HD12 ' A' ' 63' ' ' LEU . . . 100.11 17.36 25.21 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.516 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -50.07 -36.81 30.76 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.094 -1.239 . . . . 0.0 109.774 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.454 ' HA2' ' CE ' ' A' ' 28' ' ' LYS . . . -92.97 13.61 67.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.435 ' O ' ' HB3' ' A' ' 30' ' ' CYS . 54.5 t -95.4 -28.3 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.045 -1.268 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.438 ' HA2' ' HB3' ' A' ' 30' ' ' CYS . . . -91.47 -44.52 4.28 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.475 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 10.8 ptpt -51.61 -33.66 34.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.195 -1.179 . . . . 0.0 109.089 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.87 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 19.0 pt-20 -91.44 -29.41 17.05 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.218 -0.926 . . . . 0.0 109.243 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.438 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 18.0 t -84.83 -68.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 110.065 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.608 ' HZ ' HG11 ' A' ' 62' ' ' VAL . 22.1 m-85 -45.94 -32.6 2.8 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.31 -0.869 . . . . 0.0 110.564 -178.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.725 ' OG1' HG11 ' A' ' 55' ' ' VAL . 5.6 m -59.04 -52.16 66.96 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.929 -1.107 . . . . 0.0 109.124 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 36.3 mttt -55.44 -48.21 74.8 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.069 -1.019 . . . . 0.0 109.311 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.515 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.9 t80 -54.83 -54.48 41.74 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.31 -0.869 . . . . 0.0 109.336 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.745 ' CD1' HG22 ' A' ' 55' ' ' VAL . 46.0 mt -55.39 -43.29 75.05 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.64 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -68.17 0.37 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.679 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.645 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -53.37 -30.09 37.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.214 -0.929 . . . . 0.0 109.626 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.645 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 10.8 m-70 -115.2 99.84 7.71 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.754 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 24.7 m170 -82.3 -14.4 55.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.453 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -74.21 -13.78 60.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.152 -0.968 . . . . 0.0 109.62 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.895 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 2.6 mmt -104.83 -27.34 11.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.13 -0.981 . . . . 0.0 109.91 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.664 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -48.24 -41.53 27.84 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.037 -1.039 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.43 -26.02 59.81 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -0.85 . . . . 0.0 108.782 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.008 HG13 ' ND2' ' A' ' 95' ' ' ASN . 2.9 t -72.61 -47.34 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.832 ' HD2' HD13 ' A' ' 58' ' ' LEU . 25.0 m-85 -65.61 -32.74 74.49 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.874 . . . . 0.0 109.47 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.14 27.94 3.52 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.544 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.6 m-85 -123.21 172.95 8.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.21 -1.17 . . . . 0.0 109.828 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.56 19.51 16.78 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.371 -0.83 . . . . 0.0 109.215 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 151.83 -163.8 30.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.481 ' HB1' HG23 ' A' ' 32' ' ' THR . . . -98.74 36.24 1.7 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.209 -1.171 . . . . 0.0 109.704 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 67.3 p -147.46 28.94 0.96 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.613 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 54' ' ' GLY . 0.4 OUTLIER -108.15 143.62 27.76 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.26 -0.9 . . . . 0.0 109.639 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -65.95 70.27 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.998 1.525 . . . . 0.0 110.059 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.524 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -155.19 -43.56 0.02 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.149 -1.581 . . . . 0.0 109.149 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.745 HG22 ' CD1' ' A' ' 35' ' ' LEU . 61.6 t -53.0 -40.1 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.357 -1.084 . . . . 0.0 109.496 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.62 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -63.93 -20.31 65.76 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.487 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -88.55 -57.76 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.301 -0.875 . . . . 0.0 109.236 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.909 HD21 ' C1A' ' A' ' 148' ' ' HEM . 0.4 OUTLIER -57.56 -63.3 1.28 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.462 -0.774 . . . . 0.0 110.28 -179.85 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.585 ' O ' HD13 ' A' ' 63' ' ' LEU . . . -54.59 -21.7 22.24 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.203 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.674 ' HA ' HD11 ' A' ' 63' ' ' LEU . . . -83.94 -6.12 59.36 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.126 -1.22 . . . . 0.0 110.684 -179.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 56.9 mttt -113.19 -12.3 13.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.972 -1.08 . . . . 0.0 110.002 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.723 HG21 ' O ' ' A' ' 149' ' ' CMO . 93.4 t -83.2 -25.65 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.099 -1.001 . . . . 0.0 110.68 -179.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.674 HD11 ' HA ' ' A' ' 60' ' ' ALA . 0.0 OUTLIER -70.28 -4.8 23.66 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.706 -1.246 . . . . 0.0 110.697 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.479 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -85.16 -42.45 14.72 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.834 -1.166 . . . . 0.0 109.559 -179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.435 ' OE1' HG21 ' A' ' 86' ' ' VAL . 2.8 mm-40 -56.57 -47.99 78.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.107 -0.996 . . . . 0.0 108.807 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.919 ' O ' HG23 ' A' ' 70' ' ' VAL . 80.1 mt -57.32 -34.69 46.72 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.582 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.85 -57.26 12.66 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.1 t -57.33 -23.7 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.267 -1.137 . . . . 0.0 109.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.45 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -86.71 -27.88 23.43 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.447 -0.783 . . . . 0.0 109.582 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.919 HG23 ' O ' ' A' ' 66' ' ' ILE . 54.5 t -70.46 -12.39 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.181 -0.949 . . . . 0.0 109.826 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.0 t -82.58 6.63 17.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.033 . . . . 0.0 110.061 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.488 ' O ' ' N ' ' A' ' 74' ' ' GLY . 23.9 m-70 -140.08 -88.88 0.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.004 -1.06 . . . . 0.0 109.685 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.572 HD11 ' HA ' ' A' ' 70' ' ' VAL . 29.8 mt 62.29 -74.23 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.468 -0.77 . . . . 0.0 109.823 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.488 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.77 -30.69 44.62 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -101.68 91.51 4.45 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -1.083 . . . . 0.0 109.443 179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -89.76 42.92 1.12 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.3 -0.875 . . . . 0.0 109.646 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -113.6 -17.43 7.54 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.501 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 8.4 ttmt -134.53 -41.19 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.15 -1.206 . . . . 0.0 109.894 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.471 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 17.2 tmm? -48.91 -42.71 37.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.955 . . . . 0.0 109.741 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.424 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 69.3 t -71.04 -20.27 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.63 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -68.06 -33.29 74.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.712 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.471 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 17.5 mt-10 -76.7 -53.45 7.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.574 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.8 mtp -53.31 -41.07 65.28 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.201 -0.937 . . . . 0.0 109.435 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.525 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.7 OUTLIER -52.17 -31.88 33.43 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.175 -0.953 . . . . 0.0 108.723 179.24 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.3 -36.75 71.74 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.665 ' CG1' HD11 ' A' ' 141' ' ' LEU . 45.5 t -56.89 -51.75 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.282 -0.886 . . . . 0.0 109.199 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -51.8 -46.75 54.38 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.856 -1.698 . . . . 0.0 108.856 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 84' ' ' LYS . 60.8 t -50.41 -25.75 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.205 -1.173 . . . . 0.0 109.292 179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.474 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 0.2 OUTLIER -81.3 -53.3 6.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.325 -0.859 . . . . 0.0 108.743 179.352 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.672 ' HB2' HD13 ' A' ' 145' ' ' LEU . 21.1 m80 -54.72 -21.91 12.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.053 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.511 ' CD ' ' HA ' ' A' ' 147' ' ' SER . 34.0 ttpt -67.69 -12.93 61.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.448 -0.782 . . . . 0.0 110.243 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.07 55.58 0.55 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.512 ' OH ' ' CE1' ' A' ' 90' ' ' HIS . 3.8 m-30 -89.59 -100.23 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.322 -1.105 . . . . 0.0 109.645 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.44 -50.05 0.02 OUTLIER Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.066 -2.013 . . . . 0.0 108.066 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.008 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.8 p-10 -67.17 -30.44 70.41 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.489 -1.006 . . . . 0.0 108.521 178.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 43.5 mttt 51.98 22.24 1.75 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.636 -0.665 . . . . 0.0 109.805 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.2 m170 -128.64 49.48 2.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.338 -0.851 . . . . 0.0 109.149 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.469 ' CD1' ' HB3' ' A' ' 90' ' ' HIS . 76.3 mt -84.93 158.74 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.857 -179.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.511 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -142.02 144.91 33.87 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.356 -0.84 . . . . 0.0 109.983 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.708 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -80.98 -15.86 55.07 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.679 -0.638 . . . . 0.0 109.36 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 54.3 mm-40 -67.86 -22.38 65.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.128 -0.983 . . . . 0.0 109.471 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.511 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 57.2 m-85 -86.32 -26.39 24.93 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 109.79 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.812 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.7 m-85 -51.28 -59.06 4.62 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.23 -0.919 . . . . 0.0 110.281 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.506 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -54.65 -58.78 12.67 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.203 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.506 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.4 Cg_exo -48.25 -53.13 7.18 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 O-C-N 123.639 1.337 . . . . 0.0 110.398 -179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.93 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -59.48 -18.0 36.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -0.941 . . . . 0.0 109.858 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -83.99 -42.56 7.56 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.71 -57.78 9.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.078 -1.248 . . . . 0.0 109.684 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 29.5 t -60.66 -16.25 37.07 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.778 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.981 HD21 ' CE ' ' A' ' 114' ' ' MET . 3.2 tt -78.53 -36.42 44.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.075 -1.016 . . . . 0.0 109.715 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.837 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -64.36 -28.78 69.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.069 -1.019 . . . . 0.0 109.423 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.427 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 14.1 t -66.63 -35.22 79.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.699 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.87 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -80.29 -31.63 38.22 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.169 -0.957 . . . . 0.0 109.655 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.981 ' CE ' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.35 -38.09 12.34 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.019 -179.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.471 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.9 OUTLIER -62.65 -14.0 38.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.074 -1.017 . . . . 0.0 109.705 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.545 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.9 m170 -53.9 -37.54 63.88 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.911 -1.118 . . . . 0.0 109.443 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.475 ' HB3' HG12 ' A' ' 17' ' ' ILE . 1.1 ttt85 -89.81 -51.62 5.4 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.2 -0.938 . . . . 0.0 109.82 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.435 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 2.8 pt -110.04 48.73 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.161 -0.962 . . . . 0.0 109.897 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -59.57 -18.29 44.08 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -93.17 -30.61 9.14 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.7 mtpp -94.47 -25.81 16.73 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.164 -1.198 . . . . 0.0 109.537 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 1.8 tpt -61.09 96.73 0.05 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.277 -0.889 . . . . 0.0 109.431 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -106.14 -162.54 0.87 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.744 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -67.08 -46.25 74.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.355 -0.841 . . . . 0.0 110.134 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.765 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -63.58 -21.55 66.41 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.074 -1.016 . . . . 0.0 109.779 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -80.4 -47.15 14.83 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.177 -0.952 . . . . 0.0 109.563 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.573 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 17.6 ptpt -74.02 -30.68 62.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -0.891 . . . . 0.0 109.685 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.454 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -73.94 -53.34 10.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.93 . . . . 0.0 109.738 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.549 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -55.09 -43.41 73.97 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.35 -0.844 . . . . 0.0 109.71 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.837 ' HB3' HD21 ' A' ' 111' ' ' LEU . 7.5 m0 -76.09 -27.15 57.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.245 -0.909 . . . . 0.0 109.565 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.573 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.26 -30.42 68.54 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 0.0 109.169 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.78 -26.39 21.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.292 -0.88 . . . . 0.0 109.38 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.722 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -82.06 -48.38 11.47 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.482 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.517 ' CE2' ' HE2' ' A' ' 114' ' ' MET . 9.1 m-30 -52.42 -31.01 32.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.293 -0.88 . . . . 0.0 109.337 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.75 -46.39 63.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.299 -0.875 . . . . 0.0 109.219 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -73.91 -30.53 62.64 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.312 -0.867 . . . . 0.0 109.221 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.663 HD13 HG23 ' A' ' 66' ' ' ILE . 59.4 mt -67.98 -60.78 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.314 -0.866 . . . . 0.0 108.973 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 3.6 m -66.96 -31.47 72.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.487 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -69.16 -38.41 82.83 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.17 -23.74 66.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.26 -1.141 . . . . 0.0 109.528 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.849 ' O ' HD23 ' A' ' 141' ' ' LEU . 10.0 tt -76.34 -2.39 31.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.277 -0.889 . . . . 0.0 110.116 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.708 HD12 ' HB2' ' A' ' 100' ' ' ALA . 40.6 mm -92.15 31.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.961 -1.087 . . . . 0.0 109.902 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.465 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -108.73 -34.23 6.75 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.283 -0.885 . . . . 0.0 109.381 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.79 21.89 7.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.672 HD13 ' HB2' ' A' ' 90' ' ' HIS . 14.3 tp -100.89 2.39 40.86 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.345 -1.091 . . . . 0.0 110.004 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 5.2 mp0 -111.25 67.2 0.64 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.85 -1.156 . . . . 0.0 109.836 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.511 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 3.4 m . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.661 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.909 ' C1A' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.723 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.852 HD11 ' HA ' ' A' ' 133' ' ' ALA . 65.4 mt -74.93 -168.48 0.75 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -1.149 . . . . 0.0 109.485 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.404 ' OG ' ' HB2' ' A' ' 6' ' ' GLN . 0.7 OUTLIER -93.63 172.61 8.15 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.216 -0.928 . . . . 0.0 109.6 179.928 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -71.16 -19.2 62.44 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.26 -0.9 . . . . 0.0 109.679 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.861 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -94.51 -32.85 13.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.166 -0.959 . . . . 0.0 109.683 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.404 ' HB2' ' OG ' ' A' ' 3' ' ' SER . 57.8 mt-30 -71.24 -55.45 8.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.23 -0.918 . . . . 0.0 109.708 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 2.8 ptm180 -50.92 -32.36 20.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.447 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.458 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 9.4 tp-100 -70.29 -39.01 75.13 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.294 -0.879 . . . . 0.0 109.349 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.861 HG23 ' O ' ' A' ' 5' ' ' ALA . 22.0 t -69.38 -27.63 35.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.453 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 1.055 HG12 HG13 ' A' ' 70' ' ' VAL . 97.2 t -71.95 -37.96 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.282 -0.886 . . . . 0.0 109.596 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.98 -14.75 60.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.855 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.8 t -90.87 -25.62 19.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -93.56 -12.41 29.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 109.952 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.739 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.21 -24.31 21.02 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.084 -1.01 . . . . 0.0 109.788 -179.842 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -75.23 -8.37 56.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.406 ' HB3' HG21 ' A' ' 118' ' ' ILE . 1.8 m-20 -103.7 -54.06 2.65 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.085 -1.009 . . . . 0.0 109.68 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.917 HD12 ' CH2' ' A' ' 130' ' ' TRP . 46.4 mt -65.79 -36.67 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.246 -0.909 . . . . 0.0 109.712 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.939 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.69 33.56 3.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.778 -179.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.09 -66.98 2.36 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 88.3 p -115.61 -19.64 10.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.272 -1.134 . . . . 0.0 109.558 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.809 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 7.5 p-10 -87.17 -19.08 28.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.894 . . . . 0.0 109.654 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.939 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 26.2 t30 58.57 22.89 10.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.05 23.69 10.4 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.809 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -70.45 -43.43 69.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -1.159 . . . . 0.0 109.603 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.423 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -88.39 14.46 59.44 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.624 HG11 HD11 ' A' ' 63' ' ' LEU . 44.0 t -108.64 -26.15 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -1.228 . . . . 0.0 109.317 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -97.36 -36.86 4.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.478 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 17.0 ptpt -66.41 -29.07 69.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.176 -1.191 . . . . 0.0 109.554 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.478 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 13.1 pt-20 -93.86 -20.34 20.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -0.935 . . . . 0.0 109.675 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.0 t -88.25 -59.86 2.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.234 -0.916 . . . . 0.0 109.866 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.516 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.8 m-85 -54.48 -30.11 52.16 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 109.81 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.96 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -55.32 -58.47 7.57 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.162 -0.961 . . . . 0.0 109.336 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -54.31 -45.29 72.55 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.878 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.788 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -56.36 -59.09 5.47 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.162 -0.962 . . . . 0.0 109.286 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.838 ' CD1' HG22 ' A' ' 55' ' ' VAL . 26.6 mt -51.15 -43.71 61.29 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 109.632 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.467 ' HB2' ' CB ' ' A' ' 50' ' ' ALA . 2.6 t -68.82 -71.27 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.303 -0.873 . . . . 0.0 109.911 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -49.52 -29.89 7.52 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -0.888 . . . . 0.0 109.787 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.657 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 12.9 m-70 -117.85 107.49 14.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.266 -0.896 . . . . 0.0 109.944 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -86.59 -25.4 24.98 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.475 -0.765 . . . . 0.0 108.967 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -66.97 -21.62 65.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.229 -0.919 . . . . 0.0 108.931 179.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.494 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -94.99 -27.63 15.55 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.413 -0.805 . . . . 0.0 109.55 179.846 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.437 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.06 -45.0 64.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.064 -1.023 . . . . 0.0 109.248 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.4 84.51 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.341 -0.849 . . . . 0.0 109.184 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.98 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.7 t -62.96 -60.24 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.31 -0.868 . . . . 0.0 109.156 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.526 ' CE1' ' C1B' ' A' ' 148' ' ' HEM . 62.0 m-85 -61.54 -31.97 72.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.192 -0.942 . . . . 0.0 109.009 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.06 -138.59 15.08 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.517 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 2.0 m-85 61.64 162.6 0.07 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.211 -1.17 . . . . 0.0 109.915 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 32.2 t -106.71 23.36 14.42 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.42 -161.06 31.45 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.467 ' CB ' ' HB2' ' A' ' 36' ' ' SER . . . -92.32 -21.4 20.3 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.711 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 66.6 p -90.8 56.89 3.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.147 -0.97 . . . . 0.0 109.669 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.47 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -120.1 139.99 29.23 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.208 -0.933 . . . . 0.0 109.63 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 15.8 Cg_exo -62.11 -31.59 83.28 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.98 1.516 . . . . 0.0 110.067 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.517 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -37.25 40.04 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.96 HG11 HG23 ' A' ' 32' ' ' THR . 93.4 t -50.2 -37.49 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -1.103 . . . . 0.0 109.445 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -75.65 -21.47 57.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.881 . . . . 0.0 109.299 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -81.41 -40.03 24.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.486 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.823 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 mt -74.93 -59.59 2.67 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.516 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -50.5 -48.48 42.05 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.448 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -59.59 -48.41 81.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.319 -1.106 . . . . 0.0 109.468 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -62.93 -33.24 74.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.286 -0.883 . . . . 0.0 109.461 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 58' ' ' LEU . 55.1 t -75.08 -49.47 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.323 -0.861 . . . . 0.0 109.527 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.624 HD11 HG11 ' A' ' 26' ' ' VAL . 2.0 mm? -48.68 -46.23 40.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.14 -49.31 32.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.785 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -53.72 -51.58 62.84 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.277 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.953 ' O ' HG23 ' A' ' 70' ' ' VAL . 61.0 mt -53.91 -39.21 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.339 -0.85 . . . . 0.0 109.131 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.558 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -59.52 -54.5 37.19 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -60.19 -29.98 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -1.147 . . . . 0.0 109.268 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.543 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -83.56 -5.58 59.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.406 -0.809 . . . . 0.0 109.989 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.055 HG13 HG12 ' A' ' 10' ' ' VAL . 42.2 t -90.56 -16.37 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.99 -1.069 . . . . 0.0 109.954 -179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.27 16.52 5.16 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.157 -0.964 . . . . 0.0 110.101 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.534 ' CD2' ' HA3' ' A' ' 77' ' ' GLY . 36.6 m-70 -137.8 -86.59 0.28 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.305 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.602 ' HB3' HD12 ' A' ' 2' ' ' LEU . 68.1 mt 45.35 34.47 1.52 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.302 -0.873 . . . . 0.0 110.035 179.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -165.4 -47.73 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -107.96 -175.0 2.66 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.59 -0.947 . . . . 0.0 108.862 179.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -72.96 -42.99 62.81 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.025 -1.047 . . . . 0.0 108.789 179.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.534 ' HA3' ' CD2' ' A' ' 72' ' ' HIS . . . 44.9 26.34 1.16 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.448 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 28.5 ttmt 50.25 20.56 0.66 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.242 -1.152 . . . . 0.0 110.134 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -94.35 -28.18 15.69 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.999 -1.063 . . . . 0.0 108.593 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 24.3 t -75.83 -22.87 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.599 -0.84 . . . . 0.0 109.117 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.17 -22.2 27.13 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.24 -0.912 . . . . 0.0 109.137 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.859 ' O ' HG23 ' A' ' 86' ' ' VAL . 33.6 mt-10 -90.98 -37.55 13.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.339 -0.851 . . . . 0.0 109.541 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.634 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.0 OUTLIER -67.11 -51.8 49.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.124 -0.985 . . . . 0.0 109.07 179.667 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.79 -31.33 66.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.258 -0.901 . . . . 0.0 108.752 179.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -67.33 -42.6 83.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 109.006 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.859 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.8 t -53.83 -44.62 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.292 -0.88 . . . . 0.0 108.83 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.402 ' HA2' HD13 ' A' ' 145' ' ' LEU . . . -58.98 -51.46 59.1 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.738 HG23 ' HA3' ' A' ' 144' ' ' GLY . 55.1 t -58.22 -23.08 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.341 -1.094 . . . . 0.0 109.023 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -86.64 -50.06 7.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.391 -0.818 . . . . 0.0 109.074 179.713 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.542 ' HB3' HD13 ' A' ' 98' ' ' ILE . 2.9 m80 -48.42 -44.55 35.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.755 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.441 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -58.94 -17.94 29.1 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.179 -0.951 . . . . 0.0 109.822 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -114.25 37.86 3.39 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.542 ' CD2' HBA1 ' A' ' 148' ' ' HEM . 3.2 m-30 -93.76 -166.01 1.43 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -1.107 . . . . 0.0 109.519 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.51 -33.86 24.16 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.98 ' ND2' HG13 ' A' ' 44' ' ' VAL . 2.2 t30 -69.41 -59.0 3.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.486 -1.008 . . . . 0.0 109.299 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 76.13 -12.97 0.95 Allowed 'General case' 0 N--CA 1.507 2.42 0 O-C-N 121.572 -0.705 . . . . 0.0 111.491 179.589 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.3 m170 -99.78 41.94 1.13 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.633 -1.292 . . . . 0.0 109.018 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.542 HD13 ' HB3' ' A' ' 90' ' ' HIS . 57.3 mt -76.07 152.35 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.404 -0.81 . . . . 0.0 110.46 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.457 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 8.5 mttp -142.2 138.9 31.83 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 121.661 0.743 . . . . 0.0 109.809 179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.592 ' HB2' HG23 ' A' ' 142' ' ' ILE . . . -75.42 -6.8 51.91 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.713 -0.617 . . . . 0.0 109.511 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 6.0 pt-20 -74.12 -26.63 60.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.09 -1.006 . . . . 0.0 109.301 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.494 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 33.3 m-85 -81.63 -21.25 38.35 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.315 -0.865 . . . . 0.0 109.724 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.815 ' HE2' HD22 ' A' ' 141' ' ' LEU . 3.3 m-85 -55.84 -63.0 1.32 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.334 -0.854 . . . . 0.0 110.289 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.51 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.7 mt-10 -48.91 -57.82 10.25 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.165 -0.959 . . . . 0.0 110.129 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.51 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -49.62 -63.18 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.632 1.333 . . . . 0.0 110.05 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.964 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -55.1 -24.9 27.95 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.292 -0.88 . . . . 0.0 109.43 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.1 -48.74 5.9 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.58 -43.85 95.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.124 -1.221 . . . . 0.0 109.646 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 58.4 m -65.33 -19.14 65.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 0.0 109.606 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.828 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.5 tt -73.89 -38.78 64.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.617 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.926 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.9 mt -60.53 -35.75 76.75 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 109.619 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 9.3 t -65.13 -33.83 76.95 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -0.931 . . . . 0.0 109.666 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . . . . . . . . . . . -81.16 -35.11 31.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.206 -0.934 . . . . 0.0 109.794 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.491 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 0.6 OUTLIER -54.71 -28.85 50.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.812 -179.867 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.45 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -68.48 -13.88 62.62 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.253 -0.904 . . . . 0.0 109.244 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.407 ' CD2' ' N ' ' A' ' 116' ' ' HIS . 24.2 m170 -65.56 -45.18 84.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.085 -1.009 . . . . 0.0 109.772 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.417 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.0 OUTLIER -74.54 -47.95 29.79 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.506 HG12 HD11 ' A' ' 17' ' ' ILE . 4.5 pt -114.32 54.99 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.274 -0.891 . . . . 0.0 109.633 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -66.27 -18.18 66.98 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -97.63 -26.35 9.97 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.438 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.5 mmtt -96.14 -25.43 15.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.262 -1.14 . . . . 0.0 109.621 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -64.23 104.67 0.78 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.25 -0.906 . . . . 0.0 109.545 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.456 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 5.0 p-10 -106.29 -171.08 1.83 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.379 -0.825 . . . . 0.0 109.537 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -62.99 -55.31 26.89 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.244 -0.91 . . . . 0.0 109.844 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.456 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -54.23 -26.54 29.18 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.132 -0.98 . . . . 0.0 109.439 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -71.45 -54.59 10.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -0.973 . . . . 0.0 109.359 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.3 ptpt -70.04 -25.2 63.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.289 -0.882 . . . . 0.0 109.346 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.459 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.6 t0 -81.71 -34.56 30.52 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.335 -0.853 . . . . 0.0 109.326 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.406 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.21 -41.47 63.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.353 -0.842 . . . . 0.0 109.371 179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.926 ' HB3' HD21 ' A' ' 111' ' ' LEU . 8.5 m0 -75.47 -24.38 56.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 109.242 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -71.88 -29.4 64.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.64 ' C ' HD21 ' A' ' 2' ' ' LEU . . . -89.26 -34.32 16.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.852 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -70.66 -43.49 69.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.373 -0.829 . . . . 0.0 109.393 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.828 ' OH ' HD22 ' A' ' 110' ' ' LEU . 3.1 m-85 -52.02 -28.89 18.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.4 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.63 -31.15 59.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.318 -0.864 . . . . 0.0 109.458 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.18 -39.67 22.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.472 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.634 HG23 ' SD ' ' A' ' 83' ' ' MET . 76.0 mt -66.38 -57.56 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.255 -0.903 . . . . 0.0 109.35 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 1.5 p -68.65 -27.1 65.69 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.857 . . . . 0.0 109.653 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.674 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -65.28 -53.59 31.94 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.06 -16.46 31.6 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.248 -1.148 . . . . 0.0 109.859 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.815 HD22 ' HE2' ' A' ' 103' ' ' PHE . 8.1 tt -89.89 -39.18 13.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.836 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.674 HD12 ' HA2' ' A' ' 139' ' ' GLY . 11.2 mt -66.09 -11.17 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.135 -0.978 . . . . 0.0 110.002 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.02 -59.35 4.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.091 -1.006 . . . . 0.0 109.228 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.738 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -82.09 4.25 76.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.575 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.517 ' HB3' ' HA ' ' A' ' 142' ' ' ILE . 51.7 tp -82.94 171.35 13.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.004 -1.292 . . . . 0.0 109.382 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.467 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 57.91 71.7 0.56 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.294 -0.879 . . . . 0.0 109.608 -179.724 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.431 ' HB2' ' CG ' ' A' ' 91' ' ' LYS . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.613 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.891 HMB1 HG11 ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.595 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.412 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.604 HD11 ' HA ' ' A' ' 133' ' ' ALA . 11.9 mt -149.69 158.77 44.48 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.15 -1.206 . . . . 0.0 109.456 179.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.6 p -134.58 -171.82 2.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.264 -0.898 . . . . 0.0 109.621 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.98 -20.06 50.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.935 . . . . 0.0 109.557 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.827 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -88.31 -32.12 18.61 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.227 -0.921 . . . . 0.0 109.581 179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.464 ' O ' HG23 ' A' ' 10' ' ' VAL . 21.9 mt-30 -81.7 -53.03 6.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.182 -0.949 . . . . 0.0 109.819 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.27 -27.96 10.63 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.149 -0.969 . . . . 0.0 109.606 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -77.45 -44.27 29.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.89 . . . . 0.0 109.284 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.827 HG23 ' O ' ' A' ' 5' ' ' ALA . 46.3 t -62.98 -25.06 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.293 -0.88 . . . . 0.0 109.184 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.969 HG12 HG13 ' A' ' 70' ' ' VAL . 86.5 t -72.56 -46.93 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.416 -0.802 . . . . 0.0 109.358 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.68 -11.33 60.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.331 -0.856 . . . . 0.0 109.854 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.6 m -91.63 -21.23 20.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.067 -1.021 . . . . 0.0 109.694 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.464 HG21 ' HB1' ' A' ' 126' ' ' ALA . 12.1 p -101.87 -9.26 20.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.27 -0.894 . . . . 0.0 109.963 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.676 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.63 -19.9 23.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.097 -1.002 . . . . 0.0 109.771 -179.857 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -81.62 -10.7 59.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.223 -0.923 . . . . 0.0 109.933 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -103.62 -54.44 2.58 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.062 -1.024 . . . . 0.0 109.656 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.965 HD12 ' CH2' ' A' ' 130' ' ' TRP . 59.5 mt -66.04 -35.38 74.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 0.0 109.623 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.716 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.45 31.1 4.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.668 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.28 -70.46 0.95 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.8 p -107.5 -37.13 6.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.215 -1.167 . . . . 0.0 109.751 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.589 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.6 p-10 -72.42 -19.73 61.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.261 -0.899 . . . . 0.0 109.714 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.716 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 24.9 t30 56.8 26.21 11.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.209 -0.932 . . . . 0.0 109.657 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.16 23.91 23.56 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.97 -49.58 60.81 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 0.0 109.579 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.45 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -87.83 13.08 61.86 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.586 HG11 HD11 ' A' ' 63' ' ' LEU . 17.2 t -98.68 -30.59 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.094 -1.239 . . . . 0.0 109.241 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.452 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -90.06 -43.37 5.05 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.474 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.2 ptpt -56.07 -33.23 64.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.17 -1.194 . . . . 0.0 109.559 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.853 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 11.0 pt-20 -89.6 -18.57 26.31 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.958 . . . . 0.0 109.686 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.23 -61.52 1.68 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.511 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 13.6 m-85 -51.64 -31.82 26.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.185 -0.947 . . . . 0.0 109.885 -179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.892 HG23 HG11 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -56.03 -55.57 31.3 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.188 -0.945 . . . . 0.0 109.594 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -57.45 -49.11 77.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.316 -0.865 . . . . 0.0 109.678 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.683 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.3 t80 -50.91 -51.17 54.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.185 -0.947 . . . . 0.0 109.609 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.713 ' CD1' HG22 ' A' ' 55' ' ' VAL . 12.8 mt -56.41 -46.13 80.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.868 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.607 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 13.5 t -60.75 -57.59 12.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.194 -0.941 . . . . 0.0 109.83 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.619 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -66.32 -21.84 66.27 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.757 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.619 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 15.3 m-70 -122.76 105.95 10.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.244 -0.91 . . . . 0.0 109.833 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -87.02 -21.13 26.31 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.436 -0.79 . . . . 0.0 109.264 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -73.27 -20.24 60.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.644 ' HE1' HMB2 ' A' ' 148' ' ' HEM . 0.0 OUTLIER -96.65 -18.6 19.6 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 109.629 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.446 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -59.88 -57.53 12.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.472 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.73 -23.31 63.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -0.932 . . . . 0.0 109.345 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.95 HG13 ' ND2' ' A' ' 95' ' ' ASN . 49.5 t -75.05 -57.08 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.342 -0.849 . . . . 0.0 109.504 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.529 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 35.5 m-85 -55.77 -35.25 66.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.95 . . . . 0.0 109.514 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.39 28.08 2.91 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.529 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 9.3 m-85 -123.14 -168.66 1.8 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 109.784 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.1 t -133.62 21.43 3.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.507 -0.746 . . . . 0.0 109.123 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 139.84 -161.72 26.28 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.607 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -91.44 36.74 0.94 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.232 -1.158 . . . . 0.0 109.724 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.7 m -132.68 19.04 4.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.628 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -107.13 133.84 20.14 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.575 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.38 -19.87 55.26 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.947 1.498 . . . . 0.0 109.974 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.506 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.61 -27.63 64.06 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.892 HG11 HG23 ' A' ' 32' ' ' THR . 99.3 t -57.18 -35.19 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -1.167 . . . . 0.0 109.405 179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.708 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.34 -3.83 48.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.89 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -94.97 -29.97 14.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.046 -1.034 . . . . 0.0 109.397 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.798 ' O ' HG23 ' A' ' 62' ' ' VAL . 7.1 mt -86.02 -63.56 1.3 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.161 -0.962 . . . . 0.0 109.524 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.652 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -54.49 -28.83 45.91 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -63.1 -53.04 59.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.149 -1.207 . . . . 0.0 109.518 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.5 ' HB3' ' CGD' ' A' ' 148' ' ' HEM . 11.3 mtpt -76.25 -43.54 41.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.281 -0.887 . . . . 0.0 109.321 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.798 HG23 ' O ' ' A' ' 58' ' ' LEU . 63.0 t -50.16 -49.14 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.308 -0.87 . . . . 0.0 109.591 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.652 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -47.51 -45.68 26.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.144 -0.973 . . . . 0.0 109.729 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -48.67 -50.9 31.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.244 -0.91 . . . . 0.0 109.903 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 22.1 tp60 -49.9 -49.21 50.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.139 -0.976 . . . . 0.0 109.491 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.912 ' O ' HG23 ' A' ' 70' ' ' VAL . 71.1 mt -56.2 -35.83 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.325 -0.86 . . . . 0.0 109.138 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.84 -54.9 25.4 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.156 -1.578 . . . . 0.0 109.156 179.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.0 t -59.57 -24.48 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -1.142 . . . . 0.0 109.453 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.9 -25.46 26.13 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.307 -0.871 . . . . 0.0 109.534 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.969 HG13 HG12 ' A' ' 10' ' ' VAL . 55.1 t -73.66 -18.38 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 109.665 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -89.35 15.3 9.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.212 -0.93 . . . . 0.0 109.927 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.465 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 14.0 m-70 -155.97 45.59 0.45 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.076 -1.015 . . . . 0.0 109.899 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.505 HD11 HG11 ' A' ' 10' ' ' VAL . 69.3 mt -82.79 -27.79 30.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.54 -23.55 60.21 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -126.7 119.0 25.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.252 -1.146 . . . . 0.0 109.576 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -106.34 39.73 1.76 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.217 -0.927 . . . . 0.0 109.624 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -88.36 -21.7 43.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.618 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 2.8 ttpt -131.14 -37.97 1.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.213 -1.169 . . . . 0.0 109.847 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.465 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 39.8 ttp -47.93 -53.16 16.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 109.627 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.427 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 58.1 t -66.86 -19.23 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.226 -0.921 . . . . 0.0 109.456 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.618 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -69.8 -36.32 75.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 0.0 109.434 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.441 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 22.3 tp10 -81.58 -49.81 10.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -0.881 . . . . 0.0 109.437 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.4 mtp -53.04 -45.68 68.13 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.277 -0.889 . . . . 0.0 109.362 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.759 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.4 -37.53 48.82 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.196 -0.94 . . . . 0.0 109.086 179.59 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.45 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -65.33 -35.35 80.71 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.404 -0.81 . . . . 0.0 109.153 179.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.527 HG12 HD11 ' A' ' 141' ' ' LEU . 28.9 t -62.4 -53.09 51.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.318 -0.864 . . . . 0.0 109.216 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -53.12 -42.2 61.67 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.759 HG23 ' O ' ' A' ' 84' ' ' LYS . 97.7 t -52.63 -27.89 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -1.136 . . . . 0.0 109.345 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.47 ' C ' ' CE1' ' A' ' 93' ' ' TYR . 2.0 mmm180 -78.96 -51.22 9.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.094 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.705 ' HB2' HD13 ' A' ' 145' ' ' LEU . 43.2 m80 -54.0 -22.35 10.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.387 -0.821 . . . . 0.0 109.127 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.509 ' CG ' ' CB ' ' A' ' 147' ' ' SER . 14.4 ttmt -64.99 -11.33 37.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.478 -0.764 . . . . 0.0 110.281 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.76 55.63 0.52 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.505 ' CE2' ' CD2' ' A' ' 90' ' ' HIS . 4.4 m-30 -90.44 -170.15 2.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.306 -1.114 . . . . 0.0 109.661 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.11 -53.35 10.8 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.95 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.5 p-10 -62.06 -30.08 70.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.166 -1.196 . . . . 0.0 109.68 -179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.9 mtmt 60.62 35.62 19.89 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 109.942 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.414 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 47.5 m170 -132.97 -83.98 0.47 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.06 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.668 HD12 ' O ' ' A' ' 90' ' ' HIS . 22.6 mt 60.06 153.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 110.387 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.554 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -152.71 135.09 15.09 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-O 121.626 0.727 . . . . 0.0 109.725 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.733 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -72.95 -6.32 44.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.735 -0.603 . . . . 0.0 109.544 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.462 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.8 mm-40 -76.36 -24.07 54.17 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.028 -1.045 . . . . 0.0 109.115 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.554 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 73.0 m-85 -85.95 -26.52 25.46 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.328 -0.858 . . . . 0.0 109.732 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.735 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 4.1 m-85 -50.82 -59.03 4.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 110.278 -179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -54.71 -59.07 11.47 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.209 -0.932 . . . . 0.0 110.289 -179.355 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.5 Cg_exo -47.94 -55.69 3.79 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.712 1.375 . . . . 0.0 110.308 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.934 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.99 -21.42 21.08 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.933 . . . . 0.0 109.652 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.61 -48.31 10.71 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.58 -47.46 85.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.221 -1.164 . . . . 0.0 109.826 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.04 -25.12 65.09 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.689 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.3 tt -69.44 -40.72 77.05 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.688 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.742 HD21 ' HB3' ' A' ' 130' ' ' TRP . 14.8 mt -59.17 -32.78 70.2 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.228 -0.92 . . . . 0.0 109.677 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.9 p -66.83 -29.8 69.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 0.0 109.901 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.853 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -83.33 -38.82 21.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.176 -0.952 . . . . 0.0 109.845 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.614 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.2 mmt -48.45 -46.54 37.98 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 110.033 -179.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.455 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -47.96 -25.95 1.56 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 -179.633 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.448 ' ND1' ' OE1' ' A' ' 29' ' ' GLU . 18.3 m170 -54.65 -45.78 73.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.065 -1.022 . . . . 0.0 110.029 -179.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.46 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 7.0 ttt85 -78.17 -60.37 2.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.202 -0.936 . . . . 0.0 110.033 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.489 HG12 HD11 ' A' ' 17' ' ' ILE . 4.5 pt -104.7 52.36 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.172 -0.955 . . . . 0.0 109.82 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.455 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -63.5 -20.09 63.17 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -91.78 -24.29 25.85 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.446 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 25.1 mttt -100.01 -21.23 15.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.183 . . . . 0.0 109.711 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.433 ' SD ' HD11 ' A' ' 118' ' ' ILE . 5.0 tpt -60.94 98.37 0.07 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.231 -0.918 . . . . 0.0 109.562 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.745 ' OD1' ' HB2' ' A' ' 126' ' ' ALA . 14.5 p-10 -96.36 -174.37 3.04 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.28 -0.887 . . . . 0.0 109.667 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.18 79.81 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.679 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -69.26 -27.21 65.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -0.906 . . . . 0.0 109.355 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.745 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -71.93 -45.41 61.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.597 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 5.0 ptpt -74.54 -27.92 60.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.119 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.469 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 9.8 t70 -81.88 -36.56 28.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.357 -0.84 . . . . 0.0 109.115 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.466 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -68.7 -47.37 66.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.365 -0.835 . . . . 0.0 109.134 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.965 ' CH2' HD12 ' A' ' 17' ' ' ILE . 3.5 m0 -70.13 -25.77 63.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.337 -0.852 . . . . 0.0 108.985 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.597 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.95 -34.88 74.0 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.301 -0.874 . . . . 0.0 109.222 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -81.91 -28.78 32.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.282 -0.886 . . . . 0.0 109.423 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -78.59 -47.75 16.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.335 -0.853 . . . . 0.0 109.62 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.689 ' OH ' HD22 ' A' ' 110' ' ' LEU . 4.3 m-85 -49.5 -29.17 6.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -0.951 . . . . 0.0 109.491 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.02 61.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.877 . . . . 0.0 109.373 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -80.32 -36.48 34.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.479 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.614 HD13 HG23 ' A' ' 66' ' ' ILE . 65.3 mt -66.69 -58.12 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.293 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.406 ' O ' HG12 ' A' ' 142' ' ' ILE . 1.8 p -64.74 -23.73 67.34 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.298 -0.876 . . . . 0.0 109.597 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -73.42 -39.33 51.03 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -61.18 -31.09 70.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.229 -1.16 . . . . 0.0 109.654 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.917 ' O ' HD23 ' A' ' 141' ' ' LEU . 8.5 tt -73.24 -6.53 46.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.225 -0.922 . . . . 0.0 110.028 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.733 HD12 ' HB2' ' A' ' 100' ' ' ALA . 45.7 mm -88.67 16.59 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 109.936 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.43 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 4.8 t -95.93 -43.08 7.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.199 -0.938 . . . . 0.0 109.62 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -107.94 16.07 36.58 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.705 HD13 ' HB2' ' A' ' 90' ' ' HIS . 11.3 tp -105.92 16.28 25.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.162 -1.199 . . . . 0.0 109.585 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -99.13 62.54 1.28 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.916 -1.115 . . . . 0.0 109.754 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.509 ' CB ' ' CG ' ' A' ' 91' ' ' LYS . 9.2 p . . . . . 0 N--CA 1.493 1.686 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.866 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.735 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.489 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.96 HD21 ' HB3' ' A' ' 132' ' ' ALA . 9.1 mt -152.66 176.42 11.76 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.211 -1.17 . . . . 0.0 111.464 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.527 ' HA ' ' CB ' ' A' ' 7' ' ' ARG . 3.1 p 68.63 -178.71 0.22 Allowed 'General case' 0 N--CA 1.492 1.643 0 CA-C-O 122.46 1.124 . . . . 0.0 111.573 178.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.709 ' O ' ' HB2' ' A' ' 5' ' ' ALA . . . 38.51 27.68 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.357 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.72 ' O ' HG23 ' A' ' 9' ' ' VAL . . . 164.51 -62.26 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.456 -0.777 . . . . 0.0 109.106 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.714 ' O ' HG23 ' A' ' 10' ' ' VAL . 28.1 mt-30 -70.05 -26.44 64.02 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.521 -179.138 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.527 ' CB ' ' HA ' ' A' ' 3' ' ' SER . 2.8 tmm_? -77.21 -41.03 42.96 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.188 -1.005 . . . . 0.0 108.829 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -56.76 -29.37 62.53 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 5' ' ' ALA . 14.2 t -81.65 -29.53 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.915 HG12 HG13 ' A' ' 70' ' ' VAL . 53.1 t -76.92 -37.59 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.565 -0.709 . . . . 0.0 109.311 179.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.2 -11.4 59.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.323 -0.861 . . . . 0.0 109.937 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -92.67 -34.01 14.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.808 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.0 p -83.58 -15.96 47.17 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.276 -0.89 . . . . 0.0 109.77 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.713 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.15 -23.58 24.79 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.119 -0.988 . . . . 0.0 109.483 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.1 mtpt -75.78 -5.36 45.43 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.274 -0.891 . . . . 0.0 109.811 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.435 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.7 OUTLIER -110.76 -58.83 2.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.053 -1.029 . . . . 0.0 109.592 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.959 HD12 ' CH2' ' A' ' 130' ' ' TRP . 26.5 mt -56.94 -35.12 46.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.699 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.97 34.8 3.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.282 -0.886 . . . . 0.0 109.67 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.14 -72.26 0.56 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.7 p -112.05 -31.01 7.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.221 -1.164 . . . . 0.0 109.618 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.719 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.6 p-10 -76.45 -16.79 59.59 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -0.908 . . . . 0.0 109.792 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.699 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 31.4 t30 60.47 24.96 14.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.228 -0.92 . . . . 0.0 109.554 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.21 38.4 5.69 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.139 -1.584 . . . . 0.0 109.139 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.719 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -83.32 -39.36 20.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.636 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.449 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -89.32 17.19 53.42 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.645 HG21 ' CG2' ' A' ' 17' ' ' ILE . 28.5 t -105.96 -40.22 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.144 -1.209 . . . . 0.0 109.378 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.481 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -86.78 -40.14 7.29 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.494 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.0 ptpt -59.87 -30.16 68.8 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.18 -1.188 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.748 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 8.5 pt-20 -93.19 -22.21 19.19 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 36.7 t -88.21 -62.38 1.5 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.966 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.513 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 23.0 m-85 -50.54 -35.81 31.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.332 -0.855 . . . . 0.0 110.179 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.702 ' OG1' HG11 ' A' ' 55' ' ' VAL . 18.6 m -53.14 -54.78 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.985 -1.072 . . . . 0.0 109.2 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.79 -43.02 85.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.156 -0.965 . . . . 0.0 108.944 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.657 ' HB2' HD23 ' A' ' 106' ' ' LEU . 90.4 t80 -55.32 -63.26 1.22 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -0.806 . . . . 0.0 109.1 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.782 HD13 HG22 ' A' ' 55' ' ' VAL . 5.7 mt -47.82 -43.89 28.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.435 -0.79 . . . . 0.0 109.71 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.89 -63.43 1.21 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.31 -0.869 . . . . 0.0 109.574 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.581 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -59.12 -24.35 62.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.581 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 16.1 m-70 -118.62 99.12 6.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.288 -0.882 . . . . 0.0 109.648 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.4 m170 -83.88 -19.95 33.92 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.593 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -70.0 -11.23 60.72 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.256 -0.903 . . . . 0.0 109.895 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.581 ' HE3' HMB1 ' A' ' 148' ' ' HEM . 83.0 mmm -113.34 -21.6 10.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.111 -0.993 . . . . 0.0 109.888 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.494 ' HA ' HD23 ' A' ' 35' ' ' LEU . . . -48.81 -46.56 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.024 -1.047 . . . . 0.0 109.592 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.61 -21.22 61.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.254 -0.904 . . . . 0.0 109.312 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.996 HG13 ' ND2' ' A' ' 95' ' ' ASN . 7.1 t -77.28 -38.48 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.316 -0.865 . . . . 0.0 109.278 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.509 ' CG ' HD21 ' A' ' 35' ' ' LEU . 12.8 m-85 -70.47 -27.61 64.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.85 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.424 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 111.96 20.97 6.53 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.53 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 6.1 m-85 -119.75 164.88 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.282 -1.128 . . . . 0.0 109.801 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.28 -15.33 20.84 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.446 -0.784 . . . . 0.0 109.213 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.417 ' O ' ' OD2' ' A' ' 52' ' ' ASP . . . -164.57 -155.3 8.33 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.454 ' O ' HG23 ' A' ' 32' ' ' THR . . . -104.98 -0.21 27.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.438 -1.036 . . . . 0.0 110.079 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.0 t -107.24 51.9 0.73 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.949 -1.094 . . . . 0.0 109.861 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.712 ' OD1' HG23 ' A' ' 55' ' ' VAL . 0.6 OUTLIER -131.23 149.25 73.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.255 -0.903 . . . . 0.0 109.674 179.799 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 10.0 Cg_exo -65.8 -24.31 54.43 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.973 1.512 . . . . 0.0 110.296 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.53 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -48.45 -35.87 16.33 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.782 HG22 HD13 ' A' ' 35' ' ' LEU . 57.5 t -61.26 -35.61 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.315 -1.109 . . . . 0.0 109.445 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.448 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.39 -11.26 60.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.34 -31.2 16.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.148 -0.97 . . . . 0.0 109.606 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.764 ' O ' HG23 ' A' ' 62' ' ' VAL . 7.8 mt -88.42 -62.68 1.44 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.144 -0.973 . . . . 0.0 109.725 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.617 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -50.15 -33.52 22.72 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -71.81 -43.83 64.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -1.18 . . . . 0.0 109.718 -179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.8 mtpp -74.95 -36.99 62.09 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.764 HG23 ' O ' ' A' ' 58' ' ' LEU . 61.1 t -61.8 -47.65 92.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.261 -0.899 . . . . 0.0 109.819 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.617 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.6 mm? -47.28 -46.31 24.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.16 -0.962 . . . . 0.0 109.899 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -47.44 -48.4 26.59 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.417 ' NE2' ' HA ' ' A' ' 65' ' ' GLN . 17.9 tp60 -52.64 -49.69 64.65 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.101 -0.999 . . . . 0.0 109.407 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.907 ' O ' HG23 ' A' ' 70' ' ' VAL . 72.2 mt -58.1 -27.64 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.256 -0.902 . . . . 0.0 109.195 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.557 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.78 -54.88 8.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.2 t -60.67 -21.26 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.25 -1.147 . . . . 0.0 109.332 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -87.59 -25.15 23.73 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.361 -0.837 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.915 HG13 HG12 ' A' ' 10' ' ' VAL . 41.4 t -73.08 -11.74 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.248 -0.907 . . . . 0.0 109.731 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -92.36 25.4 2.98 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 109.592 179.977 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.518 ' O ' ' N ' ' A' ' 74' ' ' GLY . 28.0 m-70 -142.68 -75.34 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.525 ' N ' ' CD2' ' A' ' 73' ' ' LEU . 2.9 mm? 51.2 -85.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.711 -0.618 . . . . 0.0 110.297 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -53.52 -28.05 35.77 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -76.72 63.47 2.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -1.135 . . . . 0.0 109.461 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -69.84 82.67 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.293 -0.879 . . . . 0.0 109.526 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 173.7 -33.27 0.11 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 108.851 -1.699 . . . . 0.0 108.851 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.434 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 11.7 ttpt -109.06 -34.6 6.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -1.077 . . . . 0.0 109.472 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.454 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 5.6 tmm? -52.92 -36.28 59.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.279 -0.888 . . . . 0.0 109.55 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.829 HG22 ' HB1' ' A' ' 140' ' ' ALA . 73.0 t -79.58 -18.77 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.693 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.434 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -48.82 -51.43 29.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.788 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.517 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.0 OUTLIER -76.52 -45.36 31.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -0.919 . . . . 0.0 109.629 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.467 ' HB2' ' HA ' ' A' ' 80' ' ' VAL . 1.6 mtp -54.78 -53.44 55.18 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.428 ' HB2' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -51.12 -33.05 24.74 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.935 . . . . 0.0 109.202 179.696 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -68.89 -42.99 76.21 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.371 -0.831 . . . . 0.0 109.295 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 82' ' ' GLU . 14.4 t -58.99 -41.45 83.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.133 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -55.77 -48.86 69.26 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 108.233 -1.947 . . . . 0.0 108.233 179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 78.1 t -52.71 -40.24 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.247 -1.149 . . . . 0.0 108.901 179.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -64.28 -50.94 65.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.398 -0.814 . . . . 0.0 109.01 179.273 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.65 ' O ' HD12 ' A' ' 98' ' ' ILE . 25.4 m80 -55.5 -38.7 69.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.314 -0.866 . . . . 0.0 109.316 179.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.449 ' HA ' ' CB ' ' A' ' 147' ' ' SER . 10.0 ttpp -62.72 -15.8 54.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.304 -0.872 . . . . 0.0 109.982 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -124.06 43.28 1.43 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -88.13 -171.68 3.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.3 -1.118 . . . . 0.0 109.683 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.75 -44.6 7.16 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.996 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.1 p-10 -64.92 -33.22 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -1.134 . . . . 0.0 109.593 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 1.7 tttt 55.12 20.23 3.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.212 -0.93 . . . . 0.0 109.809 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -129.6 55.84 1.75 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.33 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.65 HD12 ' O ' ' A' ' 90' ' ' HIS . 73.4 mt -90.32 156.3 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.327 -0.858 . . . . 0.0 110.193 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.534 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 2.7 mptt -143.34 131.6 22.01 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.486 -0.759 . . . . 0.0 109.665 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.754 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -73.25 -9.02 58.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.458 -0.777 . . . . 0.0 109.795 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.6 -23.2 61.68 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.567 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 73.7 m-85 -84.9 -15.84 43.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.125 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.759 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.6 m-85 -60.61 -68.75 0.27 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.195 -0.941 . . . . 0.0 110.368 -179.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.49 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.8 OUTLIER -44.37 -59.06 4.22 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.403 -0.811 . . . . 0.0 111.096 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.8 Cg_endo -55.06 -55.4 3.22 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.629 1.331 . . . . 0.0 110.034 -179.39 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.901 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -62.78 -18.57 62.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' CE1' ' A' ' 134' ' ' TYR . . . -85.39 -39.85 8.15 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.16 45.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.231 -1.158 . . . . 0.0 109.489 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.77 -21.5 11.25 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.59 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.9 OUTLIER -67.58 -41.29 84.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.259 -0.901 . . . . 0.0 109.735 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.833 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.6 mt -60.65 -41.44 94.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.143 -0.973 . . . . 0.0 109.562 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.3 t -64.31 -29.94 71.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.852 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.748 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -83.37 -36.34 24.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.195 -0.941 . . . . 0.0 109.641 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.59 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.1 mtt -48.79 -35.89 15.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.233 -0.917 . . . . 0.0 110.3 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.439 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.7 OUTLIER -58.42 -23.19 56.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.116 -0.99 . . . . 0.0 109.66 -179.506 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.414 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 9.6 m170 -54.72 -49.14 71.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.133 -0.98 . . . . 0.0 109.56 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.481 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 0.1 OUTLIER -67.22 -62.61 1.34 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.214 -0.929 . . . . 0.0 109.504 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.522 HG23 HG12 ' A' ' 17' ' ' ILE . 13.9 pt -92.03 47.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.262 -0.899 . . . . 0.0 109.431 179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.91 125.47 37.25 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 99.42 -36.08 4.3 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.484 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.9 mmtp -87.46 -28.45 22.08 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.128 -1.219 . . . . 0.0 109.318 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -68.92 104.2 2.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.356 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.558 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 6.8 p30 -103.38 -170.14 1.74 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.37 -0.831 . . . . 0.0 109.992 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.424 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -62.32 -41.25 98.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.558 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -64.29 -25.15 67.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.209 -0.932 . . . . 0.0 109.747 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -79.07 -46.69 17.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.144 -0.973 . . . . 0.0 109.884 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.507 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.3 ptpt -74.11 -25.65 59.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.097 -1.002 . . . . 0.0 109.461 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.487 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 26.3 t0 -83.73 -43.11 15.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.323 -0.86 . . . . 0.0 109.195 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.475 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -60.98 -46.11 92.06 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.436 -0.79 . . . . 0.0 108.996 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.959 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -70.34 -31.0 68.09 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.54 ' HA ' ' CE2' ' A' ' 134' ' ' TYR . . . -55.89 -25.18 41.47 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.538 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.96 ' HB3' HD21 ' A' ' 2' ' ' LEU . . . -91.4 -32.84 15.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.494 -0.753 . . . . 0.0 109.151 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.839 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -81.59 -63.63 1.35 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.465 -0.772 . . . . 0.0 109.723 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.54 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.84 -25.37 4.41 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.947 . . . . 0.0 109.081 -179.979 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 131' ' ' ALA . . . -77.52 -47.73 18.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -0.9 . . . . 0.0 109.031 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -73.41 -29.28 62.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.385 -0.822 . . . . 0.0 109.205 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.839 HD12 ' C ' ' A' ' 133' ' ' ALA . 5.4 mt -66.99 -59.65 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.336 -0.852 . . . . 0.0 108.909 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 31.1 p -60.07 -26.54 66.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.556 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -77.55 -25.08 63.8 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.829 ' HB1' HG22 ' A' ' 80' ' ' VAL . . . -73.25 -29.82 63.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -1.12 . . . . 0.0 109.562 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.855 ' O ' HD23 ' A' ' 141' ' ' LEU . 10.4 tt -75.1 -10.76 59.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.913 . . . . 0.0 109.864 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.754 HD12 ' HB2' ' A' ' 100' ' ' ALA . 44.5 mm -92.41 37.7 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.132 -0.98 . . . . 0.0 109.697 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 21.5 m -116.74 -23.29 8.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.679 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -122.57 -8.49 6.91 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.631 HD13 ' HB2' ' A' ' 90' ' ' HIS . 26.3 tp -72.32 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.073 -1.251 . . . . 0.0 109.558 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.485 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 1.3 mp0 47.3 37.24 5.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.001 -1.062 . . . . 0.0 110.074 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.612 ' OG ' HD11 ' A' ' 145' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.494 1.739 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.817 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.616 ' C1D' HG22 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.626 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.759 HD12 HD12 ' A' ' 73' ' ' LEU . 17.6 mt 52.3 -178.17 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.321 -1.105 . . . . 0.0 109.619 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.3 p -133.86 -168.55 2.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 110.03 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.59 -22.24 40.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.446 -0.784 . . . . 0.0 109.95 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.856 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -93.39 -34.26 13.53 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.916 . . . . 0.0 109.655 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.406 ' O ' HG23 ' A' ' 10' ' ' VAL . 48.3 mt-30 -70.22 -47.14 62.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 109.58 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.54 -29.33 58.75 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.159 -0.963 . . . . 0.0 109.24 179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -80.52 -37.79 30.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.371 -0.83 . . . . 0.0 108.86 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.7 t -72.5 -32.22 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.463 -0.773 . . . . 0.0 108.993 179.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.806 HG23 ' HB1' ' A' ' 129' ' ' ALA . 55.4 t -71.31 -37.89 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.468 -0.77 . . . . 0.0 109.272 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.62 -13.02 60.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.846 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.5 t -92.24 -24.27 19.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.139 -0.976 . . . . 0.0 109.961 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.427 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 16.7 p -91.28 -17.75 25.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.196 -0.94 . . . . 0.0 109.976 -179.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.744 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -84.35 -19.38 33.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 109.762 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.6 mtpt -83.46 1.83 39.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.998 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -118.04 -54.71 2.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.45 179.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.93 HD12 ' CH2' ' A' ' 130' ' ' TRP . 81.3 mt -66.51 -33.09 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.275 -0.89 . . . . 0.0 109.467 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.716 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.67 33.08 3.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.307 -0.87 . . . . 0.0 109.575 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.65 -87.84 0.01 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.6 p -101.0 -21.44 15.04 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.671 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 18.0 p-10 -81.63 -23.16 37.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.594 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.716 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 23.5 t30 57.09 29.36 16.41 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.692 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 90.68 38.66 6.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.671 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -80.82 -58.2 3.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.266 -1.138 . . . . 0.0 109.643 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -73.18 -22.2 79.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.171 -1.572 . . . . 0.0 109.171 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.881 HG11 HD21 ' A' ' 63' ' ' LEU . 23.5 t -66.04 -29.19 46.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.325 -1.103 . . . . 0.0 109.544 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.444 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -80.11 -56.38 3.27 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.497 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 14.6 ptpt -54.28 -24.95 20.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.177 -1.19 . . . . 0.0 110.175 -179.355 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.658 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 18.8 pt-20 -97.75 -18.43 18.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.99 -1.069 . . . . 0.0 109.899 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.438 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 35.5 t -89.16 -68.84 0.75 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -0.937 . . . . 0.0 109.785 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.591 ' HB3' HG13 ' A' ' 55' ' ' VAL . 12.9 m-85 -48.17 -31.26 5.48 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.21 -0.931 . . . . 0.0 109.83 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.663 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -54.55 -54.02 46.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.931 . . . . 0.0 109.61 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.441 ' HA ' ' OG ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -60.49 -38.65 84.97 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.877 -179.887 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.674 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.1 t80 -59.11 -52.64 64.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.167 -0.958 . . . . 0.0 109.705 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.64 ' CD1' HG22 ' A' ' 55' ' ' VAL . 4.2 mt -58.86 -48.79 80.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.239 -0.913 . . . . 0.0 109.842 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.663 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 3.3 p -56.0 -52.68 63.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.731 -179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.635 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -72.53 -25.13 61.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 0.0 109.713 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.635 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 18.6 m-70 -120.35 109.04 14.87 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.281 -0.887 . . . . 0.0 109.767 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -89.86 -21.55 22.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.408 179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -71.07 -21.15 62.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.336 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.511 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -96.64 -13.87 22.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.885 . . . . 0.0 109.81 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -56.02 -64.39 0.87 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.095 -1.003 . . . . 0.0 109.514 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -54.79 -25.23 26.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.277 -0.89 . . . . 0.0 109.369 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.044 HG13 ' ND2' ' A' ' 95' ' ' ASN . 39.0 t -75.97 -43.69 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.346 -0.846 . . . . 0.0 109.419 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 41' ' ' MET . 18.1 m-85 -73.35 -18.44 61.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.911 . . . . 0.0 109.67 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.415 ' O ' ' CD1' ' A' ' 47' ' ' PHE . . . 95.03 26.47 12.49 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.498 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 15.1 m-85 -126.9 -177.1 3.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -1.128 . . . . 0.0 109.982 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.99 16.21 7.34 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.461 -0.774 . . . . 0.0 109.415 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 144.84 -163.42 27.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -79.7 -17.79 52.78 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.308 -1.113 . . . . 0.0 109.826 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.2 t -85.14 49.92 1.84 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.932 . . . . 0.0 109.665 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.32 122.9 15.14 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.261 -0.899 . . . . 0.0 109.611 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -65.83 -25.9 52.67 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.872 1.459 . . . . 0.0 110.077 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.498 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.89 -33.4 43.34 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.663 HG11 HG23 ' A' ' 32' ' ' THR . 97.6 t -52.01 -33.62 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -1.142 . . . . 0.0 109.298 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.701 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.1 -4.29 34.71 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.289 -0.882 . . . . 0.0 109.578 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -90.18 -36.02 15.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.122 -0.986 . . . . 0.0 109.791 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.727 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.6 mt -83.99 -62.16 1.64 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.032 -1.042 . . . . 0.0 109.799 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.444 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.46 -28.36 28.34 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -64.72 -53.67 43.62 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.062 -1.257 . . . . 0.0 109.756 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.608 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 9.7 mttm -79.56 -43.75 22.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.778 HG21 ' O ' ' A' ' 149' ' ' CMO . 94.8 t -46.8 -58.93 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.389 -0.819 . . . . 0.0 110.229 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.881 HD21 HG11 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -46.43 -38.84 9.59 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.205 -0.934 . . . . 0.0 109.987 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.608 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.47 -42.15 61.4 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.935 . . . . 0.0 109.521 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 62' ' ' VAL . 3.2 mm100 -60.67 -42.12 96.44 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.172 -0.955 . . . . 0.0 109.321 179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.938 ' O ' HG23 ' A' ' 70' ' ' VAL . 88.9 mt -61.13 -33.49 56.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.294 -0.879 . . . . 0.0 109.24 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.547 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -67.38 -53.66 24.04 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.921 -1.672 . . . . 0.0 108.921 179.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.4 t -59.84 -24.24 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.315 -1.109 . . . . 0.0 109.207 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.09 -30.33 22.66 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.408 -0.807 . . . . 0.0 109.578 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.938 HG23 ' O ' ' A' ' 66' ' ' ILE . 48.2 t -63.5 -21.21 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.495 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.08 44.0 1.16 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.179 -0.951 . . . . 0.0 109.874 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.529 ' O ' ' N ' ' A' ' 74' ' ' GLY . 4.3 m-70 -152.15 -84.07 0.08 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.129 -0.982 . . . . 0.0 110.311 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.77 HD22 ' N ' ' A' ' 73' ' ' LEU . 2.6 mm? 44.59 -87.7 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.774 -0.579 . . . . 0.0 110.559 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -48.3 -27.01 5.25 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -106.41 84.11 1.97 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.265 -1.138 . . . . 0.0 109.512 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -89.55 44.36 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.261 -0.9 . . . . 0.0 109.633 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -119.11 -12.71 6.81 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.51 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 0.0 OUTLIER -130.14 -38.02 1.43 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.07 -1.253 . . . . 0.0 109.876 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 3.1 tmm? -49.78 -44.95 49.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -0.939 . . . . 0.0 109.774 -179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.4 t -73.81 -8.07 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.922 . . . . 0.0 110.071 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.51 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -77.74 -32.09 52.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.989 -1.069 . . . . 0.0 109.712 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.479 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.5 mt-10 -99.34 -41.45 7.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.925 . . . . 0.0 109.639 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.47 ' SD ' HG23 ' A' ' 137' ' ' ILE . 2.4 mtp -62.53 -47.79 82.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.188 -0.945 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.453 ' HG2' ' HB2' ' A' ' 143' ' ' SER . 0.1 OUTLIER -54.96 -35.73 64.58 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.255 -0.903 . . . . 0.0 109.279 179.694 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -64.23 -35.39 80.65 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.229 -0.919 . . . . 0.0 109.266 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 82' ' ' GLU . 28.6 t -55.08 -48.96 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.352 -0.843 . . . . 0.0 109.42 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.493 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -51.99 -50.42 44.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.859 HG23 ' HA3' ' A' ' 144' ' ' GLY . 97.0 t -48.68 -25.3 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.327 -1.102 . . . . 0.0 109.596 179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.505 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.2 mmt180 -77.08 -44.67 29.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.179 -0.951 . . . . 0.0 109.127 179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.469 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 17.7 m80 -58.78 -19.87 44.7 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.349 -0.845 . . . . 0.0 109.196 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.477 ' HD3' ' HA ' ' A' ' 147' ' ' SER . 25.5 ttpt -68.04 -15.09 63.45 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.419 -0.801 . . . . 0.0 109.851 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.91 50.51 0.81 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.514 ' CD2' HBA1 ' A' ' 148' ' ' HEM . 4.8 m-30 -94.23 -172.41 2.8 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.237 -1.155 . . . . 0.0 109.328 179.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.74 -40.3 53.27 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.044 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.7 t30 -78.39 -44.68 24.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.464 -1.021 . . . . 0.0 109.001 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.1 OUTLIER 71.93 -54.24 0.68 Allowed 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.396 -0.815 . . . . 0.0 110.314 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 28.9 m170 -66.69 69.2 0.07 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.974 . . . . 0.0 110.115 -179.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.456 ' N ' ' O ' ' A' ' 96' ' ' LYS . 84.5 mt -100.61 161.76 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.213 -0.93 . . . . 0.0 109.329 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.487 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -136.92 142.54 42.7 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.139 -0.975 . . . . 0.0 109.726 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.16 -0.41 51.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.878 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.526 ' HG2' ' CD1' ' A' ' 102' ' ' TYR . 7.6 pt-20 -78.74 -28.43 44.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.104 -0.998 . . . . 0.0 109.676 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.526 ' CD1' ' HG2' ' A' ' 101' ' ' GLU . 92.8 m-85 -78.03 -13.52 59.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 109.845 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.899 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.2 m-85 -57.9 -64.57 0.86 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.203 -0.936 . . . . 0.0 110.192 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.487 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.3 mt-10 -51.38 -55.87 25.35 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.169 -0.957 . . . . 0.0 110.208 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 33.6 Cg_exo -49.42 -54.27 5.71 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.69 1.363 . . . . 0.0 110.19 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.911 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.1 tm? -57.05 -19.46 19.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.223 -0.923 . . . . 0.0 109.599 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.53 -39.82 20.69 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.63 -57.14 12.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.243 -1.151 . . . . 0.0 109.614 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.2 m -56.91 -23.23 43.48 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.608 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.698 HD22 ' OH ' ' A' ' 134' ' ' TYR . 4.4 tt -70.38 -43.77 69.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.558 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.622 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.2 mt -57.06 -30.43 64.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.503 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.4 t -66.65 -39.01 88.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.208 -0.933 . . . . 0.0 109.633 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.658 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -75.15 -39.82 60.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.21 -0.931 . . . . 0.0 109.668 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.61 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.2 mmt -48.05 -40.31 22.59 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.203 -0.936 . . . . 0.0 109.874 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.446 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -54.11 -24.57 18.13 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.264 -0.897 . . . . 0.0 109.746 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.406 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -49.65 -53.08 26.36 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.184 -0.947 . . . . 0.0 109.697 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.19 -72.55 0.29 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.153 -0.967 . . . . 0.0 109.579 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.628 HG12 HD11 ' A' ' 17' ' ' ILE . 3.1 pt -86.42 56.32 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.235 -0.916 . . . . 0.0 109.657 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.446 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -68.35 -23.69 74.99 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -94.77 -21.7 25.45 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 59.2 mttt -100.64 -21.47 15.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.627 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.489 ' CA ' HD12 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.16 80.43 0.13 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.327 -0.858 . . . . 0.0 109.632 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.558 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.9 p30 -83.79 -163.93 0.84 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.612 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -71.46 -42.17 68.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.708 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -62.67 -24.02 67.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.18 -52.8 8.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.595 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.557 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.5 ptpt -67.46 -33.2 74.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.918 . . . . 0.0 109.363 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.466 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.0 t70 -73.17 -55.42 6.49 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.413 179.774 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.806 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -51.23 -43.42 61.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.405 -0.809 . . . . 0.0 109.373 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.93 ' CH2' HD12 ' A' ' 17' ' ' ILE . 2.8 m0 -75.74 -29.34 58.85 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.351 -0.843 . . . . 0.0 109.107 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.557 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.07 -27.85 65.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 109.183 179.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -89.31 -26.63 21.02 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.305 -0.872 . . . . 0.0 109.28 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.526 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -79.49 -45.22 19.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.415 -0.803 . . . . 0.0 109.503 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.778 ' HE1' HD13 ' A' ' 66' ' ' ILE . 5.8 m-85 -48.99 -31.61 7.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.08 -36.41 69.53 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.29 -0.881 . . . . 0.0 109.39 179.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.57 -40.37 29.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.524 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.47 HG23 ' SD ' ' A' ' 83' ' ' MET . 1.9 mp -67.42 -56.68 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.864 . . . . 0.0 109.139 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.6 p -68.26 -26.58 65.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.739 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -71.02 -35.78 64.56 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.48 -21.69 66.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.189 -1.183 . . . . 0.0 109.763 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.899 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.2 tt -82.32 -12.62 57.87 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -0.945 . . . . 0.0 109.944 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 142' ' ' ILE . 36.5 mt -79.61 3.26 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.138 -0.976 . . . . 0.0 110.157 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.453 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 9.5 m -89.92 -45.06 9.48 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.015 -1.053 . . . . 0.0 109.632 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.859 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -82.56 -28.58 38.81 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.493 HD12 ' HA2' ' A' ' 87' ' ' GLY . 0.3 OUTLIER -58.83 -163.54 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -1.072 . . . . 0.0 109.609 179.94 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.488 ' H ' HD23 ' A' ' 145' ' ' LEU . 0.0 OUTLIER 27.92 59.95 0.11 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-O 121.517 0.675 . . . . 0.0 111.789 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.477 ' HA ' ' HD3' ' A' ' 91' ' ' LYS . 21.7 m . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.08 -1.012 . . . . 0.0 109.653 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.889 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.778 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.774 HD21 ' HA ' ' A' ' 133' ' ' ALA . 4.3 mm? -84.92 144.19 28.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.31 -1.112 . . . . 0.0 109.65 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.412 ' OG ' ' CG ' ' A' ' 6' ' ' GLN . 0.7 OUTLIER -88.2 178.23 6.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.24 -0.912 . . . . 0.0 109.573 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -72.39 -18.61 61.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.223 -0.923 . . . . 0.0 109.792 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.82 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -98.87 -40.05 8.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.19 -0.944 . . . . 0.0 109.785 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.467 ' O ' HG23 ' A' ' 10' ' ' VAL . 76.8 mt-30 -62.02 -52.83 62.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.539 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.616 ' HA ' HD12 ' A' ' 73' ' ' LEU . 7.5 ptm180 -50.47 -33.9 22.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.34 179.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.468 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 56.6 tp60 -75.57 -46.62 30.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.82 HG23 ' O ' ' A' ' 5' ' ' ALA . 40.7 t -60.54 -34.85 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 0.0 109.178 179.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.776 HG12 HG13 ' A' ' 70' ' ' VAL . 69.8 t -64.66 -48.73 83.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.36 -0.838 . . . . 0.0 109.343 179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.35 -11.53 60.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.337 -0.852 . . . . 0.0 109.675 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -91.17 -25.51 19.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.135 -0.978 . . . . 0.0 109.717 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.7 p -98.01 -11.75 22.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.183 -0.948 . . . . 0.0 109.809 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.552 ' CE3' ' HB3' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -88.8 -28.39 20.48 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.082 -1.011 . . . . 0.0 109.657 -179.882 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -70.76 -15.26 62.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.414 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -99.55 -61.52 1.36 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.644 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.972 HD12 ' CH2' ' A' ' 130' ' ' TRP . 55.8 mt -57.9 -39.13 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.711 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.723 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.64 36.09 2.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.702 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.8 -82.5 0.06 OUTLIER Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.256 -1.537 . . . . 0.0 109.256 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.0 p -97.93 -26.24 14.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 0.0 109.721 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.651 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 4.2 p30 -80.75 -23.8 39.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.274 -0.891 . . . . 0.0 109.639 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.723 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 27.2 t30 56.92 22.07 6.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.915 . . . . 0.0 109.552 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.528 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 101.97 23.44 9.22 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.651 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -69.57 -54.31 14.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 109.619 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.453 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -85.93 10.98 63.59 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.85 HG12 HD11 ' A' ' 63' ' ' LEU . 35.8 t -104.84 -22.66 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.09 -1.241 . . . . 0.0 109.202 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -98.95 -35.43 4.83 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.454 ' CB ' ' HA ' ' A' ' 56' ' ' ALA . 15.0 ptpt -68.88 -27.04 65.44 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.189 -1.183 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.449 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 17.5 pt-20 -100.82 -5.97 25.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 110.087 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.5 t -95.99 -67.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.054 -1.029 . . . . 0.0 109.978 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -47.18 -29.78 2.53 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.206 -0.934 . . . . 0.0 110.149 -179.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.548 HG22 ' HB1' ' A' ' 50' ' ' ALA . 0.2 OUTLIER -52.74 -63.25 1.2 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.074 -1.016 . . . . 0.0 109.207 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -50.35 -47.49 55.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.341 -0.849 . . . . 0.0 109.242 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.73 ' CG ' HD23 ' A' ' 106' ' ' LEU . 7.8 t80 -56.46 -51.26 69.1 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.18 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.862 ' CD1' HG22 ' A' ' 55' ' ' VAL . 19.5 mt -58.32 -44.7 88.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.225 -0.922 . . . . 0.0 109.496 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.576 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 0.2 OUTLIER -67.67 -62.95 1.17 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.344 -0.848 . . . . 0.0 109.612 179.965 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.637 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -52.8 -24.48 9.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.213 -0.929 . . . . 0.0 109.626 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.637 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 19.0 m-70 -125.0 101.74 7.19 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.299 -0.876 . . . . 0.0 109.738 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -84.51 -17.48 38.83 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.398 -0.814 . . . . 0.0 109.503 179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.6 p-10 -67.87 -16.11 63.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.168 -0.957 . . . . 0.0 109.702 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.783 ' HE3' HG11 ' A' ' 44' ' ' VAL . 89.6 mmm -120.04 -15.02 8.82 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 110.019 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.431 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.04 -44.84 41.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.913 -1.117 . . . . 0.0 109.525 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.0 -29.75 60.97 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.322 -0.861 . . . . 0.0 109.26 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.041 HG13 ' ND2' ' A' ' 95' ' ' ASN . 2.4 t -60.89 -27.99 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.342 -0.849 . . . . 0.0 109.173 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.581 ' CE1' HMB2 ' A' ' 148' ' ' HEM . 8.3 m-85 -82.64 -27.8 31.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.103 -0.998 . . . . 0.0 109.683 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.448 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 112.84 20.26 6.51 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.543 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 3.6 m-85 -117.88 172.84 7.12 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.231 -1.159 . . . . 0.0 109.653 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.6 t -115.28 22.09 13.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.331 -0.856 . . . . 0.0 109.029 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.45 -170.8 28.93 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.576 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -85.86 11.28 11.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -1.168 . . . . 0.0 109.97 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.04 20.3 18.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.994 . . . . 0.0 109.557 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.404 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -101.31 136.42 19.67 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.54 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -68.03 -17.01 45.97 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.916 1.482 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.0 -36.88 61.38 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.862 HG22 ' CD1' ' A' ' 35' ' ' LEU . 61.2 t -51.71 -33.27 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.238 -1.154 . . . . 0.0 109.449 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.66 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -79.28 -13.77 59.45 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.252 -0.905 . . . . 0.0 109.787 179.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -90.21 -23.14 21.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.184 -0.947 . . . . 0.0 109.494 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.75 HD21 ' CHA' ' A' ' 148' ' ' HEM . 3.4 mt -90.89 -66.43 0.93 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.902 . . . . 0.0 109.906 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.457 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -52.93 -30.89 38.27 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -1.217 . . . . 0.0 109.479 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.544 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 17.0 mttt -94.34 -38.44 10.98 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.42 -0.8 . . . . 0.0 109.485 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 58' ' ' LEU . 91.4 t -51.43 -57.99 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.38 -0.825 . . . . 0.0 109.794 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.85 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.31 -45.0 24.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.227 -0.921 . . . . 0.0 109.677 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.544 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -47.66 -40.74 20.67 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.687 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 35.2 tp60 -64.79 -41.28 95.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.195 -0.941 . . . . 0.0 109.164 179.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.795 ' O ' HG23 ' A' ' 70' ' ' VAL . 59.4 mt -60.79 -37.31 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -0.843 . . . . 0.0 109.144 179.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.76 29.68 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.2 t -58.04 -24.81 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.287 -1.125 . . . . 0.0 109.17 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.0 -34.21 22.4 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.418 -0.801 . . . . 0.0 109.433 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.795 HG23 ' O ' ' A' ' 66' ' ' ILE . 50.7 t -63.95 -19.33 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.262 -0.899 . . . . 0.0 109.425 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 24.1 m -62.2 -41.93 98.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.196 -0.94 . . . . 0.0 109.667 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 71' ' ' SER . 8.7 m-70 -131.02 84.48 2.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.724 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.624 HD11 HG11 ' A' ' 10' ' ' VAL . 42.1 mt -81.64 -46.58 14.16 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 109.6 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.8 -22.64 61.28 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.66 118.38 29.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -1.141 . . . . 0.0 109.65 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.551 ' HB3' HG21 ' A' ' 80' ' ' VAL . 25.1 mt-10 -114.41 49.07 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 109.62 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -105.84 -19.83 9.92 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 9.6 tttt -138.59 -45.24 0.49 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -1.181 . . . . 0.0 109.826 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -49.35 -33.12 12.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.947 . . . . 0.0 109.753 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.551 HG21 ' HB3' ' A' ' 76' ' ' GLU . 54.8 t -76.86 -22.51 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.258 -0.901 . . . . 0.0 109.605 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -72.47 -17.89 61.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.851 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -92.57 -49.84 5.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 109.761 -179.875 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.466 ' HE2' ' O ' ' A' ' 137' ' ' ILE . 95.8 mmm -60.74 -45.91 92.49 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.067 -1.021 . . . . 0.0 109.156 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.796 ' O ' HG23 ' A' ' 88' ' ' VAL . 2.0 mttt -51.73 -31.17 25.34 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.128 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.448 ' O ' ' CG ' ' A' ' 89' ' ' ARG . . . -79.47 -32.02 42.53 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.462 -0.774 . . . . 0.0 108.956 179.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 82' ' ' GLU . 45.2 t -69.86 -41.69 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.127 -0.983 . . . . 0.0 109.273 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.49 92.69 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.931 -1.667 . . . . 0.0 108.931 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.796 HG23 ' O ' ' A' ' 84' ' ' LYS . 97.0 t -59.25 -29.4 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -1.191 . . . . 0.0 109.178 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.478 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.9 OUTLIER -76.63 -45.7 28.93 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -0.871 . . . . 0.0 109.316 179.773 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.798 ' O ' HD12 ' A' ' 98' ' ' ILE . 22.0 m80 -59.18 -20.67 55.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.088 179.428 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.482 ' HG3' ' HA ' ' A' ' 147' ' ' SER . 8.1 ttpt -70.23 -9.54 56.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.89 . . . . 0.0 110.188 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -145.4 54.57 0.55 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.885 ' CD2' HD11 ' A' ' 98' ' ' ILE . 3.9 m-30 -88.8 -168.99 2.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -1.167 . . . . 0.0 109.613 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -76.49 -36.46 38.48 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.041 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.7 p-10 -79.67 -24.66 41.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.046 -1.267 . . . . 0.0 110.009 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 ttmm 51.41 26.79 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.153 -0.967 . . . . 0.0 109.499 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.413 ' H ' ' ND2' ' A' ' 95' ' ' ASN . 4.6 m-70 -134.28 42.97 2.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.42 -0.8 . . . . 0.0 109.323 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.885 HD11 ' CD2' ' A' ' 93' ' ' TYR . 58.9 mt -86.03 156.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.925 . . . . 0.0 110.061 -179.633 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.472 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -150.28 143.69 25.08 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.706 0.765 . . . . 0.0 109.882 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.1 -6.37 56.3 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.717 -0.614 . . . . 0.0 109.622 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.422 ' HG2' ' HB3' ' A' ' 99' ' ' LYS . 15.7 pt-20 -72.95 -28.73 62.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.091 -1.006 . . . . 0.0 109.359 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.54 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 44.8 m-85 -79.93 -20.42 45.72 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.286 -0.884 . . . . 0.0 109.724 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.84 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 5.5 m-85 -57.37 -68.13 0.26 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.338 -0.851 . . . . 0.0 110.555 -179.332 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 3.4 mt-10 -43.24 -59.96 2.81 Favored Pre-proline 0 N--CA 1.495 1.808 0 O-C-N 121.516 -0.74 . . . . 0.0 111.016 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 8.8 Cg_endo -55.99 -42.52 65.93 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.732 1.385 . . . . 0.0 110.199 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.737 HD13 ' O ' ' A' ' 106' ' ' LEU . 2.9 tm? -66.75 -27.18 67.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.145 -0.972 . . . . 0.0 109.475 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -75.36 -38.8 37.8 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.45 -48.42 72.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -1.127 . . . . 0.0 109.539 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.2 m -62.31 -26.46 68.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.548 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.424 HD22 ' CE2' ' A' ' 134' ' ' TYR . 8.3 tt -70.42 -40.22 73.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 109.563 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.938 HD21 ' HB3' ' A' ' 130' ' ' TRP . 13.0 mt -58.96 -32.04 69.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.426 179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.53 -27.75 64.41 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.282 -0.886 . . . . 0.0 109.523 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.421 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -84.18 -35.07 23.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.224 -0.922 . . . . 0.0 109.689 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.661 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.3 mmt -46.93 -50.4 18.95 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.285 -0.884 . . . . 0.0 110.227 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.475 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 8.5 pt-20 -47.23 -24.76 0.78 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.255 -0.903 . . . . 0.0 110.276 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 19.8 m170 -53.65 -31.33 47.08 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.709 -1.244 . . . . 0.0 109.651 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -91.89 -68.39 0.8 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.19 -0.944 . . . . 0.0 110.127 -179.655 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.499 HG23 HG12 ' A' ' 17' ' ' ILE . 18.3 pt -78.21 -34.16 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.116 -0.99 . . . . 0.0 109.756 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.475 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . 41.2 -98.73 0.01 OUTLIER Glycine 0 N--CA 1.498 2.794 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.61 -39.46 10.56 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.491 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.6 OUTLIER -73.29 -18.13 61.24 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.044 -1.268 . . . . 0.0 109.919 -179.806 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.449 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.5 OUTLIER -79.45 107.06 11.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 179.571 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.686 HD21 ' HB3' ' A' ' 125' ' ' ALA . 12.4 p-10 -111.61 -171.23 1.8 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.926 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.451 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.47 -49.0 79.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.424 -0.798 . . . . 0.0 109.963 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.722 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.83 -20.72 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.197 -0.939 . . . . 0.0 109.516 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -85.44 -55.73 3.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.311 -0.868 . . . . 0.0 109.791 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.451 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -69.69 -24.78 63.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.781 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -80.04 -45.35 18.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.236 -0.915 . . . . 0.0 109.524 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -65.25 -45.89 82.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.391 -0.818 . . . . 0.0 109.391 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.972 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.7 m0 -66.41 -29.4 69.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -0.864 . . . . 0.0 109.34 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.448 ' N ' HD11 ' A' ' 111' ' ' LEU . . . -69.64 -28.06 65.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.216 -0.927 . . . . 0.0 108.932 179.327 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -91.81 -31.72 15.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.44 -0.787 . . . . 0.0 109.359 179.614 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.774 ' HA ' HD21 ' A' ' 2' ' ' LEU . . . -72.06 -39.78 68.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.398 -0.814 . . . . 0.0 109.206 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.424 ' CE2' HD22 ' A' ' 110' ' ' LEU . 5.3 m-30 -52.64 -30.89 34.05 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.342 -0.849 . . . . 0.0 109.064 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.58 -35.07 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.336 -0.852 . . . . 0.0 109.242 179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -77.89 -39.07 44.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.33 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.636 HD13 HG23 ' A' ' 66' ' ' ILE . 12.2 mt -65.82 -58.48 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.297 -0.877 . . . . 0.0 109.109 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.429 ' O ' ' HB3' ' A' ' 141' ' ' LEU . 0.1 OUTLIER -68.51 -28.25 66.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -58.38 -52.72 51.09 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -54.04 -23.28 13.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.259 -1.142 . . . . 0.0 109.535 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.649 ' O ' HD23 ' A' ' 141' ' ' LEU . 10.5 tt -81.73 -18.12 45.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.703 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.714 ' O ' HG22 ' A' ' 142' ' ' ILE . 69.3 mt -89.88 37.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.78 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 60.7 m -117.84 -36.15 3.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.073 -1.017 . . . . 0.0 109.688 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -105.12 -18.01 12.98 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.443 ' HG ' ' N ' ' A' ' 146' ' ' GLN . 4.9 tp -65.31 -102.47 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.123 -1.221 . . . . 0.0 109.581 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.443 ' N ' ' HG ' ' A' ' 145' ' ' LEU . 1.4 mp0 47.2 28.44 0.99 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.835 -1.166 . . . . 0.0 110.012 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.482 ' HA ' ' HG3' ' A' ' 91' ' ' LYS . 3.1 m . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.95 -1.024 . . . . 0.0 109.589 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.84 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.478 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.411 ' O ' ' O ' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.889 HD11 HD11 ' A' ' 73' ' ' LEU . 12.3 mt 53.81 174.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.277 -1.131 . . . . 0.0 109.644 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.3 p -159.48 -157.88 0.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.183 -0.948 . . . . 0.0 109.964 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.93 -31.79 18.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.539 -0.726 . . . . 0.0 109.408 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.603 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -94.22 -16.43 23.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.343 -0.848 . . . . 0.0 109.61 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 46.9 mt-30 -81.35 -46.86 14.05 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.131 -0.981 . . . . 0.0 109.621 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.453 ' HD3' ' N ' ' A' ' 8' ' ' GLN . 0.0 OUTLIER -54.84 -31.66 59.67 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.089 -1.007 . . . . 0.0 109.468 -179.989 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.453 ' N ' ' HD3' ' A' ' 7' ' ' ARG . 27.7 mm100 -70.78 -37.43 73.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 109.336 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 5' ' ' ALA . 47.3 t -69.71 -29.18 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.207 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.931 HG12 HG13 ' A' ' 70' ' ' VAL . 63.8 t -70.73 -43.76 77.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.309 -0.869 . . . . 0.0 109.291 179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.61 -12.79 60.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.319 -0.863 . . . . 0.0 109.771 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.0 t -91.89 -27.79 17.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.7 p -90.93 -13.85 32.71 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.141 -0.974 . . . . 0.0 110.032 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.56 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -88.44 -15.07 36.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.068 -1.02 . . . . 0.0 109.865 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.42 -0.58 55.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.947 . . . . 0.0 109.924 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -113.3 -49.67 2.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.034 -1.041 . . . . 0.0 109.602 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.946 HD12 ' CH2' ' A' ' 130' ' ' TRP . 58.5 mt -69.43 -36.19 70.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.251 -0.906 . . . . 0.0 109.575 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.14 33.17 3.18 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 109.72 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.91 -61.81 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.111 -1.596 . . . . 0.0 109.111 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 p -120.39 -36.74 3.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -1.123 . . . . 0.0 109.594 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 2.0 p30 -71.26 -19.15 62.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.261 -0.899 . . . . 0.0 109.665 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.849 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 28.4 t30 57.53 19.65 5.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -0.929 . . . . 0.0 109.635 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.411 ' HA3' ' HB3' ' A' ' 63' ' ' LEU . . . 105.46 19.36 10.58 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.774 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -64.91 -52.39 56.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -1.181 . . . . 0.0 109.596 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.23 -22.73 75.65 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.69 HG21 ' CG2' ' A' ' 17' ' ' ILE . 15.5 t -71.09 -41.01 76.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -1.086 . . . . 0.0 109.855 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.401 ' HA3' ' C ' ' A' ' 59' ' ' GLY . . . -74.93 -57.19 4.53 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.924 -1.27 . . . . 0.0 109.924 -179.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.482 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 15.8 ptpt -47.39 -31.3 3.93 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.208 -1.172 . . . . 0.0 110.228 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.82 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 23.4 pt-20 -95.79 -17.81 20.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.058 -1.026 . . . . 0.0 109.939 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 29.3 t -83.54 -68.11 0.74 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.948 . . . . 0.0 109.8 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.521 ' CE1' ' HA2' ' A' ' 59' ' ' GLY . 18.8 m-85 -50.32 -32.04 16.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.254 -0.904 . . . . 0.0 109.97 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.808 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -51.95 -55.05 22.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.1 -1.0 . . . . 0.0 109.165 179.718 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 5.7 mttt -57.68 -48.6 79.07 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.32 -0.862 . . . . 0.0 109.268 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.694 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.1 t80 -55.04 -49.05 72.54 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.195 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.712 ' CD1' HG22 ' A' ' 55' ' ' VAL . 23.2 mt -59.83 -41.57 91.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.854 . . . . 0.0 109.725 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -65.79 -63.34 1.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.205 -0.935 . . . . 0.0 109.818 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.6 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -58.25 -21.36 48.12 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.203 -0.936 . . . . 0.0 109.886 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.6 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 16.5 m-70 -126.74 106.71 9.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.922 . . . . 0.0 109.933 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 5.5 m170 -85.88 -20.44 29.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.535 -0.728 . . . . 0.0 109.249 179.292 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -73.05 -20.29 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.248 -0.908 . . . . 0.0 109.098 179.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.564 ' HE1' HMB2 ' A' ' 148' ' ' HEM . 0.2 OUTLIER -91.86 -20.43 21.46 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -0.866 . . . . 0.0 109.537 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.444 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -60.26 -56.48 20.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.166 -0.959 . . . . 0.0 109.302 179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.61 63.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.288 -0.882 . . . . 0.0 109.255 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.035 HG13 ' ND2' ' A' ' 95' ' ' ASN . 22.4 t -71.4 -58.45 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.306 -0.871 . . . . 0.0 109.288 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.536 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 39.7 m-85 -57.2 -40.69 77.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.58 35.18 1.1 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 13.0 m-85 -125.62 169.0 12.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 109.858 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 t -112.34 18.07 18.85 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.351 -0.843 . . . . 0.0 109.372 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.3 -164.05 29.28 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.43 25.31 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -1.155 . . . . 0.0 109.716 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 37.6 m -124.78 31.04 5.77 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.623 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.54 135.45 21.9 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 109.642 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -64.07 -18.21 62.71 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.929 1.489 . . . . 0.0 109.972 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.62 -39.08 94.65 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.808 HG11 HG23 ' A' ' 32' ' ' THR . 65.6 t -52.09 -38.56 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.322 -1.105 . . . . 0.0 109.411 179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.01 -12.22 60.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 0.0 109.659 179.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -92.76 -35.5 13.4 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.144 -0.972 . . . . 0.0 109.662 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.869 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.9 mt -79.43 -61.16 2.09 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.241 -0.912 . . . . 0.0 109.873 -179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.864 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -55.61 -36.47 64.8 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.585 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -60.85 -52.63 64.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.09 -1.241 . . . . 0.0 109.365 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.478 ' HB2' ' CGD' ' A' ' 148' ' ' HEM . 16.6 mttt -67.5 -41.99 83.59 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.308 -0.87 . . . . 0.0 109.183 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.869 HG23 ' O ' ' A' ' 58' ' ' LEU . 63.3 t -56.42 -44.51 80.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.175 179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 59' ' ' GLY . 2.0 mm? -48.17 -46.07 34.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.919 . . . . 0.0 109.429 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.416 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -50.65 -49.46 56.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.107 -0.995 . . . . 0.0 109.33 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -52.99 -37.66 61.55 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -0.892 . . . . 0.0 109.088 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.915 ' O ' HG23 ' A' ' 70' ' ' VAL . 34.7 mm -67.87 -35.75 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 109.063 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.56 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.43 -47.22 44.06 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.786 -1.726 . . . . 0.0 108.786 179.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.559 HG11 ' OE1' ' A' ' 82' ' ' GLU . 43.9 t -62.45 -25.43 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.361 -1.082 . . . . 0.0 109.439 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.83 -30.7 24.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.931 HG13 HG12 ' A' ' 10' ' ' VAL . 53.8 t -62.68 -37.23 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.488 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.2 p -51.39 -69.28 0.12 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.923 . . . . 0.0 109.348 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.444 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 9.0 m-70 -90.82 45.32 1.25 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 109.192 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.889 HD11 HD11 ' A' ' 2' ' ' LEU . 30.4 tp -86.59 -16.53 36.49 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.244 -0.91 . . . . 0.0 109.526 -179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -80.7 -28.35 47.33 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.62 -157.12 0.59 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.327 -1.102 . . . . 0.0 109.543 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -173.36 46.38 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.913 . . . . 0.0 109.64 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -127.22 17.58 6.22 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.581 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 33.0 ttpt -163.25 -46.94 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.052 -1.264 . . . . 0.0 109.87 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.444 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 8.3 tmm? -48.25 -44.08 33.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.129 -0.982 . . . . 0.0 109.473 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.61 HG12 ' HE2' ' A' ' 84' ' ' LYS . 37.9 t -62.01 -24.46 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.857 . . . . 0.0 109.108 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.581 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -64.65 -52.86 55.11 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.266 -0.896 . . . . 0.0 109.23 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.559 ' OE1' HG11 ' A' ' 68' ' ' VAL . 5.8 tt0 -66.91 -46.16 75.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.113 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.472 ' SD ' HG23 ' A' ' 137' ' ' ILE . 1.6 mtp -52.61 -48.91 66.01 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.302 -0.874 . . . . 0.0 109.139 179.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.61 ' HE2' HG12 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -52.63 -34.22 50.27 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.182 -0.949 . . . . 0.0 108.894 179.389 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -66.58 -15.87 63.75 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.613 ' CG1' HD11 ' A' ' 141' ' ' LEU . 11.3 t -85.81 -32.52 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.033 -1.042 . . . . 0.0 108.624 179.315 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.479 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -71.26 -43.32 55.6 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 179.176 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.422 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 96.3 t -55.65 -25.93 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.38 -1.07 . . . . 0.0 108.62 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.509 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.3 OUTLIER -76.06 -49.53 17.25 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 108.996 179.301 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.866 ' HB2' HD13 ' A' ' 145' ' ' LEU . 24.5 m80 -62.04 -21.71 65.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.379 -0.826 . . . . 0.0 109.01 179.553 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.487 ' HG3' ' CB ' ' A' ' 147' ' ' SER . 0.2 OUTLIER -63.58 -14.13 48.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.396 -0.815 . . . . 0.0 109.972 -179.884 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.47 53.46 0.58 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.509 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.9 m-30 -91.31 -173.2 3.53 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -1.168 . . . . 0.0 109.349 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.45 -25.51 54.0 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 179.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.035 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.2 t30 -82.34 -45.49 14.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.463 -1.022 . . . . 0.0 109.179 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 9.0 ttpt 72.3 -53.75 0.69 Allowed 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.464 -0.773 . . . . 0.0 110.224 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 38.1 m170 -65.61 73.07 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.119 -0.988 . . . . 0.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.462 ' N ' ' O ' ' A' ' 96' ' ' LYS . 48.8 mt -104.81 155.03 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.521 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.53 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.7 mptp? -138.72 149.76 45.43 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.231 -0.918 . . . . 0.0 109.948 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.706 ' HB1' HG12 ' A' ' 142' ' ' ILE . . . -87.45 -18.79 29.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.527 -0.733 . . . . 0.0 109.628 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.459 ' HG2' ' HB3' ' A' ' 99' ' ' LYS . 17.7 pt-20 -67.22 -19.64 65.57 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.53 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 52.6 m-85 -82.06 -21.41 36.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.249 -0.907 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.842 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 4.5 m-85 -60.42 -64.56 0.91 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.294 -0.879 . . . . 0.0 110.205 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.495 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -43.77 -58.75 4.2 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.462 -0.774 . . . . 0.0 110.987 -179.328 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.519 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 7.4 Cg_endo -55.06 -47.29 27.26 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 123.63 1.332 . . . . 0.0 110.082 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.878 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -61.75 -22.43 65.39 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.151 -0.968 . . . . 0.0 109.428 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -74.98 -48.24 11.89 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.79 -51.26 70.75 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.245 -1.15 . . . . 0.0 109.595 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 m -58.9 -18.77 36.19 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.91 . . . . 0.0 109.658 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.769 HD23 ' SD ' ' A' ' 114' ' ' MET . 1.2 tt -75.71 -31.14 59.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.178 -0.951 . . . . 0.0 109.722 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.871 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.2 mt -71.29 -29.03 64.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 0.0 109.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.13 -34.29 70.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.916 -179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.82 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -80.89 -29.55 35.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.719 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.769 ' SD ' HD23 ' A' ' 110' ' ' LEU . 2.7 mtt -61.72 -34.16 75.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.896 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.448 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -61.49 -17.85 56.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.174 -0.954 . . . . 0.0 109.409 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -57.94 -49.14 77.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 109.721 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.1 ttt85 -74.25 -65.68 0.82 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.698 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.663 HG12 HD11 ' A' ' 17' ' ' ILE . 7.0 pt -92.31 53.19 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.258 -0.901 . . . . 0.0 109.726 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.448 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.49 -15.12 61.1 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.39 -30.95 6.68 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.71 -26.02 17.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -1.16 . . . . 0.0 109.791 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.423 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -60.19 97.67 0.05 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.636 -179.903 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.58 HD21 ' HB3' ' A' ' 125' ' ' ALA . 15.7 p-10 -106.42 -171.5 1.91 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.437 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -60.15 -49.48 77.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.388 -0.82 . . . . 0.0 109.952 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.58 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -58.4 -26.22 62.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.05 -1.031 . . . . 0.0 109.321 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.424 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -76.95 -54.01 7.11 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.231 -0.918 . . . . 0.0 109.849 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.498 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 6.3 ptmm? -70.9 -29.29 65.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.058 -1.026 . . . . 0.0 109.792 -179.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -77.85 -42.03 34.91 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -0.93 . . . . 0.0 109.607 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.456 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -65.53 -50.16 66.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.26 -0.9 . . . . 0.0 109.407 179.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.946 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.0 m0 -64.55 -28.77 69.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.299 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.23 -28.81 69.63 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.188 -0.945 . . . . 0.0 109.064 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.503 ' HB1' ' H ' ' A' ' 2' ' ' LEU . . . -90.58 -24.32 20.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.395 -0.816 . . . . 0.0 109.373 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.554 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -77.47 -62.8 1.54 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.355 -0.841 . . . . 0.0 109.685 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.568 ' CE1' ' CG2' ' A' ' 66' ' ' ILE . 16.2 m-30 -52.0 -26.19 10.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.228 -0.92 . . . . 0.0 109.577 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -69.67 -44.85 69.64 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.208 -0.932 . . . . 0.0 108.904 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -75.41 -32.27 60.68 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.407 -0.808 . . . . 0.0 109.281 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.554 HG12 ' HB1' ' A' ' 69' ' ' ALA . 49.1 mt -67.46 -59.29 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.321 -0.862 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.442 ' O ' ' CD1' ' A' ' 142' ' ' ILE . 2.4 p -67.25 -13.72 62.24 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.312 -0.868 . . . . 0.0 109.805 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' A' ' 142' ' ' ILE . . . -84.96 -21.74 54.69 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.453 ' O ' ' NZ ' ' A' ' 84' ' ' LYS . . . -86.24 -10.36 54.78 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 110.054 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.881 ' O ' HD23 ' A' ' 141' ' ' LEU . 3.0 tt -89.14 17.24 6.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.029 -1.045 . . . . 0.0 109.882 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.706 HG12 ' HB1' ' A' ' 100' ' ' ALA . 1.9 mp -107.52 7.15 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.099 -1.001 . . . . 0.0 110.121 -179.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.401 ' HB2' ' NZ ' ' A' ' 84' ' ' LYS . 0.3 OUTLIER -96.77 -34.48 11.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.945 -1.097 . . . . 0.0 109.63 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.83 11.1 27.52 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.866 HD13 ' HB2' ' A' ' 90' ' ' HIS . 11.4 tp -98.43 -11.66 22.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.106 -1.232 . . . . 0.0 109.863 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -98.34 62.21 1.46 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.044 -1.035 . . . . 0.0 109.725 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.487 ' CB ' ' HG3' ' A' ' 91' ' ' LYS . 2.7 m . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 117.999 -1.001 . . . . 0.0 109.696 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.842 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.504 ' O ' ' CE2' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.435 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.463 HD21 ' HA ' ' A' ' 133' ' ' ALA . 4.3 mm? 57.96 160.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.521 -0.987 . . . . 0.0 109.747 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -141.68 168.05 20.68 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.154 -0.966 . . . . 0.0 109.876 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -64.63 -28.16 69.43 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.365 -0.835 . . . . 0.0 109.601 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.552 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -82.21 -42.25 19.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -0.898 . . . . 0.0 109.596 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.427 ' O ' HG23 ' A' ' 10' ' ' VAL . 42.8 mt-30 -64.34 -44.57 91.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.219 -0.926 . . . . 0.0 109.69 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.478 ' NH1' ' HA3' ' A' ' 74' ' ' GLY . 73.7 mtp180 -48.68 -50.55 32.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.512 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -59.0 -48.38 81.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 0.0 109.057 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.711 HG11 ' O ' ' A' ' 125' ' ' ALA . 48.6 t -59.83 -36.11 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 0.0 109.145 179.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 1.058 HG12 HG13 ' A' ' 70' ' ' VAL . 65.7 t -72.14 -46.47 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.36 -0.837 . . . . 0.0 109.116 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.03 -18.01 61.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.349 -0.844 . . . . 0.0 109.53 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.8 t -87.12 -25.44 24.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.632 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.2 p -91.08 -17.19 26.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.851 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.02 -15.67 37.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.923 . . . . 0.0 109.841 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -84.45 -14.34 49.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.113 -0.992 . . . . 0.0 109.596 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.452 ' OD1' HG22 ' A' ' 118' ' ' ILE . 1.8 t70 -98.84 -51.25 3.94 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.156 -0.965 . . . . 0.0 109.614 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.956 HD12 ' CH2' ' A' ' 130' ' ' TRP . 62.2 mt -69.11 -36.41 73.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.249 -0.907 . . . . 0.0 109.585 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.855 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.27 33.16 3.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.692 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.2 -81.75 0.05 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.8 p -102.04 -17.49 16.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -1.149 . . . . 0.0 109.725 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.84 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 5.5 p-10 -89.02 -19.65 25.38 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.218 -0.926 . . . . 0.0 109.656 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.855 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.0 t30 59.32 24.57 13.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.238 -0.914 . . . . 0.0 109.674 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.94 22.69 14.93 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.027 -1.629 . . . . 0.0 109.027 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.84 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -71.12 -43.63 67.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.295 -1.12 . . . . 0.0 109.71 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.433 ' HA2' ' HD2' ' A' ' 28' ' ' LYS . . . -88.91 22.84 20.04 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.65 ' CG1' HD21 ' A' ' 110' ' ' LEU . 16.9 t -115.14 -34.23 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.17 -1.194 . . . . 0.0 109.057 179.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.477 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -92.57 -39.39 5.31 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.473 ' HB2' ' CB ' ' A' ' 56' ' ' ALA . 2.5 ptmt -63.85 -30.01 71.14 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.117 -1.225 . . . . 0.0 109.381 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.661 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 6.5 pt-20 -92.59 -22.2 19.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.442 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 37.8 t -85.47 -51.44 6.52 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.294 -0.879 . . . . 0.0 109.593 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.696 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.7 m-85 -53.63 -32.27 50.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.668 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 16.6 m -62.36 -28.38 69.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.968 . . . . 0.0 109.222 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.3 mmtt -81.65 -40.11 23.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.897 ' CG ' HD23 ' A' ' 106' ' ' LEU . 1.5 t80 -65.84 -55.55 16.51 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.265 -0.897 . . . . 0.0 109.362 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.755 ' CD1' HG22 ' A' ' 55' ' ' VAL . 25.3 mt -50.08 -44.62 52.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 0.0 109.722 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.518 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 40.1 p -66.36 -68.29 0.38 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.181 -0.949 . . . . 0.0 109.647 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.654 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -52.5 -27.17 15.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.654 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 17.7 m-70 -120.06 101.41 7.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -0.86 . . . . 0.0 109.756 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -83.63 -19.01 36.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.404 -0.81 . . . . 0.0 109.371 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -72.51 -13.02 61.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.207 -0.933 . . . . 0.0 109.597 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.496 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 0.2 OUTLIER -105.6 -14.94 15.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.938 -179.826 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.06 -65.23 0.61 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.005 -1.06 . . . . 0.0 109.533 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.42 -20.91 48.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.237 -0.914 . . . . 0.0 109.472 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.035 HG13 ' ND2' ' A' ' 95' ' ' ASN . 38.7 t -77.95 -39.0 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.288 -0.883 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.533 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 5.3 m-85 -74.39 -21.65 59.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.231 -0.918 . . . . 0.0 109.531 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.92 25.21 7.28 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.533 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.7 m-85 -123.76 175.85 6.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -1.112 . . . . 0.0 109.802 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -116.57 18.4 15.04 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.392 -0.817 . . . . 0.0 109.352 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 147.97 -163.87 28.87 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.518 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -93.09 31.8 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.201 -1.176 . . . . 0.0 109.64 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.1 t -130.46 25.58 5.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.629 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.04 138.18 20.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -66.67 -22.77 49.97 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.994 1.523 . . . . 0.0 109.976 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.508 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -55.97 -31.67 58.78 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.755 HG22 ' CD1' ' A' ' 35' ' ' LEU . 92.9 t -54.19 -35.9 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.22 -1.164 . . . . 0.0 109.379 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.473 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . . . -78.53 -5.16 51.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 0.0 109.809 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.417 ' OD2' ' HA2' ' A' ' 54' ' ' GLY . 37.0 m-20 -93.55 -27.45 16.62 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.03 -1.044 . . . . 0.0 109.558 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.862 ' O ' HG23 ' A' ' 62' ' ' VAL . 6.4 mt -88.13 -63.97 1.22 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.073 -1.017 . . . . 0.0 109.354 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.477 ' CA ' ' HA3' ' A' ' 27' ' ' GLY . . . -51.19 -37.07 37.27 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -67.32 -34.34 77.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -1.161 . . . . 0.0 109.859 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 0.0 OUTLIER -87.06 -34.49 19.15 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 109.785 -179.82 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.862 HG23 ' O ' ' A' ' 58' ' ' LEU . 24.4 t -67.24 -47.46 81.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.205 -0.935 . . . . 0.0 109.719 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.8 mm? -47.89 -46.99 32.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.79 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.78 -48.08 20.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.257 -0.902 . . . . 0.0 109.973 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -55.4 -53.3 58.01 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.111 -0.993 . . . . 0.0 109.42 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 1.007 ' O ' HG23 ' A' ' 70' ' ' VAL . 52.2 mt -51.77 -38.47 22.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.362 -0.836 . . . . 0.0 109.176 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.574 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.06 -55.69 28.84 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.465 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 98.9 t -59.94 -29.2 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -1.126 . . . . 0.0 109.758 -179.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.53 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.76 -10.64 57.03 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.296 -0.877 . . . . 0.0 110.075 -179.647 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.058 HG13 HG12 ' A' ' 10' ' ' VAL . 42.1 t -71.53 -42.32 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.012 -1.055 . . . . 0.0 109.946 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.31 -12.49 59.96 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.056 -1.027 . . . . 0.0 110.032 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.483 ' ND1' ' N ' ' A' ' 72' ' ' HIS . 9.0 m80 -110.99 52.6 0.73 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.145 -0.972 . . . . 0.0 109.998 -179.306 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.537 ' CD1' HG11 ' A' ' 10' ' ' VAL . 90.0 mt -102.7 -35.14 8.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.936 . . . . 0.0 109.168 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.478 ' HA3' ' NH1' ' A' ' 7' ' ' ARG . . . -74.68 -48.05 13.75 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.732 -1.747 . . . . 0.0 108.732 179.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -136.51 -131.68 0.14 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.475 -1.015 . . . . 0.0 108.907 179.432 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.453 ' HB3' ' HB3' ' A' ' 72' ' ' HIS . 1.4 mt-10 50.75 31.35 5.84 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 120.961 -1.087 . . . . 0.0 108.8 -179.69 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.414 ' O ' ' HB ' ' A' ' 80' ' ' VAL . . . -47.59 -26.04 3.6 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 179.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 25.5 ttpt -55.44 -34.98 64.94 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.585 -0.95 . . . . 0.0 108.874 178.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.438 ' HG2' ' HB3' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -57.46 -29.08 63.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.156 -0.965 . . . . 0.0 108.884 179.551 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.414 ' HB ' ' O ' ' A' ' 77' ' ' GLY . 57.7 t -60.48 -30.51 46.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.364 -0.835 . . . . 0.0 108.747 179.236 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.77 -42.09 97.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.355 -0.841 . . . . 0.0 108.864 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.43 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.6 OUTLIER -61.59 -53.06 61.26 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.368 -0.833 . . . . 0.0 108.931 179.428 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.459 ' CE ' ' O ' ' A' ' 137' ' ' ILE . 80.5 mmm -57.72 -40.41 79.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.278 -0.888 . . . . 0.0 108.829 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.88 -35.73 46.19 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.243 -0.911 . . . . 0.0 108.606 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.426 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -74.18 -36.06 64.03 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG12 HD11 ' A' ' 141' ' ' LEU . 49.0 t -56.92 -43.89 81.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.306 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.498 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -67.21 -51.38 38.78 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 179.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.559 HG23 ' HA3' ' A' ' 144' ' ' GLY . 53.1 t -58.76 -22.39 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.497 -1.002 . . . . 0.0 109.197 179.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.501 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 1.7 mmm180 -75.41 -41.59 55.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.213 -0.929 . . . . 0.0 109.13 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.539 ' HA ' ' CG ' ' A' ' 93' ' ' TYR . 4.8 m80 -60.31 -28.74 68.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.087 179.335 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.515 ' HG3' ' HA ' ' A' ' 147' ' ' SER . 2.0 ttmt -52.44 -26.28 12.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 110.308 -179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -130.23 45.28 1.15 Allowed Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.586 -1.292 . . . . 0.0 110.132 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.539 ' CG ' ' HA ' ' A' ' 90' ' ' HIS . 3.2 m-30 -86.01 -170.7 3.22 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.081 -1.246 . . . . 0.0 109.503 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.5 -48.15 45.88 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.035 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -72.95 -44.69 60.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.472 -1.017 . . . . 0.0 109.163 179.777 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.477 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 6.4 tttp 72.55 -54.1 0.69 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.354 -0.841 . . . . 0.0 110.145 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -62.91 78.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.188 -0.945 . . . . 0.0 109.871 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.454 ' N ' ' O ' ' A' ' 96' ' ' LYS . 71.4 mt -113.46 163.27 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.125 -0.984 . . . . 0.0 109.69 -179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.443 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -140.86 135.38 31.3 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.271 -0.893 . . . . 0.0 109.791 179.784 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.67 ' HB1' HG12 ' A' ' 142' ' ' ILE . . . -79.14 1.29 24.9 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.275 -0.89 . . . . 0.0 109.84 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.525 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -80.45 -26.43 38.34 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.058 -1.026 . . . . 0.0 109.545 179.88 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.525 ' CD1' ' HG3' ' A' ' 101' ' ' GLU . 93.3 m-85 -78.03 -10.33 59.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.185 -0.947 . . . . 0.0 109.703 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.946 ' CE2' HD22 ' A' ' 141' ' ' LEU . 6.5 m-85 -62.51 -60.71 3.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 110.066 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.0 mt-10 -52.54 -55.72 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.203 -0.936 . . . . 0.0 110.004 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.97 -62.42 0.37 Allowed 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.69 1.363 . . . . 0.0 109.768 179.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.954 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.83 -23.38 30.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.36 -0.838 . . . . 0.0 109.314 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.2 -48.17 9.97 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.41 -33.53 74.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.137 -1.213 . . . . 0.0 109.585 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -71.73 -27.86 63.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.216 -0.928 . . . . 0.0 109.5 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 1.008 HD22 ' OH ' ' A' ' 134' ' ' TYR . 2.2 tt -69.67 -35.6 75.29 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.277 -0.889 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.818 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.6 mt -59.73 -34.17 72.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 t -68.72 -33.03 73.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.913 . . . . 0.0 109.669 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.661 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -76.37 -39.93 52.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.635 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.498 ' HE2' ' CZ3' ' A' ' 130' ' ' TRP . 4.2 mtt -50.06 -38.58 38.72 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.564 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.447 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.17 -22.52 6.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.194 -0.941 . . . . 0.0 109.561 179.779 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.424 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 22.2 m170 -57.52 -47.75 81.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.4 ttt85 -73.06 -61.93 1.64 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.723 HD11 ' SD ' ' A' ' 122' ' ' MET . 14.6 pt -97.27 55.88 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.331 -0.855 . . . . 0.0 109.63 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -62.17 -14.44 46.97 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -107.73 -27.44 5.18 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 6.2 mttm -93.92 -13.44 27.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -1.212 . . . . 0.0 110.146 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.723 ' SD ' HD11 ' A' ' 118' ' ' ILE . 4.0 tpt -71.99 98.23 2.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.509 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.799 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 2.4 p-10 -104.6 169.16 8.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.447 -0.783 . . . . 0.0 109.514 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -49.16 -51.75 30.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.25 -0.906 . . . . 0.0 109.625 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.799 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -53.03 -26.72 16.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.21 -0.931 . . . . 0.0 109.441 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -75.69 -58.01 3.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.291 -0.881 . . . . 0.0 109.566 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.564 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.1 ptpt -63.68 -29.29 70.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.147 -0.97 . . . . 0.0 109.286 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.47 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 43.0 t0 -77.32 -43.04 34.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.411 -0.806 . . . . 0.0 109.407 179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.767 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -65.34 -39.61 92.59 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 109.212 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.956 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.4 m0 -77.52 -28.32 52.01 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.353 -0.842 . . . . 0.0 108.986 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.564 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -66.34 -30.29 70.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.323 -0.861 . . . . 0.0 109.026 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.439 ' O ' HD21 ' A' ' 2' ' ' LEU . . . -86.45 -34.06 20.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.393 -0.817 . . . . 0.0 109.167 179.594 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.463 ' HA ' HD21 ' A' ' 2' ' ' LEU . . . -74.07 -36.78 64.34 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.441 -0.787 . . . . 0.0 109.13 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 1.008 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.9 OUTLIER -57.65 -23.74 52.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.386 -0.821 . . . . 0.0 109.39 179.728 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.4 -32.01 42.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.281 -0.887 . . . . 0.0 109.547 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -80.86 -35.38 32.77 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 0.0 109.703 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.599 HD13 HG23 ' A' ' 66' ' ' ILE . 45.5 mt -74.62 -54.21 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.206 -0.934 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 12.2 p -71.0 -40.98 71.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 109.577 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.496 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -57.49 -47.53 87.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.86 -26.27 9.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.244 -1.151 . . . . 0.0 109.586 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.946 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.5 tt -84.98 -18.62 33.94 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.773 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.67 HG12 ' HB1' ' A' ' 100' ' ' ALA . 76.5 mt -83.04 7.0 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 110.108 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.1 m -101.81 -27.6 12.92 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.056 -1.028 . . . . 0.0 109.62 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.559 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -100.07 -25.03 9.22 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.526 HD13 HD21 ' A' ' 141' ' ' LEU . 0.5 OUTLIER -63.85 -142.12 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.287 -1.125 . . . . 0.0 109.561 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.484 ' H ' HD23 ' A' ' 145' ' ' LEU . 3.3 mt-30 55.73 53.67 9.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.141 -0.974 . . . . 0.0 110.283 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.515 ' HA ' ' HG3' ' A' ' 91' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.016 -1.052 . . . . 0.0 109.607 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.854 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.65 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.412 ' C ' HD22 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.573 HD22 ' N ' ' A' ' 2' ' ' LEU . 4.4 mm? -95.21 166.96 11.65 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.264 -1.139 . . . . 0.0 109.71 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.434 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -99.49 167.39 10.64 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 109.638 179.767 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.29 -22.91 65.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.287 -0.883 . . . . 0.0 109.667 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.956 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -88.58 -48.08 7.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.233 -0.917 . . . . 0.0 109.613 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.553 ' O ' HG23 ' A' ' 10' ' ' VAL . 96.4 mt-30 -66.62 -54.02 27.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.794 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.489 ' CG ' ' HB2' ' A' ' 73' ' ' LEU . 1.2 ttp180 -50.06 -32.44 15.57 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.207 -0.933 . . . . 0.0 109.571 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 30.9 mm-40 -75.83 -43.85 43.93 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.332 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.956 HG23 ' O ' ' A' ' 5' ' ' ALA . 24.5 t -61.67 -32.8 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.93 HG12 HG13 ' A' ' 70' ' ' VAL . 91.6 t -62.18 -45.63 98.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.285 -0.884 . . . . 0.0 109.4 179.698 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.6 -15.24 60.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 0.0 109.686 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -84.34 -24.04 29.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.188 -0.945 . . . . 0.0 109.694 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 35.5 p -100.5 -12.54 19.22 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.868 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.77 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -89.83 -27.65 19.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.102 -0.999 . . . . 0.0 109.81 -179.853 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 11.7 mtpp -74.74 -9.87 58.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.167 -0.958 . . . . 0.0 109.708 179.592 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.582 ' HB3' HG21 ' A' ' 118' ' ' ILE . 0.3 OUTLIER -102.31 -61.29 1.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.096 -1.003 . . . . 0.0 109.59 179.925 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.947 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.5 mt -57.74 -41.1 78.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.209 -0.932 . . . . 0.0 109.625 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.795 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -101.39 34.48 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.75 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.69 -69.11 1.32 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 47.2 p -113.94 -25.3 8.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.284 -1.127 . . . . 0.0 109.518 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 21' ' ' ASP . 17.7 p-10 -80.65 -19.3 45.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.679 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.795 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 20.3 t30 60.32 21.34 10.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.262 -0.899 . . . . 0.0 109.641 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.81 20.39 31.47 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -65.5 -50.88 63.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.218 -1.166 . . . . 0.0 109.532 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.94 -5.0 86.58 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.695 HG21 ' CG2' ' A' ' 17' ' ' ILE . 43.5 t -87.47 -33.08 6.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.996 -1.296 . . . . 0.0 109.724 -179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -81.97 -41.01 9.87 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.469 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.3 ptpt -63.67 -31.87 73.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -1.18 . . . . 0.0 109.826 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.45 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 15.8 pt-20 -89.58 -14.71 34.43 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.167 -0.958 . . . . 0.0 110.083 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.674 ' SG ' HD12 ' A' ' 110' ' ' LEU . 42.2 t -91.58 -63.66 1.22 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.137 -0.977 . . . . 0.0 109.999 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.518 ' CD2' ' HA2' ' A' ' 59' ' ' GLY . 14.3 m-85 -54.19 -37.34 64.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.226 -0.922 . . . . 0.0 109.907 -179.53 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.807 ' OG1' HG11 ' A' ' 55' ' ' VAL . 8.7 m -53.18 -32.88 50.15 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.051 -1.031 . . . . 0.0 108.907 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.435 ' HG2' ' O ' ' A' ' 29' ' ' GLU . 3.9 mmtt -76.14 -47.48 24.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.34 -0.85 . . . . 0.0 109.067 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.574 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.1 t80 -61.41 -49.64 76.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.854 ' CD1' HG22 ' A' ' 55' ' ' VAL . 70.2 mt -54.83 -44.22 73.68 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.129 -0.982 . . . . 0.0 109.401 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.532 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 82.7 p -73.48 -66.09 0.74 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.366 -0.834 . . . . 0.0 109.982 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.642 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -49.61 -30.08 8.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.205 -0.934 . . . . 0.0 109.702 -179.724 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.642 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 23.0 m-70 -123.63 110.12 14.6 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.264 -0.898 . . . . 0.0 109.785 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.9 m170 -88.93 -18.66 27.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.502 -0.748 . . . . 0.0 109.31 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.8 p-10 -66.51 -21.1 66.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.264 -0.897 . . . . 0.0 109.227 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.536 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 88.6 mmm -107.91 -23.94 11.84 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 109.75 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.37 -34.29 15.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.865 -1.147 . . . . 0.0 109.136 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.67 -36.75 70.73 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.354 -0.841 . . . . 0.0 109.118 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.004 HG13 ' ND2' ' A' ' 95' ' ' ASN . 20.4 t -58.41 -63.7 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.034 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.613 ' CE1' ' C1B' ' A' ' 148' ' ' HEM . 84.4 m-85 -56.42 -27.59 56.97 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.319 -0.863 . . . . 0.0 109.1 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 42' ' ' ALA . . . 108.99 -138.45 14.76 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 1.7 m-85 61.04 170.65 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.105 -1.232 . . . . 0.0 109.83 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.4 t -115.01 25.79 10.63 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.67 -163.94 27.51 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.532 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -89.25 16.36 7.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.165 -1.197 . . . . 0.0 109.901 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.99 35.29 4.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.116 -0.99 . . . . 0.0 109.691 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.463 ' CB ' ' HB3' ' A' ' 47' ' ' PHE . 2.8 t70 -114.43 137.37 22.58 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.616 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -62.75 -24.46 74.65 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 O-C-N 123.92 1.484 . . . . 0.0 110.067 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.538 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.46 -40.7 47.22 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.854 HG22 ' CD1' ' A' ' 35' ' ' LEU . 67.3 t -49.95 -34.03 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -1.143 . . . . 0.0 109.474 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.514 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -75.72 -20.66 58.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 109.427 179.777 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -86.37 -46.81 9.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.639 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.774 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.9 OUTLIER -64.59 -62.76 1.39 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.204 -0.935 . . . . 0.0 109.581 -179.984 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.518 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.97 -47.44 40.14 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.514 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -57.41 -40.21 77.83 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.185 -1.185 . . . . 0.0 109.587 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -74.55 -24.37 58.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.774 HG23 ' O ' ' A' ' 58' ' ' LEU . 51.2 t -81.9 -49.14 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.259 -0.901 . . . . 0.0 109.641 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.8 HD21 HD11 ' A' ' 110' ' ' LEU . 2.5 mm? -48.15 -46.6 34.67 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.926 . . . . 0.0 109.751 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -51.8 -50.86 59.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.256 -0.902 . . . . 0.0 109.821 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 33.5 tp60 -48.75 -51.25 29.97 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.087 -1.008 . . . . 0.0 109.577 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.937 ' O ' HG23 ' A' ' 70' ' ' VAL . 96.7 mt -56.46 -30.97 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.223 -0.923 . . . . 0.0 109.043 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.565 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -68.66 -56.9 8.71 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 87.8 t -57.8 -20.71 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.247 -1.149 . . . . 0.0 109.243 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.02 -34.1 18.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.675 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.937 HG23 ' O ' ' A' ' 66' ' ' ILE . 55.1 t -60.84 -15.89 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.202 -0.936 . . . . 0.0 109.887 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.501 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 23.9 m -91.55 16.14 11.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.182 -0.949 . . . . 0.0 110.29 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 71' ' ' SER . 7.9 m-70 -160.95 40.82 0.16 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.926 -1.109 . . . . 0.0 110.37 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.871 HD11 HG11 ' A' ' 10' ' ' VAL . 22.7 mt -68.69 -37.67 79.72 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.013 -1.055 . . . . 0.0 109.479 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.63 -26.22 36.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -103.64 96.64 6.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -1.112 . . . . 0.0 109.583 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.83 33.47 1.67 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.204 -0.935 . . . . 0.0 109.518 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -82.35 -24.97 52.93 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.466 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 5.2 ttpt -133.14 -37.62 0.98 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.251 -1.147 . . . . 0.0 109.967 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.46 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 14.7 ttp -47.84 -48.19 31.06 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.19 -0.944 . . . . 0.0 109.694 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.45 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.5 t -70.39 -23.1 24.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.222 -0.924 . . . . 0.0 109.284 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -70.76 -37.03 73.37 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.214 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.443 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.0 OUTLIER -81.39 -49.12 11.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.29 -0.881 . . . . 0.0 109.264 179.681 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.564 ' CE ' HD12 ' A' ' 141' ' ' LEU . 3.1 mtp -59.47 -46.17 89.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.233 -0.917 . . . . 0.0 109.103 179.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.659 ' O ' HG23 ' A' ' 88' ' ' VAL . 3.8 tptp -53.49 -33.4 54.2 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 108.915 179.426 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.423 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -70.9 -33.43 70.55 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.401 -0.812 . . . . 0.0 109.248 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.723 ' CG1' HD11 ' A' ' 141' ' ' LEU . 44.4 t -62.66 -52.25 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 109.237 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -52.35 -42.55 56.71 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 84' ' ' LYS . 95.7 t -51.8 -26.6 7.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.346 -1.091 . . . . 0.0 109.231 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.444 ' HB2' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -80.91 -24.76 38.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.273 -0.892 . . . . 0.0 108.848 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.738 ' O ' HD12 ' A' ' 98' ' ' ILE . 41.4 m80 -82.1 -4.67 57.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.528 -0.732 . . . . 0.0 109.894 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HD2' ' HA ' ' A' ' 88' ' ' VAL . 8.9 ptmm? -81.8 -8.64 59.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.796 -1.19 . . . . 0.0 110.357 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -164.33 59.42 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.402 -1.38 . . . . 0.0 110.153 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.755 ' HD2' HD11 ' A' ' 98' ' ' ILE . 0.9 OUTLIER -84.21 -163.5 0.8 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.267 . . . . 0.0 109.25 179.021 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.9 -26.48 74.31 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 -179.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.004 ' ND2' HG13 ' A' ' 44' ' ' VAL . 18.7 p-10 -91.79 -32.88 15.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.062 -1.258 . . . . 0.0 109.933 -179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.441 ' O ' ' CD2' ' A' ' 97' ' ' HIS . 0.0 OUTLIER 56.85 30.93 18.72 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.129 -0.982 . . . . 0.0 109.649 179.894 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.441 ' CD2' ' O ' ' A' ' 96' ' ' LYS . 38.2 m170 -137.44 47.44 2.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.159 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.755 HD11 ' HD2' ' A' ' 93' ' ' TYR . 59.7 mt -89.9 159.78 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.286 -0.884 . . . . 0.0 110.576 -179.172 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.494 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -152.27 142.17 22.08 Favored 'General case' 0 N--CA 1.487 1.424 0 CA-C-O 121.636 0.732 . . . . 0.0 109.684 179.946 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.749 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -78.98 -3.02 42.93 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.647 -0.658 . . . . 0.0 109.62 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -73.11 -33.19 65.42 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.975 -1.078 . . . . 0.0 109.488 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.564 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 85.9 m-85 -78.46 -15.58 58.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.244 -0.91 . . . . 0.0 110.125 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.764 ' CE2' HMC1 ' A' ' 148' ' ' HEM . 4.6 m-85 -59.66 -63.4 1.31 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.163 -0.961 . . . . 0.0 110.248 -179.575 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.484 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.4 mt-10 -45.49 -58.43 5.95 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.427 -0.796 . . . . 0.0 110.797 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.564 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.2 Cg_endo -59.99 -46.1 20.89 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.748 1.394 . . . . 0.0 109.923 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.919 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -67.11 -20.02 65.72 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 109.25 179.709 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 103' ' ' PHE . . . -84.47 -47.38 5.45 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.55 -28.26 66.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -1.114 . . . . 0.0 109.354 179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -71.89 -34.74 69.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.3 -0.875 . . . . 0.0 109.482 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.977 HD13 ' OH ' ' A' ' 134' ' ' TYR . 2.5 tt -65.38 -34.43 78.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.198 -0.938 . . . . 0.0 109.425 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.684 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.2 mt -58.51 -35.48 72.31 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.097 -1.002 . . . . 0.0 109.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.421 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 21.2 t -70.09 -26.31 63.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.429 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.502 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -85.93 -33.15 21.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.679 ' SD ' HD23 ' A' ' 110' ' ' LEU . 0.8 OUTLIER -53.87 -44.26 70.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.293 -0.879 . . . . 0.0 109.995 -179.675 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.452 ' O ' ' N ' ' A' ' 119' ' ' GLY . 8.1 pt-20 -51.77 -23.01 4.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.23 -0.919 . . . . 0.0 109.818 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.502 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 20.9 m170 -48.97 -41.44 34.17 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.165 -0.959 . . . . 0.0 109.71 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.3 ttt85 -83.48 -55.77 4.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.432 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.582 HG21 ' HB3' ' A' ' 16' ' ' ASP . 3.9 pt -106.64 59.23 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.302 -0.874 . . . . 0.0 109.558 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -67.48 -29.29 73.94 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.75 -18.2 56.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 13.1 mttt -105.04 -20.36 13.55 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.067 -1.255 . . . . 0.0 110.102 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.412 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -73.01 80.99 1.21 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.421 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.541 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.2 p30 -82.29 -162.17 0.53 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -0.853 . . . . 0.0 109.706 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.41 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -69.13 -43.13 74.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.469 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.541 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -60.76 -32.25 71.56 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.171 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -68.42 -53.03 26.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.462 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.473 ' HG3' ' N ' ' A' ' 128' ' ' ASP . 17.3 ptpt -70.45 -29.03 65.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.193 -0.942 . . . . 0.0 109.379 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.473 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 24.2 t0 -80.42 -40.72 25.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.329 -0.857 . . . . 0.0 109.656 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -61.66 -42.91 99.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.258 -0.901 . . . . 0.0 109.327 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.947 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.2 m0 -75.4 -34.24 61.04 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.3 -0.875 . . . . 0.0 108.846 179.671 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.43 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -55.85 -23.48 31.07 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.163 -0.961 . . . . 0.0 108.764 178.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -92.39 -46.28 7.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.43 -0.794 . . . . 0.0 109.308 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -72.34 -54.08 10.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.263 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.977 ' OH ' HD13 ' A' ' 110' ' ' LEU . 1.3 t80 -49.78 -30.46 9.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.215 179.608 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -74.61 -38.33 62.6 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.309 -0.869 . . . . 0.0 108.877 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.38 -31.69 48.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.399 -0.813 . . . . 0.0 109.27 179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.73 HD13 HG23 ' A' ' 66' ' ' ILE . 54.9 mt -66.8 -60.53 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.258 -0.901 . . . . 0.0 108.909 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.421 ' O ' HG12 ' A' ' 142' ' ' ILE . 26.4 p -66.98 -18.09 65.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -0.795 . . . . 0.0 109.765 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -75.31 -45.81 17.79 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -62.13 -22.0 65.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.222 -1.163 . . . . 0.0 109.808 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.723 HD11 ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -77.87 -13.9 59.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 0.0 109.957 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.763 HG22 HE22 ' A' ' 146' ' ' GLN . 37.1 mm -79.68 -12.99 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.438 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 27.5 m -68.54 -64.67 0.82 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.103 -0.998 . . . . 0.0 109.733 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.56 -11.28 68.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.821 HD23 ' N ' ' A' ' 146' ' ' GLN . 9.7 tt -86.27 173.71 9.57 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.036 -1.273 . . . . 0.0 109.301 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.821 ' N ' HD23 ' A' ' 145' ' ' LEU . 0.0 OUTLIER 63.36 29.15 15.69 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.684 -0.635 . . . . 0.0 110.226 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.428 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 9.9 p . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.787 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.764 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.628 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.582 HD21 ' O ' ' A' ' 132' ' ' ALA . 4.1 mm? 60.02 141.71 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.627 -0.925 . . . . 0.0 110.153 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.437 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -130.71 168.75 16.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.064 -1.023 . . . . 0.0 109.766 179.913 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.73 -38.67 72.69 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -0.891 . . . . 0.0 109.695 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.964 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -69.29 -56.55 7.21 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.27 -0.894 . . . . 0.0 109.73 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.665 ' O ' HG23 ' A' ' 10' ' ' VAL . 75.8 mt-30 -58.38 -55.74 31.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 109.661 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.825 ' HG2' HD12 ' A' ' 73' ' ' LEU . 3.0 ttp180 -49.11 -37.9 23.1 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.286 -0.884 . . . . 0.0 109.625 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.4 tp60 -74.28 -40.59 62.21 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.216 -0.928 . . . . 0.0 109.381 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.964 HG23 ' O ' ' A' ' 5' ' ' ALA . 39.5 t -65.0 -24.85 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.89 . . . . 0.0 109.449 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 1.052 HG12 HG13 ' A' ' 70' ' ' VAL . 97.4 t -70.02 -34.72 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.236 -0.915 . . . . 0.0 109.559 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.09 -13.16 59.5 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.259 -0.901 . . . . 0.0 109.913 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.74 -19.6 22.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.14 -0.975 . . . . 0.0 109.845 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.43 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.5 p -101.29 -14.83 17.49 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.126 -0.984 . . . . 0.0 109.956 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.717 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -87.03 -32.42 20.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.687 -179.776 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.2 mtpt -69.71 -11.96 61.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.215 -0.928 . . . . 0.0 109.606 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.9 m-20 -99.24 -60.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.118 -0.989 . . . . 0.0 109.638 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.918 HD12 ' CH2' ' A' ' 130' ' ' TRP . 66.3 mt -61.17 -41.15 88.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.262 -0.899 . . . . 0.0 109.538 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.681 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -96.34 31.67 2.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.293 -0.879 . . . . 0.0 109.511 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.48 -69.9 1.11 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 12.6 p -110.29 -32.66 6.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -1.163 . . . . 0.0 109.613 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.65 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 5.0 p-10 -74.93 -18.98 60.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.905 . . . . 0.0 109.638 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.681 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.6 t30 59.39 21.08 9.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 109.597 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.483 ' O ' HD13 ' A' ' 63' ' ' LEU . . . 97.89 34.68 5.36 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.65 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -85.36 -56.34 3.57 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.229 -1.16 . . . . 0.0 109.576 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -66.53 -14.74 62.87 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.777 HG12 HD11 ' A' ' 63' ' ' LEU . 37.8 t -89.18 -11.59 10.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -1.185 . . . . 0.0 109.942 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.506 ' CA ' ' CD1' ' A' ' 63' ' ' LEU . . . -100.06 -41.77 2.76 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.482 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 0.0 OUTLIER -74.74 -22.15 58.96 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.119 -1.224 . . . . 0.0 110.003 -179.512 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.447 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 22.3 pt-20 -92.38 -21.96 19.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.116 -0.99 . . . . 0.0 109.701 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.4 t -87.18 -68.0 0.78 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.254 -0.903 . . . . 0.0 110.083 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.534 ' HZ ' HG11 ' A' ' 62' ' ' VAL . 29.2 m-85 -46.62 -33.43 4.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.292 -0.88 . . . . 0.0 110.246 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.666 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -53.79 -52.11 61.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.067 -1.02 . . . . 0.0 109.384 179.699 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 7.2 mttt -65.18 -46.03 82.45 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.281 -0.887 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.714 ' CG ' HD23 ' A' ' 106' ' ' LEU . 9.4 t80 -49.53 -49.43 46.09 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.228 -0.92 . . . . 0.0 109.544 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.764 ' CD1' HG22 ' A' ' 55' ' ' VAL . 14.1 mt -57.99 -46.75 84.71 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.491 ' O ' ' CD2' ' A' ' 39' ' ' HIS . 0.4 OUTLIER -64.56 -62.15 1.76 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.923 . . . . 0.0 109.525 179.907 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.631 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -53.48 -27.15 23.66 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.222 -0.924 . . . . 0.0 109.524 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.631 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 18.9 m-70 -120.49 97.27 5.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.491 ' CD2' ' O ' ' A' ' 36' ' ' SER . 64.4 m170 -83.08 4.15 27.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.016 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 17.6 p-10 -94.95 -13.4 25.38 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.081 -1.012 . . . . 0.0 109.942 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.438 ' O ' ' N ' ' A' ' 44' ' ' VAL . 98.0 mmm -112.85 -19.25 12.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.086 -1.009 . . . . 0.0 109.966 -179.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.46 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -47.64 -40.34 19.44 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.181 -0.949 . . . . 0.0 109.859 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.154 -0.966 . . . . 0.0 109.509 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.012 HG13 ' ND2' ' A' ' 95' ' ' ASN . 45.9 t -81.2 -34.64 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.293 -0.879 . . . . 0.0 109.557 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.56 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 24.0 m-85 -76.88 -11.66 59.85 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 110.124 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.4 25.47 25.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.522 ' CD2' ' HB3' ' A' ' 45' ' ' PHE . 14.0 m-85 -125.58 168.64 13.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.912 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.99 -17.39 14.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.416 -0.802 . . . . 0.0 109.202 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.98 -161.6 23.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -96.99 28.34 3.58 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.325 -1.103 . . . . 0.0 109.713 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 72.1 p -118.02 -16.36 9.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.257 -0.902 . . . . 0.0 109.795 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.1 p-10 -73.07 142.74 82.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.213 -0.93 . . . . 0.0 109.706 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -72.89 -17.38 25.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.976 1.514 . . . . 0.0 110.19 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.5 -38.54 35.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.764 HG22 ' CD1' ' A' ' 35' ' ' LEU . 63.2 t -51.09 -35.92 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.449 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -71.15 -7.15 44.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.27 -0.894 . . . . 0.0 109.691 179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.76 -28.26 18.38 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.065 -1.022 . . . . 0.0 109.648 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.968 ' O ' HG23 ' A' ' 62' ' ' VAL . 11.5 mt -88.73 -63.74 1.25 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.071 -1.018 . . . . 0.0 109.681 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.521 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -50.29 -46.99 43.79 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.3 -24.46 19.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.235 -1.156 . . . . 0.0 109.662 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.26 -23.79 12.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.717 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.968 HG23 ' O ' ' A' ' 58' ' ' LEU . 43.4 t -73.23 -56.72 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.275 -0.891 . . . . 0.0 109.983 -179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.777 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -47.22 -41.13 17.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.141 -0.974 . . . . 0.0 109.851 -179.927 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.98 -43.19 50.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.458 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 7.2 tp-100 -62.69 -41.5 99.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.083 -1.011 . . . . 0.0 109.195 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.909 ' O ' HG23 ' A' ' 70' ' ' VAL . 63.0 mt -57.95 -36.18 55.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.278 -0.889 . . . . 0.0 108.83 179.317 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.55 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.88 -59.63 8.86 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 108.689 -1.765 . . . . 0.0 108.689 179.294 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 74.3 t -54.35 -26.16 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.276 -1.132 . . . . 0.0 109.04 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.94 -28.88 25.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.41 -0.806 . . . . 0.0 109.594 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.052 HG13 HG12 ' A' ' 10' ' ' VAL . 52.5 t -68.8 -9.64 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.499 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 18.3 t -93.2 33.57 1.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.007 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.499 ' CG ' ' O ' ' A' ' 71' ' ' SER . 9.1 m-70 -160.25 -87.41 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.189 -0.944 . . . . 0.0 109.731 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.825 HD12 ' HG2' ' A' ' 7' ' ' ARG . 24.3 mt 63.33 -72.07 0.05 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.482 -0.762 . . . . 0.0 110.037 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -75.97 -20.67 77.5 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.208 -1.557 . . . . 0.0 109.208 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -107.12 95.95 6.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.239 -1.154 . . . . 0.0 109.635 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -92.76 35.3 1.04 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.531 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.09 -18.1 63.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.599 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 12.5 ttpp -140.54 -39.3 0.43 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.034 -1.274 . . . . 0.0 110.099 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 64.4 ttp -47.78 -56.32 7.66 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.148 -0.97 . . . . 0.0 109.683 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.404 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 98.0 t -60.1 -18.19 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.24 -0.912 . . . . 0.0 109.421 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.599 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -80.8 -21.28 41.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.234 -0.916 . . . . 0.0 109.295 179.714 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.42 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.0 OUTLIER -91.91 -47.39 7.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.544 179.864 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.498 ' HE1' HD12 ' A' ' 141' ' ' LEU . 99.2 mmm -62.15 -41.08 97.93 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.144 -0.972 . . . . 0.0 109.027 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.863 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.4 OUTLIER -52.98 -32.61 47.17 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.052 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.424 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -76.31 -33.25 59.03 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.077 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.558 HG12 HD11 ' A' ' 141' ' ' LEU . 71.3 t -65.05 -53.12 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.076 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.419 ' HA3' ' HB2' ' A' ' 145' ' ' LEU . . . -53.51 -39.84 60.93 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.863 HG23 ' O ' ' A' ' 84' ' ' LYS . 85.7 t -53.98 -28.34 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -1.113 . . . . 0.0 109.266 179.705 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.8 mmt180 -75.19 -48.9 21.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 0.0 108.959 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.605 ' O ' HD12 ' A' ' 98' ' ' ILE . 54.1 m80 -57.64 -22.37 45.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.306 -0.871 . . . . 0.0 108.912 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.457 ' CG ' ' HA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -72.4 -9.82 59.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.414 -0.804 . . . . 0.0 109.941 179.86 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.76 50.39 0.75 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.6 m-30 -92.1 -174.11 3.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -1.15 . . . . 0.0 109.512 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.89 -28.48 41.86 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.012 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -83.76 -46.17 12.54 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.579 -0.953 . . . . 0.0 108.923 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.6 mtpt 72.72 -49.96 0.7 Allowed 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.56 -0.713 . . . . 0.0 110.76 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.3 m170 -66.46 63.14 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.01 -1.056 . . . . 0.0 110.596 -179.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.605 HD12 ' O ' ' A' ' 90' ' ' HIS . 96.7 mt -94.08 159.15 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.089 -1.007 . . . . 0.0 109.235 179.431 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.441 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -139.63 141.78 37.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.17 -0.956 . . . . 0.0 109.852 -179.929 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -84.86 8.24 18.12 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.855 . . . . 0.0 109.685 179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -85.09 -29.9 24.5 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.151 -0.968 . . . . 0.0 108.697 179.784 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.468 ' CB ' HBB1 ' A' ' 148' ' ' HEM . 93.5 m-85 -79.09 -17.01 55.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.32 -0.862 . . . . 0.0 109.636 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.796 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.0 m-85 -56.6 -60.14 3.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.23 -0.919 . . . . 0.0 110.169 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.499 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 3.4 mt-10 -52.82 -57.41 16.15 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.148 -0.97 . . . . 0.0 110.066 -179.453 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.499 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 34.7 Cg_exo -48.88 -58.88 1.49 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 O-C-N 123.626 1.329 . . . . 0.0 110.13 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.821 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.94 -28.89 54.64 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.388 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -73.26 -50.12 13.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -64.42 -37.49 87.72 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -1.128 . . . . 0.0 109.503 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 t -68.48 -35.25 77.27 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.326 -0.859 . . . . 0.0 109.576 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.937 HD22 ' OH ' ' A' ' 134' ' ' TYR . 3.8 tt -67.02 -31.57 72.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.939 . . . . 0.0 109.398 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.911 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -61.43 -33.35 73.57 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.161 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.418 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 2.7 t -72.93 -26.77 61.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.282 -0.886 . . . . 0.0 109.398 179.68 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.494 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -85.46 -22.75 28.13 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.487 ' SD ' ' CE3' ' A' ' 130' ' ' TRP . 1.6 mtt -65.0 -36.43 84.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.351 -0.843 . . . . 0.0 109.882 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' N ' ' A' ' 119' ' ' GLY . 12.5 pt-20 -58.53 -18.47 29.73 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.122 -0.986 . . . . 0.0 109.464 179.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.494 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 28.4 m170 -56.04 -36.12 67.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.223 -0.923 . . . . 0.0 109.483 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HD2' HG23 ' A' ' 118' ' ' ILE . 0.1 OUTLIER -89.72 -42.37 11.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.309 -0.87 . . . . 0.0 109.362 179.778 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.478 HG12 HD11 ' A' ' 17' ' ' ILE . 3.1 pt -119.03 57.01 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.317 -0.865 . . . . 0.0 109.473 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -64.57 -18.67 63.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.31 -28.53 8.03 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.462 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.8 mttt -94.44 -17.51 22.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.184 -1.186 . . . . 0.0 109.801 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.455 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -76.54 86.2 3.24 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.109 -0.995 . . . . 0.0 109.371 179.762 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.517 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 8.9 p30 -93.61 -163.2 1.02 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.845 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.456 ' HA ' ' CD ' ' A' ' 127' ' ' LYS . . . -68.44 -44.57 74.64 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -0.856 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.517 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -61.54 -26.06 67.69 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.112 -0.992 . . . . 0.0 109.313 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -77.99 -52.57 8.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.314 -0.866 . . . . 0.0 109.792 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.456 ' CD ' ' HA ' ' A' ' 124' ' ' ALA . 9.7 ptmm? -71.74 -25.69 62.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.215 -0.928 . . . . 0.0 109.906 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -84.32 -36.32 22.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.112 -0.992 . . . . 0.0 109.745 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -69.95 -43.18 72.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.236 -0.915 . . . . 0.0 109.361 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.918 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.5 m0 -71.41 -36.72 71.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.281 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.425 ' N ' HD11 ' A' ' 111' ' ' LEU . . . -60.97 -33.9 73.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.119 179.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.582 ' O ' HD21 ' A' ' 2' ' ' LEU . . . -80.66 -30.78 36.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.32 -0.862 . . . . 0.0 109.277 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.528 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -81.13 -40.19 24.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.354 -0.841 . . . . 0.0 109.288 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.937 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.8 OUTLIER -50.26 -34.75 24.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.264 179.642 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.38 -28.26 62.9 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.083 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -83.43 -39.25 20.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.381 -0.824 . . . . 0.0 109.337 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.528 HD12 ' C ' ' A' ' 133' ' ' ALA . 4.6 mt -65.95 -58.25 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.293 -0.879 . . . . 0.0 109.149 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -68.66 -19.7 64.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.403 -0.81 . . . . 0.0 109.63 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -65.96 -57.73 10.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.33 -26.36 3.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 0.0 109.756 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.859 ' O ' HD23 ' A' ' 141' ' ' LEU . 7.5 tt -74.41 -12.47 60.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.97 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.669 ' O ' HG22 ' A' ' 142' ' ' ILE . 75.6 mt -91.37 21.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.089 -1.007 . . . . 0.0 109.763 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.4 t -105.82 -32.87 8.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.167 -0.958 . . . . 0.0 109.691 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -121.46 16.39 9.1 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.541 HD12 ' HB2' ' A' ' 90' ' ' HIS . 4.5 tt -98.71 2.12 46.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.109 -1.23 . . . . 0.0 110.126 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -113.22 68.12 0.67 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.038 -1.039 . . . . 0.0 109.682 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.457 ' HA ' ' CG ' ' A' ' 91' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.65 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.623 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.447 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.588 HD13 HD12 ' A' ' 73' ' ' LEU . 11.6 mt -60.22 163.55 4.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.195 -1.179 . . . . 0.0 109.766 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 p -136.49 -172.55 3.18 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 109.542 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -10.14 59.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.936 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.653 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -107.57 -50.11 3.13 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.142 -0.974 . . . . 0.0 109.547 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.602 ' O ' HG23 ' A' ' 10' ' ' VAL . 82.9 mt-30 -60.14 -44.25 95.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.472 ' CG ' ' HB3' ' A' ' 73' ' ' LEU . 5.6 ttp180 -57.17 -29.27 63.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.506 179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 44.5 tp60 -82.89 -34.26 26.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.373 -0.829 . . . . 0.0 109.45 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.653 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.8 t -67.62 -19.57 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.177 -0.952 . . . . 0.0 109.589 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.703 HG12 HG13 ' A' ' 70' ' ' VAL . 93.0 t -73.82 -47.1 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -0.947 . . . . 0.0 109.627 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.26 -13.98 62.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.935 . . . . 0.0 109.841 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.63 -21.65 20.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.184 -0.948 . . . . 0.0 109.9 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -97.67 -12.76 22.02 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.141 -0.974 . . . . 0.0 110.023 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.564 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.03 -28.06 17.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.037 -1.039 . . . . 0.0 109.726 -179.884 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 37.3 mttp -73.26 -10.92 60.26 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.852 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -104.06 -46.71 4.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.108 -0.995 . . . . 0.0 109.62 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.958 HD12 ' CH2' ' A' ' 130' ' ' TRP . 40.5 mt -70.23 -39.58 77.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.276 -0.89 . . . . 0.0 109.685 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.899 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.1 34.42 2.72 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.552 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.51 -65.47 3.53 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 26.6 p -111.96 -33.67 6.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.236 -1.155 . . . . 0.0 109.714 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.512 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 6.7 p-10 -76.63 -18.3 58.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.739 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.899 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 4.3 t30 57.77 20.47 6.51 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.6 21.52 19.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.512 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.02 -54.3 23.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.299 -1.118 . . . . 0.0 109.566 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.471 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.48 2.02 74.22 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.515 HG21 ' CG2' ' A' ' 17' ' ' ILE . 36.9 t -91.94 -40.31 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.053 -1.263 . . . . 0.0 109.529 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -79.44 -50.54 5.67 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.658 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.473 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 6.4 ptpt -52.7 -30.29 31.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.148 -1.207 . . . . 0.0 109.784 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.473 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.5 pt-20 -91.96 -22.7 19.87 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.139 -0.976 . . . . 0.0 109.847 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 46.4 t -83.14 -65.4 1.01 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.183 -0.948 . . . . 0.0 109.989 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.504 ' O ' HD12 ' A' ' 35' ' ' LEU . 11.3 m-85 -48.46 -29.32 3.98 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.207 -0.933 . . . . 0.0 110.024 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.803 ' OG1' HG11 ' A' ' 55' ' ' VAL . 19.5 m -62.98 -60.95 2.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 109.649 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -50.02 -38.02 35.6 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.583 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.518 ' CD2' HD23 ' A' ' 106' ' ' LEU . 13.2 t80 -69.09 -54.91 12.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.321 -0.862 . . . . 0.0 109.552 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.808 HD13 HG22 ' A' ' 55' ' ' VAL . 12.4 mt -50.57 -44.11 56.62 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -0.878 . . . . 0.0 109.625 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.671 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 18.9 p -65.73 -51.45 59.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.234 -0.916 . . . . 0.0 109.719 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.567 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -67.32 -19.42 65.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.239 -0.913 . . . . 0.0 109.755 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.567 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 27.8 m-70 -124.51 101.33 7.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.955 . . . . 0.0 109.721 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -86.35 3.53 43.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 110.04 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -93.39 -20.37 20.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.032 -1.043 . . . . 0.0 109.534 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.556 ' HE1' ' CD2' ' A' ' 102' ' ' TYR . 88.1 mmm -104.68 -23.29 13.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.244 -0.91 . . . . 0.0 109.703 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.456 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -49.26 -34.14 14.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.096 -1.003 . . . . 0.0 109.614 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -78.12 -22.48 48.81 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.35 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.928 HG13 ' ND2' ' A' ' 95' ' ' ASN . 46.8 t -74.35 -58.3 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -0.868 . . . . 0.0 109.49 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.649 ' CD2' HD21 ' A' ' 35' ' ' LEU . 68.1 m-85 -52.47 -31.21 33.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 109.567 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.62 2.89 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.542 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.02 166.96 14.84 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.304 -1.115 . . . . 0.0 109.761 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.0 t -105.36 -21.07 13.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.39 -0.819 . . . . 0.0 109.114 179.308 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -169.43 -163.63 23.79 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.671 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -93.29 29.01 2.02 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.196 -1.179 . . . . 0.0 109.615 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.53 27.78 6.42 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.603 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.625 ' OD2' HG23 ' A' ' 55' ' ' VAL . 7.9 p-10 -116.52 141.09 27.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.88 . . . . 0.0 109.708 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -67.41 -22.58 45.24 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 124.01 1.531 . . . . 0.0 110.135 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -50.83 -38.58 37.67 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.808 HG22 HD13 ' A' ' 35' ' ' LEU . 88.4 t -50.8 -39.7 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -1.092 . . . . 0.0 109.428 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.439 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -72.02 -20.53 61.68 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.306 -0.871 . . . . 0.0 109.256 179.572 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -74.3 -37.29 63.69 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.48 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.895 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -85.42 -56.16 3.66 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -0.95 . . . . 0.0 109.555 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -48.52 -49.07 27.54 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -60.41 -39.41 87.29 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -1.174 . . . . 0.0 109.74 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.3 mttt -77.83 -30.26 51.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.274 -0.891 . . . . 0.0 109.646 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.895 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.6 t -76.19 -51.86 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.593 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.456 HD13 HD12 ' A' ' 66' ' ' ILE . 2.1 mm? -48.93 -47.29 43.68 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.66 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.485 ' O ' HG23 ' A' ' 68' ' ' VAL . . . -49.16 -42.95 41.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.455 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 7.4 tp-100 -58.33 -43.66 88.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 109.384 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.871 ' O ' HG23 ' A' ' 70' ' ' VAL . 40.7 mt -59.58 -38.7 76.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.264 -0.898 . . . . 0.0 109.033 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.556 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.44 -53.43 28.76 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.279 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.517 HG11 ' OE2' ' A' ' 82' ' ' GLU . 51.8 t -54.06 -31.16 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.317 -1.108 . . . . 0.0 108.962 179.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.407 ' O ' ' CD2' ' A' ' 73' ' ' LEU . . . -82.35 -31.46 29.79 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.385 -0.822 . . . . 0.0 109.27 179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.871 HG23 ' O ' ' A' ' 66' ' ' ILE . 52.1 t -69.96 -15.3 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.332 -0.855 . . . . 0.0 109.629 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.6 m -85.21 10.86 11.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.039 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.528 ' O ' ' N ' ' A' ' 74' ' ' GLY . 15.1 m-70 -126.27 -72.96 0.63 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.07 -1.019 . . . . 0.0 109.685 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.588 HD12 HD13 ' A' ' 2' ' ' LEU . 3.7 mm? 42.73 -88.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.848 -0.533 . . . . 0.0 110.642 179.669 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -50.29 -27.06 10.36 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -115.15 86.75 2.51 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.339 -1.094 . . . . 0.0 109.406 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.457 ' HA ' ' HB3' ' A' ' 79' ' ' MET . 0.6 OUTLIER -90.95 20.2 5.03 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.774 -179.883 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.77 -28.44 73.5 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.468 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 17.9 ttpp -123.09 -29.96 3.82 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.181 -1.187 . . . . 0.0 110.083 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.457 ' HB3' ' HA ' ' A' ' 76' ' ' GLU . 10.7 ttp -47.76 -57.99 4.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.154 -0.966 . . . . 0.0 109.672 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.429 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 99.0 t -62.9 -22.72 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.284 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.468 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -77.43 -21.04 53.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.225 -0.922 . . . . 0.0 109.291 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.517 ' OE2' HG11 ' A' ' 68' ' ' VAL . 27.0 tt0 -90.06 -49.18 6.73 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.331 -0.856 . . . . 0.0 109.529 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.602 ' HE1' HD12 ' A' ' 141' ' ' LEU . 93.6 mmm -60.9 -40.28 92.5 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.125 -0.985 . . . . 0.0 109.008 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.744 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.3 OUTLIER -53.04 -31.22 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.243 -0.911 . . . . 0.0 108.556 179.175 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.418 ' O ' ' HB ' ' A' ' 88' ' ' VAL . . . -75.79 -31.36 59.44 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.201 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.594 HG12 HD11 ' A' ' 141' ' ' LEU . 53.9 t -65.37 -50.33 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.096 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.559 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -54.43 -41.95 73.75 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.744 HG23 ' O ' ' A' ' 84' ' ' LYS . 88.2 t -51.36 -25.5 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.333 -1.098 . . . . 0.0 109.021 179.415 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.452 ' HB3' ' OH ' ' A' ' 93' ' ' TYR . 23.9 mmt180 -78.35 -33.33 49.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.364 -0.835 . . . . 0.0 108.904 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.651 ' HB2' HD12 ' A' ' 145' ' ' LEU . 30.9 m80 -80.86 4.7 18.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.398 -0.813 . . . . 0.0 109.611 179.253 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.497 ' CD ' ' HA ' ' A' ' 147' ' ' SER . 5.8 ttpp -88.63 -10.24 49.3 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.096 -1.003 . . . . 0.0 110.137 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -160.42 43.95 0.42 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.014 -1.565 . . . . 0.0 111.045 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.542 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.6 m-85 -75.17 -165.18 0.37 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.68 -1.483 . . . . 0.0 109.195 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.3 -36.75 55.23 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.42 -1.872 . . . . 0.0 108.42 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.928 ' ND2' HG13 ' A' ' 44' ' ' VAL . 1.7 t30 -72.16 -58.51 3.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.574 -0.956 . . . . 0.0 109.07 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.485 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 1.9 tttp 76.5 -15.67 0.7 Allowed 'General case' 0 N--CA 1.506 2.358 0 O-C-N 121.637 -0.664 . . . . 0.0 111.391 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.435 ' O ' ' CE ' ' A' ' 99' ' ' LYS . 65.9 m170 -98.73 44.01 1.04 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.598 -1.314 . . . . 0.0 109.119 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.527 HD12 ' O ' ' A' ' 90' ' ' HIS . 71.6 mt -75.22 159.04 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.331 -0.856 . . . . 0.0 109.878 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.451 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 1.0 OUTLIER -142.49 141.98 32.22 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.377 -0.827 . . . . 0.0 109.948 -179.971 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.36 2.15 26.02 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.468 -0.77 . . . . 0.0 109.565 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.457 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mt-10 -77.61 -34.53 53.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 109.55 179.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.556 ' CD2' ' HE1' ' A' ' 41' ' ' MET . 61.6 m-85 -80.42 -0.05 35.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.37 -0.831 . . . . 0.0 110.361 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.458 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.0 m-85 -70.48 -55.37 9.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.012 -1.055 . . . . 0.0 109.75 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.486 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 2.2 tt0 -59.61 -52.11 76.31 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.185 -0.947 . . . . 0.0 109.746 -179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.486 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.3 Cg_exo -54.32 -56.13 2.78 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 123.819 1.431 . . . . 0.0 109.843 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.734 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -55.31 -31.12 61.4 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.418 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' O ' ' CB ' ' A' ' 110' ' ' LEU . . . -76.06 -48.09 10.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.59 10.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.263 -1.139 . . . . 0.0 109.421 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.9 t -55.19 -21.51 14.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.271 -0.893 . . . . 0.0 109.298 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.45 ' CB ' ' O ' ' A' ' 107' ' ' GLY . 1.0 OUTLIER -69.27 -48.84 60.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.329 -0.857 . . . . 0.0 109.532 179.88 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.631 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.5 mt -55.04 -34.66 63.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.098 -1.001 . . . . 0.0 109.159 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.15 -31.67 70.49 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.888 . . . . 0.0 109.324 179.657 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.497 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -81.43 -38.41 26.52 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.409 179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.468 ' SD ' HG21 ' A' ' 17' ' ' ILE . 5.5 mmt -50.38 -45.03 55.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.234 -0.916 . . . . 0.0 109.518 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -49.66 -24.71 2.37 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.888 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.497 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 18.8 m170 -58.49 -50.87 72.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.958 . . . . 0.0 109.495 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.479 ' HD2' HG23 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.56 -52.43 38.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.253 -0.904 . . . . 0.0 109.474 179.898 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 6.1 pt -116.64 65.37 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.25 -0.906 . . . . 0.0 109.707 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -66.48 -10.4 53.61 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -106.28 -39.55 2.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.507 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 8.7 mmmt -82.24 -25.75 33.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.029 -1.277 . . . . 0.0 109.97 -179.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.437 ' HB2' HG13 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.55 84.17 0.1 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.997 -1.065 . . . . 0.0 109.164 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.813 HD21 ' HB3' ' A' ' 125' ' ' ALA . 18.7 p-10 -88.15 -171.46 3.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.373 -0.829 . . . . 0.0 109.792 -179.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.419 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -61.05 -45.2 95.75 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.276 -0.89 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.813 ' HB3' HD21 ' A' ' 123' ' ' ASN . . . -60.95 -30.13 70.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.254 -0.904 . . . . 0.0 109.382 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.99 -49.15 54.45 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.921 . . . . 0.0 109.475 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.521 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.7 OUTLIER -72.41 -30.67 64.85 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 109.558 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 25.5 t0 -78.88 -35.15 44.17 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.241 -0.912 . . . . 0.0 109.279 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.442 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -66.59 -47.37 72.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.398 -0.814 . . . . 0.0 109.322 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.958 ' CH2' HD12 ' A' ' 17' ' ' ILE . 13.9 m0 -72.56 -27.38 62.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.163 -0.96 . . . . 0.0 108.716 179.538 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -63.75 -15.12 57.79 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.349 -0.845 . . . . 0.0 108.957 178.743 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -110.98 -29.26 7.98 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.163 -0.96 . . . . 0.0 109.095 179.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.492 ' O ' HD12 ' A' ' 137' ' ' ILE . . . -83.19 -45.46 13.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.436 -0.79 . . . . 0.0 109.559 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.548 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -58.52 -18.58 30.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.892 . . . . 0.0 109.25 179.914 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.548 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -84.35 -33.13 23.92 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.222 -0.924 . . . . 0.0 108.512 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -79.58 -36.42 38.19 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.492 HD12 ' O ' ' A' ' 133' ' ' ALA . 4.1 mt -64.56 -61.44 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.541 ' OG ' HMC2 ' A' ' 148' ' ' HEM . 4.0 t -66.5 -22.4 66.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.583 -0.698 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.96 -52.99 25.23 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -51.16 -24.61 4.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -1.186 . . . . 0.0 109.436 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.715 ' O ' HD23 ' A' ' 141' ' ' LEU . 5.8 tt -74.25 -22.62 59.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.648 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.492 ' O ' HG22 ' A' ' 142' ' ' ILE . 69.4 mt -81.81 6.74 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.177 -0.952 . . . . 0.0 110.193 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.2 t -95.46 -36.13 11.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.005 -1.059 . . . . 0.0 109.71 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -111.15 14.29 28.48 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.651 HD12 ' HB2' ' A' ' 90' ' ' HIS . 4.6 tt -100.12 3.76 44.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.061 -1.258 . . . . 0.0 110.055 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -107.3 65.9 0.66 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.015 -1.053 . . . . 0.0 109.671 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.497 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 4.6 p . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.602 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.578 HMA2 ' CGA' ' A' ' 148' ' ' HEM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.598 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.493 HD22 ' N ' ' A' ' 2' ' ' LEU . 4.5 mm? -76.73 160.6 29.2 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -1.174 . . . . 0.0 109.64 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 p -102.28 -170.15 1.77 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.251 -0.906 . . . . 0.0 109.672 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.53 -30.16 57.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.029 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.73 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -85.08 -44.49 12.96 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.082 -1.011 . . . . 0.0 109.587 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' A' ' 2' ' ' LEU . 37.1 mt-30 -62.37 -57.71 10.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 110.127 -179.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -28.22 5.35 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.011 -1.055 . . . . 0.0 109.6 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.7 tp60 -78.6 -39.83 36.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.423 -0.798 . . . . 0.0 108.924 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 5' ' ' ALA . 90.0 t -66.7 -33.67 64.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.043 179.336 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.919 HG12 HG13 ' A' ' 70' ' ' VAL . 84.0 t -69.31 -47.51 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.432 -0.793 . . . . 0.0 109.372 179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.62 -13.92 62.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.306 -0.871 . . . . 0.0 109.754 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 36.5 t -90.73 -26.09 19.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.144 -0.972 . . . . 0.0 109.791 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.4 p -97.29 -10.24 26.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 110.031 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.653 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -92.48 -19.52 21.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.03 -1.044 . . . . 0.0 109.839 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.3 mtpp -81.94 -11.8 58.7 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.915 . . . . 0.0 109.748 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.403 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.2 OUTLIER -103.49 -55.63 2.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.656 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.973 HD12 ' CH2' ' A' ' 130' ' ' TRP . 61.0 mt -64.36 -36.64 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.609 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.82 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -101.85 33.7 2.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.626 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.4 -85.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.8 p -97.96 -23.94 15.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.301 -1.117 . . . . 0.0 109.678 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.689 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 11.6 p-10 -82.34 -19.88 38.43 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.247 -0.908 . . . . 0.0 109.655 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.82 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 18.5 t30 56.38 25.12 9.15 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.262 -0.899 . . . . 0.0 109.621 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.45 24.94 12.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.689 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -69.91 -52.55 23.71 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.257 -1.143 . . . . 0.0 109.648 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -75.03 -12.98 83.08 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.553 HG21 ' CG2' ' A' ' 17' ' ' ILE . 30.7 t -82.03 -36.05 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.129 -1.218 . . . . 0.0 109.873 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.442 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -78.05 -41.32 18.4 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.477 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 17.4 ptpt -66.1 -29.55 69.89 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.137 -1.214 . . . . 0.0 110.125 -179.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.717 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 22.5 pt-20 -92.5 -20.98 20.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.176 -0.952 . . . . 0.0 109.881 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 40.1 t -82.8 -60.14 2.27 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.522 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 21.0 m-85 -57.5 -32.27 66.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.888 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.691 HG23 HG11 ' A' ' 55' ' ' VAL . 0.1 OUTLIER -52.3 -53.66 41.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.178 -0.951 . . . . 0.0 109.392 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -59.69 -50.59 73.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.309 -0.869 . . . . 0.0 109.562 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.72 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.5 t80 -50.63 -47.26 58.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.738 ' CD1' HG22 ' A' ' 55' ' ' VAL . 17.6 mt -61.14 -45.37 94.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.509 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 29.8 p -67.38 -55.15 14.94 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.224 -0.922 . . . . 0.0 109.817 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.628 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -61.28 -26.53 67.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.189 -0.945 . . . . 0.0 109.708 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.628 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 21.9 m-70 -124.49 110.55 14.63 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.224 -0.922 . . . . 0.0 109.881 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.1 m170 -89.47 -8.87 51.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.472 -0.767 . . . . 0.0 109.697 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -81.94 -16.37 50.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.066 -1.021 . . . . 0.0 109.568 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.593 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 3.9 mmt -104.65 -17.12 14.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.19 -0.944 . . . . 0.0 109.789 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.441 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -54.12 -51.87 62.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.047 -1.033 . . . . 0.0 109.267 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.7 -27.44 68.34 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 109.227 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.963 HG13 ' ND2' ' A' ' 95' ' ' ASN . 9.1 t -69.54 -55.45 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.354 -0.841 . . . . 0.0 109.04 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.53 ' HA ' HMA1 ' A' ' 148' ' ' HEM . 33.5 m-85 -57.44 -28.77 63.62 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.286 -0.884 . . . . 0.0 109.58 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.65 29.62 4.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.524 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 12.6 m-85 -126.06 172.24 10.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.75 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.8 t -115.83 19.68 15.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.339 -0.85 . . . . 0.0 109.289 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 145.92 -164.18 28.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.509 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -92.96 26.32 2.84 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.171 -1.194 . . . . 0.0 109.648 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 26.6 m -121.52 28.59 7.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.25 -0.906 . . . . 0.0 109.626 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.14 135.41 23.87 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.252 -0.905 . . . . 0.0 109.569 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -66.2 -21.0 55.78 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.916 1.482 . . . . 0.0 110.061 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.512 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.52 -36.36 47.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.738 HG22 ' CD1' ' A' ' 35' ' ' LEU . 59.8 t -53.45 -42.22 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.266 -1.137 . . . . 0.0 109.456 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.432 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -67.86 -21.15 65.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.407 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -81.12 -37.25 29.2 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.289 -0.882 . . . . 0.0 109.524 179.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.774 HD21 ' CHA' ' A' ' 148' ' ' HEM . 1.7 mt -75.81 -61.56 1.88 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.522 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.72 -50.66 30.87 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.432 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -54.12 -37.27 64.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.278 -1.13 . . . . 0.0 109.493 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 25.2 mttt -80.24 -26.38 39.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 109.508 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 58' ' ' LEU . 59.9 t -82.17 -49.06 17.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.188 -0.945 . . . . 0.0 109.556 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 63' ' ' LEU . 2.2 mm? -47.83 -46.8 31.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.25 -0.906 . . . . 0.0 109.657 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.64 -52.32 31.56 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.925 . . . . 0.0 109.85 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.446 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 6.3 tp-100 -50.89 -45.92 60.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.053 -1.03 . . . . 0.0 109.346 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.935 ' O ' HG23 ' A' ' 70' ' ' VAL . 42.1 mt -57.53 -39.06 67.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.298 -0.876 . . . . 0.0 109.097 179.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.556 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.99 -54.19 32.21 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 98.6 t -56.8 -29.72 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -1.113 . . . . 0.0 109.466 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.424 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -83.26 -31.31 27.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.345 -0.847 . . . . 0.0 109.659 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.935 HG23 ' O ' ' A' ' 66' ' ' ILE . 51.5 t -61.57 -18.03 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.21 -0.931 . . . . 0.0 109.672 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.436 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 0.2 OUTLIER -89.33 -1.29 58.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.163 -0.96 . . . . 0.0 110.131 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.464 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 18.9 m-70 -135.84 52.47 1.99 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.989 -1.069 . . . . 0.0 109.954 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.422 HD11 ' HA ' ' A' ' 70' ' ' VAL . 34.9 mt -93.18 -34.59 13.54 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.123 -0.986 . . . . 0.0 109.442 179.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -73.68 -26.75 68.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -126.43 92.97 3.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.368 -1.078 . . . . 0.0 109.337 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -91.72 34.89 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 109.829 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -85.48 -20.41 56.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.413 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 1.3 tppt? -125.15 -33.71 2.84 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -1.169 . . . . 0.0 109.911 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.464 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 52.6 ttp -50.26 -36.43 31.29 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.17 -0.956 . . . . 0.0 109.512 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.472 ' O ' HG12 ' A' ' 80' ' ' VAL . 95.8 t -76.97 -0.65 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.267 -0.896 . . . . 0.0 110.012 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -83.76 -31.12 26.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.04 -1.038 . . . . 0.0 109.366 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.495 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 3.1 tp10 -94.74 -44.59 7.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.416 ' HG2' ' OE1' ' A' ' 65' ' ' GLN . 3.4 mtp -55.12 -50.03 70.27 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.228 -0.92 . . . . 0.0 109.35 179.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.478 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 1.3 mtpt -50.38 -40.71 50.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.276 -0.89 . . . . 0.0 109.151 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.495 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -57.66 -34.14 69.06 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.372 -0.83 . . . . 0.0 109.274 179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.412 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 4.0 t -68.0 -35.13 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.139 -0.976 . . . . 0.0 109.024 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.594 ' HA2' HD12 ' A' ' 145' ' ' LEU . . . -64.16 -49.45 66.55 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.735 -1.746 . . . . 0.0 108.735 179.611 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.465 ' O ' ' CG ' ' A' ' 91' ' ' LYS . 83.9 t -55.94 -19.7 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.371 -1.076 . . . . 0.0 109.575 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.523 ' HD3' ' N ' ' A' ' 89' ' ' ARG . 0.0 OUTLIER -84.67 -45.15 12.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.802 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.599 ' CD2' HD13 ' A' ' 98' ' ' ILE . 3.7 m80 -64.12 -10.52 23.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.44 -0.788 . . . . 0.0 110.637 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.488 ' CG ' ' HB2' ' A' ' 147' ' ' SER . 0.0 OUTLIER -82.25 7.4 13.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.83 -1.169 . . . . 0.0 110.335 -179.817 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.93 51.96 0.31 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.517 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.3 m-30 -91.85 -168.61 2.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -1.156 . . . . 0.0 109.912 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -63.5 -19.75 62.77 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.963 ' ND2' HG13 ' A' ' 44' ' ' VAL . 10.3 p-10 -105.06 -26.05 12.28 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.056 -1.261 . . . . 0.0 110.062 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 5.6 mttt 49.49 29.86 3.13 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.141 -0.974 . . . . 0.0 109.65 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.5 m170 -137.34 29.43 2.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.297 -0.877 . . . . 0.0 109.693 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.599 HD13 ' CD2' ' A' ' 90' ' ' HIS . 35.6 mt -72.51 158.99 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.181 -0.949 . . . . 0.0 109.684 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.64 174.06 10.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.241 -0.912 . . . . 0.0 109.817 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.551 ' CB ' HD12 ' A' ' 142' ' ' ILE . . . -100.88 -19.17 16.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.297 -0.877 . . . . 0.0 109.723 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.532 ' HG3' ' CD1' ' A' ' 102' ' ' TYR . 4.5 pt-20 -68.21 -20.61 64.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.224 -0.922 . . . . 0.0 109.563 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.539 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 46.7 m-85 -80.17 -22.06 42.37 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.201 -0.937 . . . . 0.0 109.675 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.712 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -58.99 -62.59 1.77 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.328 -0.858 . . . . 0.0 110.244 -179.295 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 2.1 mt-10 -45.06 -58.69 5.22 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.848 . . . . 0.0 110.867 -179.361 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.539 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.6 Cg_endo -56.49 -47.95 21.41 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.665 1.35 . . . . 0.0 110.213 -179.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.952 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -65.78 -20.54 66.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.165 -0.959 . . . . 0.0 109.459 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.64 -42.78 9.71 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.18 -49.33 74.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -1.212 . . . . 0.0 109.538 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.68 -18.16 52.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.649 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.794 HD23 ' SD ' ' A' ' 114' ' ' MET . 0.7 OUTLIER -73.86 -35.29 64.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.929 . . . . 0.0 109.76 -179.893 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.768 HD21 ' HB3' ' A' ' 130' ' ' TRP . 14.3 mt -68.36 -32.49 72.61 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.673 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 m -71.66 -22.4 61.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 0.0 109.803 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.717 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -87.13 -39.29 15.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.15 -0.969 . . . . 0.0 109.778 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.794 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.6 mtt -56.41 -36.33 68.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.323 -0.86 . . . . 0.0 109.863 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.456 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -54.37 -21.25 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.168 -0.957 . . . . 0.0 109.533 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 17.6 m170 -65.27 -23.75 67.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 109.905 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.507 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 4.5 ttt85 -94.07 -69.6 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.101 -0.999 . . . . 0.0 109.861 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.558 HG23 HG12 ' A' ' 17' ' ' ILE . 16.5 pt -78.28 -32.9 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.205 -0.934 . . . . 0.0 109.61 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.465 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 43.09 -97.23 0.01 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -46.64 -45.11 17.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.494 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 2.8 mptt -69.67 -11.61 60.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.456 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -84.33 79.79 9.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.087 -1.008 . . . . 0.0 109.383 179.556 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.579 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.4 p30 -80.52 -165.81 0.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.606 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.424 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -69.68 -44.56 70.2 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.92 . . . . 0.0 109.441 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.579 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -57.67 -36.6 72.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.191 179.675 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -61.05 -53.53 55.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.303 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.615 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 14.8 ptpt -70.48 -29.66 66.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.323 -0.861 . . . . 0.0 109.427 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 15.7 t70 -74.48 -50.34 18.68 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.324 -0.86 . . . . 0.0 109.34 179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.589 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -59.67 -43.34 94.03 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.389 -0.819 . . . . 0.0 109.256 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.973 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.9 m0 -73.99 -23.1 59.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.267 -0.896 . . . . 0.0 109.022 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.615 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.48 -26.82 65.67 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.301 -0.874 . . . . 0.0 108.662 178.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.54 -24.16 17.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.449 -0.782 . . . . 0.0 109.1 179.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.607 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -70.58 -59.52 2.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.368 -0.833 . . . . 0.0 109.6 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.531 ' CE2' ' HB3' ' A' ' 130' ' ' TRP . 12.1 m-85 -51.76 -27.91 13.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.16 -0.963 . . . . 0.0 109.271 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -66.92 -53.37 32.58 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.122 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -70.26 -35.77 74.0 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.22 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.607 HD12 ' C ' ' A' ' 133' ' ' ALA . 29.1 mt -68.85 -57.23 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.351 -0.843 . . . . 0.0 109.469 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 2.2 p -68.91 -27.91 66.2 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.771 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -68.37 -47.6 56.79 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.276 -1.53 . . . . 0.0 109.276 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -56.61 -30.06 62.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.207 -1.172 . . . . 0.0 109.715 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.712 HD22 ' CE2' ' A' ' 103' ' ' PHE . 8.2 tt -68.72 -18.77 64.3 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.729 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.654 HG23 HE22 ' A' ' 146' ' ' GLN . 39.5 mm -76.47 -3.81 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 0.0 110.043 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.478 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 3.1 m -81.95 -49.01 10.77 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.445 179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.454 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -83.94 -8.36 84.24 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.594 HD12 ' HA2' ' A' ' 87' ' ' GLY . 0.4 OUTLIER -79.66 -171.26 2.73 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.07 -1.253 . . . . 0.0 109.14 179.892 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.654 HE22 HG23 ' A' ' 142' ' ' ILE . 11.6 mp0 55.17 72.75 0.46 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.119 -0.988 . . . . 0.0 109.588 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.488 ' HB2' ' CG ' ' A' ' 91' ' ' LYS . 1.7 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.651 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.774 ' CHA' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.672 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.621 ' HG ' HD12 ' A' ' 73' ' ' LEU . 4.4 mm? 55.64 170.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.254 -1.145 . . . . 0.0 109.65 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.6 173.13 11.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.22 -0.925 . . . . 0.0 109.704 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -68.1 -28.11 67.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.329 -0.857 . . . . 0.0 109.572 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.834 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -82.33 -41.82 19.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.435 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.598 ' O ' HG23 ' A' ' 10' ' ' VAL . 83.9 mt-30 -71.34 -49.21 44.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.292 -0.88 . . . . 0.0 109.669 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -48.64 -31.14 6.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.224 -0.923 . . . . 0.0 109.769 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 42.4 mm-40 -80.87 -49.14 11.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.907 . . . . 0.0 109.648 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.834 HG23 ' O ' ' A' ' 5' ' ' ALA . 36.9 t -53.91 -26.82 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.184 -0.948 . . . . 0.0 109.507 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.911 HG12 HG13 ' A' ' 70' ' ' VAL . 99.0 t -68.41 -54.65 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.519 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.74 -16.09 62.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.816 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 t -86.79 -27.33 23.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.184 -0.947 . . . . 0.0 109.78 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 p -93.79 -12.54 28.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.886 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.644 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.37 -28.53 17.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.088 -1.007 . . . . 0.0 109.684 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -70.83 -13.79 62.17 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -0.891 . . . . 0.0 109.788 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -101.68 -53.74 2.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.126 -0.984 . . . . 0.0 109.527 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.954 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.2 mt -63.77 -36.61 77.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.262 -0.899 . . . . 0.0 109.603 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.899 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -102.13 25.65 8.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.311 -0.868 . . . . 0.0 109.728 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.23 -80.41 0.14 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.108 -1.597 . . . . 0.0 109.108 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.9 p -98.21 55.15 1.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -1.129 . . . . 0.0 109.563 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.42 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 7.3 p-10 -177.18 -33.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.356 -0.84 . . . . 0.0 109.915 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.899 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 20.6 t30 63.72 37.79 9.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.483 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 78.47 29.06 54.1 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.42 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -75.97 -52.17 10.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.665 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.475 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -77.75 -22.99 68.1 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.829 HG12 HD11 ' A' ' 63' ' ' LEU . 48.5 t -67.54 -19.79 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.307 -1.113 . . . . 0.0 109.757 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -91.9 -46.81 3.55 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.475 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.2 ptpt -63.38 -20.81 65.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.153 -1.204 . . . . 0.0 109.787 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.426 ' O ' ' HD2' ' A' ' 33' ' ' LYS . 11.0 pt-20 -99.11 -26.53 14.18 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.4 t -85.09 -51.84 6.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.261 -0.899 . . . . 0.0 109.636 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.635 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.1 m-85 -60.08 -46.04 90.91 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.241 -0.912 . . . . 0.0 109.937 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.638 ' OG1' HG11 ' A' ' 55' ' ' VAL . 53.1 m -49.63 -35.78 22.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.144 -0.972 . . . . 0.0 109.493 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.426 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 1.4 mttm -75.79 -43.77 44.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.4 179.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.897 ' CG ' HD23 ' A' ' 106' ' ' LEU . 6.6 t80 -60.99 -53.19 60.32 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.294 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.942 ' CD1' HG22 ' A' ' 55' ' ' VAL . 31.1 mt -57.02 -42.35 80.24 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.875 . . . . 0.0 109.617 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 43.4 t -65.58 -59.29 4.11 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.205 -0.935 . . . . 0.0 109.582 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.646 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -62.8 -26.47 68.75 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.189 -0.944 . . . . 0.0 109.631 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.646 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 17.2 m-70 -120.94 108.5 13.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.311 -0.868 . . . . 0.0 109.74 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -88.66 -21.31 24.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.42 -0.8 . . . . 0.0 109.306 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -68.11 -13.51 62.26 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.548 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.553 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -104.6 -16.55 14.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.921 -179.814 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.483 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -53.13 -66.26 0.42 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.066 -1.021 . . . . 0.0 109.634 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.84 -21.89 44.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.606 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.069 HG13 ' ND2' ' A' ' 95' ' ' ASN . 31.8 t -76.76 -37.16 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.635 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 5.2 m-85 -76.77 -27.21 55.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.93 . . . . 0.0 109.497 -179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.97 27.2 4.37 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.533 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -123.66 173.33 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.251 -1.147 . . . . 0.0 109.909 -179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.2 t -109.37 -15.93 14.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.432 -0.792 . . . . 0.0 109.199 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.64 -164.57 29.03 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.26 32.98 1.43 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.173 -1.193 . . . . 0.0 109.617 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 25.8 t -134.89 26.68 3.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.289 -0.882 . . . . 0.0 109.618 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.622 ' OD2' HG23 ' A' ' 55' ' ' VAL . 5.2 p-10 -104.39 150.12 38.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.213 -0.929 . . . . 0.0 109.715 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -74.99 -1.93 11.87 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.042 1.549 . . . . 0.0 110.439 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -77.48 -35.58 36.51 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.942 HG22 ' CD1' ' A' ' 35' ' ' LEU . 77.3 t -51.36 -44.34 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -1.116 . . . . 0.0 109.538 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -71.86 -7.22 47.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -0.855 . . . . 0.0 109.938 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.36 -30.0 14.72 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.687 ' O ' HG23 ' A' ' 62' ' ' VAL . 3.9 mt -84.66 -61.44 1.79 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 109.702 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -51.51 -30.57 27.06 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.469 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -63.51 -52.8 59.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.152 -1.204 . . . . 0.0 109.704 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.601 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 5.5 mttp -73.41 -41.75 62.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.601 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.687 HG23 ' O ' ' A' ' 58' ' ' LEU . 87.1 t -50.95 -63.67 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.818 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.829 HD11 HG12 ' A' ' 26' ' ' VAL . 0.2 OUTLIER -46.84 -40.66 14.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.214 -0.929 . . . . 0.0 109.887 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.601 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.58 -38.69 55.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -0.94 . . . . 0.0 109.422 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.408 ' HA ' ' NE2' ' A' ' 65' ' ' GLN . 17.5 tp60 -65.08 -39.87 93.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.313 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.954 ' O ' HG23 ' A' ' 70' ' ' VAL . 67.5 mt -62.46 -34.98 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.074 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.563 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -65.65 -53.73 29.84 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.5 t -59.9 -24.24 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -1.119 . . . . 0.0 109.165 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.94 -24.49 26.54 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.443 -0.786 . . . . 0.0 109.425 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.954 HG23 ' O ' ' A' ' 66' ' ' ILE . 52.0 t -68.02 -17.23 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.232 -0.918 . . . . 0.0 109.609 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.504 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.8 OUTLIER -89.65 41.62 1.05 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.146 -0.971 . . . . 0.0 109.703 179.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.506 ' O ' ' N ' ' A' ' 74' ' ' GLY . 8.1 m-70 -161.26 -73.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.588 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.621 HD12 ' HG ' ' A' ' 2' ' ' LEU . 2.4 mm? 50.76 -86.2 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.68 -0.638 . . . . 0.0 110.448 179.499 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -58.65 -21.85 51.37 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.47 75.56 1.97 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -1.135 . . . . 0.0 109.581 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -85.21 10.02 13.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.927 . . . . 0.0 109.977 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -79.23 -23.92 62.31 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.086 -1.605 . . . . 0.0 109.086 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 4.9 ttpt -122.07 -38.5 2.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.285 -1.127 . . . . 0.0 109.627 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.401 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 58.1 ttp -50.04 -38.55 38.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.607 HG12 ' HB2' ' A' ' 84' ' ' LYS . 47.5 t -74.53 -22.46 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.201 -0.937 . . . . 0.0 109.519 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.499 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -52.52 -58.44 6.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.18 -0.95 . . . . 0.0 109.52 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.698 ' O ' HG23 ' A' ' 86' ' ' VAL . 31.4 mt-10 -74.84 -44.11 50.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.46 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.473 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 0.6 OUTLIER -57.84 -57.58 12.15 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.291 -0.881 . . . . 0.0 109.421 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.607 ' HB2' HG12 ' A' ' 80' ' ' VAL . 34.5 tttt -51.49 -32.07 26.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.203 179.722 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.479 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -68.94 -43.99 73.96 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 109.311 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.698 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.4 t -54.89 -40.29 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.201 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 90' ' ' HIS . . . -53.58 -49.23 58.32 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.544 HG13 ' CD ' ' A' ' 91' ' ' LYS . 72.8 t -53.59 -49.29 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.305 -1.115 . . . . 0.0 109.084 179.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.518 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 0.7 OUTLIER -49.68 -37.55 29.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.189 -0.944 . . . . 0.0 109.658 179.703 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.64 ' O ' HD12 ' A' ' 98' ' ' ILE . 22.9 m80 -71.4 -3.69 22.2 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.544 ' CD ' HG13 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -78.96 -11.58 60.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.732 -1.23 . . . . 0.0 110.24 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -151.85 57.73 0.43 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.7 m-30 -87.57 -170.73 3.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -1.133 . . . . 0.0 109.534 179.614 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.66 -29.54 67.22 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.069 ' ND2' HG13 ' A' ' 44' ' ' VAL . 16.9 p-10 -99.24 -32.89 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -1.183 . . . . 0.0 109.505 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.456 ' CD ' ' O ' ' A' ' 96' ' ' LYS . 0.0 OUTLIER 67.74 7.36 5.65 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.414 -0.804 . . . . 0.0 110.397 179.612 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.419 ' O ' ' O ' ' A' ' 98' ' ' ILE . 3.1 m170 -95.86 -87.84 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.012 -1.055 . . . . 0.0 108.981 178.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.64 HD12 ' O ' ' A' ' 90' ' ' HIS . 15.3 mt 58.65 152.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.363 -0.836 . . . . 0.0 110.694 179.342 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.543 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -153.48 135.5 14.72 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 121.727 0.775 . . . . 0.0 109.807 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.719 ' HB2' HD12 ' A' ' 142' ' ' ILE . . . -72.23 -7.31 48.61 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.658 -0.651 . . . . 0.0 109.532 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.448 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 5.8 pt-20 -75.54 -23.74 56.66 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.086 179.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.553 ' CD2' ' CE ' ' A' ' 41' ' ' MET . 25.5 m-85 -85.41 -20.38 29.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.854 . . . . 0.0 109.631 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.931 ' CE2' HD22 ' A' ' 141' ' ' LEU . 4.5 m-85 -55.95 -61.05 2.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.26 -0.9 . . . . 0.0 110.045 -179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -52.37 -57.62 14.77 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.066 -1.021 . . . . 0.0 109.839 -179.66 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.9 Cg_exo -50.72 -63.57 0.27 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.667 1.351 . . . . 0.0 109.886 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.897 HD23 ' CG ' ' A' ' 34' ' ' PHE . 3.4 tm? -56.54 -26.76 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.295 -0.878 . . . . 0.0 109.342 179.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -75.62 -46.05 15.86 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.71 -51.86 66.68 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -1.193 . . . . 0.0 109.273 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 t -56.33 -22.25 29.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.301 -0.875 . . . . 0.0 109.247 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.51 HD23 ' CG ' ' A' ' 114' ' ' MET . 4.4 tt -67.46 -48.61 66.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.86 . . . . 0.0 109.585 179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.731 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.6 mt -54.36 -31.68 55.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.137 -0.977 . . . . 0.0 109.398 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -65.84 -49.47 68.05 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.24 -0.912 . . . . 0.0 109.657 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.48 ' HA ' ' CE1' ' A' ' 116' ' ' HIS . . . -71.45 -32.52 68.42 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -0.926 . . . . 0.0 109.601 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.51 ' CG ' HD23 ' A' ' 110' ' ' LEU . 3.4 mmt -47.57 -38.57 14.59 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.265 -0.897 . . . . 0.0 110.023 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.421 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -63.77 -16.92 62.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.565 -179.776 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.48 ' CE1' ' HA ' ' A' ' 113' ' ' ALA . 37.0 m170 -60.78 -43.97 97.39 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.082 -1.011 . . . . 0.0 109.779 -179.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.431 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -72.81 -59.37 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.781 -179.7 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.703 HD11 ' SD ' ' A' ' 122' ' ' MET . 12.3 pt -94.0 40.53 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -0.941 . . . . 0.0 109.876 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.421 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -53.46 117.07 6.52 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 112.73 -31.34 6.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.529 -1.829 . . . . 0.0 108.529 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 76.1 mttt -98.98 -24.87 14.76 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.339 -1.095 . . . . 0.0 109.13 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.703 ' SD ' HD11 ' A' ' 118' ' ' ILE . 6.5 tpt -67.56 96.34 0.52 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.025 179.428 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.461 ' O ' ' HB3' ' A' ' 126' ' ' ALA . 12.5 p-10 -100.73 -172.11 2.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 0.0 109.621 -179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.436 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -58.71 -52.93 63.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -0.881 . . . . 0.0 110.045 -179.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.713 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -54.63 -24.91 23.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.157 -0.965 . . . . 0.0 109.418 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 123' ' ' ASN . . . -76.16 -54.06 7.38 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.353 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.595 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 16.7 ptpt -70.0 -30.22 67.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.229 -0.919 . . . . 0.0 109.358 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.477 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 63.4 t0 -76.91 -38.3 53.75 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.4 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.498 ' HB2' ' O ' ' A' ' 125' ' ' ALA . . . -66.91 -43.87 82.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.402 -0.811 . . . . 0.0 109.347 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.954 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.9 m0 -75.34 -33.01 61.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.251 -0.905 . . . . 0.0 109.011 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.595 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -52.41 -39.2 60.64 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 108.984 179.205 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.586 ' O ' HD21 ' A' ' 2' ' ' LEU . . . -87.71 -23.0 24.3 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.391 -0.818 . . . . 0.0 108.985 179.321 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.693 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -83.45 -63.17 1.41 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 109.518 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.535 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -51.59 -23.97 4.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.182 -0.949 . . . . 0.0 109.098 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.81 -36.78 56.69 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.266 -0.896 . . . . 0.0 109.012 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -78.95 -38.73 36.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.409 -0.807 . . . . 0.0 109.235 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.453 ' CD1' ' O ' ' A' ' 133' ' ' ALA . 1.4 mp -62.42 -54.89 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.343 -0.848 . . . . 0.0 108.802 179.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.411 ' O ' HG12 ' A' ' 142' ' ' ILE . 83.6 p -68.44 -17.7 64.26 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -0.885 . . . . 0.0 109.659 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.39 -35.21 20.97 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -70.46 -25.5 63.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -1.151 . . . . 0.0 109.621 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.931 HD22 ' CE2' ' A' ' 103' ' ' PHE . 9.9 tt -74.04 -16.49 61.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 109.831 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.719 HD12 ' HB2' ' A' ' 100' ' ' ALA . 51.2 mm -88.19 15.42 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.996 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.6 t -93.25 -45.16 7.97 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -83.94 -23.3 52.94 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.129 -1.589 . . . . 0.0 109.129 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.606 HD23 ' HG3' ' A' ' 146' ' ' GLN . 0.3 OUTLIER -56.3 -169.06 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -1.142 . . . . 0.0 109.579 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.606 ' HG3' HD23 ' A' ' 145' ' ' LEU . 14.5 mt-30 54.8 66.72 1.16 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.257 -0.902 . . . . 0.0 109.681 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.423 ' OXT' ' HE2' ' A' ' 91' ' ' LYS . 16.0 p . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.682 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.741 HMC1 ' CE2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.661 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 mt -143.59 161.46 38.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.321 -1.105 . . . . 0.0 109.758 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.417 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.5 OUTLIER -140.69 -171.35 3.21 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.308 -0.87 . . . . 0.0 109.817 -179.818 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -76.71 -35.63 57.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.883 . . . . 0.0 109.853 -179.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.779 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -76.17 -41.86 48.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.328 -0.858 . . . . 0.0 109.663 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.758 ' O ' HG23 ' A' ' 10' ' ' VAL . 52.0 mt-30 -66.47 -48.0 71.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.16 -0.963 . . . . 0.0 109.345 179.815 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.609 ' HG2' HD12 ' A' ' 73' ' ' LEU . 3.0 ttp180 -60.84 -24.04 65.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.19 -0.944 . . . . 0.0 109.214 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.3 tp60 -83.02 -49.26 9.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.444 -0.785 . . . . 0.0 109.186 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.779 HG23 ' O ' ' A' ' 5' ' ' ALA . 86.3 t -51.56 -27.43 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.404 -0.81 . . . . 0.0 109.498 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.944 HG12 HG13 ' A' ' 70' ' ' VAL . 61.1 t -65.02 -52.22 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.769 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.05 -19.2 64.09 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.202 -0.936 . . . . 0.0 109.596 179.87 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.85 -23.84 36.16 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.232 -0.918 . . . . 0.0 109.556 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.417 HG21 ' CB ' ' A' ' 126' ' ' ALA . 21.2 p -99.89 -13.22 19.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.789 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.708 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -90.02 -28.31 19.16 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.128 -0.982 . . . . 0.0 109.759 -179.836 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 14.9 mttt -75.88 -8.7 57.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.904 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -105.4 -47.37 3.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.103 -0.998 . . . . 0.0 109.63 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.967 HD12 ' CH2' ' A' ' 130' ' ' TRP . 57.8 mt -71.9 -35.4 54.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.218 -0.926 . . . . 0.0 109.635 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.883 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -105.03 33.82 3.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.678 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.14 -75.99 0.2 Allowed Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.2 p -103.73 -37.47 7.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.229 -1.16 . . . . 0.0 109.597 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.694 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 16.0 p-10 -71.61 -20.54 61.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.61 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.883 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 19.9 t30 57.55 25.29 11.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.627 179.956 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.06 19.94 24.91 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.694 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -68.34 -59.52 3.12 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.251 -1.146 . . . . 0.0 109.56 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -67.02 -12.46 60.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.49 HG21 ' CG2' ' A' ' 17' ' ' ILE . 37.5 t -84.82 -41.25 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.149 -1.206 . . . . 0.0 109.868 -179.819 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.447 ' CA ' ' HA3' ' A' ' 59' ' ' GLY . . . -74.33 -36.73 49.42 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.306 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.477 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 9.7 ptpt -73.2 -26.55 61.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.109 -1.23 . . . . 0.0 110.207 -179.459 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.453 ' CG ' ' O ' ' A' ' 25' ' ' GLY . 19.3 pt-20 -95.42 -20.65 18.91 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.066 -1.021 . . . . 0.0 109.993 -179.746 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.542 ' SG ' HD12 ' A' ' 110' ' ' LEU . 37.3 t -88.19 -66.73 0.89 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.204 -0.935 . . . . 0.0 110.085 -179.577 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.526 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.6 m-85 -48.06 -31.53 5.59 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.048 -179.546 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.943 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -56.17 -51.18 68.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.083 -1.011 . . . . 0.0 109.348 179.705 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.414 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 6.2 mttp -59.61 -48.64 80.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.285 -0.884 . . . . 0.0 109.533 179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.732 ' CG ' HD23 ' A' ' 106' ' ' LEU . 5.8 t80 -52.63 -47.77 66.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.916 . . . . 0.0 109.453 179.863 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.831 ' CD1' HG22 ' A' ' 55' ' ' VAL . 21.5 mt -58.93 -44.01 91.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.288 -0.882 . . . . 0.0 109.607 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.5 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 0.9 OUTLIER -68.73 -60.98 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 -179.957 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.598 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -53.47 -23.05 9.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.227 -0.921 . . . . 0.0 109.589 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.598 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 28.5 m-70 -126.24 102.37 7.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.278 -0.889 . . . . 0.0 109.716 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.4 m170 -85.64 6.86 25.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.329 -0.857 . . . . 0.0 109.9 179.699 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -95.09 -18.12 21.25 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.128 -0.983 . . . . 0.0 109.427 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.482 ' CE ' HMB1 ' A' ' 148' ' ' HEM . 38.7 mmm -107.03 -19.45 13.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.754 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.39 -46.34 37.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.036 -1.04 . . . . 0.0 109.562 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.3 -26.05 60.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.099 179.478 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.009 HG13 ' ND2' ' A' ' 95' ' ' ASN . 27.9 t -70.62 -33.75 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.431 -0.793 . . . . 0.0 109.342 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.546 ' CE1' HMB2 ' A' ' 148' ' ' HEM . 10.2 m-85 -78.98 -31.17 44.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.48 26.88 4.07 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.514 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.0 m-85 -124.02 166.85 15.02 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.235 -1.156 . . . . 0.0 109.706 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 9.0 t -104.92 -11.16 16.84 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.855 . . . . 0.0 109.444 179.359 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.9 -164.82 31.84 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.5 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -95.57 30.33 2.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -1.186 . . . . 0.0 109.629 179.938 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.65 27.7 5.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 179.993 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.433 ' OD2' HG23 ' A' ' 55' ' ' VAL . 8.1 p-10 -115.62 142.13 28.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.253 -0.904 . . . . 0.0 109.632 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -66.22 -17.8 54.99 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.054 1.555 . . . . 0.0 110.111 -179.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.506 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -53.37 -39.84 60.0 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.943 HG11 HG23 ' A' ' 32' ' ' THR . 94.4 t -54.98 -34.86 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.401 -1.058 . . . . 0.0 109.53 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.455 ' O ' ' CB ' ' A' ' 60' ' ' ALA . . . -72.89 -27.93 62.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.28 -0.887 . . . . 0.0 109.449 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -75.54 -31.99 60.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.497 179.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.838 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.0 mt -81.97 -62.55 1.6 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.307 -0.871 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.526 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -49.68 -51.56 27.84 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -51.92 -37.18 51.68 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -1.145 . . . . 0.0 109.412 179.879 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -81.27 -27.69 35.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.888 . . . . 0.0 109.512 179.856 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.838 HG23 ' O ' ' A' ' 58' ' ' LEU . 46.5 t -77.84 -49.64 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.303 -0.873 . . . . 0.0 109.704 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.454 ' HA ' HD13 ' A' ' 63' ' ' LEU . 3.6 mm? -47.51 -51.25 21.23 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.714 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -46.73 -47.14 20.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.251 -0.906 . . . . 0.0 110.089 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -52.76 -53.72 44.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.099 -1.001 . . . . 0.0 109.356 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.909 ' O ' HG23 ' A' ' 70' ' ' VAL . 55.9 mt -55.49 -34.43 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.174 -0.954 . . . . 0.0 109.074 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.552 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -64.48 -54.07 31.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.751 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.8 t -60.98 -24.93 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.295 -1.121 . . . . 0.0 109.27 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HA ' ' HG2' ' A' ' 79' ' ' MET . . . -85.66 -27.93 25.05 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.355 -0.84 . . . . 0.0 109.555 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.944 HG13 HG12 ' A' ' 10' ' ' VAL . 46.2 t -68.13 -9.75 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.219 -0.925 . . . . 0.0 109.78 179.833 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.7 t -92.26 29.93 1.57 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.046 -1.034 . . . . 0.0 109.763 -179.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.487 ' O ' ' N ' ' A' ' 74' ' ' GLY . 9.4 m-70 -155.27 -91.93 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -0.948 . . . . 0.0 109.817 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.609 HD12 ' HG2' ' A' ' 7' ' ' ARG . 9.2 mt 64.4 -69.63 0.09 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.331 -0.856 . . . . 0.0 109.691 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -56.12 -39.72 81.32 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.476 ' OD2' ' CG ' ' A' ' 72' ' ' HIS . 8.1 p-10 -95.88 95.93 8.59 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.296 -1.12 . . . . 0.0 109.476 179.838 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -92.64 31.14 1.4 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.228 -0.92 . . . . 0.0 109.644 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -102.1 -20.62 12.18 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.462 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 9.2 ttmm -126.22 -45.91 1.67 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -1.137 . . . . 0.0 109.706 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 18.3 tmm? -48.53 -36.35 15.17 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.229 -0.92 . . . . 0.0 109.603 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.433 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 96.1 t -77.59 -20.59 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.255 -0.903 . . . . 0.0 109.414 179.827 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -57.42 -52.4 65.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.189 -0.944 . . . . 0.0 109.444 179.88 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.4 OUTLIER -69.73 -50.65 41.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.429 179.75 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.484 ' SD ' HG23 ' A' ' 137' ' ' ILE . 0.8 OUTLIER -56.34 -56.51 20.2 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 109.313 179.737 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.488 ' HG2' ' CB ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -53.54 -24.44 13.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.246 -0.909 . . . . 0.0 109.205 179.555 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.545 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -77.9 -44.13 27.97 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.407 -0.808 . . . . 0.0 109.479 179.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 82' ' ' GLU . 21.0 t -53.17 -35.35 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 109.369 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.474 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -60.66 -48.36 86.63 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.8 HG23 ' HA3' ' A' ' 144' ' ' GLY . 64.9 t -57.65 -18.82 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.423 -1.045 . . . . 0.0 109.432 179.332 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 0.1 OUTLIER -86.72 -46.1 10.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.134 -0.978 . . . . 0.0 109.087 179.617 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.521 ' O ' HD12 ' A' ' 98' ' ' ILE . 14.3 m80 -56.39 -37.5 70.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 109.564 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -60.96 -16.68 45.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.298 -0.876 . . . . 0.0 109.935 -179.863 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -119.97 40.76 2.11 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 5.7 m-30 -90.42 -172.12 3.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 109.53 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -82.9 -28.67 37.08 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.939 -1.664 . . . . 0.0 108.939 179.906 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.009 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -79.95 -47.94 14.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.478 -1.013 . . . . 0.0 109.18 179.78 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.471 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 0.7 OUTLIER 75.13 -48.51 0.63 Allowed 'General case' 0 N--CA 1.503 2.213 0 O-C-N 121.623 -0.673 . . . . 0.0 110.764 -179.879 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 97' ' ' HIS . 25.1 m170 -68.05 59.44 0.07 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.802 -1.186 . . . . 0.0 110.466 -179.516 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.521 HD12 ' O ' ' A' ' 90' ' ' HIS . 56.1 mt -90.41 156.96 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.069 -1.019 . . . . 0.0 109.027 179.488 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.521 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -137.94 138.93 39.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.056 -1.027 . . . . 0.0 110.055 -179.773 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -81.15 -3.69 52.95 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -0.873 . . . . 0.0 109.883 179.693 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 43.1 mm-40 -81.38 -22.25 38.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.006 -1.059 . . . . 0.0 109.489 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.531 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 55.0 m-85 -79.96 -15.09 57.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.309 -0.869 . . . . 0.0 109.891 -179.816 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.917 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 5.2 m-85 -62.93 -61.55 2.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.242 -0.911 . . . . 0.0 110.063 -179.847 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.489 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.4 OUTLIER -44.85 -58.83 4.86 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 110.746 -179.46 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 9.9 Cg_endo -57.45 -45.95 30.91 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.682 1.359 . . . . 0.0 110.003 -179.569 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.936 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -65.91 -20.09 66.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.301 179.789 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.407 ' HA2' ' CE1' ' A' ' 134' ' ' TYR . . . -86.29 -49.04 4.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.54 -45.49 92.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.2 -1.176 . . . . 0.0 109.537 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.9 m -61.56 -28.97 69.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.494 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.967 HD13 ' OH ' ' A' ' 134' ' ' TYR . 3.7 tt -67.23 -40.03 86.31 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.204 -0.935 . . . . 0.0 109.369 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.656 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.7 mt -54.17 -36.32 63.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.163 -0.961 . . . . 0.0 109.047 179.763 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.8 t -67.01 -30.72 70.9 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 109.459 179.711 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.444 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -79.96 -38.94 31.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.615 179.923 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.486 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.6 mmt -48.42 -42.91 33.49 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.228 -0.92 . . . . 0.0 109.618 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -50.67 -24.37 3.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.489 179.843 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.444 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 17.6 m170 -52.0 -53.1 45.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.959 . . . . 0.0 109.5 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -72.44 -58.73 3.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.894 . . . . 0.0 109.5 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.608 HD11 ' SD ' ' A' ' 122' ' ' MET . 6.5 pt -102.58 60.79 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.587 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -69.57 -11.01 64.65 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.886 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -105.72 -30.03 4.75 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.861 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 12.7 mttm -93.05 -24.52 18.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.173 -1.192 . . . . 0.0 110.078 -179.661 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.608 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.9 OUTLIER -64.17 79.55 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.088 -1.008 . . . . 0.0 109.432 179.947 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.668 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 8.5 p30 -81.54 -164.52 0.79 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 -179.839 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.409 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.74 -38.46 73.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.181 -0.95 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.668 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -62.74 -33.43 75.12 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.293 -0.879 . . . . 0.0 109.234 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.417 ' CB ' HG21 ' A' ' 13' ' ' THR . . . -67.25 -52.3 42.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.342 -0.849 . . . . 0.0 109.534 179.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.523 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.5 OUTLIER -71.04 -29.38 65.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.341 179.835 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.467 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 48.6 t0 -79.81 -32.15 40.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.302 -0.873 . . . . 0.0 109.362 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.477 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -73.08 -43.43 61.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.418 -0.801 . . . . 0.0 109.322 179.752 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.967 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.4 m0 -74.86 -25.8 59.23 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.257 -0.902 . . . . 0.0 108.716 179.489 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -62.48 -26.89 68.77 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.235 -0.916 . . . . 0.0 108.693 178.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.45 -40.98 9.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.51 -0.744 . . . . 0.0 109.14 179.517 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -73.6 -58.95 2.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.4 -0.812 . . . . 0.0 109.103 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.967 ' OH ' HD13 ' A' ' 110' ' ' LEU . 1.9 t80 -50.87 -28.07 8.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.33 -0.856 . . . . 0.0 108.997 179.381 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.407 ' HB2' ' O ' ' A' ' 131' ' ' ALA . . . -73.02 -41.35 64.31 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.037 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -76.68 -29.06 56.16 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.483 -0.76 . . . . 0.0 109.059 179.42 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.841 HD13 HG23 ' A' ' 66' ' ' ILE . 42.1 mt -66.54 -61.59 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 108.738 179.532 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.3 p -66.35 -20.6 66.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.431 -0.793 . . . . 0.0 109.726 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.35 -26.98 50.17 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 -179.872 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.0 -19.32 54.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.25 -1.147 . . . . 0.0 109.723 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.889 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.3 tt -79.53 -6.94 58.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.061 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.48 ' O ' HG22 ' A' ' 142' ' ' ILE . 57.5 mt -86.78 9.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.002 -1.061 . . . . 0.0 110.122 -179.88 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.488 ' CB ' ' HG2' ' A' ' 84' ' ' LYS . 7.2 m -83.08 -43.31 16.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.933 -1.104 . . . . 0.0 109.436 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.8 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -97.05 -21.24 21.2 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.517 ' O ' ' HG2' ' A' ' 146' ' ' GLN . 10.7 tp -52.51 -178.71 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -1.045 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.517 ' HG2' ' O ' ' A' ' 145' ' ' LEU . 0.0 OUTLIER 32.96 63.84 0.3 Allowed 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.698 0.761 . . . . 0.0 111.435 -179.497 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.679 179.479 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.917 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.541 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.538 HD22 ' N ' ' A' ' 2' ' ' LEU . 4.5 mm? -67.36 153.52 43.5 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.258 -1.143 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 1.2 p -104.28 173.74 6.17 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.231 -0.918 . . . . 0.0 109.656 179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -63.75 -22.08 66.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.629 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.848 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -91.66 -56.16 3.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.954 . . . . 0.0 109.545 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.522 ' O ' HG23 ' A' ' 10' ' ' VAL . 3.6 mt-30 -58.23 -54.95 41.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.29 -0.881 . . . . 0.0 109.607 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.726 ' HG2' HD12 ' A' ' 73' ' ' LEU . 10.1 ttp180 -50.8 -31.43 16.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -0.937 . . . . 0.0 109.44 179.872 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.1 tp60 -80.18 -42.05 24.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.297 -0.877 . . . . 0.0 109.331 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.848 HG23 ' O ' ' A' ' 5' ' ' ALA . 57.3 t -59.34 -25.07 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -0.911 . . . . 0.0 109.433 179.803 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 1.021 HG12 HG13 ' A' ' 70' ' ' VAL . 86.4 t -67.48 -52.39 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.507 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.55 -12.12 56.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.873 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.19 -26.65 21.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.138 -0.976 . . . . 0.0 109.891 -179.854 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.443 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 28.2 p -99.65 -7.7 25.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.107 -0.996 . . . . 0.0 109.893 179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.687 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -91.18 -19.83 22.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.02 -1.05 . . . . 0.0 109.562 -179.759 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 45.1 mtpt -79.74 -15.01 58.31 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.715 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.28 -54.82 3.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 109.663 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.878 HD12 ' CH2' ' A' ' 130' ' ' TRP . 56.9 mt -65.87 -42.18 91.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.642 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.889 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -96.45 31.78 2.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.211 -0.93 . . . . 0.0 109.711 -179.855 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.97 -73.29 0.39 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.94 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 77.6 p -107.04 -26.26 11.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.257 -1.143 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.808 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 10.5 p-10 -81.01 -19.32 44.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.222 -0.924 . . . . 0.0 109.694 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.889 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 5.3 t30 58.39 22.16 9.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.651 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.411 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 101.73 31.09 5.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.808 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -84.1 -46.49 11.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.261 -1.14 . . . . 0.0 109.584 179.925 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.476 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.38 -1.78 86.61 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.91 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.698 HG11 HD11 ' A' ' 63' ' ' LEU . 21.2 t -88.2 -40.24 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.041 -1.27 . . . . 0.0 109.426 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.49 -53.91 4.51 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.545 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.476 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 18.2 ptpt -48.9 -31.7 7.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.101 -1.235 . . . . 0.0 109.673 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.611 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 24.5 pt-20 -91.62 -21.32 20.87 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.215 -0.928 . . . . 0.0 109.387 179.713 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.422 ' HB3' ' HA2' ' A' ' 27' ' ' GLY . 20.8 t -87.6 -64.58 1.13 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.346 -0.847 . . . . 0.0 109.767 -179.794 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.554 ' HB3' HG13 ' A' ' 55' ' ' VAL . 10.5 m-85 -48.28 -34.29 10.18 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 109.955 -179.566 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.891 HG23 HG11 ' A' ' 55' ' ' VAL . 0.2 OUTLIER -56.74 -54.73 42.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 109.273 179.659 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -55.28 -51.39 66.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 179.847 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.873 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.0 t80 -54.54 -51.7 64.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 109.54 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.707 ' CD1' HG22 ' A' ' 55' ' ' VAL . 16.3 mt -54.81 -45.85 74.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.667 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.9 -59.21 3.46 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.257 -0.902 . . . . 0.0 109.671 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.582 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -58.4 -22.41 53.85 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 0.0 109.624 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.582 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 38.9 m-70 -131.0 107.85 9.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 109.786 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 48.7 m170 -88.9 -12.53 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.364 -0.835 . . . . 0.0 109.753 179.748 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -73.69 -16.89 61.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.123 -0.986 . . . . 0.0 109.715 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.571 ' HE2' ' CG ' ' A' ' 102' ' ' TYR . 73.0 mmm -109.13 -16.25 14.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.165 -0.96 . . . . 0.0 109.882 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.469 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.58 -51.3 28.49 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.986 -1.071 . . . . 0.0 109.498 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.02 -28.14 64.18 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.257 -0.902 . . . . 0.0 109.127 179.526 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.064 HG13 ' ND2' ' A' ' 95' ' ' ASN . 38.8 t -66.02 -32.1 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.407 -0.808 . . . . 0.0 109.265 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.537 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 29.3 m-85 -82.48 -25.68 33.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.159 -0.963 . . . . 0.0 109.503 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.49 26.79 5.5 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.779 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.2 m-85 -123.43 167.93 13.21 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.37 -1.077 . . . . 0.0 109.888 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 t -109.91 19.17 19.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.385 -0.822 . . . . 0.0 109.282 179.508 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.37 -163.33 29.52 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 -179.946 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.19 40.72 1.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -1.157 . . . . 0.0 109.732 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 20.9 t -139.74 21.02 2.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.687 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.21 139.02 20.06 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.207 -0.933 . . . . 0.0 109.678 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -61.21 -24.73 79.56 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 123.951 1.5 . . . . 0.0 110.089 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.534 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.25 -39.32 42.62 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.891 HG11 HG23 ' A' ' 32' ' ' THR . 59.4 t -51.31 -36.28 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -1.129 . . . . 0.0 109.367 179.796 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.581 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -73.38 -10.22 59.51 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.354 -0.841 . . . . 0.0 109.591 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.41 ' OD2' ' HA2' ' A' ' 54' ' ' GLY . 59.5 m-20 -86.78 -57.03 3.13 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.13 -0.981 . . . . 0.0 109.551 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.772 ' O ' HG23 ' A' ' 62' ' ' VAL . 10.0 mt -63.29 -61.06 2.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.782 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -47.95 -37.38 15.69 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.581 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -69.72 -59.88 2.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.107 -1.231 . . . . 0.0 109.507 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HD3' ' O1D' ' A' ' 148' ' ' HEM . 10.2 mttt -57.51 -46.57 83.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.268 -0.895 . . . . 0.0 109.34 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 58' ' ' LEU . 51.4 t -56.66 -52.12 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.268 -0.895 . . . . 0.0 109.558 179.771 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.782 HD23 ' O ' ' A' ' 59' ' ' GLY . 1.4 mm? -47.06 -46.04 22.08 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.182 -0.949 . . . . 0.0 109.753 179.875 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -50.19 -49.52 52.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.597 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 16.1 tp60 -50.2 -48.75 54.1 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.272 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.987 ' O ' HG23 ' A' ' 70' ' ' VAL . 50.1 mt -57.15 -39.21 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.374 -0.829 . . . . 0.0 109.025 179.501 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.22 -53.23 41.25 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.944 -1.662 . . . . 0.0 108.944 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.8 t -59.08 -26.73 34.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.349 -1.089 . . . . 0.0 109.35 179.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.436 ' CB ' HG12 ' A' ' 137' ' ' ILE . . . -84.62 -28.6 26.39 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.421 -0.799 . . . . 0.0 109.58 179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.021 HG13 HG12 ' A' ' 10' ' ' VAL . 58.1 t -61.39 -15.78 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.922 . . . . 0.0 109.733 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -90.94 26.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.212 -0.93 . . . . 0.0 109.959 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.469 ' O ' ' N ' ' A' ' 74' ' ' GLY . 7.9 m-70 -155.72 -87.0 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.016 . . . . 0.0 109.81 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.726 HD12 ' HG2' ' A' ' 7' ' ' ARG . 21.2 mt 63.53 -72.45 0.05 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.455 -0.778 . . . . 0.0 110.009 -179.873 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -65.51 -26.21 71.77 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -91.09 48.51 1.52 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.272 -1.134 . . . . 0.0 109.546 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.451 ' HG2' ' N ' ' A' ' 77' ' ' GLY . 0.0 OUTLIER -56.92 -19.54 18.42 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.723 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.451 ' N ' ' HG2' ' A' ' 76' ' ' GLU . . . -51.93 -24.1 13.09 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.995 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.422 ' O ' ' N ' ' A' ' 81' ' ' ALA . 15.9 ttpt -123.66 -46.22 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -1.171 . . . . 0.0 109.712 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 37.2 ttp -48.99 -27.81 3.43 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.199 -0.938 . . . . 0.0 109.666 179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 76' ' ' GLU . 47.9 t -81.19 -21.63 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.254 -0.904 . . . . 0.0 109.483 179.846 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.422 ' N ' ' O ' ' A' ' 78' ' ' LYS . . . -71.69 -28.7 63.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.427 179.908 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.424 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.6 OUTLIER -81.48 -52.3 7.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.29 -0.881 . . . . 0.0 109.5 179.875 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.474 ' HE3' ' HB2' ' A' ' 141' ' ' LEU . 99.3 mmm -56.44 -39.81 73.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.186 -0.946 . . . . 0.0 108.975 179.683 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.52 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.1 OUTLIER -52.02 -28.65 17.83 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.077 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -80.08 -33.09 39.13 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.552 -0.718 . . . . 0.0 109.097 179.324 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 89' ' ' ARG . 21.9 t -69.62 -33.83 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.22 179.688 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.478 ' CA ' ' HB2' ' A' ' 145' ' ' LEU . . . -65.37 -39.61 95.94 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 84' ' ' LYS . 90.3 t -58.7 -28.08 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.268 -1.137 . . . . 0.0 109.213 179.657 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.525 ' HA ' ' CZ ' ' A' ' 93' ' ' TYR . 0.6 OUTLIER -73.69 -25.94 60.48 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.349 -0.844 . . . . 0.0 109.26 179.641 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.535 ' CA ' HD12 ' A' ' 98' ' ' ILE . 18.5 m80 -88.04 18.19 4.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.375 -0.828 . . . . 0.0 110.169 -179.085 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.411 ' HB2' ' O ' ' A' ' 88' ' ' VAL . 1.6 tttt -79.35 -60.56 2.32 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.02 -1.05 . . . . 0.0 110.52 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.44 ' HA2' ' HB2' ' A' ' 96' ' ' LYS . . . -148.24 57.58 0.48 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -179.497 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.525 ' CZ ' ' HA ' ' A' ' 89' ' ' ARG . 2.7 m-85 -86.62 -148.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.308 -1.113 . . . . 0.0 109.812 -179.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -45.24 -70.22 0.65 Allowed Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.064 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -66.79 -50.4 62.79 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 108.802 179.559 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.484 ' HG3' ' N ' ' A' ' 97' ' ' HIS . 0.0 OUTLIER 76.58 -34.58 0.23 Allowed 'General case' 0 N--CA 1.504 2.26 0 O-C-N 121.399 -0.813 . . . . 0.0 111.48 179.277 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.484 ' N ' ' HG3' ' A' ' 96' ' ' LYS . 14.2 m170 -87.1 60.52 6.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.466 -1.396 . . . . 0.0 109.554 179.854 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.535 HD12 ' CA ' ' A' ' 90' ' ' HIS . 83.6 mt -87.21 155.06 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.122 -0.986 . . . . 0.0 110.224 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.446 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -133.97 141.37 47.25 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.528 -0.732 . . . . 0.0 109.724 -179.941 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.1 -3.28 54.43 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.358 -0.839 . . . . 0.0 110.213 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.467 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 16.9 pt-20 -78.95 -23.49 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.909 -1.12 . . . . 0.0 109.54 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.571 ' CG ' ' HE2' ' A' ' 41' ' ' MET . 71.8 m-85 -80.33 -7.0 58.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.23 -0.918 . . . . 0.0 110.026 179.837 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.755 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -70.0 -66.91 0.53 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.115 -0.99 . . . . 0.0 110.092 -179.561 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.492 ' CB ' ' CD ' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.78 -60.02 3.48 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.494 -0.754 . . . . 0.0 110.743 -179.338 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.521 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 4.2 Cg_endo -52.87 -55.7 3.5 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.683 1.359 . . . . 0.0 109.995 -179.5 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.942 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -59.98 -19.76 54.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.283 179.745 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.418 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -75.33 -45.72 18.04 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.57 -46.79 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.134 -1.215 . . . . 0.0 109.321 179.863 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.5 m -64.87 -17.64 64.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.251 -0.905 . . . . 0.0 109.407 179.584 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.889 HD21 ' CE ' ' A' ' 114' ' ' MET . 4.9 tt -74.63 -41.87 59.6 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.186 -0.947 . . . . 0.0 109.685 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.738 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -60.24 -28.89 68.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.115 -0.991 . . . . 0.0 109.39 179.636 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 8.7 t -60.26 -46.15 90.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.334 -0.854 . . . . 0.0 109.64 179.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.611 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -66.29 -36.92 84.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.889 ' CE ' HD21 ' A' ' 110' ' ' LEU . 0.0 OUTLIER -47.28 -42.69 21.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.316 -0.865 . . . . 0.0 109.85 179.904 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.458 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -53.97 -24.01 15.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.277 -0.889 . . . . 0.0 109.766 -179.932 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.513 ' CD2' ' HA ' ' A' ' 113' ' ' ALA . 16.6 m170 -52.38 -55.16 23.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 109.842 -179.784 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.463 ' CD ' ' HA ' ' A' ' 17' ' ' ILE . 3.8 ttt85 -72.03 -66.09 0.69 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.188 -0.945 . . . . 0.0 109.833 -179.841 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.687 HG12 HD11 ' A' ' 17' ' ' ILE . 6.6 pt -94.57 58.59 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.114 -0.991 . . . . 0.0 109.748 -179.826 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -65.75 -39.49 95.26 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -85.92 -13.46 69.29 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.867 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.443 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 14.2 mttm -104.71 -20.84 13.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.07 -1.253 . . . . 0.0 109.883 -179.812 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -67.47 90.45 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.132 -0.98 . . . . 0.0 109.213 179.71 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.54 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 9.1 p-10 -92.5 -172.61 3.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.224 -0.922 . . . . 0.0 110.029 -179.619 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.422 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.65 -48.99 75.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.46 -0.775 . . . . 0.0 110.308 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.63 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -60.52 -24.88 65.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.03 -1.044 . . . . 0.0 109.428 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -75.18 -49.27 20.0 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.239 -0.913 . . . . 0.0 109.461 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.534 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 20.1 ptpt -73.04 -30.85 64.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -0.911 . . . . 0.0 109.74 -179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.479 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.5 t0 -76.71 -41.93 43.42 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.503 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.465 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -64.02 -43.28 96.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.368 -0.833 . . . . 0.0 109.376 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.878 ' CH2' HD12 ' A' ' 17' ' ' ILE . 6.8 m0 -75.6 -26.24 57.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.288 -0.882 . . . . 0.0 109.314 179.761 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.534 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -64.94 -26.4 68.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.454 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -96.82 -26.37 15.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.441 -0.787 . . . . 0.0 109.276 179.659 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.844 ' C ' HD12 ' A' ' 137' ' ' ILE . . . -73.93 -57.69 3.8 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.364 -0.835 . . . . 0.0 109.449 179.819 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.497 ' CE2' ' HE2' ' A' ' 114' ' ' MET . 17.2 m-30 -50.36 -29.18 9.4 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.333 179.784 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.27 -43.95 69.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.372 -0.83 . . . . 0.0 109.08 179.554 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -75.16 -33.32 61.47 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.352 -0.843 . . . . 0.0 109.238 179.663 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.844 HD12 ' C ' ' A' ' 133' ' ' ALA . 3.5 mt -67.9 -59.06 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.314 -0.866 . . . . 0.0 109.192 179.667 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.62 ' OG ' HMC2 ' A' ' 148' ' ' HEM . 0.4 OUTLIER -68.2 -48.76 64.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.717 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -50.91 -28.59 17.4 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.189 -1.565 . . . . 0.0 109.189 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.06 3.21 31.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.276 -1.132 . . . . 0.0 110.048 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.755 HD22 ' CE2' ' A' ' 103' ' ' PHE . 7.2 tt -97.97 -24.38 15.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.933 -1.104 . . . . 0.0 109.804 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.635 ' O ' HG22 ' A' ' 142' ' ' ILE . 6.8 mt -87.2 18.23 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.382 -179.446 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 84' ' ' LYS . 0.4 OUTLIER -77.96 -20.67 52.27 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.107 -0.996 . . . . 0.0 108.872 179.489 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -130.35 1.51 5.71 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.838 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.939 HD22 ' N ' ' A' ' 146' ' ' GLN . 0.2 OUTLIER -97.68 126.89 43.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.849 -1.383 . . . . 0.0 110.1 -179.825 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.939 ' N ' HD22 ' A' ' 145' ' ' LEU . 0.4 OUTLIER 160.6 48.3 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.856 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.642 -179.959 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.654 ' C1D' HG22 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.756 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.411 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.011 -1.636 . . . . 0.0 109.011 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.454 ' HA ' HD23 ' A' ' 2' ' ' LEU . 12.3 mt 56.92 165.39 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.332 -1.099 . . . . 0.0 109.714 -180.0 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p -151.8 -179.91 7.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.546 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.43 -22.59 59.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.135 -0.978 . . . . 0.0 109.21 179.726 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.901 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -86.4 -36.39 19.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.35 -0.844 . . . . 0.0 109.539 179.723 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.548 ' O ' HG23 ' A' ' 10' ' ' VAL . 40.5 mt-30 -70.92 -48.5 53.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.217 -0.927 . . . . 0.0 109.509 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.453 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 13.9 ptm180 -56.31 -30.83 63.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.277 -0.889 . . . . 0.0 109.348 179.856 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.453 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 17.7 mm-40 -73.74 -41.73 62.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.436 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 5' ' ' ALA . 21.6 t -61.4 -22.54 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.468 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.867 HG12 HG13 ' A' ' 70' ' ' VAL . 66.4 t -73.37 -43.31 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 109.673 179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.79 -8.03 54.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.288 -0.883 . . . . 0.0 110.016 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.5 m -94.23 -30.3 14.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.032 -1.043 . . . . 0.0 109.826 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.429 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 34.2 p -92.91 -13.17 29.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.954 -179.835 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.822 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -88.04 -19.49 27.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.117 -0.989 . . . . 0.0 109.849 -179.741 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 16.2 mtpt -83.87 -4.06 58.38 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.928 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.66 -53.31 2.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.788 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.959 HD12 ' CH2' ' A' ' 130' ' ' TRP . 60.9 mt -66.16 -36.28 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.455 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.823 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -104.29 27.34 7.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.51 -69.52 1.07 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 19.5 p -107.21 -36.95 6.41 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -1.141 . . . . 0.0 109.59 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -71.79 -20.04 61.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.922 . . . . 0.0 109.667 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.823 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 17.5 t30 54.54 30.44 13.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.268 -0.895 . . . . 0.0 109.593 -179.955 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.75 59.99 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.59 -47.3 67.09 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.108 -1.231 . . . . 0.0 109.52 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -88.23 12.97 62.94 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.52 HG11 HD11 ' A' ' 63' ' ' LEU . 11.3 t -97.84 -32.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.139 -1.212 . . . . 0.0 109.116 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 31' ' ' PHE . . . -86.69 -44.24 5.85 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.495 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.7 ptpt -53.87 -35.41 61.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.168 -1.195 . . . . 0.0 109.386 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.495 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 22.3 pt-20 -86.85 -26.83 23.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 109.366 179.714 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.416 ' N ' ' HG3' ' A' ' 29' ' ' GLU . 30.4 t -85.11 -58.31 2.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.366 -0.834 . . . . 0.0 109.684 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.677 ' HB3' HG13 ' A' ' 55' ' ' VAL . 3.4 m-85 -47.3 -32.57 4.82 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.333 -0.854 . . . . 0.0 109.915 -179.72 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.677 HG23 HG11 ' A' ' 55' ' ' VAL . 0.0 OUTLIER -60.54 -49.22 78.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.158 179.669 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -52.28 64.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.363 -0.836 . . . . 0.0 109.571 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.703 ' CG ' HD23 ' A' ' 106' ' ' LEU . 6.8 t80 -52.4 -54.48 31.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.189 -0.944 . . . . 0.0 109.483 179.939 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.918 ' CD1' HG22 ' A' ' 55' ' ' VAL . 38.2 mt -55.7 -43.67 76.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.665 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.572 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 9.6 t -68.81 -65.43 0.7 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.732 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.655 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -52.67 -27.35 16.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.723 -179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.655 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 16.2 m-70 -123.06 106.72 11.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.237 -0.914 . . . . 0.0 109.837 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -87.36 -20.83 26.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.429 -0.795 . . . . 0.0 109.294 179.542 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.411 ' OD1' ' HG2' ' A' ' 41' ' ' MET . 16.4 p-10 -66.15 -17.9 65.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.371 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.51 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 84.6 mmm -106.14 -24.5 12.33 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.266 -0.896 . . . . 0.0 109.705 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.463 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.88 -46.14 42.18 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.078 -1.014 . . . . 0.0 109.61 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.75 -21.12 60.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.302 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.945 HG13 ' CG ' ' A' ' 95' ' ' ASN . 35.8 t -76.16 -40.83 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.299 -0.876 . . . . 0.0 109.412 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.733 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 11.2 m-85 -67.26 -41.79 84.97 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.227 -0.921 . . . . 0.0 109.576 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.46 32.94 1.07 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -179.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.4 m-85 -125.04 173.15 8.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.225 -1.162 . . . . 0.0 109.629 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 17.6 t -111.51 19.38 18.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.301 -0.875 . . . . 0.0 109.371 179.547 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.11 -167.34 30.07 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.572 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -80.86 -23.0 39.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.203 -1.175 . . . . 0.0 109.66 -179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 12.5 m -84.74 51.24 2.09 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.923 . . . . 0.0 109.676 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -120.51 136.21 25.13 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.597 179.971 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -68.06 -33.45 25.42 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.97 1.511 . . . . 0.0 110.033 -179.906 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.41 -32.39 30.21 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.918 HG22 ' CD1' ' A' ' 35' ' ' LEU . 91.7 t -53.92 -41.61 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.268 -1.136 . . . . 0.0 109.501 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.706 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -74.5 -11.01 60.11 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.262 -0.899 . . . . 0.0 109.872 179.905 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.401 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 11.4 t0 -91.73 -33.3 15.08 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.111 -0.993 . . . . 0.0 109.375 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.516 ' HB3' ' CE2' ' A' ' 31' ' ' PHE . 1.6 mt -81.59 -64.25 1.22 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.348 -0.845 . . . . 0.0 110.201 -179.786 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.61 ' O ' HD23 ' A' ' 63' ' ' LEU . . . -56.09 -20.77 29.1 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.37 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.706 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -72.24 -40.76 67.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.109 -1.23 . . . . 0.0 109.761 -179.719 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.502 ' HB3' ' CGD' ' A' ' 148' ' ' HEM . 28.6 mttt -84.46 -43.67 14.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.601 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.562 HG21 ' O ' ' A' ' 149' ' ' CMO . 61.6 t -52.56 -47.18 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.128 -0.983 . . . . 0.0 109.48 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -48.09 -47.85 33.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.108 -0.995 . . . . 0.0 109.773 179.81 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.6 -49.38 47.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.24 -0.912 . . . . 0.0 109.653 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -49.06 -54.96 13.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.135 -0.978 . . . . 0.0 109.378 179.849 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.947 ' O ' HG23 ' A' ' 70' ' ' VAL . 83.7 mt -52.36 -35.32 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.313 -0.867 . . . . 0.0 109.05 179.554 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.85 -57.11 15.21 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.869 -1.693 . . . . 0.0 108.869 179.416 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.5 t -57.58 -25.91 25.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.271 -1.135 . . . . 0.0 109.253 179.76 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.438 ' HB1' HG12 ' A' ' 137' ' ' ILE . . . -84.07 -19.58 34.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.391 -0.818 . . . . 0.0 109.5 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.947 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.0 t -75.47 -14.47 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.686 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.488 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -90.41 35.64 0.88 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.109 -0.994 . . . . 0.0 109.96 -179.824 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' A' ' 71' ' ' SER . 6.0 m-70 -161.68 -84.75 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.063 -1.023 . . . . 0.0 109.918 179.953 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 72' ' ' HIS . 42.2 mt 60.22 -77.67 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.599 -0.688 . . . . 0.0 109.97 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.476 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -67.19 -24.48 73.4 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.43 146.54 26.22 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -1.159 . . . . 0.0 109.668 -179.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -140.45 62.45 1.49 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.24 -0.912 . . . . 0.0 109.605 179.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -115.41 -18.52 6.16 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.527 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 22.9 ttpt -140.19 -40.62 0.43 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.079 -1.248 . . . . 0.0 109.923 -179.896 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 59.0 ttp -48.17 -49.07 33.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.19 -0.944 . . . . 0.0 109.772 -179.866 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.8 t -73.07 -14.63 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.872 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -70.78 -35.08 72.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.126 -0.983 . . . . 0.0 109.835 -179.811 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.63 ' O ' HG23 ' A' ' 86' ' ' VAL . 10.7 tt0 -98.82 -40.97 7.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.666 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.7 mtp -62.18 -46.55 88.43 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.476 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.419 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 13.1 tttt -56.18 -39.27 72.11 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.172 -0.955 . . . . 0.0 109.172 179.65 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -63.19 -39.65 95.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 0.0 109.388 179.709 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.837 ' CG1' HD11 ' A' ' 141' ' ' LEU . 48.8 t -51.92 -47.96 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.525 ' O ' HD12 ' A' ' 145' ' ' LEU . . . -52.94 -49.88 53.15 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.624 -1.791 . . . . 0.0 108.624 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.647 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.1 t -53.13 -34.75 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.389 -1.065 . . . . 0.0 109.249 179.462 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.506 ' O ' ' CE1' ' A' ' 93' ' ' TYR . 24.6 mmm180 -69.56 -49.21 56.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.865 . . . . 0.0 109.416 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.582 ' HB2' HD12 ' A' ' 145' ' ' LEU . 10.7 m80 -61.63 -15.41 39.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.235 -0.916 . . . . 0.0 109.363 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.472 ' HG3' ' CB ' ' A' ' 147' ' ' SER . 4.8 ttmt -43.21 -33.49 0.94 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.466 -0.771 . . . . 0.0 110.917 -179.568 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.39 60.95 0.28 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.11 -1.519 . . . . 0.0 110.675 -179.502 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.506 ' CE1' ' O ' ' A' ' 89' ' ' ARG . 2.9 m-30 -69.83 -166.0 0.1 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.014 -1.286 . . . . 0.0 109.257 178.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.31 -22.63 61.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.612 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.945 ' CG ' HG13 ' A' ' 44' ' ' VAL . 0.2 OUTLIER -93.61 -44.06 8.38 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.381 -1.07 . . . . 0.0 109.321 -179.955 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.489 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 27.4 mttt 79.58 -32.14 0.14 Allowed 'General case' 0 N--CA 1.509 2.512 0 O-C-N 121.954 -0.467 . . . . 0.0 111.278 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.433 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 30.7 m170 -60.69 -99.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.518 -1.364 . . . . 0.0 109.99 -179.6 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.556 HD12 ' O ' ' A' ' 90' ' ' HIS . 6.1 mt 62.83 129.81 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 120.778 -1.201 . . . . 0.0 109.903 -179.546 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.514 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.1 OUTLIER -145.4 143.35 30.03 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 122.237 1.018 . . . . 0.0 110.85 -179.935 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.477 ' HB1' HD13 ' A' ' 142' ' ' ILE . . . -69.12 -19.61 64.04 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.047 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.465 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.5 OUTLIER -64.9 -32.77 74.64 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.772 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.514 ' CD2' ' HB2' ' A' ' 99' ' ' LYS . 22.9 m-85 -81.26 -25.62 36.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.589 -0.694 . . . . 0.0 109.956 179.847 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.782 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 3.4 m-85 -53.46 -65.88 0.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.22 -0.925 . . . . 0.0 110.344 -179.382 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.6 mt-10 -46.53 -59.43 5.06 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.251 -0.906 . . . . 0.0 110.512 -179.194 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 41.0 Cg_exo -45.42 -55.06 3.78 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.712 1.375 . . . . 0.0 110.621 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.706 HD13 ' C ' ' A' ' 106' ' ' LEU . 3.0 tm? -55.43 -39.13 69.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.34 -40.33 97.75 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.27 -55.07 27.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -1.162 . . . . 0.0 109.766 -179.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.1 t -60.16 -27.43 67.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.202 -0.937 . . . . 0.0 109.703 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.857 HD22 ' OH ' ' A' ' 134' ' ' TYR . 3.2 tt -70.35 -38.92 74.91 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.205 -0.935 . . . . 0.0 109.589 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.857 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.1 mt -60.08 -29.39 68.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.15 -0.969 . . . . 0.0 109.41 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 m -73.49 -29.7 62.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.784 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.467 ' O ' ' CG ' ' A' ' 116' ' ' HIS . . . -80.68 -38.3 29.23 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.181 -0.949 . . . . 0.0 109.569 179.963 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.597 ' SD ' HD23 ' A' ' 110' ' ' LEU . 1.9 mtt -50.1 -39.68 43.43 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.283 -0.885 . . . . 0.0 109.463 179.857 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.451 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.5 OUTLIER -51.67 -24.74 6.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.23 -0.919 . . . . 0.0 109.382 179.565 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.467 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 33.8 m170 -55.67 -49.67 72.31 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.327 -0.858 . . . . 0.0 109.829 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.438 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 2.9 ttt85 -70.1 -65.37 0.73 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.272 -0.892 . . . . 0.0 109.696 -179.837 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 122' ' ' MET . 13.5 pt -87.97 46.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 109.565 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.451 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -55.49 125.25 35.92 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 95.71 -30.44 8.39 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.743 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.431 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 19.2 mmtt -90.11 -28.71 18.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.227 -1.161 . . . . 0.0 109.166 179.682 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.448 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 1.2 ttt -71.37 107.38 4.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.437 -0.789 . . . . 0.0 109.359 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.507 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 10.0 p30 -109.72 -162.1 0.79 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.177 -0.952 . . . . 0.0 109.894 -179.776 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.431 ' O ' ' HB3' ' A' ' 128' ' ' ASP . . . -67.55 -45.78 74.67 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.346 -0.847 . . . . 0.0 109.64 -179.9 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.798 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -57.62 -24.03 54.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -86.23 -57.06 3.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.8 -179.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -65.94 -27.33 68.09 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.153 -0.967 . . . . 0.0 109.692 -179.735 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.431 ' HB3' ' O ' ' A' ' 124' ' ' ALA . 32.1 t70 -80.55 -49.95 10.65 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.311 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -57.7 -50.47 73.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.394 -0.816 . . . . 0.0 109.282 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.959 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.8 m0 -63.89 -30.96 71.99 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.237 -0.915 . . . . 0.0 108.877 179.478 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.539 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.98 -30.09 67.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 108.89 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.6 -28.52 23.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.392 -0.818 . . . . 0.0 109.194 179.501 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -81.85 -40.81 21.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.406 -0.809 . . . . 0.0 109.473 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.857 ' OH ' HD22 ' A' ' 110' ' ' LEU . 1.8 m-85 -50.26 -32.01 15.65 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.191 -0.943 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.45 -34.78 72.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.281 -0.887 . . . . 0.0 109.242 179.638 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.27 -39.68 39.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 0.0 109.371 179.692 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.677 HD13 HG23 ' A' ' 66' ' ' ILE . 54.5 mt -66.05 -58.12 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.274 -0.891 . . . . 0.0 109.145 179.669 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.11 -17.5 64.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.291 -0.881 . . . . 0.0 109.645 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 142' ' ' ILE . . . -68.25 -55.56 12.59 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -49.23 -28.19 4.38 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.837 HD11 ' CG1' ' A' ' 86' ' ' VAL . 2.9 tt -74.82 -21.55 59.22 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -0.893 . . . . 0.0 109.536 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.575 ' O ' HG22 ' A' ' 142' ' ' ILE . 91.0 mt -83.78 8.36 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.292 -0.88 . . . . 0.0 110.096 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.3 m -100.13 -46.0 5.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.04 -1.038 . . . . 0.0 109.508 179.935 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.647 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -68.86 -31.55 72.94 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.582 HD12 ' HB2' ' A' ' 90' ' ' HIS . 0.4 OUTLIER -61.61 -148.35 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.414 179.869 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.51 ' H ' HD23 ' A' ' 145' ' ' LEU . 22.9 mp0 52.92 43.37 31.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.01 -1.056 . . . . 0.0 109.762 179.845 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.472 ' CB ' ' HG3' ' A' ' 91' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.671 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.782 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.562 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.187 -1.565 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.502 HD11 ' CB ' ' A' ' 133' ' ' ALA . 15.4 mt -94.13 172.24 8.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.298 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -137.29 178.48 7.06 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.811 -1.18 . . . . 0.0 110.384 -179.802 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.81 -14.88 63.16 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.494 -0.754 . . . . 0.0 110.536 -179.506 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.581 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -94.82 -48.26 6.11 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.05 -1.032 . . . . 0.0 109.819 -179.679 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.434 ' O ' HG23 ' A' ' 10' ' ' VAL . 73.6 mt-30 -66.67 -33.96 76.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.638 179.903 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 42.9 mtp180 -54.75 -41.82 70.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.289 -0.882 . . . . 0.0 109.644 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -74.73 -36.55 62.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.239 -0.913 . . . . 0.0 109.549 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 5' ' ' ALA . 33.3 t -71.26 -35.8 59.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.151 -0.968 . . . . 0.0 108.987 179.628 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.777 HG23 ' HB1' ' A' ' 129' ' ' ALA . 41.9 t -67.46 -37.24 78.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.399 -0.813 . . . . 0.0 109.057 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.26 -16.29 56.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.345 -0.847 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.6 t -90.3 -22.72 21.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.891 -179.625 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.8 p -95.24 -12.28 26.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 110.028 -179.851 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.575 ' CZ3' ' CB ' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.31 -15.07 27.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.042 -1.037 . . . . 0.0 109.973 -179.895 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 34.7 mtpt -85.92 -2.0 57.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.73 -45.16 3.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.996 -1.065 . . . . 0.0 109.667 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.948 HD12 ' CH2' ' A' ' 130' ' ' TRP . 45.8 mt -72.47 -36.34 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.446 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.677 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -103.02 31.67 4.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.323 -0.86 . . . . 0.0 109.588 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -54.62 -78.73 0.1 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.54 -27.74 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.434 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 13.4 p-10 -80.01 -20.15 46.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 0.0 109.607 179.959 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.677 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 21.4 t30 56.16 27.7 11.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.875 . . . . 0.0 109.645 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.94 22.38 42.51 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -59.21 -52.37 65.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -1.161 . . . . 0.0 109.569 179.971 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.425 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -92.92 26.11 16.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.696 HG11 HD11 ' A' ' 63' ' ' LEU . 39.2 t -110.14 -22.73 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.29 -1.123 . . . . 0.0 108.887 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.412 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -100.15 -26.97 8.01 Favored Glycine 0 N--CA 1.488 2.146 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 179.79 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.485 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 14.2 ptpt -70.19 -34.99 73.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.245 -1.15 . . . . 0.0 109.385 179.789 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.737 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -92.34 -8.9 43.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.157 -0.964 . . . . 0.0 109.839 179.678 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 35.6 t -93.25 -61.3 1.6 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.067 -1.021 . . . . 0.0 109.722 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.509 ' CE2' ' HA2' ' A' ' 59' ' ' GLY . 11.9 m-85 -55.64 -30.56 61.18 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.926 . . . . 0.0 109.768 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.759 ' OG1' HG11 ' A' ' 55' ' ' VAL . 17.8 m -58.35 -48.01 81.96 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.125 -0.984 . . . . 0.0 109.395 179.794 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -62.31 -41.33 98.44 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.317 -0.865 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.643 ' CG ' HD23 ' A' ' 106' ' ' LEU . 2.4 t80 -62.14 -44.67 96.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.251 -0.905 . . . . 0.0 109.43 179.84 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.793 ' CD1' HG22 ' A' ' 55' ' ' VAL . 15.7 mt -62.8 -45.53 92.22 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.642 ' HB3' ' HB2' ' A' ' 50' ' ' ALA . 3.2 p -66.28 -46.75 75.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 109.738 -179.934 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.587 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -70.71 -21.4 62.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.753 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.587 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 33.7 m-70 -127.82 114.31 17.07 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.758 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.0 m170 -93.22 5.29 52.03 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.357 -0.839 . . . . 0.0 109.984 179.736 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -95.6 -22.18 17.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.044 -1.035 . . . . 0.0 109.486 179.811 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.619 ' CE ' HMB2 ' A' ' 148' ' ' HEM . 0.4 OUTLIER -97.01 -22.45 16.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.309 -0.87 . . . . 0.0 109.615 179.977 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.415 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -52.16 -50.75 61.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.196 -0.94 . . . . 0.0 109.536 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -66.41 -21.39 66.22 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.895 . . . . 0.0 109.585 179.897 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.944 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.6 t -79.73 -55.98 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.238 -0.914 . . . . 0.0 109.468 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.517 ' CD2' HD21 ' A' ' 35' ' ' LEU . 33.7 m-85 -53.74 -40.9 66.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.247 -0.908 . . . . 0.0 109.5 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.79 31.78 1.41 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 -179.849 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.504 ' CE1' ' HA3' ' A' ' 54' ' ' GLY . 11.9 m-85 -125.36 -179.07 4.44 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.201 -1.176 . . . . 0.0 109.749 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 26.9 t -123.99 19.17 9.25 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.417 -0.802 . . . . 0.0 109.299 179.481 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.44 -163.38 27.53 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.101 -1.6 . . . . 0.0 109.101 -179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.642 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -77.92 -19.08 55.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.698 -180.0 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 8.5 t -85.41 50.13 1.89 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.22 -0.925 . . . . 0.0 109.578 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -128.62 117.8 19.84 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.242 -0.911 . . . . 0.0 109.615 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -59.28 -29.54 90.56 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.842 1.443 . . . . 0.0 110.108 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.504 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.96 -34.49 38.44 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.793 HG22 ' CD1' ' A' ' 35' ' ' LEU . 89.3 t -52.26 -31.47 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.274 -1.133 . . . . 0.0 109.636 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.427 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -77.36 -21.86 52.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.487 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.83 -45.55 16.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.9 . . . . 0.0 109.557 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.956 ' O ' HG23 ' A' ' 62' ' ' VAL . 2.9 mt -68.25 -59.06 3.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.22 -0.925 . . . . 0.0 109.535 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.509 ' HA2' ' CE2' ' A' ' 31' ' ' PHE . . . -51.17 -54.8 21.77 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.421 ' CB ' ' O ' ' A' ' 56' ' ' ALA . . . -53.19 -37.61 62.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -1.17 . . . . 0.0 109.59 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 mttm -77.98 -25.79 48.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.565 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.956 HG23 ' O ' ' A' ' 58' ' ' LEU . 41.9 t -82.61 -40.91 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.505 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.696 HD11 HG11 ' A' ' 26' ' ' VAL . 1.6 mm? -50.11 -55.03 16.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.554 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -43.67 36.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.229 -0.919 . . . . 0.0 109.71 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.414 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 0.2 OUTLIER -51.59 -54.17 30.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 179.79 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.78 ' O ' HG23 ' A' ' 70' ' ' VAL . 69.2 mt -55.48 -34.65 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.263 -0.898 . . . . 0.0 108.98 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.567 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.84 -55.15 18.23 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.5 t -57.79 -22.12 17.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.322 -1.105 . . . . 0.0 109.138 179.759 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.68 -31.17 21.18 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.392 -0.818 . . . . 0.0 109.461 179.837 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.78 HG23 ' O ' ' A' ' 66' ' ' ILE . 53.0 t -69.24 -17.09 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 109.484 179.728 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 m -61.97 -37.93 86.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -0.941 . . . . 0.0 109.912 -179.832 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.437 ' HB2' ' HB2' ' A' ' 79' ' ' MET . 22.5 m-70 -129.29 81.73 2.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.126 -0.984 . . . . 0.0 109.885 -179.815 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.611 HD11 HG11 ' A' ' 10' ' ' VAL . 53.5 mt -85.51 -36.39 20.55 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.892 . . . . 0.0 109.461 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -90.38 -24.52 28.57 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 108.9 -1.68 . . . . 0.0 108.9 179.686 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -86.95 120.1 27.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.348 -1.089 . . . . 0.0 109.472 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -110.22 44.19 1.27 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.231 -0.918 . . . . 0.0 109.706 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -128.16 17.12 5.98 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 3.2 ttmt -158.47 -50.12 0.06 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.162 -1.199 . . . . 0.0 109.934 179.942 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.437 ' HB2' ' HB2' ' A' ' 72' ' ' HIS . 49.5 ttp -49.11 -41.2 35.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.188 -0.945 . . . . 0.0 109.652 -179.807 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.455 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 60.0 t -77.29 -0.53 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 110.036 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -86.11 -24.12 26.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.04 -1.038 . . . . 0.0 109.595 -179.975 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.564 ' O ' HG23 ' A' ' 86' ' ' VAL . 4.6 tt0 -106.77 -41.05 5.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 109.545 179.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.638 ' HE2' HD12 ' A' ' 141' ' ' LEU . 10.1 mtp -67.98 -40.81 83.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.219 -0.926 . . . . 0.0 108.949 179.653 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.455 ' CB ' ' O ' ' A' ' 80' ' ' VAL . 6.0 tttt -56.28 -28.56 59.12 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 179.009 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.425 ' O ' ' HD3' ' A' ' 89' ' ' ARG . . . -78.49 -31.92 47.99 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.48 -0.763 . . . . 0.0 109.056 179.459 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.936 ' CG1' HD11 ' A' ' 141' ' ' LEU . 47.3 t -62.72 -41.78 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.245 -0.91 . . . . 0.0 109.06 179.607 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 141' ' ' LEU . . . -54.06 -41.78 69.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.356 -1.898 . . . . 0.0 108.356 179.53 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.442 ' O ' ' HB3' ' A' ' 91' ' ' LYS . 97.5 t -56.34 -46.54 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.426 -1.043 . . . . 0.0 109.252 179.475 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.518 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 10.4 mpt_? -52.05 -29.96 23.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.028 -1.045 . . . . 0.0 109.054 179.466 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.503 ' HA ' ' CD2' ' A' ' 93' ' ' TYR . 34.6 m80 -84.22 9.51 12.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.417 -0.802 . . . . 0.0 110.022 -179.894 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 88' ' ' VAL . 25.0 ttpt -104.36 -11.74 16.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.034 -1.041 . . . . 0.0 110.241 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.17 18.79 2.31 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.142 -1.504 . . . . 0.0 110.855 -179.242 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.518 ' CZ ' ' HB3' ' A' ' 89' ' ' ARG . 1.6 m-85 -58.9 -164.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.644 -1.504 . . . . 0.0 109.174 179.317 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.77 -31.21 40.83 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 179.625 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.944 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.5 OUTLIER -81.14 -48.67 11.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.529 -0.983 . . . . 0.0 108.787 179.703 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.8 tmtt? 76.83 -19.3 0.43 Allowed 'General case' 0 N--CA 1.507 2.414 0 O-C-N 121.652 -0.655 . . . . 0.0 111.901 179.162 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.414 ' HB2' ' OD1' ' A' ' 95' ' ' ASN . 37.8 m170 -72.31 -95.82 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.443 -1.411 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.496 HG13 ' ND2' ' A' ' 95' ' ' ASN . 8.1 mt 61.71 148.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 120.858 -1.151 . . . . 0.0 110.511 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HD2' ' O ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -156.88 149.66 23.63 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 121.943 0.878 . . . . 0.0 110.521 179.812 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.4 ' O ' ' HB2' ' A' ' 103' ' ' PHE . . . -76.83 -7.29 55.18 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.681 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.567 ' CG ' ' CD2' ' A' ' 102' ' ' TYR . 12.0 pt-20 -71.38 -34.23 70.24 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.95 -1.094 . . . . 0.0 109.082 179.461 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.567 ' CD2' ' CG ' ' A' ' 101' ' ' GLU . 94.3 m-85 -80.3 -25.46 39.35 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 109.329 179.566 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.572 ' CE1' ' CHC' ' A' ' 148' ' ' HEM . 2.7 m-85 -48.12 -62.16 1.62 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.358 -0.839 . . . . 0.0 110.236 -179.798 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.513 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.7 OUTLIER -51.97 -59.84 7.41 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.177 -0.952 . . . . 0.0 110.173 -179.366 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.513 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 36.1 Cg_exo -47.53 -59.69 1.15 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.586 1.309 . . . . 0.0 110.229 179.91 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.922 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -54.29 -22.57 12.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.91 . . . . 0.0 109.406 179.906 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.01 -44.09 9.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.96 -49.96 74.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -1.163 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 75.6 m -56.65 -31.29 64.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 109.603 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 2.6 tt -62.75 -43.83 97.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -0.899 . . . . 0.0 109.602 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.71 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.7 mt -53.87 -39.19 65.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.212 -0.93 . . . . 0.0 109.553 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 13.5 t -62.3 -32.02 72.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.235 -0.915 . . . . 0.0 109.503 179.962 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.737 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -78.91 -39.73 34.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.41 179.758 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.547 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 4.1 mmt -48.72 -45.73 39.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.306 -0.871 . . . . 0.0 109.822 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.0 OUTLIER -48.32 -29.31 3.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -0.927 . . . . 0.0 109.968 -179.838 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.419 ' CE1' ' OE1' ' A' ' 29' ' ' GLU . 17.5 m170 -49.9 -56.4 10.69 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.082 -1.011 . . . . 0.0 109.817 -179.826 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.8 ttt85 -69.77 -63.57 1.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.849 -179.82 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.532 HG12 HD11 ' A' ' 17' ' ' ILE . 4.7 pt -96.61 58.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.313 -0.867 . . . . 0.0 109.709 -179.789 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.464 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.36 -20.32 71.38 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -98.73 -21.1 17.21 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.865 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.494 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -100.62 -19.37 16.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.183 -1.187 . . . . 0.0 109.884 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.406 ' HB2' ' O ' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.95 79.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.051 -1.031 . . . . 0.0 109.799 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.742 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 15.7 p-10 -80.13 -171.97 3.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.172 179.589 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.452 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -70.12 -31.35 68.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.066 -1.021 . . . . 0.0 109.907 -179.81 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.742 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -72.18 -23.69 61.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.038 -1.039 . . . . 0.0 109.024 179.668 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.476 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -74.88 -47.55 29.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 108.892 179.403 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 6.9 ptpt -71.79 -31.28 66.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.413 -0.805 . . . . 0.0 109.232 179.569 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.477 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 29.4 t70 -75.78 -48.52 21.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.777 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -58.55 -44.57 89.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.422 -0.799 . . . . 0.0 109.493 179.844 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.948 ' CH2' HD12 ' A' ' 17' ' ' ILE . 7.0 m0 -74.88 -26.17 59.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.222 -0.924 . . . . 0.0 109.245 179.838 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.611 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -69.12 -27.3 65.45 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.246 -0.909 . . . . 0.0 108.979 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.414 ' HB3' ' OE1' ' A' ' 6' ' ' GLN . . . -93.46 -23.06 18.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.192 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.629 ' O ' HD12 ' A' ' 137' ' ' ILE . . . -79.81 -42.88 23.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.395 -0.816 . . . . 0.0 109.556 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -49.26 -33.32 12.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.207 -0.933 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.74 -25.15 49.02 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.229 -0.919 . . . . 0.0 108.938 179.412 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.436 ' N ' ' O ' ' A' ' 133' ' ' ALA . 1.7 t0 -85.95 -40.76 15.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.387 -0.821 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.629 HD12 ' O ' ' A' ' 133' ' ' ALA . 1.6 mp -65.8 -59.6 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 108.824 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.78 ' OG ' HMC2 ' A' ' 148' ' ' HEM . 0.1 OUTLIER -64.6 -25.22 67.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.243 -0.911 . . . . 0.0 109.745 -179.85 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.572 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -55.68 -49.56 65.02 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -65.94 -17.75 64.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.234 -1.156 . . . . 0.0 109.845 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.936 HD11 ' CG1' ' A' ' 86' ' ' VAL . 5.1 tt -84.19 -33.38 24.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.15 -0.969 . . . . 0.0 109.738 -179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.572 HD12 ' HA2' ' A' ' 139' ' ' GLY . 50.6 mt -68.48 -9.25 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 110.065 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 67.6 m -70.51 -65.15 0.77 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.069 -1.019 . . . . 0.0 109.595 179.835 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.45 -7.37 64.09 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.676 HD23 ' N ' ' A' ' 146' ' ' GLN . 5.9 tt -83.86 176.82 8.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.08 -1.247 . . . . 0.0 109.48 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.676 ' N ' HD23 ' A' ' 145' ' ' LEU . 0.0 OUTLIER 55.48 29.74 13.84 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.607 -0.683 . . . . 0.0 110.295 179.907 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.439 ' HA ' ' CD ' ' A' ' 91' ' ' LYS . 7.7 p . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.024 -0.988 . . . . 0.0 109.698 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.78 HMC2 ' OG ' ' A' ' 138' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.499 ' O ' ' CE1' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.444 HD11 ' HA ' ' A' ' 133' ' ' ALA . 21.9 mt -51.22 165.78 0.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.357 -1.084 . . . . 0.0 109.964 -179.928 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -111.94 -174.02 2.37 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.491 ' HA ' ' CD ' ' A' ' 7' ' ' ARG . . . -79.8 -26.35 40.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.225 -0.922 . . . . 0.0 109.64 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.765 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -85.96 -32.37 21.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.9 . . . . 0.0 109.647 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.69 -47.74 18.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.148 -0.97 . . . . 0.0 109.428 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.491 ' CD ' ' HA ' ' A' ' 4' ' ' ALA . 8.3 ptm180 -52.54 -32.69 41.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.153 -0.967 . . . . 0.0 108.738 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.42 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 49.4 tp60 -71.16 -36.01 71.85 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 5' ' ' ALA . 47.5 t -73.3 -31.74 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.391 -0.818 . . . . 0.0 108.942 179.196 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.758 HG12 HG13 ' A' ' 70' ' ' VAL . 41.9 t -70.03 -37.49 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.743 . . . . 0.0 109.357 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.08 -16.35 58.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.691 179.903 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.4 -27.22 21.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.925 . . . . 0.0 109.693 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.2 p -88.5 -14.2 38.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.79 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.562 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.34 -20.55 21.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.125 -0.985 . . . . 0.0 109.717 -179.767 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 8.5 mtpp -79.74 -0.05 32.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.255 -0.903 . . . . 0.0 109.839 179.694 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -113.32 -56.35 2.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.011 -1.055 . . . . 0.0 109.553 179.856 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.94 HD12 ' CH2' ' A' ' 130' ' ' TRP . 73.9 mt -62.54 -34.18 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.202 -0.936 . . . . 0.0 109.55 179.939 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.526 ' CB ' ' CZ3' ' A' ' 14' ' ' TRP . . . -105.5 36.66 2.44 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.271 -0.893 . . . . 0.0 109.771 -179.889 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.86 -88.19 0.01 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.9 p -112.28 15.04 20.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -1.132 . . . . 0.0 109.697 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.423 ' O ' ' HB3' ' A' ' 22' ' ' ASN . 4.3 p-10 -122.1 -9.14 8.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.164 -0.96 . . . . 0.0 110.032 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.601 ' ND2' ' HB2' ' A' ' 64' ' ' ALA . 9.0 t30 56.41 20.17 4.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 0.0 109.565 -179.711 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.586 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 80.06 34.32 30.45 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.719 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.405 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -56.39 -43.99 79.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -1.139 . . . . 0.0 109.62 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.486 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -79.96 -18.32 72.67 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.91 HG11 HD21 ' A' ' 63' ' ' LEU . 25.7 t -68.76 -31.86 52.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -1.134 . . . . 0.0 109.551 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' ' HA3' ' A' ' 59' ' ' GLY . . . -78.23 -54.32 4.44 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.611 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.486 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.7 ptpt -55.19 -24.71 28.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -1.163 . . . . 0.0 110.108 -179.487 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.783 ' HG3' ' HB1' ' A' ' 113' ' ' ALA . 23.1 pt-20 -98.23 -16.15 19.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.001 -1.062 . . . . 0.0 109.851 179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.426 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 40.5 t -90.78 -60.19 1.98 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.186 -0.946 . . . . 0.0 110.014 -179.628 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.507 ' CZ ' ' O ' ' A' ' 149' ' ' CMO . 10.5 m-85 -59.83 -32.0 70.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.218 -0.926 . . . . 0.0 110.167 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.859 ' OG1' HG11 ' A' ' 55' ' ' VAL . 16.6 m -60.65 -45.05 95.55 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.096 -1.002 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.422 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 3.3 mttm -64.7 -29.26 70.25 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 179.91 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.652 ' CG ' HD23 ' A' ' 106' ' ' LEU . 17.0 t80 -78.3 -49.58 13.39 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.279 -0.888 . . . . 0.0 109.458 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.691 HD13 HG22 ' A' ' 55' ' ' VAL . 13.3 mt -51.84 -46.43 64.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.333 -0.854 . . . . 0.0 109.687 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.476 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 7.3 t -61.82 -59.96 4.36 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 109.677 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.593 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -62.35 -23.04 66.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.24 -0.912 . . . . 0.0 109.73 -179.919 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.593 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 25.5 m-70 -121.22 99.35 6.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.211 -0.931 . . . . 0.0 109.688 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 61.9 m170 -85.33 -19.79 30.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.309 -0.87 . . . . 0.0 109.531 179.936 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -69.28 -20.53 63.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.695 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.518 ' HE2' ' CD1' ' A' ' 102' ' ' TYR . 7.3 mmm -108.83 -16.83 14.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.201 -0.937 . . . . 0.0 109.824 -179.927 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.469 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -50.47 -41.0 52.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 0.0 109.378 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -76.47 -32.1 58.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.299 -0.876 . . . . 0.0 109.159 179.583 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.03 HG13 ' ND2' ' A' ' 95' ' ' ASN . 24.7 t -59.18 -56.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.384 -0.823 . . . . 0.0 109.245 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.546 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 62.4 m-85 -54.19 -31.03 51.77 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.21 29.68 3.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 -179.873 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.546 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.5 m-85 -123.81 167.6 13.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.254 -1.145 . . . . 0.0 109.735 -179.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.6 17.93 20.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.885 . . . . 0.0 109.422 179.625 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 149.74 -164.06 29.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.476 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -93.5 28.71 2.18 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -1.15 . . . . 0.0 109.618 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 99.5 p -126.91 28.1 5.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.08 137.44 22.44 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.569 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -65.67 -24.46 55.19 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.931 1.49 . . . . 0.0 110.095 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -52.22 -36.33 44.54 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.229 -1.549 . . . . 0.0 109.229 -179.941 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.859 HG11 ' OG1' ' A' ' 32' ' ' THR . 94.6 t -50.99 -39.9 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.299 -1.118 . . . . 0.0 109.42 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.71 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -76.54 -1.25 26.42 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.292 -0.88 . . . . 0.0 109.831 179.714 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -96.47 -27.45 14.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.05 -1.031 . . . . 0.0 109.703 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.787 ' O ' HG23 ' A' ' 62' ' ' VAL . 6.9 mt -86.65 -62.27 1.55 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.151 -0.968 . . . . 0.0 109.625 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.426 ' HA3' ' HA3' ' A' ' 27' ' ' GLY . . . -57.62 -24.67 53.65 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.71 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -66.53 -31.61 72.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.634 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.507 ' CB ' ' CGD' ' A' ' 148' ' ' HEM . 9.3 mtpt -101.82 -39.58 7.33 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.428 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.787 HG23 ' O ' ' A' ' 58' ' ' LEU . 58.3 t -51.7 -53.77 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.27 -0.894 . . . . 0.0 109.857 -179.934 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.91 HD21 HG11 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -45.9 -44.5 14.63 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.321 -0.862 . . . . 0.0 110.42 -179.705 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.601 ' HB2' ' ND2' ' A' ' 22' ' ' ASN . . . -52.99 -30.02 32.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.059 -1.025 . . . . 0.0 109.674 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 60.7 tp60 -69.49 -31.97 70.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.094 -1.004 . . . . 0.0 108.834 179.178 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 70' ' ' VAL . 94.0 mt -72.97 -31.5 35.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.413 -0.804 . . . . 0.0 108.861 179.271 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.562 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -70.09 -48.37 40.12 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 179.551 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 92.1 t -63.66 -24.17 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.246 -1.149 . . . . 0.0 109.113 179.736 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -86.04 -26.46 25.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.468 -0.77 . . . . 0.0 109.481 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 66' ' ' ILE . 48.6 t -67.57 -13.71 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.212 -0.93 . . . . 0.0 109.718 179.842 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.418 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 5.0 m -81.09 -16.9 51.83 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.849 -179.921 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 5.7 m-70 -128.76 66.99 1.41 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.177 -0.952 . . . . 0.0 109.672 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.631 HD11 ' HA ' ' A' ' 70' ' ' VAL . 65.2 mt -101.37 -26.87 13.45 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.305 -0.872 . . . . 0.0 109.534 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.79 -27.21 54.45 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.023 -1.631 . . . . 0.0 109.023 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -111.24 150.28 29.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -1.117 . . . . 0.0 109.506 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -128.44 55.6 1.68 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.615 -179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -131.02 15.98 5.31 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.566 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 13.7 ttpp -164.29 -42.75 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.076 -1.25 . . . . 0.0 109.735 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.455 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 11.8 tmm? -48.64 -41.28 30.71 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.211 -0.931 . . . . 0.0 109.567 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.411 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 48.6 t -73.13 -20.43 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.895 . . . . 0.0 109.421 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.566 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -57.3 -56.63 19.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 179.761 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.61 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -64.18 -53.2 53.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.355 -0.841 . . . . 0.0 109.233 179.664 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.418 ' HG3' ' O ' ' A' ' 79' ' ' MET . 0.5 OUTLIER -53.15 -57.05 11.79 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.68 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.467 ' HD2' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.86 -29.17 18.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 0.0 109.013 179.488 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -72.39 -42.82 64.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.43 -0.794 . . . . 0.0 109.133 179.608 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 82' ' ' GLU . 16.7 t -62.27 -35.77 71.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.017 179.621 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.466 ' HA2' HD21 ' A' ' 141' ' ' LEU . . . -57.46 -44.2 93.75 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.591 -1.803 . . . . 0.0 108.591 179.612 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 90.2 t -54.96 -35.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.285 -1.127 . . . . 0.0 109.033 179.397 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 93' ' ' TYR . 6.9 mpt_? -70.69 -30.79 67.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.387 -0.821 . . . . 0.0 109.163 179.55 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.768 ' CB ' HD13 ' A' ' 145' ' ' LEU . 27.5 m80 -80.04 2.85 22.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.346 -0.846 . . . . 0.0 109.974 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.3 ttmt -101.07 14.01 33.35 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.057 -1.027 . . . . 0.0 110.011 -179.539 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -169.41 31.51 0.16 Allowed Glycine 0 N--CA 1.491 2.336 0 C-N-CA 119.231 -1.462 . . . . 0.0 110.543 -179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.53 ' CD2' ' HA ' ' A' ' 90' ' ' HIS . 1.9 m-85 -74.08 -163.82 0.2 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.739 -1.448 . . . . 0.0 109.688 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -65.29 -53.45 32.78 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.521 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.03 ' ND2' HG13 ' A' ' 44' ' ' VAL . 14.6 p-10 -67.37 -33.67 75.69 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -1.164 . . . . 0.0 109.849 -179.729 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 4.6 mttt 55.27 21.19 3.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.241 -0.912 . . . . 0.0 109.633 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -128.3 48.66 2.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.49 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.727 HD13 ' CD2' ' A' ' 90' ' ' HIS . 61.9 mt -86.33 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.771 -179.883 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.494 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 4.8 mptt -141.73 143.52 33.56 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.325 -0.859 . . . . 0.0 109.766 -179.895 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.659 ' CB ' HG23 ' A' ' 142' ' ' ILE . . . -83.19 6.93 17.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.851 179.69 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.26 -21.12 21.24 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.178 -0.951 . . . . 0.0 108.779 179.723 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.518 ' CD1' ' HE2' ' A' ' 41' ' ' MET . 61.5 m-85 -85.16 -13.16 50.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.302 -0.874 . . . . 0.0 109.872 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.753 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 4.3 m-85 -61.07 -61.2 2.74 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.164 -0.96 . . . . 0.0 110.038 -179.818 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.502 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.3 OUTLIER -49.44 -56.94 13.53 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.881 -179.612 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.502 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 37.7 Cg_exo -50.94 -62.0 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 123.684 1.36 . . . . 0.0 109.929 179.741 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.778 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.0 tm? -57.99 -25.86 61.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.29 -0.881 . . . . 0.0 109.46 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.498 ' HA3' ' CE1' ' A' ' 134' ' ' TYR . . . -72.97 -39.55 54.04 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.985 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -63.43 -50.0 71.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.217 -1.167 . . . . 0.0 109.479 179.863 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 9.0 m -57.3 -20.64 29.54 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.239 -0.913 . . . . 0.0 109.482 179.832 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.456 HD23 ' HG3' ' A' ' 114' ' ' MET . 1.1 tt -69.18 -46.17 68.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.746 -179.947 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.736 HD21 ' CB ' ' A' ' 130' ' ' TRP . 12.4 mt -58.56 -30.5 67.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.142 -0.974 . . . . 0.0 109.442 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.3 m -73.45 -40.87 63.85 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.246 -0.909 . . . . 0.0 109.671 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.783 ' HB1' ' HG3' ' A' ' 29' ' ' GLU . . . -74.46 -31.01 62.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.235 -0.915 . . . . 0.0 109.653 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.503 ' CE ' ' CZ3' ' A' ' 130' ' ' TRP . 2.8 mmt -60.06 -43.05 95.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.72 179.965 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.46 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.2 OUTLIER -49.81 -25.37 3.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.778 -179.884 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -53.76 -56.21 19.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.204 -0.935 . . . . 0.0 109.797 -179.862 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.405 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -64.59 -58.64 5.79 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.153 -0.967 . . . . 0.0 109.749 -179.877 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.526 HG12 HD11 ' A' ' 17' ' ' ILE . 5.3 pt -103.04 59.59 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.922 . . . . 0.0 109.737 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.46 ' CA ' ' O ' ' A' ' 115' ' ' GLU . . . -67.77 -27.72 73.58 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.932 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -95.69 -17.59 35.35 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 5.4 mptt -101.7 -23.37 14.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 109.758 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.456 ' CA ' HD12 ' A' ' 118' ' ' ILE . 0.3 OUTLIER -71.29 83.9 0.77 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.138 -0.977 . . . . 0.0 109.581 179.937 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.574 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.3 p30 -81.39 -167.88 1.64 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.327 -0.858 . . . . 0.0 109.54 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -65.95 -47.81 73.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.574 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -56.96 -31.68 65.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.297 -0.877 . . . . 0.0 109.395 179.768 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -66.63 -53.03 38.48 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.822 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.521 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 2.5 ptpt -70.01 -26.6 64.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.26 -0.9 . . . . 0.0 109.263 179.727 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.476 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 38.7 t0 -82.53 -36.18 26.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 109.426 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.61 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -67.02 -43.26 83.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.758 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.94 ' CH2' HD12 ' A' ' 17' ' ' ILE . 12.1 m0 -76.7 -29.13 56.13 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.238 -0.913 . . . . 0.0 109.062 179.903 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -50.68 -43.05 57.44 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.319 -0.863 . . . . 0.0 109.098 179.43 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.13 -17.32 35.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.419 -0.801 . . . . 0.0 109.228 179.33 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.711 ' HB3' ' HA ' ' A' ' 130' ' ' TRP . . . -88.01 -61.57 1.69 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.246 -0.909 . . . . 0.0 109.704 179.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.502 ' CE2' ' HA ' ' A' ' 131' ' ' ALA . 0.1 OUTLIER -50.47 -27.01 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.07 -1.019 . . . . 0.0 109.144 -179.825 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.23 -31.56 30.2 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.305 -0.872 . . . . 0.0 108.795 179.17 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -82.1 -37.83 25.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.448 -0.783 . . . . 0.0 109.405 179.729 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.45 HD12 ' N ' ' A' ' 137' ' ' ILE . 1.6 mp -65.86 -58.4 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 108.776 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -29.87 70.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 179.786 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.492 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -70.5 -35.63 68.33 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.48 -23.94 66.34 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -1.176 . . . . 0.0 109.614 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.667 ' O ' HD23 ' A' ' 141' ' ' LEU . 8.7 tt -74.55 -17.3 60.76 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.254 -0.904 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.659 HG23 ' CB ' ' A' ' 100' ' ' ALA . 58.7 mt -76.39 -0.96 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.197 -0.939 . . . . 0.0 110.101 179.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.467 ' CB ' ' HD2' ' A' ' 84' ' ' LYS . 19.5 m -66.91 -32.9 74.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.991 -1.068 . . . . 0.0 109.051 179.669 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -118.4 -10.98 8.33 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.24 -1.544 . . . . 0.0 109.24 179.62 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.768 HD13 ' CB ' ' A' ' 90' ' ' HIS . 19.2 tp -93.31 91.57 7.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.041 -1.27 . . . . 0.0 109.571 -179.904 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . . . . . . . . . 6.7 mm-40 -120.04 -11.48 9.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.013 -1.054 . . . . 0.0 109.633 -179.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.753 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.507 ' O ' ' CZ ' ' A' ' 31' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 mt -58.57 166.78 1.67 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.291 -1.123 . . . . 0.0 109.819 179.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 p -123.3 -170.16 2.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.658 179.748 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.28 -27.88 42.29 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.892 . . . . 0.0 109.967 -179.668 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.603 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -85.23 -30.38 23.91 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.169 -0.957 . . . . 0.0 109.796 -179.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.424 ' O ' HG23 ' A' ' 10' ' ' VAL . 42.1 mt-30 -78.29 -52.27 8.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.169 -0.957 . . . . 0.0 109.887 -179.856 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.98 -29.37 12.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.97 -1.081 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -70.71 -45.21 65.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 0.0 108.778 179.353 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.603 HG23 ' O ' ' A' ' 5' ' ' ALA . 44.8 t -62.12 -31.25 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.364 -0.835 . . . . 0.0 108.859 179.27 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 1.048 HG12 HG13 ' A' ' 70' ' ' VAL . 98.6 t -66.03 -50.13 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.512 -0.743 . . . . 0.0 109.4 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.11 61.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.9 m -83.45 -25.05 31.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.105 -0.997 . . . . 0.0 109.744 -179.919 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.452 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 38.2 p -100.22 -10.18 21.64 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.92 . . . . 0.0 110.043 -179.907 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.566 ' CH2' ' HA3' ' A' ' 67' ' ' GLY . 0.0 OUTLIER -91.12 -25.8 19.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.027 -1.046 . . . . 0.0 109.609 -179.968 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.9 mtpp -76.05 -12.8 60.19 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.224 -0.923 . . . . 0.0 109.641 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.468 ' HB3' ' CG2' ' A' ' 118' ' ' ILE . 0.4 OUTLIER -103.02 -52.67 3.0 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.997 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.949 HD12 ' CH2' ' A' ' 130' ' ' TRP . 44.1 mt -65.14 -34.78 72.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.271 -0.893 . . . . 0.0 109.581 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.891 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -107.91 35.24 3.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 109.719 -179.948 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.1 -84.14 0.03 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 78.3 p -97.51 -23.41 16.04 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.307 -1.114 . . . . 0.0 109.617 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.629 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 12.3 p-10 -83.34 -21.45 33.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -0.901 . . . . 0.0 109.662 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.891 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 9.9 t30 56.79 20.57 5.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.92 . . . . 0.0 109.61 179.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.2 20.94 11.39 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.629 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -67.49 -47.52 69.8 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.248 -1.148 . . . . 0.0 109.567 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' O ' ' HG2' ' A' ' 29' ' ' GLU . . . -93.34 31.63 6.26 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.517 ' CG1' HD21 ' A' ' 110' ' ' LEU . 41.9 t -119.05 -35.91 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.297 -1.12 . . . . 0.0 108.942 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.462 ' HA3' ' CA ' ' A' ' 59' ' ' GLY . . . -90.26 -41.17 5.58 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.766 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.481 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 7.3 ptpt -61.08 -30.63 70.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 109.587 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.79 ' OE2' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -90.41 -25.16 20.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.124 -0.985 . . . . 0.0 109.422 179.798 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 41.4 t -85.54 -50.63 7.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.353 -0.842 . . . . 0.0 109.574 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.553 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 5.0 m-30 -55.2 -37.56 67.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.189 -0.944 . . . . 0.0 109.585 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.574 ' OG1' HG11 ' A' ' 55' ' ' VAL . 98.6 m -55.82 -45.89 78.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.901 . . . . 0.0 109.347 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.411 ' HD2' ' O ' ' A' ' 29' ' ' GLU . 13.6 mttp -66.59 -47.63 72.12 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.403 179.738 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.532 ' CG ' HD23 ' A' ' 106' ' ' LEU . 4.3 t80 -55.7 -49.94 71.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.239 -0.913 . . . . 0.0 109.297 179.794 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.732 ' CD1' HG22 ' A' ' 55' ' ' VAL . 32.3 mt -59.48 -45.1 92.63 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.874 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.89 -61.68 2.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.691 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -58.04 -28.64 64.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.938 . . . . 0.0 109.694 -179.906 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.657 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 9.4 m-70 -118.0 103.38 9.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.203 -0.936 . . . . 0.0 109.718 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -85.61 -21.45 28.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.34 -0.85 . . . . 0.0 109.345 179.634 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 14.2 p-10 -68.23 -20.49 64.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.912 . . . . 0.0 109.275 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.504 ' HE3' ' CMB' ' A' ' 148' ' ' HEM . 92.2 mmm -103.26 -22.35 13.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.321 -0.862 . . . . 0.0 109.581 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -51.17 -44.45 61.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.031 -1.043 . . . . 0.0 109.338 179.825 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.68 -23.38 59.81 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.346 -0.846 . . . . 0.0 109.136 179.565 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.047 HG13 ' ND2' ' A' ' 95' ' ' ASN . 29.2 t -73.44 -39.96 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.423 -0.798 . . . . 0.0 109.202 179.733 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.542 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 11.2 m-85 -68.89 -38.95 79.97 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.573 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.404 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 117.66 28.22 2.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.882 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.542 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.3 m-85 -122.31 172.23 8.47 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.199 -1.177 . . . . 0.0 109.692 -179.981 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 11.7 t -111.13 19.22 18.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.316 -0.865 . . . . 0.0 109.351 179.493 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 150.95 -164.0 29.87 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.79 5.82 41.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.224 -1.162 . . . . 0.0 110.073 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 15.2 t -110.09 42.27 1.56 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.001 -1.062 . . . . 0.0 109.548 179.976 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.414 ' HA ' ' HD3' ' A' ' 53' ' ' PRO . 0.4 OUTLIER -115.85 131.54 23.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 0.0 109.624 -179.979 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 52' ' ' ASP . 16.9 Cg_exo -61.34 -20.47 68.36 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 123.81 1.426 . . . . 0.0 109.949 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -59.9 -35.95 88.52 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.732 HG22 ' CD1' ' A' ' 35' ' ' LEU . 58.9 t -54.56 -22.78 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -1.095 . . . . 0.0 109.468 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.457 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -86.47 -19.44 29.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.319 -0.863 . . . . 0.0 109.571 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.406 ' O ' ' HB2' ' A' ' 61' ' ' LYS . 0.3 OUTLIER -88.11 -26.45 22.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.296 -0.878 . . . . 0.0 109.588 -179.994 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.782 HD21 ' CHA' ' A' ' 148' ' ' HEM . 2.7 mt -86.44 -66.58 0.89 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.188 -0.945 . . . . 0.0 109.766 -179.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.553 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -49.46 -37.06 25.1 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.439 ' HB3' ' O ' ' A' ' 56' ' ' ALA . . . -72.45 -22.32 61.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.151 -1.205 . . . . 0.0 109.946 -179.698 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.406 ' HB2' ' O ' ' A' ' 57' ' ' ASP . 4.7 mttp -94.55 -21.9 18.56 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.122 -0.986 . . . . 0.0 109.827 -179.868 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 58' ' ' LEU . 23.3 t -83.71 -46.77 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.198 -0.938 . . . . 0.0 109.889 -179.784 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.671 HD21 HD11 ' A' ' 110' ' ' LEU . 2.9 mm? -47.86 -46.88 31.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -48.61 -51.91 25.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.194 -0.941 . . . . 0.0 109.992 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 31.3 tp60 -50.65 -42.98 57.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.07 -1.019 . . . . 0.0 109.438 -179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.881 ' O ' HG23 ' A' ' 70' ' ' VAL . 39.8 mt -61.34 -38.36 79.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.312 -0.868 . . . . 0.0 109.238 179.621 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.566 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -63.73 -50.97 57.62 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.873 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 86.4 t -61.22 -29.96 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.083 -1.245 . . . . 0.0 109.467 -179.823 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.607 ' O ' HD21 ' A' ' 73' ' ' LEU . . . -84.72 -14.52 48.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.424 -0.798 . . . . 0.0 110.094 -179.42 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.048 HG13 HG12 ' A' ' 10' ' ' VAL . 41.6 t -84.64 -43.36 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.027 -1.046 . . . . 0.0 110.091 -179.409 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.35 -24.75 2.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.987 -1.07 . . . . 0.0 109.33 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.562 ' CG ' ' CB ' ' A' ' 76' ' ' GLU . 3.2 m-70 -93.83 -114.08 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.532 -0.73 . . . . 0.0 109.946 -179.787 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.799 HD11 ' HA ' ' A' ' 70' ' ' VAL . 16.5 mt 66.15 -57.42 0.36 Allowed 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.027 -1.045 . . . . 0.0 110.392 -179.289 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.468 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -58.01 -45.43 93.81 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 -179.133 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.472 ' O ' ' N ' ' A' ' 77' ' ' GLY . 35.1 m-20 -140.18 -41.13 0.43 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.853 -1.38 . . . . 0.0 111.695 -179.085 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.562 ' CB ' ' CG ' ' A' ' 72' ' ' HIS . 0.3 OUTLIER -68.51 51.54 0.07 Allowed 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.325 -0.859 . . . . 0.0 111.284 -178.007 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 80' ' ' VAL . . . -65.37 -17.17 63.78 Favored Glycine 0 N--CA 1.475 1.236 0 N-CA-C 105.911 -2.876 . . . . 0.0 105.911 176.246 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 15.8 ttmt -49.9 -38.58 36.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.564 -0.963 . . . . 0.0 108.852 178.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.463 ' CG ' ' O ' ' A' ' 76' ' ' GLU . 0.0 OUTLIER -50.36 -25.81 4.24 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.16 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 77' ' ' GLY . 53.5 t -51.21 -31.11 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.076 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.24 -35.61 76.3 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.434 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.3 OUTLIER -61.27 -52.97 62.49 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.215 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.556 ' CE ' HD12 ' A' ' 141' ' ' LEU . 86.5 mmm -56.96 -38.56 73.13 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.255 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -51.45 -35.74 40.96 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.434 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -67.89 -32.37 72.81 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 1.044 HG11 HD11 ' A' ' 141' ' ' LEU . 48.6 t -59.38 -51.95 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 108.785 179.432 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.47 ' O ' HD12 ' A' ' 145' ' ' LEU . . . -56.66 -52.94 47.42 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.061 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.764 HG23 ' HA3' ' A' ' 144' ' ' GLY . 63.3 t -51.75 -33.26 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.397 -1.061 . . . . 0.0 108.817 179.065 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.508 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.0 mmm180 -76.43 -49.75 15.88 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.189 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.582 ' HB2' HD13 ' A' ' 145' ' ' LEU . 2.1 m80 -58.92 -21.24 57.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.464 -0.772 . . . . 0.0 109.115 179.332 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.501 ' CG ' ' HA ' ' A' ' 147' ' ' SER . 0.0 OUTLIER -66.72 -12.08 57.07 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.314 -0.866 . . . . 0.0 110.254 -179.704 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -143.31 53.49 0.6 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.634 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.552 ' CZ ' ' ND1' ' A' ' 90' ' ' HIS . 3.1 m-30 -89.23 -164.36 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.238 -1.154 . . . . 0.0 109.702 179.734 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -71.14 -51.14 19.33 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.047 ' ND2' HG13 ' A' ' 44' ' ' VAL . 17.1 p-10 -69.16 -32.36 71.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.14 -1.212 . . . . 0.0 109.828 -179.686 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.8 tttm 58.26 18.86 5.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.197 -0.939 . . . . 0.0 109.699 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 15.4 m170 -125.75 41.27 3.56 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.69 -179.935 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.566 HD13 ' CD2' ' A' ' 90' ' ' HIS . 36.4 mt -81.32 155.75 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.184 -0.947 . . . . 0.0 109.679 -179.97 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.473 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.1 mptp? -136.58 145.58 45.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.884 -179.825 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.782 ' HB1' ' CG1' ' A' ' 142' ' ' ILE . . . -86.4 11.77 11.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.318 -0.864 . . . . 0.0 109.954 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.566 ' CG ' ' CD1' ' A' ' 102' ' ' TYR . 15.5 pt-20 -95.48 -24.21 16.76 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.107 -0.995 . . . . 0.0 109.557 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.566 ' CD1' ' CG ' ' A' ' 101' ' ' GLU . 88.7 m-85 -83.03 -7.39 59.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.265 -0.897 . . . . 0.0 109.928 179.722 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.857 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 11.3 m-85 -66.87 -52.17 46.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.096 -1.002 . . . . 0.0 109.945 -179.739 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.504 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 1.5 tm-20 -56.54 -55.61 40.99 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.131 -0.98 . . . . 0.0 109.867 -179.685 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 35.1 Cg_exo -51.83 -61.85 0.46 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 123.755 1.397 . . . . 0.0 109.83 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.925 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.4 tm? -55.75 -23.78 31.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.291 -0.88 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.99 -48.67 6.84 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.36 65.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -1.191 . . . . 0.0 109.414 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.0 m -75.28 -31.01 60.6 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.872 . . . . 0.0 109.518 179.893 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.813 HD22 ' OH ' ' A' ' 134' ' ' TYR . 1.0 OUTLIER -70.13 -30.16 67.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 109.41 179.905 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.696 HD21 ' HB3' ' A' ' 130' ' ' TRP . 11.1 mt -64.34 -32.11 73.59 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.348 179.767 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 0.4 OUTLIER -74.89 -26.2 59.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 109.54 179.864 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.79 ' HB1' ' OE2' ' A' ' 29' ' ' GLU . . . -85.77 -35.78 20.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.247 -0.908 . . . . 0.0 109.518 -179.885 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.512 ' HE3' HD22 ' A' ' 110' ' ' LEU . 2.8 mtt -49.44 -45.08 46.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 0.0 110.116 -179.717 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' SER . 13.3 pt-20 -50.27 -25.69 3.98 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.153 -0.967 . . . . 0.0 109.907 -179.719 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.405 ' CG ' ' O ' ' A' ' 113' ' ' ALA . 29.7 m170 -50.12 -39.92 44.46 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.635 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.447 ' NE ' ' O ' ' A' ' 17' ' ' ILE . 3.2 ttt85 -80.17 -61.7 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.179 -0.951 . . . . 0.0 109.539 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.468 ' CG2' ' HB3' ' A' ' 16' ' ' ASP . 7.2 pt -89.35 44.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.236 -0.915 . . . . 0.0 109.521 179.824 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 115' ' ' GLU . . . -51.62 123.07 18.15 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 102.12 -39.82 2.64 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.873 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.431 ' O ' ' N ' ' A' ' 123' ' ' ASN . 29.9 mttp -83.54 -29.5 27.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -1.14 . . . . 0.0 109.439 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.407 ' HB2' ' CD1' ' A' ' 118' ' ' ILE . 0.0 OUTLIER -66.26 76.73 0.1 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.381 -0.824 . . . . 0.0 109.235 179.727 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.581 ' OD1' ' HB3' ' A' ' 125' ' ' ALA . 9.4 p30 -79.8 -167.67 1.33 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.311 -0.868 . . . . 0.0 109.875 -179.714 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.469 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -63.95 -45.9 87.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.839 . . . . 0.0 109.531 179.868 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.581 ' HB3' ' OD1' ' A' ' 123' ' ' ASN . . . -58.07 -33.46 69.08 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.283 -0.886 . . . . 0.0 109.283 179.832 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.01 -53.38 20.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.28 -0.888 . . . . 0.0 109.417 179.832 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.503 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 11.9 ptpt -70.47 -26.84 63.81 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.191 -0.943 . . . . 0.0 109.356 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.447 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 17.8 t70 -81.91 -39.81 23.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.218 -0.926 . . . . 0.0 109.357 179.557 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 125' ' ' ALA . . . -62.37 -43.54 98.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.375 -0.828 . . . . 0.0 109.241 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.949 ' CH2' HD12 ' A' ' 17' ' ' ILE . 9.0 m0 -75.57 -31.89 60.17 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.304 -0.873 . . . . 0.0 108.7 179.563 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.503 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -55.46 -30.84 61.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.22 -0.925 . . . . 0.0 108.631 178.867 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -87.11 -28.89 22.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.424 -0.797 . . . . 0.0 109.101 179.477 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' A' ' 136' ' ' ASP . . . -82.93 -52.65 6.5 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.431 -0.793 . . . . 0.0 109.465 179.899 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.813 ' OH ' HD22 ' A' ' 110' ' ' LEU . 0.1 OUTLIER -49.85 -30.05 9.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 0.0 109.376 179.85 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -78.73 -27.62 44.87 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.275 -0.891 . . . . 0.0 108.984 179.456 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' A' ' 133' ' ' ALA . 2.4 t0 -84.12 -39.86 18.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.435 -0.791 . . . . 0.0 109.408 179.802 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.558 HD13 HG23 ' A' ' 66' ' ' ILE . 8.2 mt -67.7 -56.33 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.497 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.556 ' O ' HD12 ' A' ' 142' ' ' ILE . 87.2 p -69.37 -36.7 77.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.334 -0.853 . . . . 0.0 109.607 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.558 ' HA2' HD13 ' A' ' 142' ' ' ILE . . . -56.23 -23.11 39.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.942 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.03 59.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 0.0 109.998 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.044 HD11 HG11 ' A' ' 86' ' ' VAL . 0.2 OUTLIER -91.4 -19.45 22.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.109 -0.994 . . . . 0.0 109.811 -179.847 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.782 ' CG1' ' HB1' ' A' ' 100' ' ' ALA . 3.2 mp -80.06 3.37 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.218 -0.926 . . . . 0.0 110.115 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 23.4 m -100.8 -31.09 11.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.01 -1.057 . . . . 0.0 109.925 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.764 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -93.1 -21.47 30.14 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.609 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.582 HD13 ' HB2' ' A' ' 90' ' ' HIS . 12.8 tp -77.46 -133.54 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.179 -1.189 . . . . 0.0 109.315 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.635 HE22 ' HB2' ' A' ' 100' ' ' ALA . 2.2 mp0 49.19 41.86 20.54 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.781 -1.199 . . . . 0.0 109.93 179.688 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.501 ' HA ' ' CG ' ' A' ' 91' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.637 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.857 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.488 ' C ' HD22 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.904 ' C ' HD12 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.262 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.904 HD12 ' C ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 42.6 34.88 0.6 Allowed 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.564 -0.962 . . . . 0.0 109.308 179.904 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.44 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 2.0 p -90.36 -156.24 0.42 Allowed 'General case' 0 C--N 1.289 -2.05 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.11 -178.604 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -65.76 -10.61 38.67 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.425 -0.797 . . . . 0.0 110.208 -179.596 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.852 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -104.56 -54.13 2.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.015 -1.053 . . . . 0.0 110.187 -179.732 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.817 ' O ' HG23 ' A' ' 10' ' ' VAL . 65.7 mt-30 -70.99 -50.5 33.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.967 -1.083 . . . . 0.0 109.43 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.475 ' HG2' ' HB2' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -53.06 -24.25 9.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.175 -0.953 . . . . 0.0 109.048 179.583 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 5.8 mp0 -83.16 -53.29 5.89 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.434 -0.791 . . . . 0.0 109.521 179.893 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 5' ' ' ALA . 21.2 t -55.37 -33.99 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.817 HG23 ' O ' ' A' ' 6' ' ' GLN . 93.8 t -57.33 -43.17 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.95 -10.12 59.16 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.271 -0.893 . . . . 0.0 109.896 179.836 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 t -93.56 -26.21 17.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.123 -0.986 . . . . 0.0 109.99 -179.718 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.449 ' OG1' ' CE2' ' A' ' 130' ' ' TRP . 20.6 p -95.74 -15.25 22.74 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -0.971 . . . . 0.0 109.965 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.799 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -88.49 -23.02 23.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.065 -1.022 . . . . 0.0 109.686 -179.933 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 73.4 mttt -81.6 1.67 32.78 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.205 -0.934 . . . . 0.0 109.852 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.57 -48.51 2.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.128 -0.982 . . . . 0.0 109.263 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.994 HD12 ' CH2' ' A' ' 130' ' ' TRP . 42.0 mt -71.31 -28.76 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 0.0 109.432 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.696 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -109.33 34.42 3.77 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.235 -0.916 . . . . 0.0 109.603 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.15 -86.93 0.01 OUTLIER Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.9 p -100.77 -24.46 14.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -1.145 . . . . 0.0 109.706 -179.99 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.647 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 9.7 p-10 -81.02 -20.77 41.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.936 . . . . 0.0 109.699 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.696 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 28.8 t30 56.93 30.06 17.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.592 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.828 ' HA3' HD22 ' A' ' 63' ' ' LEU . . . 88.53 37.71 7.4 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.647 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -79.02 -49.63 12.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.256 -1.144 . . . . 0.0 109.655 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.487 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -76.23 -23.55 70.88 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 -179.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.005 HG12 HD11 ' A' ' 63' ' ' LEU . 41.5 t -67.01 -27.2 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.334 -1.097 . . . . 0.0 109.817 -179.936 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.4 ' HA3' ' C ' ' A' ' 59' ' ' GLY . . . -84.69 -50.79 4.07 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.487 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 12.2 ptpt -57.62 -24.17 55.0 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -1.203 . . . . 0.0 110.041 -179.556 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.428 ' O ' ' CD ' ' A' ' 33' ' ' LYS . 12.2 pt-20 -97.06 -28.39 14.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.036 -1.04 . . . . 0.0 109.768 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.407 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 37.1 t -83.99 -52.5 6.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 109.709 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 59' ' ' GLY . 3.7 m-30 -60.45 -45.27 94.27 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.322 -0.861 . . . . 0.0 109.787 -179.806 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.748 ' OG1' HG11 ' A' ' 55' ' ' VAL . 21.1 m -52.07 -41.3 62.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.13 -0.981 . . . . 0.0 109.453 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.428 ' CD ' ' O ' ' A' ' 29' ' ' GLU . 8.1 mtpt -68.98 -48.18 63.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.564 179.918 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.73 ' CG ' HD23 ' A' ' 106' ' ' LEU . 9.0 t80 -58.91 -49.86 76.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.514 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.711 ' CD1' HG22 ' A' ' 55' ' ' VAL . 32.8 mt -57.35 -45.49 84.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 109.698 179.979 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.531 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 1.3 t -63.33 -59.83 4.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.194 -0.941 . . . . 0.0 109.758 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.641 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -59.95 -26.91 66.37 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.898 . . . . 0.0 109.724 -179.909 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.641 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 19.6 m-70 -119.69 104.32 10.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.771 -179.944 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 54.5 m170 -86.45 -21.93 26.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.604 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -67.66 -16.38 64.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -0.891 . . . . 0.0 109.525 179.644 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.44 ' HE3' ' CMB' ' A' ' 148' ' ' HEM . 89.7 mmm -109.35 -24.41 11.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.802 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.521 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -48.14 -40.46 23.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -77.06 -21.34 54.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.277 -0.889 . . . . 0.0 109.376 179.728 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.067 HG13 ' ND2' ' A' ' 95' ' ' ASN . 39.6 t -75.09 -39.71 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 0.0 109.563 179.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.655 ' HA ' HMA3 ' A' ' 148' ' ' HEM . 15.6 m-85 -68.08 -31.06 70.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.616 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' C ' ' CD1' ' A' ' 47' ' ' PHE . . . 113.42 27.24 3.68 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.543 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 8.9 m-85 -122.77 171.41 9.2 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.29 -1.123 . . . . 0.0 109.653 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.9 t -111.14 23.47 14.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.314 -0.866 . . . . 0.0 109.212 179.58 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 143.84 -163.78 27.59 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.531 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -93.13 29.81 1.79 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.214 -1.168 . . . . 0.0 109.59 179.92 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 18.3 m -126.52 22.98 6.92 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 109.633 -179.956 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.41 137.94 19.58 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.236 -0.915 . . . . 0.0 109.615 179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -66.51 -24.14 49.39 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 123.919 1.484 . . . . 0.0 110.07 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.505 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -54.24 -31.66 50.09 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.901 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.748 HG11 ' OG1' ' A' ' 32' ' ' THR . 97.5 t -53.66 -53.71 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.268 -1.136 . . . . 0.0 109.568 -179.946 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.721 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -63.07 -14.79 52.57 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.906 . . . . 0.0 109.769 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.52 -44.21 11.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.17 -0.956 . . . . 0.0 109.694 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.504 HD21 ' CHA' ' A' ' 148' ' ' HEM . 1.0 OUTLIER -70.22 -63.62 1.05 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.219 -0.926 . . . . 0.0 110.051 -179.8 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.54 ' N ' ' CD2' ' A' ' 31' ' ' PHE . . . -51.9 -29.3 26.76 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.765 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.721 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -67.93 -40.65 83.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -1.203 . . . . 0.0 110.029 -179.708 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 43.4 mttm -80.85 -36.31 31.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.974 . . . . 0.0 109.928 -179.77 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.753 HG21 ' O ' ' A' ' 149' ' ' CMO . 86.1 t -59.39 -53.98 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 0.0 109.903 -179.786 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 1.005 HD11 HG12 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -47.0 -38.72 11.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.195 -0.94 . . . . 0.0 109.833 -179.936 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 61' ' ' LYS . . . -51.88 -49.32 63.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.625 179.925 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.407 ' OE1' HG21 ' A' ' 86' ' ' VAL . 14.0 tp60 -52.8 -48.2 67.06 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.966 . . . . 0.0 109.437 179.855 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.984 ' O ' HG23 ' A' ' 70' ' ' VAL . 98.8 mt -55.89 -32.98 33.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.296 -0.878 . . . . 0.0 109.165 179.662 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.567 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -66.99 -57.86 9.01 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 179.503 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 63.9 t -55.31 -26.17 18.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -1.111 . . . . 0.0 109.05 179.803 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -26.23 26.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.445 -0.784 . . . . 0.0 109.535 179.955 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.984 HG23 ' O ' ' A' ' 66' ' ' ILE . 40.0 t -59.87 -19.36 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 179.859 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.45 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 34.0 t -88.7 10.14 21.81 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.221 -0.924 . . . . 0.0 110.203 -179.688 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.46 ' HB3' ' HB2' ' A' ' 79' ' ' MET . 19.3 m-70 -147.76 50.73 1.05 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.972 -1.08 . . . . 0.0 109.82 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.796 HD11 ' HB1' ' A' ' 133' ' ' ALA . 3.7 mm? -74.34 -43.9 54.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.343 -0.848 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -89.81 -33.58 8.98 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.904 -1.678 . . . . 0.0 108.904 179.864 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -97.76 69.67 2.14 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.424 -1.045 . . . . 0.0 109.359 179.787 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -88.49 15.61 7.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.891 -179.931 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.47 -30.04 61.39 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 179.904 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.558 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 1.7 tppt? -120.06 -27.08 5.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.182 -1.187 . . . . 0.0 109.834 -179.947 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.46 ' HB2' ' HB3' ' A' ' 72' ' ' HIS . 3.9 tmm? -48.83 -41.96 34.68 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.083 -1.011 . . . . 0.0 109.453 179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.463 ' O ' ' CB ' ' A' ' 84' ' ' LYS . 42.4 t -67.72 -26.66 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.358 -0.839 . . . . 0.0 109.199 179.607 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -58.24 -48.07 81.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.291 -0.88 . . . . 0.0 109.365 179.756 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.59 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 0.6 OUTLIER -78.19 -48.1 16.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.876 . . . . 0.0 109.286 179.67 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.476 ' HE2' ' HB2' ' A' ' 141' ' ' LEU . 2.7 mtp -57.22 -56.81 16.98 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.26 -0.9 . . . . 0.0 109.243 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.475 ' HG3' ' CB ' ' A' ' 143' ' ' SER . 0.1 OUTLIER -51.4 -32.86 27.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.19 -0.944 . . . . 0.0 108.856 179.372 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.59 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -65.58 -39.72 91.93 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.268 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.893 ' CG1' HD11 ' A' ' 141' ' ' LEU . 56.3 t -52.99 -50.22 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.291 -0.88 . . . . 0.0 109.18 179.502 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -50.5 -49.77 38.2 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 179.732 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.685 HG23 ' HA3' ' A' ' 144' ' ' GLY . 91.5 t -49.71 -26.23 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.324 -1.104 . . . . 0.0 109.309 179.591 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.51 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 25.4 mmt180 -78.76 -48.52 14.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.381 -0.824 . . . . 0.0 108.872 179.452 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.579 ' HB2' HD13 ' A' ' 145' ' ' LEU . 13.3 m80 -55.5 -28.28 53.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.441 -0.787 . . . . 0.0 109.327 179.618 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.493 ' HG3' ' HA ' ' A' ' 147' ' ' SER . 0.3 OUTLIER -67.93 -10.05 50.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.319 -0.863 . . . . 0.0 110.04 -179.897 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -138.73 50.71 0.79 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.792 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.51 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 3.5 m-30 -101.59 -168.55 1.57 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.18 -1.188 . . . . 0.0 109.584 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -72.96 -49.47 16.72 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 1.067 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.7 OUTLIER -68.02 -51.03 51.7 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.439 -1.036 . . . . 0.0 109.221 179.796 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.479 ' CB ' ' O ' ' A' ' 95' ' ' ASN . 4.7 tttt 74.64 -48.69 0.65 Allowed 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.528 -0.732 . . . . 0.0 110.844 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -67.81 61.22 0.07 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.958 -1.089 . . . . 0.0 110.248 -179.553 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 96' ' ' LYS . 65.9 mt -92.03 161.24 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.035 -1.041 . . . . 0.0 109.462 179.826 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.513 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 1.5 mptp? -139.8 139.38 36.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.102 -0.999 . . . . 0.0 110.017 -179.798 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 1.055 ' HB1' HD12 ' A' ' 142' ' ' ILE . . . -79.13 -5.9 55.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.421 -0.8 . . . . 0.0 109.621 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 0.6 OUTLIER -70.67 -31.52 68.47 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.103 -0.998 . . . . 0.0 109.694 179.944 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.513 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 75.5 m-85 -82.79 4.93 23.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.295 -0.878 . . . . 0.0 110.529 -179.314 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.824 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 5.5 m-85 -77.09 -57.57 3.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.959 -1.088 . . . . 0.0 109.783 179.704 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' CD ' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -58.31 -50.83 85.91 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.851 -179.698 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' CD ' ' N ' ' A' ' 104' ' ' GLU . 24.8 Cg_exo -55.62 -57.49 1.56 Allowed 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.888 1.468 . . . . 0.0 109.768 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.929 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.2 tm? -57.49 -19.5 24.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.401 179.804 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.51 -51.08 4.75 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.953 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.72 -54.3 48.41 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.166 -1.196 . . . . 0.0 109.572 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.5 t -55.98 -25.17 42.81 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -0.897 . . . . 0.0 109.598 179.964 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' A' ' 106' ' ' LEU . 5.2 tt -67.39 -45.16 77.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.235 -0.916 . . . . 0.0 109.734 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.911 HD21 ' HB3' ' A' ' 130' ' ' TRP . 13.8 mt -56.6 -31.86 64.68 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -0.921 . . . . 0.0 109.653 -179.822 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -67.52 -30.41 70.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.906 . . . . 0.0 109.799 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -82.86 -34.21 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.113 -0.992 . . . . 0.0 109.786 -179.893 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.414 ' HE1' HD21 ' A' ' 110' ' ' LEU . 5.9 mmt -46.39 -45.33 17.77 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.3 -0.875 . . . . 0.0 110.34 -179.713 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -50.32 -23.2 2.16 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.11 -0.993 . . . . 0.0 110.223 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.411 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 16.3 m170 -57.0 -46.88 81.96 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.051 -1.031 . . . . 0.0 109.703 -179.809 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.467 ' HD3' HG23 ' A' ' 17' ' ' ILE . 1.9 ttt85 -73.11 -55.8 5.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 109.815 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 121' ' ' LYS . 5.3 pt -99.92 48.69 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.127 -0.983 . . . . 0.0 110.103 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.09 100.98 0.11 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 179.64 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.44 -45.33 1.14 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.049 -1.62 . . . . 0.0 109.049 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.513 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 1.3 mmtt -82.23 -24.1 35.02 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.251 -1.146 . . . . 0.0 109.154 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.97 79.58 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.441 -0.787 . . . . 0.0 109.595 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.712 HD21 ' HB3' ' A' ' 125' ' ' ALA . 0.1 OUTLIER -88.22 -178.64 5.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.894 . . . . 0.0 110.186 -179.793 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -55.23 -34.73 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.874 -179.696 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.752 ' O ' HG11 ' A' ' 9' ' ' VAL . . . -68.61 -14.4 62.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.668 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -90.43 -50.73 5.79 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.07 -1.019 . . . . 0.0 109.624 -179.986 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.724 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 15.1 ptpt -69.42 -27.77 65.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.241 -0.912 . . . . 0.0 109.262 179.776 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.45 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 42.0 t0 -79.07 -52.56 8.05 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.32 -0.862 . . . . 0.0 109.486 179.772 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -56.66 -54.34 47.22 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.374 -0.829 . . . . 0.0 109.765 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.994 ' CH2' HD12 ' A' ' 17' ' ' ILE . 4.1 m0 -63.46 -27.83 69.55 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.724 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -68.39 -25.46 65.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.225 -0.922 . . . . 0.0 108.78 179.202 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -86.22 -41.93 14.23 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.44 -0.787 . . . . 0.0 109.121 179.466 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.796 ' HB1' HD11 ' A' ' 73' ' ' LEU . . . -70.19 -56.12 7.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.515 -0.74 . . . . 0.0 109.781 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.407 ' N ' ' CD1' ' A' ' 134' ' ' TYR . 9.0 m-30 -47.39 -27.96 1.88 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.296 -0.877 . . . . 0.0 109.636 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -71.98 -43.18 65.55 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.258 -0.901 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.76 -36.57 59.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.341 -0.85 . . . . 0.0 109.325 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.717 HD12 ' O ' ' A' ' 133' ' ' ALA . 1.3 mp -66.64 -58.44 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 108.885 179.717 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.405 ' O ' HG12 ' A' ' 142' ' ' ILE . 31.7 p -66.97 -24.08 66.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.251 -0.906 . . . . 0.0 109.62 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.32 -28.78 55.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.111 -1.595 . . . . 0.0 109.111 179.997 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -73.16 -22.86 60.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.265 -1.138 . . . . 0.0 109.595 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.901 ' O ' HD23 ' A' ' 141' ' ' LEU . 3.8 tt -86.46 11.6 12.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.271 -0.893 . . . . 0.0 109.986 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 1.055 HD12 ' HB1' ' A' ' 100' ' ' ALA . 44.0 mm -100.29 19.29 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.074 -1.016 . . . . 0.0 109.683 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.475 ' CB ' ' HG3' ' A' ' 84' ' ' LYS . 4.4 m -108.11 -52.65 2.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.634 179.962 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.685 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -75.96 -7.75 84.3 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.579 HD13 ' HB2' ' A' ' 90' ' ' HIS . 0.7 OUTLIER -94.96 -155.66 0.48 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.953 -1.322 . . . . 0.0 108.432 -179.969 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.479 ' NE2' ' HB3' ' A' ' 145' ' ' LEU . 3.0 mp0 55.83 47.74 19.61 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.776 -1.202 . . . . 0.0 109.595 -179.934 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.493 ' HA ' ' HG3' ' A' ' 91' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.65 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.824 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.753 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.937 ' CD1' HD12 ' A' ' 73' ' ' LEU . 8.0 mt -83.96 175.36 9.62 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.317 -1.108 . . . . 0.0 109.512 -179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 p -124.69 -167.6 1.69 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.177 -0.952 . . . . 0.0 110.002 179.862 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -80.84 -16.01 54.85 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.208 -0.932 . . . . 0.0 109.98 -179.746 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.784 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -104.37 -42.83 5.36 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.059 -1.026 . . . . 0.0 109.726 -179.705 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.429 ' O ' HG23 ' A' ' 10' ' ' VAL . 1.5 mt-30 -64.81 -46.1 83.43 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.225 -0.922 . . . . 0.0 109.439 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.439 ' HG3' ' HB3' ' A' ' 73' ' ' LEU . 38.6 ttp180 -55.38 -34.27 64.17 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.206 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -73.87 -41.66 61.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.261 -0.899 . . . . 0.0 109.176 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.784 HG23 ' O ' ' A' ' 5' ' ' ALA . 59.7 t -57.42 -29.85 34.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.336 -0.853 . . . . 0.0 109.426 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 1.046 HG12 HG13 ' A' ' 70' ' ' VAL . 91.9 t -66.03 -52.14 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 109.468 179.793 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.56 -9.75 51.4 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.307 -0.871 . . . . 0.0 109.988 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 6.4 p -92.94 -24.43 18.41 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.045 -1.035 . . . . 0.0 109.774 -179.88 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.4 p -98.49 -7.76 27.86 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 110.065 -179.939 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.596 ' CD1' HG21 ' A' ' 70' ' ' VAL . 0.0 OUTLIER -95.14 -23.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.093 . . . . 0.0 109.588 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.2 mttm -77.08 -2.49 34.4 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.206 -0.933 . . . . 0.0 109.852 179.756 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -114.02 -51.12 2.79 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.085 -1.009 . . . . 0.0 109.543 179.953 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.951 HD12 ' CH2' ' A' ' 130' ' ' TRP . 56.3 mt -66.34 -31.52 53.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.919 . . . . 0.0 109.448 179.876 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.888 ' HB1' ' HA ' ' A' ' 22' ' ' ASN . . . -108.77 34.03 3.9 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.315 -0.866 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.31 -85.0 0.02 OUTLIER Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 27.8 p -95.68 -31.45 13.23 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -1.14 . . . . 0.0 109.58 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.543 ' HB2' ' HB3' ' A' ' 24' ' ' ALA . 24.5 p-10 -75.51 -21.97 57.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.295 -0.878 . . . . 0.0 109.591 180.0 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.888 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 4.3 t30 56.57 21.85 6.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.207 -0.933 . . . . 0.0 109.523 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' O ' ' HG ' ' A' ' 63' ' ' LEU . . . 98.82 21.67 15.55 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.543 ' HB3' ' HB2' ' A' ' 21' ' ' ASP . . . -71.04 -56.85 5.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.252 -1.146 . . . . 0.0 109.637 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.47 ' HA2' ' CD ' ' A' ' 28' ' ' LYS . . . -70.85 -21.08 78.04 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.925 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.631 HG11 HD11 ' A' ' 63' ' ' LEU . 46.6 t -70.65 -35.03 59.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.284 -1.127 . . . . 0.0 110.005 -179.778 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.02 -43.72 13.33 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 -179.308 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.47 ' CD ' ' HA2' ' A' ' 25' ' ' GLY . 13.8 ptpt -64.28 -26.39 68.47 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.131 -1.217 . . . . 0.0 110.155 -179.385 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.763 ' CD ' ' HB1' ' A' ' 113' ' ' ALA . 0.0 OUTLIER -100.68 -11.41 20.0 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.045 -1.034 . . . . 0.0 110.156 -179.73 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.462 ' CB ' ' O ' ' A' ' 26' ' ' VAL . 34.1 t -93.05 -68.19 0.81 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 109.888 -179.797 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.528 ' CZ ' HG11 ' A' ' 62' ' ' VAL . 10.3 m-85 -50.32 -30.48 12.14 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 110.004 -179.604 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.771 ' OG1' HG11 ' A' ' 55' ' ' VAL . 15.7 m -54.33 -53.18 57.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.064 -1.023 . . . . 0.0 109.221 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.425 ' HD3' ' O ' ' A' ' 29' ' ' GLU . 0.0 OUTLIER -55.44 -48.56 74.26 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.932 . . . . 0.0 109.243 179.737 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.6 ' CG ' HD23 ' A' ' 106' ' ' LEU . 3.8 t80 -54.33 -49.65 69.23 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.322 -0.862 . . . . 0.0 109.255 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.832 ' CD1' HG22 ' A' ' 55' ' ' VAL . 24.2 mt -60.1 -46.09 90.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.642 179.866 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.439 ' OG ' ' N ' ' A' ' 37' ' ' ALA . 8.9 p -61.21 -54.41 44.57 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.732 -179.91 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.664 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -67.86 -27.09 66.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.226 -0.921 . . . . 0.0 109.62 -179.927 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.664 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 10.0 m-70 -117.51 107.37 14.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.754 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 56.3 m170 -88.41 -19.9 25.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.408 -0.808 . . . . 0.0 109.356 179.648 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -71.04 -11.29 60.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.71 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.558 ' CE ' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -107.61 -27.73 10.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.007 . . . . 0.0 109.943 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.475 ' HA ' HD22 ' A' ' 35' ' ' LEU . . . -46.99 -48.14 21.79 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.13 -0.981 . . . . 0.0 109.796 -179.825 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.6 -28.78 65.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.926 . . . . 0.0 109.122 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.984 HG13 ' ND2' ' A' ' 95' ' ' ASN . 21.3 t -70.15 -38.4 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.273 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.608 ' CE1' HMB2 ' A' ' 148' ' ' HEM . 9.8 m-85 -77.27 -29.93 54.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.243 -0.911 . . . . 0.0 109.612 179.941 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.14 29.51 3.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.374 -1.491 . . . . 0.0 109.374 179.825 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.534 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 11.0 m-85 -124.25 166.99 14.91 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -1.167 . . . . 0.0 109.91 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 39.2 t -104.29 -20.3 13.81 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.421 -0.8 . . . . 0.0 109.127 179.343 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -168.83 -164.69 24.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.816 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.42 ' HB2' ' HB3' ' A' ' 36' ' ' SER . . . -95.15 35.84 1.26 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -1.179 . . . . 0.0 109.69 -179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 56.4 p -135.07 23.2 3.53 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 109.533 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.493 ' OD2' ' CD1' ' A' ' 47' ' ' PHE . 7.8 p-10 -107.69 138.79 20.11 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.262 -0.899 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -60.33 -20.73 64.18 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.934 1.491 . . . . 0.0 109.995 -179.964 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.516 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -51.71 -44.75 54.95 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.198 -1.561 . . . . 0.0 109.198 -179.993 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.832 HG22 ' CD1' ' A' ' 35' ' ' LEU . 80.3 t -51.45 -37.99 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.401 -1.058 . . . . 0.0 109.31 179.776 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.508 ' O ' ' HB2' ' A' ' 60' ' ' ALA . . . -71.72 -24.45 61.8 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.28 -0.887 . . . . 0.0 109.251 179.602 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -79.33 -37.96 36.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.376 179.778 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.793 HD21 ' CHA' ' A' ' 148' ' ' HEM . 1.6 mt -77.19 -60.98 2.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.527 179.926 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.498 ' HA2' ' CD2' ' A' ' 31' ' ' PHE . . . -49.66 -46.65 38.42 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.508 ' HB2' ' O ' ' A' ' 56' ' ' ALA . . . -54.46 -42.04 70.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.243 -1.151 . . . . 0.0 109.39 179.842 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.8 mttt -76.54 -29.17 56.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.262 -0.899 . . . . 0.0 109.354 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' O ' ' A' ' 58' ' ' LEU . 47.6 t -78.58 -49.95 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.631 HD11 HG11 ' A' ' 26' ' ' VAL . 1.0 OUTLIER -48.43 -46.1 37.19 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.248 -0.908 . . . . 0.0 109.556 179.82 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.72 -49.93 69.58 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.303 -0.873 . . . . 0.0 109.564 179.939 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.426 ' OE1' ' HG2' ' A' ' 83' ' ' MET . 8.1 tp-100 -50.9 -43.32 59.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 109.31 179.813 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.853 ' O ' HG23 ' A' ' 70' ' ' VAL . 31.8 mm -57.6 -43.6 83.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.284 -0.885 . . . . 0.0 108.758 179.477 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.548 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -60.83 -55.16 31.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.775 -1.73 . . . . 0.0 108.775 179.371 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.3 t -54.03 -35.32 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.346 -1.09 . . . . 0.0 109.435 179.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.599 ' HB1' HG13 ' A' ' 137' ' ' ILE . . . -79.8 -30.38 40.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.88 . . . . 0.0 109.42 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.046 HG13 HG12 ' A' ' 10' ' ' VAL . 48.9 t -68.68 -16.43 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.262 -0.899 . . . . 0.0 109.584 179.895 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.41 ' O ' ' ND1' ' A' ' 72' ' ' HIS . 3.2 m -90.03 -0.05 57.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.172 -0.955 . . . . 0.0 110.199 -179.897 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.472 ' CB ' ' HB2' ' A' ' 79' ' ' MET . 21.4 m-70 -140.02 50.85 1.72 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.983 -1.073 . . . . 0.0 109.767 -179.872 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.937 HD12 ' CD1' ' A' ' 2' ' ' LEU . 4.3 mm? -58.71 -51.78 68.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.205 -0.934 . . . . 0.0 109.465 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -92.39 -25.46 21.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.838 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.45 60.11 2.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.286 -1.126 . . . . 0.0 109.639 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.445 ' HA ' ' HB3' ' A' ' 79' ' ' MET . 0.0 OUTLIER -70.37 -7.12 40.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 110.033 179.96 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.02 -19.48 30.73 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.556 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 6.5 ttmm -130.28 -39.38 1.34 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -1.21 . . . . 0.0 110.004 -179.871 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.472 ' HB2' ' CB ' ' A' ' 72' ' ' HIS . 28.2 ttp -48.53 -54.83 12.89 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.116 -0.99 . . . . 0.0 109.829 -179.847 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 84' ' ' LYS . 45.9 t -68.61 -11.64 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.218 -0.926 . . . . 0.0 109.964 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.556 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -78.44 -37.41 43.72 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.03 -1.044 . . . . 0.0 109.44 179.904 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -88.65 -41.18 12.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.468 ' HE2' HD12 ' A' ' 141' ' ' LEU . 8.9 mtp -60.36 -41.04 92.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.94 . . . . 0.0 109.247 179.809 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.554 ' O ' HG23 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -51.8 -42.04 62.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -0.918 . . . . 0.0 108.784 179.171 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.437 ' O ' ' HG2' ' A' ' 89' ' ' ARG . . . -61.28 -39.68 91.31 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.992 ' CG1' HD11 ' A' ' 141' ' ' LEU . 23.9 t -56.98 -51.86 63.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.277 -0.89 . . . . 0.0 108.774 179.496 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 145' ' ' LEU . . . -60.86 -53.59 43.95 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 107.655 -2.178 . . . . 0.0 107.655 178.826 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 84' ' ' LYS . 78.7 t -48.8 -24.96 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.451 -1.029 . . . . 0.0 109.445 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.515 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 7.5 mmm180 -83.6 -43.85 15.22 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.021 -1.049 . . . . 0.0 108.729 179.238 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.696 ' O ' HD12 ' A' ' 98' ' ' ILE . 19.5 m80 -58.75 -33.73 70.59 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.379 -0.825 . . . . 0.0 109.698 179.589 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 88' ' ' VAL . 0.0 OUTLIER -61.45 -15.78 40.64 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.257 -0.902 . . . . 0.0 110.434 -179.29 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.46 46.73 1.05 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.257 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.515 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.7 m-30 -87.28 -173.13 4.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.195 -1.179 . . . . 0.0 109.402 179.51 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -81.26 -26.42 52.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 179.668 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.984 ' ND2' HG13 ' A' ' 44' ' ' VAL . 0.6 OUTLIER -76.86 -55.23 5.67 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.559 -0.965 . . . . 0.0 109.101 179.704 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.481 ' HB3' ' O ' ' A' ' 95' ' ' ASN . 10.3 tptp 77.09 -19.02 0.45 Allowed 'General case' 0 N--CA 1.508 2.469 0 O-C-N 121.765 -0.585 . . . . 0.0 111.472 179.871 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.409 ' O ' ' HD2' ' A' ' 99' ' ' LYS . 8.2 m170 -94.05 44.01 1.11 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.601 -1.312 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.696 HD12 ' O ' ' A' ' 90' ' ' HIS . 36.3 mt -74.84 160.46 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.758 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.515 ' HB2' ' CD2' ' A' ' 102' ' ' TYR . 0.0 OUTLIER -151.21 136.24 17.43 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.349 -0.845 . . . . 0.0 109.987 179.984 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.94 -5.52 44.26 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.573 -0.704 . . . . 0.0 109.506 179.301 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.454 ' O ' ' CD ' ' A' ' 105' ' ' PRO . 2.1 mm-40 -74.98 -30.66 61.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.07 -1.019 . . . . 0.0 109.439 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.561 ' HA ' ' HG2' ' A' ' 105' ' ' PRO . 36.0 m-85 -75.66 -23.54 56.29 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.299 -0.876 . . . . 0.0 109.889 -179.746 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.818 ' CD2' HMC1 ' A' ' 148' ' ' HEM . 4.8 m-85 -54.39 -64.16 0.92 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.56 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.488 ' N ' ' HD2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -44.81 -58.55 5.25 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 110.856 -179.111 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.561 ' HG2' ' HA ' ' A' ' 102' ' ' TYR . 11.3 Cg_endo -59.49 -46.62 20.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.639 1.336 . . . . 0.0 109.63 -179.666 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.786 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.1 tm? -60.98 -27.29 68.19 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.216 -0.927 . . . . 0.0 108.841 179.414 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 110' ' ' LEU . . . -81.34 -38.0 16.16 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 179.508 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -59.19 -60.13 4.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 0.0 109.345 179.782 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.0 m -52.42 -24.86 8.55 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.902 . . . . 0.0 109.18 179.67 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.421 ' HB3' ' O ' ' A' ' 107' ' ' GLY . 2.3 tt -66.51 -48.19 70.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.347 -0.846 . . . . 0.0 109.421 179.811 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.804 HD21 ' CB ' ' A' ' 130' ' ' TRP . 13.0 mt -57.65 -32.32 67.17 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.947 . . . . 0.0 109.216 179.729 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.4 m -73.82 -38.52 64.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.339 -0.85 . . . . 0.0 109.429 179.823 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.763 ' HB1' ' CD ' ' A' ' 29' ' ' GLU . . . -72.61 -35.71 67.93 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.292 -0.88 . . . . 0.0 109.387 179.791 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.705 ' SD ' HG21 ' A' ' 17' ' ' ILE . 4.2 mmt -51.39 -42.15 61.21 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.586 179.961 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.44 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 0.3 OUTLIER -50.7 -23.7 2.85 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.99 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 21.2 m170 -53.71 -26.71 24.29 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.29 -0.882 . . . . 0.0 110.094 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.7 -73.31 0.66 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.026 -1.046 . . . . 0.0 109.877 -179.848 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.61 HG23 ' CG1' ' A' ' 17' ' ' ILE . 24.9 pt -65.33 -33.83 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 120.875 -1.14 . . . . 0.0 109.169 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.448 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 45.43 -108.64 0.23 Allowed Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 179.08 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.32 -35.88 10.16 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -179.47 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.497 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 40.3 mttt -68.06 -22.25 64.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.155 -1.203 . . . . 0.0 109.699 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.445 ' SD ' HD11 ' A' ' 118' ' ' ILE . 0.0 OUTLIER -74.99 72.42 2.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.068 -1.02 . . . . 0.0 109.111 179.443 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.758 ' ND2' ' HB3' ' A' ' 125' ' ' ALA . 15.0 p-10 -73.43 -175.88 2.09 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.275 -0.891 . . . . 0.0 109.882 -179.525 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.422 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -59.08 -45.99 89.42 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.347 -0.845 . . . . 0.0 109.302 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.758 ' HB3' ' ND2' ' A' ' 123' ' ' ASN . . . -60.12 -33.0 71.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.315 -0.865 . . . . 0.0 109.074 179.662 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.55 ' HB2' ' OD1' ' A' ' 123' ' ' ASN . . . -66.98 -51.99 48.32 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.272 -0.893 . . . . 0.0 109.429 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.517 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 14.4 ptpt -71.61 -28.96 64.15 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.251 -0.906 . . . . 0.0 109.546 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.476 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 39.3 t0 -80.07 -43.39 21.89 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.331 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.476 ' CB ' ' HB ' ' A' ' 9' ' ' VAL . . . -56.28 -46.1 79.86 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.325 -0.86 . . . . 0.0 109.213 179.675 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.951 ' CH2' HD12 ' A' ' 17' ' ' ILE . 13.1 m0 -74.63 -32.39 62.28 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.258 -0.901 . . . . 0.0 108.581 179.585 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.517 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -56.54 -26.02 53.68 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 178.962 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -94.92 -30.66 14.04 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.315 -0.866 . . . . 0.0 109.063 179.476 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.434 ' C ' HD13 ' A' ' 137' ' ' ILE . . . -83.08 -54.38 5.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.493 -0.754 . . . . 0.0 109.412 179.845 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.56 ' CD1' ' N ' ' A' ' 135' ' ' ALA . 0.1 OUTLIER -48.87 -27.31 2.96 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.307 -0.871 . . . . 0.0 109.362 -179.938 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.56 ' N ' ' CD1' ' A' ' 134' ' ' TYR . . . -80.98 -32.08 34.48 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.266 -0.896 . . . . 0.0 108.776 179.335 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.408 ' N ' ' O ' ' A' ' 133' ' ' ALA . 3.1 m-20 -81.7 -35.67 29.54 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.431 -0.793 . . . . 0.0 109.272 179.671 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.664 HG21 HD13 ' A' ' 66' ' ' ILE . 1.4 mp -66.39 -60.53 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.207 -0.933 . . . . 0.0 108.545 179.409 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.14 -12.06 46.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.95 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.676 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -75.78 -46.25 14.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -60.55 -28.73 68.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -1.142 . . . . 0.0 109.702 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.992 HD11 ' CG1' ' A' ' 86' ' ' VAL . 1.7 tt -71.64 -22.09 61.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.298 -0.876 . . . . 0.0 109.667 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.676 HD12 ' HA2' ' A' ' 139' ' ' GLY . 86.9 mt -78.12 1.34 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.177 -179.826 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.479 ' HB3' ' CE ' ' A' ' 84' ' ' LYS . 68.2 m -81.35 -44.6 17.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.045 . . . . 0.0 109.718 -179.974 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 88' ' ' VAL . . . -110.85 11.12 29.78 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.88 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.486 HD23 HE21 ' A' ' 146' ' ' GLN . 0.3 OUTLIER -72.06 -36.31 69.54 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.027 -1.278 . . . . 0.0 110.014 -179.83 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.486 HE21 HD23 ' A' ' 145' ' ' LEU . 0.0 OUTLIER -108.36 64.91 0.62 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 1.2 t . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.68 -179.869 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.818 HMC1 ' CD2' ' A' ' 103' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.614 ' O ' HG21 ' A' ' 62' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.677 HD13 HD13 ' A' ' 73' ' ' LEU . 15.7 mt -79.34 171.36 15.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.292 -1.122 . . . . 0.0 109.692 -179.912 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 p -118.67 -169.93 1.81 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.306 -0.872 . . . . 0.0 109.635 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.63 -13.33 56.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.786 179.859 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.636 ' O ' HG23 ' A' ' 9' ' ' VAL . . . -98.48 -31.53 11.94 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.158 -0.964 . . . . 0.0 109.82 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.516 ' O ' HG23 ' A' ' 10' ' ' VAL . 24.6 mt-30 -81.31 -43.01 19.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 109.911 -179.765 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.473 ' HG3' ' N ' ' A' ' 8' ' ' GLN . 12.4 ptm180 -53.78 -35.0 60.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.617 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.473 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 6.8 mm-40 -71.96 -47.74 50.1 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.226 -0.921 . . . . 0.0 109.541 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 5' ' ' ALA . 33.1 t -60.09 -27.09 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.257 -0.902 . . . . 0.0 109.461 179.954 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.857 HG12 HG13 ' A' ' 70' ' ' VAL . 54.9 t -70.63 -49.11 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.287 -0.883 . . . . 0.0 109.475 179.899 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.9 -16.25 62.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.314 -0.866 . . . . 0.0 109.795 -179.988 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -85.59 -26.16 26.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.148 -0.97 . . . . 0.0 109.705 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -95.15 -9.61 32.98 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.197 -0.94 . . . . 0.0 109.959 -179.992 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.77 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -92.61 -17.25 24.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.026 -1.046 . . . . 0.0 109.963 -179.882 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.4 mtpt -80.06 -13.71 59.09 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.121 -0.987 . . . . 0.0 109.585 179.658 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.408 ' O ' ' NE ' ' A' ' 117' ' ' ARG . 68.2 m-20 -98.62 -55.43 2.74 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 109.561 179.802 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.918 HD12 ' CH2' ' A' ' 130' ' ' TRP . 30.8 mt -65.39 -28.74 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.211 -0.931 . . . . 0.0 109.12 179.698 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.77 ' HB3' ' O ' ' A' ' 14' ' ' TRP . . . -111.42 36.56 3.18 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.39 -0.819 . . . . 0.0 109.487 179.806 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.55 -86.77 0.02 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 70.7 p -104.98 9.76 34.4 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -1.17 . . . . 0.0 109.94 -179.968 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.437 ' OD1' ' HA ' ' A' ' 18' ' ' ALA . 2.3 p30 -119.3 -12.41 9.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.1 -1.0 . . . . 0.0 109.848 179.907 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.674 ' HA ' ' HB1' ' A' ' 18' ' ' ALA . 14.8 t-20 64.03 13.03 7.4 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.234 -0.916 . . . . 0.0 109.838 -179.758 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.73 ' C ' HD13 ' A' ' 63' ' ' LEU . . . 96.3 16.28 38.2 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.918 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.421 ' O ' ' HE3' ' A' ' 28' ' ' LYS . . . -48.35 -38.19 18.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.221 -1.164 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA2' ' HG2' ' A' ' 28' ' ' LYS . . . -87.29 14.53 57.43 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.873 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.552 ' HB ' HD22 ' A' ' 63' ' ' LEU . 15.7 t -102.21 -29.44 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.075 -1.25 . . . . 0.0 109.558 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.442 ' N ' ' CD2' ' A' ' 63' ' ' LEU . . . -92.26 -37.08 6.03 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.657 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.484 ' HG3' ' N ' ' A' ' 29' ' ' GLU . 16.7 ptpt -64.07 -31.7 72.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.172 -1.193 . . . . 0.0 109.549 -179.857 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.484 ' N ' ' HG3' ' A' ' 28' ' ' LYS . 19.6 pt-20 -94.46 -19.13 20.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.125 -0.985 . . . . 0.0 109.642 179.882 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.527 ' SG ' HD12 ' A' ' 110' ' ' LEU . 35.4 t -89.25 -53.6 4.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.203 -0.936 . . . . 0.0 109.867 -179.78 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.902 ' CZ ' HG21 ' A' ' 62' ' ' VAL . 15.9 m-85 -63.41 -34.85 78.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.141 -0.974 . . . . 0.0 109.774 -179.688 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.796 ' OG1' HG11 ' A' ' 55' ' ' VAL . 12.4 m -58.71 -36.05 73.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.099 -1.001 . . . . 0.0 109.09 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.81 -42.22 50.52 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.874 . . . . 0.0 109.291 179.571 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.693 ' CG ' HD23 ' A' ' 106' ' ' LEU . 12.7 t80 -63.07 -47.41 83.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.28 -0.887 . . . . 0.0 109.313 179.661 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.82 ' CD1' HG22 ' A' ' 55' ' ' VAL . 22.0 mt -57.16 -43.69 82.8 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.876 . . . . 0.0 109.739 179.925 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.404 ' HB2' ' HB2' ' A' ' 50' ' ' ALA . 3.6 t -68.76 -63.52 1.04 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.899 . . . . 0.0 109.706 -179.923 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.614 ' HB3' ' HD2' ' A' ' 38' ' ' HIS . . . -52.56 -24.45 8.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.262 -0.899 . . . . 0.0 109.7 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.614 ' HD2' ' HB3' ' A' ' 37' ' ' ALA . 25.6 m-70 -125.49 104.29 8.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.805 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -86.71 -5.23 59.18 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.389 -0.819 . . . . 0.0 109.855 179.661 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -82.16 -21.99 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.099 -1.001 . . . . 0.0 109.535 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' MET . . . . . 0.457 ' CE ' HMB2 ' A' ' 148' ' ' HEM . 88.4 mmm -101.12 -23.88 14.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.244 -0.91 . . . . 0.0 109.692 -179.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.427 ' HA ' ' CD2' ' A' ' 35' ' ' LEU . . . -48.62 -38.13 20.06 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.226 -0.921 . . . . 0.0 109.632 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -74.67 -28.56 60.89 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.422 179.76 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.91 HG13 ' ND2' ' A' ' 95' ' ' ASN . 52.5 t -67.17 -59.69 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.351 -0.843 . . . . 0.0 109.514 179.844 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.637 ' CD2' HD21 ' A' ' 35' ' ' LEU . 68.1 m-85 -50.79 -42.08 57.72 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.236 -0.915 . . . . 0.0 109.586 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.07 35.84 0.92 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.735 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.536 ' CE2' ' HB3' ' A' ' 45' ' ' PHE . 10.4 m-85 -124.36 166.79 15.34 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.119 -1.224 . . . . 0.0 109.762 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.6 t -111.2 21.62 16.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.411 -0.805 . . . . 0.0 109.117 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 146.08 177.59 20.87 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 -179.788 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 36' ' ' SER . . . -68.79 -13.78 62.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -1.181 . . . . 0.0 109.828 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 71.9 p -87.85 45.55 1.29 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.103 -0.998 . . . . 0.0 109.688 -179.962 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.52 132.45 24.26 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.176 -0.952 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -69.23 -22.17 34.89 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 123.874 1.46 . . . . 0.0 110.083 -179.912 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.492 ' HA3' ' CE1' ' A' ' 47' ' ' PHE . . . -57.39 -26.93 57.48 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.82 HG22 ' CD1' ' A' ' 35' ' ' LEU . 87.1 t -58.33 -51.94 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.179 -1.189 . . . . 0.0 109.637 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 28' ' ' LYS . . . -58.21 -22.6 52.56 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.928 . . . . 0.0 109.552 179.933 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.96 -60.31 2.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.874 . . . . 0.0 109.604 179.992 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.878 HD21 ' C1A' ' A' ' 148' ' ' HEM . 0.5 OUTLIER -55.88 -59.04 5.45 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.677 -179.949 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.524 ' HA2' ' CE1' ' A' ' 31' ' ' PHE . . . -48.54 -60.76 5.59 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.867 ' HA ' HD21 ' A' ' 63' ' ' LEU . . . -48.23 -33.97 9.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 0.0 109.654 179.788 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -77.76 -20.26 53.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.319 -0.863 . . . . 0.0 109.419 179.769 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.902 HG21 ' CZ ' ' A' ' 31' ' ' PHE . 49.4 t -81.24 -61.16 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.31 -0.869 . . . . 0.0 109.677 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.867 HD21 ' HA ' ' A' ' 60' ' ' ALA . 0.3 OUTLIER -46.07 -43.07 14.33 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.27 -0.894 . . . . 0.0 109.835 179.914 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -49.25 -40.23 33.32 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.96 -1.088 . . . . 0.0 109.477 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -65.83 -43.37 88.77 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.249 -0.907 . . . . 0.0 109.153 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.91 ' O ' HG23 ' A' ' 70' ' ' VAL . 33.9 mt -59.96 -40.13 82.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.412 -0.805 . . . . 0.0 109.182 179.68 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.565 ' HA3' ' CH2' ' A' ' 14' ' ' TRP . . . -62.04 -50.79 62.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.88 -30.53 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 109.334 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -82.81 -24.92 33.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.404 -0.81 . . . . 0.0 109.588 -179.963 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.91 HG23 ' O ' ' A' ' 66' ' ' ILE . 46.2 t -69.8 -9.06 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.855 179.754 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.509 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 24.9 p -91.39 30.9 1.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.058 -1.027 . . . . 0.0 109.938 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.509 ' CG ' ' O ' ' A' ' 71' ' ' SER . 8.5 m-70 -160.69 -89.34 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.169 -0.957 . . . . 0.0 109.633 179.875 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.677 HD13 HD13 ' A' ' 2' ' ' LEU . 15.0 mt 63.73 -71.76 0.06 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.367 -0.833 . . . . 0.0 109.985 179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.465 ' N ' ' O ' ' A' ' 72' ' ' HIS . . . -62.06 -29.24 72.15 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 179.823 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -92.39 88.36 6.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.294 -1.121 . . . . 0.0 109.507 179.842 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -89.31 44.32 1.2 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.662 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -119.95 -7.51 9.43 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.4 ' O ' ' HB3' ' A' ' 81' ' ' ALA . 34.0 ttmt -143.29 -44.97 0.29 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.054 -1.263 . . . . 0.0 109.902 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.4 tmm? -48.8 -34.38 12.26 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.113 -0.992 . . . . 0.0 109.781 -179.877 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.431 ' O ' ' HB3' ' A' ' 84' ' ' LYS . 46.7 t -80.33 -19.6 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.268 -0.895 . . . . 0.0 109.612 179.931 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.4 ' HB3' ' O ' ' A' ' 78' ' ' LYS . . . -62.41 -40.59 97.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.593 179.958 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.573 ' O ' ' HB3' ' A' ' 85' ' ' ALA . 1.2 tp10 -87.0 -45.6 10.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.537 179.912 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 1.5 mtp -59.48 -56.92 15.91 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.25 -0.906 . . . . 0.0 109.257 179.765 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.431 ' HB3' ' O ' ' A' ' 80' ' ' VAL . 0.0 OUTLIER -52.43 -27.04 14.36 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.236 -0.915 . . . . 0.0 109.091 179.546 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.573 ' HB3' ' O ' ' A' ' 82' ' ' GLU . . . -71.04 -35.93 72.14 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.707 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 82' ' ' GLU . 16.5 t -58.72 -38.77 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.221 -0.924 . . . . 0.0 109.226 179.868 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.421 ' HA3' ' N ' ' A' ' 145' ' ' LEU . . . -55.86 -47.75 77.09 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.531 -1.827 . . . . 0.0 108.531 179.588 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.561 HG23 ' HA3' ' A' ' 144' ' ' GLY . 79.7 t -55.13 -36.13 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.32 -1.106 . . . . 0.0 108.955 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.507 ' O ' ' CD1' ' A' ' 93' ' ' TYR . 5.9 mpt_? -69.01 -52.33 29.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.41 -0.806 . . . . 0.0 108.991 179.398 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' HIS . . . . . 0.62 ' HB2' HD13 ' A' ' 145' ' ' LEU . 16.9 m80 -56.35 -29.22 61.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.836 . . . . 0.0 109.288 179.581 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HG3' ' CA ' ' A' ' 147' ' ' SER . 5.9 ttmt -66.23 -13.07 59.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.285 -0.884 . . . . 0.0 110.06 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -131.25 47.66 1.01 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.936 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.507 ' CD1' ' O ' ' A' ' 89' ' ' ARG . 4.4 m-30 -91.42 -169.29 2.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.346 -1.091 . . . . 0.0 109.817 -179.88 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.26 -52.82 7.3 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.647 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.91 ' ND2' HG13 ' A' ' 44' ' ' VAL . 11.9 p-10 -61.49 -31.65 71.64 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.128 -1.219 . . . . 0.0 109.486 -179.798 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.5 tttt 60.42 32.94 20.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -0.864 . . . . 0.0 110.147 179.595 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.414 ' O ' ' HB ' ' A' ' 98' ' ' ILE . 54.3 m170 -129.24 -85.31 0.55 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.186 -0.946 . . . . 0.0 109.092 179.503 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 90' ' ' HIS . 17.7 mt 60.13 151.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.806 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.542 ' HB2' ' CD1' ' A' ' 102' ' ' TYR . 0.2 OUTLIER -147.16 131.65 17.69 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.45 -0.781 . . . . 0.0 109.744 179.743 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.09 -12.51 61.54 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.647 -0.658 . . . . 0.0 109.461 179.5 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.421 ' O ' ' HG2' ' A' ' 105' ' ' PRO . 1.0 OUTLIER -73.23 -19.75 61.01 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.092 -1.005 . . . . 0.0 109.255 179.517 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.542 ' CD1' ' HB2' ' A' ' 99' ' ' LYS . 34.4 m-85 -88.48 -22.42 23.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.829 ' CE2' HD22 ' A' ' 141' ' ' LEU . 3.2 m-85 -54.39 -58.91 5.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.068 -179.703 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.509 ' CB ' ' HD3' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -54.3 -58.0 15.85 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.112 -0.993 . . . . 0.0 110.097 -179.498 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.509 ' HD3' ' CB ' ' A' ' 104' ' ' GLU . 31.7 Cg_exo -49.18 -59.83 1.09 Allowed 'Trans proline' 0 C--N 1.309 -1.533 0 O-C-N 123.62 1.326 . . . . 0.0 110.095 179.89 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.826 HD13 ' O ' ' A' ' 106' ' ' LEU . 3.3 tm? -53.71 -27.28 27.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.298 -0.876 . . . . 0.0 109.555 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -78.06 -45.96 9.79 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 -179.976 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -60.64 -52.87 63.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.625 -179.986 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 17.3 m -57.66 -27.74 63.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.656 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.527 HD12 ' SG ' ' A' ' 30' ' ' CYS . 4.1 tt -67.37 -43.08 82.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.215 -0.928 . . . . 0.0 109.622 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.913 HD21 ' HB3' ' A' ' 130' ' ' TRP . 12.8 mt -56.51 -34.24 66.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.206 -0.934 . . . . 0.0 109.537 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' GLU . 10.6 t -64.12 -34.44 78.05 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.721 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' ALA . . . . . 0.417 ' O ' ' HB2' ' A' ' 116' ' ' HIS . . . -81.57 -28.44 33.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.233 -0.917 . . . . 0.0 109.782 -179.732 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.471 ' HE2' ' OH ' ' A' ' 134' ' ' TYR . 5.8 mmt -51.47 -35.51 40.17 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.96 . . . . 0.0 110.291 -179.563 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.464 ' O ' ' CA ' ' A' ' 119' ' ' GLY . 7.1 pt-20 -64.85 -12.28 46.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.086 -1.009 . . . . 0.0 110.164 -179.548 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 116' ' ' HIS . . . . . 0.417 ' HB2' ' O ' ' A' ' 113' ' ' ALA . 14.7 m170 -67.59 -27.15 66.68 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.943 -1.098 . . . . 0.0 109.52 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.436 ' HB3' HG12 ' A' ' 17' ' ' ILE . 0.0 OUTLIER -94.16 -64.45 1.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.791 179.976 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.511 HG23 HG12 ' A' ' 17' ' ' ILE . 24.3 pt -84.3 -34.85 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.641 -179.898 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.49 ' N ' HG13 ' A' ' 118' ' ' ILE . . . 42.39 -94.94 0.01 OUTLIER Glycine 0 N--CA 1.497 2.71 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 118' ' ' ILE . . . -44.03 -48.22 7.98 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -179.146 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.486 ' HB2' ' HB ' ' A' ' 118' ' ' ILE . 16.0 mttt -67.32 -22.64 65.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.116 -1.226 . . . . 0.0 109.895 -179.877 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 122' ' ' MET . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' GLY . 0.1 OUTLIER -71.1 96.55 1.36 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.086 -1.008 . . . . 0.0 109.098 179.51 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.434 ' OD1' ' N ' ' A' ' 125' ' ' ALA . 8.5 p30 -100.36 -161.52 0.87 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.265 -0.897 . . . . 0.0 110.062 -179.5 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.47 ' HA ' ' HG2' ' A' ' 127' ' ' LYS . . . -72.86 -45.58 57.51 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.354 -0.841 . . . . 0.0 109.655 -179.945 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . 0.434 ' N ' ' OD1' ' A' ' 123' ' ' ASN . . . -62.47 -30.41 71.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.196 -0.94 . . . . 0.0 109.036 179.731 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -69.47 -50.23 47.36 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.624 ' O ' ' HB2' ' A' ' 131' ' ' ALA . 18.8 ptpt -72.1 -27.55 62.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 179.774 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 128' ' ' ASP . . . . . 0.462 ' N ' ' HG3' ' A' ' 127' ' ' LYS . 62.2 t0 -80.44 -41.3 24.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.168 179.603 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.505 ' HB1' HG23 ' A' ' 10' ' ' VAL . . . -63.91 -45.71 88.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 109.152 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.918 ' CH2' HD12 ' A' ' 17' ' ' ILE . 5.0 m0 -73.02 -25.73 61.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.368 -0.833 . . . . 0.0 109.138 179.544 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.624 ' HB2' ' O ' ' A' ' 127' ' ' LYS . . . -65.43 -34.08 77.45 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.289 -0.882 . . . . 0.0 108.926 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -88.47 -20.76 24.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.372 -0.83 . . . . 0.0 109.333 179.564 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.538 ' HA ' HD11 ' A' ' 2' ' ' LEU . . . -79.39 -53.39 6.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.525 179.946 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.488 ' OH ' ' CE3' ' A' ' 130' ' ' TRP . 10.4 m-30 -53.0 -28.4 23.75 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.334 179.929 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -70.9 -48.58 52.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.265 -0.897 . . . . 0.0 109.053 179.465 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.89 -34.31 66.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.322 -0.861 . . . . 0.0 109.225 179.642 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.759 HD13 HG23 ' A' ' 66' ' ' ILE . 64.1 mt -66.73 -59.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.348 -0.845 . . . . 0.0 109.16 179.743 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.403 ' O ' HG13 ' A' ' 142' ' ' ILE . 2.2 p -67.87 -25.98 65.79 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.677 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.43 ' HA2' HD12 ' A' ' 142' ' ' ILE . . . -68.87 -46.57 59.59 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -179.952 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -55.51 -26.89 45.41 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.208 -1.172 . . . . 0.0 109.66 179.975 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.829 HD22 ' CE2' ' A' ' 103' ' ' PHE . 10.1 tt -77.29 -16.35 59.01 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.203 -0.936 . . . . 0.0 109.825 179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.442 ' O ' HG22 ' A' ' 142' ' ' ILE . 60.9 mt -76.5 -0.73 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.14 -0.975 . . . . 0.0 110.151 -179.956 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 4.0 m -84.37 -43.96 14.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.037 -1.04 . . . . 0.0 109.632 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.561 ' HA3' HG23 ' A' ' 88' ' ' VAL . . . -85.53 -16.55 63.85 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.62 HD13 ' HB2' ' A' ' 90' ' ' HIS . 6.8 tp -86.23 -173.65 4.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.195 -1.179 . . . . 0.0 108.943 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 146' ' ' GLN . . . . . 0.478 ' CB ' ' O ' ' A' ' 145' ' ' LEU . 4.8 mm-40 75.27 63.88 0.06 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.366 -0.834 . . . . 0.0 109.262 -179.564 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.474 ' CA ' ' HG3' ' A' ' 91' ' ' LYS . 5.4 p . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.635 179.98 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 148' ' ' HEM . . . . . 0.878 ' C1A' HD21 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 149' ' ' CMO . . . . . 0.734 ' O ' HD22 ' A' ' 58' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_